,Type,UI,PubmedID,NameOfSubstance,RegistryNumber,MeshHeadingID,DescriptorName,MajorTopicYN,QualifierName
0,Chemical,D000900,10030778,Anti-Bacterial Agents,0,,,,
1,Chemical,D017963,10030778,Azithromycin,83905-01-5,,,,
2,DescriptorName,D000900,10030778,,,1,Anti-Bacterial Agents,N,
3,QualifierName,Q000008,10030778,,,1,,N,administration & dosage
4,DescriptorName,D017963,10030778,,,2,Azithromycin,N,
5,QualifierName,Q000008,10030778,,,2,,N,administration & dosage
6,DescriptorName,D003638,10030778,,,3,Deafness,N,
7,QualifierName,Q000139,10030778,,,3,,Y,chemically induced
8,DescriptorName,D005260,10030778,,,4,Female,N,
9,DescriptorName,D006801,10030778,,,5,Humans,N,
10,DescriptorName,D007275,10030778,,,6,"Injections, Intravenous",N,
11,DescriptorName,D008875,10030778,,,7,Middle Aged,N,
12,DescriptorName,D011024,10030778,,,8,"Pneumonia, Viral",N,
13,QualifierName,Q000150,10030778,,,8,,N,complications
14,Chemical,D000900,10030778,Anti-Bacterial Agents,0,,,,
15,Chemical,D017963,10030778,Azithromycin,83905-01-5,,,,
16,DescriptorName,D000900,10030778,,,1,Anti-Bacterial Agents,N,
17,QualifierName,Q000008,10030778,,,1,,N,administration & dosage
18,DescriptorName,D017963,10030778,,,2,Azithromycin,N,
19,QualifierName,Q000008,10030778,,,2,,N,administration & dosage
20,DescriptorName,D003638,10030778,,,3,Deafness,N,
21,QualifierName,Q000139,10030778,,,3,,Y,chemically induced
22,DescriptorName,D005260,10030778,,,4,Female,N,
23,DescriptorName,D006801,10030778,,,5,Humans,N,
24,DescriptorName,D007275,10030778,,,6,"Injections, Intravenous",N,
25,DescriptorName,D008875,10030778,,,7,Middle Aged,N,
26,DescriptorName,D011024,10030778,,,8,"Pneumonia, Viral",N,
27,QualifierName,Q000150,10030778,,,8,,N,complications
28,Chemical,D000900,10030778,Anti-Bacterial Agents,0,,,,
29,Chemical,D017963,10030778,Azithromycin,83905-01-5,,,,
30,DescriptorName,D000900,10030778,,,1,Anti-Bacterial Agents,N,
31,QualifierName,Q000008,10030778,,,1,,N,administration & dosage
32,DescriptorName,D017963,10030778,,,2,Azithromycin,N,
33,QualifierName,Q000008,10030778,,,2,,N,administration & dosage
34,DescriptorName,D003638,10030778,,,3,Deafness,N,
35,QualifierName,Q000139,10030778,,,3,,Y,chemically induced
36,DescriptorName,D005260,10030778,,,4,Female,N,
37,DescriptorName,D006801,10030778,,,5,Humans,N,
38,DescriptorName,D007275,10030778,,,6,"Injections, Intravenous",N,
39,DescriptorName,D008875,10030778,,,7,Middle Aged,N,
40,DescriptorName,D011024,10030778,,,8,"Pneumonia, Viral",N,
41,QualifierName,Q000150,10030778,,,8,,N,complications
42,Chemical,D004097,10048291,Dihydrotachysterol,R5LM3H112R,,,,
43,Chemical,D002118,10048291,Calcium,SY7Q814VUP,,,,
44,DescriptorName,D002118,10048291,,,1,Calcium,N,
45,QualifierName,Q000009,10048291,,,1,,Y,adverse effects
46,DescriptorName,D004097,10048291,,,2,Dihydrotachysterol,N,
47,QualifierName,Q000009,10048291,,,2,,Y,adverse effects
48,DescriptorName,D005260,10048291,,,3,Female,N,
49,DescriptorName,D019918,10048291,,,4,Heart Valve Prosthesis Implantation,N,
50,QualifierName,Q000009,10048291,,,4,,N,adverse effects
51,DescriptorName,D006801,10048291,,,5,Humans,N,
52,DescriptorName,D006934,10048291,,,6,Hypercalcemia,N,
53,QualifierName,Q000139,10048291,,,6,,Y,chemically induced
54,DescriptorName,D007011,10048291,,,7,Hypoparathyroidism,N,
55,QualifierName,Q000188,10048291,,,7,,Y,drug therapy
56,DescriptorName,D008875,10048291,,,8,Middle Aged,N,
57,DescriptorName,D010001,10048291,,,9,Osteitis Deformans,N,
58,QualifierName,Q000150,10048291,,,9,,N,complications
59,DescriptorName,D019338,10048291,,,10,Polypharmacy,N,
60,DescriptorName,D011183,10048291,,,11,Postoperative Complications,N,
61,QualifierName,Q000188,10048291,,,11,,N,drug therapy
62,DescriptorName,D011512,10048291,,,12,Proteus Infections,N,
63,QualifierName,Q000150,10048291,,,12,,Y,complications
64,DescriptorName,D006435,10048291,,,13,Renal Dialysis,N,
65,DescriptorName,D013964,10048291,,,14,Thyroid Neoplasms,N,
66,QualifierName,Q000601,10048291,,,14,,N,surgery
67,DescriptorName,D013965,10048291,,,15,Thyroidectomy,N,
68,QualifierName,Q000009,10048291,,,15,,N,adverse effects
69,DescriptorName,D016896,10048291,,,16,Treatment Outcome,N,
70,DescriptorName,D014552,10048291,,,17,Urinary Tract Infections,N,
71,QualifierName,Q000150,10048291,,,17,,N,complications
72,Chemical,D000894,10082597,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
73,Chemical,D011422,10082597,Propionates,0,,,,
74,Chemical,D009288,10082597,Naproxen,57Y76R9ATQ,,,,
75,Chemical,D000077431,10082597,Oxaprozin,MHJ80W9LRB,,,,
76,DescriptorName,D000328,10082597,,,1,Adult,N,
77,DescriptorName,D000894,10082597,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
78,QualifierName,Q000009,10082597,,,2,,Y,adverse effects
79,DescriptorName,D001171,10082597,,,3,"Arthritis, Juvenile",N,
80,QualifierName,Q000188,10082597,,,3,,N,drug therapy
81,DescriptorName,D003875,10082597,,,4,Drug Eruptions,N,
82,QualifierName,Q000209,10082597,,,4,,N,etiology
83,DescriptorName,D005260,10082597,,,5,Female,N,
84,DescriptorName,D006801,10082597,,,6,Humans,N,
85,DescriptorName,D017116,10082597,,,7,Low Back Pain,N,
86,QualifierName,Q000188,10082597,,,7,,N,drug therapy
87,DescriptorName,D008297,10082597,,,8,Male,N,
88,DescriptorName,D009288,10082597,,,9,Naproxen,N,
89,QualifierName,Q000009,10082597,,,9,,Y,adverse effects
90,DescriptorName,D000077431,10082597,,,10,Oxaprozin,N,
91,DescriptorName,D010787,10082597,,,11,Photosensitivity Disorders,N,
92,QualifierName,Q000139,10082597,,,11,,N,chemically induced
93,DescriptorName,D011164,10082597,,,12,Porphyrias,N,
94,QualifierName,Q000139,10082597,,,12,,Y,chemically induced
95,DescriptorName,D011422,10082597,,,13,Propionates,N,
96,QualifierName,Q000009,10082597,,,13,,Y,adverse effects
97,DescriptorName,D012872,10082597,,,14,"Skin Diseases, Vesiculobullous",N,
98,QualifierName,Q000139,10082597,,,14,,N,chemically induced
99,Chemical,D014150,10084639,Antipsychotic Agents,0,,,,
100,Chemical,D001569,10084639,Benzodiazepines,12794-10-4,,,,
101,Chemical,D010890,10084639,Pirenzepine,3G0285N20N,,,,
102,Chemical,D003024,10084639,Clozapine,J60AR2IKIC,,,,
103,Chemical,D000077152,10084639,Olanzapine,N7U69T4SZR,,,,
104,DescriptorName,D000328,10084639,,,1,Adult,N,
105,DescriptorName,D000380,10084639,,,2,Agranulocytosis,N,
106,QualifierName,Q000097,10084639,,,2,,N,blood
107,DescriptorName,D014150,10084639,,,3,Antipsychotic Agents,N,
108,QualifierName,Q000009,10084639,,,3,,N,adverse effects
109,DescriptorName,D001569,10084639,,,4,Benzodiazepines,N,
110,DescriptorName,D003024,10084639,,,5,Clozapine,N,
111,QualifierName,Q000009,10084639,,,5,,Y,adverse effects
112,DescriptorName,D005500,10084639,,,6,Follow-Up Studies,N,
113,DescriptorName,D006801,10084639,,,7,Humans,N,
114,DescriptorName,D007958,10084639,,,8,Leukocyte Count,N,
115,DescriptorName,D008297,10084639,,,9,Male,N,
116,DescriptorName,D000077152,10084639,,,10,Olanzapine,N,
117,DescriptorName,D010890,10084639,,,11,Pirenzepine,N,
118,QualifierName,Q000031,10084639,,,11,,Y,analogs & derivatives
119,DescriptorName,D011569,10084639,,,12,Psychiatric Status Rating Scales,N,
120,DescriptorName,D012559,10084639,,,13,Schizophrenia,N,
121,QualifierName,Q000175,10084639,,,13,,N,diagnosis
122,DescriptorName,D012565,10084639,,,14,Schizophrenic Psychology,N,
123,DescriptorName,D016896,10084639,,,15,Treatment Outcome,N,
124,Chemical,D010088,10099659,Oxidoreductases,EC 1.-,,,,
125,Chemical,D042943,10099659,Dihydrouracil Dehydrogenase (NADP),EC 1.3.1.2,,,,
126,Chemical,D005472,10099659,Fluorouracil,U3P01618RT,,,,
127,DescriptorName,D003110,10099659,,,1,Colonic Neoplasms,N,
128,QualifierName,Q000150,10099659,,,1,,N,complications
129,DescriptorName,D042943,10099659,,,2,Dihydrouracil Dehydrogenase (NADP),N,
130,DescriptorName,D005472,10099659,,,3,Fluorouracil,N,
131,QualifierName,Q000009,10099659,,,3,,Y,adverse effects
132,DescriptorName,D006801,10099659,,,4,Humans,N,
133,DescriptorName,D008297,10099659,,,5,Male,N,
134,DescriptorName,D008875,10099659,,,6,Middle Aged,N,
135,DescriptorName,D009422,10099659,,,7,Nervous System Diseases,N,
136,QualifierName,Q000139,10099659,,,7,,Y,chemically induced
137,DescriptorName,D010088,10099659,,,8,Oxidoreductases,N,
138,QualifierName,Q000172,10099659,,,8,,Y,deficiency
139,Chemical,D000970,10102531,Antineoplastic Agents,0,,,,
140,Chemical,D003561,10102531,Cytarabine,04079A1RDZ,,,,
141,Chemical,C015019,10102531,enocitabine,9YVR68W306,,,,
142,DescriptorName,D000293,10102531,,,1,Adolescent,N,
143,DescriptorName,D000970,10102531,,,2,Antineoplastic Agents,N,
144,QualifierName,Q000009,10102531,,,2,,Y,adverse effects
145,DescriptorName,D001921,10102531,,,3,Brain,N,
146,QualifierName,Q000000981,10102531,,,3,,N,diagnostic imaging
147,DescriptorName,D003561,10102531,,,4,Cytarabine,N,
148,QualifierName,Q000009,10102531,,,4,,N,adverse effects
149,DescriptorName,D005260,10102531,,,5,Female,N,
150,DescriptorName,D006801,10102531,,,6,Humans,N,
151,DescriptorName,D015470,10102531,,,7,"Leukemia, Myeloid, Acute",N,
152,QualifierName,Q000150,10102531,,,7,,Y,complications
153,DescriptorName,D008279,10102531,,,8,Magnetic Resonance Imaging,N,
154,DescriptorName,D011859,10102531,,,9,Radiography,N,
155,DescriptorName,D012640,10102531,,,10,Seizures,N,
156,QualifierName,Q000139,10102531,,,10,,N,chemically induced
157,Chemical,D018691,10190739,Excitatory Amino Acid Antagonists,0,,,,
158,Chemical,D019782,10190739,Riluzole,7LJ087RS6F,,,,
159,DescriptorName,D000208,10190739,,,1,Acute Disease,N,
160,DescriptorName,D000368,10190739,,,2,Aged,N,
161,DescriptorName,D056486,10190739,,,3,Chemical and Drug Induced Liver Injury,Y,
162,DescriptorName,D018691,10190739,,,4,Excitatory Amino Acid Antagonists,N,
163,QualifierName,Q000008,10190739,,,4,,N,administration & dosage
164,DescriptorName,D005260,10190739,,,5,Female,N,
165,DescriptorName,D006801,10190739,,,6,Humans,N,
166,DescriptorName,D008297,10190739,,,7,Male,N,
167,DescriptorName,D008875,10190739,,,8,Middle Aged,N,
168,DescriptorName,D019782,10190739,,,9,Riluzole,N,
169,QualifierName,Q000008,10190739,,,9,,N,administration & dosage
170,DescriptorName,D012595,10190739,,,10,"Scleroderma, Systemic",N,
171,QualifierName,Q000188,10190739,,,10,,N,drug therapy
172,Chemical,D000894,10203437,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
173,Chemical,D000974,10203437,"Antibodies, Antinuclear",0,,,,
174,Chemical,D019804,10203437,Mesalamine,4Q81I59GXC,,,,
175,DescriptorName,D000328,10203437,,,1,Adult,N,
176,DescriptorName,D000368,10203437,,,2,Aged,N,
177,DescriptorName,D000894,10203437,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
178,QualifierName,Q000009,10203437,,,3,,Y,adverse effects
179,DescriptorName,D000974,10203437,,,4,"Antibodies, Antinuclear",N,
180,QualifierName,Q000032,10203437,,,4,,N,analysis
181,DescriptorName,D003240,10203437,,,5,Connective Tissue Diseases,N,
182,QualifierName,Q000139,10203437,,,5,,Y,chemically induced
183,DescriptorName,D003424,10203437,,,6,Crohn Disease,N,
184,QualifierName,Q000188,10203437,,,6,,Y,drug therapy
185,DescriptorName,D005260,10203437,,,7,Female,N,
186,DescriptorName,D006801,10203437,,,8,Humans,N,
187,DescriptorName,D008180,10203437,,,9,"Lupus Erythematosus, Systemic",N,
188,QualifierName,Q000139,10203437,,,9,,Y,chemically induced
189,DescriptorName,D008297,10203437,,,10,Male,N,
190,DescriptorName,D019804,10203437,,,11,Mesalamine,N,
191,QualifierName,Q000009,10203437,,,11,,Y,adverse effects
192,DescriptorName,D008875,10203437,,,12,Middle Aged,N,
193,Chemical,D000468,10225085,Alkalies,0,,,,
194,Chemical,D000779,10225085,"Anesthetics, Local",0,,,,
195,Chemical,D000931,10225085,Antidotes,0,,,,
196,Chemical,D016877,10225085,Oxidants,0,,,,
197,Chemical,D017693,10225085,Sodium Bicarbonate,8MDF5V39QO,,,,
198,Chemical,D008012,10225085,Lidocaine,98PI200987,,,,
199,Chemical,D008751,10225085,Methylene Blue,T42P99266K,,,,
200,Chemical,D002045,10225085,Bupivacaine,Y8335394RO,,,,
201,DescriptorName,D000138,10225085,,,1,Acidosis,N,
202,QualifierName,Q000150,10225085,,,1,,N,complications
203,DescriptorName,D000468,10225085,,,2,Alkalies,N,
204,QualifierName,Q000627,10225085,,,2,,N,therapeutic use
205,DescriptorName,D000779,10225085,,,3,"Anesthetics, Local",N,
206,QualifierName,Q000008,10225085,,,3,,N,administration & dosage
207,DescriptorName,D000931,10225085,,,4,Antidotes,N,
208,QualifierName,Q000627,10225085,,,4,,N,therapeutic use
209,DescriptorName,D001365,10225085,,,5,Axilla,N,
210,QualifierName,Q000294,10225085,,,5,,Y,innervation
211,DescriptorName,D002045,10225085,,,6,Bupivacaine,N,
212,QualifierName,Q000008,10225085,,,6,,N,administration & dosage
213,DescriptorName,D004347,10225085,,,7,Drug Interactions,N,
214,DescriptorName,D005260,10225085,,,8,Female,N,
215,DescriptorName,D006801,10225085,,,9,Humans,N,
216,DescriptorName,D007430,10225085,,,10,Intraoperative Care,N,
217,DescriptorName,D007676,10225085,,,11,"Kidney Failure, Chronic",N,
218,QualifierName,Q000150,10225085,,,11,,N,complications
219,DescriptorName,D008012,10225085,,,12,Lidocaine,N,
220,QualifierName,Q000008,10225085,,,12,,N,administration & dosage
221,DescriptorName,D008708,10225085,,,13,Methemoglobinemia,N,
222,QualifierName,Q000139,10225085,,,13,,Y,chemically induced
223,DescriptorName,D008751,10225085,,,14,Methylene Blue,N,
224,QualifierName,Q000627,10225085,,,14,,N,therapeutic use
225,DescriptorName,D008875,10225085,,,15,Middle Aged,N,
226,DescriptorName,D017202,10225085,,,16,Myocardial Ischemia,N,
227,QualifierName,Q000150,10225085,,,16,,N,complications
228,DescriptorName,D009407,10225085,,,17,Nerve Block,N,
229,QualifierName,Q000009,10225085,,,17,,Y,adverse effects
230,DescriptorName,D016877,10225085,,,18,Oxidants,N,
231,QualifierName,Q000627,10225085,,,18,,N,therapeutic use
232,DescriptorName,D011485,10225085,,,19,Protein Binding,N,
233,QualifierName,Q000187,10225085,,,19,,N,drug effects
234,DescriptorName,D017693,10225085,,,20,Sodium Bicarbonate,N,
235,QualifierName,Q000627,10225085,,,20,,N,therapeutic use
236,Chemical,D000305,10229976,Adrenal Cortex Hormones,0,,,,
237,Chemical,D001241,10229976,Aspirin,R16CO5Y76E,,,,
238,DescriptorName,D000305,10229976,,,1,Adrenal Cortex Hormones,N,
239,QualifierName,Q000008,10229976,,,1,,N,administration & dosage
240,DescriptorName,D001241,10229976,,,2,Aspirin,N,
241,QualifierName,Q000009,10229976,,,2,,Y,adverse effects
242,DescriptorName,D001249,10229976,,,3,Asthma,N,
243,QualifierName,Q000139,10229976,,,3,,Y,chemically induced
244,DescriptorName,D001707,10229976,,,4,"Biopsy, Needle",N,
245,DescriptorName,D004802,10229976,,,5,Eosinophilia,N,
246,QualifierName,Q000209,10229976,,,5,,N,etiology
247,DescriptorName,D004804,10229976,,,6,Eosinophils,N,
248,QualifierName,Q000473,10229976,,,6,,Y,pathology
249,DescriptorName,D005500,10229976,,,7,Follow-Up Studies,N,
250,DescriptorName,D006801,10229976,,,8,Humans,N,
251,DescriptorName,D007150,10229976,,,9,Immunohistochemistry,N,
252,DescriptorName,D007958,10229976,,,10,Leukocyte Count,N,
253,DescriptorName,D008297,10229976,,,11,Male,N,
254,DescriptorName,D008875,10229976,,,12,Middle Aged,N,
255,DescriptorName,D009297,10229976,,,13,Nasal Mucosa,N,
256,QualifierName,Q000166,10229976,,,13,,N,cytology
257,DescriptorName,D009298,10229976,,,14,Nasal Polyps,N,
258,QualifierName,Q000209,10229976,,,14,,Y,etiology
259,DescriptorName,D012008,10229976,,,15,Recurrence,N,
260,Chemical,D008727,10327035,Methotrexate,YL5FZ2Y5U1,,,,
261,DescriptorName,D000208,10327035,,,1,Acute Disease,N,
262,DescriptorName,D000328,10327035,,,2,Adult,N,
263,DescriptorName,D000971,10327035,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
264,QualifierName,Q000009,10327035,,,3,,Y,adverse effects
265,DescriptorName,D001927,10327035,,,4,Brain Diseases,N,
266,QualifierName,Q000139,10327035,,,4,,Y,chemically induced
267,DescriptorName,D006801,10327035,,,5,Humans,N,
268,DescriptorName,D008279,10327035,,,6,Magnetic Resonance Imaging,N,
269,DescriptorName,D008297,10327035,,,7,Male,N,
270,DescriptorName,D008727,10327035,,,8,Methotrexate,N,
271,QualifierName,Q000008,10327035,,,8,,N,administration & dosage
272,DescriptorName,D013274,10327035,,,9,Stomach Neoplasms,N,
273,QualifierName,Q000188,10327035,,,9,,Y,drug therapy
274,Chemical,D000959,10332990,Antihypertensive Agents,0,,,,
275,Chemical,D011464,10332990,Epoprostenol,DCR9Z582X0,,,,
276,DescriptorName,D000959,10332990,,,1,Antihypertensive Agents,N,
277,QualifierName,Q000009,10332990,,,1,,Y,adverse effects
278,DescriptorName,D011464,10332990,,,2,Epoprostenol,N,
279,QualifierName,Q000009,10332990,,,2,,Y,adverse effects
280,DescriptorName,D005260,10332990,,,3,Female,N,
281,DescriptorName,D006801,10332990,,,4,Humans,N,
282,DescriptorName,D006976,10332990,,,5,"Hypertension, Pulmonary",N,
283,QualifierName,Q000150,10332990,,,5,,Y,complications
284,DescriptorName,D008875,10332990,,,6,Middle Aged,N,
285,DescriptorName,D011654,10332990,,,7,Pulmonary Edema,N,
286,QualifierName,Q000139,10332990,,,7,,Y,chemically induced
287,DescriptorName,D012594,10332990,,,8,"Scleroderma, Localized",N,
288,QualifierName,Q000150,10332990,,,8,,Y,complications
289,Chemical,D000893,10337682,Anti-Inflammatory Agents,0,,,,
290,Chemical,D011239,10337682,Prednisolone,9PHQ9Y1OLM,,,,
291,Chemical,D008775,10337682,Methylprednisolone,X4W7ZR7023,,,,
292,DescriptorName,D000293,10337682,,,1,Adolescent,N,
293,DescriptorName,D000893,10337682,,,2,Anti-Inflammatory Agents,N,
294,QualifierName,Q000009,10337682,,,2,,Y,adverse effects
295,DescriptorName,D001706,10337682,,,3,Biopsy,N,
296,DescriptorName,D003875,10337682,,,4,Drug Eruptions,N,
297,QualifierName,Q000209,10337682,,,4,,Y,etiology
298,DescriptorName,D005260,10337682,,,5,Female,N,
299,DescriptorName,D006801,10337682,,,6,Humans,N,
300,DescriptorName,D008180,10337682,,,7,"Lupus Erythematosus, Systemic",N,
301,QualifierName,Q000188,10337682,,,7,,Y,drug therapy
302,DescriptorName,D008775,10337682,,,8,Methylprednisolone,N,
303,QualifierName,Q000627,10337682,,,8,,N,therapeutic use
304,DescriptorName,D011239,10337682,,,9,Prednisolone,N,
305,QualifierName,Q000009,10337682,,,9,,Y,adverse effects
306,DescriptorName,D012867,10337682,,,10,Skin,N,
307,QualifierName,Q000473,10337682,,,10,,N,pathology
308,Chemical,D006918,10348150,Hydroxyurea,X6Q56QN5QC,,,,
309,DescriptorName,D006801,10348150,,,1,Humans,N,
310,DescriptorName,D006918,10348150,,,2,Hydroxyurea,N,
311,QualifierName,Q000009,10348150,,,2,,Y,adverse effects
312,DescriptorName,D017563,10348150,,,3,"Lung Diseases, Interstitial",N,
313,QualifierName,Q000139,10348150,,,3,,Y,chemically induced
314,DescriptorName,D008297,10348150,,,4,Male,N,
315,DescriptorName,D008875,10348150,,,5,Middle Aged,N,
316,DescriptorName,D013902,10348150,,,6,"Radiography, Thoracic",N,
317,DescriptorName,D013920,10348150,,,7,"Thrombocythemia, Essential",N,
318,QualifierName,Q000150,10348150,,,7,,Y,complications
319,Chemical,D003879,10357715,Dermatologic Agents,0,,,,
320,Chemical,C055085,10357715,calcipotriene,143NQ3779B,,,,
321,Chemical,D002117,10357715,Calcitriol,FXC9231JVH,,,,
322,DescriptorName,D000287,10357715,,,1,"Administration, Topical",N,
323,DescriptorName,D000368,10357715,,,2,Aged,N,
324,DescriptorName,D002117,10357715,,,3,Calcitriol,N,
325,QualifierName,Q000009,10357715,,,3,,N,adverse effects
326,DescriptorName,D003879,10357715,,,4,Dermatologic Agents,N,
327,QualifierName,Q000009,10357715,,,4,,Y,adverse effects
328,DescriptorName,D003875,10357715,,,5,Drug Eruptions,N,
329,QualifierName,Q000175,10357715,,,5,,N,diagnosis
330,DescriptorName,D005260,10357715,,,6,Female,N,
331,DescriptorName,D006801,10357715,,,7,Humans,N,
332,DescriptorName,D008875,10357715,,,8,Middle Aged,N,
333,DescriptorName,D010328,10357715,,,9,Patch Tests,N,
334,DescriptorName,D011565,10357715,,,10,Psoriasis,N,
335,QualifierName,Q000188,10357715,,,10,,N,drug therapy
336,Chemical,D000924,10367184,Anticholesteremic Agents,0,,,,
337,Chemical,D017035,10367184,Pravastatin,KXO2KT9N0G,,,,
338,DescriptorName,D000328,10367184,,,1,Adult,N,
339,DescriptorName,D000924,10367184,,,2,Anticholesteremic Agents,N,
340,QualifierName,Q000009,10367184,,,2,,Y,adverse effects
341,DescriptorName,D006801,10367184,,,3,Humans,N,
342,DescriptorName,D008297,10367184,,,4,Male,N,
343,DescriptorName,D009222,10367184,,,5,Myotonia,N,
344,QualifierName,Q000139,10367184,,,5,,N,chemically induced
345,DescriptorName,D017035,10367184,,,6,Pravastatin,N,
346,QualifierName,Q000009,10367184,,,6,,Y,adverse effects
347,DescriptorName,D012507,10367184,,,7,Sarcoidosis,N,
348,QualifierName,Q000150,10367184,,,7,,Y,complications
349,Chemical,D001241,10393393,Aspirin,R16CO5Y76E,,,,
350,DescriptorName,D000328,10393393,,,1,Adult,N,
351,DescriptorName,D000368,10393393,,,2,Aged,N,
352,DescriptorName,D001241,10393393,,,3,Aspirin,N,
353,QualifierName,Q000008,10393393,,,3,,N,administration & dosage
354,DescriptorName,D001249,10393393,,,4,Asthma,N,
355,QualifierName,Q000139,10393393,,,4,,N,chemically induced
356,DescriptorName,D003888,10393393,,,5,"Desensitization, Immunologic",Y,
357,DescriptorName,D003937,10393393,,,6,"Diagnosis, Differential",N,
358,DescriptorName,D004305,10393393,,,7,"Dose-Response Relationship, Drug",N,
359,DescriptorName,D003875,10393393,,,8,Drug Eruptions,N,
360,QualifierName,Q000175,10393393,,,8,,N,diagnosis
361,DescriptorName,D004342,10393393,,,9,Drug Hypersensitivity,N,
362,QualifierName,Q000175,10393393,,,9,,N,diagnosis
363,DescriptorName,D005260,10393393,,,10,Female,N,
364,DescriptorName,D006801,10393393,,,11,Humans,N,
365,DescriptorName,D008297,10393393,,,12,Male,N,
366,DescriptorName,D008875,10393393,,,13,Middle Aged,N,
367,DescriptorName,D009203,10393393,,,14,Myocardial Infarction,N,
368,QualifierName,Q000188,10393393,,,14,,Y,drug therapy
369,DescriptorName,D016896,10393393,,,15,Treatment Outcome,N,
370,Chemical,D004791,10395123,Enzyme Inhibitors,0,,,,
371,Chemical,D009853,10395123,Omeprazole,KG60484QX9,,,,
372,DescriptorName,D000328,10395123,,,1,Adult,N,
373,DescriptorName,D003937,10395123,,,2,"Diagnosis, Differential",N,
374,DescriptorName,D003875,10395123,,,3,Drug Eruptions,N,
375,QualifierName,Q000209,10395123,,,3,,Y,etiology
376,DescriptorName,D004791,10395123,,,4,Enzyme Inhibitors,N,
377,QualifierName,Q000009,10395123,,,4,,Y,adverse effects
378,DescriptorName,D005260,10395123,,,5,Female,N,
379,DescriptorName,D005764,10395123,,,6,Gastroesophageal Reflux,N,
380,QualifierName,Q000188,10395123,,,6,,N,drug therapy
381,DescriptorName,D006229,10395123,,,7,Hand Dermatoses,N,
382,QualifierName,Q000139,10395123,,,7,,Y,chemically induced
383,DescriptorName,D006801,10395123,,,8,Humans,N,
384,DescriptorName,D009853,10395123,,,9,Omeprazole,N,
385,QualifierName,Q000009,10395123,,,9,,Y,adverse effects
386,Chemical,D000893,10405480,Anti-Inflammatory Agents,0,,,,
387,Chemical,D005765,10405480,Gastrointestinal Agents,0,,,,
388,Chemical,D012460,10405480,Sulfasalazine,3XC8GUZ6CB,,,,
389,Chemical,D011239,10405480,Prednisolone,9PHQ9Y1OLM,,,,
390,DescriptorName,D000328,10405480,,,1,Adult,N,
391,DescriptorName,D000893,10405480,,,2,Anti-Inflammatory Agents,N,
392,QualifierName,Q000008,10405480,,,2,,N,administration & dosage
393,DescriptorName,D001707,10405480,,,3,"Biopsy, Needle",N,
394,DescriptorName,D003093,10405480,,,4,"Colitis, Ulcerative",N,
395,QualifierName,Q000188,10405480,,,4,,N,drug therapy
396,DescriptorName,D003875,10405480,,,5,Drug Eruptions,N,
397,QualifierName,Q000188,10405480,,,5,,N,drug therapy
398,DescriptorName,D005765,10405480,,,6,Gastrointestinal Agents,N,
399,QualifierName,Q000009,10405480,,,6,,Y,adverse effects
400,DescriptorName,D006801,10405480,,,7,Humans,N,
401,DescriptorName,D008297,10405480,,,8,Male,N,
402,DescriptorName,D010328,10405480,,,9,Patch Tests,N,
403,DescriptorName,D011239,10405480,,,10,Prednisolone,N,
404,QualifierName,Q000008,10405480,,,10,,N,administration & dosage
405,DescriptorName,D012872,10405480,,,11,"Skin Diseases, Vesiculobullous",N,
406,QualifierName,Q000139,10405480,,,11,,Y,chemically induced
407,DescriptorName,D012460,10405480,,,12,Sulfasalazine,N,
408,QualifierName,Q000009,10405480,,,12,,Y,adverse effects
409,DescriptorName,D016896,10405480,,,13,Treatment Outcome,N,
410,Chemical,D014150,10410183,Antipsychotic Agents,0,,,,
411,Chemical,D001569,10410183,Benzodiazepines,12794-10-4,,,,
412,Chemical,D010890,10410183,Pirenzepine,3G0285N20N,,,,
413,Chemical,D003402,10410183,Creatine Kinase,EC 2.7.3.2,,,,
414,Chemical,D000077152,10410183,Olanzapine,N7U69T4SZR,,,,
415,DescriptorName,D000328,10410183,,,1,Adult,N,
416,DescriptorName,D014150,10410183,,,2,Antipsychotic Agents,N,
417,QualifierName,Q000009,10410183,,,2,,Y,adverse effects
418,DescriptorName,D001569,10410183,,,3,Benzodiazepines,N,
419,DescriptorName,D002908,10410183,,,4,Chronic Disease,N,
420,DescriptorName,D003402,10410183,,,5,Creatine Kinase,N,
421,QualifierName,Q000097,10410183,,,5,,Y,blood
422,DescriptorName,D006801,10410183,,,6,Humans,N,
423,DescriptorName,D008297,10410183,,,7,Male,N,
424,DescriptorName,D000077152,10410183,,,8,Olanzapine,N,
425,DescriptorName,D010890,10410183,,,9,Pirenzepine,N,
426,QualifierName,Q000009,10410183,,,9,,N,adverse effects
427,DescriptorName,D012206,10410183,,,10,Rhabdomyolysis,N,
428,QualifierName,Q000139,10410183,,,10,,N,chemically induced
429,DescriptorName,D012559,10410183,,,11,Schizophrenia,N,
430,QualifierName,Q000150,10410183,,,11,,N,complications
431,Chemical,D000894,10414481,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
432,Chemical,D004008,10414481,Diclofenac,144O8QL0L1,,,,
433,Chemical,D001219,10414481,Aspartate Aminotransferases,EC 2.6.1.1,,,,
434,Chemical,D000410,10414481,Alanine Transaminase,EC 2.6.1.2,,,,
435,Chemical,D000469,10414481,Alkaline Phosphatase,EC 3.1.3.1,,,,
436,Chemical,D001663,10414481,Bilirubin,RFM9X3LJ49,,,,
437,DescriptorName,D000410,10414481,,,1,Alanine Transaminase,N,
438,QualifierName,Q000097,10414481,,,1,,N,blood
439,DescriptorName,D000469,10414481,,,2,Alkaline Phosphatase,N,
440,QualifierName,Q000097,10414481,,,2,,N,blood
441,DescriptorName,D000894,10414481,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
442,QualifierName,Q000009,10414481,,,3,,Y,adverse effects
443,DescriptorName,D001219,10414481,,,4,Aspartate Aminotransferases,N,
444,QualifierName,Q000097,10414481,,,4,,N,blood
445,DescriptorName,D001663,10414481,,,5,Bilirubin,N,
446,QualifierName,Q000097,10414481,,,5,,N,blood
447,DescriptorName,D001706,10414481,,,6,Biopsy,N,
448,DescriptorName,D056486,10414481,,,7,Chemical and Drug Induced Liver Injury,N,
449,QualifierName,Q000175,10414481,,,7,,N,diagnosis
450,DescriptorName,D004008,10414481,,,8,Diclofenac,N,
451,QualifierName,Q000009,10414481,,,8,,Y,adverse effects
452,DescriptorName,D016903,10414481,,,9,Drug Monitoring,N,
453,DescriptorName,D005260,10414481,,,10,Female,N,
454,DescriptorName,D005756,10414481,,,11,Gastritis,N,
455,QualifierName,Q000139,10414481,,,11,,N,chemically induced
456,DescriptorName,D006801,10414481,,,12,Humans,N,
457,DescriptorName,D008111,10414481,,,13,Liver Function Tests,N,
458,DescriptorName,D008875,10414481,,,14,Middle Aged,N,
459,DescriptorName,D010003,10414481,,,15,Osteoarthritis,N,
460,QualifierName,Q000188,10414481,,,15,,N,drug therapy
461,Chemical,D007166,10426918,Immunosuppressive Agents,0,,,,
462,Chemical,D016898,10426918,Interferon-alpha,0,,,,
463,Chemical,D017338,10426918,Cladribine,47M74X9YT5,,,,
464,DescriptorName,D000368,10426918,,,1,Aged,N,
465,DescriptorName,D000971,10426918,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
466,QualifierName,Q000627,10426918,,,2,,Y,therapeutic use
467,DescriptorName,D017338,10426918,,,3,Cladribine,N,
468,QualifierName,Q000008,10426918,,,3,,N,administration & dosage
469,DescriptorName,D006801,10426918,,,4,Humans,N,
470,DescriptorName,D007166,10426918,,,5,Immunosuppressive Agents,N,
471,QualifierName,Q000627,10426918,,,5,,Y,therapeutic use
472,DescriptorName,D016898,10426918,,,6,Interferon-alpha,N,
473,QualifierName,Q000008,10426918,,,6,,N,administration & dosage
474,DescriptorName,D007943,10426918,,,7,"Leukemia, Hairy Cell",N,
475,QualifierName,Q000150,10426918,,,7,,N,complications
476,DescriptorName,D008297,10426918,,,8,Male,N,
477,DescriptorName,D011565,10426918,,,9,Psoriasis,N,
478,QualifierName,Q000150,10426918,,,9,,N,complications
479,Chemical,D000925,10431414,Anticoagulants,0,,,,
480,Chemical,D006493,10431414,Heparin,9005-49-6,,,,
481,DescriptorName,D000328,10431414,,,1,Adult,N,
482,DescriptorName,D000925,10431414,,,2,Anticoagulants,N,
483,QualifierName,Q000009,10431414,,,2,,Y,adverse effects
484,DescriptorName,D006493,10431414,,,3,Heparin,N,
485,QualifierName,Q000009,10431414,,,3,,Y,adverse effects
486,DescriptorName,D006801,10431414,,,4,Humans,N,
487,DescriptorName,D008297,10431414,,,5,Male,N,
488,DescriptorName,D011183,10431414,,,6,Postoperative Complications,N,
489,QualifierName,Q000188,10431414,,,6,,N,drug therapy
490,DescriptorName,D011317,10431414,,,7,Priapism,N,
491,QualifierName,Q000139,10431414,,,7,,Y,chemically induced
492,Chemical,D014150,10435399,Antipsychotic Agents,0,,,,
493,Chemical,D003024,10435399,Clozapine,J60AR2IKIC,,,,
494,DescriptorName,D000328,10435399,,,1,Adult,N,
495,DescriptorName,D014150,10435399,,,2,Antipsychotic Agents,N,
496,QualifierName,Q000009,10435399,,,2,,Y,adverse effects
497,DescriptorName,D002452,10435399,,,3,Cell Count,N,
498,QualifierName,Q000187,10435399,,,3,,N,drug effects
499,DescriptorName,D002940,10435399,,,4,Circadian Rhythm,Y,
500,QualifierName,Q000187,10435399,,,4,,N,drug effects
501,DescriptorName,D003024,10435399,,,5,Clozapine,N,
502,QualifierName,Q000009,10435399,,,5,,Y,adverse effects
503,DescriptorName,D006801,10435399,,,6,Humans,N,
504,DescriptorName,D007962,10435399,,,7,Leukocytes,N,
505,QualifierName,Q000187,10435399,,,7,,Y,drug effects
506,DescriptorName,D008297,10435399,,,8,Male,N,
507,DescriptorName,D009503,10435399,,,9,Neutropenia,N,
508,QualifierName,Q000139,10435399,,,9,,Y,chemically induced
509,DescriptorName,D012559,10435399,,,10,Schizophrenia,N,
510,QualifierName,Q000097,10435399,,,10,,N,blood
511,Chemical,D000970,10439378,Antineoplastic Agents,0,,,,
512,Chemical,D014212,10439378,Tretinoin,5688UTC01R,,,,
513,DescriptorName,D000970,10439378,,,1,Antineoplastic Agents,N,
514,QualifierName,Q000009,10439378,,,1,,Y,adverse effects
515,DescriptorName,D005260,10439378,,,2,Female,N,
516,DescriptorName,D006801,10439378,,,3,Humans,N,
517,DescriptorName,D015473,10439378,,,4,"Leukemia, Promyelocytic, Acute",N,
518,QualifierName,Q000150,10439378,,,4,,N,complications
519,DescriptorName,D008875,10439378,,,5,Middle Aged,N,
520,DescriptorName,D016463,10439378,,,6,Sweet Syndrome,N,
521,QualifierName,Q000139,10439378,,,6,,Y,chemically induced
522,DescriptorName,D014212,10439378,,,7,Tretinoin,N,
523,QualifierName,Q000009,10439378,,,7,,Y,adverse effects
524,Chemical,D018687,10442258,"Antidepressive Agents, Second-Generation",0,,,,
525,Chemical,D017374,10442258,Paroxetine,41VRH5220H,,,,
526,DescriptorName,D000328,10442258,,,1,Adult,N,
527,DescriptorName,D000505,10442258,,,2,Alopecia,N,
528,QualifierName,Q000139,10442258,,,2,,Y,chemically induced
529,DescriptorName,D018687,10442258,,,3,"Antidepressive Agents, Second-Generation",N,
530,QualifierName,Q000009,10442258,,,3,,Y,adverse effects
531,DescriptorName,D003863,10442258,,,4,Depression,N,
532,QualifierName,Q000188,10442258,,,4,,N,drug therapy
533,DescriptorName,D005260,10442258,,,5,Female,N,
534,DescriptorName,D006801,10442258,,,6,Humans,N,
535,DescriptorName,D017374,10442258,,,7,Paroxetine,N,
536,QualifierName,Q000009,10442258,,,7,,Y,adverse effects
537,Chemical,D007328,10452772,Insulin,0,,,,
538,Chemical,D011479,10452772,Protamines,0,,,,
539,Chemical,D007073,10452772,Immunoglobulin E,37341-29-0,,,,
540,Chemical,D007336,10452772,"Insulin, Isophane",53027-39-7,,,,
541,DescriptorName,D000328,10452772,,,1,Adult,N,
542,DescriptorName,D003922,10452772,,,2,"Diabetes Mellitus, Type 1",N,
543,QualifierName,Q000188,10452772,,,2,,N,drug therapy
544,DescriptorName,D004342,10452772,,,3,Drug Hypersensitivity,N,
545,QualifierName,Q000150,10452772,,,3,,Y,complications
546,DescriptorName,D005260,10452772,,,4,Female,N,
547,DescriptorName,D006801,10452772,,,5,Humans,N,
548,DescriptorName,D006969,10452772,,,6,"Hypersensitivity, Immediate",N,
549,DescriptorName,D007073,10452772,,,7,Immunoglobulin E,N,
550,QualifierName,Q000097,10452772,,,7,,N,blood
551,DescriptorName,D007328,10452772,,,8,Insulin,N,
552,QualifierName,Q000009,10452772,,,8,,Y,adverse effects
553,DescriptorName,D007336,10452772,,,9,"Insulin, Isophane",N,
554,QualifierName,Q000276,10452772,,,9,,N,immunology
555,DescriptorName,D011479,10452772,,,10,Protamines,N,
556,QualifierName,Q000009,10452772,,,10,,Y,adverse effects
557,Chemical,D000316,10458196,Adrenergic alpha-Agonists,0,,,,
558,Chemical,D009883,10458196,Ophthalmic Solutions,0,,,,
559,Chemical,D011810,10458196,Quinoxalines,0,,,,
560,Chemical,D000068438,10458196,Brimonidine Tartrate,4S9CL2DY2H,,,,
561,DescriptorName,D000316,10458196,,,1,Adrenergic alpha-Agonists,N,
562,QualifierName,Q000008,10458196,,,1,,N,administration & dosage
563,DescriptorName,D000068438,10458196,,,2,Brimonidine Tartrate,N,
564,DescriptorName,D002490,10458196,,,3,Central Nervous System,N,
565,QualifierName,Q000187,10458196,,,3,,Y,drug effects
566,DescriptorName,D005500,10458196,,,4,Follow-Up Studies,N,
567,DescriptorName,D005901,10458196,,,5,Glaucoma,N,
568,QualifierName,Q000151,10458196,,,5,,N,congenital
569,DescriptorName,D006801,10458196,,,6,Humans,N,
570,DescriptorName,D007223,10458196,,,7,Infant,N,
571,DescriptorName,D007231,10458196,,,8,"Infant, Newborn",N,
572,DescriptorName,D007429,10458196,,,9,Intraocular Pressure,N,
573,QualifierName,Q000187,10458196,,,9,,N,drug effects
574,DescriptorName,D008297,10458196,,,10,Male,N,
575,DescriptorName,D009422,10458196,,,11,Nervous System Diseases,N,
576,QualifierName,Q000139,10458196,,,11,,Y,chemically induced
577,DescriptorName,D009798,10458196,,,12,Ocular Hypertension,N,
578,QualifierName,Q000188,10458196,,,12,,N,drug therapy
579,DescriptorName,D009883,10458196,,,13,Ophthalmic Solutions,N,
580,DescriptorName,D011810,10458196,,,14,Quinoxalines,N,
581,QualifierName,Q000008,10458196,,,14,,N,administration & dosage
582,Chemical,D002511,10461415,Cephalosporins,0,,,,
583,Chemical,D002443,10461415,Ceftriaxone,75J73V1629,,,,
584,Chemical,D001219,10461415,Aspartate Aminotransferases,EC 2.6.1.1,,,,
585,Chemical,D000410,10461415,Alanine Transaminase,EC 2.6.1.2,,,,
586,Chemical,D000469,10461415,Alkaline Phosphatase,EC 3.1.3.1,,,,
587,DescriptorName,D000410,10461415,,,1,Alanine Transaminase,N,
588,QualifierName,Q000097,10461415,,,1,,N,blood
589,DescriptorName,D000469,10461415,,,2,Alkaline Phosphatase,N,
590,QualifierName,Q000097,10461415,,,2,,N,blood
591,DescriptorName,D001219,10461415,,,3,Aspartate Aminotransferases,N,
592,QualifierName,Q000097,10461415,,,3,,N,blood
593,DescriptorName,D001649,10461415,,,4,Bile Duct Diseases,N,
594,QualifierName,Q000139,10461415,,,4,,N,chemically induced
595,DescriptorName,D002443,10461415,,,5,Ceftriaxone,N,
596,QualifierName,Q000009,10461415,,,5,,Y,adverse effects
597,DescriptorName,D002511,10461415,,,6,Cephalosporins,N,
598,QualifierName,Q000009,10461415,,,6,,Y,adverse effects
599,DescriptorName,D056486,10461415,,,7,Chemical and Drug Induced Liver Injury,N,
600,DescriptorName,D006801,10461415,,,8,Humans,N,
601,DescriptorName,D007223,10461415,,,9,Infant,N,
602,DescriptorName,D008297,10461415,,,10,Male,N,
603,DescriptorName,D010033,10461415,,,11,Otitis Media,N,
604,QualifierName,Q000188,10461415,,,11,,Y,drug therapy
605,Chemical,D000964,10465148,"Antimetabolites, Antineoplastic",0,,,,
606,Chemical,D008727,10465148,Methotrexate,YL5FZ2Y5U1,,,,
607,DescriptorName,D000964,10465148,,,1,"Antimetabolites, Antineoplastic",N,
608,QualifierName,Q000009,10465148,,,1,,Y,adverse effects
609,DescriptorName,D002555,10465148,,,2,Cerebrospinal Fluid,N,
610,QualifierName,Q000166,10465148,,,2,,N,cytology
611,DescriptorName,D002675,10465148,,,3,"Child, Preschool",N,
612,DescriptorName,D006801,10465148,,,4,Humans,N,
613,DescriptorName,D007278,10465148,,,5,"Injections, Spinal",N,
614,DescriptorName,D008279,10465148,,,6,Magnetic Resonance Imaging,N,
615,DescriptorName,D008297,10465148,,,7,Male,N,
616,DescriptorName,D008727,10465148,,,8,Methotrexate,N,
617,QualifierName,Q000009,10465148,,,8,,Y,adverse effects
618,DescriptorName,D010291,10465148,,,9,Paresis,N,
619,QualifierName,Q000209,10465148,,,9,,Y,etiology
620,DescriptorName,D010523,10465148,,,10,Peripheral Nervous System Diseases,N,
621,QualifierName,Q000209,10465148,,,10,,Y,etiology
622,DescriptorName,D054198,10465148,,,11,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
623,QualifierName,Q000188,10465148,,,11,,N,drug therapy
624,DescriptorName,D013126,10465148,,,12,Spinal Nerve Roots,N,
625,QualifierName,Q000473,10465148,,,12,,Y,pathology
626,Chemical,D000970,10466445,Antineoplastic Agents,0,,,,
627,Chemical,D001152,10466445,Arsenicals,0,,,,
628,Chemical,D010087,10466445,Oxides,0,,,,
629,Chemical,D014212,10466445,Tretinoin,5688UTC01R,,,,
630,Chemical,D000077237,10466445,Arsenic Trioxide,S7V92P67HO,,,,
631,DescriptorName,D000970,10466445,,,1,Antineoplastic Agents,N,
632,QualifierName,Q000009,10466445,,,1,,N,adverse effects
633,DescriptorName,D000077237,10466445,,,2,Arsenic Trioxide,N,
634,DescriptorName,D001152,10466445,,,3,Arsenicals,N,
635,QualifierName,Q000009,10466445,,,3,,N,adverse effects
636,DescriptorName,D001853,10466445,,,4,Bone Marrow,N,
637,QualifierName,Q000378,10466445,,,4,,N,metabolism
638,DescriptorName,D002871,10466445,,,5,Chromosome Banding,N,
639,DescriptorName,D003114,10466445,,,6,Colony-Forming Units Assay,N,
640,DescriptorName,D019008,10466445,,,7,"Drug Resistance, Neoplasm",N,
641,DescriptorName,D001068,10466445,,,8,Feeding and Eating Disorders,N,
642,QualifierName,Q000139,10466445,,,8,,N,chemically induced
643,DescriptorName,D005260,10466445,,,9,Female,N,
644,DescriptorName,D006801,10466445,,,10,Humans,N,
645,DescriptorName,D015473,10466445,,,11,"Leukemia, Promyelocytic, Acute",N,
646,QualifierName,Q000188,10466445,,,11,,Y,drug therapy
647,DescriptorName,D007958,10466445,,,12,Leukocyte Count,N,
648,QualifierName,Q000187,10466445,,,12,,N,drug effects
649,DescriptorName,D008677,10466445,,,13,Metaphase,N,
650,QualifierName,Q000187,10466445,,,13,,N,drug effects
651,DescriptorName,D008875,10466445,,,14,Middle Aged,N,
652,DescriptorName,D009140,10466445,,,15,Musculoskeletal Diseases,N,
653,QualifierName,Q000139,10466445,,,15,,N,chemically induced
654,DescriptorName,D010087,10466445,,,16,Oxides,N,
655,QualifierName,Q000009,10466445,,,16,,N,adverse effects
656,DescriptorName,D010146,10466445,,,17,Pain,N,
657,QualifierName,Q000139,10466445,,,17,,N,chemically induced
658,DescriptorName,D016133,10466445,,,18,Polymerase Chain Reaction,N,
659,DescriptorName,D012008,10466445,,,19,Recurrence,N,
660,DescriptorName,D014212,10466445,,,20,Tretinoin,N,
661,QualifierName,Q000494,10466445,,,20,,Y,pharmacology
662,Chemical,D000900,10467499,Anti-Bacterial Agents,0,,,,
663,Chemical,D008911,10467499,Minocycline,FYY3R43WGO,,,,
664,DescriptorName,D000152,10467499,,,1,Acne Vulgaris,N,
665,QualifierName,Q000188,10467499,,,1,,N,drug therapy
666,DescriptorName,D000328,10467499,,,2,Adult,N,
667,DescriptorName,D000900,10467499,,,3,Anti-Bacterial Agents,N,
668,QualifierName,Q000009,10467499,,,3,,Y,adverse effects
669,DescriptorName,D003937,10467499,,,4,"Diagnosis, Differential",N,
670,DescriptorName,D004342,10467499,,,5,Drug Hypersensitivity,N,
671,QualifierName,Q000175,10467499,,,5,,Y,diagnosis
672,DescriptorName,D006801,10467499,,,6,Humans,N,
673,DescriptorName,D007244,10467499,,,7,Infectious Mononucleosis,N,
674,QualifierName,Q000139,10467499,,,7,,N,chemically induced
675,DescriptorName,D008297,10467499,,,8,Male,N,
676,DescriptorName,D008911,10467499,,,9,Minocycline,N,
677,QualifierName,Q000009,10467499,,,9,,Y,adverse effects
678,DescriptorName,D013577,10467499,,,10,Syndrome,N,
679,Chemical,D000964,10473079,"Antimetabolites, Antineoplastic",0,,,,
680,Chemical,D014498,10473079,Uracil,56HH86ZVCT,,,,
681,Chemical,D010088,10473079,Oxidoreductases,EC 1.-,,,,
682,Chemical,D042943,10473079,Dihydrouracil Dehydrogenase (NADP),EC 1.3.1.2,,,,
683,Chemical,D005472,10473079,Fluorouracil,U3P01618RT,,,,
684,DescriptorName,D000368,10473079,,,1,Aged,N,
685,DescriptorName,D000964,10473079,,,2,"Antimetabolites, Antineoplastic",N,
686,QualifierName,Q000008,10473079,,,2,,N,administration & dosage
687,DescriptorName,D015153,10473079,,,3,"Blotting, Western",N,
688,DescriptorName,D002280,10473079,,,4,"Carcinoma, Basal Cell",N,
689,QualifierName,Q000188,10473079,,,4,,Y,drug therapy
690,DescriptorName,D004252,10473079,,,5,DNA Mutational Analysis,N,
691,DescriptorName,D003967,10473079,,,6,Diarrhea,N,
692,QualifierName,Q000139,10473079,,,6,,N,chemically induced
693,DescriptorName,D042943,10473079,,,7,Dihydrouracil Dehydrogenase (NADP),N,
694,DescriptorName,D005472,10473079,,,8,Fluorouracil,N,
695,QualifierName,Q000008,10473079,,,8,,N,administration & dosage
696,DescriptorName,D006471,10473079,,,9,Gastrointestinal Hemorrhage,N,
697,QualifierName,Q000139,10473079,,,9,,N,chemically induced
698,DescriptorName,D006801,10473079,,,10,Humans,N,
699,DescriptorName,D015212,10473079,,,11,Inflammatory Bowel Diseases,N,
700,QualifierName,Q000139,10473079,,,11,,N,chemically induced
701,DescriptorName,D007963,10473079,,,12,"Leukocytes, Mononuclear",N,
702,QualifierName,Q000201,10473079,,,12,,N,enzymology
703,DescriptorName,D008297,10473079,,,13,Male,N,
704,DescriptorName,D010088,10473079,,,14,Oxidoreductases,N,
705,QualifierName,Q000172,10473079,,,14,,Y,deficiency
706,DescriptorName,D016133,10473079,,,15,Polymerase Chain Reaction,N,
707,DescriptorName,D017384,10473079,,,16,Sequence Deletion,N,
708,QualifierName,Q000235,10473079,,,16,,N,genetics
709,DescriptorName,D012878,10473079,,,17,Skin Neoplasms,N,
710,QualifierName,Q000188,10473079,,,17,,Y,drug therapy
711,DescriptorName,D014498,10473079,,,18,Uracil,N,
712,QualifierName,Q000097,10473079,,,18,,N,blood
713,Chemical,D018687,10475726,"Antidepressive Agents, Second-Generation",0,,,,
714,Chemical,D003511,10475726,Cyclohexanols,0,,,,
715,Chemical,D012701,10475726,Serotonin,333DO1RDJY,,,,
716,Chemical,D000069470,10475726,Venlafaxine Hydrochloride,7D7RX5A8MO,,,,
717,Chemical,D009638,10475726,Norepinephrine,X4W3ENH1CV,,,,
718,DescriptorName,D000368,10475726,,,1,Aged,N,
719,DescriptorName,D018687,10475726,,,2,"Antidepressive Agents, Second-Generation",N,
720,QualifierName,Q000009,10475726,,,2,,Y,adverse effects
721,DescriptorName,D003326,10475726,,,3,Coronary Circulation,N,
722,QualifierName,Q000187,10475726,,,3,,N,drug effects
723,DescriptorName,D003511,10475726,,,4,Cyclohexanols,N,
724,QualifierName,Q000008,10475726,,,4,,N,administration & dosage
725,DescriptorName,D003865,10475726,,,5,"Depressive Disorder, Major",N,
726,QualifierName,Q000188,10475726,,,5,,Y,drug therapy
727,DescriptorName,D004359,10475726,,,6,"Drug Therapy, Combination",N,
728,DescriptorName,D004562,10475726,,,7,Electrocardiography,N,
729,QualifierName,Q000187,10475726,,,7,,N,drug effects
730,DescriptorName,D005260,10475726,,,8,Female,N,
731,DescriptorName,D006801,10475726,,,9,Humans,N,
732,DescriptorName,D009203,10475726,,,10,Myocardial Infarction,N,
733,QualifierName,Q000139,10475726,,,10,,Y,chemically induced
734,DescriptorName,D009638,10475726,,,11,Norepinephrine,N,
735,QualifierName,Q000502,10475726,,,11,,N,physiology
736,DescriptorName,D010974,10475726,,,12,Platelet Aggregation,N,
737,QualifierName,Q000187,10475726,,,12,,N,drug effects
738,DescriptorName,D012701,10475726,,,13,Serotonin,N,
739,QualifierName,Q000502,10475726,,,13,,N,physiology
740,DescriptorName,D000069470,10475726,,,14,Venlafaxine Hydrochloride,N,
741,Chemical,D013723,10482872,Teratogens,0,,,,
742,Chemical,D003520,10482872,Cyclophosphamide,8N3DW7272P,,,,
743,DescriptorName,D000015,10482872,,,1,"Abnormalities, Multiple",N,
744,QualifierName,Q000139,10482872,,,1,,Y,chemically induced
745,DescriptorName,D000328,10482872,,,2,Adult,N,
746,DescriptorName,D000818,10482872,,,3,Animals,N,
747,DescriptorName,D016569,10482872,,,4,Blepharophimosis,N,
748,QualifierName,Q000139,10482872,,,4,,N,chemically induced
749,DescriptorName,D003398,10482872,,,5,Craniosynostoses,N,
750,QualifierName,Q000139,10482872,,,5,,N,chemically induced
751,DescriptorName,D003520,10482872,,,6,Cyclophosphamide,N,
752,QualifierName,Q000009,10482872,,,6,,Y,adverse effects
753,DescriptorName,D002658,10482872,,,7,Developmental Disabilities,N,
754,QualifierName,Q000139,10482872,,,7,,N,chemically induced
755,DescriptorName,D004431,10482872,,,8,"Ear, External",N,
756,QualifierName,Q000002,10482872,,,8,,N,abnormalities
757,DescriptorName,D005260,10482872,,,9,Female,N,
758,DescriptorName,D006130,10482872,,,10,Growth Disorders,N,
759,QualifierName,Q000139,10482872,,,10,,N,chemically induced
760,DescriptorName,D006801,10482872,,,11,Humans,N,
761,DescriptorName,D007231,10482872,,,12,"Infant, Newborn",N,
762,DescriptorName,D017880,10482872,,,13,"Limb Deformities, Congenital",N,
763,QualifierName,Q000139,10482872,,,13,,N,chemically induced
764,DescriptorName,D008180,10482872,,,14,"Lupus Erythematosus, Systemic",N,
765,QualifierName,Q000150,10482872,,,14,,N,complications
766,DescriptorName,D008431,10482872,,,15,Maternal-Fetal Exchange,N,
767,DescriptorName,D010641,10482872,,,16,Phenotype,N,
768,DescriptorName,D011247,10482872,,,17,Pregnancy,N,
769,DescriptorName,D011248,10482872,,,18,Pregnancy Complications,N,
770,QualifierName,Q000188,10482872,,,18,,N,drug therapy
771,DescriptorName,D013723,10482872,,,19,Teratogens,N,
772,QualifierName,Q000633,10482872,,,19,,N,toxicity
773,Chemical,D000927,10487084,Anticonvulsants,0,,,,
774,Chemical,D010672,10487084,Phenytoin,6158TKW0C5,,,,
775,DescriptorName,D000328,10487084,,,1,Adult,N,
776,DescriptorName,D000927,10487084,,,2,Anticonvulsants,N,
777,QualifierName,Q000009,10487084,,,2,,Y,adverse effects
778,DescriptorName,D004305,10487084,,,3,"Dose-Response Relationship, Drug",N,
779,DescriptorName,D004827,10487084,,,4,Epilepsy,N,
780,QualifierName,Q000097,10487084,,,4,,N,blood
781,DescriptorName,D005260,10487084,,,5,Female,N,
782,DescriptorName,D006801,10487084,,,6,Humans,N,
783,DescriptorName,D008297,10487084,,,7,Male,N,
784,DescriptorName,D008875,10487084,,,8,Middle Aged,N,
785,DescriptorName,D010672,10487084,,,9,Phenytoin,N,
786,QualifierName,Q000009,10487084,,,9,,Y,adverse effects
787,DescriptorName,D012307,10487084,,,10,Risk Factors,N,
788,DescriptorName,D012640,10487084,,,11,Seizures,N,
789,QualifierName,Q000097,10487084,,,11,,N,blood
790,Chemical,D000959,10492493,Antihypertensive Agents,0,,,,
791,Chemical,D019808,10492493,Losartan,JMS50MPO89,,,,
792,DescriptorName,D000799,10492493,,,1,Angioedema,N,
793,QualifierName,Q000139,10492493,,,1,,Y,chemically induced
794,DescriptorName,D000959,10492493,,,2,Antihypertensive Agents,N,
795,QualifierName,Q000009,10492493,,,2,,Y,adverse effects
796,DescriptorName,D006073,10492493,,,3,Gout,N,
797,QualifierName,Q000188,10492493,,,3,,N,drug therapy
798,DescriptorName,D006801,10492493,,,4,Humans,N,
799,DescriptorName,D006973,10492493,,,5,Hypertension,N,
800,QualifierName,Q000188,10492493,,,5,,N,drug therapy
801,DescriptorName,D019808,10492493,,,6,Losartan,N,
802,QualifierName,Q000009,10492493,,,6,,Y,adverse effects
803,DescriptorName,D008297,10492493,,,7,Male,N,
804,DescriptorName,D008875,10492493,,,8,Middle Aged,N,
805,Chemical,D004965,10494874,Estrogen Antagonists,0,,,,
806,Chemical,D019382,10494874,Human Growth Hormone,12629-01-5,,,,
807,Chemical,D007334,10494874,Insulin-Like Growth Factor I,67763-96-6,,,,
808,Chemical,D003613,10494874,Danazol,N29QWW3BUO,,,,
809,Chemical,D015282,10494874,Octreotide,RWM8CCW8GP,,,,
810,DescriptorName,D000172,10494874,,,1,Acromegaly,N,
811,QualifierName,Q000150,10494874,,,1,,Y,complications
812,DescriptorName,D000236,10494874,,,2,Adenoma,N,
813,QualifierName,Q000139,10494874,,,2,,Y,chemically induced
814,DescriptorName,D000328,10494874,,,3,Adult,N,
815,DescriptorName,D003613,10494874,,,4,Danazol,N,
816,QualifierName,Q000009,10494874,,,4,,Y,adverse effects
817,DescriptorName,D004965,10494874,,,5,Estrogen Antagonists,N,
818,QualifierName,Q000009,10494874,,,5,,Y,adverse effects
819,DescriptorName,D005260,10494874,,,6,Female,N,
820,DescriptorName,D019382,10494874,,,7,Human Growth Hormone,N,
821,QualifierName,Q000378,10494874,,,7,,N,metabolism
822,DescriptorName,D006801,10494874,,,8,Humans,N,
823,DescriptorName,D007334,10494874,,,9,Insulin-Like Growth Factor I,N,
824,QualifierName,Q000378,10494874,,,9,,N,metabolism
825,DescriptorName,D007889,10494874,,,10,Leiomyoma,N,
826,QualifierName,Q000188,10494874,,,10,,N,drug therapy
827,DescriptorName,D008113,10494874,,,11,Liver Neoplasms,N,
828,QualifierName,Q000139,10494874,,,11,,Y,chemically induced
829,DescriptorName,D015282,10494874,,,12,Octreotide,N,
830,QualifierName,Q000627,10494874,,,12,,N,therapeutic use
831,DescriptorName,D010911,10494874,,,13,Pituitary Neoplasms,N,
832,QualifierName,Q000601,10494874,,,13,,N,surgery
833,DescriptorName,D014594,10494874,,,14,Uterine Neoplasms,N,
834,QualifierName,Q000188,10494874,,,14,,N,drug therapy
835,Chemical,D000925,10510017,Anticoagulants,0,,,,
836,Chemical,D004338,10510017,Drug Combinations,0,,,,
837,Chemical,D003871,10510017,Dermatan Sulfate,24967-94-0,,,,
838,Chemical,D006493,10510017,Heparin,9005-49-6,,,,
839,Chemical,D002809,10510017,Chondroitin Sulfates,9007-28-7,,,,
840,Chemical,D006497,10510017,Heparitin Sulfate,9050-30-0,,,,
841,Chemical,C035838,10510017,danaparoid,BI6GY4U9CW,,,,
842,DescriptorName,D000925,10510017,,,1,Anticoagulants,N,
843,QualifierName,Q000009,10510017,,,1,,Y,adverse effects
844,DescriptorName,D002315,10510017,,,2,Cardiopulmonary Bypass,N,
845,DescriptorName,D002675,10510017,,,3,"Child, Preschool",N,
846,DescriptorName,D002809,10510017,,,4,Chondroitin Sulfates,N,
847,QualifierName,Q000627,10510017,,,4,,Y,therapeutic use
848,DescriptorName,D003871,10510017,,,5,Dermatan Sulfate,N,
849,QualifierName,Q000627,10510017,,,5,,Y,therapeutic use
850,DescriptorName,D004338,10510017,,,6,Drug Combinations,N,
851,DescriptorName,D005260,10510017,,,7,Female,N,
852,DescriptorName,D006330,10510017,,,8,"Heart Defects, Congenital",N,
853,QualifierName,Q000601,10510017,,,8,,N,surgery
854,DescriptorName,D006470,10510017,,,9,Hemorrhage,N,
855,QualifierName,Q000188,10510017,,,9,,N,drug therapy
856,DescriptorName,D006493,10510017,,,10,Heparin,N,
857,QualifierName,Q000009,10510017,,,10,,Y,adverse effects
858,DescriptorName,D006497,10510017,,,11,Heparitin Sulfate,N,
859,QualifierName,Q000627,10510017,,,11,,Y,therapeutic use
860,DescriptorName,D006801,10510017,,,12,Humans,N,
861,DescriptorName,D013921,10510017,,,13,Thrombocytopenia,N,
862,QualifierName,Q000175,10510017,,,13,,Y,diagnosis
863,DescriptorName,D013927,10510017,,,14,Thrombosis,N,
864,QualifierName,Q000188,10510017,,,14,,N,drug therapy
865,Chemical,D000972,10513720,"Antineoplastic Agents, Phytogenic",0,,,,
866,Chemical,D043823,10513720,Taxoids,0,,,,
867,Chemical,D000077143,10513720,Docetaxel,15H5577CQD,,,,
868,Chemical,D017239,10513720,Paclitaxel,P88XT4IS4D,,,,
869,DescriptorName,D000328,10513720,,,1,Adult,N,
870,DescriptorName,D000972,10513720,,,2,"Antineoplastic Agents, Phytogenic",N,
871,QualifierName,Q000009,10513720,,,2,,Y,adverse effects
872,DescriptorName,D001859,10513720,,,3,Bone Neoplasms,N,
873,QualifierName,Q000188,10513720,,,3,,N,drug therapy
874,DescriptorName,D001943,10513720,,,4,Breast Neoplasms,N,
875,QualifierName,Q000473,10513720,,,4,,N,pathology
876,DescriptorName,D000077143,10513720,,,5,Docetaxel,N,
877,DescriptorName,D017809,10513720,,,6,Fatal Outcome,N,
878,DescriptorName,D005260,10513720,,,7,Female,N,
879,DescriptorName,D005902,10513720,,,8,"Glaucoma, Open-Angle",N,
880,QualifierName,Q000139,10513720,,,8,,Y,chemically induced
881,DescriptorName,D006801,10513720,,,9,Humans,N,
882,DescriptorName,D007429,10513720,,,10,Intraocular Pressure,N,
883,QualifierName,Q000187,10513720,,,10,,N,drug effects
884,DescriptorName,D017239,10513720,,,11,Paclitaxel,N,
885,QualifierName,Q000009,10513720,,,11,,Y,adverse effects
886,DescriptorName,D012008,10513720,,,12,Recurrence,N,
887,DescriptorName,D043823,10513720,,,13,Taxoids,Y,
888,Chemical,D002400,10516999,Cathartics,0,,,,
889,Chemical,D010710,10516999,Phosphates,0,,,,
890,Chemical,C018279,10516999,sodium phosphate,SE337SVY37,,,,
891,DescriptorName,D000208,10516999,,,1,Acute Disease,N,
892,DescriptorName,D002400,10516999,,,2,Cathartics,N,
893,QualifierName,Q000009,10516999,,,2,,Y,adverse effects
894,DescriptorName,D003248,10516999,,,3,Constipation,N,
895,QualifierName,Q000097,10516999,,,3,,N,blood
896,DescriptorName,D004733,10516999,,,4,Enema,Y,
897,DescriptorName,D006801,10516999,,,5,Humans,N,
898,DescriptorName,D007676,10516999,,,6,"Kidney Failure, Chronic",N,
899,QualifierName,Q000097,10516999,,,6,,N,blood
900,DescriptorName,D008107,10516999,,,7,Liver Diseases,N,
901,QualifierName,Q000097,10516999,,,7,,N,blood
902,DescriptorName,D008297,10516999,,,8,Male,N,
903,DescriptorName,D008875,10516999,,,9,Middle Aged,N,
904,DescriptorName,D010710,10516999,,,10,Phosphates,N,
905,QualifierName,Q000009,10516999,,,10,,Y,adverse effects
906,Chemical,D000981,10524732,Antiprotozoal Agents,0,,,,
907,Chemical,D009942,10524732,Organometallic Compounds,0,,,,
908,Chemical,D008536,10524732,Meglumine,6HG8UB2MUY,,,,
909,Chemical,D000077485,10524732,Meglumine Antimoniate,75G4TW236W,,,,
910,Chemical,D000638,10524732,Amiodarone,N3RQ532IUT,,,,
911,DescriptorName,D000368,10524732,,,1,Aged,N,
912,DescriptorName,D000638,10524732,,,2,Amiodarone,N,
913,QualifierName,Q000009,10524732,,,2,,Y,adverse effects
914,DescriptorName,D000981,10524732,,,3,Antiprotozoal Agents,N,
915,QualifierName,Q000009,10524732,,,3,,Y,adverse effects
916,DescriptorName,D004562,10524732,,,4,Electrocardiography,N,
917,DescriptorName,D005500,10524732,,,5,Follow-Up Studies,N,
918,DescriptorName,D006801,10524732,,,6,Humans,N,
919,DescriptorName,D007898,10524732,,,7,"Leishmaniasis, Visceral",N,
920,QualifierName,Q000175,10524732,,,7,,N,diagnosis
921,DescriptorName,D008297,10524732,,,8,Male,N,
922,DescriptorName,D008536,10524732,,,9,Meglumine,N,
923,QualifierName,Q000009,10524732,,,9,,Y,adverse effects
924,DescriptorName,D000077485,10524732,,,10,Meglumine Antimoniate,N,
925,DescriptorName,D009942,10524732,,,11,Organometallic Compounds,N,
926,QualifierName,Q000009,10524732,,,11,,Y,adverse effects
927,DescriptorName,D012075,10524732,,,12,"Remission, Spontaneous",N,
928,DescriptorName,D016171,10524732,,,13,Torsades de Pointes,N,
929,QualifierName,Q000139,10524732,,,13,,Y,chemically induced
930,Chemical,D000927,10530201,Anticonvulsants,0,,,,
931,Chemical,D010672,10530201,Phenytoin,6158TKW0C5,,,,
932,DescriptorName,D000293,10530201,,,1,Adolescent,N,
933,DescriptorName,D000927,10530201,,,2,Anticonvulsants,N,
934,QualifierName,Q000009,10530201,,,2,,N,adverse effects
935,DescriptorName,D005260,10530201,,,3,Female,N,
936,DescriptorName,D005887,10530201,,,4,Gingival Neoplasms,N,
937,QualifierName,Q000000981,10530201,,,4,,N,diagnostic imaging
938,DescriptorName,D019214,10530201,,,5,Gingival Overgrowth,N,
939,QualifierName,Q000139,10530201,,,5,,N,chemically induced
940,DescriptorName,D006801,10530201,,,6,Humans,N,
941,DescriptorName,D010672,10530201,,,7,Phenytoin,N,
942,QualifierName,Q000009,10530201,,,7,,N,adverse effects
943,DescriptorName,D011859,10530201,,,8,Radiography,N,
944,DescriptorName,D013341,10530201,,,9,Sturge-Weber Syndrome,N,
945,QualifierName,Q000150,10530201,,,9,,Y,complications
946,Chemical,D018501,10555917,Antirheumatic Agents,0,,,,
947,Chemical,D010396,10555917,Penicillamine,GNN1DV99GX,,,,
948,DescriptorName,D000368,10555917,,,1,Aged,N,
949,DescriptorName,D000740,10555917,,,2,Anemia,N,
950,QualifierName,Q000139,10555917,,,2,,N,chemically induced
951,DescriptorName,D018501,10555917,,,3,Antirheumatic Agents,N,
952,QualifierName,Q000009,10555917,,,3,,Y,adverse effects
953,DescriptorName,D003114,10555917,,,4,Colony-Forming Units Assay,N,
954,DescriptorName,D005260,10555917,,,5,Female,N,
955,DescriptorName,D006410,10555917,,,6,Hematopoiesis,N,
956,QualifierName,Q000187,10555917,,,6,,Y,drug effects
957,DescriptorName,D006801,10555917,,,7,Humans,N,
958,DescriptorName,D010396,10555917,,,8,Penicillamine,N,
959,QualifierName,Q000009,10555917,,,8,,Y,adverse effects
960,DescriptorName,D012595,10555917,,,9,"Scleroderma, Systemic",N,
961,QualifierName,Q000097,10555917,,,9,,N,blood
962,Chemical,D013956,10560960,Antithyroid Agents,0,,,,
963,Chemical,D016179,10560960,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
964,Chemical,D008713,10560960,Methimazole,554Z48XN5E,,,,
965,DescriptorName,D000368,10560960,,,1,Aged,N,
966,DescriptorName,D000380,10560960,,,2,Agranulocytosis,N,
967,QualifierName,Q000139,10560960,,,2,,Y,chemically induced
968,DescriptorName,D013956,10560960,,,3,Antithyroid Agents,N,
969,QualifierName,Q000009,10560960,,,3,,Y,adverse effects
970,DescriptorName,D005260,10560960,,,4,Female,N,
971,DescriptorName,D016179,10560960,,,5,Granulocyte Colony-Stimulating Factor,N,
972,QualifierName,Q000008,10560960,,,5,,N,administration & dosage
973,DescriptorName,D006801,10560960,,,6,Humans,N,
974,DescriptorName,D008713,10560960,,,7,Methimazole,N,
975,QualifierName,Q000009,10560960,,,7,,Y,adverse effects
976,DescriptorName,D013971,10560960,,,8,Thyrotoxicosis,N,
977,QualifierName,Q000188,10560960,,,8,,N,drug therapy
978,DescriptorName,D013997,10560960,,,9,Time Factors,N,
979,Chemical,D002400,10566542,Cathartics,0,,,,
980,Chemical,D004338,10566542,Drug Combinations,0,,,,
981,Chemical,D010710,10566542,Phosphates,0,,,,
982,Chemical,C018279,10566542,sodium phosphate,SE337SVY37,,,,
983,Chemical,D019386,10566542,Alendronate,X1J18R4W8P,,,,
984,DescriptorName,D000328,10566542,,,1,Adult,N,
985,DescriptorName,D019386,10566542,,,2,Alendronate,N,
986,QualifierName,Q000627,10566542,,,2,,Y,therapeutic use
987,DescriptorName,D002400,10566542,,,3,Cathartics,N,
988,QualifierName,Q000009,10566542,,,3,,Y,adverse effects
989,DescriptorName,D003082,10566542,,,4,Colectomy,N,
990,DescriptorName,D003113,10566542,,,5,Colonoscopy,N,
991,QualifierName,Q000379,10566542,,,5,,N,methods
992,DescriptorName,D003424,10566542,,,6,Crohn Disease,N,
993,QualifierName,Q000601,10566542,,,6,,N,surgery
994,DescriptorName,D004338,10566542,,,7,Drug Combinations,N,
995,DescriptorName,D004733,10566542,,,8,Enema,N,
996,DescriptorName,D005260,10566542,,,9,Female,N,
997,DescriptorName,D006801,10566542,,,10,Humans,N,
998,DescriptorName,D006996,10566542,,,11,Hypocalcemia,N,
999,QualifierName,Q000139,10566542,,,11,,Y,chemically induced
1000,DescriptorName,D017674,10566542,,,12,Hypophosphatemia,N,
1001,QualifierName,Q000139,10566542,,,12,,N,chemically induced
1002,DescriptorName,D010024,10566542,,,13,Osteoporosis,N,
1003,QualifierName,Q000188,10566542,,,13,,N,drug therapy
1004,DescriptorName,D010710,10566542,,,14,Phosphates,N,
1005,QualifierName,Q000009,10566542,,,14,,Y,adverse effects
1006,DescriptorName,D011183,10566542,,,15,Postoperative Complications,N,
1007,QualifierName,Q000139,10566542,,,15,,Y,chemically induced
1008,DescriptorName,D013746,10566542,,,16,Tetany,N,
1009,QualifierName,Q000139,10566542,,,16,,Y,chemically induced
1010,Chemical,D000964,10575189,"Antimetabolites, Antineoplastic",0,,,,
1011,Chemical,D003841,10575189,Deoxycytidine,0W860991D6,,,,
1012,Chemical,C056507,10575189,gemcitabine,B76N6SBZ8R,,,,
1013,Chemical,D012264,10575189,Ribonucleotide Reductases,EC 1.17.4.-,,,,
1014,DescriptorName,D000230,10575189,,,1,Adenocarcinoma,N,
1015,QualifierName,Q000188,10575189,,,1,,N,drug therapy
1016,DescriptorName,D000328,10575189,,,2,Adult,N,
1017,DescriptorName,D000964,10575189,,,3,"Antimetabolites, Antineoplastic",N,
1018,QualifierName,Q000009,10575189,,,3,,Y,adverse effects
1019,DescriptorName,D001650,10575189,,,4,Bile Duct Neoplasms,N,
1020,QualifierName,Q000188,10575189,,,4,,N,drug therapy
1021,DescriptorName,D001653,10575189,,,5,"Bile Ducts, Intrahepatic",N,
1022,QualifierName,Q000473,10575189,,,5,,N,pathology
1023,DescriptorName,D001707,10575189,,,6,"Biopsy, Needle",N,
1024,DescriptorName,D018281,10575189,,,7,Cholangiocarcinoma,N,
1025,QualifierName,Q000188,10575189,,,7,,N,drug therapy
1026,DescriptorName,D003841,10575189,,,8,Deoxycytidine,N,
1027,QualifierName,Q000009,10575189,,,8,,N,adverse effects
1028,DescriptorName,D017809,10575189,,,9,Fatal Outcome,N,
1029,DescriptorName,D005260,10575189,,,10,Female,N,
1030,DescriptorName,D006463,10575189,,,11,Hemolytic-Uremic Syndrome,N,
1031,QualifierName,Q000139,10575189,,,11,,Y,chemically induced
1032,DescriptorName,D006801,10575189,,,12,Humans,N,
1033,DescriptorName,D007676,10575189,,,13,"Kidney Failure, Chronic",N,
1034,QualifierName,Q000139,10575189,,,13,,Y,chemically induced
1035,DescriptorName,D007678,10575189,,,14,Kidney Glomerulus,N,
1036,QualifierName,Q000187,10575189,,,14,,Y,drug effects
1037,DescriptorName,D008297,10575189,,,15,Male,N,
1038,DescriptorName,D008875,10575189,,,16,Middle Aged,N,
1039,DescriptorName,D010190,10575189,,,17,Pancreatic Neoplasms,N,
1040,QualifierName,Q000188,10575189,,,17,,N,drug therapy
1041,DescriptorName,D006435,10575189,,,18,Renal Dialysis,N,
1042,DescriptorName,D012264,10575189,,,19,Ribonucleotide Reductases,N,
1043,QualifierName,Q000037,10575189,,,19,,N,antagonists & inhibitors
1044,Chemical,D000911,10579985,"Antibodies, Monoclonal",0,,,,
1045,Chemical,D005765,10579985,Gastrointestinal Agents,0,,,,
1046,Chemical,D000069285,10579985,Infliximab,B72HH48FLU,,,,
1047,DescriptorName,D000328,10579985,,,1,Adult,N,
1048,DescriptorName,D000911,10579985,,,2,"Antibodies, Monoclonal",N,
1049,QualifierName,Q000009,10579985,,,2,,Y,adverse effects
1050,DescriptorName,D003424,10579985,,,3,Crohn Disease,N,
1051,QualifierName,Q000150,10579985,,,3,,Y,complications
1052,DescriptorName,D005765,10579985,,,4,Gastrointestinal Agents,N,
1053,QualifierName,Q000009,10579985,,,4,,Y,adverse effects
1054,DescriptorName,D006801,10579985,,,5,Humans,N,
1055,DescriptorName,D000069285,10579985,,,6,Infliximab,N,
1056,DescriptorName,D008223,10579985,,,7,Lymphoma,N,
1057,QualifierName,Q000139,10579985,,,7,,Y,chemically induced
1058,DescriptorName,D008297,10579985,,,8,Male,N,
1059,DescriptorName,D008875,10579985,,,9,Middle Aged,N,
1060,Chemical,D009294,10586009,Narcotics,0,,,,
1061,Chemical,D003061,10586009,Codeine,Q830PW7520,,,,
1062,DescriptorName,D003061,10586009,,,1,Codeine,N,
1063,QualifierName,Q000506,10586009,,,1,,Y,poisoning
1064,DescriptorName,D003371,10586009,,,2,Cough,N,
1065,QualifierName,Q000188,10586009,,,2,,Y,drug therapy
1066,DescriptorName,D017809,10586009,,,3,Fatal Outcome,N,
1067,DescriptorName,D006801,10586009,,,4,Humans,N,
1068,DescriptorName,D007231,10586009,,,5,"Infant, Newborn",N,
1069,DescriptorName,D008297,10586009,,,6,Male,N,
1070,DescriptorName,D009294,10586009,,,7,Narcotics,N,
1071,QualifierName,Q000506,10586009,,,7,,Y,poisoning
1072,Chemical,D006454,10589077,Hemoglobins,0,,,,
1073,Chemical,D010654,10589077,Phenylbutyrates,0,,,,
1074,Chemical,D005319,10589077,Fetal Hemoglobin,9034-63-3,,,,
1075,Chemical,D006918,10589077,Hydroxyurea,X6Q56QN5QC,,,,
1076,DescriptorName,D000328,10589077,,,1,Adult,N,
1077,DescriptorName,D002160,10589077,,,2,Cambodia,N,
1078,QualifierName,Q000208,10589077,,,2,,N,ethnology
1079,DescriptorName,D002648,10589077,,,3,Child,N,
1080,DescriptorName,D002675,10589077,,,4,"Child, Preschool",N,
1081,DescriptorName,D002681,10589077,,,5,China,N,
1082,QualifierName,Q000208,10589077,,,5,,N,ethnology
1083,DescriptorName,D005260,10589077,,,6,Female,N,
1084,DescriptorName,D005319,10589077,,,7,Fetal Hemoglobin,N,
1085,QualifierName,Q000378,10589077,,,7,,N,metabolism
1086,DescriptorName,D006454,10589077,,,8,Hemoglobins,N,
1087,QualifierName,Q000378,10589077,,,8,,N,metabolism
1088,DescriptorName,D006801,10589077,,,9,Humans,N,
1089,DescriptorName,D006918,10589077,,,10,Hydroxyurea,N,
1090,QualifierName,Q000008,10589077,,,10,,N,administration & dosage
1091,DescriptorName,D007812,10589077,,,11,Laos,N,
1092,QualifierName,Q000208,10589077,,,11,,N,ethnology
1093,DescriptorName,D008297,10589077,,,12,Male,N,
1094,DescriptorName,D010654,10589077,,,13,Phenylbutyrates,N,
1095,QualifierName,Q000008,10589077,,,13,,N,administration & dosage
1096,DescriptorName,D010679,10589077,,,14,Philippines,N,
1097,QualifierName,Q000208,10589077,,,14,,N,ethnology
1098,DescriptorName,D014744,10589077,,,15,Vietnam,N,
1099,QualifierName,Q000208,10589077,,,15,,N,ethnology
1100,DescriptorName,D017086,10589077,,,16,beta-Thalassemia,N,
1101,QualifierName,Q000097,10589077,,,16,,N,blood
1102,Chemical,D013662,10592946,Tea,0,,,,
1103,Chemical,D002110,10592946,Caffeine,3G6A5W338E,,,,
1104,Chemical,D003402,10592946,Creatine Kinase,EC 2.7.3.2,,,,
1105,DescriptorName,D058186,10592946,,,1,Acute Kidney Injury,N,
1106,QualifierName,Q000139,10592946,,,1,,Y,chemically induced
1107,DescriptorName,D000328,10592946,,,2,Adult,N,
1108,DescriptorName,D002110,10592946,,,3,Caffeine,N,
1109,QualifierName,Q000506,10592946,,,3,,Y,poisoning
1110,DescriptorName,D003402,10592946,,,4,Creatine Kinase,N,
1111,QualifierName,Q000097,10592946,,,4,,N,blood
1112,DescriptorName,D003693,10592946,,,5,Delirium,N,
1113,QualifierName,Q000139,10592946,,,5,,N,chemically induced
1114,DescriptorName,D006801,10592946,,,6,Humans,N,
1115,DescriptorName,D007010,10592946,,,7,Hyponatremia,N,
1116,QualifierName,Q000139,10592946,,,7,,Y,chemically induced
1117,DescriptorName,D008297,10592946,,,8,Male,N,
1118,DescriptorName,D012206,10592946,,,9,Rhabdomyolysis,N,
1119,QualifierName,Q000139,10592946,,,9,,Y,chemically induced
1120,DescriptorName,D013662,10592946,,,10,Tea,N,
1121,QualifierName,Q000737,10592946,,,10,,N,chemistry
1122,Chemical,D000928,10599932,Antidepressive Agents,0,,,,
1123,Chemical,D000929,10599932,"Antidepressive Agents, Tricyclic",0,,,,
1124,Chemical,C012273,10599932,desmethylclomipramine,01DN47PPQG,,,,
1125,Chemical,D015283,10599932,Citalopram,0DHU5B8D6V,,,,
1126,Chemical,D019389,10599932,Cytochrome P-450 CYP2D6,EC 1.14.14.1,,,,
1127,Chemical,D002997,10599932,Clomipramine,NUV44L116D,,,,
1128,DescriptorName,D000328,10599932,,,1,Adult,N,
1129,DescriptorName,D000928,10599932,,,2,Antidepressive Agents,N,
1130,QualifierName,Q000009,10599932,,,2,,Y,adverse effects
1131,DescriptorName,D000929,10599932,,,3,"Antidepressive Agents, Tricyclic",N,
1132,QualifierName,Q000009,10599932,,,3,,Y,adverse effects
1133,DescriptorName,D015283,10599932,,,4,Citalopram,N,
1134,QualifierName,Q000009,10599932,,,4,,Y,adverse effects
1135,DescriptorName,D002997,10599932,,,5,Clomipramine,N,
1136,QualifierName,Q000009,10599932,,,5,,Y,adverse effects
1137,DescriptorName,D019389,10599932,,,6,Cytochrome P-450 CYP2D6,N,
1138,QualifierName,Q000235,10599932,,,6,,Y,genetics
1139,DescriptorName,D004347,10599932,,,7,Drug Interactions,N,
1140,DescriptorName,D004359,10599932,,,8,"Drug Therapy, Combination",N,
1141,DescriptorName,D005260,10599932,,,9,Female,N,
1142,DescriptorName,D005838,10599932,,,10,Genotype,N,
1143,DescriptorName,D006801,10599932,,,11,Humans,N,
1144,DescriptorName,D009771,10599932,,,12,Obsessive-Compulsive Disorder,N,
1145,QualifierName,Q000188,10599932,,,12,,N,drug therapy
1146,DescriptorName,D010641,10599932,,,13,Phenotype,N,
1147,Chemical,D017320,10607332,HIV Protease Inhibitors,0,,,,
1148,DescriptorName,D000328,10607332,,,1,Adult,N,
1149,DescriptorName,D018206,10607332,,,2,Angiolipoma,N,
1150,QualifierName,Q000139,10607332,,,2,,Y,chemically induced
1151,DescriptorName,D015658,10607332,,,3,HIV Infections,N,
1152,QualifierName,Q000188,10607332,,,3,,Y,drug therapy
1153,DescriptorName,D017320,10607332,,,4,HIV Protease Inhibitors,N,
1154,QualifierName,Q000009,10607332,,,4,,Y,adverse effects
1155,DescriptorName,D015497,10607332,,,5,HIV-1,Y,
1156,DescriptorName,D006801,10607332,,,6,Humans,N,
1157,DescriptorName,D008297,10607332,,,7,Male,N,
1158,DescriptorName,D008875,10607332,,,8,Middle Aged,N,
1159,DescriptorName,D012983,10607332,,,9,Soft Tissue Neoplasms,N,
1160,QualifierName,Q000139,10607332,,,9,,Y,chemically induced
1161,Chemical,D014150,10610018,Antipsychotic Agents,0,,,,
1162,Chemical,D014280,10610018,Triglycerides,0,,,,
1163,Chemical,D003024,10610018,Clozapine,J60AR2IKIC,,,,
1164,Chemical,D018967,10610018,Risperidone,L6UH7ZF8HC,,,,
1165,DescriptorName,D000328,10610018,,,1,Adult,N,
1166,DescriptorName,D014150,10610018,,,2,Antipsychotic Agents,N,
1167,QualifierName,Q000009,10610018,,,2,,Y,adverse effects
1168,DescriptorName,D003024,10610018,,,3,Clozapine,N,
1169,QualifierName,Q000009,10610018,,,3,,Y,adverse effects
1170,DescriptorName,D006801,10610018,,,4,Humans,N,
1171,DescriptorName,D008297,10610018,,,5,Male,N,
1172,DescriptorName,D011618,10610018,,,6,Psychotic Disorders,N,
1173,QualifierName,Q000097,10610018,,,6,,Y,blood
1174,DescriptorName,D012307,10610018,,,7,Risk Factors,N,
1175,DescriptorName,D018967,10610018,,,8,Risperidone,N,
1176,QualifierName,Q000627,10610018,,,8,,Y,therapeutic use
1177,DescriptorName,D014280,10610018,,,9,Triglycerides,N,
1178,QualifierName,Q000097,10610018,,,9,,Y,blood
1179,Chemical,D000927,10614572,Anticonvulsants,0,,,,
1180,Chemical,D014635,10614572,Valproic Acid,614OI1Z5WI,,,,
1181,DescriptorName,D000927,10614572,,,1,Anticonvulsants,N,
1182,QualifierName,Q000008,10614572,,,1,,N,administration & dosage
1183,DescriptorName,D002648,10614572,,,2,Child,N,
1184,DescriptorName,D005260,10614572,,,3,Female,N,
1185,DescriptorName,D005440,10614572,,,4,Fluid Therapy,N,
1186,DescriptorName,D006801,10614572,,,5,Humans,N,
1187,DescriptorName,D007022,10614572,,,6,Hypotension,N,
1188,QualifierName,Q000139,10614572,,,6,,Y,chemically induced
1189,DescriptorName,D007262,10614572,,,7,"Infusions, Intravenous",N,
1190,DescriptorName,D013226,10614572,,,8,Status Epilepticus,N,
1191,QualifierName,Q000188,10614572,,,8,,Y,drug therapy
1192,DescriptorName,D014635,10614572,,,9,Valproic Acid,N,
1193,QualifierName,Q000008,10614572,,,9,,N,administration & dosage
1194,Chemical,D007166,10619721,Immunosuppressive Agents,0,,,,
1195,Chemical,D011729,10619721,Pyridostigmine Bromide,KVI301NA53,,,,
1196,Chemical,D001379,10619721,Azathioprine,MRK240IY2L,,,,
1197,DescriptorName,D000328,10619721,,,1,Adult,N,
1198,DescriptorName,D001379,10619721,,,2,Azathioprine,N,
1199,QualifierName,Q000627,10619721,,,2,,Y,therapeutic use
1200,DescriptorName,D006801,10619721,,,3,Humans,N,
1201,DescriptorName,D007166,10619721,,,4,Immunosuppressive Agents,N,
1202,QualifierName,Q000627,10619721,,,4,,Y,therapeutic use
1203,DescriptorName,D008297,10619721,,,5,Male,N,
1204,DescriptorName,D008875,10619721,,,6,Middle Aged,N,
1205,DescriptorName,D009119,10619721,,,7,Muscle Contraction,N,
1206,DescriptorName,D009135,10619721,,,8,Muscular Diseases,N,
1207,QualifierName,Q000188,10619721,,,8,,Y,drug therapy
1208,DescriptorName,D009157,10619721,,,9,Myasthenia Gravis,N,
1209,QualifierName,Q000150,10619721,,,9,,Y,complications
1210,DescriptorName,D010812,10619721,,,10,Physical Stimulation,N,
1211,DescriptorName,D011729,10619721,,,11,Pyridostigmine Bromide,N,
1212,QualifierName,Q000009,10619721,,,11,,N,adverse effects
1213,Chemical,D001786,10633877,Blood Glucose,0,,,,
1214,Chemical,D007328,10633877,Insulin,0,,,,
1215,Chemical,D013806,10633877,Theophylline,C137DTR5RG,,,,
1216,DescriptorName,D000328,10633877,,,1,Adult,N,
1217,DescriptorName,D001786,10633877,,,2,Blood Glucose,N,
1218,QualifierName,Q000378,10633877,,,2,,N,metabolism
1219,DescriptorName,D002675,10633877,,,3,"Child, Preschool",N,
1220,DescriptorName,D016883,10633877,,,4,Diabetic Ketoacidosis,N,
1221,QualifierName,Q000175,10633877,,,4,,Y,diagnosis
1222,DescriptorName,D003937,10633877,,,5,"Diagnosis, Differential",N,
1223,DescriptorName,D005500,10633877,,,6,Follow-Up Studies,N,
1224,DescriptorName,D005951,10633877,,,7,Glucose Tolerance Test,N,
1225,DescriptorName,D006396,10633877,,,8,Hematemesis,N,
1226,DescriptorName,D006801,10633877,,,9,Humans,N,
1227,DescriptorName,D006943,10633877,,,10,Hyperglycemia,N,
1228,QualifierName,Q000139,10633877,,,10,,N,chemically induced
1229,DescriptorName,D007328,10633877,,,11,Insulin,N,
1230,QualifierName,Q000627,10633877,,,11,,N,therapeutic use
1231,DescriptorName,D008297,10633877,,,12,Male,N,
1232,DescriptorName,D009325,10633877,,,13,Nausea,N,
1233,DescriptorName,D010146,10633877,,,14,Pain,N,
1234,DescriptorName,D011041,10633877,,,15,Poisoning,N,
1235,QualifierName,Q000097,10633877,,,15,,N,blood
1236,DescriptorName,D013610,10633877,,,16,Tachycardia,N,
1237,DescriptorName,D013806,10633877,,,17,Theophylline,N,
1238,QualifierName,Q000506,10633877,,,17,,Y,poisoning
1239,Chemical,D018906,10646879,"Antineoplastic Agents, Alkylating",0,,,,
1240,Chemical,D004791,10646879,Enzyme Inhibitors,0,,,,
1241,Chemical,D008751,10646879,Methylene Blue,T42P99266K,,,,
1242,Chemical,D007069,10646879,Ifosfamide,UM20QQM95Y,,,,
1243,DescriptorName,D000293,10646879,,,1,Adolescent,N,
1244,DescriptorName,D000328,10646879,,,2,Adult,N,
1245,DescriptorName,D000368,10646879,,,3,Aged,N,
1246,DescriptorName,D018906,10646879,,,4,"Antineoplastic Agents, Alkylating",N,
1247,QualifierName,Q000009,10646879,,,4,,Y,adverse effects
1248,DescriptorName,D001927,10646879,,,5,Brain Diseases,N,
1249,QualifierName,Q000139,10646879,,,5,,Y,chemically induced
1250,DescriptorName,D004305,10646879,,,6,"Dose-Response Relationship, Drug",N,
1251,DescriptorName,D004791,10646879,,,7,Enzyme Inhibitors,N,
1252,QualifierName,Q000494,10646879,,,7,,N,pharmacology
1253,DescriptorName,D005260,10646879,,,8,Female,N,
1254,DescriptorName,D006801,10646879,,,9,Humans,N,
1255,DescriptorName,D007069,10646879,,,10,Ifosfamide,N,
1256,QualifierName,Q000009,10646879,,,10,,Y,adverse effects
1257,DescriptorName,D007262,10646879,,,11,"Infusions, Intravenous",N,
1258,DescriptorName,D008297,10646879,,,12,Male,N,
1259,DescriptorName,D008751,10646879,,,13,Methylene Blue,N,
1260,QualifierName,Q000494,10646879,,,13,,N,pharmacology
1261,DescriptorName,D008875,10646879,,,14,Middle Aged,N,
1262,DescriptorName,D009369,10646879,,,15,Neoplasms,N,
1263,QualifierName,Q000188,10646879,,,15,,N,drug therapy
1264,DescriptorName,D016896,10646879,,,16,Treatment Outcome,N,
1265,Chemical,D000925,10650865,Anticoagulants,0,,,,
1266,Chemical,D003029,10650865,Coagulants,0,,,,
1267,Chemical,D005165,10650865,Factor V,9001-24-5,,,,
1268,Chemical,D005169,10650865,Factor VIII,9001-27-8,,,,
1269,Chemical,D006493,10650865,Heparin,9005-49-6,,,,
1270,DescriptorName,D000293,10650865,,,1,Adolescent,N,
1271,DescriptorName,D000925,10650865,,,2,Anticoagulants,N,
1272,QualifierName,Q000627,10650865,,,2,,N,therapeutic use
1273,DescriptorName,D003029,10650865,,,3,Coagulants,N,
1274,QualifierName,Q000009,10650865,,,3,,N,adverse effects
1275,DescriptorName,D005165,10650865,,,4,Factor V,N,
1276,QualifierName,Q000235,10650865,,,4,,Y,genetics
1277,DescriptorName,D005169,10650865,,,5,Factor VIII,N,
1278,QualifierName,Q000009,10650865,,,5,,N,adverse effects
1279,DescriptorName,D006471,10650865,,,6,Gastrointestinal Hemorrhage,N,
1280,QualifierName,Q000188,10650865,,,6,,N,drug therapy
1281,DescriptorName,D006467,10650865,,,7,Hemophilia A,N,
1282,QualifierName,Q000150,10650865,,,7,,Y,complications
1283,DescriptorName,D006493,10650865,,,8,Heparin,N,
1284,QualifierName,Q000627,10650865,,,8,,N,therapeutic use
1285,DescriptorName,D006801,10650865,,,9,Humans,N,
1286,DescriptorName,D007262,10650865,,,10,"Infusions, Intravenous",N,
1287,QualifierName,Q000009,10650865,,,10,,N,adverse effects
1288,DescriptorName,D007579,10650865,,,11,Jejunal Diseases,N,
1289,QualifierName,Q000188,10650865,,,11,,N,drug therapy
1290,DescriptorName,D008297,10650865,,,12,Male,N,
1291,DescriptorName,D011169,10650865,,,13,Portal Vein,Y,
1292,DescriptorName,D019851,10650865,,,14,Thrombophilia,N,
1293,QualifierName,Q000150,10650865,,,14,,Y,complications
1294,DescriptorName,D020246,10650865,,,15,Venous Thrombosis,N,
1295,QualifierName,Q000150,10650865,,,15,,Y,complications
1296,Chemical,D007004,10656221,Hypoglycemic Agents,0,,,,
1297,Chemical,D005907,10656221,Gliclazide,G4PX8C4HKV,,,,
1298,DescriptorName,D056486,10656221,,,1,Chemical and Drug Induced Liver Injury,N,
1299,QualifierName,Q000175,10656221,,,1,,Y,diagnosis
1300,DescriptorName,D003924,10656221,,,2,"Diabetes Mellitus, Type 2",N,
1301,QualifierName,Q000188,10656221,,,2,,Y,drug therapy
1302,DescriptorName,D003937,10656221,,,3,"Diagnosis, Differential",N,
1303,DescriptorName,D005260,10656221,,,4,Female,N,
1304,DescriptorName,D005907,10656221,,,5,Gliclazide,N,
1305,QualifierName,Q000009,10656221,,,5,,Y,adverse effects
1306,DescriptorName,D006801,10656221,,,6,Humans,N,
1307,DescriptorName,D007004,10656221,,,7,Hypoglycemic Agents,N,
1308,QualifierName,Q000009,10656221,,,7,,Y,adverse effects
1309,DescriptorName,D008099,10656221,,,8,Liver,N,
1310,QualifierName,Q000473,10656221,,,8,,N,pathology
1311,DescriptorName,D008875,10656221,,,9,Middle Aged,N,
1312,Chemical,D000893,10667036,Anti-Inflammatory Agents,0,,,,
1313,Chemical,D006727,10667036,Hormone Antagonists,0,,,,
1314,Chemical,D015735,10667036,Mifepristone,320T6RNW1F,,,,
1315,Chemical,D014222,10667036,Triamcinolone Acetonide,F446C597KA,,,,
1316,DescriptorName,D000893,10667036,,,1,Anti-Inflammatory Agents,N,
1317,QualifierName,Q000008,10667036,,,1,,N,administration & dosage
1318,DescriptorName,D002062,10667036,,,2,Bursitis,N,
1319,QualifierName,Q000188,10667036,,,2,,N,drug therapy
1320,DescriptorName,D003480,10667036,,,3,Cushing Syndrome,N,
1321,QualifierName,Q000139,10667036,,,3,,Y,chemically induced
1322,DescriptorName,D062787,10667036,,,4,Drug Overdose,N,
1323,DescriptorName,D005260,10667036,,,5,Female,N,
1324,DescriptorName,D006727,10667036,,,6,Hormone Antagonists,N,
1325,QualifierName,Q000627,10667036,,,6,,N,therapeutic use
1326,DescriptorName,D006801,10667036,,,7,Humans,N,
1327,DescriptorName,D007270,10667036,,,8,"Injections, Intra-Articular",N,
1328,DescriptorName,D008508,10667036,,,9,Medication Errors,Y,
1329,DescriptorName,D008875,10667036,,,10,Middle Aged,N,
1330,DescriptorName,D015735,10667036,,,11,Mifepristone,N,
1331,QualifierName,Q000627,10667036,,,11,,N,therapeutic use
1332,DescriptorName,D014222,10667036,,,12,Triamcinolone Acetonide,N,
1333,QualifierName,Q000008,10667036,,,12,,N,administration & dosage
1334,Chemical,D000892,10679548,"Anti-Infective Agents, Urinary",0,,,,
1335,Chemical,D000893,10679548,Anti-Inflammatory Agents,0,,,,
1336,Chemical,D009582,10679548,Nitrofurantoin,927AH8112L,,,,
1337,Chemical,D011241,10679548,Prednisone,VB0R961HZT,,,,
1338,DescriptorName,D000328,10679548,,,1,Adult,N,
1339,DescriptorName,D000892,10679548,,,2,"Anti-Infective Agents, Urinary",N,
1340,QualifierName,Q000009,10679548,,,2,,Y,adverse effects
1341,DescriptorName,D000893,10679548,,,3,Anti-Inflammatory Agents,N,
1342,QualifierName,Q000627,10679548,,,3,,N,therapeutic use
1343,DescriptorName,D018549,10679548,,,4,Cryptogenic Organizing Pneumonia,N,
1344,QualifierName,Q000139,10679548,,,4,,Y,chemically induced
1345,DescriptorName,D005260,10679548,,,5,Female,N,
1346,DescriptorName,D005541,10679548,,,6,Forced Expiratory Volume,N,
1347,DescriptorName,D006801,10679548,,,7,Humans,N,
1348,DescriptorName,D008875,10679548,,,8,Middle Aged,N,
1349,DescriptorName,D009582,10679548,,,9,Nitrofurantoin,N,
1350,QualifierName,Q000009,10679548,,,9,,Y,adverse effects
1351,DescriptorName,D011241,10679548,,,10,Prednisone,N,
1352,QualifierName,Q000627,10679548,,,10,,N,therapeutic use
1353,DescriptorName,D014057,10679548,,,11,"Tomography, X-Ray Computed",N,
1354,DescriptorName,D014797,10679548,,,12,Vital Capacity,N,
1355,Chemical,D000998,10682234,Antiviral Agents,0,,,,
1356,Chemical,D015259,10682234,Dopamine Agents,0,,,,
1357,Chemical,D016898,10682234,Interferon-alpha,0,,,,
1358,Chemical,D007980,10682234,Levodopa,46627O600J,,,,
1359,DescriptorName,D000328,10682234,,,1,Adult,N,
1360,DescriptorName,D000998,10682234,,,2,Antiviral Agents,N,
1361,QualifierName,Q000009,10682234,,,2,,Y,adverse effects
1362,DescriptorName,D015259,10682234,,,3,Dopamine Agents,N,
1363,QualifierName,Q000627,10682234,,,3,,Y,therapeutic use
1364,DescriptorName,D004409,10682234,,,4,"Dyskinesia, Drug-Induced",N,
1365,QualifierName,Q000188,10682234,,,4,,Y,drug therapy
1366,DescriptorName,D019694,10682234,,,5,"Hepatitis B, Chronic",N,
1367,QualifierName,Q000188,10682234,,,5,,N,drug therapy
1368,DescriptorName,D006801,10682234,,,6,Humans,N,
1369,DescriptorName,D007275,10682234,,,7,"Injections, Intravenous",N,
1370,DescriptorName,D016898,10682234,,,8,Interferon-alpha,N,
1371,QualifierName,Q000009,10682234,,,8,,Y,adverse effects
1372,DescriptorName,D007980,10682234,,,9,Levodopa,N,
1373,QualifierName,Q000627,10682234,,,9,,Y,therapeutic use
1374,DescriptorName,D008297,10682234,,,10,Male,N,
1375,Chemical,D003520,1068531,Cyclophosphamide,8N3DW7272P,,,,
1376,DescriptorName,D001859,1068531,,,1,Bone Neoplasms,N,
1377,QualifierName,Q000188,1068531,,,1,,N,drug therapy
1378,DescriptorName,D002277,1068531,,,2,Carcinoma,N,
1379,QualifierName,Q000532,1068531,,,2,,N,radiotherapy
1380,DescriptorName,D002294,1068531,,,3,"Carcinoma, Squamous Cell",N,
1381,QualifierName,Q000601,1068531,,,3,,N,surgery
1382,DescriptorName,D003520,1068531,,,4,Cyclophosphamide,N,
1383,QualifierName,Q000009,1068531,,,4,,Y,adverse effects
1384,DescriptorName,D004359,1068531,,,5,"Drug Therapy, Combination",N,
1385,DescriptorName,D004428,1068531,,,6,Ear Neoplasms,N,
1386,QualifierName,Q000601,1068531,,,6,,N,surgery
1387,DescriptorName,D004431,1068531,,,7,"Ear, External",N,
1388,QualifierName,Q000601,1068531,,,7,,N,surgery
1389,DescriptorName,D006801,1068531,,,8,Humans,N,
1390,DescriptorName,D004915,1068531,,,9,"Leukemia, Erythroblastic, Acute",N,
1391,QualifierName,Q000139,1068531,,,9,,Y,chemically induced
1392,DescriptorName,D008297,1068531,,,10,Male,N,
1393,DescriptorName,D008875,1068531,,,11,Middle Aged,N,
1394,DescriptorName,D009101,1068531,,,12,Multiple Myeloma,N,
1395,QualifierName,Q000188,1068531,,,12,,Y,drug therapy
1396,DescriptorName,D009364,1068531,,,13,"Neoplasm Recurrence, Local",N,
1397,QualifierName,Q000532,1068531,,,13,,N,radiotherapy
1398,DescriptorName,D009378,1068531,,,14,"Neoplasms, Multiple Primary",N,
1399,DescriptorName,D011879,1068531,,,15,Radiotherapy Dosage,N,
1400,DescriptorName,D001749,1068531,,,16,Urinary Bladder Neoplasms,N,
1401,QualifierName,Q000532,1068531,,,16,,N,radiotherapy
1402,Chemical,D000964,10688731,"Antimetabolites, Antineoplastic",0,,,,
1403,Chemical,D005641,10688731,Tegafur,1548R74NSZ,,,,
1404,Chemical,D014498,10688731,Uracil,56HH86ZVCT,,,,
1405,DescriptorName,D000964,10688731,,,1,"Antimetabolites, Antineoplastic",N,
1406,QualifierName,Q000009,10688731,,,1,,Y,adverse effects
1407,DescriptorName,D000971,10688731,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
1408,QualifierName,Q000009,10688731,,,2,,Y,adverse effects
1409,DescriptorName,D006801,10688731,,,3,Humans,N,
1410,DescriptorName,D008297,10688731,,,4,Male,N,
1411,DescriptorName,D008875,10688731,,,5,Middle Aged,N,
1412,DescriptorName,D012595,10688731,,,6,"Scleroderma, Systemic",N,
1413,QualifierName,Q000139,10688731,,,6,,Y,chemically induced
1414,DescriptorName,D013274,10688731,,,7,Stomach Neoplasms,N,
1415,QualifierName,Q000188,10688731,,,7,,N,drug therapy
1416,DescriptorName,D005641,10688731,,,8,Tegafur,N,
1417,QualifierName,Q000009,10688731,,,8,,Y,adverse effects
1418,DescriptorName,D014498,10688731,,,9,Uracil,N,
1419,QualifierName,Q000009,10688731,,,9,,Y,adverse effects
1420,Chemical,D000894,10698143,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
1421,Chemical,D000931,10698143,Antidotes,0,,,,
1422,Chemical,D009270,10698143,Naloxone,36B82AMQ7N,,,,
1423,Chemical,D007052,10698143,Ibuprofen,WK2XYI10QM,,,,
1424,DescriptorName,D000138,10698143,,,1,Acidosis,N,
1425,QualifierName,Q000139,10698143,,,1,,N,chemically induced
1426,DescriptorName,D000894,10698143,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
1427,QualifierName,Q000506,10698143,,,2,,Y,poisoning
1428,DescriptorName,D000931,10698143,,,3,Antidotes,N,
1429,QualifierName,Q000494,10698143,,,3,,N,pharmacology
1430,DescriptorName,D002490,10698143,,,4,Central Nervous System,N,
1431,QualifierName,Q000187,10698143,,,4,,Y,drug effects
1432,DescriptorName,D002493,10698143,,,5,Central Nervous System Diseases,N,
1433,QualifierName,Q000139,10698143,,,5,,N,chemically induced
1434,DescriptorName,D062787,10698143,,,6,Drug Overdose,N,
1435,QualifierName,Q000188,10698143,,,6,,N,drug therapy
1436,DescriptorName,D005260,10698143,,,7,Female,N,
1437,DescriptorName,D006801,10698143,,,8,Humans,N,
1438,DescriptorName,D007052,10698143,,,9,Ibuprofen,N,
1439,QualifierName,Q000506,10698143,,,9,,Y,poisoning
1440,DescriptorName,D007223,10698143,,,10,Infant,N,
1441,DescriptorName,D009270,10698143,,,11,Naloxone,N,
1442,QualifierName,Q000494,10698143,,,11,,N,pharmacology
1443,Chemical,D000889,10707759,Anti-Arrhythmia Agents,0,,,,
1444,Chemical,D005424,10707759,Flecainide,K94FTS1806,,,,
1445,DescriptorName,D000015,10707759,,,1,"Abnormalities, Multiple",Y,
1446,QualifierName,Q000175,10707759,,,1,,N,diagnosis
1447,DescriptorName,D000208,10707759,,,2,Acute Disease,N,
1448,DescriptorName,D000889,10707759,,,3,Anti-Arrhythmia Agents,N,
1449,QualifierName,Q000009,10707759,,,3,,Y,adverse effects
1450,DescriptorName,D005424,10707759,,,4,Flecainide,N,
1451,QualifierName,Q000009,10707759,,,4,,Y,adverse effects
1452,DescriptorName,D006330,10707759,,,5,"Heart Defects, Congenital",N,
1453,QualifierName,Q000150,10707759,,,5,,Y,complications
1454,DescriptorName,D006801,10707759,,,6,Humans,N,
1455,DescriptorName,D017563,10707759,,,7,"Lung Diseases, Interstitial",N,
1456,QualifierName,Q000139,10707759,,,7,,Y,chemically induced
1457,DescriptorName,D008297,10707759,,,8,Male,N,
1458,DescriptorName,D008875,10707759,,,9,Middle Aged,N,
1459,DescriptorName,D012131,10707759,,,10,Respiratory Insufficiency,N,
1460,QualifierName,Q000139,10707759,,,10,,Y,chemically induced
1461,DescriptorName,D013577,10707759,,,11,Syndrome,N,
1462,Chemical,D000970,10717401,Antineoplastic Agents,0,,,,
1463,Chemical,D001215,10717401,Asparaginase,EC 3.5.1.1,,,,
1464,DescriptorName,D000328,10717401,,,1,Adult,N,
1465,DescriptorName,D000970,10717401,,,2,Antineoplastic Agents,N,
1466,QualifierName,Q000009,10717401,,,2,,Y,adverse effects
1467,DescriptorName,D001215,10717401,,,3,Asparaginase,N,
1468,QualifierName,Q000009,10717401,,,3,,Y,adverse effects
1469,DescriptorName,D002533,10717401,,,4,Cerebral Angiography,N,
1470,QualifierName,Q000379,10717401,,,4,,N,methods
1471,DescriptorName,D005625,10717401,,,5,Frontal Lobe,N,
1472,QualifierName,Q000473,10717401,,,5,,N,pathology
1473,DescriptorName,D006801,10717401,,,6,Humans,N,
1474,DescriptorName,D008279,10717401,,,7,Magnetic Resonance Imaging,N,
1475,DescriptorName,D008297,10717401,,,8,Male,N,
1476,DescriptorName,D010291,10717401,,,9,Paresis,N,
1477,QualifierName,Q000175,10717401,,,9,,N,diagnosis
1478,DescriptorName,D054198,10717401,,,10,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
1479,QualifierName,Q000188,10717401,,,10,,N,drug therapy
1480,DescriptorName,D018455,10717401,,,11,Protein S Deficiency,N,
1481,QualifierName,Q000139,10717401,,,11,,Y,chemically induced
1482,DescriptorName,D012851,10717401,,,12,"Sinus Thrombosis, Intracranial",N,
1483,QualifierName,Q000175,10717401,,,12,,N,diagnosis
1484,Chemical,D000900,10723699,Anti-Bacterial Agents,0,,,,
1485,Chemical,D013752,10723699,Tetracycline,F8VB5M810T,,,,
1486,DescriptorName,D000152,10723699,,,1,Acne Vulgaris,N,
1487,QualifierName,Q000188,10723699,,,1,,N,drug therapy
1488,DescriptorName,D000293,10723699,,,2,Adolescent,N,
1489,DescriptorName,D000900,10723699,,,3,Anti-Bacterial Agents,N,
1490,QualifierName,Q000009,10723699,,,3,,Y,adverse effects
1491,DescriptorName,D005260,10723699,,,4,Female,N,
1492,DescriptorName,D006801,10723699,,,5,Humans,N,
1493,DescriptorName,D019586,10723699,,,6,Intracranial Hypertension,N,
1494,QualifierName,Q000139,10723699,,,6,,Y,chemically induced
1495,DescriptorName,D013752,10723699,,,7,Tetracycline,N,
1496,QualifierName,Q000009,10723699,,,7,,Y,adverse effects
1497,Chemical,D000305,10728450,Adrenal Cortex Hormones,0,,,,
1498,Chemical,D017325,10728450,Hepatitis B Vaccines,0,,,,
1499,DescriptorName,D000305,10728450,,,1,Adrenal Cortex Hormones,N,
1500,QualifierName,Q000627,10728450,,,1,,N,therapeutic use
1501,DescriptorName,D000328,10728450,,,2,Adult,N,
1502,DescriptorName,D000671,10728450,,,3,Amputation,N,
1503,DescriptorName,D005260,10728450,,,4,Female,N,
1504,DescriptorName,D005385,10728450,,,5,Fingers,N,
1505,QualifierName,Q000098,10728450,,,5,,N,blood supply
1506,DescriptorName,D017325,10728450,,,6,Hepatitis B Vaccines,N,
1507,QualifierName,Q000276,10728450,,,6,,Y,immunology
1508,DescriptorName,D006801,10728450,,,7,Humans,N,
1509,DescriptorName,D007511,10728450,,,8,Ischemia,N,
1510,QualifierName,Q000276,10728450,,,8,,N,immunology
1511,DescriptorName,D008297,10728450,,,9,Male,N,
1512,DescriptorName,D008875,10728450,,,10,Middle Aged,N,
1513,DescriptorName,D009336,10728450,,,11,Necrosis,N,
1514,DescriptorName,D017515,10728450,,,12,Pityriasis Rosea,N,
1515,QualifierName,Q000188,10728450,,,12,,N,drug therapy
1516,DescriptorName,D010488,10728450,,,13,Polyarteritis Nodosa,N,
1517,QualifierName,Q000188,10728450,,,13,,N,drug therapy
1518,DescriptorName,D014611,10728450,,,14,Vaccination,N,
1519,QualifierName,Q000009,10728450,,,14,,Y,adverse effects
1520,Chemical,D007166,10732843,Immunosuppressive Agents,0,,,,
1521,Chemical,D008727,10732843,Methotrexate,YL5FZ2Y5U1,,,,
1522,DescriptorName,D000368,10732843,,,1,Aged,N,
1523,DescriptorName,D015535,10732843,,,2,"Arthritis, Psoriatic",N,
1524,QualifierName,Q000150,10732843,,,2,,Y,complications
1525,DescriptorName,D001706,10732843,,,3,Biopsy,N,
1526,DescriptorName,D002283,10732843,,,4,"Carcinoma, Bronchogenic",N,
1527,QualifierName,Q000000981,10732843,,,4,,N,diagnostic imaging
1528,DescriptorName,D017809,10732843,,,5,Fatal Outcome,N,
1529,DescriptorName,D006801,10732843,,,6,Humans,N,
1530,DescriptorName,D007166,10732843,,,7,Immunosuppressive Agents,N,
1531,QualifierName,Q000627,10732843,,,7,,N,therapeutic use
1532,DescriptorName,D008175,10732843,,,8,Lung Neoplasms,N,
1533,QualifierName,Q000000981,10732843,,,8,,N,diagnostic imaging
1534,DescriptorName,D008297,10732843,,,9,Male,N,
1535,DescriptorName,D008727,10732843,,,10,Methotrexate,N,
1536,QualifierName,Q000627,10732843,,,10,,N,therapeutic use
1537,DescriptorName,D012307,10732843,,,11,Risk Factors,N,
1538,DescriptorName,D012907,10732843,,,12,Smoking,N,
1539,QualifierName,Q000009,10732843,,,12,,N,adverse effects
1540,DescriptorName,D014057,10732843,,,13,"Tomography, X-Ray Computed",N,
1541,Chemical,D014665,10745478,Vasodilator Agents,0,,,,
1542,Chemical,D005996,10745478,Nitroglycerin,G59M7S0WS3,,,,
1543,Chemical,D003042,10745478,Cocaine,I5Y540LHVR,,,,
1544,DescriptorName,D000328,10745478,,,1,Adult,N,
1545,DescriptorName,D015906,10745478,,,2,"Angioplasty, Balloon, Coronary",N,
1546,DescriptorName,D003042,10745478,,,3,Cocaine,N,
1547,QualifierName,Q000009,10745478,,,3,,N,adverse effects
1548,DescriptorName,D019970,10745478,,,4,Cocaine-Related Disorders,N,
1549,QualifierName,Q000150,10745478,,,4,,Y,complications
1550,DescriptorName,D003128,10745478,,,5,Coma,N,
1551,QualifierName,Q000209,10745478,,,5,,N,etiology
1552,DescriptorName,D003329,10745478,,,6,Coronary Vasospasm,N,
1553,QualifierName,Q000188,10745478,,,6,,Y,drug therapy
1554,DescriptorName,D017809,10745478,,,7,Fatal Outcome,N,
1555,DescriptorName,D005260,10745478,,,8,Female,N,
1556,DescriptorName,D006323,10745478,,,9,Heart Arrest,N,
1557,QualifierName,Q000209,10745478,,,9,,N,etiology
1558,DescriptorName,D006801,10745478,,,10,Humans,N,
1559,DescriptorName,D007261,10745478,,,11,"Infusions, Intra-Arterial",N,
1560,DescriptorName,D005996,10745478,,,12,Nitroglycerin,N,
1561,QualifierName,Q000008,10745478,,,12,,Y,administration & dosage
1562,DescriptorName,D012008,10745478,,,13,Recurrence,N,
1563,DescriptorName,D015607,10745478,,,14,Stents,N,
1564,DescriptorName,D014665,10745478,,,15,Vasodilator Agents,N,
1565,QualifierName,Q000008,10745478,,,15,,Y,administration & dosage
1566,Chemical,D002839,10749332,Chromans,0,,,,
1567,Chemical,D007004,10749332,Hypoglycemic Agents,0,,,,
1568,Chemical,D013844,10749332,Thiazoles,0,,,,
1569,Chemical,D045162,10749332,Thiazolidinediones,0,,,,
1570,Chemical,D000077288,10749332,Troglitazone,I66ZZ0ZN0E,,,,
1571,DescriptorName,D002839,10749332,,,1,Chromans,N,
1572,QualifierName,Q000009,10749332,,,1,,Y,adverse effects
1573,DescriptorName,D003924,10749332,,,2,"Diabetes Mellitus, Type 2",N,
1574,QualifierName,Q000188,10749332,,,2,,N,drug therapy
1575,DescriptorName,D005260,10749332,,,3,Female,N,
1576,DescriptorName,D006801,10749332,,,4,Humans,N,
1577,DescriptorName,D007004,10749332,,,5,Hypoglycemic Agents,N,
1578,QualifierName,Q000009,10749332,,,5,,Y,adverse effects
1579,DescriptorName,D008099,10749332,,,6,Liver,N,
1580,QualifierName,Q000473,10749332,,,6,,N,pathology
1581,DescriptorName,D017093,10749332,,,7,Liver Failure,N,
1582,QualifierName,Q000139,10749332,,,7,,Y,chemically induced
1583,DescriptorName,D008875,10749332,,,8,Middle Aged,N,
1584,DescriptorName,D013844,10749332,,,9,Thiazoles,N,
1585,QualifierName,Q000009,10749332,,,9,,Y,adverse effects
1586,DescriptorName,D045162,10749332,,,10,Thiazolidinediones,Y,
1587,DescriptorName,D000077288,10749332,,,11,Troglitazone,N,
1588,Chemical,D009582,10752888,Nitrofurantoin,927AH8112L,,,,
1589,DescriptorName,D000368,10752888,,,1,Aged,N,
1590,DescriptorName,D004417,10752888,,,2,Dyspnea,N,
1591,QualifierName,Q000209,10752888,,,2,,N,etiology
1592,DescriptorName,D005260,10752888,,,3,Female,N,
1593,DescriptorName,D006801,10752888,,,4,Humans,N,
1594,DescriptorName,D017563,10752888,,,5,"Lung Diseases, Interstitial",N,
1595,QualifierName,Q000139,10752888,,,5,,Y,chemically induced
1596,DescriptorName,D008297,10752888,,,6,Male,N,
1597,DescriptorName,D009582,10752888,,,7,Nitrofurantoin,N,
1598,QualifierName,Q000009,10752888,,,7,,Y,adverse effects
1599,DescriptorName,D011658,10752888,,,8,Pulmonary Fibrosis,N,
1600,QualifierName,Q000139,10752888,,,8,,N,chemically induced
1601,DescriptorName,D012075,10752888,,,9,"Remission, Spontaneous",N,
1602,DescriptorName,D014057,10752888,,,10,"Tomography, X-Ray Computed",Y,
1603,DescriptorName,D014552,10752888,,,11,Urinary Tract Infections,N,
1604,QualifierName,Q000188,10752888,,,11,,N,drug therapy
1605,Chemical,D000982,10755579,Antipruritics,0,,,,
1606,Chemical,D015259,10755579,Dopamine Agents,0,,,,
1607,Chemical,D017367,10755579,Serotonin Uptake Inhibitors,0,,,,
1608,Chemical,D005473,10755579,Fluoxetine,01K63SUP8D,,,,
1609,Chemical,D008774,10755579,Methylphenidate,207ZZ9QZ49,,,,
1610,Chemical,D019389,10755579,Cytochrome P-450 CYP2D6,EC 1.14.14.1,,,,
1611,Chemical,D011398,10755579,Promethazine,FF28EJQ494,,,,
1612,DescriptorName,D000982,10755579,,,1,Antipruritics,N,
1613,QualifierName,Q000378,10755579,,,1,,N,metabolism
1614,DescriptorName,D001289,10755579,,,2,Attention Deficit Disorder with Hyperactivity,N,
1615,QualifierName,Q000097,10755579,,,2,,N,blood
1616,DescriptorName,D002648,10755579,,,3,Child,N,
1617,DescriptorName,D019389,10755579,,,4,Cytochrome P-450 CYP2D6,N,
1618,QualifierName,Q000172,10755579,,,4,,N,deficiency
1619,DescriptorName,D015259,10755579,,,5,Dopamine Agents,N,
1620,QualifierName,Q000378,10755579,,,5,,N,metabolism
1621,DescriptorName,D004832,10755579,,,6,"Epilepsy, Absence",N,
1622,QualifierName,Q000097,10755579,,,6,,N,blood
1623,DescriptorName,D017809,10755579,,,7,Fatal Outcome,N,
1624,DescriptorName,D005473,10755579,,,8,Fluoxetine,N,
1625,QualifierName,Q000378,10755579,,,8,,N,metabolism
1626,DescriptorName,D006801,10755579,,,9,Humans,N,
1627,DescriptorName,D008297,10755579,,,10,Male,N,
1628,DescriptorName,D008774,10755579,,,11,Methylphenidate,N,
1629,QualifierName,Q000378,10755579,,,11,,N,metabolism
1630,DescriptorName,D011110,10755579,,,12,"Polymorphism, Genetic",N,
1631,QualifierName,Q000235,10755579,,,12,,Y,genetics
1632,DescriptorName,D019338,10755579,,,13,Polypharmacy,N,
1633,DescriptorName,D011398,10755579,,,14,Promethazine,N,
1634,QualifierName,Q000378,10755579,,,14,,N,metabolism
1635,DescriptorName,D017367,10755579,,,15,Serotonin Uptake Inhibitors,N,
1636,QualifierName,Q000378,10755579,,,15,,N,metabolism
1637,DescriptorName,D005879,10755579,,,16,Tourette Syndrome,N,
1638,QualifierName,Q000097,10755579,,,16,,N,blood
1639,Chemical,D010080,10759907,Oxazoles,0,,,,
1640,Chemical,D023303,10759907,Oxazolidinones,0,,,,
1641,Chemical,D017366,10759907,Serotonin Receptor Agonists,0,,,,
1642,Chemical,D014363,10759907,Tryptamines,0,,,,
1643,Chemical,C089750,10759907,zolmitriptan,2FS66TH3YW,,,,
1644,DescriptorName,D005260,10759907,,,1,Female,N,
1645,DescriptorName,D006801,10759907,,,2,Humans,N,
1646,DescriptorName,D007238,10759907,,,3,Infarction,N,
1647,QualifierName,Q000139,10759907,,,3,,Y,chemically induced
1648,DescriptorName,D008598,10759907,,,4,Menstruation,N,
1649,DescriptorName,D008875,10759907,,,5,Middle Aged,N,
1650,DescriptorName,D008881,10759907,,,6,Migraine Disorders,N,
1651,QualifierName,Q000188,10759907,,,6,,N,drug therapy
1652,DescriptorName,D010080,10759907,,,7,Oxazoles,N,
1653,QualifierName,Q000009,10759907,,,7,,Y,adverse effects
1654,DescriptorName,D023303,10759907,,,8,Oxazolidinones,Y,
1655,DescriptorName,D017366,10759907,,,9,Serotonin Receptor Agonists,N,
1656,QualifierName,Q000009,10759907,,,9,,Y,adverse effects
1657,DescriptorName,D013116,10759907,,,10,Spinal Cord,N,
1658,QualifierName,Q000098,10759907,,,10,,Y,blood supply
1659,DescriptorName,D014363,10759907,,,11,Tryptamines,N,
1660,Chemical,D000970,10772434,Antineoplastic Agents,0,,,,
1661,Chemical,D016190,10772434,Carboplatin,BG3F62OND5,,,,
1662,DescriptorName,D000970,10772434,,,1,Antineoplastic Agents,N,
1663,QualifierName,Q000008,10772434,,,1,,N,administration & dosage
1664,DescriptorName,D016190,10772434,,,2,Carboplatin,N,
1665,QualifierName,Q000008,10772434,,,2,,N,administration & dosage
1666,DescriptorName,D002648,10772434,,,3,Child,N,
1667,DescriptorName,D004334,10772434,,,4,Drug Administration Schedule,N,
1668,DescriptorName,D004342,10772434,,,5,Drug Hypersensitivity,N,
1669,QualifierName,Q000209,10772434,,,5,,N,etiology
1670,DescriptorName,D005260,10772434,,,6,Female,N,
1671,DescriptorName,D006801,10772434,,,7,Humans,N,
1672,DescriptorName,D020339,10772434,,,8,Optic Nerve Glioma,N,
1673,QualifierName,Q000188,10772434,,,8,,Y,drug therapy
1674,Chemical,D000894,10774758,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
1675,Chemical,D013449,10774758,Sulfonamides,0,,,,
1676,Chemical,C012655,10774758,nimesulide,V4TKW1454M,,,,
1677,DescriptorName,D058186,10774758,,,1,Acute Kidney Injury,N,
1678,QualifierName,Q000151,10774758,,,1,,Y,congenital
1679,DescriptorName,D000328,10774758,,,2,Adult,N,
1680,DescriptorName,D000894,10774758,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
1681,QualifierName,Q000009,10774758,,,3,,Y,adverse effects
1682,DescriptorName,D018771,10774758,,,4,Arthralgia,N,
1683,QualifierName,Q000188,10774758,,,4,,N,drug therapy
1684,DescriptorName,D003371,10774758,,,5,Cough,N,
1685,QualifierName,Q000188,10774758,,,5,,N,drug therapy
1686,DescriptorName,D005260,10774758,,,6,Female,N,
1687,DescriptorName,D005334,10774758,,,7,Fever,N,
1688,QualifierName,Q000188,10774758,,,7,,N,drug therapy
1689,DescriptorName,D005500,10774758,,,8,Follow-Up Studies,N,
1690,DescriptorName,D006801,10774758,,,9,Humans,N,
1691,DescriptorName,D007231,10774758,,,10,"Infant, Newborn",N,
1692,DescriptorName,D007677,10774758,,,11,Kidney Function Tests,N,
1693,DescriptorName,D008431,10774758,,,12,Maternal-Fetal Exchange,N,
1694,DescriptorName,D009846,10774758,,,13,Oliguria,N,
1695,QualifierName,Q000139,10774758,,,13,,Y,chemically induced
1696,DescriptorName,D011247,10774758,,,14,Pregnancy,N,
1697,DescriptorName,D011248,10774758,,,15,Pregnancy Complications,N,
1698,QualifierName,Q000188,10774758,,,15,,Y,drug therapy
1699,DescriptorName,D011297,10774758,,,16,Prenatal Exposure Delayed Effects,Y,
1700,DescriptorName,D012075,10774758,,,17,"Remission, Spontaneous",N,
1701,DescriptorName,D013449,10774758,,,18,Sulfonamides,N,
1702,QualifierName,Q000009,10774758,,,18,,Y,adverse effects
1703,DescriptorName,D014463,10774758,,,19,Ultrasonography,N,
1704,Chemical,D014750,10779995,Vincristine,5J49Q6B70F,,,,
1705,Chemical,D005047,10779995,Etoposide,6PLQ3CP4P3,,,,
1706,Chemical,D003520,10779995,Cyclophosphamide,8N3DW7272P,,,,
1707,Chemical,D016190,10779995,Carboplatin,BG3F62OND5,,,,
1708,Chemical,D002945,10779995,Cisplatin,Q20Q21Q62J,,,,
1709,DescriptorName,D000284,10779995,,,1,"Administration, Oral",N,
1710,DescriptorName,D000310,10779995,,,2,Adrenal Gland Neoplasms,N,
1711,QualifierName,Q000188,10779995,,,2,,Y,drug therapy
1712,DescriptorName,D000971,10779995,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
1713,QualifierName,Q000627,10779995,,,3,,Y,therapeutic use
1714,DescriptorName,D016190,10779995,,,4,Carboplatin,N,
1715,QualifierName,Q000008,10779995,,,4,,N,administration & dosage
1716,DescriptorName,D002648,10779995,,,5,Child,N,
1717,DescriptorName,D002869,10779995,,,6,Chromosome Aberrations,N,
1718,DescriptorName,D002945,10779995,,,7,Cisplatin,N,
1719,QualifierName,Q000008,10779995,,,7,,N,administration & dosage
1720,DescriptorName,D003520,10779995,,,8,Cyclophosphamide,N,
1721,QualifierName,Q000008,10779995,,,8,,N,administration & dosage
1722,DescriptorName,D005047,10779995,,,9,Etoposide,N,
1723,QualifierName,Q000008,10779995,,,9,,N,administration & dosage
1724,DescriptorName,D006801,10779995,,,10,Humans,N,
1725,DescriptorName,D015470,10779995,,,11,"Leukemia, Myeloid, Acute",N,
1726,QualifierName,Q000139,10779995,,,11,,N,chemically induced
1727,DescriptorName,D008297,10779995,,,12,Male,N,
1728,DescriptorName,D009362,10779995,,,13,Neoplasm Metastasis,N,
1729,DescriptorName,D016609,10779995,,,14,"Neoplasms, Second Primary",N,
1730,QualifierName,Q000139,10779995,,,14,,N,chemically induced
1731,DescriptorName,D009447,10779995,,,15,Neuroblastoma,N,
1732,QualifierName,Q000188,10779995,,,15,,Y,drug therapy
1733,DescriptorName,D014750,10779995,,,16,Vincristine,N,
1734,QualifierName,Q000008,10779995,,,16,,N,administration & dosage
1735,Chemical,D000427,10803790,Alcohol Deterrents,0,,,,
1736,Chemical,D000431,10803790,Ethanol,3K9958V90M,,,,
1737,Chemical,D003484,10803790,Cyanamide,420-04-2,,,,
1738,Chemical,D001219,10803790,Aspartate Aminotransferases,EC 2.6.1.1,,,,
1739,Chemical,D000410,10803790,Alanine Transaminase,EC 2.6.1.2,,,,
1740,DescriptorName,D000328,10803790,,,1,Adult,N,
1741,DescriptorName,D000410,10803790,,,2,Alanine Transaminase,N,
1742,QualifierName,Q000097,10803790,,,2,,N,blood
1743,DescriptorName,D000427,10803790,,,3,Alcohol Deterrents,N,
1744,QualifierName,Q000009,10803790,,,3,,Y,adverse effects
1745,DescriptorName,D000437,10803790,,,4,Alcoholism,N,
1746,QualifierName,Q000188,10803790,,,4,,Y,drug therapy
1747,DescriptorName,D001219,10803790,,,5,Aspartate Aminotransferases,N,
1748,QualifierName,Q000097,10803790,,,5,,N,blood
1749,DescriptorName,D001706,10803790,,,6,Biopsy,N,
1750,DescriptorName,D056486,10803790,,,7,Chemical and Drug Induced Liver Injury,Y,
1751,DescriptorName,D003484,10803790,,,8,Cyanamide,N,
1752,QualifierName,Q000009,10803790,,,8,,Y,adverse effects
1753,DescriptorName,D000431,10803790,,,9,Ethanol,N,
1754,QualifierName,Q000008,10803790,,,9,,N,administration & dosage
1755,DescriptorName,D005260,10803790,,,10,Female,N,
1756,DescriptorName,D006801,10803790,,,11,Humans,N,
1757,DescriptorName,D002479,10803790,,,12,Inclusion Bodies,N,
1758,QualifierName,Q000473,10803790,,,12,,N,pathology
1759,DescriptorName,D008099,10803790,,,13,Liver,N,
1760,QualifierName,Q000473,10803790,,,13,,N,pathology
1761,DescriptorName,D008103,10803790,,,14,Liver Cirrhosis,N,
1762,QualifierName,Q000139,10803790,,,14,,N,chemically induced
1763,DescriptorName,D008107,10803790,,,15,Liver Diseases,N,
1764,QualifierName,Q000473,10803790,,,15,,N,pathology
1765,DescriptorName,D008297,10803790,,,16,Male,N,
1766,DescriptorName,D008875,10803790,,,17,Middle Aged,N,
1767,Chemical,D000900,10808214,Anti-Bacterial Agents,0,,,,
1768,Chemical,D007166,10808214,Immunosuppressive Agents,0,,,,
1769,Chemical,D016559,10808214,Tacrolimus,WM0HAQ4WNM,,,,
1770,DescriptorName,D000900,10808214,,,1,Anti-Bacterial Agents,N,
1771,QualifierName,Q000009,10808214,,,1,,Y,adverse effects
1772,DescriptorName,D003429,10808214,,,2,Cross Reactions,Y,
1773,QualifierName,Q000276,10808214,,,2,,N,immunology
1774,DescriptorName,D003875,10808214,,,3,Drug Eruptions,Y,
1775,QualifierName,Q000209,10808214,,,3,,N,etiology
1776,DescriptorName,D004890,10808214,,,4,Erythema,N,
1777,QualifierName,Q000139,10808214,,,4,,N,chemically induced
1778,DescriptorName,D005260,10808214,,,5,Female,N,
1779,DescriptorName,D006086,10808214,,,6,Graft vs Host Disease,N,
1780,QualifierName,Q000188,10808214,,,6,,N,drug therapy
1781,DescriptorName,D006801,10808214,,,7,Humans,N,
1782,DescriptorName,D007166,10808214,,,8,Immunosuppressive Agents,N,
1783,QualifierName,Q000009,10808214,,,8,,N,adverse effects
1784,DescriptorName,D015470,10808214,,,9,"Leukemia, Myeloid, Acute",N,
1785,QualifierName,Q000150,10808214,,,9,,N,complications
1786,DescriptorName,D008875,10808214,,,10,Middle Aged,N,
1787,DescriptorName,D016559,10808214,,,11,Tacrolimus,N,
1788,QualifierName,Q000009,10808214,,,11,,Y,adverse effects
1789,Chemical,D000701,10812579,"Analgesics, Opioid",0,,,,
1790,Chemical,D009020,10812579,Morphine,76I7G6D29C,,,,
1791,DescriptorName,D000368,10812579,,,1,Aged,N,
1792,DescriptorName,D000701,10812579,,,2,"Analgesics, Opioid",N,
1793,QualifierName,Q000009,10812579,,,2,,Y,adverse effects
1794,DescriptorName,D004569,10812579,,,3,Electroencephalography,N,
1795,DescriptorName,D005260,10812579,,,4,Female,N,
1796,DescriptorName,D006801,10812579,,,5,Humans,N,
1797,DescriptorName,D008228,10812579,,,6,"Lymphoma, Non-Hodgkin",N,
1798,QualifierName,Q000188,10812579,,,6,,N,drug therapy
1799,DescriptorName,D009020,10812579,,,7,Morphine,N,
1800,QualifierName,Q000009,10812579,,,7,,Y,adverse effects
1801,DescriptorName,D010146,10812579,,,8,Pain,N,
1802,QualifierName,Q000188,10812579,,,8,,N,drug therapy
1803,DescriptorName,D013125,10812579,,,9,Spinal Neoplasms,N,
1804,QualifierName,Q000188,10812579,,,9,,N,drug therapy
1805,DescriptorName,D013226,10812579,,,10,Status Epilepticus,N,
1806,QualifierName,Q000139,10812579,,,10,,Y,chemically induced
1807,Chemical,D014667,1082426,Vasopressins,11000-17-2,,,,
1808,DescriptorName,D000693,1082426,,,1,Anaerobiosis,N,
1809,DescriptorName,D001158,1082426,,,2,Arteries,N,
1810,DescriptorName,D001202,1082426,,,3,Ascitic Fluid,N,
1811,QualifierName,Q000382,1082426,,,3,,N,microbiology
1812,DescriptorName,D001424,1082426,,,4,Bacterial Infections,N,
1813,QualifierName,Q000209,1082426,,,4,,Y,etiology
1814,DescriptorName,D004386,1082426,,,5,Duodenum,N,
1815,QualifierName,Q000098,1082426,,,5,,N,blood supply
1816,DescriptorName,D004932,1082426,,,6,Esophageal and Gastric Varices,N,
1817,QualifierName,Q000150,1082426,,,6,,N,complications
1818,DescriptorName,D006471,1082426,,,7,Gastrointestinal Hemorrhage,N,
1819,QualifierName,Q000188,1082426,,,7,,N,drug therapy
1820,DescriptorName,D006801,1082426,,,8,Humans,N,
1821,DescriptorName,D007263,1082426,,,9,"Infusions, Parenteral",N,
1822,DescriptorName,D007422,1082426,,,10,Intestines,N,
1823,QualifierName,Q000382,1082426,,,10,,N,microbiology
1824,DescriptorName,D008297,1082426,,,11,Male,N,
1825,DescriptorName,D008638,1082426,,,12,Mesenteric Arteries,N,
1826,DescriptorName,D008875,1082426,,,13,Middle Aged,N,
1827,DescriptorName,D010538,1082426,,,14,Peritonitis,N,
1828,QualifierName,Q000209,1082426,,,14,,Y,etiology
1829,DescriptorName,D013270,1082426,,,15,Stomach,N,
1830,QualifierName,Q000098,1082426,,,15,,N,blood supply
1831,DescriptorName,D013276,1082426,,,16,Stomach Ulcer,N,
1832,QualifierName,Q000150,1082426,,,16,,N,complications
1833,DescriptorName,D014667,1082426,,,17,Vasopressins,N,
1834,QualifierName,Q000008,1082426,,,17,,N,administration & dosage
1835,Chemical,D018967,10840527,Risperidone,L6UH7ZF8HC,,,,
1836,DescriptorName,D000368,10840527,,,1,Aged,N,
1837,DescriptorName,D002986,10840527,,,2,Clinical Trials as Topic,N,
1838,DescriptorName,D003704,10840527,,,3,Dementia,N,
1839,QualifierName,Q000188,10840527,,,3,,Y,drug therapy
1840,DescriptorName,D005260,10840527,,,4,Female,N,
1841,DescriptorName,D006801,10840527,,,5,Humans,N,
1842,DescriptorName,D018967,10840527,,,6,Risperidone,N,
1843,QualifierName,Q000009,10840527,,,6,,N,adverse effects
1844,DescriptorName,D000328,10870485,,,1,Adult,N,
1845,DescriptorName,D064420,10870485,,,2,Drug-Related Side Effects and Adverse Reactions,N,
1846,DescriptorName,D006801,10870485,,,3,Humans,N,
1847,DescriptorName,D008228,10870485,,,4,"Lymphoma, Non-Hodgkin",N,
1848,QualifierName,Q000150,10870485,,,4,,Y,complications
1849,DescriptorName,D008297,10870485,,,5,Male,N,
1850,DescriptorName,D009220,10870485,,,6,Myositis,N,
1851,QualifierName,Q000209,10870485,,,6,,N,etiology
1852,DescriptorName,D013156,10870485,,,7,Splenectomy,N,
1853,DescriptorName,D013203,10870485,,,8,Staphylococcal Infections,Y,
1854,DescriptorName,D014329,10870485,,,9,Tropical Climate,N,
1855,DescriptorName,D014421,10870485,,,10,Turkey,N,
1856,Chemical,D000906,1087773,Antibodies,0,,,,
1857,Chemical,D000974,1087773,"Antibodies, Antinuclear",0,,,,
1858,Chemical,D004977,1087773,Ethambutol,8G167061QZ,,,,
1859,Chemical,D004247,1087773,DNA,9007-49-2,,,,
1860,Chemical,D012293,1087773,Rifampin,VJT6J7R4TR,,,,
1861,DescriptorName,D000906,1087773,,,1,Antibodies,N,
1862,QualifierName,Q000032,1087773,,,1,,Y,analysis
1863,DescriptorName,D000974,1087773,,,2,"Antibodies, Antinuclear",N,
1864,DescriptorName,D000918,1087773,,,3,Antibody Specificity,N,
1865,DescriptorName,D002648,1087773,,,4,Child,N,
1866,DescriptorName,D004247,1087773,,,5,DNA,N,
1867,QualifierName,Q000276,1087773,,,5,,Y,immunology
1868,DescriptorName,D004977,1087773,,,6,Ethambutol,N,
1869,QualifierName,Q000009,1087773,,,6,,Y,adverse effects
1870,DescriptorName,D006801,1087773,,,7,Humans,N,
1871,DescriptorName,D008297,1087773,,,8,Male,N,
1872,DescriptorName,D009164,1087773,,,9,Mycobacterium Infections,N,
1873,QualifierName,Q000188,1087773,,,9,,Y,drug therapy
1874,DescriptorName,D012293,1087773,,,10,Rifampin,N,
1875,QualifierName,Q000009,1087773,,,10,,Y,adverse effects
1876,Chemical,D005938,10879669,Glucocorticoids,0,,,,
1877,Chemical,D008775,10879669,Methylprednisolone,X4W7ZR7023,,,,
1878,DescriptorName,D000368,10879669,,,1,Aged,N,
1879,DescriptorName,D000743,10879669,,,2,"Anemia, Hemolytic",N,
1880,QualifierName,Q000139,10879669,,,2,,Y,chemically induced
1881,DescriptorName,D001794,10879669,,,3,Blood Pressure,N,
1882,DescriptorName,D005938,10879669,,,4,Glucocorticoids,N,
1883,QualifierName,Q000008,10879669,,,4,,N,administration & dosage
1884,DescriptorName,D006801,10879669,,,5,Humans,N,
1885,DescriptorName,D007668,10879669,,,6,Kidney,N,
1886,QualifierName,Q000473,10879669,,,6,,N,pathology
1887,DescriptorName,D017563,10879669,,,7,"Lung Diseases, Interstitial",N,
1888,QualifierName,Q000150,10879669,,,7,,N,complications
1889,DescriptorName,D008297,10879669,,,8,Male,N,
1890,DescriptorName,D008775,10879669,,,9,Methylprednisolone,N,
1891,QualifierName,Q000008,10879669,,,9,,N,administration & dosage
1892,DescriptorName,D051437,10879669,,,10,Renal Insufficiency,N,
1893,QualifierName,Q000139,10879669,,,10,,Y,chemically induced
1894,DescriptorName,D012595,10879669,,,11,"Scleroderma, Systemic",N,
1895,QualifierName,Q000150,10879669,,,11,,Y,complications
1896,Chemical,D000964,10885900,"Antimetabolites, Antineoplastic",0,,,,
1897,Chemical,D000970,10885900,Antineoplastic Agents,0,,,,
1898,Chemical,D003841,10885900,Deoxycytidine,0W860991D6,,,,
1899,Chemical,C056507,10885900,gemcitabine,B76N6SBZ8R,,,,
1900,Chemical,D016190,10885900,Carboplatin,BG3F62OND5,,,,
1901,DescriptorName,D000964,10885900,,,1,"Antimetabolites, Antineoplastic",N,
1902,QualifierName,Q000008,10885900,,,1,,N,administration & dosage
1903,DescriptorName,D000970,10885900,,,2,Antineoplastic Agents,N,
1904,QualifierName,Q000008,10885900,,,2,,N,administration & dosage
1905,DescriptorName,D000971,10885900,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
1906,QualifierName,Q000008,10885900,,,3,,N,administration & dosage
1907,DescriptorName,D016190,10885900,,,4,Carboplatin,N,
1908,QualifierName,Q000008,10885900,,,4,,N,administration & dosage
1909,DescriptorName,D003841,10885900,,,5,Deoxycytidine,N,
1910,QualifierName,Q000008,10885900,,,5,,N,administration & dosage
1911,DescriptorName,D005260,10885900,,,6,Female,N,
1912,DescriptorName,D006463,10885900,,,7,Hemolytic-Uremic Syndrome,N,
1913,QualifierName,Q000139,10885900,,,7,,Y,chemically induced
1914,DescriptorName,D006801,10885900,,,8,Humans,N,
1915,DescriptorName,D008875,10885900,,,9,Middle Aged,N,
1916,DescriptorName,D010051,10885900,,,10,Ovarian Neoplasms,N,
1917,QualifierName,Q000150,10885900,,,10,,Y,complications
1918,Chemical,D000927,10891991,Anticonvulsants,0,,,,
1919,Chemical,D014227,10891991,Triazines,0,,,,
1920,Chemical,D013739,10891991,Testosterone,3XMK78S47O,,,,
1921,Chemical,D014635,10891991,Valproic Acid,614OI1Z5WI,,,,
1922,Chemical,D000077213,10891991,Lamotrigine,U3H27498KS,,,,
1923,DescriptorName,D000293,10891991,,,1,Adolescent,N,
1924,DescriptorName,D000328,10891991,,,2,Adult,N,
1925,DescriptorName,D000927,10891991,,,3,Anticonvulsants,N,
1926,QualifierName,Q000009,10891991,,,3,,Y,adverse effects
1927,DescriptorName,D001835,10891991,,,4,Body Weight,N,
1928,QualifierName,Q000187,10891991,,,4,,N,drug effects
1929,DescriptorName,D004569,10891991,,,5,Electroencephalography,N,
1930,DescriptorName,D004827,10891991,,,6,Epilepsy,N,
1931,QualifierName,Q000188,10891991,,,6,,N,drug therapy
1932,DescriptorName,D005260,10891991,,,7,Female,N,
1933,DescriptorName,D006801,10891991,,,8,Humans,N,
1934,DescriptorName,D017588,10891991,,,9,Hyperandrogenism,N,
1935,QualifierName,Q000097,10891991,,,9,,N,blood
1936,DescriptorName,D000077213,10891991,,,10,Lamotrigine,N,
1937,DescriptorName,D008599,10891991,,,11,Menstruation Disturbances,N,
1938,QualifierName,Q000097,10891991,,,11,,N,blood
1939,DescriptorName,D010053,10891991,,,12,Ovary,N,
1940,QualifierName,Q000000981,10891991,,,12,,N,diagnostic imaging
1941,DescriptorName,D011085,10891991,,,13,Polycystic Ovary Syndrome,N,
1942,QualifierName,Q000097,10891991,,,13,,N,blood
1943,DescriptorName,D013739,10891991,,,14,Testosterone,N,
1944,QualifierName,Q000097,10891991,,,14,,N,blood
1945,DescriptorName,D016896,10891991,,,15,Treatment Outcome,N,
1946,DescriptorName,D014227,10891991,,,16,Triazines,N,
1947,QualifierName,Q000627,10891991,,,16,,N,therapeutic use
1948,DescriptorName,D014463,10891991,,,17,Ultrasonography,N,
1949,DescriptorName,D014635,10891991,,,18,Valproic Acid,N,
1950,QualifierName,Q000009,10891991,,,18,,Y,adverse effects
1951,Chemical,D007166,10897389,Immunosuppressive Agents,0,,,,
1952,Chemical,D016572,10897389,Cyclosporine,83HN0GTJ6D,,,,
1953,DescriptorName,D003093,10897389,,,1,"Colitis, Ulcerative",N,
1954,QualifierName,Q000188,10897389,,,1,,Y,drug therapy
1955,DescriptorName,D016572,10897389,,,2,Cyclosporine,N,
1956,QualifierName,Q000008,10897389,,,2,,N,administration & dosage
1957,DescriptorName,D004305,10897389,,,3,"Dose-Response Relationship, Drug",N,
1958,DescriptorName,D017809,10897389,,,4,Fatal Outcome,N,
1959,DescriptorName,D006801,10897389,,,5,Humans,N,
1960,DescriptorName,D007166,10897389,,,6,Immunosuppressive Agents,N,
1961,QualifierName,Q000008,10897389,,,6,,N,administration & dosage
1962,DescriptorName,D007262,10897389,,,7,"Infusions, Intravenous",N,
1963,DescriptorName,D008297,10897389,,,8,Male,N,
1964,DescriptorName,D008875,10897389,,,9,Middle Aged,N,
1965,DescriptorName,D012008,10897389,,,10,Recurrence,N,
1966,DescriptorName,D018805,10897389,,,11,Sepsis,N,
1967,QualifierName,Q000139,10897389,,,11,,Y,chemically induced
1968,DescriptorName,D013203,10897389,,,12,Staphylococcal Infections,N,
1969,QualifierName,Q000139,10897389,,,12,,Y,chemically induced
1970,Chemical,D003078,10904571,Colchicine,SML2Y3J35T,,,,
1971,DescriptorName,D000208,10904571,,,1,Acute Disease,N,
1972,DescriptorName,D001707,10904571,,,2,"Biopsy, Needle",N,
1973,DescriptorName,D003078,10904571,,,3,Colchicine,N,
1974,QualifierName,Q000009,10904571,,,3,,Y,adverse effects
1975,DescriptorName,D005260,10904571,,,4,Female,N,
1976,DescriptorName,D006073,10904571,,,5,Gout,N,
1977,QualifierName,Q000150,10904571,,,5,,N,complications
1978,DescriptorName,D006801,10904571,,,6,Humans,N,
1979,DescriptorName,D007676,10904571,,,7,"Kidney Failure, Chronic",N,
1980,QualifierName,Q000150,10904571,,,7,,Y,complications
1981,DescriptorName,D008875,10904571,,,8,Middle Aged,N,
1982,DescriptorName,D018908,10904571,,,9,Muscle Weakness,N,
1983,QualifierName,Q000139,10904571,,,9,,Y,chemically induced
1984,Chemical,D000972,10907391,"Antineoplastic Agents, Phytogenic",0,,,,
1985,Chemical,D009498,10907391,Neurotoxins,0,,,,
1986,Chemical,D017239,10907391,Paclitaxel,P88XT4IS4D,,,,
1987,DescriptorName,D000328,10907391,,,1,Adult,N,
1988,DescriptorName,D000368,10907391,,,2,Aged,N,
1989,DescriptorName,D000671,10907391,,,3,Amputation,N,
1990,DescriptorName,D000972,10907391,,,4,"Antineoplastic Agents, Phytogenic",N,
1991,QualifierName,Q000009,10907391,,,4,,Y,adverse effects
1992,DescriptorName,D001943,10907391,,,5,Breast Neoplasms,N,
1993,QualifierName,Q000188,10907391,,,5,,N,drug therapy
1994,DescriptorName,D018270,10907391,,,6,"Carcinoma, Ductal, Breast",N,
1995,QualifierName,Q000188,10907391,,,6,,N,drug therapy
1996,DescriptorName,D002294,10907391,,,7,"Carcinoma, Squamous Cell",N,
1997,QualifierName,Q000188,10907391,,,7,,N,drug therapy
1998,DescriptorName,D005260,10907391,,,8,Female,N,
1999,DescriptorName,D006225,10907391,,,9,Hand,N,
2000,QualifierName,Q000601,10907391,,,9,,N,surgery
2001,DescriptorName,D006801,10907391,,,10,Humans,N,
2002,DescriptorName,D007866,10907391,,,11,Leg,N,
2003,QualifierName,Q000601,10907391,,,11,,N,surgery
2004,DescriptorName,D008175,10907391,,,12,Lung Neoplasms,N,
2005,QualifierName,Q000188,10907391,,,12,,N,drug therapy
2006,DescriptorName,D008297,10907391,,,13,Male,N,
2007,DescriptorName,D009498,10907391,,,14,Neurotoxins,N,
2008,QualifierName,Q000009,10907391,,,14,,Y,adverse effects
2009,DescriptorName,D017239,10907391,,,15,Paclitaxel,N,
2010,QualifierName,Q000009,10907391,,,15,,Y,adverse effects
2011,DescriptorName,D010591,10907391,,,16,Phantom Limb,N,
2012,QualifierName,Q000139,10907391,,,16,,Y,chemically induced
2013,DescriptorName,D013709,10907391,,,17,Tendon Transfer,N,
2014,DescriptorName,D014459,10907391,,,18,Ulnar Nerve,N,
2015,QualifierName,Q000187,10907391,,,18,,N,drug effects
2016,Chemical,D000894,10923593,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
2017,Chemical,D010653,10923593,Phenylbutazone,GN5P7K3T8S,,,,
2018,DescriptorName,D000328,10923593,,,1,Adult,N,
2019,DescriptorName,D000894,10923593,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
2020,QualifierName,Q000009,10923593,,,2,,Y,adverse effects
2021,DescriptorName,D001007,10923593,,,3,Anxiety,N,
2022,QualifierName,Q000150,10923593,,,3,,N,complications
2023,DescriptorName,D003863,10923593,,,4,Depression,N,
2024,QualifierName,Q000150,10923593,,,4,,N,complications
2025,DescriptorName,D004342,10923593,,,5,Drug Hypersensitivity,N,
2026,QualifierName,Q000209,10923593,,,5,,N,etiology
2027,DescriptorName,D005076,10923593,,,6,Exanthema,N,
2028,QualifierName,Q000139,10923593,,,6,,Y,chemically induced
2029,DescriptorName,D005260,10923593,,,7,Female,N,
2030,DescriptorName,D006801,10923593,,,8,Humans,N,
2031,DescriptorName,D008206,10923593,,,9,Lymphatic Diseases,N,
2032,QualifierName,Q000139,10923593,,,9,,Y,chemically induced
2033,DescriptorName,D010653,10923593,,,10,Phenylbutazone,N,
2034,QualifierName,Q000009,10923593,,,10,,Y,adverse effects
2035,Chemical,D000319,10928688,Adrenergic beta-Antagonists,0,,,,
2036,Chemical,D002606,10928688,Charcoal,16291-96-6,,,,
2037,Chemical,D001262,10928688,Atenolol,50VV3VW0TI,,,,
2038,DescriptorName,D000319,10928688,,,1,Adrenergic beta-Antagonists,N,
2039,QualifierName,Q000009,10928688,,,1,,Y,adverse effects
2040,DescriptorName,D000328,10928688,,,2,Adult,N,
2041,DescriptorName,D001262,10928688,,,3,Atenolol,N,
2042,QualifierName,Q000009,10928688,,,3,,Y,adverse effects
2043,DescriptorName,D002606,10928688,,,4,Charcoal,N,
2044,DescriptorName,D062787,10928688,,,5,Drug Overdose,N,
2045,QualifierName,Q000628,10928688,,,5,,N,therapy
2046,DescriptorName,D004562,10928688,,,6,Electrocardiography,N,
2047,DescriptorName,D004638,10928688,,,7,Emergency Treatment,Y,
2048,DescriptorName,D006464,10928688,,,8,Hemoperfusion,N,
2049,DescriptorName,D006801,10928688,,,9,Humans,N,
2050,DescriptorName,D007676,10928688,,,10,"Kidney Failure, Chronic",Y,
2051,QualifierName,Q000150,10928688,,,10,,N,complications
2052,DescriptorName,D008297,10928688,,,11,Male,N,
2053,DescriptorName,D006435,10928688,,,12,Renal Dialysis,N,
2054,DescriptorName,D012770,10928688,,,13,"Shock, Cardiogenic",N,
2055,QualifierName,Q000139,10928688,,,13,,Y,chemically induced
2056,Chemical,D000893,10963515,Anti-Inflammatory Agents,0,,,,
2057,Chemical,D000960,10963515,Hypolipidemic Agents,0,,,,
2058,Chemical,D015248,10963515,Gemfibrozil,Q8X02027X3,,,,
2059,Chemical,D008775,10963515,Methylprednisolone,X4W7ZR7023,,,,
2060,DescriptorName,D000893,10963515,,,1,Anti-Inflammatory Agents,N,
2061,QualifierName,Q000627,10963515,,,1,,N,therapeutic use
2062,DescriptorName,D001249,10963515,,,2,Asthma,N,
2063,QualifierName,Q000150,10963515,,,2,,N,complications
2064,DescriptorName,D001706,10963515,,,3,Biopsy,N,
2065,DescriptorName,D015984,10963515,,,4,Causality,N,
2066,DescriptorName,D004342,10963515,,,5,Drug Hypersensitivity,N,
2067,QualifierName,Q000175,10963515,,,5,,N,diagnosis
2068,DescriptorName,D016145,10963515,,,6,"Endoscopy, Digestive System",N,
2069,DescriptorName,D004802,10963515,,,7,Eosinophilia,N,
2070,QualifierName,Q000097,10963515,,,7,,N,blood
2071,DescriptorName,D004804,10963515,,,8,Eosinophils,N,
2072,DescriptorName,D005260,10963515,,,9,Female,N,
2073,DescriptorName,D005759,10963515,,,10,Gastroenteritis,N,
2074,QualifierName,Q000139,10963515,,,10,,Y,chemically induced
2075,DescriptorName,D015248,10963515,,,11,Gemfibrozil,N,
2076,QualifierName,Q000009,10963515,,,11,,Y,adverse effects
2077,DescriptorName,D006801,10963515,,,12,Humans,N,
2078,DescriptorName,D006949,10963515,,,13,Hyperlipidemias,N,
2079,QualifierName,Q000150,10963515,,,13,,N,complications
2080,DescriptorName,D000960,10963515,,,14,Hypolipidemic Agents,N,
2081,QualifierName,Q000009,10963515,,,14,,Y,adverse effects
2082,DescriptorName,D007958,10963515,,,15,Leukocyte Count,N,
2083,DescriptorName,D008775,10963515,,,16,Methylprednisolone,N,
2084,QualifierName,Q000627,10963515,,,16,,N,therapeutic use
2085,DescriptorName,D008875,10963515,,,17,Middle Aged,N,
2086,DescriptorName,D012220,10963515,,,18,Rhinitis,N,
2087,QualifierName,Q000150,10963515,,,18,,N,complications
2088,DescriptorName,D013997,10963515,,,19,Time Factors,N,
2089,Chemical,D019380,10970989,Anti-HIV Agents,0,,,,
2090,Chemical,D019259,10970989,Lamivudine,2T8Q726O95,,,,
2091,Chemical,D019344,10970989,Lactic Acid,33X04XA5AT,,,,
2092,Chemical,D003999,10970989,Dichloroacetic Acid,9LSH52S3LQ,,,,
2093,Chemical,D018119,10970989,Stavudine,BO9LE4QFZF,,,,
2094,DescriptorName,D000140,10970989,,,1,"Acidosis, Lactic",N,
2095,QualifierName,Q000097,10970989,,,1,,N,blood
2096,DescriptorName,D000163,10970989,,,2,Acquired Immunodeficiency Syndrome,N,
2097,QualifierName,Q000188,10970989,,,2,,Y,drug therapy
2098,DescriptorName,D000328,10970989,,,3,Adult,N,
2099,DescriptorName,D019380,10970989,,,4,Anti-HIV Agents,N,
2100,QualifierName,Q000009,10970989,,,4,,Y,adverse effects
2101,DescriptorName,D003999,10970989,,,5,Dichloroacetic Acid,N,
2102,QualifierName,Q000627,10970989,,,5,,N,therapeutic use
2103,DescriptorName,D005260,10970989,,,6,Female,N,
2104,DescriptorName,D006801,10970989,,,7,Humans,N,
2105,DescriptorName,D019344,10970989,,,8,Lactic Acid,N,
2106,QualifierName,Q000097,10970989,,,8,,N,blood
2107,DescriptorName,D019259,10970989,,,9,Lamivudine,N,
2108,QualifierName,Q000009,10970989,,,9,,N,adverse effects
2109,DescriptorName,D018119,10970989,,,10,Stavudine,N,
2110,QualifierName,Q000009,10970989,,,10,,N,adverse effects
2111,Chemical,D000889,10981493,Anti-Arrhythmia Agents,0,,,,
2112,Chemical,D011405,10981493,Propafenone,68IQX3T69U,,,,
2113,Chemical,D000638,10981493,Amiodarone,N3RQ532IUT,,,,
2114,DescriptorName,D000368,10981493,,,1,Aged,N,
2115,DescriptorName,D000369,10981493,,,2,"Aged, 80 and over",N,
2116,DescriptorName,D000638,10981493,,,3,Amiodarone,N,
2117,QualifierName,Q000627,10981493,,,3,,N,therapeutic use
2118,DescriptorName,D000889,10981493,,,4,Anti-Arrhythmia Agents,N,
2119,QualifierName,Q000009,10981493,,,4,,Y,adverse effects
2120,DescriptorName,D001259,10981493,,,5,Ataxia,N,
2121,QualifierName,Q000139,10981493,,,5,,Y,chemically induced
2122,DescriptorName,D001281,10981493,,,6,Atrial Fibrillation,N,
2123,QualifierName,Q000188,10981493,,,6,,N,drug therapy
2124,DescriptorName,D001921,10981493,,,7,Brain,N,
2125,QualifierName,Q000000981,10981493,,,7,,N,diagnostic imaging
2126,DescriptorName,D005260,10981493,,,8,Female,N,
2127,DescriptorName,D006801,10981493,,,9,Humans,N,
2128,DescriptorName,D008297,10981493,,,10,Male,N,
2129,DescriptorName,D011405,10981493,,,11,Propafenone,N,
2130,QualifierName,Q000009,10981493,,,11,,Y,adverse effects
2131,DescriptorName,D014057,10981493,,,12,"Tomography, X-Ray Computed",N,
2132,Chemical,D000889,10987357,Anti-Arrhythmia Agents,0,,,,
2133,Chemical,D026941,10987357,Sodium Channel Blockers,0,,,,
2134,Chemical,D008012,10987357,Lidocaine,98PI200987,,,,
2135,Chemical,C042288,10987357,pilsicainide,AV0X7V6CSE,,,,
2136,DescriptorName,D000284,10987357,,,1,"Administration, Oral",N,
2137,DescriptorName,D000368,10987357,,,2,Aged,N,
2138,DescriptorName,D000889,10987357,,,3,Anti-Arrhythmia Agents,N,
2139,QualifierName,Q000008,10987357,,,3,,N,administration & dosage
2140,DescriptorName,D001281,10987357,,,4,Atrial Fibrillation,N,
2141,QualifierName,Q000188,10987357,,,4,,Y,drug therapy
2142,DescriptorName,D003244,10987357,,,5,Consciousness Disorders,N,
2143,QualifierName,Q000139,10987357,,,5,,N,chemically induced
2144,DescriptorName,D004562,10987357,,,6,Electrocardiography,N,
2145,QualifierName,Q000187,10987357,,,6,,Y,drug effects
2146,DescriptorName,D006801,10987357,,,7,Humans,N,
2147,DescriptorName,D008012,10987357,,,8,Lidocaine,N,
2148,QualifierName,Q000008,10987357,,,8,,N,administration & dosage
2149,DescriptorName,D008297,10987357,,,9,Male,N,
2150,DescriptorName,D026941,10987357,,,10,Sodium Channel Blockers,Y,
2151,Chemical,D014150,11001600,Antipsychotic Agents,0,,,,
2152,DescriptorName,D000368,11001600,,,1,Aged,N,
2153,DescriptorName,D000369,11001600,,,2,"Aged, 80 and over",N,
2154,DescriptorName,D000544,11001600,,,3,Alzheimer Disease,N,
2155,QualifierName,Q000150,11001600,,,3,,N,complications
2156,DescriptorName,D014150,11001600,,,4,Antipsychotic Agents,N,
2157,QualifierName,Q000009,11001600,,,4,,Y,adverse effects
2158,DescriptorName,D003704,11001600,,,5,Dementia,N,
2159,QualifierName,Q000150,11001600,,,5,,Y,complications
2160,DescriptorName,D004421,11001600,,,6,Dystonia,N,
2161,QualifierName,Q000139,11001600,,,6,,Y,chemically induced
2162,DescriptorName,D005260,11001600,,,7,Female,N,
2163,DescriptorName,D006801,11001600,,,8,Humans,N,
2164,DescriptorName,D008297,11001600,,,9,Male,N,
2165,DescriptorName,D008875,11001600,,,10,Middle Aged,N,
2166,DescriptorName,D011605,11001600,,,11,"Psychoses, Substance-Induced",N,
2167,QualifierName,Q000150,11001600,,,11,,N,complications
2168,Chemical,D000927,11008259,Anticonvulsants,0,,,,
2169,Chemical,D018755,11008259,GABA Agonists,0,,,,
2170,Chemical,D014179,11008259,Neurotransmitter Uptake Inhibitors,0,,,,
2171,Chemical,D009557,11008259,Nipecotic Acids,0,,,,
2172,Chemical,D000078308,11008259,Tiagabine,Z80I64HMNP,,,,
2173,DescriptorName,D000293,11008259,,,1,Adolescent,N,
2174,DescriptorName,D000927,11008259,,,2,Anticonvulsants,N,
2175,QualifierName,Q000008,11008259,,,2,,N,administration & dosage
2176,DescriptorName,D002648,11008259,,,3,Child,N,
2177,DescriptorName,D004827,11008259,,,4,Epilepsy,N,
2178,QualifierName,Q000188,11008259,,,4,,N,drug therapy
2179,DescriptorName,D005260,11008259,,,5,Female,N,
2180,DescriptorName,D018755,11008259,,,6,GABA Agonists,N,
2181,QualifierName,Q000008,11008259,,,6,,N,administration & dosage
2182,DescriptorName,D006801,11008259,,,7,Humans,N,
2183,DescriptorName,D014179,11008259,,,8,Neurotransmitter Uptake Inhibitors,N,
2184,QualifierName,Q000009,11008259,,,8,,Y,adverse effects
2185,DescriptorName,D009557,11008259,,,9,Nipecotic Acids,N,
2186,QualifierName,Q000008,11008259,,,9,,N,administration & dosage
2187,DescriptorName,D013226,11008259,,,10,Status Epilepticus,N,
2188,QualifierName,Q000139,11008259,,,10,,Y,chemically induced
2189,DescriptorName,D000078308,11008259,,,11,Tiagabine,N,
2190,Chemical,D008094,110153,Lithium,9FN79X2M3F,,,,
2191,DescriptorName,D000293,110153,,,1,Adolescent,N,
2192,DescriptorName,D000328,110153,,,2,Adult,N,
2193,DescriptorName,D017109,110153,,,3,"Akathisia, Drug-Induced",N,
2194,DescriptorName,D001714,110153,,,4,Bipolar Disorder,N,
2195,QualifierName,Q000188,110153,,,4,,N,drug therapy
2196,DescriptorName,D003221,110153,,,5,Confusion,N,
2197,QualifierName,Q000139,110153,,,5,,N,chemically induced
2198,DescriptorName,D003693,110153,,,6,Delirium,N,
2199,QualifierName,Q000139,110153,,,6,,N,chemically induced
2200,DescriptorName,D004830,110153,,,7,"Epilepsy, Tonic-Clonic",N,
2201,QualifierName,Q000139,110153,,,7,,N,chemically induced
2202,DescriptorName,D005260,110153,,,8,Female,N,
2203,DescriptorName,D006801,110153,,,9,Humans,N,
2204,DescriptorName,D008094,110153,,,10,Lithium,N,
2205,QualifierName,Q000009,110153,,,10,,Y,adverse effects
2206,DescriptorName,D008297,110153,,,11,Male,N,
2207,DescriptorName,D009422,110153,,,12,Nervous System Diseases,N,
2208,QualifierName,Q000139,110153,,,12,,Y,chemically induced
2209,DescriptorName,D011605,110153,,,13,"Psychoses, Substance-Induced",N,
2210,QualifierName,Q000209,110153,,,13,,N,etiology
2211,DescriptorName,D012559,110153,,,14,Schizophrenia,N,
2212,QualifierName,Q000188,110153,,,14,,N,drug therapy
2213,Chemical,D000927,11020127,Anticonvulsants,0,,,,
2214,Chemical,D017320,11020127,HIV Protease Inhibitors,0,,,,
2215,Chemical,D002220,11020127,Carbamazepine,33CM23913M,,,,
2216,Chemical,D003577,11020127,Cytochrome P-450 Enzyme System,9035-51-2,,,,
2217,Chemical,D006899,11020127,Mixed Function Oxygenases,EC 1.-,,,,
2218,Chemical,C104464,11020127,"CYP3A protein, human",EC 1.14.14.1,,,,
2219,Chemical,D051544,11020127,Cytochrome P-450 CYP3A,EC 1.14.14.1,,,,
2220,Chemical,C510163,11020127,"CYP3A4 protein, human",EC 1.14.14.55,,,,
2221,Chemical,D019438,11020127,Ritonavir,O3J8G9O825,,,,
2222,DescriptorName,D000328,11020127,,,1,Adult,N,
2223,DescriptorName,D000927,11020127,,,2,Anticonvulsants,N,
2224,QualifierName,Q000009,11020127,,,2,,Y,adverse effects
2225,DescriptorName,D002220,11020127,,,3,Carbamazepine,N,
2226,QualifierName,Q000009,11020127,,,3,,Y,adverse effects
2227,DescriptorName,D051544,11020127,,,4,Cytochrome P-450 CYP3A,N,
2228,DescriptorName,D003577,11020127,,,5,Cytochrome P-450 Enzyme System,N,
2229,QualifierName,Q000378,11020127,,,5,,N,metabolism
2230,DescriptorName,D004347,11020127,,,6,Drug Interactions,N,
2231,DescriptorName,D004828,11020127,,,7,"Epilepsies, Partial",N,
2232,QualifierName,Q000188,11020127,,,7,,N,drug therapy
2233,DescriptorName,D017320,11020127,,,8,HIV Protease Inhibitors,N,
2234,QualifierName,Q000009,11020127,,,8,,Y,adverse effects
2235,DescriptorName,D006801,11020127,,,9,Humans,N,
2236,DescriptorName,D008297,11020127,,,10,Male,N,
2237,DescriptorName,D006899,11020127,,,11,Mixed Function Oxygenases,N,
2238,QualifierName,Q000378,11020127,,,11,,N,metabolism
2239,DescriptorName,D010291,11020127,,,12,Paresis,N,
2240,QualifierName,Q000188,11020127,,,12,,N,drug therapy
2241,DescriptorName,D019438,11020127,,,13,Ritonavir,N,
2242,QualifierName,Q000009,11020127,,,13,,Y,adverse effects
2243,DescriptorName,D013997,11020127,,,14,Time Factors,N,
2244,Chemical,D007073,11022272,Immunoglobulin E,37341-29-0,,,,
2245,Chemical,C028815,11022272,salmon calcitonin,7SFC6U2VI5,,,,
2246,Chemical,D002116,11022272,Calcitonin,9007-12-9,,,,
2247,Chemical,D012697,11022272,Serine Endopeptidases,EC 3.4.21.-,,,,
2248,Chemical,D053802,11022272,Tryptases,EC 3.4.21.59,,,,
2249,DescriptorName,D000707,11022272,,,1,Anaphylaxis,N,
2250,QualifierName,Q000139,11022272,,,1,,Y,chemically induced
2251,DescriptorName,D002116,11022272,,,2,Calcitonin,N,
2252,QualifierName,Q000008,11022272,,,2,,N,administration & dosage
2253,DescriptorName,D004342,11022272,,,3,Drug Hypersensitivity,N,
2254,QualifierName,Q000209,11022272,,,3,,Y,etiology
2255,DescriptorName,D005260,11022272,,,4,Female,N,
2256,DescriptorName,D006636,11022272,,,5,Histamine Release,N,
2257,DescriptorName,D006801,11022272,,,6,Humans,N,
2258,DescriptorName,D007073,11022272,,,7,Immunoglobulin E,N,
2259,QualifierName,Q000276,11022272,,,7,,N,immunology
2260,DescriptorName,D007273,11022272,,,8,"Injections, Intramuscular",N,
2261,DescriptorName,D008875,11022272,,,9,Middle Aged,N,
2262,DescriptorName,D009299,11022272,,,10,Nasal Provocation Tests,N,
2263,DescriptorName,D010024,11022272,,,11,Osteoporosis,N,
2264,QualifierName,Q000188,11022272,,,11,,N,drug therapy
2265,DescriptorName,D012697,11022272,,,12,Serine Endopeptidases,N,
2266,QualifierName,Q000097,11022272,,,12,,N,blood
2267,DescriptorName,D012882,11022272,,,13,Skin Tests,N,
2268,DescriptorName,D053802,11022272,,,14,Tryptases,N,
2269,Chemical,D000900,11026106,Anti-Bacterial Agents,0,,,,
2270,Chemical,D000974,11026106,"Antibodies, Antinuclear",0,,,,
2271,Chemical,D005938,11026106,Glucocorticoids,0,,,,
2272,Chemical,D008911,11026106,Minocycline,FYY3R43WGO,,,,
2273,DescriptorName,D000293,11026106,,,1,Adolescent,N,
2274,DescriptorName,D000328,11026106,,,2,Adult,N,
2275,DescriptorName,D000900,11026106,,,3,Anti-Bacterial Agents,N,
2276,QualifierName,Q000009,11026106,,,3,,Y,adverse effects
2277,DescriptorName,D000974,11026106,,,4,"Antibodies, Antinuclear",N,
2278,QualifierName,Q000097,11026106,,,4,,N,blood
2279,DescriptorName,D001706,11026106,,,5,Biopsy,N,
2280,DescriptorName,D001799,11026106,,,6,Blood Sedimentation,N,
2281,DescriptorName,D056486,11026106,,,7,Chemical and Drug Induced Liver Injury,N,
2282,QualifierName,Q000097,11026106,,,7,,N,blood
2283,DescriptorName,D005260,11026106,,,8,Female,N,
2284,DescriptorName,D005938,11026106,,,9,Glucocorticoids,N,
2285,QualifierName,Q000627,11026106,,,9,,N,therapeutic use
2286,DescriptorName,D019693,11026106,,,10,"Hepatitis, Autoimmune",N,
2287,QualifierName,Q000097,11026106,,,10,,N,blood
2288,DescriptorName,D006801,11026106,,,11,Humans,N,
2289,DescriptorName,D008099,11026106,,,12,Liver,N,
2290,QualifierName,Q000187,11026106,,,12,,Y,drug effects
2291,DescriptorName,D008111,11026106,,,13,Liver Function Tests,N,
2292,DescriptorName,D008297,11026106,,,14,Male,N,
2293,DescriptorName,D008875,11026106,,,15,Middle Aged,N,
2294,DescriptorName,D008911,11026106,,,16,Minocycline,N,
2295,QualifierName,Q000009,11026106,,,16,,Y,adverse effects
2296,DescriptorName,D009130,11026106,,,17,"Muscle, Smooth",N,
2297,QualifierName,Q000276,11026106,,,17,,N,immunology
2298,Chemical,D001215,11030530,Asparaginase,EC 3.5.1.1,,,,
2299,DescriptorName,D000328,11030530,,,1,Adult,N,
2300,DescriptorName,D001215,11030530,,,2,Asparaginase,N,
2301,QualifierName,Q000008,11030530,,,2,,N,administration & dosage
2302,DescriptorName,D002493,11030530,,,3,Central Nervous System Diseases,N,
2303,QualifierName,Q000139,11030530,,,3,,Y,chemically induced
2304,DescriptorName,D005260,11030530,,,4,Female,N,
2305,DescriptorName,D006801,11030530,,,5,Humans,N,
2306,DescriptorName,D008279,11030530,,,6,Magnetic Resonance Imaging,N,
2307,DescriptorName,D054198,11030530,,,7,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
2308,QualifierName,Q000150,11030530,,,7,,N,complications
2309,DescriptorName,D012640,11030530,,,8,Seizures,N,
2310,QualifierName,Q000139,11030530,,,8,,Y,chemically induced
2311,Chemical,D004338,11033734,Drug Combinations,0,,,,
2312,Chemical,D011480,11033734,Protease Inhibitors,0,,,,
2313,Chemical,D013845,11033734,Thienamycins,0,,,,
2314,Chemical,D015377,11033734,Cilastatin,141A6AMN38,,,,
2315,Chemical,D015378,11033734,Imipenem,71OTZ9ZE0A,,,,
2316,Chemical,D000077728,11033734,"Cilastatin, Imipenem Drug Combination",92309-29-0,,,,
2317,DescriptorName,D000293,11033734,,,1,Adolescent,N,
2318,DescriptorName,D002648,11033734,,,2,Child,N,
2319,DescriptorName,D015377,11033734,,,3,Cilastatin,N,
2320,QualifierName,Q000009,11033734,,,3,,Y,adverse effects
2321,DescriptorName,D000077728,11033734,,,4,"Cilastatin, Imipenem Drug Combination",N,
2322,DescriptorName,D004338,11033734,,,5,Drug Combinations,N,
2323,DescriptorName,D005260,11033734,,,6,Female,N,
2324,DescriptorName,D005334,11033734,,,7,Fever,N,
2325,QualifierName,Q000188,11033734,,,7,,N,drug therapy
2326,DescriptorName,D006801,11033734,,,8,Humans,N,
2327,DescriptorName,D015378,11033734,,,9,Imipenem,N,
2328,QualifierName,Q000009,11033734,,,9,,Y,adverse effects
2329,DescriptorName,D009369,11033734,,,10,Neoplasms,N,
2330,QualifierName,Q000150,11033734,,,10,,Y,complications
2331,DescriptorName,D009503,11033734,,,11,Neutropenia,N,
2332,QualifierName,Q000150,11033734,,,11,,N,complications
2333,DescriptorName,D011480,11033734,,,12,Protease Inhibitors,N,
2334,QualifierName,Q000009,11033734,,,12,,Y,adverse effects
2335,DescriptorName,D012640,11033734,,,13,Seizures,N,
2336,QualifierName,Q000139,11033734,,,13,,Y,chemically induced
2337,DescriptorName,D013845,11033734,,,14,Thienamycins,N,
2338,QualifierName,Q000009,11033734,,,14,,Y,adverse effects
2339,Chemical,D000085,11034877,Acetates,0,,,,
2340,Chemical,D000588,11034877,Amines,0,,,,
2341,Chemical,D000927,11034877,Anticonvulsants,0,,,,
2342,Chemical,D003509,11034877,Cyclohexanecarboxylic Acids,0,,,,
2343,Chemical,D005680,11034877,gamma-Aminobutyric Acid,56-12-2,,,,
2344,Chemical,D000077206,11034877,Gabapentin,6CW7F3G59X,,,,
2345,DescriptorName,D000085,11034877,,,1,Acetates,N,
2346,QualifierName,Q000009,11034877,,,1,,Y,adverse effects
2347,DescriptorName,D000328,11034877,,,2,Adult,N,
2348,DescriptorName,D000339,11034877,,,3,Affect,N,
2349,QualifierName,Q000187,11034877,,,3,,Y,drug effects
2350,DescriptorName,D000588,11034877,,,4,Amines,Y,
2351,DescriptorName,D000927,11034877,,,5,Anticonvulsants,N,
2352,QualifierName,Q000009,11034877,,,5,,Y,adverse effects
2353,DescriptorName,D002690,11034877,,,6,Chlamydia Infections,N,
2354,QualifierName,Q000150,11034877,,,6,,Y,complications
2355,DescriptorName,D003509,11034877,,,7,Cyclohexanecarboxylic Acids,Y,
2356,DescriptorName,D004679,11034877,,,8,Encephalomyelitis,N,
2357,QualifierName,Q000150,11034877,,,8,,Y,complications
2358,DescriptorName,D004828,11034877,,,9,"Epilepsies, Partial",N,
2359,QualifierName,Q000188,11034877,,,9,,Y,drug therapy
2360,DescriptorName,D005260,11034877,,,10,Female,N,
2361,DescriptorName,D000077206,11034877,,,11,Gabapentin,N,
2362,DescriptorName,D006801,11034877,,,12,Humans,N,
2363,DescriptorName,D010292,11034877,,,13,Paresthesia,N,
2364,QualifierName,Q000188,11034877,,,13,,Y,drug therapy
2365,DescriptorName,D012920,11034877,,,14,Social Behavior Disorders,N,
2366,QualifierName,Q000139,11034877,,,14,,N,chemically induced
2367,DescriptorName,D016896,11034877,,,15,Treatment Outcome,N,
2368,DescriptorName,D005680,11034877,,,16,gamma-Aminobutyric Acid,Y,
2369,Chemical,D000636,11059196,Aminosalicylic Acids,0,,,,
2370,DescriptorName,D000208,11059196,,,1,Acute Disease,N,
2371,DescriptorName,D000636,11059196,,,2,Aminosalicylic Acids,N,
2372,QualifierName,Q000009,11059196,,,2,,Y,adverse effects
2373,DescriptorName,D002648,11059196,,,3,Child,N,
2374,DescriptorName,D003093,11059196,,,4,"Colitis, Ulcerative",N,
2375,QualifierName,Q000150,11059196,,,4,,Y,complications
2376,DescriptorName,D005500,11059196,,,5,Follow-Up Studies,N,
2377,DescriptorName,D006801,11059196,,,6,Humans,N,
2378,DescriptorName,D008134,11059196,,,7,Long-Term Care,N,
2379,DescriptorName,D008297,11059196,,,8,Male,N,
2380,DescriptorName,D010195,11059196,,,9,Pancreatitis,N,
2381,QualifierName,Q000139,11059196,,,9,,Y,chemically induced
2382,Chemical,D020888,11077455,Vigabatrin,GR120KRT6K,,,,
2383,DescriptorName,D000328,11077455,,,1,Adult,N,
2384,DescriptorName,D004585,11077455,,,2,Electrooculography,N,
2385,QualifierName,Q000706,11077455,,,2,,Y,statistics & numerical data
2386,DescriptorName,D004594,11077455,,,3,Electrophysiology,N,
2387,DescriptorName,D004596,11077455,,,4,Electroretinography,N,
2388,QualifierName,Q000706,11077455,,,4,,Y,statistics & numerical data
2389,DescriptorName,D004827,11077455,,,5,Epilepsy,N,
2390,QualifierName,Q000188,11077455,,,5,,Y,drug therapy
2391,DescriptorName,D005074,11077455,,,6,"Evoked Potentials, Visual",N,
2392,QualifierName,Q000502,11077455,,,6,,Y,physiology
2393,DescriptorName,D005260,11077455,,,7,Female,N,
2394,DescriptorName,D006801,11077455,,,8,Humans,N,
2395,DescriptorName,D008297,11077455,,,9,Male,N,
2396,DescriptorName,D008875,11077455,,,10,Middle Aged,N,
2397,DescriptorName,D012164,11077455,,,11,Retinal Diseases,N,
2398,QualifierName,Q000139,11077455,,,11,,Y,chemically induced
2399,DescriptorName,D020888,11077455,,,12,Vigabatrin,N,
2400,QualifierName,Q000009,11077455,,,12,,Y,adverse effects
2401,DescriptorName,D014786,11077455,,,13,Vision Disorders,N,
2402,QualifierName,Q000139,11077455,,,13,,Y,chemically induced
2403,DescriptorName,D058609,11077455,,,14,Visual Field Tests,N,
2404,QualifierName,Q000706,11077455,,,14,,N,statistics & numerical data
2405,DescriptorName,D014794,11077455,,,15,Visual Fields,N,
2406,QualifierName,Q000187,11077455,,,15,,Y,drug effects
2407,Chemical,D000928,11093071,Antidepressive Agents,0,,,,
2408,Chemical,D000998,11093071,Antiviral Agents,0,,,,
2409,Chemical,D007370,11093071,Interferon Type I,0,,,,
2410,Chemical,D011994,11093071,Recombinant Proteins,0,,,,
2411,Chemical,D012254,11093071,Ribavirin,49717AWG6K,,,,
2412,DescriptorName,D000328,11093071,,,1,Adult,N,
2413,DescriptorName,D000928,11093071,,,2,Antidepressive Agents,N,
2414,QualifierName,Q000627,11093071,,,2,,Y,therapeutic use
2415,DescriptorName,D000998,11093071,,,3,Antiviral Agents,N,
2416,QualifierName,Q000009,11093071,,,3,,Y,adverse effects
2417,DescriptorName,D005260,11093071,,,4,Female,N,
2418,DescriptorName,D019698,11093071,,,5,"Hepatitis C, Chronic",N,
2419,QualifierName,Q000150,11093071,,,5,,N,complications
2420,DescriptorName,D006801,11093071,,,6,Humans,N,
2421,DescriptorName,D007370,11093071,,,7,Interferon Type I,N,
2422,QualifierName,Q000009,11093071,,,7,,Y,adverse effects
2423,DescriptorName,D011569,11093071,,,8,Psychiatric Status Rating Scales,N,
2424,DescriptorName,D011618,11093071,,,9,Psychotic Disorders,N,
2425,QualifierName,Q000150,11093071,,,9,,N,complications
2426,DescriptorName,D011994,11093071,,,10,Recombinant Proteins,N,
2427,DescriptorName,D012254,11093071,,,11,Ribavirin,N,
2428,QualifierName,Q000627,11093071,,,11,,N,therapeutic use
2429,Chemical,D000900,11096051,Anti-Bacterial Agents,0,,,,
2430,Chemical,D015314,11096051,Dialysis Solutions,0,,,,
2431,Chemical,D010758,11096051,Phosphorus,27YLU75U4W,,,,
2432,Chemical,D014640,11096051,Vancomycin,6Q205EH1VU,,,,
2433,DescriptorName,D000328,11096051,,,1,Adult,N,
2434,DescriptorName,D000368,11096051,,,2,Aged,N,
2435,DescriptorName,D000900,11096051,,,3,Anti-Bacterial Agents,N,
2436,QualifierName,Q000506,11096051,,,3,,Y,poisoning
2437,DescriptorName,D015314,11096051,,,4,Dialysis Solutions,N,
2438,QualifierName,Q000008,11096051,,,4,,Y,administration & dosage
2439,DescriptorName,D062787,11096051,,,5,Drug Overdose,N,
2440,QualifierName,Q000628,11096051,,,5,,N,therapy
2441,DescriptorName,D017583,11096051,,,6,Hemodiafiltration,N,
2442,QualifierName,Q000009,11096051,,,6,,Y,adverse effects
2443,DescriptorName,D006801,11096051,,,7,Humans,N,
2444,DescriptorName,D017674,11096051,,,8,Hypophosphatemia,N,
2445,QualifierName,Q000188,11096051,,,8,,N,drug therapy
2446,DescriptorName,D007262,11096051,,,9,"Infusions, Intravenous",N,
2447,DescriptorName,D008297,11096051,,,10,Male,N,
2448,DescriptorName,D016106,11096051,,,11,Methicillin Resistance,N,
2449,DescriptorName,D010758,11096051,,,12,Phosphorus,N,
2450,QualifierName,Q000008,11096051,,,12,,N,administration & dosage
2451,DescriptorName,D013203,11096051,,,13,Staphylococcal Infections,N,
2452,QualifierName,Q000188,11096051,,,13,,N,drug therapy
2453,DescriptorName,D014640,11096051,,,14,Vancomycin,N,
2454,QualifierName,Q000506,11096051,,,14,,Y,poisoning
2455,Chemical,D000927,11099623,Anticonvulsants,0,,,,
2456,DescriptorName,D000927,11099623,,,1,Anticonvulsants,N,
2457,QualifierName,Q000627,11099623,,,1,,N,therapeutic use
2458,DescriptorName,D002544,11099623,,,2,Cerebral Infarction,N,
2459,QualifierName,Q000000981,11099623,,,2,,N,diagnostic imaging
2460,DescriptorName,D002547,11099623,,,3,Cerebral Palsy,N,
2461,QualifierName,Q000150,11099623,,,3,,N,complications
2462,DescriptorName,D002675,11099623,,,4,"Child, Preschool",N,
2463,DescriptorName,D004618,11099623,,,5,"Embolism, Air",N,
2464,QualifierName,Q000209,11099623,,,5,,N,etiology
2465,DescriptorName,D005764,11099623,,,6,Gastroesophageal Reflux,N,
2466,QualifierName,Q000209,11099623,,,6,,Y,etiology
2467,DescriptorName,D006801,11099623,,,7,Humans,N,
2468,DescriptorName,D006931,11099623,,,8,Hyperbaric Oxygenation,N,
2469,QualifierName,Q000009,11099623,,,8,,Y,adverse effects
2470,DescriptorName,D007223,11099623,,,9,Infant,N,
2471,DescriptorName,D008297,11099623,,,10,Male,N,
2472,DescriptorName,D011696,11099623,,,11,"Purpura, Thrombocytopenic",N,
2473,QualifierName,Q000209,11099623,,,11,,N,etiology
2474,DescriptorName,D011859,11099623,,,12,Radiography,N,
2475,DescriptorName,D012131,11099623,,,13,Respiratory Insufficiency,N,
2476,QualifierName,Q000209,11099623,,,13,,Y,etiology
2477,DescriptorName,D012640,11099623,,,14,Seizures,N,
2478,QualifierName,Q000150,11099623,,,14,,N,complications
2479,Chemical,D004396,11105373,Coloring Agents,0,,,,
2480,Chemical,D006873,11105373,Hydroquinones,0,,,,
2481,Chemical,D014212,11105373,Tretinoin,5688UTC01R,,,,
2482,Chemical,C031927,11105373,hydroquinone,XV74C1N1AE,,,,
2483,DescriptorName,D000287,11105373,,,1,"Administration, Topical",N,
2484,DescriptorName,D000328,11105373,,,2,Adult,N,
2485,DescriptorName,D004396,11105373,,,3,Coloring Agents,N,
2486,DescriptorName,D005148,11105373,,,4,Facial Dermatoses,N,
2487,QualifierName,Q000188,11105373,,,4,,Y,drug therapy
2488,DescriptorName,D005500,11105373,,,5,Follow-Up Studies,N,
2489,DescriptorName,D006801,11105373,,,6,Humans,N,
2490,DescriptorName,D006873,11105373,,,7,Hydroquinones,N,
2491,QualifierName,Q000008,11105373,,,7,,N,administration & dosage
2492,DescriptorName,D017495,11105373,,,8,Hyperpigmentation,N,
2493,QualifierName,Q000188,11105373,,,8,,Y,drug therapy
2494,DescriptorName,D008297,11105373,,,9,Male,N,
2495,DescriptorName,D009260,11105373,,,10,Nail Diseases,N,
2496,QualifierName,Q000139,11105373,,,10,,Y,chemically induced
2497,DescriptorName,D014212,11105373,,,11,Tretinoin,N,
2498,QualifierName,Q000008,11105373,,,11,,N,administration & dosage
2499,Chemical,D001761,11109149,Bleomycin,11056-06-7,,,,
2500,Chemical,D008727,11109149,Methotrexate,YL5FZ2Y5U1,,,,
2501,DescriptorName,D000971,11109149,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
2502,QualifierName,Q000009,11109149,,,1,,Y,adverse effects
2503,DescriptorName,D001761,11109149,,,2,Bleomycin,N,
2504,QualifierName,Q000009,11109149,,,2,,N,adverse effects
2505,DescriptorName,D002294,11109149,,,3,"Carcinoma, Squamous Cell",N,
2506,QualifierName,Q000188,11109149,,,3,,N,drug therapy
2507,DescriptorName,D003490,11109149,,,4,Cyanosis,N,
2508,QualifierName,Q000139,11109149,,,4,,N,chemically induced
2509,DescriptorName,D005385,11109149,,,5,Fingers,N,
2510,QualifierName,Q000473,11109149,,,5,,Y,pathology
2511,DescriptorName,D005734,11109149,,,6,Gangrene,N,
2512,QualifierName,Q000139,11109149,,,6,,Y,chemically induced
2513,DescriptorName,D006801,11109149,,,7,Humans,N,
2514,DescriptorName,D007511,11109149,,,8,Ischemia,N,
2515,QualifierName,Q000139,11109149,,,8,,N,chemically induced
2516,DescriptorName,D008297,11109149,,,9,Male,N,
2517,DescriptorName,D008727,11109149,,,10,Methotrexate,N,
2518,QualifierName,Q000009,11109149,,,10,,N,adverse effects
2519,DescriptorName,D008875,11109149,,,11,Middle Aged,N,
2520,DescriptorName,D010610,11109149,,,12,Pharyngeal Neoplasms,N,
2521,QualifierName,Q000188,11109149,,,12,,N,drug therapy
2522,Chemical,D000924,11111942,Anticholesteremic Agents,0,,,,
2523,Chemical,D000925,11111942,Anticoagulants,0,,,,
2524,Chemical,D004791,11111942,Enzyme Inhibitors,0,,,,
2525,Chemical,D006454,11111942,Hemoglobins,0,,,,
2526,Chemical,D002792,11111942,Cholestyramine Resin,11041-12-6,,,,
2527,Chemical,D014812,11111942,Vitamin K,12001-79-5,,,,
2528,Chemical,D014859,11111942,Warfarin,5Q7ZVV76EI,,,,
2529,Chemical,D012293,11111942,Rifampin,VJT6J7R4TR,,,,
2530,DescriptorName,D000368,11111942,,,1,Aged,N,
2531,DescriptorName,D000924,11111942,,,2,Anticholesteremic Agents,N,
2532,QualifierName,Q000627,11111942,,,2,,Y,therapeutic use
2533,DescriptorName,D000925,11111942,,,3,Anticoagulants,N,
2534,QualifierName,Q000009,11111942,,,3,,Y,adverse effects
2535,DescriptorName,D001774,11111942,,,4,Blood Chemical Analysis,N,
2536,DescriptorName,D002792,11111942,,,5,Cholestyramine Resin,N,
2537,QualifierName,Q000627,11111942,,,5,,Y,therapeutic use
2538,DescriptorName,D003967,11111942,,,6,Diarrhea,N,
2539,QualifierName,Q000188,11111942,,,6,,N,drug therapy
2540,DescriptorName,D004562,11111942,,,7,Electrocardiography,N,
2541,DescriptorName,D004791,11111942,,,8,Enzyme Inhibitors,N,
2542,QualifierName,Q000008,11111942,,,8,,N,administration & dosage
2543,DescriptorName,D005260,11111942,,,9,Female,N,
2544,DescriptorName,D006400,11111942,,,10,Hematocrit,N,
2545,DescriptorName,D006454,11111942,,,11,Hemoglobins,N,
2546,QualifierName,Q000032,11111942,,,11,,N,analysis
2547,DescriptorName,D006801,11111942,,,12,Humans,N,
2548,DescriptorName,D007958,11111942,,,13,Leukocyte Count,N,
2549,DescriptorName,D010314,11111942,,,14,Partial Thromboplastin Time,N,
2550,DescriptorName,D010976,11111942,,,15,Platelet Count,N,
2551,DescriptorName,D011517,11111942,,,16,Prothrombin Time,N,
2552,DescriptorName,D012293,11111942,,,17,Rifampin,N,
2553,QualifierName,Q000008,11111942,,,17,,N,administration & dosage
2554,DescriptorName,D014812,11111942,,,18,Vitamin K,N,
2555,QualifierName,Q000008,11111942,,,18,,N,administration & dosage
2556,DescriptorName,D014859,11111942,,,19,Warfarin,N,
2557,QualifierName,Q000009,11111942,,,19,,Y,adverse effects
2558,Chemical,D019774,11122162,Blood Coagulation Factor Inhibitors,0,,,,
2559,Chemical,D001779,11122162,Blood Coagulation Factors,0,,,,
2560,Chemical,D011994,11122162,Recombinant Proteins,0,,,,
2561,Chemical,C025667,11122162,prothrombin complex concentrates,37224-63-8,,,,
2562,Chemical,D005169,11122162,Factor VIII,9001-27-8,,,,
2563,Chemical,D015942,11122162,Factor VIIa,EC 3.4.21.21,,,,
2564,DescriptorName,D000005,11122162,,,1,Abdomen,N,
2565,DescriptorName,D000328,11122162,,,2,Adult,N,
2566,DescriptorName,D000368,11122162,,,3,Aged,N,
2567,DescriptorName,D019774,11122162,,,4,Blood Coagulation Factor Inhibitors,N,
2568,QualifierName,Q000097,11122162,,,4,,N,blood
2569,DescriptorName,D001779,11122162,,,5,Blood Coagulation Factors,N,
2570,QualifierName,Q000009,11122162,,,5,,Y,adverse effects
2571,DescriptorName,D005169,11122162,,,6,Factor VIII,N,
2572,DescriptorName,D015942,11122162,,,7,Factor VIIa,N,
2573,QualifierName,Q000627,11122162,,,7,,Y,therapeutic use
2574,DescriptorName,D006395,11122162,,,8,Hemarthrosis,N,
2575,QualifierName,Q000188,11122162,,,8,,Y,drug therapy
2576,DescriptorName,D006406,11122162,,,9,Hematoma,N,
2577,QualifierName,Q000188,11122162,,,9,,N,drug therapy
2578,DescriptorName,D006467,11122162,,,10,Hemophilia A,N,
2579,QualifierName,Q000097,11122162,,,10,,N,blood
2580,DescriptorName,D006801,11122162,,,11,Humans,N,
2581,DescriptorName,D007719,11122162,,,12,Knee Joint,N,
2582,DescriptorName,D008297,11122162,,,13,Male,N,
2583,DescriptorName,D009203,11122162,,,14,Myocardial Infarction,N,
2584,QualifierName,Q000209,11122162,,,14,,Y,etiology
2585,DescriptorName,D011994,11122162,,,15,Recombinant Proteins,N,
2586,QualifierName,Q000009,11122162,,,15,,N,adverse effects
2587,Chemical,D009125,11126885,"Muscle Relaxants, Central",0,,,,
2588,Chemical,D011803,11126885,Quinine,A7V27PHC7A,,,,
2589,DescriptorName,D000368,11126885,,,1,Aged,N,
2590,DescriptorName,D003937,11126885,,,2,"Diagnosis, Differential",N,
2591,DescriptorName,D006801,11126885,,,3,Humans,N,
2592,DescriptorName,D008297,11126885,,,4,Male,N,
2593,DescriptorName,D009125,11126885,,,5,"Muscle Relaxants, Central",N,
2594,QualifierName,Q000009,11126885,,,5,,Y,adverse effects
2595,DescriptorName,D011803,11126885,,,6,Quinine,N,
2596,QualifierName,Q000009,11126885,,,6,,Y,adverse effects
2597,DescriptorName,D012008,11126885,,,7,Recurrence,N,
2598,DescriptorName,D020922,11126885,,,8,Sleep-Wake Transition Disorders,N,
2599,QualifierName,Q000188,11126885,,,8,,N,drug therapy
2600,DescriptorName,D013921,11126885,,,9,Thrombocytopenia,N,
2601,QualifierName,Q000139,11126885,,,9,,Y,chemically induced
2602,Chemical,D006074,11131346,Gout Suppressants,0,,,,
2603,Chemical,D003078,11131346,Colchicine,SML2Y3J35T,,,,
2604,DescriptorName,D001628,11131346,,,1,Beverages,N,
2605,DescriptorName,D002648,11131346,,,2,Child,N,
2606,DescriptorName,D002957,11131346,,,3,Citrus,N,
2607,DescriptorName,D003078,11131346,,,4,Colchicine,N,
2608,QualifierName,Q000009,11131346,,,4,,Y,adverse effects
2609,DescriptorName,D010505,11131346,,,5,Familial Mediterranean Fever,N,
2610,QualifierName,Q000188,11131346,,,5,,Y,drug therapy
2611,DescriptorName,D005260,11131346,,,6,Female,N,
2612,DescriptorName,D006074,11131346,,,7,Gout Suppressants,N,
2613,QualifierName,Q000009,11131346,,,7,,Y,adverse effects
2614,DescriptorName,D006801,11131346,,,8,Humans,N,
2615,Chemical,D000964,11142491,"Antimetabolites, Antineoplastic",0,,,,
2616,Chemical,D011994,11142491,Recombinant Proteins,0,,,,
2617,Chemical,D003561,11142491,Cytarabine,04079A1RDZ,,,,
2618,Chemical,D016179,11142491,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
2619,Chemical,D005047,11142491,Etoposide,6PLQ3CP4P3,,,,
2620,Chemical,D014740,11142491,Vidarabine,FA2DM6879K,,,,
2621,Chemical,C024352,11142491,fludarabine,P2K93U8740,,,,
2622,Chemical,D002330,11142491,Carmustine,U68WG3173Y,,,,
2623,DescriptorName,D000208,11142491,,,1,Acute Disease,N,
2624,DescriptorName,D000964,11142491,,,2,"Antimetabolites, Antineoplastic",N,
2625,QualifierName,Q000627,11142491,,,2,,Y,therapeutic use
2626,DescriptorName,D000971,11142491,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
2627,QualifierName,Q000008,11142491,,,3,,N,administration & dosage
2628,DescriptorName,D002330,11142491,,,4,Carmustine,N,
2629,QualifierName,Q000008,11142491,,,4,,N,administration & dosage
2630,DescriptorName,D003561,11142491,,,5,Cytarabine,N,
2631,QualifierName,Q000008,11142491,,,5,,N,administration & dosage
2632,DescriptorName,D005047,11142491,,,6,Etoposide,N,
2633,QualifierName,Q000008,11142491,,,6,,N,administration & dosage
2634,DescriptorName,D017809,11142491,,,7,Fatal Outcome,N,
2635,DescriptorName,D020022,11142491,,,8,Genetic Predisposition to Disease,N,
2636,DescriptorName,D016179,11142491,,,9,Granulocyte Colony-Stimulating Factor,N,
2637,QualifierName,Q000009,11142491,,,9,,N,adverse effects
2638,DescriptorName,D019650,11142491,,,10,Hematopoietic Stem Cell Mobilization,N,
2639,DescriptorName,D018380,11142491,,,11,Hematopoietic Stem Cell Transplantation,Y,
2640,QualifierName,Q000009,11142491,,,11,,N,adverse effects
2641,DescriptorName,D006801,11142491,,,12,Humans,N,
2642,DescriptorName,D015451,11142491,,,13,"Leukemia, Lymphocytic, Chronic, B-Cell",N,
2643,QualifierName,Q000188,11142491,,,13,,N,drug therapy
2644,DescriptorName,D007951,11142491,,,14,"Leukemia, Myeloid",N,
2645,QualifierName,Q000209,11142491,,,14,,Y,etiology
2646,DescriptorName,D008175,11142491,,,15,Lung Neoplasms,N,
2647,QualifierName,Q000209,11142491,,,15,,Y,etiology
2648,DescriptorName,D008297,11142491,,,16,Male,N,
2649,DescriptorName,D008875,11142491,,,17,Middle Aged,N,
2650,DescriptorName,D018365,11142491,,,18,"Neoplasm, Residual",N,
2651,DescriptorName,D009378,11142491,,,19,"Neoplasms, Multiple Primary",Y,
2652,DescriptorName,D016609,11142491,,,20,"Neoplasms, Second Primary",Y,
2653,DescriptorName,D011994,11142491,,,21,Recombinant Proteins,N,
2654,QualifierName,Q000009,11142491,,,21,,N,adverse effects
2655,DescriptorName,D012306,11142491,,,22,Risk,N,
2656,DescriptorName,D012907,11142491,,,23,Smoking,N,
2657,QualifierName,Q000009,11142491,,,23,,N,adverse effects
2658,DescriptorName,D019172,11142491,,,24,Transplantation Conditioning,N,
2659,QualifierName,Q000009,11142491,,,24,,N,adverse effects
2660,DescriptorName,D014182,11142491,,,25,"Transplantation, Autologous",N,
2661,DescriptorName,D014740,11142491,,,26,Vidarabine,N,
2662,QualifierName,Q000009,11142491,,,26,,N,adverse effects
2663,Chemical,D003511,11147747,Cyclohexanols,0,,,,
2664,Chemical,D017367,11147747,Serotonin Uptake Inhibitors,0,,,,
2665,Chemical,D017374,11147747,Paroxetine,41VRH5220H,,,,
2666,Chemical,D000069470,11147747,Venlafaxine Hydrochloride,7D7RX5A8MO,,,,
2667,Chemical,D020280,11147747,Sertraline,QUC7NX6WMB,,,,
2668,DescriptorName,D000328,11147747,,,1,Adult,N,
2669,DescriptorName,D001714,11147747,,,2,Bipolar Disorder,N,
2670,QualifierName,Q000188,11147747,,,2,,Y,drug therapy
2671,DescriptorName,D003511,11147747,,,3,Cyclohexanols,N,
2672,QualifierName,Q000009,11147747,,,3,,Y,adverse effects
2673,DescriptorName,D003866,11147747,,,4,Depressive Disorder,N,
2674,QualifierName,Q000188,11147747,,,4,,N,drug therapy
2675,DescriptorName,D005260,11147747,,,5,Female,N,
2676,DescriptorName,D006801,11147747,,,6,Humans,N,
2677,DescriptorName,D008875,11147747,,,7,Middle Aged,N,
2678,DescriptorName,D017374,11147747,,,8,Paroxetine,N,
2679,QualifierName,Q000009,11147747,,,8,,Y,adverse effects
2680,DescriptorName,D017367,11147747,,,9,Serotonin Uptake Inhibitors,N,
2681,QualifierName,Q000009,11147747,,,9,,Y,adverse effects
2682,DescriptorName,D020280,11147747,,,10,Sertraline,N,
2683,QualifierName,Q000009,11147747,,,10,,Y,adverse effects
2684,DescriptorName,D014549,11147747,,,11,Urinary Incontinence,N,
2685,QualifierName,Q000139,11147747,,,11,,Y,chemically induced
2686,DescriptorName,D000069470,11147747,,,12,Venlafaxine Hydrochloride,N,
2687,Chemical,D000925,11155197,Anticoagulants,0,,,,
2688,Chemical,D006493,11155197,Heparin,9005-49-6,,,,
2689,DescriptorName,D000368,11155197,,,1,Aged,N,
2690,DescriptorName,D000925,11155197,,,2,Anticoagulants,N,
2691,QualifierName,Q000009,11155197,,,2,,Y,adverse effects
2692,DescriptorName,D005260,11155197,,,3,Female,N,
2693,DescriptorName,D006493,11155197,,,4,Heparin,N,
2694,QualifierName,Q000009,11155197,,,4,,Y,adverse effects
2695,DescriptorName,D006801,11155197,,,5,Humans,N,
2696,DescriptorName,D008297,11155197,,,6,Male,N,
2697,DescriptorName,D008875,11155197,,,7,Middle Aged,N,
2698,DescriptorName,D013921,11155197,,,8,Thrombocytopenia,N,
2699,QualifierName,Q000139,11155197,,,8,,Y,chemically induced
2700,Chemical,D000959,11171531,Antihypertensive Agents,0,,,,
2701,Chemical,D007854,11171531,Lead,2P299V784P,,,,
2702,Chemical,D002118,11171531,Calcium,SY7Q814VUP,,,,
2703,DescriptorName,D000368,11171531,,,1,Aged,N,
2704,DescriptorName,D000959,11171531,,,2,Antihypertensive Agents,N,
2705,QualifierName,Q000627,11171531,,,2,,N,therapeutic use
2706,DescriptorName,D002118,11171531,,,3,Calcium,N,
2707,QualifierName,Q000627,11171531,,,3,,N,therapeutic use
2708,DescriptorName,D006801,11171531,,,4,Humans,N,
2709,DescriptorName,D006973,11171531,,,5,Hypertension,N,
2710,QualifierName,Q000139,11171531,,,5,,Y,chemically induced
2711,DescriptorName,D007854,11171531,,,6,Lead,N,
2712,QualifierName,Q000009,11171531,,,6,,Y,adverse effects
2713,DescriptorName,D007855,11171531,,,7,Lead Poisoning,N,
2714,QualifierName,Q000150,11171531,,,7,,Y,complications
2715,DescriptorName,D008297,11171531,,,8,Male,N,
2716,DescriptorName,D008875,11171531,,,9,Middle Aged,N,
2717,DescriptorName,D016273,11171531,,,10,Occupational Exposure,Y,
2718,DescriptorName,D010150,11171531,,,11,Paint,N,
2719,Chemical,D019380,11174414,Anti-HIV Agents,0,,,,
2720,Chemical,D019829,11174414,Nevirapine,99DK7FVK1H,,,,
2721,DescriptorName,D000328,11174414,,,1,Adult,N,
2722,DescriptorName,D019380,11174414,,,2,Anti-HIV Agents,N,
2723,QualifierName,Q000009,11174414,,,2,,Y,adverse effects
2724,DescriptorName,D015658,11174414,,,3,HIV Infections,N,
2725,QualifierName,Q000175,11174414,,,3,,N,diagnosis
2726,DescriptorName,D015497,11174414,,,4,HIV-1,N,
2727,QualifierName,Q000302,11174414,,,4,,Y,isolation & purification
2728,DescriptorName,D006801,11174414,,,5,Humans,N,
2729,DescriptorName,D008297,11174414,,,6,Male,N,
2730,DescriptorName,D008875,11174414,,,7,Middle Aged,N,
2731,DescriptorName,D019829,11174414,,,8,Nevirapine,N,
2732,QualifierName,Q000009,11174414,,,8,,Y,adverse effects
2733,DescriptorName,D011379,11174414,,,9,Prognosis,N,
2734,DescriptorName,D018570,11174414,,,10,Risk Assessment,N,
2735,DescriptorName,D013262,11174414,,,11,Stevens-Johnson Syndrome,N,
2736,QualifierName,Q000139,11174414,,,11,,Y,chemically induced
2737,Chemical,D018680,11180704,Cholinergic Antagonists,0,,,,
2738,Chemical,D004791,11180704,Enzyme Inhibitors,0,,,,
2739,Chemical,D065089,11180704,Glycoside Hydrolase Inhibitors,0,,,,
2740,Chemical,D007004,11180704,Hypoglycemic Agents,0,,,,
2741,Chemical,D020909,11180704,Acarbose,T58MSI464G,,,,
2742,DescriptorName,D020909,11180704,,,1,Acarbose,N,
2743,QualifierName,Q000008,11180704,,,1,,N,administration & dosage
2744,DescriptorName,D000368,11180704,,,2,Aged,N,
2745,DescriptorName,D018680,11180704,,,3,Cholinergic Antagonists,N,
2746,QualifierName,Q000008,11180704,,,3,,N,administration & dosage
2747,DescriptorName,D003139,11180704,,,4,Common Cold,N,
2748,QualifierName,Q000188,11180704,,,4,,N,drug therapy
2749,DescriptorName,D003924,11180704,,,5,"Diabetes Mellitus, Type 2",N,
2750,QualifierName,Q000150,11180704,,,5,,N,complications
2751,DescriptorName,D004357,11180704,,,6,Drug Synergism,N,
2752,DescriptorName,D004791,11180704,,,7,Enzyme Inhibitors,N,
2753,QualifierName,Q000008,11180704,,,7,,N,administration & dosage
2754,DescriptorName,D065089,11180704,,,8,Glycoside Hydrolase Inhibitors,Y,
2755,DescriptorName,D006801,11180704,,,9,Humans,N,
2756,DescriptorName,D007004,11180704,,,10,Hypoglycemic Agents,N,
2757,QualifierName,Q000008,11180704,,,10,,N,administration & dosage
2758,DescriptorName,D007415,11180704,,,11,Intestinal Obstruction,N,
2759,QualifierName,Q000139,11180704,,,11,,Y,chemically induced
2760,DescriptorName,D008297,11180704,,,12,Male,N,
2761,Chemical,D000959,11191005,Antihypertensive Agents,0,,,,
2762,Chemical,D001581,11191005,Benzothiadiazines,0,,,,
2763,Chemical,D004232,11191005,Diuretics,0,,,,
2764,Chemical,D000960,11191005,Hypolipidemic Agents,0,,,,
2765,Chemical,D049993,11191005,Sodium Chloride Symporter Inhibitors,0,,,,
2766,Chemical,D014527,11191005,Uric Acid,268B43MJ25,,,,
2767,Chemical,D019808,11191005,Losartan,JMS50MPO89,,,,
2768,Chemical,D011345,11191005,Fenofibrate,U202363UOS,,,,
2769,DescriptorName,D000959,11191005,,,1,Antihypertensive Agents,N,
2770,QualifierName,Q000009,11191005,,,1,,Y,adverse effects
2771,DescriptorName,D001161,11191005,,,2,Arteriosclerosis,N,
2772,QualifierName,Q000097,11191005,,,2,,N,blood
2773,DescriptorName,D001581,11191005,,,3,Benzothiadiazines,N,
2774,DescriptorName,D004232,11191005,,,4,Diuretics,N,
2775,DescriptorName,D005260,11191005,,,5,Female,N,
2776,DescriptorName,D011345,11191005,,,6,Fenofibrate,N,
2777,QualifierName,Q000627,11191005,,,6,,N,therapeutic use
2778,DescriptorName,D006801,11191005,,,7,Humans,N,
2779,DescriptorName,D006949,11191005,,,8,Hyperlipidemias,N,
2780,QualifierName,Q000097,11191005,,,8,,N,blood
2781,DescriptorName,D006973,11191005,,,9,Hypertension,N,
2782,QualifierName,Q000097,11191005,,,9,,N,blood
2783,DescriptorName,D000960,11191005,,,10,Hypolipidemic Agents,N,
2784,QualifierName,Q000627,11191005,,,10,,N,therapeutic use
2785,DescriptorName,D019808,11191005,,,11,Losartan,N,
2786,QualifierName,Q000009,11191005,,,11,,N,adverse effects
2787,DescriptorName,D008297,11191005,,,12,Male,N,
2788,DescriptorName,D008875,11191005,,,13,Middle Aged,N,
2789,DescriptorName,D012307,11191005,,,14,Risk Factors,N,
2790,DescriptorName,D049993,11191005,,,15,Sodium Chloride Symporter Inhibitors,N,
2791,QualifierName,Q000009,11191005,,,15,,N,adverse effects
2792,DescriptorName,D014527,11191005,,,16,Uric Acid,N,
2793,QualifierName,Q000097,11191005,,,16,,Y,blood
2794,Chemical,D018501,11200291,Antirheumatic Agents,0,,,,
2795,Chemical,D007074,11200291,Immunoglobulin G,0,,,,
2796,Chemical,D018124,11200291,"Receptors, Tumor Necrosis Factor",0,,,,
2797,Chemical,D008790,11200291,Metoprolol,GEB06NHM23,,,,
2798,Chemical,D000068800,11200291,Etanercept,OP401G7OJC,,,,
2799,Chemical,D008727,11200291,Methotrexate,YL5FZ2Y5U1,,,,
2800,DescriptorName,D018501,11200291,,,1,Antirheumatic Agents,N,
2801,QualifierName,Q000009,11200291,,,1,,Y,adverse effects
2802,DescriptorName,D001172,11200291,,,2,"Arthritis, Rheumatoid",N,
2803,QualifierName,Q000188,11200291,,,2,,N,drug therapy
2804,DescriptorName,D001281,11200291,,,3,Atrial Fibrillation,N,
2805,QualifierName,Q000139,11200291,,,3,,Y,chemically induced
2806,DescriptorName,D004359,11200291,,,4,"Drug Therapy, Combination",N,
2807,DescriptorName,D000068800,11200291,,,5,Etanercept,N,
2808,DescriptorName,D005500,11200291,,,6,Follow-Up Studies,N,
2809,DescriptorName,D006801,11200291,,,7,Humans,N,
2810,DescriptorName,D007074,11200291,,,8,Immunoglobulin G,N,
2811,QualifierName,Q000009,11200291,,,8,,Y,adverse effects
2812,DescriptorName,D008297,11200291,,,9,Male,N,
2813,DescriptorName,D008727,11200291,,,10,Methotrexate,N,
2814,QualifierName,Q000009,11200291,,,10,,Y,adverse effects
2815,DescriptorName,D008790,11200291,,,11,Metoprolol,N,
2816,QualifierName,Q000627,11200291,,,11,,N,therapeutic use
2817,DescriptorName,D008875,11200291,,,12,Middle Aged,N,
2818,DescriptorName,D018124,11200291,,,13,"Receptors, Tumor Necrosis Factor",N,
2819,QualifierName,Q000627,11200291,,,13,,N,therapeutic use
2820,Chemical,D007166,11202801,Immunosuppressive Agents,0,,,,
2821,Chemical,D003520,11202801,Cyclophosphamide,8N3DW7272P,,,,
2822,DescriptorName,D003520,11202801,,,1,Cyclophosphamide,N,
2823,QualifierName,Q000009,11202801,,,1,,Y,adverse effects
2824,DescriptorName,D006394,11202801,,,2,Hemangiosarcoma,N,
2825,QualifierName,Q000139,11202801,,,2,,Y,chemically induced
2826,DescriptorName,D006801,11202801,,,3,Humans,N,
2827,DescriptorName,D007166,11202801,,,4,Immunosuppressive Agents,N,
2828,QualifierName,Q000009,11202801,,,4,,Y,adverse effects
2829,DescriptorName,D008113,11202801,,,5,Liver Neoplasms,N,
2830,QualifierName,Q000139,11202801,,,5,,Y,chemically induced
2831,DescriptorName,D008297,11202801,,,6,Male,N,
2832,DescriptorName,D008875,11202801,,,7,Middle Aged,N,
2833,DescriptorName,D010488,11202801,,,8,Polyarteritis Nodosa,N,
2834,QualifierName,Q000188,11202801,,,8,,N,drug therapy
2835,Chemical,D000964,11207969,"Antimetabolites, Antineoplastic",0,,,,
2836,Chemical,D003561,11207969,Cytarabine,04079A1RDZ,,,,
2837,DescriptorName,D000005,11207969,,,1,Abdomen,N,
2838,DescriptorName,D000293,11207969,,,2,Adolescent,N,
2839,DescriptorName,D000964,11207969,,,3,"Antimetabolites, Antineoplastic",N,
2840,QualifierName,Q000008,11207969,,,3,,N,administration & dosage
2841,DescriptorName,D001132,11207969,,,4,Arm,N,
2842,DescriptorName,D003561,11207969,,,5,Cytarabine,N,
2843,QualifierName,Q000008,11207969,,,5,,N,administration & dosage
2844,DescriptorName,D017809,11207969,,,6,Fatal Outcome,N,
2845,DescriptorName,D005260,11207969,,,7,Female,N,
2846,DescriptorName,D006257,11207969,,,8,Head,N,
2847,DescriptorName,D006801,11207969,,,9,Humans,N,
2848,DescriptorName,D054198,11207969,,,10,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
2849,QualifierName,Q000188,11207969,,,10,,Y,drug therapy
2850,DescriptorName,D013262,11207969,,,11,Stevens-Johnson Syndrome,N,
2851,QualifierName,Q000209,11207969,,,11,,Y,etiology
2852,Chemical,D014150,11212595,Antipsychotic Agents,0,,,,
2853,Chemical,D003987,11212595,Dibenzothiazepines,0,,,,
2854,Chemical,D000069348,11212595,Quetiapine Fumarate,2S3PL1B6UJ,,,,
2855,DescriptorName,D000328,11212595,,,1,Adult,N,
2856,DescriptorName,D014150,11212595,,,2,Antipsychotic Agents,N,
2857,QualifierName,Q000009,11212595,,,2,,Y,adverse effects
2858,DescriptorName,D003987,11212595,,,3,Dibenzothiazepines,N,
2859,QualifierName,Q000009,11212595,,,3,,Y,adverse effects
2860,DescriptorName,D006801,11212595,,,4,Humans,N,
2861,DescriptorName,D008297,11212595,,,5,Male,N,
2862,DescriptorName,D009771,11212595,,,6,Obsessive-Compulsive Disorder,N,
2863,QualifierName,Q000188,11212595,,,6,,Y,drug therapy
2864,DescriptorName,D011569,11212595,,,7,Psychiatric Status Rating Scales,N,
2865,DescriptorName,D000069348,11212595,,,8,Quetiapine Fumarate,N,
2866,Chemical,D000929,11215836,"Antidepressive Agents, Tricyclic",0,,,,
2867,Chemical,D014150,11215836,Antipsychotic Agents,0,,,,
2868,Chemical,D003024,11215836,Clozapine,J60AR2IKIC,,,,
2869,Chemical,D002997,11215836,Clomipramine,NUV44L116D,,,,
2870,DescriptorName,D000328,11215836,,,1,Adult,N,
2871,DescriptorName,D000929,11215836,,,2,"Antidepressive Agents, Tricyclic",N,
2872,QualifierName,Q000009,11215836,,,2,,Y,adverse effects
2873,DescriptorName,D014150,11215836,,,3,Antipsychotic Agents,N,
2874,QualifierName,Q000009,11215836,,,3,,Y,adverse effects
2875,DescriptorName,D002997,11215836,,,4,Clomipramine,N,
2876,QualifierName,Q000009,11215836,,,4,,Y,adverse effects
2877,DescriptorName,D003024,11215836,,,5,Clozapine,N,
2878,QualifierName,Q000009,11215836,,,5,,Y,adverse effects
2879,DescriptorName,D006801,11215836,,,6,Humans,N,
2880,DescriptorName,D008297,11215836,,,7,Male,N,
2881,DescriptorName,D009771,11215836,,,8,Obsessive-Compulsive Disorder,N,
2882,QualifierName,Q000150,11215836,,,8,,N,complications
2883,DescriptorName,D012559,11215836,,,9,Schizophrenia,N,
2884,QualifierName,Q000150,11215836,,,9,,N,complications
2885,DescriptorName,D020230,11215836,,,10,Serotonin Syndrome,N,
2886,QualifierName,Q000523,11215836,,,10,,Y,psychology
2887,DescriptorName,D013375,11215836,,,11,Substance Withdrawal Syndrome,N,
2888,QualifierName,Q000523,11215836,,,11,,Y,psychology
2889,Chemical,D009125,11225532,"Muscle Relaxants, Central",0,,,,
2890,Chemical,D011803,11225532,Quinine,A7V27PHC7A,,,,
2891,DescriptorName,D000368,11225532,,,1,Aged,N,
2892,DescriptorName,D000766,11225532,,,2,"Anesthesia, Dental",N,
2893,DescriptorName,D003812,11225532,,,3,Dentist-Patient Relations,N,
2894,DescriptorName,D006406,11225532,,,4,Hematoma,N,
2895,QualifierName,Q000209,11225532,,,4,,N,etiology
2896,DescriptorName,D006801,11225532,,,5,Humans,N,
2897,DescriptorName,D008297,11225532,,,6,Male,N,
2898,DescriptorName,D008340,11225532,,,7,Mandibular Nerve,N,
2899,DescriptorName,D009060,11225532,,,8,Mouth Floor,N,
2900,QualifierName,Q000473,11225532,,,8,,N,pathology
2901,DescriptorName,D009120,11225532,,,9,Muscle Cramp,N,
2902,QualifierName,Q000188,11225532,,,9,,N,drug therapy
2903,DescriptorName,D009125,11225532,,,10,"Muscle Relaxants, Central",N,
2904,QualifierName,Q000009,11225532,,,10,,Y,adverse effects
2905,DescriptorName,D009407,11225532,,,11,Nerve Block,N,
2906,DescriptorName,D006472,11225532,,,12,Oral Hemorrhage,N,
2907,QualifierName,Q000209,11225532,,,12,,N,etiology
2908,DescriptorName,D011803,11225532,,,13,Quinine,N,
2909,QualifierName,Q000009,11225532,,,13,,Y,adverse effects
2910,DescriptorName,D012651,11225532,,,14,Self Medication,N,
2911,QualifierName,Q000009,11225532,,,14,,N,adverse effects
2912,DescriptorName,D013921,11225532,,,15,Thrombocytopenia,N,
2913,QualifierName,Q000139,11225532,,,15,,Y,chemically induced
2914,DescriptorName,D014060,11225532,,,16,Tongue Diseases,N,
2915,QualifierName,Q000209,11225532,,,16,,N,etiology
2916,Chemical,D014150,11236070,Antipsychotic Agents,0,,,,
2917,Chemical,D001569,11236070,Benzodiazepines,12794-10-4,,,,
2918,Chemical,D010890,11236070,Pirenzepine,3G0285N20N,,,,
2919,Chemical,D000077152,11236070,Olanzapine,N7U69T4SZR,,,,
2920,DescriptorName,D000293,11236070,,,1,Adolescent,N,
2921,DescriptorName,D000328,11236070,,,2,Adult,N,
2922,DescriptorName,D014150,11236070,,,3,Antipsychotic Agents,N,
2923,QualifierName,Q000009,11236070,,,3,,Y,adverse effects
2924,DescriptorName,D001569,11236070,,,4,Benzodiazepines,N,
2925,DescriptorName,D004305,11236070,,,5,"Dose-Response Relationship, Drug",N,
2926,DescriptorName,D005260,11236070,,,6,Female,N,
2927,DescriptorName,D006801,11236070,,,7,Humans,N,
2928,DescriptorName,D007970,11236070,,,8,Leukopenia,N,
2929,QualifierName,Q000139,11236070,,,8,,Y,chemically induced
2930,DescriptorName,D008297,11236070,,,9,Male,N,
2931,DescriptorName,D000077152,11236070,,,10,Olanzapine,N,
2932,DescriptorName,D010890,11236070,,,11,Pirenzepine,N,
2933,QualifierName,Q000009,11236070,,,11,,Y,adverse effects
2934,DescriptorName,D012559,11236070,,,12,Schizophrenia,N,
2935,QualifierName,Q000188,11236070,,,12,,N,drug therapy
2936,Chemical,D007166,11243427,Immunosuppressive Agents,0,,,,
2937,Chemical,D005472,11243427,Fluorouracil,U3P01618RT,,,,
2938,DescriptorName,D000368,11243427,,,1,Aged,N,
2939,DescriptorName,D003937,11243427,,,2,"Diagnosis, Differential",N,
2940,DescriptorName,D004483,11243427,,,3,Ectropion,N,
2941,QualifierName,Q000139,11243427,,,3,,Y,chemically induced
2942,DescriptorName,D005472,11243427,,,4,Fluorouracil,N,
2943,QualifierName,Q000008,11243427,,,4,,N,administration & dosage
2944,DescriptorName,D006801,11243427,,,5,Humans,N,
2945,DescriptorName,D007166,11243427,,,6,Immunosuppressive Agents,N,
2946,QualifierName,Q000008,11243427,,,6,,N,administration & dosage
2947,DescriptorName,D007275,11243427,,,7,"Injections, Intravenous",N,
2948,DescriptorName,D007414,11243427,,,8,Intestinal Neoplasms,N,
2949,QualifierName,Q000188,11243427,,,8,,N,drug therapy
2950,DescriptorName,D008297,11243427,,,9,Male,N,
2951,DescriptorName,D012075,11243427,,,10,"Remission, Spontaneous",N,
2952,Chemical,D001639,1124417,Bicarbonates,0,,,,
2953,Chemical,D003404,1124417,Creatinine,AYI8EX34EU,,,,
2954,Chemical,D000086,1124417,Acetazolamide,O3FX965V0I,,,,
2955,Chemical,D011188,1124417,Potassium,RWP5GA015D,,,,
2956,DescriptorName,D000086,1124417,,,1,Acetazolamide,N,
2957,QualifierName,Q000009,1124417,,,1,,Y,adverse effects
2958,DescriptorName,D058186,1124417,,,2,Acute Kidney Injury,N,
2959,QualifierName,Q000097,1124417,,,2,,N,blood
2960,DescriptorName,D000368,1124417,,,3,Aged,N,
2961,DescriptorName,D001639,1124417,,,4,Bicarbonates,N,
2962,QualifierName,Q000097,1124417,,,4,,N,blood
2963,DescriptorName,D001806,1124417,,,5,Blood Urea Nitrogen,N,
2964,DescriptorName,D001835,1124417,,,6,Body Weight,N,
2965,DescriptorName,D003404,1124417,,,7,Creatinine,N,
2966,QualifierName,Q000097,1124417,,,7,,N,blood
2967,DescriptorName,D005901,1124417,,,8,Glaucoma,N,
2968,QualifierName,Q000188,1124417,,,8,,Y,drug therapy
2969,DescriptorName,D006801,1124417,,,9,Humans,N,
2970,DescriptorName,D008297,1124417,,,10,Male,N,
2971,DescriptorName,D011188,1124417,,,11,Potassium,N,
2972,QualifierName,Q000097,1124417,,,11,,N,blood
2973,Chemical,D000894,11247558,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
2974,Chemical,D052246,11247558,Cyclooxygenase 2 Inhibitors,0,,,,
2975,Chemical,D016861,11247558,Cyclooxygenase Inhibitors,0,,,,
2976,Chemical,D007527,11247558,Isoenzymes,0,,,,
2977,Chemical,D008565,11247558,Membrane Proteins,0,,,,
2978,Chemical,D013843,11247558,Thiazines,0,,,,
2979,Chemical,D013844,11247558,Thiazoles,0,,,,
2980,Chemical,D051546,11247558,Cyclooxygenase 2,EC 1.14.99.1,,,,
2981,Chemical,C496540,11247558,"PTGS2 protein, human",EC 1.14.99.1,,,,
2982,Chemical,D011451,11247558,Prostaglandin-Endoperoxide Synthases,EC 1.14.99.1,,,,
2983,Chemical,D000077239,11247558,Meloxicam,VG2QF83CGL,,,,
2984,DescriptorName,D000894,11247558,,,1,"Anti-Inflammatory Agents, Non-Steroidal",N,
2985,QualifierName,Q000008,11247558,,,1,,N,administration & dosage
2986,DescriptorName,D017091,11247558,,,2,"Colitis, Ischemic",N,
2987,QualifierName,Q000139,11247558,,,2,,Y,chemically induced
2988,DescriptorName,D051546,11247558,,,3,Cyclooxygenase 2,N,
2989,DescriptorName,D052246,11247558,,,4,Cyclooxygenase 2 Inhibitors,N,
2990,DescriptorName,D016861,11247558,,,5,Cyclooxygenase Inhibitors,N,
2991,QualifierName,Q000008,11247558,,,5,,N,administration & dosage
2992,DescriptorName,D004305,11247558,,,6,"Dose-Response Relationship, Drug",N,
2993,DescriptorName,D005260,11247558,,,7,Female,N,
2994,DescriptorName,D006801,11247558,,,8,Humans,N,
2995,DescriptorName,D007527,11247558,,,9,Isoenzymes,N,
2996,QualifierName,Q000037,11247558,,,9,,Y,antagonists & inhibitors
2997,DescriptorName,D000077239,11247558,,,10,Meloxicam,N,
2998,DescriptorName,D008565,11247558,,,11,Membrane Proteins,N,
2999,DescriptorName,D008875,11247558,,,12,Middle Aged,N,
3000,DescriptorName,D010003,11247558,,,13,Osteoarthritis,N,
3001,QualifierName,Q000188,11247558,,,13,,Y,drug therapy
3002,DescriptorName,D011451,11247558,,,14,Prostaglandin-Endoperoxide Synthases,N,
3003,DescriptorName,D013843,11247558,,,15,Thiazines,N,
3004,QualifierName,Q000008,11247558,,,15,,N,administration & dosage
3005,DescriptorName,D013844,11247558,,,16,Thiazoles,N,
3006,QualifierName,Q000008,11247558,,,16,,N,administration & dosage
3007,Chemical,D004232,11250985,Diuretics,0,,,,
3008,Chemical,D000451,11250985,Mineralocorticoid Receptor Antagonists,0,,,,
3009,Chemical,D013148,11250985,Spironolactone,27O7W4T232,,,,
3010,DescriptorName,D000368,11250985,,,1,Aged,N,
3011,DescriptorName,D003967,11250985,,,2,Diarrhea,N,
3012,QualifierName,Q000209,11250985,,,2,,N,etiology
3013,DescriptorName,D004232,11250985,,,3,Diuretics,N,
3014,QualifierName,Q000009,11250985,,,3,,Y,adverse effects
3015,DescriptorName,D017809,11250985,,,4,Fatal Outcome,N,
3016,DescriptorName,D006323,11250985,,,5,Heart Arrest,N,
3017,QualifierName,Q000209,11250985,,,5,,N,etiology
3018,DescriptorName,D006333,11250985,,,6,Heart Failure,N,
3019,QualifierName,Q000188,11250985,,,6,,Y,drug therapy
3020,DescriptorName,D006801,11250985,,,7,Humans,N,
3021,DescriptorName,D006947,11250985,,,8,Hyperkalemia,N,
3022,QualifierName,Q000139,11250985,,,8,,Y,chemically induced
3023,DescriptorName,D008297,11250985,,,9,Male,N,
3024,DescriptorName,D008875,11250985,,,10,Middle Aged,N,
3025,DescriptorName,D000451,11250985,,,11,Mineralocorticoid Receptor Antagonists,N,
3026,QualifierName,Q000009,11250985,,,11,,Y,adverse effects
3027,DescriptorName,D013148,11250985,,,12,Spironolactone,N,
3028,QualifierName,Q000009,11250985,,,12,,Y,adverse effects
3029,Chemical,D000970,11292139,Antineoplastic Agents,0,,,,
3030,Chemical,D009944,11292139,Organoplatinum Compounds,0,,,,
3031,Chemical,D000077150,11292139,Oxaliplatin,04ZR38536J,,,,
3032,DescriptorName,D000970,11292139,,,1,Antineoplastic Agents,N,
3033,QualifierName,Q000009,11292139,,,1,,Y,adverse effects
3034,DescriptorName,D003110,11292139,,,2,Colonic Neoplasms,N,
3035,QualifierName,Q000188,11292139,,,2,,Y,drug therapy
3036,DescriptorName,D003131,11292139,,,3,Combined Modality Therapy,N,
3037,DescriptorName,D003875,11292139,,,4,Drug Eruptions,N,
3038,QualifierName,Q000209,11292139,,,4,,Y,etiology
3039,DescriptorName,D006801,11292139,,,5,Humans,N,
3040,DescriptorName,D008297,11292139,,,6,Male,N,
3041,DescriptorName,D008875,11292139,,,7,Middle Aged,N,
3042,DescriptorName,D009944,11292139,,,8,Organoplatinum Compounds,N,
3043,QualifierName,Q000009,11292139,,,8,,Y,adverse effects
3044,DescriptorName,D000077150,11292139,,,9,Oxaliplatin,N,
3045,DescriptorName,D010166,11292139,,,10,Palliative Care,N,
3046,DescriptorName,D011878,11292139,,,11,Radiotherapy,N,
3047,QualifierName,Q000009,11292139,,,11,,Y,adverse effects
3048,Chemical,D000894,11295724,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
3049,Chemical,D002991,11295724,Clofazimine,D959AE5USF,,,,
3050,DescriptorName,D000894,11295724,,,1,"Anti-Inflammatory Agents, Non-Steroidal",N,
3051,QualifierName,Q000009,11295724,,,1,,Y,adverse effects
3052,DescriptorName,D001706,11295724,,,2,Biopsy,N,
3053,DescriptorName,D016026,11295724,,,3,Bone Marrow Transplantation,N,
3054,QualifierName,Q000276,11295724,,,3,,Y,immunology
3055,DescriptorName,D002648,11295724,,,4,Child,N,
3056,DescriptorName,D002991,11295724,,,5,Clofazimine,N,
3057,QualifierName,Q000009,11295724,,,5,,Y,adverse effects
3058,DescriptorName,D004378,11295724,,,6,Duodenal Diseases,N,
3059,QualifierName,Q000139,11295724,,,6,,Y,chemically induced
3060,DescriptorName,D004386,11295724,,,7,Duodenum,N,
3061,QualifierName,Q000473,11295724,,,7,,N,pathology
3062,DescriptorName,D016099,11295724,,,8,"Endoscopy, Gastrointestinal",N,
3063,DescriptorName,D006086,11295724,,,9,Graft vs Host Disease,N,
3064,QualifierName,Q000188,11295724,,,9,,Y,drug therapy
3065,DescriptorName,D006801,11295724,,,10,Humans,N,
3066,DescriptorName,D007077,11295724,,,11,Ileal Diseases,N,
3067,QualifierName,Q000139,11295724,,,11,,Y,chemically induced
3068,DescriptorName,D008297,11295724,,,12,Male,N,
3069,Chemical,D004338,11302479,Drug Combinations,0,,,,
3070,Chemical,D017984,11302479,Enoxaparin,0,,,,
3071,Chemical,D065427,11302479,Factor Xa Inhibitors,0,,,,
3072,Chemical,C095381,11302479,factor V Leiden,0,,,,
3073,Chemical,D003871,11302479,Dermatan Sulfate,24967-94-0,,,,
3074,Chemical,D005165,11302479,Factor V,9001-24-5,,,,
3075,Chemical,D002809,11302479,Chondroitin Sulfates,9007-28-7,,,,
3076,Chemical,D006497,11302479,Heparitin Sulfate,9050-30-0,,,,
3077,Chemical,C035838,11302479,danaparoid,BI6GY4U9CW,,,,
3078,DescriptorName,D000328,11302479,,,1,Adult,N,
3079,DescriptorName,D002585,11302479,,,2,Cesarean Section,N,
3080,DescriptorName,D002809,11302479,,,3,Chondroitin Sulfates,N,
3081,QualifierName,Q000008,11302479,,,3,,N,administration & dosage
3082,DescriptorName,D003871,11302479,,,4,Dermatan Sulfate,N,
3083,QualifierName,Q000008,11302479,,,4,,N,administration & dosage
3084,DescriptorName,D004338,11302479,,,5,Drug Combinations,N,
3085,DescriptorName,D004342,11302479,,,6,Drug Hypersensitivity,Y,
3086,DescriptorName,D017984,11302479,,,7,Enoxaparin,N,
3087,QualifierName,Q000009,11302479,,,7,,Y,adverse effects
3088,DescriptorName,D005165,11302479,,,8,Factor V,N,
3089,QualifierName,Q000235,11302479,,,8,,N,genetics
3090,DescriptorName,D065427,11302479,,,9,Factor Xa Inhibitors,N,
3091,DescriptorName,D005260,11302479,,,10,Female,N,
3092,DescriptorName,D005865,11302479,,,11,Gestational Age,N,
3093,DescriptorName,D006497,11302479,,,12,Heparitin Sulfate,N,
3094,QualifierName,Q000008,11302479,,,12,,N,administration & dosage
3095,DescriptorName,D006579,11302479,,,13,Heterozygote,N,
3096,DescriptorName,D006801,11302479,,,14,Humans,N,
3097,DescriptorName,D007279,11302479,,,15,"Injections, Subcutaneous",N,
3098,DescriptorName,D008895,11302479,,,16,"Milk, Human",N,
3099,QualifierName,Q000737,11302479,,,16,,N,chemistry
3100,DescriptorName,D009154,11302479,,,17,Mutation,N,
3101,DescriptorName,D011247,11302479,,,18,Pregnancy,N,
3102,DescriptorName,D020246,11302479,,,19,Venous Thrombosis,N,
3103,QualifierName,Q000188,11302479,,,19,,Y,drug therapy
3104,Chemical,D000889,11315123,Anti-Arrhythmia Agents,0,,,,
3105,Chemical,D002316,11315123,Cardiotonic Agents,0,,,,
3106,Chemical,D007093,11315123,Imidazoles,0,,,,
3107,Chemical,D007552,11315123,Isotonic Solutions,0,,,,
3108,Chemical,D000077325,11315123,Ringer's Lactate,0,,,,
3109,Chemical,D004280,11315123,Dobutamine,3S12J47372,,,,
3110,Chemical,C032151,11315123,cifenline,Z7489237QT,,,,
3111,DescriptorName,D000368,11315123,,,1,Aged,N,
3112,DescriptorName,D000889,11315123,,,2,Anti-Arrhythmia Agents,N,
3113,QualifierName,Q000506,11315123,,,2,,Y,poisoning
3114,DescriptorName,D002037,11315123,,,3,Bundle-Branch Block,N,
3115,QualifierName,Q000139,11315123,,,3,,Y,chemically induced
3116,DescriptorName,D002303,11315123,,,4,"Cardiac Output, Low",N,
3117,QualifierName,Q000139,11315123,,,4,,Y,chemically induced
3118,DescriptorName,D002316,11315123,,,5,Cardiotonic Agents,N,
3119,QualifierName,Q000627,11315123,,,5,,N,therapeutic use
3120,DescriptorName,D004280,11315123,,,6,Dobutamine,N,
3121,QualifierName,Q000627,11315123,,,6,,N,therapeutic use
3122,DescriptorName,D005260,11315123,,,7,Female,N,
3123,DescriptorName,D006801,11315123,,,8,Humans,N,
3124,DescriptorName,D007093,11315123,,,9,Imidazoles,N,
3125,QualifierName,Q000506,11315123,,,9,,Y,poisoning
3126,DescriptorName,D007552,11315123,,,10,Isotonic Solutions,N,
3127,QualifierName,Q000627,11315123,,,10,,N,therapeutic use
3128,DescriptorName,D000077325,11315123,,,11,Ringer's Lactate,N,
3129,DescriptorName,D014786,11315123,,,12,Vision Disorders,N,
3130,QualifierName,Q000139,11315123,,,12,,Y,chemically induced
3131,Chemical,D007166,11319599,Immunosuppressive Agents,0,,,,
3132,Chemical,D014740,11319599,Vidarabine,FA2DM6879K,,,,
3133,Chemical,C024352,11319599,fludarabine,P2K93U8740,,,,
3134,DescriptorName,D000328,11319599,,,1,Adult,N,
3135,DescriptorName,D001168,11319599,,,2,Arthritis,N,
3136,QualifierName,Q000382,11319599,,,2,,Y,microbiology
3137,DescriptorName,D001228,11319599,,,3,Aspergillosis,Y,
3138,DescriptorName,D006086,11319599,,,4,Graft vs Host Disease,N,
3139,QualifierName,Q000188,11319599,,,4,,N,drug therapy
3140,DescriptorName,D018380,11319599,,,5,Hematopoietic Stem Cell Transplantation,N,
3141,QualifierName,Q000009,11319599,,,5,,Y,adverse effects
3142,DescriptorName,D006801,11319599,,,6,Humans,N,
3143,DescriptorName,D007166,11319599,,,7,Immunosuppressive Agents,N,
3144,QualifierName,Q000008,11319599,,,7,,N,administration & dosage
3145,DescriptorName,D007719,11319599,,,8,Knee Joint,N,
3146,QualifierName,Q000473,11319599,,,8,,N,pathology
3147,DescriptorName,D008297,11319599,,,9,Male,N,
3148,DescriptorName,D008875,11319599,,,10,Middle Aged,N,
3149,DescriptorName,D014740,11319599,,,11,Vidarabine,N,
3150,QualifierName,Q000008,11319599,,,11,,N,administration & dosage
3151,Chemical,D017367,11328247,Serotonin Uptake Inhibitors,0,,,,
3152,Chemical,D016666,11328247,Fluvoxamine,O4L1XPO44W,,,,
3153,DescriptorName,D000328,11328247,,,1,Adult,N,
3154,DescriptorName,D001008,11328247,,,2,Anxiety Disorders,N,
3155,QualifierName,Q000150,11328247,,,2,,N,complications
3156,DescriptorName,D003863,11328247,,,3,Depression,N,
3157,QualifierName,Q000150,11328247,,,3,,N,complications
3158,DescriptorName,D005260,11328247,,,4,Female,N,
3159,DescriptorName,D016666,11328247,,,5,Fluvoxamine,N,
3160,QualifierName,Q000008,11328247,,,5,,N,administration & dosage
3161,DescriptorName,D006801,11328247,,,6,Humans,N,
3162,DescriptorName,D007989,11328247,,,7,Libido,N,
3163,QualifierName,Q000187,11328247,,,7,,Y,drug effects
3164,DescriptorName,D017367,11328247,,,8,Serotonin Uptake Inhibitors,N,
3165,QualifierName,Q000008,11328247,,,8,,N,administration & dosage
3166,Chemical,D000981,11332679,Antiprotozoal Agents,0,,,,
3167,Chemical,D009942,11332679,Organometallic Compounds,0,,,,
3168,Chemical,D000493,11332679,Allopurinol,63CZ7GJN5I,,,,
3169,Chemical,D008536,11332679,Meglumine,6HG8UB2MUY,,,,
3170,Chemical,D000077485,11332679,Meglumine Antimoniate,75G4TW236W,,,,
3171,Chemical,D007654,11332679,Ketoconazole,R9400W927I,,,,
3172,DescriptorName,D000208,11332679,,,1,Acute Disease,N,
3173,DescriptorName,D000493,11332679,,,2,Allopurinol,N,
3174,QualifierName,Q000627,11332679,,,2,,Y,therapeutic use
3175,DescriptorName,D000981,11332679,,,3,Antiprotozoal Agents,N,
3176,QualifierName,Q000009,11332679,,,3,,N,adverse effects
3177,DescriptorName,D002675,11332679,,,4,"Child, Preschool",N,
3178,DescriptorName,D006801,11332679,,,5,Humans,N,
3179,DescriptorName,D007654,11332679,,,6,Ketoconazole,N,
3180,QualifierName,Q000627,11332679,,,6,,Y,therapeutic use
3181,DescriptorName,D007898,11332679,,,7,"Leishmaniasis, Visceral",N,
3182,QualifierName,Q000188,11332679,,,7,,Y,drug therapy
3183,DescriptorName,D008297,11332679,,,8,Male,N,
3184,DescriptorName,D008536,11332679,,,9,Meglumine,N,
3185,QualifierName,Q000009,11332679,,,9,,Y,adverse effects
3186,DescriptorName,D000077485,11332679,,,10,Meglumine Antimoniate,N,
3187,DescriptorName,D009942,11332679,,,11,Organometallic Compounds,N,
3188,QualifierName,Q000009,11332679,,,11,,Y,adverse effects
3189,DescriptorName,D010195,11332679,,,12,Pancreatitis,N,
3190,QualifierName,Q000139,11332679,,,12,,Y,chemically induced
3191,Chemical,D001323,11335880,Autoantibodies,0,,,,
3192,Chemical,D015805,11335880,HLA-DR5 Antigen,0,,,,
3193,Chemical,D016898,11335880,Interferon-alpha,0,,,,
3194,DescriptorName,D001323,11335880,,,1,Autoantibodies,N,
3195,QualifierName,Q000032,11335880,,,1,,N,analysis
3196,DescriptorName,D005260,11335880,,,2,Female,N,
3197,DescriptorName,D015805,11335880,,,3,HLA-DR5 Antigen,N,
3198,QualifierName,Q000235,11335880,,,3,,Y,genetics
3199,DescriptorName,D019698,11335880,,,4,"Hepatitis C, Chronic",N,
3200,QualifierName,Q000150,11335880,,,4,,Y,complications
3201,DescriptorName,D006650,11335880,,,5,Histocompatibility Testing,N,
3202,DescriptorName,D006801,11335880,,,6,Humans,N,
3203,DescriptorName,D016898,11335880,,,7,Interferon-alpha,N,
3204,QualifierName,Q000009,11335880,,,7,,N,adverse effects
3205,DescriptorName,D008875,11335880,,,8,Middle Aged,N,
3206,DescriptorName,D013967,11335880,,,9,"Thyroiditis, Autoimmune",N,
3207,QualifierName,Q000235,11335880,,,9,,Y,genetics
3208,Chemical,D053799,11341670,2-Pyridinylmethylsulfinylbenzimidazoles,0,,,,
3209,Chemical,D000897,11341670,Anti-Ulcer Agents,0,,,,
3210,Chemical,D001562,11341670,Benzimidazoles,0,,,,
3211,Chemical,D054328,11341670,Proton Pump Inhibitors,0,,,,
3212,Chemical,D013454,11341670,Sulfoxides,0,,,,
3213,Chemical,D064747,11341670,Lansoprazole,0K5C5T2QPG,,,,
3214,Chemical,D000077402,11341670,Pantoprazole,D8TST4O562,,,,
3215,Chemical,D009853,11341670,Omeprazole,KG60484QX9,,,,
3216,DescriptorName,D053799,11341670,,,1,2-Pyridinylmethylsulfinylbenzimidazoles,N,
3217,DescriptorName,D000328,11341670,,,2,Adult,N,
3218,DescriptorName,D000897,11341670,,,3,Anti-Ulcer Agents,N,
3219,QualifierName,Q000009,11341670,,,3,,Y,adverse effects
3220,DescriptorName,D001562,11341670,,,4,Benzimidazoles,N,
3221,QualifierName,Q000009,11341670,,,4,,Y,adverse effects
3222,DescriptorName,D004487,11341670,,,5,Edema,N,
3223,QualifierName,Q000139,11341670,,,5,,Y,chemically induced
3224,DescriptorName,D005260,11341670,,,6,Female,N,
3225,DescriptorName,D006801,11341670,,,7,Humans,N,
3226,DescriptorName,D064747,11341670,,,8,Lansoprazole,N,
3227,DescriptorName,D008875,11341670,,,9,Middle Aged,N,
3228,DescriptorName,D009853,11341670,,,10,Omeprazole,N,
3229,QualifierName,Q000009,11341670,,,10,,Y,adverse effects
3230,DescriptorName,D000077402,11341670,,,11,Pantoprazole,N,
3231,DescriptorName,D010437,11341670,,,12,Peptic Ulcer,N,
3232,QualifierName,Q000188,11341670,,,12,,Y,drug therapy
3233,DescriptorName,D054328,11341670,,,13,Proton Pump Inhibitors,Y,
3234,DescriptorName,D013454,11341670,,,14,Sulfoxides,N,
3235,QualifierName,Q000009,11341670,,,14,,Y,adverse effects
3236,Chemical,D000978,11346113,Antiparkinson Agents,0,,,,
3237,DescriptorName,D000368,11346113,,,1,Aged,N,
3238,DescriptorName,D000978,11346113,,,2,Antiparkinson Agents,N,
3239,QualifierName,Q000009,11346113,,,2,,N,adverse effects
3240,DescriptorName,D003937,11346113,,,3,"Diagnosis, Differential",N,
3241,DescriptorName,D019317,11346113,,,4,Evidence-Based Medicine,N,
3242,DescriptorName,D005260,11346113,,,5,Female,N,
3243,DescriptorName,D006801,11346113,,,6,Humans,N,
3244,DescriptorName,D008297,11346113,,,7,Male,N,
3245,DescriptorName,D019578,11346113,,,8,Multiple System Atrophy,N,
3246,QualifierName,Q000175,11346113,,,8,,N,diagnosis
3247,DescriptorName,D010300,11346113,,,9,Parkinson Disease,Y,
3248,QualifierName,Q000175,11346113,,,9,,N,diagnosis
3249,DescriptorName,D010302,11346113,,,10,"Parkinson Disease, Secondary",Y,
3250,QualifierName,Q000175,11346113,,,10,,N,diagnosis
3251,DescriptorName,D011379,11346113,,,11,Prognosis,N,
3252,Chemical,D000894,11352235,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
3253,Chemical,D007555,11352235,Isoxazoles,0,,,,
3254,Chemical,D000077339,11352235,Leflunomide,G162GK9U4W,,,,
3255,DescriptorName,D000368,11352235,,,1,Aged,N,
3256,DescriptorName,D000894,11352235,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
3257,QualifierName,Q000009,11352235,,,2,,Y,adverse effects
3258,DescriptorName,D001172,11352235,,,3,"Arthritis, Rheumatoid",N,
3259,QualifierName,Q000188,11352235,,,3,,Y,drug therapy
3260,DescriptorName,D005260,11352235,,,4,Female,N,
3261,DescriptorName,D006801,11352235,,,5,Humans,N,
3262,DescriptorName,D007555,11352235,,,6,Isoxazoles,N,
3263,QualifierName,Q000009,11352235,,,6,,Y,adverse effects
3264,DescriptorName,D000077339,11352235,,,7,Leflunomide,N,
3265,DescriptorName,D008297,11352235,,,8,Male,N,
3266,DescriptorName,D008875,11352235,,,9,Middle Aged,N,
3267,DescriptorName,D010085,11352235,,,10,Oxidative Phosphorylation,N,
3268,QualifierName,Q000187,11352235,,,10,,N,drug effects
3269,DescriptorName,D015431,11352235,,,11,Weight Loss,N,
3270,QualifierName,Q000187,11352235,,,11,,Y,drug effects
3271,Chemical,D000998,11359026,Antiviral Agents,0,,,,
3272,Chemical,D011355,11359026,Prodrugs,0,,,,
3273,Chemical,D014633,11359026,Valine,HG18B9YRS7,,,,
3274,Chemical,D000077483,11359026,Valacyclovir,MZ1IW7Q79D,,,,
3275,Chemical,D000212,11359026,Acyclovir,X4HES1O11F,,,,
3276,DescriptorName,D000212,11359026,,,1,Acyclovir,N,
3277,QualifierName,Q000031,11359026,,,1,,Y,analogs & derivatives
3278,DescriptorName,D000998,11359026,,,2,Antiviral Agents,N,
3279,QualifierName,Q000493,11359026,,,2,,N,pharmacokinetics
3280,DescriptorName,D005260,11359026,,,3,Female,N,
3281,DescriptorName,D006212,11359026,,,4,Hallucinations,N,
3282,QualifierName,Q000139,11359026,,,4,,N,chemically induced
3283,DescriptorName,D006562,11359026,,,5,Herpes Zoster,N,
3284,QualifierName,Q000188,11359026,,,5,,N,drug therapy
3285,DescriptorName,D006801,11359026,,,6,Humans,N,
3286,DescriptorName,D008875,11359026,,,7,Middle Aged,N,
3287,DescriptorName,D010531,11359026,,,8,"Peritoneal Dialysis, Continuous Ambulatory",Y,
3288,DescriptorName,D011355,11359026,,,9,Prodrugs,N,
3289,QualifierName,Q000493,11359026,,,9,,Y,pharmacokinetics
3290,DescriptorName,D000077483,11359026,,,10,Valacyclovir,N,
3291,DescriptorName,D014633,11359026,,,11,Valine,N,
3292,QualifierName,Q000031,11359026,,,11,,Y,analogs & derivatives
3293,Chemical,D000970,11373877,Antineoplastic Agents,0,,,,
3294,Chemical,D017373,11373877,Cyproterone Acetate,4KM2BN5JHF,,,,
3295,DescriptorName,D000230,11373877,,,1,Adenocarcinoma,N,
3296,QualifierName,Q000188,11373877,,,1,,N,drug therapy
3297,DescriptorName,D000368,11373877,,,2,Aged,N,
3298,DescriptorName,D000970,11373877,,,3,Antineoplastic Agents,N,
3299,QualifierName,Q000009,11373877,,,3,,Y,adverse effects
3300,DescriptorName,D017373,11373877,,,4,Cyproterone Acetate,N,
3301,QualifierName,Q000009,11373877,,,4,,Y,adverse effects
3302,DescriptorName,D003937,11373877,,,5,"Diagnosis, Differential",N,
3303,DescriptorName,D005271,11373877,,,6,Femur Head Necrosis,N,
3304,QualifierName,Q000175,11373877,,,6,,Y,diagnosis
3305,DescriptorName,D006801,11373877,,,7,Humans,N,
3306,DescriptorName,D008297,11373877,,,8,Male,N,
3307,DescriptorName,D008875,11373877,,,9,Middle Aged,N,
3308,DescriptorName,D011471,11373877,,,10,Prostatic Neoplasms,N,
3309,QualifierName,Q000188,11373877,,,10,,N,drug therapy
3310,DescriptorName,D011878,11373877,,,11,Radiotherapy,N,
3311,QualifierName,Q000009,11373877,,,11,,Y,adverse effects
3312,Chemical,D000892,11388112,"Anti-Infective Agents, Urinary",0,,,,
3313,Chemical,D064704,11388112,Levofloxacin,6GNT3Y5LMF,,,,
3314,Chemical,D015242,11388112,Ofloxacin,A4P49JAZ9H,,,,
3315,DescriptorName,D000892,11388112,,,1,"Anti-Infective Agents, Urinary",N,
3316,QualifierName,Q000009,11388112,,,1,,Y,adverse effects
3317,DescriptorName,D004562,11388112,,,2,Electrocardiography,N,
3318,DescriptorName,D005260,11388112,,,3,Female,N,
3319,DescriptorName,D006801,11388112,,,4,Humans,N,
3320,DescriptorName,D064704,11388112,,,5,Levofloxacin,Y,
3321,DescriptorName,D008875,11388112,,,6,Middle Aged,N,
3322,DescriptorName,D015242,11388112,,,7,Ofloxacin,N,
3323,QualifierName,Q000009,11388112,,,7,,Y,adverse effects
3324,DescriptorName,D013575,11388112,,,8,Syncope,N,
3325,QualifierName,Q000139,11388112,,,8,,N,chemically induced
3326,DescriptorName,D017180,11388112,,,9,"Tachycardia, Ventricular",N,
3327,QualifierName,Q000139,11388112,,,9,,Y,chemically induced
3328,DescriptorName,D014552,11388112,,,10,Urinary Tract Infections,N,
3329,QualifierName,Q000188,11388112,,,10,,N,drug therapy
3330,Chemical,D005343,11399735,Fibrinolytic Agents,0,,,,
3331,Chemical,D010975,11399735,Platelet Aggregation Inhibitors,0,,,,
3332,Chemical,D013988,11399735,Ticlopidine,OM90ZUW7M1,,,,
3333,DescriptorName,D000368,11399735,,,1,Aged,N,
3334,DescriptorName,D005260,11399735,,,2,Female,N,
3335,DescriptorName,D005343,11399735,,,3,Fibrinolytic Agents,N,
3336,QualifierName,Q000009,11399735,,,3,,Y,adverse effects
3337,DescriptorName,D006801,11399735,,,4,Humans,N,
3338,DescriptorName,D002546,11399735,,,5,"Ischemic Attack, Transient",N,
3339,QualifierName,Q000188,11399735,,,5,,N,drug therapy
3340,DescriptorName,D017563,11399735,,,6,"Lung Diseases, Interstitial",N,
3341,QualifierName,Q000139,11399735,,,6,,Y,chemically induced
3342,DescriptorName,D010975,11399735,,,7,Platelet Aggregation Inhibitors,N,
3343,QualifierName,Q000009,11399735,,,7,,Y,adverse effects
3344,DescriptorName,D013988,11399735,,,8,Ticlopidine,N,
3345,QualifierName,Q000009,11399735,,,8,,Y,adverse effects
3346,Chemical,D000701,11406880,"Analgesics, Opioid",0,,,,
3347,Chemical,D008691,11406880,Methadone,UC6VBE7V1Z,,,,
3348,DescriptorName,D000701,11406880,,,1,"Analgesics, Opioid",N,
3349,QualifierName,Q000009,11406880,,,1,,Y,adverse effects
3350,DescriptorName,D003110,11406880,,,2,Colonic Neoplasms,N,
3351,QualifierName,Q000150,11406880,,,2,,Y,complications
3352,DescriptorName,D017809,11406880,,,3,Fatal Outcome,N,
3353,DescriptorName,D005260,11406880,,,4,Female,N,
3354,DescriptorName,D006801,11406880,,,5,Humans,N,
3355,DescriptorName,D008691,11406880,,,6,Methadone,N,
3356,QualifierName,Q000009,11406880,,,6,,Y,adverse effects
3357,DescriptorName,D008875,11406880,,,7,Middle Aged,N,
3358,DescriptorName,D009207,11406880,,,8,Myoclonus,N,
3359,QualifierName,Q000139,11406880,,,8,,Y,chemically induced
3360,DescriptorName,D010146,11406880,,,9,Pain,N,
3361,QualifierName,Q000188,11406880,,,9,,Y,drug therapy
3362,DescriptorName,D013727,11406880,,,10,Terminal Care,N,
3363,QualifierName,Q000379,11406880,,,10,,Y,methods
3364,Chemical,D000970,11414270,Antineoplastic Agents,0,,,,
3365,Chemical,D009467,11414270,Neuromuscular Depolarizing Agents,0,,,,
3366,Chemical,D013390,11414270,Succinylcholine,J2R869A8YF,,,,
3367,DescriptorName,D000328,11414270,,,1,Adult,N,
3368,DescriptorName,D000970,11414270,,,2,Antineoplastic Agents,N,
3369,QualifierName,Q000009,11414270,,,2,,Y,adverse effects
3370,DescriptorName,D017809,11414270,,,3,Fatal Outcome,N,
3371,DescriptorName,D005260,11414270,,,4,Female,N,
3372,DescriptorName,D006801,11414270,,,5,Humans,N,
3373,DescriptorName,D006947,11414270,,,6,Hyperkalemia,N,
3374,QualifierName,Q000139,11414270,,,6,,Y,chemically induced
3375,DescriptorName,D015470,11414270,,,7,"Leukemia, Myeloid, Acute",N,
3376,QualifierName,Q000188,11414270,,,7,,N,drug therapy
3377,DescriptorName,D009467,11414270,,,8,Neuromuscular Depolarizing Agents,N,
3378,QualifierName,Q000009,11414270,,,8,,Y,adverse effects
3379,DescriptorName,D012131,11414270,,,9,Respiratory Insufficiency,N,
3380,QualifierName,Q000628,11414270,,,9,,N,therapy
3381,DescriptorName,D013280,11414270,,,10,Stomatitis,N,
3382,QualifierName,Q000139,11414270,,,10,,Y,chemically induced
3383,DescriptorName,D013390,11414270,,,11,Succinylcholine,N,
3384,QualifierName,Q000009,11414270,,,11,,Y,adverse effects
3385,Chemical,D000431,11424102,Ethanol,3K9958V90M,,,,
3386,DescriptorName,D000368,11424102,,,1,Aged,N,
3387,DescriptorName,D000369,11424102,,,2,"Aged, 80 and over",N,
3388,DescriptorName,D006528,11424102,,,3,"Carcinoma, Hepatocellular",N,
3389,QualifierName,Q000188,11424102,,,3,,N,drug therapy
3390,DescriptorName,D000431,11424102,,,4,Ethanol,N,
3391,QualifierName,Q000008,11424102,,,4,,Y,administration & dosage
3392,DescriptorName,D006801,11424102,,,5,Humans,N,
3393,DescriptorName,D007279,11424102,,,6,"Injections, Subcutaneous",N,
3394,DescriptorName,D008113,11424102,,,7,Liver Neoplasms,N,
3395,QualifierName,Q000188,11424102,,,7,,Y,drug therapy
3396,DescriptorName,D008297,11424102,,,8,Male,N,
3397,DescriptorName,D009366,11424102,,,9,Neoplasm Seeding,Y,
3398,DescriptorName,D012878,11424102,,,10,Skin Neoplasms,N,
3399,QualifierName,Q000556,11424102,,,10,,Y,secondary
3400,DescriptorName,D018084,11424102,,,11,"Ultrasonography, Interventional",N,
3401,QualifierName,Q000009,11424102,,,11,,Y,adverse effects
3402,Chemical,D000889,11428480,Anti-Arrhythmia Agents,0,,,,
3403,Chemical,D000241,11428480,Adenosine,K72T3FS567,,,,
3404,DescriptorName,D000241,11428480,,,1,Adenosine,N,
3405,QualifierName,Q000009,11428480,,,1,,Y,adverse effects
3406,DescriptorName,D000328,11428480,,,2,Adult,N,
3407,DescriptorName,D000889,11428480,,,3,Anti-Arrhythmia Agents,N,
3408,QualifierName,Q000009,11428480,,,3,,Y,adverse effects
3409,DescriptorName,D004554,11428480,,,4,Electric Countershock,N,
3410,DescriptorName,D004562,11428480,,,5,Electrocardiography,Y,
3411,DescriptorName,D004636,11428480,,,6,"Emergency Service, Hospital",N,
3412,DescriptorName,D005500,11428480,,,7,Follow-Up Studies,N,
3413,DescriptorName,D006801,11428480,,,8,Humans,N,
3414,DescriptorName,D007262,11428480,,,9,"Infusions, Intravenous",N,
3415,DescriptorName,D008297,11428480,,,10,Male,N,
3416,DescriptorName,D018570,11428480,,,11,Risk Assessment,N,
3417,DescriptorName,D013617,11428480,,,12,"Tachycardia, Supraventricular",N,
3418,QualifierName,Q000175,11428480,,,12,,Y,diagnosis
3419,DescriptorName,D014693,11428480,,,13,Ventricular Fibrillation,N,
3420,QualifierName,Q000139,11428480,,,13,,Y,chemically induced
3421,Chemical,D018927,11431864,Anti-Asthmatic Agents,0,,,,
3422,Chemical,D008775,11431864,Methylprednisolone,X4W7ZR7023,,,,
3423,DescriptorName,D018927,11431864,,,1,Anti-Asthmatic Agents,N,
3424,QualifierName,Q000009,11431864,,,1,,Y,adverse effects
3425,DescriptorName,D001249,11431864,,,2,Asthma,N,
3426,QualifierName,Q000188,11431864,,,2,,Y,drug therapy
3427,DescriptorName,D002675,11431864,,,3,"Child, Preschool",N,
3428,DescriptorName,D005260,11431864,,,4,Female,N,
3429,DescriptorName,D006801,11431864,,,5,Humans,N,
3430,DescriptorName,D008775,11431864,,,6,Methylprednisolone,N,
3431,QualifierName,Q000009,11431864,,,6,,Y,adverse effects
3432,DescriptorName,D011605,11431864,,,7,"Psychoses, Substance-Induced",N,
3433,QualifierName,Q000209,11431864,,,7,,Y,etiology
3434,Chemical,D002220,11435808,Carbamazepine,33CM23913M,,,,
3435,DescriptorName,D000328,11435808,,,1,Adult,N,
3436,DescriptorName,D001921,11435808,,,2,Brain,N,
3437,QualifierName,Q000473,11435808,,,2,,N,pathology
3438,DescriptorName,D002220,11435808,,,3,Carbamazepine,N,
3439,QualifierName,Q000506,11435808,,,3,,Y,poisoning
3440,DescriptorName,D003128,11435808,,,4,Coma,N,
3441,QualifierName,Q000209,11435808,,,4,,N,etiology
3442,DescriptorName,D062787,11435808,,,5,Drug Overdose,N,
3443,QualifierName,Q000150,11435808,,,5,,N,complications
3444,DescriptorName,D004569,11435808,,,6,Electroencephalography,N,
3445,QualifierName,Q000187,11435808,,,6,,Y,drug effects
3446,DescriptorName,D004830,11435808,,,7,"Epilepsy, Tonic-Clonic",N,
3447,QualifierName,Q000150,11435808,,,7,,N,complications
3448,DescriptorName,D017809,11435808,,,8,Fatal Outcome,N,
3449,DescriptorName,D005260,11435808,,,9,Female,N,
3450,DescriptorName,D006323,11435808,,,10,Heart Arrest,N,
3451,QualifierName,Q000209,11435808,,,10,,N,etiology
3452,DescriptorName,D006801,11435808,,,11,Humans,N,
3453,DescriptorName,D008991,11435808,,,12,"Monitoring, Physiologic",N,
3454,DescriptorName,D011669,11435808,,,13,Pulmonary Wedge Pressure,N,
3455,DescriptorName,D012128,11435808,,,14,"Respiratory Distress Syndrome, Adult",N,
3456,QualifierName,Q000150,11435808,,,14,,N,complications
3457,DescriptorName,D013116,11435808,,,15,Spinal Cord,N,
3458,QualifierName,Q000473,11435808,,,15,,N,pathology
3459,Chemical,D013956,11443640,Antithyroid Agents,0,,,,
3460,Chemical,D008713,11443640,Methimazole,554Z48XN5E,,,,
3461,DescriptorName,D000293,11443640,,,1,Adolescent,N,
3462,DescriptorName,D013956,11443640,,,2,Antithyroid Agents,N,
3463,QualifierName,Q000008,11443640,,,2,,N,administration & dosage
3464,DescriptorName,D001853,11443640,,,3,Bone Marrow,N,
3465,QualifierName,Q000187,11443640,,,3,,N,drug effects
3466,DescriptorName,D001855,11443640,,,4,Bone Marrow Diseases,N,
3467,QualifierName,Q000139,11443640,,,4,,N,chemically induced
3468,DescriptorName,D003937,11443640,,,5,"Diagnosis, Differential",N,
3469,DescriptorName,D005260,11443640,,,6,Female,N,
3470,DescriptorName,D006111,11443640,,,7,Graves Disease,N,
3471,QualifierName,Q000150,11443640,,,7,,N,complications
3472,DescriptorName,D006801,11443640,,,8,Humans,N,
3473,DescriptorName,D007964,11443640,,,9,Leukocytosis,N,
3474,QualifierName,Q000139,11443640,,,9,,Y,chemically induced
3475,DescriptorName,D008713,11443640,,,10,Methimazole,N,
3476,QualifierName,Q000008,11443640,,,10,,N,administration & dosage
3477,DescriptorName,D009101,11443640,,,11,Multiple Myeloma,N,
3478,DescriptorName,D010198,11443640,,,12,Pancytopenia,N,
3479,QualifierName,Q000209,11443640,,,12,,N,etiology
3480,DescriptorName,D010950,11443640,,,13,Plasma Cells,N,
3481,QualifierName,Q000187,11443640,,,13,,N,drug effects
3482,Chemical,D019380,11450788,Anti-HIV Agents,0,,,,
3483,Chemical,D016049,11450788,Didanosine,K3GDH6OH08,,,,
3484,DescriptorName,D000006,11450788,,,1,"Abdomen, Acute",N,
3485,QualifierName,Q000175,11450788,,,1,,N,diagnosis
3486,DescriptorName,D000140,11450788,,,2,"Acidosis, Lactic",N,
3487,QualifierName,Q000175,11450788,,,2,,Y,diagnosis
3488,DescriptorName,D000328,11450788,,,3,Adult,N,
3489,DescriptorName,D019380,11450788,,,4,Anti-HIV Agents,N,
3490,QualifierName,Q000009,11450788,,,4,,Y,adverse effects
3491,DescriptorName,D003937,11450788,,,5,"Diagnosis, Differential",N,
3492,DescriptorName,D016049,11450788,,,6,Didanosine,N,
3493,QualifierName,Q000009,11450788,,,6,,Y,adverse effects
3494,DescriptorName,D005234,11450788,,,7,Fatty Liver,N,
3495,QualifierName,Q000139,11450788,,,7,,Y,chemically induced
3496,DescriptorName,D005260,11450788,,,8,Female,N,
3497,DescriptorName,D015658,11450788,,,9,HIV Infections,N,
3498,QualifierName,Q000188,11450788,,,9,,Y,drug therapy
3499,DescriptorName,D006801,11450788,,,10,Humans,N,
3500,DescriptorName,D008099,11450788,,,11,Liver,N,
3501,QualifierName,Q000473,11450788,,,11,,N,pathology
3502,DescriptorName,D017093,11450788,,,12,Liver Failure,N,
3503,QualifierName,Q000139,11450788,,,12,,Y,chemically induced
3504,Chemical,D000932,11452688,Antiemetics,0,,,,
3505,Chemical,D003907,11452688,Dexamethasone,7S5I7G3JQL,,,,
3506,DescriptorName,D000328,11452688,,,1,Adult,N,
3507,DescriptorName,D000932,11452688,,,2,Antiemetics,N,
3508,QualifierName,Q000008,11452688,,,2,,N,administration & dosage
3509,DescriptorName,D000971,11452688,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
3510,QualifierName,Q000009,11452688,,,3,,N,adverse effects
3511,DescriptorName,D003907,11452688,,,4,Dexamethasone,N,
3512,QualifierName,Q000008,11452688,,,4,,N,administration & dosage
3513,DescriptorName,D005271,11452688,,,5,Femur Head Necrosis,N,
3514,QualifierName,Q000139,11452688,,,5,,Y,chemically induced
3515,DescriptorName,D006801,11452688,,,6,Humans,N,
3516,DescriptorName,D008279,11452688,,,7,Magnetic Resonance Imaging,N,
3517,QualifierName,Q000379,11452688,,,7,,N,methods
3518,DescriptorName,D008297,11452688,,,8,Male,N,
3519,DescriptorName,D011859,11452688,,,9,Radiography,N,
3520,DescriptorName,D013736,11452688,,,10,Testicular Neoplasms,N,
3521,QualifierName,Q000188,11452688,,,10,,N,drug therapy
3522,Chemical,D007004,11468878,Hypoglycemic Agents,0,,,,
3523,Chemical,D008687,11468878,Metformin,9100L32L2N,,,,
3524,DescriptorName,D000328,11468878,,,1,Adult,N,
3525,DescriptorName,D006471,11468878,,,2,Gastrointestinal Hemorrhage,N,
3526,QualifierName,Q000139,11468878,,,2,,N,chemically induced
3527,DescriptorName,D006801,11468878,,,3,Humans,N,
3528,DescriptorName,D007004,11468878,,,4,Hypoglycemic Agents,Y,
3529,QualifierName,Q000009,11468878,,,4,,N,adverse effects
3530,DescriptorName,D008297,11468878,,,5,Male,N,
3531,DescriptorName,D008467,11468878,,,6,Meckel Diverticulum,N,
3532,QualifierName,Q000139,11468878,,,6,,N,chemically induced
3533,DescriptorName,D008687,11468878,,,7,Metformin,Y,
3534,QualifierName,Q000009,11468878,,,7,,N,adverse effects
3535,DescriptorName,D009765,11468878,,,8,Obesity,N,
3536,QualifierName,Q000188,11468878,,,8,,N,drug therapy
3537,Chemical,D000890,11476690,Anti-Infective Agents,0,,,,
3538,Chemical,D002939,11476690,Ciprofloxacin,5E8K9I0O4U,,,,
3539,DescriptorName,D000890,11476690,,,1,Anti-Infective Agents,N,
3540,QualifierName,Q000627,11476690,,,1,,N,therapeutic use
3541,DescriptorName,D001251,11476690,,,2,Astigmatism,N,
3542,QualifierName,Q000628,11476690,,,2,,N,therapy
3543,DescriptorName,D002648,11476690,,,3,Child,N,
3544,DescriptorName,D002939,11476690,,,4,Ciprofloxacin,N,
3545,QualifierName,Q000627,11476690,,,4,,N,therapeutic use
3546,DescriptorName,D003261,11476690,,,5,Contact Lenses,N,
3547,QualifierName,Q000009,11476690,,,5,,Y,adverse effects
3548,DescriptorName,D003315,11476690,,,6,Cornea,N,
3549,QualifierName,Q000382,11476690,,,6,,N,microbiology
3550,DescriptorName,D003320,11476690,,,7,Corneal Ulcer,N,
3551,QualifierName,Q000188,11476690,,,7,,N,drug therapy
3552,DescriptorName,D015818,11476690,,,8,"Eye Infections, Bacterial",N,
3553,QualifierName,Q000188,11476690,,,8,,N,drug therapy
3554,DescriptorName,D006801,11476690,,,9,Humans,N,
3555,DescriptorName,D008297,11476690,,,10,Male,N,
3556,DescriptorName,D009216,11476690,,,11,Myopia,N,
3557,QualifierName,Q000628,11476690,,,11,,N,therapy
3558,DescriptorName,D012307,11476690,,,12,Risk Factors,N,
3559,DescriptorName,D016868,11476690,,,13,Serratia Infections,N,
3560,QualifierName,Q000188,11476690,,,13,,N,drug therapy
3561,DescriptorName,D012706,11476690,,,14,Serratia marcescens,N,
3562,QualifierName,Q000302,11476690,,,14,,Y,isolation & purification
3563,DescriptorName,D014792,11476690,,,15,Visual Acuity,N,
3564,Chemical,D002219,11483161,Carbamates,0,,,,
3565,Chemical,D017320,11483161,HIV Protease Inhibitors,0,,,,
3566,Chemical,D013449,11483161,Sulfonamides,0,,,,
3567,Chemical,C095108,11483161,amprenavir,5S0W860XNR,,,,
3568,Chemical,D005169,11483161,Factor VIII,9001-27-8,,,,
3569,DescriptorName,D000328,11483161,,,1,Adult,N,
3570,DescriptorName,D002219,11483161,,,2,Carbamates,N,
3571,DescriptorName,D003937,11483161,,,3,"Diagnosis, Differential",N,
3572,DescriptorName,D005169,11483161,,,4,Factor VIII,N,
3573,QualifierName,Q000627,11483161,,,4,,N,therapeutic use
3574,DescriptorName,D015658,11483161,,,5,HIV Infections,N,
3575,QualifierName,Q000150,11483161,,,5,,N,complications
3576,DescriptorName,D017320,11483161,,,6,HIV Protease Inhibitors,N,
3577,QualifierName,Q000009,11483161,,,6,,Y,adverse effects
3578,DescriptorName,D006467,11483161,,,7,Hemophilia A,N,
3579,QualifierName,Q000150,11483161,,,7,,Y,complications
3580,DescriptorName,D006801,11483161,,,8,Humans,N,
3581,DescriptorName,D020300,11483161,,,9,Intracranial Hemorrhages,N,
3582,QualifierName,Q000139,11483161,,,9,,N,chemically induced
3583,DescriptorName,D008297,11483161,,,10,Male,N,
3584,DescriptorName,D013449,11483161,,,11,Sulfonamides,N,
3585,QualifierName,Q000009,11483161,,,11,,Y,adverse effects
3586,DescriptorName,D014057,11483161,,,12,"Tomography, X-Ray Computed",N,
3587,Chemical,D000893,11485141,Anti-Inflammatory Agents,0,,,,
3588,Chemical,D000964,11485141,"Antimetabolites, Antineoplastic",0,,,,
3589,Chemical,D005938,11485141,Glucocorticoids,0,,,,
3590,Chemical,D007070,11485141,Immunoglobulin A,0,,,,
3591,Chemical,D003841,11485141,Deoxycytidine,0W860991D6,,,,
3592,Chemical,C056507,11485141,gemcitabine,B76N6SBZ8R,,,,
3593,Chemical,D008775,11485141,Methylprednisolone,X4W7ZR7023,,,,
3594,DescriptorName,D000287,11485141,,,1,"Administration, Topical",N,
3595,DescriptorName,D000893,11485141,,,2,Anti-Inflammatory Agents,N,
3596,QualifierName,Q000627,11485141,,,2,,N,therapeutic use
3597,DescriptorName,D000964,11485141,,,3,"Antimetabolites, Antineoplastic",N,
3598,QualifierName,Q000009,11485141,,,3,,Y,adverse effects
3599,DescriptorName,D003841,11485141,,,4,Deoxycytidine,N,
3600,QualifierName,Q000009,11485141,,,4,,Y,adverse effects
3601,DescriptorName,D005938,11485141,,,5,Glucocorticoids,N,
3602,DescriptorName,D006801,11485141,,,6,Humans,N,
3603,DescriptorName,D007070,11485141,,,7,Immunoglobulin A,N,
3604,QualifierName,Q000378,11485141,,,7,,Y,metabolism
3605,DescriptorName,D008297,11485141,,,8,Male,N,
3606,DescriptorName,D008775,11485141,,,9,Methylprednisolone,N,
3607,QualifierName,Q000627,11485141,,,9,,N,therapeutic use
3608,DescriptorName,D008875,11485141,,,10,Middle Aged,N,
3609,DescriptorName,D012872,11485141,,,11,"Skin Diseases, Vesiculobullous",N,
3610,QualifierName,Q000139,11485141,,,11,,Y,chemically induced
3611,Chemical,D000972,11487721,"Antineoplastic Agents, Phytogenic",0,,,,
3612,Chemical,D017239,11487721,Paclitaxel,P88XT4IS4D,,,,
3613,DescriptorName,D000972,11487721,,,1,"Antineoplastic Agents, Phytogenic",N,
3614,QualifierName,Q000009,11487721,,,1,,Y,adverse effects
3615,DescriptorName,D002277,11487721,,,2,Carcinoma,N,
3616,QualifierName,Q000188,11487721,,,2,,Y,drug therapy
3617,DescriptorName,D005260,11487721,,,3,Female,N,
3618,DescriptorName,D006801,11487721,,,4,Humans,N,
3619,DescriptorName,D007866,11487721,,,5,Leg,N,
3620,DescriptorName,D008875,11487721,,,6,Middle Aged,N,
3621,DescriptorName,D010051,11487721,,,7,Ovarian Neoplasms,N,
3622,QualifierName,Q000188,11487721,,,7,,Y,drug therapy
3623,DescriptorName,D017239,11487721,,,8,Paclitaxel,N,
3624,QualifierName,Q000009,11487721,,,8,,Y,adverse effects
3625,DescriptorName,D010146,11487721,,,9,Pain,N,
3626,QualifierName,Q000139,11487721,,,9,,N,chemically induced
3627,DescriptorName,D010523,11487721,,,10,Peripheral Nervous System Diseases,N,
3628,QualifierName,Q000139,11487721,,,10,,Y,chemically induced
3629,DescriptorName,D011434,11487721,,,11,Proprioception,N,
3630,QualifierName,Q000187,11487721,,,11,,Y,drug effects
3631,Chemical,D000701,11489400,"Analgesics, Opioid",0,,,,
3632,Chemical,D009292,11489400,Narcotic Antagonists,0,,,,
3633,Chemical,D009270,11489400,Naloxone,36B82AMQ7N,,,,
3634,Chemical,D009020,11489400,Morphine,76I7G6D29C,,,,
3635,DescriptorName,D000328,11489400,,,1,Adult,N,
3636,DescriptorName,D000701,11489400,,,2,"Analgesics, Opioid",N,
3637,QualifierName,Q000009,11489400,,,2,,Y,adverse effects
3638,DescriptorName,D001660,11489400,,,3,Biliary Tract Diseases,N,
3639,QualifierName,Q000175,11489400,,,3,,N,diagnosis
3640,DescriptorName,D002763,11489400,,,4,Cholecystectomy,N,
3641,DescriptorName,D003085,11489400,,,5,Colic,N,
3642,QualifierName,Q000175,11489400,,,5,,N,diagnosis
3643,DescriptorName,D004636,11489400,,,6,"Emergency Service, Hospital",Y,
3644,DescriptorName,D005260,11489400,,,7,Female,N,
3645,DescriptorName,D006801,11489400,,,8,Humans,N,
3646,DescriptorName,D009020,11489400,,,9,Morphine,N,
3647,QualifierName,Q000009,11489400,,,9,,Y,adverse effects
3648,DescriptorName,D009270,11489400,,,10,Naloxone,N,
3649,QualifierName,Q000627,11489400,,,10,,Y,therapeutic use
3650,DescriptorName,D009292,11489400,,,11,Narcotic Antagonists,N,
3651,QualifierName,Q000627,11489400,,,11,,Y,therapeutic use
3652,DescriptorName,D010146,11489400,,,12,Pain,N,
3653,QualifierName,Q000139,11489400,,,12,,Y,chemically induced
3654,DescriptorName,D011184,11489400,,,13,Postoperative Period,N,
3655,DescriptorName,D013035,11489400,,,14,Spasm,N,
3656,QualifierName,Q000139,11489400,,,14,,Y,chemically induced
3657,DescriptorName,D009803,11489400,,,15,Sphincter of Oddi,N,
3658,QualifierName,Q000187,11489400,,,15,,Y,drug effects
3659,Chemical,D000998,11506739,Antiviral Agents,0,,,,
3660,Chemical,D007370,11506739,Interferon Type I,0,,,,
3661,Chemical,D011994,11506739,Recombinant Proteins,0,,,,
3662,DescriptorName,D000998,11506739,,,1,Antiviral Agents,N,
3663,QualifierName,Q000008,11506739,,,1,,N,administration & dosage
3664,DescriptorName,D004334,11506739,,,2,Drug Administration Schedule,N,
3665,DescriptorName,D019698,11506739,,,3,"Hepatitis C, Chronic",N,
3666,QualifierName,Q000175,11506739,,,3,,N,diagnosis
3667,DescriptorName,D006801,11506739,,,4,Humans,N,
3668,DescriptorName,D007370,11506739,,,5,Interferon Type I,N,
3669,QualifierName,Q000008,11506739,,,5,,N,administration & dosage
3670,DescriptorName,D008297,11506739,,,6,Male,N,
3671,DescriptorName,D008875,11506739,,,7,Middle Aged,N,
3672,DescriptorName,D009157,11506739,,,8,Myasthenia Gravis,N,
3673,QualifierName,Q000139,11506739,,,8,,Y,chemically induced
3674,DescriptorName,D011994,11506739,,,9,Recombinant Proteins,N,
3675,Chemical,D006052,115078,Gold Sodium Thiomalate,12244-57-4,,,,
3676,DescriptorName,D001172,115078,,,1,"Arthritis, Rheumatoid",N,
3677,QualifierName,Q000188,115078,,,1,,N,drug therapy
3678,DescriptorName,D001706,115078,,,2,Biopsy,N,
3679,DescriptorName,D056486,115078,,,3,Chemical and Drug Induced Liver Injury,N,
3680,QualifierName,Q000209,115078,,,3,,Y,etiology
3681,DescriptorName,D002780,115078,,,4,"Cholestasis, Intrahepatic",N,
3682,QualifierName,Q000139,115078,,,4,,Y,chemically induced
3683,DescriptorName,D006052,115078,,,5,Gold Sodium Thiomalate,N,
3684,QualifierName,Q000009,115078,,,5,,Y,adverse effects
3685,DescriptorName,D006801,115078,,,6,Humans,N,
3686,DescriptorName,D008099,115078,,,7,Liver,N,
3687,QualifierName,Q000473,115078,,,7,,N,pathology
3688,DescriptorName,D008297,115078,,,8,Male,N,
3689,DescriptorName,D008875,115078,,,9,Middle Aged,N,
3690,Chemical,D009944,11510798,Organoplatinum Compounds,0,,,,
3691,Chemical,D000077150,11510798,Oxaliplatin,04ZR38536J,,,,
3692,Chemical,D005472,11510798,Fluorouracil,U3P01618RT,,,,
3693,DescriptorName,D000208,11510798,,,1,Acute Disease,N,
3694,DescriptorName,D000971,11510798,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
3695,QualifierName,Q000008,11510798,,,2,,N,administration & dosage
3696,DescriptorName,D005472,11510798,,,3,Fluorouracil,N,
3697,QualifierName,Q000008,11510798,,,3,,N,administration & dosage
3698,DescriptorName,D006801,11510798,,,4,Humans,N,
3699,DescriptorName,D008168,11510798,,,5,Lung,N,
3700,QualifierName,Q000187,11510798,,,5,,N,drug effects
3701,DescriptorName,D008297,11510798,,,6,Male,N,
3702,DescriptorName,D008875,11510798,,,7,Middle Aged,N,
3703,DescriptorName,D009944,11510798,,,8,Organoplatinum Compounds,N,
3704,QualifierName,Q000008,11510798,,,8,,N,administration & dosage
3705,DescriptorName,D000077150,11510798,,,9,Oxaliplatin,N,
3706,DescriptorName,D011658,11510798,,,10,Pulmonary Fibrosis,N,
3707,QualifierName,Q000139,11510798,,,10,,Y,chemically induced
3708,DescriptorName,D012004,11510798,,,11,Rectal Neoplasms,N,
3709,QualifierName,Q000188,11510798,,,11,,N,drug therapy
3710,DescriptorName,D014057,11510798,,,12,"Tomography, X-Ray Computed",N,
3711,Chemical,D007641,11514944,Keratolytic Agents,0,,,,
3712,Chemical,D015474,11514944,Isotretinoin,EH28UP18IF,,,,
3713,DescriptorName,D000014,11514944,,,1,"Abnormalities, Drug-Induced",N,
3714,QualifierName,Q000453,11514944,,,1,,Y,epidemiology
3715,DescriptorName,D000022,11514944,,,2,"Abortion, Spontaneous",N,
3716,QualifierName,Q000139,11514944,,,2,,N,chemically induced
3717,DescriptorName,D000152,11514944,,,3,Acne Vulgaris,N,
3718,QualifierName,Q000188,11514944,,,3,,N,drug therapy
3719,DescriptorName,D000293,11514944,,,4,Adolescent,N,
3720,DescriptorName,D000328,11514944,,,5,Adult,N,
3721,DescriptorName,D003267,11514944,,,6,Contraception,N,
3722,DescriptorName,D003268,11514944,,,7,Contraception Behavior,N,
3723,DescriptorName,D000075202,11514944,,,8,Contraindications,N,
3724,DescriptorName,D005260,11514944,,,9,Female,N,
3725,DescriptorName,D006801,11514944,,,10,Humans,N,
3726,DescriptorName,D015994,11514944,,,11,Incidence,N,
3727,DescriptorName,D015474,11514944,,,12,Isotretinoin,N,
3728,QualifierName,Q000009,11514944,,,12,,Y,adverse effects
3729,DescriptorName,D007641,11514944,,,13,Keratolytic Agents,N,
3730,QualifierName,Q000009,11514944,,,13,,Y,adverse effects
3731,DescriptorName,D010353,11514944,,,14,Patient Education as Topic,N,
3732,DescriptorName,D011247,11514944,,,15,Pregnancy,N,
3733,DescriptorName,D011248,11514944,,,16,Pregnancy Complications,N,
3734,QualifierName,Q000139,11514944,,,16,,N,chemically induced
3735,DescriptorName,D011256,11514944,,,17,Pregnancy Outcome,N,
3736,DescriptorName,D011261,11514944,,,18,"Pregnancy Trimester, First",N,
3737,DescriptorName,D013997,11514944,,,19,Time Factors,N,
3738,Chemical,D018927,11518127,Anti-Asthmatic Agents,0,,,,
3739,Chemical,D002867,11518127,Chromones,0,,,,
3740,Chemical,D020024,11518127,Leukotriene Antagonists,0,,,,
3741,Chemical,C047681,11518127,pranlukast,TB8Z891092,,,,
3742,DescriptorName,D000208,11518127,,,1,Acute Disease,N,
3743,DescriptorName,D018927,11518127,,,2,Anti-Asthmatic Agents,N,
3744,QualifierName,Q000009,11518127,,,2,,Y,adverse effects
3745,DescriptorName,D001249,11518127,,,3,Asthma,N,
3746,QualifierName,Q000188,11518127,,,3,,N,drug therapy
3747,DescriptorName,D002867,11518127,,,4,Chromones,N,
3748,QualifierName,Q000009,11518127,,,4,,Y,adverse effects
3749,DescriptorName,D003937,11518127,,,5,"Diagnosis, Differential",N,
3750,DescriptorName,D005260,11518127,,,6,Female,N,
3751,DescriptorName,D006801,11518127,,,7,Humans,N,
3752,DescriptorName,D020024,11518127,,,8,Leukotriene Antagonists,N,
3753,QualifierName,Q000009,11518127,,,8,,Y,adverse effects
3754,DescriptorName,D017563,11518127,,,9,"Lung Diseases, Interstitial",N,
3755,QualifierName,Q000139,11518127,,,9,,Y,chemically induced
3756,DescriptorName,D008875,11518127,,,10,Middle Aged,N,
3757,DescriptorName,D011859,11518127,,,11,Radiography,N,
3758,Chemical,D017320,11545487,HIV Protease Inhibitors,0,,,,
3759,Chemical,D019469,11545487,Indinavir,5W6YA9PKKH,,,,
3760,DescriptorName,D000328,11545487,,,1,Adult,N,
3761,DescriptorName,D023241,11545487,,,2,"Antiretroviral Therapy, Highly Active",N,
3762,QualifierName,Q000009,11545487,,,2,,N,adverse effects
3763,DescriptorName,D005260,11545487,,,3,Female,N,
3764,DescriptorName,D015658,11545487,,,4,HIV Infections,N,
3765,QualifierName,Q000188,11545487,,,4,,N,drug therapy
3766,DescriptorName,D017320,11545487,,,5,HIV Protease Inhibitors,N,
3767,QualifierName,Q000009,11545487,,,5,,Y,adverse effects
3768,DescriptorName,D015497,11545487,,,6,HIV-1,N,
3769,QualifierName,Q000302,11545487,,,6,,N,isolation & purification
3770,DescriptorName,D006801,11545487,,,7,Humans,N,
3771,DescriptorName,D019469,11545487,,,8,Indinavir,N,
3772,QualifierName,Q000009,11545487,,,8,,Y,adverse effects
3773,DescriptorName,D007681,11545487,,,9,Kidney Papillary Necrosis,N,
3774,QualifierName,Q000139,11545487,,,9,,Y,chemically induced
3775,Chemical,D016861,11550988,Cyclooxygenase Inhibitors,0,,,,
3776,Chemical,D007783,11550988,Lactones,0,,,,
3777,Chemical,D013450,11550988,Sulfones,0,,,,
3778,Chemical,C116926,11550988,rofecoxib,0QTW8Z7MCR,,,,
3779,DescriptorName,D058186,11550988,,,1,Acute Kidney Injury,N,
3780,QualifierName,Q000139,11550988,,,1,,Y,chemically induced
3781,DescriptorName,D000328,11550988,,,2,Adult,N,
3782,DescriptorName,D015535,11550988,,,3,"Arthritis, Psoriatic",N,
3783,QualifierName,Q000175,11550988,,,3,,N,diagnosis
3784,DescriptorName,D016861,11550988,,,4,Cyclooxygenase Inhibitors,N,
3785,QualifierName,Q000009,11550988,,,4,,Y,adverse effects
3786,DescriptorName,D005500,11550988,,,5,Follow-Up Studies,N,
3787,DescriptorName,D006801,11550988,,,6,Humans,N,
3788,DescriptorName,D007668,11550988,,,7,Kidney,N,
3789,QualifierName,Q000187,11550988,,,7,,Y,drug effects
3790,DescriptorName,D007677,11550988,,,8,Kidney Function Tests,N,
3791,DescriptorName,D016030,11550988,,,9,Kidney Transplantation,N,
3792,DescriptorName,D007783,11550988,,,10,Lactones,N,
3793,QualifierName,Q000009,11550988,,,10,,Y,adverse effects
3794,DescriptorName,D008297,11550988,,,11,Male,N,
3795,DescriptorName,D008875,11550988,,,12,Middle Aged,N,
3796,DescriptorName,D010003,11550988,,,13,Osteoarthritis,N,
3797,QualifierName,Q000175,11550988,,,13,,N,diagnosis
3798,DescriptorName,D006435,11550988,,,14,Renal Dialysis,N,
3799,QualifierName,Q000379,11550988,,,14,,N,methods
3800,DescriptorName,D018570,11550988,,,15,Risk Assessment,N,
3801,DescriptorName,D013450,11550988,,,16,Sulfones,N,
3802,Chemical,D000927,11554897,Anticonvulsants,0,,,,
3803,Chemical,D014227,11554897,Triazines,0,,,,
3804,Chemical,D014635,11554897,Valproic Acid,614OI1Z5WI,,,,
3805,Chemical,D000077213,11554897,Lamotrigine,U3H27498KS,,,,
3806,DescriptorName,D000927,11554897,,,1,Anticonvulsants,N,
3807,QualifierName,Q000506,11554897,,,1,,Y,poisoning
3808,DescriptorName,D003128,11554897,,,2,Coma,N,
3809,QualifierName,Q000139,11554897,,,2,,Y,chemically induced
3810,DescriptorName,D062787,11554897,,,3,Drug Overdose,N,
3811,QualifierName,Q000523,11554897,,,3,,N,psychology
3812,DescriptorName,D017029,11554897,,,4,"Epilepsy, Complex Partial",N,
3813,QualifierName,Q000188,11554897,,,4,,Y,drug therapy
3814,DescriptorName,D005260,11554897,,,5,Female,N,
3815,DescriptorName,D006801,11554897,,,6,Humans,N,
3816,DescriptorName,D000077213,11554897,,,7,Lamotrigine,N,
3817,DescriptorName,D008875,11554897,,,8,Middle Aged,N,
3818,DescriptorName,D020258,11554897,,,9,Neurotoxicity Syndromes,N,
3819,QualifierName,Q000209,11554897,,,9,,N,etiology
3820,DescriptorName,D013406,11554897,,,10,"Suicide, Attempted",N,
3821,QualifierName,Q000523,11554897,,,10,,Y,psychology
3822,DescriptorName,D014227,11554897,,,11,Triazines,N,
3823,QualifierName,Q000506,11554897,,,11,,Y,poisoning
3824,DescriptorName,D014635,11554897,,,12,Valproic Acid,N,
3825,QualifierName,Q000506,11554897,,,12,,N,poisoning
3826,Chemical,D014150,11563738,Antipsychotic Agents,0,,,,
3827,Chemical,D001569,11563738,Benzodiazepines,12794-10-4,,,,
3828,Chemical,D010890,11563738,Pirenzepine,3G0285N20N,,,,
3829,Chemical,D000077152,11563738,Olanzapine,N7U69T4SZR,,,,
3830,DescriptorName,D000328,11563738,,,1,Adult,N,
3831,DescriptorName,D014150,11563738,,,2,Antipsychotic Agents,N,
3832,QualifierName,Q000493,11563738,,,2,,Y,pharmacokinetics
3833,DescriptorName,D001344,11563738,,,3,Autopsy,N,
3834,DescriptorName,D001569,11563738,,,4,Benzodiazepines,N,
3835,DescriptorName,D062787,11563738,,,5,Drug Overdose,N,
3836,QualifierName,Q000473,11563738,,,5,,Y,pathology
3837,DescriptorName,D018732,11563738,,,6,Forensic Anthropology,N,
3838,DescriptorName,D008401,11563738,,,7,Gas Chromatography-Mass Spectrometry,N,
3839,DescriptorName,D006801,11563738,,,8,Humans,N,
3840,DescriptorName,D008297,11563738,,,9,Male,N,
3841,DescriptorName,D000077152,11563738,,,10,Olanzapine,N,
3842,DescriptorName,D010890,11563738,,,11,Pirenzepine,N,
3843,QualifierName,Q000031,11563738,,,11,,Y,analogs & derivatives
3844,DescriptorName,D011180,11563738,,,12,Postmortem Changes,N,
3845,DescriptorName,D012559,11563738,,,13,Schizophrenia,N,
3846,QualifierName,Q000188,11563738,,,13,,Y,drug therapy
3847,DescriptorName,D014018,11563738,,,14,Tissue Distribution,N,
3848,Chemical,D012459,11568758,Salicylates,0,,,,
3849,Chemical,C014182,11568758,salicylsalicylic acid,V9MO595C9I,,,,
3850,DescriptorName,D000287,11568758,,,1,"Administration, Topical",N,
3851,DescriptorName,D000368,11568758,,,2,Aged,N,
3852,DescriptorName,D000369,11568758,,,3,"Aged, 80 and over",N,
3853,DescriptorName,D001168,11568758,,,4,Arthritis,N,
3854,QualifierName,Q000150,11568758,,,4,,N,complications
3855,DescriptorName,D003875,11568758,,,5,Drug Eruptions,N,
3856,QualifierName,Q000473,11568758,,,5,,Y,pathology
3857,DescriptorName,D006801,11568758,,,6,Humans,N,
3858,DescriptorName,D008010,11568758,,,7,Lichen Planus,N,
3859,QualifierName,Q000139,11568758,,,7,,Y,chemically induced
3860,DescriptorName,D008297,11568758,,,8,Male,N,
3861,DescriptorName,D010146,11568758,,,9,Pain,N,
3862,QualifierName,Q000188,11568758,,,9,,N,drug therapy
3863,DescriptorName,D012459,11568758,,,10,Salicylates,N,
3864,QualifierName,Q000008,11568758,,,10,,N,administration & dosage
3865,DescriptorName,D016896,11568758,,,11,Treatment Outcome,N,
3866,Chemical,D000935,11573852,Antifungal Agents,0,,,,
3867,Chemical,D000666,11573852,Amphotericin B,7XU7A7DROE,,,,
3868,DescriptorName,D017088,11573852,,,1,AIDS-Related Opportunistic Infections,N,
3869,QualifierName,Q000188,11573852,,,1,,Y,drug therapy
3870,DescriptorName,D000666,11573852,,,2,Amphotericin B,N,
3871,QualifierName,Q000009,11573852,,,2,,Y,adverse effects
3872,DescriptorName,D000935,11573852,,,3,Antifungal Agents,N,
3873,QualifierName,Q000009,11573852,,,3,,Y,adverse effects
3874,DescriptorName,D006801,11573852,,,4,Humans,N,
3875,DescriptorName,D007262,11573852,,,5,"Infusions, Intravenous",N,
3876,DescriptorName,D008297,11573852,,,6,Male,N,
3877,DescriptorName,D016919,11573852,,,7,"Meningitis, Cryptococcal",N,
3878,QualifierName,Q000188,11573852,,,7,,Y,drug therapy
3879,DescriptorName,D008875,11573852,,,8,Middle Aged,N,
3880,DescriptorName,D012640,11573852,,,9,Seizures,N,
3881,QualifierName,Q000139,11573852,,,9,,Y,chemically induced
3882,Chemical,D000779,11576059,"Anesthetics, Local",0,,,,
3883,Chemical,D002045,11576059,Bupivacaine,Y8335394RO,,,,
3884,DescriptorName,D000779,11576059,,,1,"Anesthetics, Local",N,
3885,QualifierName,Q000009,11576059,,,1,,Y,adverse effects
3886,DescriptorName,D002045,11576059,,,2,Bupivacaine,N,
3887,QualifierName,Q000009,11576059,,,2,,Y,adverse effects
3888,DescriptorName,D002675,11576059,,,3,"Child, Preschool",N,
3889,DescriptorName,D005260,11576059,,,4,Female,N,
3890,DescriptorName,D006801,11576059,,,5,Humans,N,
3891,DescriptorName,D010149,11576059,,,6,"Pain, Postoperative",N,
3892,QualifierName,Q000188,11576059,,,6,,Y,drug therapy
3893,DescriptorName,D014068,11576059,,,7,Tonsillectomy,Y,
3894,DescriptorName,D014826,11576059,,,8,Vocal Cord Paralysis,N,
3895,QualifierName,Q000139,11576059,,,8,,Y,chemically induced
3896,Chemical,D000927,11590881,Anticonvulsants,0,,,,
3897,Chemical,D002220,11590881,Carbamazepine,33CM23913M,,,,
3898,DescriptorName,D000927,11590881,,,1,Anticonvulsants,N,
3899,QualifierName,Q000009,11590881,,,1,,Y,adverse effects
3900,DescriptorName,D002037,11590881,,,2,Bundle-Branch Block,N,
3901,QualifierName,Q000139,11590881,,,2,,Y,chemically induced
3902,DescriptorName,D002220,11590881,,,3,Carbamazepine,N,
3903,QualifierName,Q000009,11590881,,,3,,Y,adverse effects
3904,DescriptorName,D004305,11590881,,,4,"Dose-Response Relationship, Drug",N,
3905,DescriptorName,D004562,11590881,,,5,Electrocardiography,N,
3906,DescriptorName,D004830,11590881,,,6,"Epilepsy, Tonic-Clonic",N,
3907,QualifierName,Q000188,11590881,,,6,,N,drug therapy
3908,DescriptorName,D005500,11590881,,,7,Follow-Up Studies,N,
3909,DescriptorName,D006116,11590881,,,8,Greenland,N,
3910,DescriptorName,D006801,11590881,,,9,Humans,N,
3911,DescriptorName,D008297,11590881,,,10,Male,N,
3912,DescriptorName,D008875,11590881,,,11,Middle Aged,N,
3913,DescriptorName,D018570,11590881,,,12,Risk Assessment,N,
3914,Chemical,D000322,11642488,Adrenergic Agonists,0,,,,
3915,Chemical,C015173,11642488,dipivefrin,8Q1PVL543G,,,,
3916,Chemical,D004837,11642488,Epinephrine,YKH834O4BH,,,,
3917,DescriptorName,D000322,11642488,,,1,Adrenergic Agonists,N,
3918,QualifierName,Q000009,11642488,,,1,,Y,adverse effects
3919,DescriptorName,D000368,11642488,,,2,Aged,N,
3920,DescriptorName,D000369,11642488,,,3,"Aged, 80 and over",N,
3921,DescriptorName,D002921,11642488,,,4,Cicatrix,N,
3922,QualifierName,Q000139,11642488,,,4,,N,chemically induced
3923,DescriptorName,D004774,11642488,,,5,Entropion,N,
3924,QualifierName,Q000139,11642488,,,5,,Y,chemically induced
3925,DescriptorName,D004837,11642488,,,6,Epinephrine,N,
3926,QualifierName,Q000009,11642488,,,6,,Y,adverse effects
3927,DescriptorName,D005143,11642488,,,7,Eyelids,N,
3928,QualifierName,Q000187,11642488,,,7,,Y,drug effects
3929,DescriptorName,D005260,11642488,,,8,Female,N,
3930,DescriptorName,D005901,11642488,,,9,Glaucoma,N,
3931,QualifierName,Q000188,11642488,,,9,,N,drug therapy
3932,DescriptorName,D006801,11642488,,,10,Humans,N,
3933,DescriptorName,D008297,11642488,,,11,Male,N,
3934,DescriptorName,D012189,11642488,,,12,Retrospective Studies,N,
3935,Chemical,D018501,11672959,Antirheumatic Agents,0,,,,
3936,Chemical,D012460,11672959,Sulfasalazine,3XC8GUZ6CB,,,,
3937,DescriptorName,D000328,11672959,,,1,Adult,N,
3938,DescriptorName,D018501,11672959,,,2,Antirheumatic Agents,N,
3939,QualifierName,Q000009,11672959,,,2,,Y,adverse effects
3940,DescriptorName,D001172,11672959,,,3,"Arthritis, Rheumatoid",N,
3941,QualifierName,Q000188,11672959,,,3,,Y,drug therapy
3942,DescriptorName,D017809,11672959,,,4,Fatal Outcome,N,
3943,DescriptorName,D005260,11672959,,,5,Female,N,
3944,DescriptorName,D006505,11672959,,,6,Hepatitis,N,
3945,QualifierName,Q000473,11672959,,,6,,Y,pathology
3946,DescriptorName,D006801,11672959,,,7,Humans,N,
3947,DescriptorName,D009205,11672959,,,8,Myocarditis,N,
3948,QualifierName,Q000139,11672959,,,8,,N,chemically induced
3949,DescriptorName,D009336,11672959,,,9,Necrosis,N,
3950,DescriptorName,D012460,11672959,,,10,Sulfasalazine,N,
3951,QualifierName,Q000009,11672959,,,10,,Y,adverse effects
3952,DescriptorName,D013577,11672959,,,11,Syndrome,N,
3953,Chemical,D000970,11688826,Antineoplastic Agents,0,,,,
3954,Chemical,D000972,11688826,"Antineoplastic Agents, Phytogenic",0,,,,
3955,Chemical,D016190,11688826,Carboplatin,BG3F62OND5,,,,
3956,Chemical,D002945,11688826,Cisplatin,Q20Q21Q62J,,,,
3957,Chemical,D014751,11688826,Vindesine,RSA8KO39WH,,,,
3958,DescriptorName,D002282,11688826,,,1,"Adenocarcinoma, Bronchiolo-Alveolar",N,
3959,QualifierName,Q000188,11688826,,,1,,Y,drug therapy
3960,DescriptorName,D000368,11688826,,,2,Aged,N,
3961,DescriptorName,D000970,11688826,,,3,Antineoplastic Agents,N,
3962,QualifierName,Q000009,11688826,,,3,,Y,adverse effects
3963,DescriptorName,D000972,11688826,,,4,"Antineoplastic Agents, Phytogenic",N,
3964,QualifierName,Q000008,11688826,,,4,,N,administration & dosage
3965,DescriptorName,D000971,11688826,,,5,Antineoplastic Combined Chemotherapy Protocols,N,
3966,QualifierName,Q000009,11688826,,,5,,Y,adverse effects
3967,DescriptorName,D016190,11688826,,,6,Carboplatin,N,
3968,QualifierName,Q000008,11688826,,,6,,N,administration & dosage
3969,DescriptorName,D002945,11688826,,,7,Cisplatin,N,
3970,QualifierName,Q000009,11688826,,,7,,Y,adverse effects
3971,DescriptorName,D005260,11688826,,,8,Female,N,
3972,DescriptorName,D006801,11688826,,,9,Humans,N,
3973,DescriptorName,D007177,11688826,,,10,Inappropriate ADH Syndrome,N,
3974,QualifierName,Q000139,11688826,,,10,,Y,chemically induced
3975,DescriptorName,D008175,11688826,,,11,Lung Neoplasms,N,
3976,QualifierName,Q000188,11688826,,,11,,Y,drug therapy
3977,DescriptorName,D012008,11688826,,,12,Recurrence,N,
3978,DescriptorName,D013997,11688826,,,13,Time Factors,N,
3979,DescriptorName,D014751,11688826,,,14,Vindesine,N,
3980,QualifierName,Q000008,11688826,,,14,,N,administration & dosage
3981,Chemical,D000759,11696132,"Adjuvants, Anesthesia",0,,,,
3982,Chemical,D012601,11696132,Scopolamine,DL48G20X8X,,,,
3983,Chemical,D004091,11696132,Hydromorphone,Q812464R06,,,,
3984,DescriptorName,D000759,11696132,,,1,"Adjuvants, Anesthesia",N,
3985,QualifierName,Q000009,11696132,,,1,,Y,adverse effects
3986,DescriptorName,D000279,11696132,,,2,"Administration, Cutaneous",N,
3987,DescriptorName,D000293,11696132,,,3,Adolescent,N,
3988,DescriptorName,D016058,11696132,,,4,"Analgesia, Patient-Controlled",N,
3989,DescriptorName,D015875,11696132,,,5,Anisocoria,N,
3990,QualifierName,Q000139,11696132,,,5,,Y,chemically induced
3991,DescriptorName,D001228,11696132,,,6,Aspergillosis,N,
3992,QualifierName,Q000150,11696132,,,6,,Y,complications
3993,DescriptorName,D006105,11696132,,,7,"Granulomatous Disease, Chronic",N,
3994,QualifierName,Q000150,11696132,,,7,,Y,complications
3995,DescriptorName,D006261,11696132,,,8,Headache,N,
3996,QualifierName,Q000188,11696132,,,8,,N,drug therapy
3997,DescriptorName,D006801,11696132,,,9,Humans,N,
3998,DescriptorName,D004091,11696132,,,10,Hydromorphone,N,
3999,QualifierName,Q000627,11696132,,,10,,N,therapeutic use
4000,DescriptorName,D008297,11696132,,,11,Male,N,
4001,DescriptorName,D012601,11696132,,,12,Scopolamine,N,
4002,QualifierName,Q000009,11696132,,,12,,Y,adverse effects
4003,DescriptorName,D020069,11696132,,,13,Shoulder Pain,N,
4004,QualifierName,Q000188,11696132,,,13,,N,drug therapy
4005,Chemical,D014151,11700998,Anti-Anxiety Agents,0,,,,
4006,Chemical,D008140,11700998,Lorazepam,O26FZP769L,,,,
4007,DescriptorName,D017668,11700998,,,1,Age of Onset,N,
4008,DescriptorName,D000368,11700998,,,2,Aged,N,
4009,DescriptorName,D014151,11700998,,,3,Anti-Anxiety Agents,N,
4010,QualifierName,Q000009,11700998,,,3,,Y,adverse effects
4011,DescriptorName,D001008,11700998,,,4,Anxiety Disorders,N,
4012,QualifierName,Q000188,11700998,,,4,,N,drug therapy
4013,DescriptorName,D003221,11700998,,,5,Confusion,N,
4014,QualifierName,Q000209,11700998,,,5,,Y,etiology
4015,DescriptorName,D003937,11700998,,,6,"Diagnosis, Differential",N,
4016,DescriptorName,D004569,11700998,,,7,Electroencephalography,N,
4017,DescriptorName,D005260,11700998,,,8,Female,N,
4018,DescriptorName,D006801,11700998,,,9,Humans,N,
4019,DescriptorName,D008140,11700998,,,10,Lorazepam,N,
4020,QualifierName,Q000009,11700998,,,10,,Y,adverse effects
4021,DescriptorName,D013226,11700998,,,11,Status Epilepticus,N,
4022,QualifierName,Q000139,11700998,,,11,,Y,chemically induced
4023,DescriptorName,D013375,11700998,,,12,Substance Withdrawal Syndrome,N,
4024,QualifierName,Q000175,11700998,,,12,,Y,diagnosis
4025,Chemical,D000972,11703329,"Antineoplastic Agents, Phytogenic",0,,,,
4026,Chemical,D014750,11703329,Vincristine,5J49Q6B70F,,,,
4027,DescriptorName,D000328,11703329,,,1,Adult,N,
4028,DescriptorName,D000972,11703329,,,2,"Antineoplastic Agents, Phytogenic",N,
4029,QualifierName,Q000009,11703329,,,2,,Y,adverse effects
4030,DescriptorName,D002607,11703329,,,3,Charcot-Marie-Tooth Disease,N,
4031,QualifierName,Q000150,11703329,,,3,,Y,complications
4032,DescriptorName,D000075202,11703329,,,4,Contraindications,N,
4033,DescriptorName,D005260,11703329,,,5,Female,N,
4034,DescriptorName,D006689,11703329,,,6,Hodgkin Disease,N,
4035,QualifierName,Q000188,11703329,,,6,,N,drug therapy
4036,DescriptorName,D006801,11703329,,,7,Humans,N,
4037,DescriptorName,D010243,11703329,,,8,Paralysis,N,
4038,QualifierName,Q000209,11703329,,,8,,Y,etiology
4039,DescriptorName,D014750,11703329,,,9,Vincristine,N,
4040,QualifierName,Q000009,11703329,,,9,,Y,adverse effects
4041,Chemical,D000962,11706664,Antimalarials,0,,,,
4042,Chemical,D037621,11706664,Artemisinins,0,,,,
4043,Chemical,D004338,11706664,Drug Combinations,0,,,,
4044,Chemical,D012717,11706664,Sesquiterpenes,0,,,,
4045,Chemical,D000655,11706664,Amodiaquine,220236ED28,,,,
4046,Chemical,D000077332,11706664,Artesunate,60W3249T9M,,,,
4047,DescriptorName,D000328,11706664,,,1,Adult,N,
4048,DescriptorName,D000655,11706664,,,2,Amodiaquine,N,
4049,QualifierName,Q000009,11706664,,,2,,Y,adverse effects
4050,DescriptorName,D000962,11706664,,,3,Antimalarials,N,
4051,QualifierName,Q000009,11706664,,,3,,Y,adverse effects
4052,DescriptorName,D037621,11706664,,,4,Artemisinins,Y,
4053,DescriptorName,D000077332,11706664,,,5,Artesunate,N,
4054,DescriptorName,D056486,11706664,,,6,Chemical and Drug Induced Liver Injury,N,
4055,QualifierName,Q000201,11706664,,,6,,N,enzymology
4056,DescriptorName,D018592,11706664,,,7,Cross-Over Studies,N,
4057,DescriptorName,D004338,11706664,,,8,Drug Combinations,N,
4058,DescriptorName,D005260,11706664,,,9,Female,N,
4059,DescriptorName,D006801,11706664,,,10,Humans,N,
4060,DescriptorName,D008099,11706664,,,11,Liver,N,
4061,QualifierName,Q000201,11706664,,,11,,N,enzymology
4062,DescriptorName,D016778,11706664,,,12,"Malaria, Falciparum",N,
4063,QualifierName,Q000188,11706664,,,12,,N,drug therapy
4064,DescriptorName,D012717,11706664,,,13,Sesquiterpenes,N,
4065,QualifierName,Q000009,11706664,,,13,,Y,adverse effects
4066,Chemical,D008730,11712064,Methoxsalen,U4VJ29L7BQ,,,,
4067,DescriptorName,D000328,11712064,,,1,Adult,N,
4068,DescriptorName,D017449,11712064,,,2,"Dermatitis, Allergic Contact",N,
4069,QualifierName,Q000175,11712064,,,2,,Y,diagnosis
4070,DescriptorName,D003937,11712064,,,3,"Diagnosis, Differential",N,
4071,DescriptorName,D005260,11712064,,,4,Female,N,
4072,DescriptorName,D006801,11712064,,,5,Humans,N,
4073,DescriptorName,D008730,11712064,,,6,Methoxsalen,N,
4074,QualifierName,Q000009,11712064,,,6,,Y,adverse effects
4075,DescriptorName,D011701,11712064,,,7,PUVA Therapy,N,
4076,QualifierName,Q000009,11712064,,,7,,Y,adverse effects
4077,DescriptorName,D010328,11712064,,,8,Patch Tests,N,
4078,DescriptorName,D011565,11712064,,,9,Psoriasis,N,
4079,QualifierName,Q000188,11712064,,,9,,Y,drug therapy
4080,Chemical,D018680,11719751,Cholinergic Antagonists,0,,,,
4081,Chemical,D001590,11719751,Benztropine,1NHL2J4X8K,,,,
4082,Chemical,D009388,11719751,Neostigmine,3982TWQ96G,,,,
4083,DescriptorName,D000328,11719751,,,1,Adult,N,
4084,DescriptorName,D001590,11719751,,,2,Benztropine,N,
4085,QualifierName,Q000009,11719751,,,2,,Y,adverse effects
4086,DescriptorName,D018680,11719751,,,3,Cholinergic Antagonists,N,
4087,QualifierName,Q000009,11719751,,,3,,Y,adverse effects
4088,DescriptorName,D004636,11719751,,,4,"Emergency Service, Hospital",N,
4089,DescriptorName,D005769,11719751,,,5,Gastrointestinal Motility,N,
4090,QualifierName,Q000187,11719751,,,5,,N,drug effects
4091,DescriptorName,D006801,11719751,,,6,Humans,N,
4092,DescriptorName,D007415,11719751,,,7,Intestinal Obstruction,N,
4093,QualifierName,Q000139,11719751,,,7,,Y,chemically induced
4094,DescriptorName,D008297,11719751,,,8,Male,N,
4095,DescriptorName,D009388,11719751,,,9,Neostigmine,N,
4096,QualifierName,Q000627,11719751,,,9,,Y,therapeutic use
4097,DescriptorName,D019966,11719751,,,10,Substance-Related Disorders,N,
4098,QualifierName,Q000150,11719751,,,10,,Y,complications
4099,Chemical,D014150,11722307,Antipsychotic Agents,0,,,,
4100,Chemical,D003987,11722307,Dibenzothiazepines,0,,,,
4101,Chemical,D000069348,11722307,Quetiapine Fumarate,2S3PL1B6UJ,,,,
4102,DescriptorName,D000328,11722307,,,1,Adult,N,
4103,DescriptorName,D000380,11722307,,,2,Agranulocytosis,N,
4104,QualifierName,Q000139,11722307,,,2,,Y,chemically induced
4105,DescriptorName,D014150,11722307,,,3,Antipsychotic Agents,N,
4106,QualifierName,Q000009,11722307,,,3,,Y,adverse effects
4107,DescriptorName,D003987,11722307,,,4,Dibenzothiazepines,N,
4108,QualifierName,Q000009,11722307,,,4,,Y,adverse effects
4109,DescriptorName,D004305,11722307,,,5,"Dose-Response Relationship, Drug",N,
4110,DescriptorName,D006801,11722307,,,6,Humans,N,
4111,DescriptorName,D008297,11722307,,,7,Male,N,
4112,DescriptorName,D008875,11722307,,,8,Middle Aged,N,
4113,DescriptorName,D011569,11722307,,,9,Psychiatric Status Rating Scales,N,
4114,DescriptorName,D000069348,11722307,,,10,Quetiapine Fumarate,N,
4115,DescriptorName,D012563,11722307,,,11,"Schizophrenia, Paranoid",N,
4116,QualifierName,Q000175,11722307,,,11,,N,diagnosis
4117,Chemical,D000890,11724089,Anti-Infective Agents,0,,,,
4118,Chemical,D015242,11724089,Ofloxacin,A4P49JAZ9H,,,,
4119,DescriptorName,D000368,11724089,,,1,Aged,N,
4120,DescriptorName,D000890,11724089,,,2,Anti-Infective Agents,N,
4121,QualifierName,Q000009,11724089,,,2,,Y,adverse effects
4122,DescriptorName,D004823,11724089,,,3,Epididymitis,N,
4123,QualifierName,Q000188,11724089,,,3,,N,drug therapy
4124,DescriptorName,D017809,11724089,,,4,Fatal Outcome,N,
4125,DescriptorName,D006801,11724089,,,5,Humans,N,
4126,DescriptorName,D008297,11724089,,,6,Male,N,
4127,DescriptorName,D015242,11724089,,,7,Ofloxacin,N,
4128,QualifierName,Q000009,11724089,,,7,,Y,adverse effects
4129,DescriptorName,D013262,11724089,,,8,Stevens-Johnson Syndrome,N,
4130,QualifierName,Q000473,11724089,,,8,,Y,pathology
4131,Chemical,D016179,11737689,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
4132,DescriptorName,D000293,11737689,,,1,Adolescent,N,
4133,DescriptorName,D003875,11737689,,,2,Drug Eruptions,N,
4134,QualifierName,Q000473,11737689,,,2,,Y,pathology
4135,DescriptorName,D005260,11737689,,,3,Female,N,
4136,DescriptorName,D016179,11737689,,,4,Granulocyte Colony-Stimulating Factor,N,
4137,QualifierName,Q000009,11737689,,,4,,Y,adverse effects
4138,DescriptorName,D006801,11737689,,,5,Humans,N,
4139,DescriptorName,D008297,11737689,,,6,Male,N,
4140,DescriptorName,D009503,11737689,,,7,Neutropenia,N,
4141,QualifierName,Q000188,11737689,,,7,,Y,drug therapy
4142,DescriptorName,D009504,11737689,,,8,Neutrophils,N,
4143,QualifierName,Q000473,11737689,,,8,,N,pathology
4144,DescriptorName,D015434,11737689,,,9,Panniculitis,N,
4145,QualifierName,Q000139,11737689,,,9,,Y,chemically induced
4146,Chemical,D014284,1174301,Triiodothyronine,06LU7C9H1V,,,,
4147,Chemical,D001539,1174301,Bendroflumethiazide,5Q52X6ICJI,,,,
4148,Chemical,D011441,1174301,Propylthiouracil,721M9407IY,,,,
4149,Chemical,D011241,1174301,Prednisone,VB0R961HZT,,,,
4150,DescriptorName,D001539,1174301,,,1,Bendroflumethiazide,N,
4151,QualifierName,Q000627,1174301,,,1,,N,therapeutic use
4152,DescriptorName,D005260,1174301,,,2,Female,N,
4153,DescriptorName,D006111,1174301,,,3,Graves Disease,Y,
4154,QualifierName,Q000503,1174301,,,3,,N,physiopathology
4155,DescriptorName,D006801,1174301,,,4,Humans,N,
4156,DescriptorName,D006980,1174301,,,5,Hyperthyroidism,N,
4157,QualifierName,Q000139,1174301,,,5,,Y,chemically induced
4158,DescriptorName,D008875,1174301,,,6,Middle Aged,N,
4159,DescriptorName,D011241,1174301,,,7,Prednisone,N,
4160,QualifierName,Q000627,1174301,,,7,,N,therapeutic use
4161,DescriptorName,D011441,1174301,,,8,Propylthiouracil,N,
4162,QualifierName,Q000627,1174301,,,8,,N,therapeutic use
4163,DescriptorName,D013960,1174301,,,9,Thyroid Function Tests,N,
4164,QualifierName,Q000009,1174301,,,9,,Y,adverse effects
4165,DescriptorName,D013961,1174301,,,10,Thyroid Gland,N,
4166,QualifierName,Q000503,1174301,,,10,,N,physiopathology
4167,DescriptorName,D014284,1174301,,,11,Triiodothyronine,Y,
4168,QualifierName,Q000009,1174301,,,11,,N,adverse effects
4169,Chemical,D000927,11749112,Anticonvulsants,0,,,,
4170,Chemical,D009557,11749112,Nipecotic Acids,0,,,,
4171,Chemical,D000078308,11749112,Tiagabine,Z80I64HMNP,,,,
4172,DescriptorName,D000328,11749112,,,1,Adult,N,
4173,DescriptorName,D000927,11749112,,,2,Anticonvulsants,N,
4174,QualifierName,Q000009,11749112,,,2,,Y,adverse effects
4175,DescriptorName,D004827,11749112,,,3,Epilepsy,N,
4176,QualifierName,Q000188,11749112,,,3,,Y,drug therapy
4177,DescriptorName,D006801,11749112,,,4,Humans,N,
4178,DescriptorName,D008297,11749112,,,5,Male,N,
4179,DescriptorName,D009557,11749112,,,6,Nipecotic Acids,N,
4180,QualifierName,Q000009,11749112,,,6,,Y,adverse effects
4181,DescriptorName,D012720,11749112,,,7,Severity of Illness Index,N,
4182,DescriptorName,D000078308,11749112,,,8,Tiagabine,N,
4183,DescriptorName,D014786,11749112,,,9,Vision Disorders,N,
4184,QualifierName,Q000139,11749112,,,9,,Y,chemically induced
4185,DescriptorName,D014794,11749112,,,10,Visual Fields,N,
4186,QualifierName,Q000187,11749112,,,10,,Y,drug effects
4187,Chemical,D000962,11757641,Antimalarials,0,,,,
4188,Chemical,D015767,11757641,Mefloquine,TML814419R,,,,
4189,DescriptorName,D000962,11757641,,,1,Antimalarials,N,
4190,QualifierName,Q000009,11757641,,,1,,Y,adverse effects
4191,DescriptorName,D006801,11757641,,,2,Humans,N,
4192,DescriptorName,D016778,11757641,,,3,"Malaria, Falciparum",N,
4193,QualifierName,Q000188,11757641,,,3,,N,drug therapy
4194,DescriptorName,D008297,11757641,,,4,Male,N,
4195,DescriptorName,D015767,11757641,,,5,Mefloquine,N,
4196,QualifierName,Q000009,11757641,,,5,,Y,adverse effects
4197,DescriptorName,D008875,11757641,,,6,Middle Aged,N,
4198,DescriptorName,D011650,11757641,,,7,Pulmonary Alveoli,N,
4199,QualifierName,Q000473,11757641,,,7,,N,pathology
4200,DescriptorName,D012128,11757641,,,8,"Respiratory Distress Syndrome, Adult",N,
4201,QualifierName,Q000139,11757641,,,8,,Y,chemically induced
4202,DescriptorName,D014057,11757641,,,9,"Tomography, X-Ray Computed",N,
4203,Chemical,D000931,11762672,Antidotes,0,,,,
4204,Chemical,D002021,11762672,Buffers,0,,,,
4205,Chemical,D002492,11762672,Central Nervous System Depressants,0,,,,
4206,Chemical,D011720,11762672,Pyrazoles,0,,,,
4207,Chemical,D012997,11762672,Solvents,0,,,,
4208,Chemical,D000431,11762672,Ethanol,3K9958V90M,,,,
4209,Chemical,D000077604,11762672,Fomepizole,83LCM6L2BY,,,,
4210,Chemical,D017693,11762672,Sodium Bicarbonate,8MDF5V39QO,,,,
4211,Chemical,D000432,11762672,Methanol,Y4S76JWI15,,,,
4212,DescriptorName,D000328,11762672,,,1,Adult,N,
4213,DescriptorName,D000931,11762672,,,2,Antidotes,N,
4214,QualifierName,Q000009,11762672,,,2,,N,adverse effects
4215,DescriptorName,D002021,11762672,,,3,Buffers,N,
4216,DescriptorName,D002492,11762672,,,4,Central Nervous System Depressants,N,
4217,QualifierName,Q000097,11762672,,,4,,N,blood
4218,DescriptorName,D000431,11762672,,,5,Ethanol,N,
4219,QualifierName,Q000097,11762672,,,5,,N,blood
4220,DescriptorName,D000077604,11762672,,,6,Fomepizole,N,
4221,DescriptorName,D006801,11762672,,,7,Humans,N,
4222,DescriptorName,D008297,11762672,,,8,Male,N,
4223,DescriptorName,D000432,11762672,,,9,Methanol,N,
4224,QualifierName,Q000037,11762672,,,9,,Y,antagonists & inhibitors
4225,DescriptorName,D011720,11762672,,,10,Pyrazoles,N,
4226,QualifierName,Q000009,11762672,,,10,,N,adverse effects
4227,DescriptorName,D012164,11762672,,,11,Retinal Diseases,N,
4228,QualifierName,Q000139,11762672,,,11,,Y,chemically induced
4229,DescriptorName,D017693,11762672,,,12,Sodium Bicarbonate,N,
4230,QualifierName,Q000627,11762672,,,12,,N,therapeutic use
4231,DescriptorName,D012997,11762672,,,13,Solvents,N,
4232,QualifierName,Q000506,11762672,,,13,,Y,poisoning
4233,DescriptorName,D014786,11762672,,,14,Vision Disorders,N,
4234,QualifierName,Q000139,11762672,,,14,,Y,chemically induced
4235,Chemical,D000900,11788010,Anti-Bacterial Agents,0,,,,
4236,Chemical,D004873,11788010,Ergolines,0,,,,
4237,Chemical,D007334,11788010,Insulin-Like Growth Factor I,67763-96-6,,,,
4238,Chemical,D002784,11788010,Cholesterol,97C5T2UQ7J,,,,
4239,Chemical,D000077465,11788010,Cabergoline,LL60K9J05T,,,,
4240,Chemical,D001663,11788010,Bilirubin,RFM9X3LJ49,,,,
4241,Chemical,D015282,11788010,Octreotide,RWM8CCW8GP,,,,
4242,DescriptorName,D015746,11788010,,,1,Abdominal Pain,N,
4243,DescriptorName,D000172,11788010,,,2,Acromegaly,N,
4244,QualifierName,Q000188,11788010,,,2,,Y,drug therapy
4245,DescriptorName,D000236,11788010,,,3,Adenoma,N,
4246,QualifierName,Q000601,11788010,,,3,,N,surgery
4247,DescriptorName,D000328,11788010,,,4,Adult,N,
4248,DescriptorName,D000900,11788010,,,5,Anti-Bacterial Agents,N,
4249,QualifierName,Q000627,11788010,,,5,,N,therapeutic use
4250,DescriptorName,D001653,11788010,,,6,"Bile Ducts, Intrahepatic",Y,
4251,DescriptorName,D001663,11788010,,,7,Bilirubin,N,
4252,QualifierName,Q000032,11788010,,,7,,N,analysis
4253,DescriptorName,D000077465,11788010,,,8,Cabergoline,N,
4254,DescriptorName,D056486,11788010,,,9,Chemical and Drug Induced Liver Injury,Y,
4255,DescriptorName,D002760,11788010,,,10,"Cholangiopancreatography, Endoscopic Retrograde",N,
4256,DescriptorName,D002769,11788010,,,11,Cholelithiasis,N,
4257,QualifierName,Q000139,11788010,,,11,,Y,chemically induced
4258,DescriptorName,D002784,11788010,,,12,Cholesterol,N,
4259,QualifierName,Q000032,11788010,,,12,,N,analysis
4260,DescriptorName,D004873,11788010,,,13,Ergolines,N,
4261,QualifierName,Q000627,11788010,,,13,,N,therapeutic use
4262,DescriptorName,D016905,11788010,,,14,Gram-Negative Bacterial Infections,N,
4263,DescriptorName,D006498,11788010,,,15,Hepatectomy,N,
4264,DescriptorName,D006801,11788010,,,16,Humans,N,
4265,DescriptorName,D007334,11788010,,,17,Insulin-Like Growth Factor I,N,
4266,QualifierName,Q000032,11788010,,,17,,N,analysis
4267,DescriptorName,D008099,11788010,,,18,Liver,N,
4268,QualifierName,Q000293,11788010,,,18,,N,injuries
4269,DescriptorName,D008107,11788010,,,19,Liver Diseases,N,
4270,QualifierName,Q000175,11788010,,,19,,N,diagnosis
4271,DescriptorName,D008297,11788010,,,20,Male,N,
4272,DescriptorName,D015282,11788010,,,21,Octreotide,N,
4273,QualifierName,Q000009,11788010,,,21,,Y,adverse effects
4274,DescriptorName,D010911,11788010,,,22,Pituitary Neoplasms,N,
4275,QualifierName,Q000601,11788010,,,22,,N,surgery
4276,DescriptorName,D011183,11788010,,,23,Postoperative Complications,N,
4277,DescriptorName,D018805,11788010,,,24,Sepsis,N,
4278,QualifierName,Q000150,11788010,,,24,,N,complications
4279,DescriptorName,D013530,11788010,,,25,Surgical Wound Infection,N,
4280,QualifierName,Q000188,11788010,,,25,,N,drug therapy
4281,Chemical,D020845,11795358,Selective Estrogen Receptor Modulators,0,,,,
4282,Chemical,D013629,11795358,Tamoxifen,094ZI81Y45,,,,
4283,Chemical,D020849,11795358,Raloxifene Hydrochloride,4F86W47BR6,,,,
4284,DescriptorName,D001943,11795358,,,1,Breast Neoplasms,N,
4285,QualifierName,Q000188,11795358,,,1,,N,drug therapy
4286,DescriptorName,D016889,11795358,,,2,Endometrial Neoplasms,N,
4287,QualifierName,Q000139,11795358,,,2,,Y,chemically induced
4288,DescriptorName,D004717,11795358,,,3,Endometrium,N,
4289,QualifierName,Q000187,11795358,,,3,,Y,drug effects
4290,DescriptorName,D005260,11795358,,,4,Female,N,
4291,DescriptorName,D006801,11795358,,,5,Humans,N,
4292,DescriptorName,D009361,11795358,,,6,Neoplasm Invasiveness,N,
4293,QualifierName,Q000517,11795358,,,6,,N,prevention & control
4294,DescriptorName,D020849,11795358,,,7,Raloxifene Hydrochloride,N,
4295,QualifierName,Q000627,11795358,,,7,,N,therapeutic use
4296,DescriptorName,D020845,11795358,,,8,Selective Estrogen Receptor Modulators,N,
4297,QualifierName,Q000494,11795358,,,8,,Y,pharmacology
4298,DescriptorName,D013629,11795358,,,9,Tamoxifen,N,
4299,QualifierName,Q000009,11795358,,,9,,N,adverse effects
4300,Chemical,D000995,11804071,Antitubercular Agents,0,,,,
4301,Chemical,D011718,11804071,Pyrazinamide,2KNI5N06TI,,,,
4302,Chemical,D004977,11804071,Ethambutol,8G167061QZ,,,,
4303,Chemical,D007538,11804071,Isoniazid,V83O1VOZ8L,,,,
4304,Chemical,D012293,11804071,Rifampin,VJT6J7R4TR,,,,
4305,DescriptorName,D000328,11804071,,,1,Adult,N,
4306,DescriptorName,D000505,11804071,,,2,Alopecia,N,
4307,QualifierName,Q000139,11804071,,,2,,Y,chemically induced
4308,DescriptorName,D000995,11804071,,,3,Antitubercular Agents,N,
4309,QualifierName,Q000009,11804071,,,3,,Y,adverse effects
4310,DescriptorName,D004977,11804071,,,4,Ethambutol,N,
4311,QualifierName,Q000009,11804071,,,4,,N,adverse effects
4312,DescriptorName,D005260,11804071,,,5,Female,N,
4313,DescriptorName,D006801,11804071,,,6,Humans,N,
4314,DescriptorName,D007538,11804071,,,7,Isoniazid,N,
4315,QualifierName,Q000009,11804071,,,7,,N,adverse effects
4316,DescriptorName,D017512,11804071,,,8,Lichenoid Eruptions,N,
4317,QualifierName,Q000139,11804071,,,8,,Y,chemically induced
4318,DescriptorName,D011718,11804071,,,9,Pyrazinamide,N,
4319,QualifierName,Q000009,11804071,,,9,,N,adverse effects
4320,DescriptorName,D012293,11804071,,,10,Rifampin,N,
4321,QualifierName,Q000009,11804071,,,10,,N,adverse effects
4322,DescriptorName,D012536,11804071,,,11,Scalp Dermatoses,N,
4323,QualifierName,Q000139,11804071,,,11,,Y,chemically induced
4324,DescriptorName,D014385,11804071,,,12,"Tuberculosis, Gastrointestinal",N,
4325,QualifierName,Q000188,11804071,,,12,,Y,drug therapy
4326,Chemical,D018712,11807466,"Analgesics, Non-Narcotic",0,,,,
4327,Chemical,D007070,11807466,Immunoglobulin A,0,,,,
4328,Chemical,D002220,11807466,Carbamazepine,33CM23913M,,,,
4329,DescriptorName,D018712,11807466,,,1,"Analgesics, Non-Narcotic",N,
4330,QualifierName,Q000009,11807466,,,1,,Y,adverse effects
4331,DescriptorName,D002220,11807466,,,2,Carbamazepine,N,
4332,QualifierName,Q000009,11807466,,,2,,Y,adverse effects
4333,DescriptorName,D003875,11807466,,,3,Drug Eruptions,N,
4334,QualifierName,Q000209,11807466,,,3,,Y,etiology
4335,DescriptorName,D005260,11807466,,,4,Female,N,
4336,DescriptorName,D006801,11807466,,,5,Humans,N,
4337,DescriptorName,D007070,11807466,,,6,Immunoglobulin A,N,
4338,QualifierName,Q000276,11807466,,,6,,N,immunology
4339,DescriptorName,D008875,11807466,,,7,Middle Aged,N,
4340,DescriptorName,D012872,11807466,,,8,"Skin Diseases, Vesiculobullous",N,
4341,QualifierName,Q000139,11807466,,,8,,Y,chemically induced
4342,DescriptorName,D014277,11807466,,,9,Trigeminal Neuralgia,N,
4343,QualifierName,Q000188,11807466,,,9,,Y,drug therapy
4344,Chemical,D003511,11816261,Cyclohexanols,0,,,,
4345,Chemical,D018492,11816261,Dopamine Antagonists,0,,,,
4346,Chemical,D017367,11816261,Serotonin Uptake Inhibitors,0,,,,
4347,Chemical,D000069470,11816261,Venlafaxine Hydrochloride,7D7RX5A8MO,,,,
4348,Chemical,D008787,11816261,Metoclopramide,L4YEB44I46,,,,
4349,Chemical,D020280,11816261,Sertraline,QUC7NX6WMB,,,,
4350,DescriptorName,D000058,11816261,,,1,Accidental Falls,N,
4351,DescriptorName,D000328,11816261,,,2,Adult,N,
4352,DescriptorName,D000368,11816261,,,3,Aged,N,
4353,DescriptorName,D001480,11816261,,,4,Basal Ganglia Diseases,N,
4354,QualifierName,Q000139,11816261,,,4,,N,chemically induced
4355,DescriptorName,D003511,11816261,,,5,Cyclohexanols,N,
4356,QualifierName,Q000009,11816261,,,5,,N,adverse effects
4357,DescriptorName,D003866,11816261,,,6,Depressive Disorder,N,
4358,QualifierName,Q000150,11816261,,,6,,N,complications
4359,DescriptorName,D018492,11816261,,,7,Dopamine Antagonists,N,
4360,QualifierName,Q000009,11816261,,,7,,Y,adverse effects
4361,DescriptorName,D004347,11816261,,,8,Drug Interactions,N,
4362,DescriptorName,D005260,11816261,,,9,Female,N,
4363,DescriptorName,D006801,11816261,,,10,Humans,N,
4364,DescriptorName,D008787,11816261,,,11,Metoclopramide,N,
4365,QualifierName,Q000009,11816261,,,11,,Y,adverse effects
4366,DescriptorName,D020230,11816261,,,12,Serotonin Syndrome,N,
4367,QualifierName,Q000139,11816261,,,12,,Y,chemically induced
4368,DescriptorName,D017367,11816261,,,13,Serotonin Uptake Inhibitors,N,
4369,QualifierName,Q000009,11816261,,,13,,Y,adverse effects
4370,DescriptorName,D020280,11816261,,,14,Sertraline,N,
4371,QualifierName,Q000009,11816261,,,14,,N,adverse effects
4372,DescriptorName,D013978,11816261,,,15,Tibial Fractures,N,
4373,QualifierName,Q000150,11816261,,,15,,N,complications
4374,DescriptorName,D000069470,11816261,,,16,Venlafaxine Hydrochloride,N,
4375,Chemical,D014150,11819156,Antipsychotic Agents,0,,,,
4376,Chemical,D019389,11819156,Cytochrome P-450 CYP2D6,EC 1.14.14.1,,,,
4377,Chemical,D000445,11819156,Aldehyde Oxidoreductases,EC 1.2.-,,,,
4378,Chemical,C493643,11819156,"ALDH5A1 protein, human",EC 1.2.1.24,,,,
4379,Chemical,D050644,11819156,Succinate-Semialdehyde Dehydrogenase,EC 1.2.1.24,,,,
4380,Chemical,D006220,11819156,Haloperidol,J6292F8L3D,,,,
4381,DescriptorName,D000328,11819156,,,1,Adult,N,
4382,DescriptorName,D000445,11819156,,,2,Aldehyde Oxidoreductases,N,
4383,QualifierName,Q000172,11819156,,,2,,Y,deficiency
4384,DescriptorName,D014150,11819156,,,3,Antipsychotic Agents,N,
4385,QualifierName,Q000009,11819156,,,3,,Y,adverse effects
4386,DescriptorName,D019389,11819156,,,4,Cytochrome P-450 CYP2D6,N,
4387,QualifierName,Q000235,11819156,,,4,,N,genetics
4388,DescriptorName,D006220,11819156,,,5,Haloperidol,N,
4389,QualifierName,Q000009,11819156,,,5,,Y,adverse effects
4390,DescriptorName,D006801,11819156,,,6,Humans,N,
4391,DescriptorName,D008607,11819156,,,7,Intellectual Disability,N,
4392,QualifierName,Q000188,11819156,,,7,,N,drug therapy
4393,DescriptorName,D008297,11819156,,,8,Male,N,
4394,DescriptorName,D009459,11819156,,,9,Neuroleptic Malignant Syndrome,N,
4395,QualifierName,Q000378,11819156,,,9,,Y,metabolism
4396,DescriptorName,D011110,11819156,,,10,"Polymorphism, Genetic",N,
4397,DescriptorName,D050644,11819156,,,11,Succinate-Semialdehyde Dehydrogenase,N,
4398,Chemical,D000806,11834188,Angiotensin-Converting Enzyme Inhibitors,0,,,,
4399,Chemical,D004656,11834188,Enalapril,69PN84IO1A,,,,
4400,Chemical,D002216,11834188,Captopril,9G64RSX1XD,,,,
4401,Chemical,D017706,11834188,Lisinopril,E7199S1YWR,,,,
4402,DescriptorName,D000368,11834188,,,1,Aged,N,
4403,DescriptorName,D000806,11834188,,,2,Angiotensin-Converting Enzyme Inhibitors,N,
4404,QualifierName,Q000009,11834188,,,2,,Y,adverse effects
4405,DescriptorName,D002216,11834188,,,3,Captopril,N,
4406,QualifierName,Q000009,11834188,,,3,,Y,adverse effects
4407,DescriptorName,D004311,11834188,,,4,Double-Blind Method,N,
4408,DescriptorName,D003875,11834188,,,5,Drug Eruptions,N,
4409,QualifierName,Q000209,11834188,,,5,,Y,etiology
4410,DescriptorName,D004656,11834188,,,6,Enalapril,N,
4411,DescriptorName,D006801,11834188,,,7,Humans,N,
4412,DescriptorName,D006973,11834188,,,8,Hypertension,N,
4413,QualifierName,Q000188,11834188,,,8,,N,drug therapy
4414,DescriptorName,D017706,11834188,,,9,Lisinopril,N,
4415,DescriptorName,D008297,11834188,,,10,Male,N,
4416,Chemical,D014859,11837564,Warfarin,5Q7ZVV76EI,,,,
4417,DescriptorName,D001281,11837564,,,1,Atrial Fibrillation,N,
4418,QualifierName,Q000150,11837564,,,1,,N,complications
4419,DescriptorName,D003110,11837564,,,2,Colonic Neoplasms,N,
4420,QualifierName,Q000150,11837564,,,2,,N,complications
4421,DescriptorName,D006470,11837564,,,3,Hemorrhage,N,
4422,QualifierName,Q000139,11837564,,,3,,Y,chemically induced
4423,DescriptorName,D006801,11837564,,,4,Humans,N,
4424,DescriptorName,D008297,11837564,,,5,Male,N,
4425,DescriptorName,D008875,11837564,,,6,Middle Aged,N,
4426,DescriptorName,D009780,11837564,,,7,Occult Blood,N,
4427,DescriptorName,D014859,11837564,,,8,Warfarin,N,
4428,QualifierName,Q000009,11837564,,,8,,Y,adverse effects
4429,Chemical,D000305,11850606,Adrenal Cortex Hormones,0,,,,
4430,Chemical,D000998,11850606,Antiviral Agents,0,,,,
4431,Chemical,D016756,11850606,"Immunoglobulins, Intravenous",0,,,,
4432,Chemical,D016898,11850606,Interferon-alpha,0,,,,
4433,Chemical,D001219,11850606,Aspartate Aminotransferases,EC 2.6.1.1,,,,
4434,Chemical,D018826,11850606,CD13 Antigens,EC 3.4.11.2,,,,
4435,DescriptorName,D000305,11850606,,,1,Adrenal Cortex Hormones,N,
4436,QualifierName,Q000627,11850606,,,1,,N,therapeutic use
4437,DescriptorName,D000328,11850606,,,2,Adult,N,
4438,DescriptorName,D000998,11850606,,,3,Antiviral Agents,N,
4439,QualifierName,Q000009,11850606,,,3,,Y,adverse effects
4440,DescriptorName,D001219,11850606,,,4,Aspartate Aminotransferases,N,
4441,QualifierName,Q000097,11850606,,,4,,N,blood
4442,DescriptorName,D018826,11850606,,,5,CD13 Antigens,N,
4443,QualifierName,Q000097,11850606,,,5,,N,blood
4444,DescriptorName,D002311,11850606,,,6,"Cardiomyopathy, Dilated",N,
4445,QualifierName,Q000097,11850606,,,6,,N,blood
4446,DescriptorName,D019694,11850606,,,7,"Hepatitis B, Chronic",N,
4447,QualifierName,Q000097,11850606,,,7,,N,blood
4448,DescriptorName,D006801,11850606,,,8,Humans,N,
4449,DescriptorName,D016756,11850606,,,9,"Immunoglobulins, Intravenous",N,
4450,QualifierName,Q000627,11850606,,,9,,N,therapeutic use
4451,DescriptorName,D016898,11850606,,,10,Interferon-alpha,N,
4452,QualifierName,Q000009,11850606,,,10,,Y,adverse effects
4453,DescriptorName,D008297,11850606,,,11,Male,N,
4454,DescriptorName,D017285,11850606,,,12,Polymyositis,N,
4455,QualifierName,Q000097,11850606,,,12,,N,blood
4456,DescriptorName,D016896,11850606,,,13,Treatment Outcome,N,
4457,Chemical,D000431,11868077,Ethanol,3K9958V90M,,,,
4458,DescriptorName,D000009,11868077,,,1,Abdominal Muscles,N,
4459,QualifierName,Q000000981,11868077,,,1,,N,diagnostic imaging
4460,DescriptorName,D000368,11868077,,,2,Aged,N,
4461,DescriptorName,D001707,11868077,,,3,"Biopsy, Needle",N,
4462,QualifierName,Q000009,11868077,,,3,,N,adverse effects
4463,DescriptorName,D006528,11868077,,,4,"Carcinoma, Hepatocellular",N,
4464,QualifierName,Q000188,11868077,,,4,,N,drug therapy
4465,DescriptorName,D000431,11868077,,,5,Ethanol,N,
4466,QualifierName,Q000008,11868077,,,5,,Y,administration & dosage
4467,DescriptorName,D005260,11868077,,,6,Female,N,
4468,DescriptorName,D005500,11868077,,,7,Follow-Up Studies,N,
4469,DescriptorName,D006801,11868077,,,8,Humans,N,
4470,DescriptorName,D015552,11868077,,,9,"Injections, Intralesional",N,
4471,QualifierName,Q000009,11868077,,,9,,Y,adverse effects
4472,DescriptorName,D008113,11868077,,,10,Liver Neoplasms,N,
4473,QualifierName,Q000188,11868077,,,10,,N,drug therapy
4474,DescriptorName,D009366,11868077,,,11,Neoplasm Seeding,Y,
4475,DescriptorName,D012878,11868077,,,12,Skin Neoplasms,N,
4476,QualifierName,Q000556,11868077,,,12,,Y,secondary
4477,DescriptorName,D014057,11868077,,,13,"Tomography, X-Ray Computed",N,
4478,Chemical,D013629,11876387,Tamoxifen,094ZI81Y45,,,,
4479,DescriptorName,D001707,11876387,,,1,"Biopsy, Needle",N,
4480,DescriptorName,D001943,11876387,,,2,Breast Neoplasms,N,
4481,QualifierName,Q000188,11876387,,,2,,N,drug therapy
4482,DescriptorName,D002277,11876387,,,3,Carcinoma,N,
4483,QualifierName,Q000139,11876387,,,3,,Y,chemically induced
4484,DescriptorName,D018270,11876387,,,4,"Carcinoma, Ductal, Breast",N,
4485,QualifierName,Q000188,11876387,,,4,,N,drug therapy
4486,DescriptorName,D016889,11876387,,,5,Endometrial Neoplasms,N,
4487,QualifierName,Q000139,11876387,,,5,,Y,chemically induced
4488,DescriptorName,D019160,11876387,,,6,Endosonography,N,
4489,QualifierName,Q000379,11876387,,,6,,Y,methods
4490,DescriptorName,D005260,11876387,,,7,Female,N,
4491,DescriptorName,D006801,11876387,,,8,Humans,N,
4492,DescriptorName,D015412,11876387,,,9,"Mastectomy, Segmental",N,
4493,QualifierName,Q000379,11876387,,,9,,N,methods
4494,DescriptorName,D008875,11876387,,,10,Middle Aged,N,
4495,DescriptorName,D009367,11876387,,,11,Neoplasm Staging,N,
4496,DescriptorName,D065006,11876387,,,12,Papanicolaou Test,N,
4497,DescriptorName,D018570,11876387,,,13,Risk Assessment,N,
4498,DescriptorName,D012680,11876387,,,14,Sensitivity and Specificity,N,
4499,DescriptorName,D012720,11876387,,,15,Severity of Illness Index,N,
4500,DescriptorName,D013629,11876387,,,16,Tamoxifen,N,
4501,QualifierName,Q000009,11876387,,,16,,Y,adverse effects
4502,DescriptorName,D014621,11876387,,,17,Vagina,N,
4503,QualifierName,Q000000981,11876387,,,17,,Y,diagnostic imaging
4504,DescriptorName,D014626,11876387,,,18,Vaginal Smears,N,
4505,Chemical,D000935,11881322,Antifungal Agents,0,,,,
4506,Chemical,D017964,11881322,Itraconazole,304NUG5GF4,,,,
4507,DescriptorName,D000368,11881322,,,1,Aged,N,
4508,DescriptorName,D000935,11881322,,,2,Antifungal Agents,N,
4509,QualifierName,Q000009,11881322,,,2,,Y,adverse effects
4510,DescriptorName,D001228,11881322,,,3,Aspergillosis,N,
4511,QualifierName,Q000188,11881322,,,3,,N,drug therapy
4512,DescriptorName,D001707,11881322,,,4,"Biopsy, Needle",N,
4513,DescriptorName,D056486,11881322,,,5,Chemical and Drug Induced Liver Injury,Y,
4514,DescriptorName,D005260,11881322,,,6,Female,N,
4515,DescriptorName,D005500,11881322,,,7,Follow-Up Studies,N,
4516,DescriptorName,D006801,11881322,,,8,Humans,N,
4517,DescriptorName,D017964,11881322,,,9,Itraconazole,N,
4518,QualifierName,Q000009,11881322,,,9,,Y,adverse effects
4519,DescriptorName,D008099,11881322,,,10,Liver,N,
4520,QualifierName,Q000187,11881322,,,10,,Y,drug effects
4521,DescriptorName,D008107,11881322,,,11,Liver Diseases,N,
4522,QualifierName,Q000473,11881322,,,11,,Y,pathology
4523,DescriptorName,D008111,11881322,,,12,Liver Function Tests,N,
4524,DescriptorName,D008875,11881322,,,13,Middle Aged,N,
4525,DescriptorName,D018570,11881322,,,14,Risk Assessment,N,
4526,DescriptorName,D012720,11881322,,,15,Severity of Illness Index,N,
4527,DescriptorName,D014005,11881322,,,16,Tinea,N,
4528,QualifierName,Q000188,11881322,,,16,,N,drug therapy
4529,Chemical,D001323,11886466,Autoantibodies,0,,,,
4530,Chemical,D005169,11886466,Factor VIII,9001-27-8,,,,
4531,DescriptorName,D000368,11886466,,,1,Aged,N,
4532,DescriptorName,D000818,11886466,,,2,Animals,N,
4533,DescriptorName,D001172,11886466,,,3,"Arthritis, Rheumatoid",N,
4534,DescriptorName,D001323,11886466,,,4,Autoantibodies,N,
4535,QualifierName,Q000097,11886466,,,4,,N,blood
4536,DescriptorName,D001327,11886466,,,5,Autoimmune Diseases,N,
4537,QualifierName,Q000150,11886466,,,5,,N,complications
4538,DescriptorName,D005169,11886466,,,6,Factor VIII,N,
4539,QualifierName,Q000008,11886466,,,6,,N,administration & dosage
4540,DescriptorName,D017809,11886466,,,7,Fatal Outcome,N,
4541,DescriptorName,D006467,11886466,,,8,Hemophilia A,N,
4542,QualifierName,Q000150,11886466,,,8,,Y,complications
4543,DescriptorName,D006801,11886466,,,9,Humans,N,
4544,DescriptorName,D020767,11886466,,,10,Intracranial Thrombosis,N,
4545,QualifierName,Q000139,11886466,,,10,,Y,chemically induced
4546,DescriptorName,D008297,11886466,,,11,Male,N,
4547,DescriptorName,D013552,11886466,,,12,Swine,N,
4548,Chemical,D000998,11903249,Antiviral Agents,0,,,,
4549,Chemical,D016898,11903249,Interferon-alpha,0,,,,
4550,Chemical,D012254,11903249,Ribavirin,49717AWG6K,,,,
4551,DescriptorName,D000328,11903249,,,1,Adult,N,
4552,DescriptorName,D000998,11903249,,,2,Antiviral Agents,N,
4553,QualifierName,Q000009,11903249,,,2,,Y,adverse effects
4554,DescriptorName,D003875,11903249,,,3,Drug Eruptions,N,
4555,QualifierName,Q000209,11903249,,,3,,Y,etiology
4556,DescriptorName,D004359,11903249,,,4,"Drug Therapy, Combination",N,
4557,DescriptorName,D005260,11903249,,,5,Female,N,
4558,DescriptorName,D019698,11903249,,,6,"Hepatitis C, Chronic",N,
4559,QualifierName,Q000188,11903249,,,6,,Y,drug therapy
4560,DescriptorName,D006801,11903249,,,7,Humans,N,
4561,DescriptorName,D016898,11903249,,,8,Interferon-alpha,N,
4562,QualifierName,Q000009,11903249,,,8,,Y,adverse effects
4563,DescriptorName,D012254,11903249,,,9,Ribavirin,N,
4564,QualifierName,Q000009,11903249,,,9,,Y,adverse effects
4565,DescriptorName,D012507,11903249,,,10,Sarcoidosis,N,
4566,QualifierName,Q000139,11903249,,,10,,Y,chemically induced
4567,Chemical,D000929,11918514,"Antidepressive Agents, Tricyclic",0,,,,
4568,Chemical,D008803,11918514,Mianserin,250PJI13LM,,,,
4569,Chemical,D000078785,11918514,Mirtazapine,A051Q2099Q,,,,
4570,DescriptorName,D000368,11918514,,,1,Aged,N,
4571,DescriptorName,D000929,11918514,,,2,"Antidepressive Agents, Tricyclic",N,
4572,QualifierName,Q000009,11918514,,,2,,Y,adverse effects
4573,DescriptorName,D003863,11918514,,,3,Depression,N,
4574,QualifierName,Q000188,11918514,,,3,,Y,drug therapy
4575,DescriptorName,D006801,11918514,,,4,Humans,N,
4576,DescriptorName,D008297,11918514,,,5,Male,N,
4577,DescriptorName,D008803,11918514,,,6,Mianserin,N,
4578,QualifierName,Q000009,11918514,,,6,,Y,adverse effects
4579,DescriptorName,D000078785,11918514,,,7,Mirtazapine,N,
4580,DescriptorName,D020230,11918514,,,8,Serotonin Syndrome,N,
4581,QualifierName,Q000139,11918514,,,8,,Y,chemically induced
4582,Chemical,D000970,11943900,Antineoplastic Agents,0,,,,
4583,Chemical,D011344,11943900,Procarbazine,35S93Y190K,,,,
4584,Chemical,D008466,11943900,Mechlorethamine,50D9XSG0VR,,,,
4585,Chemical,D014750,11943900,Vincristine,5J49Q6B70F,,,,
4586,Chemical,D011241,11943900,Prednisone,VB0R961HZT,,,,
4587,DescriptorName,D000970,11943900,,,1,Antineoplastic Agents,N,
4588,QualifierName,Q000009,11943900,,,1,,Y,adverse effects
4589,DescriptorName,D000971,11943900,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
4590,QualifierName,Q000009,11943900,,,2,,N,adverse effects
4591,DescriptorName,D006689,11943900,,,3,Hodgkin Disease,N,
4592,QualifierName,Q000188,11943900,,,3,,N,drug therapy
4593,DescriptorName,D006801,11943900,,,4,Humans,N,
4594,DescriptorName,D008297,11943900,,,5,Male,N,
4595,DescriptorName,D008466,11943900,,,6,Mechlorethamine,N,
4596,QualifierName,Q000009,11943900,,,6,,N,adverse effects
4597,DescriptorName,D008875,11943900,,,7,Middle Aged,N,
4598,DescriptorName,D011014,11943900,,,8,Pneumonia,N,
4599,QualifierName,Q000139,11943900,,,8,,Y,chemically induced
4600,DescriptorName,D011241,11943900,,,9,Prednisone,N,
4601,QualifierName,Q000009,11943900,,,9,,N,adverse effects
4602,DescriptorName,D011344,11943900,,,10,Procarbazine,N,
4603,QualifierName,Q000009,11943900,,,10,,Y,adverse effects
4604,DescriptorName,D014750,11943900,,,11,Vincristine,N,
4605,QualifierName,Q000009,11943900,,,11,,N,adverse effects
4606,Chemical,D016899,11961411,Interferon-beta,77238-31-4,,,,
4607,DescriptorName,D003131,11961411,,,1,Combined Modality Therapy,N,
4608,DescriptorName,D003920,11961411,,,2,Diabetes Mellitus,N,
4609,DescriptorName,D006801,11961411,,,3,Humans,N,
4610,DescriptorName,D016899,11961411,,,4,Interferon-beta,N,
4611,QualifierName,Q000009,11961411,,,4,,Y,adverse effects
4612,DescriptorName,D007678,11961411,,,5,Kidney Glomerulus,N,
4613,QualifierName,Q000473,11961411,,,5,,N,pathology
4614,DescriptorName,D008297,11961411,,,6,Male,N,
4615,DescriptorName,D008545,11961411,,,7,Melanoma,N,
4616,QualifierName,Q000188,11961411,,,7,,Y,drug therapy
4617,DescriptorName,D008875,11961411,,,8,Middle Aged,N,
4618,DescriptorName,D009402,11961411,,,9,"Nephrosis, Lipoid",N,
4619,QualifierName,Q000209,11961411,,,9,,Y,etiology
4620,DescriptorName,D011507,11961411,,,10,Proteinuria,N,
4621,QualifierName,Q000209,11961411,,,10,,N,etiology
4622,Chemical,D000890,11972105,Anti-Infective Agents,0,,,,
4623,Chemical,D000964,11972105,"Antimetabolites, Antineoplastic",0,,,,
4624,Chemical,D002939,11972105,Ciprofloxacin,5E8K9I0O4U,,,,
4625,Chemical,D008727,11972105,Methotrexate,YL5FZ2Y5U1,,,,
4626,DescriptorName,D000293,11972105,,,1,Adolescent,N,
4627,DescriptorName,D000890,11972105,,,2,Anti-Infective Agents,N,
4628,QualifierName,Q000009,11972105,,,2,,Y,adverse effects
4629,DescriptorName,D000964,11972105,,,3,"Antimetabolites, Antineoplastic",N,
4630,QualifierName,Q000009,11972105,,,3,,Y,adverse effects
4631,DescriptorName,D001859,11972105,,,4,Bone Neoplasms,N,
4632,QualifierName,Q000188,11972105,,,4,,N,drug therapy
4633,DescriptorName,D002648,11972105,,,5,Child,N,
4634,DescriptorName,D002675,11972105,,,6,"Child, Preschool",N,
4635,DescriptorName,D002939,11972105,,,7,Ciprofloxacin,N,
4636,QualifierName,Q000009,11972105,,,7,,Y,adverse effects
4637,DescriptorName,D004347,11972105,,,8,Drug Interactions,N,
4638,DescriptorName,D005260,11972105,,,9,Female,N,
4639,DescriptorName,D006801,11972105,,,10,Humans,N,
4640,DescriptorName,D008297,11972105,,,11,Male,N,
4641,DescriptorName,D008727,11972105,,,12,Methotrexate,N,
4642,QualifierName,Q000009,11972105,,,12,,Y,adverse effects
4643,DescriptorName,D009447,11972105,,,13,Neuroblastoma,N,
4644,QualifierName,Q000188,11972105,,,13,,N,drug therapy
4645,DescriptorName,D012516,11972105,,,14,Osteosarcoma,N,
4646,QualifierName,Q000188,11972105,,,14,,N,drug therapy
4647,Chemical,D053799,11978156,2-Pyridinylmethylsulfinylbenzimidazoles,0,,,,
4648,Chemical,D000897,11978156,Anti-Ulcer Agents,0,,,,
4649,Chemical,D064747,11978156,Lansoprazole,0K5C5T2QPG,,,,
4650,Chemical,D009853,11978156,Omeprazole,KG60484QX9,,,,
4651,DescriptorName,D053799,11978156,,,1,2-Pyridinylmethylsulfinylbenzimidazoles,N,
4652,DescriptorName,D000368,11978156,,,2,Aged,N,
4653,DescriptorName,D000369,11978156,,,3,"Aged, 80 and over",N,
4654,DescriptorName,D000897,11978156,,,4,Anti-Ulcer Agents,N,
4655,QualifierName,Q000008,11978156,,,4,,N,administration & dosage
4656,DescriptorName,D006471,11978156,,,5,Gastrointestinal Hemorrhage,N,
4657,QualifierName,Q000188,11978156,,,5,,N,drug therapy
4658,DescriptorName,D006801,11978156,,,6,Humans,N,
4659,DescriptorName,D064747,11978156,,,7,Lansoprazole,N,
4660,DescriptorName,D008297,11978156,,,8,Male,N,
4661,DescriptorName,D009853,11978156,,,9,Omeprazole,N,
4662,QualifierName,Q000008,11978156,,,9,,N,administration & dosage
4663,DescriptorName,D013276,11978156,,,10,Stomach Ulcer,N,
4664,QualifierName,Q000150,11978156,,,10,,N,complications
4665,DescriptorName,D013921,11978156,,,11,Thrombocytopenia,N,
4666,QualifierName,Q000139,11978156,,,11,,Y,chemically induced
4667,Chemical,D011837,11984077,Radiation-Protective Agents,0,,,,
4668,Chemical,D004999,11984077,Amifostine,M487QF2F4V,,,,
4669,DescriptorName,D004999,11984077,,,1,Amifostine,N,
4670,QualifierName,Q000009,11984077,,,1,,Y,adverse effects
4671,DescriptorName,D000707,11984077,,,2,Anaphylaxis,N,
4672,QualifierName,Q000139,11984077,,,2,,Y,chemically induced
4673,DescriptorName,D003131,11984077,,,3,Combined Modality Therapy,N,
4674,DescriptorName,D003882,11984077,,,4,Dermatomyositis,N,
4675,QualifierName,Q000150,11984077,,,4,,N,complications
4676,DescriptorName,D006801,11984077,,,5,Humans,N,
4677,DescriptorName,D008279,11984077,,,6,Magnetic Resonance Imaging,N,
4678,DescriptorName,D008297,11984077,,,7,Male,N,
4679,DescriptorName,D008875,11984077,,,8,Middle Aged,N,
4680,DescriptorName,D009303,11984077,,,9,Nasopharyngeal Neoplasms,N,
4681,QualifierName,Q000150,11984077,,,9,,N,complications
4682,DescriptorName,D011837,11984077,,,10,Radiation-Protective Agents,N,
4683,QualifierName,Q000009,11984077,,,10,,Y,adverse effects
4684,DescriptorName,D014057,11984077,,,11,"Tomography, X-Ray Computed",N,
4685,Chemical,D003024,11999915,Clozapine,J60AR2IKIC,,,,
4686,DescriptorName,D000328,11999915,,,1,Adult,N,
4687,DescriptorName,D000380,11999915,,,2,Agranulocytosis,N,
4688,QualifierName,Q000097,11999915,,,2,,N,blood
4689,DescriptorName,D003024,11999915,,,3,Clozapine,N,
4690,QualifierName,Q000009,11999915,,,3,,Y,adverse effects
4691,DescriptorName,D005260,11999915,,,4,Female,N,
4692,DescriptorName,D006801,11999915,,,5,Humans,N,
4693,DescriptorName,D008297,11999915,,,6,Male,N,
4694,DescriptorName,D012559,11999915,,,7,Schizophrenia,N,
4695,QualifierName,Q000097,11999915,,,7,,N,blood
4696,Chemical,D014150,12013364,Antipsychotic Agents,0,,,,
4697,Chemical,D001569,12013364,Benzodiazepines,12794-10-4,,,,
4698,Chemical,D010890,12013364,Pirenzepine,3G0285N20N,,,,
4699,Chemical,D000077152,12013364,Olanzapine,N7U69T4SZR,,,,
4700,DescriptorName,D014150,12013364,,,1,Antipsychotic Agents,N,
4701,QualifierName,Q000009,12013364,,,1,,Y,adverse effects
4702,DescriptorName,D001569,12013364,,,2,Benzodiazepines,N,
4703,DescriptorName,D001772,12013364,,,3,Blood Cell Count,N,
4704,DescriptorName,D006212,12013364,,,4,Hallucinations,N,
4705,DescriptorName,D006801,12013364,,,5,Humans,N,
4706,DescriptorName,D008297,12013364,,,6,Male,N,
4707,DescriptorName,D008875,12013364,,,7,Middle Aged,N,
4708,DescriptorName,D009459,12013364,,,8,Neuroleptic Malignant Syndrome,N,
4709,QualifierName,Q000503,12013364,,,8,,Y,physiopathology
4710,DescriptorName,D000077152,12013364,,,9,Olanzapine,N,
4711,DescriptorName,D010890,12013364,,,10,Pirenzepine,N,
4712,QualifierName,Q000009,12013364,,,10,,Y,adverse effects
4713,DescriptorName,D012563,12013364,,,11,"Schizophrenia, Paranoid",N,
4714,QualifierName,Q000150,12013364,,,11,,N,complications
4715,DescriptorName,D012565,12013364,,,12,Schizophrenic Psychology,N,
4716,Chemical,D014150,12022905,Antipsychotic Agents,0,,,,
4717,Chemical,D003006,12022905,Clopenthixol,982-24-1,,,,
4718,Chemical,D009638,12022905,Norepinephrine,X4W3ENH1CV,,,,
4719,DescriptorName,D000328,12022905,,,1,Adult,N,
4720,DescriptorName,D014150,12022905,,,2,Antipsychotic Agents,N,
4721,QualifierName,Q000009,12022905,,,2,,Y,adverse effects
4722,DescriptorName,D003006,12022905,,,3,Clopenthixol,N,
4723,QualifierName,Q000009,12022905,,,3,,Y,adverse effects
4724,DescriptorName,D006801,12022905,,,4,Humans,N,
4725,DescriptorName,D008297,12022905,,,5,Male,N,
4726,DescriptorName,D009638,12022905,,,6,Norepinephrine,N,
4727,QualifierName,Q000627,12022905,,,6,,N,therapeutic use
4728,DescriptorName,D011317,12022905,,,7,Priapism,N,
4729,QualifierName,Q000139,12022905,,,7,,Y,chemically induced
4730,Chemical,D000894,12042592,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
4731,Chemical,D011720,12042592,Pyrazoles,0,,,,
4732,Chemical,D047069,12042592,Pyrazolones,0,,,,
4733,Chemical,C038362,12042592,pyrazolone,39455-90-8,,,,
4734,Chemical,D004177,12042592,Dipyrone,6429L0L52Y,,,,
4735,DescriptorName,D000380,12042592,,,1,Agranulocytosis,N,
4736,QualifierName,Q000139,12042592,,,1,,N,chemically induced
4737,DescriptorName,D000894,12042592,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
4738,QualifierName,Q000009,12042592,,,2,,Y,adverse effects
4739,DescriptorName,D002675,12042592,,,3,"Child, Preschool",N,
4740,DescriptorName,D004177,12042592,,,4,Dipyrone,N,
4741,QualifierName,Q000009,12042592,,,4,,Y,adverse effects
4742,DescriptorName,D004641,12042592,,,5,Emigration and Immigration,N,
4743,QualifierName,Q000706,12042592,,,5,,Y,statistics & numerical data
4744,DescriptorName,D006630,12042592,,,6,Hispanic Americans,N,
4745,QualifierName,Q000523,12042592,,,6,,N,psychology
4746,DescriptorName,D006801,12042592,,,7,Humans,N,
4747,DescriptorName,D007880,12042592,,,8,"Legislation, Drug",N,
4748,QualifierName,Q000592,12042592,,,8,,N,standards
4749,DescriptorName,D008297,12042592,,,9,Male,N,
4750,DescriptorName,D008519,12042592,,,10,"Medicine, Traditional",Y,
4751,DescriptorName,D008800,12042592,,,11,Mexico,N,
4752,DescriptorName,D009503,12042592,,,12,Neutropenia,N,
4753,QualifierName,Q000139,12042592,,,12,,N,chemically induced
4754,DescriptorName,D010146,12042592,,,13,Pain,N,
4755,QualifierName,Q000188,12042592,,,13,,N,drug therapy
4756,DescriptorName,D011720,12042592,,,14,Pyrazoles,N,
4757,QualifierName,Q000009,12042592,,,14,,N,adverse effects
4758,DescriptorName,D047069,12042592,,,15,Pyrazolones,Y,
4759,DescriptorName,D018805,12042592,,,16,Sepsis,N,
4760,QualifierName,Q000139,12042592,,,16,,N,chemically induced
4761,DescriptorName,D014481,12042592,,,17,United States,N,
4762,Chemical,D000903,12053072,"Antibiotics, Antineoplastic",0,,,,
4763,Chemical,D004921,12053072,Erythropoietin,11096-26-7,,,,
4764,Chemical,D016685,12053072,Mitomycin,50SG953SK6,,,,
4765,DescriptorName,D000903,12053072,,,1,"Antibiotics, Antineoplastic",N,
4766,QualifierName,Q000009,12053072,,,1,,Y,adverse effects
4767,DescriptorName,D003110,12053072,,,2,Colonic Neoplasms,N,
4768,QualifierName,Q000188,12053072,,,2,,N,drug therapy
4769,DescriptorName,D004921,12053072,,,3,Erythropoietin,N,
4770,QualifierName,Q000627,12053072,,,3,,Y,therapeutic use
4771,DescriptorName,D005260,12053072,,,4,Female,N,
4772,DescriptorName,D006463,12053072,,,5,Hemolytic-Uremic Syndrome,N,
4773,QualifierName,Q000139,12053072,,,5,,Y,chemically induced
4774,DescriptorName,D006801,12053072,,,6,Humans,N,
4775,DescriptorName,D008875,12053072,,,7,Middle Aged,N,
4776,DescriptorName,D016685,12053072,,,8,Mitomycin,N,
4777,QualifierName,Q000009,12053072,,,8,,Y,adverse effects
4778,Chemical,D000890,12066972,Anti-Infective Agents,0,,,,
4779,Chemical,D064704,12066972,Levofloxacin,6GNT3Y5LMF,,,,
4780,Chemical,D015242,12066972,Ofloxacin,A4P49JAZ9H,,,,
4781,DescriptorName,D000368,12066972,,,1,Aged,N,
4782,DescriptorName,D000890,12066972,,,2,Anti-Infective Agents,N,
4783,QualifierName,Q000009,12066972,,,2,,Y,adverse effects
4784,DescriptorName,D017714,12066972,,,3,Community-Acquired Infections,N,
4785,QualifierName,Q000188,12066972,,,3,,N,drug therapy
4786,DescriptorName,D005260,12066972,,,4,Female,N,
4787,DescriptorName,D005440,12066972,,,5,Fluid Therapy,N,
4788,DescriptorName,D006801,12066972,,,6,Humans,N,
4789,DescriptorName,D064704,12066972,,,7,Levofloxacin,Y,
4790,DescriptorName,D015242,12066972,,,8,Ofloxacin,N,
4791,QualifierName,Q000009,12066972,,,8,,Y,adverse effects
4792,DescriptorName,D011014,12066972,,,9,Pneumonia,N,
4793,QualifierName,Q000188,12066972,,,9,,N,drug therapy
4794,DescriptorName,D029424,12066972,,,10,"Pulmonary Disease, Chronic Obstructive",N,
4795,QualifierName,Q000150,12066972,,,10,,N,complications
4796,DescriptorName,D012867,12066972,,,11,Skin,N,
4797,QualifierName,Q000473,12066972,,,11,,N,pathology
4798,DescriptorName,D013262,12066972,,,12,Stevens-Johnson Syndrome,N,
4799,QualifierName,Q000473,12066972,,,12,,Y,pathology
4800,Chemical,D000927,12078977,Anticonvulsants,0,,,,
4801,Chemical,D001761,12078977,Bleomycin,11056-06-7,,,,
4802,Chemical,D014747,12078977,Vinblastine,5V9KLZ54CY,,,,
4803,Chemical,D010672,12078977,Phenytoin,6158TKW0C5,,,,
4804,Chemical,D002945,12078977,Cisplatin,Q20Q21Q62J,,,,
4805,DescriptorName,D000328,12078977,,,1,Adult,N,
4806,DescriptorName,D000927,12078977,,,2,Anticonvulsants,N,
4807,QualifierName,Q000627,12078977,,,2,,N,therapeutic use
4808,DescriptorName,D000971,12078977,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
4809,QualifierName,Q000009,12078977,,,3,,Y,adverse effects
4810,DescriptorName,D001761,12078977,,,4,Bleomycin,N,
4811,QualifierName,Q000009,12078977,,,4,,N,adverse effects
4812,DescriptorName,D001927,12078977,,,5,Brain Diseases,N,
4813,QualifierName,Q000139,12078977,,,5,,Y,chemically induced
4814,DescriptorName,D002945,12078977,,,6,Cisplatin,N,
4815,QualifierName,Q000009,12078977,,,6,,N,adverse effects
4816,DescriptorName,D004569,12078977,,,7,Electroencephalography,N,
4817,DescriptorName,D005260,12078977,,,8,Female,N,
4818,DescriptorName,D006801,12078977,,,9,Humans,N,
4819,DescriptorName,D008279,12078977,,,10,Magnetic Resonance Imaging,N,
4820,DescriptorName,D010051,12078977,,,11,Ovarian Neoplasms,N,
4821,QualifierName,Q000188,12078977,,,11,,Y,drug therapy
4822,DescriptorName,D010672,12078977,,,12,Phenytoin,N,
4823,QualifierName,Q000627,12078977,,,12,,N,therapeutic use
4824,DescriptorName,D012640,12078977,,,13,Seizures,N,
4825,QualifierName,Q000188,12078977,,,13,,N,drug therapy
4826,DescriptorName,D014057,12078977,,,14,"Tomography, X-Ray Computed",N,
4827,DescriptorName,D014747,12078977,,,15,Vinblastine,N,
4828,QualifierName,Q000009,12078977,,,15,,N,adverse effects
4829,Chemical,D000970,12086549,Antineoplastic Agents,0,,,,
4830,Chemical,D007376,12086549,Interleukin-2,0,,,,
4831,DescriptorName,D000368,12086549,,,1,Aged,N,
4832,DescriptorName,D000970,12086549,,,2,Antineoplastic Agents,N,
4833,QualifierName,Q000009,12086549,,,2,,Y,adverse effects
4834,DescriptorName,D002292,12086549,,,3,"Carcinoma, Renal Cell",N,
4835,QualifierName,Q000188,12086549,,,3,,N,drug therapy
4836,DescriptorName,D017809,12086549,,,4,Fatal Outcome,N,
4837,DescriptorName,D005260,12086549,,,5,Female,N,
4838,DescriptorName,D006801,12086549,,,6,Humans,N,
4839,DescriptorName,D007376,12086549,,,7,Interleukin-2,N,
4840,QualifierName,Q000009,12086549,,,7,,Y,adverse effects
4841,DescriptorName,D007680,12086549,,,8,Kidney Neoplasms,N,
4842,QualifierName,Q000188,12086549,,,8,,N,drug therapy
4843,DescriptorName,D013262,12086549,,,9,Stevens-Johnson Syndrome,N,
4844,QualifierName,Q000209,12086549,,,9,,Y,etiology
4845,Chemical,D010952,12092878,Plasma Substitutes,0,,,,
4846,Chemical,D013386,12092878,Succinates,0,,,,
4847,Chemical,C060085,12092878,succinylated gelatin,39340-57-3,,,,
4848,Chemical,D005780,12092878,Gelatin,9000-70-8,,,,
4849,DescriptorName,D003875,12092878,,,1,Drug Eruptions,N,
4850,QualifierName,Q000209,12092878,,,1,,Y,etiology
4851,DescriptorName,D004342,12092878,,,2,Drug Hypersensitivity,N,
4852,QualifierName,Q000517,12092878,,,2,,Y,prevention & control
4853,DescriptorName,D005780,12092878,,,3,Gelatin,N,
4854,QualifierName,Q000009,12092878,,,3,,Y,adverse effects
4855,DescriptorName,D006801,12092878,,,4,Humans,N,
4856,DescriptorName,D020896,12092878,,,5,Hypovolemia,N,
4857,QualifierName,Q000188,12092878,,,5,,Y,drug therapy
4858,DescriptorName,D008297,12092878,,,6,Male,N,
4859,DescriptorName,D008875,12092878,,,7,Middle Aged,N,
4860,DescriptorName,D010952,12092878,,,8,Plasma Substitutes,N,
4861,QualifierName,Q000009,12092878,,,8,,Y,adverse effects
4862,DescriptorName,D013386,12092878,,,9,Succinates,N,
4863,QualifierName,Q000009,12092878,,,9,,Y,adverse effects
4864,Chemical,D000927,12095907,Anticonvulsants,0,,,,
4865,Chemical,D014635,12095907,Valproic Acid,614OI1Z5WI,,,,
4866,DescriptorName,D000368,12095907,,,1,Aged,N,
4867,DescriptorName,D000369,12095907,,,2,"Aged, 80 and over",N,
4868,DescriptorName,D000927,12095907,,,3,Anticonvulsants,N,
4869,QualifierName,Q000009,12095907,,,3,,Y,adverse effects
4870,DescriptorName,D003072,12095907,,,4,Cognition Disorders,N,
4871,QualifierName,Q000175,12095907,,,4,,N,diagnosis
4872,DescriptorName,D006801,12095907,,,5,Humans,N,
4873,DescriptorName,D022124,12095907,,,6,Hyperammonemia,N,
4874,QualifierName,Q000139,12095907,,,6,,Y,chemically induced
4875,DescriptorName,D009483,12095907,,,7,Neuropsychological Tests,N,
4876,DescriptorName,D012640,12095907,,,8,Seizures,N,
4877,QualifierName,Q000188,12095907,,,8,,Y,drug therapy
4878,DescriptorName,D014635,12095907,,,9,Valproic Acid,N,
4879,QualifierName,Q000009,12095907,,,9,,Y,adverse effects
4880,Chemical,D003520,12100953,Cyclophosphamide,8N3DW7272P,,,,
4881,DescriptorName,D000328,12100953,,,1,Adult,N,
4882,DescriptorName,D003520,12100953,,,2,Cyclophosphamide,N,
4883,QualifierName,Q000009,12100953,,,2,,N,adverse effects
4884,DescriptorName,D015653,12100953,,,3,Cystectomy,N,
4885,QualifierName,Q000379,12100953,,,3,,N,methods
4886,DescriptorName,D006417,12100953,,,4,Hematuria,N,
4887,QualifierName,Q000175,12100953,,,4,,N,diagnosis
4888,DescriptorName,D006801,12100953,,,5,Humans,N,
4889,DescriptorName,D007890,12100953,,,6,Leiomyosarcoma,N,
4890,QualifierName,Q000175,12100953,,,6,,Y,diagnosis
4891,DescriptorName,D008297,12100953,,,7,Male,N,
4892,DescriptorName,D011379,12100953,,,8,Prognosis,N,
4893,DescriptorName,D019572,12100953,,,9,Retinal Neoplasms,N,
4894,QualifierName,Q000188,12100953,,,9,,Y,drug therapy
4895,DescriptorName,D012175,12100953,,,10,Retinoblastoma,N,
4896,QualifierName,Q000188,12100953,,,10,,Y,drug therapy
4897,DescriptorName,D001749,12100953,,,11,Urinary Bladder Neoplasms,N,
4898,QualifierName,Q000175,12100953,,,11,,Y,diagnosis
4899,DescriptorName,D014547,12100953,,,12,Urinary Diversion,N,
4900,QualifierName,Q000379,12100953,,,12,,N,methods
4901,Chemical,D014150,12107858,Antipsychotic Agents,0,,,,
4902,Chemical,D013469,12107858,Sulpiride,7MNE9M8287,,,,
4903,Chemical,D000077582,12107858,Amisulpride,8110R61I4U,,,,
4904,Chemical,D003024,12107858,Clozapine,J60AR2IKIC,,,,
4905,Chemical,D018967,12107858,Risperidone,L6UH7ZF8HC,,,,
4906,DescriptorName,D000077582,12107858,,,1,Amisulpride,N,
4907,DescriptorName,D014150,12107858,,,2,Antipsychotic Agents,N,
4908,QualifierName,Q000009,12107858,,,2,,Y,adverse effects
4909,DescriptorName,D003024,12107858,,,3,Clozapine,N,
4910,QualifierName,Q000009,12107858,,,3,,N,adverse effects
4911,DescriptorName,D005260,12107858,,,4,Female,N,
4912,DescriptorName,D006801,12107858,,,5,Humans,N,
4913,DescriptorName,D008875,12107858,,,6,Middle Aged,N,
4914,DescriptorName,D009459,12107858,,,7,Neuroleptic Malignant Syndrome,N,
4915,QualifierName,Q000209,12107858,,,7,,Y,etiology
4916,DescriptorName,D018967,12107858,,,8,Risperidone,N,
4917,QualifierName,Q000009,12107858,,,8,,N,adverse effects
4918,DescriptorName,D012559,12107858,,,9,Schizophrenia,N,
4919,QualifierName,Q000188,12107858,,,9,,N,drug therapy
4920,DescriptorName,D013469,12107858,,,10,Sulpiride,N,
4921,QualifierName,Q000009,12107858,,,10,,N,adverse effects
4922,Chemical,D000970,12111771,Antineoplastic Agents,0,,,,
4923,Chemical,D014740,12111771,Vidarabine,FA2DM6879K,,,,
4924,Chemical,C024352,12111771,fludarabine,P2K93U8740,,,,
4925,Chemical,D011241,12111771,Prednisone,VB0R961HZT,,,,
4926,DescriptorName,D000368,12111771,,,1,Aged,N,
4927,DescriptorName,D000970,12111771,,,2,Antineoplastic Agents,N,
4928,QualifierName,Q000009,12111771,,,2,,Y,adverse effects
4929,DescriptorName,D005260,12111771,,,3,Female,N,
4930,DescriptorName,D006801,12111771,,,4,Humans,N,
4931,DescriptorName,D015451,12111771,,,5,"Leukemia, Lymphocytic, Chronic, B-Cell",N,
4932,QualifierName,Q000188,12111771,,,5,,N,drug therapy
4933,DescriptorName,D008171,12111771,,,6,Lung Diseases,N,
4934,QualifierName,Q000139,12111771,,,6,,Y,chemically induced
4935,DescriptorName,D011241,12111771,,,7,Prednisone,N,
4936,QualifierName,Q000627,12111771,,,7,,N,therapeutic use
4937,DescriptorName,D014057,12111771,,,8,"Tomography, X-Ray Computed",N,
4938,DescriptorName,D014740,12111771,,,9,Vidarabine,N,
4939,QualifierName,Q000009,12111771,,,9,,Y,adverse effects
4940,Chemical,D000959,12114387,Antihypertensive Agents,0,,,,
4941,Chemical,D011464,12114387,Epoprostenol,DCR9Z582X0,,,,
4942,DescriptorName,D000959,12114387,,,1,Antihypertensive Agents,N,
4943,QualifierName,Q000009,12114387,,,1,,Y,adverse effects
4944,DescriptorName,D003873,12114387,,,2,"Dermatitis, Exfoliative",N,
4945,QualifierName,Q000139,12114387,,,2,,Y,chemically induced
4946,DescriptorName,D004342,12114387,,,3,Drug Hypersensitivity,N,
4947,QualifierName,Q000473,12114387,,,3,,Y,pathology
4948,DescriptorName,D011464,12114387,,,4,Epoprostenol,N,
4949,QualifierName,Q000009,12114387,,,4,,Y,adverse effects
4950,DescriptorName,D005260,12114387,,,5,Female,N,
4951,DescriptorName,D006801,12114387,,,6,Humans,N,
4952,DescriptorName,D006976,12114387,,,7,"Hypertension, Pulmonary",N,
4953,QualifierName,Q000188,12114387,,,7,,N,drug therapy
4954,DescriptorName,D008875,12114387,,,8,Middle Aged,N,
4955,Chemical,D010975,12121061,Platelet Aggregation Inhibitors,0,,,,
4956,Chemical,D016572,12121061,Cyclosporine,83HN0GTJ6D,,,,
4957,Chemical,D013988,12121061,Ticlopidine,OM90ZUW7M1,,,,
4958,DescriptorName,D001855,12121061,,,1,Bone Marrow Diseases,N,
4959,QualifierName,Q000139,12121061,,,1,,N,chemically induced
4960,DescriptorName,D016572,12121061,,,2,Cyclosporine,N,
4961,QualifierName,Q000008,12121061,,,2,,Y,administration & dosage
4962,DescriptorName,D048909,12121061,,,3,Diabetes Complications,N,
4963,DescriptorName,D003920,12121061,,,4,Diabetes Mellitus,N,
4964,QualifierName,Q000188,12121061,,,4,,N,drug therapy
4965,DescriptorName,D006801,12121061,,,5,Humans,N,
4966,DescriptorName,D008297,12121061,,,6,Male,N,
4967,DescriptorName,D008875,12121061,,,7,Middle Aged,N,
4968,DescriptorName,D010975,12121061,,,8,Platelet Aggregation Inhibitors,N,
4969,QualifierName,Q000009,12121061,,,8,,Y,adverse effects
4970,DescriptorName,D013988,12121061,,,9,Ticlopidine,N,
4971,QualifierName,Q000009,12121061,,,9,,Y,adverse effects
4972,DescriptorName,D016896,12121061,,,10,Treatment Outcome,N,
4973,Chemical,D013844,12126225,Thiazoles,0,,,,
4974,Chemical,D045162,12126225,Thiazolidinediones,0,,,,
4975,Chemical,C089946,12126225,"2,4-thiazolidinedione",AA68LXK93C,,,,
4976,DescriptorName,D000368,12126225,,,1,Aged,N,
4977,DescriptorName,D004487,12126225,,,2,Edema,N,
4978,QualifierName,Q000139,12126225,,,2,,Y,chemically induced
4979,DescriptorName,D006801,12126225,,,3,Humans,N,
4980,DescriptorName,D008297,12126225,,,4,Male,N,
4981,DescriptorName,D008875,12126225,,,5,Middle Aged,N,
4982,DescriptorName,D013844,12126225,,,6,Thiazoles,N,
4983,QualifierName,Q000009,12126225,,,6,,Y,adverse effects
4984,DescriptorName,D045162,12126225,,,7,Thiazolidinediones,Y,
4985,Chemical,D000889,12135176,Anti-Arrhythmia Agents,0,,,,
4986,Chemical,D014700,12135176,Verapamil,CJ0O37KU29,,,,
4987,DescriptorName,D000889,12135176,,,1,Anti-Arrhythmia Agents,N,
4988,QualifierName,Q000009,12135176,,,1,,Y,adverse effects
4989,DescriptorName,D017115,12135176,,,2,Catheter Ablation,N,
4990,DescriptorName,D004562,12135176,,,3,Electrocardiography,N,
4991,DescriptorName,D022062,12135176,,,4,"Electrophysiologic Techniques, Cardiac",N,
4992,DescriptorName,D005260,12135176,,,5,Female,N,
4993,DescriptorName,D006801,12135176,,,6,Humans,N,
4994,DescriptorName,D008297,12135176,,,7,Male,N,
4995,DescriptorName,D008875,12135176,,,8,Middle Aged,N,
4996,DescriptorName,D013617,12135176,,,9,"Tachycardia, Supraventricular",N,
4997,QualifierName,Q000188,12135176,,,9,,Y,drug therapy
4998,DescriptorName,D017180,12135176,,,10,"Tachycardia, Ventricular",N,
4999,QualifierName,Q000139,12135176,,,10,,Y,chemically induced
5000,DescriptorName,D016896,12135176,,,11,Treatment Outcome,N,
5001,DescriptorName,D014700,12135176,,,12,Verapamil,N,
5002,QualifierName,Q000009,12135176,,,12,,Y,adverse effects
5003,Chemical,D000933,12141409,Antifibrinolytic Agents,0,,,,
5004,Chemical,D003404,12141409,Creatinine,AYI8EX34EU,,,,
5005,Chemical,D015119,12141409,Aminocaproic Acid,U6F3787206,,,,
5006,DescriptorName,D058186,12141409,,,1,Acute Kidney Injury,N,
5007,QualifierName,Q000139,12141409,,,1,,Y,chemically induced
5008,DescriptorName,D000368,12141409,,,2,Aged,N,
5009,DescriptorName,D015119,12141409,,,3,Aminocaproic Acid,N,
5010,QualifierName,Q000009,12141409,,,3,,Y,adverse effects
5011,DescriptorName,D000933,12141409,,,4,Antifibrinolytic Agents,N,
5012,QualifierName,Q000009,12141409,,,4,,Y,adverse effects
5013,DescriptorName,D003404,12141409,,,5,Creatinine,N,
5014,QualifierName,Q000097,12141409,,,5,,N,blood
5015,DescriptorName,D005260,12141409,,,6,Female,N,
5016,DescriptorName,D006417,12141409,,,7,Hematuria,N,
5017,DescriptorName,D006801,12141409,,,8,Humans,N,
5018,DescriptorName,D006869,12141409,,,9,Hydronephrosis,N,
5019,QualifierName,Q000000981,12141409,,,9,,N,diagnostic imaging
5020,DescriptorName,D007668,12141409,,,10,Kidney,N,
5021,QualifierName,Q000000981,12141409,,,10,,N,diagnostic imaging
5022,DescriptorName,D009403,12141409,,,11,"Nephrostomy, Percutaneous",N,
5023,DescriptorName,D011859,12141409,,,12,Radiography,N,
5024,DescriptorName,D013927,12141409,,,13,Thrombosis,N,
5025,QualifierName,Q000188,12141409,,,13,,N,drug therapy
5026,DescriptorName,D014463,12141409,,,14,Ultrasonography,N,
5027,Chemical,D000889,12150593,Anti-Arrhythmia Agents,0,,,,
5028,Chemical,D000927,12150593,Anticonvulsants,0,,,,
5029,Chemical,D010672,12150593,Phenytoin,6158TKW0C5,,,,
5030,Chemical,D008012,12150593,Lidocaine,98PI200987,,,,
5031,Chemical,D010634,12150593,Phenobarbital,YQE403BP4D,,,,
5032,DescriptorName,D000889,12150593,,,1,Anti-Arrhythmia Agents,N,
5033,QualifierName,Q000008,12150593,,,1,,N,administration & dosage
5034,DescriptorName,D000927,12150593,,,2,Anticonvulsants,N,
5035,QualifierName,Q000008,12150593,,,2,,N,administration & dosage
5036,DescriptorName,D003937,12150593,,,3,"Diagnosis, Differential",N,
5037,DescriptorName,D062787,12150593,,,4,Drug Overdose,N,
5038,DescriptorName,D004359,12150593,,,5,"Drug Therapy, Combination",N,
5039,DescriptorName,D004830,12150593,,,6,"Epilepsy, Tonic-Clonic",N,
5040,QualifierName,Q000188,12150593,,,6,,Y,drug therapy
5041,DescriptorName,D006801,12150593,,,7,Humans,N,
5042,DescriptorName,D007231,12150593,,,8,"Infant, Newborn",N,
5043,DescriptorName,D008012,12150593,,,9,Lidocaine,N,
5044,QualifierName,Q000008,12150593,,,9,,N,administration & dosage
5045,DescriptorName,D008297,12150593,,,10,Male,N,
5046,DescriptorName,D015878,12150593,,,11,Mydriasis,N,
5047,QualifierName,Q000139,12150593,,,11,,Y,chemically induced
5048,DescriptorName,D010634,12150593,,,12,Phenobarbital,N,
5049,QualifierName,Q000627,12150593,,,12,,N,therapeutic use
5050,DescriptorName,D010672,12150593,,,13,Phenytoin,N,
5051,QualifierName,Q000627,12150593,,,13,,N,therapeutic use
5052,Chemical,D000964,12153007,"Antimetabolites, Antineoplastic",0,,,,
5053,Chemical,D015649,12153007,Pentostatin,395575MZO7,,,,
5054,DescriptorName,D000208,12153007,,,1,Acute Disease,N,
5055,DescriptorName,D000368,12153007,,,2,Aged,N,
5056,DescriptorName,D000964,12153007,,,3,"Antimetabolites, Antineoplastic",N,
5057,QualifierName,Q000009,12153007,,,3,,Y,adverse effects
5058,DescriptorName,D017809,12153007,,,4,Fatal Outcome,N,
5059,DescriptorName,D006801,12153007,,,5,Humans,N,
5060,DescriptorName,D007943,12153007,,,6,"Leukemia, Hairy Cell",N,
5061,QualifierName,Q000150,12153007,,,6,,N,complications
5062,DescriptorName,D007951,12153007,,,7,"Leukemia, Myeloid",N,
5063,QualifierName,Q000139,12153007,,,7,,Y,chemically induced
5064,DescriptorName,D007958,12153007,,,8,Leukocyte Count,N,
5065,DescriptorName,D008297,12153007,,,9,Male,N,
5066,DescriptorName,D009190,12153007,,,10,Myelodysplastic Syndromes,N,
5067,QualifierName,Q000139,12153007,,,10,,Y,chemically induced
5068,DescriptorName,D016609,12153007,,,11,"Neoplasms, Second Primary",N,
5069,QualifierName,Q000139,12153007,,,11,,Y,chemically induced
5070,DescriptorName,D015649,12153007,,,12,Pentostatin,N,
5071,QualifierName,Q000009,12153007,,,12,,Y,adverse effects
5072,DescriptorName,D010976,12153007,,,13,Platelet Count,N,
5073,Chemical,D014662,12163813,Vasoconstrictor Agents,0,,,,
5074,Chemical,D014667,12163813,Vasopressins,11000-17-2,,,,
5075,DescriptorName,D004305,12163813,,,1,"Dose-Response Relationship, Drug",N,
5076,DescriptorName,D005119,12163813,,,2,Extravasation of Diagnostic and Therapeutic Materials,N,
5077,DescriptorName,D005260,12163813,,,3,Female,N,
5078,DescriptorName,D006801,12163813,,,4,Humans,N,
5079,DescriptorName,D007087,12163813,,,5,Illinois,N,
5080,DescriptorName,D007262,12163813,,,6,"Infusions, Intravenous",N,
5081,DescriptorName,D008875,12163813,,,7,Middle Aged,N,
5082,DescriptorName,D009336,12163813,,,8,Necrosis,N,
5083,DescriptorName,D011552,12163813,,,9,Pseudomonas Infections,N,
5084,QualifierName,Q000150,12163813,,,9,,Y,complications
5085,DescriptorName,D012772,12163813,,,10,"Shock, Septic",N,
5086,QualifierName,Q000150,12163813,,,10,,Y,complications
5087,DescriptorName,D012867,12163813,,,11,Skin,N,
5088,QualifierName,Q000187,12163813,,,11,,Y,drug effects
5089,DescriptorName,D017211,12163813,,,12,Treatment Failure,N,
5090,DescriptorName,D014662,12163813,,,13,Vasoconstrictor Agents,N,
5091,QualifierName,Q000008,12163813,,,13,,Y,administration & dosage
5092,DescriptorName,D014667,12163813,,,14,Vasopressins,N,
5093,QualifierName,Q000008,12163813,,,14,,Y,administration & dosage
5094,Chemical,D000477,12166705,Alkylating Agents,0,,,,
5095,Chemical,D000903,12166705,"Antibiotics, Antineoplastic",0,,,,
5096,Chemical,D016685,12166705,Mitomycin,50SG953SK6,,,,
5097,DescriptorName,D000230,12166705,,,1,Adenocarcinoma,N,
5098,QualifierName,Q000175,12166705,,,1,,N,diagnosis
5099,DescriptorName,D000477,12166705,,,2,Alkylating Agents,N,
5100,QualifierName,Q000009,12166705,,,2,,Y,adverse effects
5101,DescriptorName,D000903,12166705,,,3,"Antibiotics, Antineoplastic",N,
5102,QualifierName,Q000009,12166705,,,3,,Y,adverse effects
5103,DescriptorName,D003110,12166705,,,4,Colonic Neoplasms,N,
5104,QualifierName,Q000175,12166705,,,4,,N,diagnosis
5105,DescriptorName,D003937,12166705,,,5,"Diagnosis, Differential",N,
5106,DescriptorName,D005260,12166705,,,6,Female,N,
5107,DescriptorName,D006463,12166705,,,7,Hemolytic-Uremic Syndrome,N,
5108,QualifierName,Q000139,12166705,,,7,,Y,chemically induced
5109,DescriptorName,D006801,12166705,,,8,Humans,N,
5110,DescriptorName,D008875,12166705,,,9,Middle Aged,N,
5111,DescriptorName,D016685,12166705,,,10,Mitomycin,N,
5112,QualifierName,Q000009,12166705,,,10,,Y,adverse effects
5113,DescriptorName,D051437,12166705,,,11,Renal Insufficiency,N,
5114,QualifierName,Q000139,12166705,,,11,,N,chemically induced
5115,Chemical,D017338,12181031,Cladribine,47M74X9YT5,,,,
5116,DescriptorName,D000368,12181031,,,1,Aged,N,
5117,DescriptorName,D017338,12181031,,,2,Cladribine,N,
5118,QualifierName,Q000008,12181031,,,2,,N,administration & dosage
5119,DescriptorName,D005260,12181031,,,3,Female,N,
5120,DescriptorName,D006801,12181031,,,4,Humans,N,
5121,DescriptorName,D007943,12181031,,,5,"Leukemia, Hairy Cell",N,
5122,QualifierName,Q000150,12181031,,,5,,Y,complications
5123,DescriptorName,D051437,12181031,,,6,Renal Insufficiency,N,
5124,QualifierName,Q000209,12181031,,,6,,N,etiology
5125,DescriptorName,D013921,12181031,,,7,Thrombocytopenia,N,
5126,QualifierName,Q000139,12181031,,,7,,N,chemically induced
5127,DescriptorName,D016896,12181031,,,8,Treatment Outcome,N,
5128,DescriptorName,D014657,12181031,,,9,Vasculitis,N,
5129,QualifierName,Q000139,12181031,,,9,,Y,chemically induced
5130,Chemical,D000894,12187348,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
5131,Chemical,D003545,12187348,Cysteine,K848JZ4886,,,,
5132,Chemical,C026535,12187348,bucillamine,R80LRA5WTF,,,,
5133,DescriptorName,D000328,12187348,,,1,Adult,N,
5134,DescriptorName,D000894,12187348,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
5135,QualifierName,Q000009,12187348,,,2,,Y,adverse effects
5136,DescriptorName,D001172,12187348,,,3,"Arthritis, Rheumatoid",N,
5137,QualifierName,Q000188,12187348,,,3,,N,drug therapy
5138,DescriptorName,D001940,12187348,,,4,Breast,N,
5139,QualifierName,Q000473,12187348,,,4,,Y,pathology
5140,DescriptorName,D001941,12187348,,,5,Breast Diseases,N,
5141,QualifierName,Q000139,12187348,,,5,,Y,chemically induced
5142,DescriptorName,D003545,12187348,,,6,Cysteine,N,
5143,QualifierName,Q000009,12187348,,,6,,Y,adverse effects
5144,DescriptorName,D005260,12187348,,,7,Female,N,
5145,DescriptorName,D006801,12187348,,,8,Humans,N,
5146,DescriptorName,D006965,12187348,,,9,Hyperplasia,N,
5147,QualifierName,Q000139,12187348,,,9,,N,chemically induced
5148,DescriptorName,D006984,12187348,,,10,Hypertrophy,N,
5149,QualifierName,Q000139,12187348,,,10,,N,chemically induced
5150,DescriptorName,D016462,12187348,,,11,Mammaplasty,N,
5151,QualifierName,Q000379,12187348,,,11,,N,methods
5152,DescriptorName,D016896,12187348,,,12,Treatment Outcome,N,
5153,Chemical,D014635,12196666,Valproic Acid,614OI1Z5WI,,,,
5154,DescriptorName,D000014,12196666,,,1,"Abnormalities, Drug-Induced",Y,
5155,QualifierName,Q000175,12196666,,,1,,N,diagnosis
5156,DescriptorName,D000015,12196666,,,2,"Abnormalities, Multiple",N,
5157,QualifierName,Q000139,12196666,,,2,,Y,chemically induced
5158,DescriptorName,D002648,12196666,,,3,Child,N,
5159,DescriptorName,D002675,12196666,,,4,"Child, Preschool",N,
5160,DescriptorName,D002658,12196666,,,5,Developmental Disabilities,N,
5161,QualifierName,Q000139,12196666,,,5,,Y,chemically induced
5162,DescriptorName,D004827,12196666,,,6,Epilepsy,N,
5163,QualifierName,Q000188,12196666,,,6,,N,drug therapy
5164,DescriptorName,D005145,12196666,,,7,Face,N,
5165,QualifierName,Q000002,12196666,,,7,,Y,abnormalities
5166,DescriptorName,D005260,12196666,,,8,Female,N,
5167,DescriptorName,D020022,12196666,,,9,Genetic Predisposition to Disease,Y,
5168,DescriptorName,D006801,12196666,,,10,Humans,N,
5169,DescriptorName,D007223,12196666,,,11,Infant,N,
5170,DescriptorName,D007231,12196666,,,12,"Infant, Newborn",N,
5171,DescriptorName,D008297,12196666,,,13,Male,N,
5172,DescriptorName,D008431,12196666,,,14,Maternal-Fetal Exchange,N,
5173,DescriptorName,D011247,12196666,,,15,Pregnancy,N,
5174,DescriptorName,D011248,12196666,,,16,Pregnancy Complications,N,
5175,QualifierName,Q000188,12196666,,,16,,N,drug therapy
5176,DescriptorName,D013577,12196666,,,17,Syndrome,N,
5177,DescriptorName,D014635,12196666,,,18,Valproic Acid,N,
5178,QualifierName,Q000009,12196666,,,18,,Y,adverse effects
5179,Chemical,D018501,12218252,Antirheumatic Agents,0,,,,
5180,Chemical,D007074,12218252,Immunoglobulin G,0,,,,
5181,Chemical,D007166,12218252,Immunosuppressive Agents,0,,,,
5182,Chemical,D018124,12218252,"Receptors, Tumor Necrosis Factor",0,,,,
5183,Chemical,D014409,12218252,Tumor Necrosis Factor-alpha,0,,,,
5184,Chemical,D016572,12218252,Cyclosporine,83HN0GTJ6D,,,,
5185,Chemical,D000068800,12218252,Etanercept,OP401G7OJC,,,,
5186,DescriptorName,D018501,12218252,,,1,Antirheumatic Agents,N,
5187,QualifierName,Q000009,12218252,,,1,,Y,adverse effects
5188,DescriptorName,D015535,12218252,,,2,"Arthritis, Psoriatic",N,
5189,QualifierName,Q000188,12218252,,,2,,N,drug therapy
5190,DescriptorName,D016572,12218252,,,3,Cyclosporine,N,
5191,QualifierName,Q000009,12218252,,,3,,Y,adverse effects
5192,DescriptorName,D000068800,12218252,,,4,Etanercept,N,
5193,DescriptorName,D006801,12218252,,,5,Humans,N,
5194,DescriptorName,D007074,12218252,,,6,Immunoglobulin G,N,
5195,QualifierName,Q000627,12218252,,,6,,Y,therapeutic use
5196,DescriptorName,D007166,12218252,,,7,Immunosuppressive Agents,N,
5197,QualifierName,Q000009,12218252,,,7,,Y,adverse effects
5198,DescriptorName,D008297,12218252,,,8,Male,N,
5199,DescriptorName,D008875,12218252,,,9,Middle Aged,N,
5200,DescriptorName,D011565,12218252,,,10,Psoriasis,N,
5201,QualifierName,Q000188,12218252,,,10,,Y,drug therapy
5202,DescriptorName,D018124,12218252,,,11,"Receptors, Tumor Necrosis Factor",N,
5203,QualifierName,Q000627,12218252,,,11,,Y,therapeutic use
5204,DescriptorName,D014409,12218252,,,12,Tumor Necrosis Factor-alpha,N,
5205,QualifierName,Q000037,12218252,,,12,,Y,antagonists & inhibitors
5206,Chemical,D000900,12221670,Anti-Bacterial Agents,0,,,,
5207,Chemical,D010975,12221670,Platelet Aggregation Inhibitors,0,,,,
5208,Chemical,D016179,12221670,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
5209,Chemical,D013988,12221670,Ticlopidine,OM90ZUW7M1,,,,
5210,DescriptorName,D017677,12221670,,,1,Age Distribution,N,
5211,DescriptorName,D000368,12221670,,,2,Aged,N,
5212,DescriptorName,D000369,12221670,,,3,"Aged, 80 and over",N,
5213,DescriptorName,D000380,12221670,,,4,Agranulocytosis,N,
5214,QualifierName,Q000139,12221670,,,4,,N,chemically induced
5215,DescriptorName,D000741,12221670,,,5,"Anemia, Aplastic",N,
5216,QualifierName,Q000139,12221670,,,5,,Y,chemically induced
5217,DescriptorName,D000900,12221670,,,6,Anti-Bacterial Agents,N,
5218,DescriptorName,D001803,12221670,,,7,Blood Transfusion,N,
5219,DescriptorName,D001853,12221670,,,8,Bone Marrow,N,
5220,QualifierName,Q000473,12221670,,,8,,N,pathology
5221,DescriptorName,D003924,12221670,,,9,"Diabetes Mellitus, Type 2",N,
5222,QualifierName,Q000150,12221670,,,9,,N,complications
5223,DescriptorName,D003951,12221670,,,10,Diagnostic Errors,N,
5224,DescriptorName,D004359,12221670,,,11,"Drug Therapy, Combination",N,
5225,QualifierName,Q000627,12221670,,,11,,N,therapeutic use
5226,DescriptorName,D016179,12221670,,,12,Granulocyte Colony-Stimulating Factor,N,
5227,QualifierName,Q000627,12221670,,,12,,N,therapeutic use
5228,DescriptorName,D006412,12221670,,,13,Hematopoietic Stem Cells,N,
5229,QualifierName,Q000187,12221670,,,13,,N,drug effects
5230,DescriptorName,D006801,12221670,,,14,Humans,N,
5231,DescriptorName,D008297,12221670,,,15,Male,N,
5232,DescriptorName,D016491,12221670,,,16,Peripheral Vascular Diseases,N,
5233,QualifierName,Q000150,12221670,,,16,,N,complications
5234,DescriptorName,D010975,12221670,,,17,Platelet Aggregation Inhibitors,N,
5235,QualifierName,Q000009,12221670,,,17,,Y,adverse effects
5236,DescriptorName,D018805,12221670,,,18,Sepsis,N,
5237,QualifierName,Q000188,12221670,,,18,,N,drug therapy
5238,DescriptorName,D017678,12221670,,,19,Sex Distribution,N,
5239,DescriptorName,D013921,12221670,,,20,Thrombocytopenia,N,
5240,QualifierName,Q000139,12221670,,,20,,N,chemically induced
5241,DescriptorName,D013988,12221670,,,21,Ticlopidine,N,
5242,QualifierName,Q000009,12221670,,,21,,Y,adverse effects
5243,Chemical,D000894,12234159,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
5244,Chemical,D007783,12234159,Lactones,0,,,,
5245,Chemical,D013450,12234159,Sulfones,0,,,,
5246,Chemical,C116926,12234159,rofecoxib,0QTW8Z7MCR,,,,
5247,DescriptorName,D000328,12234159,,,1,Adult,N,
5248,DescriptorName,D000894,12234159,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
5249,QualifierName,Q000009,12234159,,,2,,Y,adverse effects
5250,DescriptorName,D003875,12234159,,,3,Drug Eruptions,N,
5251,QualifierName,Q000209,12234159,,,3,,Y,etiology
5252,DescriptorName,D004412,12234159,,,4,Dysmenorrhea,N,
5253,QualifierName,Q000150,12234159,,,4,,N,complications
5254,DescriptorName,D004890,12234159,,,5,Erythema,N,
5255,QualifierName,Q000139,12234159,,,5,,N,chemically induced
5256,DescriptorName,D005260,12234159,,,6,Female,N,
5257,DescriptorName,D006801,12234159,,,7,Humans,N,
5258,DescriptorName,D007783,12234159,,,8,Lactones,N,
5259,QualifierName,Q000009,12234159,,,8,,Y,adverse effects
5260,DescriptorName,D013450,12234159,,,9,Sulfones,N,
5261,Chemical,D014284,122410,Triiodothyronine,06LU7C9H1V,,,,
5262,Chemical,D013973,122410,Thyrotropin-Releasing Hormone,5Y5F15120W,,,,
5263,Chemical,D013972,122410,Thyrotropin,9002-71-5,,,,
5264,Chemical,D013974,122410,Thyroxine,Q51BO43MG4,,,,
5265,DescriptorName,D000293,122410,,,1,Adolescent,N,
5266,DescriptorName,D005260,122410,,,2,Female,N,
5267,DescriptorName,D006801,122410,,,3,Humans,N,
5268,DescriptorName,D007037,122410,,,4,Hypothyroidism,N,
5269,QualifierName,Q000188,122410,,,4,,Y,drug therapy
5270,DescriptorName,D007700,122410,,,5,Kinetics,N,
5271,DescriptorName,D013972,122410,,,6,Thyrotropin,N,
5272,QualifierName,Q000097,122410,,,6,,N,blood
5273,DescriptorName,D013973,122410,,,7,Thyrotropin-Releasing Hormone,N,
5274,QualifierName,Q000172,122410,,,7,,Y,deficiency
5275,DescriptorName,D013974,122410,,,8,Thyroxine,N,
5276,QualifierName,Q000009,122410,,,8,,Y,adverse effects
5277,DescriptorName,D014284,122410,,,9,Triiodothyronine,N,
5278,QualifierName,Q000627,122410,,,9,,Y,therapeutic use
5279,Chemical,D000964,12324937,"Antimetabolites, Antineoplastic",0,,,,
5280,Chemical,D003841,12324937,Deoxycytidine,0W860991D6,,,,
5281,Chemical,C056507,12324937,gemcitabine,B76N6SBZ8R,,,,
5282,Chemical,D012264,12324937,Ribonucleotide Reductases,EC 1.17.4.-,,,,
5283,DescriptorName,D000964,12324937,,,1,"Antimetabolites, Antineoplastic",N,
5284,QualifierName,Q000009,12324937,,,1,,N,adverse effects
5285,DescriptorName,D003841,12324937,,,2,Deoxycytidine,N,
5286,QualifierName,Q000009,12324937,,,2,,Y,adverse effects
5287,DescriptorName,D005260,12324937,,,3,Female,N,
5288,DescriptorName,D006463,12324937,,,4,Hemolytic-Uremic Syndrome,N,
5289,QualifierName,Q000139,12324937,,,4,,Y,chemically induced
5290,DescriptorName,D006801,12324937,,,5,Humans,N,
5291,DescriptorName,D008297,12324937,,,6,Male,N,
5292,DescriptorName,D008875,12324937,,,7,Middle Aged,N,
5293,DescriptorName,D010051,12324937,,,8,Ovarian Neoplasms,N,
5294,QualifierName,Q000188,12324937,,,8,,Y,drug therapy
5295,DescriptorName,D012264,12324937,,,9,Ribonucleotide Reductases,N,
5296,QualifierName,Q000037,12324937,,,9,,N,antagonists & inhibitors
5297,Chemical,D000889,12365708,Anti-Arrhythmia Agents,0,,,,
5298,Chemical,D000638,12365708,Amiodarone,N3RQ532IUT,,,,
5299,DescriptorName,D000368,12365708,,,1,Aged,N,
5300,DescriptorName,D000638,12365708,,,2,Amiodarone,N,
5301,QualifierName,Q000009,12365708,,,2,,Y,adverse effects
5302,DescriptorName,D000889,12365708,,,3,Anti-Arrhythmia Agents,N,
5303,QualifierName,Q000009,12365708,,,3,,Y,adverse effects
5304,DescriptorName,D001145,12365708,,,4,"Arrhythmias, Cardiac",N,
5305,QualifierName,Q000188,12365708,,,4,,N,drug therapy
5306,DescriptorName,D006801,12365708,,,5,Humans,N,
5307,DescriptorName,D008297,12365708,,,6,Male,N,
5308,DescriptorName,D019338,12365708,,,7,Polypharmacy,N,
5309,DescriptorName,D014786,12365708,,,8,Vision Disorders,N,
5310,QualifierName,Q000139,12365708,,,8,,Y,chemically induced
5311,DescriptorName,D014792,12365708,,,9,Visual Acuity,N,
5312,QualifierName,Q000187,12365708,,,9,,N,drug effects
5313,Chemical,D001548,1238016,Benzalkonium Compounds,0,,,,
5314,DescriptorName,D001548,1238016,,,1,Benzalkonium Compounds,N,
5315,QualifierName,Q000008,1238016,,,1,,N,administration & dosage
5316,DescriptorName,D002057,1238016,,,2,"Burns, Chemical",N,
5317,QualifierName,Q000209,1238016,,,2,,Y,etiology
5318,DescriptorName,D002180,1238016,,,3,"Candidiasis, Oral",N,
5319,QualifierName,Q000188,1238016,,,3,,N,drug therapy
5320,DescriptorName,D004200,1238016,,,4,Diseases in Twins,Y,
5321,DescriptorName,D005260,1238016,,,5,Female,N,
5322,DescriptorName,D006801,1238016,,,6,Humans,N,
5323,DescriptorName,D007223,1238016,,,7,Infant,N,
5324,DescriptorName,D008297,1238016,,,8,Male,N,
5325,DescriptorName,D008508,1238016,,,9,Medication Errors,N,
5326,DescriptorName,D011247,1238016,,,10,Pregnancy,N,
5327,DescriptorName,D014429,1238016,,,11,"Twins, Dizygotic",N,
5328,Chemical,D000904,12390172,"Antibiotics, Antitubercular",0,,,,
5329,Chemical,D017828,12390172,Rifabutin,1W306TDA6S,,,,
5330,DescriptorName,D000869,12390172,,,1,Anterior Eye Segment,N,
5331,QualifierName,Q000187,12390172,,,1,,Y,drug effects
5332,DescriptorName,D000904,12390172,,,2,"Antibiotics, Antitubercular",N,
5333,QualifierName,Q000009,12390172,,,2,,Y,adverse effects
5334,DescriptorName,D002648,12390172,,,3,Child,N,
5335,DescriptorName,D004596,12390172,,,4,Electroretinography,N,
5336,DescriptorName,D006801,12390172,,,5,Humans,N,
5337,DescriptorName,D008297,12390172,,,6,Male,N,
5338,DescriptorName,D010019,12390172,,,7,Osteomyelitis,N,
5339,QualifierName,Q000150,12390172,,,7,,N,complications
5340,DescriptorName,D012160,12390172,,,8,Retina,N,
5341,QualifierName,Q000187,12390172,,,8,,Y,drug effects
5342,DescriptorName,D012164,12390172,,,9,Retinal Diseases,N,
5343,QualifierName,Q000139,12390172,,,9,,Y,chemically induced
5344,DescriptorName,D017828,12390172,,,10,Rifabutin,N,
5345,QualifierName,Q000009,12390172,,,10,,Y,adverse effects
5346,DescriptorName,D014792,12390172,,,11,Visual Acuity,N,
5347,DescriptorName,D014794,12390172,,,12,Visual Fields,N,
5348,Chemical,D014151,12397859,Anti-Anxiety Agents,0,,,,
5349,Chemical,D018687,12397859,"Antidepressive Agents, Second-Generation",0,,,,
5350,Chemical,D003511,12397859,Cyclohexanols,0,,,,
5351,Chemical,D010879,12397859,Piperazines,0,,,,
5352,Chemical,D014230,12397859,Triazoles,0,,,,
5353,Chemical,C051752,12397859,nefazodone,59H4FCV1TF,,,,
5354,Chemical,D000069470,12397859,Venlafaxine Hydrochloride,7D7RX5A8MO,,,,
5355,Chemical,D000525,12397859,Alprazolam,YU55MQ3IZY,,,,
5356,DescriptorName,D000525,12397859,,,1,Alprazolam,N,
5357,QualifierName,Q000009,12397859,,,1,,Y,adverse effects
5358,DescriptorName,D014151,12397859,,,2,Anti-Anxiety Agents,N,
5359,QualifierName,Q000009,12397859,,,2,,Y,adverse effects
5360,DescriptorName,D018687,12397859,,,3,"Antidepressive Agents, Second-Generation",N,
5361,QualifierName,Q000009,12397859,,,3,,Y,adverse effects
5362,DescriptorName,D003511,12397859,,,4,Cyclohexanols,N,
5363,QualifierName,Q000627,12397859,,,4,,N,therapeutic use
5364,DescriptorName,D004347,12397859,,,5,Drug Interactions,N,
5365,DescriptorName,D005260,12397859,,,6,Female,N,
5366,DescriptorName,D006801,12397859,,,7,Humans,N,
5367,DescriptorName,D008875,12397859,,,8,Middle Aged,N,
5368,DescriptorName,D016584,12397859,,,9,Panic Disorder,N,
5369,QualifierName,Q000188,12397859,,,9,,N,drug therapy
5370,DescriptorName,D010879,12397859,,,10,Piperazines,N,
5371,DescriptorName,D013375,12397859,,,11,Substance Withdrawal Syndrome,N,
5372,QualifierName,Q000503,12397859,,,11,,N,physiopathology
5373,DescriptorName,D014230,12397859,,,12,Triazoles,N,
5374,QualifierName,Q000009,12397859,,,12,,Y,adverse effects
5375,DescriptorName,D000069470,12397859,,,13,Venlafaxine Hydrochloride,N,
5376,Chemical,C438657,12399645,"AVP protein, human",0,,,,
5377,Chemical,D000894,12399645,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
5378,Chemical,D009481,12399645,Neurophysins,0,,,,
5379,Chemical,D011498,12399645,Protein Precursors,0,,,,
5380,Chemical,D012263,12399645,Ribonucleosides,0,,,,
5381,Chemical,D014667,12399645,Vasopressins,11000-17-2,,,,
5382,Chemical,C010052,12399645,mizoribine,4JR41A10VP,,,,
5383,Chemical,D012964,12399645,Sodium,9NEZ333N27,,,,
5384,DescriptorName,D000368,12399645,,,1,Aged,N,
5385,DescriptorName,D000894,12399645,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
5386,QualifierName,Q000009,12399645,,,2,,Y,adverse effects
5387,DescriptorName,D001172,12399645,,,3,"Arthritis, Rheumatoid",N,
5388,QualifierName,Q000188,12399645,,,3,,N,drug therapy
5389,DescriptorName,D004326,12399645,,,4,Drinking,N,
5390,DescriptorName,D006801,12399645,,,5,Humans,N,
5391,DescriptorName,D007177,12399645,,,6,Inappropriate ADH Syndrome,N,
5392,QualifierName,Q000139,12399645,,,6,,Y,chemically induced
5393,DescriptorName,D008297,12399645,,,7,Male,N,
5394,DescriptorName,D009481,12399645,,,8,Neurophysins,N,
5395,QualifierName,Q000378,12399645,,,8,,N,metabolism
5396,DescriptorName,D009994,12399645,,,9,Osmolar Concentration,N,
5397,DescriptorName,D011498,12399645,,,10,Protein Precursors,N,
5398,QualifierName,Q000378,12399645,,,10,,N,metabolism
5399,DescriptorName,D012263,12399645,,,11,Ribonucleosides,N,
5400,QualifierName,Q000009,12399645,,,11,,Y,adverse effects
5401,DescriptorName,D012964,12399645,,,12,Sodium,N,
5402,QualifierName,Q000097,12399645,,,12,,N,blood
5403,DescriptorName,D014667,12399645,,,13,Vasopressins,N,
5404,QualifierName,Q000378,12399645,,,13,,N,metabolism
5405,Chemical,D007166,12405893,Immunosuppressive Agents,0,,,,
5406,Chemical,D016572,12405893,Cyclosporine,83HN0GTJ6D,,,,
5407,Chemical,D008727,12405893,Methotrexate,YL5FZ2Y5U1,,,,
5408,DescriptorName,D001172,12405893,,,1,"Arthritis, Rheumatoid",N,
5409,QualifierName,Q000150,12405893,,,1,,N,complications
5410,DescriptorName,D002081,12405893,,,2,Buttocks,N,
5411,DescriptorName,D016572,12405893,,,3,Cyclosporine,N,
5412,QualifierName,Q000008,12405893,,,3,,Y,administration & dosage
5413,DescriptorName,D004359,12405893,,,4,"Drug Therapy, Combination",N,
5414,DescriptorName,D006801,12405893,,,5,Humans,N,
5415,DescriptorName,D007166,12405893,,,6,Immunosuppressive Agents,N,
5416,QualifierName,Q000008,12405893,,,6,,Y,administration & dosage
5417,DescriptorName,D016393,12405893,,,7,"Lymphoma, B-Cell",N,
5418,QualifierName,Q000150,12405893,,,7,,N,complications
5419,DescriptorName,D016403,12405893,,,8,"Lymphoma, Large B-Cell, Diffuse",N,
5420,QualifierName,Q000150,12405893,,,8,,N,complications
5421,DescriptorName,D008297,12405893,,,9,Male,N,
5422,DescriptorName,D008727,12405893,,,10,Methotrexate,N,
5423,QualifierName,Q000008,12405893,,,10,,Y,administration & dosage
5424,DescriptorName,D008875,12405893,,,11,Middle Aged,N,
5425,DescriptorName,D019042,12405893,,,12,Muscle Neoplasms,N,
5426,QualifierName,Q000150,12405893,,,12,,N,complications
5427,DescriptorName,D018482,12405893,,,13,"Muscle, Skeletal",N,
5428,QualifierName,Q000473,12405893,,,13,,N,pathology
5429,DescriptorName,D012075,12405893,,,14,"Remission, Spontaneous",N,
5430,Chemical,D007370,12424571,Interferon Type I,0,,,,
5431,Chemical,D011994,12424571,Recombinant Proteins,0,,,,
5432,DescriptorName,D000208,12424571,,,1,Acute Disease,N,
5433,DescriptorName,D005260,12424571,,,2,Female,N,
5434,DescriptorName,D019698,12424571,,,3,"Hepatitis C, Chronic",N,
5435,QualifierName,Q000188,12424571,,,3,,Y,drug therapy
5436,DescriptorName,D006801,12424571,,,4,Humans,N,
5437,DescriptorName,D007370,12424571,,,5,Interferon Type I,N,
5438,QualifierName,Q000009,12424571,,,5,,Y,adverse effects
5439,DescriptorName,D008875,12424571,,,6,Middle Aged,N,
5440,DescriptorName,D009404,12424571,,,7,Nephrotic Syndrome,N,
5441,QualifierName,Q000139,12424571,,,7,,Y,chemically induced
5442,DescriptorName,D011994,12424571,,,8,Recombinant Proteins,N,
5443,DescriptorName,D019233,12424571,,,9,Retreatment,N,
5444,Chemical,D016899,12432978,Interferon-beta,77238-31-4,,,,
5445,Chemical,D002997,12432978,Clomipramine,NUV44L116D,,,,
5446,Chemical,D000068556,12432978,Interferon beta-1a,XRO4566Q4R,,,,
5447,DescriptorName,D000328,12432978,,,1,Adult,N,
5448,DescriptorName,D020817,12432978,,,2,Asperger Syndrome,N,
5449,QualifierName,Q000188,12432978,,,2,,Y,drug therapy
5450,DescriptorName,D001480,12432978,,,3,Basal Ganglia Diseases,N,
5451,QualifierName,Q000139,12432978,,,3,,N,chemically induced
5452,DescriptorName,D002997,12432978,,,4,Clomipramine,N,
5453,QualifierName,Q000009,12432978,,,4,,Y,adverse effects
5454,DescriptorName,D006801,12432978,,,5,Humans,N,
5455,DescriptorName,D000068556,12432978,,,6,Interferon beta-1a,N,
5456,DescriptorName,D016899,12432978,,,7,Interferon-beta,N,
5457,QualifierName,Q000009,12432978,,,7,,Y,adverse effects
5458,DescriptorName,D008297,12432978,,,8,Male,N,
5459,DescriptorName,D009103,12432978,,,9,Multiple Sclerosis,N,
5460,QualifierName,Q000150,12432978,,,9,,N,complications
5461,DescriptorName,D012640,12432978,,,10,Seizures,N,
5462,QualifierName,Q000139,12432978,,,10,,Y,chemically induced
5463,DescriptorName,D005879,12432978,,,11,Tourette Syndrome,N,
5464,QualifierName,Q000188,12432978,,,11,,Y,drug therapy
5465,Chemical,D003520,12439602,Cyclophosphamide,8N3DW7272P,,,,
5466,Chemical,D016190,12439602,Carboplatin,BG3F62OND5,,,,
5467,DescriptorName,D000368,12439602,,,1,Aged,N,
5468,DescriptorName,D000971,12439602,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
5469,QualifierName,Q000008,12439602,,,2,,N,administration & dosage
5470,DescriptorName,D001024,12439602,,,3,Aortic Valve Stenosis,N,
5471,QualifierName,Q000150,12439602,,,3,,N,complications
5472,DescriptorName,D002114,12439602,,,4,Calcinosis,N,
5473,QualifierName,Q000150,12439602,,,4,,N,complications
5474,DescriptorName,D016190,12439602,,,5,Carboplatin,N,
5475,QualifierName,Q000008,12439602,,,5,,N,administration & dosage
5476,DescriptorName,D003329,12439602,,,6,Coronary Vasospasm,N,
5477,QualifierName,Q000139,12439602,,,6,,Y,chemically induced
5478,DescriptorName,D003520,12439602,,,7,Cyclophosphamide,N,
5479,QualifierName,Q000008,12439602,,,7,,N,administration & dosage
5480,DescriptorName,D004342,12439602,,,8,Drug Hypersensitivity,N,
5481,QualifierName,Q000209,12439602,,,8,,Y,etiology
5482,DescriptorName,D004569,12439602,,,9,Electroencephalography,N,
5483,DescriptorName,D005260,12439602,,,10,Female,N,
5484,DescriptorName,D006801,12439602,,,11,Humans,N,
5485,DescriptorName,D007262,12439602,,,12,"Infusions, Intravenous",N,
5486,DescriptorName,D010051,12439602,,,13,Ovarian Neoplasms,N,
5487,QualifierName,Q000188,12439602,,,13,,N,drug therapy
5488,DescriptorName,D016066,12439602,,,14,"Pleural Effusion, Malignant",N,
5489,QualifierName,Q000150,12439602,,,14,,N,complications
5490,Chemical,D013830,1244265,Thiadiazoles,0,,,,
5491,Chemical,D008704,1244265,Methazolamide,W733B0S9SD,,,,
5492,DescriptorName,D000142,1244265,,,1,"Acidosis, Respiratory",N,
5493,QualifierName,Q000139,1244265,,,1,,N,chemically induced
5494,DescriptorName,D001991,1244265,,,2,Bronchitis,N,
5495,QualifierName,Q000188,1244265,,,2,,N,drug therapy
5496,DescriptorName,D002908,1244265,,,3,Chronic Disease,N,
5497,DescriptorName,D006801,1244265,,,4,Humans,N,
5498,DescriptorName,D008297,1244265,,,5,Male,N,
5499,DescriptorName,D008704,1244265,,,6,Methazolamide,N,
5500,QualifierName,Q000009,1244265,,,6,,Y,adverse effects
5501,DescriptorName,D008875,1244265,,,7,Middle Aged,N,
5502,DescriptorName,D012131,1244265,,,8,Respiratory Insufficiency,N,
5503,QualifierName,Q000139,1244265,,,8,,Y,chemically induced
5504,DescriptorName,D013830,1244265,,,9,Thiadiazoles,N,
5505,QualifierName,Q000009,1244265,,,9,,Y,adverse effects
5506,Chemical,D000970,12452753,Antineoplastic Agents,0,,,,
5507,Chemical,D003841,12452753,Deoxycytidine,0W860991D6,,,,
5508,Chemical,D000069287,12452753,Capecitabine,6804DJ8Z9U,,,,
5509,Chemical,D005472,12452753,Fluorouracil,U3P01618RT,,,,
5510,DescriptorName,D000328,12452753,,,1,Adult,N,
5511,DescriptorName,D000970,12452753,,,2,Antineoplastic Agents,N,
5512,QualifierName,Q000008,12452753,,,2,,N,administration & dosage
5513,DescriptorName,D001943,12452753,,,3,Breast Neoplasms,N,
5514,QualifierName,Q000188,12452753,,,3,,Y,drug therapy
5515,DescriptorName,D000069287,12452753,,,4,Capecitabine,N,
5516,DescriptorName,D003841,12452753,,,5,Deoxycytidine,N,
5517,QualifierName,Q000009,12452753,,,5,,Y,adverse effects
5518,DescriptorName,D004342,12452753,,,6,Drug Hypersensitivity,Y,
5519,DescriptorName,D005260,12452753,,,7,Female,N,
5520,DescriptorName,D005472,12452753,,,8,Fluorouracil,N,
5521,QualifierName,Q000008,12452753,,,8,,N,administration & dosage
5522,DescriptorName,D006801,12452753,,,9,Humans,N,
5523,DescriptorName,D016879,12452753,,,10,Salvage Therapy,N,
5524,QualifierName,Q000009,12452753,,,10,,N,adverse effects
5525,Chemical,D005938,12455453,Glucocorticoids,0,,,,
5526,Chemical,D008775,12455453,Methylprednisolone,X4W7ZR7023,,,,
5527,DescriptorName,D000293,12455453,,,1,Adolescent,N,
5528,DescriptorName,D003424,12455453,,,2,Crohn Disease,N,
5529,QualifierName,Q000188,12455453,,,2,,Y,drug therapy
5530,DescriptorName,D003920,12455453,,,3,Diabetes Mellitus,N,
5531,QualifierName,Q000139,12455453,,,3,,Y,chemically induced
5532,DescriptorName,D005938,12455453,,,4,Glucocorticoids,N,
5533,QualifierName,Q000009,12455453,,,4,,Y,adverse effects
5534,DescriptorName,D006801,12455453,,,5,Humans,N,
5535,DescriptorName,D008297,12455453,,,6,Male,N,
5536,DescriptorName,D008775,12455453,,,7,Methylprednisolone,N,
5537,QualifierName,Q000009,12455453,,,7,,Y,adverse effects
5538,Chemical,D003561,12460237,Cytarabine,04079A1RDZ,,,,
5539,DescriptorName,D000328,12460237,,,1,Adult,N,
5540,DescriptorName,D000075202,12460237,,,2,Contraindications,N,
5541,DescriptorName,D003561,12460237,,,3,Cytarabine,N,
5542,QualifierName,Q000008,12460237,,,3,,N,administration & dosage
5543,DescriptorName,D003875,12460237,,,4,Drug Eruptions,N,
5544,QualifierName,Q000209,12460237,,,4,,N,etiology
5545,DescriptorName,D004890,12460237,,,5,Erythema,N,
5546,QualifierName,Q000139,12460237,,,5,,N,chemically induced
5547,DescriptorName,D005533,12460237,,,6,Foot Dermatoses,N,
5548,QualifierName,Q000139,12460237,,,6,,N,chemically induced
5549,DescriptorName,D006229,12460237,,,7,Hand Dermatoses,N,
5550,QualifierName,Q000139,12460237,,,7,,N,chemically induced
5551,DescriptorName,D006801,12460237,,,8,Humans,N,
5552,DescriptorName,D008297,12460237,,,9,Male,N,
5553,DescriptorName,D010292,12460237,,,10,Paresthesia,N,
5554,QualifierName,Q000139,12460237,,,10,,Y,chemically induced
5555,DescriptorName,D054198,12460237,,,11,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
5556,QualifierName,Q000150,12460237,,,11,,N,complications
5557,DescriptorName,D012008,12460237,,,12,Recurrence,N,
5558,DescriptorName,D012871,12460237,,,13,Skin Diseases,N,
5559,QualifierName,Q000139,12460237,,,13,,Y,chemically induced
5560,Chemical,D018931,12477460,"Antineoplastic Agents, Hormonal",0,,,,
5561,Chemical,D013629,12477460,Tamoxifen,094ZI81Y45,,,,
5562,DescriptorName,D000368,12477460,,,1,Aged,N,
5563,DescriptorName,D018931,12477460,,,2,"Antineoplastic Agents, Hormonal",N,
5564,QualifierName,Q000009,12477460,,,2,,Y,adverse effects
5565,DescriptorName,D001943,12477460,,,3,Breast Neoplasms,N,
5566,QualifierName,Q000188,12477460,,,3,,Y,drug therapy
5567,DescriptorName,D018269,12477460,,,4,"Carcinoma, Endometrioid",N,
5568,QualifierName,Q000139,12477460,,,4,,N,chemically induced
5569,DescriptorName,D002471,12477460,,,5,"Cell Transformation, Neoplastic",N,
5570,QualifierName,Q000187,12477460,,,5,,N,drug effects
5571,DescriptorName,D004715,12477460,,,6,Endometriosis,N,
5572,QualifierName,Q000150,12477460,,,6,,N,complications
5573,DescriptorName,D005260,12477460,,,7,Female,N,
5574,DescriptorName,D006801,12477460,,,8,Humans,N,
5575,DescriptorName,D016609,12477460,,,9,"Neoplasms, Second Primary",N,
5576,QualifierName,Q000139,12477460,,,9,,N,chemically induced
5577,DescriptorName,D010048,12477460,,,10,Ovarian Cysts,N,
5578,QualifierName,Q000150,12477460,,,10,,Y,complications
5579,DescriptorName,D010051,12477460,,,11,Ovarian Neoplasms,N,
5580,QualifierName,Q000139,12477460,,,11,,N,chemically induced
5581,DescriptorName,D013629,12477460,,,12,Tamoxifen,N,
5582,QualifierName,Q000009,12477460,,,12,,Y,adverse effects
5583,Chemical,D000890,12488741,Anti-Infective Agents,0,,,,
5584,Chemical,D008795,12488741,Metronidazole,140QMO216E,,,,
5585,Chemical,D019344,12488741,Lactic Acid,33X04XA5AT,,,,
5586,DescriptorName,D000293,12488741,,,1,Adolescent,N,
5587,DescriptorName,D000890,12488741,,,2,Anti-Infective Agents,N,
5588,QualifierName,Q000009,12488741,,,2,,Y,adverse effects
5589,DescriptorName,D001479,12488741,,,3,Basal Ganglia,N,
5590,QualifierName,Q000473,12488741,,,3,,Y,pathology
5591,DescriptorName,D001923,12488741,,,4,Brain Chemistry,N,
5592,DescriptorName,D001933,12488741,,,5,Brain Stem,N,
5593,QualifierName,Q000473,12488741,,,5,,Y,pathology
5594,DescriptorName,D003337,12488741,,,6,Corpus Callosum,N,
5595,QualifierName,Q000473,12488741,,,6,,Y,pathology
5596,DescriptorName,D003424,12488741,,,7,Crohn Disease,N,
5597,QualifierName,Q000188,12488741,,,7,,Y,drug therapy
5598,DescriptorName,D004314,12488741,,,8,Down Syndrome,N,
5599,DescriptorName,D006801,12488741,,,9,Humans,N,
5600,DescriptorName,D019344,12488741,,,10,Lactic Acid,N,
5601,QualifierName,Q000032,12488741,,,10,,Y,analysis
5602,DescriptorName,D008279,12488741,,,11,Magnetic Resonance Imaging,N,
5603,DescriptorName,D009682,12488741,,,12,Magnetic Resonance Spectroscopy,N,
5604,DescriptorName,D008297,12488741,,,13,Male,N,
5605,DescriptorName,D008795,12488741,,,14,Metronidazole,N,
5606,QualifierName,Q000009,12488741,,,14,,Y,adverse effects
5607,Chemical,D000970,12494253,Antineoplastic Agents,0,,,,
5608,Chemical,D002945,12494253,Cisplatin,Q20Q21Q62J,,,,
5609,DescriptorName,D000707,12494253,,,1,Anaphylaxis,N,
5610,QualifierName,Q000139,12494253,,,1,,Y,chemically induced
5611,DescriptorName,D000970,12494253,,,2,Antineoplastic Agents,N,
5612,QualifierName,Q000009,12494253,,,2,,Y,adverse effects
5613,DescriptorName,D002294,12494253,,,3,"Carcinoma, Squamous Cell",N,
5614,QualifierName,Q000188,12494253,,,3,,N,drug therapy
5615,DescriptorName,D002945,12494253,,,4,Cisplatin,N,
5616,QualifierName,Q000009,12494253,,,4,,Y,adverse effects
5617,DescriptorName,D003131,12494253,,,5,Combined Modality Therapy,N,
5618,DescriptorName,D005260,12494253,,,6,Female,N,
5619,DescriptorName,D006801,12494253,,,7,Humans,N,
5620,DescriptorName,D008875,12494253,,,8,Middle Aged,N,
5621,DescriptorName,D002583,12494253,,,9,Uterine Cervical Neoplasms,N,
5622,QualifierName,Q000188,12494253,,,9,,N,drug therapy
5623,Chemical,D000900,12503933,Anti-Bacterial Agents,0,,,,
5624,Chemical,D017291,12503933,Clarithromycin,H1250JIK0A,,,,
5625,DescriptorName,D000900,12503933,,,1,Anti-Bacterial Agents,N,
5626,QualifierName,Q000009,12503933,,,1,,Y,adverse effects
5627,DescriptorName,D017291,12503933,,,2,Clarithromycin,N,
5628,QualifierName,Q000009,12503933,,,2,,Y,adverse effects
5629,DescriptorName,D005260,12503933,,,3,Female,N,
5630,DescriptorName,D006801,12503933,,,4,Humans,N,
5631,DescriptorName,D017093,12503933,,,5,Liver Failure,N,
5632,QualifierName,Q000139,12503933,,,5,,Y,chemically induced
5633,DescriptorName,D008111,12503933,,,6,Liver Function Tests,N,
5634,DescriptorName,D008875,12503933,,,7,Middle Aged,N,
5635,DescriptorName,D011014,12503933,,,8,Pneumonia,N,
5636,QualifierName,Q000188,12503933,,,8,,N,drug therapy
5637,Chemical,D000316,12504711,Adrenergic alpha-Agonists,0,,,,
5638,Chemical,D011810,12504711,Quinoxalines,0,,,,
5639,Chemical,D000068438,12504711,Brimonidine Tartrate,4S9CL2DY2H,,,,
5640,DescriptorName,D000316,12504711,,,1,Adrenergic alpha-Agonists,N,
5641,QualifierName,Q000009,12504711,,,1,,Y,adverse effects
5642,DescriptorName,D000368,12504711,,,2,Aged,N,
5643,DescriptorName,D000068438,12504711,,,3,Brimonidine Tartrate,N,
5644,DescriptorName,D005260,12504711,,,4,Female,N,
5645,DescriptorName,D005902,12504711,,,5,"Glaucoma, Open-Angle",N,
5646,QualifierName,Q000188,12504711,,,5,,N,drug therapy
5647,DescriptorName,D006801,12504711,,,6,Humans,N,
5648,DescriptorName,D007429,12504711,,,7,Intraocular Pressure,N,
5649,QualifierName,Q000187,12504711,,,7,,Y,drug effects
5650,DescriptorName,D009798,12504711,,,8,Ocular Hypertension,N,
5651,QualifierName,Q000139,12504711,,,8,,Y,chemically induced
5652,DescriptorName,D011810,12504711,,,9,Quinoxalines,N,
5653,QualifierName,Q000009,12504711,,,9,,Y,adverse effects
5654,Chemical,D000085,12507063,Acetates,0,,,,
5655,Chemical,D000588,12507063,Amines,0,,,,
5656,Chemical,D000700,12507063,Analgesics,0,,,,
5657,Chemical,D003509,12507063,Cyclohexanecarboxylic Acids,0,,,,
5658,Chemical,D005680,12507063,gamma-Aminobutyric Acid,56-12-2,,,,
5659,Chemical,D000077206,12507063,Gabapentin,6CW7F3G59X,,,,
5660,DescriptorName,D000085,12507063,,,1,Acetates,N,
5661,QualifierName,Q000009,12507063,,,1,,Y,adverse effects
5662,DescriptorName,D000328,12507063,,,2,Adult,N,
5663,DescriptorName,D000588,12507063,,,3,Amines,Y,
5664,DescriptorName,D000700,12507063,,,4,Analgesics,N,
5665,QualifierName,Q000009,12507063,,,4,,Y,adverse effects
5666,DescriptorName,D003509,12507063,,,5,Cyclohexanecarboxylic Acids,Y,
5667,DescriptorName,D000077206,12507063,,,6,Gabapentin,N,
5668,DescriptorName,D006801,12507063,,,7,Humans,N,
5669,DescriptorName,D017116,12507063,,,8,Low Back Pain,N,
5670,QualifierName,Q000188,12507063,,,8,,N,drug therapy
5671,DescriptorName,D008297,12507063,,,9,Male,N,
5672,DescriptorName,D013131,12507063,,,10,Spine,N,
5673,QualifierName,Q000601,12507063,,,10,,N,surgery
5674,DescriptorName,D013226,12507063,,,11,Status Epilepticus,N,
5675,QualifierName,Q000503,12507063,,,11,,Y,physiopathology
5676,DescriptorName,D013375,12507063,,,12,Substance Withdrawal Syndrome,N,
5677,QualifierName,Q000503,12507063,,,12,,Y,physiopathology
5678,DescriptorName,D005680,12507063,,,13,gamma-Aminobutyric Acid,Y,
5679,Chemical,D000927,12523465,Anticonvulsants,0,,,,
5680,Chemical,D014635,12523465,Valproic Acid,614OI1Z5WI,,,,
5681,DescriptorName,D000293,12523465,,,1,Adolescent,N,
5682,DescriptorName,D000328,12523465,,,2,Adult,N,
5683,DescriptorName,D000927,12523465,,,3,Anticonvulsants,N,
5684,QualifierName,Q000009,12523465,,,3,,Y,adverse effects
5685,DescriptorName,D002648,12523465,,,4,Child,N,
5686,DescriptorName,D005260,12523465,,,5,Female,N,
5687,DescriptorName,D006212,12523465,,,6,Hallucinations,N,
5688,QualifierName,Q000139,12523465,,,6,,Y,chemically induced
5689,DescriptorName,D006801,12523465,,,7,Humans,N,
5690,DescriptorName,D018887,12523465,,,8,Landau-Kleffner Syndrome,N,
5691,QualifierName,Q000188,12523465,,,8,,Y,drug therapy
5692,DescriptorName,D012640,12523465,,,9,Seizures,N,
5693,QualifierName,Q000188,12523465,,,9,,Y,drug therapy
5694,DescriptorName,D014635,12523465,,,10,Valproic Acid,N,
5695,QualifierName,Q000009,12523465,,,10,,Y,adverse effects
5696,Chemical,D000900,12540009,Anti-Bacterial Agents,0,,,,
5697,Chemical,D004318,12540009,Doxycycline,N12000U13O,,,,
5698,DescriptorName,D000152,12540009,,,1,Acne Vulgaris,N,
5699,QualifierName,Q000150,12540009,,,1,,N,complications
5700,DescriptorName,D000328,12540009,,,2,Adult,N,
5701,DescriptorName,D000900,12540009,,,3,Anti-Bacterial Agents,N,
5702,QualifierName,Q000009,12540009,,,3,,Y,adverse effects
5703,DescriptorName,D004318,12540009,,,4,Doxycycline,N,
5704,QualifierName,Q000009,12540009,,,4,,Y,adverse effects
5705,DescriptorName,D006801,12540009,,,5,Humans,N,
5706,DescriptorName,D007003,12540009,,,6,Hypoglycemia,N,
5707,QualifierName,Q000139,12540009,,,6,,Y,chemically induced
5708,DescriptorName,D008297,12540009,,,7,Male,N,
5709,DescriptorName,D008382,12540009,,,8,Marfan Syndrome,N,
5710,QualifierName,Q000150,12540009,,,8,,N,complications
5711,Chemical,D005493,12546343,Folic Acid Antagonists,0,,,,
5712,Chemical,D008727,12546343,Methotrexate,YL5FZ2Y5U1,,,,
5713,DescriptorName,D000328,12546343,,,1,Adult,N,
5714,DescriptorName,D000707,12546343,,,2,Anaphylaxis,N,
5715,QualifierName,Q000139,12546343,,,2,,Y,chemically induced
5716,DescriptorName,D001859,12546343,,,3,Bone Neoplasms,N,
5717,QualifierName,Q000188,12546343,,,3,,N,drug therapy
5718,DescriptorName,D003888,12546343,,,4,"Desensitization, Immunologic",Y,
5719,DescriptorName,D004305,12546343,,,5,"Dose-Response Relationship, Drug",N,
5720,DescriptorName,D005493,12546343,,,6,Folic Acid Antagonists,N,
5721,QualifierName,Q000008,12546343,,,6,,Y,administration & dosage
5722,DescriptorName,D006801,12546343,,,7,Humans,N,
5723,DescriptorName,D008297,12546343,,,8,Male,N,
5724,DescriptorName,D008727,12546343,,,9,Methotrexate,N,
5725,QualifierName,Q000008,12546343,,,9,,Y,administration & dosage
5726,DescriptorName,D012516,12546343,,,10,Osteosarcoma,N,
5727,QualifierName,Q000188,12546343,,,10,,N,drug therapy
5728,Chemical,D003561,12552054,Cytarabine,04079A1RDZ,,,,
5729,Chemical,D008727,12552054,Methotrexate,YL5FZ2Y5U1,,,,
5730,DescriptorName,D000208,12552054,,,1,Acute Disease,N,
5731,DescriptorName,D000971,12552054,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
5732,QualifierName,Q000008,12552054,,,2,,N,administration & dosage
5733,DescriptorName,D001766,12552054,,,3,Blindness,N,
5734,QualifierName,Q000209,12552054,,,3,,N,etiology
5735,DescriptorName,D001927,12552054,,,4,Brain Diseases,N,
5736,QualifierName,Q000139,12552054,,,4,,Y,chemically induced
5737,DescriptorName,D002536,12552054,,,5,Cerebral Arteries,N,
5738,QualifierName,Q000473,12552054,,,5,,N,pathology
5739,DescriptorName,D002544,12552054,,,6,Cerebral Infarction,N,
5740,QualifierName,Q000209,12552054,,,6,,N,etiology
5741,DescriptorName,D003561,12552054,,,7,Cytarabine,N,
5742,QualifierName,Q000008,12552054,,,7,,N,administration & dosage
5743,DescriptorName,D018450,12552054,,,8,Disease Progression,N,
5744,DescriptorName,D005260,12552054,,,9,Female,N,
5745,DescriptorName,D006801,12552054,,,10,Humans,N,
5746,DescriptorName,D007278,12552054,,,11,"Injections, Spinal",N,
5747,DescriptorName,D018810,12552054,,,12,Magnetic Resonance Angiography,N,
5748,DescriptorName,D008279,12552054,,,13,Magnetic Resonance Imaging,N,
5749,DescriptorName,D008727,12552054,,,14,Methotrexate,N,
5750,QualifierName,Q000008,12552054,,,14,,N,administration & dosage
5751,DescriptorName,D008875,12552054,,,15,Middle Aged,N,
5752,DescriptorName,D015835,12552054,,,16,Ocular Motility Disorders,N,
5753,QualifierName,Q000209,12552054,,,16,,N,etiology
5754,DescriptorName,D054198,12552054,,,17,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
5755,QualifierName,Q000188,12552054,,,17,,Y,drug therapy
5756,DescriptorName,D020127,12552054,,,18,Recovery of Function,N,
5757,DescriptorName,D013577,12552054,,,19,Syndrome,N,
5758,DescriptorName,D013610,12552054,,,20,Tachycardia,N,
5759,QualifierName,Q000150,12552054,,,20,,N,complications
5760,DescriptorName,D020301,12552054,,,21,"Vasospasm, Intracranial",N,
5761,QualifierName,Q000139,12552054,,,21,,Y,chemically induced
5762,Chemical,D018906,12561997,"Antineoplastic Agents, Alkylating",0,,,,
5763,Chemical,D005780,12561997,Gelatin,9000-70-8,,,,
5764,Chemical,D008558,12561997,Melphalan,Q41OR9510P,,,,
5765,DescriptorName,D018906,12561997,,,1,"Antineoplastic Agents, Alkylating",N,
5766,QualifierName,Q000009,12561997,,,1,,Y,adverse effects
5767,DescriptorName,D000971,12561997,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
5768,QualifierName,Q000009,12561997,,,2,,N,adverse effects
5769,DescriptorName,D001284,12561997,,,3,Atrophy,N,
5770,DescriptorName,D001706,12561997,,,4,Biopsy,N,
5771,DescriptorName,D001853,12561997,,,5,Bone Marrow,N,
5772,QualifierName,Q000473,12561997,,,5,,Y,pathology
5773,DescriptorName,D005780,12561997,,,6,Gelatin,N,
5774,QualifierName,Q000378,12561997,,,6,,N,metabolism
5775,DescriptorName,D006801,12561997,,,7,Humans,N,
5776,DescriptorName,D015470,12561997,,,8,"Leukemia, Myeloid, Acute",N,
5777,QualifierName,Q000188,12561997,,,8,,N,drug therapy
5778,DescriptorName,D008297,12561997,,,9,Male,N,
5779,DescriptorName,D008558,12561997,,,10,Melphalan,N,
5780,QualifierName,Q000009,12561997,,,10,,Y,adverse effects
5781,DescriptorName,D008875,12561997,,,11,Middle Aged,N,
5782,Chemical,D000700,12567347,Analgesics,0,,,,
5783,DescriptorName,D000328,12567347,,,1,Adult,N,
5784,DescriptorName,D000700,12567347,,,2,Analgesics,N,
5785,QualifierName,Q000627,12567347,,,2,,N,therapeutic use
5786,DescriptorName,D000971,12567347,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
5787,QualifierName,Q000627,12567347,,,3,,N,therapeutic use
5788,DescriptorName,D017217,12567347,,,4,"Blood Patch, Epidural",N,
5789,DescriptorName,D006261,12567347,,,5,Headache,N,
5790,QualifierName,Q000188,12567347,,,5,,N,drug therapy
5791,DescriptorName,D006801,12567347,,,6,Humans,N,
5792,DescriptorName,D015459,12567347,,,7,"Leukemia-Lymphoma, Adult T-Cell",N,
5793,QualifierName,Q000150,12567347,,,7,,N,complications
5794,DescriptorName,D008279,12567347,,,8,Magnetic Resonance Imaging,N,
5795,DescriptorName,D008297,12567347,,,9,Male,N,
5796,DescriptorName,D020225,12567347,,,10,Sagittal Sinus Thrombosis,N,
5797,QualifierName,Q000175,12567347,,,10,,N,diagnosis
5798,DescriptorName,D013129,12567347,,,11,Spinal Puncture,N,
5799,QualifierName,Q000009,12567347,,,11,,Y,adverse effects
5800,Chemical,D007166,12581772,Immunosuppressive Agents,0,,,,
5801,Chemical,D020123,12581772,Sirolimus,W36ZG6FT64,,,,
5802,DescriptorName,D000328,12581772,,,1,Adult,N,
5803,DescriptorName,D016041,12581772,,,2,Heart-Lung Transplantation,N,
5804,DescriptorName,D006801,12581772,,,3,Humans,N,
5805,DescriptorName,D007166,12581772,,,4,Immunosuppressive Agents,N,
5806,QualifierName,Q000009,12581772,,,4,,Y,adverse effects
5807,DescriptorName,D007674,12581772,,,5,Kidney Diseases,N,
5808,QualifierName,Q000188,12581772,,,5,,N,drug therapy
5809,DescriptorName,D017563,12581772,,,6,"Lung Diseases, Interstitial",N,
5810,QualifierName,Q000139,12581772,,,6,,Y,chemically induced
5811,DescriptorName,D016040,12581772,,,7,Lung Transplantation,Y,
5812,DescriptorName,D008297,12581772,,,8,Male,N,
5813,DescriptorName,D020123,12581772,,,9,Sirolimus,N,
5814,QualifierName,Q000009,12581772,,,9,,Y,adverse effects
5815,Chemical,D014150,12587815,Antipsychotic Agents,0,,,,
5816,Chemical,D001569,12587815,Benzodiazepines,12794-10-4,,,,
5817,Chemical,D010890,12587815,Pirenzepine,3G0285N20N,,,,
5818,Chemical,D008094,12587815,Lithium,9FN79X2M3F,,,,
5819,Chemical,D000077152,12587815,Olanzapine,N7U69T4SZR,,,,
5820,DescriptorName,D000293,12587815,,,1,Adolescent,N,
5821,DescriptorName,D014150,12587815,,,2,Antipsychotic Agents,N,
5822,QualifierName,Q000008,12587815,,,2,,N,administration & dosage
5823,DescriptorName,D001569,12587815,,,3,Benzodiazepines,N,
5824,DescriptorName,D001714,12587815,,,4,Bipolar Disorder,N,
5825,QualifierName,Q000188,12587815,,,4,,Y,drug therapy
5826,DescriptorName,D003937,12587815,,,5,"Diagnosis, Differential",N,
5827,DescriptorName,D004359,12587815,,,6,"Drug Therapy, Combination",N,
5828,DescriptorName,D006801,12587815,,,7,Humans,N,
5829,DescriptorName,D008094,12587815,,,8,Lithium,N,
5830,QualifierName,Q000008,12587815,,,8,,N,administration & dosage
5831,DescriptorName,D008297,12587815,,,9,Male,N,
5832,DescriptorName,D009459,12587815,,,10,Neuroleptic Malignant Syndrome,N,
5833,QualifierName,Q000175,12587815,,,10,,N,diagnosis
5834,DescriptorName,D000077152,12587815,,,11,Olanzapine,N,
5835,DescriptorName,D010890,12587815,,,12,Pirenzepine,N,
5836,QualifierName,Q000008,12587815,,,12,,N,administration & dosage
5837,Chemical,D000964,12590235,"Antimetabolites, Antineoplastic",0,,,,
5838,Chemical,D015122,12590235,Mercaptopurine,E7WED276I5,,,,
5839,Chemical,D001219,12590235,Aspartate Aminotransferases,EC 2.6.1.1,,,,
5840,Chemical,D000410,12590235,Alanine Transaminase,EC 2.6.1.2,,,,
5841,Chemical,D013866,12590235,Thioguanine,FTK8U1GZNX,,,,
5842,DescriptorName,D000328,12590235,,,1,Adult,N,
5843,DescriptorName,D000410,12590235,,,2,Alanine Transaminase,N,
5844,QualifierName,Q000627,12590235,,,2,,N,therapeutic use
5845,DescriptorName,D000964,12590235,,,3,"Antimetabolites, Antineoplastic",N,
5846,QualifierName,Q000009,12590235,,,3,,Y,adverse effects
5847,DescriptorName,D001219,12590235,,,4,Aspartate Aminotransferases,N,
5848,QualifierName,Q000627,12590235,,,4,,N,therapeutic use
5849,DescriptorName,D003424,12590235,,,5,Crohn Disease,N,
5850,QualifierName,Q000188,12590235,,,5,,Y,drug therapy
5851,DescriptorName,D005260,12590235,,,6,Female,N,
5852,DescriptorName,D006801,12590235,,,7,Humans,N,
5853,DescriptorName,D008099,12590235,,,8,Liver,N,
5854,QualifierName,Q000187,12590235,,,8,,Y,drug effects
5855,DescriptorName,D008111,12590235,,,9,Liver Function Tests,N,
5856,DescriptorName,D015122,12590235,,,10,Mercaptopurine,N,
5857,QualifierName,Q000378,12590235,,,10,,N,metabolism
5858,DescriptorName,D013866,12590235,,,11,Thioguanine,N,
5859,QualifierName,Q000009,12590235,,,11,,Y,adverse effects
5860,Chemical,D000806,12598508,Angiotensin-Converting Enzyme Inhibitors,0,,,,
5861,Chemical,D017706,12598508,Lisinopril,E7199S1YWR,,,,
5862,DescriptorName,D000806,12598508,,,1,Angiotensin-Converting Enzyme Inhibitors,N,
5863,QualifierName,Q000009,12598508,,,1,,Y,adverse effects
5864,DescriptorName,D005260,12598508,,,2,Female,N,
5865,DescriptorName,D006801,12598508,,,3,Humans,N,
5866,DescriptorName,D006973,12598508,,,4,Hypertension,N,
5867,QualifierName,Q000188,12598508,,,4,,N,drug therapy
5868,DescriptorName,D007231,12598508,,,5,"Infant, Newborn",N,
5869,DescriptorName,D017706,12598508,,,6,Lisinopril,N,
5870,QualifierName,Q000009,12598508,,,6,,Y,adverse effects
5871,DescriptorName,D008431,12598508,,,7,Maternal-Fetal Exchange,N,
5872,DescriptorName,D009102,12598508,,,8,Multiple Organ Failure,N,
5873,QualifierName,Q000139,12598508,,,8,,N,chemically induced
5874,DescriptorName,D010530,12598508,,,9,Peritoneal Dialysis,Y,
5875,DescriptorName,D011247,12598508,,,10,Pregnancy,N,
5876,DescriptorName,D011249,12598508,,,11,"Pregnancy Complications, Cardiovascular",N,
5877,QualifierName,Q000188,12598508,,,11,,N,drug therapy
5878,DescriptorName,D011297,12598508,,,12,Prenatal Exposure Delayed Effects,Y,
5879,Chemical,D007166,12605322,Immunosuppressive Agents,0,,,,
5880,Chemical,D011239,12605322,Prednisolone,9PHQ9Y1OLM,,,,
5881,DescriptorName,D000328,12605322,,,1,Adult,N,
5882,DescriptorName,D000361,12605322,,,2,Agammaglobulinemia,N,
5883,QualifierName,Q000139,12605322,,,2,,Y,chemically induced
5884,DescriptorName,D001402,12605322,,,3,B-Lymphocytes,Y,
5885,DescriptorName,D005260,12605322,,,4,Female,N,
5886,DescriptorName,D006801,12605322,,,5,Humans,N,
5887,DescriptorName,D007166,12605322,,,6,Immunosuppressive Agents,N,
5888,QualifierName,Q000009,12605322,,,6,,Y,adverse effects
5889,DescriptorName,D020945,12605322,,,7,"Lupus Vasculitis, Central Nervous System",N,
5890,QualifierName,Q000150,12605322,,,7,,N,complications
5891,DescriptorName,D008231,12605322,,,8,Lymphopenia,N,
5892,QualifierName,Q000139,12605322,,,8,,Y,chemically induced
5893,DescriptorName,D008279,12605322,,,9,Magnetic Resonance Imaging,N,
5894,DescriptorName,D011239,12605322,,,10,Prednisolone,N,
5895,QualifierName,Q000009,12605322,,,10,,Y,adverse effects
5896,Chemical,D011441,1261772,Propylthiouracil,721M9407IY,,,,
5897,DescriptorName,D000328,1261772,,,1,Adult,N,
5898,DescriptorName,D056486,1261772,,,2,Chemical and Drug Induced Liver Injury,N,
5899,QualifierName,Q000209,1261772,,,2,,Y,etiology
5900,DescriptorName,D005260,1261772,,,3,Female,N,
5901,DescriptorName,D006801,1261772,,,4,Humans,N,
5902,DescriptorName,D006980,1261772,,,5,Hyperthyroidism,N,
5903,QualifierName,Q000188,1261772,,,5,,N,drug therapy
5904,DescriptorName,D008099,1261772,,,6,Liver,N,
5905,QualifierName,Q000187,1261772,,,6,,Y,drug effects
5906,DescriptorName,D008213,1261772,,,7,Lymphocyte Activation,N,
5907,DescriptorName,D008214,1261772,,,8,Lymphocytes,N,
5908,QualifierName,Q000187,1261772,,,8,,N,drug effects
5909,DescriptorName,D009336,1261772,,,9,Necrosis,N,
5910,DescriptorName,D011441,1261772,,,10,Propylthiouracil,N,
5911,QualifierName,Q000009,1261772,,,10,,Y,adverse effects
5912,Chemical,D014150,12621956,Antipsychotic Agents,0,,,,
5913,Chemical,D018967,12621956,Risperidone,L6UH7ZF8HC,,,,
5914,DescriptorName,D014150,12621956,,,1,Antipsychotic Agents,N,
5915,QualifierName,Q000009,12621956,,,1,,Y,adverse effects
5916,DescriptorName,D005260,12621956,,,2,Female,N,
5917,DescriptorName,D006801,12621956,,,3,Humans,N,
5918,DescriptorName,D007035,12621956,,,4,Hypothermia,N,
5919,QualifierName,Q000139,12621956,,,4,,Y,chemically induced
5920,DescriptorName,D008875,12621956,,,5,Middle Aged,N,
5921,DescriptorName,D018967,12621956,,,6,Risperidone,N,
5922,QualifierName,Q000009,12621956,,,6,,Y,adverse effects
5923,DescriptorName,D012559,12621956,,,7,Schizophrenia,N,
5924,QualifierName,Q000188,12621956,,,7,,N,drug therapy
5925,Chemical,D000319,12625995,Adrenergic beta-Antagonists,0,,,,
5926,Chemical,D014150,12625995,Antipsychotic Agents,0,,,,
5927,Chemical,D003024,12625995,Clozapine,J60AR2IKIC,,,,
5928,DescriptorName,D000319,12625995,,,1,Adrenergic beta-Antagonists,N,
5929,QualifierName,Q000627,12625995,,,1,,N,therapeutic use
5930,DescriptorName,D017109,12625995,,,2,"Akathisia, Drug-Induced",N,
5931,QualifierName,Q000175,12625995,,,2,,N,diagnosis
5932,DescriptorName,D014150,12625995,,,3,Antipsychotic Agents,N,
5933,QualifierName,Q000009,12625995,,,3,,Y,adverse effects
5934,DescriptorName,D002648,12625995,,,4,Child,N,
5935,DescriptorName,D003024,12625995,,,5,Clozapine,N,
5936,QualifierName,Q000009,12625995,,,5,,Y,adverse effects
5937,DescriptorName,D005260,12625995,,,6,Female,N,
5938,DescriptorName,D006801,12625995,,,7,Humans,N,
5939,DescriptorName,D008297,12625995,,,8,Male,N,
5940,DescriptorName,D012561,12625995,,,9,"Schizophrenia, Childhood",N,
5941,QualifierName,Q000188,12625995,,,9,,Y,drug therapy
5942,Chemical,D018692,12630660,Antimanic Agents,0,,,,
5943,Chemical,D018020,12630660,Lithium Compounds,0,,,,
5944,DescriptorName,D000328,12630660,,,1,Adult,N,
5945,DescriptorName,D018692,12630660,,,2,Antimanic Agents,N,
5946,QualifierName,Q000008,12630660,,,2,,N,administration & dosage
5947,DescriptorName,D001714,12630660,,,3,Bipolar Disorder,N,
5948,QualifierName,Q000188,12630660,,,3,,Y,drug therapy
5949,DescriptorName,D001766,12630660,,,4,Blindness,N,
5950,QualifierName,Q000139,12630660,,,4,,Y,chemically induced
5951,DescriptorName,D003693,12630660,,,5,Delirium,N,
5952,QualifierName,Q000139,12630660,,,5,,N,chemically induced
5953,DescriptorName,D005260,12630660,,,6,Female,N,
5954,DescriptorName,D005500,12630660,,,7,Follow-Up Studies,N,
5955,DescriptorName,D005829,12630660,,,8,Geniculate Bodies,N,
5956,QualifierName,Q000187,12630660,,,8,,N,drug effects
5957,DescriptorName,D006801,12630660,,,9,Humans,N,
5958,DescriptorName,D007427,12630660,,,10,Intracranial Pressure,N,
5959,QualifierName,Q000187,12630660,,,10,,N,drug effects
5960,DescriptorName,D018020,12630660,,,11,Lithium Compounds,N,
5961,QualifierName,Q000008,12630660,,,11,,N,administration & dosage
5962,DescriptorName,D017116,12630660,,,12,Low Back Pain,N,
5963,QualifierName,Q000139,12630660,,,12,,N,chemically induced
5964,DescriptorName,D008279,12630660,,,13,Magnetic Resonance Imaging,N,
5965,DescriptorName,D017590,12630660,,,14,"Myelinolysis, Central Pontine",N,
5966,QualifierName,Q000139,12630660,,,14,,Y,chemically induced
5967,DescriptorName,D009460,12630660,,,15,Neurologic Examination,N,
5968,QualifierName,Q000187,12630660,,,15,,N,drug effects
5969,DescriptorName,D013681,12630660,,,16,Tegmentum Mesencephali,N,
5970,QualifierName,Q000187,12630660,,,16,,N,drug effects
5971,Chemical,D013956,12635752,Antithyroid Agents,0,,,,
5972,Chemical,D011441,12635752,Propylthiouracil,721M9407IY,,,,
5973,Chemical,D002231,12635752,Carbimazole,8KQ660G60G,,,,
5974,DescriptorName,D000328,12635752,,,1,Adult,N,
5975,DescriptorName,D013956,12635752,,,2,Antithyroid Agents,N,
5976,QualifierName,Q000008,12635752,,,2,,N,administration & dosage
5977,DescriptorName,D002231,12635752,,,3,Carbimazole,N,
5978,QualifierName,Q000008,12635752,,,3,,N,administration & dosage
5979,DescriptorName,D056486,12635752,,,4,Chemical and Drug Induced Liver Injury,N,
5980,QualifierName,Q000175,12635752,,,4,,Y,diagnosis
5981,DescriptorName,D003937,12635752,,,5,"Diagnosis, Differential",N,
5982,DescriptorName,D005260,12635752,,,6,Female,N,
5983,DescriptorName,D006801,12635752,,,7,Humans,N,
5984,DescriptorName,D006980,12635752,,,8,Hyperthyroidism,N,
5985,QualifierName,Q000188,12635752,,,8,,Y,drug therapy
5986,DescriptorName,D011247,12635752,,,9,Pregnancy,N,
5987,DescriptorName,D011248,12635752,,,10,Pregnancy Complications,N,
5988,QualifierName,Q000188,12635752,,,10,,Y,drug therapy
5989,DescriptorName,D011295,12635752,,,11,Prenatal Care,N,
5990,DescriptorName,D011441,12635752,,,12,Propylthiouracil,N,
5991,QualifierName,Q000009,12635752,,,12,,Y,adverse effects
5992,Chemical,D000998,12639299,Antiviral Agents,0,,,,
5993,Chemical,D007370,12639299,Interferon Type I,0,,,,
5994,Chemical,D011994,12639299,Recombinant Proteins,0,,,,
5995,DescriptorName,D000328,12639299,,,1,Adult,N,
5996,DescriptorName,D000998,12639299,,,2,Antiviral Agents,N,
5997,QualifierName,Q000009,12639299,,,2,,Y,adverse effects
5998,DescriptorName,D003449,12639299,,,3,Cryoglobulinemia,N,
5999,QualifierName,Q000209,12639299,,,3,,N,etiology
6000,DescriptorName,D015432,12639299,,,4,"Glomerulonephritis, Membranoproliferative",N,
6001,QualifierName,Q000209,12639299,,,4,,N,etiology
6002,DescriptorName,D019698,12639299,,,5,"Hepatitis C, Chronic",N,
6003,QualifierName,Q000150,12639299,,,5,,Y,complications
6004,DescriptorName,D006801,12639299,,,6,Humans,N,
6005,DescriptorName,D007370,12639299,,,7,Interferon Type I,N,
6006,QualifierName,Q000009,12639299,,,7,,Y,adverse effects
6007,DescriptorName,D008297,12639299,,,8,Male,N,
6008,DescriptorName,D009402,12639299,,,9,"Nephrosis, Lipoid",N,
6009,QualifierName,Q000175,12639299,,,9,,N,diagnosis
6010,DescriptorName,D011994,12639299,,,10,Recombinant Proteins,N,
6011,Chemical,D000970,12656748,Antineoplastic Agents,0,,,,
6012,Chemical,D016898,12656748,Interferon-alpha,0,,,,
6013,Chemical,D006918,12656748,Hydroxyurea,X6Q56QN5QC,,,,
6014,DescriptorName,D000970,12656748,,,1,Antineoplastic Agents,N,
6015,QualifierName,Q000009,12656748,,,1,,N,adverse effects
6016,DescriptorName,D001856,12656748,,,2,Bone Marrow Examination,N,
6017,DescriptorName,D006801,12656748,,,3,Humans,N,
6018,DescriptorName,D006918,12656748,,,4,Hydroxyurea,N,
6019,QualifierName,Q000009,12656748,,,4,,N,adverse effects
6020,DescriptorName,D016898,12656748,,,5,Interferon-alpha,N,
6021,QualifierName,Q000627,12656748,,,5,,N,therapeutic use
6022,DescriptorName,D007621,12656748,,,6,Karyotyping,N,
6023,DescriptorName,D015464,12656748,,,7,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
6024,QualifierName,Q000139,12656748,,,7,,N,chemically induced
6025,DescriptorName,D008297,12656748,,,8,Male,N,
6026,DescriptorName,D008875,12656748,,,9,Middle Aged,N,
6027,DescriptorName,D036102,12656748,,,10,Peripheral Blood Stem Cell Transplantation,N,
6028,DescriptorName,D010677,12656748,,,11,Philadelphia Chromosome,N,
6029,DescriptorName,D012074,12656748,,,12,Remission Induction,N,
6030,DescriptorName,D013920,12656748,,,13,"Thrombocythemia, Essential",N,
6031,QualifierName,Q000150,12656748,,,13,,N,complications
6032,DescriptorName,D014184,12656748,,,14,"Transplantation, Homologous",N,
6033,Chemical,D000962,12659609,Antimalarials,0,,,,
6034,Chemical,D009285,12659609,Naphthoquinones,0,,,,
6035,Chemical,D002738,12659609,Chloroquine,886U3H6UFF,,,,
6036,Chemical,D011319,12659609,Primaquine,MVR3634GX1,,,,
6037,Chemical,D002727,12659609,Proguanil,S61K3P7B2V,,,,
6038,Chemical,D053626,12659609,Atovaquone,Y883P1Z2LT,,,,
6039,DescriptorName,D000328,12659609,,,1,Adult,N,
6040,DescriptorName,D000818,12659609,,,2,Animals,N,
6041,DescriptorName,D000962,12659609,,,3,Antimalarials,N,
6042,QualifierName,Q000008,12659609,,,3,,N,administration & dosage
6043,DescriptorName,D053626,12659609,,,4,Atovaquone,N,
6044,DescriptorName,D002738,12659609,,,5,Chloroquine,N,
6045,QualifierName,Q000008,12659609,,,5,,N,administration & dosage
6046,DescriptorName,D062787,12659609,,,6,Drug Overdose,N,
6047,DescriptorName,D006801,12659609,,,7,Humans,N,
6048,DescriptorName,D016780,12659609,,,8,"Malaria, Vivax",N,
6049,QualifierName,Q000188,12659609,,,8,,Y,drug therapy
6050,DescriptorName,D008297,12659609,,,9,Male,N,
6051,DescriptorName,D009285,12659609,,,10,Naphthoquinones,N,
6052,QualifierName,Q000627,12659609,,,10,,N,therapeutic use
6053,DescriptorName,D010966,12659609,,,11,Plasmodium vivax,N,
6054,DescriptorName,D011319,12659609,,,12,Primaquine,N,
6055,QualifierName,Q000627,12659609,,,12,,N,therapeutic use
6056,DescriptorName,D002727,12659609,,,13,Proguanil,N,
6057,QualifierName,Q000627,12659609,,,13,,N,therapeutic use
6058,Chemical,D013956,12661801,Antithyroid Agents,0,,,,
6059,Chemical,D011994,12661801,Recombinant Proteins,0,,,,
6060,Chemical,D016179,12661801,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
6061,Chemical,D002231,12661801,Carbimazole,8KQ660G60G,,,,
6062,DescriptorName,D000368,12661801,,,1,Aged,N,
6063,DescriptorName,D000380,12661801,,,2,Agranulocytosis,N,
6064,QualifierName,Q000139,12661801,,,2,,N,chemically induced
6065,DescriptorName,D013956,12661801,,,3,Antithyroid Agents,N,
6066,QualifierName,Q000009,12661801,,,3,,Y,adverse effects
6067,DescriptorName,D002231,12661801,,,4,Carbimazole,N,
6068,QualifierName,Q000009,12661801,,,4,,Y,adverse effects
6069,DescriptorName,D005260,12661801,,,5,Female,N,
6070,DescriptorName,D016179,12661801,,,6,Granulocyte Colony-Stimulating Factor,N,
6071,QualifierName,Q000627,12661801,,,6,,Y,therapeutic use
6072,DescriptorName,D006801,12661801,,,7,Humans,N,
6073,DescriptorName,D010808,12661801,,,8,Physical Examination,N,
6074,DescriptorName,D011994,12661801,,,9,Recombinant Proteins,N,
6075,DescriptorName,D013971,12661801,,,10,Thyrotoxicosis,N,
6076,QualifierName,Q000188,12661801,,,10,,N,drug therapy
6077,DescriptorName,D016896,12661801,,,11,Treatment Outcome,N,
6078,Chemical,D000903,12665232,"Antibiotics, Antineoplastic",0,,,,
6079,Chemical,D016685,12665232,Mitomycin,50SG953SK6,,,,
6080,DescriptorName,D000328,12665232,,,1,Adult,N,
6081,DescriptorName,D000903,12665232,,,2,"Antibiotics, Antineoplastic",N,
6082,QualifierName,Q000009,12665232,,,2,,Y,adverse effects
6083,DescriptorName,D003316,12665232,,,3,Corneal Diseases,N,
6084,QualifierName,Q000139,12665232,,,3,,Y,chemically induced
6085,DescriptorName,D006801,12665232,,,4,Humans,N,
6086,DescriptorName,D007499,12665232,,,5,Iris Diseases,N,
6087,QualifierName,Q000139,12665232,,,5,,N,chemically induced
6088,DescriptorName,D008297,12665232,,,6,Male,N,
6089,DescriptorName,D016685,12665232,,,7,Mitomycin,N,
6090,QualifierName,Q000009,12665232,,,7,,Y,adverse effects
6091,DescriptorName,D011391,12665232,,,8,Prolapse,N,
6092,DescriptorName,D011625,12665232,,,9,Pterygium,N,
6093,QualifierName,Q000188,12665232,,,9,,N,drug therapy
6094,DescriptorName,D012590,12665232,,,10,Sclera,N,
6095,QualifierName,Q000187,12665232,,,10,,Y,drug effects
6096,DescriptorName,D015422,12665232,,,11,Scleral Diseases,N,
6097,QualifierName,Q000139,12665232,,,11,,Y,chemically induced
6098,Chemical,D009883,1267457,Ophthalmic Solutions,0,,,,
6099,Chemical,D013449,1267457,Sulfonamides,0,,,,
6100,DescriptorName,D000368,1267457,,,1,Aged,N,
6101,DescriptorName,D003231,1267457,,,2,Conjunctivitis,N,
6102,QualifierName,Q000188,1267457,,,2,,N,drug therapy
6103,DescriptorName,D006801,1267457,,,3,Humans,N,
6104,DescriptorName,D007239,1267457,,,4,Infections,N,
6105,QualifierName,Q000188,1267457,,,4,,N,drug therapy
6106,DescriptorName,D008297,1267457,,,5,Male,N,
6107,DescriptorName,D009883,1267457,,,6,Ophthalmic Solutions,N,
6108,DescriptorName,D013211,1267457,,,7,Staphylococcus aureus,N,
6109,DescriptorName,D013262,1267457,,,8,Stevens-Johnson Syndrome,N,
6110,QualifierName,Q000139,1267457,,,8,,Y,chemically induced
6111,DescriptorName,D013449,1267457,,,9,Sulfonamides,N,
6112,QualifierName,Q000008,1267457,,,9,,N,administration & dosage
6113,Chemical,D016651,12680486,Lithium Carbonate,2BMD2GNA4V,,,,
6114,Chemical,D000584,12680486,Amiloride,7DZO8EB0Z3,,,,
6115,DescriptorName,D000584,12680486,,,1,Amiloride,N,
6116,QualifierName,Q000627,12680486,,,1,,Y,therapeutic use
6117,DescriptorName,D003919,12680486,,,2,Diabetes Insipidus,N,
6118,QualifierName,Q000097,12680486,,,2,,N,blood
6119,DescriptorName,D005260,12680486,,,3,Female,N,
6120,DescriptorName,D006801,12680486,,,4,Humans,N,
6121,DescriptorName,D016651,12680486,,,5,Lithium Carbonate,N,
6122,QualifierName,Q000009,12680486,,,5,,Y,adverse effects
6123,DescriptorName,D008875,12680486,,,6,Middle Aged,N,
6124,Chemical,D016179,12692521,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
6125,Chemical,D013792,12692521,Thalidomide,4Z8R6ORS6L,,,,
6126,Chemical,D014750,12692521,Vincristine,5J49Q6B70F,,,,
6127,Chemical,D003907,12692521,Dexamethasone,7S5I7G3JQL,,,,
6128,Chemical,D004317,12692521,Doxorubicin,80168379AG,,,,
6129,Chemical,D003520,12692521,Cyclophosphamide,8N3DW7272P,,,,
6130,Chemical,D008775,12692521,Methylprednisolone,X4W7ZR7023,,,,
6131,Chemical,D006918,12692521,Hydroxyurea,X6Q56QN5QC,,,,
6132,DescriptorName,D000328,12692521,,,1,Adult,N,
6133,DescriptorName,D000971,12692521,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
6134,QualifierName,Q000008,12692521,,,2,,N,administration & dosage
6135,DescriptorName,D019559,12692521,,,3,Capillary Leak Syndrome,N,
6136,QualifierName,Q000139,12692521,,,3,,Y,chemically induced
6137,DescriptorName,D003131,12692521,,,4,Combined Modality Therapy,N,
6138,DescriptorName,D003422,12692521,,,5,Critical Care,N,
6139,DescriptorName,D003520,12692521,,,6,Cyclophosphamide,N,
6140,QualifierName,Q000627,12692521,,,6,,N,therapeutic use
6141,DescriptorName,D003907,12692521,,,7,Dexamethasone,N,
6142,QualifierName,Q000008,12692521,,,7,,N,administration & dosage
6143,DescriptorName,D004317,12692521,,,8,Doxorubicin,N,
6144,QualifierName,Q000008,12692521,,,8,,N,administration & dosage
6145,DescriptorName,D004417,12692521,,,9,Dyspnea,N,
6146,QualifierName,Q000209,12692521,,,9,,N,etiology
6147,DescriptorName,D004487,12692521,,,10,Edema,N,
6148,QualifierName,Q000209,12692521,,,10,,N,etiology
6149,DescriptorName,D019115,12692521,,,11,"Fasciitis, Necrotizing",N,
6150,QualifierName,Q000209,12692521,,,11,,N,etiology
6151,DescriptorName,D017809,12692521,,,12,Fatal Outcome,N,
6152,DescriptorName,D016179,12692521,,,13,Granulocyte Colony-Stimulating Factor,N,
6153,QualifierName,Q000009,12692521,,,13,,Y,adverse effects
6154,DescriptorName,D019650,12692521,,,14,Hematopoietic Stem Cell Mobilization,N,
6155,QualifierName,Q000009,12692521,,,14,,Y,adverse effects
6156,DescriptorName,D006801,12692521,,,15,Humans,N,
6157,DescriptorName,D006918,12692521,,,16,Hydroxyurea,N,
6158,QualifierName,Q000008,12692521,,,16,,N,administration & dosage
6159,DescriptorName,D015464,12692521,,,17,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
6160,QualifierName,Q000150,12692521,,,17,,Y,complications
6161,DescriptorName,D008297,12692521,,,18,Male,N,
6162,DescriptorName,D008775,12692521,,,19,Methylprednisolone,N,
6163,QualifierName,Q000627,12692521,,,19,,N,therapeutic use
6164,DescriptorName,D008875,12692521,,,20,Middle Aged,N,
6165,DescriptorName,D008954,12692521,,,21,"Models, Biological",N,
6166,DescriptorName,D009101,12692521,,,22,Multiple Myeloma,N,
6167,QualifierName,Q000150,12692521,,,22,,Y,complications
6168,DescriptorName,D036102,12692521,,,23,Peripheral Blood Stem Cell Transplantation,N,
6169,DescriptorName,D013792,12692521,,,24,Thalidomide,N,
6170,QualifierName,Q000627,12692521,,,24,,N,therapeutic use
6171,DescriptorName,D018366,12692521,,,25,"Vasculitis, Leukocytoclastic, Cutaneous",N,
6172,QualifierName,Q000139,12692521,,,25,,N,chemically induced
6173,DescriptorName,D014750,12692521,,,26,Vincristine,N,
6174,QualifierName,Q000008,12692521,,,26,,N,administration & dosage
6175,Chemical,D007166,12699871,Immunosuppressive Agents,0,,,,
6176,Chemical,D016559,12699871,Tacrolimus,WM0HAQ4WNM,,,,
6177,DescriptorName,D000293,12699871,,,1,Adolescent,N,
6178,DescriptorName,D005260,12699871,,,2,Female,N,
6179,DescriptorName,D006084,12699871,,,3,Graft Rejection,N,
6180,QualifierName,Q000188,12699871,,,3,,Y,drug therapy
6181,DescriptorName,D006801,12699871,,,4,Humans,N,
6182,DescriptorName,D007166,12699871,,,5,Immunosuppressive Agents,N,
6183,QualifierName,Q000009,12699871,,,5,,Y,adverse effects
6184,DescriptorName,D016031,12699871,,,6,Liver Transplantation,Y,
6185,DescriptorName,D008279,12699871,,,7,Magnetic Resonance Imaging,N,
6186,DescriptorName,D009155,12699871,,,8,Mutism,N,
6187,QualifierName,Q000139,12699871,,,8,,Y,chemically induced
6188,DescriptorName,D016559,12699871,,,9,Tacrolimus,N,
6189,QualifierName,Q000009,12699871,,,9,,Y,adverse effects
6190,Chemical,D000893,12702914,Anti-Inflammatory Agents,0,,,,
6191,Chemical,D007004,12702914,Hypoglycemic Agents,0,,,,
6192,Chemical,D007328,12702914,Insulin,0,,,,
6193,Chemical,D011241,12702914,Prednisone,VB0R961HZT,,,,
6194,DescriptorName,D000368,12702914,,,1,Aged,N,
6195,DescriptorName,D000893,12702914,,,2,Anti-Inflammatory Agents,N,
6196,QualifierName,Q000627,12702914,,,2,,N,therapeutic use
6197,DescriptorName,D003924,12702914,,,3,"Diabetes Mellitus, Type 2",N,
6198,QualifierName,Q000150,12702914,,,3,,N,complications
6199,DescriptorName,D004487,12702914,,,4,Edema,N,
6200,QualifierName,Q000150,12702914,,,4,,Y,complications
6201,DescriptorName,D005260,12702914,,,5,Female,N,
6202,DescriptorName,D019693,12702914,,,6,"Hepatitis, Autoimmune",N,
6203,QualifierName,Q000150,12702914,,,6,,Y,complications
6204,DescriptorName,D006801,12702914,,,7,Humans,N,
6205,DescriptorName,D006946,12702914,,,8,Hyperinsulinism,N,
6206,QualifierName,Q000150,12702914,,,8,,Y,complications
6207,DescriptorName,D007004,12702914,,,9,Hypoglycemic Agents,N,
6208,QualifierName,Q000009,12702914,,,9,,Y,adverse effects
6209,DescriptorName,D007328,12702914,,,10,Insulin,N,
6210,QualifierName,Q000009,12702914,,,10,,Y,adverse effects
6211,DescriptorName,D007333,12702914,,,11,Insulin Resistance,N,
6212,DescriptorName,D011241,12702914,,,12,Prednisone,N,
6213,QualifierName,Q000627,12702914,,,12,,N,therapeutic use
6214,Chemical,D000964,12707728,"Antimetabolites, Antineoplastic",0,,,,
6215,Chemical,D008727,12707728,Methotrexate,YL5FZ2Y5U1,,,,
6216,DescriptorName,D000208,12707728,,,1,Acute Disease,N,
6217,DescriptorName,D000328,12707728,,,2,Adult,N,
6218,DescriptorName,D000964,12707728,,,3,"Antimetabolites, Antineoplastic",N,
6219,QualifierName,Q000008,12707728,,,3,,N,administration & dosage
6220,DescriptorName,D002526,12707728,,,4,Cerebellar Diseases,N,
6221,QualifierName,Q000139,12707728,,,4,,Y,chemically induced
6222,DescriptorName,D003422,12707728,,,5,Critical Care,N,
6223,DescriptorName,D005260,12707728,,,6,Female,N,
6224,DescriptorName,D006801,12707728,,,7,Humans,N,
6225,DescriptorName,D007278,12707728,,,8,"Injections, Spinal",N,
6226,DescriptorName,D008727,12707728,,,9,Methotrexate,N,
6227,QualifierName,Q000008,12707728,,,9,,N,administration & dosage
6228,DescriptorName,D054198,12707728,,,10,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
6229,QualifierName,Q000188,12707728,,,10,,Y,drug therapy
6230,DescriptorName,D016896,12707728,,,11,Treatment Outcome,N,
6231,Chemical,D000900,12729371,Anti-Bacterial Agents,0,,,,
6232,Chemical,D004318,12729371,Doxycycline,N12000U13O,,,,
6233,DescriptorName,D000368,12729371,,,1,Aged,N,
6234,DescriptorName,D000369,12729371,,,2,"Aged, 80 and over",N,
6235,DescriptorName,D000900,12729371,,,3,Anti-Bacterial Agents,N,
6236,QualifierName,Q000627,12729371,,,3,,Y,therapeutic use
6237,DescriptorName,D001796,12729371,,,4,Blood Protein Disorders,N,
6238,QualifierName,Q000139,12729371,,,4,,Y,chemically induced
6239,DescriptorName,D004318,12729371,,,5,Doxycycline,N,
6240,QualifierName,Q000009,12729371,,,5,,Y,adverse effects
6241,DescriptorName,D017809,12729371,,,6,Fatal Outcome,N,
6242,DescriptorName,D006801,12729371,,,7,Humans,N,
6243,DescriptorName,D007119,12729371,,,8,Immunoblastic Lymphadenopathy,N,
6244,QualifierName,Q000139,12729371,,,8,,Y,chemically induced
6245,DescriptorName,D008297,12729371,,,9,Male,N,
6246,DescriptorName,D011379,12729371,,,10,Prognosis,N,
6247,Chemical,D000995,12751276,Antitubercular Agents,0,,,,
6248,Chemical,D007538,12751276,Isoniazid,V83O1VOZ8L,,,,
6249,DescriptorName,D000328,12751276,,,1,Adult,N,
6250,DescriptorName,D000707,12751276,,,2,Anaphylaxis,N,
6251,QualifierName,Q000139,12751276,,,2,,Y,chemically induced
6252,DescriptorName,D000995,12751276,,,3,Antitubercular Agents,N,
6253,QualifierName,Q000009,12751276,,,3,,Y,adverse effects
6254,DescriptorName,D006801,12751276,,,4,Humans,N,
6255,DescriptorName,D007538,12751276,,,5,Isoniazid,N,
6256,QualifierName,Q000009,12751276,,,5,,Y,adverse effects
6257,DescriptorName,D008297,12751276,,,6,Male,N,
6258,DescriptorName,D011329,12751276,,,7,Prisoners,N,
6259,DescriptorName,D012882,12751276,,,8,Skin Tests,N,
6260,DescriptorName,D014397,12751276,,,9,"Tuberculosis, Pulmonary",N,
6261,QualifierName,Q000188,12751276,,,9,,N,drug therapy
6262,Chemical,D010281,1275625,Parathyroid Hormone,0,,,,
6263,Chemical,D008278,1275625,Magnesium Sulfate,7487-88-9,,,,
6264,Chemical,D011188,1275625,Potassium,RWP5GA015D,,,,
6265,Chemical,D002118,1275625,Calcium,SY7Q814VUP,,,,
6266,DescriptorName,D000328,1275625,,,1,Adult,N,
6267,DescriptorName,D002118,1275625,,,2,Calcium,N,
6268,QualifierName,Q000097,1275625,,,2,,N,blood
6269,DescriptorName,D005260,1275625,,,3,Female,N,
6270,DescriptorName,D006801,1275625,,,4,Humans,N,
6271,DescriptorName,D006996,1275625,,,5,Hypocalcemia,N,
6272,QualifierName,Q000139,1275625,,,5,,Y,chemically induced
6273,DescriptorName,D008278,1275625,,,6,Magnesium Sulfate,N,
6274,QualifierName,Q000009,1275625,,,6,,Y,adverse effects
6275,DescriptorName,D010280,1275625,,,7,Parathyroid Glands,N,
6276,QualifierName,Q000503,1275625,,,7,,N,physiopathology
6277,DescriptorName,D010281,1275625,,,8,Parathyroid Hormone,N,
6278,QualifierName,Q000097,1275625,,,8,,N,blood
6279,DescriptorName,D011188,1275625,,,9,Potassium,N,
6280,QualifierName,Q000008,1275625,,,9,,N,administration & dosage
6281,DescriptorName,D011225,1275625,,,10,Pre-Eclampsia,N,
6282,QualifierName,Q000188,1275625,,,10,,Y,drug therapy
6283,DescriptorName,D011247,1275625,,,11,Pregnancy,N,
6284,Chemical,D002220,12757344,Carbamazepine,33CM23913M,,,,
6285,DescriptorName,D000368,12757344,,,1,Aged,N,
6286,DescriptorName,D002220,12757344,,,2,Carbamazepine,N,
6287,QualifierName,Q000009,12757344,,,2,,Y,adverse effects
6288,DescriptorName,D002315,12757344,,,3,Cardiopulmonary Bypass,N,
6289,QualifierName,Q000009,12757344,,,3,,N,adverse effects
6290,DescriptorName,D003327,12757344,,,4,Coronary Disease,N,
6291,QualifierName,Q000175,12757344,,,4,,N,diagnosis
6292,DescriptorName,D017558,12757344,,,5,Elective Surgical Procedures,N,
6293,DescriptorName,D005500,12757344,,,6,Follow-Up Studies,N,
6294,DescriptorName,D006801,12757344,,,7,Humans,N,
6295,DescriptorName,D007010,12757344,,,8,Hyponatremia,N,
6296,QualifierName,Q000139,12757344,,,8,,Y,chemically induced
6297,DescriptorName,D008297,12757344,,,9,Male,N,
6298,DescriptorName,D011183,12757344,,,10,Postoperative Complications,N,
6299,QualifierName,Q000209,12757344,,,10,,N,etiology
6300,DescriptorName,D011184,12757344,,,11,Postoperative Period,N,
6301,DescriptorName,D018570,12757344,,,12,Risk Assessment,N,
6302,DescriptorName,D014277,12757344,,,13,Trigeminal Neuralgia,N,
6303,QualifierName,Q000188,12757344,,,13,,N,drug therapy
6304,Chemical,D000894,12763355,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
6305,Chemical,D019804,12763355,Mesalamine,4Q81I59GXC,,,,
6306,DescriptorName,D000368,12763355,,,1,Aged,N,
6307,DescriptorName,D000894,12763355,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
6308,QualifierName,Q000009,12763355,,,2,,Y,adverse effects
6309,DescriptorName,D003093,12763355,,,3,"Colitis, Ulcerative",N,
6310,QualifierName,Q000188,12763355,,,3,,N,drug therapy
6311,DescriptorName,D007839,12763355,,,4,Functional Laterality,N,
6312,DescriptorName,D006801,12763355,,,5,Humans,N,
6313,DescriptorName,D008297,12763355,,,6,Male,N,
6314,DescriptorName,D019804,12763355,,,7,Mesalamine,N,
6315,QualifierName,Q000009,12763355,,,7,,Y,adverse effects
6316,DescriptorName,D009046,12763355,,,8,Motor Neurons,N,
6317,QualifierName,Q000187,12763355,,,8,,N,drug effects
6318,DescriptorName,D018482,12763355,,,9,"Muscle, Skeletal",N,
6319,QualifierName,Q000187,12763355,,,9,,N,drug effects
6320,DescriptorName,D011115,12763355,,,10,Polyneuropathies,N,
6321,QualifierName,Q000139,12763355,,,10,,Y,chemically induced
6322,DescriptorName,D011826,12763355,,,11,Radial Nerve,N,
6323,QualifierName,Q000187,12763355,,,11,,N,drug effects
6324,DescriptorName,D055139,12763355,,,12,Sensory Gating,N,
6325,QualifierName,Q000187,12763355,,,12,,N,drug effects
6326,DescriptorName,D014459,12763355,,,13,Ulnar Nerve,N,
6327,QualifierName,Q000187,12763355,,,13,,N,drug effects
6328,Chemical,D000935,12773807,Antifungal Agents,0,,,,
6329,Chemical,D015725,12773807,Fluconazole,8VZV102JFY,,,,
6330,Chemical,D011241,12773807,Prednisone,VB0R961HZT,,,,
6331,DescriptorName,D000935,12773807,,,1,Antifungal Agents,N,
6332,QualifierName,Q000008,12773807,,,1,,N,administration & dosage
6333,DescriptorName,D002481,12773807,,,2,Cellulitis,N,
6334,QualifierName,Q000150,12773807,,,2,,N,complications
6335,DescriptorName,D003453,12773807,,,3,Cryptococcosis,N,
6336,QualifierName,Q000150,12773807,,,3,,N,complications
6337,DescriptorName,D003924,12773807,,,4,"Diabetes Mellitus, Type 2",N,
6338,DescriptorName,D003937,12773807,,,5,"Diagnosis, Differential",N,
6339,DescriptorName,D004334,12773807,,,6,Drug Administration Schedule,N,
6340,DescriptorName,D015725,12773807,,,7,Fluconazole,N,
6341,QualifierName,Q000008,12773807,,,7,,N,administration & dosage
6342,DescriptorName,D006801,12773807,,,8,Humans,N,
6343,DescriptorName,D016867,12773807,,,9,Immunocompromised Host,Y,
6344,DescriptorName,D007871,12773807,,,10,Leg Ulcer,N,
6345,QualifierName,Q000150,12773807,,,10,,N,complications
6346,DescriptorName,D008297,12773807,,,11,Male,N,
6347,DescriptorName,D008875,12773807,,,12,Middle Aged,N,
6348,DescriptorName,D010392,12773807,,,13,Pemphigus,N,
6349,QualifierName,Q000150,12773807,,,13,,N,complications
6350,DescriptorName,D011241,12773807,,,14,Prednisone,N,
6351,QualifierName,Q000008,12773807,,,14,,N,administration & dosage
6352,Chemical,D000894,12786839,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
6353,Chemical,D012460,12786839,Sulfasalazine,3XC8GUZ6CB,,,,
6354,Chemical,D001191,12786839,Arylamine N-Acetyltransferase,EC 2.3.1.5,,,,
6355,Chemical,C478900,12786839,"NAT2 protein, human",EC 2.3.1.5,,,,
6356,DescriptorName,D000107,12786839,,,1,Acetylation,N,
6357,DescriptorName,D000328,12786839,,,2,Adult,N,
6358,DescriptorName,D000894,12786839,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
6359,QualifierName,Q000009,12786839,,,3,,Y,adverse effects
6360,DescriptorName,D001191,12786839,,,4,Arylamine N-Acetyltransferase,N,
6361,QualifierName,Q000235,12786839,,,4,,Y,genetics
6362,DescriptorName,D016022,12786839,,,5,Case-Control Studies,N,
6363,DescriptorName,D003875,12786839,,,6,Drug Eruptions,N,
6364,QualifierName,Q000235,12786839,,,6,,Y,genetics
6365,DescriptorName,D005260,12786839,,,7,Female,N,
6366,DescriptorName,D005838,12786839,,,8,Genotype,N,
6367,DescriptorName,D006801,12786839,,,9,Humans,N,
6368,DescriptorName,D015212,12786839,,,10,Inflammatory Bowel Diseases,N,
6369,QualifierName,Q000188,12786839,,,10,,N,drug therapy
6370,DescriptorName,D008297,12786839,,,11,Male,N,
6371,DescriptorName,D008875,12786839,,,12,Middle Aged,N,
6372,DescriptorName,D012150,12786839,,,13,"Polymorphism, Restriction Fragment Length",N,
6373,DescriptorName,D012460,12786839,,,14,Sulfasalazine,N,
6374,QualifierName,Q000009,12786839,,,14,,Y,adverse effects
6375,Chemical,D000911,12792223,"Antibodies, Monoclonal",0,,,,
6376,Chemical,D000069285,12792223,Infliximab,B72HH48FLU,,,,
6377,Chemical,D008727,12792223,Methotrexate,YL5FZ2Y5U1,,,,
6378,DescriptorName,D000911,12792223,,,1,"Antibodies, Monoclonal",N,
6379,QualifierName,Q000009,12792223,,,1,,Y,adverse effects
6380,DescriptorName,D003424,12792223,,,2,Crohn Disease,N,
6381,QualifierName,Q000188,12792223,,,2,,Y,drug therapy
6382,DescriptorName,D003937,12792223,,,3,"Diagnosis, Differential",N,
6383,DescriptorName,D005260,12792223,,,4,Female,N,
6384,DescriptorName,D006801,12792223,,,5,Humans,N,
6385,DescriptorName,D000069285,12792223,,,6,Infliximab,N,
6386,DescriptorName,D007262,12792223,,,7,"Infusions, Intravenous",N,
6387,DescriptorName,D007279,12792223,,,8,"Injections, Subcutaneous",N,
6388,DescriptorName,D008177,12792223,,,9,Lupus Vulgaris,N,
6389,QualifierName,Q000139,12792223,,,9,,N,chemically induced
6390,DescriptorName,D008727,12792223,,,10,Methotrexate,N,
6391,QualifierName,Q000008,12792223,,,10,,N,administration & dosage
6392,DescriptorName,D008875,12792223,,,11,Middle Aged,N,
6393,DescriptorName,D013577,12792223,,,12,Syndrome,N,
6394,Chemical,D000970,12796597,Antineoplastic Agents,0,,,,
6395,Chemical,D007155,12796597,Immunologic Factors,0,,,,
6396,Chemical,D016898,12796597,Interferon-alpha,0,,,,
6397,DescriptorName,D000328,12796597,,,1,Adult,N,
6398,DescriptorName,D000970,12796597,,,2,Antineoplastic Agents,N,
6399,QualifierName,Q000009,12796597,,,2,,Y,adverse effects
6400,DescriptorName,D005923,12796597,,,3,"Glomerulosclerosis, Focal Segmental",N,
6401,QualifierName,Q000139,12796597,,,3,,Y,chemically induced
6402,DescriptorName,D019698,12796597,,,4,"Hepatitis C, Chronic",N,
6403,QualifierName,Q000150,12796597,,,4,,Y,complications
6404,DescriptorName,D006801,12796597,,,5,Humans,N,
6405,DescriptorName,D007155,12796597,,,6,Immunologic Factors,N,
6406,QualifierName,Q000009,12796597,,,6,,Y,adverse effects
6407,DescriptorName,D016898,12796597,,,7,Interferon-alpha,N,
6408,QualifierName,Q000009,12796597,,,7,,Y,adverse effects
6409,DescriptorName,D015464,12796597,,,8,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
6410,QualifierName,Q000150,12796597,,,8,,Y,complications
6411,DescriptorName,D008297,12796597,,,9,Male,N,
6412,Chemical,D000911,12802933,"Antibodies, Monoclonal",0,,,,
6413,Chemical,D058846,12802933,"Antibodies, Monoclonal, Murine-Derived",0,,,,
6414,Chemical,D007075,12802933,Immunoglobulin M,0,,,,
6415,Chemical,D000069283,12802933,Rituximab,4F4X42SYQ6,,,,
6416,DescriptorName,D000744,12802933,,,1,"Anemia, Hemolytic, Autoimmune",N,
6417,QualifierName,Q000139,12802933,,,1,,Y,chemically induced
6418,DescriptorName,D000911,12802933,,,2,"Antibodies, Monoclonal",N,
6419,QualifierName,Q000009,12802933,,,2,,Y,adverse effects
6420,DescriptorName,D058846,12802933,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
6421,DescriptorName,D002471,12802933,,,4,"Cell Transformation, Neoplastic",N,
6422,DescriptorName,D018450,12802933,,,5,Disease Progression,N,
6423,DescriptorName,D006801,12802933,,,6,Humans,N,
6424,DescriptorName,D007075,12802933,,,7,Immunoglobulin M,N,
6425,DescriptorName,D015451,12802933,,,8,"Leukemia, Lymphocytic, Chronic, B-Cell",N,
6426,QualifierName,Q000150,12802933,,,8,,N,complications
6427,DescriptorName,D008232,12802933,,,9,Lymphoproliferative Disorders,N,
6428,QualifierName,Q000150,12802933,,,9,,Y,complications
6429,DescriptorName,D008297,12802933,,,10,Male,N,
6430,DescriptorName,D008875,12802933,,,11,Middle Aged,N,
6431,DescriptorName,D000069283,12802933,,,12,Rituximab,N,
6432,DescriptorName,D013163,12802933,,,13,Splenomegaly,N,
6433,Chemical,D000893,12806509,Anti-Inflammatory Agents,0,,,,
6434,Chemical,D017325,12806509,Hepatitis B Vaccines,0,,,,
6435,Chemical,D016756,12806509,"Immunoglobulins, Intravenous",0,,,,
6436,Chemical,D008775,12806509,Methylprednisolone,X4W7ZR7023,,,,
6437,DescriptorName,D000208,12806509,,,1,Acute Disease,N,
6438,DescriptorName,D017668,12806509,,,2,Age of Onset,N,
6439,DescriptorName,D000893,12806509,,,3,Anti-Inflammatory Agents,N,
6440,QualifierName,Q000627,12806509,,,3,,N,therapeutic use
6441,DescriptorName,D002675,12806509,,,4,"Child, Preschool",N,
6442,DescriptorName,D017325,12806509,,,5,Hepatitis B Vaccines,N,
6443,QualifierName,Q000009,12806509,,,5,,Y,adverse effects
6444,DescriptorName,D006801,12806509,,,6,Humans,N,
6445,DescriptorName,D016756,12806509,,,7,"Immunoglobulins, Intravenous",N,
6446,QualifierName,Q000627,12806509,,,7,,N,therapeutic use
6447,DescriptorName,D008297,12806509,,,8,Male,N,
6448,DescriptorName,D008775,12806509,,,9,Methylprednisolone,N,
6449,QualifierName,Q000627,12806509,,,9,,N,therapeutic use
6450,DescriptorName,D009188,12806509,,,10,"Myelitis, Transverse",N,
6451,QualifierName,Q000175,12806509,,,10,,N,diagnosis
6452,DescriptorName,D011379,12806509,,,11,Prognosis,N,
6453,DescriptorName,D012141,12806509,,,12,Respiratory Tract Infections,N,
6454,QualifierName,Q000150,12806509,,,12,,Y,complications
6455,DescriptorName,D014777,12806509,,,13,Virus Diseases,N,
6456,QualifierName,Q000150,12806509,,,13,,Y,complications
6457,Chemical,D004338,12811715,Drug Combinations,0,,,,
6458,Chemical,D006982,12811715,Hypertonic Solutions,0,,,,
6459,Chemical,D006993,12811715,Hypnotics and Sedatives,0,,,,
6460,Chemical,D004366,12811715,Nonprescription Drugs,0,,,,
6461,Chemical,D012457,12811715,Salicylamides,0,,,,
6462,Chemical,D000082,12811715,Acetaminophen,362O9ITL9D,,,,
6463,Chemical,D004155,12811715,Diphenhydramine,8GTS82S83M,,,,
6464,Chemical,D017693,12811715,Sodium Bicarbonate,8MDF5V39QO,,,,
6465,Chemical,D008701,12811715,Methapyrilene,A01LX40298,,,,
6466,Chemical,D001241,12811715,Aspirin,R16CO5Y76E,,,,
6467,DescriptorName,D000082,12811715,,,1,Acetaminophen,N,
6468,QualifierName,Q000506,12811715,,,1,,N,poisoning
6469,DescriptorName,D000328,12811715,,,2,Adult,N,
6470,DescriptorName,D001145,12811715,,,3,"Arrhythmias, Cardiac",N,
6471,QualifierName,Q000139,12811715,,,3,,Y,chemically induced
6472,DescriptorName,D001241,12811715,,,4,Aspirin,N,
6473,QualifierName,Q000506,12811715,,,4,,N,poisoning
6474,DescriptorName,D004155,12811715,,,5,Diphenhydramine,N,
6475,QualifierName,Q000506,12811715,,,5,,Y,poisoning
6476,DescriptorName,D004338,12811715,,,6,Drug Combinations,N,
6477,DescriptorName,D017809,12811715,,,7,Fatal Outcome,N,
6478,DescriptorName,D005260,12811715,,,8,Female,N,
6479,DescriptorName,D006801,12811715,,,9,Humans,N,
6480,DescriptorName,D006982,12811715,,,10,Hypertonic Solutions,N,
6481,DescriptorName,D006993,12811715,,,11,Hypnotics and Sedatives,N,
6482,QualifierName,Q000506,12811715,,,11,,N,poisoning
6483,DescriptorName,D007262,12811715,,,12,"Infusions, Intravenous",N,
6484,DescriptorName,D008297,12811715,,,13,Male,N,
6485,DescriptorName,D008701,12811715,,,14,Methapyrilene,N,
6486,QualifierName,Q000506,12811715,,,14,,N,poisoning
6487,DescriptorName,D004366,12811715,,,15,Nonprescription Drugs,N,
6488,QualifierName,Q000506,12811715,,,15,,N,poisoning
6489,DescriptorName,D012457,12811715,,,16,Salicylamides,N,
6490,QualifierName,Q000506,12811715,,,16,,N,poisoning
6491,DescriptorName,D017693,12811715,,,17,Sodium Bicarbonate,N,
6492,QualifierName,Q000008,12811715,,,17,,Y,administration & dosage
6493,DescriptorName,D013406,12811715,,,18,"Suicide, Attempted",N,
6494,DescriptorName,D016896,12811715,,,19,Treatment Outcome,N,
6495,DescriptorName,D000368,12823045,,,1,Aged,N,
6496,DescriptorName,D000971,12823045,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
6497,QualifierName,Q000009,12823045,,,2,,N,adverse effects
6498,DescriptorName,D002176,12823045,,,3,Candida albicans,N,
6499,QualifierName,Q000302,12823045,,,3,,Y,isolation & purification
6500,DescriptorName,D002177,12823045,,,4,Candidiasis,N,
6501,QualifierName,Q000175,12823045,,,4,,Y,diagnosis
6502,DescriptorName,D003937,12823045,,,5,"Diagnosis, Differential",N,
6503,DescriptorName,D017809,12823045,,,6,Fatal Outcome,N,
6504,DescriptorName,D006801,12823045,,,7,Humans,N,
6505,DescriptorName,D008228,12823045,,,8,"Lymphoma, Non-Hodgkin",N,
6506,QualifierName,Q000188,12823045,,,8,,N,drug therapy
6507,DescriptorName,D008297,12823045,,,9,Male,N,
6508,DescriptorName,D009102,12823045,,,10,Multiple Organ Failure,N,
6509,QualifierName,Q000382,12823045,,,10,,N,microbiology
6510,DescriptorName,D009894,12823045,,,11,Opportunistic Infections,N,
6511,QualifierName,Q000175,12823045,,,11,,N,diagnosis
6512,Chemical,D005938,12836099,Glucocorticoids,0,,,,
6513,Chemical,D011239,12836099,Prednisolone,9PHQ9Y1OLM,,,,
6514,Chemical,D008775,12836099,Methylprednisolone,X4W7ZR7023,,,,
6515,DescriptorName,D000284,12836099,,,1,"Administration, Oral",N,
6516,DescriptorName,D000293,12836099,,,2,Adolescent,N,
6517,DescriptorName,D005938,12836099,,,3,Glucocorticoids,N,
6518,QualifierName,Q000008,12836099,,,3,,N,administration & dosage
6519,DescriptorName,D006801,12836099,,,4,Humans,N,
6520,DescriptorName,D007275,12836099,,,5,"Injections, Intravenous",N,
6521,DescriptorName,D008297,12836099,,,6,Male,N,
6522,DescriptorName,D008775,12836099,,,7,Methylprednisolone,N,
6523,QualifierName,Q000008,12836099,,,7,,N,administration & dosage
6524,DescriptorName,D009404,12836099,,,8,Nephrotic Syndrome,N,
6525,QualifierName,Q000150,12836099,,,8,,Y,complications
6526,DescriptorName,D011239,12836099,,,9,Prednisolone,N,
6527,QualifierName,Q000008,12836099,,,9,,N,administration & dosage
6528,DescriptorName,D013262,12836099,,,10,Stevens-Johnson Syndrome,N,
6529,QualifierName,Q000150,12836099,,,10,,Y,complications
6530,Chemical,D011241,12847760,Prednisone,VB0R961HZT,,,,
6531,Chemical,D012293,12847760,Rifampin,VJT6J7R4TR,,,,
6532,DescriptorName,D000328,12847760,,,1,Adult,N,
6533,DescriptorName,D006801,12847760,,,2,Humans,N,
6534,DescriptorName,D007918,12847760,,,3,Leprosy,N,
6535,QualifierName,Q000188,12847760,,,3,,Y,drug therapy
6536,DescriptorName,D008297,12847760,,,4,Male,N,
6537,DescriptorName,D011241,12847760,,,5,Prednisone,N,
6538,QualifierName,Q000627,12847760,,,5,,Y,therapeutic use
6539,DescriptorName,D012293,12847760,,,6,Rifampin,N,
6540,QualifierName,Q000009,12847760,,,6,,Y,adverse effects
6541,DescriptorName,D012720,12847760,,,7,Severity of Illness Index,N,
6542,Chemical,D013792,12852380,Thalidomide,4Z8R6ORS6L,,,,
6543,DescriptorName,D000328,12852380,,,1,Adult,N,
6544,DescriptorName,D020031,12852380,,,2,Epstein-Barr Virus Infections,N,
6545,QualifierName,Q000150,12852380,,,2,,N,complications
6546,DescriptorName,D004892,12852380,,,3,Erythema Multiforme,N,
6547,QualifierName,Q000150,12852380,,,3,,N,complications
6548,DescriptorName,D005260,12852380,,,4,Female,N,
6549,DescriptorName,D006801,12852380,,,5,Humans,N,
6550,DescriptorName,D008875,12852380,,,6,Middle Aged,N,
6551,DescriptorName,D013792,12852380,,,7,Thalidomide,N,
6552,QualifierName,Q000009,12852380,,,7,,N,adverse effects
6553,Chemical,D000970,12854039,Antineoplastic Agents,0,,,,
6554,Chemical,D000998,12854039,Antiviral Agents,0,,,,
6555,Chemical,D007370,12854039,Interferon Type I,0,,,,
6556,Chemical,D016898,12854039,Interferon-alpha,0,,,,
6557,Chemical,D011994,12854039,Recombinant Proteins,0,,,,
6558,DescriptorName,D000328,12854039,,,1,Adult,N,
6559,DescriptorName,D000783,12854039,,,2,Aneurysm,N,
6560,QualifierName,Q000139,12854039,,,2,,N,chemically induced
6561,DescriptorName,D000970,12854039,,,3,Antineoplastic Agents,N,
6562,QualifierName,Q000009,12854039,,,3,,Y,adverse effects
6563,DescriptorName,D000998,12854039,,,4,Antiviral Agents,N,
6564,QualifierName,Q000009,12854039,,,4,,Y,adverse effects
6565,DescriptorName,D005123,12854039,,,5,Eye,N,
6566,QualifierName,Q000098,12854039,,,5,,N,blood supply
6567,DescriptorName,D005260,12854039,,,6,Female,N,
6568,DescriptorName,D005451,12854039,,,7,Fluorescein Angiography,N,
6569,DescriptorName,D019698,12854039,,,8,"Hepatitis C, Chronic",N,
6570,QualifierName,Q000188,12854039,,,8,,N,drug therapy
6571,DescriptorName,D006801,12854039,,,9,Humans,N,
6572,DescriptorName,D007370,12854039,,,10,Interferon Type I,N,
6573,QualifierName,Q000009,12854039,,,10,,Y,adverse effects
6574,DescriptorName,D016898,12854039,,,11,Interferon-alpha,N,
6575,QualifierName,Q000009,12854039,,,11,,Y,adverse effects
6576,DescriptorName,D015464,12854039,,,12,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
6577,QualifierName,Q000188,12854039,,,12,,N,drug therapy
6578,DescriptorName,D008279,12854039,,,13,Magnetic Resonance Imaging,N,
6579,DescriptorName,D008875,12854039,,,14,Middle Aged,N,
6580,DescriptorName,D009103,12854039,,,15,Multiple Sclerosis,N,
6581,QualifierName,Q000139,12854039,,,15,,Y,chemically induced
6582,DescriptorName,D009422,12854039,,,16,Nervous System Diseases,N,
6583,QualifierName,Q000139,12854039,,,16,,N,chemically induced
6584,DescriptorName,D009902,12854039,,,17,Optic Neuritis,N,
6585,QualifierName,Q000139,12854039,,,17,,Y,chemically induced
6586,DescriptorName,D011994,12854039,,,18,Recombinant Proteins,N,
6587,Chemical,D018931,12860350,"Antineoplastic Agents, Hormonal",0,,,,
6588,Chemical,D020845,12860350,Selective Estrogen Receptor Modulators,0,,,,
6589,Chemical,D013629,12860350,Tamoxifen,094ZI81Y45,,,,
6590,DescriptorName,D015746,12860350,,,1,Abdominal Pain,N,
6591,QualifierName,Q000139,12860350,,,1,,N,chemically induced
6592,DescriptorName,D000208,12860350,,,2,Acute Disease,N,
6593,DescriptorName,D000328,12860350,,,3,Adult,N,
6594,DescriptorName,D018931,12860350,,,4,"Antineoplastic Agents, Hormonal",N,
6595,QualifierName,Q000009,12860350,,,4,,Y,adverse effects
6596,DescriptorName,D001943,12860350,,,5,Breast Neoplasms,N,
6597,QualifierName,Q000188,12860350,,,5,,N,drug therapy
6598,DescriptorName,D018270,12860350,,,6,"Carcinoma, Ductal, Breast",N,
6599,QualifierName,Q000188,12860350,,,6,,N,drug therapy
6600,DescriptorName,D004715,12860350,,,7,Endometriosis,N,
6601,QualifierName,Q000139,12860350,,,7,,Y,chemically induced
6602,DescriptorName,D005260,12860350,,,8,Female,N,
6603,DescriptorName,D006801,12860350,,,9,Humans,N,
6604,DescriptorName,D010048,12860350,,,10,Ovarian Cysts,N,
6605,QualifierName,Q000175,12860350,,,10,,N,diagnosis
6606,DescriptorName,D017697,12860350,,,11,Premenopause,Y,
6607,DescriptorName,D020845,12860350,,,12,Selective Estrogen Receptor Modulators,N,
6608,QualifierName,Q000009,12860350,,,12,,Y,adverse effects
6609,DescriptorName,D013629,12860350,,,13,Tamoxifen,N,
6610,QualifierName,Q000009,12860350,,,13,,Y,adverse effects
6611,Chemical,D003622,12862258,Dapsone,8W5C518302,,,,
6612,DescriptorName,D000380,12862258,,,1,Agranulocytosis,N,
6613,QualifierName,Q000139,12862258,,,1,,Y,chemically induced
6614,DescriptorName,D003622,12862258,,,2,Dapsone,N,
6615,QualifierName,Q000009,12862258,,,2,,Y,adverse effects
6616,DescriptorName,D017809,12862258,,,3,Fatal Outcome,N,
6617,DescriptorName,D006801,12862258,,,4,Humans,N,
6618,DescriptorName,D015439,12862258,,,5,"Leprosy, Borderline",N,
6619,QualifierName,Q000188,12862258,,,5,,Y,drug therapy
6620,DescriptorName,D008297,12862258,,,6,Male,N,
6621,DescriptorName,D008875,12862258,,,7,Middle Aged,N,
6622,Chemical,D000925,12869178,Anticoagulants,0,,,,
6623,Chemical,D006629,12869178,Hirudins,0,,,,
6624,Chemical,D011994,12869178,Recombinant Proteins,0,,,,
6625,Chemical,D006493,12869178,Heparin,9005-49-6,,,,
6626,Chemical,C083544,12869178,lepirudin,Y43GF64R34,,,,
6627,DescriptorName,D000368,12869178,,,1,Aged,N,
6628,DescriptorName,D000925,12869178,,,2,Anticoagulants,N,
6629,QualifierName,Q000009,12869178,,,2,,Y,adverse effects
6630,DescriptorName,D001026,12869178,,,3,Coronary Artery Bypass,Y,
6631,DescriptorName,D005260,12869178,,,4,Female,N,
6632,DescriptorName,D006493,12869178,,,5,Heparin,N,
6633,QualifierName,Q000009,12869178,,,5,,Y,adverse effects
6634,DescriptorName,D006629,12869178,,,6,Hirudins,N,
6635,QualifierName,Q000031,12869178,,,6,,Y,analogs & derivatives
6636,DescriptorName,D006801,12869178,,,7,Humans,N,
6637,DescriptorName,D011183,12869178,,,8,Postoperative Complications,N,
6638,QualifierName,Q000188,12869178,,,8,,Y,drug therapy
6639,DescriptorName,D011655,12869178,,,9,Pulmonary Embolism,N,
6640,QualifierName,Q000188,12869178,,,9,,Y,drug therapy
6641,DescriptorName,D011994,12869178,,,10,Recombinant Proteins,N,
6642,QualifierName,Q000627,12869178,,,10,,Y,therapeutic use
6643,DescriptorName,D013921,12869178,,,11,Thrombocytopenia,N,
6644,QualifierName,Q000139,12869178,,,11,,Y,chemically induced
6645,Chemical,D000927,12875956,Anticonvulsants,0,,,,
6646,Chemical,D000077287,12875956,Levetiracetam,44YRR34555,,,,
6647,Chemical,D014635,12875956,Valproic Acid,614OI1Z5WI,,,,
6648,Chemical,D010889,12875956,Piracetam,ZH516LNZ10,,,,
6649,DescriptorName,D000927,12875956,,,1,Anticonvulsants,N,
6650,QualifierName,Q000009,12875956,,,1,,Y,adverse effects
6651,DescriptorName,D002648,12875956,,,2,Child,N,
6652,DescriptorName,D004305,12875956,,,3,"Dose-Response Relationship, Drug",N,
6653,DescriptorName,D004334,12875956,,,4,Drug Administration Schedule,N,
6654,DescriptorName,D004359,12875956,,,5,"Drug Therapy, Combination",N,
6655,DescriptorName,D004828,12875956,,,6,"Epilepsies, Partial",N,
6656,QualifierName,Q000188,12875956,,,6,,Y,drug therapy
6657,DescriptorName,D005260,12875956,,,7,Female,N,
6658,DescriptorName,D006801,12875956,,,8,Humans,N,
6659,DescriptorName,D000077287,12875956,,,9,Levetiracetam,N,
6660,DescriptorName,D010889,12875956,,,10,Piracetam,N,
6661,QualifierName,Q000009,12875956,,,10,,Y,adverse effects
6662,DescriptorName,D011605,12875956,,,11,"Psychoses, Substance-Induced",N,
6663,QualifierName,Q000175,12875956,,,11,,N,diagnosis
6664,DescriptorName,D014635,12875956,,,12,Valproic Acid,N,
6665,QualifierName,Q000009,12875956,,,12,,N,adverse effects
6666,Chemical,D014150,12880504,Antipsychotic Agents,0,,,,
6667,Chemical,D018967,12880504,Risperidone,L6UH7ZF8HC,,,,
6668,DescriptorName,D000328,12880504,,,1,Adult,N,
6669,DescriptorName,D000374,12880504,,,2,Aggression,N,
6670,DescriptorName,D014150,12880504,,,3,Antipsychotic Agents,N,
6671,QualifierName,Q000009,12880504,,,3,,Y,adverse effects
6672,DescriptorName,D001289,12880504,,,4,Attention Deficit Disorder with Hyperactivity,N,
6673,QualifierName,Q000150,12880504,,,4,,N,complications
6674,DescriptorName,D005260,12880504,,,5,Female,N,
6675,DescriptorName,D006801,12880504,,,6,Humans,N,
6676,DescriptorName,D008607,12880504,,,7,Intellectual Disability,N,
6677,QualifierName,Q000150,12880504,,,7,,N,complications
6678,DescriptorName,D008297,12880504,,,8,Male,N,
6679,DescriptorName,D009771,12880504,,,9,Obsessive-Compulsive Disorder,N,
6680,QualifierName,Q000139,12880504,,,9,,Y,chemically induced
6681,DescriptorName,D018967,12880504,,,10,Risperidone,N,
6682,QualifierName,Q000009,12880504,,,10,,Y,adverse effects
6683,DescriptorName,D013981,12880504,,,11,Tic Disorders,N,
6684,QualifierName,Q000150,12880504,,,11,,N,complications
6685,Chemical,D016178,1288290,Granulocyte-Macrophage Colony-Stimulating Factor,83869-56-1,,,,
6686,DescriptorName,D001853,1288290,,,1,Bone Marrow,N,
6687,QualifierName,Q000473,1288290,,,1,,Y,pathology
6688,DescriptorName,D016026,1288290,,,2,Bone Marrow Transplantation,Y,
6689,DescriptorName,D002455,1288290,,,3,Cell Division,N,
6690,QualifierName,Q000187,1288290,,,3,,N,drug effects
6691,DescriptorName,D002478,1288290,,,4,"Cells, Cultured",N,
6692,DescriptorName,D002675,1288290,,,5,"Child, Preschool",N,
6693,DescriptorName,D004305,1288290,,,6,"Dose-Response Relationship, Drug",N,
6694,DescriptorName,D016178,1288290,,,7,Granulocyte-Macrophage Colony-Stimulating Factor,N,
6695,QualifierName,Q000009,1288290,,,7,,Y,adverse effects
6696,DescriptorName,D006644,1288290,,,8,Histiocytes,N,
6697,QualifierName,Q000473,1288290,,,8,,Y,pathology
6698,DescriptorName,D006801,1288290,,,9,Humans,N,
6699,DescriptorName,D008297,1288290,,,10,Male,N,
6700,DescriptorName,D008059,1288290,,,11,Mucopolysaccharidosis I,N,
6701,QualifierName,Q000188,1288290,,,11,,N,drug therapy
6702,DescriptorName,D009994,1288290,,,12,Osmolar Concentration,N,
6703,Chemical,D007004,12885108,Hypoglycemic Agents,0,,,,
6704,Chemical,D045162,12885108,Thiazolidinediones,0,,,,
6705,Chemical,D000077154,12885108,Rosiglitazone,05V02F2KDG,,,,
6706,DescriptorName,D000368,12885108,,,1,Aged,N,
6707,DescriptorName,D003924,12885108,,,2,"Diabetes Mellitus, Type 2",N,
6708,QualifierName,Q000188,12885108,,,2,,N,drug therapy
6709,DescriptorName,D006333,12885108,,,3,Heart Failure,N,
6710,QualifierName,Q000139,12885108,,,3,,Y,chemically induced
6711,DescriptorName,D006801,12885108,,,4,Humans,N,
6712,DescriptorName,D007004,12885108,,,5,Hypoglycemic Agents,N,
6713,QualifierName,Q000009,12885108,,,5,,Y,adverse effects
6714,DescriptorName,D008297,12885108,,,6,Male,N,
6715,DescriptorName,D000077154,12885108,,,7,Rosiglitazone,N,
6716,DescriptorName,D045162,12885108,,,8,Thiazolidinediones,N,
6717,QualifierName,Q000009,12885108,,,8,,Y,adverse effects
6718,Chemical,D017984,12889716,Enoxaparin,0,,,,
6719,DescriptorName,D001707,12889716,,,1,"Biopsy, Needle",N,
6720,DescriptorName,D003875,12889716,,,2,Drug Eruptions,N,
6721,QualifierName,Q000209,12889716,,,2,,Y,etiology
6722,DescriptorName,D017984,12889716,,,3,Enoxaparin,N,
6723,QualifierName,Q000009,12889716,,,3,,Y,adverse effects
6724,DescriptorName,D005076,12889716,,,4,Exanthema,N,
6725,QualifierName,Q000139,12889716,,,4,,Y,chemically induced
6726,DescriptorName,D005260,12889716,,,5,Female,N,
6727,DescriptorName,D005500,12889716,,,6,Follow-Up Studies,N,
6728,DescriptorName,D006801,12889716,,,7,Humans,N,
6729,DescriptorName,D007150,12889716,,,8,Immunohistochemistry,N,
6730,DescriptorName,D007279,12889716,,,9,"Injections, Subcutaneous",N,
6731,DescriptorName,D008875,12889716,,,10,Middle Aged,N,
6732,DescriptorName,D009767,12889716,,,11,"Obesity, Morbid",N,
6733,DescriptorName,D018570,12889716,,,12,Risk Assessment,N,
6734,DescriptorName,D012720,12889716,,,13,Severity of Illness Index,N,
6735,DescriptorName,D020246,12889716,,,14,Venous Thrombosis,N,
6736,QualifierName,Q000175,12889716,,,14,,N,diagnosis
6737,Chemical,D000927,12908837,Anticonvulsants,0,,,,
6738,Chemical,D002998,12908837,Clonazepam,5PE9FDE8GB,,,,
6739,DescriptorName,D000374,12908837,,,1,Aggression,N,
6740,DescriptorName,D000927,12908837,,,2,Anticonvulsants,N,
6741,QualifierName,Q000009,12908837,,,2,,Y,adverse effects
6742,DescriptorName,D002998,12908837,,,3,Clonazepam,N,
6743,QualifierName,Q000009,12908837,,,3,,Y,adverse effects
6744,DescriptorName,D006801,12908837,,,4,Humans,N,
6745,DescriptorName,D008607,12908837,,,5,Intellectual Disability,N,
6746,QualifierName,Q000188,12908837,,,5,,Y,drug therapy
6747,DescriptorName,D008297,12908837,,,6,Male,N,
6748,DescriptorName,D001523,12908837,,,7,Mental Disorders,N,
6749,QualifierName,Q000209,12908837,,,7,,Y,etiology
6750,DescriptorName,D008875,12908837,,,8,Middle Aged,N,
6751,DescriptorName,D016728,12908837,,,9,Self-Injurious Behavior,N,
6752,QualifierName,Q000209,12908837,,,9,,N,etiology
6753,Chemical,D000900,12915840,Anti-Bacterial Agents,0,,,,
6754,Chemical,D000888,12915840,"Antibodies, Anti-Idiotypic",0,,,,
6755,Chemical,D007074,12915840,Immunoglobulin G,0,,,,
6756,Chemical,D002444,12915840,Cefuroxime,O1R9FJ93ED,,,,
6757,DescriptorName,D000743,12915840,,,1,"Anemia, Hemolytic",N,
6758,QualifierName,Q000139,12915840,,,1,,Y,chemically induced
6759,DescriptorName,D000900,12915840,,,2,Anti-Bacterial Agents,N,
6760,QualifierName,Q000009,12915840,,,2,,Y,adverse effects
6761,DescriptorName,D000888,12915840,,,3,"Antibodies, Anti-Idiotypic",N,
6762,DescriptorName,D002444,12915840,,,4,Cefuroxime,N,
6763,QualifierName,Q000009,12915840,,,4,,Y,adverse effects
6764,DescriptorName,D002675,12915840,,,5,"Child, Preschool",N,
6765,DescriptorName,D003298,12915840,,,6,Coombs Test,N,
6766,DescriptorName,D003681,12915840,,,7,Dehydration,N,
6767,QualifierName,Q000150,12915840,,,7,,N,complications
6768,DescriptorName,D005260,12915840,,,8,Female,N,
6769,DescriptorName,D006323,12915840,,,9,Heart Arrest,N,
6770,QualifierName,Q000150,12915840,,,9,,N,complications
6771,DescriptorName,D006417,12915840,,,10,Hematuria,N,
6772,QualifierName,Q000209,12915840,,,10,,N,etiology
6773,DescriptorName,D006801,12915840,,,11,Humans,N,
6774,DescriptorName,D007074,12915840,,,12,Immunoglobulin G,N,
6775,QualifierName,Q000276,12915840,,,12,,Y,immunology
6776,DescriptorName,D011014,12915840,,,13,Pneumonia,N,
6777,QualifierName,Q000150,12915840,,,13,,N,complications
6778,DescriptorName,D012131,12915840,,,14,Respiratory Insufficiency,N,
6779,QualifierName,Q000150,12915840,,,14,,N,complications
6780,Chemical,D000925,12921505,Anticoagulants,0,,,,
6781,Chemical,D010875,12921505,Pipecolic Acids,0,,,,
6782,Chemical,D006493,12921505,Heparin,9005-49-6,,,,
6783,Chemical,C031942,12921505,argatroban,IY90U61Z3S,,,,
6784,DescriptorName,D000208,12921505,,,1,Acute Disease,N,
6785,DescriptorName,D000328,12921505,,,2,Adult,N,
6786,DescriptorName,D000925,12921505,,,3,Anticoagulants,N,
6787,QualifierName,Q000008,12921505,,,3,,N,administration & dosage
6788,DescriptorName,D017809,12921505,,,4,Fatal Outcome,N,
6789,DescriptorName,D006493,12921505,,,5,Heparin,N,
6790,QualifierName,Q000008,12921505,,,5,,N,administration & dosage
6791,DescriptorName,D006801,12921505,,,6,Humans,N,
6792,DescriptorName,D007262,12921505,,,7,"Infusions, Intravenous",N,
6793,DescriptorName,D017093,12921505,,,8,Liver Failure,N,
6794,QualifierName,Q000150,12921505,,,8,,N,complications
6795,DescriptorName,D008297,12921505,,,9,Male,N,
6796,DescriptorName,D010875,12921505,,,10,Pipecolic Acids,N,
6797,QualifierName,Q000008,12921505,,,10,,N,administration & dosage
6798,DescriptorName,D006435,12921505,,,11,Renal Dialysis,N,
6799,DescriptorName,D051437,12921505,,,12,Renal Insufficiency,N,
6800,QualifierName,Q000150,12921505,,,12,,N,complications
6801,DescriptorName,D013921,12921505,,,13,Thrombocytopenia,N,
6802,QualifierName,Q000139,12921505,,,13,,Y,chemically induced
6803,DescriptorName,D020246,12921505,,,14,Venous Thrombosis,N,
6804,QualifierName,Q000150,12921505,,,14,,N,complications
6805,Chemical,D018687,12923827,"Antidepressive Agents, Second-Generation",0,,,,
6806,Chemical,D014150,12923827,Antipsychotic Agents,0,,,,
6807,Chemical,D006220,12923827,Haloperidol,J6292F8L3D,,,,
6808,Chemical,D016666,12923827,Fluvoxamine,O4L1XPO44W,,,,
6809,DescriptorName,D000328,12923827,,,1,Adult,N,
6810,DescriptorName,D018687,12923827,,,2,"Antidepressive Agents, Second-Generation",N,
6811,QualifierName,Q000009,12923827,,,2,,Y,adverse effects
6812,DescriptorName,D014150,12923827,,,3,Antipsychotic Agents,N,
6813,QualifierName,Q000627,12923827,,,3,,N,therapeutic use
6814,DescriptorName,D003702,12923827,,,4,Delusions,N,
6815,QualifierName,Q000139,12923827,,,4,,Y,chemically induced
6816,DescriptorName,D003937,12923827,,,5,"Diagnosis, Differential",N,
6817,DescriptorName,D016666,12923827,,,6,Fluvoxamine,N,
6818,QualifierName,Q000009,12923827,,,6,,Y,adverse effects
6819,DescriptorName,D006212,12923827,,,7,Hallucinations,N,
6820,QualifierName,Q000139,12923827,,,7,,Y,chemically induced
6821,DescriptorName,D006220,12923827,,,8,Haloperidol,N,
6822,QualifierName,Q000627,12923827,,,8,,N,therapeutic use
6823,DescriptorName,D006801,12923827,,,9,Humans,N,
6824,DescriptorName,D008297,12923827,,,10,Male,N,
6825,DescriptorName,D016584,12923827,,,11,Panic Disorder,N,
6826,QualifierName,Q000188,12923827,,,11,,Y,drug therapy
6827,DescriptorName,D016896,12923827,,,12,Treatment Outcome,N,
6828,Chemical,D014150,12927328,Antipsychotic Agents,0,,,,
6829,Chemical,D003024,12927328,Clozapine,J60AR2IKIC,,,,
6830,DescriptorName,D014150,12927328,,,1,Antipsychotic Agents,N,
6831,QualifierName,Q000009,12927328,,,1,,N,adverse effects
6832,DescriptorName,D001921,12927328,,,2,Brain,N,
6833,QualifierName,Q000000981,12927328,,,2,,N,diagnostic imaging
6834,DescriptorName,D003024,12927328,,,3,Clozapine,N,
6835,QualifierName,Q000627,12927328,,,3,,Y,therapeutic use
6836,DescriptorName,D003937,12927328,,,4,"Diagnosis, Differential",N,
6837,DescriptorName,D005260,12927328,,,5,Female,N,
6838,DescriptorName,D006801,12927328,,,6,Humans,N,
6839,DescriptorName,D008875,12927328,,,7,Middle Aged,N,
6840,DescriptorName,D010302,12927328,,,8,"Parkinson Disease, Secondary",N,
6841,QualifierName,Q000139,12927328,,,8,,N,chemically induced
6842,DescriptorName,D020734,12927328,,,9,Parkinsonian Disorders,N,
6843,QualifierName,Q000150,12927328,,,9,,Y,complications
6844,DescriptorName,D012008,12927328,,,10,Recurrence,N,
6845,DescriptorName,D012559,12927328,,,11,Schizophrenia,N,
6846,QualifierName,Q000150,12927328,,,11,,Y,complications
6847,DescriptorName,D012565,12927328,,,12,Schizophrenic Psychology,N,
6848,DescriptorName,D015899,12927328,,,13,"Tomography, Emission-Computed, Single-Photon",N,
6849,Chemical,D000998,12932249,Antiviral Agents,0,,,,
6850,Chemical,D000077190,12932249,Interferon alpha-2,0,,,,
6851,Chemical,D016898,12932249,Interferon-alpha,0,,,,
6852,Chemical,D011994,12932249,Recombinant Proteins,0,,,,
6853,DescriptorName,D000998,12932249,,,1,Antiviral Agents,N,
6854,QualifierName,Q000009,12932249,,,1,,Y,adverse effects
6855,DescriptorName,D003875,12932249,,,2,Drug Eruptions,N,
6856,QualifierName,Q000209,12932249,,,2,,Y,etiology
6857,DescriptorName,D005260,12932249,,,3,Female,N,
6858,DescriptorName,D019698,12932249,,,4,"Hepatitis C, Chronic",N,
6859,QualifierName,Q000188,12932249,,,4,,Y,drug therapy
6860,DescriptorName,D006801,12932249,,,5,Humans,N,
6861,DescriptorName,D017495,12932249,,,6,Hyperpigmentation,N,
6862,QualifierName,Q000139,12932249,,,6,,Y,chemically induced
6863,DescriptorName,D000077190,12932249,,,7,Interferon alpha-2,N,
6864,DescriptorName,D016898,12932249,,,8,Interferon-alpha,N,
6865,QualifierName,Q000009,12932249,,,8,,Y,adverse effects
6866,DescriptorName,D008297,12932249,,,9,Male,N,
6867,DescriptorName,D008875,12932249,,,10,Middle Aged,N,
6868,DescriptorName,D011994,12932249,,,11,Recombinant Proteins,N,
6869,DescriptorName,D014060,12932249,,,12,Tongue Diseases,N,
6870,QualifierName,Q000139,12932249,,,12,,N,chemically induced
6871,Chemical,D000900,12944250,Anti-Bacterial Agents,0,,,,
6872,Chemical,D002939,12944250,Ciprofloxacin,5E8K9I0O4U,,,,
6873,Chemical,D010397,12944250,Penicillanic Acid,87-53-6,,,,
6874,Chemical,D000078142,12944250,Tazobactam,SE10G96M8W,,,,
6875,Chemical,D010878,12944250,Piperacillin,X00B0D5O0E,,,,
6876,DescriptorName,D000900,12944250,,,1,Anti-Bacterial Agents,N,
6877,QualifierName,Q000009,12944250,,,1,,N,adverse effects
6878,DescriptorName,D002939,12944250,,,2,Ciprofloxacin,N,
6879,QualifierName,Q000009,12944250,,,2,,Y,adverse effects
6880,DescriptorName,D004359,12944250,,,3,"Drug Therapy, Combination",N,
6881,DescriptorName,D006801,12944250,,,4,Humans,N,
6882,DescriptorName,D008297,12944250,,,5,Male,N,
6883,DescriptorName,D008875,12944250,,,6,Middle Aged,N,
6884,DescriptorName,D010397,12944250,,,7,Penicillanic Acid,N,
6885,QualifierName,Q000009,12944250,,,7,,Y,adverse effects
6886,DescriptorName,D010878,12944250,,,8,Piperacillin,N,
6887,QualifierName,Q000009,12944250,,,8,,N,adverse effects
6888,DescriptorName,D010976,12944250,,,9,Platelet Count,N,
6889,DescriptorName,D018410,12944250,,,10,"Pneumonia, Bacterial",N,
6890,QualifierName,Q000150,12944250,,,10,,N,complications
6891,DescriptorName,D000078142,12944250,,,11,Tazobactam,N,
6892,DescriptorName,D013922,12944250,,,12,Thrombocytosis,N,
6893,QualifierName,Q000139,12944250,,,12,,Y,chemically induced
6894,Chemical,D010450,129501,Endopeptidases,EC 3.4.-,,,,
6895,Chemical,D002917,129501,Chymopapain,EC 3.4.22.6,,,,
6896,DescriptorName,D000328,129501,,,1,Adult,N,
6897,DescriptorName,D000707,129501,,,2,Anaphylaxis,N,
6898,QualifierName,Q000139,129501,,,2,,Y,chemically induced
6899,DescriptorName,D001344,129501,,,3,Autopsy,N,
6900,DescriptorName,D001416,129501,,,4,Back Pain,N,
6901,QualifierName,Q000188,129501,,,4,,N,drug therapy
6902,DescriptorName,D002917,129501,,,5,Chymopapain,N,
6903,QualifierName,Q000009,129501,,,5,,Y,adverse effects
6904,DescriptorName,D010450,129501,,,6,Endopeptidases,N,
6905,QualifierName,Q000009,129501,,,6,,Y,adverse effects
6906,DescriptorName,D005260,129501,,,7,Female,N,
6907,DescriptorName,D006801,129501,,,8,Humans,N,
6908,DescriptorName,D007405,129501,,,9,Intervertebral Disc Displacement,N,
6909,QualifierName,Q000188,129501,,,9,,Y,drug therapy
6910,DescriptorName,D008875,129501,,,10,Middle Aged,N,
6911,Chemical,D008094,12951892,Lithium,9FN79X2M3F,,,,
6912,DescriptorName,D000328,12951892,,,1,Adult,N,
6913,DescriptorName,D001714,12951892,,,2,Bipolar Disorder,N,
6914,QualifierName,Q000188,12951892,,,2,,Y,drug therapy
6915,DescriptorName,D005260,12951892,,,3,Female,N,
6916,DescriptorName,D006801,12951892,,,4,Humans,N,
6917,DescriptorName,D007231,12951892,,,5,"Infant, Newborn",N,
6918,DescriptorName,D007232,12951892,,,6,"Infant, Newborn, Diseases",N,
6919,QualifierName,Q000097,12951892,,,6,,N,blood
6920,DescriptorName,D008094,12951892,,,7,Lithium,N,
6921,QualifierName,Q000008,12951892,,,7,,N,administration & dosage
6922,DescriptorName,D009123,12951892,,,8,Muscle Hypotonia,N,
6923,QualifierName,Q000097,12951892,,,8,,N,blood
6924,DescriptorName,D011247,12951892,,,9,Pregnancy,N,
6925,DescriptorName,D011248,12951892,,,10,Pregnancy Complications,N,
6926,QualifierName,Q000188,12951892,,,10,,Y,drug therapy
6927,DescriptorName,D011297,12951892,,,11,Prenatal Exposure Delayed Effects,Y,
6928,DescriptorName,D012894,12951892,,,12,Sleep Stages,N,
6929,Chemical,D002220,1295628,Carbamazepine,33CM23913M,,,,
6930,Chemical,D011239,1295628,Prednisolone,9PHQ9Y1OLM,,,,
6931,DescriptorName,D000293,1295628,,,1,Adolescent,N,
6932,DescriptorName,D002220,1295628,,,2,Carbamazepine,N,
6933,QualifierName,Q000009,1295628,,,2,,Y,adverse effects
6934,DescriptorName,D004827,1295628,,,3,Epilepsy,N,
6935,QualifierName,Q000188,1295628,,,3,,N,drug therapy
6936,DescriptorName,D005260,1295628,,,4,Female,N,
6937,DescriptorName,D006801,1295628,,,5,Humans,N,
6938,DescriptorName,D008180,1295628,,,6,"Lupus Erythematosus, Systemic",N,
6939,QualifierName,Q000139,1295628,,,6,,Y,chemically induced
6940,DescriptorName,D011239,1295628,,,7,Prednisolone,N,
6941,QualifierName,Q000627,1295628,,,7,,N,therapeutic use
6942,Chemical,D000995,12962465,Antitubercular Agents,0,,,,
6943,Chemical,D007538,12962465,Isoniazid,V83O1VOZ8L,,,,
6944,DescriptorName,D000328,12962465,,,1,Adult,N,
6945,DescriptorName,D000995,12962465,,,2,Antitubercular Agents,N,
6946,QualifierName,Q000009,12962465,,,2,,Y,adverse effects
6947,DescriptorName,D006177,12962465,,,3,Gynecomastia,N,
6948,QualifierName,Q000139,12962465,,,3,,Y,chemically induced
6949,DescriptorName,D006801,12962465,,,4,Humans,N,
6950,DescriptorName,D007538,12962465,,,5,Isoniazid,N,
6951,QualifierName,Q000009,12962465,,,5,,Y,adverse effects
6952,DescriptorName,D008297,12962465,,,6,Male,N,
6953,DescriptorName,D010146,12962465,,,7,Pain,N,
6954,QualifierName,Q000209,12962465,,,7,,Y,etiology
6955,DescriptorName,D014397,12962465,,,8,"Tuberculosis, Pulmonary",N,
6956,QualifierName,Q000188,12962465,,,8,,Y,drug therapy
6957,Chemical,D005343,1310879,Fibrinolytic Agents,0,,,,
6958,Chemical,D006025,1310879,Glycosaminoglycans,0,,,,
6959,Chemical,D006495,1310879,"Heparin, Low-Molecular-Weight",0,,,,
6960,Chemical,D003871,1310879,Dermatan Sulfate,24967-94-0,,,,
6961,Chemical,D006493,1310879,Heparin,9005-49-6,,,,
6962,Chemical,D002809,1310879,Chondroitin Sulfates,9007-28-7,,,,
6963,Chemical,D006497,1310879,Heparitin Sulfate,9050-30-0,,,,
6964,Chemical,C035838,1310879,danaparoid,BI6GY4U9CW,,,,
6965,DescriptorName,D000368,1310879,,,1,Aged,N,
6966,DescriptorName,D002809,1310879,,,2,Chondroitin Sulfates,Y,
6967,DescriptorName,D003429,1310879,,,3,Cross Reactions,N,
6968,DescriptorName,D003871,1310879,,,4,Dermatan Sulfate,Y,
6969,DescriptorName,D005343,1310879,,,5,Fibrinolytic Agents,N,
6970,QualifierName,Q000627,1310879,,,5,,N,therapeutic use
6971,DescriptorName,D006025,1310879,,,6,Glycosaminoglycans,N,
6972,QualifierName,Q000627,1310879,,,6,,N,therapeutic use
6973,DescriptorName,D006493,1310879,,,7,Heparin,N,
6974,QualifierName,Q000009,1310879,,,7,,Y,adverse effects
6975,DescriptorName,D006495,1310879,,,8,"Heparin, Low-Molecular-Weight",N,
6976,QualifierName,Q000276,1310879,,,8,,N,immunology
6977,DescriptorName,D006497,1310879,,,9,Heparitin Sulfate,Y,
6978,DescriptorName,D006801,1310879,,,10,Humans,N,
6979,DescriptorName,D008297,1310879,,,11,Male,N,
6980,DescriptorName,D013921,1310879,,,12,Thrombocytopenia,N,
6981,QualifierName,Q000139,1310879,,,12,,N,chemically induced
6982,Chemical,D007741,1316047,Labetalol,R5H8897N95,,,,
6983,DescriptorName,D000328,1316047,,,1,Adult,N,
6984,DescriptorName,D002585,1316047,,,2,Cesarean Section,N,
6985,DescriptorName,D005260,1316047,,,3,Female,N,
6986,DescriptorName,D006801,1316047,,,4,Humans,N,
6987,DescriptorName,D007022,1316047,,,5,Hypotension,N,
6988,QualifierName,Q000139,1316047,,,5,,Y,chemically induced
6989,DescriptorName,D007741,1316047,,,6,Labetalol,N,
6990,QualifierName,Q000009,1316047,,,6,,Y,adverse effects
6991,DescriptorName,D011225,1316047,,,7,Pre-Eclampsia,N,
6992,QualifierName,Q000188,1316047,,,7,,Y,drug therapy
6993,DescriptorName,D011247,1316047,,,8,Pregnancy,N,
6994,DescriptorName,D011292,1316047,,,9,Premedication,N,
6995,DescriptorName,D013610,1316047,,,10,Tachycardia,N,
6996,QualifierName,Q000139,1316047,,,10,,Y,chemically induced
6997,Chemical,D015259,1348483,Dopamine Agents,0,,,,
6998,Chemical,D004873,1348483,Ergolines,0,,,,
6999,Chemical,D001971,1348483,Bromocriptine,3A64E3G5ZO,,,,
7000,Chemical,D000077465,1348483,Cabergoline,LL60K9J05T,,,,
7001,DescriptorName,D001971,1348483,,,1,Bromocriptine,N,
7002,QualifierName,Q000627,1348483,,,1,,N,therapeutic use
7003,DescriptorName,D000077465,1348483,,,2,Cabergoline,N,
7004,DescriptorName,D015259,1348483,,,3,Dopamine Agents,N,
7005,QualifierName,Q000008,1348483,,,3,,N,administration & dosage
7006,DescriptorName,D004873,1348483,,,4,Ergolines,N,
7007,QualifierName,Q000008,1348483,,,4,,N,administration & dosage
7008,DescriptorName,D006801,1348483,,,5,Humans,N,
7009,DescriptorName,D008171,1348483,,,6,Lung Diseases,N,
7010,QualifierName,Q000139,1348483,,,6,,Y,chemically induced
7011,DescriptorName,D008297,1348483,,,7,Male,N,
7012,DescriptorName,D008875,1348483,,,8,Middle Aged,N,
7013,DescriptorName,D010300,1348483,,,9,Parkinson Disease,N,
7014,QualifierName,Q000188,1348483,,,9,,Y,drug therapy
7015,DescriptorName,D010996,1348483,,,10,Pleural Effusion,N,
7016,QualifierName,Q000139,1348483,,,10,,N,chemically induced
7017,Chemical,D014673,1356045,Vecuronium Bromide,7E4PHP5N1D,,,,
7018,Chemical,D000251,1356045,Adenosine Triphosphatases,EC 3.6.1.-,,,,
7019,Chemical,D008775,1356045,Methylprednisolone,X4W7ZR7023,,,,
7020,DescriptorName,D000208,1356045,,,1,Acute Disease,N,
7021,DescriptorName,D000251,1356045,,,2,Adenosine Triphosphatases,N,
7022,QualifierName,Q000378,1356045,,,2,,N,metabolism
7023,DescriptorName,D000293,1356045,,,3,Adolescent,N,
7024,DescriptorName,D000328,1356045,,,4,Adult,N,
7025,DescriptorName,D005260,1356045,,,5,Female,N,
7026,DescriptorName,D006651,1356045,,,6,Histocytochemistry,N,
7027,DescriptorName,D006801,1356045,,,7,Humans,N,
7028,DescriptorName,D008297,1356045,,,8,Male,N,
7029,DescriptorName,D008775,1356045,,,9,Methylprednisolone,N,
7030,QualifierName,Q000009,1356045,,,9,,Y,adverse effects
7031,DescriptorName,D009132,1356045,,,10,Muscles,N,
7032,QualifierName,Q000294,1356045,,,10,,N,innervation
7033,DescriptorName,D009135,1356045,,,11,Muscular Diseases,N,
7034,QualifierName,Q000139,1356045,,,11,,Y,chemically induced
7035,DescriptorName,D009410,1356045,,,12,Nerve Degeneration,N,
7036,QualifierName,Q000502,1356045,,,12,,N,physiology
7037,DescriptorName,D009413,1356045,,,13,"Nerve Fibers, Myelinated",N,
7038,QualifierName,Q000502,1356045,,,13,,Y,physiology
7039,DescriptorName,D013224,1356045,,,14,Status Asthmaticus,N,
7040,QualifierName,Q000150,1356045,,,14,,Y,complications
7041,DescriptorName,D014673,1356045,,,15,Vecuronium Bromide,N,
7042,QualifierName,Q000009,1356045,,,15,,Y,adverse effects
7043,Chemical,D012460,1359782,Sulfasalazine,3XC8GUZ6CB,,,,
7044,DescriptorName,D000368,1359782,,,1,Aged,N,
7045,DescriptorName,D001989,1359782,,,2,Bronchiolitis Obliterans,N,
7046,QualifierName,Q000139,1359782,,,2,,Y,chemically induced
7047,DescriptorName,D003093,1359782,,,3,"Colitis, Ulcerative",N,
7048,QualifierName,Q000188,1359782,,,3,,N,drug therapy
7049,DescriptorName,D003875,1359782,,,4,Drug Eruptions,N,
7050,QualifierName,Q000209,1359782,,,4,,Y,etiology
7051,DescriptorName,D006801,1359782,,,5,Humans,N,
7052,DescriptorName,D008297,1359782,,,6,Male,N,
7053,DescriptorName,D010859,1359782,,,7,Pigmentation Disorders,N,
7054,QualifierName,Q000139,1359782,,,7,,Y,chemically induced
7055,DescriptorName,D011658,1359782,,,8,Pulmonary Fibrosis,N,
7056,QualifierName,Q000139,1359782,,,8,,Y,chemically induced
7057,DescriptorName,D012880,1359782,,,9,Skin Pigmentation,N,
7058,QualifierName,Q000187,1359782,,,9,,Y,drug effects
7059,DescriptorName,D012460,1359782,,,10,Sulfasalazine,N,
7060,QualifierName,Q000009,1359782,,,10,,Y,adverse effects
7061,Chemical,D015474,13680140,Isotretinoin,EH28UP18IF,,,,
7062,DescriptorName,D015502,13680140,,,1,"Absorptiometry, Photon",N,
7063,DescriptorName,D000153,13680140,,,2,Acne Keloid,N,
7064,QualifierName,Q000188,13680140,,,2,,N,drug therapy
7065,DescriptorName,D000284,13680140,,,3,"Administration, Oral",N,
7066,DescriptorName,D000328,13680140,,,4,Adult,N,
7067,DescriptorName,D002114,13680140,,,5,Calcinosis,N,
7068,QualifierName,Q000139,13680140,,,5,,N,chemically induced
7069,DescriptorName,D018450,13680140,,,6,Disease Progression,N,
7070,DescriptorName,D004334,13680140,,,7,Drug Administration Schedule,N,
7071,DescriptorName,D005269,13680140,,,8,Femur,N,
7072,QualifierName,Q000000981,13680140,,,8,,N,diagnostic imaging
7073,DescriptorName,D006801,13680140,,,9,Humans,N,
7074,DescriptorName,D015576,13680140,,,10,Hyperostosis,N,
7075,QualifierName,Q000139,13680140,,,10,,Y,chemically induced
7076,DescriptorName,D015474,13680140,,,11,Isotretinoin,N,
7077,QualifierName,Q000008,13680140,,,11,,N,administration & dosage
7078,DescriptorName,D008159,13680140,,,12,Lumbar Vertebrae,N,
7079,QualifierName,Q000000981,13680140,,,12,,N,diagnostic imaging
7080,DescriptorName,D008297,13680140,,,13,Male,N,
7081,DescriptorName,D010026,13680140,,,14,Osteosclerosis,N,
7082,QualifierName,Q000139,13680140,,,14,,Y,chemically induced
7083,DescriptorName,D012074,13680140,,,15,Remission Induction,N,
7084,QualifierName,Q000379,13680140,,,15,,N,methods
7085,DescriptorName,D013904,13680140,,,16,Thoracic Vertebrae,N,
7086,QualifierName,Q000000981,13680140,,,16,,N,diagnostic imaging
7087,Chemical,D001761,1378497,Bleomycin,11056-06-7,,,,
7088,DescriptorName,D000328,1378497,,,1,Adult,N,
7089,DescriptorName,D000368,1378497,,,2,Aged,N,
7090,DescriptorName,D001761,1378497,,,3,Bleomycin,N,
7091,QualifierName,Q000009,1378497,,,3,,Y,adverse effects
7092,DescriptorName,D004305,1378497,,,4,"Dose-Response Relationship, Drug",N,
7093,DescriptorName,D006801,1378497,,,5,Humans,N,
7094,DescriptorName,D008297,1378497,,,6,Male,N,
7095,DescriptorName,D008479,1378497,,,7,Mediastinal Neoplasms,N,
7096,QualifierName,Q000188,1378497,,,7,,N,drug therapy
7097,DescriptorName,D012595,1378497,,,8,"Scleroderma, Systemic",N,
7098,QualifierName,Q000139,1378497,,,8,,Y,chemically induced
7099,Chemical,D004837,1389744,Epinephrine,YKH834O4BH,,,,
7100,DescriptorName,D000328,1389744,,,1,Adult,N,
7101,DescriptorName,D001249,1389744,,,2,Asthma,N,
7102,QualifierName,Q000188,1389744,,,2,,N,drug therapy
7103,DescriptorName,D002311,1389744,,,3,"Cardiomyopathy, Dilated",N,
7104,QualifierName,Q000139,1389744,,,3,,Y,chemically induced
7105,DescriptorName,D004837,1389744,,,4,Epinephrine,N,
7106,QualifierName,Q000008,1389744,,,4,,N,administration & dosage
7107,DescriptorName,D006801,1389744,,,5,Humans,N,
7108,DescriptorName,D008297,1389744,,,6,Male,N,
7109,DescriptorName,D009330,1389744,,,7,Nebulizers and Vaporizers,N,
7110,DescriptorName,D012651,1389744,,,8,Self Medication,N,
7111,QualifierName,Q000009,1389744,,,8,,Y,adverse effects
7112,DescriptorName,D019966,1389744,,,9,Substance-Related Disorders,N,
7113,QualifierName,Q000150,1389744,,,9,,Y,complications
7114,DescriptorName,D013997,1389744,,,10,Time Factors,N,
7115,Chemical,D000974,1393348,"Antibodies, Antinuclear",0,,,,
7116,Chemical,D002220,1393348,Carbamazepine,33CM23913M,,,,
7117,DescriptorName,D000328,1393348,,,1,Adult,N,
7118,DescriptorName,D000974,1393348,,,2,"Antibodies, Antinuclear",N,
7119,QualifierName,Q000032,1393348,,,2,,N,analysis
7120,DescriptorName,D001714,1393348,,,3,Bipolar Disorder,N,
7121,QualifierName,Q000188,1393348,,,3,,Y,drug therapy
7122,DescriptorName,D002220,1393348,,,4,Carbamazepine,N,
7123,QualifierName,Q000009,1393348,,,4,,Y,adverse effects
7124,DescriptorName,D005260,1393348,,,5,Female,N,
7125,DescriptorName,D006801,1393348,,,6,Humans,N,
7126,DescriptorName,D008180,1393348,,,7,"Lupus Erythematosus, Systemic",N,
7127,QualifierName,Q000139,1393348,,,7,,Y,chemically induced
7128,Chemical,D015474,1401493,Isotretinoin,EH28UP18IF,,,,
7129,DescriptorName,D000152,1401493,,,1,Acne Vulgaris,N,
7130,QualifierName,Q000150,1401493,,,1,,N,complications
7131,DescriptorName,D000293,1401493,,,2,Adolescent,N,
7132,DescriptorName,D003560,1401493,,,3,Cysts,N,
7133,QualifierName,Q000139,1401493,,,3,,Y,chemically induced
7134,DescriptorName,D006801,1401493,,,4,Humans,N,
7135,DescriptorName,D015474,1401493,,,5,Isotretinoin,N,
7136,QualifierName,Q000009,1401493,,,5,,Y,adverse effects
7137,DescriptorName,D008297,1401493,,,6,Male,N,
7138,DescriptorName,D012871,1401493,,,7,Skin Diseases,N,
7139,QualifierName,Q000139,1401493,,,7,,Y,chemically induced
7140,Chemical,D005973,1414247,Glutamine,0RH81L854J,,,,
7141,Chemical,D014635,1414247,Valproic Acid,614OI1Z5WI,,,,
7142,Chemical,D010672,1414247,Phenytoin,6158TKW0C5,,,,
7143,Chemical,D000641,1414247,Ammonia,7664-41-7,,,,
7144,Chemical,D002222,1414247,Carbamoyl-Phosphate Synthase (Ammonia),EC 6.3.4.16,,,,
7145,DescriptorName,D000328,1414247,,,1,Adult,N,
7146,DescriptorName,D000592,1414247,,,2,"Amino Acid Metabolism, Inborn Errors",N,
7147,QualifierName,Q000175,1414247,,,2,,N,diagnosis
7148,DescriptorName,D000641,1414247,,,3,Ammonia,N,
7149,QualifierName,Q000097,1414247,,,3,,N,blood
7150,DescriptorName,D001284,1414247,,,4,Atrophy,N,
7151,DescriptorName,D002222,1414247,,,5,Carbamoyl-Phosphate Synthase (Ammonia),N,
7152,QualifierName,Q000172,1414247,,,5,,Y,deficiency
7153,DescriptorName,D003128,1414247,,,6,Coma,N,
7154,QualifierName,Q000139,1414247,,,6,,Y,chemically induced
7155,DescriptorName,D003337,1414247,,,7,Corpus Callosum,N,
7156,QualifierName,Q000473,1414247,,,7,,N,pathology
7157,DescriptorName,D004305,1414247,,,8,"Dose-Response Relationship, Drug",N,
7158,DescriptorName,D004359,1414247,,,9,"Drug Therapy, Combination",N,
7159,DescriptorName,D004829,1414247,,,10,"Epilepsy, Generalized",N,
7160,QualifierName,Q000188,1414247,,,10,,Y,drug therapy
7161,DescriptorName,D005260,1414247,,,11,Female,N,
7162,DescriptorName,D005973,1414247,,,12,Glutamine,N,
7163,QualifierName,Q000134,1414247,,,12,,N,cerebrospinal fluid
7164,DescriptorName,D006801,1414247,,,13,Humans,N,
7165,DescriptorName,D010672,1414247,,,14,Phenytoin,N,
7166,QualifierName,Q000627,1414247,,,14,,N,therapeutic use
7167,DescriptorName,D014057,1414247,,,15,"Tomography, X-Ray Computed",N,
7168,DescriptorName,D014635,1414247,,,16,Valproic Acid,N,
7169,QualifierName,Q000009,1414247,,,16,,Y,adverse effects
7170,Chemical,D002220,1420650,Carbamazepine,33CM23913M,,,,
7171,DescriptorName,D000328,1420650,,,1,Adult,N,
7172,DescriptorName,D001714,1420650,,,2,Bipolar Disorder,N,
7173,QualifierName,Q000188,1420650,,,2,,Y,drug therapy
7174,DescriptorName,D002220,1420650,,,3,Carbamazepine,N,
7175,QualifierName,Q000009,1420650,,,3,,Y,adverse effects
7176,DescriptorName,D004305,1420650,,,4,"Dose-Response Relationship, Drug",N,
7177,DescriptorName,D004359,1420650,,,5,"Drug Therapy, Combination",N,
7178,DescriptorName,D004576,1420650,,,6,Electromyography,N,
7179,QualifierName,Q000187,1420650,,,6,,N,drug effects
7180,DescriptorName,D005260,1420650,,,7,Female,N,
7181,DescriptorName,D006801,1420650,,,8,Humans,N,
7182,DescriptorName,D008297,1420650,,,9,Male,N,
7183,DescriptorName,D008875,1420650,,,10,Middle Aged,N,
7184,DescriptorName,D009460,1420650,,,11,Neurologic Examination,N,
7185,QualifierName,Q000187,1420650,,,11,,N,drug effects
7186,DescriptorName,D012559,1420650,,,12,Schizophrenia,N,
7187,QualifierName,Q000188,1420650,,,12,,Y,drug therapy
7188,DescriptorName,D012565,1420650,,,13,Schizophrenic Psychology,Y,
7189,DescriptorName,D014202,1420650,,,14,Tremor,N,
7190,QualifierName,Q000139,1420650,,,14,,Y,chemically induced
7191,Chemical,D000534,1422497,Alum Compounds,0,,,,
7192,Chemical,C041524,1422497,aluminum sulfate,34S289N54E,,,,
7193,Chemical,D003520,1422497,Cyclophosphamide,8N3DW7272P,,,,
7194,Chemical,D000535,1422497,Aluminum,CPD4NFA903,,,,
7195,DescriptorName,D000283,1422497,,,1,"Administration, Intravesical",N,
7196,DescriptorName,D000293,1422497,,,2,Adolescent,N,
7197,DescriptorName,D000328,1422497,,,3,Adult,N,
7198,DescriptorName,D000534,1422497,,,4,Alum Compounds,N,
7199,QualifierName,Q000008,1422497,,,4,,N,administration & dosage
7200,DescriptorName,D000535,1422497,,,5,Aluminum,N,
7201,QualifierName,Q000097,1422497,,,5,,N,blood
7202,DescriptorName,D003520,1422497,,,6,Cyclophosphamide,N,
7203,QualifierName,Q000009,1422497,,,6,,N,adverse effects
7204,DescriptorName,D003556,1422497,,,7,Cystitis,N,
7205,QualifierName,Q000139,1422497,,,7,,N,chemically induced
7206,DescriptorName,D004660,1422497,,,8,Encephalitis,N,
7207,QualifierName,Q000097,1422497,,,8,,N,blood
7208,DescriptorName,D006470,1422497,,,9,Hemorrhage,N,
7209,QualifierName,Q000139,1422497,,,9,,N,chemically induced
7210,DescriptorName,D006801,1422497,,,10,Humans,N,
7211,DescriptorName,D007938,1422497,,,11,Leukemia,N,
7212,QualifierName,Q000188,1422497,,,11,,N,drug therapy
7213,DescriptorName,D008297,1422497,,,12,Male,N,
7214,DescriptorName,D012640,1422497,,,13,Seizures,N,
7215,QualifierName,Q000097,1422497,,,13,,N,blood
7216,Chemical,D000336,1433432,Aerosols,0,,,,
7217,Chemical,D003894,1433432,Deamino Arginine Vasopressin,ENR1LLB0FP,,,,
7218,DescriptorName,D000281,1433432,,,1,"Administration, Intranasal",N,
7219,DescriptorName,D000336,1433432,,,2,Aerosols,N,
7220,DescriptorName,D002675,1433432,,,3,"Child, Preschool",N,
7221,DescriptorName,D003894,1433432,,,4,Deamino Arginine Vasopressin,N,
7222,QualifierName,Q000008,1433432,,,4,,N,administration & dosage
7223,DescriptorName,D004326,1433432,,,5,Drinking,N,
7224,DescriptorName,D004775,1433432,,,6,Enuresis,N,
7225,QualifierName,Q000188,1433432,,,6,,Y,drug therapy
7226,DescriptorName,D004830,1433432,,,7,"Epilepsy, Tonic-Clonic",N,
7227,QualifierName,Q000139,1433432,,,7,,Y,chemically induced
7228,DescriptorName,D006801,1433432,,,8,Humans,N,
7229,DescriptorName,D007010,1433432,,,9,Hyponatremia,N,
7230,QualifierName,Q000139,1433432,,,9,,Y,chemically induced
7231,DescriptorName,D008297,1433432,,,10,Male,N,
7232,DescriptorName,D014869,1433432,,,11,Water Intoxication,N,
7233,QualifierName,Q000139,1433432,,,11,,Y,chemically induced
7234,Chemical,D002220,1440123,Carbamazepine,33CM23913M,,,,
7235,DescriptorName,D000328,1440123,,,1,Adult,N,
7236,DescriptorName,D000766,1440123,,,2,"Anesthesia, Dental",Y,
7237,DescriptorName,D000768,1440123,,,3,"Anesthesia, General",Y,
7238,DescriptorName,D002220,1440123,,,4,Carbamazepine,N,
7239,QualifierName,Q000009,1440123,,,4,,Y,adverse effects
7240,DescriptorName,D000075202,1440123,,,5,Contraindications,N,
7241,DescriptorName,D003730,1440123,,,6,Dental Care for Disabled,Y,
7242,DescriptorName,D006801,1440123,,,7,Humans,N,
7243,DescriptorName,D007177,1440123,,,8,Inappropriate ADH Syndrome,N,
7244,QualifierName,Q000139,1440123,,,8,,Y,chemically induced
7245,DescriptorName,D008607,1440123,,,9,Intellectual Disability,N,
7246,DescriptorName,D008297,1440123,,,10,Male,N,
7247,DescriptorName,D012640,1440123,,,11,Seizures,N,
7248,QualifierName,Q000188,1440123,,,11,,N,drug therapy
7249,Chemical,D007328,1445134,Insulin,0,,,,
7250,Chemical,D009640,1445134,Norethindrone,T18F433X4S,,,,
7251,DescriptorName,D000328,1445134,,,1,Adult,N,
7252,DescriptorName,D002987,1445134,,,2,Clitoris,N,
7253,QualifierName,Q000473,1445134,,,2,,N,pathology
7254,DescriptorName,D016640,1445134,,,3,"Diabetes, Gestational",N,
7255,QualifierName,Q000139,1445134,,,3,,Y,chemically induced
7256,DescriptorName,D005260,1445134,,,4,Female,N,
7257,DescriptorName,D005500,1445134,,,5,Follow-Up Studies,N,
7258,DescriptorName,D005951,1445134,,,6,Glucose Tolerance Test,N,
7259,DescriptorName,D006801,1445134,,,7,Humans,N,
7260,DescriptorName,D006984,1445134,,,8,Hypertrophy,N,
7261,QualifierName,Q000139,1445134,,,8,,N,chemically induced
7262,DescriptorName,D007226,1445134,,,9,Infant Mortality,N,
7263,DescriptorName,D007231,1445134,,,10,"Infant, Newborn",N,
7264,DescriptorName,D007328,1445134,,,11,Insulin,N,
7265,QualifierName,Q000627,1445134,,,11,,N,therapeutic use
7266,DescriptorName,D008875,1445134,,,12,Middle Aged,N,
7267,DescriptorName,D009640,1445134,,,13,Norethindrone,N,
7268,QualifierName,Q000009,1445134,,,13,,Y,adverse effects
7269,DescriptorName,D011247,1445134,,,14,Pregnancy,N,
7270,DescriptorName,D016896,1445134,,,15,Treatment Outcome,N,
7271,Chemical,D002316,1450506,Cardiotonic Agents,0,,,,
7272,Chemical,D004232,1450506,Diuretics,0,,,,
7273,Chemical,D007155,1450506,Immunologic Factors,0,,,,
7274,Chemical,D007370,1450506,Interferon Type I,0,,,,
7275,Chemical,D011994,1450506,Recombinant Proteins,0,,,,
7276,Chemical,D003520,1450506,Cyclophosphamide,8N3DW7272P,,,,
7277,Chemical,D011239,1450506,Prednisolone,9PHQ9Y1OLM,,,,
7278,Chemical,D008558,1450506,Melphalan,Q41OR9510P,,,,
7279,Chemical,D014751,1450506,Vindesine,RSA8KO39WH,,,,
7280,DescriptorName,D000971,1450506,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
7281,QualifierName,Q000627,1450506,,,1,,N,therapeutic use
7282,DescriptorName,D002316,1450506,,,2,Cardiotonic Agents,N,
7283,QualifierName,Q000627,1450506,,,2,,N,therapeutic use
7284,DescriptorName,D003131,1450506,,,3,Combined Modality Therapy,N,
7285,DescriptorName,D003520,1450506,,,4,Cyclophosphamide,N,
7286,QualifierName,Q000008,1450506,,,4,,N,administration & dosage
7287,DescriptorName,D004232,1450506,,,5,Diuretics,N,
7288,QualifierName,Q000627,1450506,,,5,,N,therapeutic use
7289,DescriptorName,D005260,1450506,,,6,Female,N,
7290,DescriptorName,D006333,1450506,,,7,Heart Failure,N,
7291,QualifierName,Q000139,1450506,,,7,,Y,chemically induced
7292,DescriptorName,D006801,1450506,,,8,Humans,N,
7293,DescriptorName,D007155,1450506,,,9,Immunologic Factors,N,
7294,QualifierName,Q000009,1450506,,,9,,Y,adverse effects
7295,DescriptorName,D007370,1450506,,,10,Interferon Type I,N,
7296,QualifierName,Q000009,1450506,,,10,,Y,adverse effects
7297,DescriptorName,D008558,1450506,,,11,Melphalan,N,
7298,QualifierName,Q000008,1450506,,,11,,N,administration & dosage
7299,DescriptorName,D008875,1450506,,,12,Middle Aged,N,
7300,DescriptorName,D009101,1450506,,,13,Multiple Myeloma,N,
7301,QualifierName,Q000150,1450506,,,13,,Y,complications
7302,DescriptorName,D010956,1450506,,,14,Plasmapheresis,N,
7303,DescriptorName,D011239,1450506,,,15,Prednisolone,N,
7304,QualifierName,Q000008,1450506,,,15,,N,administration & dosage
7305,DescriptorName,D011994,1450506,,,16,Recombinant Proteins,N,
7306,DescriptorName,D014751,1450506,,,17,Vindesine,N,
7307,QualifierName,Q000008,1450506,,,17,,N,administration & dosage
7308,Chemical,D007166,14514135,Immunosuppressive Agents,0,,,,
7309,Chemical,D003520,14514135,Cyclophosphamide,8N3DW7272P,,,,
7310,DescriptorName,D000328,14514135,,,1,Adult,N,
7311,DescriptorName,D003520,14514135,,,2,Cyclophosphamide,N,
7312,QualifierName,Q000009,14514135,,,2,,Y,adverse effects
7313,DescriptorName,D003937,14514135,,,3,"Diagnosis, Differential",N,
7314,DescriptorName,D005260,14514135,,,4,Female,N,
7315,DescriptorName,D016575,14514135,,,5,Hidradenitis,N,
7316,QualifierName,Q000139,14514135,,,5,,Y,chemically induced
7317,DescriptorName,D006801,14514135,,,6,Humans,N,
7318,DescriptorName,D007166,14514135,,,7,Immunosuppressive Agents,N,
7319,QualifierName,Q000009,14514135,,,7,,Y,adverse effects
7320,DescriptorName,D008181,14514135,,,8,Lupus Nephritis,N,
7321,QualifierName,Q000188,14514135,,,8,,Y,drug therapy
7322,DescriptorName,D018366,14514135,,,9,"Vasculitis, Leukocytoclastic, Cutaneous",N,
7323,QualifierName,Q000175,14514135,,,9,,Y,diagnosis
7324,Chemical,D000998,14522628,Antiviral Agents,0,,,,
7325,Chemical,D015774,14522628,Ganciclovir,P9G3CKZ4P5,,,,
7326,DescriptorName,D017088,14522628,,,1,AIDS-Related Opportunistic Infections,N,
7327,QualifierName,Q000188,14522628,,,1,,Y,drug therapy
7328,DescriptorName,D000328,14522628,,,2,Adult,N,
7329,DescriptorName,D000998,14522628,,,3,Antiviral Agents,N,
7330,QualifierName,Q000009,14522628,,,3,,Y,adverse effects
7331,DescriptorName,D003586,14522628,,,4,Cytomegalovirus Infections,N,
7332,QualifierName,Q000188,14522628,,,4,,Y,drug therapy
7333,DescriptorName,D005076,14522628,,,5,Exanthema,N,
7334,QualifierName,Q000139,14522628,,,5,,Y,chemically induced
7335,DescriptorName,D017809,14522628,,,6,Fatal Outcome,N,
7336,DescriptorName,D005260,14522628,,,7,Female,N,
7337,DescriptorName,D015774,14522628,,,8,Ganciclovir,N,
7338,QualifierName,Q000009,14522628,,,8,,Y,adverse effects
7339,DescriptorName,D006470,14522628,,,9,Hemorrhage,N,
7340,QualifierName,Q000139,14522628,,,9,,Y,chemically induced
7341,DescriptorName,D006801,14522628,,,10,Humans,N,
7342,Chemical,D015575,14526130,Roxithromycin,21KOF230FA,,,,
7343,Chemical,D001623,14526130,Betamethasone,9842X06Q6M,,,,
7344,DescriptorName,D000208,14526130,,,1,Acute Disease,N,
7345,DescriptorName,D001623,14526130,,,2,Betamethasone,N,
7346,QualifierName,Q000009,14526130,,,2,,Y,adverse effects
7347,DescriptorName,D006801,14526130,,,3,Humans,N,
7348,DescriptorName,D008297,14526130,,,4,Male,N,
7349,DescriptorName,D008875,14526130,,,5,Middle Aged,N,
7350,DescriptorName,D010195,14526130,,,6,Pancreatitis,N,
7351,QualifierName,Q000139,14526130,,,6,,Y,chemically induced
7352,DescriptorName,D012141,14526130,,,7,Respiratory Tract Infections,N,
7353,QualifierName,Q000150,14526130,,,7,,N,complications
7354,DescriptorName,D015575,14526130,,,8,Roxithromycin,N,
7355,QualifierName,Q000009,14526130,,,8,,Y,adverse effects
7356,Chemical,D005665,14530108,Furosemide,7LXU5N7ZO5,,,,
7357,Chemical,D017693,14530108,Sodium Bicarbonate,8MDF5V39QO,,,,
7358,Chemical,D016559,14530108,Tacrolimus,WM0HAQ4WNM,,,,
7359,DescriptorName,D000141,14530108,,,1,"Acidosis, Renal Tubular",N,
7360,QualifierName,Q000139,14530108,,,1,,Y,chemically induced
7361,DescriptorName,D004359,14530108,,,2,"Drug Therapy, Combination",N,
7362,DescriptorName,D005260,14530108,,,3,Female,N,
7363,DescriptorName,D005500,14530108,,,4,Follow-Up Studies,N,
7364,DescriptorName,D005665,14530108,,,5,Furosemide,N,
7365,QualifierName,Q000008,14530108,,,5,,N,administration & dosage
7366,DescriptorName,D006801,14530108,,,6,Humans,N,
7367,DescriptorName,D007223,14530108,,,7,Infant,N,
7368,DescriptorName,D016031,14530108,,,8,Liver Transplantation,N,
7369,QualifierName,Q000009,14530108,,,8,,Y,adverse effects
7370,DescriptorName,D019520,14530108,,,9,Living Donors,Y,
7371,DescriptorName,D018570,14530108,,,10,Risk Assessment,N,
7372,DescriptorName,D012720,14530108,,,11,Severity of Illness Index,N,
7373,DescriptorName,D017693,14530108,,,12,Sodium Bicarbonate,N,
7374,QualifierName,Q000008,14530108,,,12,,N,administration & dosage
7375,DescriptorName,D016559,14530108,,,13,Tacrolimus,N,
7376,QualifierName,Q000009,14530108,,,13,,Y,adverse effects
7377,DescriptorName,D014181,14530108,,,14,Transplantation Immunology,N,
7378,DescriptorName,D016896,14530108,,,15,Treatment Outcome,N,
7379,Chemical,D000978,14557583,Antiparkinson Agents,0,,,,
7380,Chemical,D010479,14557583,Pergolide,24MJ822NZ9,,,,
7381,Chemical,D012642,14557583,Selegiline,2K1V7GP655,,,,
7382,Chemical,D007980,14557583,Levodopa,46627O600J,,,,
7383,DescriptorName,D000368,14557583,,,1,Aged,N,
7384,DescriptorName,D000978,14557583,,,2,Antiparkinson Agents,N,
7385,QualifierName,Q000009,14557583,,,2,,Y,adverse effects
7386,DescriptorName,D006970,14557583,,,3,Disorders of Excessive Somnolence,N,
7387,QualifierName,Q000097,14557583,,,3,,N,blood
7388,DescriptorName,D004311,14557583,,,4,Double-Blind Method,N,
7389,DescriptorName,D005260,14557583,,,5,Female,N,
7390,DescriptorName,D006801,14557583,,,6,Humans,N,
7391,DescriptorName,D007980,14557583,,,7,Levodopa,N,
7392,QualifierName,Q000009,14557583,,,7,,Y,adverse effects
7393,DescriptorName,D010300,14557583,,,8,Parkinson Disease,N,
7394,QualifierName,Q000188,14557583,,,8,,Y,drug therapy
7395,DescriptorName,D010479,14557583,,,9,Pergolide,N,
7396,QualifierName,Q000627,14557583,,,9,,N,therapeutic use
7397,DescriptorName,D017286,14557583,,,10,Polysomnography,N,
7398,QualifierName,Q000379,14557583,,,10,,N,methods
7399,DescriptorName,D011930,14557583,,,11,Reaction Time,N,
7400,QualifierName,Q000187,14557583,,,11,,N,drug effects
7401,DescriptorName,D012642,14557583,,,12,Selegiline,N,
7402,QualifierName,Q000627,14557583,,,12,,N,therapeutic use
7403,Chemical,D000964,14561622,"Antimetabolites, Antineoplastic",0,,,,
7404,Chemical,D008727,14561622,Methotrexate,YL5FZ2Y5U1,,,,
7405,DescriptorName,D000208,14561622,,,1,Acute Disease,N,
7406,DescriptorName,D000293,14561622,,,2,Adolescent,N,
7407,DescriptorName,D000964,14561622,,,3,"Antimetabolites, Antineoplastic",N,
7408,QualifierName,Q000008,14561622,,,3,,N,administration & dosage
7409,DescriptorName,D001921,14561622,,,4,Brain,N,
7410,QualifierName,Q000473,14561622,,,4,,N,pathology
7411,DescriptorName,D001929,14561622,,,5,Brain Edema,N,
7412,QualifierName,Q000139,14561622,,,5,,N,chemically induced
7413,DescriptorName,D038524,14561622,,,6,Diffusion Magnetic Resonance Imaging,N,
7414,DescriptorName,D005260,14561622,,,7,Female,N,
7415,DescriptorName,D006801,14561622,,,8,Humans,N,
7416,DescriptorName,D007278,14561622,,,9,"Injections, Spinal",N,
7417,DescriptorName,D008727,14561622,,,10,Methotrexate,N,
7418,QualifierName,Q000008,14561622,,,10,,N,administration & dosage
7419,DescriptorName,D020258,14561622,,,11,Neurotoxicity Syndromes,N,
7420,QualifierName,Q000209,14561622,,,11,,Y,etiology
7421,DescriptorName,D054198,14561622,,,12,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
7422,QualifierName,Q000188,14561622,,,12,,N,drug therapy
7423,Chemical,D000927,14566215,Anticonvulsants,0,,,,
7424,Chemical,D014635,14566215,Valproic Acid,614OI1Z5WI,,,,
7425,DescriptorName,D000328,14566215,,,1,Adult,N,
7426,DescriptorName,D000927,14566215,,,2,Anticonvulsants,N,
7427,QualifierName,Q000009,14566215,,,2,,Y,adverse effects
7428,DescriptorName,D001714,14566215,,,3,Bipolar Disorder,N,
7429,QualifierName,Q000188,14566215,,,3,,N,drug therapy
7430,DescriptorName,D002986,14566215,,,4,Clinical Trials as Topic,N,
7431,DescriptorName,D019317,14566215,,,5,Evidence-Based Medicine,N,
7432,DescriptorName,D005260,14566215,,,6,Female,N,
7433,DescriptorName,D005333,14566215,,,7,Fetus,N,
7434,QualifierName,Q000187,14566215,,,7,,N,drug effects
7435,DescriptorName,D006801,14566215,,,8,Humans,N,
7436,DescriptorName,D008603,14566215,,,9,Mental Health,N,
7437,DescriptorName,D011247,14566215,,,10,Pregnancy,N,
7438,DescriptorName,D011248,14566215,,,11,Pregnancy Complications,N,
7439,QualifierName,Q000188,14566215,,,11,,Y,drug therapy
7440,DescriptorName,D014635,14566215,,,12,Valproic Acid,N,
7441,QualifierName,Q000009,14566215,,,12,,N,adverse effects
7442,Chemical,D015282,14585456,Octreotide,RWM8CCW8GP,,,,
7443,Chemical,D005905,14585456,Glyburide,SX6K58TVWC,,,,
7444,DescriptorName,D000328,14585456,,,1,Adult,N,
7445,DescriptorName,D005260,14585456,,,2,Female,N,
7446,DescriptorName,D005905,14585456,,,3,Glyburide,N,
7447,QualifierName,Q000008,14585456,,,3,,N,administration & dosage
7448,DescriptorName,D006801,14585456,,,4,Humans,N,
7449,DescriptorName,D007003,14585456,,,5,Hypoglycemia,N,
7450,QualifierName,Q000139,14585456,,,5,,N,chemically induced
7451,DescriptorName,D015282,14585456,,,6,Octreotide,N,
7452,QualifierName,Q000627,14585456,,,6,,Y,therapeutic use
7453,DescriptorName,D013406,14585456,,,7,"Suicide, Attempted",N,
7454,Chemical,D000995,14601701,Antitubercular Agents,0,,,,
7455,Chemical,D004977,14601701,Ethambutol,8G167061QZ,,,,
7456,DescriptorName,D000328,14601701,,,1,Adult,N,
7457,DescriptorName,D000995,14601701,,,2,Antitubercular Agents,N,
7458,QualifierName,Q000009,14601701,,,2,,Y,adverse effects
7459,DescriptorName,D004977,14601701,,,3,Ethambutol,N,
7460,QualifierName,Q000009,14601701,,,3,,Y,adverse effects
7461,DescriptorName,D006801,14601701,,,4,Humans,N,
7462,DescriptorName,D008297,14601701,,,5,Male,N,
7463,DescriptorName,D009901,14601701,,,6,Optic Nerve Diseases,N,
7464,QualifierName,Q000139,14601701,,,6,,Y,chemically induced
7465,DescriptorName,D014376,14601701,,,7,Tuberculosis,N,
7466,QualifierName,Q000188,14601701,,,7,,Y,drug therapy
7467,Chemical,D004366,14607011,Nonprescription Drugs,0,,,,
7468,Chemical,D003915,14607011,Dextromethorphan,7355X3ROTS,,,,
7469,Chemical,D004809,14607011,Ephedrine,GN83C131XS,,,,
7470,Chemical,D001977,14607011,Brompheniramine,H57G17P2FN,,,,
7471,DescriptorName,D001977,14607011,,,1,Brompheniramine,N,
7472,QualifierName,Q000032,14607011,,,1,,N,analysis
7473,DescriptorName,D002849,14607011,,,2,"Chromatography, Gas",N,
7474,DescriptorName,D003139,14607011,,,3,Common Cold,N,
7475,QualifierName,Q000188,14607011,,,3,,N,drug therapy
7476,DescriptorName,D003915,14607011,,,4,Dextromethorphan,N,
7477,QualifierName,Q000032,14607011,,,4,,N,analysis
7478,DescriptorName,D004809,14607011,,,5,Ephedrine,N,
7479,QualifierName,Q000032,14607011,,,5,,N,analysis
7480,DescriptorName,D017809,14607011,,,6,Fatal Outcome,N,
7481,DescriptorName,D005260,14607011,,,7,Female,N,
7482,DescriptorName,D006801,14607011,,,8,Humans,N,
7483,DescriptorName,D007223,14607011,,,9,Infant,N,
7484,DescriptorName,D008099,14607011,,,10,Liver,N,
7485,QualifierName,Q000737,14607011,,,10,,N,chemistry
7486,DescriptorName,D004366,14607011,,,11,Nonprescription Drugs,N,
7487,QualifierName,Q000032,14607011,,,11,,Y,analysis
7488,Chemical,D000925,14614357,Anticoagulants,0,,,,
7489,Chemical,C450260,14614357,"CYP2C9 protein, human",EC 1.14.13.-,,,,
7490,Chemical,D065729,14614357,Cytochrome P-450 CYP2C9,EC 1.14.13.-,,,,
7491,Chemical,D001189,14614357,Aryl Hydrocarbon Hydroxylases,EC 1.14.14.1,,,,
7492,Chemical,D000074,14614357,Acenocoumarol,I6WP63U32H,,,,
7493,DescriptorName,D000074,14614357,,,1,Acenocoumarol,N,
7494,QualifierName,Q000009,14614357,,,1,,Y,adverse effects
7495,DescriptorName,D000328,14614357,,,2,Adult,N,
7496,DescriptorName,D000925,14614357,,,3,Anticoagulants,N,
7497,QualifierName,Q000009,14614357,,,3,,Y,adverse effects
7498,DescriptorName,D001189,14614357,,,4,Aryl Hydrocarbon Hydroxylases,N,
7499,QualifierName,Q000235,14614357,,,4,,Y,genetics
7500,DescriptorName,D001778,14614357,,,5,Blood Coagulation Disorders,N,
7501,QualifierName,Q000139,14614357,,,5,,Y,chemically induced
7502,DescriptorName,D065729,14614357,,,6,Cytochrome P-450 CYP2C9,N,
7503,DescriptorName,D005260,14614357,,,7,Female,N,
7504,DescriptorName,D005838,14614357,,,8,Genotype,N,
7505,DescriptorName,D006801,14614357,,,9,Humans,N,
7506,DescriptorName,D011110,14614357,,,10,"Polymorphism, Genetic",Y,
7507,DescriptorName,D012307,14614357,,,11,Risk Factors,N,
7508,DescriptorName,D013927,14614357,,,12,Thrombosis,N,
7509,QualifierName,Q000188,14614357,,,12,,N,drug therapy
7510,Chemical,D003078,14632592,Colchicine,SML2Y3J35T,,,,
7511,DescriptorName,D000293,14632592,,,1,Adolescent,N,
7512,DescriptorName,D003078,14632592,,,2,Colchicine,N,
7513,QualifierName,Q000009,14632592,,,2,,Y,adverse effects
7514,DescriptorName,D010505,14632592,,,3,Familial Mediterranean Fever,N,
7515,QualifierName,Q000188,14632592,,,3,,Y,drug therapy
7516,DescriptorName,D006801,14632592,,,4,Humans,N,
7517,DescriptorName,D008297,14632592,,,5,Male,N,
7518,DescriptorName,D018908,14632592,,,6,Muscle Weakness,N,
7519,QualifierName,Q000139,14632592,,,6,,Y,chemically induced
7520,DescriptorName,D009135,14632592,,,7,Muscular Diseases,N,
7521,QualifierName,Q000139,14632592,,,7,,N,chemically induced
7522,Chemical,D001993,14641354,Bronchodilator Agents,0,,,,
7523,Chemical,D019819,14641354,Budesonide,51333-22-3,,,,
7524,DescriptorName,D000280,14641354,,,1,"Administration, Inhalation",N,
7525,DescriptorName,D000328,14641354,,,2,Adult,N,
7526,DescriptorName,D000799,14641354,,,3,Angioedema,N,
7527,QualifierName,Q000139,14641354,,,3,,Y,chemically induced
7528,DescriptorName,D001249,14641354,,,4,Asthma,N,
7529,QualifierName,Q000188,14641354,,,4,,N,drug therapy
7530,DescriptorName,D001985,14641354,,,5,Bronchial Provocation Tests,N,
7531,DescriptorName,D001993,14641354,,,6,Bronchodilator Agents,N,
7532,QualifierName,Q000009,14641354,,,6,,Y,adverse effects
7533,DescriptorName,D019819,14641354,,,7,Budesonide,N,
7534,QualifierName,Q000008,14641354,,,7,,N,administration & dosage
7535,DescriptorName,D003680,14641354,,,8,Deglutition Disorders,N,
7536,QualifierName,Q000139,14641354,,,8,,Y,chemically induced
7537,DescriptorName,D017449,14641354,,,9,"Dermatitis, Allergic Contact",N,
7538,QualifierName,Q000209,14641354,,,9,,Y,etiology
7539,DescriptorName,D005260,14641354,,,10,Female,N,
7540,DescriptorName,D006801,14641354,,,11,Humans,N,
7541,DescriptorName,D012882,14641354,,,12,Skin Tests,N,
7542,Chemical,D000970,14660304,Antineoplastic Agents,0,,,,
7543,Chemical,D003907,14660304,Dexamethasone,7S5I7G3JQL,,,,
7544,Chemical,D011241,14660304,Prednisone,VB0R961HZT,,,,
7545,DescriptorName,D000293,14660304,,,1,Adolescent,N,
7546,DescriptorName,D000970,14660304,,,2,Antineoplastic Agents,N,
7547,QualifierName,Q000009,14660304,,,2,,Y,adverse effects
7548,DescriptorName,D041022,14660304,,,3,Candida tropicalis,N,
7549,DescriptorName,D002177,14660304,,,4,Candidiasis,N,
7550,QualifierName,Q000209,14660304,,,4,,N,etiology
7551,DescriptorName,D002675,14660304,,,5,"Child, Preschool",N,
7552,DescriptorName,D003907,14660304,,,6,Dexamethasone,N,
7553,QualifierName,Q000009,14660304,,,6,,Y,adverse effects
7554,DescriptorName,D004198,14660304,,,7,Disease Susceptibility,N,
7555,QualifierName,Q000139,14660304,,,7,,N,chemically induced
7556,DescriptorName,D005260,14660304,,,8,Female,N,
7557,DescriptorName,D006801,14660304,,,9,Humans,N,
7558,DescriptorName,D008297,14660304,,,10,Male,N,
7559,DescriptorName,D054198,14660304,,,11,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
7560,QualifierName,Q000150,14660304,,,11,,N,complications
7561,DescriptorName,D011241,14660304,,,12,Prednisone,N,
7562,QualifierName,Q000627,14660304,,,12,,N,therapeutic use
7563,DescriptorName,D013203,14660304,,,13,Staphylococcal Infections,N,
7564,QualifierName,Q000209,14660304,,,13,,N,etiology
7565,Chemical,D003561,1467295,Cytarabine,04079A1RDZ,,,,
7566,Chemical,D008942,1467295,Mitoxantrone,BZ114NVM5P,,,,
7567,Chemical,D008775,1467295,Methylprednisolone,X4W7ZR7023,,,,
7568,DescriptorName,D000328,1467295,,,1,Adult,N,
7569,DescriptorName,D003561,1467295,,,2,Cytarabine,N,
7570,QualifierName,Q000009,1467295,,,2,,N,adverse effects
7571,DescriptorName,D004439,1467295,,,3,Eccrine Glands,N,
7572,QualifierName,Q000473,1467295,,,3,,Y,pathology
7573,DescriptorName,D005260,1467295,,,4,Female,N,
7574,DescriptorName,D016575,1467295,,,5,Hidradenitis,N,
7575,QualifierName,Q000139,1467295,,,5,,N,chemically induced
7576,DescriptorName,D006801,1467295,,,6,Humans,N,
7577,DescriptorName,D007275,1467295,,,7,"Injections, Intravenous",N,
7578,DescriptorName,D015470,1467295,,,8,"Leukemia, Myeloid, Acute",N,
7579,QualifierName,Q000188,1467295,,,8,,N,drug therapy
7580,DescriptorName,D008775,1467295,,,9,Methylprednisolone,N,
7581,QualifierName,Q000008,1467295,,,9,,N,administration & dosage
7582,DescriptorName,D008942,1467295,,,10,Mitoxantrone,N,
7583,QualifierName,Q000009,1467295,,,10,,N,adverse effects
7584,DescriptorName,D012008,1467295,,,11,Recurrence,N,
7585,DescriptorName,D012867,1467295,,,12,Skin,N,
7586,QualifierName,Q000473,1467295,,,12,,Y,pathology
7587,Chemical,D000974,14674674,"Antibodies, Antinuclear",0,,,,
7588,Chemical,D000911,14674674,"Antibodies, Monoclonal",0,,,,
7589,Chemical,D005765,14674674,Gastrointestinal Agents,0,,,,
7590,Chemical,D000069285,14674674,Infliximab,B72HH48FLU,,,,
7591,DescriptorName,D000293,14674674,,,1,Adolescent,N,
7592,DescriptorName,D000974,14674674,,,2,"Antibodies, Antinuclear",N,
7593,QualifierName,Q000097,14674674,,,2,,N,blood
7594,DescriptorName,D000911,14674674,,,3,"Antibodies, Monoclonal",N,
7595,QualifierName,Q000008,14674674,,,3,,N,administration & dosage
7596,DescriptorName,D003424,14674674,,,4,Crohn Disease,N,
7597,QualifierName,Q000188,14674674,,,4,,Y,drug therapy
7598,DescriptorName,D005765,14674674,,,5,Gastrointestinal Agents,N,
7599,QualifierName,Q000008,14674674,,,5,,N,administration & dosage
7600,DescriptorName,D006801,14674674,,,6,Humans,N,
7601,DescriptorName,D000069285,14674674,,,7,Infliximab,N,
7602,DescriptorName,D008180,14674674,,,8,"Lupus Erythematosus, Systemic",N,
7603,QualifierName,Q000139,14674674,,,8,,Y,chemically induced
7604,DescriptorName,D008297,14674674,,,9,Male,N,
7605,Chemical,D000317,14677199,Adrenergic alpha-Antagonists,0,,,,
7606,Chemical,D015016,14677199,Yohimbine,2Y49VWD90Q,,,,
7607,DescriptorName,D000317,14677199,,,1,Adrenergic alpha-Antagonists,N,
7608,QualifierName,Q000009,14677199,,,1,,Y,adverse effects
7609,DescriptorName,D000368,14677199,,,2,Aged,N,
7610,DescriptorName,D017675,14677199,,,3,CREST Syndrome,N,
7611,QualifierName,Q000150,14677199,,,3,,Y,complications
7612,DescriptorName,D007172,14677199,,,4,Erectile Dysfunction,N,
7613,QualifierName,Q000150,14677199,,,4,,Y,complications
7614,DescriptorName,D006801,14677199,,,5,Humans,N,
7615,DescriptorName,D008297,14677199,,,6,Male,N,
7616,DescriptorName,D011928,14677199,,,7,Raynaud Disease,N,
7617,QualifierName,Q000503,14677199,,,7,,Y,physiopathology
7618,DescriptorName,D012720,14677199,,,8,Severity of Illness Index,N,
7619,DescriptorName,D015016,14677199,,,9,Yohimbine,N,
7620,QualifierName,Q000009,14677199,,,9,,Y,adverse effects
7621,Chemical,D001581,14684937,Benzothiadiazines,0,,,,
7622,Chemical,D003879,14684937,Dermatologic Agents,0,,,,
7623,Chemical,D004100,14684937,Dihydroxycholecalciferols,0,,,,
7624,Chemical,D004232,14684937,Diuretics,0,,,,
7625,Chemical,D009824,14684937,Ointments,0,,,,
7626,Chemical,D049993,14684937,Sodium Chloride Symporter Inhibitors,0,,,,
7627,Chemical,C023850,14684937,"1 alpha,24-dihydroxyvitamin D3",60965-80-2,,,,
7628,Chemical,D002118,14684937,Calcium,SY7Q814VUP,,,,
7629,DescriptorName,D000279,14684937,,,1,"Administration, Cutaneous",N,
7630,DescriptorName,D000368,14684937,,,2,Aged,N,
7631,DescriptorName,D001581,14684937,,,3,Benzothiadiazines,Y,
7632,DescriptorName,D002118,14684937,,,4,Calcium,N,
7633,QualifierName,Q000097,14684937,,,4,,N,blood
7634,DescriptorName,D003879,14684937,,,5,Dermatologic Agents,N,
7635,QualifierName,Q000008,14684937,,,5,,N,administration & dosage
7636,DescriptorName,D003937,14684937,,,6,"Diagnosis, Differential",N,
7637,DescriptorName,D004100,14684937,,,7,Dihydroxycholecalciferols,N,
7638,QualifierName,Q000008,14684937,,,7,,N,administration & dosage
7639,DescriptorName,D004232,14684937,,,8,Diuretics,N,
7640,DescriptorName,D006801,14684937,,,9,Humans,N,
7641,DescriptorName,D006934,14684937,,,10,Hypercalcemia,N,
7642,QualifierName,Q000139,14684937,,,10,,Y,chemically induced
7643,DescriptorName,D006973,14684937,,,11,Hypertension,N,
7644,QualifierName,Q000188,14684937,,,11,,N,drug therapy
7645,DescriptorName,D007049,14684937,,,12,Iatrogenic Disease,N,
7646,DescriptorName,D008297,14684937,,,13,Male,N,
7647,DescriptorName,D009824,14684937,,,14,Ointments,N,
7648,DescriptorName,D011565,14684937,,,15,Psoriasis,N,
7649,QualifierName,Q000188,14684937,,,15,,N,drug therapy
7650,DescriptorName,D049993,14684937,,,16,Sodium Chloride Symporter Inhibitors,N,
7651,QualifierName,Q000008,14684937,,,16,,N,administration & dosage
7652,Chemical,D017338,14690166,Cladribine,47M74X9YT5,,,,
7653,DescriptorName,D000328,14690166,,,1,Adult,N,
7654,DescriptorName,D005871,14690166,,,2,Castleman Disease,N,
7655,QualifierName,Q000188,14690166,,,2,,Y,drug therapy
7656,DescriptorName,D017338,14690166,,,3,Cladribine,N,
7657,QualifierName,Q000009,14690166,,,3,,Y,adverse effects
7658,DescriptorName,D005260,14690166,,,4,Female,N,
7659,DescriptorName,D006801,14690166,,,5,Humans,N,
7660,DescriptorName,D008228,14690166,,,6,"Lymphoma, Non-Hodgkin",N,
7661,QualifierName,Q000139,14690166,,,6,,Y,chemically induced
7662,DescriptorName,D008297,14690166,,,7,Male,N,
7663,DescriptorName,D008875,14690166,,,8,Middle Aged,N,
7664,DescriptorName,D012074,14690166,,,9,Remission Induction,N,
7665,DescriptorName,D016896,14690166,,,10,Treatment Outcome,N,
7666,Chemical,D000888,1469187,"Antibodies, Anti-Idiotypic",0,,,,
7667,Chemical,D007140,1469187,Immunoglobulin Fab Fragments,0,,,,
7668,Chemical,D004074,1469187,Digitoxin,E90NZP2L9U,,,,
7669,DescriptorName,D000328,1469187,,,1,Adult,N,
7670,DescriptorName,D000888,1469187,,,2,"Antibodies, Anti-Idiotypic",N,
7671,QualifierName,Q000008,1469187,,,2,,N,administration & dosage
7672,DescriptorName,D004070,1469187,,,3,Digitalis,N,
7673,QualifierName,Q000276,1469187,,,3,,Y,immunology
7674,DescriptorName,D004074,1469187,,,4,Digitoxin,N,
7675,QualifierName,Q000097,1469187,,,4,,N,blood
7676,DescriptorName,D004591,1469187,,,5,"Electrophoresis, Polyacrylamide Gel",N,
7677,DescriptorName,D006801,1469187,,,6,Humans,N,
7678,DescriptorName,D007140,1469187,,,7,Immunoglobulin Fab Fragments,N,
7679,QualifierName,Q000008,1469187,,,7,,N,administration & dosage
7680,DescriptorName,D007262,1469187,,,8,"Infusions, Intravenous",N,
7681,DescriptorName,D008297,1469187,,,9,Male,N,
7682,DescriptorName,D008657,1469187,,,10,Metabolic Clearance Rate,N,
7683,DescriptorName,D010946,1469187,,,11,"Plants, Medicinal",Y,
7684,DescriptorName,D010947,1469187,,,12,"Plants, Toxic",Y,
7685,DescriptorName,D011041,1469187,,,13,Poisoning,N,
7686,QualifierName,Q000097,1469187,,,13,,N,blood
7687,DescriptorName,D013406,1469187,,,14,"Suicide, Attempted",N,
7688,Chemical,D000927,14693027,Anticonvulsants,0,,,,
7689,Chemical,D010672,14693027,Phenytoin,6158TKW0C5,,,,
7690,DescriptorName,D000927,14693027,,,1,Anticonvulsants,N,
7691,QualifierName,Q000009,14693027,,,1,,Y,adverse effects
7692,DescriptorName,D001932,14693027,,,2,Brain Neoplasms,N,
7693,QualifierName,Q000150,14693027,,,2,,N,complications
7694,DescriptorName,D003875,14693027,,,3,Drug Eruptions,N,
7695,QualifierName,Q000209,14693027,,,3,,Y,etiology
7696,DescriptorName,D004892,14693027,,,4,Erythema Multiforme,N,
7697,QualifierName,Q000209,14693027,,,4,,Y,etiology
7698,DescriptorName,D006801,14693027,,,5,Humans,N,
7699,DescriptorName,D008297,14693027,,,6,Male,N,
7700,DescriptorName,D008875,14693027,,,7,Middle Aged,N,
7701,DescriptorName,D010672,14693027,,,8,Phenytoin,N,
7702,QualifierName,Q000009,14693027,,,8,,Y,adverse effects
7703,DescriptorName,D011878,14693027,,,9,Radiotherapy,N,
7704,QualifierName,Q000009,14693027,,,9,,N,adverse effects
7705,DescriptorName,D012640,14693027,,,10,Seizures,N,
7706,QualifierName,Q000188,14693027,,,10,,N,drug therapy
7707,Chemical,D007166,14697943,Immunosuppressive Agents,0,,,,
7708,Chemical,D016572,14697943,Cyclosporine,83HN0GTJ6D,,,,
7709,Chemical,D011241,14697943,Prednisone,VB0R961HZT,,,,
7710,Chemical,D016559,14697943,Tacrolimus,WM0HAQ4WNM,,,,
7711,DescriptorName,D000328,14697943,,,1,Adult,N,
7712,DescriptorName,D016572,14697943,,,2,Cyclosporine,N,
7713,QualifierName,Q000009,14697943,,,2,,N,adverse effects
7714,DescriptorName,D005260,14697943,,,3,Female,N,
7715,DescriptorName,D006801,14697943,,,4,Humans,N,
7716,DescriptorName,D007166,14697943,,,5,Immunosuppressive Agents,N,
7717,QualifierName,Q000009,14697943,,,5,,N,adverse effects
7718,DescriptorName,D016030,14697943,,,6,Kidney Transplantation,N,
7719,QualifierName,Q000009,14697943,,,6,,Y,adverse effects
7720,DescriptorName,D008297,14697943,,,7,Male,N,
7721,DescriptorName,D011241,14697943,,,8,Prednisone,N,
7722,QualifierName,Q000627,14697943,,,8,,N,therapeutic use
7723,DescriptorName,D012019,14697943,,,9,Reflex Sympathetic Dystrophy,N,
7724,QualifierName,Q000188,14697943,,,9,,N,drug therapy
7725,DescriptorName,D016559,14697943,,,10,Tacrolimus,N,
7726,QualifierName,Q000009,14697943,,,10,,Y,adverse effects
7727,DescriptorName,D016896,14697943,,,11,Treatment Outcome,N,
7728,Chemical,D000927,14700673,Anticonvulsants,0,,,,
7729,Chemical,D000077236,14700673,Topiramate,0H73WJJ391,,,,
7730,Chemical,D005632,14700673,Fructose,30237-26-4,,,,
7731,DescriptorName,D000208,14700673,,,1,Acute Disease,N,
7732,DescriptorName,D000328,14700673,,,2,Adult,N,
7733,DescriptorName,D000867,14700673,,,3,Anterior Chamber,N,
7734,QualifierName,Q000000981,14700673,,,3,,N,diagnostic imaging
7735,DescriptorName,D000927,14700673,,,4,Anticonvulsants,N,
7736,QualifierName,Q000009,14700673,,,4,,Y,adverse effects
7737,DescriptorName,D004827,14700673,,,5,Epilepsy,N,
7738,QualifierName,Q000188,14700673,,,5,,N,drug therapy
7739,DescriptorName,D005260,14700673,,,6,Female,N,
7740,DescriptorName,D005632,14700673,,,7,Fructose,N,
7741,QualifierName,Q000009,14700673,,,7,,Y,adverse effects
7742,DescriptorName,D015812,14700673,,,8,"Glaucoma, Angle-Closure",N,
7743,QualifierName,Q000139,14700673,,,8,,Y,chemically induced
7744,DescriptorName,D006801,14700673,,,9,Humans,N,
7745,DescriptorName,D007429,14700673,,,10,Intraocular Pressure,N,
7746,DescriptorName,D008875,14700673,,,11,Middle Aged,N,
7747,DescriptorName,D009216,14700673,,,12,Myopia,N,
7748,QualifierName,Q000139,14700673,,,12,,Y,chemically induced
7749,DescriptorName,D000077236,14700673,,,13,Topiramate,N,
7750,DescriptorName,D014463,14700673,,,14,Ultrasonography,N,
7751,Chemical,D000900,14711147,Anti-Bacterial Agents,0,,,,
7752,Chemical,D004318,14711147,Doxycycline,N12000U13O,,,,
7753,DescriptorName,D000152,14711147,,,1,Acne Vulgaris,N,
7754,QualifierName,Q000188,14711147,,,1,,N,drug therapy
7755,DescriptorName,D000328,14711147,,,2,Adult,N,
7756,DescriptorName,D000900,14711147,,,3,Anti-Bacterial Agents,N,
7757,QualifierName,Q000009,14711147,,,3,,Y,adverse effects
7758,DescriptorName,D003937,14711147,,,4,"Diagnosis, Differential",N,
7759,DescriptorName,D004318,14711147,,,5,Doxycycline,N,
7760,QualifierName,Q000009,14711147,,,5,,Y,adverse effects
7761,DescriptorName,D005260,14711147,,,6,Female,N,
7762,DescriptorName,D006229,14711147,,,7,Hand Dermatoses,N,
7763,QualifierName,Q000139,14711147,,,7,,N,chemically induced
7764,DescriptorName,D006801,14711147,,,8,Humans,N,
7765,DescriptorName,D017495,14711147,,,9,Hyperpigmentation,N,
7766,QualifierName,Q000139,14711147,,,9,,N,chemically induced
7767,DescriptorName,D009260,14711147,,,10,Nail Diseases,N,
7768,QualifierName,Q000139,14711147,,,10,,N,chemically induced
7769,DescriptorName,D010787,14711147,,,11,Photosensitivity Disorders,N,
7770,QualifierName,Q000139,14711147,,,11,,N,chemically induced
7771,Chemical,D000900,14723711,Anti-Bacterial Agents,0,,,,
7772,Chemical,D008911,14723711,Minocycline,FYY3R43WGO,,,,
7773,DescriptorName,D000152,14723711,,,1,Acne Vulgaris,N,
7774,QualifierName,Q000188,14723711,,,1,,Y,drug therapy
7775,DescriptorName,D000328,14723711,,,2,Adult,N,
7776,DescriptorName,D000900,14723711,,,3,Anti-Bacterial Agents,N,
7777,QualifierName,Q000009,14723711,,,3,,Y,adverse effects
7778,DescriptorName,D001706,14723711,,,4,Biopsy,N,
7779,QualifierName,Q000379,14723711,,,4,,N,methods
7780,DescriptorName,D006801,14723711,,,5,Humans,N,
7781,DescriptorName,D017495,14723711,,,6,Hyperpigmentation,N,
7782,QualifierName,Q000139,14723711,,,6,,Y,chemically induced
7783,DescriptorName,D008297,14723711,,,7,Male,N,
7784,DescriptorName,D008911,14723711,,,8,Minocycline,N,
7785,QualifierName,Q000009,14723711,,,8,,Y,adverse effects
7786,DescriptorName,D012867,14723711,,,9,Skin,N,
7787,QualifierName,Q000473,14723711,,,9,,Y,pathology
7788,Chemical,D002939,14735388,Ciprofloxacin,5E8K9I0O4U,,,,
7789,DescriptorName,D000328,14735388,,,1,Adult,N,
7790,DescriptorName,D002939,14735388,,,2,Ciprofloxacin,N,
7791,QualifierName,Q000009,14735388,,,2,,Y,adverse effects
7792,DescriptorName,D003131,14735388,,,3,Combined Modality Therapy,N,
7793,DescriptorName,D018450,14735388,,,4,Disease Progression,N,
7794,DescriptorName,D017809,14735388,,,5,Fatal Outcome,N,
7795,DescriptorName,D005260,14735388,,,6,Female,N,
7796,DescriptorName,D006801,14735388,,,7,Humans,N,
7797,DescriptorName,D008180,14735388,,,8,"Lupus Erythematosus, Systemic",N,
7798,QualifierName,Q000175,14735388,,,8,,N,diagnosis
7799,DescriptorName,D009426,14735388,,,9,Netherlands,N,
7800,DescriptorName,D018570,14735388,,,10,Risk Assessment,N,
7801,DescriptorName,D012720,14735388,,,11,Severity of Illness Index,N,
7802,DescriptorName,D013262,14735388,,,12,Stevens-Johnson Syndrome,N,
7803,QualifierName,Q000209,14735388,,,12,,Y,etiology
7804,Chemical,D011355,14740795,Prodrugs,0,,,,
7805,Chemical,D011837,14740795,Radiation-Protective Agents,0,,,,
7806,Chemical,D004999,14740795,Amifostine,M487QF2F4V,,,,
7807,DescriptorName,D004999,14740795,,,1,Amifostine,N,
7808,QualifierName,Q000008,14740795,,,1,,N,administration & dosage
7809,DescriptorName,D002294,14740795,,,2,"Carcinoma, Squamous Cell",N,
7810,QualifierName,Q000532,14740795,,,2,,N,radiotherapy
7811,DescriptorName,D003131,14740795,,,3,Combined Modality Therapy,N,
7812,DescriptorName,D005334,14740795,,,4,Fever,N,
7813,QualifierName,Q000139,14740795,,,4,,Y,chemically induced
7814,DescriptorName,D006258,14740795,,,5,Head and Neck Neoplasms,N,
7815,QualifierName,Q000628,14740795,,,5,,N,therapy
7816,DescriptorName,D006801,14740795,,,6,Humans,N,
7817,DescriptorName,D007262,14740795,,,7,"Infusions, Intravenous",N,
7818,DescriptorName,D008297,14740795,,,8,Male,N,
7819,DescriptorName,D008875,14740795,,,9,Middle Aged,N,
7820,DescriptorName,D009362,14740795,,,10,Neoplasm Metastasis,N,
7821,DescriptorName,D011355,14740795,,,11,Prodrugs,N,
7822,DescriptorName,D011837,14740795,,,12,Radiation-Protective Agents,N,
7823,QualifierName,Q000008,14740795,,,12,,N,administration & dosage
7824,DescriptorName,D014987,14740795,,,13,Xerostomia,N,
7825,QualifierName,Q000188,14740795,,,13,,N,drug therapy
7826,Chemical,D053799,14742791,2-Pyridinylmethylsulfinylbenzimidazoles,0,,,,
7827,Chemical,D001562,14742791,Benzimidazoles,0,,,,
7828,Chemical,D054328,14742791,Proton Pump Inhibitors,0,,,,
7829,Chemical,D017494,14742791,Proton Pumps,0,,,,
7830,Chemical,D013454,14742791,Sulfoxides,0,,,,
7831,Chemical,D002939,14742791,Ciprofloxacin,5E8K9I0O4U,,,,
7832,Chemical,D003404,14742791,Creatinine,AYI8EX34EU,,,,
7833,Chemical,D000077402,14742791,Pantoprazole,D8TST4O562,,,,
7834,Chemical,D009853,14742791,Omeprazole,KG60484QX9,,,,
7835,Chemical,D011241,14742791,Prednisone,VB0R961HZT,,,,
7836,DescriptorName,D053799,14742791,,,1,2-Pyridinylmethylsulfinylbenzimidazoles,N,
7837,DescriptorName,D000208,14742791,,,2,Acute Disease,Y,
7838,DescriptorName,D000284,14742791,,,3,"Administration, Oral",N,
7839,DescriptorName,D000368,14742791,,,4,Aged,N,
7840,DescriptorName,D001562,14742791,,,5,Benzimidazoles,N,
7841,QualifierName,Q000008,14742791,,,5,,N,administration & dosage
7842,DescriptorName,D001706,14742791,,,6,Biopsy,N,
7843,DescriptorName,D002939,14742791,,,7,Ciprofloxacin,N,
7844,QualifierName,Q000008,14742791,,,7,,N,administration & dosage
7845,DescriptorName,D003404,14742791,,,8,Creatinine,N,
7846,QualifierName,Q000097,14742791,,,8,,N,blood
7847,DescriptorName,D005260,14742791,,,9,Female,N,
7848,DescriptorName,D005764,14742791,,,10,Gastroesophageal Reflux,N,
7849,QualifierName,Q000150,14742791,,,10,,N,complications
7850,DescriptorName,D006801,14742791,,,11,Humans,N,
7851,DescriptorName,D007668,14742791,,,12,Kidney,N,
7852,QualifierName,Q000473,14742791,,,12,,N,pathology
7853,DescriptorName,D009395,14742791,,,13,"Nephritis, Interstitial",N,
7854,QualifierName,Q000139,14742791,,,13,,Y,chemically induced
7855,DescriptorName,D009846,14742791,,,14,Oliguria,N,
7856,DescriptorName,D009853,14742791,,,15,Omeprazole,N,
7857,QualifierName,Q000031,14742791,,,15,,N,analogs & derivatives
7858,DescriptorName,D000077402,14742791,,,16,Pantoprazole,N,
7859,DescriptorName,D011241,14742791,,,17,Prednisone,N,
7860,QualifierName,Q000008,14742791,,,17,,N,administration & dosage
7861,DescriptorName,D054328,14742791,,,18,Proton Pump Inhibitors,N,
7862,DescriptorName,D017494,14742791,,,19,Proton Pumps,N,
7863,QualifierName,Q000009,14742791,,,19,,N,adverse effects
7864,DescriptorName,D013454,14742791,,,20,Sulfoxides,N,
7865,QualifierName,Q000008,14742791,,,20,,N,administration & dosage
7866,DescriptorName,D013997,14742791,,,21,Time Factors,N,
7867,Chemical,D004791,14746605,Enzyme Inhibitors,0,,,,
7868,Chemical,D018120,14746605,Finasteride,57GNO57U7G,,,,
7869,DescriptorName,D000328,14746605,,,1,Adult,N,
7870,DescriptorName,D000505,14746605,,,2,Alopecia,N,
7871,QualifierName,Q000188,14746605,,,2,,N,drug therapy
7872,DescriptorName,D002386,14746605,,,3,Cataract,N,
7873,QualifierName,Q000139,14746605,,,3,,Y,chemically induced
7874,DescriptorName,D002387,14746605,,,4,Cataract Extraction,N,
7875,DescriptorName,D004791,14746605,,,5,Enzyme Inhibitors,N,
7876,QualifierName,Q000009,14746605,,,5,,Y,adverse effects
7877,DescriptorName,D018120,14746605,,,6,Finasteride,N,
7878,QualifierName,Q000009,14746605,,,6,,Y,adverse effects
7879,DescriptorName,D006801,14746605,,,7,Humans,N,
7880,DescriptorName,D019654,14746605,,,8,"Lens Implantation, Intraocular",N,
7881,DescriptorName,D007908,14746605,,,9,"Lens, Crystalline",N,
7882,QualifierName,Q000187,14746605,,,9,,Y,drug effects
7883,DescriptorName,D008297,14746605,,,10,Male,N,
7884,DescriptorName,D014792,14746605,,,11,Visual Acuity,N,
7885,Chemical,D000276,14760958,"Adjuvants, Immunologic",0,,,,
7886,Chemical,D016756,14760958,"Immunoglobulins, Intravenous",0,,,,
7887,Chemical,D016899,14760958,Interferon-beta,77238-31-4,,,,
7888,Chemical,D000068556,14760958,Interferon beta-1a,XRO4566Q4R,,,,
7889,DescriptorName,D000276,14760958,,,1,"Adjuvants, Immunologic",N,
7890,QualifierName,Q000009,14760958,,,1,,Y,adverse effects
7891,DescriptorName,D000328,14760958,,,2,Adult,N,
7892,DescriptorName,D005260,14760958,,,3,Female,N,
7893,DescriptorName,D006801,14760958,,,4,Humans,N,
7894,DescriptorName,D016756,14760958,,,5,"Immunoglobulins, Intravenous",N,
7895,QualifierName,Q000627,14760958,,,5,,N,therapeutic use
7896,DescriptorName,D000068556,14760958,,,6,Interferon beta-1a,N,
7897,DescriptorName,D016899,14760958,,,7,Interferon-beta,N,
7898,QualifierName,Q000009,14760958,,,7,,Y,adverse effects
7899,DescriptorName,D017512,14760958,,,8,Lichenoid Eruptions,N,
7900,QualifierName,Q000139,14760958,,,8,,Y,chemically induced
7901,DescriptorName,D009103,14760958,,,9,Multiple Sclerosis,N,
7902,QualifierName,Q000150,14760958,,,9,,N,complications
7903,DescriptorName,D009230,14760958,,,10,Myxedema,N,
7904,QualifierName,Q000139,14760958,,,10,,Y,chemically induced
7905,DescriptorName,D010265,14760958,,,11,Paraproteinemias,N,
7906,QualifierName,Q000150,14760958,,,11,,N,complications
7907,Chemical,D008263,1477441,Macrophage Migration-Inhibitory Factors,0,,,,
7908,Chemical,D008774,1477441,Methylphenidate,207ZZ9QZ49,,,,
7909,DescriptorName,D001289,1477441,,,1,Attention Deficit Disorder with Hyperactivity,N,
7910,QualifierName,Q000188,1477441,,,1,,N,drug therapy
7911,DescriptorName,D002648,1477441,,,2,Child,N,
7912,DescriptorName,D003875,1477441,,,3,Drug Eruptions,N,
7913,QualifierName,Q000209,1477441,,,3,,Y,etiology
7914,DescriptorName,D005832,1477441,,,4,"Genital Diseases, Male",N,
7915,QualifierName,Q000139,1477441,,,4,,N,chemically induced
7916,DescriptorName,D006801,1477441,,,5,Humans,N,
7917,DescriptorName,D008263,1477441,,,6,Macrophage Migration-Inhibitory Factors,N,
7918,QualifierName,Q000032,1477441,,,6,,N,analysis
7919,DescriptorName,D008297,1477441,,,7,Male,N,
7920,DescriptorName,D008774,1477441,,,8,Methylphenidate,N,
7921,QualifierName,Q000009,1477441,,,8,,Y,adverse effects
7922,DescriptorName,D012611,1477441,,,9,Scrotum,Y,
7923,Chemical,D008727,1495728,Methotrexate,YL5FZ2Y5U1,,,,
7924,DescriptorName,D000328,1495728,,,1,Adult,N,
7925,DescriptorName,D005260,1495728,,,2,Female,N,
7926,DescriptorName,D006801,1495728,,,3,Humans,N,
7927,DescriptorName,D008423,1495728,,,4,Maternal Age,N,
7928,DescriptorName,D008727,1495728,,,5,Methotrexate,N,
7929,QualifierName,Q000009,1495728,,,5,,Y,adverse effects
7930,DescriptorName,D011014,1495728,,,6,Pneumonia,N,
7931,QualifierName,Q000139,1495728,,,6,,Y,chemically induced
7932,DescriptorName,D011247,1495728,,,7,Pregnancy,N,
7933,DescriptorName,D018566,1495728,,,8,"Pregnancy, High-Risk",N,
7934,DescriptorName,D011274,1495728,,,9,"Pregnancy, Tubal",N,
7935,QualifierName,Q000188,1495728,,,9,,Y,drug therapy
7936,DescriptorName,D011859,1495728,,,10,Radiography,N,
7937,DescriptorName,D012907,1495728,,,11,Smoking,N,
7938,Chemical,D000925,14960440,Anticoagulants,0,,,,
7939,Chemical,D014859,14960440,Warfarin,5Q7ZVV76EI,,,,
7940,DescriptorName,D000368,14960440,,,1,Aged,N,
7941,DescriptorName,D000369,14960440,,,2,"Aged, 80 and over",N,
7942,DescriptorName,D000784,14960440,,,3,"Aneurysm, Dissecting",N,
7943,QualifierName,Q000139,14960440,,,3,,Y,chemically induced
7944,DescriptorName,D000925,14960440,,,4,Anticoagulants,N,
7945,QualifierName,Q000009,14960440,,,4,,Y,adverse effects
7946,DescriptorName,D001011,14960440,,,5,Aorta,N,
7947,QualifierName,Q000601,14960440,,,5,,N,surgery
7948,DescriptorName,D017545,14960440,,,6,"Aortic Aneurysm, Thoracic",N,
7949,QualifierName,Q000139,14960440,,,6,,Y,chemically induced
7950,DescriptorName,D001281,14960440,,,7,Atrial Fibrillation,N,
7951,QualifierName,Q000188,14960440,,,7,,N,drug therapy
7952,DescriptorName,D002637,14960440,,,8,Chest Pain,N,
7953,DescriptorName,D005260,14960440,,,9,Female,N,
7954,DescriptorName,D005500,14960440,,,10,Follow-Up Studies,N,
7955,DescriptorName,D006801,14960440,,,11,Humans,N,
7956,DescriptorName,D012907,14960440,,,12,Smoking,N,
7957,DescriptorName,D014057,14960440,,,13,"Tomography, X-Ray Computed",N,
7958,DescriptorName,D014859,14960440,,,14,Warfarin,N,
7959,QualifierName,Q000009,14960440,,,14,,Y,adverse effects
7960,Chemical,D000806,14964753,Angiotensin-Converting Enzyme Inhibitors,0,,,,
7961,Chemical,D017257,14964753,Ramipril,L35JN3I7SJ,,,,
7962,DescriptorName,D000806,14964753,,,1,Angiotensin-Converting Enzyme Inhibitors,N,
7963,QualifierName,Q000009,14964753,,,1,,Y,adverse effects
7964,DescriptorName,D003937,14964753,,,2,"Diagnosis, Differential",N,
7965,DescriptorName,D003875,14964753,,,3,Drug Eruptions,N,
7966,QualifierName,Q000175,14964753,,,3,,Y,diagnosis
7967,DescriptorName,D005528,14964753,,,4,Foot,N,
7968,DescriptorName,D006801,14964753,,,5,Humans,N,
7969,DescriptorName,D008297,14964753,,,6,Male,N,
7970,DescriptorName,D008875,14964753,,,7,Middle Aged,N,
7971,DescriptorName,D017257,14964753,,,8,Ramipril,N,
7972,QualifierName,Q000009,14964753,,,8,,Y,adverse effects
7973,DescriptorName,D018487,14964753,,,9,"Ventricular Dysfunction, Left",N,
7974,QualifierName,Q000188,14964753,,,9,,Y,drug therapy
7975,Chemical,D000903,14968106,"Antibiotics, Antineoplastic",0,,,,
7976,Chemical,D004317,14968106,Doxorubicin,80168379AG,,,,
7977,DescriptorName,D000328,14968106,,,1,Adult,N,
7978,DescriptorName,D000903,14968106,,,2,"Antibiotics, Antineoplastic",N,
7979,QualifierName,Q000008,14968106,,,2,,N,administration & dosage
7980,DescriptorName,D004317,14968106,,,3,Doxorubicin,N,
7981,QualifierName,Q000008,14968106,,,3,,N,administration & dosage
7982,DescriptorName,D004576,14968106,,,4,Electromyography,N,
7983,DescriptorName,D005260,14968106,,,5,Female,N,
7984,DescriptorName,D006801,14968106,,,6,Humans,N,
7985,DescriptorName,D007278,14968106,,,7,"Injections, Spinal",N,
7986,DescriptorName,D018482,14968106,,,8,"Muscle, Skeletal",N,
7987,QualifierName,Q000503,14968106,,,8,,N,physiopathology
7988,DescriptorName,D054198,14968106,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
7989,QualifierName,Q000188,14968106,,,9,,N,drug therapy
7990,DescriptorName,D020127,14968106,,,10,Recovery of Function,N,
7991,DescriptorName,D013118,14968106,,,11,Spinal Cord Diseases,N,
7992,QualifierName,Q000139,14968106,,,11,,Y,chemically induced
7993,DescriptorName,D016896,14968106,,,12,Treatment Outcome,N,
7994,Chemical,D000911,14971874,"Antibodies, Monoclonal",0,,,,
7995,Chemical,D018501,14971874,Antirheumatic Agents,0,,,,
7996,Chemical,D014409,14971874,Tumor Necrosis Factor-alpha,0,,,,
7997,Chemical,D000069285,14971874,Infliximab,B72HH48FLU,,,,
7998,DescriptorName,D000911,14971874,,,1,"Antibodies, Monoclonal",N,
7999,QualifierName,Q000009,14971874,,,1,,Y,adverse effects
8000,DescriptorName,D018501,14971874,,,2,Antirheumatic Agents,N,
8001,QualifierName,Q000009,14971874,,,2,,Y,adverse effects
8002,DescriptorName,D001172,14971874,,,3,"Arthritis, Rheumatoid",N,
8003,QualifierName,Q000188,14971874,,,3,,Y,drug therapy
8004,DescriptorName,D005260,14971874,,,4,Female,N,
8005,DescriptorName,D006801,14971874,,,5,Humans,N,
8006,DescriptorName,D000069285,14971874,,,6,Infliximab,N,
8007,DescriptorName,D008875,14971874,,,7,Middle Aged,N,
8008,DescriptorName,D020181,14971874,,,8,"Sleep Apnea, Obstructive",N,
8009,QualifierName,Q000209,14971874,,,8,,Y,etiology
8010,DescriptorName,D014409,14971874,,,9,Tumor Necrosis Factor-alpha,N,
8011,QualifierName,Q000037,14971874,,,9,,Y,antagonists & inhibitors
8012,Chemical,D002411,14996269,Cation Exchange Resins,0,,,,
8013,Chemical,D011137,14996269,Polystyrenes,0,,,,
8014,Chemical,C003321,14996269,polystyrene sulfonic acid,70KO0R01RY,,,,
8015,DescriptorName,D002411,14996269,,,1,Cation Exchange Resins,N,
8016,QualifierName,Q000009,14996269,,,1,,Y,adverse effects
8017,DescriptorName,D005260,14996269,,,2,Female,N,
8018,DescriptorName,D006801,14996269,,,3,Humans,N,
8019,DescriptorName,D006947,14996269,,,4,Hyperkalemia,N,
8020,QualifierName,Q000188,14996269,,,4,,Y,drug therapy
8021,DescriptorName,D006955,14996269,,,5,Hypernatremia,N,
8022,QualifierName,Q000139,14996269,,,5,,Y,chemically induced
8023,DescriptorName,D007231,14996269,,,6,"Infant, Newborn",N,
8024,DescriptorName,D007235,14996269,,,7,"Infant, Premature, Diseases",N,
8025,QualifierName,Q000188,14996269,,,7,,Y,drug therapy
8026,DescriptorName,D019102,14996269,,,8,"Infant, Very Low Birth Weight",Y,
8027,DescriptorName,D011137,14996269,,,9,Polystyrenes,N,
8028,QualifierName,Q000009,14996269,,,9,,Y,adverse effects
8029,Chemical,D000962,15013892,Antimalarials,0,,,,
8030,Chemical,D011796,15013892,Quinacrine,H0C805XYDE,,,,
8031,DescriptorName,D000962,15013892,,,1,Antimalarials,N,
8032,QualifierName,Q000009,15013892,,,1,,Y,adverse effects
8033,DescriptorName,D004596,15013892,,,2,Electroretinography,N,
8034,DescriptorName,D005451,15013892,,,3,Fluorescein Angiography,N,
8035,DescriptorName,D006801,15013892,,,4,Humans,N,
8036,DescriptorName,D016780,15013892,,,5,"Malaria, Vivax",N,
8037,QualifierName,Q000188,15013892,,,5,,Y,drug therapy
8038,DescriptorName,D008297,15013892,,,6,Male,N,
8039,DescriptorName,D008875,15013892,,,7,Middle Aged,N,
8040,DescriptorName,D011796,15013892,,,8,Quinacrine,N,
8041,QualifierName,Q000009,15013892,,,8,,Y,adverse effects
8042,DescriptorName,D012164,15013892,,,9,Retinal Diseases,N,
8043,QualifierName,Q000139,15013892,,,9,,Y,chemically induced
8044,DescriptorName,D014792,15013892,,,10,Visual Acuity,N,
8045,Chemical,D014663,15028328,Nasal Decongestants,0,,,,
8046,Chemical,D004366,15028328,Nonprescription Drugs,0,,,,
8047,Chemical,D010665,15028328,Phenylpropanolamine,33RU150WUN,,,,
8048,DescriptorName,D002544,15028328,,,1,Cerebral Infarction,N,
8049,QualifierName,Q000139,15028328,,,1,,Y,chemically induced
8050,DescriptorName,D002648,15028328,,,2,Child,N,
8051,DescriptorName,D004335,15028328,,,3,Drug and Narcotic Control,Y,
8052,DescriptorName,D006261,15028328,,,4,Headache,N,
8053,QualifierName,Q000209,15028328,,,4,,N,etiology
8054,DescriptorName,D006801,15028328,,,5,Humans,N,
8055,DescriptorName,D006973,15028328,,,6,Hypertension,N,
8056,QualifierName,Q000150,15028328,,,6,,N,complications
8057,DescriptorName,D007668,15028328,,,7,Kidney,N,
8058,QualifierName,Q000002,15028328,,,7,,N,abnormalities
8059,DescriptorName,D008297,15028328,,,8,Male,N,
8060,DescriptorName,D014663,15028328,,,9,Nasal Decongestants,N,
8061,QualifierName,Q000009,15028328,,,9,,Y,adverse effects
8062,DescriptorName,D004366,15028328,,,10,Nonprescription Drugs,N,
8063,QualifierName,Q000009,15028328,,,10,,Y,adverse effects
8064,DescriptorName,D010530,15028328,,,11,Peritoneal Dialysis,N,
8065,DescriptorName,D010665,15028328,,,12,Phenylpropanolamine,N,
8066,QualifierName,Q000009,15028328,,,12,,Y,adverse effects
8067,DescriptorName,D012141,15028328,,,13,Respiratory Tract Infections,N,
8068,QualifierName,Q000150,15028328,,,13,,N,complications
8069,DescriptorName,D012640,15028328,,,14,Seizures,N,
8070,QualifierName,Q000209,15028328,,,14,,N,etiology
8071,DescriptorName,D016896,15028328,,,15,Treatment Outcome,N,
8072,DescriptorName,D014657,15028328,,,16,Vasculitis,N,
8073,QualifierName,Q000175,15028328,,,16,,N,diagnosis
8074,DescriptorName,D014786,15028328,,,17,Vision Disorders,N,
8075,QualifierName,Q000209,15028328,,,17,,N,etiology
8076,Chemical,D002939,1504404,Ciprofloxacin,5E8K9I0O4U,,,,
8077,Chemical,D013888,1504404,Thiothixene,7318FJ13YJ,,,,
8078,DescriptorName,D002939,1504404,,,1,Ciprofloxacin,N,
8079,QualifierName,Q000008,1504404,,,1,,N,administration & dosage
8080,DescriptorName,D006801,1504404,,,2,Humans,N,
8081,DescriptorName,D008297,1504404,,,3,Male,N,
8082,DescriptorName,D008875,1504404,,,4,Middle Aged,N,
8083,DescriptorName,D011605,1504404,,,5,"Psychoses, Substance-Induced",N,
8084,QualifierName,Q000188,1504404,,,5,,N,drug therapy
8085,DescriptorName,D013888,1504404,,,6,Thiothixene,N,
8086,QualifierName,Q000627,1504404,,,6,,N,therapeutic use
8087,Chemical,D000900,15053046,Anti-Bacterial Agents,0,,,,
8088,Chemical,D016179,15053046,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
8089,Chemical,D014640,15053046,Vancomycin,6Q205EH1VU,,,,
8090,DescriptorName,D000368,15053046,,,1,Aged,N,
8091,DescriptorName,D000380,15053046,,,2,Agranulocytosis,N,
8092,QualifierName,Q000139,15053046,,,2,,Y,chemically induced
8093,DescriptorName,D000900,15053046,,,3,Anti-Bacterial Agents,N,
8094,QualifierName,Q000009,15053046,,,3,,Y,adverse effects
8095,DescriptorName,D002408,15053046,,,4,"Catheters, Indwelling",N,
8096,QualifierName,Q000382,15053046,,,4,,N,microbiology
8097,DescriptorName,D016179,15053046,,,5,Granulocyte Colony-Stimulating Factor,N,
8098,QualifierName,Q000627,15053046,,,5,,N,therapeutic use
8099,DescriptorName,D006801,15053046,,,6,Humans,N,
8100,DescriptorName,D007676,15053046,,,7,"Kidney Failure, Chronic",N,
8101,QualifierName,Q000150,15053046,,,7,,N,complications
8102,DescriptorName,D008297,15053046,,,8,Male,N,
8103,DescriptorName,D010531,15053046,,,9,"Peritoneal Dialysis, Continuous Ambulatory",N,
8104,DescriptorName,D013203,15053046,,,10,Staphylococcal Infections,N,
8105,QualifierName,Q000188,15053046,,,10,,N,drug therapy
8106,DescriptorName,D014640,15053046,,,11,Vancomycin,N,
8107,QualifierName,Q000009,15053046,,,11,,Y,adverse effects
8108,Chemical,D000932,15061230,Antiemetics,0,,,,
8109,Chemical,D000970,15061230,Antineoplastic Agents,0,,,,
8110,Chemical,D012702,15061230,Serotonin Antagonists,0,,,,
8111,Chemical,D003907,15061230,Dexamethasone,7S5I7G3JQL,,,,
8112,DescriptorName,D000328,15061230,,,1,Adult,N,
8113,DescriptorName,D000932,15061230,,,2,Antiemetics,N,
8114,QualifierName,Q000008,15061230,,,2,,N,administration & dosage
8115,DescriptorName,D000970,15061230,,,3,Antineoplastic Agents,N,
8116,QualifierName,Q000009,15061230,,,3,,N,adverse effects
8117,DescriptorName,D003907,15061230,,,4,Dexamethasone,N,
8118,QualifierName,Q000008,15061230,,,4,,N,administration & dosage
8119,DescriptorName,D004359,15061230,,,5,"Drug Therapy, Combination",N,
8120,DescriptorName,D005271,15061230,,,6,Femur Head Necrosis,N,
8121,QualifierName,Q000139,15061230,,,6,,Y,chemically induced
8122,DescriptorName,D006801,15061230,,,7,Humans,N,
8123,DescriptorName,D008297,15061230,,,8,Male,N,
8124,DescriptorName,D012307,15061230,,,9,Risk Factors,N,
8125,DescriptorName,D012702,15061230,,,10,Serotonin Antagonists,N,
8126,QualifierName,Q000008,15061230,,,10,,N,administration & dosage
8127,DescriptorName,D013736,15061230,,,11,Testicular Neoplasms,N,
8128,QualifierName,Q000188,15061230,,,11,,Y,drug therapy
8129,DescriptorName,D014839,15061230,,,12,Vomiting,N,
8130,QualifierName,Q000139,15061230,,,12,,N,chemically induced
8131,Chemical,D000893,15072497,Anti-Inflammatory Agents,0,,,,
8132,Chemical,D003078,15072497,Colchicine,SML2Y3J35T,,,,
8133,DescriptorName,D000328,15072497,,,1,Adult,N,
8134,DescriptorName,D000893,15072497,,,2,Anti-Inflammatory Agents,N,
8135,QualifierName,Q000008,15072497,,,2,,N,administration & dosage
8136,DescriptorName,D003078,15072497,,,3,Colchicine,N,
8137,QualifierName,Q000008,15072497,,,3,,N,administration & dosage
8138,DescriptorName,D010505,15072497,,,4,Familial Mediterranean Fever,N,
8139,QualifierName,Q000188,15072497,,,4,,N,drug therapy
8140,DescriptorName,D006801,15072497,,,5,Humans,N,
8141,DescriptorName,D008297,15072497,,,6,Male,N,
8142,DescriptorName,D008875,15072497,,,7,Middle Aged,N,
8143,DescriptorName,D010411,15072497,,,8,Penile Induration,N,
8144,QualifierName,Q000139,15072497,,,8,,Y,chemically induced
8145,DescriptorName,D013997,15072497,,,9,Time Factors,N,
8146,Chemical,D009582,150825,Nitrofurantoin,927AH8112L,,,,
8147,DescriptorName,D000328,150825,,,1,Adult,N,
8148,DescriptorName,D056486,150825,,,2,Chemical and Drug Induced Liver Injury,N,
8149,QualifierName,Q000209,150825,,,2,,Y,etiology
8150,DescriptorName,D002779,150825,,,3,Cholestasis,N,
8151,QualifierName,Q000139,150825,,,3,,Y,chemically induced
8152,DescriptorName,D048909,150825,,,4,Diabetes Complications,N,
8153,DescriptorName,D003875,150825,,,5,Drug Eruptions,N,
8154,QualifierName,Q000209,150825,,,5,,N,etiology
8155,DescriptorName,D005260,150825,,,6,Female,N,
8156,DescriptorName,D006801,150825,,,7,Humans,N,
8157,DescriptorName,D009582,150825,,,8,Nitrofurantoin,N,
8158,QualifierName,Q000008,150825,,,8,,N,administration & dosage
8159,DescriptorName,D014552,150825,,,9,Urinary Tract Infections,N,
8160,QualifierName,Q000188,150825,,,9,,N,drug therapy
8161,Chemical,D002746,1509179,Chlorpromazine,U42B7VYA4P,,,,
8162,Chemical,D010634,1509179,Phenobarbital,YQE403BP4D,,,,
8163,DescriptorName,D000328,1509179,,,1,Adult,N,
8164,DescriptorName,D000374,1509179,,,2,Aggression,N,
8165,QualifierName,Q000187,1509179,,,2,,Y,drug effects
8166,DescriptorName,D002746,1509179,,,3,Chlorpromazine,N,
8167,QualifierName,Q000627,1509179,,,3,,Y,therapeutic use
8168,DescriptorName,D003937,1509179,,,4,"Diagnosis, Differential",N,
8169,DescriptorName,D004305,1509179,,,5,"Dose-Response Relationship, Drug",N,
8170,DescriptorName,D004830,1509179,,,6,"Epilepsy, Tonic-Clonic",N,
8171,QualifierName,Q000188,1509179,,,6,,Y,drug therapy
8172,DescriptorName,D005260,1509179,,,7,Female,N,
8173,DescriptorName,D006801,1509179,,,8,Humans,N,
8174,DescriptorName,D008607,1509179,,,9,Intellectual Disability,N,
8175,QualifierName,Q000188,1509179,,,9,,Y,drug therapy
8176,DescriptorName,D010634,1509179,,,10,Phenobarbital,N,
8177,QualifierName,Q000009,1509179,,,10,,Y,adverse effects
8178,DescriptorName,D012189,1509179,,,11,Retrospective Studies,N,
8179,DescriptorName,D016728,1509179,,,12,Self-Injurious Behavior,N,
8180,QualifierName,Q000139,1509179,,,12,,N,chemically induced
8181,DescriptorName,D012919,1509179,,,13,Social Behavior,Y,
8182,Chemical,D018721,15093850,Muscarinic Agonists,0,,,,
8183,Chemical,D010862,15093850,Pilocarpine,01MI4Q9DI3,,,,
8184,DescriptorName,D000284,15093850,,,1,"Administration, Oral",N,
8185,DescriptorName,D062787,15093850,,,2,Drug Overdose,N,
8186,DescriptorName,D005260,15093850,,,3,Female,N,
8187,DescriptorName,D006801,15093850,,,4,Humans,N,
8188,DescriptorName,D008875,15093850,,,5,Middle Aged,N,
8189,DescriptorName,D018721,15093850,,,6,Muscarinic Agonists,N,
8190,QualifierName,Q000008,15093850,,,6,,N,administration & dosage
8191,DescriptorName,D010862,15093850,,,7,Pilocarpine,N,
8192,QualifierName,Q000008,15093850,,,7,,N,administration & dosage
8193,DescriptorName,D012859,15093850,,,8,Sjogren's Syndrome,N,
8194,QualifierName,Q000150,15093850,,,8,,N,complications
8195,DescriptorName,D014987,15093850,,,9,Xerostomia,N,
8196,QualifierName,Q000188,15093850,,,9,,Y,drug therapy
8197,Chemical,D000927,15097937,Anticonvulsants,0,,,,
8198,Chemical,D001533,15097937,Belladonna Alkaloids,0,,,,
8199,Chemical,D004338,15097937,Drug Combinations,0,,,,
8200,Chemical,D004879,15097937,Ergotamines,0,,,,
8201,Chemical,C014350,15097937,"bellodona alkaloid, ergotamine, phenolbarbital drug combination",77190-10-4,,,,
8202,Chemical,D010634,15097937,Phenobarbital,YQE403BP4D,,,,
8203,DescriptorName,D000927,15097937,,,1,Anticonvulsants,N,
8204,QualifierName,Q000009,15097937,,,1,,Y,adverse effects
8205,DescriptorName,D001533,15097937,,,2,Belladonna Alkaloids,N,
8206,QualifierName,Q000009,15097937,,,2,,Y,adverse effects
8207,DescriptorName,D004338,15097937,,,3,Drug Combinations,N,
8208,DescriptorName,D004342,15097937,,,4,Drug Hypersensitivity,N,
8209,QualifierName,Q000209,15097937,,,4,,Y,etiology
8210,DescriptorName,D004879,15097937,,,5,Ergotamines,N,
8211,QualifierName,Q000009,15097937,,,5,,Y,adverse effects
8212,DescriptorName,D005260,15097937,,,6,Female,N,
8213,DescriptorName,D019584,15097937,,,7,Hot Flashes,N,
8214,QualifierName,Q000188,15097937,,,7,,Y,drug therapy
8215,DescriptorName,D006801,15097937,,,8,Humans,N,
8216,DescriptorName,D008593,15097937,,,9,Menopause,N,
8217,DescriptorName,D008875,15097937,,,10,Middle Aged,N,
8218,DescriptorName,D010634,15097937,,,11,Phenobarbital,N,
8219,QualifierName,Q000009,15097937,,,11,,Y,adverse effects
8220,Chemical,D014150,15107195,Antipsychotic Agents,0,,,,
8221,Chemical,D009125,15107195,"Muscle Relaxants, Central",0,,,,
8222,Chemical,D003620,15107195,Dantrolene,F64QU97QCR,,,,
8223,Chemical,D003024,15107195,Clozapine,J60AR2IKIC,,,,
8224,DescriptorName,D000328,15107195,,,1,Adult,N,
8225,DescriptorName,D014150,15107195,,,2,Antipsychotic Agents,N,
8226,QualifierName,Q000009,15107195,,,2,,Y,adverse effects
8227,DescriptorName,D003024,15107195,,,3,Clozapine,N,
8228,QualifierName,Q000009,15107195,,,3,,Y,adverse effects
8229,DescriptorName,D003620,15107195,,,4,Dantrolene,N,
8230,QualifierName,Q000627,15107195,,,4,,N,therapeutic use
8231,DescriptorName,D018883,15107195,,,5,Heat Stroke,N,
8232,QualifierName,Q000175,15107195,,,5,,Y,diagnosis
8233,DescriptorName,D006801,15107195,,,6,Humans,N,
8234,DescriptorName,D008297,15107195,,,7,Male,N,
8235,DescriptorName,D009125,15107195,,,8,"Muscle Relaxants, Central",N,
8236,QualifierName,Q000627,15107195,,,8,,N,therapeutic use
8237,DescriptorName,D012559,15107195,,,9,Schizophrenia,N,
8238,QualifierName,Q000150,15107195,,,9,,N,complications
8239,Chemical,D013256,15112258,Steroids,0,,,,
8240,Chemical,D003841,15112258,Deoxycytidine,0W860991D6,,,,
8241,Chemical,C056507,15112258,gemcitabine,B76N6SBZ8R,,,,
8242,DescriptorName,D000230,15112258,,,1,Adenocarcinoma,N,
8243,QualifierName,Q000188,15112258,,,1,,Y,drug therapy
8244,DescriptorName,D003131,15112258,,,2,Combined Modality Therapy,N,
8245,DescriptorName,D003841,15112258,,,3,Deoxycytidine,N,
8246,QualifierName,Q000009,15112258,,,3,,Y,adverse effects
8247,DescriptorName,D005500,15112258,,,4,Follow-Up Studies,N,
8248,DescriptorName,D006801,15112258,,,5,Humans,N,
8249,DescriptorName,D008297,15112258,,,6,Male,N,
8250,DescriptorName,D008875,15112258,,,7,Middle Aged,N,
8251,DescriptorName,D009220,15112258,,,8,Myositis,N,
8252,QualifierName,Q000188,15112258,,,8,,N,drug therapy
8253,DescriptorName,D009367,15112258,,,9,Neoplasm Staging,N,
8254,DescriptorName,D010166,15112258,,,10,Palliative Care,N,
8255,QualifierName,Q000379,15112258,,,10,,N,methods
8256,DescriptorName,D010190,15112258,,,11,Pancreatic Neoplasms,N,
8257,QualifierName,Q000188,15112258,,,11,,Y,drug therapy
8258,DescriptorName,D011829,15112258,,,12,Radiation Dosage,N,
8259,DescriptorName,D011832,15112258,,,13,Radiation Injuries,N,
8260,QualifierName,Q000139,15112258,,,13,,Y,chemically induced
8261,DescriptorName,D018570,15112258,,,14,Risk Assessment,N,
8262,DescriptorName,D013256,15112258,,,15,Steroids,N,
8263,QualifierName,Q000627,15112258,,,15,,N,therapeutic use
8264,Chemical,D000577,15126179,Amides,0,,,,
8265,Chemical,D000959,15126179,Antihypertensive Agents,0,,,,
8266,Chemical,D008055,15126179,Lipids,0,,,,
8267,Chemical,D011461,15126179,"Prostaglandins F, Synthetic",0,,,,
8268,Chemical,D003008,15126179,Cloprostenol,4208238832,,,,
8269,Chemical,D000077338,15126179,Latanoprost,6Z5B6HVF6O,,,,
8270,Chemical,D000069580,15126179,Bimatoprost,QXS94885MZ,,,,
8271,DescriptorName,D000368,15126179,,,1,Aged,N,
8272,DescriptorName,D000577,15126179,,,2,Amides,N,
8273,DescriptorName,D000959,15126179,,,3,Antihypertensive Agents,N,
8274,QualifierName,Q000009,15126179,,,3,,Y,adverse effects
8275,DescriptorName,D000069580,15126179,,,4,Bimatoprost,N,
8276,DescriptorName,D003008,15126179,,,5,Cloprostenol,N,
8277,QualifierName,Q000031,15126179,,,5,,N,analogs & derivatives
8278,DescriptorName,D003228,15126179,,,6,Conjunctiva,N,
8279,QualifierName,Q000098,15126179,,,6,,N,blood supply
8280,DescriptorName,D005451,15126179,,,7,Fluorescein Angiography,N,
8281,DescriptorName,D005902,15126179,,,8,"Glaucoma, Open-Angle",N,
8282,QualifierName,Q000188,15126179,,,8,,N,drug therapy
8283,DescriptorName,D006801,15126179,,,9,Humans,N,
8284,DescriptorName,D006940,15126179,,,10,Hyperemia,N,
8285,QualifierName,Q000139,15126179,,,10,,N,chemically induced
8286,DescriptorName,D007429,15126179,,,11,Intraocular Pressure,N,
8287,QualifierName,Q000187,15126179,,,11,,N,drug effects
8288,DescriptorName,D000077338,15126179,,,12,Latanoprost,N,
8289,DescriptorName,D008055,15126179,,,13,Lipids,N,
8290,QualifierName,Q000009,15126179,,,13,,Y,adverse effects
8291,DescriptorName,D008269,15126179,,,14,Macular Edema,N,
8292,QualifierName,Q000139,15126179,,,14,,Y,chemically induced
8293,DescriptorName,D008297,15126179,,,15,Male,N,
8294,DescriptorName,D011461,15126179,,,16,"Prostaglandins F, Synthetic",N,
8295,QualifierName,Q000627,15126179,,,16,,Y,therapeutic use
8296,DescriptorName,D019591,15126179,,,17,Pseudophakia,N,
8297,QualifierName,Q000150,15126179,,,17,,N,complications
8298,DescriptorName,D012307,15126179,,,18,Risk Factors,N,
8299,Chemical,D000941,15157248,Antigens,0,,,,
8300,Chemical,D000970,15157248,Antineoplastic Agents,0,,,,
8301,Chemical,D007074,15157248,Immunoglobulin G,0,,,,
8302,Chemical,D009944,15157248,Organoplatinum Compounds,0,,,,
8303,Chemical,D000077150,15157248,Oxaliplatin,04ZR38536J,,,,
8304,Chemical,D003841,15157248,Deoxycytidine,0W860991D6,,,,
8305,Chemical,D000069287,15157248,Capecitabine,6804DJ8Z9U,,,,
8306,Chemical,D000077146,15157248,Irinotecan,7673326042,,,,
8307,Chemical,D003907,15157248,Dexamethasone,7S5I7G3JQL,,,,
8308,Chemical,D002955,15157248,Leucovorin,Q573I9DVLP,,,,
8309,Chemical,D005472,15157248,Fluorouracil,U3P01618RT,,,,
8310,Chemical,D002166,15157248,Camptothecin,XT3Z54Z28A,,,,
8311,DescriptorName,D000230,15157248,,,1,Adenocarcinoma,N,
8312,QualifierName,Q000188,15157248,,,1,,N,drug therapy
8313,DescriptorName,D000744,15157248,,,2,"Anemia, Hemolytic, Autoimmune",N,
8314,QualifierName,Q000139,15157248,,,2,,Y,chemically induced
8315,DescriptorName,D000918,15157248,,,3,Antibody Specificity,N,
8316,DescriptorName,D000941,15157248,,,4,Antigens,N,
8317,QualifierName,Q000187,15157248,,,4,,N,drug effects
8318,DescriptorName,D000970,15157248,,,5,Antineoplastic Agents,N,
8319,QualifierName,Q000008,15157248,,,5,,N,administration & dosage
8320,DescriptorName,D000971,15157248,,,6,Antineoplastic Combined Chemotherapy Protocols,N,
8321,QualifierName,Q000627,15157248,,,6,,N,therapeutic use
8322,DescriptorName,D001788,15157248,,,7,Blood Grouping and Crossmatching,N,
8323,DescriptorName,D001803,15157248,,,8,Blood Transfusion,N,
8324,DescriptorName,D002166,15157248,,,9,Camptothecin,N,
8325,QualifierName,Q000008,15157248,,,9,,N,administration & dosage
8326,DescriptorName,D000069287,15157248,,,10,Capecitabine,N,
8327,DescriptorName,D015179,15157248,,,11,Colorectal Neoplasms,N,
8328,QualifierName,Q000188,15157248,,,11,,N,drug therapy
8329,DescriptorName,D003841,15157248,,,12,Deoxycytidine,N,
8330,QualifierName,Q000008,15157248,,,12,,N,administration & dosage
8331,DescriptorName,D003907,15157248,,,13,Dexamethasone,N,
8332,QualifierName,Q000008,15157248,,,13,,N,administration & dosage
8333,DescriptorName,D018450,15157248,,,14,Disease Progression,N,
8334,DescriptorName,D017809,15157248,,,15,Fatal Outcome,N,
8335,DescriptorName,D005260,15157248,,,16,Female,N,
8336,DescriptorName,D005472,15157248,,,17,Fluorouracil,N,
8337,QualifierName,Q000008,15157248,,,17,,N,administration & dosage
8338,DescriptorName,D006801,15157248,,,18,Humans,N,
8339,DescriptorName,D007074,15157248,,,19,Immunoglobulin G,N,
8340,QualifierName,Q000276,15157248,,,19,,N,immunology
8341,DescriptorName,D000077146,15157248,,,20,Irinotecan,N,
8342,DescriptorName,D002955,15157248,,,21,Leucovorin,N,
8343,QualifierName,Q000008,15157248,,,21,,N,administration & dosage
8344,DescriptorName,D008875,15157248,,,22,Middle Aged,N,
8345,DescriptorName,D009944,15157248,,,23,Organoplatinum Compounds,N,
8346,QualifierName,Q000008,15157248,,,23,,N,administration & dosage
8347,DescriptorName,D000077150,15157248,,,24,Oxaliplatin,N,
8348,Chemical,D000964,15162903,"Antimetabolites, Antineoplastic",0,,,,
8349,Chemical,D008727,15162903,Methotrexate,YL5FZ2Y5U1,,,,
8350,DescriptorName,D000328,15162903,,,1,Adult,N,
8351,DescriptorName,D000964,15162903,,,2,"Antimetabolites, Antineoplastic",N,
8352,QualifierName,Q000008,15162903,,,2,,N,administration & dosage
8353,DescriptorName,D004679,15162903,,,3,Encephalomyelitis,N,
8354,QualifierName,Q000139,15162903,,,3,,Y,chemically induced
8355,DescriptorName,D017809,15162903,,,4,Fatal Outcome,N,
8356,DescriptorName,D006801,15162903,,,5,Humans,N,
8357,DescriptorName,D007278,15162903,,,6,"Injections, Spinal",N,
8358,DescriptorName,D008297,15162903,,,7,Male,N,
8359,DescriptorName,D008727,15162903,,,8,Methotrexate,N,
8360,QualifierName,Q000008,15162903,,,8,,N,administration & dosage
8361,DescriptorName,D054198,15162903,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
8362,QualifierName,Q000188,15162903,,,9,,N,drug therapy
8363,Chemical,D000900,1517501,Anti-Bacterial Agents,0,,,,
8364,DescriptorName,D000367,1517501,,,1,Age Factors,N,
8365,DescriptorName,D000900,1517501,,,2,Anti-Bacterial Agents,N,
8366,QualifierName,Q000009,1517501,,,2,,Y,adverse effects
8367,DescriptorName,D004927,1517501,,,3,Escherichia coli Infections,N,
8368,QualifierName,Q000188,1517501,,,3,,N,drug therapy
8369,DescriptorName,D006801,1517501,,,4,Humans,N,
8370,DescriptorName,D007223,1517501,,,5,Infant,N,
8371,DescriptorName,D008297,1517501,,,6,Male,N,
8372,DescriptorName,D013262,1517501,,,7,Stevens-Johnson Syndrome,N,
8373,QualifierName,Q000209,1517501,,,7,,Y,etiology
8374,Chemical,D006493,15176542,Heparin,9005-49-6,,,,
8375,DescriptorName,D000368,15176542,,,1,Aged,N,
8376,DescriptorName,D003937,15176542,,,2,"Diagnosis, Differential",N,
8377,DescriptorName,D004935,15176542,,,3,Esophageal Diseases,N,
8378,QualifierName,Q000175,15176542,,,3,,Y,diagnosis
8379,DescriptorName,D005260,15176542,,,4,Female,N,
8380,DescriptorName,D006471,15176542,,,5,Gastrointestinal Hemorrhage,N,
8381,QualifierName,Q000139,15176542,,,5,,Y,chemically induced
8382,DescriptorName,D006493,15176542,,,6,Heparin,N,
8383,QualifierName,Q000009,15176542,,,6,,Y,adverse effects
8384,DescriptorName,D006801,15176542,,,7,Humans,N,
8385,DescriptorName,D008297,15176542,,,8,Male,N,
8386,DescriptorName,D008875,15176542,,,9,Middle Aged,N,
8387,DescriptorName,D009203,15176542,,,10,Myocardial Infarction,N,
8388,QualifierName,Q000175,15176542,,,10,,Y,diagnosis
8389,DescriptorName,D011655,15176542,,,11,Pulmonary Embolism,N,
8390,QualifierName,Q000175,15176542,,,11,,Y,diagnosis
8391,DescriptorName,D018570,15176542,,,12,Risk Assessment,N,
8392,DescriptorName,D012422,15176542,,,13,"Rupture, Spontaneous",N,
8393,QualifierName,Q000175,15176542,,,13,,N,diagnosis
8394,DescriptorName,D013577,15176542,,,14,Syndrome,N,
8395,Chemical,D004121,15183980,Dimethyl Sulfoxide,YOW8V9698H,,,,
8396,DescriptorName,D015746,15183980,,,1,Abdominal Pain,N,
8397,QualifierName,Q000209,15183980,,,1,,N,etiology
8398,DescriptorName,D000283,15183980,,,2,"Administration, Intravesical",N,
8399,DescriptorName,D003556,15183980,,,3,Cystitis,N,
8400,QualifierName,Q000139,15183980,,,3,,Y,chemically induced
8401,DescriptorName,D003558,15183980,,,4,Cystoscopy,N,
8402,DescriptorName,D004121,15183980,,,5,Dimethyl Sulfoxide,N,
8403,QualifierName,Q000008,15183980,,,5,,N,administration & dosage
8404,DescriptorName,D004802,15183980,,,6,Eosinophilia,N,
8405,QualifierName,Q000139,15183980,,,6,,Y,chemically induced
8406,DescriptorName,D005260,15183980,,,7,Female,N,
8407,DescriptorName,D006417,15183980,,,8,Hematuria,N,
8408,QualifierName,Q000209,15183980,,,8,,N,etiology
8409,DescriptorName,D006801,15183980,,,9,Humans,N,
8410,DescriptorName,D008875,15183980,,,10,Middle Aged,N,
8411,DescriptorName,D014549,15183980,,,11,Urinary Incontinence,N,
8412,QualifierName,Q000209,15183980,,,11,,N,etiology
8413,DescriptorName,D014555,15183980,,,12,Urination Disorders,N,
8414,QualifierName,Q000209,15183980,,,12,,N,etiology
8415,Chemical,D000077190,15190230,Interferon alpha-2,0,,,,
8416,Chemical,D016898,15190230,Interferon-alpha,0,,,,
8417,Chemical,D011994,15190230,Recombinant Proteins,0,,,,
8418,Chemical,D011092,15190230,Polyethylene Glycols,3WJQ0SDW1A,,,,
8419,Chemical,C100416,15190230,peginterferon alfa-2a,Q46947FE7K,,,,
8420,DescriptorName,D000328,15190230,,,1,Adult,N,
8421,DescriptorName,D004421,15190230,,,2,Dystonia,N,
8422,QualifierName,Q000139,15190230,,,2,,Y,chemically induced
8423,DescriptorName,D019694,15190230,,,3,"Hepatitis B, Chronic",N,
8424,QualifierName,Q000150,15190230,,,3,,N,complications
8425,DescriptorName,D006801,15190230,,,4,Humans,N,
8426,DescriptorName,D000077190,15190230,,,5,Interferon alpha-2,N,
8427,DescriptorName,D016898,15190230,,,6,Interferon-alpha,N,
8428,QualifierName,Q000009,15190230,,,6,,Y,adverse effects
8429,DescriptorName,D008297,15190230,,,7,Male,N,
8430,DescriptorName,D011092,15190230,,,8,Polyethylene Glycols,N,
8431,QualifierName,Q000009,15190230,,,8,,Y,adverse effects
8432,DescriptorName,D011994,15190230,,,9,Recombinant Proteins,N,
8433,Chemical,D000998,15197722,Antiviral Agents,0,,,,
8434,Chemical,D016898,15197722,Interferon-alpha,0,,,,
8435,DescriptorName,D000998,15197722,,,1,Antiviral Agents,N,
8436,QualifierName,Q000009,15197722,,,1,,Y,adverse effects
8437,DescriptorName,D001706,15197722,,,2,Biopsy,N,
8438,DescriptorName,D019698,15197722,,,3,"Hepatitis C, Chronic",N,
8439,QualifierName,Q000188,15197722,,,3,,N,drug therapy
8440,DescriptorName,D006801,15197722,,,4,Humans,N,
8441,DescriptorName,D016898,15197722,,,5,Interferon-alpha,N,
8442,QualifierName,Q000009,15197722,,,5,,Y,adverse effects
8443,DescriptorName,D008099,15197722,,,6,Liver,N,
8444,QualifierName,Q000473,15197722,,,6,,N,pathology
8445,DescriptorName,D008297,15197722,,,7,Male,N,
8446,DescriptorName,D008875,15197722,,,8,Middle Aged,N,
8447,DescriptorName,D012148,15197722,,,9,Restless Legs Syndrome,N,
8448,QualifierName,Q000139,15197722,,,9,,Y,chemically induced
8449,DescriptorName,D012720,15197722,,,10,Severity of Illness Index,N,
8450,Chemical,D003692,15203443,Delayed-Action Preparations,0,,,,
8451,Chemical,D004343,15203443,Drug Implants,0,,,,
8452,Chemical,D009292,15203443,Narcotic Antagonists,0,,,,
8453,Chemical,D009271,15203443,Naltrexone,5S6W795CQM,,,,
8454,DescriptorName,D000208,15203443,,,1,Acute Disease,N,
8455,DescriptorName,D000328,15203443,,,2,Adult,N,
8456,DescriptorName,D003692,15203443,,,3,Delayed-Action Preparations,N,
8457,DescriptorName,D004343,15203443,,,4,Drug Implants,N,
8458,DescriptorName,D006509,15203443,,,5,Hepatitis B,Y,
8459,QualifierName,Q000097,15203443,,,5,,N,blood
8460,DescriptorName,D006526,15203443,,,6,Hepatitis C,Y,
8461,QualifierName,Q000097,15203443,,,6,,N,blood
8462,DescriptorName,D006556,15203443,,,7,Heroin Dependence,N,
8463,QualifierName,Q000188,15203443,,,7,,Y,drug therapy
8464,DescriptorName,D006801,15203443,,,8,Humans,N,
8465,DescriptorName,D008111,15203443,,,9,Liver Function Tests,N,
8466,DescriptorName,D008297,15203443,,,10,Male,N,
8467,DescriptorName,D009271,15203443,,,11,Naltrexone,N,
8468,QualifierName,Q000008,15203443,,,11,,N,administration & dosage
8469,DescriptorName,D009292,15203443,,,12,Narcotic Antagonists,N,
8470,QualifierName,Q000008,15203443,,,12,,N,administration & dosage
8471,Chemical,D011994,15224368,Recombinant Proteins,0,,,,
8472,Chemical,D003561,15224368,Cytarabine,04079A1RDZ,,,,
8473,Chemical,C081222,15224368,sargramostim,5TAA004E22,,,,
8474,Chemical,D016178,15224368,Granulocyte-Macrophage Colony-Stimulating Factor,83869-56-1,,,,
8475,Chemical,D011241,15224368,Prednisone,VB0R961HZT,,,,
8476,Chemical,D003630,15224368,Daunorubicin,ZS7284E0ZP,,,,
8477,DescriptorName,D000971,15224368,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
8478,QualifierName,Q000008,15224368,,,1,,N,administration & dosage
8479,DescriptorName,D001706,15224368,,,2,Biopsy,N,
8480,DescriptorName,D003561,15224368,,,3,Cytarabine,N,
8481,QualifierName,Q000008,15224368,,,3,,N,administration & dosage
8482,DescriptorName,D003630,15224368,,,4,Daunorubicin,N,
8483,QualifierName,Q000008,15224368,,,4,,N,administration & dosage
8484,DescriptorName,D016178,15224368,,,5,Granulocyte-Macrophage Colony-Stimulating Factor,N,
8485,QualifierName,Q000008,15224368,,,5,,N,administration & dosage
8486,DescriptorName,D006801,15224368,,,6,Humans,N,
8487,DescriptorName,D015470,15224368,,,7,"Leukemia, Myeloid, Acute",N,
8488,QualifierName,Q000188,15224368,,,7,,Y,drug therapy
8489,DescriptorName,D008297,15224368,,,8,Male,N,
8490,DescriptorName,D008875,15224368,,,9,Middle Aged,N,
8491,DescriptorName,D011241,15224368,,,10,Prednisone,N,
8492,QualifierName,Q000627,15224368,,,10,,N,therapeutic use
8493,DescriptorName,D011994,15224368,,,11,Recombinant Proteins,N,
8494,DescriptorName,D012074,15224368,,,12,Remission Induction,N,
8495,DescriptorName,D012867,15224368,,,13,Skin,N,
8496,QualifierName,Q000473,15224368,,,13,,N,pathology
8497,DescriptorName,D016463,15224368,,,14,Sweet Syndrome,N,
8498,QualifierName,Q000139,15224368,,,14,,Y,chemically induced
8499,Chemical,D014150,15235919,Antipsychotic Agents,0,,,,
8500,Chemical,D003024,15235919,Clozapine,J60AR2IKIC,,,,
8501,DescriptorName,D000328,15235919,,,1,Adult,N,
8502,DescriptorName,D014150,15235919,,,2,Antipsychotic Agents,N,
8503,QualifierName,Q000009,15235919,,,2,,Y,adverse effects
8504,DescriptorName,D003024,15235919,,,3,Clozapine,N,
8505,QualifierName,Q000009,15235919,,,3,,Y,adverse effects
8506,DescriptorName,D016757,15235919,,,4,"Death, Sudden, Cardiac",N,
8507,QualifierName,Q000209,15235919,,,4,,Y,etiology
8508,DescriptorName,D017809,15235919,,,5,Fatal Outcome,N,
8509,DescriptorName,D006801,15235919,,,6,Humans,N,
8510,DescriptorName,D006968,15235919,,,7,"Hypersensitivity, Delayed",N,
8511,QualifierName,Q000209,15235919,,,7,,Y,etiology
8512,DescriptorName,D008297,15235919,,,8,Male,N,
8513,DescriptorName,D009205,15235919,,,9,Myocarditis,N,
8514,QualifierName,Q000139,15235919,,,9,,Y,chemically induced
8515,DescriptorName,D012559,15235919,,,10,Schizophrenia,N,
8516,QualifierName,Q000188,15235919,,,10,,N,drug therapy
8517,Chemical,D000927,15239684,Anticonvulsants,0,,,,
8518,Chemical,D010672,15239684,Phenytoin,6158TKW0C5,,,,
8519,DescriptorName,D000368,15239684,,,1,Aged,N,
8520,DescriptorName,D000369,15239684,,,2,"Aged, 80 and over",N,
8521,DescriptorName,D000927,15239684,,,3,Anticonvulsants,N,
8522,QualifierName,Q000008,15239684,,,3,,N,administration & dosage
8523,DescriptorName,D006225,15239684,,,4,Hand,N,
8524,QualifierName,Q000473,15239684,,,4,,Y,pathology
8525,DescriptorName,D006801,15239684,,,5,Humans,N,
8526,DescriptorName,D007262,15239684,,,6,"Infusions, Intravenous",N,
8527,QualifierName,Q000009,15239684,,,6,,Y,adverse effects
8528,DescriptorName,D008297,15239684,,,7,Male,N,
8529,DescriptorName,D010672,15239684,,,8,Phenytoin,N,
8530,QualifierName,Q000008,15239684,,,8,,N,administration & dosage
8531,DescriptorName,D012640,15239684,,,9,Seizures,N,
8532,QualifierName,Q000188,15239684,,,9,,N,drug therapy
8533,DescriptorName,D017695,15239684,,,10,Soft Tissue Injuries,N,
8534,QualifierName,Q000209,15239684,,,10,,N,etiology
8535,DescriptorName,D013927,15239684,,,11,Thrombosis,N,
8536,QualifierName,Q000473,15239684,,,11,,N,pathology
8537,Chemical,D000978,15261876,Antiparkinson Agents,0,,,,
8538,Chemical,D007980,15261876,Levodopa,46627O600J,,,,
8539,DescriptorName,D000368,15261876,,,1,Aged,N,
8540,DescriptorName,D000505,15261876,,,2,Alopecia,N,
8541,QualifierName,Q000139,15261876,,,2,,Y,chemically induced
8542,DescriptorName,D000978,15261876,,,3,Antiparkinson Agents,N,
8543,QualifierName,Q000008,15261876,,,3,,N,administration & dosage
8544,DescriptorName,D003131,15261876,,,4,Combined Modality Therapy,N,
8545,DescriptorName,D004599,15261876,,,5,Electric Stimulation Therapy,Y,
8546,DescriptorName,D006197,15261876,,,6,Hair,N,
8547,QualifierName,Q000187,15261876,,,6,,N,drug effects
8548,DescriptorName,D006801,15261876,,,7,Humans,N,
8549,DescriptorName,D007980,15261876,,,8,Levodopa,N,
8550,QualifierName,Q000008,15261876,,,8,,N,administration & dosage
8551,DescriptorName,D008297,15261876,,,9,Male,N,
8552,DescriptorName,D010300,15261876,,,10,Parkinson Disease,N,
8553,QualifierName,Q000188,15261876,,,10,,Y,drug therapy
8554,DescriptorName,D020531,15261876,,,11,Subthalamic Nucleus,N,
8555,Chemical,D000959,15266150,Antihypertensive Agents,0,,,,
8556,Chemical,D003008,15266150,Cloprostenol,4208238832,,,,
8557,Chemical,D000069557,15266150,Travoprost,WJ68R08KX9,,,,
8558,DescriptorName,D000368,15266150,,,1,Aged,N,
8559,DescriptorName,D000959,15266150,,,2,Antihypertensive Agents,N,
8560,QualifierName,Q000009,15266150,,,2,,Y,adverse effects
8561,DescriptorName,D017115,15266150,,,3,Catheter Ablation,N,
8562,DescriptorName,D003008,15266150,,,4,Cloprostenol,N,
8563,QualifierName,Q000009,15266150,,,4,,Y,adverse effects
8564,DescriptorName,D005140,15266150,,,5,Eyelashes,N,
8565,QualifierName,Q000187,15266150,,,5,,Y,drug effects
8566,DescriptorName,D005260,15266150,,,6,Female,N,
8567,DescriptorName,D005902,15266150,,,7,"Glaucoma, Open-Angle",N,
8568,QualifierName,Q000188,15266150,,,7,,N,drug therapy
8569,DescriptorName,D006801,15266150,,,8,Humans,N,
8570,DescriptorName,D006983,15266150,,,9,Hypertrichosis,N,
8571,QualifierName,Q000139,15266150,,,9,,Y,chemically induced
8572,DescriptorName,D000069557,15266150,,,10,Travoprost,N,
8573,Chemical,D018906,15286697,"Antineoplastic Agents, Alkylating",0,,,,
8574,Chemical,D007527,15286697,Isoenzymes,0,,,,
8575,Chemical,D008565,15286697,Membrane Proteins,0,,,,
8576,Chemical,D020574,15286697,Proto-Oncogene Proteins c-sis,0,,,,
8577,Chemical,C508960,15286697,"TGFB1 protein, human",0,,,,
8578,Chemical,D016212,15286697,Transforming Growth Factor beta,0,,,,
8579,Chemical,D053773,15286697,Transforming Growth Factor beta1,0,,,,
8580,Chemical,D007334,15286697,Insulin-Like Growth Factor I,67763-96-6,,,,
8581,Chemical,D051546,15286697,Cyclooxygenase 2,EC 1.14.99.1,,,,
8582,Chemical,C496540,15286697,"PTGS2 protein, human",EC 1.14.99.1,,,,
8583,Chemical,D011451,15286697,Prostaglandin-Endoperoxide Synthases,EC 1.14.99.1,,,,
8584,Chemical,D002330,15286697,Carmustine,U68WG3173Y,,,,
8585,DescriptorName,D000328,15286697,,,1,Adult,N,
8586,DescriptorName,D018906,15286697,,,2,"Antineoplastic Agents, Alkylating",N,
8587,QualifierName,Q000009,15286697,,,2,,Y,adverse effects
8588,DescriptorName,D002330,15286697,,,3,Carmustine,N,
8589,QualifierName,Q000009,15286697,,,3,,Y,adverse effects
8590,DescriptorName,D051546,15286697,,,4,Cyclooxygenase 2,N,
8591,DescriptorName,D017809,15286697,,,5,Fatal Outcome,N,
8592,DescriptorName,D005260,15286697,,,6,Female,N,
8593,DescriptorName,D006801,15286697,,,7,Humans,N,
8594,DescriptorName,D007334,15286697,,,8,Insulin-Like Growth Factor I,N,
8595,QualifierName,Q000378,15286697,,,8,,N,metabolism
8596,DescriptorName,D007527,15286697,,,9,Isoenzymes,N,
8597,QualifierName,Q000378,15286697,,,9,,N,metabolism
8598,DescriptorName,D008168,15286697,,,10,Lung,N,
8599,QualifierName,Q000473,15286697,,,10,,N,pathology
8600,DescriptorName,D016393,15286697,,,11,"Lymphoma, B-Cell",N,
8601,QualifierName,Q000150,15286697,,,11,,N,complications
8602,DescriptorName,D016403,15286697,,,12,"Lymphoma, Large B-Cell, Diffuse",N,
8603,QualifierName,Q000150,15286697,,,12,,N,complications
8604,DescriptorName,D008565,15286697,,,13,Membrane Proteins,N,
8605,DescriptorName,D011451,15286697,,,14,Prostaglandin-Endoperoxide Synthases,N,
8606,QualifierName,Q000378,15286697,,,14,,N,metabolism
8607,DescriptorName,D020574,15286697,,,15,Proto-Oncogene Proteins c-sis,N,
8608,QualifierName,Q000378,15286697,,,15,,N,metabolism
8609,DescriptorName,D011658,15286697,,,16,Pulmonary Fibrosis,N,
8610,QualifierName,Q000139,15286697,,,16,,Y,chemically induced
8611,DescriptorName,D016212,15286697,,,17,Transforming Growth Factor beta,N,
8612,QualifierName,Q000378,15286697,,,17,,N,metabolism
8613,DescriptorName,D053773,15286697,,,18,Transforming Growth Factor beta1,N,
8614,Chemical,D000959,15289139,Antihypertensive Agents,0,,,,
8615,Chemical,D002257,15289139,Carbonic Anhydrase Inhibitors,0,,,,
8616,Chemical,D013449,15289139,Sulfonamides,0,,,,
8617,Chemical,D013876,15289139,Thiophenes,0,,,,
8618,Chemical,C062765,15289139,dorzolamide,9JDX055TW1,,,,
8619,DescriptorName,D000368,15289139,,,1,Aged,N,
8620,DescriptorName,D000959,15289139,,,2,Antihypertensive Agents,N,
8621,QualifierName,Q000009,15289139,,,2,,Y,adverse effects
8622,DescriptorName,D002257,15289139,,,3,Carbonic Anhydrase Inhibitors,N,
8623,QualifierName,Q000009,15289139,,,3,,Y,adverse effects
8624,DescriptorName,D015862,15289139,,,4,Choroid Diseases,N,
8625,QualifierName,Q000139,15289139,,,4,,Y,chemically induced
8626,DescriptorName,D005260,15289139,,,5,Female,N,
8627,DescriptorName,D005902,15289139,,,6,"Glaucoma, Open-Angle",N,
8628,QualifierName,Q000188,15289139,,,6,,N,drug therapy
8629,DescriptorName,D006801,15289139,,,7,Humans,N,
8630,DescriptorName,D013449,15289139,,,8,Sulfonamides,N,
8631,QualifierName,Q000009,15289139,,,8,,Y,adverse effects
8632,DescriptorName,D013876,15289139,,,9,Thiophenes,N,
8633,QualifierName,Q000009,15289139,,,9,,Y,adverse effects
8634,DescriptorName,D014463,15289139,,,10,Ultrasonography,N,
8635,Chemical,D000577,15300114,Amides,0,,,,
8636,Chemical,D000959,15300114,Antihypertensive Agents,0,,,,
8637,Chemical,D008055,15300114,Lipids,0,,,,
8638,Chemical,D009883,15300114,Ophthalmic Solutions,0,,,,
8639,Chemical,D003008,15300114,Cloprostenol,4208238832,,,,
8640,Chemical,D000069580,15300114,Bimatoprost,QXS94885MZ,,,,
8641,DescriptorName,D000287,15300114,,,1,"Administration, Topical",N,
8642,DescriptorName,D000368,15300114,,,2,Aged,N,
8643,DescriptorName,D000369,15300114,,,3,"Aged, 80 and over",N,
8644,DescriptorName,D000577,15300114,,,4,Amides,N,
8645,DescriptorName,D000959,15300114,,,5,Antihypertensive Agents,N,
8646,QualifierName,Q000009,15300114,,,5,,Y,adverse effects
8647,DescriptorName,D000069580,15300114,,,6,Bimatoprost,N,
8648,DescriptorName,D003008,15300114,,,7,Cloprostenol,N,
8649,QualifierName,Q000031,15300114,,,7,,N,analogs & derivatives
8650,DescriptorName,D005141,15300114,,,8,Eyelid Diseases,N,
8651,QualifierName,Q000139,15300114,,,8,,Y,chemically induced
8652,DescriptorName,D005260,15300114,,,9,Female,N,
8653,DescriptorName,D005901,15300114,,,10,Glaucoma,N,
8654,QualifierName,Q000188,15300114,,,10,,N,drug therapy
8655,DescriptorName,D006801,15300114,,,11,Humans,N,
8656,DescriptorName,D007429,15300114,,,12,Intraocular Pressure,N,
8657,QualifierName,Q000187,15300114,,,12,,N,drug effects
8658,DescriptorName,D008055,15300114,,,13,Lipids,N,
8659,QualifierName,Q000009,15300114,,,13,,Y,adverse effects
8660,DescriptorName,D008297,15300114,,,14,Male,N,
8661,DescriptorName,D008875,15300114,,,15,Middle Aged,N,
8662,DescriptorName,D009883,15300114,,,16,Ophthalmic Solutions,N,
8663,QualifierName,Q000009,15300114,,,16,,N,adverse effects
8664,Chemical,D005938,15304176,Glucocorticoids,0,,,,
8665,Chemical,D017325,15304176,Hepatitis B Vaccines,0,,,,
8666,Chemical,D002990,15304176,Clobetasol,ADN79D536H,,,,
8667,Chemical,D011241,15304176,Prednisone,VB0R961HZT,,,,
8668,DescriptorName,D000328,15304176,,,1,Adult,N,
8669,DescriptorName,D002990,15304176,,,2,Clobetasol,N,
8670,QualifierName,Q000627,15304176,,,2,,N,therapeutic use
8671,DescriptorName,D005938,15304176,,,3,Glucocorticoids,N,
8672,QualifierName,Q000627,15304176,,,3,,N,therapeutic use
8673,DescriptorName,D017325,15304176,,,4,Hepatitis B Vaccines,N,
8674,QualifierName,Q000009,15304176,,,4,,Y,adverse effects
8675,DescriptorName,D006801,15304176,,,5,Humans,N,
8676,DescriptorName,D008010,15304176,,,6,Lichen Planus,N,
8677,QualifierName,Q000188,15304176,,,6,,N,drug therapy
8678,DescriptorName,D008297,15304176,,,7,Male,N,
8679,DescriptorName,D011241,15304176,,,8,Prednisone,N,
8680,QualifierName,Q000627,15304176,,,8,,N,therapeutic use
8681,DescriptorName,D012008,15304176,,,9,Recurrence,N,
8682,DescriptorName,D016896,15304176,,,10,Treatment Outcome,N,
8683,Chemical,D000962,15307435,Antimalarials,0,,,,
8684,Chemical,D004338,15307435,Drug Combinations,0,,,,
8685,Chemical,C001205,15307435,"fanasil, pyrimethamine drug combination",37338-39-9,,,,
8686,Chemical,D013413,15307435,Sulfadoxine,88463U4SM5,,,,
8687,Chemical,D011739,15307435,Pyrimethamine,Z3614QOX8W,,,,
8688,DescriptorName,D000962,15307435,,,1,Antimalarials,N,
8689,QualifierName,Q000009,15307435,,,1,,Y,adverse effects
8690,DescriptorName,D004338,15307435,,,2,Drug Combinations,N,
8691,DescriptorName,D006801,15307435,,,3,Humans,N,
8692,DescriptorName,D007003,15307435,,,4,Hypoglycemia,N,
8693,QualifierName,Q000139,15307435,,,4,,Y,chemically induced
8694,DescriptorName,D007223,15307435,,,5,Infant,N,
8695,DescriptorName,D016778,15307435,,,6,"Malaria, Falciparum",N,
8696,QualifierName,Q000188,15307435,,,6,,Y,drug therapy
8697,DescriptorName,D008297,15307435,,,7,Male,N,
8698,DescriptorName,D011739,15307435,,,8,Pyrimethamine,N,
8699,QualifierName,Q000009,15307435,,,8,,Y,adverse effects
8700,DescriptorName,D013413,15307435,,,9,Sulfadoxine,N,
8701,QualifierName,Q000009,15307435,,,9,,Y,adverse effects
8702,DescriptorName,D000328,15311565,,,1,Adult,N,
8703,DescriptorName,D000368,15311565,,,2,Aged,N,
8704,DescriptorName,D004452,15311565,,,3,Echocardiography,N,
8705,QualifierName,Q000379,15311565,,,3,,N,methods
8706,DescriptorName,D005260,15311565,,,4,Female,N,
8707,DescriptorName,D006331,15311565,,,5,Heart Diseases,N,
8708,QualifierName,Q000000981,15311565,,,5,,N,diagnostic imaging
8709,DescriptorName,D006801,15311565,,,6,Humans,N,
8710,DescriptorName,D011655,15311565,,,7,Pulmonary Embolism,N,
8711,QualifierName,Q000188,15311565,,,7,,Y,drug therapy
8712,DescriptorName,D013923,15311565,,,8,Thromboembolism,N,
8713,QualifierName,Q000000981,15311565,,,8,,N,diagnostic imaging
8714,DescriptorName,D015912,15311565,,,9,Thrombolytic Therapy,N,
8715,QualifierName,Q000009,15311565,,,9,,Y,adverse effects
8716,Chemical,D000911,15316423,"Antibodies, Monoclonal",0,,,,
8717,Chemical,D005765,15316423,Gastrointestinal Agents,0,,,,
8718,Chemical,D014409,15316423,Tumor Necrosis Factor-alpha,0,,,,
8719,Chemical,D000069285,15316423,Infliximab,B72HH48FLU,,,,
8720,DescriptorName,D000328,15316423,,,1,Adult,N,
8721,DescriptorName,D000911,15316423,,,2,"Antibodies, Monoclonal",N,
8722,QualifierName,Q000009,15316423,,,2,,Y,adverse effects
8723,DescriptorName,D003424,15316423,,,3,Crohn Disease,N,
8724,QualifierName,Q000188,15316423,,,3,,N,drug therapy
8725,DescriptorName,D004342,15316423,,,4,Drug Hypersensitivity,N,
8726,QualifierName,Q000209,15316423,,,4,,Y,etiology
8727,DescriptorName,D005260,15316423,,,5,Female,N,
8728,DescriptorName,D005542,15316423,,,6,Forearm,N,
8729,QualifierName,Q000098,15316423,,,6,,Y,blood supply
8730,DescriptorName,D005765,15316423,,,7,Gastrointestinal Agents,N,
8731,QualifierName,Q000009,15316423,,,7,,Y,adverse effects
8732,DescriptorName,D006801,15316423,,,8,Humans,N,
8733,DescriptorName,D000069285,15316423,,,9,Infliximab,N,
8734,DescriptorName,D014409,15316423,,,10,Tumor Necrosis Factor-alpha,N,
8735,QualifierName,Q000037,15316423,,,10,,N,antagonists & inhibitors
8736,DescriptorName,D020246,15316423,,,11,Venous Thrombosis,N,
8737,QualifierName,Q000139,15316423,,,11,,Y,chemically induced
8738,Chemical,D000959,15331204,Antihypertensive Agents,0,,,,
8739,Chemical,D001786,15331204,Blood Glucose,0,,,,
8740,Chemical,D007190,15331204,Indapamide,F089I0511L,,,,
8741,Chemical,D017328,15331204,Fosinopril,R43D2573WO,,,,
8742,DescriptorName,D000328,15331204,,,1,Adult,N,
8743,DescriptorName,D000959,15331204,,,2,Antihypertensive Agents,N,
8744,QualifierName,Q000009,15331204,,,2,,Y,adverse effects
8745,DescriptorName,D001786,15331204,,,3,Blood Glucose,N,
8746,QualifierName,Q000378,15331204,,,3,,N,metabolism
8747,DescriptorName,D003920,15331204,,,4,Diabetes Mellitus,N,
8748,QualifierName,Q000139,15331204,,,4,,Y,chemically induced
8749,DescriptorName,D004359,15331204,,,5,"Drug Therapy, Combination",N,
8750,DescriptorName,D005260,15331204,,,6,Female,N,
8751,DescriptorName,D017328,15331204,,,7,Fosinopril,N,
8752,QualifierName,Q000627,15331204,,,7,,N,therapeutic use
8753,DescriptorName,D006801,15331204,,,8,Humans,N,
8754,DescriptorName,D006973,15331204,,,9,Hypertension,N,
8755,QualifierName,Q000188,15331204,,,9,,Y,drug therapy
8756,DescriptorName,D007190,15331204,,,10,Indapamide,N,
8757,QualifierName,Q000009,15331204,,,10,,Y,adverse effects
8758,DescriptorName,D008297,15331204,,,11,Male,N,
8759,DescriptorName,D008875,15331204,,,12,Middle Aged,N,
8760,DescriptorName,D013997,15331204,,,13,Time Factors,N,
8761,Chemical,D000970,15338554,Antineoplastic Agents,0,,,,
8762,Chemical,D001549,15338554,Benzamides,0,,,,
8763,Chemical,D010879,15338554,Piperazines,0,,,,
8764,Chemical,D011743,15338554,Pyrimidines,0,,,,
8765,Chemical,D000068877,15338554,Imatinib Mesylate,8A1O1M485B,,,,
8766,DescriptorName,D000328,15338554,,,1,Adult,N,
8767,DescriptorName,D000970,15338554,,,2,Antineoplastic Agents,N,
8768,QualifierName,Q000009,15338554,,,2,,N,adverse effects
8769,DescriptorName,D001549,15338554,,,3,Benzamides,N,
8770,DescriptorName,D001752,15338554,,,4,Blast Crisis,N,
8771,QualifierName,Q000235,15338554,,,4,,N,genetics
8772,DescriptorName,D001853,15338554,,,5,Bone Marrow,N,
8773,QualifierName,Q000473,15338554,,,5,,N,pathology
8774,DescriptorName,D020732,15338554,,,6,Cytogenetic Analysis,N,
8775,DescriptorName,D018450,15338554,,,7,Disease Progression,N,
8776,DescriptorName,D005355,15338554,,,8,Fibrosis,N,
8777,DescriptorName,D006801,15338554,,,9,Humans,N,
8778,DescriptorName,D000068877,15338554,,,10,Imatinib Mesylate,N,
8779,DescriptorName,D015464,15338554,,,11,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
8780,QualifierName,Q000188,15338554,,,11,,N,drug therapy
8781,DescriptorName,D008297,15338554,,,12,Male,N,
8782,DescriptorName,D010879,15338554,,,13,Piperazines,N,
8783,QualifierName,Q000009,15338554,,,13,,N,adverse effects
8784,DescriptorName,D011743,15338554,,,14,Pyrimidines,N,
8785,QualifierName,Q000009,15338554,,,14,,N,adverse effects
8786,Chemical,D009553,15359206,Nimodipine,57WA9QZ5WH,,,,
8787,Chemical,D002125,15359206,Calcium Gluconate,SQE6VB453K,,,,
8788,DescriptorName,D000368,15359206,,,1,Aged,N,
8789,DescriptorName,D000369,15359206,,,2,"Aged, 80 and over",N,
8790,DescriptorName,D002125,15359206,,,3,Calcium Gluconate,N,
8791,QualifierName,Q000008,15359206,,,3,,Y,administration & dosage
8792,DescriptorName,D004636,15359206,,,4,"Emergency Service, Hospital",N,
8793,DescriptorName,D005260,15359206,,,5,Female,N,
8794,DescriptorName,D005500,15359206,,,6,Follow-Up Studies,N,
8795,DescriptorName,D006801,15359206,,,7,Humans,N,
8796,DescriptorName,D007022,15359206,,,8,Hypotension,N,
8797,QualifierName,Q000139,15359206,,,8,,Y,chemically induced
8798,DescriptorName,D000860,15359206,,,9,Hypoxia,N,
8799,QualifierName,Q000139,15359206,,,9,,Y,chemically induced
8800,DescriptorName,D009553,15359206,,,10,Nimodipine,N,
8801,QualifierName,Q000009,15359206,,,10,,Y,adverse effects
8802,DescriptorName,D018570,15359206,,,11,Risk Assessment,N,
8803,DescriptorName,D012720,15359206,,,12,Severity of Illness Index,N,
8804,DescriptorName,D016896,15359206,,,13,Treatment Outcome,N,
8805,Chemical,D000890,15362597,Anti-Infective Agents,0,,,,
8806,Chemical,D001786,15362597,Blood Glucose,0,,,,
8807,Chemical,D007004,15362597,Hypoglycemic Agents,0,,,,
8808,Chemical,D002939,15362597,Ciprofloxacin,5E8K9I0O4U,,,,
8809,Chemical,D005947,15362597,Glucose,IY9XDZ35W2,,,,
8810,Chemical,D005905,15362597,Glyburide,SX6K58TVWC,,,,
8811,DescriptorName,D000368,15362597,,,1,Aged,N,
8812,DescriptorName,D000890,15362597,,,2,Anti-Infective Agents,N,
8813,QualifierName,Q000009,15362597,,,2,,Y,adverse effects
8814,DescriptorName,D001786,15362597,,,3,Blood Glucose,N,
8815,QualifierName,Q000378,15362597,,,3,,N,metabolism
8816,DescriptorName,D002939,15362597,,,4,Ciprofloxacin,N,
8817,QualifierName,Q000009,15362597,,,4,,Y,adverse effects
8818,DescriptorName,D003924,15362597,,,5,"Diabetes Mellitus, Type 2",N,
8819,QualifierName,Q000150,15362597,,,5,,N,complications
8820,DescriptorName,D004032,15362597,,,6,Diet,N,
8821,DescriptorName,D004347,15362597,,,7,Drug Interactions,N,
8822,DescriptorName,D005947,15362597,,,8,Glucose,N,
8823,QualifierName,Q000008,15362597,,,8,,N,administration & dosage
8824,DescriptorName,D005905,15362597,,,9,Glyburide,N,
8825,QualifierName,Q000009,15362597,,,9,,Y,adverse effects
8826,DescriptorName,D006801,15362597,,,10,Humans,N,
8827,DescriptorName,D007003,15362597,,,11,Hypoglycemia,N,
8828,QualifierName,Q000139,15362597,,,11,,Y,chemically induced
8829,DescriptorName,D007004,15362597,,,12,Hypoglycemic Agents,N,
8830,QualifierName,Q000009,15362597,,,12,,Y,adverse effects
8831,DescriptorName,D007275,15362597,,,13,"Injections, Intravenous",N,
8832,DescriptorName,D008297,15362597,,,14,Male,N,
8833,DescriptorName,D014552,15362597,,,15,Urinary Tract Infections,N,
8834,QualifierName,Q000150,15362597,,,15,,N,complications
8835,Chemical,D005029,1536494,Ethylenediamines,0,,,,
8836,Chemical,D000628,1536494,Aminophylline,27Y3KJK423,,,,
8837,Chemical,C031234,1536494,ethylenediamine,60V9STC53F,,,,
8838,DescriptorName,D000208,1536494,,,1,Acute Disease,N,
8839,DescriptorName,D000628,1536494,,,2,Aminophylline,N,
8840,QualifierName,Q000008,1536494,,,2,,N,administration & dosage
8841,DescriptorName,D001249,1536494,,,3,Asthma,N,
8842,QualifierName,Q000188,1536494,,,3,,Y,drug therapy
8843,DescriptorName,D004342,1536494,,,4,Drug Hypersensitivity,N,
8844,QualifierName,Q000175,1536494,,,4,,N,diagnosis
8845,DescriptorName,D004636,1536494,,,5,"Emergency Service, Hospital",N,
8846,DescriptorName,D005029,1536494,,,6,Ethylenediamines,N,
8847,QualifierName,Q000008,1536494,,,6,,N,administration & dosage
8848,DescriptorName,D005260,1536494,,,7,Female,N,
8849,DescriptorName,D006801,1536494,,,8,Humans,N,
8850,DescriptorName,D006968,1536494,,,9,"Hypersensitivity, Delayed",N,
8851,QualifierName,Q000175,1536494,,,9,,N,diagnosis
8852,DescriptorName,D007275,1536494,,,10,"Injections, Intravenous",N,
8853,DescriptorName,D008875,1536494,,,11,Middle Aged,N,
8854,DescriptorName,D010328,1536494,,,12,Patch Tests,N,
8855,Chemical,D000970,15368548,Antineoplastic Agents,0,,,,
8856,Chemical,D001215,15368548,Asparaginase,EC 3.5.1.1,,,,
8857,DescriptorName,D000293,15368548,,,1,Adolescent,N,
8858,DescriptorName,D000970,15368548,,,2,Antineoplastic Agents,N,
8859,QualifierName,Q000009,15368548,,,2,,Y,adverse effects
8860,DescriptorName,D000971,15368548,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
8861,QualifierName,Q000627,15368548,,,3,,N,therapeutic use
8862,DescriptorName,D001215,15368548,,,4,Asparaginase,N,
8863,QualifierName,Q000009,15368548,,,4,,Y,adverse effects
8864,DescriptorName,D004322,15368548,,,5,Drainage,N,
8865,QualifierName,Q000379,15368548,,,5,,Y,methods
8866,DescriptorName,D005260,15368548,,,6,Female,N,
8867,DescriptorName,D006801,15368548,,,7,Humans,N,
8868,DescriptorName,D019283,15368548,,,8,"Pancreatitis, Acute Necrotizing",N,
8869,QualifierName,Q000139,15368548,,,8,,Y,chemically induced
8870,DescriptorName,D054198,15368548,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
8871,QualifierName,Q000188,15368548,,,9,,N,drug therapy
8872,DescriptorName,D016896,15368548,,,10,Treatment Outcome,N,
8873,Chemical,D000427,15379082,Alcohol Deterrents,0,,,,
8874,Chemical,D004221,15379082,Disulfiram,TR3MLJ1UAI,,,,
8875,DescriptorName,D000328,15379082,,,1,Adult,N,
8876,DescriptorName,D000427,15379082,,,2,Alcohol Deterrents,N,
8877,QualifierName,Q000009,15379082,,,2,,Y,adverse effects
8878,DescriptorName,D000437,15379082,,,3,Alcoholism,N,
8879,QualifierName,Q000188,15379082,,,3,,Y,drug therapy
8880,DescriptorName,D004221,15379082,,,4,Disulfiram,N,
8881,QualifierName,Q000009,15379082,,,4,,Y,adverse effects
8882,DescriptorName,D006801,15379082,,,5,Humans,N,
8883,DescriptorName,D017093,15379082,,,6,Liver Failure,N,
8884,QualifierName,Q000139,15379082,,,6,,Y,chemically induced
8885,DescriptorName,D008297,15379082,,,7,Male,N,
8886,DescriptorName,D008889,15379082,,,8,Military Personnel,Y,
8887,Chemical,D000927,15388215,Anticonvulsants,0,,,,
8888,Chemical,D006993,15388215,Hypnotics and Sedatives,0,,,,
8889,Chemical,D009557,15388215,Nipecotic Acids,0,,,,
8890,Chemical,D008874,15388215,Midazolam,R60L0SM5BC,,,,
8891,Chemical,D000078308,15388215,Tiagabine,Z80I64HMNP,,,,
8892,DescriptorName,D000927,15388215,,,1,Anticonvulsants,N,
8893,QualifierName,Q000506,15388215,,,1,,Y,poisoning
8894,DescriptorName,D062787,15388215,,,2,Drug Overdose,N,
8895,DescriptorName,D005260,15388215,,,3,Female,N,
8896,DescriptorName,D006801,15388215,,,4,Humans,N,
8897,DescriptorName,D006993,15388215,,,5,Hypnotics and Sedatives,N,
8898,QualifierName,Q000627,15388215,,,5,,N,therapeutic use
8899,DescriptorName,D008874,15388215,,,6,Midazolam,N,
8900,QualifierName,Q000627,15388215,,,6,,N,therapeutic use
8901,DescriptorName,D008875,15388215,,,7,Middle Aged,N,
8902,DescriptorName,D009422,15388215,,,8,Nervous System Diseases,N,
8903,QualifierName,Q000139,15388215,,,8,,N,chemically induced
8904,DescriptorName,D009557,15388215,,,9,Nipecotic Acids,N,
8905,QualifierName,Q000506,15388215,,,9,,Y,poisoning
8906,DescriptorName,D000078308,15388215,,,10,Tiagabine,N,
8907,DescriptorName,D016896,15388215,,,11,Treatment Outcome,N,
8908,Chemical,D000081,15454180,Acetamides,0,,,,
8909,Chemical,D000890,15454180,Anti-Infective Agents,0,,,,
8910,Chemical,D023303,15454180,Oxazolidinones,0,,,,
8911,Chemical,D000069349,15454180,Linezolid,ISQ9I6J12J,,,,
8912,DescriptorName,D000081,15454180,,,1,Acetamides,N,
8913,QualifierName,Q000009,15454180,,,1,,Y,adverse effects
8914,DescriptorName,D000756,15454180,,,2,"Anemia, Sideroblastic",N,
8915,QualifierName,Q000139,15454180,,,2,,Y,chemically induced
8916,DescriptorName,D000890,15454180,,,3,Anti-Infective Agents,N,
8917,QualifierName,Q000009,15454180,,,3,,Y,adverse effects
8918,DescriptorName,D016027,15454180,,,4,Heart Transplantation,N,
8919,DescriptorName,D006353,15454180,,,5,Heart-Assist Devices,Y,
8920,DescriptorName,D006801,15454180,,,6,Humans,N,
8921,DescriptorName,D000069349,15454180,,,7,Linezolid,N,
8922,DescriptorName,D008297,15454180,,,8,Male,N,
8923,DescriptorName,D008875,15454180,,,9,Middle Aged,N,
8924,DescriptorName,D023303,15454180,,,10,Oxazolidinones,N,
8925,QualifierName,Q000009,15454180,,,10,,Y,adverse effects
8926,DescriptorName,D016459,15454180,,,11,Prosthesis-Related Infections,N,
8927,QualifierName,Q000188,15454180,,,11,,N,drug therapy
8928,DescriptorName,D013203,15454180,,,12,Staphylococcal Infections,N,
8929,QualifierName,Q000188,15454180,,,12,,Y,drug therapy
8930,DescriptorName,D013212,15454180,,,13,Staphylococcus epidermidis,N,
8931,DescriptorName,D014850,15454180,,,14,Waiting Lists,N,
8932,Chemical,D010975,15461766,Platelet Aggregation Inhibitors,0,,,,
8933,Chemical,D000527,15461766,Alprostadil,F5TD010360,,,,
8934,DescriptorName,D000527,15461766,,,1,Alprostadil,N,
8935,QualifierName,Q000008,15461766,,,1,,N,administration & dosage
8936,DescriptorName,D003937,15461766,,,2,"Diagnosis, Differential",N,
8937,DescriptorName,D005260,15461766,,,3,Female,N,
8938,DescriptorName,D006330,15461766,,,4,"Heart Defects, Congenital",N,
8939,QualifierName,Q000150,15461766,,,4,,Y,complications
8940,DescriptorName,D006345,15461766,,,5,"Heart Septal Defects, Ventricular",N,
8941,QualifierName,Q000150,15461766,,,5,,N,complications
8942,DescriptorName,D006801,15461766,,,6,Humans,N,
8943,DescriptorName,D007231,15461766,,,7,"Infant, Newborn",N,
8944,DescriptorName,D007262,15461766,,,8,"Infusions, Intravenous",N,
8945,DescriptorName,D010859,15461766,,,9,Pigmentation Disorders,N,
8946,QualifierName,Q000139,15461766,,,9,,N,chemically induced
8947,DescriptorName,D010975,15461766,,,10,Platelet Aggregation Inhibitors,N,
8948,QualifierName,Q000008,15461766,,,10,,N,administration & dosage
8949,DescriptorName,D018633,15461766,,,11,Pulmonary Atresia,N,
8950,QualifierName,Q000150,15461766,,,11,,N,complications
8951,DescriptorName,D014188,15461766,,,12,Transposition of Great Vessels,N,
8952,QualifierName,Q000150,15461766,,,12,,N,complications
8953,Chemical,D000890,15463865,Anti-Infective Agents,0,,,,
8954,Chemical,D002939,15463865,Ciprofloxacin,5E8K9I0O4U,,,,
8955,Chemical,D003404,15463865,Creatinine,AYI8EX34EU,,,,
8956,DescriptorName,D058186,15463865,,,1,Acute Kidney Injury,N,
8957,QualifierName,Q000139,15463865,,,1,,Y,chemically induced
8958,DescriptorName,D000293,15463865,,,2,Adolescent,N,
8959,DescriptorName,D000328,15463865,,,3,Adult,N,
8960,DescriptorName,D000890,15463865,,,4,Anti-Infective Agents,N,
8961,QualifierName,Q000009,15463865,,,4,,Y,adverse effects
8962,DescriptorName,D001806,15463865,,,5,Blood Urea Nitrogen,N,
8963,DescriptorName,D002939,15463865,,,6,Ciprofloxacin,N,
8964,QualifierName,Q000009,15463865,,,6,,Y,adverse effects
8965,DescriptorName,D003404,15463865,,,7,Creatinine,N,
8966,QualifierName,Q000097,15463865,,,7,,N,blood
8967,DescriptorName,D003550,15463865,,,8,Cystic Fibrosis,N,
8968,QualifierName,Q000188,15463865,,,8,,Y,drug therapy
8969,DescriptorName,D005260,15463865,,,9,Female,N,
8970,DescriptorName,D006801,15463865,,,10,Humans,N,
8971,Chemical,D000911,15468380,"Antibodies, Monoclonal",0,,,,
8972,Chemical,D018501,15468380,Antirheumatic Agents,0,,,,
8973,Chemical,D014409,15468380,Tumor Necrosis Factor-alpha,0,,,,
8974,Chemical,D000069285,15468380,Infliximab,B72HH48FLU,,,,
8975,DescriptorName,D000328,15468380,,,1,Adult,N,
8976,DescriptorName,D000911,15468380,,,2,"Antibodies, Monoclonal",Y,
8977,QualifierName,Q000009,15468380,,,2,,N,adverse effects
8978,DescriptorName,D018501,15468380,,,3,Antirheumatic Agents,Y,
8979,QualifierName,Q000009,15468380,,,3,,N,adverse effects
8980,DescriptorName,D001172,15468380,,,4,"Arthritis, Rheumatoid",N,
8981,QualifierName,Q000188,15468380,,,4,,Y,drug therapy
8982,DescriptorName,D005260,15468380,,,5,Female,N,
8983,DescriptorName,D006801,15468380,,,6,Humans,N,
8984,DescriptorName,D000069285,15468380,,,7,Infliximab,N,
8985,DescriptorName,D008875,15468380,,,8,Middle Aged,N,
8986,DescriptorName,D009475,15468380,,,9,"Neurons, Afferent",N,
8987,QualifierName,Q000473,15468380,,,9,,Y,pathology
8988,DescriptorName,D011129,15468380,,,10,Polyradiculoneuropathy,N,
8989,QualifierName,Q000473,15468380,,,10,,Y,pathology
8990,DescriptorName,D014409,15468380,,,11,Tumor Necrosis Factor-alpha,N,
8991,QualifierName,Q000037,15468380,,,11,,N,antagonists & inhibitors
8992,DescriptorName,D020293,15468380,,,12,"Vasculitis, Central Nervous System",Y,
8993,QualifierName,Q000139,15468380,,,12,,N,chemically induced
8994,Chemical,D016898,15479299,Interferon-alpha,0,,,,
8995,Chemical,D007376,15479299,Interleukin-2,0,,,,
8996,DescriptorName,D000740,15479299,,,1,Anemia,N,
8997,QualifierName,Q000139,15479299,,,1,,Y,chemically induced
8998,DescriptorName,D000971,15479299,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
8999,QualifierName,Q000008,15479299,,,2,,N,administration & dosage
9000,DescriptorName,D002292,15479299,,,3,"Carcinoma, Renal Cell",N,
9001,QualifierName,Q000188,15479299,,,3,,Y,drug therapy
9002,DescriptorName,D018450,15479299,,,4,Disease Progression,N,
9003,DescriptorName,D005260,15479299,,,5,Female,N,
9004,DescriptorName,D006801,15479299,,,6,Humans,N,
9005,DescriptorName,D016898,15479299,,,7,Interferon-alpha,N,
9006,QualifierName,Q000008,15479299,,,7,,N,administration & dosage
9007,DescriptorName,D007376,15479299,,,8,Interleukin-2,N,
9008,QualifierName,Q000008,15479299,,,8,,N,administration & dosage
9009,DescriptorName,D007680,15479299,,,9,Kidney Neoplasms,N,
9010,QualifierName,Q000188,15479299,,,9,,Y,drug therapy
9011,DescriptorName,D008875,15479299,,,10,Middle Aged,N,
9012,DescriptorName,D012720,15479299,,,11,Severity of Illness Index,N,
9013,Chemical,D000925,15482394,Anticoagulants,0,,,,
9014,Chemical,D014859,15482394,Warfarin,5Q7ZVV76EI,,,,
9015,DescriptorName,D000368,15482394,,,1,Aged,N,
9016,DescriptorName,D000925,15482394,,,2,Anticoagulants,N,
9017,QualifierName,Q000009,15482394,,,2,,Y,adverse effects
9018,DescriptorName,D016638,15482394,,,3,Critical Illness,N,
9019,DescriptorName,D004342,15482394,,,4,Drug Hypersensitivity,Y,
9020,DescriptorName,D006470,15482394,,,5,Hemorrhage,N,
9021,QualifierName,Q000139,15482394,,,5,,Y,chemically induced
9022,DescriptorName,D006801,15482394,,,6,Humans,N,
9023,DescriptorName,D019934,15482394,,,7,International Normalized Ratio,N,
9024,DescriptorName,D008297,15482394,,,8,Male,N,
9025,DescriptorName,D011655,15482394,,,9,Pulmonary Embolism,N,
9026,QualifierName,Q000188,15482394,,,9,,Y,drug therapy
9027,DescriptorName,D012307,15482394,,,10,Risk Factors,N,
9028,DescriptorName,D014859,15482394,,,11,Warfarin,N,
9029,QualifierName,Q000009,15482394,,,11,,Y,adverse effects
9030,Chemical,D007166,15489872,Immunosuppressive Agents,0,,,,
9031,Chemical,D007555,15489872,Isoxazoles,0,,,,
9032,Chemical,D017245,15489872,Foscarnet,364P9RVW4X,,,,
9033,Chemical,D000077339,15489872,Leflunomide,G162GK9U4W,,,,
9034,DescriptorName,D016026,15489872,,,1,Bone Marrow Transplantation,N,
9035,QualifierName,Q000009,15489872,,,1,,Y,adverse effects
9036,DescriptorName,D003586,15489872,,,2,Cytomegalovirus Infections,N,
9037,QualifierName,Q000188,15489872,,,2,,Y,drug therapy
9038,DescriptorName,D024882,15489872,,,3,"Drug Resistance, Viral",N,
9039,DescriptorName,D004359,15489872,,,4,"Drug Therapy, Combination",N,
9040,DescriptorName,D017809,15489872,,,5,Fatal Outcome,N,
9041,DescriptorName,D005260,15489872,,,6,Female,N,
9042,DescriptorName,D017245,15489872,,,7,Foscarnet,N,
9043,QualifierName,Q000627,15489872,,,7,,N,therapeutic use
9044,DescriptorName,D006086,15489872,,,8,Graft vs Host Disease,N,
9045,DescriptorName,D006801,15489872,,,9,Humans,N,
9046,DescriptorName,D007166,15489872,,,10,Immunosuppressive Agents,N,
9047,QualifierName,Q000627,15489872,,,10,,N,therapeutic use
9048,DescriptorName,D007555,15489872,,,11,Isoxazoles,N,
9049,QualifierName,Q000627,15489872,,,11,,Y,therapeutic use
9050,DescriptorName,D000077339,15489872,,,12,Leflunomide,N,
9051,DescriptorName,D015464,15489872,,,13,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
9052,QualifierName,Q000150,15489872,,,13,,N,complications
9053,DescriptorName,D017093,15489872,,,14,Liver Failure,N,
9054,DescriptorName,D008875,15489872,,,15,Middle Aged,N,
9055,DescriptorName,D016879,15489872,,,16,Salvage Therapy,N,
9056,QualifierName,Q000379,15489872,,,16,,Y,methods
9057,DescriptorName,D014184,15489872,,,17,"Transplantation, Homologous",N,
9058,DescriptorName,D019562,15489872,,,18,Viral Load,N,
9059,QualifierName,Q000379,15489872,,,18,,N,methods
9060,Chemical,D011355,15494638,Prodrugs,0,,,,
9061,Chemical,D003841,15494638,Deoxycytidine,0W860991D6,,,,
9062,Chemical,D000069287,15494638,Capecitabine,6804DJ8Z9U,,,,
9063,Chemical,D042943,15494638,Dihydrouracil Dehydrogenase (NADP),EC 1.3.1.2,,,,
9064,Chemical,D005472,15494638,Fluorouracil,U3P01618RT,,,,
9065,DescriptorName,D000069287,15494638,,,1,Capecitabine,N,
9066,DescriptorName,D017322,15494638,,,2,"Clinical Trials, Phase II as Topic",N,
9067,DescriptorName,D003841,15494638,,,3,Deoxycytidine,N,
9068,QualifierName,Q000009,15494638,,,3,,Y,adverse effects
9069,DescriptorName,D042943,15494638,,,4,Dihydrouracil Dehydrogenase (NADP),N,
9070,DescriptorName,D004334,15494638,,,5,Drug Administration Schedule,N,
9071,DescriptorName,D005260,15494638,,,6,Female,N,
9072,DescriptorName,D005472,15494638,,,7,Fluorouracil,N,
9073,QualifierName,Q000378,15494638,,,7,,N,metabolism
9074,DescriptorName,D005544,15494638,,,8,Forecasting,N,
9075,DescriptorName,D006801,15494638,,,9,Humans,N,
9076,DescriptorName,D008297,15494638,,,10,Male,N,
9077,DescriptorName,D008875,15494638,,,11,Middle Aged,N,
9078,DescriptorName,D010190,15494638,,,12,Pancreatic Neoplasms,N,
9079,QualifierName,Q000175,15494638,,,12,,N,diagnosis
9080,DescriptorName,D010523,15494638,,,13,Peripheral Nervous System Diseases,N,
9081,QualifierName,Q000139,15494638,,,13,,Y,chemically induced
9082,DescriptorName,D011355,15494638,,,14,Prodrugs,N,
9083,QualifierName,Q000378,15494638,,,14,,N,metabolism
9084,Chemical,D016632,15504988,Apolipoprotein A-I,0,,,,
9085,Chemical,D008076,15504988,"Cholesterol, HDL",0,,,,
9086,Chemical,D007004,15504988,Hypoglycemic Agents,0,,,,
9087,Chemical,D045162,15504988,Thiazolidinediones,0,,,,
9088,Chemical,D000077154,15504988,Rosiglitazone,05V02F2KDG,,,,
9089,DescriptorName,D016632,15504988,,,1,Apolipoprotein A-I,N,
9090,QualifierName,Q000037,15504988,,,1,,Y,antagonists & inhibitors
9091,DescriptorName,D008076,15504988,,,2,"Cholesterol, HDL",N,
9092,QualifierName,Q000037,15504988,,,2,,Y,antagonists & inhibitors
9093,DescriptorName,D003924,15504988,,,3,"Diabetes Mellitus, Type 2",N,
9094,QualifierName,Q000097,15504988,,,3,,N,blood
9095,DescriptorName,D005260,15504988,,,4,Female,N,
9096,DescriptorName,D006801,15504988,,,5,Humans,N,
9097,DescriptorName,D007004,15504988,,,6,Hypoglycemic Agents,N,
9098,QualifierName,Q000009,15504988,,,6,,Y,adverse effects
9099,DescriptorName,D008297,15504988,,,7,Male,N,
9100,DescriptorName,D008875,15504988,,,8,Middle Aged,N,
9101,DescriptorName,D000077154,15504988,,,9,Rosiglitazone,N,
9102,DescriptorName,D045162,15504988,,,10,Thiazolidinediones,N,
9103,QualifierName,Q000009,15504988,,,10,,Y,adverse effects
9104,Chemical,D019380,15507779,Anti-HIV Agents,0,,,,
9105,Chemical,D019829,15507779,Nevirapine,99DK7FVK1H,,,,
9106,DescriptorName,D000328,15507779,,,1,Adult,N,
9107,DescriptorName,D019380,15507779,,,2,Anti-HIV Agents,N,
9108,QualifierName,Q000009,15507779,,,2,,Y,adverse effects
9109,DescriptorName,D056486,15507779,,,3,Chemical and Drug Induced Liver Injury,Y,
9110,DescriptorName,D005260,15507779,,,4,Female,N,
9111,DescriptorName,D015658,15507779,,,5,HIV Infections,N,
9112,QualifierName,Q000188,15507779,,,5,,Y,drug therapy
9113,DescriptorName,D006801,15507779,,,6,Humans,N,
9114,DescriptorName,D007970,15507779,,,7,Leukopenia,N,
9115,QualifierName,Q000139,15507779,,,7,,Y,chemically induced
9116,DescriptorName,D019829,15507779,,,8,Nevirapine,N,
9117,QualifierName,Q000009,15507779,,,8,,Y,adverse effects
9118,Chemical,D014150,15516308,Antipsychotic Agents,0,,,,
9119,Chemical,D003987,15516308,Dibenzothiazepines,0,,,,
9120,Chemical,D000069348,15516308,Quetiapine Fumarate,2S3PL1B6UJ,,,,
9121,DescriptorName,D000328,15516308,,,1,Adult,N,
9122,DescriptorName,D014150,15516308,,,2,Antipsychotic Agents,N,
9123,QualifierName,Q000032,15516308,,,2,,N,analysis
9124,DescriptorName,D001714,15516308,,,3,Bipolar Disorder,N,
9125,QualifierName,Q000188,15516308,,,3,,N,drug therapy
9126,DescriptorName,D003987,15516308,,,4,Dibenzothiazepines,N,
9127,QualifierName,Q000032,15516308,,,4,,N,analysis
9128,DescriptorName,D062787,15516308,,,5,Drug Overdose,N,
9129,DescriptorName,D017809,15516308,,,6,Fatal Outcome,N,
9130,DescriptorName,D005260,15516308,,,7,Female,N,
9131,DescriptorName,D008401,15516308,,,8,Gas Chromatography-Mass Spectrometry,N,
9132,DescriptorName,D006801,15516308,,,9,Humans,N,
9133,DescriptorName,D008875,15516308,,,10,Middle Aged,N,
9134,DescriptorName,D000069348,15516308,,,11,Quetiapine Fumarate,N,
9135,DescriptorName,D012559,15516308,,,12,Schizophrenia,N,
9136,QualifierName,Q000150,15516308,,,12,,N,complications
9137,DescriptorName,D013405,15516308,,,13,Suicide,N,
9138,Chemical,D017367,15522120,Serotonin Uptake Inhibitors,0,,,,
9139,Chemical,D005473,15522120,Fluoxetine,01K63SUP8D,,,,
9140,Chemical,D012701,15522120,Serotonin,333DO1RDJY,,,,
9141,Chemical,D020280,15522120,Sertraline,QUC7NX6WMB,,,,
9142,DescriptorName,D002099,15522120,,,1,Cacao,N,
9143,QualifierName,Q000009,15522120,,,1,,Y,adverse effects
9144,DescriptorName,D003866,15522120,,,2,Depressive Disorder,N,
9145,QualifierName,Q000188,15522120,,,2,,Y,drug therapy
9146,DescriptorName,D005076,15522120,,,3,Exanthema,N,
9147,QualifierName,Q000139,15522120,,,3,,N,chemically induced
9148,DescriptorName,D005473,15522120,,,4,Fluoxetine,N,
9149,QualifierName,Q000009,15522120,,,4,,Y,adverse effects
9150,DescriptorName,D006801,15522120,,,5,Humans,N,
9151,DescriptorName,D008297,15522120,,,6,Male,N,
9152,DescriptorName,D008875,15522120,,,7,Middle Aged,N,
9153,DescriptorName,D011537,15522120,,,8,Pruritus,N,
9154,QualifierName,Q000139,15522120,,,8,,N,chemically induced
9155,DescriptorName,D012701,15522120,,,9,Serotonin,N,
9156,QualifierName,Q000502,15522120,,,9,,N,physiology
9157,DescriptorName,D017367,15522120,,,10,Serotonin Uptake Inhibitors,N,
9158,QualifierName,Q000009,15522120,,,10,,Y,adverse effects
9159,DescriptorName,D020280,15522120,,,11,Sertraline,N,
9160,QualifierName,Q000009,15522120,,,11,,Y,adverse effects
9161,Chemical,D015703,15529178,"Antigens, CD",0,,,,
9162,Chemical,D015214,15529178,"Antigens, Differentiation, Myelomonocytic",0,,,,
9163,Chemical,D018501,15529178,Antirheumatic Agents,0,,,,
9164,Chemical,D017252,15529178,CD3 Complex,0,,,,
9165,Chemical,D018956,15529178,CD5 Antigens,0,,,,
9166,Chemical,C067980,15529178,"CD68 antigen, human",0,,,,
9167,Chemical,D007074,15529178,Immunoglobulin G,0,,,,
9168,Chemical,D051917,15529178,Leukosialin,0,,,,
9169,Chemical,D018124,15529178,"Receptors, Tumor Necrosis Factor",0,,,,
9170,Chemical,D012795,15529178,Sialoglycoproteins,0,,,,
9171,Chemical,C465014,15529178,"UN1 sialoglycoprotein, human",0,,,,
9172,Chemical,D019938,15529178,Cyclin D1,136601-57-5,,,,
9173,Chemical,D000068800,15529178,Etanercept,OP401G7OJC,,,,
9174,DescriptorName,D000328,15529178,,,1,Adult,N,
9175,DescriptorName,D000368,15529178,,,2,Aged,N,
9176,DescriptorName,D015703,15529178,,,3,"Antigens, CD",N,
9177,QualifierName,Q000032,15529178,,,3,,N,analysis
9178,DescriptorName,D015214,15529178,,,4,"Antigens, Differentiation, Myelomonocytic",N,
9179,QualifierName,Q000032,15529178,,,4,,N,analysis
9180,DescriptorName,D018501,15529178,,,5,Antirheumatic Agents,N,
9181,QualifierName,Q000009,15529178,,,5,,Y,adverse effects
9182,DescriptorName,D001172,15529178,,,6,"Arthritis, Rheumatoid",N,
9183,QualifierName,Q000188,15529178,,,6,,N,drug therapy
9184,DescriptorName,D017252,15529178,,,7,CD3 Complex,N,
9185,QualifierName,Q000032,15529178,,,7,,N,analysis
9186,DescriptorName,D018956,15529178,,,8,CD5 Antigens,N,
9187,QualifierName,Q000032,15529178,,,8,,N,analysis
9188,DescriptorName,D003371,15529178,,,9,Cough,N,
9189,QualifierName,Q000139,15529178,,,9,,N,chemically induced
9190,DescriptorName,D019938,15529178,,,10,Cyclin D1,N,
9191,QualifierName,Q000032,15529178,,,10,,N,analysis
9192,DescriptorName,D003937,15529178,,,11,"Diagnosis, Differential",N,
9193,DescriptorName,D004417,15529178,,,12,Dyspnea,N,
9194,QualifierName,Q000139,15529178,,,12,,N,chemically induced
9195,DescriptorName,D000068800,15529178,,,13,Etanercept,N,
9196,DescriptorName,D005260,15529178,,,14,Female,N,
9197,DescriptorName,D006099,15529178,,,15,Granuloma,N,
9198,QualifierName,Q000139,15529178,,,15,,N,chemically induced
9199,DescriptorName,D006644,15529178,,,16,Histiocytes,N,
9200,QualifierName,Q000737,15529178,,,16,,N,chemistry
9201,DescriptorName,D006801,15529178,,,17,Humans,N,
9202,DescriptorName,D007074,15529178,,,18,Immunoglobulin G,N,
9203,QualifierName,Q000009,15529178,,,18,,Y,adverse effects
9204,DescriptorName,D007150,15529178,,,19,Immunohistochemistry,N,
9205,DescriptorName,D051917,15529178,,,20,Leukosialin,N,
9206,DescriptorName,D008171,15529178,,,21,Lung Diseases,N,
9207,QualifierName,Q000139,15529178,,,21,,N,chemically induced
9208,DescriptorName,D008214,15529178,,,22,Lymphocytes,N,
9209,QualifierName,Q000737,15529178,,,22,,N,chemistry
9210,DescriptorName,D008875,15529178,,,23,Middle Aged,N,
9211,DescriptorName,D018124,15529178,,,24,"Receptors, Tumor Necrosis Factor",N,
9212,QualifierName,Q000627,15529178,,,24,,N,therapeutic use
9213,DescriptorName,D012795,15529178,,,25,Sialoglycoproteins,N,
9214,QualifierName,Q000032,15529178,,,25,,N,analysis
9215,Chemical,D000631,15533031,Aminopyridines,0,,,,
9216,Chemical,D000700,15533031,Analgesics,0,,,,
9217,Chemical,D000927,15533031,Anticonvulsants,0,,,,
9218,Chemical,D051676,15533031,G Protein-Coupled Inwardly-Rectifying Potassium Channels,0,,,,
9219,Chemical,D024661,15533031,"Potassium Channels, Inwardly Rectifying",0,,,,
9220,Chemical,D001569,15533031,Benzodiazepines,12794-10-4,,,,
9221,Chemical,D010672,15533031,Phenytoin,6158TKW0C5,,,,
9222,Chemical,C034161,15533031,flupirtine,MOH3ET196H,,,,
9223,DescriptorName,D000328,15533031,,,1,Adult,N,
9224,DescriptorName,D000631,15533031,,,2,Aminopyridines,N,
9225,QualifierName,Q000506,15533031,,,2,,Y,poisoning
9226,DescriptorName,D000700,15533031,,,3,Analgesics,N,
9227,QualifierName,Q000506,15533031,,,3,,Y,poisoning
9228,DescriptorName,D000927,15533031,,,4,Anticonvulsants,N,
9229,QualifierName,Q000627,15533031,,,4,,N,therapeutic use
9230,DescriptorName,D001569,15533031,,,5,Benzodiazepines,N,
9231,QualifierName,Q000627,15533031,,,5,,N,therapeutic use
9232,DescriptorName,D002540,15533031,,,6,Cerebral Cortex,N,
9233,QualifierName,Q000503,15533031,,,6,,Y,physiopathology
9234,DescriptorName,D004569,15533031,,,7,Electroencephalography,N,
9235,QualifierName,Q000187,15533031,,,7,,N,drug effects
9236,DescriptorName,D005260,15533031,,,8,Female,N,
9237,DescriptorName,D051676,15533031,,,9,G Protein-Coupled Inwardly-Rectifying Potassium Channels,N,
9238,DescriptorName,D006801,15533031,,,10,Humans,N,
9239,DescriptorName,D010672,15533031,,,11,Phenytoin,N,
9240,QualifierName,Q000627,15533031,,,11,,N,therapeutic use
9241,DescriptorName,D024661,15533031,,,12,"Potassium Channels, Inwardly Rectifying",N,
9242,QualifierName,Q000819,15533031,,,12,,N,agonists
9243,DescriptorName,D012640,15533031,,,13,Seizures,N,
9244,QualifierName,Q000139,15533031,,,13,,Y,chemically induced
9245,Chemical,D000998,15543388,Antiviral Agents,0,,,,
9246,Chemical,D000077190,15543388,Interferon alpha-2,0,,,,
9247,Chemical,D016898,15543388,Interferon-alpha,0,,,,
9248,Chemical,D011994,15543388,Recombinant Proteins,0,,,,
9249,Chemical,D011092,15543388,Polyethylene Glycols,3WJQ0SDW1A,,,,
9250,Chemical,D012254,15543388,Ribavirin,49717AWG6K,,,,
9251,Chemical,C100416,15543388,peginterferon alfa-2a,Q46947FE7K,,,,
9252,DescriptorName,D000328,15543388,,,1,Adult,N,
9253,DescriptorName,D000998,15543388,,,2,Antiviral Agents,N,
9254,QualifierName,Q000009,15543388,,,2,,Y,adverse effects
9255,DescriptorName,D002446,15543388,,,3,Celiac Disease,N,
9256,QualifierName,Q000139,15543388,,,3,,Y,chemically induced
9257,DescriptorName,D004359,15543388,,,4,"Drug Therapy, Combination",N,
9258,DescriptorName,D005260,15543388,,,5,Female,N,
9259,DescriptorName,D019698,15543388,,,6,"Hepatitis C, Chronic",N,
9260,QualifierName,Q000188,15543388,,,6,,N,drug therapy
9261,DescriptorName,D006801,15543388,,,7,Humans,N,
9262,DescriptorName,D000077190,15543388,,,8,Interferon alpha-2,N,
9263,DescriptorName,D016898,15543388,,,9,Interferon-alpha,N,
9264,QualifierName,Q000009,15543388,,,9,,Y,adverse effects
9265,DescriptorName,D011092,15543388,,,10,Polyethylene Glycols,N,
9266,QualifierName,Q000009,15543388,,,10,,Y,adverse effects
9267,DescriptorName,D011994,15543388,,,11,Recombinant Proteins,N,
9268,DescriptorName,D012254,15543388,,,12,Ribavirin,N,
9269,QualifierName,Q000009,15543388,,,12,,Y,adverse effects
9270,Chemical,D000322,15549981,Adrenergic Agonists,0,,,,
9271,Chemical,D014662,15549981,Vasoconstrictor Agents,0,,,,
9272,Chemical,D008680,15549981,Metaraminol,818U2PZ2EH,,,,
9273,Chemical,D004837,15549981,Epinephrine,YKH834O4BH,,,,
9274,DescriptorName,D000322,15549981,,,1,Adrenergic Agonists,N,
9275,QualifierName,Q000627,15549981,,,1,,Y,therapeutic use
9276,DescriptorName,D000368,15549981,,,2,Aged,N,
9277,DescriptorName,D000707,15549981,,,3,Anaphylaxis,N,
9278,QualifierName,Q000139,15549981,,,3,,N,chemically induced
9279,DescriptorName,D000768,15549981,,,4,"Anesthesia, General",N,
9280,QualifierName,Q000009,15549981,,,4,,Y,adverse effects
9281,DescriptorName,D004837,15549981,,,5,Epinephrine,N,
9282,QualifierName,Q000627,15549981,,,5,,N,therapeutic use
9283,DescriptorName,D006801,15549981,,,6,Humans,N,
9284,DescriptorName,D007431,15549981,,,7,Intraoperative Complications,N,
9285,QualifierName,Q000139,15549981,,,7,,N,chemically induced
9286,DescriptorName,D008297,15549981,,,8,Male,N,
9287,DescriptorName,D008680,15549981,,,9,Metaraminol,N,
9288,QualifierName,Q000627,15549981,,,9,,Y,therapeutic use
9289,DescriptorName,D008875,15549981,,,10,Middle Aged,N,
9290,DescriptorName,D017211,15549981,,,11,Treatment Failure,N,
9291,DescriptorName,D014662,15549981,,,12,Vasoconstrictor Agents,N,
9292,QualifierName,Q000627,15549981,,,12,,N,therapeutic use
9293,Chemical,D007166,15554737,Immunosuppressive Agents,0,,,,
9294,Chemical,D010455,15554737,Peptides,0,,,,
9295,Chemical,D000068717,15554737,Glatiramer Acetate,5M691HL4BO,,,,
9296,DescriptorName,D004305,15554737,,,1,"Dose-Response Relationship, Drug",N,
9297,DescriptorName,D005260,15554737,,,2,Female,N,
9298,DescriptorName,D000068717,15554737,,,3,Glatiramer Acetate,N,
9299,DescriptorName,D006801,15554737,,,4,Humans,N,
9300,DescriptorName,D007166,15554737,,,5,Immunosuppressive Agents,N,
9301,QualifierName,Q000008,15554737,,,5,,N,administration & dosage
9302,DescriptorName,D007279,15554737,,,6,"Injections, Subcutaneous",N,
9303,DescriptorName,D008060,15554737,,,7,Lipodystrophy,N,
9304,QualifierName,Q000139,15554737,,,7,,Y,chemically induced
9305,DescriptorName,D008875,15554737,,,8,Middle Aged,N,
9306,DescriptorName,D020529,15554737,,,9,"Multiple Sclerosis, Relapsing-Remitting",N,
9307,QualifierName,Q000188,15554737,,,9,,Y,drug therapy
9308,DescriptorName,D015434,15554737,,,10,Panniculitis,N,
9309,QualifierName,Q000139,15554737,,,10,,Y,chemically induced
9310,DescriptorName,D010455,15554737,,,11,Peptides,N,
9311,QualifierName,Q000008,15554737,,,11,,N,administration & dosage
9312,DescriptorName,D012307,15554737,,,12,Risk Factors,N,
9313,DescriptorName,D013997,15554737,,,13,Time Factors,N,
9314,Chemical,D014700,1557089,Verapamil,CJ0O37KU29,,,,
9315,DescriptorName,D000075202,1557089,,,1,Contraindications,N,
9316,DescriptorName,D001026,1557089,,,2,Coronary Artery Bypass,N,
9317,DescriptorName,D003327,1557089,,,3,Coronary Disease,N,
9318,QualifierName,Q000150,1557089,,,3,,N,complications
9319,DescriptorName,D004576,1557089,,,4,Electromyography,N,
9320,DescriptorName,D006801,1557089,,,5,Humans,N,
9321,DescriptorName,D008297,1557089,,,6,Male,N,
9322,DescriptorName,D008875,1557089,,,7,Middle Aged,N,
9323,DescriptorName,D009157,1557089,,,8,Myasthenia Gravis,N,
9324,QualifierName,Q000139,1557089,,,8,,Y,chemically induced
9325,DescriptorName,D009469,1557089,,,9,Neuromuscular Junction,N,
9326,QualifierName,Q000187,1557089,,,9,,N,drug effects
9327,DescriptorName,D011183,1557089,,,10,Postoperative Complications,N,
9328,QualifierName,Q000188,1557089,,,10,,N,drug therapy
9329,DescriptorName,D013610,1557089,,,11,Tachycardia,N,
9330,QualifierName,Q000188,1557089,,,11,,Y,drug therapy
9331,DescriptorName,D014700,1557089,,,12,Verapamil,N,
9332,QualifierName,Q000009,1557089,,,12,,Y,adverse effects
9333,Chemical,D000925,15571949,Anticoagulants,0,,,,
9334,Chemical,D000970,15571949,Antineoplastic Agents,0,,,,
9335,Chemical,D006493,15571949,Heparin,9005-49-6,,,,
9336,DescriptorName,D000293,15571949,,,1,Adolescent,N,
9337,DescriptorName,D000925,15571949,,,2,Anticoagulants,N,
9338,QualifierName,Q000627,15571949,,,2,,N,therapeutic use
9339,DescriptorName,D000970,15571949,,,3,Antineoplastic Agents,N,
9340,QualifierName,Q000009,15571949,,,3,,Y,adverse effects
9341,DescriptorName,D002648,15571949,,,4,Child,N,
9342,DescriptorName,D002675,15571949,,,5,"Child, Preschool",N,
9343,DescriptorName,D005260,15571949,,,6,Female,N,
9344,DescriptorName,D006493,15571949,,,7,Heparin,N,
9345,QualifierName,Q000627,15571949,,,7,,N,therapeutic use
9346,DescriptorName,D006801,15571949,,,8,Humans,N,
9347,DescriptorName,D008297,15571949,,,9,Male,N,
9348,DescriptorName,D009369,15571949,,,10,Neoplasms,N,
9349,QualifierName,Q000188,15571949,,,10,,Y,drug therapy
9350,DescriptorName,D011169,15571949,,,11,Portal Vein,Y,
9351,DescriptorName,D012307,15571949,,,12,Risk Factors,N,
9352,DescriptorName,D016896,15571949,,,13,Treatment Outcome,N,
9353,DescriptorName,D020246,15571949,,,14,Venous Thrombosis,N,
9354,QualifierName,Q000139,15571949,,,14,,Y,chemically induced
9355,Chemical,D000998,15580406,Antiviral Agents,0,,,,
9356,Chemical,D000077190,15580406,Interferon alpha-2,0,,,,
9357,Chemical,D016898,15580406,Interferon-alpha,0,,,,
9358,Chemical,D011994,15580406,Recombinant Proteins,0,,,,
9359,DescriptorName,D000328,15580406,,,1,Adult,N,
9360,DescriptorName,D000998,15580406,,,2,Antiviral Agents,N,
9361,QualifierName,Q000009,15580406,,,2,,Y,adverse effects
9362,DescriptorName,D019698,15580406,,,3,"Hepatitis C, Chronic",N,
9363,QualifierName,Q000188,15580406,,,3,,Y,drug therapy
9364,DescriptorName,D006801,15580406,,,4,Humans,N,
9365,DescriptorName,D000077190,15580406,,,5,Interferon alpha-2,N,
9366,DescriptorName,D016898,15580406,,,6,Interferon-alpha,N,
9367,QualifierName,Q000009,15580406,,,6,,Y,adverse effects
9368,DescriptorName,D008297,15580406,,,7,Male,N,
9369,DescriptorName,D011994,15580406,,,8,Recombinant Proteins,N,
9370,DescriptorName,D012880,15580406,,,9,Skin Pigmentation,N,
9371,DescriptorName,D013997,15580406,,,10,Time Factors,N,
9372,DescriptorName,D014607,15580406,,,11,Uveomeningoencephalitic Syndrome,N,
9373,QualifierName,Q000139,15580406,,,11,,Y,chemically induced
9374,Chemical,D014284,15588385,Triiodothyronine,06LU7C9H1V,,,,
9375,Chemical,D011441,15588385,Propylthiouracil,721M9407IY,,,,
9376,Chemical,D000638,15588385,Amiodarone,N3RQ532IUT,,,,
9377,DescriptorName,D000328,15588385,,,1,Adult,N,
9378,DescriptorName,D000638,15588385,,,2,Amiodarone,N,
9379,QualifierName,Q000008,15588385,,,2,,N,administration & dosage
9380,DescriptorName,D005260,15588385,,,3,Female,N,
9381,DescriptorName,D006801,15588385,,,4,Humans,N,
9382,DescriptorName,D006980,15588385,,,5,Hyperthyroidism,N,
9383,QualifierName,Q000188,15588385,,,5,,Y,drug therapy
9384,DescriptorName,D017114,15588385,,,6,"Liver Failure, Acute",N,
9385,QualifierName,Q000139,15588385,,,6,,Y,chemically induced
9386,DescriptorName,D011441,15588385,,,7,Propylthiouracil,N,
9387,QualifierName,Q000009,15588385,,,7,,Y,adverse effects
9388,DescriptorName,D014284,15588385,,,8,Triiodothyronine,N,
9389,QualifierName,Q000097,15588385,,,8,,N,blood
9390,Chemical,D018501,15595320,Antirheumatic Agents,0,,,,
9391,Chemical,D016861,15595320,Cyclooxygenase Inhibitors,0,,,,
9392,Chemical,D007783,15595320,Lactones,0,,,,
9393,Chemical,D013450,15595320,Sulfones,0,,,,
9394,Chemical,C116926,15595320,rofecoxib,0QTW8Z7MCR,,,,
9395,Chemical,D008727,15595320,Methotrexate,YL5FZ2Y5U1,,,,
9396,DescriptorName,D000328,15595320,,,1,Adult,N,
9397,DescriptorName,D018501,15595320,,,2,Antirheumatic Agents,N,
9398,QualifierName,Q000009,15595320,,,2,,Y,adverse effects
9399,DescriptorName,D001172,15595320,,,3,"Arthritis, Rheumatoid",N,
9400,QualifierName,Q000188,15595320,,,3,,Y,drug therapy
9401,DescriptorName,D016861,15595320,,,4,Cyclooxygenase Inhibitors,N,
9402,QualifierName,Q000009,15595320,,,4,,Y,adverse effects
9403,DescriptorName,D004347,15595320,,,5,Drug Interactions,N,
9404,DescriptorName,D020031,15595320,,,6,Epstein-Barr Virus Infections,N,
9405,QualifierName,Q000139,15595320,,,6,,Y,chemically induced
9406,DescriptorName,D005260,15595320,,,7,Female,N,
9407,DescriptorName,D006801,15595320,,,8,Humans,N,
9408,DescriptorName,D007783,15595320,,,9,Lactones,N,
9409,QualifierName,Q000009,15595320,,,9,,Y,adverse effects
9410,DescriptorName,D008232,15595320,,,10,Lymphoproliferative Disorders,N,
9411,QualifierName,Q000139,15595320,,,10,,Y,chemically induced
9412,DescriptorName,D008727,15595320,,,11,Methotrexate,N,
9413,QualifierName,Q000009,15595320,,,11,,Y,adverse effects
9414,DescriptorName,D013450,15595320,,,12,Sulfones,N,
9415,QualifierName,Q000009,15595320,,,12,,Y,adverse effects
9416,Chemical,D000634,15611427,Aminoquinolines,0,,,,
9417,Chemical,D007369,15611427,Interferon Inducers,0,,,,
9418,Chemical,D008562,15611427,Membrane Glycoproteins,0,,,,
9419,Chemical,D011956,15611427,"Receptors, Cell Surface",0,,,,
9420,Chemical,C495348,15611427,"TLR7 protein, human",0,,,,
9421,Chemical,D051199,15611427,Toll-Like Receptor 7,0,,,,
9422,Chemical,D051193,15611427,Toll-Like Receptors,0,,,,
9423,Chemical,D000077271,15611427,Imiquimod,P1QW714R7M,,,,
9424,DescriptorName,D000287,15611427,,,1,"Administration, Topical",N,
9425,DescriptorName,D000634,15611427,,,2,Aminoquinolines,N,
9426,QualifierName,Q000008,15611427,,,2,,N,administration & dosage
9427,DescriptorName,D001706,15611427,,,3,Biopsy,N,
9428,DescriptorName,D003713,15611427,,,4,Dendritic Cells,N,
9429,QualifierName,Q000473,15611427,,,4,,N,pathology
9430,DescriptorName,D003951,15611427,,,5,Diagnostic Errors,N,
9431,DescriptorName,D005455,15611427,,,6,Fluorescent Antibody Technique,N,
9432,DescriptorName,D006801,15611427,,,7,Humans,N,
9433,DescriptorName,D000077271,15611427,,,8,Imiquimod,N,
9434,DescriptorName,D007150,15611427,,,9,Immunohistochemistry,N,
9435,DescriptorName,D007369,15611427,,,10,Interferon Inducers,N,
9436,QualifierName,Q000008,15611427,,,10,,N,administration & dosage
9437,DescriptorName,D008297,15611427,,,11,Male,N,
9438,DescriptorName,D008562,15611427,,,12,Membrane Glycoproteins,N,
9439,QualifierName,Q000819,15611427,,,12,,Y,agonists
9440,DescriptorName,D008875,15611427,,,13,Middle Aged,N,
9441,DescriptorName,D010950,15611427,,,14,Plasma Cells,N,
9442,QualifierName,Q000473,15611427,,,14,,N,pathology
9443,DescriptorName,D011565,15611427,,,15,Psoriasis,N,
9444,QualifierName,Q000188,15611427,,,15,,Y,drug therapy
9445,DescriptorName,D011956,15611427,,,16,"Receptors, Cell Surface",N,
9446,QualifierName,Q000819,15611427,,,16,,Y,agonists
9447,DescriptorName,D012867,15611427,,,17,Skin,N,
9448,QualifierName,Q000473,15611427,,,17,,Y,pathology
9449,DescriptorName,D013234,15611427,,,18,Stem Cells,N,
9450,QualifierName,Q000473,15611427,,,18,,N,pathology
9451,DescriptorName,D051199,15611427,,,19,Toll-Like Receptor 7,N,
9452,DescriptorName,D051193,15611427,,,20,Toll-Like Receptors,N,
9453,Chemical,D000998,15623719,Antiviral Agents,0,,,,
9454,Chemical,D017245,15623719,Foscarnet,364P9RVW4X,,,,
9455,Chemical,D011241,15623719,Prednisone,VB0R961HZT,,,,
9456,Chemical,D000212,15623719,Acyclovir,X4HES1O11F,,,,
9457,Chemical,D008775,15623719,Methylprednisolone,X4W7ZR7023,,,,
9458,DescriptorName,D017088,15623719,,,1,AIDS-Related Opportunistic Infections,N,
9459,QualifierName,Q000150,15623719,,,1,,Y,complications
9460,DescriptorName,D000212,15623719,,,2,Acyclovir,N,
9461,QualifierName,Q000627,15623719,,,2,,N,therapeutic use
9462,DescriptorName,D000328,15623719,,,3,Adult,N,
9463,DescriptorName,D000998,15623719,,,4,Antiviral Agents,N,
9464,QualifierName,Q000627,15623719,,,4,,N,therapeutic use
9465,DescriptorName,D003586,15623719,,,5,Cytomegalovirus Infections,N,
9466,QualifierName,Q000150,15623719,,,5,,N,complications
9467,DescriptorName,D017726,15623719,,,6,Cytomegalovirus Retinitis,N,
9468,QualifierName,Q000150,15623719,,,6,,Y,complications
9469,DescriptorName,D003951,15623719,,,7,Diagnostic Errors,N,
9470,DescriptorName,D004172,15623719,,,8,Diplopia,N,
9471,QualifierName,Q000209,15623719,,,8,,N,etiology
9472,DescriptorName,D018450,15623719,,,9,Disease Progression,N,
9473,DescriptorName,D018792,15623719,,,10,"Encephalitis, Viral",N,
9474,QualifierName,Q000150,15623719,,,10,,N,complications
9475,DescriptorName,D005260,15623719,,,11,Female,N,
9476,DescriptorName,D017245,15623719,,,12,Foscarnet,N,
9477,QualifierName,Q000627,15623719,,,12,,N,therapeutic use
9478,DescriptorName,D006562,15623719,,,13,Herpes Zoster,N,
9479,QualifierName,Q000150,15623719,,,13,,Y,complications
9480,DescriptorName,D006801,15623719,,,14,Humans,N,
9481,DescriptorName,D008279,15623719,,,15,Magnetic Resonance Imaging,N,
9482,DescriptorName,D008775,15623719,,,16,Methylprednisolone,N,
9483,QualifierName,Q000009,15623719,,,16,,N,adverse effects
9484,DescriptorName,D008875,15623719,,,17,Middle Aged,N,
9485,DescriptorName,D009336,15623719,,,18,Necrosis,N,
9486,DescriptorName,D009902,15623719,,,19,Optic Neuritis,N,
9487,QualifierName,Q000188,15623719,,,19,,N,drug therapy
9488,DescriptorName,D010291,15623719,,,20,Paresis,N,
9489,QualifierName,Q000209,15623719,,,20,,N,etiology
9490,DescriptorName,D011241,15623719,,,21,Prednisone,N,
9491,QualifierName,Q000009,15623719,,,21,,N,adverse effects
9492,DescriptorName,D012160,15623719,,,22,Retina,N,
9493,QualifierName,Q000473,15623719,,,22,,Y,pathology
9494,Chemical,D007166,15628319,Immunosuppressive Agents,0,,,,
9495,Chemical,D001379,15628319,Azathioprine,MRK240IY2L,,,,
9496,DescriptorName,D001379,15628319,,,1,Azathioprine,N,
9497,QualifierName,Q000009,15628319,,,1,,Y,adverse effects
9498,DescriptorName,D003937,15628319,,,2,"Diagnosis, Differential",N,
9499,DescriptorName,D003875,15628319,,,3,Drug Eruptions,N,
9500,QualifierName,Q000175,15628319,,,3,,Y,diagnosis
9501,DescriptorName,D005260,15628319,,,4,Female,N,
9502,DescriptorName,D006801,15628319,,,5,Humans,N,
9503,DescriptorName,D007166,15628319,,,6,Immunosuppressive Agents,N,
9504,QualifierName,Q000009,15628319,,,6,,Y,adverse effects
9505,DescriptorName,D008213,15628319,,,7,Lymphocyte Activation,N,
9506,DescriptorName,D008875,15628319,,,8,Middle Aged,N,
9507,DescriptorName,D017285,15628319,,,9,Polymyositis,N,
9508,QualifierName,Q000188,15628319,,,9,,N,drug therapy
9509,DescriptorName,D012595,15628319,,,10,"Scleroderma, Systemic",N,
9510,QualifierName,Q000188,15628319,,,10,,N,drug therapy
9511,Chemical,D014150,15644988,Antipsychotic Agents,0,,,,
9512,Chemical,D010879,15644988,Piperazines,0,,,,
9513,Chemical,D013844,15644988,Thiazoles,0,,,,
9514,Chemical,C092292,15644988,ziprasidone,6UKA5VEJ6X,,,,
9515,DescriptorName,D000328,15644988,,,1,Adult,N,
9516,DescriptorName,D014150,15644988,,,2,Antipsychotic Agents,N,
9517,QualifierName,Q000009,15644988,,,2,,Y,adverse effects
9518,DescriptorName,D003702,15644988,,,3,Delusions,N,
9519,QualifierName,Q000188,15644988,,,3,,N,drug therapy
9520,DescriptorName,D004305,15644988,,,4,"Dose-Response Relationship, Drug",N,
9521,DescriptorName,D004334,15644988,,,5,Drug Administration Schedule,N,
9522,DescriptorName,D004409,15644988,,,6,"Dyskinesia, Drug-Induced",N,
9523,QualifierName,Q000175,15644988,,,6,,N,diagnosis
9524,DescriptorName,D005500,15644988,,,7,Follow-Up Studies,N,
9525,DescriptorName,D006212,15644988,,,8,Hallucinations,N,
9526,QualifierName,Q000188,15644988,,,8,,N,drug therapy
9527,DescriptorName,D006801,15644988,,,9,Humans,N,
9528,DescriptorName,D008134,15644988,,,10,Long-Term Care,N,
9529,DescriptorName,D008297,15644988,,,11,Male,N,
9530,DescriptorName,D009460,15644988,,,12,Neurologic Examination,N,
9531,QualifierName,Q000187,15644988,,,12,,N,drug effects
9532,DescriptorName,D010879,15644988,,,13,Piperazines,N,
9533,QualifierName,Q000009,15644988,,,13,,Y,adverse effects
9534,DescriptorName,D011569,15644988,,,14,Psychiatric Status Rating Scales,N,
9535,DescriptorName,D012008,15644988,,,15,Recurrence,N,
9536,DescriptorName,D012559,15644988,,,16,Schizophrenia,N,
9537,QualifierName,Q000188,15644988,,,16,,Y,drug therapy
9538,DescriptorName,D013844,15644988,,,17,Thiazoles,N,
9539,QualifierName,Q000009,15644988,,,17,,Y,adverse effects
9540,Chemical,D000927,15661067,Anticonvulsants,0,,,,
9541,Chemical,D002220,15661067,Carbamazepine,33CM23913M,,,,
9542,DescriptorName,D000328,15661067,,,1,Adult,N,
9543,DescriptorName,D000927,15661067,,,2,Anticonvulsants,N,
9544,QualifierName,Q000009,15661067,,,2,,Y,adverse effects
9545,DescriptorName,D002220,15661067,,,3,Carbamazepine,N,
9546,QualifierName,Q000009,15661067,,,3,,Y,adverse effects
9547,DescriptorName,D004827,15661067,,,4,Epilepsy,N,
9548,QualifierName,Q000188,15661067,,,4,,N,drug therapy
9549,DescriptorName,D006801,15661067,,,5,Humans,N,
9550,DescriptorName,D007248,15661067,,,6,"Infertility, Male",N,
9551,QualifierName,Q000139,15661067,,,6,,Y,chemically induced
9552,DescriptorName,D008297,15661067,,,7,Male,N,
9553,DescriptorName,D013081,15661067,,,8,Sperm Motility,N,
9554,QualifierName,Q000187,15661067,,,8,,Y,drug effects
9555,Chemical,D000970,15663666,Antineoplastic Agents,0,,,,
9556,Chemical,D014212,15663666,Tretinoin,5688UTC01R,,,,
9557,DescriptorName,D000284,15663666,,,1,"Administration, Oral",N,
9558,DescriptorName,D000328,15663666,,,2,Adult,N,
9559,DescriptorName,D000970,15663666,,,3,Antineoplastic Agents,N,
9560,QualifierName,Q000008,15663666,,,3,,N,administration & dosage
9561,DescriptorName,D005832,15663666,,,4,"Genital Diseases, Male",N,
9562,QualifierName,Q000139,15663666,,,4,,Y,chemically induced
9563,DescriptorName,D006801,15663666,,,5,Humans,N,
9564,DescriptorName,D015473,15663666,,,6,"Leukemia, Promyelocytic, Acute",N,
9565,QualifierName,Q000188,15663666,,,6,,Y,drug therapy
9566,DescriptorName,D008297,15663666,,,7,Male,N,
9567,DescriptorName,D012611,15663666,,,8,Scrotum,N,
9568,QualifierName,Q000187,15663666,,,8,,Y,drug effects
9569,DescriptorName,D012883,15663666,,,9,Skin Ulcer,N,
9570,QualifierName,Q000139,15663666,,,9,,Y,chemically induced
9571,DescriptorName,D014212,15663666,,,10,Tretinoin,N,
9572,QualifierName,Q000008,15663666,,,10,,N,administration & dosage
9573,Chemical,D000927,15671134,Anticonvulsants,0,,,,
9574,Chemical,D014150,15671134,Antipsychotic Agents,0,,,,
9575,Chemical,D014635,15671134,Valproic Acid,614OI1Z5WI,,,,
9576,Chemical,D003024,15671134,Clozapine,J60AR2IKIC,,,,
9577,DescriptorName,D000328,15671134,,,1,Adult,N,
9578,DescriptorName,D000927,15671134,,,2,Anticonvulsants,N,
9579,QualifierName,Q000627,15671134,,,2,,Y,therapeutic use
9580,DescriptorName,D014150,15671134,,,3,Antipsychotic Agents,N,
9581,QualifierName,Q000009,15671134,,,3,,Y,adverse effects
9582,DescriptorName,D003024,15671134,,,4,Clozapine,N,
9583,QualifierName,Q000009,15671134,,,4,,Y,adverse effects
9584,DescriptorName,D004830,15671134,,,5,"Epilepsy, Tonic-Clonic",N,
9585,QualifierName,Q000139,15671134,,,5,,Y,chemically induced
9586,DescriptorName,D005260,15671134,,,6,Female,N,
9587,DescriptorName,D006801,15671134,,,7,Humans,N,
9588,DescriptorName,D012563,15671134,,,8,"Schizophrenia, Paranoid",N,
9589,QualifierName,Q000150,15671134,,,8,,N,complications
9590,DescriptorName,D014635,15671134,,,9,Valproic Acid,N,
9591,QualifierName,Q000627,15671134,,,9,,Y,therapeutic use
9592,Chemical,D000894,15681911,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
9593,Chemical,D007783,15681911,Lactones,0,,,,
9594,Chemical,D013450,15681911,Sulfones,0,,,,
9595,Chemical,C116926,15681911,rofecoxib,0QTW8Z7MCR,,,,
9596,DescriptorName,D000328,15681911,,,1,Adult,N,
9597,DescriptorName,D000368,15681911,,,2,Aged,N,
9598,DescriptorName,D000894,15681911,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
9599,QualifierName,Q000009,15681911,,,3,,Y,adverse effects
9600,DescriptorName,D018771,15681911,,,4,Arthralgia,N,
9601,QualifierName,Q000188,15681911,,,4,,N,drug therapy
9602,DescriptorName,D001706,15681911,,,5,Biopsy,N,
9603,DescriptorName,D003093,15681911,,,6,"Colitis, Ulcerative",N,
9604,QualifierName,Q000139,15681911,,,6,,Y,chemically induced
9605,DescriptorName,D003106,15681911,,,7,Colon,N,
9606,QualifierName,Q000187,15681911,,,7,,Y,drug effects
9607,DescriptorName,D003113,15681911,,,8,Colonoscopy,N,
9608,DescriptorName,D005260,15681911,,,9,Female,N,
9609,DescriptorName,D006801,15681911,,,10,Humans,N,
9610,DescriptorName,D007783,15681911,,,11,Lactones,N,
9611,QualifierName,Q000009,15681911,,,11,,Y,adverse effects
9612,DescriptorName,D008297,15681911,,,12,Male,N,
9613,DescriptorName,D008875,15681911,,,13,Middle Aged,N,
9614,DescriptorName,D013450,15681911,,,14,Sulfones,N,
9615,QualifierName,Q000009,15681911,,,14,,Y,adverse effects
9616,Chemical,D018712,15685264,"Analgesics, Non-Narcotic",0,,,,
9617,Chemical,D008333,15685264,Mandelic Acids,0,,,,
9618,Chemical,D009125,15685264,"Muscle Relaxants, Central",0,,,,
9619,Chemical,D002220,15685264,Carbamazepine,33CM23913M,,,,
9620,Chemical,D003620,15685264,Dantrolene,F64QU97QCR,,,,
9621,Chemical,C005419,15685264,oxybutynin,K9P6MC7092,,,,
9622,DescriptorName,D000328,15685264,,,1,Adult,N,
9623,DescriptorName,D018712,15685264,,,2,"Analgesics, Non-Narcotic",N,
9624,QualifierName,Q000009,15685264,,,2,,Y,adverse effects
9625,DescriptorName,D002220,15685264,,,3,Carbamazepine,N,
9626,QualifierName,Q000009,15685264,,,3,,Y,adverse effects
9627,DescriptorName,D003620,15685264,,,4,Dantrolene,N,
9628,QualifierName,Q000008,15685264,,,4,,Y,administration & dosage
9629,DescriptorName,D004244,15685264,,,5,Dizziness,N,
9630,QualifierName,Q000139,15685264,,,5,,Y,chemically induced
9631,DescriptorName,D004347,15685264,,,6,Drug Interactions,N,
9632,DescriptorName,D004359,15685264,,,7,"Drug Therapy, Combination",N,
9633,DescriptorName,D005260,15685264,,,8,Female,N,
9634,DescriptorName,D006801,15685264,,,9,Humans,N,
9635,DescriptorName,D008333,15685264,,,10,Mandelic Acids,N,
9636,QualifierName,Q000008,15685264,,,10,,Y,administration & dosage
9637,DescriptorName,D009125,15685264,,,11,"Muscle Relaxants, Central",N,
9638,QualifierName,Q000008,15685264,,,11,,N,administration & dosage
9639,DescriptorName,D009437,15685264,,,12,Neuralgia,N,
9640,QualifierName,Q000188,15685264,,,12,,N,drug therapy
9641,DescriptorName,D011782,15685264,,,13,Quadriplegia,N,
9642,QualifierName,Q000150,15685264,,,13,,N,complications
9643,DescriptorName,D014839,15685264,,,14,Vomiting,N,
9644,QualifierName,Q000139,15685264,,,14,,N,chemically induced
9645,Chemical,D002216,1569260,Captopril,9G64RSX1XD,,,,
9646,DescriptorName,D000368,1569260,,,1,Aged,N,
9647,DescriptorName,D000369,1569260,,,2,"Aged, 80 and over",N,
9648,DescriptorName,D002216,1569260,,,3,Captopril,N,
9649,QualifierName,Q000009,1569260,,,3,,Y,adverse effects
9650,DescriptorName,D005260,1569260,,,4,Female,N,
9651,DescriptorName,D006801,1569260,,,5,Humans,N,
9652,DescriptorName,D006973,1569260,,,6,Hypertension,N,
9653,QualifierName,Q000188,1569260,,,6,,N,drug therapy
9654,DescriptorName,D010392,1569260,,,7,Pemphigus,N,
9655,QualifierName,Q000139,1569260,,,7,,Y,chemically induced
9656,DescriptorName,D013997,1569260,,,8,Time Factors,N,
9657,Chemical,D009498,15694139,Neurotoxins,0,,,,
9658,Chemical,D013792,15694139,Thalidomide,4Z8R6ORS6L,,,,
9659,DescriptorName,D000200,15694139,,,1,Action Potentials,N,
9660,QualifierName,Q000187,15694139,,,1,,N,drug effects
9661,DescriptorName,D000293,15694139,,,2,Adolescent,N,
9662,DescriptorName,D001932,15694139,,,3,Brain Neoplasms,N,
9663,QualifierName,Q000188,15694139,,,3,,N,drug therapy
9664,DescriptorName,D002648,15694139,,,4,Child,N,
9665,DescriptorName,D003424,15694139,,,5,Crohn Disease,N,
9666,QualifierName,Q000188,15694139,,,5,,N,drug therapy
9667,DescriptorName,D018450,15694139,,,6,Disease Progression,N,
9668,DescriptorName,D004576,15694139,,,7,Electromyography,N,
9669,DescriptorName,D004806,15694139,,,8,Ependymoma,N,
9670,QualifierName,Q000188,15694139,,,8,,N,drug therapy
9671,DescriptorName,D020233,15694139,,,9,"Gait Disorders, Neurologic",N,
9672,QualifierName,Q000139,15694139,,,9,,Y,chemically induced
9673,DescriptorName,D006801,15694139,,,10,Humans,N,
9674,DescriptorName,D008297,15694139,,,11,Male,N,
9675,DescriptorName,D018908,15694139,,,12,Muscle Weakness,N,
9676,QualifierName,Q000139,15694139,,,12,,N,chemically induced
9677,DescriptorName,D018482,15694139,,,13,"Muscle, Skeletal",N,
9678,QualifierName,Q000294,15694139,,,13,,N,innervation
9679,DescriptorName,D009431,15694139,,,14,Neural Conduction,N,
9680,QualifierName,Q000187,15694139,,,14,,N,drug effects
9681,DescriptorName,D009460,15694139,,,15,Neurologic Examination,N,
9682,QualifierName,Q000592,15694139,,,15,,N,standards
9683,DescriptorName,D009498,15694139,,,16,Neurotoxins,N,
9684,QualifierName,Q000009,15694139,,,16,,N,adverse effects
9685,DescriptorName,D010525,15694139,,,17,Peripheral Nerves,N,
9686,QualifierName,Q000187,15694139,,,17,,Y,drug effects
9687,DescriptorName,D010523,15694139,,,18,Peripheral Nervous System Diseases,N,
9688,QualifierName,Q000139,15694139,,,18,,Y,chemically induced
9689,DescriptorName,D013792,15694139,,,19,Thalidomide,N,
9690,QualifierName,Q000009,15694139,,,19,,Y,adverse effects
9691,DescriptorName,D014456,15694139,,,20,Ulcer,N,
9692,QualifierName,Q000188,15694139,,,20,,N,drug therapy
9693,DescriptorName,D028761,15694139,,,21,Withholding Treatment,N,
9694,Chemical,D018906,15701285,"Antineoplastic Agents, Alkylating",0,,,,
9695,Chemical,D001672,15701285,Biocompatible Materials,0,,,,
9696,Chemical,D003652,15701285,Decanoic Acids,0,,,,
9697,Chemical,D004343,15701285,Drug Implants,0,,,,
9698,Chemical,D011091,15701285,Polyesters,0,,,,
9699,Chemical,C055401,15701285,"decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer",90409-78-2,,,,
9700,Chemical,D002330,15701285,Carmustine,U68WG3173Y,,,,
9701,DescriptorName,D018906,15701285,,,1,"Antineoplastic Agents, Alkylating",N,
9702,QualifierName,Q000008,15701285,,,1,,N,administration & dosage
9703,DescriptorName,D001672,15701285,,,2,Biocompatible Materials,N,
9704,QualifierName,Q000009,15701285,,,2,,Y,adverse effects
9705,DescriptorName,D001929,15701285,,,3,Brain Edema,N,
9706,QualifierName,Q000209,15701285,,,3,,Y,etiology
9707,DescriptorName,D001932,15701285,,,4,Brain Neoplasms,N,
9708,QualifierName,Q000188,15701285,,,4,,N,drug therapy
9709,DescriptorName,D002330,15701285,,,5,Carmustine,N,
9710,QualifierName,Q000008,15701285,,,5,,N,administration & dosage
9711,DescriptorName,D003652,15701285,,,6,Decanoic Acids,N,
9712,QualifierName,Q000009,15701285,,,6,,Y,adverse effects
9713,DescriptorName,D004343,15701285,,,7,Drug Implants,N,
9714,DescriptorName,D005260,15701285,,,8,Female,N,
9715,DescriptorName,D005910,15701285,,,9,Glioma,N,
9716,QualifierName,Q000188,15701285,,,9,,N,drug therapy
9717,DescriptorName,D006801,15701285,,,10,Humans,N,
9718,DescriptorName,D008279,15701285,,,11,Magnetic Resonance Imaging,N,
9719,DescriptorName,D008875,15701285,,,12,Middle Aged,N,
9720,DescriptorName,D011091,15701285,,,13,Polyesters,N,
9721,QualifierName,Q000009,15701285,,,13,,Y,adverse effects
9722,Chemical,D000970,15719254,Antineoplastic Agents,0,,,,
9723,Chemical,D014212,15719254,Tretinoin,5688UTC01R,,,,
9724,DescriptorName,D000970,15719254,,,1,Antineoplastic Agents,N,
9725,QualifierName,Q000008,15719254,,,1,,N,administration & dosage
9726,DescriptorName,D016026,15719254,,,2,Bone Marrow Transplantation,N,
9727,QualifierName,Q000009,15719254,,,2,,Y,adverse effects
9728,DescriptorName,D002675,15719254,,,3,"Child, Preschool",N,
9729,DescriptorName,D005260,15719254,,,4,Female,N,
9730,DescriptorName,D006801,15719254,,,5,Humans,N,
9731,DescriptorName,D007668,15719254,,,6,Kidney,N,
9732,QualifierName,Q000473,15719254,,,6,,N,pathology
9733,DescriptorName,D007674,15719254,,,7,Kidney Diseases,N,
9734,QualifierName,Q000209,15719254,,,7,,Y,etiology
9735,DescriptorName,D008297,15719254,,,8,Male,N,
9736,DescriptorName,D009367,15719254,,,9,Neoplasm Staging,N,
9737,DescriptorName,D009447,15719254,,,10,Neuroblastoma,N,
9738,QualifierName,Q000188,15719254,,,10,,Y,drug therapy
9739,DescriptorName,D011182,15719254,,,11,Postoperative Care,N,
9740,DescriptorName,D013237,15719254,,,12,Stereoisomerism,N,
9741,DescriptorName,D014212,15719254,,,13,Tretinoin,N,
9742,QualifierName,Q000008,15719254,,,13,,N,administration & dosage
9743,Chemical,D000634,15727358,Aminoquinolines,0,,,,
9744,Chemical,D000077271,15727358,Imiquimod,P1QW714R7M,,,,
9745,DescriptorName,D000287,15727358,,,1,"Administration, Topical",N,
9746,DescriptorName,D000634,15727358,,,2,Aminoquinolines,N,
9747,QualifierName,Q000008,15727358,,,2,,N,administration & dosage
9748,DescriptorName,D002280,15727358,,,3,"Carcinoma, Basal Cell",N,
9749,QualifierName,Q000188,15727358,,,3,,N,drug therapy
9750,DescriptorName,D017679,15727358,,,4,Cryotherapy,Y,
9751,DescriptorName,D003475,15727358,,,5,Curettage,Y,
9752,DescriptorName,D006801,15727358,,,6,Humans,N,
9753,DescriptorName,D000077271,15727358,,,7,Imiquimod,N,
9754,DescriptorName,D008297,15727358,,,8,Male,N,
9755,DescriptorName,D008875,15727358,,,9,Middle Aged,N,
9756,DescriptorName,D055502,15727358,,,10,Secondary Prevention,N,
9757,DescriptorName,D012878,15727358,,,11,Skin Neoplasms,N,
9758,QualifierName,Q000188,15727358,,,11,,N,drug therapy
9759,DescriptorName,D016896,15727358,,,12,Treatment Outcome,N,
9760,Chemical,D014150,15729090,Antipsychotic Agents,0,,,,
9761,Chemical,D003987,15729090,Dibenzothiazepines,0,,,,
9762,Chemical,D000069348,15729090,Quetiapine Fumarate,2S3PL1B6UJ,,,,
9763,DescriptorName,D014150,15729090,,,1,Antipsychotic Agents,N,
9764,QualifierName,Q000008,15729090,,,1,,N,administration & dosage
9765,DescriptorName,D003987,15729090,,,2,Dibenzothiazepines,N,
9766,QualifierName,Q000008,15729090,,,2,,N,administration & dosage
9767,DescriptorName,D004305,15729090,,,3,"Dose-Response Relationship, Drug",N,
9768,DescriptorName,D004562,15729090,,,4,Electrocardiography,N,
9769,DescriptorName,D006801,15729090,,,5,Humans,N,
9770,DescriptorName,D008297,15729090,,,6,Male,N,
9771,DescriptorName,D008875,15729090,,,7,Middle Aged,N,
9772,DescriptorName,D009207,15729090,,,8,Myoclonus,N,
9773,QualifierName,Q000139,15729090,,,8,,Y,chemically induced
9774,DescriptorName,D000069348,15729090,,,9,Quetiapine Fumarate,N,
9775,DescriptorName,D012563,15729090,,,10,"Schizophrenia, Paranoid",N,
9776,QualifierName,Q000150,15729090,,,10,,N,complications
9777,Chemical,D018906,15735923,"Antineoplastic Agents, Alkylating",0,,,,
9778,Chemical,D003606,15735923,Dacarbazine,7GR28W0FJI,,,,
9779,Chemical,D000077204,15735923,Temozolomide,YF1K15M17Y,,,,
9780,DescriptorName,D000208,15735923,,,1,Acute Disease,N,
9781,DescriptorName,D000328,15735923,,,2,Adult,N,
9782,DescriptorName,D018906,15735923,,,3,"Antineoplastic Agents, Alkylating",N,
9783,QualifierName,Q000009,15735923,,,3,,Y,adverse effects
9784,DescriptorName,D001254,15735923,,,4,Astrocytoma,N,
9785,QualifierName,Q000188,15735923,,,4,,Y,drug therapy
9786,DescriptorName,D001932,15735923,,,5,Brain Neoplasms,N,
9787,QualifierName,Q000188,15735923,,,5,,Y,drug therapy
9788,DescriptorName,D002880,15735923,,,6,"Chromosomes, Human, Pair 11",N,
9789,DescriptorName,D003606,15735923,,,7,Dacarbazine,N,
9790,QualifierName,Q000009,15735923,,,7,,Y,adverse effects
9791,DescriptorName,D017809,15735923,,,8,Fatal Outcome,N,
9792,DescriptorName,D005260,15735923,,,9,Female,N,
9793,DescriptorName,D017353,15735923,,,10,Gene Deletion,N,
9794,DescriptorName,D006801,15735923,,,11,Humans,N,
9795,DescriptorName,D007938,15735923,,,12,Leukemia,N,
9796,QualifierName,Q000139,15735923,,,12,,Y,chemically induced
9797,DescriptorName,D009190,15735923,,,13,Myelodysplastic Syndromes,N,
9798,QualifierName,Q000139,15735923,,,13,,Y,chemically induced
9799,DescriptorName,D009364,15735923,,,14,"Neoplasm Recurrence, Local",N,
9800,QualifierName,Q000188,15735923,,,14,,Y,drug therapy
9801,DescriptorName,D000077204,15735923,,,15,Temozolomide,N,
9802,Chemical,D009254,1575118,Nafcillin,4CNZ27M7RV,,,,
9803,DescriptorName,D001168,1575118,,,1,Arthritis,N,
9804,QualifierName,Q000188,1575118,,,1,,N,drug therapy
9805,DescriptorName,D002648,1575118,,,2,Child,N,
9806,DescriptorName,D006801,1575118,,,3,Humans,N,
9807,DescriptorName,D007719,1575118,,,4,Knee Joint,N,
9808,DescriptorName,D007958,1575118,,,5,Leukocyte Count,N,
9809,QualifierName,Q000187,1575118,,,5,,N,drug effects
9810,DescriptorName,D008297,1575118,,,6,Male,N,
9811,DescriptorName,D009254,1575118,,,7,Nafcillin,N,
9812,QualifierName,Q000009,1575118,,,7,,Y,adverse effects
9813,DescriptorName,D009503,1575118,,,8,Neutropenia,N,
9814,QualifierName,Q000139,1575118,,,8,,Y,chemically induced
9815,DescriptorName,D009504,1575118,,,9,Neutrophils,N,
9816,DescriptorName,D013203,1575118,,,10,Staphylococcal Infections,N,
9817,QualifierName,Q000188,1575118,,,10,,N,drug therapy
9818,DescriptorName,D013290,1575118,,,11,Streptococcal Infections,N,
9819,QualifierName,Q000188,1575118,,,11,,N,drug therapy
9820,Chemical,D000970,15752306,Antineoplastic Agents,0,,,,
9821,Chemical,D000077190,15752306,Interferon alpha-2,0,,,,
9822,Chemical,D016898,15752306,Interferon-alpha,0,,,,
9823,Chemical,D011994,15752306,Recombinant Proteins,0,,,,
9824,DescriptorName,D000368,15752306,,,1,Aged,N,
9825,DescriptorName,D000970,15752306,,,2,Antineoplastic Agents,N,
9826,QualifierName,Q000009,15752306,,,2,,Y,adverse effects
9827,DescriptorName,D005260,15752306,,,3,Female,N,
9828,DescriptorName,D006801,15752306,,,4,Humans,N,
9829,DescriptorName,D000077190,15752306,,,5,Interferon alpha-2,N,
9830,DescriptorName,D016898,15752306,,,6,Interferon-alpha,N,
9831,QualifierName,Q000009,15752306,,,6,,Y,adverse effects
9832,DescriptorName,D008297,15752306,,,7,Male,N,
9833,DescriptorName,D008545,15752306,,,8,Melanoma,N,
9834,QualifierName,Q000188,15752306,,,8,,Y,drug therapy
9835,DescriptorName,D008875,15752306,,,9,Middle Aged,N,
9836,DescriptorName,D011994,15752306,,,10,Recombinant Proteins,N,
9837,DescriptorName,D017445,15752306,,,11,"Skin Diseases, Vascular",N,
9838,QualifierName,Q000139,15752306,,,11,,Y,chemically induced
9839,DescriptorName,D012878,15752306,,,12,Skin Neoplasms,N,
9840,QualifierName,Q000188,15752306,,,12,,Y,drug therapy
9841,Chemical,D000305,15760792,Adrenal Cortex Hormones,0,,,,
9842,Chemical,D019268,15760792,"Antibodies, Antineutrophil Cytoplasmic",0,,,,
9843,Chemical,D013956,15760792,Antithyroid Agents,0,,,,
9844,Chemical,D007166,15760792,Immunosuppressive Agents,0,,,,
9845,Chemical,D011441,15760792,Propylthiouracil,721M9407IY,,,,
9846,Chemical,D001379,15760792,Azathioprine,MRK240IY2L,,,,
9847,DescriptorName,D000305,15760792,,,1,Adrenal Cortex Hormones,N,
9848,QualifierName,Q000627,15760792,,,1,,N,therapeutic use
9849,DescriptorName,D000328,15760792,,,2,Adult,N,
9850,DescriptorName,D019268,15760792,,,3,"Antibodies, Antineutrophil Cytoplasmic",N,
9851,QualifierName,Q000276,15760792,,,3,,Y,immunology
9852,DescriptorName,D013956,15760792,,,4,Antithyroid Agents,N,
9853,QualifierName,Q000009,15760792,,,4,,Y,adverse effects
9854,DescriptorName,D001299,15760792,,,5,Audiometry,N,
9855,DescriptorName,D001379,15760792,,,6,Azathioprine,N,
9856,QualifierName,Q000627,15760792,,,6,,N,therapeutic use
9857,DescriptorName,D005260,15760792,,,7,Female,N,
9858,DescriptorName,D006111,15760792,,,8,Graves Disease,N,
9859,QualifierName,Q000188,15760792,,,8,,N,drug therapy
9860,DescriptorName,D006319,15760792,,,9,"Hearing Loss, Sensorineural",N,
9861,QualifierName,Q000175,15760792,,,9,,N,diagnosis
9862,DescriptorName,D006801,15760792,,,10,Humans,N,
9863,DescriptorName,D007166,15760792,,,11,Immunosuppressive Agents,N,
9864,QualifierName,Q000627,15760792,,,11,,N,therapeutic use
9865,DescriptorName,D011441,15760792,,,12,Propylthiouracil,N,
9866,QualifierName,Q000009,15760792,,,12,,Y,adverse effects
9867,DescriptorName,D013965,15760792,,,13,Thyroidectomy,N,
9868,DescriptorName,D016896,15760792,,,14,Treatment Outcome,N,
9869,DescriptorName,D014657,15760792,,,15,Vasculitis,N,
9870,QualifierName,Q000209,15760792,,,15,,Y,etiology
9871,Chemical,D000995,15770343,Antitubercular Agents,0,,,,
9872,Chemical,D004977,15770343,Ethambutol,8G167061QZ,,,,
9873,DescriptorName,D058186,15770343,,,1,Acute Kidney Injury,N,
9874,QualifierName,Q000209,15770343,,,1,,Y,etiology
9875,DescriptorName,D000995,15770343,,,2,Antitubercular Agents,N,
9876,QualifierName,Q000009,15770343,,,2,,N,adverse effects
9877,DescriptorName,D001766,15770343,,,3,Blindness,N,
9878,QualifierName,Q000188,15770343,,,3,,N,drug therapy
9879,DescriptorName,D004977,15770343,,,4,Ethambutol,N,
9880,QualifierName,Q000009,15770343,,,4,,N,adverse effects
9881,DescriptorName,D006801,15770343,,,5,Humans,N,
9882,DescriptorName,D008297,15770343,,,6,Male,N,
9883,DescriptorName,D008875,15770343,,,7,Middle Aged,N,
9884,DescriptorName,D011859,15770343,,,8,Radiography,N,
9885,DescriptorName,D014391,15770343,,,9,"Tuberculosis, Miliary",N,
9886,QualifierName,Q000150,15770343,,,9,,Y,complications
9887,Chemical,D000900,15773973,Anti-Bacterial Agents,0,,,,
9888,Chemical,D005436,15773973,Floxacillin,43B2M34G2V,,,,
9889,DescriptorName,D000328,15773973,,,1,Adult,N,
9890,DescriptorName,D000741,15773973,,,2,"Anemia, Aplastic",N,
9891,QualifierName,Q000139,15773973,,,2,,Y,chemically induced
9892,DescriptorName,D000900,15773973,,,3,Anti-Bacterial Agents,N,
9893,QualifierName,Q000009,15773973,,,3,,Y,adverse effects
9894,DescriptorName,D005260,15773973,,,4,Female,N,
9895,DescriptorName,D005436,15773973,,,5,Floxacillin,N,
9896,QualifierName,Q000009,15773973,,,5,,Y,adverse effects
9897,DescriptorName,D006801,15773973,,,6,Humans,N,
9898,DescriptorName,D007958,15773973,,,7,Leukocyte Count,N,
9899,DescriptorName,D017708,15773973,,,8,Leukocyte Transfusion,N,
9900,DescriptorName,D017093,15773973,,,9,Liver Failure,N,
9901,QualifierName,Q000139,15773973,,,9,,Y,chemically induced
9902,DescriptorName,D016031,15773973,,,10,Liver Transplantation,N,
9903,DescriptorName,D009504,15773973,,,11,Neutrophils,N,
9904,QualifierName,Q000473,15773973,,,11,,N,pathology
9905,DescriptorName,D011182,15773973,,,12,Postoperative Care,N,
9906,DescriptorName,D017192,15773973,,,13,"Skin Diseases, Bacterial",N,
9907,QualifierName,Q000188,15773973,,,13,,N,drug therapy
9908,Chemical,D004164,15779196,Diphosphonates,0,,,,
9909,Chemical,D007093,15779196,Imidazoles,0,,,,
9910,Chemical,D000077211,15779196,Zoledronic Acid,6XC1PAD3KF,,,,
9911,DescriptorName,D000230,15779196,,,1,Adenocarcinoma,N,
9912,QualifierName,Q000473,15779196,,,1,,N,pathology
9913,DescriptorName,D000368,15779196,,,2,Aged,N,
9914,DescriptorName,D001859,15779196,,,3,Bone Neoplasms,N,
9915,QualifierName,Q000188,15779196,,,3,,Y,drug therapy
9916,DescriptorName,D001862,15779196,,,4,Bone Resorption,N,
9917,QualifierName,Q000517,15779196,,,4,,Y,prevention & control
9918,DescriptorName,D004164,15779196,,,5,Diphosphonates,N,
9919,QualifierName,Q000008,15779196,,,5,,N,administration & dosage
9920,DescriptorName,D006801,15779196,,,6,Humans,N,
9921,DescriptorName,D006996,15779196,,,7,Hypocalcemia,N,
9922,QualifierName,Q000139,15779196,,,7,,Y,chemically induced
9923,DescriptorName,D007093,15779196,,,8,Imidazoles,N,
9924,QualifierName,Q000008,15779196,,,8,,N,administration & dosage
9925,DescriptorName,D008297,15779196,,,9,Male,N,
9926,DescriptorName,D010146,15779196,,,10,Pain,N,
9927,QualifierName,Q000188,15779196,,,10,,N,drug therapy
9928,DescriptorName,D011471,15779196,,,11,Prostatic Neoplasms,N,
9929,QualifierName,Q000473,15779196,,,11,,N,pathology
9930,DescriptorName,D000077211,15779196,,,12,Zoledronic Acid,N,
9931,Chemical,D003520,1577957,Cyclophosphamide,8N3DW7272P,,,,
9932,DescriptorName,D000293,1577957,,,1,Adolescent,N,
9933,DescriptorName,D001245,1577957,,,2,Association Learning,N,
9934,QualifierName,Q000187,1577957,,,2,,N,drug effects
9935,DescriptorName,D003131,1577957,,,3,Combined Modality Therapy,N,
9936,DescriptorName,D003214,1577957,,,4,"Conditioning, Classical",Y,
9937,QualifierName,Q000187,1577957,,,4,,N,drug effects
9938,DescriptorName,D003520,1577957,,,5,Cyclophosphamide,N,
9939,QualifierName,Q000008,1577957,,,5,,Y,administration & dosage
9940,DescriptorName,D004305,1577957,,,6,"Dose-Response Relationship, Drug",N,
9941,DescriptorName,D005260,1577957,,,7,Female,N,
9942,DescriptorName,D006801,1577957,,,8,Humans,N,
9943,DescriptorName,D007262,1577957,,,9,"Infusions, Intravenous",N,
9944,DescriptorName,D008180,1577957,,,10,"Lupus Erythematosus, Systemic",N,
9945,QualifierName,Q000188,1577957,,,10,,Y,drug therapy
9946,DescriptorName,D015990,1577957,,,11,Placebo Effect,N,
9947,Chemical,D007166,15785053,Immunosuppressive Agents,0,,,,
9948,Chemical,D016559,15785053,Tacrolimus,WM0HAQ4WNM,,,,
9949,DescriptorName,D000279,15785053,,,1,"Administration, Cutaneous",N,
9950,DescriptorName,D000368,15785053,,,2,Aged,N,
9951,DescriptorName,D003937,15785053,,,3,"Diagnosis, Differential",N,
9952,DescriptorName,D005260,15785053,,,4,Female,N,
9953,DescriptorName,D006801,15785053,,,5,Humans,N,
9954,DescriptorName,D017495,15785053,,,6,Hyperpigmentation,N,
9955,QualifierName,Q000139,15785053,,,6,,N,chemically induced
9956,DescriptorName,D007166,15785053,,,7,Immunosuppressive Agents,N,
9957,QualifierName,Q000008,15785053,,,7,,N,administration & dosage
9958,DescriptorName,D017676,15785053,,,8,"Lichen Planus, Oral",N,
9959,QualifierName,Q000188,15785053,,,8,,Y,drug therapy
9960,DescriptorName,D009059,15785053,,,9,Mouth Diseases,N,
9961,QualifierName,Q000139,15785053,,,9,,N,chemically induced
9962,DescriptorName,D009061,15785053,,,10,Mouth Mucosa,N,
9963,QualifierName,Q000473,15785053,,,10,,N,pathology
9964,DescriptorName,D016559,15785053,,,11,Tacrolimus,N,
9965,QualifierName,Q000008,15785053,,,11,,N,administration & dosage
9966,Chemical,D008727,15790469,Methotrexate,YL5FZ2Y5U1,,,,
9967,DescriptorName,D000293,15790469,,,1,Adolescent,N,
9968,DescriptorName,D001171,15790469,,,2,"Arthritis, Juvenile",N,
9969,QualifierName,Q000150,15790469,,,2,,Y,complications
9970,DescriptorName,D004305,15790469,,,3,"Dose-Response Relationship, Drug",N,
9971,DescriptorName,D005260,15790469,,,4,Female,N,
9972,DescriptorName,D006801,15790469,,,5,Humans,N,
9973,DescriptorName,D016393,15790469,,,6,"Lymphoma, B-Cell",N,
9974,QualifierName,Q000139,15790469,,,6,,N,chemically induced
9975,DescriptorName,D008727,15790469,,,7,Methotrexate,N,
9976,QualifierName,Q000008,15790469,,,7,,N,administration & dosage
9977,DescriptorName,D010051,15790469,,,8,Ovarian Neoplasms,N,
9978,QualifierName,Q000139,15790469,,,8,,N,chemically induced
9979,Chemical,D014150,15795553,Antipsychotic Agents,0,,,,
9980,Chemical,D018492,15795553,Dopamine Antagonists,0,,,,
9981,Chemical,D012702,15795553,Serotonin Antagonists,0,,,,
9982,Chemical,D018967,15795553,Risperidone,L6UH7ZF8HC,,,,
9983,DescriptorName,D000368,15795553,,,1,Aged,N,
9984,DescriptorName,D000369,15795553,,,2,"Aged, 80 and over",N,
9985,DescriptorName,D014150,15795553,,,3,Antipsychotic Agents,N,
9986,QualifierName,Q000009,15795553,,,3,,Y,adverse effects
9987,DescriptorName,D003704,15795553,,,4,Dementia,N,
9988,QualifierName,Q000188,15795553,,,4,,N,drug therapy
9989,DescriptorName,D018492,15795553,,,5,Dopamine Antagonists,N,
9990,DescriptorName,D004409,15795553,,,6,"Dyskinesia, Drug-Induced",N,
9991,QualifierName,Q000175,15795553,,,6,,N,diagnosis
9992,DescriptorName,D005260,15795553,,,7,Female,N,
9993,DescriptorName,D006801,15795553,,,8,Humans,N,
9994,DescriptorName,D012120,15795553,,,9,Respiration Disorders,N,
9995,QualifierName,Q000139,15795553,,,9,,Y,chemically induced
9996,DescriptorName,D018967,15795553,,,10,Risperidone,N,
9997,QualifierName,Q000009,15795553,,,10,,Y,adverse effects
9998,DescriptorName,D012702,15795553,,,11,Serotonin Antagonists,N,
9999,DescriptorName,D013375,15795553,,,12,Substance Withdrawal Syndrome,N,
10000,QualifierName,Q000175,15795553,,,12,,N,diagnosis
10001,Chemical,C096323,15806568,rimabotulinumtoxinB,0Y70779M1F,,,,
10002,Chemical,D001905,15806568,Botulinum Toxins,EC 3.4.24.69,,,,
10003,Chemical,D019274,15806568,"Botulinum Toxins, Type A",EC 3.4.24.69,,,,
10004,DescriptorName,D000328,15806568,,,1,Adult,N,
10005,DescriptorName,D001342,15806568,,,2,Autonomic Nervous System Diseases,N,
10006,QualifierName,Q000150,15806568,,,2,,Y,complications
10007,DescriptorName,D001905,15806568,,,3,Botulinum Toxins,N,
10008,QualifierName,Q000009,15806568,,,3,,Y,adverse effects
10009,DescriptorName,D019274,15806568,,,4,"Botulinum Toxins, Type A",N,
10010,DescriptorName,D005260,15806568,,,5,Female,N,
10011,DescriptorName,D006801,15806568,,,6,Humans,N,
10012,DescriptorName,D008297,15806568,,,7,Male,N,
10013,DescriptorName,D009069,15806568,,,8,Movement Disorders,N,
10014,QualifierName,Q000188,15806568,,,8,,N,drug therapy
10015,DescriptorName,D014786,15806568,,,9,Vision Disorders,N,
10016,QualifierName,Q000139,15806568,,,9,,Y,chemically induced
10017,Chemical,D004921,1580986,Erythropoietin,11096-26-7,,,,
10018,Chemical,D004656,1580986,Enalapril,69PN84IO1A,,,,
10019,DescriptorName,D000328,1580986,,,1,Adult,N,
10020,DescriptorName,D000740,1580986,,,2,Anemia,N,
10021,QualifierName,Q000139,1580986,,,2,,Y,chemically induced
10022,DescriptorName,D004656,1580986,,,3,Enalapril,N,
10023,QualifierName,Q000009,1580986,,,3,,Y,adverse effects
10024,DescriptorName,D004921,1580986,,,4,Erythropoietin,N,
10025,QualifierName,Q000097,1580986,,,4,,N,blood
10026,DescriptorName,D005260,1580986,,,5,Female,N,
10027,DescriptorName,D006801,1580986,,,6,Humans,N,
10028,DescriptorName,D006973,1580986,,,7,Hypertension,N,
10029,QualifierName,Q000188,1580986,,,7,,N,drug therapy
10030,DescriptorName,D016030,1580986,,,8,Kidney Transplantation,N,
10031,QualifierName,Q000009,1580986,,,8,,Y,adverse effects
10032,DescriptorName,D008297,1580986,,,9,Male,N,
10033,DescriptorName,D012079,1580986,,,10,Renal Circulation,N,
10034,QualifierName,Q000187,1580986,,,10,,N,drug effects
10035,Chemical,D009211,15811174,Myoglobin,0,,,,
10036,Chemical,D011725,15811174,Pyridines,0,,,,
10037,Chemical,D003577,15811174,Cytochrome P-450 Enzyme System,9035-51-2,,,,
10038,Chemical,D019821,15811174,Simvastatin,AGG2FN16EV,,,,
10039,Chemical,C086276,15811174,cerivastatin,AM91H2KS67,,,,
10040,Chemical,D003404,15811174,Creatinine,AYI8EX34EU,,,,
10041,Chemical,D001189,15811174,Aryl Hydrocarbon Hydroxylases,EC 1.14.14.1,,,,
10042,Chemical,C450259,15811174,"CYP2C8 protein, human",EC 1.14.14.1,,,,
10043,Chemical,C104464,15811174,"CYP3A protein, human",EC 1.14.14.1,,,,
10044,Chemical,D065727,15811174,Cytochrome P-450 CYP2C8,EC 1.14.14.1,,,,
10045,Chemical,D051544,15811174,Cytochrome P-450 CYP3A,EC 1.14.14.1,,,,
10046,Chemical,C510163,15811174,"CYP3A4 protein, human",EC 1.14.14.55,,,,
10047,DescriptorName,D000208,15811174,,,1,Acute Disease,N,
10048,DescriptorName,D000368,15811174,,,2,Aged,N,
10049,DescriptorName,D001189,15811174,,,3,Aryl Hydrocarbon Hydroxylases,N,
10050,QualifierName,Q000187,15811174,,,3,,N,drug effects
10051,DescriptorName,D003404,15811174,,,4,Creatinine,N,
10052,QualifierName,Q000097,15811174,,,4,,N,blood
10053,DescriptorName,D065727,15811174,,,5,Cytochrome P-450 CYP2C8,N,
10054,DescriptorName,D051544,15811174,,,6,Cytochrome P-450 CYP3A,N,
10055,DescriptorName,D003577,15811174,,,7,Cytochrome P-450 Enzyme System,N,
10056,QualifierName,Q000187,15811174,,,7,,N,drug effects
10057,DescriptorName,D004334,15811174,,,8,Drug Administration Schedule,N,
10058,DescriptorName,D005260,15811174,,,9,Female,N,
10059,DescriptorName,D006207,15811174,,,10,Half-Life,N,
10060,DescriptorName,D006801,15811174,,,11,Humans,N,
10061,DescriptorName,D006937,15811174,,,12,Hypercholesterolemia,N,
10062,QualifierName,Q000150,15811174,,,12,,N,complications
10063,DescriptorName,D008657,15811174,,,13,Metabolic Clearance Rate,N,
10064,QualifierName,Q000187,15811174,,,13,,Y,drug effects
10065,DescriptorName,D009211,15811174,,,14,Myoglobin,N,
10066,QualifierName,Q000097,15811174,,,14,,N,blood
10067,DescriptorName,D009212,15811174,,,15,Myoglobinuria,N,
10068,QualifierName,Q000139,15811174,,,15,,N,chemically induced
10069,DescriptorName,D011725,15811174,,,16,Pyridines,N,
10070,QualifierName,Q000008,15811174,,,16,,N,administration & dosage
10071,DescriptorName,D012206,15811174,,,17,Rhabdomyolysis,N,
10072,QualifierName,Q000139,15811174,,,17,,Y,chemically induced
10073,DescriptorName,D019821,15811174,,,18,Simvastatin,N,
10074,QualifierName,Q000008,15811174,,,18,,N,administration & dosage
10075,DescriptorName,D013997,15811174,,,19,Time Factors,N,
10076,Chemical,D016190,15823103,Carboplatin,BG3F62OND5,,,,
10077,Chemical,D017239,15823103,Paclitaxel,P88XT4IS4D,,,,
10078,Chemical,D002945,15823103,Cisplatin,Q20Q21Q62J,,,,
10079,DescriptorName,D000368,15823103,,,1,Aged,N,
10080,DescriptorName,D000971,15823103,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
10081,QualifierName,Q000627,15823103,,,2,,Y,therapeutic use
10082,DescriptorName,D019540,15823103,,,3,Area Under Curve,N,
10083,DescriptorName,D016190,15823103,,,4,Carboplatin,N,
10084,QualifierName,Q000009,15823103,,,4,,Y,adverse effects
10085,DescriptorName,D002945,15823103,,,5,Cisplatin,N,
10086,QualifierName,Q000008,15823103,,,5,,N,administration & dosage
10087,DescriptorName,D004305,15823103,,,6,"Dose-Response Relationship, Drug",N,
10088,DescriptorName,D004334,15823103,,,7,Drug Administration Schedule,N,
10089,DescriptorName,D004342,15823103,,,8,Drug Hypersensitivity,Y,
10090,DescriptorName,D005260,15823103,,,9,Female,N,
10091,DescriptorName,D006801,15823103,,,10,Humans,N,
10092,DescriptorName,D008875,15823103,,,11,Middle Aged,N,
10093,DescriptorName,D009364,15823103,,,12,"Neoplasm Recurrence, Local",N,
10094,QualifierName,Q000188,15823103,,,12,,N,drug therapy
10095,DescriptorName,D010051,15823103,,,13,Ovarian Neoplasms,N,
10096,QualifierName,Q000188,15823103,,,13,,Y,drug therapy
10097,DescriptorName,D017239,15823103,,,14,Paclitaxel,N,
10098,QualifierName,Q000008,15823103,,,14,,N,administration & dosage
10099,Chemical,D000904,15827670,"Antibiotics, Antitubercular",0,,,,
10100,Chemical,D007166,15827670,Immunosuppressive Agents,0,,,,
10101,Chemical,D016572,15827670,Cyclosporine,83HN0GTJ6D,,,,
10102,Chemical,D012293,15827670,Rifampin,VJT6J7R4TR,,,,
10103,DescriptorName,D000904,15827670,,,1,"Antibiotics, Antitubercular",N,
10104,QualifierName,Q000494,15827670,,,1,,N,pharmacology
10105,DescriptorName,D016572,15827670,,,2,Cyclosporine,N,
10106,QualifierName,Q000008,15827670,,,2,,N,administration & dosage
10107,DescriptorName,D004347,15827670,,,3,Drug Interactions,N,
10108,DescriptorName,D006801,15827670,,,4,Humans,N,
10109,DescriptorName,D016867,15827670,,,5,Immunocompromised Host,N,
10110,DescriptorName,D007166,15827670,,,6,Immunosuppressive Agents,N,
10111,QualifierName,Q000008,15827670,,,6,,N,administration & dosage
10112,DescriptorName,D016031,15827670,,,7,Liver Transplantation,N,
10113,QualifierName,Q000009,15827670,,,7,,Y,adverse effects
10114,DescriptorName,D008297,15827670,,,8,Male,N,
10115,DescriptorName,D008875,15827670,,,9,Middle Aged,N,
10116,DescriptorName,D012293,15827670,,,10,Rifampin,N,
10117,QualifierName,Q000494,15827670,,,10,,N,pharmacology
10118,DescriptorName,D014397,15827670,,,11,"Tuberculosis, Pulmonary",N,
10119,QualifierName,Q000188,15827670,,,11,,N,drug therapy
10120,Chemical,D000893,15836666,Anti-Inflammatory Agents,0,,,,
10121,Chemical,D009294,15836666,Narcotics,0,,,,
10122,Chemical,D005283,15836666,Fentanyl,UF599785JZ,,,,
10123,Chemical,D006854,15836666,Hydrocortisone,WI4X0X7BPJ,,,,
10124,DescriptorName,D000279,15836666,,,1,"Administration, Cutaneous",N,
10125,DescriptorName,D000309,15836666,,,2,Adrenal Insufficiency,N,
10126,QualifierName,Q000139,15836666,,,2,,Y,chemically induced
10127,DescriptorName,D000893,15836666,,,3,Anti-Inflammatory Agents,N,
10128,QualifierName,Q000627,15836666,,,3,,N,therapeutic use
10129,DescriptorName,D004334,15836666,,,4,Drug Administration Schedule,N,
10130,DescriptorName,D005283,15836666,,,5,Fentanyl,N,
10131,QualifierName,Q000008,15836666,,,5,,N,administration & dosage
10132,DescriptorName,D006801,15836666,,,6,Humans,N,
10133,DescriptorName,D006854,15836666,,,7,Hydrocortisone,N,
10134,QualifierName,Q000627,15836666,,,7,,N,therapeutic use
10135,DescriptorName,D008297,15836666,,,8,Male,N,
10136,DescriptorName,D008875,15836666,,,9,Middle Aged,N,
10137,DescriptorName,D009294,15836666,,,10,Narcotics,N,
10138,QualifierName,Q000008,15836666,,,10,,N,administration & dosage
10139,DescriptorName,D010148,15836666,,,11,"Pain, Intractable",N,
10140,QualifierName,Q000188,15836666,,,11,,N,drug therapy
10141,DescriptorName,D012585,15836666,,,12,Sciatica,N,
10142,QualifierName,Q000150,15836666,,,12,,N,complications
10143,Chemical,D014150,15840734,Antipsychotic Agents,0,,,,
10144,Chemical,D005476,15840734,Fluphenazine,S79426A41Z,,,,
10145,DescriptorName,D000328,15840734,,,1,Adult,N,
10146,DescriptorName,D014150,15840734,,,2,Antipsychotic Agents,N,
10147,QualifierName,Q000009,15840734,,,2,,N,adverse effects
10148,DescriptorName,D005476,15840734,,,3,Fluphenazine,N,
10149,QualifierName,Q000009,15840734,,,3,,Y,adverse effects
10150,DescriptorName,D006801,15840734,,,4,Humans,N,
10151,DescriptorName,D007273,15840734,,,5,"Injections, Intramuscular",N,
10152,DescriptorName,D008297,15840734,,,6,Male,N,
10153,DescriptorName,D009459,15840734,,,7,Neuroleptic Malignant Syndrome,N,
10154,QualifierName,Q000209,15840734,,,7,,Y,etiology
10155,DescriptorName,D012307,15840734,,,8,Risk Factors,N,
10156,DescriptorName,D012559,15840734,,,9,Schizophrenia,N,
10157,QualifierName,Q000188,15840734,,,9,,Y,drug therapy
10158,Chemical,D014640,1584367,Vancomycin,6Q205EH1VU,,,,
10159,Chemical,D002442,1584367,Ceftazidime,9M416Z9QNR,,,,
10160,DescriptorName,D002442,1584367,,,1,Ceftazidime,N,
10161,QualifierName,Q000627,1584367,,,1,,N,therapeutic use
10162,DescriptorName,D002552,1584367,,,2,Cerebral Ventricles,N,
10163,DescriptorName,D002555,1584367,,,3,Cerebrospinal Fluid,N,
10164,QualifierName,Q000166,1584367,,,3,,N,cytology
10165,DescriptorName,D002557,1584367,,,4,Cerebrospinal Fluid Shunts,N,
10166,QualifierName,Q000009,1584367,,,4,,N,adverse effects
10167,DescriptorName,D002675,1584367,,,5,"Child, Preschool",N,
10168,DescriptorName,D003616,1584367,,,6,Dandy-Walker Syndrome,N,
10169,QualifierName,Q000134,1584367,,,6,,Y,cerebrospinal fluid
10170,DescriptorName,D004359,1584367,,,7,"Drug Therapy, Combination",N,
10171,QualifierName,Q000627,1584367,,,7,,N,therapeutic use
10172,DescriptorName,D004660,1584367,,,8,Encephalitis,N,
10173,QualifierName,Q000150,1584367,,,8,,N,complications
10174,DescriptorName,D004802,1584367,,,9,Eosinophilia,N,
10175,QualifierName,Q000139,1584367,,,9,,Y,chemically induced
10176,DescriptorName,D005260,1584367,,,10,Female,N,
10177,DescriptorName,D005549,1584367,,,11,Foreign-Body Reaction,N,
10178,QualifierName,Q000134,1584367,,,11,,N,cerebrospinal fluid
10179,DescriptorName,D006801,1584367,,,12,Humans,N,
10180,DescriptorName,D007223,1584367,,,13,Infant,N,
10181,DescriptorName,D007276,1584367,,,14,"Injections, Intraventricular",N,
10182,DescriptorName,D013203,1584367,,,15,Staphylococcal Infections,N,
10183,QualifierName,Q000188,1584367,,,15,,N,drug therapy
10184,DescriptorName,D013212,1584367,,,16,Staphylococcus epidermidis,N,
10185,QualifierName,Q000302,1584367,,,16,,N,isolation & purification
10186,DescriptorName,D014640,1584367,,,17,Vancomycin,N,
10187,QualifierName,Q000008,1584367,,,17,,N,administration & dosage
10188,Chemical,D000813,15852680,Anilides,0,,,,
10189,Chemical,D000893,15852680,Anti-Inflammatory Agents,0,,,,
10190,Chemical,D018931,15852680,"Antineoplastic Agents, Hormonal",0,,,,
10191,Chemical,D009570,15852680,Nitriles,0,,,,
10192,Chemical,D014105,15852680,Tosyl Compounds,0,,,,
10193,Chemical,D008776,15852680,Methylprednisolone Hemisuccinate,5GMR90S4KN,,,,
10194,Chemical,C053541,15852680,bicalutamide,A0Z3NAU9DP,,,,
10195,Chemical,D016729,15852680,Leuprolide,EFY6W0M8TG,,,,
10196,DescriptorName,D000230,15852680,,,1,Adenocarcinoma,N,
10197,QualifierName,Q000188,15852680,,,1,,Y,drug therapy
10198,DescriptorName,D000368,15852680,,,2,Aged,N,
10199,DescriptorName,D000813,15852680,,,3,Anilides,N,
10200,QualifierName,Q000009,15852680,,,3,,N,adverse effects
10201,DescriptorName,D000893,15852680,,,4,Anti-Inflammatory Agents,N,
10202,QualifierName,Q000627,15852680,,,4,,N,therapeutic use
10203,DescriptorName,D018931,15852680,,,5,"Antineoplastic Agents, Hormonal",N,
10204,QualifierName,Q000009,15852680,,,5,,Y,adverse effects
10205,DescriptorName,D001859,15852680,,,6,Bone Neoplasms,N,
10206,QualifierName,Q000556,15852680,,,6,,N,secondary
10207,DescriptorName,D006801,15852680,,,7,Humans,N,
10208,DescriptorName,D016729,15852680,,,8,Leuprolide,N,
10209,QualifierName,Q000009,15852680,,,8,,N,adverse effects
10210,DescriptorName,D017563,15852680,,,9,"Lung Diseases, Interstitial",N,
10211,QualifierName,Q000139,15852680,,,9,,Y,chemically induced
10212,DescriptorName,D008297,15852680,,,10,Male,N,
10213,DescriptorName,D008776,15852680,,,11,Methylprednisolone Hemisuccinate,N,
10214,QualifierName,Q000627,15852680,,,11,,N,therapeutic use
10215,DescriptorName,D009570,15852680,,,12,Nitriles,N,
10216,DescriptorName,D011471,15852680,,,13,Prostatic Neoplasms,N,
10217,QualifierName,Q000188,15852680,,,13,,Y,drug therapy
10218,DescriptorName,D014105,15852680,,,14,Tosyl Compounds,N,
10219,Chemical,D000900,15857283,Anti-Bacterial Agents,0,,,,
10220,Chemical,D017828,15857283,Rifabutin,1W306TDA6S,,,,
10221,DescriptorName,D017088,15857283,,,1,AIDS-Related Opportunistic Infections,N,
10222,QualifierName,Q000517,15857283,,,1,,Y,prevention & control
10223,DescriptorName,D000328,15857283,,,2,Adult,N,
10224,DescriptorName,D000900,15857283,,,3,Anti-Bacterial Agents,N,
10225,QualifierName,Q000008,15857283,,,3,,N,administration & dosage
10226,DescriptorName,D002648,15857283,,,4,Child,N,
10227,DescriptorName,D003941,15857283,,,5,"Diagnostic Techniques, Ophthalmological",N,
10228,DescriptorName,D004334,15857283,,,6,Drug Administration Schedule,N,
10229,DescriptorName,D004728,15857283,,,7,"Endothelium, Corneal",N,
10230,QualifierName,Q000187,15857283,,,7,,Y,drug effects
10231,DescriptorName,D005260,15857283,,,8,Female,N,
10232,DescriptorName,D006801,15857283,,,9,Humans,N,
10233,DescriptorName,D008297,15857283,,,10,Male,N,
10234,DescriptorName,D008875,15857283,,,11,Middle Aged,N,
10235,DescriptorName,D015270,15857283,,,12,Mycobacterium avium-intracellulare Infection,N,
10236,QualifierName,Q000517,15857283,,,12,,Y,prevention & control
10237,DescriptorName,D012189,15857283,,,13,Retrospective Studies,N,
10238,DescriptorName,D017828,15857283,,,14,Rifabutin,N,
10239,QualifierName,Q000008,15857283,,,14,,N,administration & dosage
10240,DescriptorName,D014388,15857283,,,15,"Tuberculosis, Lymph Node",N,
10241,QualifierName,Q000188,15857283,,,15,,Y,drug therapy
10242,Chemical,D020845,15863610,Selective Estrogen Receptor Modulators,0,,,,
10243,Chemical,D020849,15863610,Raloxifene Hydrochloride,4F86W47BR6,,,,
10244,DescriptorName,D001707,15863610,,,1,"Biopsy, Needle",N,
10245,DescriptorName,D017024,15863610,,,2,"Chemotherapy, Adjuvant",N,
10246,DescriptorName,D003131,15863610,,,3,Combined Modality Therapy,N,
10247,DescriptorName,D005260,15863610,,,4,Female,N,
10248,DescriptorName,D005500,15863610,,,5,Follow-Up Studies,N,
10249,DescriptorName,D006801,15863610,,,6,Humans,N,
10250,DescriptorName,D007044,15863610,,,7,Hysterectomy,N,
10251,QualifierName,Q000379,15863610,,,7,,N,methods
10252,DescriptorName,D007150,15863610,,,8,Immunohistochemistry,N,
10253,DescriptorName,D008875,15863610,,,9,Middle Aged,N,
10254,DescriptorName,D018200,15863610,,,10,"Mixed Tumor, Mullerian",N,
10255,QualifierName,Q000139,15863610,,,10,,Y,chemically induced
10256,DescriptorName,D009367,15863610,,,11,Neoplasm Staging,N,
10257,DescriptorName,D015663,15863610,,,12,"Osteoporosis, Postmenopausal",N,
10258,QualifierName,Q000175,15863610,,,12,,N,diagnosis
10259,DescriptorName,D010052,15863610,,,13,Ovariectomy,N,
10260,QualifierName,Q000379,15863610,,,13,,N,methods
10261,DescriptorName,D018714,15863610,,,14,"Radiotherapy, Adjuvant",N,
10262,DescriptorName,D020849,15863610,,,15,Raloxifene Hydrochloride,N,
10263,QualifierName,Q000009,15863610,,,15,,Y,adverse effects
10264,DescriptorName,D020845,15863610,,,16,Selective Estrogen Receptor Modulators,N,
10265,QualifierName,Q000009,15863610,,,16,,Y,adverse effects
10266,DescriptorName,D016896,15863610,,,17,Treatment Outcome,N,
10267,DescriptorName,D014594,15863610,,,18,Uterine Neoplasms,N,
10268,QualifierName,Q000139,15863610,,,18,,Y,chemically induced
10269,Chemical,D009173,15866658,Mycophenolic Acid,HU9DX48N0T,,,,
10270,DescriptorName,D005260,15866658,,,1,Female,N,
10271,DescriptorName,D006084,15866658,,,2,Graft Rejection,N,
10272,QualifierName,Q000188,15866658,,,2,,N,drug therapy
10273,DescriptorName,D006801,15866658,,,3,Humans,N,
10274,DescriptorName,D016031,15866658,,,4,Liver Transplantation,N,
10275,QualifierName,Q000009,15866658,,,4,,Y,adverse effects
10276,DescriptorName,D008297,15866658,,,5,Male,N,
10277,DescriptorName,D008875,15866658,,,6,Middle Aged,N,
10278,DescriptorName,D009173,15866658,,,7,Mycophenolic Acid,N,
10279,QualifierName,Q000009,15866658,,,7,,N,adverse effects
10280,DescriptorName,D009503,15866658,,,8,Neutropenia,N,
10281,QualifierName,Q000139,15866658,,,8,,Y,chemically induced
10282,DescriptorName,D016896,15866658,,,9,Treatment Outcome,N,
10283,Chemical,D006454,15878975,Hemoglobins,0,,,,
10284,Chemical,D016756,15878975,"Immunoglobulins, Intravenous",0,,,,
10285,Chemical,D007518,15878975,Isoantibodies,0,,,,
10286,Chemical,C061961,15878975,RHO(D) antibody,0,,,,
10287,Chemical,D018029,15878975,Rho(D) Immune Globulin,0,,,,
10288,DescriptorName,D000208,15878975,,,1,Acute Disease,N,
10289,DescriptorName,D000328,15878975,,,2,Adult,N,
10290,DescriptorName,D000368,15878975,,,3,Aged,N,
10291,DescriptorName,D000369,15878975,,,4,"Aged, 80 and over",N,
10292,DescriptorName,D002648,15878975,,,5,Child,N,
10293,DescriptorName,D004211,15878975,,,6,Disseminated Intravascular Coagulation,N,
10294,QualifierName,Q000150,15878975,,,6,,Y,complications
10295,DescriptorName,D004305,15878975,,,7,"Dose-Response Relationship, Drug",N,
10296,DescriptorName,D005260,15878975,,,8,Female,N,
10297,DescriptorName,D006454,15878975,,,9,Hemoglobins,N,
10298,QualifierName,Q000032,15878975,,,9,,N,analysis
10299,DescriptorName,D006456,15878975,,,10,Hemoglobinuria,N,
10300,QualifierName,Q000150,15878975,,,10,,Y,complications
10301,DescriptorName,D006801,15878975,,,11,Humans,N,
10302,DescriptorName,D016756,15878975,,,12,"Immunoglobulins, Intravenous",N,
10303,QualifierName,Q000008,15878975,,,12,,N,administration & dosage
10304,DescriptorName,D007518,15878975,,,13,Isoantibodies,N,
10305,QualifierName,Q000008,15878975,,,13,,N,administration & dosage
10306,DescriptorName,D008297,15878975,,,14,Male,N,
10307,DescriptorName,D011696,15878975,,,15,"Purpura, Thrombocytopenic",N,
10308,QualifierName,Q000097,15878975,,,15,,N,blood
10309,DescriptorName,D018029,15878975,,,16,Rho(D) Immune Globulin,N,
10310,Chemical,D000911,15895899,"Antibodies, Monoclonal",0,,,,
10311,Chemical,D018501,15895899,Antirheumatic Agents,0,,,,
10312,Chemical,D001323,15895899,Autoantibodies,0,,,,
10313,Chemical,D011994,15895899,Recombinant Proteins,0,,,,
10314,Chemical,D014409,15895899,Tumor Necrosis Factor-alpha,0,,,,
10315,Chemical,D016179,15895899,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
10316,Chemical,D000069285,15895899,Infliximab,B72HH48FLU,,,,
10317,Chemical,D000069585,15895899,Filgrastim,PVI5M0M1GW,,,,
10318,DescriptorName,D000328,15895899,,,1,Adult,N,
10319,DescriptorName,D000911,15895899,,,2,"Antibodies, Monoclonal",N,
10320,QualifierName,Q000009,15895899,,,2,,Y,adverse effects
10321,DescriptorName,D018501,15895899,,,3,Antirheumatic Agents,N,
10322,QualifierName,Q000009,15895899,,,3,,Y,adverse effects
10323,DescriptorName,D001323,15895899,,,4,Autoantibodies,N,
10324,QualifierName,Q000276,15895899,,,4,,N,immunology
10325,DescriptorName,D015551,15895899,,,5,Autoimmunity,N,
10326,DescriptorName,D003424,15895899,,,6,Crohn Disease,N,
10327,QualifierName,Q000150,15895899,,,6,,Y,complications
10328,DescriptorName,D000069585,15895899,,,7,Filgrastim,N,
10329,DescriptorName,D016179,15895899,,,8,Granulocyte Colony-Stimulating Factor,N,
10330,QualifierName,Q000627,15895899,,,8,,N,therapeutic use
10331,DescriptorName,D006801,15895899,,,9,Humans,N,
10332,DescriptorName,D000069285,15895899,,,10,Infliximab,N,
10333,DescriptorName,D008297,15895899,,,11,Male,N,
10334,DescriptorName,D009503,15895899,,,12,Neutropenia,N,
10335,QualifierName,Q000139,15895899,,,12,,Y,chemically induced
10336,DescriptorName,D011994,15895899,,,13,Recombinant Proteins,N,
10337,DescriptorName,D025242,15895899,,,14,Spondylarthropathies,N,
10338,QualifierName,Q000150,15895899,,,14,,Y,complications
10339,DescriptorName,D016896,15895899,,,15,Treatment Outcome,N,
10340,DescriptorName,D014409,15895899,,,16,Tumor Necrosis Factor-alpha,N,
10341,QualifierName,Q000037,15895899,,,16,,Y,antagonists & inhibitors
10342,Chemical,D000081,15907341,Acetamides,0,,,,
10343,Chemical,D000890,15907341,Anti-Infective Agents,0,,,,
10344,Chemical,D023303,15907341,Oxazolidinones,0,,,,
10345,Chemical,D000069349,15907341,Linezolid,ISQ9I6J12J,,,,
10346,DescriptorName,D000081,15907341,,,1,Acetamides,N,
10347,QualifierName,Q000009,15907341,,,1,,Y,adverse effects
10348,DescriptorName,D000328,15907341,,,2,Adult,N,
10349,DescriptorName,D000740,15907341,,,3,Anemia,N,
10350,QualifierName,Q000139,15907341,,,3,,Y,chemically induced
10351,DescriptorName,D000890,15907341,,,4,Anti-Infective Agents,N,
10352,QualifierName,Q000009,15907341,,,4,,Y,adverse effects
10353,DescriptorName,D001855,15907341,,,5,Bone Marrow Diseases,N,
10354,QualifierName,Q000139,15907341,,,5,,Y,chemically induced
10355,DescriptorName,D004359,15907341,,,6,"Drug Therapy, Combination",N,
10356,DescriptorName,D005260,15907341,,,7,Female,N,
10357,DescriptorName,D006801,15907341,,,8,Humans,N,
10358,DescriptorName,D000069349,15907341,,,9,Linezolid,N,
10359,DescriptorName,D008297,15907341,,,10,Male,N,
10360,DescriptorName,D008826,15907341,,,11,Microbial Sensitivity Tests,N,
10361,QualifierName,Q000379,15907341,,,11,,N,methods
10362,DescriptorName,D008875,15907341,,,12,Middle Aged,N,
10363,DescriptorName,D023303,15907341,,,13,Oxazolidinones,N,
10364,QualifierName,Q000009,15907341,,,13,,Y,adverse effects
10365,DescriptorName,D010523,15907341,,,14,Peripheral Nervous System Diseases,N,
10366,QualifierName,Q000139,15907341,,,14,,Y,chemically induced
10367,DescriptorName,D016896,15907341,,,15,Treatment Outcome,N,
10368,DescriptorName,D018088,15907341,,,16,"Tuberculosis, Multidrug-Resistant",N,
10369,QualifierName,Q000188,15907341,,,16,,Y,drug therapy
10370,Chemical,D018931,15920338,"Antineoplastic Agents, Hormonal",0,,,,
10371,Chemical,D013629,15920338,Tamoxifen,094ZI81Y45,,,,
10372,DescriptorName,D018931,15920338,,,1,"Antineoplastic Agents, Hormonal",N,
10373,QualifierName,Q000009,15920338,,,1,,Y,adverse effects
10374,DescriptorName,D001943,15920338,,,2,Breast Neoplasms,N,
10375,QualifierName,Q000188,15920338,,,2,,Y,drug therapy
10376,DescriptorName,D005260,15920338,,,3,Female,N,
10377,DescriptorName,D006801,15920338,,,4,Humans,N,
10378,DescriptorName,D007044,15920338,,,5,Hysterectomy,N,
10379,DescriptorName,D007150,15920338,,,6,Immunohistochemistry,N,
10380,DescriptorName,D008875,15920338,,,7,Middle Aged,N,
10381,DescriptorName,D016609,15920338,,,8,"Neoplasms, Second Primary",N,
10382,QualifierName,Q000139,15920338,,,8,,Y,chemically induced
10383,DescriptorName,D018203,15920338,,,9,"Sarcoma, Endometrial Stromal",N,
10384,QualifierName,Q000139,15920338,,,9,,Y,chemically induced
10385,DescriptorName,D013629,15920338,,,10,Tamoxifen,N,
10386,QualifierName,Q000009,15920338,,,10,,Y,adverse effects
10387,DescriptorName,D014594,15920338,,,11,Uterine Neoplasms,N,
10388,QualifierName,Q000139,15920338,,,11,,Y,chemically induced
10389,Chemical,D000935,15927910,Antifungal Agents,0,,,,
10390,Chemical,D010419,15927910,Pentamidine,673LC5J4LQ,,,,
10391,DescriptorName,D000935,15927910,,,1,Antifungal Agents,N,
10392,QualifierName,Q000009,15927910,,,1,,Y,adverse effects
10393,DescriptorName,D001919,15927910,,,2,Bradycardia,N,
10394,QualifierName,Q000139,15927910,,,2,,Y,chemically induced
10395,DescriptorName,D006327,15927910,,,3,Heart Block,N,
10396,QualifierName,Q000139,15927910,,,3,,Y,chemically induced
10397,DescriptorName,D006801,15927910,,,4,Humans,N,
10398,DescriptorName,D008297,15927910,,,5,Male,N,
10399,DescriptorName,D008875,15927910,,,6,Middle Aged,N,
10400,DescriptorName,D010419,15927910,,,7,Pentamidine,N,
10401,QualifierName,Q000009,15927910,,,7,,Y,adverse effects
10402,DescriptorName,D045363,15927910,,,8,Pneumocystis carinii,Y,
10403,DescriptorName,D011020,15927910,,,9,"Pneumonia, Pneumocystis",N,
10404,QualifierName,Q000188,15927910,,,9,,Y,drug therapy
10405,Chemical,D016642,1592841,Bupropion,01ZG3TPX31,,,,
10406,DescriptorName,D000367,1592841,,,1,Age Factors,N,
10407,DescriptorName,D000368,1592841,,,2,Aged,N,
10408,DescriptorName,D001480,1592841,,,3,Basal Ganglia Diseases,N,
10409,QualifierName,Q000139,1592841,,,3,,N,chemically induced
10410,DescriptorName,D016642,1592841,,,4,Bupropion,N,
10411,QualifierName,Q000009,1592841,,,4,,Y,adverse effects
10412,DescriptorName,D003866,1592841,,,5,Depressive Disorder,N,
10413,QualifierName,Q000188,1592841,,,5,,Y,drug therapy
10414,DescriptorName,D004409,1592841,,,6,"Dyskinesia, Drug-Induced",N,
10415,QualifierName,Q000209,1592841,,,6,,Y,etiology
10416,DescriptorName,D005260,1592841,,,7,Female,N,
10417,DescriptorName,D006801,1592841,,,8,Humans,N,
10418,DescriptorName,D010302,1592841,,,9,"Parkinson Disease, Secondary",N,
10419,QualifierName,Q000150,1592841,,,9,,N,complications
10420,DescriptorName,D011187,1592841,,,10,Posture,Y,
10421,Chemical,D000927,15941649,Anticonvulsants,0,,,,
10422,Chemical,D020888,15941649,Vigabatrin,GR120KRT6K,,,,
10423,DescriptorName,D000328,15941649,,,1,Adult,N,
10424,DescriptorName,D000927,15941649,,,2,Anticonvulsants,N,
10425,QualifierName,Q000009,15941649,,,2,,Y,adverse effects
10426,DescriptorName,D002648,15941649,,,3,Child,N,
10427,DescriptorName,D004827,15941649,,,4,Epilepsy,N,
10428,QualifierName,Q000188,15941649,,,4,,N,drug therapy
10429,DescriptorName,D005260,15941649,,,5,Female,N,
10430,DescriptorName,D007839,15941649,,,6,Functional Laterality,N,
10431,DescriptorName,D006801,15941649,,,7,Humans,N,
10432,DescriptorName,D008297,15941649,,,8,Male,N,
10433,DescriptorName,D009460,15941649,,,9,Neurologic Examination,N,
10434,QualifierName,Q000379,15941649,,,9,,N,methods
10435,DescriptorName,D011247,15941649,,,10,Pregnancy,N,
10436,DescriptorName,D011297,15941649,,,11,Prenatal Exposure Delayed Effects,Y,
10437,DescriptorName,D011930,15941649,,,12,Reaction Time,N,
10438,QualifierName,Q000187,15941649,,,12,,N,drug effects
10439,DescriptorName,D014599,15941649,,,13,Uterus,N,
10440,QualifierName,Q000187,15941649,,,13,,N,drug effects
10441,DescriptorName,D020888,15941649,,,14,Vigabatrin,N,
10442,QualifierName,Q000009,15941649,,,14,,Y,adverse effects
10443,DescriptorName,D014786,15941649,,,15,Vision Disorders,N,
10444,QualifierName,Q000209,15941649,,,15,,Y,etiology
10445,DescriptorName,D014792,15941649,,,16,Visual Acuity,N,
10446,QualifierName,Q000187,15941649,,,16,,N,drug effects
10447,DescriptorName,D014794,15941649,,,17,Visual Fields,N,
10448,QualifierName,Q000187,15941649,,,17,,N,drug effects
10449,Chemical,D016898,15944830,Interferon-alpha,0,,,,
10450,Chemical,D016899,15944830,Interferon-beta,77238-31-4,,,,
10451,DescriptorName,D000328,15944830,,,1,Adult,N,
10452,DescriptorName,D003941,15944830,,,2,"Diagnostic Techniques, Ophthalmological",N,
10453,DescriptorName,D019698,15944830,,,3,"Hepatitis C, Chronic",N,
10454,QualifierName,Q000188,15944830,,,3,,N,drug therapy
10455,DescriptorName,D006801,15944830,,,4,Humans,N,
10456,DescriptorName,D016898,15944830,,,5,Interferon-alpha,N,
10457,QualifierName,Q000009,15944830,,,5,,Y,adverse effects
10458,DescriptorName,D016899,15944830,,,6,Interferon-beta,N,
10459,QualifierName,Q000009,15944830,,,6,,Y,adverse effects
10460,DescriptorName,D015464,15944830,,,7,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
10461,QualifierName,Q000188,15944830,,,7,,N,drug therapy
10462,DescriptorName,D008269,15944830,,,8,Macular Edema,N,
10463,QualifierName,Q000139,15944830,,,8,,Y,chemically induced
10464,DescriptorName,D008297,15944830,,,9,Male,N,
10465,DescriptorName,D008875,15944830,,,10,Middle Aged,N,
10466,DescriptorName,D012160,15944830,,,11,Retina,N,
10467,QualifierName,Q000187,15944830,,,11,,Y,drug effects
10468,DescriptorName,D041623,15944830,,,12,"Tomography, Optical Coherence",Y,
10469,DescriptorName,D014786,15944830,,,13,Vision Disorders,N,
10470,QualifierName,Q000139,15944830,,,13,,N,chemically induced
10471,DescriptorName,D014792,15944830,,,14,Visual Acuity,N,
10472,Chemical,D000998,15961942,Antiviral Agents,0,,,,
10473,Chemical,D016898,15961942,Interferon-alpha,0,,,,
10474,Chemical,D012254,15961942,Ribavirin,49717AWG6K,,,,
10475,DescriptorName,D000998,15961942,,,1,Antiviral Agents,N,
10476,QualifierName,Q000009,15961942,,,1,,Y,adverse effects
10477,DescriptorName,D015551,15961942,,,2,Autoimmunity,Y,
10478,DescriptorName,D003920,15961942,,,3,Diabetes Mellitus,N,
10479,QualifierName,Q000139,15961942,,,3,,Y,chemically induced
10480,DescriptorName,D019698,15961942,,,4,"Hepatitis C, Chronic",N,
10481,QualifierName,Q000150,15961942,,,4,,N,complications
10482,DescriptorName,D006801,15961942,,,5,Humans,N,
10483,DescriptorName,D016898,15961942,,,6,Interferon-alpha,N,
10484,QualifierName,Q000009,15961942,,,6,,Y,adverse effects
10485,DescriptorName,D008297,15961942,,,7,Male,N,
10486,DescriptorName,D008875,15961942,,,8,Middle Aged,N,
10487,DescriptorName,D009850,15961942,,,9,Oman,N,
10488,DescriptorName,D012254,15961942,,,10,Ribavirin,N,
10489,QualifierName,Q000009,15961942,,,10,,Y,adverse effects
10490,DescriptorName,D016896,15961942,,,11,Treatment Outcome,N,
10491,Chemical,D000998,15965422,Antiviral Agents,0,,,,
10492,Chemical,D000077190,15965422,Interferon alpha-2,0,,,,
10493,Chemical,D016898,15965422,Interferon-alpha,0,,,,
10494,Chemical,D011994,15965422,Recombinant Proteins,0,,,,
10495,Chemical,D011092,15965422,Polyethylene Glycols,3WJQ0SDW1A,,,,
10496,Chemical,C417083,15965422,peginterferon alfa-2b,G8RGG88B68,,,,
10497,DescriptorName,D000368,15965422,,,1,Aged,N,
10498,DescriptorName,D000998,15965422,,,2,Antiviral Agents,N,
10499,QualifierName,Q000008,15965422,,,2,,N,administration & dosage
10500,DescriptorName,D005260,15965422,,,3,Female,N,
10501,DescriptorName,D019698,15965422,,,4,"Hepatitis C, Chronic",N,
10502,QualifierName,Q000188,15965422,,,4,,N,drug therapy
10503,DescriptorName,D006801,15965422,,,5,Humans,N,
10504,DescriptorName,D007267,15965422,,,6,Injections,N,
10505,DescriptorName,D000077190,15965422,,,7,Interferon alpha-2,N,
10506,DescriptorName,D016898,15965422,,,8,Interferon-alpha,N,
10507,QualifierName,Q000008,15965422,,,8,,N,administration & dosage
10508,DescriptorName,D015464,15965422,,,9,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
10509,QualifierName,Q000188,15965422,,,9,,N,drug therapy
10510,DescriptorName,D008297,15965422,,,10,Male,N,
10511,DescriptorName,D008875,15965422,,,11,Middle Aged,N,
10512,DescriptorName,D009336,15965422,,,12,Necrosis,N,
10513,QualifierName,Q000139,15965422,,,12,,N,chemically induced
10514,DescriptorName,D011092,15965422,,,13,Polyethylene Glycols,N,
10515,DescriptorName,D011994,15965422,,,14,Recombinant Proteins,N,
10516,DescriptorName,D012867,15965422,,,15,Skin,N,
10517,QualifierName,Q000473,15965422,,,15,,Y,pathology
10518,DescriptorName,D012883,15965422,,,16,Skin Ulcer,N,
10519,QualifierName,Q000139,15965422,,,16,,Y,chemically induced
10520,Chemical,D007211,15977922,Indoles,0,,,,
10521,Chemical,D058828,15977922,Serotonin 5-HT4 Receptor Agonists,0,,,,
10522,Chemical,D017366,15977922,Serotonin Receptor Agonists,0,,,,
10523,Chemical,C105050,15977922,tegaserod,458VC51857,,,,
10524,DescriptorName,D000328,15977922,,,1,Adult,N,
10525,DescriptorName,D017091,15977922,,,2,"Colitis, Ischemic",N,
10526,QualifierName,Q000139,15977922,,,2,,Y,chemically induced
10527,DescriptorName,D005260,15977922,,,3,Female,N,
10528,DescriptorName,D006801,15977922,,,4,Humans,N,
10529,DescriptorName,D007211,15977922,,,5,Indoles,N,
10530,QualifierName,Q000009,15977922,,,5,,Y,adverse effects
10531,DescriptorName,D043183,15977922,,,6,Irritable Bowel Syndrome,N,
10532,QualifierName,Q000150,15977922,,,6,,N,complications
10533,DescriptorName,D058828,15977922,,,7,Serotonin 5-HT4 Receptor Agonists,N,
10534,DescriptorName,D017366,15977922,,,8,Serotonin Receptor Agonists,N,
10535,QualifierName,Q000009,15977922,,,8,,Y,adverse effects
10536,Chemical,D053799,16001348,2-Pyridinylmethylsulfinylbenzimidazoles,0,,,,
10537,Chemical,D054328,16001348,Proton Pump Inhibitors,0,,,,
10538,Chemical,D064747,16001348,Lansoprazole,0K5C5T2QPG,,,,
10539,Chemical,D003094,16001348,Collagen,9007-34-5,,,,
10540,Chemical,D009853,16001348,Omeprazole,KG60484QX9,,,,
10541,DescriptorName,D053799,16001348,,,1,2-Pyridinylmethylsulfinylbenzimidazoles,N,
10542,DescriptorName,D001706,16001348,,,2,Biopsy,N,
10543,DescriptorName,D003092,16001348,,,3,Colitis,N,
10544,QualifierName,Q000139,16001348,,,3,,Y,chemically induced
10545,DescriptorName,D003094,16001348,,,4,Collagen,N,
10546,QualifierName,Q000648,16001348,,,4,,Y,ultrastructure
10547,DescriptorName,D003113,16001348,,,5,Colonoscopy,N,
10548,DescriptorName,D003937,16001348,,,6,"Diagnosis, Differential",N,
10549,DescriptorName,D003967,16001348,,,7,Diarrhea,N,
10550,QualifierName,Q000139,16001348,,,7,,Y,chemically induced
10551,DescriptorName,D005764,16001348,,,8,Gastroesophageal Reflux,N,
10552,QualifierName,Q000188,16001348,,,8,,N,drug therapy
10553,DescriptorName,D016481,16001348,,,9,Helicobacter Infections,N,
10554,QualifierName,Q000188,16001348,,,9,,Y,drug therapy
10555,DescriptorName,D016480,16001348,,,10,Helicobacter pylori,Y,
10556,DescriptorName,D006801,16001348,,,11,Humans,N,
10557,DescriptorName,D007413,16001348,,,12,Intestinal Mucosa,N,
10558,QualifierName,Q000187,16001348,,,12,,N,drug effects
10559,DescriptorName,D064747,16001348,,,13,Lansoprazole,N,
10560,DescriptorName,D008297,16001348,,,14,Male,N,
10561,DescriptorName,D008875,16001348,,,15,Middle Aged,N,
10562,DescriptorName,D009853,16001348,,,16,Omeprazole,N,
10563,QualifierName,Q000009,16001348,,,16,,N,adverse effects
10564,DescriptorName,D054328,16001348,,,17,Proton Pump Inhibitors,Y,
10565,Chemical,D000276,16008658,"Adjuvants, Immunologic",0,,,,
10566,Chemical,D017984,16008658,Enoxaparin,0,,,,
10567,Chemical,D005343,16008658,Fibrinolytic Agents,0,,,,
10568,Chemical,D000068576,16008658,Interferon beta-1b,145155-23-3,,,,
10569,Chemical,D003871,16008658,Dermatan Sulfate,24967-94-0,,,,
10570,Chemical,D016899,16008658,Interferon-beta,77238-31-4,,,,
10571,Chemical,D002809,16008658,Chondroitin Sulfates,9007-28-7,,,,
10572,Chemical,D006497,16008658,Heparitin Sulfate,9050-30-0,,,,
10573,Chemical,C035838,16008658,danaparoid,BI6GY4U9CW,,,,
10574,DescriptorName,D034861,16008658,,,1,Abdominal Wall,Y,
10575,DescriptorName,D000276,16008658,,,2,"Adjuvants, Immunologic",N,
10576,QualifierName,Q000008,16008658,,,2,,N,administration & dosage
10577,DescriptorName,D002809,16008658,,,3,Chondroitin Sulfates,N,
10578,QualifierName,Q000627,16008658,,,3,,N,therapeutic use
10579,DescriptorName,D003871,16008658,,,4,Dermatan Sulfate,N,
10580,QualifierName,Q000627,16008658,,,4,,N,therapeutic use
10581,DescriptorName,D017984,16008658,,,5,Enoxaparin,N,
10582,QualifierName,Q000627,16008658,,,5,,N,therapeutic use
10583,DescriptorName,D005260,16008658,,,6,Female,N,
10584,DescriptorName,D005343,16008658,,,7,Fibrinolytic Agents,N,
10585,QualifierName,Q000008,16008658,,,7,,N,administration & dosage
10586,DescriptorName,D006497,16008658,,,8,Heparitin Sulfate,N,
10587,QualifierName,Q000627,16008658,,,8,,N,therapeutic use
10588,DescriptorName,D006801,16008658,,,9,Humans,N,
10589,DescriptorName,D007279,16008658,,,10,"Injections, Subcutaneous",N,
10590,DescriptorName,D000068576,16008658,,,11,Interferon beta-1b,N,
10591,DescriptorName,D016899,16008658,,,12,Interferon-beta,N,
10592,QualifierName,Q000008,16008658,,,12,,N,administration & dosage
10593,DescriptorName,D008875,16008658,,,13,Middle Aged,N,
10594,DescriptorName,D017520,16008658,,,14,Mucinoses,N,
10595,QualifierName,Q000139,16008658,,,14,,Y,chemically induced
10596,DescriptorName,D009103,16008658,,,15,Multiple Sclerosis,N,
10597,QualifierName,Q000188,16008658,,,15,,N,drug therapy
10598,DescriptorName,D013927,16008658,,,16,Thrombosis,N,
10599,QualifierName,Q000139,16008658,,,16,,N,chemically induced
10600,DescriptorName,D016896,16008658,,,17,Treatment Outcome,N,
10601,DescriptorName,D014456,16008658,,,18,Ulcer,N,
10602,QualifierName,Q000139,16008658,,,18,,Y,chemically induced
10603,Chemical,D000935,16012330,Antifungal Agents,0,,,,
10604,Chemical,D000972,16012330,"Antineoplastic Agents, Phytogenic",0,,,,
10605,Chemical,D017964,16012330,Itraconazole,304NUG5GF4,,,,
10606,Chemical,D014750,16012330,Vincristine,5J49Q6B70F,,,,
10607,DescriptorName,D000935,16012330,,,1,Antifungal Agents,N,
10608,QualifierName,Q000627,16012330,,,1,,Y,therapeutic use
10609,DescriptorName,D000972,16012330,,,2,"Antineoplastic Agents, Phytogenic",N,
10610,QualifierName,Q000633,16012330,,,2,,Y,toxicity
10611,DescriptorName,D002675,16012330,,,3,"Child, Preschool",N,
10612,DescriptorName,D004336,16012330,,,4,Drug Antagonism,N,
10613,DescriptorName,D006801,16012330,,,5,Humans,N,
10614,DescriptorName,D017964,16012330,,,6,Itraconazole,N,
10615,QualifierName,Q000627,16012330,,,6,,Y,therapeutic use
10616,DescriptorName,D008297,16012330,,,7,Male,N,
10617,DescriptorName,D054198,16012330,,,8,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
10618,QualifierName,Q000188,16012330,,,8,,Y,drug therapy
10619,DescriptorName,D016896,16012330,,,9,Treatment Outcome,N,
10620,DescriptorName,D014750,16012330,,,10,Vincristine,N,
10621,QualifierName,Q000633,16012330,,,10,,Y,toxicity
10622,Chemical,D013566,16018164,Sympathomimetics,0,,,,
10623,Chemical,D004809,16018164,Ephedrine,GN83C131XS,,,,
10624,DescriptorName,D001929,16018164,,,1,Brain Edema,N,
10625,QualifierName,Q000209,16018164,,,1,,N,etiology
10626,DescriptorName,D015984,16018164,,,2,Causality,N,
10627,DescriptorName,D002533,16018164,,,3,Cerebral Angiography,N,
10628,DescriptorName,D002536,16018164,,,4,Cerebral Arteries,N,
10629,QualifierName,Q000473,16018164,,,4,,N,pathology
10630,DescriptorName,D015897,16018164,,,5,Comorbidity,N,
10631,DescriptorName,D004621,16018164,,,6,"Embolization, Therapeutic",N,
10632,DescriptorName,D004809,16018164,,,7,Ephedrine,N,
10633,QualifierName,Q000009,16018164,,,7,,Y,adverse effects
10634,DescriptorName,D006801,16018164,,,8,Humans,N,
10635,DescriptorName,D002538,16018164,,,9,Intracranial Arteriovenous Malformations,N,
10636,QualifierName,Q000473,16018164,,,9,,Y,pathology
10637,DescriptorName,D020299,16018164,,,10,"Intracranial Hemorrhage, Hypertensive",N,
10638,QualifierName,Q000139,16018164,,,10,,Y,chemically induced
10639,DescriptorName,D019586,16018164,,,11,Intracranial Hypertension,N,
10640,QualifierName,Q000139,16018164,,,11,,N,chemically induced
10641,DescriptorName,D008279,16018164,,,12,Magnetic Resonance Imaging,N,
10642,DescriptorName,D008297,16018164,,,13,Male,N,
10643,DescriptorName,D008875,16018164,,,14,Middle Aged,N,
10644,DescriptorName,D012852,16018164,,,15,Sinusitis,N,
10645,QualifierName,Q000188,16018164,,,15,,N,drug therapy
10646,DescriptorName,D013566,16018164,,,16,Sympathomimetics,N,
10647,QualifierName,Q000009,16018164,,,16,,Y,adverse effects
10648,DescriptorName,D014057,16018164,,,17,"Tomography, X-Ray Computed",N,
10649,DescriptorName,D016896,16018164,,,18,Treatment Outcome,N,
10650,Chemical,D014150,16025424,Antipsychotic Agents,0,,,,
10651,Chemical,D003987,16025424,Dibenzothiazepines,0,,,,
10652,Chemical,D000069348,16025424,Quetiapine Fumarate,2S3PL1B6UJ,,,,
10653,DescriptorName,D000368,16025424,,,1,Aged,N,
10654,DescriptorName,D000437,16025424,,,2,Alcoholism,N,
10655,QualifierName,Q000150,16025424,,,2,,N,complications
10656,DescriptorName,D014150,16025424,,,3,Antipsychotic Agents,N,
10657,QualifierName,Q000009,16025424,,,3,,Y,adverse effects
10658,DescriptorName,D003704,16025424,,,4,Dementia,N,
10659,QualifierName,Q000150,16025424,,,4,,N,complications
10660,DescriptorName,D003924,16025424,,,5,"Diabetes Mellitus, Type 2",N,
10661,QualifierName,Q000150,16025424,,,5,,N,complications
10662,DescriptorName,D016883,16025424,,,6,Diabetic Ketoacidosis,N,
10663,QualifierName,Q000139,16025424,,,6,,Y,chemically induced
10664,DescriptorName,D003987,16025424,,,7,Dibenzothiazepines,N,
10665,QualifierName,Q000009,16025424,,,7,,Y,adverse effects
10666,DescriptorName,D006801,16025424,,,8,Humans,N,
10667,DescriptorName,D008297,16025424,,,9,Male,N,
10668,DescriptorName,D000069348,16025424,,,10,Quetiapine Fumarate,N,
10669,Chemical,D014212,1602800,Tretinoin,5688UTC01R,,,,
10670,DescriptorName,D006801,1602800,,,1,Humans,N,
10671,DescriptorName,D015473,1602800,,,2,"Leukemia, Promyelocytic, Acute",N,
10672,QualifierName,Q000188,1602800,,,2,,Y,drug therapy
10673,DescriptorName,D007962,1602800,,,3,Leukocytes,N,
10674,QualifierName,Q000473,1602800,,,3,,Y,pathology
10675,DescriptorName,D008171,1602800,,,4,Lung Diseases,N,
10676,QualifierName,Q000139,1602800,,,4,,Y,chemically induced
10677,DescriptorName,D008297,1602800,,,5,Male,N,
10678,DescriptorName,D008875,1602800,,,6,Middle Aged,N,
10679,DescriptorName,D012074,1602800,,,7,Remission Induction,N,
10680,DescriptorName,D014212,1602800,,,8,Tretinoin,N,
10681,QualifierName,Q000009,1602800,,,8,,Y,adverse effects
10682,Chemical,D000634,16029707,Aminoquinolines,0,,,,
10683,Chemical,D000970,16029707,Antineoplastic Agents,0,,,,
10684,Chemical,D003879,16029707,Dermatologic Agents,0,,,,
10685,Chemical,D012176,16029707,Retinoids,0,,,,
10686,Chemical,D000077271,16029707,Imiquimod,P1QW714R7M,,,,
10687,DescriptorName,D000287,16029707,,,1,"Administration, Topical",N,
10688,DescriptorName,D000368,16029707,,,2,Aged,N,
10689,DescriptorName,D000634,16029707,,,3,Aminoquinolines,N,
10690,QualifierName,Q000008,16029707,,,3,,N,administration & dosage
10691,DescriptorName,D000970,16029707,,,4,Antineoplastic Agents,N,
10692,QualifierName,Q000008,16029707,,,4,,N,administration & dosage
10693,DescriptorName,D002280,16029707,,,5,"Carcinoma, Basal Cell",N,
10694,QualifierName,Q000188,16029707,,,5,,Y,drug therapy
10695,DescriptorName,D003879,16029707,,,6,Dermatologic Agents,N,
10696,QualifierName,Q000008,16029707,,,6,,N,administration & dosage
10697,DescriptorName,D005260,16029707,,,7,Female,N,
10698,DescriptorName,D006801,16029707,,,8,Humans,N,
10699,DescriptorName,D000077271,16029707,,,9,Imiquimod,N,
10700,DescriptorName,D012176,16029707,,,10,Retinoids,N,
10701,QualifierName,Q000008,16029707,,,10,,N,administration & dosage
10702,DescriptorName,D012871,16029707,,,11,Skin Diseases,N,
10703,QualifierName,Q000188,16029707,,,11,,N,drug therapy
10704,DescriptorName,D012878,16029707,,,12,Skin Neoplasms,N,
10705,QualifierName,Q000188,16029707,,,12,,Y,drug therapy
10706,DescriptorName,D016896,16029707,,,13,Treatment Outcome,N,
10707,Chemical,D000927,16035204,Anticonvulsants,0,,,,
10708,Chemical,D018687,16035204,"Antidepressive Agents, Second-Generation",0,,,,
10709,Chemical,D018757,16035204,GABA Modulators,0,,,,
10710,Chemical,D005473,16035204,Fluoxetine,01K63SUP8D,,,,
10711,Chemical,D003975,16035204,Diazepam,Q3JTX2Q7TU,,,,
10712,Chemical,D008874,16035204,Midazolam,R60L0SM5BC,,,,
10713,DescriptorName,D000328,16035204,,,1,Adult,N,
10714,DescriptorName,D000927,16035204,,,2,Anticonvulsants,N,
10715,QualifierName,Q000627,16035204,,,2,,N,therapeutic use
10716,DescriptorName,D018687,16035204,,,3,"Antidepressive Agents, Second-Generation",N,
10717,QualifierName,Q000097,16035204,,,3,,Y,blood
10718,DescriptorName,D001919,16035204,,,4,Bradycardia,N,
10719,QualifierName,Q000139,16035204,,,4,,N,chemically induced
10720,DescriptorName,D002675,16035204,,,5,"Child, Preschool",N,
10721,DescriptorName,D003975,16035204,,,6,Diazepam,N,
10722,QualifierName,Q000627,16035204,,,6,,N,therapeutic use
10723,DescriptorName,D004562,16035204,,,7,Electrocardiography,N,
10724,QualifierName,Q000187,16035204,,,7,,N,drug effects
10725,DescriptorName,D004830,16035204,,,8,"Epilepsy, Tonic-Clonic",N,
10726,QualifierName,Q000139,16035204,,,8,,N,chemically induced
10727,DescriptorName,D017809,16035204,,,9,Fatal Outcome,N,
10728,DescriptorName,D005473,16035204,,,10,Fluoxetine,N,
10729,QualifierName,Q000097,16035204,,,10,,Y,blood
10730,DescriptorName,D018757,16035204,,,11,GABA Modulators,N,
10731,QualifierName,Q000627,16035204,,,11,,N,therapeutic use
10732,DescriptorName,D006323,16035204,,,12,Heart Arrest,N,
10733,QualifierName,Q000139,16035204,,,12,,N,chemically induced
10734,DescriptorName,D006801,16035204,,,13,Humans,N,
10735,DescriptorName,D008297,16035204,,,14,Male,N,
10736,DescriptorName,D008874,16035204,,,15,Midazolam,N,
10737,QualifierName,Q000627,16035204,,,15,,N,therapeutic use
10738,DescriptorName,D009765,16035204,,,16,Obesity,N,
10739,QualifierName,Q000150,16035204,,,16,,N,complications
10740,DescriptorName,D014693,16035204,,,17,Ventricular Fibrillation,N,
10741,QualifierName,Q000139,16035204,,,17,,N,chemically induced
10742,Chemical,D005290,16044093,Ferric Compounds,0,,,,
10743,Chemical,D017262,16044093,Siderophores,0,,,,
10744,Chemical,D000077605,16044093,"Ferric Oxide, Saccharated",FZ7NYF5N8L,,,,
10745,Chemical,D003676,16044093,Deferoxamine,J06Y7MXW4D,,,,
10746,Chemical,D005937,16044093,Glucaric Acid,QLZ991V4A2,,,,
10747,DescriptorName,D018798,16044093,,,1,"Anemia, Iron-Deficiency",N,
10748,QualifierName,Q000175,16044093,,,1,,N,diagnosis
10749,DescriptorName,D056486,16044093,,,2,Chemical and Drug Induced Liver Injury,Y,
10750,DescriptorName,D002675,16044093,,,3,"Child, Preschool",N,
10751,DescriptorName,D003676,16044093,,,4,Deferoxamine,N,
10752,QualifierName,Q000627,16044093,,,4,,N,therapeutic use
10753,DescriptorName,D005290,16044093,,,5,Ferric Compounds,N,
10754,QualifierName,Q000008,16044093,,,5,,N,administration & dosage
10755,DescriptorName,D000077605,16044093,,,6,"Ferric Oxide, Saccharated",N,
10756,DescriptorName,D005767,16044093,,,7,Gastrointestinal Diseases,N,
10757,QualifierName,Q000139,16044093,,,7,,N,chemically induced
10758,DescriptorName,D005937,16044093,,,8,Glucaric Acid,N,
10759,DescriptorName,D006801,16044093,,,9,Humans,N,
10760,DescriptorName,D007262,16044093,,,10,"Infusions, Intravenous",N,
10761,DescriptorName,D008107,16044093,,,11,Liver Diseases,N,
10762,QualifierName,Q000150,16044093,,,11,,N,complications
10763,DescriptorName,D008297,16044093,,,12,Male,N,
10764,DescriptorName,D017262,16044093,,,13,Siderophores,N,
10765,QualifierName,Q000627,16044093,,,13,,N,therapeutic use
10766,DescriptorName,D016896,16044093,,,14,Treatment Outcome,N,
10767,Chemical,D007464,160443,Clioquinol,7BHQ856EJ5,,,,
10768,DescriptorName,D000328,160443,,,1,Adult,N,
10769,DescriptorName,D000647,160443,,,2,Amnesia,N,
10770,QualifierName,Q000139,160443,,,2,,Y,chemically induced
10771,DescriptorName,D007464,160443,,,3,Clioquinol,N,
10772,QualifierName,Q000009,160443,,,3,,Y,adverse effects
10773,DescriptorName,D003967,160443,,,4,Diarrhea,N,
10774,QualifierName,Q000188,160443,,,4,,N,drug therapy
10775,DescriptorName,D004305,160443,,,5,"Dose-Response Relationship, Drug",N,
10776,DescriptorName,D004569,160443,,,6,Electroencephalography,N,
10777,DescriptorName,D005071,160443,,,7,Evoked Potentials,N,
10778,QualifierName,Q000187,160443,,,7,,N,drug effects
10779,DescriptorName,D005260,160443,,,8,Female,N,
10780,DescriptorName,D006801,160443,,,9,Humans,N,
10781,DescriptorName,D008297,160443,,,10,Male,N,
10782,DescriptorName,D011939,160443,,,11,Mental Recall,N,
10783,QualifierName,Q000187,160443,,,11,,N,drug effects
10784,DescriptorName,D008875,160443,,,12,Middle Aged,N,
10785,DescriptorName,D009949,160443,,,13,Orientation,N,
10786,QualifierName,Q000187,160443,,,13,,N,drug effects
10787,Chemical,D000276,16046172,"Adjuvants, Immunologic",0,,,,
10788,Chemical,D000900,16046172,Anti-Bacterial Agents,0,,,,
10789,Chemical,D000893,16046172,Anti-Inflammatory Agents,0,,,,
10790,Chemical,D005938,16046172,Glucocorticoids,0,,,,
10791,Chemical,D006820,16046172,Hyaluronic Acid,9004-61-9,,,,
10792,Chemical,D010068,16046172,Oxacillin,UH95VD7V76,,,,
10793,DescriptorName,D000276,16046172,,,1,"Adjuvants, Immunologic",N,
10794,QualifierName,Q000008,16046172,,,1,,N,administration & dosage
10795,DescriptorName,D000368,16046172,,,2,Aged,N,
10796,DescriptorName,D000369,16046172,,,3,"Aged, 80 and over",N,
10797,DescriptorName,D000900,16046172,,,4,Anti-Bacterial Agents,N,
10798,QualifierName,Q000627,16046172,,,4,,N,therapeutic use
10799,DescriptorName,D000893,16046172,,,5,Anti-Inflammatory Agents,N,
10800,QualifierName,Q000627,16046172,,,5,,N,therapeutic use
10801,DescriptorName,D001170,16046172,,,6,"Arthritis, Infectious",N,
10802,QualifierName,Q000188,16046172,,,6,,N,drug therapy
10803,DescriptorName,D004359,16046172,,,7,"Drug Therapy, Combination",N,
10804,DescriptorName,D005260,16046172,,,8,Female,N,
10805,DescriptorName,D005938,16046172,,,9,Glucocorticoids,N,
10806,QualifierName,Q000627,16046172,,,9,,N,therapeutic use
10807,DescriptorName,D006801,16046172,,,10,Humans,N,
10808,DescriptorName,D006820,16046172,,,11,Hyaluronic Acid,N,
10809,QualifierName,Q000008,16046172,,,11,,N,administration & dosage
10810,DescriptorName,D007270,16046172,,,12,"Injections, Intra-Articular",N,
10811,DescriptorName,D007719,16046172,,,13,Knee Joint,N,
10812,QualifierName,Q000187,16046172,,,13,,N,drug effects
10813,DescriptorName,D042807,16046172,,,14,Neisseria mucosa,N,
10814,QualifierName,Q000302,16046172,,,14,,N,isolation & purification
10815,DescriptorName,D016870,16046172,,,15,Neisseriaceae Infections,N,
10816,QualifierName,Q000209,16046172,,,15,,Y,etiology
10817,DescriptorName,D020370,16046172,,,16,"Osteoarthritis, Knee",N,
10818,QualifierName,Q000150,16046172,,,16,,N,complications
10819,DescriptorName,D010068,16046172,,,17,Oxacillin,N,
10820,QualifierName,Q000627,16046172,,,17,,N,therapeutic use
10821,DescriptorName,D013203,16046172,,,18,Staphylococcal Infections,N,
10822,QualifierName,Q000209,16046172,,,18,,Y,etiology
10823,DescriptorName,D013211,16046172,,,19,Staphylococcus aureus,N,
10824,QualifierName,Q000302,16046172,,,19,,N,isolation & purification
10825,Chemical,D019380,16062101,Anti-HIV Agents,0,,,,
10826,Chemical,D019259,16062101,Lamivudine,2T8Q726O95,,,,
10827,DescriptorName,D000208,16062101,,,1,Acute Disease,N,
10828,DescriptorName,D000328,16062101,,,2,Adult,N,
10829,DescriptorName,D019380,16062101,,,3,Anti-HIV Agents,N,
10830,QualifierName,Q000009,16062101,,,3,,Y,adverse effects
10831,DescriptorName,D001415,16062101,,,4,Back,N,
10832,DescriptorName,D004421,16062101,,,5,Dystonia,N,
10833,QualifierName,Q000139,16062101,,,5,,Y,chemically induced
10834,DescriptorName,D019416,16062101,,,6,Head Movements,N,
10835,DescriptorName,D019694,16062101,,,7,"Hepatitis B, Chronic",N,
10836,QualifierName,Q000150,16062101,,,7,,N,complications
10837,DescriptorName,D006801,16062101,,,8,Humans,N,
10838,DescriptorName,D019259,16062101,,,9,Lamivudine,N,
10839,QualifierName,Q000009,16062101,,,9,,Y,adverse effects
10840,DescriptorName,D008297,16062101,,,10,Male,N,
10841,DescriptorName,D009334,16062101,,,11,Neck Muscles,N,
10842,QualifierName,Q000503,16062101,,,11,,N,physiopathology
10843,Chemical,D000978,16087771,Antiparkinson Agents,0,,,,
10844,Chemical,D052160,16087771,Benzothiazoles,0,,,,
10845,Chemical,D018491,16087771,Dopamine Agonists,0,,,,
10846,Chemical,D013844,16087771,Thiazoles,0,,,,
10847,Chemical,D010479,16087771,Pergolide,24MJ822NZ9,,,,
10848,Chemical,D000077487,16087771,Pramipexole,83619PEU5T,,,,
10849,DescriptorName,D000368,16087771,,,1,Aged,N,
10850,DescriptorName,D000978,16087771,,,2,Antiparkinson Agents,N,
10851,QualifierName,Q000009,16087771,,,2,,N,adverse effects
10852,DescriptorName,D052160,16087771,,,3,Benzothiazoles,N,
10853,DescriptorName,D018491,16087771,,,4,Dopamine Agonists,N,
10854,QualifierName,Q000009,16087771,,,4,,N,adverse effects
10855,DescriptorName,D004334,16087771,,,5,Drug Administration Schedule,N,
10856,DescriptorName,D006801,16087771,,,6,Humans,N,
10857,DescriptorName,D008168,16087771,,,7,Lung,N,
10858,QualifierName,Q000000981,16087771,,,7,,N,diagnostic imaging
10859,DescriptorName,D008297,16087771,,,8,Male,N,
10860,DescriptorName,D015394,16087771,,,9,Molecular Structure,N,
10861,DescriptorName,D010300,16087771,,,10,Parkinson Disease,N,
10862,QualifierName,Q000188,16087771,,,10,,N,drug therapy
10863,DescriptorName,D010479,16087771,,,11,Pergolide,N,
10864,QualifierName,Q000009,16087771,,,11,,Y,adverse effects
10865,DescriptorName,D010994,16087771,,,12,Pleura,N,
10866,QualifierName,Q000000981,16087771,,,12,,N,diagnostic imaging
10867,DescriptorName,D010995,16087771,,,13,Pleural Diseases,N,
10868,QualifierName,Q000139,16087771,,,13,,Y,chemically induced
10869,DescriptorName,D000077487,16087771,,,14,Pramipexole,N,
10870,DescriptorName,D011658,16087771,,,15,Pulmonary Fibrosis,N,
10871,QualifierName,Q000139,16087771,,,15,,Y,chemically induced
10872,DescriptorName,D013844,16087771,,,16,Thiazoles,N,
10873,QualifierName,Q000627,16087771,,,16,,N,therapeutic use
10874,DescriptorName,D014057,16087771,,,17,"Tomography, X-Ray Computed",N,
10875,Chemical,D018967,16092915,Risperidone,L6UH7ZF8HC,,,,
10876,DescriptorName,D000293,16092915,,,1,Adolescent,N,
10877,DescriptorName,D003866,16092915,,,2,Depressive Disorder,N,
10878,QualifierName,Q000139,16092915,,,2,,Y,chemically induced
10879,DescriptorName,D004830,16092915,,,3,"Epilepsy, Tonic-Clonic",N,
10880,QualifierName,Q000150,16092915,,,3,,N,complications
10881,DescriptorName,D005260,16092915,,,4,Female,N,
10882,DescriptorName,D006801,16092915,,,5,Humans,N,
10883,DescriptorName,D028361,16092915,,,6,Mitochondrial Diseases,N,
10884,QualifierName,Q000150,16092915,,,6,,Y,complications
10885,DescriptorName,D019964,16092915,,,7,Mood Disorders,N,
10886,QualifierName,Q000139,16092915,,,7,,N,chemically induced
10887,DescriptorName,D011605,16092915,,,8,"Psychoses, Substance-Induced",N,
10888,QualifierName,Q000523,16092915,,,8,,Y,psychology
10889,DescriptorName,D018967,16092915,,,9,Risperidone,N,
10890,QualifierName,Q000009,16092915,,,9,,Y,adverse effects
10891,Chemical,D002066,16097572,Busulfan,G1LN9045DK,,,,
10892,Chemical,D008558,16097572,Melphalan,Q41OR9510P,,,,
10893,DescriptorName,D000293,16097572,,,1,Adolescent,N,
10894,DescriptorName,D000971,16097572,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
10895,QualifierName,Q000627,16097572,,,2,,Y,therapeutic use
10896,DescriptorName,D001859,16097572,,,3,Bone Neoplasms,N,
10897,QualifierName,Q000188,16097572,,,3,,N,drug therapy
10898,DescriptorName,D002066,16097572,,,4,Busulfan,N,
10899,QualifierName,Q000008,16097572,,,4,,N,administration & dosage
10900,DescriptorName,D003131,16097572,,,5,Combined Modality Therapy,N,
10901,DescriptorName,D017809,16097572,,,6,Fatal Outcome,N,
10902,DescriptorName,D006801,16097572,,,7,Humans,N,
10903,DescriptorName,D008297,16097572,,,8,Male,N,
10904,DescriptorName,D008558,16097572,,,9,Melphalan,N,
10905,QualifierName,Q000008,16097572,,,9,,Y,administration & dosage
10906,DescriptorName,D011878,16097572,,,10,Radiotherapy,N,
10907,QualifierName,Q000009,16097572,,,10,,Y,adverse effects
10908,DescriptorName,D012512,16097572,,,11,"Sarcoma, Ewing",N,
10909,QualifierName,Q000188,16097572,,,11,,Y,drug therapy
10910,DescriptorName,D013116,16097572,,,12,Spinal Cord,N,
10911,QualifierName,Q000528,16097572,,,12,,N,radiation effects
10912,DescriptorName,D013118,16097572,,,13,Spinal Cord Diseases,N,
10913,QualifierName,Q000209,16097572,,,13,,Y,etiology
10914,Chemical,D003841,16109609,Deoxycytidine,0W860991D6,,,,
10915,Chemical,C056507,16109609,gemcitabine,B76N6SBZ8R,,,,
10916,DescriptorName,D000328,16109609,,,1,Adult,N,
10917,DescriptorName,D002305,16109609,,,2,Cardiac Tamponade,N,
10918,QualifierName,Q000139,16109609,,,2,,Y,chemically induced
10919,DescriptorName,D003841,16109609,,,3,Deoxycytidine,N,
10920,QualifierName,Q000009,16109609,,,3,,N,adverse effects
10921,DescriptorName,D005260,16109609,,,4,Female,N,
10922,DescriptorName,D006321,16109609,,,5,Heart,N,
10923,QualifierName,Q000528,16109609,,,5,,N,radiation effects
10924,DescriptorName,D006801,16109609,,,6,Humans,N,
10925,DescriptorName,D008223,16109609,,,7,Lymphoma,N,
10926,QualifierName,Q000188,16109609,,,7,,N,drug therapy
10927,DescriptorName,D008297,16109609,,,8,Male,N,
10928,DescriptorName,D008482,16109609,,,9,Mediastinum,N,
10929,QualifierName,Q000528,16109609,,,9,,N,radiation effects
10930,DescriptorName,D008875,16109609,,,10,Middle Aged,N,
10931,DescriptorName,D010490,16109609,,,11,Pericardial Effusion,N,
10932,QualifierName,Q000139,16109609,,,11,,Y,chemically induced
10933,DescriptorName,D011832,16109609,,,12,Radiation Injuries,N,
10934,QualifierName,Q000209,16109609,,,12,,N,etiology
10935,Chemical,D000911,16116136,"Antibodies, Monoclonal",0,,,,
10936,Chemical,D058846,16116136,"Antibodies, Monoclonal, Murine-Derived",0,,,,
10937,Chemical,D000970,16116136,Antineoplastic Agents,0,,,,
10938,Chemical,D007166,16116136,Immunosuppressive Agents,0,,,,
10939,Chemical,D000069283,16116136,Rituximab,4F4X42SYQ6,,,,
10940,Chemical,D009173,16116136,Mycophenolic Acid,HU9DX48N0T,,,,
10941,Chemical,D011729,16116136,Pyridostigmine Bromide,KVI301NA53,,,,
10942,Chemical,D011241,16116136,Prednisone,VB0R961HZT,,,,
10943,DescriptorName,D000369,16116136,,,1,"Aged, 80 and over",N,
10944,DescriptorName,D000911,16116136,,,2,"Antibodies, Monoclonal",N,
10945,QualifierName,Q000627,16116136,,,2,,N,therapeutic use
10946,DescriptorName,D058846,16116136,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
10947,DescriptorName,D000970,16116136,,,4,Antineoplastic Agents,N,
10948,QualifierName,Q000627,16116136,,,4,,N,therapeutic use
10949,DescriptorName,D001932,16116136,,,5,Brain Neoplasms,N,
10950,QualifierName,Q000139,16116136,,,5,,Y,chemically induced
10951,DescriptorName,D002471,16116136,,,6,"Cell Transformation, Neoplastic",N,
10952,QualifierName,Q000187,16116136,,,6,,N,drug effects
10953,DescriptorName,D004359,16116136,,,7,"Drug Therapy, Combination",N,
10954,DescriptorName,D005260,16116136,,,8,Female,N,
10955,DescriptorName,D005625,16116136,,,9,Frontal Lobe,N,
10956,QualifierName,Q000473,16116136,,,9,,N,pathology
10957,DescriptorName,D006801,16116136,,,10,Humans,N,
10958,DescriptorName,D007111,16116136,,,11,"Immunity, Cellular",N,
10959,QualifierName,Q000187,16116136,,,11,,N,drug effects
10960,DescriptorName,D007166,16116136,,,12,Immunosuppressive Agents,N,
10961,QualifierName,Q000009,16116136,,,12,,Y,adverse effects
10962,DescriptorName,D016393,16116136,,,13,"Lymphoma, B-Cell",N,
10963,QualifierName,Q000139,16116136,,,13,,Y,chemically induced
10964,DescriptorName,D008279,16116136,,,14,Magnetic Resonance Imaging,N,
10965,DescriptorName,D009157,16116136,,,15,Myasthenia Gravis,N,
10966,QualifierName,Q000150,16116136,,,15,,Y,complications
10967,DescriptorName,D009173,16116136,,,16,Mycophenolic Acid,N,
10968,QualifierName,Q000009,16116136,,,16,,N,adverse effects
10969,DescriptorName,D010296,16116136,,,17,Parietal Lobe,N,
10970,QualifierName,Q000473,16116136,,,17,,N,pathology
10971,DescriptorName,D011241,16116136,,,18,Prednisone,N,
10972,QualifierName,Q000627,16116136,,,18,,N,therapeutic use
10973,DescriptorName,D011729,16116136,,,19,Pyridostigmine Bromide,N,
10974,QualifierName,Q000627,16116136,,,19,,N,therapeutic use
10975,DescriptorName,D000069283,16116136,,,20,Rituximab,N,
10976,DescriptorName,D013601,16116136,,,21,T-Lymphocytes,N,
10977,QualifierName,Q000187,16116136,,,21,,N,drug effects
10978,DescriptorName,D016896,16116136,,,22,Treatment Outcome,N,
10979,Chemical,D009125,16119501,"Muscle Relaxants, Central",0,,,,
10980,Chemical,D001418,16119501,Baclofen,H789N3FKE8,,,,
10981,DescriptorName,D000328,16119501,,,1,Adult,N,
10982,DescriptorName,D001418,16119501,,,2,Baclofen,N,
10983,QualifierName,Q000009,16119501,,,2,,Y,adverse effects
10984,DescriptorName,D003937,16119501,,,3,"Diagnosis, Differential",N,
10985,DescriptorName,D004305,16119501,,,4,"Dose-Response Relationship, Drug",N,
10986,DescriptorName,D005260,16119501,,,5,Female,N,
10987,DescriptorName,D005334,16119501,,,6,Fever,N,
10988,QualifierName,Q000139,16119501,,,6,,Y,chemically induced
10989,DescriptorName,D006801,16119501,,,7,Humans,N,
10990,DescriptorName,D007362,16119501,,,8,Intensive Care Units,Y,
10991,DescriptorName,D009125,16119501,,,9,"Muscle Relaxants, Central",N,
10992,QualifierName,Q000009,16119501,,,9,,Y,adverse effects
10993,DescriptorName,D009456,16119501,,,10,Neurofibromatosis 1,N,
10994,QualifierName,Q000188,16119501,,,10,,N,drug therapy
10995,DescriptorName,D013375,16119501,,,11,Substance Withdrawal Syndrome,N,
10996,QualifierName,Q000175,16119501,,,11,,Y,diagnosis
10997,DescriptorName,D013997,16119501,,,12,Time Factors,N,
10998,Chemical,D000806,16132305,Angiotensin-Converting Enzyme Inhibitors,0,,,,
10999,Chemical,D000959,16132305,Antihypertensive Agents,0,,,,
11000,Chemical,D002216,16132305,Captopril,9G64RSX1XD,,,,
11001,DescriptorName,D000806,16132305,,,1,Angiotensin-Converting Enzyme Inhibitors,N,
11002,QualifierName,Q000009,16132305,,,1,,Y,adverse effects
11003,DescriptorName,D000959,16132305,,,2,Antihypertensive Agents,N,
11004,QualifierName,Q000009,16132305,,,2,,N,adverse effects
11005,DescriptorName,D002216,16132305,,,3,Captopril,N,
11006,QualifierName,Q000009,16132305,,,3,,Y,adverse effects
11007,DescriptorName,D004342,16132305,,,4,Drug Hypersensitivity,N,
11008,DescriptorName,D005260,16132305,,,5,Female,N,
11009,DescriptorName,D018610,16132305,,,6,"Heart Bypass, Right",N,
11010,DescriptorName,D006330,16132305,,,7,"Heart Defects, Congenital",N,
11011,QualifierName,Q000188,16132305,,,7,,Y,drug therapy
11012,DescriptorName,D006801,16132305,,,8,Humans,N,
11013,DescriptorName,D007223,16132305,,,9,Infant,N,
11014,DescriptorName,D011657,16132305,,,10,Pulmonary Eosinophilia,N,
11015,QualifierName,Q000139,16132305,,,10,,Y,chemically induced
11016,DescriptorName,D013902,16132305,,,11,"Radiography, Thoracic",N,
11017,Chemical,D018686,16146480,"Anesthetics, Intravenous",0,,,,
11018,Chemical,D000681,16146480,Amylases,EC 3.2.1.-,,,,
11019,Chemical,D015742,16146480,Propofol,YI7VU623SF,,,,
11020,DescriptorName,D000208,16146480,,,1,Acute Disease,N,
11021,DescriptorName,D000328,16146480,,,2,Adult,N,
11022,DescriptorName,D000681,16146480,,,3,Amylases,N,
11023,QualifierName,Q000097,16146480,,,3,,N,blood
11024,DescriptorName,D018686,16146480,,,4,"Anesthetics, Intravenous",N,
11025,QualifierName,Q000009,16146480,,,4,,Y,adverse effects
11026,DescriptorName,D003480,16146480,,,5,Cushing Syndrome,N,
11027,QualifierName,Q000150,16146480,,,5,,Y,complications
11028,DescriptorName,D005260,16146480,,,6,Female,N,
11029,DescriptorName,D006801,16146480,,,7,Humans,N,
11030,DescriptorName,D007016,16146480,,,8,Hypophysectomy,N,
11031,DescriptorName,D008297,16146480,,,9,Male,N,
11032,DescriptorName,D010146,16146480,,,10,Pain,N,
11033,QualifierName,Q000188,16146480,,,10,,N,drug therapy
11034,DescriptorName,D010195,16146480,,,11,Pancreatitis,N,
11035,QualifierName,Q000139,16146480,,,11,,Y,chemically induced
11036,DescriptorName,D011183,16146480,,,12,Postoperative Complications,N,
11037,QualifierName,Q000139,16146480,,,12,,Y,chemically induced
11038,DescriptorName,D015742,16146480,,,13,Propofol,N,
11039,QualifierName,Q000009,16146480,,,13,,Y,adverse effects
11040,DescriptorName,D014057,16146480,,,14,"Tomography, X-Ray Computed",N,
11041,DescriptorName,D014463,16146480,,,15,Ultrasonography,N,
11042,Chemical,D014150,16156485,Antipsychotic Agents,0,,,,
11043,Chemical,D008094,16156485,Lithium,9FN79X2M3F,,,,
11044,DescriptorName,D000328,16156485,,,1,Adult,N,
11045,DescriptorName,D000368,16156485,,,2,Aged,N,
11046,DescriptorName,D014150,16156485,,,3,Antipsychotic Agents,N,
11047,QualifierName,Q000008,16156485,,,3,,N,administration & dosage
11048,DescriptorName,D001714,16156485,,,4,Bipolar Disorder,N,
11049,QualifierName,Q000150,16156485,,,4,,N,complications
11050,DescriptorName,D001812,16156485,,,5,Blood-Brain Barrier,N,
11051,QualifierName,Q000187,16156485,,,5,,N,drug effects
11052,DescriptorName,D003131,16156485,,,6,Combined Modality Therapy,N,
11053,DescriptorName,D003865,16156485,,,7,"Depressive Disorder, Major",N,
11054,QualifierName,Q000150,16156485,,,7,,N,complications
11055,DescriptorName,D004565,16156485,,,8,Electroconvulsive Therapy,N,
11056,QualifierName,Q000009,16156485,,,8,,N,adverse effects
11057,DescriptorName,D005260,16156485,,,9,Female,N,
11058,DescriptorName,D006801,16156485,,,10,Humans,N,
11059,DescriptorName,D008094,16156485,,,11,Lithium,N,
11060,QualifierName,Q000008,16156485,,,11,,N,administration & dosage
11061,DescriptorName,D008297,16156485,,,12,Male,N,
11062,DescriptorName,D008875,16156485,,,13,Middle Aged,N,
11063,Chemical,D000911,16160485,"Antibodies, Monoclonal",0,,,,
11064,Chemical,D058846,16160485,"Antibodies, Monoclonal, Murine-Derived",0,,,,
11065,Chemical,D018951,16160485,"Antigens, CD20",0,,,,
11066,Chemical,D000970,16160485,Antineoplastic Agents,0,,,,
11067,Chemical,D000069283,16160485,Rituximab,4F4X42SYQ6,,,,
11068,DescriptorName,D000328,16160485,,,1,Adult,N,
11069,DescriptorName,D000911,16160485,,,2,"Antibodies, Monoclonal",N,
11070,QualifierName,Q000009,16160485,,,2,,N,adverse effects
11071,DescriptorName,D058846,16160485,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
11072,DescriptorName,D018951,16160485,,,4,"Antigens, CD20",N,
11073,QualifierName,Q000378,16160485,,,4,,Y,metabolism
11074,DescriptorName,D000970,16160485,,,5,Antineoplastic Agents,N,
11075,QualifierName,Q000009,16160485,,,5,,N,adverse effects
11076,DescriptorName,D006689,16160485,,,6,Hodgkin Disease,N,
11077,QualifierName,Q000188,16160485,,,6,,Y,drug therapy
11078,DescriptorName,D006801,16160485,,,7,Humans,N,
11079,DescriptorName,D007150,16160485,,,8,Immunohistochemistry,N,
11080,DescriptorName,D017403,16160485,,,9,In Situ Hybridization,N,
11081,DescriptorName,D007834,16160485,,,10,Lasers,N,
11082,DescriptorName,D008175,16160485,,,11,Lung Neoplasms,N,
11083,QualifierName,Q000139,16160485,,,11,,N,chemically induced
11084,DescriptorName,D016393,16160485,,,12,"Lymphoma, B-Cell",N,
11085,QualifierName,Q000139,16160485,,,12,,N,chemically induced
11086,DescriptorName,D008297,16160485,,,13,Male,N,
11087,DescriptorName,D042282,16160485,,,14,Microdissection,N,
11088,DescriptorName,D016609,16160485,,,15,"Neoplasms, Second Primary",N,
11089,QualifierName,Q000139,16160485,,,15,,N,chemically induced
11090,DescriptorName,D016133,16160485,,,16,Polymerase Chain Reaction,N,
11091,DescriptorName,D000069283,16160485,,,17,Rituximab,N,
11092,DescriptorName,D013601,16160485,,,18,T-Lymphocytes,N,
11093,QualifierName,Q000276,16160485,,,18,,Y,immunology
11094,Chemical,D007502,16167682,Iron Chelating Agents,0,,,,
11095,Chemical,D003676,16167682,Deferoxamine,J06Y7MXW4D,,,,
11096,DescriptorName,D000328,16167682,,,1,Adult,N,
11097,DescriptorName,D000741,16167682,,,2,"Anemia, Aplastic",N,
11098,QualifierName,Q000628,16167682,,,2,,N,therapy
11099,DescriptorName,D003676,16167682,,,3,Deferoxamine,N,
11100,QualifierName,Q000627,16167682,,,3,,Y,therapeutic use
11101,DescriptorName,D017809,16167682,,,4,Fatal Outcome,N,
11102,DescriptorName,D005260,16167682,,,5,Female,N,
11103,DescriptorName,D006486,16167682,,,6,Hemosiderosis,N,
11104,QualifierName,Q000175,16167682,,,6,,N,diagnosis
11105,DescriptorName,D006801,16167682,,,7,Humans,N,
11106,DescriptorName,D007502,16167682,,,8,Iron Chelating Agents,N,
11107,QualifierName,Q000627,16167682,,,8,,Y,therapeutic use
11108,DescriptorName,D065227,16167682,,,9,Transfusion Reaction,Y,
11109,DescriptorName,D017211,16167682,,,10,Treatment Failure,N,
11110,Chemical,D005938,16181292,Glucocorticoids,0,,,,
11111,Chemical,D017319,16181292,Photosensitizing Agents,0,,,,
11112,Chemical,D014222,16181292,Triamcinolone Acetonide,F446C597KA,,,,
11113,DescriptorName,D000368,16181292,,,1,Aged,N,
11114,DescriptorName,D001766,16181292,,,2,Blindness,N,
11115,QualifierName,Q000209,16181292,,,2,,Y,etiology
11116,DescriptorName,D002386,16181292,,,3,Cataract,N,
11117,QualifierName,Q000139,16181292,,,3,,Y,chemically induced
11118,DescriptorName,D002387,16181292,,,4,Cataract Extraction,N,
11119,QualifierName,Q000009,16181292,,,4,,Y,adverse effects
11120,DescriptorName,D004359,16181292,,,5,"Drug Therapy, Combination",N,
11121,DescriptorName,D005260,16181292,,,6,Female,N,
11122,DescriptorName,D005451,16181292,,,7,Fluorescein Angiography,N,
11123,DescriptorName,D005938,16181292,,,8,Glucocorticoids,N,
11124,QualifierName,Q000009,16181292,,,8,,N,adverse effects
11125,DescriptorName,D006801,16181292,,,9,Humans,N,
11126,DescriptorName,D007267,16181292,,,10,Injections,N,
11127,DescriptorName,D008268,16181292,,,11,Macular Degeneration,N,
11128,QualifierName,Q000188,16181292,,,11,,Y,drug therapy
11129,DescriptorName,D010778,16181292,,,12,Photochemotherapy,N,
11130,QualifierName,Q000009,16181292,,,12,,Y,adverse effects
11131,DescriptorName,D017319,16181292,,,13,Photosensitizing Agents,N,
11132,QualifierName,Q000009,16181292,,,13,,N,adverse effects
11133,DescriptorName,D014222,16181292,,,14,Triamcinolone Acetonide,N,
11134,QualifierName,Q000009,16181292,,,14,,Y,adverse effects
11135,DescriptorName,D014792,16181292,,,15,Visual Acuity,N,
11136,DescriptorName,D014822,16181292,,,16,Vitreous Body,N,
11137,Chemical,D015149,16192734,Tocolytic Agents,0,,,,
11138,Chemical,D003402,16192734,Creatine Kinase,EC 2.7.3.2,,,,
11139,Chemical,D012312,16192734,Ritodrine,I0Q6O6740J,,,,
11140,DescriptorName,D000328,16192734,,,1,Adult,N,
11141,DescriptorName,D003402,16192734,,,2,Creatine Kinase,N,
11142,QualifierName,Q000097,16192734,,,2,,N,blood
11143,DescriptorName,D004576,16192734,,,3,Electromyography,N,
11144,DescriptorName,D005260,16192734,,,4,Female,N,
11145,DescriptorName,D005865,16192734,,,5,Gestational Age,N,
11146,DescriptorName,D006801,16192734,,,6,Humans,N,
11147,DescriptorName,D007231,16192734,,,7,"Infant, Newborn",N,
11148,DescriptorName,D008297,16192734,,,8,Male,N,
11149,DescriptorName,D009223,16192734,,,9,Myotonic Dystrophy,N,
11150,QualifierName,Q000150,16192734,,,9,,Y,complications
11151,DescriptorName,D007752,16192734,,,10,"Obstetric Labor, Premature",N,
11152,QualifierName,Q000188,16192734,,,10,,N,drug therapy
11153,DescriptorName,D011247,16192734,,,11,Pregnancy,N,
11154,DescriptorName,D011248,16192734,,,12,Pregnancy Complications,Y,
11155,QualifierName,Q000139,16192734,,,12,,N,chemically induced
11156,DescriptorName,D011256,16192734,,,13,Pregnancy Outcome,N,
11157,DescriptorName,D012206,16192734,,,14,Rhabdomyolysis,N,
11158,QualifierName,Q000139,16192734,,,14,,Y,chemically induced
11159,DescriptorName,D012312,16192734,,,15,Ritodrine,N,
11160,QualifierName,Q000008,16192734,,,15,,N,administration & dosage
11161,DescriptorName,D015149,16192734,,,16,Tocolytic Agents,N,
11162,QualifierName,Q000009,16192734,,,16,,Y,adverse effects
11163,Chemical,D016756,16196187,"Immunoglobulins, Intravenous",0,,,,
11164,Chemical,D004837,16196187,Epinephrine,YKH834O4BH,,,,
11165,DescriptorName,D000208,16196187,,,1,Acute Disease,N,
11166,DescriptorName,D000293,16196187,,,2,Adolescent,N,
11167,DescriptorName,D004305,16196187,,,3,"Dose-Response Relationship, Drug",N,
11168,DescriptorName,D004562,16196187,,,4,Electrocardiography,N,
11169,DescriptorName,D004837,16196187,,,5,Epinephrine,N,
11170,QualifierName,Q000009,16196187,,,5,,Y,adverse effects
11171,DescriptorName,D005500,16196187,,,6,Follow-Up Studies,N,
11172,DescriptorName,D006801,16196187,,,7,Humans,N,
11173,DescriptorName,D006967,16196187,,,8,Hypersensitivity,N,
11174,QualifierName,Q000188,16196187,,,8,,N,drug therapy
11175,DescriptorName,D016756,16196187,,,9,"Immunoglobulins, Intravenous",N,
11176,QualifierName,Q000009,16196187,,,9,,Y,adverse effects
11177,DescriptorName,D007262,16196187,,,10,"Infusions, Intravenous",N,
11178,DescriptorName,D008297,16196187,,,11,Male,N,
11179,DescriptorName,D008508,16196187,,,12,Medication Errors,Y,
11180,DescriptorName,D017202,16196187,,,13,Myocardial Ischemia,N,
11181,QualifierName,Q000139,16196187,,,13,,Y,chemically induced
11182,DescriptorName,D018570,16196187,,,14,Risk Assessment,N,
11183,DescriptorName,D016511,16196187,,,15,Severe Combined Immunodeficiency,N,
11184,QualifierName,Q000175,16196187,,,15,,N,diagnosis
11185,DescriptorName,D016896,16196187,,,16,Treatment Outcome,N,
11186,Chemical,D000978,16200540,Antiparkinson Agents,0,,,,
11187,Chemical,D007980,16200540,Levodopa,46627O600J,,,,
11188,DescriptorName,D000368,16200540,,,1,Aged,N,
11189,DescriptorName,D000978,16200540,,,2,Antiparkinson Agents,N,
11190,QualifierName,Q000008,16200540,,,2,,N,administration & dosage
11191,DescriptorName,D018450,16200540,,,3,Disease Progression,N,
11192,DescriptorName,D004305,16200540,,,4,"Dose-Response Relationship, Drug",N,
11193,DescriptorName,D004334,16200540,,,5,Drug Administration Schedule,N,
11194,DescriptorName,D005260,16200540,,,6,Female,N,
11195,DescriptorName,D006801,16200540,,,7,Humans,N,
11196,DescriptorName,D007980,16200540,,,8,Levodopa,N,
11197,QualifierName,Q000008,16200540,,,8,,N,administration & dosage
11198,DescriptorName,D008657,16200540,,,9,Metabolic Clearance Rate,N,
11199,QualifierName,Q000502,16200540,,,9,,N,physiology
11200,DescriptorName,D017286,16200540,,,10,Polysomnography,Y,
11201,DescriptorName,D012148,16200540,,,11,Restless Legs Syndrome,N,
11202,QualifierName,Q000097,16200540,,,11,,N,blood
11203,DescriptorName,D013035,16200540,,,12,Spasm,N,
11204,QualifierName,Q000097,16200540,,,12,,N,blood
11205,Chemical,D000911,16204273,"Antibodies, Monoclonal",0,,,,
11206,Chemical,D003879,16204273,Dermatologic Agents,0,,,,
11207,Chemical,D014409,16204273,Tumor Necrosis Factor-alpha,0,,,,
11208,Chemical,D000069285,16204273,Infliximab,B72HH48FLU,,,,
11209,DescriptorName,D000328,16204273,,,1,Adult,N,
11210,DescriptorName,D000911,16204273,,,2,"Antibodies, Monoclonal",N,
11211,QualifierName,Q000009,16204273,,,2,,Y,adverse effects
11212,DescriptorName,D003879,16204273,,,3,Dermatologic Agents,N,
11213,QualifierName,Q000009,16204273,,,3,,Y,adverse effects
11214,DescriptorName,D003937,16204273,,,4,"Diagnosis, Differential",N,
11215,DescriptorName,D005260,16204273,,,5,Female,N,
11216,DescriptorName,D006801,16204273,,,6,Humans,N,
11217,DescriptorName,D000069285,16204273,,,7,Infliximab,N,
11218,DescriptorName,D007678,16204273,,,8,Kidney Glomerulus,N,
11219,QualifierName,Q000648,16204273,,,8,,N,ultrastructure
11220,DescriptorName,D008854,16204273,,,9,"Microscopy, Electron",N,
11221,DescriptorName,D009404,16204273,,,10,Nephrotic Syndrome,N,
11222,QualifierName,Q000139,16204273,,,10,,Y,chemically induced
11223,DescriptorName,D011565,16204273,,,11,Psoriasis,N,
11224,QualifierName,Q000188,16204273,,,11,,N,drug therapy
11225,DescriptorName,D012720,16204273,,,12,Severity of Illness Index,N,
11226,DescriptorName,D014409,16204273,,,13,Tumor Necrosis Factor-alpha,N,
11227,QualifierName,Q000276,16204273,,,13,,Y,immunology
11228,Chemical,D000081,16207263,Acetamides,0,,,,
11229,Chemical,D006454,16207263,Hemoglobins,0,,,,
11230,Chemical,D023303,16207263,Oxazolidinones,0,,,,
11231,Chemical,D011500,16207263,Protein Synthesis Inhibitors,0,,,,
11232,Chemical,D002701,16207263,Chloramphenicol,66974FR9Q1,,,,
11233,Chemical,D000069349,16207263,Linezolid,ISQ9I6J12J,,,,
11234,DescriptorName,D000081,16207263,,,1,Acetamides,N,
11235,QualifierName,Q000009,16207263,,,1,,Y,adverse effects
11236,DescriptorName,D000368,16207263,,,2,Aged,N,
11237,DescriptorName,D000743,16207263,,,3,"Anemia, Hemolytic",N,
11238,QualifierName,Q000097,16207263,,,3,,N,blood
11239,DescriptorName,D001853,16207263,,,4,Bone Marrow,N,
11240,QualifierName,Q000473,16207263,,,4,,N,pathology
11241,DescriptorName,D002701,16207263,,,5,Chloramphenicol,N,
11242,QualifierName,Q000009,16207263,,,5,,N,adverse effects
11243,DescriptorName,D004920,16207263,,,6,Erythropoiesis,N,
11244,QualifierName,Q000187,16207263,,,6,,Y,drug effects
11245,DescriptorName,D006454,16207263,,,7,Hemoglobins,N,
11246,QualifierName,Q000378,16207263,,,7,,N,metabolism
11247,DescriptorName,D006801,16207263,,,8,Humans,N,
11248,DescriptorName,D000069349,16207263,,,9,Linezolid,N,
11249,DescriptorName,D008297,16207263,,,10,Male,N,
11250,DescriptorName,D008875,16207263,,,11,Middle Aged,N,
11251,DescriptorName,D023303,16207263,,,12,Oxazolidinones,N,
11252,QualifierName,Q000009,16207263,,,12,,Y,adverse effects
11253,DescriptorName,D011500,16207263,,,13,Protein Synthesis Inhibitors,N,
11254,QualifierName,Q000009,16207263,,,13,,Y,adverse effects
11255,DescriptorName,D017701,16207263,,,14,Reticulocyte Count,N,
11256,DescriptorName,D012156,16207263,,,15,Reticulocytes,N,
11257,QualifierName,Q000187,16207263,,,15,,N,drug effects
11258,DescriptorName,D018805,16207263,,,16,Sepsis,N,
11259,QualifierName,Q000188,16207263,,,16,,N,drug therapy
11260,DescriptorName,D013203,16207263,,,17,Staphylococcal Infections,N,
11261,QualifierName,Q000188,16207263,,,17,,N,drug therapy
11262,Chemical,D000929,1621023,"Antidepressive Agents, Tricyclic",0,,,,
11263,Chemical,D005473,1621023,Fluoxetine,01K63SUP8D,,,,
11264,DescriptorName,D000328,1621023,,,1,Adult,N,
11265,DescriptorName,D000929,1621023,,,2,"Antidepressive Agents, Tricyclic",N,
11266,QualifierName,Q000009,1621023,,,2,,N,adverse effects
11267,DescriptorName,D001143,1621023,,,3,Arousal,N,
11268,QualifierName,Q000187,1621023,,,3,,N,drug effects
11269,DescriptorName,D001921,1621023,,,4,Brain,N,
11270,QualifierName,Q000187,1621023,,,4,,N,drug effects
11271,DescriptorName,D003866,1621023,,,5,Depressive Disorder,N,
11272,QualifierName,Q000188,1621023,,,5,,Y,drug therapy
11273,DescriptorName,D004325,1621023,,,6,Dreams,N,
11274,QualifierName,Q000187,1621023,,,6,,N,drug effects
11275,DescriptorName,D004569,1621023,,,7,Electroencephalography,N,
11276,QualifierName,Q000187,1621023,,,7,,N,drug effects
11277,DescriptorName,D004585,1621023,,,8,Electrooculography,N,
11278,QualifierName,Q000187,1621023,,,8,,N,drug effects
11279,DescriptorName,D005133,1621023,,,9,Eye Movements,N,
11280,QualifierName,Q000187,1621023,,,9,,Y,drug effects
11281,DescriptorName,D005260,1621023,,,10,Female,N,
11282,DescriptorName,D005473,1621023,,,11,Fluoxetine,N,
11283,QualifierName,Q000009,1621023,,,11,,Y,adverse effects
11284,DescriptorName,D006801,1621023,,,12,Humans,N,
11285,DescriptorName,D008297,1621023,,,13,Male,N,
11286,DescriptorName,D008875,1621023,,,14,Middle Aged,N,
11287,DescriptorName,D009043,1621023,,,15,Motor Activity,N,
11288,QualifierName,Q000187,1621023,,,15,,N,drug effects
11289,DescriptorName,D009771,1621023,,,16,Obsessive-Compulsive Disorder,N,
11290,QualifierName,Q000188,1621023,,,16,,Y,drug therapy
11291,DescriptorName,D012894,1621023,,,17,Sleep Stages,N,
11292,QualifierName,Q000187,1621023,,,17,,Y,drug effects
11293,DescriptorName,D012893,1621023,,,18,Sleep Wake Disorders,N,
11294,QualifierName,Q000139,1621023,,,18,,Y,chemically induced
11295,DescriptorName,D012895,1621023,,,19,"Sleep, REM",N,
11296,QualifierName,Q000187,1621023,,,19,,Y,drug effects
11297,Chemical,D000889,16211208,Anti-Arrhythmia Agents,0,,,,
11298,Chemical,D010627,16211208,Phenethylamines,0,,,,
11299,Chemical,D013449,16211208,Sulfonamides,0,,,,
11300,Chemical,C063533,16211208,dofetilide,R4Z9X1N2ND,,,,
11301,DescriptorName,D000368,16211208,,,1,Aged,N,
11302,DescriptorName,D000889,16211208,,,2,Anti-Arrhythmia Agents,N,
11303,QualifierName,Q000009,16211208,,,2,,Y,adverse effects
11304,DescriptorName,D001281,16211208,,,3,Atrial Fibrillation,N,
11305,QualifierName,Q000188,16211208,,,3,,Y,drug therapy
11306,DescriptorName,D004562,16211208,,,4,Electrocardiography,N,
11307,QualifierName,Q000187,16211208,,,4,,Y,drug effects
11308,DescriptorName,D006801,16211208,,,5,Humans,N,
11309,DescriptorName,D008297,16211208,,,6,Male,N,
11310,DescriptorName,D017202,16211208,,,7,Myocardial Ischemia,N,
11311,QualifierName,Q000150,16211208,,,7,,Y,complications
11312,DescriptorName,D010627,16211208,,,8,Phenethylamines,N,
11313,QualifierName,Q000009,16211208,,,8,,Y,adverse effects
11314,DescriptorName,D013449,16211208,,,9,Sulfonamides,N,
11315,QualifierName,Q000009,16211208,,,9,,Y,adverse effects
11316,DescriptorName,D016171,16211208,,,10,Torsades de Pointes,N,
11317,QualifierName,Q000139,16211208,,,10,,Y,chemically induced
11318,Chemical,D000959,16216617,Antihypertensive Agents,0,,,,
11319,Chemical,D010656,16216617,Phenylephrine,1WS297W6MV,,,,
11320,DescriptorName,D000368,16216617,,,1,Aged,N,
11321,DescriptorName,D000959,16216617,,,2,Antihypertensive Agents,N,
11322,QualifierName,Q000008,16216617,,,2,,N,administration & dosage
11323,DescriptorName,D001145,16216617,,,3,"Arrhythmias, Cardiac",N,
11324,QualifierName,Q000139,16216617,,,3,,Y,chemically induced
11325,DescriptorName,D002545,16216617,,,4,Brain Ischemia,N,
11326,QualifierName,Q000150,16216617,,,4,,N,complications
11327,DescriptorName,D004562,16216617,,,5,Electrocardiography,N,
11328,QualifierName,Q000187,16216617,,,5,,Y,drug effects
11329,DescriptorName,D005260,16216617,,,6,Female,N,
11330,DescriptorName,D006801,16216617,,,7,Humans,N,
11331,DescriptorName,D007275,16216617,,,8,"Injections, Intravenous",N,
11332,DescriptorName,D010656,16216617,,,9,Phenylephrine,N,
11333,QualifierName,Q000008,16216617,,,9,,Y,administration & dosage
11334,Chemical,D007166,16221163,Immunosuppressive Agents,0,,,,
11335,Chemical,D013256,16221163,Steroids,0,,,,
11336,Chemical,D016572,16221163,Cyclosporine,83HN0GTJ6D,,,,
11337,Chemical,D009173,16221163,Mycophenolic Acid,HU9DX48N0T,,,,
11338,Chemical,D020123,16221163,Sirolimus,W36ZG6FT64,,,,
11339,DescriptorName,D000208,16221163,,,1,Acute Disease,N,
11340,DescriptorName,D000328,16221163,,,2,Adult,N,
11341,DescriptorName,D056486,16221163,,,3,Chemical and Drug Induced Liver Injury,N,
11342,QualifierName,Q000209,16221163,,,3,,Y,etiology
11343,DescriptorName,D016572,16221163,,,4,Cyclosporine,N,
11344,QualifierName,Q000008,16221163,,,4,,N,administration & dosage
11345,DescriptorName,D004359,16221163,,,5,"Drug Therapy, Combination",N,
11346,DescriptorName,D006084,16221163,,,6,Graft Rejection,N,
11347,QualifierName,Q000188,16221163,,,6,,Y,drug therapy
11348,DescriptorName,D006801,16221163,,,7,Humans,N,
11349,DescriptorName,D007166,16221163,,,8,Immunosuppressive Agents,N,
11350,QualifierName,Q000008,16221163,,,8,,N,administration & dosage
11351,DescriptorName,D016030,16221163,,,9,Kidney Transplantation,Y,
11352,DescriptorName,D008297,16221163,,,10,Male,N,
11353,DescriptorName,D009173,16221163,,,11,Mycophenolic Acid,N,
11354,QualifierName,Q000008,16221163,,,11,,N,administration & dosage
11355,DescriptorName,D020123,16221163,,,12,Sirolimus,N,
11356,QualifierName,Q000008,16221163,,,12,,N,administration & dosage
11357,DescriptorName,D013256,16221163,,,13,Steroids,N,
11358,QualifierName,Q000008,16221163,,,13,,N,administration & dosage
11359,Chemical,D007370,16225183,Interferon Type I,0,,,,
11360,Chemical,D011994,16225183,Recombinant Proteins,0,,,,
11361,DescriptorName,D000328,16225183,,,1,Adult,N,
11362,DescriptorName,D015433,16225183,,,2,"Glomerulonephritis, Membranous",N,
11363,QualifierName,Q000139,16225183,,,2,,N,chemically induced
11364,DescriptorName,D006801,16225183,,,3,Humans,N,
11365,DescriptorName,D007370,16225183,,,4,Interferon Type I,N,
11366,QualifierName,Q000009,16225183,,,4,,Y,adverse effects
11367,DescriptorName,D007677,16225183,,,5,Kidney Function Tests,N,
11368,DescriptorName,D008279,16225183,,,6,Magnetic Resonance Imaging,N,
11369,DescriptorName,D008297,16225183,,,7,Male,N,
11370,DescriptorName,D020529,16225183,,,8,"Multiple Sclerosis, Relapsing-Remitting",N,
11371,QualifierName,Q000150,16225183,,,8,,Y,complications
11372,DescriptorName,D009404,16225183,,,9,Nephrotic Syndrome,N,
11373,QualifierName,Q000139,16225183,,,9,,Y,chemically induced
11374,DescriptorName,D011994,16225183,,,10,Recombinant Proteins,N,
11375,Chemical,D000964,16237130,"Antimetabolites, Antineoplastic",0,,,,
11376,Chemical,D003841,16237130,Deoxycytidine,0W860991D6,,,,
11377,Chemical,D000069287,16237130,Capecitabine,6804DJ8Z9U,,,,
11378,Chemical,D005472,16237130,Fluorouracil,U3P01618RT,,,,
11379,DescriptorName,D000328,16237130,,,1,Adult,N,
11380,DescriptorName,D000368,16237130,,,2,Aged,N,
11381,DescriptorName,D000964,16237130,,,3,"Antimetabolites, Antineoplastic",N,
11382,QualifierName,Q000009,16237130,,,3,,Y,adverse effects
11383,DescriptorName,D001921,16237130,,,4,Brain,N,
11384,QualifierName,Q000187,16237130,,,4,,Y,drug effects
11385,DescriptorName,D001943,16237130,,,5,Breast Neoplasms,N,
11386,QualifierName,Q000188,16237130,,,5,,N,drug therapy
11387,DescriptorName,D000069287,16237130,,,6,Capecitabine,N,
11388,DescriptorName,D002277,16237130,,,7,Carcinoma,N,
11389,QualifierName,Q000188,16237130,,,7,,N,drug therapy
11390,DescriptorName,D003841,16237130,,,8,Deoxycytidine,N,
11391,QualifierName,Q000009,16237130,,,8,,N,adverse effects
11392,DescriptorName,D005260,16237130,,,9,Female,N,
11393,DescriptorName,D005472,16237130,,,10,Fluorouracil,N,
11394,QualifierName,Q000031,16237130,,,10,,N,analogs & derivatives
11395,DescriptorName,D006801,16237130,,,11,Humans,N,
11396,DescriptorName,D008279,16237130,,,12,Magnetic Resonance Imaging,N,
11397,DescriptorName,D008875,16237130,,,13,Middle Aged,N,
11398,DescriptorName,D009362,16237130,,,14,Neoplasm Metastasis,N,
11399,QualifierName,Q000188,16237130,,,14,,N,drug therapy
11400,DescriptorName,D020258,16237130,,,15,Neurotoxicity Syndromes,N,
11401,QualifierName,Q000175,16237130,,,15,,Y,diagnosis
11402,DescriptorName,D010190,16237130,,,16,Pancreatic Neoplasms,N,
11403,QualifierName,Q000188,16237130,,,16,,N,drug therapy
11404,DescriptorName,D028761,16237130,,,17,Withholding Treatment,N,
11405,Chemical,D003511,16239768,Cyclohexanols,0,,,,
11406,Chemical,D017367,16239768,Serotonin Uptake Inhibitors,0,,,,
11407,Chemical,D012701,16239768,Serotonin,333DO1RDJY,,,,
11408,Chemical,D000069470,16239768,Venlafaxine Hydrochloride,7D7RX5A8MO,,,,
11409,DescriptorName,D003511,16239768,,,1,Cyclohexanols,N,
11410,QualifierName,Q000009,16239768,,,1,,Y,adverse effects
11411,DescriptorName,D003866,16239768,,,2,Depressive Disorder,N,
11412,QualifierName,Q000150,16239768,,,2,,N,complications
11413,DescriptorName,D005260,16239768,,,3,Female,N,
11414,DescriptorName,D006801,16239768,,,4,Humans,N,
11415,DescriptorName,D008875,16239768,,,5,Middle Aged,N,
11416,DescriptorName,D012701,16239768,,,6,Serotonin,N,
11417,QualifierName,Q000627,16239768,,,6,,Y,therapeutic use
11418,DescriptorName,D017367,16239768,,,7,Serotonin Uptake Inhibitors,N,
11419,QualifierName,Q000009,16239768,,,7,,Y,adverse effects
11420,DescriptorName,D014549,16239768,,,8,Urinary Incontinence,N,
11421,QualifierName,Q000139,16239768,,,8,,Y,chemically induced
11422,DescriptorName,D000069470,16239768,,,9,Venlafaxine Hydrochloride,N,
11423,Chemical,D007370,1624172,Interferon Type I,0,,,,
11424,Chemical,D011994,1624172,Recombinant Proteins,0,,,,
11425,Chemical,D013974,1624172,Thyroxine,Q51BO43MG4,,,,
11426,DescriptorName,D000328,1624172,,,1,Adult,N,
11427,DescriptorName,D002908,1624172,,,2,Chronic Disease,N,
11428,DescriptorName,D005260,1624172,,,3,Female,N,
11429,DescriptorName,D006526,1624172,,,4,Hepatitis C,N,
11430,QualifierName,Q000188,1624172,,,4,,Y,drug therapy
11431,DescriptorName,D006801,1624172,,,5,Humans,N,
11432,DescriptorName,D007037,1624172,,,6,Hypothyroidism,N,
11433,QualifierName,Q000139,1624172,,,6,,Y,chemically induced
11434,DescriptorName,D007370,1624172,,,7,Interferon Type I,N,
11435,QualifierName,Q000009,1624172,,,7,,Y,adverse effects
11436,DescriptorName,D011994,1624172,,,8,Recombinant Proteins,N,
11437,DescriptorName,D013974,1624172,,,9,Thyroxine,N,
11438,QualifierName,Q000627,1624172,,,9,,N,therapeutic use
11439,Chemical,D007093,16244351,Imidazoles,0,,,,
11440,Chemical,D010726,16244351,Phosphodiesterase Inhibitors,0,,,,
11441,Chemical,D010879,16244351,Piperazines,0,,,,
11442,Chemical,D013450,16244351,Sulfones,0,,,,
11443,Chemical,D014227,16244351,Triazines,0,,,,
11444,Chemical,D000069058,16244351,Vardenafil Dihydrochloride,5O8R96XMH7,,,,
11445,DescriptorName,D001281,16244351,,,1,Atrial Fibrillation,N,
11446,QualifierName,Q000139,16244351,,,1,,Y,chemically induced
11447,DescriptorName,D007172,16244351,,,2,Erectile Dysfunction,N,
11448,QualifierName,Q000188,16244351,,,2,,Y,drug therapy
11449,DescriptorName,D006801,16244351,,,3,Humans,N,
11450,DescriptorName,D007093,16244351,,,4,Imidazoles,N,
11451,QualifierName,Q000009,16244351,,,4,,Y,adverse effects
11452,DescriptorName,D008297,16244351,,,5,Male,N,
11453,DescriptorName,D008875,16244351,,,6,Middle Aged,N,
11454,DescriptorName,D010726,16244351,,,7,Phosphodiesterase Inhibitors,N,
11455,QualifierName,Q000009,16244351,,,7,,Y,adverse effects
11456,DescriptorName,D010879,16244351,,,8,Piperazines,N,
11457,QualifierName,Q000009,16244351,,,8,,Y,adverse effects
11458,DescriptorName,D013450,16244351,,,9,Sulfones,N,
11459,QualifierName,Q000009,16244351,,,9,,N,adverse effects
11460,DescriptorName,D014227,16244351,,,10,Triazines,N,
11461,QualifierName,Q000009,16244351,,,10,,N,adverse effects
11462,DescriptorName,D000069058,16244351,,,11,Vardenafil Dihydrochloride,N,
11463,Chemical,D000911,16249064,"Antibodies, Monoclonal",0,,,,
11464,Chemical,D014409,16249064,Tumor Necrosis Factor-alpha,0,,,,
11465,Chemical,D000069285,16249064,Infliximab,B72HH48FLU,,,,
11466,DescriptorName,D000368,16249064,,,1,Aged,N,
11467,DescriptorName,D000818,16249064,,,2,Animals,N,
11468,DescriptorName,D000911,16249064,,,3,"Antibodies, Monoclonal",N,
11469,QualifierName,Q000008,16249064,,,3,,N,administration & dosage
11470,DescriptorName,D001172,16249064,,,4,"Arthritis, Rheumatoid",N,
11471,QualifierName,Q000188,16249064,,,4,,Y,drug therapy
11472,DescriptorName,D005260,16249064,,,5,Female,N,
11473,DescriptorName,D006801,16249064,,,6,Humans,N,
11474,DescriptorName,D000069285,16249064,,,7,Infliximab,N,
11475,DescriptorName,D051379,16249064,,,8,Mice,N,
11476,DescriptorName,D009161,16249064,,,9,Mycobacterium,N,
11477,QualifierName,Q000145,16249064,,,9,,Y,classification
11478,DescriptorName,D009164,16249064,,,10,Mycobacterium Infections,N,
11479,QualifierName,Q000175,16249064,,,10,,Y,diagnosis
11480,DescriptorName,D014409,16249064,,,11,Tumor Necrosis Factor-alpha,N,
11481,QualifierName,Q000037,16249064,,,11,,Y,antagonists & inhibitors
11482,Chemical,D000970,16265343,Antineoplastic Agents,0,,,,
11483,Chemical,D000077190,16265343,Interferon alpha-2,0,,,,
11484,Chemical,D016898,16265343,Interferon-alpha,0,,,,
11485,Chemical,D011994,16265343,Recombinant Proteins,0,,,,
11486,DescriptorName,D000970,16265343,,,1,Antineoplastic Agents,N,
11487,QualifierName,Q000009,16265343,,,1,,Y,adverse effects
11488,DescriptorName,D009202,16265343,,,2,Cardiomyopathies,N,
11489,QualifierName,Q000139,16265343,,,2,,Y,chemically induced
11490,DescriptorName,D005500,16265343,,,3,Follow-Up Studies,N,
11491,DescriptorName,D006258,16265343,,,4,Head and Neck Neoplasms,N,
11492,QualifierName,Q000188,16265343,,,4,,N,drug therapy
11493,DescriptorName,D006333,16265343,,,5,Heart Failure,N,
11494,QualifierName,Q000139,16265343,,,5,,N,chemically induced
11495,DescriptorName,D006801,16265343,,,6,Humans,N,
11496,DescriptorName,D000077190,16265343,,,7,Interferon alpha-2,N,
11497,DescriptorName,D016898,16265343,,,8,Interferon-alpha,N,
11498,QualifierName,Q000009,16265343,,,8,,Y,adverse effects
11499,DescriptorName,D008297,16265343,,,9,Male,N,
11500,DescriptorName,D008545,16265343,,,10,Melanoma,N,
11501,QualifierName,Q000188,16265343,,,10,,N,drug therapy
11502,DescriptorName,D008875,16265343,,,11,Middle Aged,N,
11503,DescriptorName,D009205,16265343,,,12,Myocarditis,N,
11504,QualifierName,Q000139,16265343,,,12,,N,chemically induced
11505,DescriptorName,D011994,16265343,,,13,Recombinant Proteins,N,
11506,DescriptorName,D012878,16265343,,,14,Skin Neoplasms,N,
11507,QualifierName,Q000188,16265343,,,14,,N,drug therapy
11508,DescriptorName,D018487,16265343,,,15,"Ventricular Dysfunction, Left",N,
11509,QualifierName,Q000139,16265343,,,15,,N,chemically induced
11510,Chemical,D002400,16268429,Cathartics,0,,,,
11511,Chemical,D012676,16268429,Senna Extract,8013-11-4,,,,
11512,DescriptorName,D000368,16268429,,,1,Aged,N,
11513,DescriptorName,D001706,16268429,,,2,Biopsy,N,
11514,DescriptorName,D002400,16268429,,,3,Cathartics,N,
11515,QualifierName,Q000009,16268429,,,3,,Y,adverse effects
11516,DescriptorName,D056486,16268429,,,4,Chemical and Drug Induced Liver Injury,N,
11517,QualifierName,Q000209,16268429,,,4,,Y,etiology
11518,DescriptorName,D002780,16268429,,,5,"Cholestasis, Intrahepatic",N,
11519,QualifierName,Q000139,16268429,,,5,,Y,chemically induced
11520,DescriptorName,D002908,16268429,,,6,Chronic Disease,N,
11521,DescriptorName,D003248,16268429,,,7,Constipation,N,
11522,QualifierName,Q000188,16268429,,,7,,Y,drug therapy
11523,DescriptorName,D006801,16268429,,,8,Humans,N,
11524,DescriptorName,D008297,16268429,,,9,Male,N,
11525,DescriptorName,D012676,16268429,,,10,Senna Extract,N,
11526,QualifierName,Q000009,16268429,,,10,,Y,adverse effects
11527,Chemical,D007328,16284443,Insulin,0,,,,
11528,DescriptorName,D017667,16284443,,,1,Adipocytes,N,
11529,QualifierName,Q000473,16284443,,,1,,N,pathology
11530,DescriptorName,D000369,16284443,,,2,"Aged, 80 and over",N,
11531,DescriptorName,D003924,16284443,,,3,"Diabetes Mellitus, Type 2",N,
11532,QualifierName,Q000150,16284443,,,3,,N,complications
11533,DescriptorName,D005260,16284443,,,4,Female,N,
11534,DescriptorName,D006801,16284443,,,5,Humans,N,
11535,DescriptorName,D007328,16284443,,,6,Insulin,N,
11536,QualifierName,Q000009,16284443,,,6,,Y,adverse effects
11537,DescriptorName,D008060,16284443,,,7,Lipodystrophy,N,
11538,QualifierName,Q000139,16284443,,,7,,Y,chemically induced
11539,DescriptorName,D008855,16284443,,,8,"Microscopy, Electron, Scanning",N,
11540,Chemical,D001379,1628669,Azathioprine,MRK240IY2L,,,,
11541,Chemical,D011241,1628669,Prednisone,VB0R961HZT,,,,
11542,DescriptorName,D000744,1628669,,,1,"Anemia, Hemolytic, Autoimmune",N,
11543,QualifierName,Q000150,1628669,,,1,,Y,complications
11544,DescriptorName,D001379,1628669,,,2,Azathioprine,N,
11545,QualifierName,Q000009,1628669,,,2,,Y,adverse effects
11546,DescriptorName,D003920,1628669,,,3,Diabetes Mellitus,N,
11547,QualifierName,Q000139,1628669,,,3,,Y,chemically induced
11548,DescriptorName,D004357,1628669,,,4,Drug Synergism,N,
11549,DescriptorName,D010188,1628669,,,5,Exocrine Pancreatic Insufficiency,N,
11550,QualifierName,Q000139,1628669,,,5,,Y,chemically induced
11551,DescriptorName,D005260,1628669,,,6,Female,N,
11552,DescriptorName,D006801,1628669,,,7,Humans,N,
11553,DescriptorName,D007223,1628669,,,8,Infant,N,
11554,DescriptorName,D011241,1628669,,,9,Prednisone,N,
11555,QualifierName,Q000009,1628669,,,9,,Y,adverse effects
11556,Chemical,D010406,16288069,Penicillins,0,,,,
11557,Chemical,D010400,16288069,Penicillin G,Q42T66VG0C,,,,
11558,DescriptorName,D015658,16288069,,,1,HIV Infections,N,
11559,QualifierName,Q000150,16288069,,,1,,N,complications
11560,DescriptorName,D006679,16288069,,,2,HIV Seropositivity,N,
11561,DescriptorName,D006801,16288069,,,3,Humans,N,
11562,DescriptorName,D008297,16288069,,,4,Male,N,
11563,DescriptorName,D008875,16288069,,,5,Middle Aged,N,
11564,DescriptorName,D009494,16288069,,,6,Neurosyphilis,N,
11565,QualifierName,Q000150,16288069,,,6,,Y,complications
11566,DescriptorName,D010400,16288069,,,7,Penicillin G,N,
11567,QualifierName,Q000009,16288069,,,7,,Y,adverse effects
11568,DescriptorName,D010406,16288069,,,8,Penicillins,N,
11569,QualifierName,Q000009,16288069,,,8,,Y,adverse effects
11570,Chemical,D000911,16298824,"Antibodies, Monoclonal",0,,,,
11571,Chemical,D058846,16298824,"Antibodies, Monoclonal, Murine-Derived",0,,,,
11572,Chemical,D000970,16298824,Antineoplastic Agents,0,,,,
11573,Chemical,D000069283,16298824,Rituximab,4F4X42SYQ6,,,,
11574,DescriptorName,D000328,16298824,,,1,Adult,N,
11575,DescriptorName,D000911,16298824,,,2,"Antibodies, Monoclonal",N,
11576,QualifierName,Q000009,16298824,,,2,,Y,adverse effects
11577,DescriptorName,D058846,16298824,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
11578,DescriptorName,D000970,16298824,,,4,Antineoplastic Agents,N,
11579,QualifierName,Q000009,16298824,,,4,,Y,adverse effects
11580,DescriptorName,D017809,16298824,,,5,Fatal Outcome,N,
11581,DescriptorName,D006801,16298824,,,6,Humans,N,
11582,DescriptorName,D008223,16298824,,,7,Lymphoma,N,
11583,QualifierName,Q000188,16298824,,,7,,Y,drug therapy
11584,DescriptorName,D008297,16298824,,,8,Male,N,
11585,DescriptorName,D013902,16298824,,,9,"Radiography, Thoracic",N,
11586,DescriptorName,D012128,16298824,,,10,"Respiratory Distress Syndrome, Adult",N,
11587,QualifierName,Q000139,16298824,,,10,,Y,chemically induced
11588,DescriptorName,D000069283,16298824,,,11,Rituximab,N,
11589,DescriptorName,D014057,16298824,,,12,"Tomography, X-Ray Computed",N,
11590,Chemical,D050071,16313549,Bone Density Conservation Agents,0,,,,
11591,Chemical,D004164,16313549,Diphosphonates,0,,,,
11592,Chemical,D007093,16313549,Imidazoles,0,,,,
11593,Chemical,D000077211,16313549,Zoledronic Acid,6XC1PAD3KF,,,,
11594,Chemical,D002117,16313549,Calcitriol,FXC9231JVH,,,,
11595,Chemical,D002119,16313549,Calcium Carbonate,H0G9379FGK,,,,
11596,Chemical,D000077268,16313549,Pamidronate,OYY3447OMC,,,,
11597,DescriptorName,D058186,16313549,,,1,Acute Kidney Injury,N,
11598,QualifierName,Q000139,16313549,,,1,,N,chemically induced
11599,DescriptorName,D000368,16313549,,,2,Aged,N,
11600,DescriptorName,D050071,16313549,,,3,Bone Density Conservation Agents,N,
11601,QualifierName,Q000009,16313549,,,3,,Y,adverse effects
11602,DescriptorName,D002117,16313549,,,4,Calcitriol,N,
11603,QualifierName,Q000627,16313549,,,4,,N,therapeutic use
11604,DescriptorName,D002119,16313549,,,5,Calcium Carbonate,N,
11605,QualifierName,Q000627,16313549,,,5,,N,therapeutic use
11606,DescriptorName,D004164,16313549,,,6,Diphosphonates,N,
11607,QualifierName,Q000009,16313549,,,6,,Y,adverse effects
11608,DescriptorName,D017809,16313549,,,7,Fatal Outcome,N,
11609,DescriptorName,D005260,16313549,,,8,Female,N,
11610,DescriptorName,D006801,16313549,,,9,Humans,N,
11611,DescriptorName,D006996,16313549,,,10,Hypocalcemia,N,
11612,QualifierName,Q000097,16313549,,,10,,N,blood
11613,DescriptorName,D007093,16313549,,,11,Imidazoles,N,
11614,QualifierName,Q000009,16313549,,,11,,Y,adverse effects
11615,DescriptorName,D007275,16313549,,,12,"Injections, Intravenous",N,
11616,DescriptorName,D008275,16313549,,,13,Magnesium Deficiency,N,
11617,QualifierName,Q000097,16313549,,,13,,N,blood
11618,DescriptorName,D008297,16313549,,,14,Male,N,
11619,DescriptorName,D008875,16313549,,,15,Middle Aged,N,
11620,DescriptorName,D009101,16313549,,,16,Multiple Myeloma,N,
11621,QualifierName,Q000188,16313549,,,16,,Y,drug therapy
11622,DescriptorName,D000077268,16313549,,,17,Pamidronate,N,
11623,DescriptorName,D000077211,16313549,,,18,Zoledronic Acid,N,
11624,Chemical,D000964,16317298,"Antimetabolites, Antineoplastic",0,,,,
11625,Chemical,D003841,16317298,Deoxycytidine,0W860991D6,,,,
11626,Chemical,C056507,16317298,gemcitabine,B76N6SBZ8R,,,,
11627,DescriptorName,D000964,16317298,,,1,"Antimetabolites, Antineoplastic",N,
11628,QualifierName,Q000009,16317298,,,1,,Y,adverse effects
11629,DescriptorName,D003131,16317298,,,2,Combined Modality Therapy,N,
11630,DescriptorName,D003841,16317298,,,3,Deoxycytidine,N,
11631,QualifierName,Q000009,16317298,,,3,,N,adverse effects
11632,DescriptorName,D006471,16317298,,,4,Gastrointestinal Hemorrhage,N,
11633,QualifierName,Q000209,16317298,,,4,,N,etiology
11634,DescriptorName,D006801,16317298,,,5,Humans,N,
11635,DescriptorName,D008297,16317298,,,6,Male,N,
11636,DescriptorName,D008875,16317298,,,7,Middle Aged,N,
11637,DescriptorName,D010190,16317298,,,8,Pancreatic Neoplasms,N,
11638,QualifierName,Q000188,16317298,,,8,,Y,drug therapy
11639,DescriptorName,D011832,16317298,,,9,Radiation Injuries,Y,
11640,QualifierName,Q000503,16317298,,,9,,N,physiopathology
11641,Chemical,D002955,16326413,Leucovorin,Q573I9DVLP,,,,
11642,Chemical,D008727,16326413,Methotrexate,YL5FZ2Y5U1,,,,
11643,DescriptorName,D058186,16326413,,,1,Acute Kidney Injury,N,
11644,QualifierName,Q000139,16326413,,,1,,Y,chemically induced
11645,DescriptorName,D000293,16326413,,,2,Adolescent,N,
11646,DescriptorName,D000971,16326413,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
11647,QualifierName,Q000627,16326413,,,3,,N,therapeutic use
11648,DescriptorName,D016026,16326413,,,4,Bone Marrow Transplantation,N,
11649,DescriptorName,D006801,16326413,,,5,Humans,N,
11650,DescriptorName,D002955,16326413,,,6,Leucovorin,N,
11651,QualifierName,Q000627,16326413,,,6,,N,therapeutic use
11652,DescriptorName,D008297,16326413,,,7,Male,N,
11653,DescriptorName,D008727,16326413,,,8,Methotrexate,N,
11654,QualifierName,Q000009,16326413,,,8,,Y,adverse effects
11655,DescriptorName,D054198,16326413,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
11656,QualifierName,Q000150,16326413,,,9,,Y,complications
11657,DescriptorName,D016896,16326413,,,10,Treatment Outcome,N,
11658,Chemical,D001672,16341621,Biocompatible Materials,0,,,,
11659,Chemical,D017886,16341621,Durapatite,91D9GV0Z28,,,,
11660,DescriptorName,D001672,16341621,,,1,Biocompatible Materials,N,
11661,QualifierName,Q000008,16341621,,,1,,N,administration & dosage
11662,DescriptorName,D017886,16341621,,,2,Durapatite,N,
11663,QualifierName,Q000008,16341621,,,2,,N,administration & dosage
11664,DescriptorName,D005260,16341621,,,3,Female,N,
11665,DescriptorName,D015745,16341621,,,4,"Granuloma, Foreign-Body",N,
11666,QualifierName,Q000150,16341621,,,4,,Y,complications
11667,DescriptorName,D006801,16341621,,,5,Humans,N,
11668,DescriptorName,D008875,16341621,,,6,Middle Aged,N,
11669,DescriptorName,D009092,16341621,,,7,Mucous Membrane,N,
11670,DescriptorName,D011391,16341621,,,8,Prolapse,N,
11671,DescriptorName,D014521,16341621,,,9,Urethra,N,
11672,DescriptorName,D014522,16341621,,,10,Urethral Diseases,N,
11673,QualifierName,Q000209,16341621,,,10,,Y,etiology
11674,DescriptorName,D014550,16341621,,,11,"Urinary Incontinence, Stress",N,
11675,QualifierName,Q000188,16341621,,,11,,Y,drug therapy
11676,Chemical,D049994,16352777,Sodium Potassium Chloride Symporter Inhibitors,0,,,,
11677,Chemical,D013449,16352777,Sulfonamides,0,,,,
11678,DescriptorName,D009202,16352777,,,1,Cardiomyopathies,N,
11679,QualifierName,Q000150,16352777,,,1,,N,complications
11680,DescriptorName,D004342,16352777,,,2,Drug Hypersensitivity,N,
11681,QualifierName,Q000150,16352777,,,2,,N,complications
11682,DescriptorName,D005260,16352777,,,3,Female,N,
11683,DescriptorName,D006801,16352777,,,4,Humans,N,
11684,DescriptorName,D008875,16352777,,,5,Middle Aged,N,
11685,DescriptorName,D010195,16352777,,,6,Pancreatitis,N,
11686,QualifierName,Q000139,16352777,,,6,,Y,chemically induced
11687,DescriptorName,D049994,16352777,,,7,Sodium Potassium Chloride Symporter Inhibitors,N,
11688,QualifierName,Q000009,16352777,,,7,,Y,adverse effects
11689,DescriptorName,D013449,16352777,,,8,Sulfonamides,N,
11690,QualifierName,Q000276,16352777,,,8,,Y,immunology
11691,Chemical,D000925,16355099,Anticoagulants,0,,,,
11692,Chemical,D006493,16355099,Heparin,9005-49-6,,,,
11693,DescriptorName,D000925,16355099,,,1,Anticoagulants,N,
11694,QualifierName,Q000009,16355099,,,1,,Y,adverse effects
11695,DescriptorName,D005268,16355099,,,2,Femoral Vein,N,
11696,DescriptorName,D005500,16355099,,,3,Follow-Up Studies,N,
11697,DescriptorName,D006493,16355099,,,4,Heparin,N,
11698,QualifierName,Q000009,16355099,,,4,,Y,adverse effects
11699,DescriptorName,D006801,16355099,,,5,Humans,N,
11700,DescriptorName,D008297,16355099,,,6,Male,N,
11701,DescriptorName,D008875,16355099,,,7,Middle Aged,N,
11702,DescriptorName,D010690,16355099,,,8,Phlebography,N,
11703,DescriptorName,D011152,16355099,,,9,Popliteal Vein,N,
11704,DescriptorName,D011475,16355099,,,10,Prosthesis Failure,N,
11705,DescriptorName,D011655,16355099,,,11,Pulmonary Embolism,N,
11706,QualifierName,Q000000981,16355099,,,11,,N,diagnostic imaging
11707,DescriptorName,D013921,16355099,,,12,Thrombocytopenia,N,
11708,QualifierName,Q000139,16355099,,,12,,Y,chemically induced
11709,DescriptorName,D014057,16355099,,,13,"Tomography, X-Ray Computed",N,
11710,DescriptorName,D016306,16355099,,,14,Vena Cava Filters,N,
11711,QualifierName,Q000009,16355099,,,14,,Y,adverse effects
11712,DescriptorName,D014682,16355099,,,15,"Vena Cava, Inferior",Y,
11713,DescriptorName,D020246,16355099,,,16,Venous Thrombosis,N,
11714,QualifierName,Q000000981,16355099,,,16,,N,diagnostic imaging
11715,Chemical,D000527,1635565,Alprostadil,F5TD010360,,,,
11716,DescriptorName,D000527,1635565,,,1,Alprostadil,N,
11717,QualifierName,Q000008,1635565,,,1,,N,administration & dosage
11718,DescriptorName,D004373,1635565,,,2,Ductus Arteriosus,N,
11719,QualifierName,Q000187,1635565,,,2,,N,drug effects
11720,DescriptorName,D004452,1635565,,,3,Echocardiography,N,
11721,DescriptorName,D005260,1635565,,,4,Female,N,
11722,DescriptorName,D005753,1635565,,,5,Gastric Mucosa,N,
11723,QualifierName,Q000187,1635565,,,5,,N,drug effects
11724,DescriptorName,D006330,1635565,,,6,"Heart Defects, Congenital",N,
11725,QualifierName,Q000188,1635565,,,6,,N,drug therapy
11726,DescriptorName,D006801,1635565,,,7,Humans,N,
11727,DescriptorName,D006965,1635565,,,8,Hyperplasia,N,
11728,DescriptorName,D006976,1635565,,,9,"Hypertension, Pulmonary",N,
11729,QualifierName,Q000188,1635565,,,9,,N,drug therapy
11730,DescriptorName,D007231,1635565,,,10,"Infant, Newborn",N,
11731,DescriptorName,D007263,1635565,,,11,"Infusions, Parenteral",N,
11732,DescriptorName,D011706,1635565,,,12,Pyloric Antrum,N,
11733,QualifierName,Q000473,1635565,,,12,,N,pathology
11734,Chemical,D005938,16357738,Glucocorticoids,0,,,,
11735,Chemical,D007166,16357738,Immunosuppressive Agents,0,,,,
11736,Chemical,D014750,16357738,Vincristine,5J49Q6B70F,,,,
11737,Chemical,D016572,16357738,Cyclosporine,83HN0GTJ6D,,,,
11738,Chemical,D011239,16357738,Prednisolone,9PHQ9Y1OLM,,,,
11739,DescriptorName,D000328,16357738,,,1,Adult,N,
11740,DescriptorName,D001921,16357738,,,2,Brain,N,
11741,QualifierName,Q000473,16357738,,,2,,N,pathology
11742,DescriptorName,D016572,16357738,,,3,Cyclosporine,N,
11743,QualifierName,Q000008,16357738,,,3,,N,administration & dosage
11744,DescriptorName,D005260,16357738,,,4,Female,N,
11745,DescriptorName,D005938,16357738,,,5,Glucocorticoids,N,
11746,QualifierName,Q000627,16357738,,,5,,N,therapeutic use
11747,DescriptorName,D006801,16357738,,,6,Humans,N,
11748,DescriptorName,D020343,16357738,,,7,Hypertensive Encephalopathy,N,
11749,QualifierName,Q000139,16357738,,,7,,Y,chemically induced
11750,DescriptorName,D007166,16357738,,,8,Immunosuppressive Agents,N,
11751,QualifierName,Q000008,16357738,,,8,,N,administration & dosage
11752,DescriptorName,D008180,16357738,,,9,"Lupus Erythematosus, Systemic",N,
11753,QualifierName,Q000150,16357738,,,9,,N,complications
11754,DescriptorName,D008279,16357738,,,10,Magnetic Resonance Imaging,N,
11755,DescriptorName,D011239,16357738,,,11,Prednisolone,N,
11756,QualifierName,Q000627,16357738,,,11,,N,therapeutic use
11757,DescriptorName,D012640,16357738,,,12,Seizures,N,
11758,QualifierName,Q000139,16357738,,,12,,Y,chemically induced
11759,DescriptorName,D013921,16357738,,,13,Thrombocytopenia,N,
11760,QualifierName,Q000188,16357738,,,13,,N,drug therapy
11761,DescriptorName,D014750,16357738,,,14,Vincristine,N,
11762,QualifierName,Q000627,16357738,,,14,,N,therapeutic use
11763,Chemical,D011744,16368918,Pyrimidinones,0,,,,
11764,Chemical,D061466,16368918,Lopinavir,2494G1JF75,,,,
11765,Chemical,D014635,16368918,Valproic Acid,614OI1Z5WI,,,,
11766,Chemical,D019438,16368918,Ritonavir,O3J8G9O825,,,,
11767,DescriptorName,D000328,16368918,,,1,Adult,N,
11768,DescriptorName,D023241,16368918,,,2,"Antiretroviral Therapy, Highly Active",N,
11769,QualifierName,Q000379,16368918,,,2,,N,methods
11770,DescriptorName,D001714,16368918,,,3,Bipolar Disorder,N,
11771,QualifierName,Q000139,16368918,,,3,,Y,chemically induced
11772,DescriptorName,D004305,16368918,,,4,"Dose-Response Relationship, Drug",N,
11773,DescriptorName,D004347,16368918,,,5,Drug Interactions,N,
11774,DescriptorName,D015658,16368918,,,6,HIV Infections,N,
11775,QualifierName,Q000150,16368918,,,6,,N,complications
11776,DescriptorName,D006526,16368918,,,7,Hepatitis C,N,
11777,QualifierName,Q000150,16368918,,,7,,N,complications
11778,DescriptorName,D006801,16368918,,,8,Humans,N,
11779,DescriptorName,D061466,16368918,,,9,Lopinavir,N,
11780,DescriptorName,D008297,16368918,,,10,Male,N,
11781,DescriptorName,D011744,16368918,,,11,Pyrimidinones,N,
11782,QualifierName,Q000009,16368918,,,11,,Y,adverse effects
11783,DescriptorName,D019438,16368918,,,12,Ritonavir,N,
11784,QualifierName,Q000009,16368918,,,12,,Y,adverse effects
11785,DescriptorName,D014635,16368918,,,13,Valproic Acid,N,
11786,QualifierName,Q000009,16368918,,,13,,Y,adverse effects
11787,Chemical,D005938,16371793,Glucocorticoids,0,,,,
11788,Chemical,D014222,16371793,Triamcinolone Acetonide,F446C597KA,,,,
11789,DescriptorName,D000328,16371793,,,1,Adult,N,
11790,DescriptorName,D005451,16371793,,,2,Fluorescein Angiography,N,
11791,DescriptorName,D005500,16371793,,,3,Follow-Up Studies,N,
11792,DescriptorName,D005584,16371793,,,4,Fovea Centralis,N,
11793,QualifierName,Q000473,16371793,,,4,,N,pathology
11794,DescriptorName,D005654,16371793,,,5,Fundus Oculi,N,
11795,DescriptorName,D005938,16371793,,,6,Glucocorticoids,N,
11796,QualifierName,Q000008,16371793,,,6,,Y,administration & dosage
11797,DescriptorName,D006801,16371793,,,7,Humans,N,
11798,DescriptorName,D007267,16371793,,,8,Injections,N,
11799,DescriptorName,D007640,16371793,,,9,Keratoconus,N,
11800,QualifierName,Q000601,16371793,,,9,,N,surgery
11801,DescriptorName,D015948,16371793,,,10,"Keratoplasty, Penetrating",N,
11802,QualifierName,Q000009,16371793,,,10,,Y,adverse effects
11803,DescriptorName,D008269,16371793,,,11,Macular Edema,N,
11804,QualifierName,Q000175,16371793,,,11,,N,diagnosis
11805,DescriptorName,D011183,16371793,,,12,Postoperative Complications,N,
11806,DescriptorName,D041623,16371793,,,13,"Tomography, Optical Coherence",N,
11807,DescriptorName,D014222,16371793,,,14,Triamcinolone Acetonide,N,
11808,QualifierName,Q000008,16371793,,,14,,Y,administration & dosage
11809,DescriptorName,D014822,16371793,,,15,Vitreous Body,N,
11810,Chemical,D000276,16393774,"Adjuvants, Immunologic",0,,,,
11811,Chemical,D016899,16393774,Interferon-beta,77238-31-4,,,,
11812,Chemical,D000068556,16393774,Interferon beta-1a,XRO4566Q4R,,,,
11813,DescriptorName,D000276,16393774,,,1,"Adjuvants, Immunologic",N,
11814,QualifierName,Q000009,16393774,,,1,,Y,adverse effects
11815,DescriptorName,D000328,16393774,,,2,Adult,N,
11816,DescriptorName,D001168,16393774,,,3,Arthritis,N,
11817,QualifierName,Q000139,16393774,,,3,,Y,chemically induced
11818,DescriptorName,D002062,16393774,,,4,Bursitis,N,
11819,QualifierName,Q000139,16393774,,,4,,Y,chemically induced
11820,DescriptorName,D005260,16393774,,,5,Female,N,
11821,DescriptorName,D006801,16393774,,,6,Humans,N,
11822,DescriptorName,D000068556,16393774,,,7,Interferon beta-1a,N,
11823,DescriptorName,D016899,16393774,,,8,Interferon-beta,N,
11824,QualifierName,Q000009,16393774,,,8,,Y,adverse effects
11825,DescriptorName,D009103,16393774,,,9,Multiple Sclerosis,N,
11826,QualifierName,Q000188,16393774,,,9,,Y,drug therapy
11827,DescriptorName,D013967,16393774,,,10,"Thyroiditis, Autoimmune",N,
11828,QualifierName,Q000139,16393774,,,10,,N,chemically induced
11829,DescriptorName,D016896,16393774,,,11,Treatment Outcome,N,
11830,Chemical,D000890,16396068,Anti-Infective Agents,0,,,,
11831,Chemical,D015662,16396068,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
11832,DescriptorName,D000163,16396068,,,1,Acquired Immunodeficiency Syndrome,N,
11833,QualifierName,Q000150,16396068,,,1,,N,complications
11834,DescriptorName,D016907,16396068,,,2,Adverse Drug Reaction Reporting Systems,N,
11835,DescriptorName,D000890,16396068,,,3,Anti-Infective Agents,N,
11836,QualifierName,Q000009,16396068,,,3,,Y,adverse effects
11837,DescriptorName,D006801,16396068,,,4,Humans,N,
11838,DescriptorName,D008297,16396068,,,5,Male,N,
11839,DescriptorName,D008582,16396068,,,6,"Meningitis, Aseptic",N,
11840,QualifierName,Q000139,16396068,,,6,,Y,chemically induced
11841,DescriptorName,D008875,16396068,,,7,Middle Aged,N,
11842,DescriptorName,D011020,16396068,,,8,"Pneumonia, Pneumocystis",N,
11843,QualifierName,Q000188,16396068,,,8,,N,drug therapy
11844,DescriptorName,D012307,16396068,,,9,Risk Factors,N,
11845,DescriptorName,D015662,16396068,,,10,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
11846,QualifierName,Q000009,16396068,,,10,,Y,adverse effects
11847,Chemical,D000890,16404563,Anti-Infective Agents,0,,,,
11848,Chemical,D000893,16404563,Anti-Inflammatory Agents,0,,,,
11849,Chemical,D018501,16404563,Antirheumatic Agents,0,,,,
11850,Chemical,C023676,16404563,chloroquine diphosphate,6E17K3343P,,,,
11851,Chemical,D002443,16404563,Ceftriaxone,75J73V1629,,,,
11852,Chemical,D015662,16404563,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
11853,Chemical,D002738,16404563,Chloroquine,886U3H6UFF,,,,
11854,Chemical,D008775,16404563,Methylprednisolone,X4W7ZR7023,,,,
11855,DescriptorName,D000328,16404563,,,1,Adult,N,
11856,DescriptorName,D000890,16404563,,,2,Anti-Infective Agents,N,
11857,QualifierName,Q000627,16404563,,,2,,N,therapeutic use
11858,DescriptorName,D000893,16404563,,,3,Anti-Inflammatory Agents,N,
11859,QualifierName,Q000009,16404563,,,3,,Y,adverse effects
11860,DescriptorName,D016736,16404563,,,4,Antiphospholipid Syndrome,N,
11861,QualifierName,Q000150,16404563,,,4,,N,complications
11862,DescriptorName,D018501,16404563,,,5,Antirheumatic Agents,N,
11863,QualifierName,Q000627,16404563,,,5,,N,therapeutic use
11864,DescriptorName,D002443,16404563,,,6,Ceftriaxone,N,
11865,QualifierName,Q000627,16404563,,,6,,N,therapeutic use
11866,DescriptorName,D002738,16404563,,,7,Chloroquine,N,
11867,QualifierName,Q000031,16404563,,,7,,N,analogs & derivatives
11868,DescriptorName,D005260,16404563,,,8,Female,N,
11869,DescriptorName,D006801,16404563,,,9,Humans,N,
11870,DescriptorName,D016867,16404563,,,10,Immunocompromised Host,N,
11871,DescriptorName,D008775,16404563,,,11,Methylprednisolone,N,
11872,QualifierName,Q000009,16404563,,,11,,Y,adverse effects
11873,DescriptorName,D009617,16404563,,,12,Nocardia Infections,N,
11874,QualifierName,Q000175,16404563,,,12,,N,diagnosis
11875,DescriptorName,D013921,16404563,,,13,Thrombocytopenia,N,
11876,QualifierName,Q000188,16404563,,,13,,Y,drug therapy
11877,DescriptorName,D015662,16404563,,,14,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
11878,QualifierName,Q000627,16404563,,,14,,N,therapeutic use
11879,Chemical,D000962,16405935,Antimalarials,0,,,,
11880,Chemical,D002738,16405935,Chloroquine,886U3H6UFF,,,,
11881,DescriptorName,D000962,16405935,,,1,Antimalarials,N,
11882,QualifierName,Q000009,16405935,,,1,,Y,adverse effects
11883,DescriptorName,D001763,16405935,,,2,Blepharoptosis,N,
11884,QualifierName,Q000139,16405935,,,2,,Y,chemically induced
11885,DescriptorName,D002675,16405935,,,3,"Child, Preschool",N,
11886,DescriptorName,D002738,16405935,,,4,Chloroquine,N,
11887,QualifierName,Q000009,16405935,,,4,,Y,adverse effects
11888,DescriptorName,D006801,16405935,,,5,Humans,N,
11889,DescriptorName,D016778,16405935,,,6,"Malaria, Falciparum",N,
11890,QualifierName,Q000188,16405935,,,6,,N,drug therapy
11891,DescriptorName,D008297,16405935,,,7,Male,N,
11892,Chemical,D000964,16411025,"Antimetabolites, Antineoplastic",0,,,,
11893,Chemical,D008727,16411025,Methotrexate,YL5FZ2Y5U1,,,,
11894,DescriptorName,D000293,16411025,,,1,Adolescent,N,
11895,DescriptorName,D000964,16411025,,,2,"Antimetabolites, Antineoplastic",N,
11896,QualifierName,Q000009,16411025,,,2,,Y,adverse effects
11897,DescriptorName,D001921,16411025,,,3,Brain,N,
11898,QualifierName,Q000473,16411025,,,3,,Y,pathology
11899,DescriptorName,D038524,16411025,,,4,Diffusion Magnetic Resonance Imaging,N,
11900,DescriptorName,D004487,16411025,,,5,Edema,N,
11901,QualifierName,Q000139,16411025,,,5,,N,chemically induced
11902,DescriptorName,D005260,16411025,,,6,Female,N,
11903,DescriptorName,D006801,16411025,,,7,Humans,N,
11904,DescriptorName,D015448,16411025,,,8,"Leukemia, B-Cell",N,
11905,QualifierName,Q000188,16411025,,,8,,N,drug therapy
11906,DescriptorName,D007945,16411025,,,9,"Leukemia, Lymphoid",N,
11907,QualifierName,Q000150,16411025,,,9,,N,complications
11908,DescriptorName,D008279,16411025,,,10,Magnetic Resonance Imaging,N,
11909,DescriptorName,D008727,16411025,,,11,Methotrexate,N,
11910,QualifierName,Q000009,16411025,,,11,,Y,adverse effects
11911,DescriptorName,D020258,16411025,,,12,Neurotoxicity Syndromes,N,
11912,QualifierName,Q000473,16411025,,,12,,Y,pathology
11913,DescriptorName,D012189,16411025,,,13,Retrospective Studies,N,
11914,Chemical,D018692,16416684,Antimanic Agents,0,,,,
11915,Chemical,D016651,16416684,Lithium Carbonate,2BMD2GNA4V,,,,
11916,Chemical,D008094,16416684,Lithium,9FN79X2M3F,,,,
11917,DescriptorName,D000328,16416684,,,1,Adult,N,
11918,DescriptorName,D018692,16416684,,,2,Antimanic Agents,N,
11919,QualifierName,Q000506,16416684,,,2,,Y,poisoning
11920,DescriptorName,D001714,16416684,,,3,Bipolar Disorder,N,
11921,QualifierName,Q000188,16416684,,,3,,N,drug therapy
11922,DescriptorName,D062787,16416684,,,4,Drug Overdose,N,
11923,DescriptorName,D005260,16416684,,,5,Female,N,
11924,DescriptorName,D006801,16416684,,,6,Humans,N,
11925,DescriptorName,D008094,16416684,,,7,Lithium,N,
11926,QualifierName,Q000097,16416684,,,7,,N,blood
11927,DescriptorName,D016651,16416684,,,8,Lithium Carbonate,N,
11928,QualifierName,Q000506,16416684,,,8,,Y,poisoning
11929,DescriptorName,D012121,16416684,,,9,"Respiration, Artificial",Y,
11930,DescriptorName,D012128,16416684,,,10,"Respiratory Distress Syndrome, Adult",N,
11931,QualifierName,Q000209,16416684,,,10,,N,etiology
11932,Chemical,D000978,16421117,Antiparkinson Agents,0,,,,
11933,Chemical,D007980,16421117,Levodopa,46627O600J,,,,
11934,Chemical,D000547,16421117,Amantadine,BF4C9Z1J53,,,,
11935,DescriptorName,D000328,16421117,,,1,Adult,N,
11936,DescriptorName,D000368,16421117,,,2,Aged,N,
11937,DescriptorName,D000547,16421117,,,3,Amantadine,N,
11938,QualifierName,Q000627,16421117,,,3,,Y,therapeutic use
11939,DescriptorName,D000978,16421117,,,4,Antiparkinson Agents,N,
11940,QualifierName,Q000009,16421117,,,4,,Y,adverse effects
11941,DescriptorName,D004292,16421117,,,5,"Dominance, Cerebral",N,
11942,QualifierName,Q000502,16421117,,,5,,N,physiology
11943,DescriptorName,D020820,16421117,,,6,Dyskinesias,N,
11944,QualifierName,Q000188,16421117,,,6,,Y,drug therapy
11945,DescriptorName,D004599,16421117,,,7,Electric Stimulation Therapy,N,
11946,DescriptorName,D005260,16421117,,,8,Female,N,
11947,DescriptorName,D006801,16421117,,,9,Humans,N,
11948,DescriptorName,D007980,16421117,,,10,Levodopa,N,
11949,QualifierName,Q000009,16421117,,,10,,Y,adverse effects
11950,DescriptorName,D008297,16421117,,,11,Male,N,
11951,DescriptorName,D009460,16421117,,,12,Neurologic Examination,N,
11952,QualifierName,Q000187,16421117,,,12,,N,drug effects
11953,DescriptorName,D010300,16421117,,,13,Parkinson Disease,N,
11954,QualifierName,Q000601,16421117,,,13,,Y,surgery
11955,DescriptorName,D011183,16421117,,,14,Postoperative Complications,N,
11956,QualifierName,Q000188,16421117,,,14,,Y,drug therapy
11957,DescriptorName,D020531,16421117,,,15,Subthalamic Nucleus,N,
11958,QualifierName,Q000601,16421117,,,15,,Y,surgery
11959,DescriptorName,D016896,16421117,,,16,Treatment Outcome,N,
11960,Chemical,D014229,1642627,Triazolam,1HM943223R,,,,
11961,DescriptorName,D000647,1642627,,,1,Amnesia,N,
11962,QualifierName,Q000139,1642627,,,1,,Y,chemically induced
11963,DescriptorName,D005260,1642627,,,2,Female,N,
11964,DescriptorName,D006801,1642627,,,3,Humans,N,
11965,DescriptorName,D006963,1642627,,,4,Hyperphagia,N,
11966,QualifierName,Q000139,1642627,,,4,,Y,chemically induced
11967,DescriptorName,D008875,1642627,,,5,Middle Aged,N,
11968,DescriptorName,D009765,1642627,,,6,Obesity,N,
11969,QualifierName,Q000139,1642627,,,6,,N,chemically induced
11970,DescriptorName,D007319,1642627,,,7,Sleep Initiation and Maintenance Disorders,N,
11971,QualifierName,Q000188,1642627,,,7,,Y,drug therapy
11972,DescriptorName,D012893,1642627,,,8,Sleep Wake Disorders,N,
11973,QualifierName,Q000139,1642627,,,8,,Y,chemically induced
11974,DescriptorName,D014229,1642627,,,9,Triazolam,N,
11975,QualifierName,Q000008,1642627,,,9,,N,administration & dosage
11976,Chemical,D000077190,16432996,Interferon alpha-2,0,,,,
11977,Chemical,D016898,16432996,Interferon-alpha,0,,,,
11978,Chemical,D011994,16432996,Recombinant Proteins,0,,,,
11979,Chemical,D012254,16432996,Ribavirin,49717AWG6K,,,,
11980,DescriptorName,D015746,16432996,,,1,Abdominal Pain,N,
11981,QualifierName,Q000175,16432996,,,1,,N,diagnosis
11982,DescriptorName,D001707,16432996,,,2,"Biopsy, Needle",N,
11983,DescriptorName,D004359,16432996,,,3,"Drug Therapy, Combination",N,
11984,DescriptorName,D005260,16432996,,,4,Female,N,
11985,DescriptorName,D005500,16432996,,,5,Follow-Up Studies,N,
11986,DescriptorName,D019698,16432996,,,6,"Hepatitis C, Chronic",N,
11987,QualifierName,Q000188,16432996,,,6,,Y,drug therapy
11988,DescriptorName,D006801,16432996,,,7,Humans,N,
11989,DescriptorName,D007150,16432996,,,8,Immunohistochemistry,N,
11990,DescriptorName,D000077190,16432996,,,9,Interferon alpha-2,N,
11991,DescriptorName,D016898,16432996,,,10,Interferon-alpha,N,
11992,QualifierName,Q000009,16432996,,,10,,Y,adverse effects
11993,DescriptorName,D008111,16432996,,,11,Liver Function Tests,N,
11994,DescriptorName,D008875,16432996,,,12,Middle Aged,N,
11995,DescriptorName,D011994,16432996,,,13,Recombinant Proteins,N,
11996,DescriptorName,D012254,16432996,,,14,Ribavirin,N,
11997,QualifierName,Q000009,16432996,,,14,,Y,adverse effects
11998,DescriptorName,D018570,16432996,,,15,Risk Assessment,N,
11999,DescriptorName,D017565,16432996,,,16,"Sarcoidosis, Pulmonary",N,
12000,QualifierName,Q000139,16432996,,,16,,Y,chemically induced
12001,DescriptorName,D012720,16432996,,,17,Severity of Illness Index,N,
12002,DescriptorName,D014057,16432996,,,18,"Tomography, X-Ray Computed",N,
12003,Chemical,D006063,16436462,Chorionic Gonadotropin,0,,,,
12004,Chemical,D009944,16436462,Organoplatinum Compounds,0,,,,
12005,Chemical,D005719,16436462,gamma-Globulins,0,,,,
12006,Chemical,D000077146,16436462,Irinotecan,7673326042,,,,
12007,Chemical,C053989,16436462,nedaplatin,8UQ3W6JXAN,,,,
12008,Chemical,D002166,16436462,Camptothecin,XT3Z54Z28A,,,,
12009,DescriptorName,D000971,16436462,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
12010,QualifierName,Q000009,16436462,,,1,,Y,adverse effects
12011,DescriptorName,D002166,16436462,,,2,Camptothecin,N,
12012,QualifierName,Q000009,16436462,,,2,,N,adverse effects
12013,DescriptorName,D006063,16436462,,,3,Chorionic Gonadotropin,N,
12014,QualifierName,Q000097,16436462,,,3,,N,blood
12015,DescriptorName,D004334,16436462,,,4,Drug Administration Schedule,N,
12016,DescriptorName,D044504,16436462,,,5,"Enterocolitis, Neutropenic",N,
12017,QualifierName,Q000139,16436462,,,5,,Y,chemically induced
12018,DescriptorName,D006801,16436462,,,6,Humans,N,
12019,DescriptorName,D000077146,16436462,,,7,Irinotecan,N,
12020,DescriptorName,D008175,16436462,,,8,Lung Neoplasms,N,
12021,QualifierName,Q000188,16436462,,,8,,N,drug therapy
12022,DescriptorName,D008297,16436462,,,9,Male,N,
12023,DescriptorName,D008875,16436462,,,10,Middle Aged,N,
12024,DescriptorName,D009944,16436462,,,11,Organoplatinum Compounds,N,
12025,QualifierName,Q000009,16436462,,,11,,N,adverse effects
12026,DescriptorName,D011860,16436462,,,12,"Radiography, Abdominal",N,
12027,DescriptorName,D013736,16436462,,,13,Testicular Neoplasms,N,
12028,QualifierName,Q000188,16436462,,,13,,Y,drug therapy
12029,DescriptorName,D014057,16436462,,,14,"Tomography, X-Ray Computed",N,
12030,DescriptorName,D005719,16436462,,,15,gamma-Globulins,N,
12031,QualifierName,Q000008,16436462,,,15,,N,administration & dosage
12032,Chemical,D009281,16441824,Naphthalenes,0,,,,
12033,Chemical,D044169,16441824,"Receptors, Calcium-Sensing",0,,,,
12034,Chemical,D000069449,16441824,Cinacalcet,UAZ6V7728S,,,,
12035,DescriptorName,D000328,16441824,,,1,Adult,N,
12036,DescriptorName,D000069449,16441824,,,2,Cinacalcet,N,
12037,DescriptorName,D005260,16441824,,,3,Female,N,
12038,DescriptorName,D006801,16441824,,,4,Humans,N,
12039,DescriptorName,D006934,16441824,,,5,Hypercalcemia,N,
12040,QualifierName,Q000139,16441824,,,5,,Y,chemically induced
12041,DescriptorName,D006962,16441824,,,6,"Hyperparathyroidism, Secondary",N,
12042,QualifierName,Q000188,16441824,,,6,,Y,drug therapy
12043,DescriptorName,D007103,16441824,,,7,Immobilization,N,
12044,DescriptorName,D009281,16441824,,,8,Naphthalenes,N,
12045,QualifierName,Q000009,16441824,,,8,,Y,adverse effects
12046,DescriptorName,D044169,16441824,,,9,"Receptors, Calcium-Sensing",N,
12047,QualifierName,Q000187,16441824,,,9,,N,drug effects
12048,Chemical,D000305,16446228,Adrenal Cortex Hormones,0,,,,
12049,Chemical,D007166,16446228,Immunosuppressive Agents,0,,,,
12050,Chemical,D020123,16446228,Sirolimus,W36ZG6FT64,,,,
12051,DescriptorName,D000305,16446228,,,1,Adrenal Cortex Hormones,N,
12052,QualifierName,Q000627,16446228,,,1,,N,therapeutic use
12053,DescriptorName,D016027,16446228,,,2,Heart Transplantation,N,
12054,QualifierName,Q000276,16446228,,,2,,Y,immunology
12055,DescriptorName,D006801,16446228,,,3,Humans,N,
12056,DescriptorName,D007166,16446228,,,4,Immunosuppressive Agents,N,
12057,QualifierName,Q000009,16446228,,,4,,Y,adverse effects
12058,DescriptorName,D017563,16446228,,,5,"Lung Diseases, Interstitial",N,
12059,QualifierName,Q000139,16446228,,,5,,Y,chemically induced
12060,DescriptorName,D008297,16446228,,,6,Male,N,
12061,DescriptorName,D008875,16446228,,,7,Middle Aged,N,
12062,DescriptorName,D020123,16446228,,,8,Sirolimus,N,
12063,QualifierName,Q000009,16446228,,,8,,Y,adverse effects
12064,DescriptorName,D014057,16446228,,,9,"Tomography, X-Ray Computed",N,
12065,Chemical,D000927,16449538,Anticonvulsants,0,,,,
12066,Chemical,D018906,16449538,"Antineoplastic Agents, Alkylating",0,,,,
12067,Chemical,D000077287,16449538,Levetiracetam,44YRR34555,,,,
12068,Chemical,D003975,16449538,Diazepam,Q3JTX2Q7TU,,,,
12069,Chemical,D007069,16449538,Ifosfamide,UM20QQM95Y,,,,
12070,Chemical,D010889,16449538,Piracetam,ZH516LNZ10,,,,
12071,DescriptorName,D000927,16449538,,,1,Anticonvulsants,N,
12072,QualifierName,Q000627,16449538,,,1,,N,therapeutic use
12073,DescriptorName,D018906,16449538,,,2,"Antineoplastic Agents, Alkylating",N,
12074,QualifierName,Q000008,16449538,,,2,,N,administration & dosage
12075,DescriptorName,D003975,16449538,,,3,Diazepam,N,
12076,QualifierName,Q000627,16449538,,,3,,N,therapeutic use
12077,DescriptorName,D005260,16449538,,,4,Female,N,
12078,DescriptorName,D006801,16449538,,,5,Humans,N,
12079,DescriptorName,D007069,16449538,,,6,Ifosfamide,N,
12080,QualifierName,Q000008,16449538,,,6,,N,administration & dosage
12081,DescriptorName,D000077287,16449538,,,7,Levetiracetam,N,
12082,DescriptorName,D008875,16449538,,,8,Middle Aged,N,
12083,DescriptorName,D009369,16449538,,,9,Neoplasms,N,
12084,QualifierName,Q000188,16449538,,,9,,N,drug therapy
12085,DescriptorName,D010889,16449538,,,10,Piracetam,N,
12086,QualifierName,Q000031,16449538,,,10,,N,analogs & derivatives
12087,DescriptorName,D013226,16449538,,,11,Status Epilepticus,N,
12088,QualifierName,Q000139,16449538,,,11,,Y,chemically induced
12089,Chemical,D000319,16453964,Adrenergic beta-Antagonists,0,,,,
12090,Chemical,D000777,16453964,Anesthetics,0,,,,
12091,Chemical,C115675,16453964,Hemaccel,0,,,,
12092,Chemical,D011108,16453964,Polymers,0,,,,
12093,Chemical,D005780,16453964,Gelatin,9000-70-8,,,,
12094,Chemical,D012697,16453964,Serine Endopeptidases,EC 3.4.21.-,,,,
12095,Chemical,D053802,16453964,Tryptases,EC 3.4.21.59,,,,
12096,DescriptorName,D000319,16453964,,,1,Adrenergic beta-Antagonists,N,
12097,QualifierName,Q000627,16453964,,,1,,N,therapeutic use
12098,DescriptorName,D000368,16453964,,,2,Aged,N,
12099,DescriptorName,D000707,16453964,,,3,Anaphylaxis,N,
12100,QualifierName,Q000209,16453964,,,3,,Y,etiology
12101,DescriptorName,D000768,16453964,,,4,"Anesthesia, General",N,
12102,QualifierName,Q000009,16453964,,,4,,N,adverse effects
12103,DescriptorName,D000777,16453964,,,5,Anesthetics,N,
12104,QualifierName,Q000009,16453964,,,5,,N,adverse effects
12105,DescriptorName,D004342,16453964,,,6,Drug Hypersensitivity,Y,
12106,DescriptorName,D005260,16453964,,,7,Female,N,
12107,DescriptorName,D005780,16453964,,,8,Gelatin,N,
12108,QualifierName,Q000009,16453964,,,8,,Y,adverse effects
12109,DescriptorName,D006801,16453964,,,9,Humans,N,
12110,DescriptorName,D006973,16453964,,,10,Hypertension,N,
12111,QualifierName,Q000188,16453964,,,10,,N,drug therapy
12112,DescriptorName,D007022,16453964,,,11,Hypotension,N,
12113,QualifierName,Q000209,16453964,,,11,,N,etiology
12114,DescriptorName,D007431,16453964,,,12,Intraoperative Complications,N,
12115,QualifierName,Q000209,16453964,,,12,,Y,etiology
12116,DescriptorName,D011108,16453964,,,13,Polymers,N,
12117,QualifierName,Q000009,16453964,,,13,,Y,adverse effects
12118,DescriptorName,D012697,16453964,,,14,Serine Endopeptidases,N,
12119,QualifierName,Q000097,16453964,,,14,,N,blood
12120,DescriptorName,D053802,16453964,,,15,Tryptases,N,
12121,DescriptorName,D001749,16453964,,,16,Urinary Bladder Neoplasms,N,
12122,QualifierName,Q000601,16453964,,,16,,N,surgery
12123,Chemical,D000995,16459502,Antitubercular Agents,0,,,,
12124,Chemical,D001500,16459502,BCG Vaccine,0,,,,
12125,DescriptorName,D000283,16459502,,,1,"Administration, Intravesical",N,
12126,DescriptorName,D000995,16459502,,,2,Antitubercular Agents,N,
12127,QualifierName,Q000627,16459502,,,2,,N,therapeutic use
12128,DescriptorName,D001500,16459502,,,3,BCG Vaccine,N,
12129,QualifierName,Q000009,16459502,,,3,,Y,adverse effects
12130,DescriptorName,D001707,16459502,,,4,"Biopsy, Needle",N,
12131,DescriptorName,D002295,16459502,,,5,"Carcinoma, Transitional Cell",N,
12132,QualifierName,Q000188,16459502,,,5,,Y,drug therapy
12133,DescriptorName,D005500,16459502,,,6,Follow-Up Studies,N,
12134,DescriptorName,D006229,16459502,,,7,Hand Dermatoses,N,
12135,QualifierName,Q000209,16459502,,,7,,N,etiology
12136,DescriptorName,D006801,16459502,,,8,Humans,N,
12137,DescriptorName,D007150,16459502,,,9,Immunohistochemistry,N,
12138,DescriptorName,D008297,16459502,,,10,Male,N,
12139,DescriptorName,D008875,16459502,,,11,Middle Aged,N,
12140,DescriptorName,D009169,16459502,,,12,Mycobacterium tuberculosis,N,
12141,QualifierName,Q000302,16459502,,,12,,N,isolation & purification
12142,DescriptorName,D016896,16459502,,,13,Treatment Outcome,N,
12143,DescriptorName,D014382,16459502,,,14,"Tuberculosis, Cutaneous",N,
12144,QualifierName,Q000175,16459502,,,14,,N,diagnosis
12145,DescriptorName,D001749,16459502,,,15,Urinary Bladder Neoplasms,N,
12146,QualifierName,Q000188,16459502,,,15,,Y,drug therapy
12147,Chemical,D018501,16463436,Antirheumatic Agents,0,,,,
12148,Chemical,D006886,16463436,Hydroxychloroquine,4QWG6N8QKH,,,,
12149,DescriptorName,D000328,16463436,,,1,Adult,N,
12150,DescriptorName,D018501,16463436,,,2,Antirheumatic Agents,N,
12151,QualifierName,Q000009,16463436,,,2,,N,adverse effects
12152,DescriptorName,D003888,16463436,,,3,"Desensitization, Immunologic",N,
12153,QualifierName,Q000379,16463436,,,3,,Y,methods
12154,DescriptorName,D003875,16463436,,,4,Drug Eruptions,N,
12155,QualifierName,Q000209,16463436,,,4,,N,etiology
12156,DescriptorName,D004342,16463436,,,5,Drug Hypersensitivity,N,
12157,QualifierName,Q000209,16463436,,,5,,N,etiology
12158,DescriptorName,D004361,16463436,,,6,Drug Tolerance,N,
12159,QualifierName,Q000276,16463436,,,6,,N,immunology
12160,DescriptorName,D005260,16463436,,,7,Female,N,
12161,DescriptorName,D006801,16463436,,,8,Humans,N,
12162,DescriptorName,D006886,16463436,,,9,Hydroxychloroquine,N,
12163,QualifierName,Q000009,16463436,,,9,,N,adverse effects
12164,DescriptorName,D008875,16463436,,,10,Middle Aged,N,
12165,DescriptorName,D012216,16463436,,,11,Rheumatic Diseases,N,
12166,QualifierName,Q000150,16463436,,,11,,N,complications
12167,Chemical,D017366,16472339,Serotonin Receptor Agonists,0,,,,
12168,Chemical,D018170,16472339,Sumatriptan,8R78F6L9VO,,,,
12169,DescriptorName,D000328,16472339,,,1,Adult,N,
12170,DescriptorName,D003951,16472339,,,2,Diagnostic Errors,Y,
12171,DescriptorName,D005260,16472339,,,3,Female,N,
12172,DescriptorName,D006801,16472339,,,4,Humans,N,
12173,DescriptorName,D008297,16472339,,,5,Male,N,
12174,DescriptorName,D008881,16472339,,,6,Migraine Disorders,N,
12175,QualifierName,Q000188,16472339,,,6,,N,drug therapy
12176,DescriptorName,D010146,16472339,,,7,Pain,N,
12177,QualifierName,Q000188,16472339,,,7,,N,drug therapy
12178,DescriptorName,D017366,16472339,,,8,Serotonin Receptor Agonists,N,
12179,QualifierName,Q000009,16472339,,,8,,Y,adverse effects
12180,DescriptorName,D013345,16472339,,,9,Subarachnoid Hemorrhage,N,
12181,QualifierName,Q000175,16472339,,,9,,Y,diagnosis
12182,DescriptorName,D018170,16472339,,,10,Sumatriptan,N,
12183,QualifierName,Q000009,16472339,,,10,,Y,adverse effects
12184,DescriptorName,D020301,16472339,,,11,"Vasospasm, Intracranial",N,
12185,QualifierName,Q000139,16472339,,,11,,N,chemically induced
12186,Chemical,D014150,16480245,Antipsychotic Agents,0,,,,
12187,Chemical,D003987,16480245,Dibenzothiazepines,0,,,,
12188,Chemical,D007004,16480245,Hypoglycemic Agents,0,,,,
12189,Chemical,D000069348,16480245,Quetiapine Fumarate,2S3PL1B6UJ,,,,
12190,Chemical,D008687,16480245,Metformin,9100L32L2N,,,,
12191,Chemical,D018967,16480245,Risperidone,L6UH7ZF8HC,,,,
12192,DescriptorName,D000328,16480245,,,1,Adult,N,
12193,DescriptorName,D014150,16480245,,,2,Antipsychotic Agents,N,
12194,QualifierName,Q000009,16480245,,,2,,Y,adverse effects
12195,DescriptorName,D003924,16480245,,,3,"Diabetes Mellitus, Type 2",N,
12196,QualifierName,Q000097,16480245,,,3,,N,blood
12197,DescriptorName,D003987,16480245,,,4,Dibenzothiazepines,N,
12198,QualifierName,Q000009,16480245,,,4,,Y,adverse effects
12199,DescriptorName,D005260,16480245,,,5,Female,N,
12200,DescriptorName,D006801,16480245,,,6,Humans,N,
12201,DescriptorName,D007004,16480245,,,7,Hypoglycemic Agents,N,
12202,QualifierName,Q000627,16480245,,,7,,N,therapeutic use
12203,DescriptorName,D008297,16480245,,,8,Male,N,
12204,DescriptorName,D008687,16480245,,,9,Metformin,N,
12205,QualifierName,Q000627,16480245,,,9,,N,therapeutic use
12206,DescriptorName,D008875,16480245,,,10,Middle Aged,N,
12207,DescriptorName,D000069348,16480245,,,11,Quetiapine Fumarate,N,
12208,DescriptorName,D018967,16480245,,,12,Risperidone,N,
12209,QualifierName,Q000009,16480245,,,12,,Y,adverse effects
12210,DescriptorName,D012559,16480245,,,13,Schizophrenia,N,
12211,QualifierName,Q000188,16480245,,,13,,Y,drug therapy
12212,DescriptorName,D012720,16480245,,,14,Severity of Illness Index,N,
12213,Chemical,D000900,16484748,Anti-Bacterial Agents,0,,,,
12214,Chemical,D000914,16484748,"Antibodies, Viral",0,,,,
12215,Chemical,D004279,16484748,"DNA, Viral",0,,,,
12216,Chemical,D005938,16484748,Glucocorticoids,0,,,,
12217,Chemical,D015662,16484748,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
12218,DescriptorName,D000328,16484748,,,1,Adult,N,
12219,DescriptorName,D000900,16484748,,,2,Anti-Bacterial Agents,N,
12220,QualifierName,Q000009,16484748,,,2,,Y,adverse effects
12221,DescriptorName,D019072,16484748,,,3,Antibiotic Prophylaxis,N,
12222,DescriptorName,D000914,16484748,,,4,"Antibodies, Viral",N,
12223,DescriptorName,D001249,16484748,,,5,Asthma,N,
12224,QualifierName,Q000150,16484748,,,5,,N,complications
12225,DescriptorName,D004279,16484748,,,6,"DNA, Viral",N,
12226,DescriptorName,D003875,16484748,,,7,Drug Eruptions,N,
12227,QualifierName,Q000209,16484748,,,7,,Y,etiology
12228,DescriptorName,D004751,16484748,,,8,Enteritis,N,
12229,QualifierName,Q000150,16484748,,,8,,N,complications
12230,DescriptorName,D005938,16484748,,,9,Glucocorticoids,N,
12231,QualifierName,Q000627,16484748,,,9,,N,therapeutic use
12232,DescriptorName,D015654,16484748,,,10,"Herpesvirus 6, Human",N,
12233,QualifierName,Q000276,16484748,,,10,,N,immunology
12234,DescriptorName,D006801,16484748,,,11,Humans,N,
12235,DescriptorName,D008297,16484748,,,12,Male,N,
12236,DescriptorName,D009894,16484748,,,13,Opportunistic Infections,N,
12237,QualifierName,Q000209,16484748,,,13,,N,etiology
12238,DescriptorName,D011657,16484748,,,14,Pulmonary Eosinophilia,N,
12239,QualifierName,Q000150,16484748,,,14,,N,complications
12240,DescriptorName,D012008,16484748,,,15,Recurrence,N,
12241,DescriptorName,D019349,16484748,,,16,Roseolovirus Infections,N,
12242,QualifierName,Q000209,16484748,,,16,,Y,etiology
12243,DescriptorName,D016896,16484748,,,17,Treatment Outcome,N,
12244,DescriptorName,D015662,16484748,,,18,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
12245,QualifierName,Q000009,16484748,,,18,,Y,adverse effects
12246,DescriptorName,D014775,16484748,,,19,Virus Activation,N,
12247,QualifierName,Q000187,16484748,,,19,,N,drug effects
12248,Chemical,D000959,16490518,Antihypertensive Agents,0,,,,
12249,Chemical,D005938,16490518,Glucocorticoids,0,,,,
12250,Chemical,D014222,16490518,Triamcinolone Acetonide,F446C597KA,,,,
12251,DescriptorName,D000328,16490518,,,1,Adult,N,
12252,DescriptorName,D000959,16490518,,,2,Antihypertensive Agents,N,
12253,QualifierName,Q000627,16490518,,,2,,N,therapeutic use
12254,DescriptorName,D003930,16490518,,,3,Diabetic Retinopathy,N,
12255,QualifierName,Q000188,16490518,,,3,,N,drug therapy
12256,DescriptorName,D005451,16490518,,,4,Fluorescein Angiography,N,
12257,DescriptorName,D005901,16490518,,,5,Glaucoma,N,
12258,QualifierName,Q000139,16490518,,,5,,Y,chemically induced
12259,DescriptorName,D005938,16490518,,,6,Glucocorticoids,N,
12260,QualifierName,Q000009,16490518,,,6,,Y,adverse effects
12261,DescriptorName,D006801,16490518,,,7,Humans,N,
12262,DescriptorName,D007267,16490518,,,8,Injections,N,
12263,DescriptorName,D007429,16490518,,,9,Intraocular Pressure,N,
12264,DescriptorName,D008269,16490518,,,10,Macular Edema,N,
12265,QualifierName,Q000188,16490518,,,10,,N,drug therapy
12266,DescriptorName,D008297,16490518,,,11,Male,N,
12267,DescriptorName,D012189,16490518,,,12,Retrospective Studies,N,
12268,DescriptorName,D014222,16490518,,,13,Triamcinolone Acetonide,N,
12269,QualifierName,Q000009,16490518,,,13,,Y,adverse effects
12270,DescriptorName,D014786,16490518,,,14,Vision Disorders,N,
12271,QualifierName,Q000139,16490518,,,14,,N,chemically induced
12272,DescriptorName,D014794,16490518,,,15,Visual Fields,N,
12273,QualifierName,Q000187,16490518,,,15,,N,drug effects
12274,DescriptorName,D014822,16490518,,,16,Vitreous Body,N,
12275,Chemical,D007370,16498048,Interferon Type I,0,,,,
12276,Chemical,D011994,16498048,Recombinant Proteins,0,,,,
12277,Chemical,D013963,16498048,Thyroid Hormones,0,,,,
12278,DescriptorName,D000328,16498048,,,1,Adult,N,
12279,DescriptorName,D006111,16498048,,,2,Graves Disease,N,
12280,QualifierName,Q000139,16498048,,,2,,Y,chemically induced
12281,DescriptorName,D006526,16498048,,,3,Hepatitis C,N,
12282,QualifierName,Q000150,16498048,,,3,,N,complications
12283,DescriptorName,D006801,16498048,,,4,Humans,N,
12284,DescriptorName,D006980,16498048,,,5,Hyperthyroidism,N,
12285,QualifierName,Q000139,16498048,,,5,,Y,chemically induced
12286,DescriptorName,D007370,16498048,,,6,Interferon Type I,N,
12287,QualifierName,Q000009,16498048,,,6,,Y,adverse effects
12288,DescriptorName,D008297,16498048,,,7,Male,N,
12289,DescriptorName,D011877,16498048,,,8,Radionuclide Imaging,N,
12290,DescriptorName,D011994,16498048,,,9,Recombinant Proteins,N,
12291,DescriptorName,D013960,16498048,,,10,Thyroid Function Tests,N,
12292,DescriptorName,D013963,16498048,,,11,Thyroid Hormones,N,
12293,QualifierName,Q000097,16498048,,,11,,N,blood
12294,DescriptorName,D013966,16498048,,,12,Thyroiditis,N,
12295,QualifierName,Q000139,16498048,,,12,,Y,chemically induced
12296,Chemical,D000894,16503727,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
12297,Chemical,D016179,16503727,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
12298,Chemical,D004177,16503727,Dipyrone,6429L0L52Y,,,,
12299,DescriptorName,D000328,16503727,,,1,Adult,N,
12300,DescriptorName,D000894,16503727,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
12301,QualifierName,Q000009,16503727,,,2,,Y,adverse effects
12302,DescriptorName,D004177,16503727,,,3,Dipyrone,N,
12303,QualifierName,Q000009,16503727,,,3,,Y,adverse effects
12304,DescriptorName,D005260,16503727,,,4,Female,N,
12305,DescriptorName,D005334,16503727,,,5,Fever,N,
12306,QualifierName,Q000209,16503727,,,5,,N,etiology
12307,DescriptorName,D016179,16503727,,,6,Granulocyte Colony-Stimulating Factor,N,
12308,QualifierName,Q000627,16503727,,,6,,N,therapeutic use
12309,DescriptorName,D006801,16503727,,,7,Humans,N,
12310,DescriptorName,D009503,16503727,,,8,Neutropenia,N,
12311,QualifierName,Q000139,16503727,,,8,,Y,chemically induced
12312,Chemical,D000911,16507211,"Antibodies, Monoclonal",0,,,,
12313,Chemical,D061067,16507211,"Antibodies, Monoclonal, Humanized",0,,,,
12314,Chemical,D007155,16507211,Immunologic Factors,0,,,,
12315,Chemical,D000069285,16507211,Infliximab,B72HH48FLU,,,,
12316,Chemical,C472181,16507211,efalizumab,XX2MN88N5D,,,,
12317,DescriptorName,D000911,16507211,,,1,"Antibodies, Monoclonal",N,
12318,QualifierName,Q000008,16507211,,,1,,Y,administration & dosage
12319,DescriptorName,D061067,16507211,,,2,"Antibodies, Monoclonal, Humanized",N,
12320,DescriptorName,D001172,16507211,,,3,"Arthritis, Rheumatoid",N,
12321,QualifierName,Q000150,16507211,,,3,,N,complications
12322,DescriptorName,D018414,16507211,,,4,CD8-Positive T-Lymphocytes,N,
12323,QualifierName,Q000473,16507211,,,4,,Y,pathology
12324,DescriptorName,D006801,16507211,,,5,Humans,N,
12325,DescriptorName,D007155,16507211,,,6,Immunologic Factors,N,
12326,QualifierName,Q000008,16507211,,,6,,Y,administration & dosage
12327,DescriptorName,D000069285,16507211,,,7,Infliximab,N,
12328,DescriptorName,D016399,16507211,,,8,"Lymphoma, T-Cell",N,
12329,QualifierName,Q000209,16507211,,,8,,N,etiology
12330,DescriptorName,D008297,16507211,,,9,Male,N,
12331,DescriptorName,D008875,16507211,,,10,Middle Aged,N,
12332,DescriptorName,D011565,16507211,,,11,Psoriasis,N,
12333,QualifierName,Q000150,16507211,,,11,,N,complications
12334,DescriptorName,D012878,16507211,,,12,Skin Neoplasms,N,
12335,QualifierName,Q000209,16507211,,,12,,N,etiology
12336,Chemical,D000981,16511396,Antiprotozoal Agents,0,,,,
12337,Chemical,D013411,16511396,Sulfadiazine,0N7609K889,,,,
12338,Chemical,D011739,16511396,Pyrimethamine,Z3614QOX8W,,,,
12339,DescriptorName,D000818,16511396,,,1,Animals,N,
12340,DescriptorName,D000981,16511396,,,2,Antiprotozoal Agents,N,
12341,QualifierName,Q000008,16511396,,,2,,N,administration & dosage
12342,DescriptorName,D002648,16511396,,,3,Child,N,
12343,DescriptorName,D002825,16511396,,,4,Chorioretinitis,N,
12344,QualifierName,Q000151,16511396,,,4,,Y,congenital
12345,DescriptorName,D004342,16511396,,,5,Drug Hypersensitivity,N,
12346,QualifierName,Q000209,16511396,,,5,,N,etiology
12347,DescriptorName,D004359,16511396,,,6,"Drug Therapy, Combination",N,
12348,DescriptorName,D004802,16511396,,,7,Eosinophilia,N,
12349,QualifierName,Q000209,16511396,,,7,,N,etiology
12350,DescriptorName,D005260,16511396,,,8,Female,N,
12351,DescriptorName,D006801,16511396,,,9,Humans,N,
12352,DescriptorName,D011739,16511396,,,10,Pyrimethamine,N,
12353,QualifierName,Q000008,16511396,,,10,,N,administration & dosage
12354,DescriptorName,D012008,16511396,,,11,Recurrence,N,
12355,DescriptorName,D012720,16511396,,,12,Severity of Illness Index,N,
12356,DescriptorName,D013411,16511396,,,13,Sulfadiazine,N,
12357,QualifierName,Q000008,16511396,,,13,,N,administration & dosage
12358,DescriptorName,D014122,16511396,,,14,Toxoplasma,N,
12359,QualifierName,Q000187,16511396,,,14,,N,drug effects
12360,DescriptorName,D014126,16511396,,,15,"Toxoplasmosis, Ocular",N,
12361,QualifierName,Q000151,16511396,,,15,,Y,congenital
12362,Chemical,D000972,16515630,"Antineoplastic Agents, Phytogenic",0,,,,
12363,Chemical,D005938,16515630,Glucocorticoids,0,,,,
12364,Chemical,D016190,16515630,Carboplatin,BG3F62OND5,,,,
12365,Chemical,D017239,16515630,Paclitaxel,P88XT4IS4D,,,,
12366,Chemical,D008775,16515630,Methylprednisolone,X4W7ZR7023,,,,
12367,DescriptorName,D000230,16515630,,,1,Adenocarcinoma,N,
12368,QualifierName,Q000188,16515630,,,1,,N,drug therapy
12369,DescriptorName,D000972,16515630,,,2,"Antineoplastic Agents, Phytogenic",N,
12370,QualifierName,Q000009,16515630,,,2,,Y,adverse effects
12371,DescriptorName,D000971,16515630,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
12372,QualifierName,Q000008,16515630,,,3,,Y,administration & dosage
12373,DescriptorName,D016190,16515630,,,4,Carboplatin,N,
12374,QualifierName,Q000008,16515630,,,4,,N,administration & dosage
12375,DescriptorName,D017809,16515630,,,5,Fatal Outcome,N,
12376,DescriptorName,D005260,16515630,,,6,Female,N,
12377,DescriptorName,D005938,16515630,,,7,Glucocorticoids,N,
12378,QualifierName,Q000627,16515630,,,7,,N,therapeutic use
12379,DescriptorName,D006801,16515630,,,8,Humans,N,
12380,DescriptorName,D017563,16515630,,,9,"Lung Diseases, Interstitial",N,
12381,QualifierName,Q000139,16515630,,,9,,Y,chemically induced
12382,DescriptorName,D008775,16515630,,,10,Methylprednisolone,N,
12383,QualifierName,Q000627,16515630,,,10,,N,therapeutic use
12384,DescriptorName,D008875,16515630,,,11,Middle Aged,N,
12385,DescriptorName,D010051,16515630,,,12,Ovarian Neoplasms,N,
12386,QualifierName,Q000188,16515630,,,12,,N,drug therapy
12387,DescriptorName,D017239,16515630,,,13,Paclitaxel,N,
12388,QualifierName,Q000009,16515630,,,13,,Y,adverse effects
12389,DescriptorName,D011658,16515630,,,14,Pulmonary Fibrosis,N,
12390,QualifierName,Q000139,16515630,,,14,,Y,chemically induced
12391,Chemical,D000911,16521231,"Antibodies, Monoclonal",0,,,,
12392,Chemical,D000069285,16521231,Infliximab,B72HH48FLU,,,,
12393,DescriptorName,D000911,16521231,,,1,"Antibodies, Monoclonal",N,
12394,QualifierName,Q000009,16521231,,,1,,N,adverse effects
12395,DescriptorName,D003424,16521231,,,2,Crohn Disease,N,
12396,QualifierName,Q000188,16521231,,,2,,Y,drug therapy
12397,DescriptorName,D006509,16521231,,,3,Hepatitis B,N,
12398,QualifierName,Q000175,16521231,,,3,,Y,diagnosis
12399,DescriptorName,D006515,16521231,,,4,Hepatitis B virus,N,
12400,QualifierName,Q000302,16521231,,,4,,Y,isolation & purification
12401,DescriptorName,D006801,16521231,,,5,Humans,N,
12402,DescriptorName,D000069285,16521231,,,6,Infliximab,N,
12403,DescriptorName,D008297,16521231,,,7,Male,N,
12404,DescriptorName,D008403,16521231,,,8,Mass Screening,N,
12405,DescriptorName,D008875,16521231,,,9,Middle Aged,N,
12406,Chemical,D019800,16527771,Phenol,339NCG44TV,,,,
12407,Chemical,D008353,16527771,Mannitol,3OWL53L36A,,,,
12408,Chemical,D011239,16527771,Prednisolone,9PHQ9Y1OLM,,,,
12409,DescriptorName,D000208,16527771,,,1,Acute Disease,N,
12410,DescriptorName,D000368,16527771,,,2,Aged,N,
12411,DescriptorName,D001766,16527771,,,3,Blindness,N,
12412,QualifierName,Q000139,16527771,,,3,,Y,chemically induced
12413,DescriptorName,D003131,16527771,,,4,Combined Modality Therapy,N,
12414,DescriptorName,D005500,16527771,,,5,Follow-Up Studies,N,
12415,DescriptorName,D006801,16527771,,,6,Humans,N,
12416,DescriptorName,D007279,16527771,,,7,"Injections, Subcutaneous",N,
12417,DescriptorName,D008279,16527771,,,8,Magnetic Resonance Imaging,N,
12418,DescriptorName,D008297,16527771,,,9,Male,N,
12419,DescriptorName,D008353,16527771,,,10,Mannitol,N,
12420,QualifierName,Q000627,16527771,,,10,,N,therapeutic use
12421,DescriptorName,D013508,16527771,,,11,Ophthalmologic Surgical Procedures,N,
12422,QualifierName,Q000379,16527771,,,11,,N,methods
12423,DescriptorName,D019800,16527771,,,12,Phenol,N,
12424,QualifierName,Q000009,16527771,,,12,,Y,adverse effects
12425,DescriptorName,D011239,16527771,,,13,Prednisolone,N,
12426,QualifierName,Q000627,16527771,,,13,,N,therapeutic use
12427,DescriptorName,D018570,16527771,,,14,Risk Assessment,N,
12428,DescriptorName,D017211,16527771,,,15,Treatment Failure,N,
12429,DescriptorName,D014277,16527771,,,16,Trigeminal Neuralgia,N,
12430,QualifierName,Q000175,16527771,,,16,,N,diagnosis
12431,DescriptorName,D014792,16527771,,,17,Visual Acuity,N,
12432,Chemical,D000276,16531969,"Adjuvants, Immunologic",0,,,,
12433,Chemical,D016899,16531969,Interferon-beta,77238-31-4,,,,
12434,Chemical,D011241,16531969,Prednisone,VB0R961HZT,,,,
12435,DescriptorName,D000276,16531969,,,1,"Adjuvants, Immunologic",N,
12436,QualifierName,Q000009,16531969,,,1,,Y,adverse effects
12437,DescriptorName,D000328,16531969,,,2,Adult,N,
12438,DescriptorName,D001707,16531969,,,3,"Biopsy, Needle",N,
12439,DescriptorName,D056486,16531969,,,4,Chemical and Drug Induced Liver Injury,Y,
12440,DescriptorName,D005260,16531969,,,5,Female,N,
12441,DescriptorName,D005500,16531969,,,6,Follow-Up Studies,N,
12442,DescriptorName,D006801,16531969,,,7,Humans,N,
12443,DescriptorName,D007150,16531969,,,8,Immunohistochemistry,N,
12444,DescriptorName,D016899,16531969,,,9,Interferon-beta,N,
12445,QualifierName,Q000009,16531969,,,9,,Y,adverse effects
12446,DescriptorName,D008099,16531969,,,10,Liver,N,
12447,QualifierName,Q000187,16531969,,,10,,N,drug effects
12448,DescriptorName,D008107,16531969,,,11,Liver Diseases,N,
12449,QualifierName,Q000188,16531969,,,11,,N,drug therapy
12450,DescriptorName,D008111,16531969,,,12,Liver Function Tests,N,
12451,DescriptorName,D009103,16531969,,,13,Multiple Sclerosis,N,
12452,QualifierName,Q000188,16531969,,,13,,Y,drug therapy
12453,DescriptorName,D011241,16531969,,,14,Prednisone,N,
12454,QualifierName,Q000627,16531969,,,14,,N,therapeutic use
12455,DescriptorName,D018570,16531969,,,15,Risk Assessment,N,
12456,DescriptorName,D012720,16531969,,,16,Severity of Illness Index,N,
12457,DescriptorName,D016896,16531969,,,17,Treatment Outcome,N,
12458,Chemical,D000658,16540070,Amoxicillin,804826J2HU,,,,
12459,Chemical,D002444,16540070,Cefuroxime,O1R9FJ93ED,,,,
12460,Chemical,D003023,16540070,Cloxacillin,O6X5QGC2VB,,,,
12461,DescriptorName,D000038,16540070,,,1,Abscess,N,
12462,QualifierName,Q000188,16540070,,,1,,N,drug therapy
12463,DescriptorName,D000658,16540070,,,2,Amoxicillin,N,
12464,DescriptorName,D000799,16540070,,,3,Angioedema,N,
12465,QualifierName,Q000139,16540070,,,3,,Y,chemically induced
12466,DescriptorName,D002444,16540070,,,4,Cefuroxime,N,
12467,DescriptorName,D002481,16540070,,,5,Cellulitis,N,
12468,QualifierName,Q000188,16540070,,,5,,N,drug therapy
12469,DescriptorName,D003023,16540070,,,6,Cloxacillin,N,
12470,QualifierName,Q000009,16540070,,,6,,Y,adverse effects
12471,DescriptorName,D003875,16540070,,,7,Drug Eruptions,N,
12472,QualifierName,Q000209,16540070,,,7,,Y,etiology
12473,DescriptorName,D005260,16540070,,,8,Female,N,
12474,DescriptorName,D006801,16540070,,,9,Humans,N,
12475,DescriptorName,D007428,16540070,,,10,Intradermal Tests,N,
12476,DescriptorName,D008875,16540070,,,11,Middle Aged,N,
12477,DescriptorName,D016037,16540070,,,12,Single-Blind Method,N,
12478,DescriptorName,D012882,16540070,,,13,Skin Tests,N,
12479,Chemical,D002330,1655228,Carmustine,U68WG3173Y,,,,
12480,DescriptorName,D000328,1655228,,,1,Adult,N,
12481,DescriptorName,D000787,1655228,,,2,Angina Pectoris,N,
12482,QualifierName,Q000139,1655228,,,2,,Y,chemically induced
12483,DescriptorName,D000971,1655228,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
12484,QualifierName,Q000627,1655228,,,3,,N,therapeutic use
12485,DescriptorName,D016026,1655228,,,4,Bone Marrow Transplantation,N,
12486,DescriptorName,D001943,1655228,,,5,Breast Neoplasms,N,
12487,QualifierName,Q000188,1655228,,,5,,N,drug therapy
12488,DescriptorName,D002277,1655228,,,6,Carcinoma,N,
12489,QualifierName,Q000188,1655228,,,6,,N,drug therapy
12490,DescriptorName,D002285,1655228,,,7,"Carcinoma, Intraductal, Noninfiltrating",N,
12491,QualifierName,Q000188,1655228,,,7,,N,drug therapy
12492,DescriptorName,D002330,1655228,,,8,Carmustine,N,
12493,QualifierName,Q000008,1655228,,,8,,N,administration & dosage
12494,DescriptorName,D003131,1655228,,,9,Combined Modality Therapy,N,
12495,DescriptorName,D003327,1655228,,,10,Coronary Disease,N,
12496,QualifierName,Q000139,1655228,,,10,,Y,chemically induced
12497,DescriptorName,D004562,1655228,,,11,Electrocardiography,N,
12498,QualifierName,Q000187,1655228,,,11,,N,drug effects
12499,DescriptorName,D005260,1655228,,,12,Female,N,
12500,DescriptorName,D006801,1655228,,,13,Humans,N,
12501,DescriptorName,D007262,1655228,,,14,"Infusions, Intravenous",N,
12502,DescriptorName,D008545,1655228,,,15,Melanoma,N,
12503,QualifierName,Q000188,1655228,,,15,,N,drug therapy
12504,DescriptorName,D013616,1655228,,,16,"Tachycardia, Sinus",N,
12505,QualifierName,Q000139,1655228,,,16,,N,chemically induced
12506,Chemical,D000894,16599252,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
12507,Chemical,D020024,16599252,Leukotriene Antagonists,0,,,,
12508,Chemical,D014105,16599252,Tosyl Compounds,0,,,,
12509,Chemical,C062735,16599252,zafirlukast,XZ629S5L50,,,,
12510,DescriptorName,D000894,16599252,,,1,"Anti-Inflammatory Agents, Non-Steroidal",N,
12511,QualifierName,Q000276,16599252,,,1,,N,immunology
12512,DescriptorName,D001249,16599252,,,2,Asthma,N,
12513,QualifierName,Q000188,16599252,,,2,,Y,drug therapy
12514,DescriptorName,D015267,16599252,,,3,Churg-Strauss Syndrome,N,
12515,QualifierName,Q000139,16599252,,,3,,Y,chemically induced
12516,DescriptorName,D006801,16599252,,,4,Humans,N,
12517,DescriptorName,D020024,16599252,,,5,Leukotriene Antagonists,N,
12518,QualifierName,Q000009,16599252,,,5,,Y,adverse effects
12519,DescriptorName,D008297,16599252,,,6,Male,N,
12520,DescriptorName,D008875,16599252,,,7,Middle Aged,N,
12521,DescriptorName,D014105,16599252,,,8,Tosyl Compounds,N,
12522,QualifierName,Q000009,16599252,,,8,,Y,adverse effects
12523,Chemical,D011994,16603845,Recombinant Proteins,0,,,,
12524,Chemical,D016179,16603845,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
12525,Chemical,C455861,16603845,pegfilgrastim,3A58010674,,,,
12526,Chemical,D011092,16603845,Polyethylene Glycols,3WJQ0SDW1A,,,,
12527,Chemical,D000069585,16603845,Filgrastim,PVI5M0M1GW,,,,
12528,DescriptorName,D000328,16603845,,,1,Adult,N,
12529,DescriptorName,D000069585,16603845,,,2,Filgrastim,N,
12530,DescriptorName,D016179,16603845,,,3,Granulocyte Colony-Stimulating Factor,N,
12531,QualifierName,Q000009,16603845,,,3,,Y,adverse effects
12532,DescriptorName,D006689,16603845,,,4,Hodgkin Disease,N,
12533,QualifierName,Q000188,16603845,,,4,,N,drug therapy
12534,DescriptorName,D006801,16603845,,,5,Humans,N,
12535,DescriptorName,D008297,16603845,,,6,Male,N,
12536,DescriptorName,D011092,16603845,,,7,Polyethylene Glycols,N,
12537,DescriptorName,D017511,16603845,,,8,Pyoderma Gangrenosum,N,
12538,QualifierName,Q000139,16603845,,,8,,Y,chemically induced
12539,DescriptorName,D011994,16603845,,,9,Recombinant Proteins,N,
12540,DescriptorName,D012883,16603845,,,10,Skin Ulcer,N,
12541,QualifierName,Q000139,16603845,,,10,,N,chemically induced
12542,Chemical,D001323,16609346,Autoantibodies,0,,,,
12543,Chemical,D005464,16609346,Fluorobenzenes,0,,,,
12544,Chemical,D019161,16609346,Hydroxymethylglutaryl-CoA Reductase Inhibitors,0,,,,
12545,Chemical,D011743,16609346,Pyrimidines,0,,,,
12546,Chemical,D011950,16609346,"Receptors, Cholinergic",0,,,,
12547,Chemical,D013449,16609346,Sulfonamides,0,,,,
12548,Chemical,D000068718,16609346,Rosuvastatin Calcium,83MVU38M7Q,,,,
12549,Chemical,D019821,16609346,Simvastatin,AGG2FN16EV,,,,
12550,Chemical,D017035,16609346,Pravastatin,KXO2KT9N0G,,,,
12551,DescriptorName,D000368,16609346,,,1,Aged,N,
12552,DescriptorName,D001323,16609346,,,2,Autoantibodies,N,
12553,QualifierName,Q000097,16609346,,,2,,N,blood
12554,DescriptorName,D005260,16609346,,,3,Female,N,
12555,DescriptorName,D005464,16609346,,,4,Fluorobenzenes,N,
12556,QualifierName,Q000008,16609346,,,4,,N,administration & dosage
12557,DescriptorName,D006801,16609346,,,5,Humans,N,
12558,DescriptorName,D019161,16609346,,,6,Hydroxymethylglutaryl-CoA Reductase Inhibitors,N,
12559,QualifierName,Q000009,16609346,,,6,,Y,adverse effects
12560,DescriptorName,D006949,16609346,,,7,Hyperlipidemias,N,
12561,QualifierName,Q000188,16609346,,,7,,N,drug therapy
12562,DescriptorName,D008297,16609346,,,8,Male,N,
12563,DescriptorName,D008875,16609346,,,9,Middle Aged,N,
12564,DescriptorName,D009157,16609346,,,10,Myasthenia Gravis,N,
12565,QualifierName,Q000139,16609346,,,10,,Y,chemically induced
12566,DescriptorName,D017035,16609346,,,11,Pravastatin,N,
12567,QualifierName,Q000009,16609346,,,11,,N,adverse effects
12568,DescriptorName,D011743,16609346,,,12,Pyrimidines,N,
12569,QualifierName,Q000008,16609346,,,12,,N,administration & dosage
12570,DescriptorName,D011950,16609346,,,13,"Receptors, Cholinergic",N,
12571,QualifierName,Q000276,16609346,,,13,,N,immunology
12572,DescriptorName,D000068718,16609346,,,14,Rosuvastatin Calcium,N,
12573,DescriptorName,D019821,16609346,,,15,Simvastatin,N,
12574,QualifierName,Q000009,16609346,,,15,,N,adverse effects
12575,DescriptorName,D013449,16609346,,,16,Sulfonamides,N,
12576,QualifierName,Q000008,16609346,,,16,,N,administration & dosage
12577,Chemical,D007166,1661260,Immunosuppressive Agents,0,,,,
12578,DescriptorName,D000368,1661260,,,1,Aged,N,
12579,DescriptorName,D003586,1661260,,,2,Cytomegalovirus Infections,N,
12580,QualifierName,Q000150,1661260,,,2,,Y,complications
12581,DescriptorName,D005260,1661260,,,3,Female,N,
12582,DescriptorName,D006471,1661260,,,4,Gastrointestinal Hemorrhage,N,
12583,QualifierName,Q000209,1661260,,,4,,Y,etiology
12584,DescriptorName,D014890,1661260,,,5,Granulomatosis with Polyangiitis,N,
12585,QualifierName,Q000188,1661260,,,5,,N,drug therapy
12586,DescriptorName,D006801,1661260,,,6,Humans,N,
12587,DescriptorName,D007077,1661260,,,7,Ileal Diseases,N,
12588,QualifierName,Q000209,1661260,,,7,,Y,etiology
12589,DescriptorName,D007166,1661260,,,8,Immunosuppressive Agents,N,
12590,QualifierName,Q000009,1661260,,,8,,N,adverse effects
12591,DescriptorName,D009894,1661260,,,9,Opportunistic Infections,N,
12592,QualifierName,Q000150,1661260,,,9,,Y,complications
12593,DescriptorName,D014657,1661260,,,10,Vasculitis,N,
12594,QualifierName,Q000150,1661260,,,10,,Y,complications
12595,Chemical,D018501,16615675,Antirheumatic Agents,0,,,,
12596,Chemical,D006886,16615675,Hydroxychloroquine,4QWG6N8QKH,,,,
12597,DescriptorName,D000368,16615675,,,1,Aged,N,
12598,DescriptorName,D018501,16615675,,,2,Antirheumatic Agents,N,
12599,QualifierName,Q000008,16615675,,,2,,N,administration & dosage
12600,DescriptorName,D004562,16615675,,,3,Electrocardiography,N,
12601,DescriptorName,D005260,16615675,,,4,Female,N,
12602,DescriptorName,D006801,16615675,,,5,Humans,N,
12603,DescriptorName,D006886,16615675,,,6,Hydroxychloroquine,N,
12604,QualifierName,Q000008,16615675,,,6,,N,administration & dosage
12605,DescriptorName,D008133,16615675,,,7,Long QT Syndrome,N,
12606,QualifierName,Q000139,16615675,,,7,,Y,chemically induced
12607,DescriptorName,D008180,16615675,,,8,"Lupus Erythematosus, Systemic",N,
12608,QualifierName,Q000188,16615675,,,8,,N,drug therapy
12609,DescriptorName,D013997,16615675,,,9,Time Factors,N,
12610,DescriptorName,D018879,16615675,,,10,Ventricular Premature Complexes,N,
12611,QualifierName,Q000139,16615675,,,10,,Y,chemically induced
12612,Chemical,D007004,16620273,Hypoglycemic Agents,0,,,,
12613,Chemical,D008687,16620273,Metformin,9100L32L2N,,,,
12614,DescriptorName,D018806,16620273,,,1,APACHE,N,
12615,DescriptorName,D000140,16620273,,,2,"Acidosis, Lactic",N,
12616,QualifierName,Q000139,16620273,,,2,,Y,chemically induced
12617,DescriptorName,D058186,16620273,,,3,Acute Kidney Injury,N,
12618,QualifierName,Q000139,16620273,,,3,,N,chemically induced
12619,DescriptorName,D000368,16620273,,,4,Aged,N,
12620,DescriptorName,D000369,16620273,,,5,"Aged, 80 and over",N,
12621,DescriptorName,D003924,16620273,,,6,"Diabetes Mellitus, Type 2",N,
12622,QualifierName,Q000150,16620273,,,6,,N,complications
12623,DescriptorName,D004630,16620273,,,7,Emergencies,N,
12624,DescriptorName,D005260,16620273,,,8,Female,N,
12625,DescriptorName,D006801,16620273,,,9,Humans,N,
12626,DescriptorName,D007004,16620273,,,10,Hypoglycemic Agents,N,
12627,QualifierName,Q000009,16620273,,,10,,Y,adverse effects
12628,DescriptorName,D008297,16620273,,,11,Male,N,
12629,DescriptorName,D008687,16620273,,,12,Metformin,N,
12630,QualifierName,Q000009,16620273,,,12,,Y,adverse effects
12631,DescriptorName,D008875,16620273,,,13,Middle Aged,N,
12632,DescriptorName,D015996,16620273,,,14,Survival Rate,N,
12633,Chemical,D014150,16623611,Antipsychotic Agents,0,,,,
12634,Chemical,D007004,16623611,Hypoglycemic Agents,0,,,,
12635,Chemical,D001569,16623611,Benzodiazepines,12794-10-4,,,,
12636,Chemical,D000077152,16623611,Olanzapine,N7U69T4SZR,,,,
12637,DescriptorName,D014150,16623611,,,1,Antipsychotic Agents,N,
12638,QualifierName,Q000009,16623611,,,1,,Y,adverse effects
12639,DescriptorName,D001569,16623611,,,2,Benzodiazepines,N,
12640,QualifierName,Q000009,16623611,,,2,,N,adverse effects
12641,DescriptorName,D001714,16623611,,,3,Bipolar Disorder,N,
12642,QualifierName,Q000150,16623611,,,3,,N,complications
12643,DescriptorName,D003924,16623611,,,4,"Diabetes Mellitus, Type 2",N,
12644,QualifierName,Q000150,16623611,,,4,,Y,complications
12645,DescriptorName,D006801,16623611,,,5,Humans,N,
12646,DescriptorName,D006943,16623611,,,6,Hyperglycemia,N,
12647,QualifierName,Q000139,16623611,,,6,,Y,chemically induced
12648,DescriptorName,D007004,16623611,,,7,Hypoglycemic Agents,N,
12649,QualifierName,Q000627,16623611,,,7,,N,therapeutic use
12650,DescriptorName,D008297,16623611,,,8,Male,N,
12651,DescriptorName,D008875,16623611,,,9,Middle Aged,N,
12652,DescriptorName,D000077152,16623611,,,10,Olanzapine,N,
12653,DescriptorName,D015430,16623611,,,11,Weight Gain,N,
12654,QualifierName,Q000187,16623611,,,11,,Y,drug effects
12655,Chemical,D000900,16629074,Anti-Bacterial Agents,0,,,,
12656,Chemical,D009883,16629074,Ophthalmic Solutions,0,,,,
12657,DescriptorName,D000328,16629074,,,1,Adult,N,
12658,DescriptorName,D000900,16629074,,,2,Anti-Bacterial Agents,N,
12659,QualifierName,Q000008,16629074,,,2,,N,administration & dosage
12660,DescriptorName,D003315,16629074,,,3,Cornea,N,
12661,QualifierName,Q000382,16629074,,,3,,N,microbiology
12662,DescriptorName,D065306,16629074,,,4,Corneal Injuries,N,
12663,DescriptorName,D004754,16629074,,,5,Enterobacter,N,
12664,QualifierName,Q000302,16629074,,,5,,N,isolation & purification
12665,DescriptorName,D004756,16629074,,,6,Enterobacteriaceae Infections,N,
12666,QualifierName,Q000188,16629074,,,6,,N,drug therapy
12667,DescriptorName,D015818,16629074,,,7,"Eye Infections, Bacterial",N,
12668,QualifierName,Q000188,16629074,,,7,,N,drug therapy
12669,DescriptorName,D005500,16629074,,,8,Follow-Up Studies,N,
12670,DescriptorName,D006801,16629074,,,9,Humans,N,
12671,DescriptorName,D007634,16629074,,,10,Keratitis,N,
12672,QualifierName,Q000188,16629074,,,10,,N,drug therapy
12673,DescriptorName,D020731,16629074,,,11,"Keratomileusis, Laser In Situ",N,
12674,QualifierName,Q000009,16629074,,,11,,Y,adverse effects
12675,DescriptorName,D008297,16629074,,,12,Male,N,
12676,DescriptorName,D009883,16629074,,,13,Ophthalmic Solutions,N,
12677,DescriptorName,D013524,16629074,,,14,Surgical Flaps,Y,
12678,DescriptorName,D013529,16629074,,,15,Surgical Wound Dehiscence,N,
12679,QualifierName,Q000188,16629074,,,15,,N,drug therapy
12680,Chemical,D000893,16632429,Anti-Inflammatory Agents,0,,,,
12681,Chemical,D043823,16632429,Taxoids,0,,,,
12682,Chemical,D003841,16632429,Deoxycytidine,0W860991D6,,,,
12683,Chemical,D000077143,16632429,Docetaxel,15H5577CQD,,,,
12684,Chemical,C056507,16632429,gemcitabine,B76N6SBZ8R,,,,
12685,Chemical,D008775,16632429,Methylprednisolone,X4W7ZR7023,,,,
12686,DescriptorName,D002282,16632429,,,1,"Adenocarcinoma, Bronchiolo-Alveolar",N,
12687,QualifierName,Q000139,16632429,,,1,,N,chemically induced
12688,DescriptorName,D000893,16632429,,,2,Anti-Inflammatory Agents,N,
12689,QualifierName,Q000627,16632429,,,2,,N,therapeutic use
12690,DescriptorName,D000971,16632429,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
12691,QualifierName,Q000009,16632429,,,3,,Y,adverse effects
12692,DescriptorName,D018549,16632429,,,4,Cryptogenic Organizing Pneumonia,N,
12693,QualifierName,Q000139,16632429,,,4,,N,chemically induced
12694,DescriptorName,D003841,16632429,,,5,Deoxycytidine,N,
12695,QualifierName,Q000008,16632429,,,5,,N,administration & dosage
12696,DescriptorName,D003937,16632429,,,6,"Diagnosis, Differential",N,
12697,DescriptorName,D018450,16632429,,,7,Disease Progression,N,
12698,DescriptorName,D000077143,16632429,,,8,Docetaxel,N,
12699,DescriptorName,D006801,16632429,,,9,Humans,N,
12700,DescriptorName,D008175,16632429,,,10,Lung Neoplasms,N,
12701,QualifierName,Q000150,16632429,,,10,,N,complications
12702,DescriptorName,D008297,16632429,,,11,Male,N,
12703,DescriptorName,D008775,16632429,,,12,Methylprednisolone,N,
12704,QualifierName,Q000627,16632429,,,12,,N,therapeutic use
12705,DescriptorName,D008875,16632429,,,13,Middle Aged,N,
12706,DescriptorName,D012131,16632429,,,14,Respiratory Insufficiency,N,
12707,QualifierName,Q000209,16632429,,,14,,N,etiology
12708,DescriptorName,D043823,16632429,,,15,Taxoids,N,
12709,QualifierName,Q000008,16632429,,,15,,N,administration & dosage
12710,DescriptorName,D014057,16632429,,,16,"Tomography, X-Ray Computed",N,
12711,Chemical,D000925,16637972,Anticoagulants,0,,,,
12712,Chemical,D014859,16637972,Warfarin,5Q7ZVV76EI,,,,
12713,DescriptorName,D000368,16637972,,,1,Aged,N,
12714,DescriptorName,D000925,16637972,,,2,Anticoagulants,N,
12715,QualifierName,Q000009,16637972,,,2,,Y,adverse effects
12716,DescriptorName,D001281,16637972,,,3,Atrial Fibrillation,N,
12717,QualifierName,Q000188,16637972,,,3,,N,drug therapy
12718,DescriptorName,D003229,16637972,,,4,Conjunctival Diseases,N,
12719,QualifierName,Q000139,16637972,,,4,,Y,chemically induced
12720,DescriptorName,D005130,16637972,,,5,Eye Hemorrhage,N,
12721,QualifierName,Q000139,16637972,,,5,,Y,chemically induced
12722,DescriptorName,D006406,16637972,,,6,Hematoma,N,
12723,QualifierName,Q000139,16637972,,,6,,Y,chemically induced
12724,DescriptorName,D006801,16637972,,,7,Humans,N,
12725,DescriptorName,D008297,16637972,,,8,Male,N,
12726,DescriptorName,D014859,16637972,,,9,Warfarin,N,
12727,QualifierName,Q000009,16637972,,,9,,Y,adverse effects
12728,Chemical,D000927,16641839,Anticonvulsants,0,,,,
12729,Chemical,D002220,16641839,Carbamazepine,33CM23913M,,,,
12730,DescriptorName,D000328,16641839,,,1,Adult,N,
12731,DescriptorName,D000799,16641839,,,2,Angioedema,N,
12732,QualifierName,Q000139,16641839,,,2,,Y,chemically induced
12733,DescriptorName,D000927,16641839,,,3,Anticonvulsants,N,
12734,QualifierName,Q000009,16641839,,,3,,Y,adverse effects
12735,DescriptorName,D002220,16641839,,,4,Carbamazepine,N,
12736,QualifierName,Q000009,16641839,,,4,,Y,adverse effects
12737,DescriptorName,D003875,16641839,,,5,Drug Eruptions,N,
12738,QualifierName,Q000209,16641839,,,5,,Y,etiology
12739,DescriptorName,D005260,16641839,,,6,Female,N,
12740,DescriptorName,D006801,16641839,,,7,Humans,N,
12741,DescriptorName,D010267,16641839,,,8,Parapsoriasis,N,
12742,QualifierName,Q000139,16641839,,,8,,Y,chemically induced
12743,DescriptorName,D011618,16641839,,,9,Psychotic Disorders,N,
12744,QualifierName,Q000188,16641839,,,9,,N,drug therapy
12745,DescriptorName,D011644,16641839,,,10,Puerperal Disorders,N,
12746,QualifierName,Q000188,16641839,,,10,,N,drug therapy
12747,DescriptorName,D012720,16641839,,,11,Severity of Illness Index,N,
12748,Chemical,D000911,16678268,"Antibodies, Monoclonal",0,,,,
12749,Chemical,D014409,16678268,Tumor Necrosis Factor-alpha,0,,,,
12750,Chemical,D000069285,16678268,Infliximab,B72HH48FLU,,,,
12751,DescriptorName,D000258,16678268,,,1,"Adenovirus Infections, Human",N,
12752,QualifierName,Q000209,16678268,,,1,,Y,etiology
12753,DescriptorName,D000328,16678268,,,2,Adult,N,
12754,DescriptorName,D000911,16678268,,,3,"Antibodies, Monoclonal",N,
12755,QualifierName,Q000009,16678268,,,3,,Y,adverse effects
12756,DescriptorName,D003424,16678268,,,4,Crohn Disease,N,
12757,QualifierName,Q000150,16678268,,,4,,Y,complications
12758,DescriptorName,D006801,16678268,,,5,Humans,N,
12759,DescriptorName,D000069285,16678268,,,6,Infliximab,N,
12760,DescriptorName,D008297,16678268,,,7,Male,N,
12761,DescriptorName,D011024,16678268,,,8,"Pneumonia, Viral",N,
12762,QualifierName,Q000209,16678268,,,8,,Y,etiology
12763,DescriptorName,D014409,16678268,,,9,Tumor Necrosis Factor-alpha,N,
12764,QualifierName,Q000037,16678268,,,9,,N,antagonists & inhibitors
12765,DescriptorName,D014481,16678268,,,10,United States,N,
12766,Chemical,D000977,16682062,Antiparasitic Agents,0,,,,
12767,Chemical,D007559,16682062,Ivermectin,70288-86-7,,,,
12768,DescriptorName,D000328,16682062,,,1,Adult,N,
12769,DescriptorName,D000818,16682062,,,2,Animals,N,
12770,DescriptorName,D000977,16682062,,,3,Antiparasitic Agents,N,
12771,QualifierName,Q000009,16682062,,,3,,Y,adverse effects
12772,DescriptorName,D002163,16682062,,,4,Cameroon,N,
12773,DescriptorName,D056486,16682062,,,5,Chemical and Drug Induced Liver Injury,N,
12774,QualifierName,Q000209,16682062,,,5,,Y,etiology
12775,DescriptorName,D005260,16682062,,,6,Female,N,
12776,DescriptorName,D006801,16682062,,,7,Humans,N,
12777,DescriptorName,D007559,16682062,,,8,Ivermectin,N,
12778,QualifierName,Q000009,16682062,,,8,,Y,adverse effects
12779,DescriptorName,D008117,16682062,,,9,Loa,N,
12780,QualifierName,Q000302,16682062,,,9,,N,isolation & purification
12781,DescriptorName,D008118,16682062,,,10,Loiasis,N,
12782,QualifierName,Q000188,16682062,,,10,,Y,drug therapy
12783,DescriptorName,D008842,16682062,,,11,Microfilariae,N,
12784,QualifierName,Q000302,16682062,,,11,,N,isolation & purification
12785,Chemical,D011838,16685112,Radiation-Sensitizing Agents,0,,,,
12786,Chemical,D003841,16685112,Deoxycytidine,0W860991D6,,,,
12787,Chemical,C056507,16685112,gemcitabine,B76N6SBZ8R,,,,
12788,DescriptorName,D000009,16685112,,,1,Abdominal Muscles,Y,
12789,DescriptorName,D003841,16685112,,,2,Deoxycytidine,N,
12790,QualifierName,Q000009,16685112,,,2,,N,adverse effects
12791,DescriptorName,D006801,16685112,,,3,Humans,N,
12792,DescriptorName,D008297,16685112,,,4,Male,N,
12793,DescriptorName,D008875,16685112,,,5,Middle Aged,N,
12794,DescriptorName,D009220,16685112,,,6,Myositis,N,
12795,QualifierName,Q000139,16685112,,,6,,N,chemically induced
12796,DescriptorName,D010190,16685112,,,7,Pancreatic Neoplasms,N,
12797,QualifierName,Q000188,16685112,,,7,,N,drug therapy
12798,DescriptorName,D011832,16685112,,,8,Radiation Injuries,N,
12799,QualifierName,Q000150,16685112,,,8,,Y,complications
12800,DescriptorName,D011838,16685112,,,9,Radiation-Sensitizing Agents,N,
12801,QualifierName,Q000009,16685112,,,9,,Y,adverse effects
12802,DescriptorName,D011855,16685112,,,10,Radiodermatitis,N,
12803,QualifierName,Q000209,16685112,,,10,,N,etiology
12804,DescriptorName,D014057,16685112,,,11,"Tomography, X-Ray Computed",N,
12805,Chemical,D000924,16688722,Anticholesteremic Agents,0,,,,
12806,Chemical,C417736,16688722,"CAV3 protein, human",0,,,,
12807,Chemical,D051244,16688722,Caveolin 3,0,,,,
12808,Chemical,C114839,16688722,"DYSF protein, human",0,,,,
12809,Chemical,D000073939,16688722,Dysferlin,0,,,,
12810,Chemical,D008565,16688722,Membrane Proteins,0,,,,
12811,Chemical,D009124,16688722,Muscle Proteins,0,,,,
12812,Chemical,D019821,16688722,Simvastatin,AGG2FN16EV,,,,
12813,Chemical,D002118,16688722,Calcium,SY7Q814VUP,,,,
12814,DescriptorName,D000924,16688722,,,1,Anticholesteremic Agents,N,
12815,QualifierName,Q000009,16688722,,,1,,Y,adverse effects
12816,DescriptorName,D002118,16688722,,,2,Calcium,N,
12817,QualifierName,Q000378,16688722,,,2,,N,metabolism
12818,DescriptorName,D051244,16688722,,,3,Caveolin 3,N,
12819,QualifierName,Q000378,16688722,,,3,,N,metabolism
12820,DescriptorName,D000073939,16688722,,,4,Dysferlin,N,
12821,DescriptorName,D006706,16688722,,,5,Homeostasis,N,
12822,QualifierName,Q000502,16688722,,,5,,N,physiology
12823,DescriptorName,D006801,16688722,,,6,Humans,N,
12824,DescriptorName,D006937,16688722,,,7,Hypercholesterolemia,N,
12825,QualifierName,Q000188,16688722,,,7,,N,drug therapy
12826,DescriptorName,D008297,16688722,,,8,Male,N,
12827,DescriptorName,D008565,16688722,,,9,Membrane Proteins,N,
12828,QualifierName,Q000378,16688722,,,9,,N,metabolism
12829,DescriptorName,D008875,16688722,,,10,Middle Aged,N,
12830,DescriptorName,D009119,16688722,,,11,Muscle Contraction,N,
12831,QualifierName,Q000187,16688722,,,11,,N,drug effects
12832,DescriptorName,D009124,16688722,,,12,Muscle Proteins,N,
12833,QualifierName,Q000378,16688722,,,12,,N,metabolism
12834,DescriptorName,D018482,16688722,,,13,"Muscle, Skeletal",N,
12835,QualifierName,Q000187,16688722,,,13,,N,drug effects
12836,DescriptorName,D009135,16688722,,,14,Muscular Diseases,N,
12837,QualifierName,Q000139,16688722,,,14,,Y,chemically induced
12838,DescriptorName,D009157,16688722,,,15,Myasthenia Gravis,N,
12839,DescriptorName,D019821,16688722,,,16,Simvastatin,N,
12840,QualifierName,Q000009,16688722,,,16,,Y,adverse effects
12841,Chemical,D000964,16697705,"Antimetabolites, Antineoplastic",0,,,,
12842,Chemical,D011355,16697705,Prodrugs,0,,,,
12843,Chemical,D003841,16697705,Deoxycytidine,0W860991D6,,,,
12844,Chemical,D000069287,16697705,Capecitabine,6804DJ8Z9U,,,,
12845,Chemical,D005472,16697705,Fluorouracil,U3P01618RT,,,,
12846,DescriptorName,D000964,16697705,,,1,"Antimetabolites, Antineoplastic",N,
12847,QualifierName,Q000009,16697705,,,1,,Y,adverse effects
12848,DescriptorName,D000069287,16697705,,,2,Capecitabine,N,
12849,DescriptorName,D003110,16697705,,,3,Colonic Neoplasms,N,
12850,QualifierName,Q000188,16697705,,,3,,N,drug therapy
12851,DescriptorName,D017023,16697705,,,4,Coronary Angiography,N,
12852,DescriptorName,D003327,16697705,,,5,Coronary Disease,N,
12853,QualifierName,Q000139,16697705,,,5,,Y,chemically induced
12854,DescriptorName,D003841,16697705,,,6,Deoxycytidine,N,
12855,QualifierName,Q000009,16697705,,,6,,N,adverse effects
12856,DescriptorName,D003937,16697705,,,7,"Diagnosis, Differential",N,
12857,DescriptorName,D004562,16697705,,,8,Electrocardiography,N,
12858,QualifierName,Q000187,16697705,,,8,,N,drug effects
12859,DescriptorName,D005260,16697705,,,9,Female,N,
12860,DescriptorName,D005472,16697705,,,10,Fluorouracil,N,
12861,QualifierName,Q000009,16697705,,,10,,N,adverse effects
12862,DescriptorName,D006801,16697705,,,11,Humans,N,
12863,DescriptorName,D008875,16697705,,,12,Middle Aged,N,
12864,DescriptorName,D011355,16697705,,,13,Prodrugs,N,
12865,Chemical,D000927,16708747,Anticonvulsants,0,,,,
12866,Chemical,D002220,16708747,Carbamazepine,33CM23913M,,,,
12867,DescriptorName,D000208,16708747,,,1,Acute Disease,N,
12868,DescriptorName,D000328,16708747,,,2,Adult,N,
12869,DescriptorName,D000927,16708747,,,3,Anticonvulsants,N,
12870,QualifierName,Q000009,16708747,,,3,,Y,adverse effects
12871,DescriptorName,D002220,16708747,,,4,Carbamazepine,N,
12872,QualifierName,Q000009,16708747,,,4,,Y,adverse effects
12873,DescriptorName,D016903,16708747,,,5,Drug Monitoring,N,
12874,DescriptorName,D064420,16708747,,,6,Drug-Related Side Effects and Adverse Reactions,N,
12875,QualifierName,Q000628,16708747,,,6,,N,therapy
12876,DescriptorName,D004834,16708747,,,7,"Epilepsy, Post-Traumatic",N,
12877,QualifierName,Q000188,16708747,,,7,,N,drug therapy
12878,DescriptorName,D005260,16708747,,,8,Female,N,
12879,DescriptorName,D006801,16708747,,,9,Humans,N,
12880,DescriptorName,D006435,16708747,,,10,Renal Dialysis,N,
12881,QualifierName,Q000295,16708747,,,10,,N,instrumentation
12882,Chemical,D019382,16728538,Human Growth Hormone,12629-01-5,,,,
12883,Chemical,D005723,16728538,gamma-Glutamyltransferase,EC 2.3.2.2,,,,
12884,Chemical,D001219,16728538,Aspartate Aminotransferases,EC 2.6.1.1,,,,
12885,Chemical,D000410,16728538,Alanine Transaminase,EC 2.6.1.2,,,,
12886,Chemical,C406545,16728538,pegvisomant,N824AOU5XV,,,,
12887,Chemical,D015282,16728538,Octreotide,RWM8CCW8GP,,,,
12888,DescriptorName,D000172,16728538,,,1,Acromegaly,N,
12889,QualifierName,Q000150,16728538,,,1,,N,complications
12890,DescriptorName,D000410,16728538,,,2,Alanine Transaminase,N,
12891,QualifierName,Q000097,16728538,,,2,,N,blood
12892,DescriptorName,D001219,16728538,,,3,Aspartate Aminotransferases,N,
12893,QualifierName,Q000097,16728538,,,3,,N,blood
12894,DescriptorName,D056486,16728538,,,4,Chemical and Drug Induced Liver Injury,N,
12895,QualifierName,Q000209,16728538,,,4,,Y,etiology
12896,DescriptorName,D019382,16728538,,,5,Human Growth Hormone,N,
12897,QualifierName,Q000009,16728538,,,5,,N,adverse effects
12898,DescriptorName,D006801,16728538,,,6,Humans,N,
12899,DescriptorName,D008099,16728538,,,7,Liver,N,
12900,QualifierName,Q000201,16728538,,,7,,N,enzymology
12901,DescriptorName,D008297,16728538,,,8,Male,N,
12902,DescriptorName,D008875,16728538,,,9,Middle Aged,N,
12903,DescriptorName,D015282,16728538,,,10,Octreotide,N,
12904,QualifierName,Q000627,16728538,,,10,,Y,therapeutic use
12905,DescriptorName,D005723,16728538,,,11,gamma-Glutamyltransferase,N,
12906,QualifierName,Q000097,16728538,,,11,,N,blood
12907,Chemical,D004337,1673494,Drug Carriers,0,,,,
12908,Chemical,D008081,1673494,Liposomes,0,,,,
12909,Chemical,C068538,1673494,liposomal amphotericin B,0,,,,
12910,Chemical,D000666,1673494,Amphotericin B,7XU7A7DROE,,,,
12911,DescriptorName,D000666,1673494,,,1,Amphotericin B,N,
12912,QualifierName,Q000008,1673494,,,1,,Y,administration & dosage
12913,DescriptorName,D000818,1673494,,,2,Animals,N,
12914,DescriptorName,D004334,1673494,,,3,Drug Administration Schedule,N,
12915,DescriptorName,D004337,1673494,,,4,Drug Carriers,N,
12916,DescriptorName,D004351,1673494,,,5,Drug Resistance,N,
12917,DescriptorName,D006801,1673494,,,6,Humans,N,
12918,DescriptorName,D007223,1673494,,,7,Infant,N,
12919,DescriptorName,D007893,1673494,,,8,Leishmania donovani,N,
12920,QualifierName,Q000187,1673494,,,8,,Y,drug effects
12921,DescriptorName,D007898,1673494,,,9,"Leishmaniasis, Visceral",N,
12922,QualifierName,Q000188,1673494,,,9,,Y,drug therapy
12923,DescriptorName,D008081,1673494,,,10,Liposomes,N,
12924,DescriptorName,D008297,1673494,,,11,Male,N,
12925,DescriptorName,D051379,1673494,,,12,Mice,N,
12926,DescriptorName,D008807,1673494,,,13,"Mice, Inbred BALB C",N,
12927,DescriptorName,D008875,1673494,,,14,Middle Aged,N,
12928,Chemical,D018906,16757971,"Antineoplastic Agents, Alkylating",0,,,,
12929,Chemical,D003606,16757971,Dacarbazine,7GR28W0FJI,,,,
12930,Chemical,D000077204,16757971,Temozolomide,YF1K15M17Y,,,,
12931,DescriptorName,D018906,16757971,,,1,"Antineoplastic Agents, Alkylating",N,
12932,QualifierName,Q000009,16757971,,,1,,Y,adverse effects
12933,DescriptorName,D001922,16757971,,,2,Brain Abscess,N,
12934,QualifierName,Q000139,16757971,,,2,,Y,chemically induced
12935,DescriptorName,D001932,16757971,,,3,Brain Neoplasms,N,
12936,QualifierName,Q000188,16757971,,,3,,Y,drug therapy
12937,DescriptorName,D003606,16757971,,,4,Dacarbazine,N,
12938,QualifierName,Q000009,16757971,,,4,,N,adverse effects
12939,DescriptorName,D005909,16757971,,,5,Glioblastoma,N,
12940,QualifierName,Q000188,16757971,,,5,,Y,drug therapy
12941,DescriptorName,D006801,16757971,,,6,Humans,N,
12942,DescriptorName,D008088,16757971,,,7,Listeriosis,N,
12943,QualifierName,Q000139,16757971,,,7,,Y,chemically induced
12944,DescriptorName,D008297,16757971,,,8,Male,N,
12945,DescriptorName,D008875,16757971,,,9,Middle Aged,N,
12946,DescriptorName,D020360,16757971,,,10,Neoadjuvant Therapy,N,
12947,QualifierName,Q000009,16757971,,,10,,N,adverse effects
12948,DescriptorName,D045363,16757971,,,11,Pneumocystis carinii,Y,
12949,DescriptorName,D011020,16757971,,,12,"Pneumonia, Pneumocystis",N,
12950,QualifierName,Q000139,16757971,,,12,,Y,chemically induced
12951,DescriptorName,D012514,16757971,,,13,"Sarcoma, Kaposi",N,
12952,QualifierName,Q000139,16757971,,,13,,Y,chemically induced
12953,DescriptorName,D000077204,16757971,,,14,Temozolomide,N,
12954,Chemical,D004234,16765687,"Diuretics, Osmotic",0,,,,
12955,Chemical,D005938,16765687,Glucocorticoids,0,,,,
12956,Chemical,D000077236,16765687,Topiramate,0H73WJJ391,,,,
12957,Chemical,D005632,16765687,Fructose,30237-26-4,,,,
12958,Chemical,D008353,16765687,Mannitol,3OWL53L36A,,,,
12959,Chemical,D008775,16765687,Methylprednisolone,X4W7ZR7023,,,,
12960,DescriptorName,D000328,16765687,,,1,Adult,N,
12961,DescriptorName,D000869,16765687,,,2,Anterior Eye Segment,N,
12962,QualifierName,Q000000981,16765687,,,2,,N,diagnostic imaging
12963,DescriptorName,D004234,16765687,,,3,"Diuretics, Osmotic",N,
12964,QualifierName,Q000627,16765687,,,3,,Y,therapeutic use
12965,DescriptorName,D004359,16765687,,,4,"Drug Therapy, Combination",N,
12966,DescriptorName,D005260,16765687,,,5,Female,N,
12967,DescriptorName,D005632,16765687,,,6,Fructose,N,
12968,QualifierName,Q000009,16765687,,,6,,N,adverse effects
12969,DescriptorName,D015812,16765687,,,7,"Glaucoma, Angle-Closure",N,
12970,QualifierName,Q000139,16765687,,,7,,Y,chemically induced
12971,DescriptorName,D005938,16765687,,,8,Glucocorticoids,N,
12972,QualifierName,Q000627,16765687,,,8,,Y,therapeutic use
12973,DescriptorName,D006801,16765687,,,9,Humans,N,
12974,DescriptorName,D007429,16765687,,,10,Intraocular Pressure,N,
12975,QualifierName,Q000187,16765687,,,10,,N,drug effects
12976,DescriptorName,D008353,16765687,,,11,Mannitol,N,
12977,QualifierName,Q000627,16765687,,,11,,Y,therapeutic use
12978,DescriptorName,D008775,16765687,,,12,Methylprednisolone,N,
12979,QualifierName,Q000627,16765687,,,12,,Y,therapeutic use
12980,DescriptorName,D033401,16765687,,,13,"Microscopy, Acoustic",N,
12981,DescriptorName,D000077236,16765687,,,14,Topiramate,N,
12982,DescriptorName,D014792,16765687,,,15,Visual Acuity,N,
12983,QualifierName,Q000187,16765687,,,15,,N,drug effects
12984,Chemical,D010455,16767537,Peptides,0,,,,
12985,Chemical,D044302,16767537,"Receptor, Serotonin, 5-HT1B",0,,,,
12986,Chemical,D017366,16767537,Serotonin Receptor Agonists,0,,,,
12987,Chemical,D014662,16767537,Vasoconstrictor Agents,0,,,,
12988,Chemical,D018170,16767537,Sumatriptan,8R78F6L9VO,,,,
12989,DescriptorName,D015984,16767537,,,1,Causality,N,
12990,DescriptorName,D002536,16767537,,,2,Cerebral Arteries,N,
12991,QualifierName,Q000187,16767537,,,2,,N,drug effects
12992,DescriptorName,D005260,16767537,,,3,Female,N,
12993,DescriptorName,D006801,16767537,,,4,Humans,N,
12994,DescriptorName,D008875,16767537,,,5,Middle Aged,N,
12995,DescriptorName,D008881,16767537,,,6,Migraine Disorders,N,
12996,QualifierName,Q000188,16767537,,,6,,N,drug therapy
12997,DescriptorName,D009131,16767537,,,7,"Muscle, Smooth, Vascular",N,
12998,QualifierName,Q000187,16767537,,,7,,N,drug effects
12999,DescriptorName,D010455,16767537,,,8,Peptides,N,
13000,QualifierName,Q000037,16767537,,,8,,N,antagonists & inhibitors
13001,DescriptorName,D044302,16767537,,,9,"Receptor, Serotonin, 5-HT1B",N,
13002,QualifierName,Q000187,16767537,,,9,,N,drug effects
13003,DescriptorName,D017366,16767537,,,10,Serotonin Receptor Agonists,N,
13004,QualifierName,Q000009,16767537,,,10,,N,adverse effects
13005,DescriptorName,D013154,16767537,,,11,Spleen,N,
13006,QualifierName,Q000000981,16767537,,,11,,N,diagnostic imaging
13007,DescriptorName,D013157,16767537,,,12,Splenic Artery,N,
13008,QualifierName,Q000187,16767537,,,12,,N,drug effects
13009,DescriptorName,D013159,16767537,,,13,Splenic Infarction,N,
13010,QualifierName,Q000139,16767537,,,13,,Y,chemically induced
13011,DescriptorName,D018170,16767537,,,14,Sumatriptan,N,
13012,QualifierName,Q000009,16767537,,,14,,Y,adverse effects
13013,DescriptorName,D014057,16767537,,,15,"Tomography, X-Ray Computed",N,
13014,DescriptorName,D014661,16767537,,,16,Vasoconstriction,N,
13015,QualifierName,Q000187,16767537,,,16,,N,drug effects
13016,DescriptorName,D014662,16767537,,,17,Vasoconstrictor Agents,N,
13017,QualifierName,Q000009,16767537,,,17,,N,adverse effects
13018,Chemical,D005938,16791713,Glucocorticoids,0,,,,
13019,Chemical,D008775,16791713,Methylprednisolone,X4W7ZR7023,,,,
13020,DescriptorName,D000368,16791713,,,1,Aged,N,
13021,DescriptorName,D001794,16791713,,,2,Blood Pressure,N,
13022,QualifierName,Q000187,16791713,,,2,,N,drug effects
13023,DescriptorName,D005260,16791713,,,3,Female,N,
13024,DescriptorName,D005938,16791713,,,4,Glucocorticoids,N,
13025,QualifierName,Q000008,16791713,,,4,,Y,administration & dosage
13026,DescriptorName,D049970,16791713,,,5,Graves Ophthalmopathy,N,
13027,QualifierName,Q000188,16791713,,,5,,Y,drug therapy
13028,DescriptorName,D006801,16791713,,,6,Humans,N,
13029,DescriptorName,D006973,16791713,,,7,Hypertension,N,
13030,QualifierName,Q000139,16791713,,,7,,N,chemically induced
13031,DescriptorName,D008775,16791713,,,8,Methylprednisolone,N,
13032,QualifierName,Q000008,16791713,,,8,,Y,administration & dosage
13033,DescriptorName,D009203,16791713,,,9,Myocardial Infarction,N,
13034,QualifierName,Q000139,16791713,,,9,,Y,chemically induced
13035,Chemical,D012460,1680596,Sulfasalazine,3XC8GUZ6CB,,,,
13036,DescriptorName,D000368,1680596,,,1,Aged,N,
13037,DescriptorName,D001172,1680596,,,2,"Arthritis, Rheumatoid",N,
13038,QualifierName,Q000188,1680596,,,2,,Y,drug therapy
13039,DescriptorName,D005260,1680596,,,3,Female,N,
13040,DescriptorName,D006229,1680596,,,4,Hand Dermatoses,N,
13041,QualifierName,Q000139,1680596,,,4,,N,chemically induced
13042,DescriptorName,D006801,1680596,,,5,Humans,N,
13043,DescriptorName,D011565,1680596,,,6,Psoriasis,N,
13044,QualifierName,Q000139,1680596,,,6,,Y,chemically induced
13045,DescriptorName,D012460,1680596,,,7,Sulfasalazine,N,
13046,QualifierName,Q000009,1680596,,,7,,Y,adverse effects
13047,Chemical,D000972,16816519,"Antineoplastic Agents, Phytogenic",0,,,,
13048,Chemical,D002800,16816519,Cholinesterase Inhibitors,0,,,,
13049,Chemical,D014803,16816519,Vitamin B Complex,12001-76-2,,,,
13050,Chemical,D014750,16816519,Vincristine,5J49Q6B70F,,,,
13051,Chemical,D011736,16816519,Pyridoxine,KV2JZ1BI6Z,,,,
13052,Chemical,D011729,16816519,Pyridostigmine Bromide,KVI301NA53,,,,
13053,DescriptorName,D000972,16816519,,,1,"Antineoplastic Agents, Phytogenic",N,
13054,QualifierName,Q000009,16816519,,,1,,Y,adverse effects
13055,DescriptorName,D001763,16816519,,,2,Blepharoptosis,N,
13056,QualifierName,Q000139,16816519,,,2,,N,chemically induced
13057,DescriptorName,D002675,16816519,,,3,"Child, Preschool",N,
13058,DescriptorName,D002800,16816519,,,4,Cholinesterase Inhibitors,N,
13059,QualifierName,Q000627,16816519,,,4,,Y,therapeutic use
13060,DescriptorName,D003389,16816519,,,5,Cranial Nerve Diseases,N,
13061,QualifierName,Q000139,16816519,,,5,,Y,chemically induced
13062,DescriptorName,D005260,16816519,,,6,Female,N,
13063,DescriptorName,D006801,16816519,,,7,Humans,N,
13064,DescriptorName,D009886,16816519,,,8,Ophthalmoplegia,N,
13065,QualifierName,Q000139,16816519,,,8,,N,chemically induced
13066,DescriptorName,D011115,16816519,,,9,Polyneuropathies,N,
13067,QualifierName,Q000139,16816519,,,9,,Y,chemically induced
13068,DescriptorName,D054198,16816519,,,10,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
13069,QualifierName,Q000188,16816519,,,10,,N,drug therapy
13070,DescriptorName,D011729,16816519,,,11,Pyridostigmine Bromide,N,
13071,QualifierName,Q000627,16816519,,,11,,N,therapeutic use
13072,DescriptorName,D011736,16816519,,,12,Pyridoxine,N,
13073,QualifierName,Q000627,16816519,,,12,,N,therapeutic use
13074,DescriptorName,D014750,16816519,,,13,Vincristine,N,
13075,QualifierName,Q000009,16816519,,,13,,Y,adverse effects
13076,DescriptorName,D014803,16816519,,,14,Vitamin B Complex,N,
13077,QualifierName,Q000627,16816519,,,14,,Y,therapeutic use
13078,Chemical,D000701,16843118,"Analgesics, Opioid",0,,,,
13079,Chemical,D009020,16843118,Morphine,76I7G6D29C,,,,
13080,DescriptorName,D000208,16843118,,,1,Acute Disease,N,
13081,DescriptorName,D000328,16843118,,,2,Adult,N,
13082,DescriptorName,D000701,16843118,,,3,"Analgesics, Opioid",N,
13083,QualifierName,Q000009,16843118,,,3,,Y,adverse effects
13084,DescriptorName,D003875,16843118,,,4,Drug Eruptions,N,
13085,QualifierName,Q000276,16843118,,,4,,N,immunology
13086,DescriptorName,D005076,16843118,,,5,Exanthema,N,
13087,QualifierName,Q000139,16843118,,,5,,Y,chemically induced
13088,DescriptorName,D006801,16843118,,,6,Humans,N,
13089,DescriptorName,D008213,16843118,,,7,Lymphocyte Activation,N,
13090,DescriptorName,D008297,16843118,,,8,Male,N,
13091,DescriptorName,D009020,16843118,,,9,Morphine,N,
13092,QualifierName,Q000009,16843118,,,9,,Y,adverse effects
13093,DescriptorName,D010149,16843118,,,10,"Pain, Postoperative",N,
13094,QualifierName,Q000188,16843118,,,10,,N,drug therapy
13095,DescriptorName,D010328,16843118,,,11,Patch Tests,N,
13096,DescriptorName,D012872,16843118,,,12,"Skin Diseases, Vesiculobullous",N,
13097,QualifierName,Q000139,16843118,,,12,,Y,chemically induced
13098,Chemical,D047428,16854757,Protein Kinase Inhibitors,0,,,,
13099,Chemical,D011799,16854757,Quinazolines,0,,,,
13100,Chemical,D000069347,16854757,Erlotinib Hydrochloride,DA87705X9K,,,,
13101,Chemical,D066246,16854757,ErbB Receptors,EC 2.7.10.1,,,,
13102,DescriptorName,D000368,16854757,,,1,Aged,N,
13103,DescriptorName,D002289,16854757,,,2,"Carcinoma, Non-Small-Cell Lung",N,
13104,QualifierName,Q000188,16854757,,,2,,N,drug therapy
13105,DescriptorName,D003937,16854757,,,3,"Diagnosis, Differential",N,
13106,DescriptorName,D003875,16854757,,,4,Drug Eruptions,N,
13107,QualifierName,Q000175,16854757,,,4,,Y,diagnosis
13108,DescriptorName,D066246,16854757,,,5,ErbB Receptors,N,
13109,QualifierName,Q000037,16854757,,,5,,Y,antagonists & inhibitors
13110,DescriptorName,D000069347,16854757,,,6,Erlotinib Hydrochloride,N,
13111,DescriptorName,D006801,16854757,,,7,Humans,N,
13112,DescriptorName,D008175,16854757,,,8,Lung Neoplasms,N,
13113,QualifierName,Q000188,16854757,,,8,,N,drug therapy
13114,DescriptorName,D008297,16854757,,,9,Male,N,
13115,DescriptorName,D047428,16854757,,,10,Protein Kinase Inhibitors,N,
13116,QualifierName,Q000009,16854757,,,10,,Y,adverse effects
13117,DescriptorName,D011799,16854757,,,11,Quinazolines,N,
13118,QualifierName,Q000009,16854757,,,11,,Y,adverse effects
13119,Chemical,D014150,16863495,Antipsychotic Agents,0,,,,
13120,Chemical,D001569,16863495,Benzodiazepines,12794-10-4,,,,
13121,Chemical,D000077152,16863495,Olanzapine,N7U69T4SZR,,,,
13122,DescriptorName,D000368,16863495,,,1,Aged,N,
13123,DescriptorName,D014150,16863495,,,2,Antipsychotic Agents,N,
13124,QualifierName,Q000009,16863495,,,2,,Y,adverse effects
13125,DescriptorName,D001569,16863495,,,3,Benzodiazepines,N,
13126,QualifierName,Q000009,16863495,,,3,,N,adverse effects
13127,DescriptorName,D005260,16863495,,,4,Female,N,
13128,DescriptorName,D006801,16863495,,,5,Humans,N,
13129,DescriptorName,D009459,16863495,,,6,Neuroleptic Malignant Syndrome,N,
13130,QualifierName,Q000175,16863495,,,6,,Y,diagnosis
13131,DescriptorName,D000077152,16863495,,,7,Olanzapine,N,
13132,DescriptorName,D012563,16863495,,,8,"Schizophrenia, Paranoid",N,
13133,QualifierName,Q000188,16863495,,,8,,Y,drug therapy
13134,Chemical,D001585,16882109,Benzoyl Peroxide,W9WZN9A0GM,,,,
13135,DescriptorName,D000152,16882109,,,1,Acne Vulgaris,N,
13136,QualifierName,Q000188,16882109,,,1,,N,drug therapy
13137,DescriptorName,D000328,16882109,,,2,Adult,N,
13138,DescriptorName,D000799,16882109,,,3,Angioedema,N,
13139,QualifierName,Q000139,16882109,,,3,,Y,chemically induced
13140,DescriptorName,D001585,16882109,,,4,Benzoyl Peroxide,N,
13141,QualifierName,Q000009,16882109,,,4,,Y,adverse effects
13142,DescriptorName,D017449,16882109,,,5,"Dermatitis, Allergic Contact",N,
13143,QualifierName,Q000175,16882109,,,5,,N,diagnosis
13144,DescriptorName,D005260,16882109,,,6,Female,N,
13145,DescriptorName,D006801,16882109,,,7,Humans,N,
13146,DescriptorName,D010328,16882109,,,8,Patch Tests,N,
13147,Chemical,D000964,16884425,"Antimetabolites, Antineoplastic",0,,,,
13148,Chemical,D005472,16884425,Fluorouracil,U3P01618RT,,,,
13149,DescriptorName,D000328,16884425,,,1,Adult,N,
13150,DescriptorName,D000964,16884425,,,2,"Antimetabolites, Antineoplastic",N,
13151,QualifierName,Q000008,16884425,,,2,,N,administration & dosage
13152,DescriptorName,D001005,16884425,,,3,Anus Neoplasms,N,
13153,QualifierName,Q000188,16884425,,,3,,N,drug therapy
13154,DescriptorName,D002294,16884425,,,4,"Carcinoma, Squamous Cell",N,
13155,QualifierName,Q000188,16884425,,,4,,N,drug therapy
13156,DescriptorName,D003337,16884425,,,5,Corpus Callosum,N,
13157,DescriptorName,D005260,16884425,,,6,Female,N,
13158,DescriptorName,D005472,16884425,,,7,Fluorouracil,N,
13159,QualifierName,Q000008,16884425,,,7,,N,administration & dosage
13160,DescriptorName,D006801,16884425,,,8,Humans,N,
13161,DescriptorName,D007262,16884425,,,9,"Infusions, Intravenous",N,
13162,DescriptorName,D008279,16884425,,,10,Magnetic Resonance Imaging,N,
13163,QualifierName,Q000379,16884425,,,10,,Y,methods
13164,DescriptorName,D020258,16884425,,,11,Neurotoxicity Syndromes,N,
13165,QualifierName,Q000175,16884425,,,11,,Y,diagnosis
13166,Chemical,D000319,1688693,Adrenergic beta-Antagonists,0,,,,
13167,Chemical,D011412,1688693,Propanolamines,0,,,,
13168,Chemical,D002110,1688693,Caffeine,3G6A5W338E,,,,
13169,Chemical,C036604,1688693,esmolol,MDY902UXSR,,,,
13170,DescriptorName,D000319,1688693,,,1,Adrenergic beta-Antagonists,N,
13171,QualifierName,Q000627,1688693,,,1,,Y,therapeutic use
13172,DescriptorName,D002110,1688693,,,2,Caffeine,N,
13173,QualifierName,Q000506,1688693,,,2,,Y,poisoning
13174,DescriptorName,D005117,1688693,,,3,"Cardiac Complexes, Premature",N,
13175,QualifierName,Q000139,1688693,,,3,,N,chemically induced
13176,DescriptorName,D005260,1688693,,,4,Female,N,
13177,DescriptorName,D006801,1688693,,,5,Humans,N,
13178,DescriptorName,D007262,1688693,,,6,"Infusions, Intravenous",N,
13179,DescriptorName,D008875,1688693,,,7,Middle Aged,N,
13180,DescriptorName,D011412,1688693,,,8,Propanolamines,N,
13181,QualifierName,Q000008,1688693,,,8,,N,administration & dosage
13182,DescriptorName,D013406,1688693,,,9,"Suicide, Attempted",N,
13183,DescriptorName,D013617,1688693,,,10,"Tachycardia, Supraventricular",N,
13184,QualifierName,Q000139,1688693,,,10,,Y,chemically induced
13185,Chemical,D000894,16889287,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
13186,Chemical,D003622,16889287,Dapsone,8W5C518302,,,,
13187,DescriptorName,D000328,16889287,,,1,Adult,N,
13188,DescriptorName,D000894,16889287,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
13189,QualifierName,Q000009,16889287,,,2,,N,adverse effects
13190,DescriptorName,D003622,16889287,,,3,Dapsone,N,
13191,QualifierName,Q000009,16889287,,,3,,Y,adverse effects
13192,DescriptorName,D003874,16889287,,,4,Dermatitis Herpetiformis,N,
13193,QualifierName,Q000188,16889287,,,4,,N,drug therapy
13194,DescriptorName,D003875,16889287,,,5,Drug Eruptions,N,
13195,QualifierName,Q000209,16889287,,,5,,N,etiology
13196,DescriptorName,D004342,16889287,,,6,Drug Hypersensitivity,N,
13197,QualifierName,Q000175,16889287,,,6,,N,diagnosis
13198,DescriptorName,D005076,16889287,,,7,Exanthema,N,
13199,QualifierName,Q000175,16889287,,,7,,N,diagnosis
13200,DescriptorName,D005260,16889287,,,8,Female,N,
13201,DescriptorName,D006801,16889287,,,9,Humans,N,
13202,DescriptorName,D008708,16889287,,,10,Methemoglobinemia,N,
13203,QualifierName,Q000139,16889287,,,10,,N,chemically induced
13204,DescriptorName,D013577,16889287,,,11,Syndrome,N,
13205,Chemical,D012965,16901609,Sodium Chloride,451W47IQ8X,,,,
13206,Chemical,D003932,16901609,Heroin,70D95007SX,,,,
13207,Chemical,D004809,16901609,Ephedrine,GN83C131XS,,,,
13208,Chemical,D006854,16901609,Hydrocortisone,WI4X0X7BPJ,,,,
13209,Chemical,D004837,16901609,Epinephrine,YKH834O4BH,,,,
13210,DescriptorName,D000328,16901609,,,1,Adult,N,
13211,DescriptorName,D000707,16901609,,,2,Anaphylaxis,N,
13212,QualifierName,Q000139,16901609,,,2,,Y,chemically induced
13213,DescriptorName,D004809,16901609,,,3,Ephedrine,N,
13214,QualifierName,Q000627,16901609,,,3,,N,therapeutic use
13215,DescriptorName,D004837,16901609,,,4,Epinephrine,N,
13216,QualifierName,Q000627,16901609,,,4,,N,therapeutic use
13217,DescriptorName,D003932,16901609,,,5,Heroin,N,
13218,QualifierName,Q000008,16901609,,,5,,N,administration & dosage
13219,DescriptorName,D006801,16901609,,,6,Humans,N,
13220,DescriptorName,D006854,16901609,,,7,Hydrocortisone,N,
13221,QualifierName,Q000627,16901609,,,7,,N,therapeutic use
13222,DescriptorName,D007278,16901609,,,8,"Injections, Spinal",N,
13223,QualifierName,Q000009,16901609,,,8,,N,adverse effects
13224,DescriptorName,D008297,16901609,,,9,Male,N,
13225,DescriptorName,D015394,16901609,,,10,Molecular Structure,N,
13226,DescriptorName,D012965,16901609,,,11,Sodium Chloride,N,
13227,QualifierName,Q000627,16901609,,,11,,N,therapeutic use
13228,Chemical,D014361,16914372,Trypsin Inhibitors,0,,,,
13229,Chemical,D007611,16914372,Aprotinin,9087-70-1,,,,
13230,DescriptorName,D000125,16914372,,,1,Achilles Tendon,N,
13231,QualifierName,Q000293,16914372,,,1,,Y,injuries
13232,DescriptorName,D007611,16914372,,,2,Aprotinin,N,
13233,QualifierName,Q000009,16914372,,,2,,Y,adverse effects
13234,DescriptorName,D004342,16914372,,,3,Drug Hypersensitivity,Y,
13235,DescriptorName,D005260,16914372,,,4,Female,N,
13236,DescriptorName,D006801,16914372,,,5,Humans,N,
13237,DescriptorName,D008875,16914372,,,6,Middle Aged,N,
13238,DescriptorName,D052256,16914372,,,7,Tendinopathy,N,
13239,QualifierName,Q000188,16914372,,,7,,N,drug therapy
13240,DescriptorName,D014361,16914372,,,8,Trypsin Inhibitors,N,
13241,QualifierName,Q000009,16914372,,,8,,Y,adverse effects
13242,Chemical,D000927,16923659,Anticonvulsants,0,,,,
13243,Chemical,D014150,16923659,Antipsychotic Agents,0,,,,
13244,Chemical,D017367,16923659,Serotonin Uptake Inhibitors,0,,,,
13245,Chemical,D000077236,16923659,Topiramate,0H73WJJ391,,,,
13246,Chemical,D003533,16923659,Cyproheptadine,2YHB6175DO,,,,
13247,Chemical,D005632,16923659,Fructose,30237-26-4,,,,
13248,Chemical,D002220,16923659,Carbamazepine,33CM23913M,,,,
13249,Chemical,D001971,16923659,Bromocriptine,3A64E3G5ZO,,,,
13250,Chemical,D014635,16923659,Valproic Acid,614OI1Z5WI,,,,
13251,Chemical,D003402,16923659,Creatine Kinase,EC 2.7.3.2,,,,
13252,Chemical,D003620,16923659,Dantrolene,F64QU97QCR,,,,
13253,Chemical,D018967,16923659,Risperidone,L6UH7ZF8HC,,,,
13254,DescriptorName,D000328,16923659,,,1,Adult,N,
13255,DescriptorName,D000927,16923659,,,2,Anticonvulsants,N,
13256,QualifierName,Q000008,16923659,,,2,,N,administration & dosage
13257,DescriptorName,D014150,16923659,,,3,Antipsychotic Agents,N,
13258,QualifierName,Q000008,16923659,,,3,,N,administration & dosage
13259,DescriptorName,D001714,16923659,,,4,Bipolar Disorder,N,
13260,QualifierName,Q000188,16923659,,,4,,Y,drug therapy
13261,DescriptorName,D001971,16923659,,,5,Bromocriptine,N,
13262,QualifierName,Q000627,16923659,,,5,,N,therapeutic use
13263,DescriptorName,D002220,16923659,,,6,Carbamazepine,N,
13264,QualifierName,Q000008,16923659,,,6,,N,administration & dosage
13265,DescriptorName,D015897,16923659,,,7,Comorbidity,N,
13266,DescriptorName,D003402,16923659,,,8,Creatine Kinase,N,
13267,QualifierName,Q000097,16923659,,,8,,N,blood
13268,DescriptorName,D003422,16923659,,,9,Critical Care,Y,
13269,DescriptorName,D003533,16923659,,,10,Cyproheptadine,N,
13270,QualifierName,Q000627,16923659,,,10,,N,therapeutic use
13271,DescriptorName,D003620,16923659,,,11,Dantrolene,N,
13272,QualifierName,Q000627,16923659,,,11,,N,therapeutic use
13273,DescriptorName,D003937,16923659,,,12,"Diagnosis, Differential",N,
13274,DescriptorName,D004347,16923659,,,13,Drug Interactions,N,
13275,DescriptorName,D062787,16923659,,,14,Drug Overdose,N,
13276,QualifierName,Q000175,16923659,,,14,,Y,diagnosis
13277,DescriptorName,D005260,16923659,,,15,Female,N,
13278,DescriptorName,D005632,16923659,,,16,Fructose,N,
13279,QualifierName,Q000008,16923659,,,16,,N,administration & dosage
13280,DescriptorName,D006801,16923659,,,17,Humans,N,
13281,DescriptorName,D009459,16923659,,,18,Neuroleptic Malignant Syndrome,N,
13282,QualifierName,Q000175,16923659,,,18,,Y,diagnosis
13283,DescriptorName,D018967,16923659,,,19,Risperidone,N,
13284,QualifierName,Q000008,16923659,,,19,,N,administration & dosage
13285,DescriptorName,D020230,16923659,,,20,Serotonin Syndrome,N,
13286,QualifierName,Q000175,16923659,,,20,,Y,diagnosis
13287,DescriptorName,D017367,16923659,,,21,Serotonin Uptake Inhibitors,N,
13288,QualifierName,Q000008,16923659,,,21,,N,administration & dosage
13289,DescriptorName,D000077236,16923659,,,22,Topiramate,N,
13290,DescriptorName,D014635,16923659,,,23,Valproic Acid,N,
13291,QualifierName,Q000008,16923659,,,23,,N,administration & dosage
13292,Chemical,D000927,16935446,Anticonvulsants,0,,,,
13293,Chemical,D011324,16935446,Primidone,13AFD7670Q,,,,
13294,Chemical,D010672,16935446,Phenytoin,6158TKW0C5,,,,
13295,DescriptorName,D000927,16935446,,,1,Anticonvulsants,N,
13296,QualifierName,Q000009,16935446,,,1,,Y,adverse effects
13297,DescriptorName,D002648,16935446,,,2,Child,N,
13298,DescriptorName,D004359,16935446,,,3,"Drug Therapy, Combination",N,
13299,DescriptorName,D004828,16935446,,,4,"Epilepsies, Partial",N,
13300,QualifierName,Q000188,16935446,,,4,,Y,drug therapy
13301,DescriptorName,D006801,16935446,,,5,Humans,N,
13302,DescriptorName,D008297,16935446,,,6,Male,N,
13303,DescriptorName,D010672,16935446,,,7,Phenytoin,N,
13304,QualifierName,Q000009,16935446,,,7,,Y,adverse effects
13305,DescriptorName,D011324,16935446,,,8,Primidone,N,
13306,QualifierName,Q000627,16935446,,,8,,N,therapeutic use
13307,Chemical,D000927,16939867,Anticonvulsants,0,,,,
13308,Chemical,D014227,16939867,Triazines,0,,,,
13309,Chemical,D000077213,16939867,Lamotrigine,U3H27498KS,,,,
13310,DescriptorName,D000927,16939867,,,1,Anticonvulsants,N,
13311,QualifierName,Q000008,16939867,,,1,,N,administration & dosage
13312,DescriptorName,D002648,16939867,,,2,Child,N,
13313,DescriptorName,D004334,16939867,,,3,Drug Administration Schedule,N,
13314,DescriptorName,D004828,16939867,,,4,"Epilepsies, Partial",N,
13315,QualifierName,Q000188,16939867,,,4,,N,drug therapy
13316,DescriptorName,D005260,16939867,,,5,Female,N,
13317,DescriptorName,D006801,16939867,,,6,Humans,N,
13318,DescriptorName,D000077213,16939867,,,7,Lamotrigine,N,
13319,DescriptorName,D011693,16939867,,,8,Purpura,N,
13320,QualifierName,Q000139,16939867,,,8,,Y,chemically induced
13321,DescriptorName,D014227,16939867,,,9,Triazines,N,
13322,QualifierName,Q000008,16939867,,,9,,N,administration & dosage
13323,Chemical,D047228,16945058,Angiotensin II Type 1 Receptor Blockers,0,,,,
13324,Chemical,D000806,16945058,Angiotensin-Converting Enzyme Inhibitors,0,,,,
13325,Chemical,D017706,16945058,Lisinopril,E7199S1YWR,,,,
13326,Chemical,D019808,16945058,Losartan,JMS50MPO89,,,,
13327,DescriptorName,D058186,16945058,,,1,Acute Kidney Injury,N,
13328,QualifierName,Q000139,16945058,,,1,,Y,chemically induced
13329,DescriptorName,D047228,16945058,,,2,Angiotensin II Type 1 Receptor Blockers,N,
13330,QualifierName,Q000009,16945058,,,2,,Y,adverse effects
13331,DescriptorName,D000806,16945058,,,3,Angiotensin-Converting Enzyme Inhibitors,N,
13332,QualifierName,Q000009,16945058,,,3,,Y,adverse effects
13333,DescriptorName,D002648,16945058,,,4,Child,N,
13334,DescriptorName,D004359,16945058,,,5,"Drug Therapy, Combination",N,
13335,DescriptorName,D006801,16945058,,,6,Humans,N,
13336,DescriptorName,D007022,16945058,,,7,Hypotension,N,
13337,QualifierName,Q000139,16945058,,,7,,N,chemically induced
13338,DescriptorName,D017706,16945058,,,8,Lisinopril,N,
13339,QualifierName,Q000009,16945058,,,8,,Y,adverse effects
13340,DescriptorName,D019808,16945058,,,9,Losartan,N,
13341,QualifierName,Q000009,16945058,,,9,,Y,adverse effects
13342,DescriptorName,D008297,16945058,,,10,Male,N,
13343,DescriptorName,D011507,16945058,,,11,Proteinuria,N,
13344,QualifierName,Q000188,16945058,,,11,,Y,drug therapy
13345,Chemical,D009824,1694575,Ointments,0,,,,
13346,Chemical,D007633,1694575,Keratins,68238-35-7,,,,
13347,Chemical,D005472,1694575,Fluorouracil,U3P01618RT,,,,
13348,DescriptorName,D000368,1694575,,,1,Aged,N,
13349,DescriptorName,D003228,1694575,,,2,Conjunctiva,N,
13350,QualifierName,Q000378,1694575,,,2,,N,metabolism
13351,DescriptorName,D003316,1694575,,,3,Corneal Diseases,N,
13352,QualifierName,Q000188,1694575,,,3,,N,drug therapy
13353,DescriptorName,D005472,1694575,,,4,Fluorouracil,N,
13354,QualifierName,Q000009,1694575,,,4,,Y,adverse effects
13355,DescriptorName,D005902,1694575,,,5,"Glaucoma, Open-Angle",N,
13356,QualifierName,Q000150,1694575,,,5,,N,complications
13357,DescriptorName,D006801,1694575,,,6,Humans,N,
13358,DescriptorName,D007429,1694575,,,7,Intraocular Pressure,N,
13359,DescriptorName,D007633,1694575,,,8,Keratins,Y,
13360,DescriptorName,D008297,1694575,,,9,Male,N,
13361,DescriptorName,D009824,1694575,,,10,Ointments,N,
13362,QualifierName,Q000627,1694575,,,10,,N,therapeutic use
13363,DescriptorName,D010390,1694575,,,11,"Pemphigoid, Benign Mucous Membrane",N,
13364,QualifierName,Q000150,1694575,,,11,,N,complications
13365,DescriptorName,D012086,1694575,,,12,Reoperation,N,
13366,DescriptorName,D014130,1694575,,,13,Trabeculectomy,N,
13367,QualifierName,Q000009,1694575,,,13,,Y,adverse effects
13368,Chemical,D000893,16948177,Anti-Inflammatory Agents,0,,,,
13369,Chemical,D000911,16948177,"Antibodies, Monoclonal",0,,,,
13370,Chemical,D058846,16948177,"Antibodies, Monoclonal, Murine-Derived",0,,,,
13371,Chemical,D000970,16948177,Antineoplastic Agents,0,,,,
13372,Chemical,D000069283,16948177,Rituximab,4F4X42SYQ6,,,,
13373,Chemical,D011241,16948177,Prednisone,VB0R961HZT,,,,
13374,DescriptorName,D000893,16948177,,,1,Anti-Inflammatory Agents,N,
13375,QualifierName,Q000008,16948177,,,1,,N,administration & dosage
13376,DescriptorName,D000911,16948177,,,2,"Antibodies, Monoclonal",N,
13377,QualifierName,Q000008,16948177,,,2,,N,administration & dosage
13378,DescriptorName,D058846,16948177,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
13379,DescriptorName,D000970,16948177,,,4,Antineoplastic Agents,N,
13380,QualifierName,Q000008,16948177,,,4,,N,administration & dosage
13381,DescriptorName,D018549,16948177,,,5,Cryptogenic Organizing Pneumonia,N,
13382,QualifierName,Q000139,16948177,,,5,,Y,chemically induced
13383,DescriptorName,D006801,16948177,,,6,Humans,N,
13384,DescriptorName,D016393,16948177,,,7,"Lymphoma, B-Cell",Y,
13385,QualifierName,Q000188,16948177,,,7,,N,drug therapy
13386,DescriptorName,D008297,16948177,,,8,Male,N,
13387,DescriptorName,D008875,16948177,,,9,Middle Aged,N,
13388,DescriptorName,D011241,16948177,,,10,Prednisone,N,
13389,QualifierName,Q000008,16948177,,,10,,N,administration & dosage
13390,DescriptorName,D012074,16948177,,,11,Remission Induction,N,
13391,DescriptorName,D000069283,16948177,,,12,Rituximab,N,
13392,Chemical,D003029,16960880,Coagulants,0,,,,
13393,Chemical,D013917,16960880,Thrombin,EC 3.4.21.5,,,,
13394,DescriptorName,D000368,16960880,,,1,Aged,N,
13395,DescriptorName,D017541,16960880,,,2,"Aneurysm, False",N,
13396,QualifierName,Q000000981,16960880,,,2,,N,diagnostic imaging
13397,DescriptorName,D003029,16960880,,,3,Coagulants,N,
13398,QualifierName,Q000008,16960880,,,3,,N,administration & dosage
13399,DescriptorName,D005260,16960880,,,4,Female,N,
13400,DescriptorName,D005263,16960880,,,5,Femoral Artery,Y,
13401,DescriptorName,D006801,16960880,,,6,Humans,N,
13402,DescriptorName,D007267,16960880,,,7,Injections,N,
13403,DescriptorName,D007866,16960880,,,8,Leg,N,
13404,QualifierName,Q000098,16960880,,,8,,Y,blood supply
13405,DescriptorName,D013917,16960880,,,9,Thrombin,N,
13406,QualifierName,Q000008,16960880,,,9,,N,administration & dosage
13407,DescriptorName,D013927,16960880,,,10,Thrombosis,N,
13408,QualifierName,Q000139,16960880,,,10,,Y,chemically induced
13409,DescriptorName,D018084,16960880,,,11,"Ultrasonography, Interventional",N,
13410,Chemical,D000970,16968538,Antineoplastic Agents,0,,,,
13411,Chemical,D009944,16968538,Organoplatinum Compounds,0,,,,
13412,Chemical,D000077150,16968538,Oxaliplatin,04ZR38536J,,,,
13413,DescriptorName,D000970,16968538,,,1,Antineoplastic Agents,N,
13414,QualifierName,Q000008,16968538,,,1,,N,administration & dosage
13415,DescriptorName,D015179,16968538,,,2,Colorectal Neoplasms,N,
13416,QualifierName,Q000188,16968538,,,2,,Y,drug therapy
13417,DescriptorName,D004359,16968538,,,3,"Drug Therapy, Combination",N,
13418,DescriptorName,D006463,16968538,,,4,Hemolytic-Uremic Syndrome,N,
13419,QualifierName,Q000139,16968538,,,4,,Y,chemically induced
13420,DescriptorName,D006801,16968538,,,5,Humans,N,
13421,DescriptorName,D007262,16968538,,,6,"Infusions, Intravenous",N,
13422,DescriptorName,D008297,16968538,,,7,Male,N,
13423,DescriptorName,D008875,16968538,,,8,Middle Aged,N,
13424,DescriptorName,D009944,16968538,,,9,Organoplatinum Compounds,N,
13425,QualifierName,Q000008,16968538,,,9,,N,administration & dosage
13426,DescriptorName,D000077150,16968538,,,10,Oxaliplatin,N,
13427,Chemical,D014150,16978752,Antipsychotic Agents,0,,,,
13428,Chemical,D001569,16978752,Benzodiazepines,12794-10-4,,,,
13429,Chemical,D000077152,16978752,Olanzapine,N7U69T4SZR,,,,
13430,DescriptorName,D000328,16978752,,,1,Adult,N,
13431,DescriptorName,D000380,16978752,,,2,Agranulocytosis,N,
13432,QualifierName,Q000139,16978752,,,2,,Y,chemically induced
13433,DescriptorName,D014150,16978752,,,3,Antipsychotic Agents,N,
13434,QualifierName,Q000009,16978752,,,3,,Y,adverse effects
13435,DescriptorName,D001569,16978752,,,4,Benzodiazepines,N,
13436,QualifierName,Q000009,16978752,,,4,,N,adverse effects
13437,DescriptorName,D001772,16978752,,,5,Blood Cell Count,N,
13438,DescriptorName,D001854,16978752,,,6,Bone Marrow Cells,N,
13439,QualifierName,Q000473,16978752,,,6,,N,pathology
13440,DescriptorName,D017809,16978752,,,7,Fatal Outcome,N,
13441,DescriptorName,D006801,16978752,,,8,Humans,N,
13442,DescriptorName,D008297,16978752,,,9,Male,N,
13443,DescriptorName,D009190,16978752,,,10,Myelodysplastic Syndromes,N,
13444,QualifierName,Q000150,16978752,,,10,,Y,complications
13445,DescriptorName,D009503,16978752,,,11,Neutropenia,N,
13446,QualifierName,Q000139,16978752,,,11,,N,chemically induced
13447,DescriptorName,D000077152,16978752,,,12,Olanzapine,N,
13448,DescriptorName,D012563,16978752,,,13,"Schizophrenia, Paranoid",N,
13449,QualifierName,Q000150,16978752,,,13,,Y,complications
13450,Chemical,D014150,16986159,Antipsychotic Agents,0,,,,
13451,DescriptorName,D014150,16986159,,,1,Antipsychotic Agents,N,
13452,QualifierName,Q000009,16986159,,,1,,Y,adverse effects
13453,DescriptorName,D003291,16986159,,,2,Conversion Disorder,N,
13454,QualifierName,Q000139,16986159,,,2,,Y,chemically induced
13455,DescriptorName,D003863,16986159,,,3,Depression,N,
13456,QualifierName,Q000188,16986159,,,3,,N,drug therapy
13457,DescriptorName,D004565,16986159,,,4,Electroconvulsive Therapy,N,
13458,QualifierName,Q000379,16986159,,,4,,Y,methods
13459,DescriptorName,D005260,16986159,,,5,Female,N,
13460,DescriptorName,D006801,16986159,,,6,Humans,N,
13461,DescriptorName,D008875,16986159,,,7,Middle Aged,N,
13462,Chemical,D000928,16997047,Antidepressive Agents,0,,,,
13463,Chemical,D000929,16997047,"Antidepressive Agents, Tricyclic",0,,,,
13464,Chemical,D004573,16997047,Electrolytes,0,,,,
13465,Chemical,D015283,16997047,Citalopram,0DHU5B8D6V,,,,
13466,Chemical,D008803,16997047,Mianserin,250PJI13LM,,,,
13467,Chemical,D012964,16997047,Sodium,9NEZ333N27,,,,
13468,Chemical,D000078785,16997047,Mirtazapine,A051Q2099Q,,,,
13469,DescriptorName,D000368,16997047,,,1,Aged,N,
13470,DescriptorName,D000928,16997047,,,2,Antidepressive Agents,N,
13471,QualifierName,Q000009,16997047,,,2,,Y,adverse effects
13472,DescriptorName,D000929,16997047,,,3,"Antidepressive Agents, Tricyclic",N,
13473,QualifierName,Q000009,16997047,,,3,,Y,adverse effects
13474,DescriptorName,D015283,16997047,,,4,Citalopram,N,
13475,QualifierName,Q000009,16997047,,,4,,Y,adverse effects
13476,DescriptorName,D003863,16997047,,,5,Depression,N,
13477,QualifierName,Q000188,16997047,,,5,,N,drug therapy
13478,DescriptorName,D003937,16997047,,,6,"Diagnosis, Differential",N,
13479,DescriptorName,D004573,16997047,,,7,Electrolytes,N,
13480,QualifierName,Q000097,16997047,,,7,,N,blood
13481,DescriptorName,D005260,16997047,,,8,Female,N,
13482,DescriptorName,D006801,16997047,,,9,Humans,N,
13483,DescriptorName,D007010,16997047,,,10,Hyponatremia,N,
13484,QualifierName,Q000097,16997047,,,10,,Y,blood
13485,DescriptorName,D007177,16997047,,,11,Inappropriate ADH Syndrome,N,
13486,QualifierName,Q000139,16997047,,,11,,N,chemically induced
13487,DescriptorName,D008803,16997047,,,12,Mianserin,N,
13488,QualifierName,Q000009,16997047,,,12,,N,adverse effects
13489,DescriptorName,D000078785,16997047,,,13,Mirtazapine,N,
13490,DescriptorName,D012008,16997047,,,14,Recurrence,N,
13491,DescriptorName,D012964,16997047,,,15,Sodium,N,
13492,QualifierName,Q000097,16997047,,,15,,N,blood
13493,Chemical,D000276,17009081,"Adjuvants, Immunologic",0,,,,
13494,Chemical,D005938,17009081,Glucocorticoids,0,,,,
13495,Chemical,D000068576,17009081,Interferon beta-1b,145155-23-3,,,,
13496,Chemical,D016899,17009081,Interferon-beta,77238-31-4,,,,
13497,Chemical,D011239,17009081,Prednisolone,9PHQ9Y1OLM,,,,
13498,DescriptorName,D000276,17009081,,,1,"Adjuvants, Immunologic",N,
13499,QualifierName,Q000009,17009081,,,1,,Y,adverse effects
13500,DescriptorName,D000328,17009081,,,2,Adult,N,
13501,DescriptorName,D001706,17009081,,,3,Biopsy,N,
13502,DescriptorName,D005260,17009081,,,4,Female,N,
13503,DescriptorName,D005938,17009081,,,5,Glucocorticoids,N,
13504,QualifierName,Q000627,17009081,,,5,,N,therapeutic use
13505,DescriptorName,D006801,17009081,,,6,Humans,N,
13506,DescriptorName,D000068576,17009081,,,7,Interferon beta-1b,N,
13507,DescriptorName,D016899,17009081,,,8,Interferon-beta,N,
13508,QualifierName,Q000009,17009081,,,8,,Y,adverse effects
13509,DescriptorName,D007668,17009081,,,9,Kidney,N,
13510,QualifierName,Q000473,17009081,,,9,,N,pathology
13511,DescriptorName,D009103,17009081,,,10,Multiple Sclerosis,N,
13512,QualifierName,Q000188,17009081,,,10,,Y,drug therapy
13513,DescriptorName,D009402,17009081,,,11,"Nephrosis, Lipoid",N,
13514,QualifierName,Q000139,17009081,,,11,,Y,chemically induced
13515,DescriptorName,D011239,17009081,,,12,Prednisolone,N,
13516,QualifierName,Q000627,17009081,,,12,,N,therapeutic use
13517,Chemical,D006634,17016002,Histamine H1 Antagonists,0,,,,
13518,Chemical,D013229,17016002,Stearic Acids,0,,,,
13519,Chemical,D013607,17016002,Tablets,0,,,,
13520,Chemical,C031183,17016002,stearic acid,4ELV7Z65AP,,,,
13521,Chemical,C034022,17016002,homochlorocyclizine,N5MVC31W2N,,,,
13522,Chemical,D003501,17016002,Cyclizine,QRW9FCR9P2,,,,
13523,DescriptorName,D000208,17016002,,,1,Acute Disease,N,
13524,DescriptorName,D000284,17016002,,,2,"Administration, Oral",N,
13525,DescriptorName,D000368,17016002,,,3,Aged,N,
13526,DescriptorName,D003501,17016002,,,4,Cyclizine,N,
13527,QualifierName,Q000008,17016002,,,4,,N,administration & dosage
13528,DescriptorName,D004802,17016002,,,5,Eosinophilia,N,
13529,QualifierName,Q000139,17016002,,,5,,N,chemically induced
13530,DescriptorName,D006634,17016002,,,6,Histamine H1 Antagonists,N,
13531,QualifierName,Q000008,17016002,,,6,,N,administration & dosage
13532,DescriptorName,D006801,17016002,,,7,Humans,N,
13533,DescriptorName,D008297,17016002,,,8,Male,N,
13534,DescriptorName,D011537,17016002,,,9,Pruritus,N,
13535,QualifierName,Q000188,17016002,,,9,,N,drug therapy
13536,DescriptorName,D011657,17016002,,,10,Pulmonary Eosinophilia,N,
13537,QualifierName,Q000139,17016002,,,10,,Y,chemically induced
13538,DescriptorName,D013229,17016002,,,11,Stearic Acids,N,
13539,QualifierName,Q000008,17016002,,,11,,N,administration & dosage
13540,DescriptorName,D013607,17016002,,,12,Tablets,N,
13541,QualifierName,Q000737,17016002,,,12,,N,chemistry
13542,Chemical,D000893,17026827,Anti-Inflammatory Agents,0,,,,
13543,Chemical,D050071,17026827,Bone Density Conservation Agents,0,,,,
13544,Chemical,D004164,17026827,Diphosphonates,0,,,,
13545,Chemical,D007093,17026827,Imidazoles,0,,,,
13546,Chemical,D000077211,17026827,Zoledronic Acid,6XC1PAD3KF,,,,
13547,Chemical,D000077268,17026827,Pamidronate,OYY3447OMC,,,,
13548,DescriptorName,D000368,17026827,,,1,Aged,N,
13549,DescriptorName,D000893,17026827,,,2,Anti-Inflammatory Agents,N,
13550,QualifierName,Q000008,17026827,,,2,,Y,administration & dosage
13551,DescriptorName,D050071,17026827,,,3,Bone Density Conservation Agents,N,
13552,QualifierName,Q000008,17026827,,,3,,N,administration & dosage
13553,DescriptorName,D004164,17026827,,,4,Diphosphonates,N,
13554,QualifierName,Q000008,17026827,,,4,,Y,administration & dosage
13555,DescriptorName,D006801,17026827,,,5,Humans,N,
13556,DescriptorName,D007093,17026827,,,6,Imidazoles,N,
13557,QualifierName,Q000008,17026827,,,6,,N,administration & dosage
13558,DescriptorName,D008297,17026827,,,7,Male,N,
13559,DescriptorName,D009101,17026827,,,8,Multiple Myeloma,N,
13560,QualifierName,Q000150,17026827,,,8,,N,complications
13561,DescriptorName,D000077268,17026827,,,9,Pamidronate,N,
13562,DescriptorName,D011859,17026827,,,10,Radiography,N,
13563,DescriptorName,D015423,17026827,,,11,Scleritis,N,
13564,QualifierName,Q000139,17026827,,,11,,N,chemically induced
13565,DescriptorName,D000077211,17026827,,,12,Zoledronic Acid,N,
13566,Chemical,D000911,17034541,"Antibodies, Monoclonal",0,,,,
13567,Chemical,D058846,17034541,"Antibodies, Monoclonal, Murine-Derived",0,,,,
13568,Chemical,D000970,17034541,Antineoplastic Agents,0,,,,
13569,Chemical,D000069283,17034541,Rituximab,4F4X42SYQ6,,,,
13570,DescriptorName,D000368,17034541,,,1,Aged,N,
13571,DescriptorName,D000911,17034541,,,2,"Antibodies, Monoclonal",N,
13572,QualifierName,Q000009,17034541,,,2,,Y,adverse effects
13573,DescriptorName,D058846,17034541,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
13574,DescriptorName,D000970,17034541,,,4,Antineoplastic Agents,N,
13575,QualifierName,Q000009,17034541,,,4,,Y,adverse effects
13576,DescriptorName,D017809,17034541,,,5,Fatal Outcome,N,
13577,DescriptorName,D005260,17034541,,,6,Female,N,
13578,DescriptorName,D006509,17034541,,,7,Hepatitis B,N,
13579,QualifierName,Q000139,17034541,,,7,,N,chemically induced
13580,DescriptorName,D006515,17034541,,,8,Hepatitis B virus,N,
13581,QualifierName,Q000502,17034541,,,8,,Y,physiology
13582,DescriptorName,D006801,17034541,,,9,Humans,N,
13583,DescriptorName,D016393,17034541,,,10,"Lymphoma, B-Cell",N,
13584,QualifierName,Q000188,17034541,,,10,,Y,drug therapy
13585,DescriptorName,D008224,17034541,,,11,"Lymphoma, Follicular",N,
13586,QualifierName,Q000188,17034541,,,11,,N,drug therapy
13587,DescriptorName,D000069283,17034541,,,12,Rituximab,N,
13588,DescriptorName,D012878,17034541,,,13,Skin Neoplasms,N,
13589,QualifierName,Q000188,17034541,,,13,,Y,drug therapy
13590,DescriptorName,D014775,17034541,,,14,Virus Activation,N,
13591,QualifierName,Q000187,17034541,,,14,,Y,drug effects
13592,Chemical,D000666,1703754,Amphotericin B,7XU7A7DROE,,,,
13593,Chemical,D011239,1703754,Prednisolone,9PHQ9Y1OLM,,,,
13594,Chemical,D005437,1703754,Flucytosine,D83282DT06,,,,
13595,Chemical,D001379,1703754,Azathioprine,MRK240IY2L,,,,
13596,DescriptorName,D000666,1703754,,,1,Amphotericin B,N,
13597,QualifierName,Q000008,1703754,,,1,,N,administration & dosage
13598,DescriptorName,D001379,1703754,,,2,Azathioprine,N,
13599,QualifierName,Q000009,1703754,,,2,,N,adverse effects
13600,DescriptorName,D002555,1703754,,,3,Cerebrospinal Fluid,N,
13601,QualifierName,Q000737,1703754,,,3,,N,chemistry
13602,DescriptorName,D002648,1703754,,,4,Child,N,
13603,DescriptorName,D003453,1703754,,,5,Cryptococcosis,N,
13604,QualifierName,Q000175,1703754,,,5,,N,diagnosis
13605,DescriptorName,D003937,1703754,,,6,"Diagnosis, Differential",N,
13606,DescriptorName,D005260,1703754,,,7,Female,N,
13607,DescriptorName,D005437,1703754,,,8,Flucytosine,N,
13608,QualifierName,Q000008,1703754,,,8,,N,administration & dosage
13609,DescriptorName,D006801,1703754,,,9,Humans,N,
13610,DescriptorName,D008180,1703754,,,10,"Lupus Erythematosus, Systemic",N,
13611,QualifierName,Q000150,1703754,,,10,,Y,complications
13612,DescriptorName,D008581,1703754,,,11,Meningitis,N,
13613,QualifierName,Q000175,1703754,,,11,,N,diagnosis
13614,DescriptorName,D011239,1703754,,,12,Prednisolone,N,
13615,QualifierName,Q000009,1703754,,,12,,N,adverse effects
13616,Chemical,D000903,17039658,"Antibiotics, Antineoplastic",0,,,,
13617,Chemical,D004317,17039658,Doxorubicin,80168379AG,,,,
13618,DescriptorName,D000903,17039658,,,1,"Antibiotics, Antineoplastic",N,
13619,QualifierName,Q000008,17039658,,,1,,N,administration & dosage
13620,DescriptorName,D001365,17039658,,,2,Axilla,N,
13621,QualifierName,Q000473,17039658,,,2,,N,pathology
13622,DescriptorName,D001943,17039658,,,3,Breast Neoplasms,N,
13623,QualifierName,Q000188,17039658,,,3,,Y,drug therapy
13624,DescriptorName,D003937,17039658,,,4,"Diagnosis, Differential",N,
13625,DescriptorName,D004317,17039658,,,5,Doxorubicin,N,
13626,QualifierName,Q000008,17039658,,,5,,N,administration & dosage
13627,DescriptorName,D003875,17039658,,,6,Drug Eruptions,N,
13628,QualifierName,Q000175,17039658,,,6,,Y,diagnosis
13629,DescriptorName,D005260,17039658,,,7,Female,N,
13630,DescriptorName,D006119,17039658,,,8,Groin,N,
13631,QualifierName,Q000473,17039658,,,8,,N,pathology
13632,DescriptorName,D006801,17039658,,,9,Humans,N,
13633,DescriptorName,D007402,17039658,,,10,Intertrigo,N,
13634,QualifierName,Q000139,17039658,,,10,,N,chemically induced
13635,DescriptorName,D008175,17039658,,,11,Lung Neoplasms,N,
13636,QualifierName,Q000188,17039658,,,11,,Y,drug therapy
13637,DescriptorName,D008875,17039658,,,12,Middle Aged,N,
13638,DescriptorName,D009362,17039658,,,13,Neoplasm Metastasis,N,
13639,Chemical,D000925,17044380,Anticoagulants,0,,,,
13640,Chemical,D014859,17044380,Warfarin,5Q7ZVV76EI,,,,
13641,Chemical,D006493,17044380,Heparin,9005-49-6,,,,
13642,DescriptorName,D000230,17044380,,,1,Adenocarcinoma,N,
13643,QualifierName,Q000150,17044380,,,1,,N,complications
13644,DescriptorName,D000925,17044380,,,2,Anticoagulants,N,
13645,QualifierName,Q000009,17044380,,,2,,Y,adverse effects
13646,DescriptorName,D001984,17044380,,,3,Bronchial Neoplasms,N,
13647,QualifierName,Q000150,17044380,,,3,,N,complications
13648,DescriptorName,D004696,17044380,,,4,Endocarditis,N,
13649,QualifierName,Q000601,17044380,,,4,,Y,surgery
13650,DescriptorName,D017809,17044380,,,5,Fatal Outcome,N,
13651,DescriptorName,D006349,17044380,,,6,Heart Valve Diseases,N,
13652,QualifierName,Q000601,17044380,,,6,,N,surgery
13653,DescriptorName,D019918,17044380,,,7,Heart Valve Prosthesis Implantation,Y,
13654,DescriptorName,D006493,17044380,,,8,Heparin,N,
13655,QualifierName,Q000009,17044380,,,8,,Y,adverse effects
13656,DescriptorName,D006801,17044380,,,9,Humans,N,
13657,DescriptorName,D020766,17044380,,,10,Intracranial Embolism,N,
13658,QualifierName,Q000188,17044380,,,10,,N,drug therapy
13659,DescriptorName,D008297,17044380,,,11,Male,N,
13660,DescriptorName,D008875,17044380,,,12,Middle Aged,N,
13661,DescriptorName,D008943,17044380,,,13,Mitral Valve,N,
13662,QualifierName,Q000601,17044380,,,13,,Y,surgery
13663,DescriptorName,D009336,17044380,,,14,Necrosis,N,
13664,QualifierName,Q000139,17044380,,,14,,N,chemically induced
13665,DescriptorName,D011183,17044380,,,15,Postoperative Complications,N,
13666,QualifierName,Q000209,17044380,,,15,,N,etiology
13667,DescriptorName,D012867,17044380,,,16,Skin,N,
13668,QualifierName,Q000187,17044380,,,16,,N,drug effects
13669,DescriptorName,D013921,17044380,,,17,Thrombocytopenia,N,
13670,QualifierName,Q000139,17044380,,,17,,Y,chemically induced
13671,DescriptorName,D014859,17044380,,,18,Warfarin,N,
13672,QualifierName,Q000009,17044380,,,18,,Y,adverse effects
13673,Chemical,D015149,17060191,Tocolytic Agents,0,,,,
13674,Chemical,D007213,17060191,Indomethacin,XXE1CET956,,,,
13675,DescriptorName,D000328,17060191,,,1,Adult,N,
13676,DescriptorName,D000013,17060191,,,2,Congenital Abnormalities,N,
13677,QualifierName,Q000209,17060191,,,2,,N,etiology
13678,DescriptorName,D004373,17060191,,,3,Ductus Arteriosus,N,
13679,QualifierName,Q000187,17060191,,,3,,Y,drug effects
13680,DescriptorName,D017809,17060191,,,4,Fatal Outcome,N,
13681,DescriptorName,D005260,17060191,,,5,Female,N,
13682,DescriptorName,D005330,17060191,,,6,Fetofetal Transfusion,N,
13683,DescriptorName,D020022,17060191,,,7,Genetic Predisposition to Disease,N,
13684,QualifierName,Q000235,17060191,,,7,,N,genetics
13685,DescriptorName,D006801,17060191,,,8,Humans,N,
13686,DescriptorName,D000860,17060191,,,9,Hypoxia,N,
13687,QualifierName,Q000139,17060191,,,9,,N,chemically induced
13688,DescriptorName,D007213,17060191,,,10,Indomethacin,N,
13689,QualifierName,Q000009,17060191,,,10,,Y,adverse effects
13690,DescriptorName,D007231,17060191,,,11,"Infant, Newborn",N,
13691,DescriptorName,D006831,17060191,,,12,Polyhydramnios,N,
13692,QualifierName,Q000188,17060191,,,12,,N,drug therapy
13693,DescriptorName,D011247,17060191,,,13,Pregnancy,N,
13694,DescriptorName,D047928,17060191,,,14,Premature Birth,N,
13695,QualifierName,Q000517,17060191,,,14,,N,prevention & control
13696,DescriptorName,D015149,17060191,,,15,Tocolytic Agents,N,
13697,QualifierName,Q000009,17060191,,,15,,Y,adverse effects
13698,DescriptorName,D014430,17060191,,,16,"Twins, Monozygotic",N,
13699,QualifierName,Q000187,17060191,,,16,,Y,drug effects
13700,Chemical,D000890,17068466,Anti-Infective Agents,0,,,,
13701,Chemical,D001372,17068466,Aza Compounds,0,,,,
13702,Chemical,D024841,17068466,Fluoroquinolones,0,,,,
13703,Chemical,D005938,17068466,Glucocorticoids,0,,,,
13704,Chemical,D009883,17068466,Ophthalmic Solutions,0,,,,
13705,Chemical,D011804,17068466,Quinolines,0,,,,
13706,Chemical,D000077266,17068466,Moxifloxacin,U188XYD42P,,,,
13707,DescriptorName,D000328,17068466,,,1,Adult,N,
13708,DescriptorName,D000369,17068466,,,2,"Aged, 80 and over",N,
13709,DescriptorName,D000890,17068466,,,3,Anti-Infective Agents,N,
13710,QualifierName,Q000008,17068466,,,3,,N,administration & dosage
13711,DescriptorName,D001372,17068466,,,4,Aza Compounds,N,
13712,QualifierName,Q000008,17068466,,,4,,N,administration & dosage
13713,DescriptorName,D015715,17068466,,,5,Corneal Edema,N,
13714,QualifierName,Q000139,17068466,,,5,,Y,chemically induced
13715,DescriptorName,D016039,17068466,,,6,Corneal Transplantation,N,
13716,DescriptorName,D003320,17068466,,,7,Corneal Ulcer,N,
13717,QualifierName,Q000139,17068466,,,7,,Y,chemically induced
13718,DescriptorName,D003937,17068466,,,8,"Diagnosis, Differential",N,
13719,DescriptorName,D005260,17068466,,,9,Female,N,
13720,DescriptorName,D024841,17068466,,,10,Fluoroquinolones,N,
13721,QualifierName,Q000008,17068466,,,10,,N,administration & dosage
13722,DescriptorName,D005500,17068466,,,11,Follow-Up Studies,N,
13723,DescriptorName,D005938,17068466,,,12,Glucocorticoids,N,
13724,QualifierName,Q000008,17068466,,,12,,N,administration & dosage
13725,DescriptorName,D006801,17068466,,,13,Humans,N,
13726,DescriptorName,D007634,17068466,,,14,Keratitis,N,
13727,QualifierName,Q000188,17068466,,,14,,N,drug therapy
13728,DescriptorName,D008297,17068466,,,15,Male,N,
13729,DescriptorName,D000077266,17068466,,,16,Moxifloxacin,N,
13730,DescriptorName,D009883,17068466,,,17,Ophthalmic Solutions,N,
13731,DescriptorName,D011804,17068466,,,18,Quinolines,N,
13732,QualifierName,Q000008,17068466,,,18,,N,administration & dosage
13733,Chemical,D000894,17083900,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
13734,Chemical,D013449,17083900,Sulfonamides,0,,,,
13735,Chemical,C012655,17083900,nimesulide,V4TKW1454M,,,,
13736,DescriptorName,D000894,17083900,,,1,"Anti-Inflammatory Agents, Non-Steroidal",N,
13737,QualifierName,Q000009,17083900,,,1,,Y,adverse effects
13738,DescriptorName,D003875,17083900,,,2,Drug Eruptions,N,
13739,QualifierName,Q000175,17083900,,,2,,N,diagnosis
13740,DescriptorName,D005188,17083900,,,3,False Negative Reactions,N,
13741,DescriptorName,D005260,17083900,,,4,Female,N,
13742,DescriptorName,D006801,17083900,,,5,Humans,N,
13743,DescriptorName,D008875,17083900,,,6,Middle Aged,N,
13744,DescriptorName,D010328,17083900,,,7,Patch Tests,N,
13745,DescriptorName,D010612,17083900,,,8,Pharyngitis,N,
13746,QualifierName,Q000188,17083900,,,8,,N,drug therapy
13747,DescriptorName,D017444,17083900,,,9,"Skin Diseases, Papulosquamous",N,
13748,QualifierName,Q000139,17083900,,,9,,Y,chemically induced
13749,DescriptorName,D013449,17083900,,,10,Sulfonamides,N,
13750,QualifierName,Q000009,17083900,,,10,,Y,adverse effects
13751,Chemical,D004338,17090724,Drug Combinations,0,,,,
13752,Chemical,D003840,17090724,Deoxycholic Acid,005990WHZZ,,,,
13753,Chemical,D000666,17090724,Amphotericin B,7XU7A7DROE,,,,
13754,Chemical,C059765,17090724,"amphotericin B, deoxycholate drug combination",87687-70-5,,,,
13755,DescriptorName,D000208,17090724,,,1,Acute Disease,N,
13756,DescriptorName,D000328,17090724,,,2,Adult,N,
13757,DescriptorName,D000666,17090724,,,3,Amphotericin B,N,
13758,QualifierName,Q000008,17090724,,,3,,N,administration & dosage
13759,DescriptorName,D001145,17090724,,,4,"Arrhythmias, Cardiac",N,
13760,QualifierName,Q000139,17090724,,,4,,N,chemically induced
13761,DescriptorName,D002626,17090724,,,5,"Chemistry, Pharmaceutical",N,
13762,DescriptorName,D003840,17090724,,,6,Deoxycholic Acid,N,
13763,QualifierName,Q000008,17090724,,,6,,N,administration & dosage
13764,DescriptorName,D004338,17090724,,,7,Drug Combinations,N,
13765,DescriptorName,D062787,17090724,,,8,Drug Overdose,N,
13766,DescriptorName,D017809,17090724,,,9,Fatal Outcome,N,
13767,DescriptorName,D005260,17090724,,,10,Female,N,
13768,DescriptorName,D006801,17090724,,,11,Humans,N,
13769,DescriptorName,D008508,17090724,,,12,Medication Errors,N,
13770,QualifierName,Q000517,17090724,,,12,,N,prevention & control
13771,DescriptorName,D016919,17090724,,,13,"Meningitis, Cryptococcal",N,
13772,QualifierName,Q000188,17090724,,,13,,N,drug therapy
13773,Chemical,D005277,17109650,Fenfluramine,2DS058H2CF,,,,
13774,Chemical,C001584,17109650,benfluorex,403FO0NQG3,,,,
13775,DescriptorName,D005260,17109650,,,1,Female,N,
13776,DescriptorName,D005277,17109650,,,2,Fenfluramine,N,
13777,QualifierName,Q000009,17109650,,,2,,N,adverse effects
13778,DescriptorName,D018149,17109650,,,3,Glucose Intolerance,N,
13779,QualifierName,Q000188,17109650,,,3,,N,drug therapy
13780,DescriptorName,D006801,17109650,,,4,Humans,N,
13781,DescriptorName,D008875,17109650,,,5,Middle Aged,N,
13782,DescriptorName,D008944,17109650,,,6,Mitral Valve Insufficiency,N,
13783,QualifierName,Q000209,17109650,,,6,,Y,etiology
13784,DescriptorName,D014262,17109650,,,7,Tricuspid Valve Insufficiency,N,
13785,QualifierName,Q000209,17109650,,,7,,N,etiology
13786,Chemical,D008299,1711090,Maleic Anhydrides,0,,,,
13787,Chemical,D011137,1711090,Polystyrenes,0,,,,
13788,Chemical,D000509,1711090,alpha-Fetoproteins,0,,,,
13789,Chemical,C035755,1711090,poly(maleic acid-styrene)neocarzinostatin,0,,,,
13790,Chemical,D007459,1711090,Iodized Oil,8001-40-9,,,,
13791,Chemical,D004317,1711090,Doxorubicin,80168379AG,,,,
13792,Chemical,D009353,1711090,Zinostatin,9014-02-2,,,,
13793,DescriptorName,D000368,1711090,,,1,Aged,N,
13794,DescriptorName,D000971,1711090,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
13795,QualifierName,Q000008,1711090,,,2,,Y,administration & dosage
13796,DescriptorName,D006528,1711090,,,3,"Carcinoma, Hepatocellular",N,
13797,QualifierName,Q000150,1711090,,,3,,N,complications
13798,DescriptorName,D003131,1711090,,,4,Combined Modality Therapy,N,
13799,DescriptorName,D004317,1711090,,,5,Doxorubicin,N,
13800,QualifierName,Q000008,1711090,,,5,,N,administration & dosage
13801,DescriptorName,D005260,1711090,,,6,Female,N,
13802,DescriptorName,D006499,1711090,,,7,Hepatic Artery,N,
13803,DescriptorName,D006358,1711090,,,8,Hot Temperature,N,
13804,QualifierName,Q000627,1711090,,,8,,Y,therapeutic use
13805,DescriptorName,D006801,1711090,,,9,Humans,N,
13806,DescriptorName,D007269,1711090,,,10,"Injections, Intra-Arterial",N,
13807,DescriptorName,D007459,1711090,,,11,Iodized Oil,N,
13808,QualifierName,Q000008,1711090,,,11,,N,administration & dosage
13809,DescriptorName,D008103,1711090,,,12,Liver Cirrhosis,N,
13810,QualifierName,Q000150,1711090,,,12,,N,complications
13811,DescriptorName,D008113,1711090,,,13,Liver Neoplasms,N,
13812,QualifierName,Q000150,1711090,,,13,,N,complications
13813,DescriptorName,D008297,1711090,,,14,Male,N,
13814,DescriptorName,D008299,1711090,,,15,Maleic Anhydrides,N,
13815,QualifierName,Q000008,1711090,,,15,,N,administration & dosage
13816,DescriptorName,D008875,1711090,,,16,Middle Aged,N,
13817,DescriptorName,D011137,1711090,,,17,Polystyrenes,N,
13818,QualifierName,Q000008,1711090,,,17,,N,administration & dosage
13819,DescriptorName,D000078702,1711090,,,18,Radiofrequency Therapy,N,
13820,DescriptorName,D009353,1711090,,,19,Zinostatin,N,
13821,QualifierName,Q000008,1711090,,,19,,N,administration & dosage
13822,DescriptorName,D000509,1711090,,,20,alpha-Fetoproteins,N,
13823,QualifierName,Q000378,1711090,,,20,,N,metabolism
13824,Chemical,D007166,17123120,Immunosuppressive Agents,0,,,,
13825,Chemical,D013256,17123120,Steroids,0,,,,
13826,Chemical,D016559,17123120,Tacrolimus,WM0HAQ4WNM,,,,
13827,DescriptorName,D058186,17123120,,,1,Acute Kidney Injury,N,
13828,QualifierName,Q000175,17123120,,,1,,N,diagnosis
13829,DescriptorName,D001706,17123120,,,2,Biopsy,N,
13830,DescriptorName,D002648,17123120,,,3,Child,N,
13831,DescriptorName,D004351,17123120,,,4,Drug Resistance,N,
13832,DescriptorName,D005923,17123120,,,5,"Glomerulosclerosis, Focal Segmental",N,
13833,QualifierName,Q000150,17123120,,,5,,N,complications
13834,DescriptorName,D006463,17123120,,,6,Hemolytic-Uremic Syndrome,N,
13835,QualifierName,Q000139,17123120,,,6,,Y,chemically induced
13836,DescriptorName,D006801,17123120,,,7,Humans,N,
13837,DescriptorName,D007166,17123120,,,8,Immunosuppressive Agents,N,
13838,QualifierName,Q000009,17123120,,,8,,Y,adverse effects
13839,DescriptorName,D007668,17123120,,,9,Kidney,N,
13840,QualifierName,Q000473,17123120,,,9,,N,pathology
13841,DescriptorName,D008297,17123120,,,10,Male,N,
13842,DescriptorName,D009404,17123120,,,11,Nephrotic Syndrome,N,
13843,QualifierName,Q000150,17123120,,,11,,Y,complications
13844,DescriptorName,D013256,17123120,,,12,Steroids,N,
13845,QualifierName,Q000627,17123120,,,12,,N,therapeutic use
13846,DescriptorName,D016559,17123120,,,13,Tacrolimus,N,
13847,QualifierName,Q000009,17123120,,,13,,Y,adverse effects
13848,Chemical,D019380,17133571,Anti-HIV Agents,0,,,,
13849,Chemical,D019829,17133571,Nevirapine,99DK7FVK1H,,,,
13850,DescriptorName,D000328,17133571,,,1,Adult,N,
13851,DescriptorName,D019380,17133571,,,2,Anti-HIV Agents,N,
13852,QualifierName,Q000009,17133571,,,2,,Y,adverse effects
13853,DescriptorName,D005260,17133571,,,3,Female,N,
13854,DescriptorName,D015658,17133571,,,4,HIV Infections,N,
13855,QualifierName,Q000188,17133571,,,4,,N,drug therapy
13856,DescriptorName,D015497,17133571,,,5,HIV-1,N,
13857,DescriptorName,D006505,17133571,,,6,Hepatitis,N,
13858,QualifierName,Q000209,17133571,,,6,,N,etiology
13859,DescriptorName,D006801,17133571,,,7,Humans,N,
13860,DescriptorName,D017114,17133571,,,8,"Liver Failure, Acute",N,
13861,QualifierName,Q000139,17133571,,,8,,N,chemically induced
13862,DescriptorName,D016031,17133571,,,9,Liver Transplantation,Y,
13863,DescriptorName,D019829,17133571,,,10,Nevirapine,N,
13864,QualifierName,Q000009,17133571,,,10,,Y,adverse effects
13865,DescriptorName,D016896,17133571,,,11,Treatment Outcome,N,
13866,Chemical,D002756,17163271,Cholagogues and Choleretics,0,,,,
13867,Chemical,D007166,17163271,Immunosuppressive Agents,0,,,,
13868,Chemical,D014580,17163271,Ursodeoxycholic Acid,724L30Y2QR,,,,
13869,Chemical,D016572,17163271,Cyclosporine,83HN0GTJ6D,,,,
13870,DescriptorName,D000328,17163271,,,1,Adult,N,
13871,DescriptorName,D002756,17163271,,,2,Cholagogues and Choleretics,N,
13872,QualifierName,Q000627,17163271,,,2,,N,therapeutic use
13873,DescriptorName,D002769,17163271,,,3,Cholelithiasis,N,
13874,QualifierName,Q000139,17163271,,,3,,Y,chemically induced
13875,DescriptorName,D016572,17163271,,,4,Cyclosporine,N,
13876,QualifierName,Q000009,17163271,,,4,,Y,adverse effects
13877,DescriptorName,D005260,17163271,,,5,Female,N,
13878,DescriptorName,D006801,17163271,,,6,Humans,N,
13879,DescriptorName,D007166,17163271,,,7,Immunosuppressive Agents,N,
13880,QualifierName,Q000009,17163271,,,7,,N,adverse effects
13881,DescriptorName,D016030,17163271,,,8,Kidney Transplantation,Y,
13882,DescriptorName,D012169,17163271,,,9,Retinal Vein,N,
13883,QualifierName,Q000187,17163271,,,9,,Y,drug effects
13884,DescriptorName,D013927,17163271,,,10,Thrombosis,N,
13885,QualifierName,Q000139,17163271,,,10,,Y,chemically induced
13886,DescriptorName,D013997,17163271,,,11,Time Factors,N,
13887,DescriptorName,D014463,17163271,,,12,Ultrasonography,N,
13888,QualifierName,Q000379,17163271,,,12,,N,methods
13889,DescriptorName,D014580,17163271,,,13,Ursodeoxycholic Acid,N,
13890,QualifierName,Q000627,17163271,,,13,,N,therapeutic use
13891,Chemical,D000726,17167851,Androgen Antagonists,0,,,,
13892,Chemical,D017373,17167851,Cyproterone Acetate,4KM2BN5JHF,,,,
13893,Chemical,D001219,17167851,Aspartate Aminotransferases,EC 2.6.1.1,,,,
13894,Chemical,D001663,17167851,Bilirubin,RFM9X3LJ49,,,,
13895,DescriptorName,D000368,17167851,,,1,Aged,N,
13896,DescriptorName,D000369,17167851,,,2,"Aged, 80 and over",N,
13897,DescriptorName,D000726,17167851,,,3,Androgen Antagonists,N,
13898,QualifierName,Q000008,17167851,,,3,,N,administration & dosage
13899,DescriptorName,D001219,17167851,,,4,Aspartate Aminotransferases,N,
13900,QualifierName,Q000097,17167851,,,4,,N,blood
13901,DescriptorName,D001663,17167851,,,5,Bilirubin,N,
13902,QualifierName,Q000097,17167851,,,5,,N,blood
13903,DescriptorName,D056486,17167851,,,6,Chemical and Drug Induced Liver Injury,Y,
13904,DescriptorName,D017373,17167851,,,7,Cyproterone Acetate,N,
13905,QualifierName,Q000008,17167851,,,7,,N,administration & dosage
13906,DescriptorName,D006801,17167851,,,8,Humans,N,
13907,DescriptorName,D008107,17167851,,,9,Liver Diseases,N,
13908,QualifierName,Q000473,17167851,,,9,,N,pathology
13909,DescriptorName,D008297,17167851,,,10,Male,N,
13910,DescriptorName,D011471,17167851,,,11,Prostatic Neoplasms,N,
13911,QualifierName,Q000188,17167851,,,11,,N,drug therapy
13912,Chemical,D000305,17176478,Adrenal Cortex Hormones,0,,,,
13913,Chemical,D007166,17176478,Immunosuppressive Agents,0,,,,
13914,DescriptorName,D000305,17176478,,,1,Adrenal Cortex Hormones,N,
13915,QualifierName,Q000009,17176478,,,1,,Y,adverse effects
13916,DescriptorName,D000368,17176478,,,2,Aged,N,
13917,DescriptorName,D000818,17176478,,,3,Animals,N,
13918,DescriptorName,D005260,17176478,,,4,Female,N,
13919,DescriptorName,D006801,17176478,,,5,Humans,N,
13920,DescriptorName,D007166,17176478,,,6,Immunosuppressive Agents,N,
13921,QualifierName,Q000009,17176478,,,6,,Y,adverse effects
13922,DescriptorName,D018314,17176478,,,7,Leishmania infantum,N,
13923,QualifierName,Q000302,17176478,,,7,,Y,isolation & purification
13924,DescriptorName,D007898,17176478,,,8,"Leishmaniasis, Visceral",N,
13925,QualifierName,Q000139,17176478,,,8,,N,chemically induced
13926,DescriptorName,D008297,17176478,,,9,Male,N,
13927,DescriptorName,D008875,17176478,,,10,Middle Aged,N,
13928,DescriptorName,D018417,17176478,,,11,Th1 Cells,N,
13929,QualifierName,Q000187,17176478,,,11,,N,drug effects
13930,Chemical,D008774,17182354,Methylphenidate,207ZZ9QZ49,,,,
13931,DescriptorName,D001289,17182354,,,1,Attention Deficit Disorder with Hyperactivity,N,
13932,QualifierName,Q000188,17182354,,,1,,Y,drug therapy
13933,DescriptorName,D002386,17182354,,,2,Cataract,N,
13934,QualifierName,Q000139,17182354,,,2,,Y,chemically induced
13935,DescriptorName,D002648,17182354,,,3,Child,N,
13936,DescriptorName,D005901,17182354,,,4,Glaucoma,N,
13937,QualifierName,Q000139,17182354,,,4,,Y,chemically induced
13938,DescriptorName,D006801,17182354,,,5,Humans,N,
13939,DescriptorName,D008297,17182354,,,6,Male,N,
13940,DescriptorName,D008774,17182354,,,7,Methylphenidate,N,
13941,QualifierName,Q000009,17182354,,,7,,Y,adverse effects
13942,Chemical,D020533,17188061,Angiogenesis Inhibitors,0,,,,
13943,Chemical,D000911,17188061,"Antibodies, Monoclonal",0,,,,
13944,Chemical,D061067,17188061,"Antibodies, Monoclonal, Humanized",0,,,,
13945,Chemical,C467484,17188061,"VEGFA protein, human",0,,,,
13946,Chemical,D042461,17188061,Vascular Endothelial Growth Factor A,0,,,,
13947,Chemical,D000068258,17188061,Bevacizumab,2S9ZZM9Q9V,,,,
13948,DescriptorName,D000369,17188061,,,1,"Aged, 80 and over",N,
13949,DescriptorName,D020533,17188061,,,2,Angiogenesis Inhibitors,N,
13950,QualifierName,Q000009,17188061,,,2,,Y,adverse effects
13951,DescriptorName,D000911,17188061,,,3,"Antibodies, Monoclonal",N,
13952,QualifierName,Q000009,17188061,,,3,,Y,adverse effects
13953,DescriptorName,D061067,17188061,,,4,"Antibodies, Monoclonal, Humanized",N,
13954,DescriptorName,D000068258,17188061,,,5,Bevacizumab,N,
13955,DescriptorName,D020256,17188061,,,6,Choroidal Neovascularization,N,
13956,QualifierName,Q000188,17188061,,,6,,Y,drug therapy
13957,DescriptorName,D005260,17188061,,,7,Female,N,
13958,DescriptorName,D006212,17188061,,,8,Hallucinations,N,
13959,QualifierName,Q000139,17188061,,,8,,Y,chemically induced
13960,DescriptorName,D006801,17188061,,,9,Humans,N,
13961,DescriptorName,D007267,17188061,,,10,Injections,N,
13962,DescriptorName,D008268,17188061,,,11,Macular Degeneration,N,
13963,QualifierName,Q000188,17188061,,,11,,Y,drug therapy
13964,DescriptorName,D042461,17188061,,,12,Vascular Endothelial Growth Factor A,N,
13965,QualifierName,Q000037,17188061,,,12,,N,antagonists & inhibitors
13966,DescriptorName,D014822,17188061,,,13,Vitreous Body,N,
13967,Chemical,D000932,17195428,Antiemetics,0,,,,
13968,Chemical,D018492,17195428,Dopamine Antagonists,0,,,,
13969,Chemical,D006634,17195428,Histamine H1 Antagonists,0,,,,
13970,Chemical,D004155,17195428,Diphenhydramine,8GTS82S83M,,,,
13971,Chemical,D008787,17195428,Metoclopramide,L4YEB44I46,,,,
13972,DescriptorName,D000293,17195428,,,1,Adolescent,N,
13973,DescriptorName,D000932,17195428,,,2,Antiemetics,N,
13974,QualifierName,Q000009,17195428,,,2,,Y,adverse effects
13975,DescriptorName,D004155,17195428,,,3,Diphenhydramine,N,
13976,QualifierName,Q000627,17195428,,,3,,N,therapeutic use
13977,DescriptorName,D018492,17195428,,,4,Dopamine Antagonists,N,
13978,QualifierName,Q000009,17195428,,,4,,Y,adverse effects
13979,DescriptorName,D004421,17195428,,,5,Dystonia,N,
13980,QualifierName,Q000139,17195428,,,5,,N,chemically induced
13981,DescriptorName,D005260,17195428,,,6,Female,N,
13982,DescriptorName,D018662,17195428,,,7,Fundoplication,N,
13983,QualifierName,Q000009,17195428,,,7,,N,adverse effects
13984,DescriptorName,D006634,17195428,,,8,Histamine H1 Antagonists,N,
13985,QualifierName,Q000627,17195428,,,8,,N,therapeutic use
13986,DescriptorName,D006801,17195428,,,9,Humans,N,
13987,DescriptorName,D008787,17195428,,,10,Metoclopramide,N,
13988,QualifierName,Q000009,17195428,,,10,,Y,adverse effects
13989,DescriptorName,D009325,17195428,,,11,Nausea,N,
13990,QualifierName,Q000188,17195428,,,11,,N,drug therapy
13991,DescriptorName,D015835,17195428,,,12,Ocular Motility Disorders,N,
13992,QualifierName,Q000139,17195428,,,12,,Y,chemically induced
13993,DescriptorName,D014839,17195428,,,13,Vomiting,N,
13994,QualifierName,Q000188,17195428,,,13,,N,drug therapy
13995,Chemical,D007166,17199845,Immunosuppressive Agents,0,,,,
13996,Chemical,D016572,17199845,Cyclosporine,83HN0GTJ6D,,,,
13997,Chemical,D011239,17199845,Prednisolone,9PHQ9Y1OLM,,,,
13998,Chemical,D009173,17199845,Mycophenolic Acid,HU9DX48N0T,,,,
13999,DescriptorName,D000328,17199845,,,1,Adult,N,
14000,DescriptorName,D016572,17199845,,,2,Cyclosporine,N,
14001,QualifierName,Q000009,17199845,,,2,,Y,adverse effects
14002,DescriptorName,D003928,17199845,,,3,Diabetic Nephropathies,N,
14003,QualifierName,Q000139,17199845,,,3,,N,chemically induced
14004,DescriptorName,D004341,17199845,,,4,Drug Evaluation,N,
14005,DescriptorName,D005260,17199845,,,5,Female,N,
14006,DescriptorName,D006801,17199845,,,6,Humans,N,
14007,DescriptorName,D006977,17199845,,,7,"Hypertension, Renal",N,
14008,QualifierName,Q000139,17199845,,,7,,N,chemically induced
14009,DescriptorName,D007166,17199845,,,8,Immunosuppressive Agents,N,
14010,QualifierName,Q000009,17199845,,,8,,N,adverse effects
14011,DescriptorName,D007674,17199845,,,9,Kidney Diseases,N,
14012,QualifierName,Q000097,17199845,,,9,,N,blood
14013,DescriptorName,D007676,17199845,,,10,"Kidney Failure, Chronic",N,
14014,QualifierName,Q000209,17199845,,,10,,N,etiology
14015,DescriptorName,D008297,17199845,,,11,Male,N,
14016,DescriptorName,D008875,17199845,,,12,Middle Aged,N,
14017,DescriptorName,D009157,17199845,,,13,Myasthenia Gravis,N,
14018,QualifierName,Q000188,17199845,,,13,,Y,drug therapy
14019,DescriptorName,D009173,17199845,,,14,Mycophenolic Acid,N,
14020,QualifierName,Q000031,17199845,,,14,,Y,analogs & derivatives
14021,DescriptorName,D010951,17199845,,,15,Plasma Exchange,N,
14022,DescriptorName,D011239,17199845,,,16,Prednisolone,N,
14023,QualifierName,Q000009,17199845,,,16,,N,adverse effects
14024,DescriptorName,D012008,17199845,,,17,Recurrence,N,
14025,DescriptorName,D013934,17199845,,,18,Thymectomy,N,
14026,Chemical,D044005,17205927,Tetrahydroisoquinolines,0,,,,
14027,Chemical,D005424,17205927,Flecainide,K94FTS1806,,,,
14028,Chemical,D000077583,17205927,Quinapril,RJ84Y44811,,,,
14029,DescriptorName,D000293,17205927,,,1,Adolescent,N,
14030,DescriptorName,D001794,17205927,,,2,Blood Pressure,N,
14031,QualifierName,Q000187,17205927,,,2,,N,drug effects
14032,DescriptorName,D004562,17205927,,,3,Electrocardiography,N,
14033,DescriptorName,D005260,17205927,,,4,Female,N,
14034,DescriptorName,D005424,17205927,,,5,Flecainide,N,
14035,QualifierName,Q000009,17205927,,,5,,N,adverse effects
14036,DescriptorName,D006801,17205927,,,6,Humans,N,
14037,DescriptorName,D000077583,17205927,,,7,Quinapril,N,
14038,DescriptorName,D013610,17205927,,,8,Tachycardia,N,
14039,QualifierName,Q000188,17205927,,,8,,N,drug therapy
14040,DescriptorName,D044005,17205927,,,9,Tetrahydroisoquinolines,N,
14041,QualifierName,Q000009,17205927,,,9,,N,adverse effects
14042,Chemical,D003609,172214,Dactinomycin,1CC1JFE158,,,,
14043,Chemical,D004317,172214,Doxorubicin,80168379AG,,,,
14044,Chemical,D008926,172214,Plicamycin,NIJ123W41V,,,,
14045,DescriptorName,D000328,172214,,,1,Adult,N,
14046,DescriptorName,D003609,172214,,,2,Dactinomycin,N,
14047,QualifierName,Q000009,172214,,,2,,Y,adverse effects
14048,DescriptorName,D004317,172214,,,3,Doxorubicin,N,
14049,QualifierName,Q000008,172214,,,3,,N,administration & dosage
14050,DescriptorName,D004357,172214,,,4,Drug Synergism,N,
14051,DescriptorName,D006331,172214,,,5,Heart Diseases,N,
14052,QualifierName,Q000139,172214,,,5,,Y,chemically induced
14053,DescriptorName,D006333,172214,,,6,Heart Failure,N,
14054,QualifierName,Q000209,172214,,,6,,N,etiology
14055,DescriptorName,D006801,172214,,,7,Humans,N,
14056,DescriptorName,D008297,172214,,,8,Male,N,
14057,DescriptorName,D008928,172214,,,9,Mitochondria,N,
14058,QualifierName,Q000648,172214,,,9,,N,ultrastructure
14059,DescriptorName,D009206,172214,,,10,Myocardium,N,
14060,QualifierName,Q000473,172214,,,10,,N,pathology
14061,DescriptorName,D008926,172214,,,11,Plicamycin,N,
14062,QualifierName,Q000009,172214,,,11,,Y,adverse effects
14063,DescriptorName,D013584,172214,,,12,"Sarcoma, Synovial",N,
14064,QualifierName,Q000188,172214,,,12,,N,drug therapy
14065,Chemical,D000894,17224428,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
14066,Chemical,D019804,17224428,Mesalamine,4Q81I59GXC,,,,
14067,DescriptorName,D000328,17224428,,,1,Adult,N,
14068,DescriptorName,D000894,17224428,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
14069,QualifierName,Q000009,17224428,,,2,,Y,adverse effects
14070,DescriptorName,D053840,17224428,,,3,Brugada Syndrome,N,
14071,QualifierName,Q000175,17224428,,,3,,Y,diagnosis
14072,DescriptorName,D003424,17224428,,,4,Crohn Disease,N,
14073,QualifierName,Q000188,17224428,,,4,,N,drug therapy
14074,DescriptorName,D003937,17224428,,,5,"Diagnosis, Differential",N,
14075,DescriptorName,D004562,17224428,,,6,Electrocardiography,N,
14076,DescriptorName,D006801,17224428,,,7,Humans,N,
14077,DescriptorName,D008297,17224428,,,8,Male,N,
14078,DescriptorName,D019804,17224428,,,9,Mesalamine,N,
14079,QualifierName,Q000009,17224428,,,9,,Y,adverse effects
14080,DescriptorName,D010493,17224428,,,10,Pericarditis,N,
14081,QualifierName,Q000139,17224428,,,10,,Y,chemically induced
14082,Chemical,D047428,17228132,Protein Kinase Inhibitors,0,,,,
14083,Chemical,D011799,17228132,Quinazolines,0,,,,
14084,Chemical,D000069347,17228132,Erlotinib Hydrochloride,DA87705X9K,,,,
14085,Chemical,D001219,17228132,Aspartate Aminotransferases,EC 2.6.1.1,,,,
14086,Chemical,D000410,17228132,Alanine Transaminase,EC 2.6.1.2,,,,
14087,Chemical,D066246,17228132,ErbB Receptors,EC 2.7.10.1,,,,
14088,DescriptorName,D000230,17228132,,,1,Adenocarcinoma,N,
14089,QualifierName,Q000188,17228132,,,1,,Y,drug therapy
14090,DescriptorName,D000368,17228132,,,2,Aged,N,
14091,DescriptorName,D000410,17228132,,,3,Alanine Transaminase,N,
14092,QualifierName,Q000097,17228132,,,3,,N,blood
14093,DescriptorName,D001219,17228132,,,4,Aspartate Aminotransferases,N,
14094,QualifierName,Q000097,17228132,,,4,,N,blood
14095,DescriptorName,D056486,17228132,,,5,Chemical and Drug Induced Liver Injury,N,
14096,QualifierName,Q000097,17228132,,,5,,N,blood
14097,DescriptorName,D066246,17228132,,,6,ErbB Receptors,N,
14098,QualifierName,Q000037,17228132,,,6,,N,antagonists & inhibitors
14099,DescriptorName,D000069347,17228132,,,7,Erlotinib Hydrochloride,N,
14100,DescriptorName,D006801,17228132,,,8,Humans,N,
14101,DescriptorName,D008297,17228132,,,9,Male,N,
14102,DescriptorName,D010190,17228132,,,10,Pancreatic Neoplasms,N,
14103,QualifierName,Q000188,17228132,,,10,,Y,drug therapy
14104,DescriptorName,D047428,17228132,,,11,Protein Kinase Inhibitors,N,
14105,QualifierName,Q000009,17228132,,,11,,Y,adverse effects
14106,DescriptorName,D011799,17228132,,,12,Quinazolines,N,
14107,QualifierName,Q000009,17228132,,,12,,Y,adverse effects
14108,Chemical,D010975,1722991,Platelet Aggregation Inhibitors,0,,,,
14109,Chemical,D004176,1722991,Dipyridamole,64ALC7F90C,,,,
14110,Chemical,D006493,1722991,Heparin,9005-49-6,,,,
14111,Chemical,D016285,1722991,Iloprost,JED5K35YGL,,,,
14112,Chemical,D001241,1722991,Aspirin,R16CO5Y76E,,,,
14113,DescriptorName,D000368,1722991,,,1,Aged,N,
14114,DescriptorName,D001012,1722991,,,2,"Aorta, Abdominal",N,
14115,DescriptorName,D001241,1722991,,,3,Aspirin,N,
14116,QualifierName,Q000627,1722991,,,3,,Y,therapeutic use
14117,DescriptorName,D004176,1722991,,,4,Dipyridamole,N,
14118,QualifierName,Q000627,1722991,,,4,,Y,therapeutic use
14119,DescriptorName,D005260,1722991,,,5,Female,N,
14120,DescriptorName,D005268,1722991,,,6,Femoral Vein,N,
14121,DescriptorName,D006493,1722991,,,7,Heparin,N,
14122,QualifierName,Q000009,1722991,,,7,,Y,adverse effects
14123,DescriptorName,D006801,1722991,,,8,Humans,N,
14124,DescriptorName,D007083,1722991,,,9,Iliac Artery,N,
14125,DescriptorName,D007084,1722991,,,10,Iliac Vein,N,
14126,DescriptorName,D016285,1722991,,,11,Iloprost,N,
14127,QualifierName,Q000627,1722991,,,11,,Y,therapeutic use
14128,DescriptorName,D007511,1722991,,,12,Ischemia,N,
14129,QualifierName,Q000188,1722991,,,12,,N,drug therapy
14130,DescriptorName,D010974,1722991,,,13,Platelet Aggregation,N,
14131,QualifierName,Q000187,1722991,,,13,,N,drug effects
14132,DescriptorName,D010975,1722991,,,14,Platelet Aggregation Inhibitors,N,
14133,QualifierName,Q000627,1722991,,,14,,Y,therapeutic use
14134,DescriptorName,D013921,1722991,,,15,Thrombocytopenia,N,
14135,QualifierName,Q000139,1722991,,,15,,Y,chemically induced
14136,DescriptorName,D013927,1722991,,,16,Thrombosis,N,
14137,QualifierName,Q000139,1722991,,,16,,Y,chemically induced
14138,DescriptorName,D014682,1722991,,,17,"Vena Cava, Inferior",N,
14139,Chemical,D002243,17241588,Carbolines,0,,,,
14140,Chemical,D010726,17241588,Phosphodiesterase Inhibitors,0,,,,
14141,Chemical,D000068581,17241588,Tadalafil,742SXX0ICT,,,,
14142,DescriptorName,D002243,17241588,,,1,Carbolines,N,
14143,QualifierName,Q000009,17241588,,,1,,Y,adverse effects
14144,DescriptorName,D003875,17241588,,,2,Drug Eruptions,N,
14145,QualifierName,Q000209,17241588,,,2,,Y,etiology
14146,DescriptorName,D007172,17241588,,,3,Erectile Dysfunction,N,
14147,QualifierName,Q000188,17241588,,,3,,Y,drug therapy
14148,DescriptorName,D006801,17241588,,,4,Humans,N,
14149,DescriptorName,D008297,17241588,,,5,Male,N,
14150,DescriptorName,D008875,17241588,,,6,Middle Aged,N,
14151,DescriptorName,D010413,17241588,,,7,Penis,N,
14152,DescriptorName,D010726,17241588,,,8,Phosphodiesterase Inhibitors,N,
14153,QualifierName,Q000009,17241588,,,8,,Y,adverse effects
14154,DescriptorName,D000068581,17241588,,,9,Tadalafil,N,
14155,Chemical,D000970,17260498,Antineoplastic Agents,0,,,,
14156,Chemical,D043823,17260498,Taxoids,0,,,,
14157,Chemical,D000077143,17260498,Docetaxel,15H5577CQD,,,,
14158,DescriptorName,D000368,17260498,,,1,Aged,N,
14159,DescriptorName,D000970,17260498,,,2,Antineoplastic Agents,N,
14160,QualifierName,Q000008,17260498,,,2,,N,administration & dosage
14161,DescriptorName,D000077143,17260498,,,3,Docetaxel,N,
14162,DescriptorName,D017809,17260498,,,4,Fatal Outcome,N,
14163,DescriptorName,D006801,17260498,,,5,Humans,N,
14164,DescriptorName,D008168,17260498,,,6,Lung,N,
14165,QualifierName,Q000187,17260498,,,6,,Y,drug effects
14166,DescriptorName,D017563,17260498,,,7,"Lung Diseases, Interstitial",N,
14167,QualifierName,Q000139,17260498,,,7,,Y,chemically induced
14168,DescriptorName,D008297,17260498,,,8,Male,N,
14169,DescriptorName,D011471,17260498,,,9,Prostatic Neoplasms,N,
14170,QualifierName,Q000188,17260498,,,9,,Y,drug therapy
14171,DescriptorName,D043823,17260498,,,10,Taxoids,N,
14172,QualifierName,Q000008,17260498,,,10,,N,administration & dosage
14173,Chemical,D015662,17266059,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
14174,DescriptorName,D000328,17266059,,,1,Adult,N,
14175,DescriptorName,D000743,17266059,,,2,"Anemia, Hemolytic",N,
14176,QualifierName,Q000188,17266059,,,2,,N,drug therapy
14177,DescriptorName,D005260,17266059,,,3,Female,N,
14178,DescriptorName,D006801,17266059,,,4,Humans,N,
14179,DescriptorName,D033221,17266059,,,5,Jehovah's Witnesses,Y,
14180,DescriptorName,D011697,17266059,,,6,"Purpura, Thrombotic Thrombocytopenic",N,
14181,QualifierName,Q000139,17266059,,,6,,Y,chemically induced
14182,DescriptorName,D015662,17266059,,,7,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
14183,QualifierName,Q000009,17266059,,,7,,Y,adverse effects
14184,Chemical,D000927,17275666,Anticonvulsants,0,,,,
14185,Chemical,D014635,17275666,Valproic Acid,614OI1Z5WI,,,,
14186,DescriptorName,D000927,17275666,,,1,Anticonvulsants,N,
14187,QualifierName,Q000008,17275666,,,1,,N,administration & dosage
14188,DescriptorName,D002648,17275666,,,2,Child,N,
14189,DescriptorName,D004569,17275666,,,3,Electroencephalography,N,
14190,QualifierName,Q000187,17275666,,,3,,N,drug effects
14191,DescriptorName,D004832,17275666,,,4,"Epilepsy, Absence",N,
14192,QualifierName,Q000139,17275666,,,4,,Y,chemically induced
14193,DescriptorName,D005260,17275666,,,5,Female,N,
14194,DescriptorName,D006801,17275666,,,6,Humans,N,
14195,DescriptorName,D007275,17275666,,,7,"Injections, Intravenous",N,
14196,DescriptorName,D012720,17275666,,,8,Severity of Illness Index,Y,
14197,DescriptorName,D014635,17275666,,,9,Valproic Acid,N,
14198,QualifierName,Q000008,17275666,,,9,,N,administration & dosage
14199,DescriptorName,D014741,17275666,,,10,Video Recording,N,
14200,Chemical,D020533,17277758,Angiogenesis Inhibitors,0,,,,
14201,Chemical,D000911,17277758,"Antibodies, Monoclonal",0,,,,
14202,Chemical,D061067,17277758,"Antibodies, Monoclonal, Humanized",0,,,,
14203,Chemical,D000068258,17277758,Bevacizumab,2S9ZZM9Q9V,,,,
14204,DescriptorName,D000208,17277758,,,1,Acute Disease,N,
14205,DescriptorName,D000369,17277758,,,2,"Aged, 80 and over",N,
14206,DescriptorName,D020533,17277758,,,3,Angiogenesis Inhibitors,N,
14207,QualifierName,Q000008,17277758,,,3,,N,administration & dosage
14208,DescriptorName,D000911,17277758,,,4,"Antibodies, Monoclonal",N,
14209,QualifierName,Q000008,17277758,,,4,,N,administration & dosage
14210,DescriptorName,D061067,17277758,,,5,"Antibodies, Monoclonal, Humanized",N,
14211,DescriptorName,D000068258,17277758,,,6,Bevacizumab,N,
14212,DescriptorName,D009877,17277758,,,7,Endophthalmitis,N,
14213,QualifierName,Q000139,17277758,,,7,,Y,chemically induced
14214,DescriptorName,D005260,17277758,,,8,Female,N,
14215,DescriptorName,D006801,17277758,,,9,Humans,N,
14216,DescriptorName,D007267,17277758,,,10,Injections,N,
14217,QualifierName,Q000379,17277758,,,10,,N,methods
14218,DescriptorName,D008268,17277758,,,11,Macular Degeneration,N,
14219,QualifierName,Q000188,17277758,,,11,,N,drug therapy
14220,DescriptorName,D008297,17277758,,,12,Male,N,
14221,DescriptorName,D013203,17277758,,,13,Staphylococcal Infections,N,
14222,QualifierName,Q000139,17277758,,,13,,Y,chemically induced
14223,DescriptorName,D014822,17277758,,,14,Vitreous Body,N,
14224,QualifierName,Q000382,17277758,,,14,,N,microbiology
14225,Chemical,D018692,17285101,Antimanic Agents,0,,,,
14226,Chemical,D005473,17285101,Fluoxetine,01K63SUP8D,,,,
14227,Chemical,D016651,17285101,Lithium Carbonate,2BMD2GNA4V,,,,
14228,DescriptorName,D018692,17285101,,,1,Antimanic Agents,N,
14229,QualifierName,Q000009,17285101,,,1,,Y,adverse effects
14230,DescriptorName,D001714,17285101,,,2,Bipolar Disorder,N,
14231,QualifierName,Q000188,17285101,,,2,,Y,drug therapy
14232,DescriptorName,D003937,17285101,,,3,"Diagnosis, Differential",N,
14233,DescriptorName,D004359,17285101,,,4,"Drug Therapy, Combination",N,
14234,DescriptorName,D004452,17285101,,,5,Echocardiography,N,
14235,DescriptorName,D005260,17285101,,,6,Female,N,
14236,DescriptorName,D005473,17285101,,,7,Fluoxetine,N,
14237,QualifierName,Q000009,17285101,,,7,,N,adverse effects
14238,DescriptorName,D006801,17285101,,,8,Humans,N,
14239,DescriptorName,D006976,17285101,,,9,"Hypertension, Pulmonary",N,
14240,QualifierName,Q000139,17285101,,,9,,Y,chemically induced
14241,DescriptorName,D016651,17285101,,,10,Lithium Carbonate,N,
14242,QualifierName,Q000009,17285101,,,10,,Y,adverse effects
14243,DescriptorName,D008875,17285101,,,11,Middle Aged,N,
14244,Chemical,D000911,17298107,"Antibodies, Monoclonal",0,,,,
14245,Chemical,D003879,17298107,Dermatologic Agents,0,,,,
14246,Chemical,D011993,17298107,Recombinant Fusion Proteins,0,,,,
14247,Chemical,D000069285,17298107,Infliximab,B72HH48FLU,,,,
14248,Chemical,D000077944,17298107,Alefacept,ELK3V90G6C,,,,
14249,DescriptorName,D000328,17298107,,,1,Adult,N,
14250,DescriptorName,D000077944,17298107,,,2,Alefacept,N,
14251,DescriptorName,D000911,17298107,,,3,"Antibodies, Monoclonal",N,
14252,QualifierName,Q000009,17298107,,,3,,N,adverse effects
14253,DescriptorName,D003879,17298107,,,4,Dermatologic Agents,N,
14254,QualifierName,Q000627,17298107,,,4,,Y,therapeutic use
14255,DescriptorName,D006801,17298107,,,5,Humans,N,
14256,DescriptorName,D000069285,17298107,,,6,Infliximab,N,
14257,DescriptorName,D008178,17298107,,,7,"Lupus Erythematosus, Cutaneous",N,
14258,QualifierName,Q000150,17298107,,,7,,Y,complications
14259,DescriptorName,D008297,17298107,,,8,Male,N,
14260,DescriptorName,D011565,17298107,,,9,Psoriasis,N,
14261,QualifierName,Q000150,17298107,,,9,,Y,complications
14262,DescriptorName,D011993,17298107,,,10,Recombinant Fusion Proteins,N,
14263,QualifierName,Q000627,17298107,,,10,,Y,therapeutic use
14264,DescriptorName,D012867,17298107,,,11,Skin,N,
14265,QualifierName,Q000473,17298107,,,11,,N,pathology
14266,DescriptorName,D016896,17298107,,,12,Treatment Outcome,N,
14267,Chemical,D007211,17301517,Indoles,0,,,,
14268,Chemical,D054833,17301517,Isoindoles,0,,,,
14269,Chemical,D013844,17301517,Thiazoles,0,,,,
14270,Chemical,D018967,17301517,Risperidone,L6UH7ZF8HC,,,,
14271,Chemical,C065533,17301517,perospirone,N303OK87DT,,,,
14272,DescriptorName,D000328,17301517,,,1,Adult,N,
14273,DescriptorName,D016883,17301517,,,2,Diabetic Ketoacidosis,N,
14274,QualifierName,Q000139,17301517,,,2,,Y,chemically induced
14275,DescriptorName,D004305,17301517,,,3,"Dose-Response Relationship, Drug",N,
14276,DescriptorName,D004334,17301517,,,4,Drug Administration Schedule,N,
14277,DescriptorName,D004359,17301517,,,5,"Drug Therapy, Combination",N,
14278,DescriptorName,D005500,17301517,,,6,Follow-Up Studies,N,
14279,DescriptorName,D006801,17301517,,,7,Humans,N,
14280,DescriptorName,D007211,17301517,,,8,Indoles,N,
14281,QualifierName,Q000009,17301517,,,8,,Y,adverse effects
14282,DescriptorName,D054833,17301517,,,9,Isoindoles,N,
14283,DescriptorName,D008297,17301517,,,10,Male,N,
14284,DescriptorName,D018570,17301517,,,11,Risk Assessment,N,
14285,DescriptorName,D018967,17301517,,,12,Risperidone,N,
14286,QualifierName,Q000009,17301517,,,12,,Y,adverse effects
14287,DescriptorName,D012559,17301517,,,13,Schizophrenia,N,
14288,QualifierName,Q000175,17301517,,,13,,N,diagnosis
14289,DescriptorName,D012720,17301517,,,14,Severity of Illness Index,N,
14290,DescriptorName,D013844,17301517,,,15,Thiazoles,N,
14291,QualifierName,Q000009,17301517,,,15,,Y,adverse effects
14292,DescriptorName,D016896,17301517,,,16,Treatment Outcome,N,
14293,Chemical,D000970,17310853,Antineoplastic Agents,0,,,,
14294,Chemical,D001549,17310853,Benzamides,0,,,,
14295,Chemical,D010879,17310853,Piperazines,0,,,,
14296,Chemical,D011743,17310853,Pyrimidines,0,,,,
14297,Chemical,D000068877,17310853,Imatinib Mesylate,8A1O1M485B,,,,
14298,DescriptorName,D000970,17310853,,,1,Antineoplastic Agents,N,
14299,QualifierName,Q000009,17310853,,,1,,Y,adverse effects
14300,DescriptorName,D001344,17310853,,,2,Autopsy,N,
14301,DescriptorName,D001549,17310853,,,3,Benzamides,N,
14302,DescriptorName,D017809,17310853,,,4,Fatal Outcome,N,
14303,DescriptorName,D046152,17310853,,,5,Gastrointestinal Stromal Tumors,N,
14304,QualifierName,Q000188,17310853,,,5,,Y,drug therapy
14305,DescriptorName,D006801,17310853,,,6,Humans,N,
14306,DescriptorName,D000068877,17310853,,,7,Imatinib Mesylate,N,
14307,DescriptorName,D008297,17310853,,,8,Male,N,
14308,DescriptorName,D008875,17310853,,,9,Middle Aged,N,
14309,DescriptorName,D010879,17310853,,,10,Piperazines,N,
14310,QualifierName,Q000009,17310853,,,10,,Y,adverse effects
14311,DescriptorName,D011743,17310853,,,11,Pyrimidines,N,
14312,QualifierName,Q000009,17310853,,,11,,Y,adverse effects
14313,DescriptorName,D013923,17310853,,,12,Thromboembolism,N,
14314,QualifierName,Q000139,17310853,,,12,,Y,chemically induced
14315,Chemical,D000970,17316891,Antineoplastic Agents,0,,,,
14316,Chemical,D007166,17316891,Immunosuppressive Agents,0,,,,
14317,Chemical,D003841,17316891,Deoxycytidine,0W860991D6,,,,
14318,Chemical,C056507,17316891,gemcitabine,B76N6SBZ8R,,,,
14319,Chemical,D012264,17316891,Ribonucleotide Reductases,EC 1.17.4.-,,,,
14320,Chemical,D002945,17316891,Cisplatin,Q20Q21Q62J,,,,
14321,DescriptorName,D000970,17316891,,,1,Antineoplastic Agents,N,
14322,QualifierName,Q000009,17316891,,,1,,Y,adverse effects
14323,DescriptorName,D002289,17316891,,,2,"Carcinoma, Non-Small-Cell Lung",N,
14324,QualifierName,Q000175,17316891,,,2,,N,diagnosis
14325,DescriptorName,D002945,17316891,,,3,Cisplatin,N,
14326,QualifierName,Q000009,17316891,,,3,,N,adverse effects
14327,DescriptorName,D003841,17316891,,,4,Deoxycytidine,N,
14328,QualifierName,Q000009,17316891,,,4,,N,adverse effects
14329,DescriptorName,D003937,17316891,,,5,"Diagnosis, Differential",N,
14330,DescriptorName,D004359,17316891,,,6,"Drug Therapy, Combination",N,
14331,DescriptorName,D004569,17316891,,,7,Electroencephalography,N,
14332,DescriptorName,D005260,17316891,,,8,Female,N,
14333,DescriptorName,D005500,17316891,,,9,Follow-Up Studies,N,
14334,DescriptorName,D006801,17316891,,,10,Humans,N,
14335,DescriptorName,D007166,17316891,,,11,Immunosuppressive Agents,N,
14336,QualifierName,Q000009,17316891,,,11,,Y,adverse effects
14337,DescriptorName,D007968,17316891,,,12,"Leukoencephalopathy, Progressive Multifocal",N,
14338,QualifierName,Q000139,17316891,,,12,,Y,chemically induced
14339,DescriptorName,D008175,17316891,,,13,Lung Neoplasms,N,
14340,QualifierName,Q000188,17316891,,,13,,Y,drug therapy
14341,DescriptorName,D008279,17316891,,,14,Magnetic Resonance Imaging,N,
14342,DescriptorName,D008577,17316891,,,15,Meningeal Neoplasms,N,
14343,QualifierName,Q000175,17316891,,,15,,N,diagnosis
14344,DescriptorName,D008875,17316891,,,16,Middle Aged,N,
14345,DescriptorName,D012264,17316891,,,17,Ribonucleotide Reductases,N,
14346,QualifierName,Q000009,17316891,,,17,,N,adverse effects
14347,DescriptorName,D014057,17316891,,,18,"Tomography, X-Ray Computed",N,
14348,Chemical,D000701,17319250,"Analgesics, Opioid",0,,,,
14349,Chemical,D008691,17319250,Methadone,UC6VBE7V1Z,,,,
14350,DescriptorName,D000701,17319250,,,1,"Analgesics, Opioid",N,
14351,QualifierName,Q000008,17319250,,,1,,N,administration & dosage
14352,DescriptorName,D004305,17319250,,,2,"Dose-Response Relationship, Drug",N,
14353,DescriptorName,D004562,17319250,,,3,Electrocardiography,N,
14354,DescriptorName,D005260,17319250,,,4,Female,N,
14355,DescriptorName,D006801,17319250,,,5,Humans,N,
14356,DescriptorName,D008133,17319250,,,6,Long QT Syndrome,N,
14357,QualifierName,Q000139,17319250,,,6,,Y,chemically induced
14358,DescriptorName,D008691,17319250,,,7,Methadone,N,
14359,QualifierName,Q000008,17319250,,,7,,N,administration & dosage
14360,DescriptorName,D008875,17319250,,,8,Middle Aged,N,
14361,DescriptorName,D012019,17319250,,,9,Reflex Sympathetic Dystrophy,N,
14362,QualifierName,Q000188,17319250,,,9,,Y,drug therapy
14363,Chemical,D000928,17324248,Antidepressive Agents,0,,,,
14364,Chemical,D003521,17324248,Cyclopropanes,0,,,,
14365,Chemical,D000078764,17324248,Milnacipran,G56VK1HF36,,,,
14366,Chemical,D016666,17324248,Fluvoxamine,O4L1XPO44W,,,,
14367,Chemical,D007099,17324248,Imipramine,OGG85SX4E4,,,,
14368,Chemical,D009638,17324248,Norepinephrine,X4W3ENH1CV,,,,
14369,DescriptorName,D000328,17324248,,,1,Adult,N,
14370,DescriptorName,D000928,17324248,,,2,Antidepressive Agents,N,
14371,QualifierName,Q000009,17324248,,,2,,Y,adverse effects
14372,DescriptorName,D003521,17324248,,,3,Cyclopropanes,N,
14373,QualifierName,Q000009,17324248,,,3,,Y,adverse effects
14374,DescriptorName,D005260,17324248,,,4,Female,N,
14375,DescriptorName,D016666,17324248,,,5,Fluvoxamine,N,
14376,QualifierName,Q000009,17324248,,,5,,Y,adverse effects
14377,DescriptorName,D006801,17324248,,,6,Humans,N,
14378,DescriptorName,D007099,17324248,,,7,Imipramine,N,
14379,QualifierName,Q000009,17324248,,,7,,Y,adverse effects
14380,DescriptorName,D000078764,17324248,,,8,Milnacipran,N,
14381,DescriptorName,D008954,17324248,,,9,"Models, Biological",N,
14382,DescriptorName,D009638,17324248,,,10,Norepinephrine,N,
14383,QualifierName,Q000378,17324248,,,10,,N,metabolism
14384,DescriptorName,D016584,17324248,,,11,Panic Disorder,N,
14385,QualifierName,Q000188,17324248,,,11,,Y,drug therapy
14386,DescriptorName,D010863,17324248,,,12,Piloerection,N,
14387,QualifierName,Q000187,17324248,,,12,,Y,drug effects
14388,Chemical,D011241,17331261,Prednisone,VB0R961HZT,,,,
14389,Chemical,D014031,17331261,Tobramycin,VZ8RRZ51VK,,,,
14390,DescriptorName,D000280,17331261,,,1,"Administration, Inhalation",N,
14391,DescriptorName,D001986,17331261,,,2,Bronchial Spasm,N,
14392,QualifierName,Q000139,17331261,,,2,,Y,chemically induced
14393,DescriptorName,D002675,17331261,,,3,"Child, Preschool",N,
14394,DescriptorName,D003550,17331261,,,4,Cystic Fibrosis,N,
14395,QualifierName,Q000175,17331261,,,4,,N,diagnosis
14396,DescriptorName,D004305,17331261,,,5,"Dose-Response Relationship, Drug",N,
14397,DescriptorName,D004334,17331261,,,6,Drug Administration Schedule,N,
14398,DescriptorName,D005500,17331261,,,7,Follow-Up Studies,N,
14399,DescriptorName,D006801,17331261,,,8,Humans,N,
14400,DescriptorName,D008297,17331261,,,9,Male,N,
14401,DescriptorName,D018410,17331261,,,10,"Pneumonia, Bacterial",N,
14402,QualifierName,Q000188,17331261,,,10,,Y,drug therapy
14403,DescriptorName,D011241,17331261,,,11,Prednisone,N,
14404,QualifierName,Q000627,17331261,,,11,,N,therapeutic use
14405,DescriptorName,D011657,17331261,,,12,Pulmonary Eosinophilia,N,
14406,QualifierName,Q000139,17331261,,,12,,Y,chemically induced
14407,DescriptorName,D012008,17331261,,,13,Recurrence,N,
14408,DescriptorName,D018570,17331261,,,14,Risk Assessment,N,
14409,DescriptorName,D012720,17331261,,,15,Severity of Illness Index,N,
14410,DescriptorName,D014031,17331261,,,16,Tobramycin,N,
14411,QualifierName,Q000008,17331261,,,16,,N,administration & dosage
14412,Chemical,D050071,17346586,Bone Density Conservation Agents,0,,,,
14413,Chemical,D004164,17346586,Diphosphonates,0,,,,
14414,DescriptorName,D000224,17346586,,,1,Addison Disease,N,
14415,QualifierName,Q000188,17346586,,,1,,N,drug therapy
14416,DescriptorName,D000328,17346586,,,2,Adult,N,
14417,DescriptorName,D000368,17346586,,,3,Aged,N,
14418,DescriptorName,D050071,17346586,,,4,Bone Density Conservation Agents,N,
14419,QualifierName,Q000009,17346586,,,4,,Y,adverse effects
14420,DescriptorName,D004164,17346586,,,5,Diphosphonates,N,
14421,QualifierName,Q000009,17346586,,,5,,Y,adverse effects
14422,DescriptorName,D005260,17346586,,,6,Female,N,
14423,DescriptorName,D006801,17346586,,,7,Humans,N,
14424,DescriptorName,D008297,17346586,,,8,Male,N,
14425,DescriptorName,D008312,17346586,,,9,"Malocclusion, Angle Class II",N,
14426,QualifierName,Q000000981,17346586,,,9,,N,diagnostic imaging
14427,DescriptorName,D008336,17346586,,,10,Mandibular Diseases,N,
14428,QualifierName,Q000139,17346586,,,10,,Y,chemically induced
14429,DescriptorName,D009101,17346586,,,11,Multiple Myeloma,N,
14430,QualifierName,Q000188,17346586,,,11,,N,drug therapy
14431,DescriptorName,D019516,17346586,,,12,Orthodontic Space Closure,N,
14432,QualifierName,Q000009,17346586,,,12,,Y,adverse effects
14433,DescriptorName,D010020,17346586,,,13,Osteonecrosis,N,
14434,QualifierName,Q000139,17346586,,,13,,Y,chemically induced
14435,DescriptorName,D011859,17346586,,,14,Radiography,N,
14436,DescriptorName,D014081,17346586,,,15,Tooth Extraction,N,
14437,QualifierName,Q000009,17346586,,,15,,N,adverse effects
14438,DescriptorName,D016896,17346586,,,16,Treatment Outcome,N,
14439,Chemical,D000889,17352036,Anti-Arrhythmia Agents,0,,,,
14440,Chemical,D011405,17352036,Propafenone,68IQX3T69U,,,,
14441,Chemical,D000638,17352036,Amiodarone,N3RQ532IUT,,,,
14442,DescriptorName,D000208,17352036,,,1,Acute Disease,N,
14443,DescriptorName,D000368,17352036,,,2,Aged,N,
14444,DescriptorName,D000638,17352036,,,3,Amiodarone,N,
14445,QualifierName,Q000009,17352036,,,3,,Y,adverse effects
14446,DescriptorName,D000889,17352036,,,4,Anti-Arrhythmia Agents,N,
14447,QualifierName,Q000009,17352036,,,4,,Y,adverse effects
14448,DescriptorName,D005260,17352036,,,5,Female,N,
14449,DescriptorName,D006801,17352036,,,6,Humans,N,
14450,DescriptorName,D010195,17352036,,,7,Pancreatitis,N,
14451,QualifierName,Q000139,17352036,,,7,,Y,chemically induced
14452,DescriptorName,D011405,17352036,,,8,Propafenone,N,
14453,QualifierName,Q000627,17352036,,,8,,N,therapeutic use
14454,DescriptorName,D013610,17352036,,,9,Tachycardia,N,
14455,QualifierName,Q000188,17352036,,,9,,N,drug therapy
14456,Chemical,D018501,17364199,Antirheumatic Agents,0,,,,
14457,Chemical,D000995,17364199,Antitubercular Agents,0,,,,
14458,Chemical,D007074,17364199,Immunoglobulin G,0,,,,
14459,Chemical,D018124,17364199,"Receptors, Tumor Necrosis Factor",0,,,,
14460,Chemical,D011718,17364199,Pyrazinamide,2KNI5N06TI,,,,
14461,Chemical,D000068800,17364199,Etanercept,OP401G7OJC,,,,
14462,Chemical,D007538,17364199,Isoniazid,V83O1VOZ8L,,,,
14463,Chemical,D012293,17364199,Rifampin,VJT6J7R4TR,,,,
14464,DescriptorName,D018501,17364199,,,1,Antirheumatic Agents,N,
14465,QualifierName,Q000009,17364199,,,1,,Y,adverse effects
14466,DescriptorName,D000995,17364199,,,2,Antitubercular Agents,N,
14467,QualifierName,Q000627,17364199,,,2,,N,therapeutic use
14468,DescriptorName,D001082,17364199,,,3,Aqueous Humor,N,
14469,QualifierName,Q000382,17364199,,,3,,N,microbiology
14470,DescriptorName,D001172,17364199,,,4,"Arthritis, Rheumatoid",N,
14471,QualifierName,Q000188,17364199,,,4,,N,drug therapy
14472,DescriptorName,D004359,17364199,,,5,"Drug Therapy, Combination",N,
14473,DescriptorName,D000068800,17364199,,,6,Etanercept,N,
14474,DescriptorName,D005260,17364199,,,7,Female,N,
14475,DescriptorName,D006099,17364199,,,8,Granuloma,N,
14476,QualifierName,Q000175,17364199,,,8,,N,diagnosis
14477,DescriptorName,D006801,17364199,,,9,Humans,N,
14478,DescriptorName,D007074,17364199,,,10,Immunoglobulin G,N,
14479,QualifierName,Q000009,17364199,,,10,,Y,adverse effects
14480,DescriptorName,D007538,17364199,,,11,Isoniazid,N,
14481,QualifierName,Q000627,17364199,,,11,,N,therapeutic use
14482,DescriptorName,D008875,17364199,,,12,Middle Aged,N,
14483,DescriptorName,D009169,17364199,,,13,Mycobacterium tuberculosis,N,
14484,QualifierName,Q000302,17364199,,,13,,N,isolation & purification
14485,DescriptorName,D015864,17364199,,,14,Panuveitis,N,
14486,QualifierName,Q000175,17364199,,,14,,N,diagnosis
14487,DescriptorName,D011718,17364199,,,15,Pyrazinamide,N,
14488,QualifierName,Q000627,17364199,,,15,,N,therapeutic use
14489,DescriptorName,D018124,17364199,,,16,"Receptors, Tumor Necrosis Factor",N,
14490,DescriptorName,D012189,17364199,,,17,Retrospective Studies,N,
14491,DescriptorName,D012293,17364199,,,18,Rifampin,N,
14492,QualifierName,Q000627,17364199,,,18,,N,therapeutic use
14493,DescriptorName,D014392,17364199,,,19,"Tuberculosis, Ocular",N,
14494,QualifierName,Q000175,17364199,,,19,,N,diagnosis
14495,Chemical,D000970,17366681,Antineoplastic Agents,0,,,,
14496,Chemical,D005971,17366681,Glutamates,0,,,,
14497,Chemical,D000068437,17366681,Pemetrexed,04Q9AIZ7NO,,,,
14498,Chemical,D006147,17366681,Guanine,5Z93L87A1R,,,,
14499,DescriptorName,D000230,17366681,,,1,Adenocarcinoma,N,
14500,QualifierName,Q000188,17366681,,,1,,Y,drug therapy
14501,DescriptorName,D000970,17366681,,,2,Antineoplastic Agents,N,
14502,QualifierName,Q000009,17366681,,,2,,Y,adverse effects
14503,DescriptorName,D005971,17366681,,,3,Glutamates,N,
14504,QualifierName,Q000009,17366681,,,3,,Y,adverse effects
14505,DescriptorName,D006147,17366681,,,4,Guanine,N,
14506,QualifierName,Q000009,17366681,,,4,,N,adverse effects
14507,DescriptorName,D006801,17366681,,,5,Humans,N,
14508,DescriptorName,D008175,17366681,,,6,Lung Neoplasms,N,
14509,QualifierName,Q000188,17366681,,,6,,Y,drug therapy
14510,DescriptorName,D008297,17366681,,,7,Male,N,
14511,DescriptorName,D008875,17366681,,,8,Middle Aged,N,
14512,DescriptorName,D009260,17366681,,,9,Nail Diseases,N,
14513,QualifierName,Q000139,17366681,,,9,,Y,chemically induced
14514,DescriptorName,D000068437,17366681,,,10,Pemetrexed,N,
14515,Chemical,D000911,17373180,"Antibodies, Monoclonal",0,,,,
14516,Chemical,D014409,17373180,Tumor Necrosis Factor-alpha,0,,,,
14517,Chemical,D000069285,17373180,Infliximab,B72HH48FLU,,,,
14518,DescriptorName,D000911,17373180,,,1,"Antibodies, Monoclonal",N,
14519,QualifierName,Q000009,17373180,,,1,,Y,adverse effects
14520,DescriptorName,D015535,17373180,,,2,"Arthritis, Psoriatic",N,
14521,QualifierName,Q000150,17373180,,,2,,N,complications
14522,DescriptorName,D006801,17373180,,,3,Humans,N,
14523,DescriptorName,D000069285,17373180,,,4,Infliximab,N,
14524,DescriptorName,D008297,17373180,,,5,Male,N,
14525,DescriptorName,D008875,17373180,,,6,Middle Aged,N,
14526,DescriptorName,D010019,17373180,,,7,Osteomyelitis,N,
14527,QualifierName,Q000139,17373180,,,7,,Y,chemically induced
14528,DescriptorName,D011565,17373180,,,8,Psoriasis,N,
14529,QualifierName,Q000150,17373180,,,8,,Y,complications
14530,DescriptorName,D014409,17373180,,,9,Tumor Necrosis Factor-alpha,N,
14531,QualifierName,Q000037,17373180,,,9,,N,antagonists & inhibitors
14532,Chemical,D017367,17381671,Serotonin Uptake Inhibitors,0,,,,
14533,Chemical,D015283,17381671,Citalopram,0DHU5B8D6V,,,,
14534,Chemical,D005283,17381671,Fentanyl,UF599785JZ,,,,
14535,DescriptorName,D000368,17381671,,,1,Aged,N,
14536,DescriptorName,D015283,17381671,,,2,Citalopram,N,
14537,QualifierName,Q000009,17381671,,,2,,Y,adverse effects
14538,DescriptorName,D004347,17381671,,,3,Drug Interactions,Y,
14539,DescriptorName,D004359,17381671,,,4,"Drug Therapy, Combination",N,
14540,DescriptorName,D005283,17381671,,,5,Fentanyl,N,
14541,QualifierName,Q000009,17381671,,,5,,Y,adverse effects
14542,DescriptorName,D006801,17381671,,,6,Humans,N,
14543,DescriptorName,D009190,17381671,,,7,Myelodysplastic Syndromes,N,
14544,QualifierName,Q000188,17381671,,,7,,N,drug therapy
14545,DescriptorName,D009196,17381671,,,8,Myeloproliferative Disorders,N,
14546,QualifierName,Q000188,17381671,,,8,,N,drug therapy
14547,DescriptorName,D020230,17381671,,,9,Serotonin Syndrome,N,
14548,QualifierName,Q000139,17381671,,,9,,Y,chemically induced
14549,DescriptorName,D017367,17381671,,,10,Serotonin Uptake Inhibitors,N,
14550,QualifierName,Q000009,17381671,,,10,,N,adverse effects
14551,Chemical,D000964,17387702,"Antimetabolites, Antineoplastic",0,,,,
14552,Chemical,D042965,17387702,Methylenetetrahydrofolate Reductase (NADPH2),EC 1.5.1.20,,,,
14553,Chemical,D008727,17387702,Methotrexate,YL5FZ2Y5U1,,,,
14554,DescriptorName,D058186,17387702,,,1,Acute Kidney Injury,N,
14555,QualifierName,Q000139,17387702,,,1,,Y,chemically induced
14556,DescriptorName,D000964,17387702,,,2,"Antimetabolites, Antineoplastic",N,
14557,QualifierName,Q000008,17387702,,,2,,N,administration & dosage
14558,DescriptorName,D002648,17387702,,,3,Child,N,
14559,DescriptorName,D005260,17387702,,,4,Female,N,
14560,DescriptorName,D006720,17387702,,,5,Homozygote,N,
14561,DescriptorName,D006801,17387702,,,6,Humans,N,
14562,DescriptorName,D016399,17387702,,,7,"Lymphoma, T-Cell",N,
14563,QualifierName,Q000188,17387702,,,7,,N,drug therapy
14564,DescriptorName,D008727,17387702,,,8,Methotrexate,N,
14565,QualifierName,Q000008,17387702,,,8,,N,administration & dosage
14566,DescriptorName,D042965,17387702,,,9,Methylenetetrahydrofolate Reductase (NADPH2),N,
14567,QualifierName,Q000235,17387702,,,9,,Y,genetics
14568,DescriptorName,D011110,17387702,,,10,"Polymorphism, Genetic",Y,
14569,Chemical,D000972,17404582,"Antineoplastic Agents, Phytogenic",0,,,,
14570,Chemical,D043823,17404582,Taxoids,0,,,,
14571,Chemical,D000077143,17404582,Docetaxel,15H5577CQD,,,,
14572,DescriptorName,D000368,17404582,,,1,Aged,N,
14573,DescriptorName,D000972,17404582,,,2,"Antineoplastic Agents, Phytogenic",N,
14574,QualifierName,Q000009,17404582,,,2,,Y,adverse effects
14575,DescriptorName,D002369,17404582,,,3,Castration,N,
14576,DescriptorName,D017043,17404582,,,4,Chalazion,N,
14577,QualifierName,Q000139,17404582,,,4,,Y,chemically induced
14578,DescriptorName,D000077143,17404582,,,5,Docetaxel,N,
14579,DescriptorName,D005141,17404582,,,6,Eyelid Diseases,N,
14580,QualifierName,Q000139,17404582,,,6,,Y,chemically induced
14581,DescriptorName,D006801,17404582,,,7,Humans,N,
14582,DescriptorName,D008297,17404582,,,8,Male,N,
14583,DescriptorName,D008537,17404582,,,9,Meibomian Glands,N,
14584,QualifierName,Q000187,17404582,,,9,,Y,drug effects
14585,DescriptorName,D011471,17404582,,,10,Prostatic Neoplasms,N,
14586,QualifierName,Q000188,17404582,,,10,,Y,drug therapy
14587,DescriptorName,D043823,17404582,,,11,Taxoids,N,
14588,QualifierName,Q000009,17404582,,,11,,Y,adverse effects
14589,Chemical,D000964,17406804,"Antimetabolites, Antineoplastic",0,,,,
14590,Chemical,D003841,17406804,Deoxycytidine,0W860991D6,,,,
14591,Chemical,C056507,17406804,gemcitabine,B76N6SBZ8R,,,,
14592,DescriptorName,D000964,17406804,,,1,"Antimetabolites, Antineoplastic",N,
14593,QualifierName,Q000009,17406804,,,1,,Y,adverse effects
14594,DescriptorName,D000971,17406804,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
14595,QualifierName,Q000627,17406804,,,2,,N,therapeutic use
14596,DescriptorName,D003131,17406804,,,3,Combined Modality Therapy,N,
14597,DescriptorName,D003841,17406804,,,4,Deoxycytidine,N,
14598,QualifierName,Q000009,17406804,,,4,,N,adverse effects
14599,DescriptorName,D004938,17406804,,,5,Esophageal Neoplasms,N,
14600,QualifierName,Q000188,17406804,,,5,,Y,drug therapy
14601,DescriptorName,D005260,17406804,,,6,Female,N,
14602,DescriptorName,D006801,17406804,,,7,Humans,N,
14603,DescriptorName,D008207,17406804,,,8,Lymphatic Metastasis,N,
14604,DescriptorName,D008875,17406804,,,9,Middle Aged,N,
14605,DescriptorName,D009362,17406804,,,10,Neoplasm Metastasis,N,
14606,DescriptorName,D011014,17406804,,,11,Pneumonia,N,
14607,QualifierName,Q000139,17406804,,,11,,Y,chemically induced
14608,DescriptorName,D011877,17406804,,,12,Radionuclide Imaging,N,
14609,DescriptorName,D016896,17406804,,,13,Treatment Outcome,N,
14610,Chemical,D000900,17426073,Anti-Bacterial Agents,0,,,,
14611,Chemical,D017334,17426073,Teicoplanin,61036-62-2,,,,
14612,Chemical,D014640,17426073,Vancomycin,6Q205EH1VU,,,,
14613,DescriptorName,D000900,17426073,,,1,Anti-Bacterial Agents,N,
14614,QualifierName,Q000009,17426073,,,1,,Y,adverse effects
14615,DescriptorName,D003429,17426073,,,2,Cross Reactions,N,
14616,DescriptorName,D005260,17426073,,,3,Female,N,
14617,DescriptorName,D006801,17426073,,,4,Humans,N,
14618,DescriptorName,D007958,17426073,,,5,Leukocyte Count,N,
14619,DescriptorName,D008875,17426073,,,6,Middle Aged,N,
14620,DescriptorName,D009503,17426073,,,7,Neutropenia,N,
14621,QualifierName,Q000097,17426073,,,7,,N,blood
14622,DescriptorName,D013207,17426073,,,8,Staphylococcal Skin Infections,N,
14623,QualifierName,Q000188,17426073,,,8,,N,drug therapy
14624,DescriptorName,D013211,17426073,,,9,Staphylococcus aureus,N,
14625,DescriptorName,D017334,17426073,,,10,Teicoplanin,N,
14626,QualifierName,Q000009,17426073,,,10,,Y,adverse effects
14627,DescriptorName,D014640,17426073,,,11,Vancomycin,N,
14628,QualifierName,Q000009,17426073,,,11,,Y,adverse effects
14629,Chemical,D010419,1743388,Pentamidine,673LC5J4LQ,,,,
14630,DescriptorName,D000328,1743388,,,1,Adult,N,
14631,DescriptorName,D005260,1743388,,,2,Female,N,
14632,DescriptorName,D005542,1743388,,,3,Forearm,Y,
14633,DescriptorName,D006229,1743388,,,4,Hand Dermatoses,N,
14634,QualifierName,Q000139,1743388,,,4,,Y,chemically induced
14635,DescriptorName,D006801,1743388,,,5,Humans,N,
14636,DescriptorName,D007275,1743388,,,6,"Injections, Intravenous",N,
14637,DescriptorName,D016030,1743388,,,7,Kidney Transplantation,N,
14638,DescriptorName,D010419,1743388,,,8,Pentamidine,N,
14639,QualifierName,Q000008,1743388,,,8,,N,administration & dosage
14640,DescriptorName,D011020,1743388,,,9,"Pneumonia, Pneumocystis",N,
14641,QualifierName,Q000188,1743388,,,9,,N,drug therapy
14642,DescriptorName,D012883,1743388,,,10,Skin Ulcer,N,
14643,QualifierName,Q000139,1743388,,,10,,Y,chemically induced
14644,Chemical,D000276,17438184,"Adjuvants, Immunologic",0,,,,
14645,Chemical,D000998,17438184,Antiviral Agents,0,,,,
14646,Chemical,C445359,17438184,Artecoll,0,,,,
14647,Chemical,D000077190,17438184,Interferon alpha-2,0,,,,
14648,Chemical,D016898,17438184,Interferon-alpha,0,,,,
14649,Chemical,D011994,17438184,Recombinant Proteins,0,,,,
14650,Chemical,D011092,17438184,Polyethylene Glycols,3WJQ0SDW1A,,,,
14651,Chemical,D012254,17438184,Ribavirin,49717AWG6K,,,,
14652,Chemical,D003094,17438184,Collagen,9007-34-5,,,,
14653,Chemical,D019904,17438184,Polymethyl Methacrylate,9011-14-7,,,,
14654,Chemical,C100416,17438184,peginterferon alfa-2a,Q46947FE7K,,,,
14655,DescriptorName,D000276,17438184,,,1,"Adjuvants, Immunologic",N,
14656,QualifierName,Q000009,17438184,,,1,,N,adverse effects
14657,DescriptorName,D000998,17438184,,,2,Antiviral Agents,N,
14658,QualifierName,Q000008,17438184,,,2,,N,administration & dosage
14659,DescriptorName,D003094,17438184,,,3,Collagen,Y,
14660,DescriptorName,D003357,17438184,,,4,Cosmetic Techniques,Y,
14661,DescriptorName,D005145,17438184,,,5,Face,Y,
14662,DescriptorName,D005260,17438184,,,6,Female,N,
14663,DescriptorName,D015745,17438184,,,7,"Granuloma, Foreign-Body",N,
14664,QualifierName,Q000139,17438184,,,7,,N,chemically induced
14665,DescriptorName,D019698,17438184,,,8,"Hepatitis C, Chronic",N,
14666,QualifierName,Q000188,17438184,,,8,,N,drug therapy
14667,DescriptorName,D006801,17438184,,,9,Humans,N,
14668,DescriptorName,D007267,17438184,,,10,Injections,N,
14669,DescriptorName,D000077190,17438184,,,11,Interferon alpha-2,N,
14670,DescriptorName,D016898,17438184,,,12,Interferon-alpha,N,
14671,QualifierName,Q000008,17438184,,,12,,N,administration & dosage
14672,DescriptorName,D008875,17438184,,,13,Middle Aged,N,
14673,DescriptorName,D011092,17438184,,,14,Polyethylene Glycols,N,
14674,QualifierName,Q000008,17438184,,,14,,N,administration & dosage
14675,DescriptorName,D019904,17438184,,,15,Polymethyl Methacrylate,N,
14676,DescriptorName,D011994,17438184,,,16,Recombinant Proteins,N,
14677,DescriptorName,D012254,17438184,,,17,Ribavirin,N,
14678,QualifierName,Q000008,17438184,,,17,,N,administration & dosage
14679,Chemical,D000970,17444802,Antineoplastic Agents,0,,,,
14680,Chemical,D000077190,17444802,Interferon alpha-2,0,,,,
14681,Chemical,D016898,17444802,Interferon-alpha,0,,,,
14682,Chemical,D009883,17444802,Ophthalmic Solutions,0,,,,
14683,Chemical,D011994,17444802,Recombinant Proteins,0,,,,
14684,DescriptorName,D000287,17444802,,,1,"Administration, Topical",N,
14685,DescriptorName,D000369,17444802,,,2,"Aged, 80 and over",N,
14686,DescriptorName,D000970,17444802,,,3,Antineoplastic Agents,N,
14687,QualifierName,Q000009,17444802,,,3,,N,adverse effects
14688,DescriptorName,D002278,17444802,,,4,Carcinoma in Situ,N,
14689,QualifierName,Q000188,17444802,,,4,,Y,drug therapy
14690,DescriptorName,D003230,17444802,,,5,Conjunctival Neoplasms,N,
14691,QualifierName,Q000188,17444802,,,5,,Y,drug therapy
14692,DescriptorName,D003316,17444802,,,6,Corneal Diseases,N,
14693,QualifierName,Q000188,17444802,,,6,,Y,drug therapy
14694,DescriptorName,D005134,17444802,,,7,Eye Neoplasms,N,
14695,QualifierName,Q000188,17444802,,,7,,N,drug therapy
14696,DescriptorName,D006801,17444802,,,8,Humans,N,
14697,DescriptorName,D000077190,17444802,,,9,Interferon alpha-2,N,
14698,DescriptorName,D016898,17444802,,,10,Interferon-alpha,N,
14699,QualifierName,Q000009,17444802,,,10,,N,adverse effects
14700,DescriptorName,D008297,17444802,,,11,Male,N,
14701,DescriptorName,D009883,17444802,,,12,Ophthalmic Solutions,N,
14702,DescriptorName,D011994,17444802,,,13,Recombinant Proteins,N,
14703,DescriptorName,D012074,17444802,,,14,Remission Induction,N,
14704,DescriptorName,D047368,17444802,,,15,Tumor Burden,N,
14705,QualifierName,Q000187,17444802,,,15,,N,drug effects
14706,Chemical,D000889,17448102,Anti-Arrhythmia Agents,0,,,,
14707,Chemical,D002606,17448102,Charcoal,16291-96-6,,,,
14708,Chemical,D005424,17448102,Flecainide,K94FTS1806,,,,
14709,Chemical,D004837,17448102,Epinephrine,YKH834O4BH,,,,
14710,DescriptorName,D000328,17448102,,,1,Adult,N,
14711,DescriptorName,D000889,17448102,,,2,Anti-Arrhythmia Agents,N,
14712,QualifierName,Q000506,17448102,,,2,,Y,poisoning
14713,DescriptorName,D002318,17448102,,,3,Cardiovascular Diseases,N,
14714,QualifierName,Q000139,17448102,,,3,,Y,chemically induced
14715,DescriptorName,D002606,17448102,,,4,Charcoal,N,
14716,QualifierName,Q000008,17448102,,,4,,N,administration & dosage
14717,DescriptorName,D062787,17448102,,,5,Drug Overdose,N,
14718,DescriptorName,D004562,17448102,,,6,Electrocardiography,N,
14719,DescriptorName,D004837,17448102,,,7,Epinephrine,N,
14720,QualifierName,Q000008,17448102,,,7,,N,administration & dosage
14721,DescriptorName,D005260,17448102,,,8,Female,N,
14722,DescriptorName,D005424,17448102,,,9,Flecainide,N,
14723,QualifierName,Q000506,17448102,,,9,,Y,poisoning
14724,DescriptorName,D005440,17448102,,,10,Fluid Therapy,N,
14725,DescriptorName,D015600,17448102,,,11,Glasgow Coma Scale,N,
14726,DescriptorName,D006801,17448102,,,12,Humans,N,
14727,DescriptorName,D007442,17448102,,,13,"Intubation, Intratracheal",N,
14728,DescriptorName,D011041,17448102,,,14,Poisoning,N,
14729,QualifierName,Q000628,17448102,,,14,,Y,therapy
14730,DescriptorName,D013406,17448102,,,15,"Suicide, Attempted",N,
14731,DescriptorName,D013617,17448102,,,16,"Tachycardia, Supraventricular",N,
14732,QualifierName,Q000188,17448102,,,16,,N,drug therapy
14733,Chemical,D000924,17458405,Anticholesteremic Agents,0,,,,
14734,Chemical,D001384,17458405,Azetidines,0,,,,
14735,Chemical,D008049,17458405,Lipase,EC 3.1.1.3,,,,
14736,Chemical,D000069438,17458405,Ezetimibe,EOR26LQQ24,,,,
14737,DescriptorName,D000924,17458405,,,1,Anticholesteremic Agents,N,
14738,QualifierName,Q000009,17458405,,,1,,Y,adverse effects
14739,DescriptorName,D001384,17458405,,,2,Azetidines,N,
14740,QualifierName,Q000009,17458405,,,2,,Y,adverse effects
14741,DescriptorName,D003937,17458405,,,3,"Diagnosis, Differential",N,
14742,DescriptorName,D050171,17458405,,,4,Dyslipidemias,N,
14743,QualifierName,Q000188,17458405,,,4,,N,drug therapy
14744,DescriptorName,D000069438,17458405,,,5,Ezetimibe,N,
14745,DescriptorName,D005260,17458405,,,6,Female,N,
14746,DescriptorName,D005500,17458405,,,7,Follow-Up Studies,N,
14747,DescriptorName,D006801,17458405,,,8,Humans,N,
14748,DescriptorName,D008049,17458405,,,9,Lipase,N,
14749,QualifierName,Q000097,17458405,,,9,,N,blood
14750,DescriptorName,D008875,17458405,,,10,Middle Aged,N,
14751,DescriptorName,D019283,17458405,,,11,"Pancreatitis, Acute Necrotizing",N,
14752,QualifierName,Q000139,17458405,,,11,,Y,chemically induced
14753,Chemical,D020845,17473493,Selective Estrogen Receptor Modulators,0,,,,
14754,Chemical,D020849,17473493,Raloxifene Hydrochloride,4F86W47BR6,,,,
14755,Chemical,D001219,17473493,Aspartate Aminotransferases,EC 2.6.1.1,,,,
14756,Chemical,D000410,17473493,Alanine Transaminase,EC 2.6.1.2,,,,
14757,DescriptorName,D000410,17473493,,,1,Alanine Transaminase,N,
14758,QualifierName,Q000097,17473493,,,1,,N,blood
14759,DescriptorName,D001219,17473493,,,2,Aspartate Aminotransferases,N,
14760,QualifierName,Q000097,17473493,,,2,,N,blood
14761,DescriptorName,D056486,17473493,,,3,Chemical and Drug Induced Liver Injury,N,
14762,QualifierName,Q000150,17473493,,,3,,N,complications
14763,DescriptorName,D005234,17473493,,,4,Fatty Liver,N,
14764,QualifierName,Q000139,17473493,,,4,,Y,chemically induced
14765,DescriptorName,D005260,17473493,,,5,Female,N,
14766,DescriptorName,D018149,17473493,,,6,Glucose Intolerance,N,
14767,QualifierName,Q000139,17473493,,,6,,N,chemically induced
14768,DescriptorName,D006801,17473493,,,7,Humans,N,
14769,DescriptorName,D007333,17473493,,,8,Insulin Resistance,N,
14770,DescriptorName,D008099,17473493,,,9,Liver,N,
14771,QualifierName,Q000201,17473493,,,9,,N,enzymology
14772,DescriptorName,D008103,17473493,,,10,Liver Cirrhosis,N,
14773,QualifierName,Q000209,17473493,,,10,,N,etiology
14774,DescriptorName,D008875,17473493,,,11,Middle Aged,N,
14775,DescriptorName,D015663,17473493,,,12,"Osteoporosis, Postmenopausal",N,
14776,QualifierName,Q000188,17473493,,,12,,N,drug therapy
14777,DescriptorName,D020849,17473493,,,13,Raloxifene Hydrochloride,N,
14778,QualifierName,Q000009,17473493,,,13,,Y,adverse effects
14779,DescriptorName,D012307,17473493,,,14,Risk Factors,N,
14780,DescriptorName,D020845,17473493,,,15,Selective Estrogen Receptor Modulators,N,
14781,QualifierName,Q000009,17473493,,,15,,Y,adverse effects
14782,DescriptorName,D012720,17473493,,,16,Severity of Illness Index,N,
14783,Chemical,D003613,1747495,Danazol,N29QWW3BUO,,,,
14784,DescriptorName,D056486,1747495,,,1,Chemical and Drug Induced Liver Injury,Y,
14785,DescriptorName,D003613,1747495,,,2,Danazol,N,
14786,QualifierName,Q000009,1747495,,,2,,Y,adverse effects
14787,DescriptorName,D005260,1747495,,,3,Female,N,
14788,DescriptorName,D005348,1747495,,,4,Fibrocystic Breast Disease,N,
14789,QualifierName,Q000188,1747495,,,4,,N,drug therapy
14790,DescriptorName,D006801,1747495,,,5,Humans,N,
14791,DescriptorName,D008107,1747495,,,6,Liver Diseases,N,
14792,QualifierName,Q000473,1747495,,,6,,N,pathology
14793,DescriptorName,D008111,1747495,,,7,Liver Function Tests,N,
14794,DescriptorName,D008875,1747495,,,8,Middle Aged,N,
14795,Chemical,D000970,17494808,Antineoplastic Agents,0,,,,
14796,Chemical,D013792,17494808,Thalidomide,4Z8R6ORS6L,,,,
14797,Chemical,D003907,17494808,Dexamethasone,7S5I7G3JQL,,,,
14798,Chemical,D000077269,17494808,Lenalidomide,F0P408N6V4,,,,
14799,DescriptorName,D000542,17494808,,,1,"Alveolitis, Extrinsic Allergic",N,
14800,QualifierName,Q000139,17494808,,,1,,Y,chemically induced
14801,DescriptorName,D000970,17494808,,,2,Antineoplastic Agents,N,
14802,QualifierName,Q000009,17494808,,,2,,Y,adverse effects
14803,DescriptorName,D003907,17494808,,,3,Dexamethasone,N,
14804,QualifierName,Q000627,17494808,,,3,,N,therapeutic use
14805,DescriptorName,D004359,17494808,,,4,"Drug Therapy, Combination",N,
14806,DescriptorName,D004417,17494808,,,5,Dyspnea,N,
14807,QualifierName,Q000139,17494808,,,5,,N,chemically induced
14808,DescriptorName,D005260,17494808,,,6,Female,N,
14809,DescriptorName,D005334,17494808,,,7,Fever,N,
14810,QualifierName,Q000139,17494808,,,7,,N,chemically induced
14811,DescriptorName,D006801,17494808,,,8,Humans,N,
14812,DescriptorName,D000077269,17494808,,,9,Lenalidomide,N,
14813,DescriptorName,D008875,17494808,,,10,Middle Aged,N,
14814,DescriptorName,D009101,17494808,,,11,Multiple Myeloma,N,
14815,QualifierName,Q000188,17494808,,,11,,N,drug therapy
14816,DescriptorName,D013577,17494808,,,12,Syndrome,N,
14817,DescriptorName,D013792,17494808,,,13,Thalidomide,N,
14818,QualifierName,Q000009,17494808,,,13,,N,adverse effects
14819,Chemical,D005938,17505739,Glucocorticoids,0,,,,
14820,Chemical,D017319,17505739,Photosensitizing Agents,0,,,,
14821,Chemical,D011166,17505739,Porphyrins,0,,,,
14822,Chemical,D000077362,17505739,Verteporfin,0X9PA28K43,,,,
14823,Chemical,D014222,17505739,Triamcinolone Acetonide,F446C597KA,,,,
14824,DescriptorName,D000369,17505739,,,1,"Aged, 80 and over",N,
14825,DescriptorName,D002825,17505739,,,2,Chorioretinitis,N,
14826,QualifierName,Q000188,17505739,,,2,,N,drug therapy
14827,DescriptorName,D020256,17505739,,,3,Choroidal Neovascularization,N,
14828,QualifierName,Q000188,17505739,,,3,,N,drug therapy
14829,DescriptorName,D005260,17505739,,,4,Female,N,
14830,DescriptorName,D005451,17505739,,,5,Fluorescein Angiography,N,
14831,DescriptorName,D005938,17505739,,,6,Glucocorticoids,N,
14832,QualifierName,Q000008,17505739,,,6,,N,administration & dosage
14833,DescriptorName,D006801,17505739,,,7,Humans,N,
14834,DescriptorName,D016867,17505739,,,8,Immunocompromised Host,Y,
14835,DescriptorName,D008268,17505739,,,9,Macular Degeneration,N,
14836,QualifierName,Q000150,17505739,,,9,,N,complications
14837,DescriptorName,D008297,17505739,,,10,Male,N,
14838,DescriptorName,D010778,17505739,,,11,Photochemotherapy,N,
14839,QualifierName,Q000009,17505739,,,11,,Y,adverse effects
14840,DescriptorName,D017319,17505739,,,12,Photosensitizing Agents,N,
14841,QualifierName,Q000008,17505739,,,12,,N,administration & dosage
14842,DescriptorName,D011166,17505739,,,13,Porphyrins,N,
14843,QualifierName,Q000008,17505739,,,13,,N,administration & dosage
14844,DescriptorName,D012720,17505739,,,14,Severity of Illness Index,N,
14845,DescriptorName,D014126,17505739,,,15,"Toxoplasmosis, Ocular",N,
14846,QualifierName,Q000188,17505739,,,15,,N,drug therapy
14847,DescriptorName,D014222,17505739,,,16,Triamcinolone Acetonide,N,
14848,QualifierName,Q000008,17505739,,,16,,N,administration & dosage
14849,DescriptorName,D000077362,17505739,,,17,Verteporfin,N,
14850,DescriptorName,D014792,17505739,,,18,Visual Acuity,N,
14851,Chemical,D000995,17509184,Antitubercular Agents,0,,,,
14852,Chemical,D004977,17509184,Ethambutol,8G167061QZ,,,,
14853,DescriptorName,D000328,17509184,,,1,Adult,N,
14854,DescriptorName,D000995,17509184,,,2,Antitubercular Agents,N,
14855,QualifierName,Q000009,17509184,,,2,,Y,adverse effects
14856,DescriptorName,D004359,17509184,,,3,"Drug Therapy, Combination",N,
14857,DescriptorName,D004977,17509184,,,4,Ethambutol,N,
14858,QualifierName,Q000009,17509184,,,4,,Y,adverse effects
14859,DescriptorName,D006801,17509184,,,5,Humans,N,
14860,DescriptorName,D008297,17509184,,,6,Male,N,
14861,DescriptorName,D015270,17509184,,,7,Mycobacterium avium-intracellulare Infection,N,
14862,QualifierName,Q000188,17509184,,,7,,Y,drug therapy
14863,DescriptorName,D011605,17509184,,,8,"Psychoses, Substance-Induced",N,
14864,QualifierName,Q000209,17509184,,,8,,Y,etiology
14865,Chemical,D007370,1751354,Interferon Type I,0,,,,
14866,Chemical,D011994,1751354,Recombinant Proteins,0,,,,
14867,DescriptorName,D000368,1751354,,,1,Aged,N,
14868,DescriptorName,D002276,1751354,,,2,Carcinoid Tumor,N,
14869,QualifierName,Q000188,1751354,,,2,,N,drug therapy
14870,DescriptorName,D004334,1751354,,,3,Drug Administration Schedule,N,
14871,DescriptorName,D005260,1751354,,,4,Female,N,
14872,DescriptorName,D006801,1751354,,,5,Humans,N,
14873,DescriptorName,D007370,1751354,,,6,Interferon Type I,N,
14874,QualifierName,Q000008,1751354,,,6,,N,administration & dosage
14875,DescriptorName,D007680,1751354,,,7,Kidney Neoplasms,N,
14876,QualifierName,Q000188,1751354,,,7,,N,drug therapy
14877,DescriptorName,D008297,1751354,,,8,Male,N,
14878,DescriptorName,D008875,1751354,,,9,Middle Aged,N,
14879,DescriptorName,D011565,1751354,,,10,Psoriasis,N,
14880,QualifierName,Q000139,1751354,,,10,,Y,chemically induced
14881,DescriptorName,D011994,1751354,,,11,Recombinant Proteins,N,
14882,Chemical,D000893,17519584,Anti-Inflammatory Agents,0,,,,
14883,Chemical,D000914,17519584,"Antibodies, Viral",0,,,,
14884,Chemical,D015662,17519584,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
14885,Chemical,D008775,17519584,Methylprednisolone,X4W7ZR7023,,,,
14886,DescriptorName,D000893,17519584,,,1,Anti-Inflammatory Agents,N,
14887,QualifierName,Q000627,17519584,,,1,,N,therapeutic use
14888,DescriptorName,D000914,17519584,,,2,"Antibodies, Viral",N,
14889,QualifierName,Q000097,17519584,,,2,,N,blood
14890,DescriptorName,D004342,17519584,,,3,Drug Hypersensitivity,N,
14891,QualifierName,Q000150,17519584,,,3,,Y,complications
14892,DescriptorName,D006801,17519584,,,4,Humans,N,
14893,DescriptorName,D008297,17519584,,,5,Male,N,
14894,DescriptorName,D008775,17519584,,,6,Methylprednisolone,N,
14895,QualifierName,Q000627,17519584,,,6,,N,therapeutic use
14896,DescriptorName,D008875,17519584,,,7,Middle Aged,N,
14897,DescriptorName,D010223,17519584,,,8,"Parainfluenza Virus 2, Human",N,
14898,QualifierName,Q000276,17519584,,,8,,Y,immunology
14899,DescriptorName,D018184,17519584,,,9,Paramyxoviridae Infections,N,
14900,QualifierName,Q000276,17519584,,,9,,N,immunology
14901,DescriptorName,D045743,17519584,,,10,"Scleroderma, Diffuse",N,
14902,QualifierName,Q000150,17519584,,,10,,Y,complications
14903,DescriptorName,D015662,17519584,,,11,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
14904,QualifierName,Q000009,17519584,,,11,,Y,adverse effects
14905,Chemical,D000927,17522786,Anticonvulsants,0,,,,
14906,Chemical,D014635,17522786,Valproic Acid,614OI1Z5WI,,,,
14907,DescriptorName,D000328,17522786,,,1,Adult,N,
14908,DescriptorName,D000927,17522786,,,2,Anticonvulsants,N,
14909,QualifierName,Q000506,17522786,,,2,,Y,poisoning
14910,DescriptorName,D001929,17522786,,,3,Brain Edema,N,
14911,QualifierName,Q000139,17522786,,,3,,N,chemically induced
14912,DescriptorName,D003422,17522786,,,4,Critical Care,N,
14913,QualifierName,Q000379,17522786,,,4,,Y,methods
14914,DescriptorName,D004830,17522786,,,5,"Epilepsy, Tonic-Clonic",N,
14915,QualifierName,Q000188,17522786,,,5,,Y,drug therapy
14916,DescriptorName,D006801,17522786,,,6,Humans,N,
14917,DescriptorName,D019586,17522786,,,7,Intracranial Hypertension,N,
14918,QualifierName,Q000139,17522786,,,7,,Y,chemically induced
14919,DescriptorName,D008297,17522786,,,8,Male,N,
14920,DescriptorName,D008991,17522786,,,9,"Monitoring, Physiologic",N,
14921,DescriptorName,D012720,17522786,,,10,Severity of Illness Index,N,
14922,DescriptorName,D014057,17522786,,,11,"Tomography, X-Ray Computed",N,
14923,DescriptorName,D014635,17522786,,,12,Valproic Acid,N,
14924,QualifierName,Q000506,17522786,,,12,,Y,poisoning
14925,Chemical,D000903,17526968,"Antibiotics, Antineoplastic",0,,,,
14926,Chemical,D001761,17526968,Bleomycin,11056-06-7,,,,
14927,DescriptorName,D000903,17526968,,,1,"Antibiotics, Antineoplastic",N,
14928,QualifierName,Q000009,17526968,,,1,,Y,adverse effects
14929,DescriptorName,D001761,17526968,,,2,Bleomycin,N,
14930,QualifierName,Q000009,17526968,,,2,,Y,adverse effects
14931,DescriptorName,D002675,17526968,,,3,"Child, Preschool",N,
14932,DescriptorName,D018240,17526968,,,4,Endodermal Sinus Tumor,N,
14933,QualifierName,Q000188,17526968,,,4,,Y,drug therapy
14934,DescriptorName,D005260,17526968,,,5,Female,N,
14935,DescriptorName,D006801,17526968,,,6,Humans,N,
14936,DescriptorName,D017495,17526968,,,7,Hyperpigmentation,N,
14937,QualifierName,Q000139,17526968,,,7,,Y,chemically induced
14938,DescriptorName,D013997,17526968,,,8,Time Factors,N,
14939,Chemical,D000964,17536204,"Antimetabolites, Antineoplastic",0,,,,
14940,Chemical,D003841,17536204,Deoxycytidine,0W860991D6,,,,
14941,Chemical,D000069287,17536204,Capecitabine,6804DJ8Z9U,,,,
14942,Chemical,D004110,17536204,Diltiazem,EE92BBP03H,,,,
14943,Chemical,D005472,17536204,Fluorouracil,U3P01618RT,,,,
14944,DescriptorName,D000328,17536204,,,1,Adult,N,
14945,DescriptorName,D000964,17536204,,,2,"Antimetabolites, Antineoplastic",N,
14946,QualifierName,Q000009,17536204,,,2,,Y,adverse effects
14947,DescriptorName,D000069287,17536204,,,3,Capecitabine,N,
14948,DescriptorName,D003841,17536204,,,4,Deoxycytidine,N,
14949,QualifierName,Q000009,17536204,,,4,,N,adverse effects
14950,DescriptorName,D004110,17536204,,,5,Diltiazem,N,
14951,QualifierName,Q000627,17536204,,,5,,Y,therapeutic use
14952,DescriptorName,D005260,17536204,,,6,Female,N,
14953,DescriptorName,D005472,17536204,,,7,Fluorouracil,N,
14954,QualifierName,Q000009,17536204,,,7,,N,adverse effects
14955,DescriptorName,D006261,17536204,,,8,Headache,N,
14956,QualifierName,Q000139,17536204,,,8,,Y,chemically induced
14957,DescriptorName,D006801,17536204,,,9,Humans,N,
14958,DescriptorName,D012004,17536204,,,10,Rectal Neoplasms,N,
14959,QualifierName,Q000188,17536204,,,10,,Y,drug therapy
14960,Chemical,D018020,17547624,Lithium Compounds,0,,,,
14961,Chemical,D011405,17547624,Propafenone,68IQX3T69U,,,,
14962,DescriptorName,D053840,17547624,,,1,Brugada Syndrome,N,
14963,QualifierName,Q000139,17547624,,,1,,Y,chemically induced
14964,DescriptorName,D004562,17547624,,,2,Electrocardiography,Y,
14965,DescriptorName,D005260,17547624,,,3,Female,N,
14966,DescriptorName,D006801,17547624,,,4,Humans,N,
14967,DescriptorName,D018020,17547624,,,5,Lithium Compounds,N,
14968,QualifierName,Q000009,17547624,,,5,,Y,adverse effects
14969,DescriptorName,D008875,17547624,,,6,Middle Aged,N,
14970,DescriptorName,D011405,17547624,,,7,Propafenone,N,
14971,QualifierName,Q000009,17547624,,,7,,Y,adverse effects
14972,DescriptorName,D014927,17547624,,,8,Wolff-Parkinson-White Syndrome,N,
14973,QualifierName,Q000188,17547624,,,8,,Y,drug therapy
14974,Chemical,D000970,17551408,Antineoplastic Agents,0,,,,
14975,DescriptorName,D000293,17551408,,,1,Adolescent,N,
14976,DescriptorName,D000970,17551408,,,2,Antineoplastic Agents,N,
14977,QualifierName,Q000009,17551408,,,2,,N,adverse effects
14978,DescriptorName,D003937,17551408,,,3,"Diagnosis, Differential",N,
14979,DescriptorName,D004238,17551408,,,4,Diverticulitis,N,
14980,QualifierName,Q000139,17551408,,,4,,Y,chemically induced
14981,DescriptorName,D006801,17551408,,,5,Humans,N,
14982,DescriptorName,D007813,17551408,,,6,Laparotomy,N,
14983,DescriptorName,D008297,17551408,,,7,Male,N,
14984,DescriptorName,D008467,17551408,,,8,Meckel Diverticulum,Y,
14985,DescriptorName,D052016,17551408,,,9,Mucositis,N,
14986,QualifierName,Q000175,17551408,,,9,,N,diagnosis
14987,DescriptorName,D054198,17551408,,,10,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
14988,QualifierName,Q000188,17551408,,,10,,Y,drug therapy
14989,DescriptorName,D012074,17551408,,,11,Remission Induction,N,
14990,DescriptorName,D016896,17551408,,,12,Treatment Outcome,N,
14991,Chemical,D000970,17556909,Antineoplastic Agents,0,,,,
14992,Chemical,D001897,17556909,Boronic Acids,0,,,,
14993,Chemical,D011480,17556909,Protease Inhibitors,0,,,,
14994,Chemical,D011719,17556909,Pyrazines,0,,,,
14995,Chemical,D000069286,17556909,Bortezomib,69G8BD63PP,,,,
14996,DescriptorName,D000970,17556909,,,1,Antineoplastic Agents,N,
14997,QualifierName,Q000009,17556909,,,1,,Y,adverse effects
14998,DescriptorName,D001897,17556909,,,2,Boronic Acids,N,
14999,QualifierName,Q000009,17556909,,,2,,Y,adverse effects
15000,DescriptorName,D000069286,17556909,,,3,Bortezomib,N,
15001,DescriptorName,D006801,17556909,,,4,Humans,N,
15002,DescriptorName,D007418,17556909,,,5,Intestinal Pseudo-Obstruction,N,
15003,QualifierName,Q000139,17556909,,,5,,Y,chemically induced
15004,DescriptorName,D008297,17556909,,,6,Male,N,
15005,DescriptorName,D008875,17556909,,,7,Middle Aged,N,
15006,DescriptorName,D009101,17556909,,,8,Multiple Myeloma,N,
15007,QualifierName,Q000188,17556909,,,8,,N,drug therapy
15008,DescriptorName,D011480,17556909,,,9,Protease Inhibitors,N,
15009,QualifierName,Q000009,17556909,,,9,,Y,adverse effects
15010,DescriptorName,D011719,17556909,,,10,Pyrazines,N,
15011,QualifierName,Q000009,17556909,,,10,,Y,adverse effects
15012,DescriptorName,D011859,17556909,,,11,Radiography,N,
15013,Chemical,D010624,1756352,Phenelzine,O408N561GF,,,,
15014,DescriptorName,D000368,1756352,,,1,Aged,N,
15015,DescriptorName,D003702,1756352,,,2,Delusions,N,
15016,QualifierName,Q000139,1756352,,,2,,Y,chemically induced
15017,DescriptorName,D003866,1756352,,,3,Depressive Disorder,N,
15018,QualifierName,Q000188,1756352,,,3,,Y,drug therapy
15019,DescriptorName,D004478,1756352,,,4,Ectoparasitic Infestations,N,
15020,QualifierName,Q000523,1756352,,,4,,Y,psychology
15021,DescriptorName,D005260,1756352,,,5,Female,N,
15022,DescriptorName,D006801,1756352,,,6,Humans,N,
15023,DescriptorName,D010624,1756352,,,7,Phenelzine,N,
15024,QualifierName,Q000009,1756352,,,7,,Y,adverse effects
15025,DescriptorName,D011605,1756352,,,8,"Psychoses, Substance-Induced",N,
15026,QualifierName,Q000523,1756352,,,8,,Y,psychology
15027,DescriptorName,D012008,1756352,,,9,Recurrence,N,
15028,Chemical,D000911,17596682,"Antibodies, Monoclonal",0,,,,
15029,Chemical,D058846,17596682,"Antibodies, Monoclonal, Murine-Derived",0,,,,
15030,Chemical,D000970,17596682,Antineoplastic Agents,0,,,,
15031,Chemical,D000069283,17596682,Rituximab,4F4X42SYQ6,,,,
15032,DescriptorName,D000369,17596682,,,1,"Aged, 80 and over",N,
15033,DescriptorName,D000911,17596682,,,2,"Antibodies, Monoclonal",N,
15034,QualifierName,Q000009,17596682,,,2,,Y,adverse effects
15035,DescriptorName,D058846,17596682,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
15036,DescriptorName,D000970,17596682,,,4,Antineoplastic Agents,N,
15037,QualifierName,Q000009,17596682,,,4,,Y,adverse effects
15038,DescriptorName,D006469,17596682,,,5,Hemoptysis,N,
15039,QualifierName,Q000139,17596682,,,5,,Y,chemically induced
15040,DescriptorName,D006801,17596682,,,6,Humans,N,
15041,DescriptorName,D017563,17596682,,,7,"Lung Diseases, Interstitial",N,
15042,QualifierName,Q000139,17596682,,,7,,Y,chemically induced
15043,DescriptorName,D008297,17596682,,,8,Male,N,
15044,DescriptorName,D000069283,17596682,,,9,Rituximab,N,
15045,DescriptorName,D008258,17596682,,,10,Waldenstrom Macroglobulinemia,N,
15046,QualifierName,Q000188,17596682,,,10,,N,drug therapy
15047,Chemical,D003620,1759924,Dantrolene,F64QU97QCR,,,,
15048,Chemical,D008787,1759924,Metoclopramide,L4YEB44I46,,,,
15049,DescriptorName,D000368,1759924,,,1,Aged,N,
15050,DescriptorName,D003620,1759924,,,2,Dantrolene,N,
15051,QualifierName,Q000008,1759924,,,2,,Y,administration & dosage
15052,DescriptorName,D006801,1759924,,,3,Humans,N,
15053,DescriptorName,D007262,1759924,,,4,"Infusions, Intravenous",N,
15054,DescriptorName,D008297,1759924,,,5,Male,N,
15055,DescriptorName,D008787,1759924,,,6,Metoclopramide,N,
15056,QualifierName,Q000009,1759924,,,6,,Y,adverse effects
15057,DescriptorName,D009459,1759924,,,7,Neuroleptic Malignant Syndrome,N,
15058,QualifierName,Q000188,1759924,,,7,,Y,drug therapy
15059,Chemical,D014665,17610180,Vasodilator Agents,0,,,,
15060,Chemical,D000527,17610180,Alprostadil,F5TD010360,,,,
15061,DescriptorName,D000527,17610180,,,1,Alprostadil,N,
15062,QualifierName,Q000008,17610180,,,1,,N,administration & dosage
15063,DescriptorName,D003937,17610180,,,2,"Diagnosis, Differential",N,
15064,DescriptorName,D004374,17610180,,,3,"Ductus Arteriosus, Patent",N,
15065,QualifierName,Q000000981,17610180,,,3,,Y,diagnostic imaging
15066,DescriptorName,D004452,17610180,,,4,Echocardiography,Y,
15067,DescriptorName,D005260,17610180,,,5,Female,N,
15068,DescriptorName,D005753,17610180,,,6,Gastric Mucosa,N,
15069,QualifierName,Q000000981,17610180,,,6,,N,diagnostic imaging
15070,DescriptorName,D017219,17610180,,,7,Gastric Outlet Obstruction,N,
15071,QualifierName,Q000139,17610180,,,7,,Y,chemically induced
15072,DescriptorName,D006801,17610180,,,8,Humans,N,
15073,DescriptorName,D007049,17610180,,,9,Iatrogenic Disease,Y,
15074,DescriptorName,D007231,17610180,,,10,"Infant, Newborn",N,
15075,DescriptorName,D007262,17610180,,,11,"Infusions, Intravenous",N,
15076,DescriptorName,D046248,17610180,,,12,"Pyloric Stenosis, Hypertrophic",N,
15077,QualifierName,Q000139,17610180,,,12,,Y,chemically induced
15078,DescriptorName,D013771,17610180,,,13,Tetralogy of Fallot,N,
15079,QualifierName,Q000000981,17610180,,,13,,Y,diagnostic imaging
15080,DescriptorName,D014665,17610180,,,14,Vasodilator Agents,N,
15081,QualifierName,Q000008,17610180,,,14,,N,administration & dosage
15082,Chemical,D006074,17619811,Gout Suppressants,0,,,,
15083,Chemical,D003078,17619811,Colchicine,SML2Y3J35T,,,,
15084,DescriptorName,D000368,17619811,,,1,Aged,N,
15085,DescriptorName,D015210,17619811,,,2,"Arthritis, Gouty",N,
15086,QualifierName,Q000188,17619811,,,2,,Y,drug therapy
15087,DescriptorName,D001706,17619811,,,3,Biopsy,N,
15088,DescriptorName,D003078,17619811,,,4,Colchicine,N,
15089,QualifierName,Q000009,17619811,,,4,,Y,adverse effects
15090,DescriptorName,D005500,17619811,,,5,Follow-Up Studies,N,
15091,DescriptorName,D006074,17619811,,,6,Gout Suppressants,N,
15092,QualifierName,Q000009,17619811,,,6,,Y,adverse effects
15093,DescriptorName,D006801,17619811,,,7,Humans,N,
15094,DescriptorName,D008297,17619811,,,8,Male,N,
15095,DescriptorName,D018482,17619811,,,9,"Muscle, Skeletal",N,
15096,QualifierName,Q000473,17619811,,,9,,N,pathology
15097,DescriptorName,D012206,17619811,,,10,Rhabdomyolysis,N,
15098,QualifierName,Q000139,17619811,,,10,,Y,chemically induced
15099,Chemical,D000964,17624096,"Antimetabolites, Antineoplastic",0,,,,
15100,Chemical,D005472,17624096,Fluorouracil,U3P01618RT,,,,
15101,DescriptorName,D000208,17624096,,,1,Acute Disease,N,
15102,DescriptorName,D000328,17624096,,,2,Adult,N,
15103,DescriptorName,D000964,17624096,,,3,"Antimetabolites, Antineoplastic",N,
15104,QualifierName,Q000008,17624096,,,3,,N,administration & dosage
15105,DescriptorName,D002294,17624096,,,4,"Carcinoma, Squamous Cell",N,
15106,QualifierName,Q000188,17624096,,,4,,Y,drug therapy
15107,DescriptorName,D002303,17624096,,,5,"Cardiac Output, Low",N,
15108,QualifierName,Q000139,17624096,,,5,,Y,chemically induced
15109,DescriptorName,D004562,17624096,,,6,Electrocardiography,N,
15110,DescriptorName,D005260,17624096,,,7,Female,N,
15111,DescriptorName,D005472,17624096,,,8,Fluorouracil,N,
15112,QualifierName,Q000008,17624096,,,8,,N,administration & dosage
15113,DescriptorName,D006801,17624096,,,9,Humans,N,
15114,DescriptorName,D016896,17624096,,,10,Treatment Outcome,N,
15115,DescriptorName,D002583,17624096,,,11,Uterine Cervical Neoplasms,N,
15116,QualifierName,Q000188,17624096,,,11,,Y,drug therapy
15117,Chemical,D045166,17627694,Estradiol Congeners,0,,,,
15118,Chemical,D007202,17627694,Indicators and Reagents,0,,,,
15119,Chemical,D014622,17627694,"Vaginal Creams, Foams, and Jellies",0,,,,
15120,Chemical,D019342,17627694,Acetic Acid,Q40Q9N063P,,,,
15121,DescriptorName,D019342,17627694,,,1,Acetic Acid,N,
15122,QualifierName,Q000008,17627694,,,1,,N,administration & dosage
15123,DescriptorName,D000287,17627694,,,2,"Administration, Topical",N,
15124,DescriptorName,D002057,17627694,,,3,"Burns, Chemical",N,
15125,QualifierName,Q000188,17627694,,,3,,Y,drug therapy
15126,DescriptorName,D045166,17627694,,,4,Estradiol Congeners,N,
15127,QualifierName,Q000008,17627694,,,4,,Y,administration & dosage
15128,DescriptorName,D005260,17627694,,,5,Female,N,
15129,DescriptorName,D006801,17627694,,,6,Humans,N,
15130,DescriptorName,D007202,17627694,,,7,Indicators and Reagents,N,
15131,QualifierName,Q000008,17627694,,,7,,N,administration & dosage
15132,DescriptorName,D008508,17627694,,,8,Medication Errors,Y,
15133,DescriptorName,D008875,17627694,,,9,Middle Aged,N,
15134,DescriptorName,D009092,17627694,,,10,Mucous Membrane,N,
15135,QualifierName,Q000293,17627694,,,10,,N,injuries
15136,DescriptorName,D014621,17627694,,,11,Vagina,N,
15137,DescriptorName,D014622,17627694,,,12,"Vaginal Creams, Foams, and Jellies",N,
15138,Chemical,D000906,1765991,Antibodies,0,,,,
15139,Chemical,D000974,1765991,"Antibodies, Antinuclear",0,,,,
15140,Chemical,D001324,1765991,Autoantigens,0,,,,
15141,Chemical,D011994,1765991,Recombinant Proteins,0,,,,
15142,Chemical,D017411,1765991,"Ribonucleoproteins, Small Nuclear",0,,,,
15143,Chemical,D055517,1765991,snRNP Core Proteins,0,,,,
15144,Chemical,D007371,1765991,Interferon-gamma,82115-62-6,,,,
15145,DescriptorName,D000328,1765991,,,1,Adult,N,
15146,DescriptorName,D000906,1765991,,,2,Antibodies,N,
15147,QualifierName,Q000032,1765991,,,2,,N,analysis
15148,DescriptorName,D000974,1765991,,,3,"Antibodies, Antinuclear",N,
15149,QualifierName,Q000032,1765991,,,3,,N,analysis
15150,DescriptorName,D001172,1765991,,,4,"Arthritis, Rheumatoid",N,
15151,QualifierName,Q000150,1765991,,,4,,N,complications
15152,DescriptorName,D001324,1765991,,,5,Autoantigens,N,
15153,QualifierName,Q000032,1765991,,,5,,N,analysis
15154,DescriptorName,D005260,1765991,,,6,Female,N,
15155,DescriptorName,D005921,1765991,,,7,Glomerulonephritis,N,
15156,QualifierName,Q000150,1765991,,,7,,N,complications
15157,DescriptorName,D006801,1765991,,,8,Humans,N,
15158,DescriptorName,D015151,1765991,,,9,Immunoblotting,N,
15159,DescriptorName,D007371,1765991,,,10,Interferon-gamma,N,
15160,QualifierName,Q000009,1765991,,,10,,Y,adverse effects
15161,DescriptorName,D008180,1765991,,,11,"Lupus Erythematosus, Systemic",N,
15162,QualifierName,Q000139,1765991,,,11,,Y,chemically induced
15163,DescriptorName,D011994,1765991,,,12,Recombinant Proteins,N,
15164,QualifierName,Q000009,1765991,,,12,,N,adverse effects
15165,DescriptorName,D017411,1765991,,,13,"Ribonucleoproteins, Small Nuclear",Y,
15166,DescriptorName,D013997,1765991,,,14,Time Factors,N,
15167,DescriptorName,D055517,1765991,,,15,snRNP Core Proteins,N,
15168,Chemical,D000900,17660778,Anti-Bacterial Agents,0,,,,
15169,Chemical,D050071,17660778,Bone Density Conservation Agents,0,,,,
15170,Chemical,D004164,17660778,Diphosphonates,0,,,,
15171,Chemical,D002981,17660778,Clindamycin,3U02EL437C,,,,
15172,DescriptorName,D000900,17660778,,,1,Anti-Bacterial Agents,N,
15173,QualifierName,Q000627,17660778,,,1,,N,therapeutic use
15174,DescriptorName,D050071,17660778,,,2,Bone Density Conservation Agents,N,
15175,QualifierName,Q000009,17660778,,,2,,Y,adverse effects
15176,DescriptorName,D001943,17660778,,,3,Breast Neoplasms,N,
15177,QualifierName,Q000473,17660778,,,3,,N,pathology
15178,DescriptorName,D002294,17660778,,,4,"Carcinoma, Squamous Cell",N,
15179,QualifierName,Q000175,17660778,,,4,,Y,diagnosis
15180,DescriptorName,D002981,17660778,,,5,Clindamycin,N,
15181,QualifierName,Q000627,17660778,,,5,,N,therapeutic use
15182,DescriptorName,D003937,17660778,,,6,"Diagnosis, Differential",N,
15183,DescriptorName,D004164,17660778,,,7,Diphosphonates,N,
15184,QualifierName,Q000009,17660778,,,7,,Y,adverse effects
15185,DescriptorName,D005260,17660778,,,8,Female,N,
15186,DescriptorName,D006801,17660778,,,9,Humans,N,
15187,DescriptorName,D008439,17660778,,,10,Maxillary Diseases,N,
15188,QualifierName,Q000139,17660778,,,10,,Y,chemically induced
15189,DescriptorName,D008441,17660778,,,11,Maxillary Neoplasms,N,
15190,QualifierName,Q000175,17660778,,,11,,Y,diagnosis
15191,DescriptorName,D008875,17660778,,,12,Middle Aged,N,
15192,DescriptorName,D010020,17660778,,,13,Osteonecrosis,N,
15193,QualifierName,Q000139,17660778,,,13,,Y,chemically induced
15194,Chemical,D014150,17665812,Antipsychotic Agents,0,,,,
15195,Chemical,D003987,17665812,Dibenzothiazepines,0,,,,
15196,Chemical,D000069348,17665812,Quetiapine Fumarate,2S3PL1B6UJ,,,,
15197,Chemical,D003024,17665812,Clozapine,J60AR2IKIC,,,,
15198,DescriptorName,D000328,17665812,,,1,Adult,N,
15199,DescriptorName,D014150,17665812,,,2,Antipsychotic Agents,N,
15200,QualifierName,Q000009,17665812,,,2,,Y,adverse effects
15201,DescriptorName,D003024,17665812,,,3,Clozapine,N,
15202,QualifierName,Q000009,17665812,,,3,,Y,adverse effects
15203,DescriptorName,D003987,17665812,,,4,Dibenzothiazepines,N,
15204,QualifierName,Q000627,17665812,,,4,,Y,therapeutic use
15205,DescriptorName,D004342,17665812,,,5,Drug Hypersensitivity,N,
15206,QualifierName,Q000175,17665812,,,5,,Y,diagnosis
15207,DescriptorName,D004802,17665812,,,6,Eosinophilia,N,
15208,QualifierName,Q000139,17665812,,,6,,Y,chemically induced
15209,DescriptorName,D004804,17665812,,,7,Eosinophils,N,
15210,QualifierName,Q000187,17665812,,,7,,N,drug effects
15211,DescriptorName,D006801,17665812,,,8,Humans,N,
15212,DescriptorName,D007958,17665812,,,9,Leukocyte Count,N,
15213,DescriptorName,D008297,17665812,,,10,Male,N,
15214,DescriptorName,D010359,17665812,,,11,Patient Readmission,N,
15215,DescriptorName,D000069348,17665812,,,12,Quetiapine Fumarate,N,
15216,DescriptorName,D012559,17665812,,,13,Schizophrenia,N,
15217,QualifierName,Q000175,17665812,,,13,,N,diagnosis
15218,DescriptorName,D012565,17665812,,,14,Schizophrenic Psychology,N,
15219,Chemical,D007004,17667216,Hypoglycemic Agents,0,,,,
15220,Chemical,D008687,17667216,Metformin,9100L32L2N,,,,
15221,DescriptorName,D000140,17667216,,,1,"Acidosis, Lactic",N,
15222,QualifierName,Q000139,17667216,,,1,,Y,chemically induced
15223,DescriptorName,D058186,17667216,,,2,Acute Kidney Injury,N,
15224,QualifierName,Q000150,17667216,,,2,,N,complications
15225,DescriptorName,D003681,17667216,,,3,Dehydration,N,
15226,QualifierName,Q000150,17667216,,,3,,N,complications
15227,DescriptorName,D003924,17667216,,,4,"Diabetes Mellitus, Type 2",N,
15228,QualifierName,Q000188,17667216,,,4,,N,drug therapy
15229,DescriptorName,D003967,17667216,,,5,Diarrhea,N,
15230,QualifierName,Q000150,17667216,,,5,,Y,complications
15231,DescriptorName,D006801,17667216,,,6,Humans,N,
15232,DescriptorName,D007004,17667216,,,7,Hypoglycemic Agents,N,
15233,QualifierName,Q000009,17667216,,,7,,Y,adverse effects
15234,DescriptorName,D008297,17667216,,,8,Male,N,
15235,DescriptorName,D008687,17667216,,,9,Metformin,N,
15236,QualifierName,Q000009,17667216,,,9,,Y,adverse effects
15237,DescriptorName,D008875,17667216,,,10,Middle Aged,N,
15238,DescriptorName,D006435,17667216,,,11,Renal Dialysis,N,
15239,Chemical,D007166,17671884,Immunosuppressive Agents,0,,,,
15240,Chemical,D009173,17671884,Mycophenolic Acid,HU9DX48N0T,,,,
15241,Chemical,D011241,17671884,Prednisone,VB0R961HZT,,,,
15242,DescriptorName,D000740,17671884,,,1,Anemia,N,
15243,QualifierName,Q000139,17671884,,,1,,Y,chemically induced
15244,DescriptorName,D004359,17671884,,,2,"Drug Therapy, Combination",N,
15245,DescriptorName,D004906,17671884,,,3,Erythrocyte Count,N,
15246,DescriptorName,D005260,17671884,,,4,Female,N,
15247,DescriptorName,D006801,17671884,,,5,Humans,N,
15248,DescriptorName,D007166,17671884,,,6,Immunosuppressive Agents,N,
15249,QualifierName,Q000009,17671884,,,6,,Y,adverse effects
15250,DescriptorName,D008875,17671884,,,7,Middle Aged,N,
15251,DescriptorName,D009173,17671884,,,8,Mycophenolic Acid,N,
15252,QualifierName,Q000009,17671884,,,8,,N,adverse effects
15253,DescriptorName,D010392,17671884,,,9,Pemphigus,N,
15254,QualifierName,Q000097,17671884,,,9,,Y,blood
15255,DescriptorName,D011241,17671884,,,10,Prednisone,N,
15256,QualifierName,Q000627,17671884,,,10,,Y,therapeutic use
15257,Chemical,D000927,17675030,Anticonvulsants,0,,,,
15258,Chemical,D002220,17675030,Carbamazepine,33CM23913M,,,,
15259,Chemical,D000078330,17675030,Oxcarbazepine,VZI5B1W380,,,,
15260,DescriptorName,D000799,17675030,,,1,Angioedema,N,
15261,QualifierName,Q000139,17675030,,,1,,Y,chemically induced
15262,DescriptorName,D000927,17675030,,,2,Anticonvulsants,N,
15263,QualifierName,Q000009,17675030,,,2,,Y,adverse effects
15264,DescriptorName,D002220,17675030,,,3,Carbamazepine,N,
15265,QualifierName,Q000009,17675030,,,3,,N,adverse effects
15266,DescriptorName,D002675,17675030,,,4,"Child, Preschool",N,
15267,DescriptorName,D004827,17675030,,,5,Epilepsy,N,
15268,QualifierName,Q000188,17675030,,,5,,Y,drug therapy
15269,DescriptorName,D006801,17675030,,,6,Humans,N,
15270,DescriptorName,D008297,17675030,,,7,Male,N,
15271,DescriptorName,D000078330,17675030,,,8,Oxcarbazepine,N,
15272,DescriptorName,D014481,17675030,,,9,United States,N,
15273,Chemical,D007166,17697264,Immunosuppressive Agents,0,,,,
15274,Chemical,D001379,17697264,Azathioprine,MRK240IY2L,,,,
15275,DescriptorName,D001379,17697264,,,1,Azathioprine,N,
15276,QualifierName,Q000009,17697264,,,1,,Y,adverse effects
15277,DescriptorName,D001706,17697264,,,2,Biopsy,N,
15278,DescriptorName,D005500,17697264,,,3,Follow-Up Studies,N,
15279,DescriptorName,D006084,17697264,,,4,Graft Rejection,N,
15280,QualifierName,Q000188,17697264,,,4,,Y,drug therapy
15281,DescriptorName,D006504,17697264,,,5,Hepatic Veno-Occlusive Disease,N,
15282,QualifierName,Q000139,17697264,,,5,,Y,chemically induced
15283,DescriptorName,D006801,17697264,,,6,Humans,N,
15284,DescriptorName,D007166,17697264,,,7,Immunosuppressive Agents,N,
15285,QualifierName,Q000009,17697264,,,7,,Y,adverse effects
15286,DescriptorName,D008099,17697264,,,8,Liver,N,
15287,QualifierName,Q000473,17697264,,,8,,N,pathology
15288,DescriptorName,D016040,17697264,,,9,Lung Transplantation,Y,
15289,DescriptorName,D008297,17697264,,,10,Male,N,
15290,DescriptorName,D008875,17697264,,,11,Middle Aged,N,
15291,Chemical,D000927,17705565,Anticonvulsants,0,,,,
15292,Chemical,D002220,17705565,Carbamazepine,33CM23913M,,,,
15293,DescriptorName,D000927,17705565,,,1,Anticonvulsants,N,
15294,QualifierName,Q000009,17705565,,,1,,Y,adverse effects
15295,DescriptorName,D002220,17705565,,,2,Carbamazepine,N,
15296,QualifierName,Q000009,17705565,,,2,,Y,adverse effects
15297,DescriptorName,D015984,17705565,,,3,Causality,N,
15298,DescriptorName,D002648,17705565,,,4,Child,N,
15299,DescriptorName,D002675,17705565,,,5,"Child, Preschool",N,
15300,DescriptorName,D004342,17705565,,,6,Drug Hypersensitivity,N,
15301,QualifierName,Q000175,17705565,,,6,,Y,diagnosis
15302,DescriptorName,D005260,17705565,,,7,Female,N,
15303,DescriptorName,D006801,17705565,,,8,Humans,N,
15304,DescriptorName,D008297,17705565,,,9,Male,N,
15305,DescriptorName,D010818,17705565,,,10,"Practice Patterns, Physicians'",N,
15306,DescriptorName,D011336,17705565,,,11,Probability,N,
15307,DescriptorName,D012640,17705565,,,12,Seizures,N,
15308,QualifierName,Q000188,17705565,,,12,,N,drug therapy
15309,DescriptorName,D012720,17705565,,,13,Severity of Illness Index,N,
15310,DescriptorName,D011795,17705565,,,14,Surveys and Questionnaires,N,
15311,DescriptorName,D013577,17705565,,,15,Syndrome,N,
15312,Chemical,D000972,17710018,"Antineoplastic Agents, Phytogenic",0,,,,
15313,Chemical,D019275,17710018,Radiopharmaceuticals,0,,,,
15314,Chemical,D019788,17710018,Fluorodeoxyglucose F18,0Z5B2CJX4D,,,,
15315,Chemical,D005047,17710018,Etoposide,6PLQ3CP4P3,,,,
15316,DescriptorName,D000284,17710018,,,1,"Administration, Oral",N,
15317,DescriptorName,D000368,17710018,,,2,Aged,N,
15318,DescriptorName,D000972,17710018,,,3,"Antineoplastic Agents, Phytogenic",N,
15319,QualifierName,Q000009,17710018,,,3,,N,adverse effects
15320,DescriptorName,D005047,17710018,,,4,Etoposide,N,
15321,QualifierName,Q000008,17710018,,,4,,N,administration & dosage
15322,DescriptorName,D019788,17710018,,,5,Fluorodeoxyglucose F18,Y,
15323,DescriptorName,D006801,17710018,,,6,Humans,N,
15324,DescriptorName,D015464,17710018,,,7,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
15325,QualifierName,Q000188,17710018,,,7,,N,drug therapy
15326,DescriptorName,D008171,17710018,,,8,Lung Diseases,N,
15327,QualifierName,Q000139,17710018,,,8,,Y,chemically induced
15328,DescriptorName,D008297,17710018,,,9,Male,N,
15329,DescriptorName,D049268,17710018,,,10,Positron-Emission Tomography,N,
15330,QualifierName,Q000379,17710018,,,10,,Y,methods
15331,DescriptorName,D019275,17710018,,,11,Radiopharmaceuticals,N,
15332,DescriptorName,D035583,17710018,,,12,Rare Diseases,N,
15333,QualifierName,Q000139,17710018,,,12,,N,chemically induced
15334,Chemical,D000906,1772299,Antibodies,0,,,,
15335,Chemical,D014364,1772299,Tryptophan,8DUH1N11BX,,,,
15336,Chemical,D008775,1772299,Methylprednisolone,X4W7ZR7023,,,,
15337,DescriptorName,D000906,1772299,,,1,Antibodies,N,
15338,QualifierName,Q000032,1772299,,,1,,Y,analysis
15339,DescriptorName,D003593,1772299,,,2,Cytoplasm,N,
15340,QualifierName,Q000276,1772299,,,2,,N,immunology
15341,DescriptorName,D016603,1772299,,,3,Eosinophilia-Myalgia Syndrome,N,
15342,QualifierName,Q000139,1772299,,,3,,N,chemically induced
15343,DescriptorName,D005260,1772299,,,4,Female,N,
15344,DescriptorName,D006801,1772299,,,5,Humans,N,
15345,DescriptorName,D008775,1772299,,,6,Methylprednisolone,N,
15346,QualifierName,Q000627,1772299,,,6,,N,therapeutic use
15347,DescriptorName,D008875,1772299,,,7,Middle Aged,N,
15348,DescriptorName,D009504,1772299,,,8,Neutrophils,N,
15349,QualifierName,Q000276,1772299,,,8,,Y,immunology
15350,DescriptorName,D014364,1772299,,,9,Tryptophan,N,
15351,QualifierName,Q000009,1772299,,,9,,Y,adverse effects
15352,Chemical,D000904,17725438,"Antibiotics, Antitubercular",0,,,,
15353,Chemical,D012293,17725438,Rifampin,VJT6J7R4TR,,,,
15354,DescriptorName,D000328,17725438,,,1,Adult,N,
15355,DescriptorName,D000904,17725438,,,2,"Antibiotics, Antitubercular",N,
15356,QualifierName,Q000009,17725438,,,2,,Y,adverse effects
15357,DescriptorName,D005260,17725438,,,3,Female,N,
15358,DescriptorName,D006801,17725438,,,4,Humans,N,
15359,DescriptorName,D007037,17725438,,,5,Hypothyroidism,N,
15360,QualifierName,Q000139,17725438,,,5,,Y,chemically induced
15361,DescriptorName,D012293,17725438,,,6,Rifampin,N,
15362,QualifierName,Q000009,17725438,,,6,,Y,adverse effects
15363,DescriptorName,D013960,17725438,,,7,Thyroid Function Tests,N,
15364,DescriptorName,D013961,17725438,,,8,Thyroid Gland,N,
15365,QualifierName,Q000187,17725438,,,8,,N,drug effects
15366,DescriptorName,D014397,17725438,,,9,"Tuberculosis, Pulmonary",N,
15367,QualifierName,Q000188,17725438,,,9,,Y,drug therapy
15368,Chemical,D000894,1775411,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
15369,Chemical,D002074,1775411,Butanones,0,,,,
15370,Chemical,D011239,1775411,Prednisolone,9PHQ9Y1OLM,,,,
15371,Chemical,D000077430,1775411,Nabumetone,LW0TIW155Z,,,,
15372,DescriptorName,D000368,1775411,,,1,Aged,N,
15373,DescriptorName,D000894,1775411,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
15374,QualifierName,Q000009,1775411,,,2,,Y,adverse effects
15375,DescriptorName,D002074,1775411,,,3,Butanones,N,
15376,QualifierName,Q000009,1775411,,,3,,Y,adverse effects
15377,DescriptorName,D005260,1775411,,,4,Female,N,
15378,DescriptorName,D006801,1775411,,,5,Humans,N,
15379,DescriptorName,D008168,1775411,,,6,Lung,N,
15380,QualifierName,Q000000981,1775411,,,6,,N,diagnostic imaging
15381,DescriptorName,D000077430,1775411,,,7,Nabumetone,N,
15382,DescriptorName,D011239,1775411,,,8,Prednisolone,N,
15383,QualifierName,Q000627,1775411,,,8,,N,therapeutic use
15384,DescriptorName,D011658,1775411,,,9,Pulmonary Fibrosis,N,
15385,QualifierName,Q000139,1775411,,,9,,Y,chemically induced
15386,DescriptorName,D011859,1775411,,,10,Radiography,N,
15387,Chemical,D000924,17763133,Anticholesteremic Agents,0,,,,
15388,Chemical,D007166,17763133,Immunosuppressive Agents,0,,,,
15389,Chemical,D016572,17763133,Cyclosporine,83HN0GTJ6D,,,,
15390,Chemical,D019821,17763133,Simvastatin,AGG2FN16EV,,,,
15391,DescriptorName,D000368,17763133,,,1,Aged,N,
15392,DescriptorName,D000924,17763133,,,2,Anticholesteremic Agents,N,
15393,QualifierName,Q000009,17763133,,,2,,Y,adverse effects
15394,DescriptorName,D002908,17763133,,,3,Chronic Disease,N,
15395,DescriptorName,D016572,17763133,,,4,Cyclosporine,N,
15396,QualifierName,Q000627,17763133,,,4,,Y,therapeutic use
15397,DescriptorName,D004347,17763133,,,5,Drug Interactions,N,
15398,DescriptorName,D005260,17763133,,,6,Female,N,
15399,DescriptorName,D005500,17763133,,,7,Follow-Up Studies,N,
15400,DescriptorName,D006801,17763133,,,8,Humans,N,
15401,DescriptorName,D006937,17763133,,,9,Hypercholesterolemia,N,
15402,QualifierName,Q000150,17763133,,,9,,N,complications
15403,DescriptorName,D007166,17763133,,,10,Immunosuppressive Agents,N,
15404,QualifierName,Q000627,17763133,,,10,,Y,therapeutic use
15405,DescriptorName,D012206,17763133,,,11,Rhabdomyolysis,N,
15406,QualifierName,Q000139,17763133,,,11,,Y,chemically induced
15407,DescriptorName,D019821,17763133,,,12,Simvastatin,N,
15408,QualifierName,Q000009,17763133,,,12,,Y,adverse effects
15409,DescriptorName,D015866,17763133,,,13,"Uveitis, Posterior",N,
15410,QualifierName,Q000150,17763133,,,13,,N,complications
15411,Chemical,D000998,17823522,Antiviral Agents,0,,,,
15412,Chemical,D016898,17823522,Interferon-alpha,0,,,,
15413,Chemical,D012254,17823522,Ribavirin,49717AWG6K,,,,
15414,DescriptorName,D000998,17823522,,,1,Antiviral Agents,N,
15415,QualifierName,Q000009,17823522,,,1,,Y,adverse effects
15416,DescriptorName,D005260,17823522,,,2,Female,N,
15417,DescriptorName,D006225,17823522,,,3,Hand,N,
15418,DescriptorName,D006526,17823522,,,4,Hepatitis C,N,
15419,QualifierName,Q000188,17823522,,,4,,Y,drug therapy
15420,DescriptorName,D006801,17823522,,,5,Humans,N,
15421,DescriptorName,D016898,17823522,,,6,Interferon-alpha,N,
15422,QualifierName,Q000009,17823522,,,6,,Y,adverse effects
15423,DescriptorName,D017513,17823522,,,7,Lichen Nitidus,N,
15424,QualifierName,Q000139,17823522,,,7,,N,chemically induced
15425,DescriptorName,D008875,17823522,,,8,Middle Aged,N,
15426,DescriptorName,D012254,17823522,,,9,Ribavirin,N,
15427,QualifierName,Q000009,17823522,,,9,,N,adverse effects
15428,Chemical,D007166,17827517,Immunosuppressive Agents,0,,,,
15429,Chemical,D010975,17827517,Platelet Aggregation Inhibitors,0,,,,
15430,Chemical,D000077144,17827517,Clopidogrel,A74586SNO7,,,,
15431,Chemical,D013988,17827517,Ticlopidine,OM90ZUW7M1,,,,
15432,Chemical,D020123,17827517,Sirolimus,W36ZG6FT64,,,,
15433,DescriptorName,D000328,17827517,,,1,Adult,N,
15434,DescriptorName,D000077144,17827517,,,2,Clopidogrel,N,
15435,DescriptorName,D017023,17827517,,,3,Coronary Angiography,N,
15436,DescriptorName,D003324,17827517,,,4,Coronary Artery Disease,N,
15437,QualifierName,Q000188,17827517,,,4,,N,drug therapy
15438,DescriptorName,D003328,17827517,,,5,Coronary Thrombosis,N,
15439,QualifierName,Q000000981,17827517,,,5,,N,diagnostic imaging
15440,DescriptorName,D016503,17827517,,,6,Drug Delivery Systems,N,
15441,DescriptorName,D006801,17827517,,,7,Humans,N,
15442,DescriptorName,D007166,17827517,,,8,Immunosuppressive Agents,N,
15443,QualifierName,Q000008,17827517,,,8,,Y,administration & dosage
15444,DescriptorName,D008297,17827517,,,9,Male,N,
15445,DescriptorName,D010975,17827517,,,10,Platelet Aggregation Inhibitors,N,
15446,QualifierName,Q000627,17827517,,,10,,Y,therapeutic use
15447,DescriptorName,D020123,17827517,,,11,Sirolimus,N,
15448,QualifierName,Q000008,17827517,,,11,,Y,administration & dosage
15449,DescriptorName,D015607,17827517,,,12,Stents,N,
15450,QualifierName,Q000009,17827517,,,12,,Y,adverse effects
15451,DescriptorName,D013988,17827517,,,13,Ticlopidine,N,
15452,QualifierName,Q000031,17827517,,,13,,Y,analogs & derivatives
15453,DescriptorName,D013997,17827517,,,14,Time Factors,N,
15454,Chemical,D014212,17852449,Tretinoin,5688UTC01R,,,,
15455,DescriptorName,D000328,17852449,,,1,Adult,N,
15456,DescriptorName,D005260,17852449,,,2,Female,N,
15457,DescriptorName,D006801,17852449,,,3,Humans,N,
15458,DescriptorName,D007231,17852449,,,4,"Infant, Newborn",N,
15459,DescriptorName,D015473,17852449,,,5,"Leukemia, Promyelocytic, Acute",N,
15460,QualifierName,Q000188,17852449,,,5,,N,drug therapy
15461,DescriptorName,D011247,17852449,,,6,Pregnancy,N,
15462,DescriptorName,D011252,17852449,,,7,"Pregnancy Complications, Neoplastic",N,
15463,DescriptorName,D011256,17852449,,,8,Pregnancy Outcome,N,
15464,DescriptorName,D011261,17852449,,,9,"Pregnancy Trimester, First",N,
15465,DescriptorName,D014212,17852449,,,10,Tretinoin,N,
15466,QualifierName,Q000009,17852449,,,10,,Y,adverse effects
15467,Chemical,D047428,17873198,Protein Kinase Inhibitors,0,,,,
15468,Chemical,D011799,17873198,Quinazolines,0,,,,
15469,Chemical,D000069347,17873198,Erlotinib Hydrochloride,DA87705X9K,,,,
15470,DescriptorName,D002289,17873198,,,1,"Carcinoma, Non-Small-Cell Lung",N,
15471,QualifierName,Q000188,17873198,,,1,,N,drug therapy
15472,DescriptorName,D000069347,17873198,,,2,Erlotinib Hydrochloride,N,
15473,DescriptorName,D017809,17873198,,,3,Fatal Outcome,N,
15474,DescriptorName,D006801,17873198,,,4,Humans,N,
15475,DescriptorName,D017563,17873198,,,5,"Lung Diseases, Interstitial",N,
15476,QualifierName,Q000139,17873198,,,5,,Y,chemically induced
15477,DescriptorName,D008175,17873198,,,6,Lung Neoplasms,N,
15478,QualifierName,Q000188,17873198,,,6,,N,drug therapy
15479,DescriptorName,D008297,17873198,,,7,Male,N,
15480,DescriptorName,D008875,17873198,,,8,Middle Aged,N,
15481,DescriptorName,D047428,17873198,,,9,Protein Kinase Inhibitors,N,
15482,QualifierName,Q000009,17873198,,,9,,Y,adverse effects
15483,DescriptorName,D011799,17873198,,,10,Quinazolines,N,
15484,QualifierName,Q000009,17873198,,,10,,Y,adverse effects
15485,Chemical,D000890,17876386,Anti-Infective Agents,0,,,,
15486,Chemical,D001372,17876386,Aza Compounds,0,,,,
15487,Chemical,D024841,17876386,Fluoroquinolones,0,,,,
15488,Chemical,D011804,17876386,Quinolines,0,,,,
15489,Chemical,D000077266,17876386,Moxifloxacin,U188XYD42P,,,,
15490,DescriptorName,D000369,17876386,,,1,"Aged, 80 and over",N,
15491,DescriptorName,D000890,17876386,,,2,Anti-Infective Agents,N,
15492,QualifierName,Q000009,17876386,,,2,,Y,adverse effects
15493,DescriptorName,D001372,17876386,,,3,Aza Compounds,N,
15494,QualifierName,Q000009,17876386,,,3,,Y,adverse effects
15495,DescriptorName,D001919,17876386,,,4,Bradycardia,N,
15496,DescriptorName,D002304,17876386,,,5,"Cardiac Pacing, Artificial",N,
15497,DescriptorName,D005260,17876386,,,6,Female,N,
15498,DescriptorName,D024841,17876386,,,7,Fluoroquinolones,N,
15499,QualifierName,Q000009,17876386,,,7,,Y,adverse effects
15500,DescriptorName,D006801,17876386,,,8,Humans,N,
15501,DescriptorName,D008133,17876386,,,9,Long QT Syndrome,N,
15502,QualifierName,Q000139,17876386,,,9,,Y,chemically induced
15503,DescriptorName,D000077266,17876386,,,10,Moxifloxacin,N,
15504,DescriptorName,D011014,17876386,,,11,Pneumonia,N,
15505,QualifierName,Q000188,17876386,,,11,,N,drug therapy
15506,DescriptorName,D011804,17876386,,,12,Quinolines,N,
15507,QualifierName,Q000009,17876386,,,12,,Y,adverse effects
15508,DescriptorName,D012307,17876386,,,13,Risk Factors,N,
15509,DescriptorName,D013575,17876386,,,14,Syncope,N,
15510,DescriptorName,D016171,17876386,,,15,Torsades de Pointes,N,
15511,QualifierName,Q000209,17876386,,,15,,Y,etiology
15512,DescriptorName,D016896,17876386,,,16,Treatment Outcome,Y,
15513,Chemical,D014662,17880357,Vasoconstrictor Agents,0,,,,
15514,Chemical,D008236,17880357,Lypressin,50-57-7,,,,
15515,Chemical,D000077585,17880357,Terlipressin,7Z5X49W53P,,,,
15516,DescriptorName,D005260,17880357,,,1,Female,N,
15517,DescriptorName,D006801,17880357,,,2,Humans,N,
15518,DescriptorName,D007511,17880357,,,3,Ischemia,N,
15519,QualifierName,Q000139,17880357,,,3,,Y,chemically induced
15520,DescriptorName,D008103,17880357,,,4,Liver Cirrhosis,N,
15521,QualifierName,Q000150,17880357,,,4,,Y,complications
15522,DescriptorName,D008236,17880357,,,5,Lypressin,N,
15523,QualifierName,Q000009,17880357,,,5,,N,adverse effects
15524,DescriptorName,D008297,17880357,,,6,Male,N,
15525,DescriptorName,D008875,17880357,,,7,Middle Aged,N,
15526,DescriptorName,D009336,17880357,,,8,Necrosis,N,
15527,DescriptorName,D012867,17880357,,,9,Skin,N,
15528,QualifierName,Q000098,17880357,,,9,,Y,blood supply
15529,DescriptorName,D000077585,17880357,,,10,Terlipressin,N,
15530,DescriptorName,D014662,17880357,,,11,Vasoconstrictor Agents,N,
15531,QualifierName,Q000009,17880357,,,11,,Y,adverse effects
15532,Chemical,D006074,17921794,Gout Suppressants,0,,,,
15533,Chemical,D019161,17921794,Hydroxymethylglutaryl-CoA Reductase Inhibitors,0,,,,
15534,Chemical,D019821,17921794,Simvastatin,AGG2FN16EV,,,,
15535,Chemical,D003078,17921794,Colchicine,SML2Y3J35T,,,,
15536,DescriptorName,D015210,17921794,,,1,"Arthritis, Gouty",N,
15537,QualifierName,Q000188,17921794,,,1,,N,drug therapy
15538,DescriptorName,D002062,17921794,,,2,Bursitis,N,
15539,QualifierName,Q000188,17921794,,,2,,N,drug therapy
15540,DescriptorName,D003078,17921794,,,3,Colchicine,N,
15541,QualifierName,Q000009,17921794,,,3,,Y,adverse effects
15542,DescriptorName,D004357,17921794,,,4,Drug Synergism,N,
15543,DescriptorName,D005260,17921794,,,5,Female,N,
15544,DescriptorName,D006074,17921794,,,6,Gout Suppressants,N,
15545,QualifierName,Q000009,17921794,,,6,,Y,adverse effects
15546,DescriptorName,D006801,17921794,,,7,Humans,N,
15547,DescriptorName,D019161,17921794,,,8,Hydroxymethylglutaryl-CoA Reductase Inhibitors,N,
15548,QualifierName,Q000009,17921794,,,8,,Y,adverse effects
15549,DescriptorName,D008875,17921794,,,9,Middle Aged,N,
15550,DescriptorName,D051436,17921794,,,10,"Renal Insufficiency, Chronic",N,
15551,QualifierName,Q000150,17921794,,,10,,Y,complications
15552,DescriptorName,D012206,17921794,,,11,Rhabdomyolysis,N,
15553,QualifierName,Q000139,17921794,,,11,,Y,chemically induced
15554,DescriptorName,D019821,17921794,,,12,Simvastatin,N,
15555,QualifierName,Q000009,17921794,,,12,,Y,adverse effects
15556,Chemical,D008727,1792646,Methotrexate,YL5FZ2Y5U1,,,,
15557,DescriptorName,D000328,1792646,,,1,Adult,N,
15558,DescriptorName,D001249,1792646,,,2,Asthma,N,
15559,QualifierName,Q000188,1792646,,,2,,Y,drug therapy
15560,DescriptorName,D006801,1792646,,,3,Humans,N,
15561,DescriptorName,D007165,1792646,,,4,Immunosuppression,N,
15562,DescriptorName,D008297,1792646,,,5,Male,N,
15563,DescriptorName,D008727,1792646,,,6,Methotrexate,N,
15564,QualifierName,Q000008,1792646,,,6,,N,administration & dosage
15565,DescriptorName,D009894,1792646,,,7,Opportunistic Infections,N,
15566,QualifierName,Q000209,1792646,,,7,,Y,etiology
15567,DescriptorName,D011020,1792646,,,8,"Pneumonia, Pneumocystis",N,
15568,QualifierName,Q000209,1792646,,,8,,Y,etiology
15569,Chemical,D017262,17931455,Siderophores,0,,,,
15570,Chemical,D003676,17931455,Deferoxamine,J06Y7MXW4D,,,,
15571,DescriptorName,D001855,17931455,,,1,Bone Marrow Diseases,N,
15572,QualifierName,Q000150,17931455,,,1,,Y,complications
15573,DescriptorName,D002648,17931455,,,2,Child,N,
15574,DescriptorName,D003676,17931455,,,3,Deferoxamine,N,
15575,QualifierName,Q000009,17931455,,,3,,Y,adverse effects
15576,DescriptorName,D034381,17931455,,,4,Hearing Loss,N,
15577,QualifierName,Q000139,17931455,,,4,,Y,chemically induced
15578,DescriptorName,D006801,17931455,,,5,Humans,N,
15579,DescriptorName,D008297,17931455,,,6,Male,N,
15580,DescriptorName,D017262,17931455,,,7,Siderophores,N,
15581,QualifierName,Q000009,17931455,,,7,,Y,adverse effects
15582,DescriptorName,D017086,17931455,,,8,beta-Thalassemia,N,
15583,QualifierName,Q000188,17931455,,,8,,Y,drug therapy
15584,Chemical,D018501,17937473,Antirheumatic Agents,0,,,,
15585,Chemical,D007555,17937473,Isoxazoles,0,,,,
15586,Chemical,D000077339,17937473,Leflunomide,G162GK9U4W,,,,
15587,DescriptorName,D000328,17937473,,,1,Adult,N,
15588,DescriptorName,D000368,17937473,,,2,Aged,N,
15589,DescriptorName,D018501,17937473,,,3,Antirheumatic Agents,N,
15590,QualifierName,Q000009,17937473,,,3,,Y,adverse effects
15591,DescriptorName,D001172,17937473,,,4,"Arthritis, Rheumatoid",N,
15592,QualifierName,Q000188,17937473,,,4,,Y,drug therapy
15593,DescriptorName,D002481,17937473,,,5,Cellulitis,N,
15594,QualifierName,Q000209,17937473,,,5,,N,etiology
15595,DescriptorName,D005260,17937473,,,6,Female,N,
15596,DescriptorName,D006760,17937473,,,7,Hospitalization,N,
15597,DescriptorName,D006801,17937473,,,8,Humans,N,
15598,DescriptorName,D007239,17937473,,,9,Infections,N,
15599,QualifierName,Q000209,17937473,,,9,,Y,etiology
15600,DescriptorName,D007555,17937473,,,10,Isoxazoles,N,
15601,QualifierName,Q000009,17937473,,,10,,Y,adverse effects
15602,DescriptorName,D000077339,17937473,,,11,Leflunomide,N,
15603,DescriptorName,D008297,17937473,,,12,Male,N,
15604,DescriptorName,D008875,17937473,,,13,Middle Aged,N,
15605,DescriptorName,D009520,17937473,,,14,New Zealand,N,
15606,DescriptorName,D018805,17937473,,,15,Sepsis,N,
15607,QualifierName,Q000209,17937473,,,15,,N,etiology
15608,DescriptorName,D013203,17937473,,,16,Staphylococcal Infections,N,
15609,QualifierName,Q000209,17937473,,,16,,N,etiology
15610,DescriptorName,D014386,17937473,,,17,"Tuberculosis, Hepatic",N,
15611,QualifierName,Q000209,17937473,,,17,,N,etiology
15612,Chemical,D018501,17952482,Antirheumatic Agents,0,,,,
15613,Chemical,D012460,17952482,Sulfasalazine,3XC8GUZ6CB,,,,
15614,DescriptorName,D018501,17952482,,,1,Antirheumatic Agents,N,
15615,QualifierName,Q000009,17952482,,,1,,Y,adverse effects
15616,DescriptorName,D001172,17952482,,,2,"Arthritis, Rheumatoid",N,
15617,QualifierName,Q000150,17952482,,,2,,N,complications
15618,DescriptorName,D004342,17952482,,,3,Drug Hypersensitivity,N,
15619,QualifierName,Q000209,17952482,,,3,,Y,etiology
15620,DescriptorName,D020031,17952482,,,4,Epstein-Barr Virus Infections,N,
15621,QualifierName,Q000150,17952482,,,4,,Y,complications
15622,DescriptorName,D005260,17952482,,,5,Female,N,
15623,DescriptorName,D006801,17952482,,,6,Humans,N,
15624,DescriptorName,D051359,17952482,,,7,"Lymphohistiocytosis, Hemophagocytic",N,
15625,QualifierName,Q000209,17952482,,,7,,N,etiology
15626,DescriptorName,D008875,17952482,,,8,Middle Aged,N,
15627,DescriptorName,D012859,17952482,,,9,Sjogren's Syndrome,N,
15628,QualifierName,Q000150,17952482,,,9,,N,complications
15629,DescriptorName,D012460,17952482,,,10,Sulfasalazine,N,
15630,QualifierName,Q000009,17952482,,,10,,Y,adverse effects
15631,DescriptorName,D017735,17952482,,,11,Virus Latency,N,
15632,QualifierName,Q000187,17952482,,,11,,Y,drug effects
15633,Chemical,D000927,17955169,Anticonvulsants,0,,,,
15634,Chemical,D002220,17955169,Carbamazepine,33CM23913M,,,,
15635,Chemical,D000078330,17955169,Oxcarbazepine,VZI5B1W380,,,,
15636,DescriptorName,D000208,17955169,,,1,Acute Disease,N,
15637,DescriptorName,D000328,17955169,,,2,Adult,N,
15638,DescriptorName,D000927,17955169,,,3,Anticonvulsants,N,
15639,QualifierName,Q000009,17955169,,,3,,N,adverse effects
15640,DescriptorName,D001932,17955169,,,4,Brain Neoplasms,N,
15641,QualifierName,Q000150,17955169,,,4,,Y,complications
15642,DescriptorName,D002220,17955169,,,5,Carbamazepine,N,
15643,QualifierName,Q000009,17955169,,,5,,N,adverse effects
15644,DescriptorName,D020785,17955169,,,6,Central Nervous System Vascular Malformations,N,
15645,QualifierName,Q000150,17955169,,,6,,N,complications
15646,DescriptorName,D018450,17955169,,,7,Disease Progression,N,
15647,DescriptorName,D004827,17955169,,,8,Epilepsy,N,
15648,QualifierName,Q000150,17955169,,,8,,Y,complications
15649,DescriptorName,D005260,17955169,,,9,Female,N,
15650,DescriptorName,D020773,17955169,,,10,Headache Disorders,N,
15651,QualifierName,Q000139,17955169,,,10,,Y,chemically induced
15652,DescriptorName,D006801,17955169,,,11,Humans,N,
15653,DescriptorName,D008881,17955169,,,12,Migraine Disorders,N,
15654,QualifierName,Q000139,17955169,,,12,,Y,chemically induced
15655,DescriptorName,D018302,17955169,,,13,"Neoplasms, Neuroepithelial",N,
15656,QualifierName,Q000150,17955169,,,13,,Y,complications
15657,DescriptorName,D000078330,17955169,,,14,Oxcarbazepine,N,
15658,Chemical,D004280,17959575,Dobutamine,3S12J47372,,,,
15659,DescriptorName,D000368,17959575,,,1,Aged,N,
15660,DescriptorName,D004280,17959575,,,2,Dobutamine,N,
15661,QualifierName,Q000008,17959575,,,2,,Y,administration & dosage
15662,DescriptorName,D006801,17959575,,,3,Humans,N,
15663,DescriptorName,D007262,17959575,,,4,"Infusions, Intravenous",N,
15664,DescriptorName,D007676,17959575,,,5,"Kidney Failure, Chronic",N,
15665,QualifierName,Q000188,17959575,,,5,,Y,drug therapy
15666,DescriptorName,D008297,17959575,,,6,Male,N,
15667,DescriptorName,D009207,17959575,,,7,Myoclonus,N,
15668,QualifierName,Q000139,17959575,,,7,,Y,chemically induced
15669,Chemical,D011137,17965530,Polystyrenes,0,,,,
15670,Chemical,D013012,17965530,Sorbitol,506T60A25R,,,,
15671,Chemical,C003321,17965530,polystyrene sulfonic acid,70KO0R01RY,,,,
15672,DescriptorName,D000368,17965530,,,1,Aged,N,
15673,DescriptorName,D003108,17965530,,,2,Colonic Diseases,N,
15674,QualifierName,Q000139,17965530,,,2,,Y,chemically induced
15675,DescriptorName,D015653,17965530,,,3,Cystectomy,N,
15676,DescriptorName,D013505,17965530,,,4,Digestive System Surgical Procedures,N,
15677,DescriptorName,D005260,17965530,,,5,Female,N,
15678,DescriptorName,D006801,17965530,,,6,Humans,N,
15679,DescriptorName,D007008,17965530,,,7,Hypokalemia,N,
15680,QualifierName,Q000188,17965530,,,7,,N,drug therapy
15681,DescriptorName,D007412,17965530,,,8,Intestinal Fistula,N,
15682,QualifierName,Q000139,17965530,,,8,,Y,chemically induced
15683,DescriptorName,D011137,17965530,,,9,Polystyrenes,N,
15684,QualifierName,Q000009,17965530,,,9,,Y,adverse effects
15685,DescriptorName,D012810,17965530,,,10,Sigmoid Diseases,N,
15686,QualifierName,Q000139,17965530,,,10,,Y,chemically induced
15687,DescriptorName,D013012,17965530,,,11,Sorbitol,N,
15688,QualifierName,Q000009,17965530,,,11,,Y,adverse effects
15689,DescriptorName,D016896,17965530,,,12,Treatment Outcome,N,
15690,DescriptorName,D014456,17965530,,,13,Ulcer,N,
15691,QualifierName,Q000139,17965530,,,13,,Y,chemically induced
15692,Chemical,D048588,17968817,Benzoxazines,0,,,,
15693,Chemical,D018894,17968817,Reverse Transcriptase Inhibitors,0,,,,
15694,Chemical,D001189,17968817,Aryl Hydrocarbon Hydroxylases,EC 1.14.14.1,,,,
15695,Chemical,C585599,17968817,"CYP2B6 protein, human",EC 1.14.14.1,,,,
15696,Chemical,D065702,17968817,Cytochrome P-450 CYP2B6,EC 1.14.14.1,,,,
15697,Chemical,D010089,17968817,"Oxidoreductases, N-Demethylating",EC 1.5.-,,,,
15698,Chemical,C098320,17968817,efavirenz,JE6H2O27P8,,,,
15699,DescriptorName,D001189,17968817,,,1,Aryl Hydrocarbon Hydroxylases,N,
15700,QualifierName,Q000235,17968817,,,1,,N,genetics
15701,DescriptorName,D048588,17968817,,,2,Benzoxazines,N,
15702,QualifierName,Q000009,17968817,,,2,,Y,adverse effects
15703,DescriptorName,D002648,17968817,,,3,Child,N,
15704,DescriptorName,D065702,17968817,,,4,Cytochrome P-450 CYP2B6,N,
15705,DescriptorName,D005260,17968817,,,5,Female,N,
15706,DescriptorName,D015658,17968817,,,6,HIV Infections,N,
15707,QualifierName,Q000150,17968817,,,6,,Y,complications
15708,DescriptorName,D006579,17968817,,,7,Heterozygote,N,
15709,DescriptorName,D006801,17968817,,,8,Humans,N,
15710,DescriptorName,D010089,17968817,,,9,"Oxidoreductases, N-Demethylating",N,
15711,QualifierName,Q000235,17968817,,,9,,N,genetics
15712,DescriptorName,D017354,17968817,,,10,Point Mutation,N,
15713,DescriptorName,D011605,17968817,,,11,"Psychoses, Substance-Induced",N,
15714,QualifierName,Q000209,17968817,,,11,,Y,etiology
15715,DescriptorName,D018894,17968817,,,12,Reverse Transcriptase Inhibitors,N,
15716,QualifierName,Q000009,17968817,,,12,,Y,adverse effects
15717,Chemical,D000893,17983451,Anti-Inflammatory Agents,0,,,,
15718,Chemical,D000911,17983451,"Antibodies, Monoclonal",0,,,,
15719,Chemical,D000069285,17983451,Infliximab,B72HH48FLU,,,,
15720,DescriptorName,D000328,17983451,,,1,Adult,N,
15721,DescriptorName,D000893,17983451,,,2,Anti-Inflammatory Agents,N,
15722,QualifierName,Q000009,17983451,,,2,,Y,adverse effects
15723,DescriptorName,D000911,17983451,,,3,"Antibodies, Monoclonal",N,
15724,QualifierName,Q000009,17983451,,,3,,Y,adverse effects
15725,DescriptorName,D003424,17983451,,,4,Crohn Disease,N,
15726,QualifierName,Q000188,17983451,,,4,,Y,drug therapy
15727,DescriptorName,D005260,17983451,,,5,Female,N,
15728,DescriptorName,D005533,17983451,,,6,Foot Dermatoses,N,
15729,QualifierName,Q000139,17983451,,,6,,N,chemically induced
15730,DescriptorName,D006801,17983451,,,7,Humans,N,
15731,DescriptorName,D000069285,17983451,,,8,Infliximab,N,
15732,DescriptorName,D009165,17983451,,,9,"Mycobacterium Infections, Nontuberculous",N,
15733,QualifierName,Q000139,17983451,,,9,,Y,chemically induced
15734,DescriptorName,D019910,17983451,,,10,Mycobacterium marinum,Y,
15735,QualifierName,Q000302,17983451,,,10,,N,isolation & purification
15736,DescriptorName,D017192,17983451,,,11,"Skin Diseases, Bacterial",N,
15737,QualifierName,Q000139,17983451,,,11,,Y,chemically induced
15738,DescriptorName,D013551,17983451,,,12,Swimming Pools,N,
15739,Chemical,D000889,18006091,Anti-Arrhythmia Agents,0,,,,
15740,Chemical,D000241,18006091,Adenosine,K72T3FS567,,,,
15741,DescriptorName,D000241,18006091,,,1,Adenosine,N,
15742,QualifierName,Q000008,18006091,,,1,,N,administration & dosage
15743,DescriptorName,D000328,18006091,,,2,Adult,N,
15744,DescriptorName,D000889,18006091,,,3,Anti-Arrhythmia Agents,N,
15745,QualifierName,Q000008,18006091,,,3,,N,administration & dosage
15746,DescriptorName,D004562,18006091,,,4,Electrocardiography,N,
15747,DescriptorName,D005260,18006091,,,5,Female,N,
15748,DescriptorName,D006339,18006091,,,6,Heart Rate,N,
15749,DescriptorName,D006801,18006091,,,7,Humans,N,
15750,DescriptorName,D007275,18006091,,,8,"Injections, Intravenous",N,
15751,DescriptorName,D013610,18006091,,,9,Tachycardia,N,
15752,QualifierName,Q000175,18006091,,,9,,N,diagnosis
15753,DescriptorName,D017180,18006091,,,10,"Tachycardia, Ventricular",N,
15754,QualifierName,Q000139,18006091,,,10,,Y,chemically induced
15755,DescriptorName,D018879,18006091,,,11,Ventricular Premature Complexes,N,
15756,QualifierName,Q000139,18006091,,,11,,N,chemically induced
15757,Chemical,D014150,18020545,Antipsychotic Agents,0,,,,
15758,Chemical,D003024,18020545,Clozapine,J60AR2IKIC,,,,
15759,DescriptorName,D000328,18020545,,,1,Adult,N,
15760,DescriptorName,D014150,18020545,,,2,Antipsychotic Agents,N,
15761,QualifierName,Q000009,18020545,,,2,,Y,adverse effects
15762,DescriptorName,D003024,18020545,,,3,Clozapine,N,
15763,QualifierName,Q000009,18020545,,,3,,Y,adverse effects
15764,DescriptorName,D004409,18020545,,,4,"Dyskinesia, Drug-Induced",N,
15765,QualifierName,Q000209,18020545,,,4,,Y,etiology
15766,DescriptorName,D005260,18020545,,,5,Female,N,
15767,DescriptorName,D020022,18020545,,,6,Genetic Predisposition to Disease,N,
15768,DescriptorName,D006801,18020545,,,7,Humans,N,
15769,DescriptorName,D008875,18020545,,,8,Middle Aged,N,
15770,DescriptorName,D015835,18020545,,,9,Ocular Motility Disorders,N,
15771,QualifierName,Q000139,18020545,,,9,,Y,chemically induced
15772,DescriptorName,D012559,18020545,,,10,Schizophrenia,N,
15773,QualifierName,Q000188,18020545,,,10,,N,drug therapy
15774,Chemical,D008795,180258,Metronidazole,140QMO216E,,,,
15775,DescriptorName,D000328,180258,,,1,Adult,N,
15776,DescriptorName,D003424,180258,,,2,Crohn Disease,N,
15777,QualifierName,Q000188,180258,,,2,,N,drug therapy
15778,DescriptorName,D003937,180258,,,3,"Diagnosis, Differential",N,
15779,DescriptorName,D004568,180258,,,4,Electrodiagnosis,N,
15780,DescriptorName,D005260,180258,,,5,Female,N,
15781,DescriptorName,D006801,180258,,,6,Humans,N,
15782,DescriptorName,D008297,180258,,,7,Male,N,
15783,DescriptorName,D008795,180258,,,8,Metronidazole,N,
15784,QualifierName,Q000009,180258,,,8,,Y,adverse effects
15785,DescriptorName,D008875,180258,,,9,Middle Aged,N,
15786,DescriptorName,D010292,180258,,,10,Paresthesia,N,
15787,QualifierName,Q000139,180258,,,10,,Y,chemically induced
15788,DescriptorName,D010523,180258,,,11,Peripheral Nervous System Diseases,N,
15789,QualifierName,Q000139,180258,,,11,,Y,chemically induced
15790,Chemical,D018501,18034202,Antirheumatic Agents,0,,,,
15791,Chemical,D007166,18034202,Immunosuppressive Agents,0,,,,
15792,Chemical,D014409,18034202,Tumor Necrosis Factor-alpha,0,,,,
15793,Chemical,D008727,18034202,Methotrexate,YL5FZ2Y5U1,,,,
15794,DescriptorName,D000368,18034202,,,1,Aged,N,
15795,DescriptorName,D018501,18034202,,,2,Antirheumatic Agents,N,
15796,QualifierName,Q000009,18034202,,,2,,N,adverse effects
15797,DescriptorName,D001172,18034202,,,3,"Arthritis, Rheumatoid",N,
15798,QualifierName,Q000150,18034202,,,3,,N,complications
15799,DescriptorName,D006622,18034202,,,4,Hip Prosthesis,N,
15800,QualifierName,Q000382,18034202,,,4,,Y,microbiology
15801,DescriptorName,D006801,18034202,,,5,Humans,N,
15802,DescriptorName,D007166,18034202,,,6,Immunosuppressive Agents,N,
15803,QualifierName,Q000009,18034202,,,6,,N,adverse effects
15804,DescriptorName,D008297,18034202,,,7,Male,N,
15805,DescriptorName,D008727,18034202,,,8,Methotrexate,N,
15806,QualifierName,Q000009,18034202,,,8,,N,adverse effects
15807,DescriptorName,D009165,18034202,,,9,"Mycobacterium Infections, Nontuberculous",N,
15808,QualifierName,Q000175,18034202,,,9,,Y,diagnosis
15809,DescriptorName,D016926,18034202,,,10,Mycobacterium chelonae,N,
15810,QualifierName,Q000472,18034202,,,10,,Y,pathogenicity
15811,DescriptorName,D009169,18034202,,,11,Mycobacterium tuberculosis,N,
15812,QualifierName,Q000472,18034202,,,11,,Y,pathogenicity
15813,DescriptorName,D009894,18034202,,,12,Opportunistic Infections,N,
15814,QualifierName,Q000175,18034202,,,12,,Y,diagnosis
15815,DescriptorName,D014376,18034202,,,13,Tuberculosis,N,
15816,QualifierName,Q000175,18034202,,,13,,Y,diagnosis
15817,DescriptorName,D014409,18034202,,,14,Tumor Necrosis Factor-alpha,N,
15818,QualifierName,Q000037,18034202,,,14,,N,antagonists & inhibitors
15819,Chemical,D020533,18037876,Angiogenesis Inhibitors,0,,,,
15820,Chemical,D013792,18037876,Thalidomide,4Z8R6ORS6L,,,,
15821,DescriptorName,D000368,18037876,,,1,Aged,N,
15822,DescriptorName,D020533,18037876,,,2,Angiogenesis Inhibitors,N,
15823,QualifierName,Q000009,18037876,,,2,,Y,adverse effects
15824,DescriptorName,D006801,18037876,,,3,Humans,N,
15825,DescriptorName,D007952,18037876,,,4,"Leukemia, Plasma Cell",N,
15826,QualifierName,Q000188,18037876,,,4,,Y,drug therapy
15827,DescriptorName,D008297,18037876,,,5,Male,N,
15828,DescriptorName,D017180,18037876,,,6,"Tachycardia, Ventricular",N,
15829,QualifierName,Q000139,18037876,,,6,,Y,chemically induced
15830,DescriptorName,D013792,18037876,,,7,Thalidomide,N,
15831,QualifierName,Q000009,18037876,,,7,,Y,adverse effects
15832,Chemical,D007166,18042092,Immunosuppressive Agents,0,,,,
15833,Chemical,D010455,18042092,Peptides,0,,,,
15834,Chemical,D000068717,18042092,Glatiramer Acetate,5M691HL4BO,,,,
15835,DescriptorName,D000005,18042092,,,1,Abdomen,N,
15836,DescriptorName,D004334,18042092,,,2,Drug Administration Schedule,N,
15837,DescriptorName,D003875,18042092,,,3,Drug Eruptions,N,
15838,QualifierName,Q000175,18042092,,,3,,N,diagnosis
15839,DescriptorName,D000068717,18042092,,,4,Glatiramer Acetate,N,
15840,DescriptorName,D006801,18042092,,,5,Humans,N,
15841,DescriptorName,D007166,18042092,,,6,Immunosuppressive Agents,N,
15842,QualifierName,Q000008,18042092,,,6,,N,administration & dosage
15843,DescriptorName,D007279,18042092,,,7,"Injections, Subcutaneous",N,
15844,DescriptorName,D015603,18042092,,,8,Keratinocytes,N,
15845,QualifierName,Q000473,18042092,,,8,,N,pathology
15846,DescriptorName,D008297,18042092,,,9,Male,N,
15847,DescriptorName,D008875,18042092,,,10,Middle Aged,N,
15848,DescriptorName,D009103,18042092,,,11,Multiple Sclerosis,N,
15849,QualifierName,Q000188,18042092,,,11,,Y,drug therapy
15850,DescriptorName,D009336,18042092,,,12,Necrosis,N,
15851,DescriptorName,D010455,18042092,,,13,Peptides,N,
15852,QualifierName,Q000008,18042092,,,13,,N,administration & dosage
15853,DescriptorName,D012867,18042092,,,14,Skin,N,
15854,QualifierName,Q000098,18042092,,,14,,N,blood supply
15855,DescriptorName,D013927,18042092,,,15,Thrombosis,N,
15856,QualifierName,Q000139,18042092,,,15,,Y,chemically induced
15857,Chemical,D000889,18067642,Anti-Arrhythmia Agents,0,,,,
15858,Chemical,D000638,18067642,Amiodarone,N3RQ532IUT,,,,
15859,DescriptorName,D000368,18067642,,,1,Aged,N,
15860,DescriptorName,D000638,18067642,,,2,Amiodarone,N,
15861,QualifierName,Q000009,18067642,,,2,,Y,adverse effects
15862,DescriptorName,D000686,18067642,,,3,Amyloidosis,N,
15863,QualifierName,Q000209,18067642,,,3,,N,etiology
15864,DescriptorName,D000889,18067642,,,4,Anti-Arrhythmia Agents,N,
15865,QualifierName,Q000009,18067642,,,4,,Y,adverse effects
15866,DescriptorName,D005260,18067642,,,5,Female,N,
15867,DescriptorName,D006801,18067642,,,6,Humans,N,
15868,DescriptorName,D007037,18067642,,,7,Hypothyroidism,N,
15869,QualifierName,Q000139,18067642,,,7,,Y,chemically induced
15870,DescriptorName,D009101,18067642,,,8,Multiple Myeloma,N,
15871,QualifierName,Q000150,18067642,,,8,,N,complications
15872,DescriptorName,D013614,18067642,,,9,"Tachycardia, Paroxysmal",N,
15873,QualifierName,Q000188,18067642,,,9,,N,drug therapy
15874,DescriptorName,D013617,18067642,,,10,"Tachycardia, Supraventricular",N,
15875,QualifierName,Q000188,18067642,,,10,,N,drug therapy
15876,DescriptorName,D013961,18067642,,,11,Thyroid Gland,N,
15877,QualifierName,Q000187,18067642,,,11,,Y,drug effects
15878,Chemical,D014151,18071101,Anti-Anxiety Agents,0,,,,
15879,Chemical,D018692,18071101,Antimanic Agents,0,,,,
15880,Chemical,D014150,18071101,Antipsychotic Agents,0,,,,
15881,Chemical,D003987,18071101,Dibenzothiazepines,0,,,,
15882,Chemical,C060342,18071101,clopenthixol acetate ester,0A4EBG0F53,,,,
15883,Chemical,D000069348,18071101,Quetiapine Fumarate,2S3PL1B6UJ,,,,
15884,Chemical,D014635,18071101,Valproic Acid,614OI1Z5WI,,,,
15885,Chemical,D003006,18071101,Clopenthixol,982-24-1,,,,
15886,Chemical,D018967,18071101,Risperidone,L6UH7ZF8HC,,,,
15887,Chemical,D008140,18071101,Lorazepam,O26FZP769L,,,,
15888,DescriptorName,D014151,18071101,,,1,Anti-Anxiety Agents,N,
15889,QualifierName,Q000008,18071101,,,1,,N,administration & dosage
15890,DescriptorName,D018692,18071101,,,2,Antimanic Agents,N,
15891,QualifierName,Q000008,18071101,,,2,,N,administration & dosage
15892,DescriptorName,D014150,18071101,,,3,Antipsychotic Agents,N,
15893,QualifierName,Q000008,18071101,,,3,,N,administration & dosage
15894,DescriptorName,D001714,18071101,,,4,Bipolar Disorder,N,
15895,QualifierName,Q000150,18071101,,,4,,N,complications
15896,DescriptorName,D003006,18071101,,,5,Clopenthixol,N,
15897,QualifierName,Q000008,18071101,,,5,,N,administration & dosage
15898,DescriptorName,D003987,18071101,,,6,Dibenzothiazepines,N,
15899,QualifierName,Q000009,18071101,,,6,,Y,adverse effects
15900,DescriptorName,D006801,18071101,,,7,Humans,N,
15901,DescriptorName,D007958,18071101,,,8,Leukocyte Count,N,
15902,DescriptorName,D007962,18071101,,,9,Leukocytes,N,
15903,QualifierName,Q000187,18071101,,,9,,N,drug effects
15904,DescriptorName,D007970,18071101,,,10,Leukopenia,N,
15905,QualifierName,Q000139,18071101,,,10,,Y,chemically induced
15906,DescriptorName,D008140,18071101,,,11,Lorazepam,N,
15907,QualifierName,Q000008,18071101,,,11,,N,administration & dosage
15908,DescriptorName,D008297,18071101,,,12,Male,N,
15909,DescriptorName,D008875,18071101,,,13,Middle Aged,N,
15910,DescriptorName,D009504,18071101,,,14,Neutrophils,N,
15911,QualifierName,Q000187,18071101,,,14,,N,drug effects
15912,DescriptorName,D011595,18071101,,,15,Psychomotor Agitation,N,
15913,QualifierName,Q000150,18071101,,,15,,N,complications
15914,DescriptorName,D000069348,18071101,,,16,Quetiapine Fumarate,N,
15915,DescriptorName,D018967,18071101,,,17,Risperidone,N,
15916,QualifierName,Q000008,18071101,,,17,,N,administration & dosage
15917,DescriptorName,D013921,18071101,,,18,Thrombocytopenia,N,
15918,QualifierName,Q000139,18071101,,,18,,Y,chemically induced
15919,DescriptorName,D014635,18071101,,,19,Valproic Acid,N,
15920,Chemical,D000666,18076602,Amphotericin B,7XU7A7DROE,,,,
15921,DescriptorName,D000328,18076602,,,1,Adult,N,
15922,DescriptorName,D000666,18076602,,,2,Amphotericin B,N,
15923,QualifierName,Q000009,18076602,,,2,,Y,adverse effects
15924,DescriptorName,D001706,18076602,,,3,Biopsy,N,
15925,DescriptorName,D005260,18076602,,,4,Female,N,
15926,DescriptorName,D006801,18076602,,,5,Humans,N,
15927,DescriptorName,D009181,18076602,,,6,Mycoses,N,
15928,QualifierName,Q000188,18076602,,,6,,N,drug therapy
15929,DescriptorName,D012871,18076602,,,7,Skin Diseases,N,
15930,QualifierName,Q000473,18076602,,,7,,Y,pathology
15931,DescriptorName,D014657,18076602,,,8,Vasculitis,N,
15932,QualifierName,Q000473,18076602,,,8,,Y,pathology
15933,Chemical,D000964,18079582,"Antimetabolites, Antineoplastic",0,,,,
15934,Chemical,D005472,18079582,Fluorouracil,U3P01618RT,,,,
15935,DescriptorName,D000328,18079582,,,1,Adult,N,
15936,DescriptorName,D000964,18079582,,,2,"Antimetabolites, Antineoplastic",N,
15937,QualifierName,Q000009,18079582,,,2,,Y,adverse effects
15938,DescriptorName,D001919,18079582,,,3,Bradycardia,N,
15939,QualifierName,Q000139,18079582,,,3,,Y,chemically induced
15940,DescriptorName,D005260,18079582,,,4,Female,N,
15941,DescriptorName,D005472,18079582,,,5,Fluorouracil,N,
15942,QualifierName,Q000009,18079582,,,5,,Y,adverse effects
15943,DescriptorName,D006801,18079582,,,6,Humans,N,
15944,DescriptorName,D008297,18079582,,,7,Male,N,
15945,DescriptorName,D008875,18079582,,,8,Middle Aged,N,
15946,DescriptorName,D009369,18079582,,,9,Neoplasms,N,
15947,QualifierName,Q000188,18079582,,,9,,Y,drug therapy
15948,Chemical,D007166,18094347,Immunosuppressive Agents,0,,,,
15949,Chemical,D008727,18094347,Methotrexate,YL5FZ2Y5U1,,,,
15950,DescriptorName,D003875,18094347,,,1,Drug Eruptions,N,
15951,QualifierName,Q000209,18094347,,,1,,Y,etiology
15952,DescriptorName,D005260,18094347,,,2,Female,N,
15953,DescriptorName,D006801,18094347,,,3,Humans,N,
15954,DescriptorName,D007166,18094347,,,4,Immunosuppressive Agents,N,
15955,QualifierName,Q000009,18094347,,,4,,Y,adverse effects
15956,DescriptorName,D007273,18094347,,,5,"Injections, Intramuscular",N,
15957,DescriptorName,D008727,18094347,,,6,Methotrexate,N,
15958,QualifierName,Q000009,18094347,,,6,,Y,adverse effects
15959,DescriptorName,D008875,18094347,,,7,Middle Aged,N,
15960,DescriptorName,D011537,18094347,,,8,Pruritus,N,
15961,QualifierName,Q000139,18094347,,,8,,N,chemically induced
15962,DescriptorName,D011565,18094347,,,9,Psoriasis,N,
15963,QualifierName,Q000188,18094347,,,9,,N,drug therapy
15964,DescriptorName,D012867,18094347,,,10,Skin,N,
15965,QualifierName,Q000187,18094347,,,10,,N,drug effects
15966,DescriptorName,D012871,18094347,,,11,Skin Diseases,N,
15967,QualifierName,Q000139,18094347,,,11,,Y,chemically induced
15968,Chemical,D001639,1814986,Bicarbonates,0,,,,
15969,Chemical,D000086,1814986,Acetazolamide,O3FX965V0I,,,,
15970,DescriptorName,D000086,1814986,,,1,Acetazolamide,N,
15971,QualifierName,Q000009,1814986,,,1,,Y,adverse effects
15972,DescriptorName,D000136,1814986,,,2,Acid-Base Equilibrium,N,
15973,QualifierName,Q000187,1814986,,,2,,N,drug effects
15974,DescriptorName,D000138,1814986,,,3,Acidosis,N,
15975,QualifierName,Q000139,1814986,,,3,,Y,chemically induced
15976,DescriptorName,D000368,1814986,,,4,Aged,N,
15977,DescriptorName,D001639,1814986,,,5,Bicarbonates,N,
15978,QualifierName,Q000627,1814986,,,5,,N,therapeutic use
15979,DescriptorName,D001784,1814986,,,6,Blood Gas Analysis,N,
15980,DescriptorName,D006801,1814986,,,7,Humans,N,
15981,DescriptorName,D006863,1814986,,,8,Hydrogen-Ion Concentration,N,
15982,DescriptorName,D008297,1814986,,,9,Male,N,
15983,Chemical,D010975,18160579,Platelet Aggregation Inhibitors,0,,,,
15984,Chemical,D000077144,18160579,Clopidogrel,A74586SNO7,,,,
15985,Chemical,D013988,18160579,Ticlopidine,OM90ZUW7M1,,,,
15986,Chemical,D001241,18160579,Aspirin,R16CO5Y76E,,,,
15987,DescriptorName,D001241,18160579,,,1,Aspirin,N,
15988,QualifierName,Q000008,18160579,,,1,,N,administration & dosage
15989,DescriptorName,D000077144,18160579,,,2,Clopidogrel,N,
15990,DescriptorName,D006470,18160579,,,3,Hemorrhage,N,
15991,QualifierName,Q000139,18160579,,,3,,Y,chemically induced
15992,DescriptorName,D006801,18160579,,,4,Humans,N,
15993,DescriptorName,D008297,18160579,,,5,Male,N,
15994,DescriptorName,D008875,18160579,,,6,Middle Aged,N,
15995,DescriptorName,D010490,18160579,,,7,Pericardial Effusion,N,
15996,QualifierName,Q000139,18160579,,,7,,Y,chemically induced
15997,DescriptorName,D010975,18160579,,,8,Platelet Aggregation Inhibitors,N,
15998,QualifierName,Q000008,18160579,,,8,,N,administration & dosage
15999,DescriptorName,D013920,18160579,,,9,"Thrombocythemia, Essential",N,
16000,QualifierName,Q000188,18160579,,,9,,Y,drug therapy
16001,DescriptorName,D013927,18160579,,,10,Thrombosis,N,
16002,QualifierName,Q000517,18160579,,,10,,N,prevention & control
16003,DescriptorName,D013988,18160579,,,11,Ticlopidine,N,
16004,QualifierName,Q000008,18160579,,,11,,N,administration & dosage
16005,Chemical,D019380,18176653,Anti-HIV Agents,0,,,,
16006,Chemical,D019829,18176653,Nevirapine,99DK7FVK1H,,,,
16007,DescriptorName,D000328,18176653,,,1,Adult,N,
16008,DescriptorName,D019380,18176653,,,2,Anti-HIV Agents,N,
16009,QualifierName,Q000009,18176653,,,2,,Y,adverse effects
16010,DescriptorName,D023241,18176653,,,3,"Antiretroviral Therapy, Highly Active",N,
16011,QualifierName,Q000009,18176653,,,3,,N,adverse effects
16012,DescriptorName,D002054,18176653,,,4,Burning Mouth Syndrome,N,
16013,QualifierName,Q000139,18176653,,,4,,N,chemically induced
16014,DescriptorName,D018791,18176653,,,5,CD4 Lymphocyte Count,N,
16015,DescriptorName,D005076,18176653,,,6,Exanthema,N,
16016,QualifierName,Q000097,18176653,,,6,,N,blood
16017,DescriptorName,D015658,18176653,,,7,HIV Infections,N,
16018,QualifierName,Q000097,18176653,,,7,,N,blood
16019,DescriptorName,D006801,18176653,,,8,Humans,N,
16020,DescriptorName,D008297,18176653,,,9,Male,N,
16021,DescriptorName,D009059,18176653,,,10,Mouth Diseases,N,
16022,QualifierName,Q000097,18176653,,,10,,N,blood
16023,DescriptorName,D019829,18176653,,,11,Nevirapine,N,
16024,QualifierName,Q000009,18176653,,,11,,Y,adverse effects
16025,DescriptorName,D013651,18176653,,,12,Taste Disorders,N,
16026,QualifierName,Q000139,18176653,,,12,,N,chemically induced
16027,DescriptorName,D019562,18176653,,,13,Viral Load,N,
16028,DescriptorName,D014987,18176653,,,14,Xerostomia,N,
16029,QualifierName,Q000139,18176653,,,14,,N,chemically induced
16030,Chemical,D007166,18191947,Immunosuppressive Agents,0,,,,
16031,Chemical,D008727,18191947,Methotrexate,YL5FZ2Y5U1,,,,
16032,DescriptorName,D000328,18191947,,,1,Adult,N,
16033,DescriptorName,D001927,18191947,,,2,Brain Diseases,N,
16034,QualifierName,Q000150,18191947,,,2,,N,complications
16035,DescriptorName,D038524,18191947,,,3,Diffusion Magnetic Resonance Imaging,Y,
16036,DescriptorName,D006801,18191947,,,4,Humans,N,
16037,DescriptorName,D007166,18191947,,,5,Immunosuppressive Agents,N,
16038,QualifierName,Q000009,18191947,,,5,,Y,adverse effects
16039,DescriptorName,D008297,18191947,,,6,Male,N,
16040,DescriptorName,D008727,18191947,,,7,Methotrexate,N,
16041,QualifierName,Q000009,18191947,,,7,,Y,adverse effects
16042,DescriptorName,D020258,18191947,,,8,Neurotoxicity Syndromes,N,
16043,QualifierName,Q000175,18191947,,,8,,Y,diagnosis
16044,DescriptorName,D054198,18191947,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
16045,QualifierName,Q000150,18191947,,,9,,N,complications
16046,Chemical,D007074,18203308,Immunoglobulin G,0,,,,
16047,Chemical,D007155,18203308,Immunologic Factors,0,,,,
16048,Chemical,D018124,18203308,"Receptors, Tumor Necrosis Factor",0,,,,
16049,Chemical,D014409,18203308,Tumor Necrosis Factor-alpha,0,,,,
16050,Chemical,D000068800,18203308,Etanercept,OP401G7OJC,,,,
16051,DescriptorName,D000328,18203308,,,1,Adult,N,
16052,DescriptorName,D002986,18203308,,,2,Clinical Trials as Topic,N,
16053,DescriptorName,D003424,18203308,,,3,Crohn Disease,N,
16054,QualifierName,Q000139,18203308,,,3,,N,chemically induced
16055,DescriptorName,D000068800,18203308,,,4,Etanercept,N,
16056,DescriptorName,D005260,18203308,,,5,Female,N,
16057,DescriptorName,D006801,18203308,,,6,Humans,N,
16058,DescriptorName,D007074,18203308,,,7,Immunoglobulin G,N,
16059,QualifierName,Q000009,18203308,,,7,,Y,adverse effects
16060,DescriptorName,D007155,18203308,,,8,Immunologic Factors,N,
16061,QualifierName,Q000009,18203308,,,8,,Y,adverse effects
16062,DescriptorName,D008297,18203308,,,9,Male,N,
16063,DescriptorName,D008875,18203308,,,10,Middle Aged,N,
16064,DescriptorName,D018124,18203308,,,11,"Receptors, Tumor Necrosis Factor",N,
16065,DescriptorName,D013167,18203308,,,12,"Spondylitis, Ankylosing",N,
16066,QualifierName,Q000188,18203308,,,12,,Y,drug therapy
16067,DescriptorName,D014409,18203308,,,13,Tumor Necrosis Factor-alpha,N,
16068,QualifierName,Q000037,18203308,,,13,,N,antagonists & inhibitors
16069,Chemical,D010975,18252776,Platelet Aggregation Inhibitors,0,,,,
16070,Chemical,D000077144,18252776,Clopidogrel,A74586SNO7,,,,
16071,Chemical,D013988,18252776,Ticlopidine,OM90ZUW7M1,,,,
16072,Chemical,D001241,18252776,Aspirin,R16CO5Y76E,,,,
16073,DescriptorName,D000368,18252776,,,1,Aged,N,
16074,DescriptorName,D001241,18252776,,,2,Aspirin,N,
16075,QualifierName,Q000008,18252776,,,2,,N,administration & dosage
16076,DescriptorName,D001803,18252776,,,3,Blood Transfusion,N,
16077,DescriptorName,D000077144,18252776,,,4,Clopidogrel,N,
16078,DescriptorName,D003327,18252776,,,5,Coronary Disease,N,
16079,QualifierName,Q000150,18252776,,,5,,N,complications
16080,DescriptorName,D004359,18252776,,,6,"Drug Therapy, Combination",N,
16081,DescriptorName,D016099,18252776,,,7,"Endoscopy, Gastrointestinal",N,
16082,QualifierName,Q000379,18252776,,,7,,N,methods
16083,DescriptorName,D005260,18252776,,,8,Female,N,
16084,DescriptorName,D006471,18252776,,,9,Gastrointestinal Hemorrhage,N,
16085,QualifierName,Q000139,18252776,,,9,,Y,chemically induced
16086,DescriptorName,D006801,18252776,,,10,Humans,N,
16087,DescriptorName,D010975,18252776,,,11,Platelet Aggregation Inhibitors,N,
16088,QualifierName,Q000008,18252776,,,11,,N,administration & dosage
16089,DescriptorName,D010976,18252776,,,12,Platelet Count,N,
16090,DescriptorName,D016032,18252776,,,13,Randomized Controlled Trials as Topic,N,
16091,DescriptorName,D013988,18252776,,,14,Ticlopidine,N,
16092,QualifierName,Q000008,18252776,,,14,,N,administration & dosage
16093,DescriptorName,D016896,18252776,,,15,Treatment Outcome,N,
16094,Chemical,D000970,18258513,Antineoplastic Agents,0,,,,
16095,Chemical,D004317,18258513,Doxorubicin,80168379AG,,,,
16096,DescriptorName,D000970,18258513,,,1,Antineoplastic Agents,N,
16097,QualifierName,Q000008,18258513,,,1,,Y,administration & dosage
16098,DescriptorName,D001943,18258513,,,2,Breast Neoplasms,N,
16099,QualifierName,Q000188,18258513,,,2,,Y,drug therapy
16100,DescriptorName,D002405,18258513,,,3,"Catheterization, Central Venous",N,
16101,QualifierName,Q000009,18258513,,,3,,Y,adverse effects
16102,DescriptorName,D002408,18258513,,,4,"Catheters, Indwelling",N,
16103,QualifierName,Q000009,18258513,,,4,,N,adverse effects
16104,DescriptorName,D004317,18258513,,,5,Doxorubicin,N,
16105,QualifierName,Q000008,18258513,,,5,,Y,administration & dosage
16106,DescriptorName,D005119,18258513,,,6,Extravasation of Diagnostic and Therapeutic Materials,N,
16107,QualifierName,Q000150,18258513,,,6,,Y,complications
16108,DescriptorName,D005260,18258513,,,7,Female,N,
16109,DescriptorName,D006801,18258513,,,8,Humans,N,
16110,DescriptorName,D007262,18258513,,,9,"Infusions, Intravenous",N,
16111,DescriptorName,D008482,18258513,,,10,Mediastinum,N,
16112,QualifierName,Q000473,18258513,,,10,,Y,pathology
16113,DescriptorName,D008875,18258513,,,11,Middle Aged,N,
16114,DescriptorName,D010996,18258513,,,12,Pleural Effusion,N,
16115,QualifierName,Q000209,18258513,,,12,,N,etiology
16116,Chemical,D000970,1827039,Antineoplastic Agents,0,,,,
16117,Chemical,D017373,1827039,Cyproterone Acetate,4KM2BN5JHF,,,,
16118,Chemical,D003534,1827039,Cyproterone,E61Q31EK2F,,,,
16119,DescriptorName,D000368,1827039,,,1,Aged,N,
16120,DescriptorName,D000369,1827039,,,2,"Aged, 80 and over",N,
16121,DescriptorName,D000970,1827039,,,3,Antineoplastic Agents,N,
16122,QualifierName,Q000009,1827039,,,3,,Y,adverse effects
16123,DescriptorName,D056486,1827039,,,4,Chemical and Drug Induced Liver Injury,N,
16124,QualifierName,Q000209,1827039,,,4,,Y,etiology
16125,DescriptorName,D003534,1827039,,,5,Cyproterone,N,
16126,QualifierName,Q000009,1827039,,,5,,N,adverse effects
16127,DescriptorName,D017373,1827039,,,6,Cyproterone Acetate,N,
16128,DescriptorName,D006801,1827039,,,7,Humans,N,
16129,DescriptorName,D008297,1827039,,,8,Male,N,
16130,DescriptorName,D011471,1827039,,,9,Prostatic Neoplasms,N,
16131,QualifierName,Q000188,1827039,,,9,,N,drug therapy
16132,Chemical,D000998,18277922,Antiviral Agents,0,,,,
16133,Chemical,D004279,18277922,"DNA, Viral",0,,,,
16134,Chemical,D014667,18277922,Vasopressins,11000-17-2,,,,
16135,Chemical,D000212,18277922,Acyclovir,X4HES1O11F,,,,
16136,DescriptorName,D015746,18277922,,,1,Abdominal Pain,N,
16137,QualifierName,Q000209,18277922,,,1,,N,etiology
16138,DescriptorName,D000212,18277922,,,2,Acyclovir,N,
16139,QualifierName,Q000627,18277922,,,2,,N,therapeutic use
16140,DescriptorName,D000328,18277922,,,3,Adult,N,
16141,DescriptorName,D000998,18277922,,,4,Antiviral Agents,N,
16142,QualifierName,Q000627,18277922,,,4,,N,therapeutic use
16143,DescriptorName,D004279,18277922,,,5,"DNA, Viral",N,
16144,QualifierName,Q000097,18277922,,,5,,N,blood
16145,DescriptorName,D005260,18277922,,,6,Female,N,
16146,DescriptorName,D018380,18277922,,,7,Hematopoietic Stem Cell Transplantation,N,
16147,QualifierName,Q000009,18277922,,,7,,Y,adverse effects
16148,DescriptorName,D006562,18277922,,,8,Herpes Zoster,N,
16149,QualifierName,Q000175,18277922,,,8,,Y,diagnosis
16150,DescriptorName,D014645,18277922,,,9,"Herpesvirus 3, Human",N,
16151,QualifierName,Q000302,18277922,,,9,,Y,isolation & purification
16152,DescriptorName,D006801,18277922,,,10,Humans,N,
16153,DescriptorName,D010195,18277922,,,11,Pancreatitis,N,
16154,QualifierName,Q000209,18277922,,,11,,N,etiology
16155,DescriptorName,D011006,18277922,,,12,Pneumatosis Cystoides Intestinalis,N,
16156,QualifierName,Q000209,18277922,,,12,,N,etiology
16157,DescriptorName,D016133,18277922,,,13,Polymerase Chain Reaction,N,
16158,QualifierName,Q000379,18277922,,,13,,Y,methods
16159,DescriptorName,D014667,18277922,,,14,Vasopressins,N,
16160,QualifierName,Q000097,18277922,,,14,,N,blood
16161,Chemical,D018906,18294121,"Antineoplastic Agents, Alkylating",0,,,,
16162,Chemical,D003606,18294121,Dacarbazine,7GR28W0FJI,,,,
16163,Chemical,D000077204,18294121,Temozolomide,YF1K15M17Y,,,,
16164,DescriptorName,D000328,18294121,,,1,Adult,N,
16165,DescriptorName,D018906,18294121,,,2,"Antineoplastic Agents, Alkylating",N,
16166,QualifierName,Q000009,18294121,,,2,,Y,adverse effects
16167,DescriptorName,D003606,18294121,,,3,Dacarbazine,N,
16168,QualifierName,Q000009,18294121,,,3,,N,adverse effects
16169,DescriptorName,D003875,18294121,,,4,Drug Eruptions,N,
16170,QualifierName,Q000209,18294121,,,4,,Y,etiology
16171,DescriptorName,D005260,18294121,,,5,Female,N,
16172,DescriptorName,D006801,18294121,,,6,Humans,N,
16173,DescriptorName,D008545,18294121,,,7,Melanoma,N,
16174,QualifierName,Q000188,18294121,,,7,,Y,drug therapy
16175,DescriptorName,D012878,18294121,,,8,Skin Neoplasms,N,
16176,QualifierName,Q000188,18294121,,,8,,Y,drug therapy
16177,DescriptorName,D000077204,18294121,,,9,Temozolomide,N,
16178,Chemical,D014031,1829999,Tobramycin,VZ8RRZ51VK,,,,
16179,DescriptorName,D003875,1829999,,,1,Drug Eruptions,N,
16180,QualifierName,Q000209,1829999,,,1,,Y,etiology
16181,DescriptorName,D005260,1829999,,,2,Female,N,
16182,DescriptorName,D006801,1829999,,,3,Humans,N,
16183,DescriptorName,D007274,1829999,,,4,"Injections, Intraperitoneal",N,
16184,DescriptorName,D007275,1829999,,,5,"Injections, Intravenous",N,
16185,DescriptorName,D008875,1829999,,,6,Middle Aged,N,
16186,DescriptorName,D010531,1829999,,,7,"Peritoneal Dialysis, Continuous Ambulatory",N,
16187,QualifierName,Q000009,1829999,,,7,,N,adverse effects
16188,DescriptorName,D010538,1829999,,,8,Peritonitis,N,
16189,QualifierName,Q000188,1829999,,,8,,N,drug therapy
16190,DescriptorName,D013203,1829999,,,9,Staphylococcal Infections,N,
16191,QualifierName,Q000188,1829999,,,9,,N,drug therapy
16192,DescriptorName,D014031,1829999,,,10,Tobramycin,N,
16193,QualifierName,Q000008,1829999,,,10,,N,administration & dosage
16194,Chemical,D000911,18306483,"Antibodies, Monoclonal",0,,,,
16195,Chemical,D058846,18306483,"Antibodies, Monoclonal, Murine-Derived",0,,,,
16196,Chemical,D000069283,18306483,Rituximab,4F4X42SYQ6,,,,
16197,Chemical,D014750,18306483,Vincristine,5J49Q6B70F,,,,
16198,Chemical,D004317,18306483,Doxorubicin,80168379AG,,,,
16199,Chemical,D003520,18306483,Cyclophosphamide,8N3DW7272P,,,,
16200,Chemical,D011241,18306483,Prednisone,VB0R961HZT,,,,
16201,DescriptorName,D000368,18306483,,,1,Aged,N,
16202,DescriptorName,D000911,18306483,,,2,"Antibodies, Monoclonal",N,
16203,QualifierName,Q000009,18306483,,,2,,Y,adverse effects
16204,DescriptorName,D058846,18306483,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
16205,DescriptorName,D000971,18306483,,,4,Antineoplastic Combined Chemotherapy Protocols,N,
16206,QualifierName,Q000009,18306483,,,4,,Y,adverse effects
16207,DescriptorName,D001706,18306483,,,5,Biopsy,N,
16208,DescriptorName,D003520,18306483,,,6,Cyclophosphamide,N,
16209,QualifierName,Q000009,18306483,,,6,,N,adverse effects
16210,DescriptorName,D004317,18306483,,,7,Doxorubicin,N,
16211,QualifierName,Q000009,18306483,,,7,,N,adverse effects
16212,DescriptorName,D006801,18306483,,,8,Humans,N,
16213,DescriptorName,D017563,18306483,,,9,"Lung Diseases, Interstitial",N,
16214,QualifierName,Q000139,18306483,,,9,,Y,chemically induced
16215,DescriptorName,D018442,18306483,,,10,"Lymphoma, B-Cell, Marginal Zone",N,
16216,QualifierName,Q000188,18306483,,,10,,Y,drug therapy
16217,DescriptorName,D008297,18306483,,,11,Male,N,
16218,DescriptorName,D011241,18306483,,,12,Prednisone,N,
16219,QualifierName,Q000009,18306483,,,12,,N,adverse effects
16220,DescriptorName,D000069283,18306483,,,13,Rituximab,N,
16221,DescriptorName,D014057,18306483,,,14,"Tomography, X-Ray Computed",N,
16222,DescriptorName,D014750,18306483,,,15,Vincristine,N,
16223,QualifierName,Q000009,18306483,,,15,,N,adverse effects
16224,Chemical,D000927,18315788,Anticonvulsants,0,,,,
16225,Chemical,D010672,18315788,Phenytoin,6158TKW0C5,,,,
16226,DescriptorName,D000368,18315788,,,1,Aged,N,
16227,DescriptorName,D000927,18315788,,,2,Anticonvulsants,N,
16228,QualifierName,Q000009,18315788,,,2,,Y,adverse effects
16229,DescriptorName,D002526,18315788,,,3,Cerebellar Diseases,N,
16230,QualifierName,Q000139,18315788,,,3,,Y,chemically induced
16231,DescriptorName,D004827,18315788,,,4,Epilepsy,N,
16232,QualifierName,Q000188,18315788,,,4,,N,drug therapy
16233,DescriptorName,D006801,18315788,,,5,Humans,N,
16234,DescriptorName,D008297,18315788,,,6,Male,N,
16235,DescriptorName,D008875,18315788,,,7,Middle Aged,N,
16236,DescriptorName,D010672,18315788,,,8,Phenytoin,N,
16237,QualifierName,Q000009,18315788,,,8,,Y,adverse effects
16238,Chemical,D000911,18343993,"Antibodies, Monoclonal",0,,,,
16239,Chemical,D061067,18343993,"Antibodies, Monoclonal, Humanized",0,,,,
16240,Chemical,D000970,18343993,Antineoplastic Agents,0,,,,
16241,Chemical,D000068878,18343993,Trastuzumab,P188ANX8CK,,,,
16242,DescriptorName,D000911,18343993,,,1,"Antibodies, Monoclonal",N,
16243,QualifierName,Q000009,18343993,,,1,,Y,adverse effects
16244,DescriptorName,D061067,18343993,,,2,"Antibodies, Monoclonal, Humanized",N,
16245,DescriptorName,D000970,18343993,,,3,Antineoplastic Agents,N,
16246,QualifierName,Q000009,18343993,,,3,,Y,adverse effects
16247,DescriptorName,D001943,18343993,,,4,Breast Neoplasms,N,
16248,QualifierName,Q000188,18343993,,,4,,Y,drug therapy
16249,DescriptorName,D005260,18343993,,,5,Female,N,
16250,DescriptorName,D006801,18343993,,,6,Humans,N,
16251,DescriptorName,D017563,18343993,,,7,"Lung Diseases, Interstitial",N,
16252,QualifierName,Q000139,18343993,,,7,,Y,chemically induced
16253,DescriptorName,D008875,18343993,,,8,Middle Aged,N,
16254,DescriptorName,D000068878,18343993,,,9,Trastuzumab,N,
16255,Chemical,D001572,1834424,Benzofurans,0,,,,
16256,Chemical,C043708,1834424,7-chloro-4-nitrobenzofuran,115491-60-6,,,,
16257,Chemical,D011223,1834424,Praziquantel,6490C9U457,,,,
16258,DescriptorName,D000208,1834424,,,1,Acute Disease,N,
16259,DescriptorName,D000328,1834424,,,2,Adult,N,
16260,DescriptorName,D001572,1834424,,,3,Benzofurans,N,
16261,QualifierName,Q000009,1834424,,,3,,Y,adverse effects
16262,DescriptorName,D003877,1834424,,,4,"Dermatitis, Contact",N,
16263,QualifierName,Q000188,1834424,,,4,,N,drug therapy
16264,DescriptorName,D009783,1834424,,,5,"Dermatitis, Occupational",N,
16265,QualifierName,Q000139,1834424,,,5,,Y,chemically induced
16266,DescriptorName,D005260,1834424,,,6,Female,N,
16267,DescriptorName,D006801,1834424,,,7,Humans,N,
16268,DescriptorName,D011223,1834424,,,8,Praziquantel,N,
16269,QualifierName,Q000009,1834424,,,8,,N,adverse effects
16270,Chemical,D014150,18344734,Antipsychotic Agents,0,,,,
16271,Chemical,D010879,18344734,Piperazines,0,,,,
16272,Chemical,D015363,18344734,Quinolones,0,,,,
16273,Chemical,D001569,18344734,Benzodiazepines,12794-10-4,,,,
16274,Chemical,D000068180,18344734,Aripiprazole,82VFR53I78,,,,
16275,Chemical,D000077152,18344734,Olanzapine,N7U69T4SZR,,,,
16276,DescriptorName,D014150,18344734,,,1,Antipsychotic Agents,N,
16277,QualifierName,Q000009,18344734,,,1,,N,adverse effects
16278,DescriptorName,D000068180,18344734,,,2,Aripiprazole,N,
16279,DescriptorName,D001569,18344734,,,3,Benzodiazepines,N,
16280,QualifierName,Q000009,18344734,,,3,,Y,adverse effects
16281,DescriptorName,D001714,18344734,,,4,Bipolar Disorder,N,
16282,QualifierName,Q000188,18344734,,,4,,N,drug therapy
16283,DescriptorName,D004890,18344734,,,5,Erythema,N,
16284,QualifierName,Q000139,18344734,,,5,,N,chemically induced
16285,DescriptorName,D005260,18344734,,,6,Female,N,
16286,DescriptorName,D006801,18344734,,,7,Humans,N,
16287,DescriptorName,D008875,18344734,,,8,Middle Aged,N,
16288,DescriptorName,D000077152,18344734,,,9,Olanzapine,N,
16289,DescriptorName,D054039,18344734,,,10,Onycholysis,N,
16290,QualifierName,Q000139,18344734,,,10,,Y,chemically induced
16291,DescriptorName,D010787,18344734,,,11,Photosensitivity Disorders,N,
16292,QualifierName,Q000139,18344734,,,11,,Y,chemically induced
16293,DescriptorName,D010879,18344734,,,12,Piperazines,N,
16294,QualifierName,Q000009,18344734,,,12,,Y,adverse effects
16295,DescriptorName,D015363,18344734,,,13,Quinolones,N,
16296,QualifierName,Q000009,18344734,,,13,,Y,adverse effects
16297,Chemical,D000894,18347524,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
16298,Chemical,D007555,18347524,Isoxazoles,0,,,,
16299,Chemical,D000077339,18347524,Leflunomide,G162GK9U4W,,,,
16300,Chemical,D008775,18347524,Methylprednisolone,X4W7ZR7023,,,,
16301,DescriptorName,D000328,18347524,,,1,Adult,N,
16302,DescriptorName,D000894,18347524,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
16303,QualifierName,Q000009,18347524,,,2,,Y,adverse effects
16304,DescriptorName,D001172,18347524,,,3,"Arthritis, Rheumatoid",N,
16305,QualifierName,Q000188,18347524,,,3,,Y,drug therapy
16306,DescriptorName,D001706,18347524,,,4,Biopsy,N,
16307,DescriptorName,D003937,18347524,,,5,"Diagnosis, Differential",N,
16308,DescriptorName,D004417,18347524,,,6,Dyspnea,N,
16309,QualifierName,Q000139,18347524,,,6,,N,chemically induced
16310,DescriptorName,D006469,18347524,,,7,Hemoptysis,N,
16311,QualifierName,Q000139,18347524,,,7,,N,chemically induced
16312,DescriptorName,D006470,18347524,,,8,Hemorrhage,N,
16313,QualifierName,Q000139,18347524,,,8,,Y,chemically induced
16314,DescriptorName,D006801,18347524,,,9,Humans,N,
16315,DescriptorName,D007555,18347524,,,10,Isoxazoles,N,
16316,QualifierName,Q000009,18347524,,,10,,Y,adverse effects
16317,DescriptorName,D007668,18347524,,,11,Kidney,N,
16318,QualifierName,Q000187,18347524,,,11,,N,drug effects
16319,DescriptorName,D000077339,18347524,,,12,Leflunomide,N,
16320,DescriptorName,D008168,18347524,,,13,Lung,N,
16321,QualifierName,Q000000981,18347524,,,13,,N,diagnostic imaging
16322,DescriptorName,D008171,18347524,,,14,Lung Diseases,N,
16323,QualifierName,Q000139,18347524,,,14,,Y,chemically induced
16324,DescriptorName,D008297,18347524,,,15,Male,N,
16325,DescriptorName,D008775,18347524,,,16,Methylprednisolone,N,
16326,QualifierName,Q000627,18347524,,,16,,N,therapeutic use
16327,DescriptorName,D018908,18347524,,,17,Muscle Weakness,N,
16328,QualifierName,Q000139,18347524,,,17,,N,chemically induced
16329,DescriptorName,D010996,18347524,,,18,Pleural Effusion,N,
16330,QualifierName,Q000139,18347524,,,18,,N,chemically induced
16331,DescriptorName,D011650,18347524,,,19,Pulmonary Alveoli,N,
16332,QualifierName,Q000187,18347524,,,19,,Y,drug effects
16333,DescriptorName,D014057,18347524,,,20,"Tomography, X-Ray Computed",N,
16334,Chemical,D000927,18354950,Anticonvulsants,0,,,,
16335,Chemical,D002220,18354950,Carbamazepine,33CM23913M,,,,
16336,DescriptorName,D000328,18354950,,,1,Adult,N,
16337,DescriptorName,D000927,18354950,,,2,Anticonvulsants,N,
16338,QualifierName,Q000008,18354950,,,2,,N,administration & dosage
16339,DescriptorName,D002220,18354950,,,3,Carbamazepine,N,
16340,QualifierName,Q000008,18354950,,,3,,N,administration & dosage
16341,DescriptorName,D005260,18354950,,,4,Female,N,
16342,DescriptorName,D006801,18354950,,,5,Humans,N,
16343,DescriptorName,D007010,18354950,,,6,Hyponatremia,N,
16344,QualifierName,Q000097,18354950,,,6,,N,blood
16345,DescriptorName,D012307,18354950,,,7,Risk Factors,N,
16346,DescriptorName,D012640,18354950,,,8,Seizures,N,
16347,QualifierName,Q000188,18354950,,,8,,N,drug therapy
16348,Chemical,D004655,18359591,Emulsions,0,,,,
16349,Chemical,D007166,18359591,Immunosuppressive Agents,0,,,,
16350,Chemical,D016572,18359591,Cyclosporine,83HN0GTJ6D,,,,
16351,DescriptorName,D000284,18359591,,,1,"Administration, Oral",N,
16352,DescriptorName,D000328,18359591,,,2,Adult,N,
16353,DescriptorName,D003093,18359591,,,3,"Colitis, Ulcerative",N,
16354,QualifierName,Q000188,18359591,,,3,,Y,drug therapy
16355,DescriptorName,D016572,18359591,,,4,Cyclosporine,N,
16356,QualifierName,Q000008,18359591,,,4,,N,administration & dosage
16357,DescriptorName,D003586,18359591,,,5,Cytomegalovirus Infections,N,
16358,DescriptorName,D004655,18359591,,,6,Emulsions,N,
16359,DescriptorName,D005260,18359591,,,7,Female,N,
16360,DescriptorName,D006801,18359591,,,8,Humans,N,
16361,DescriptorName,D007166,18359591,,,9,Immunosuppressive Agents,N,
16362,QualifierName,Q000008,18359591,,,9,,N,administration & dosage
16363,DescriptorName,D012720,18359591,,,10,Severity of Illness Index,N,
16364,Chemical,D000970,18362995,Antineoplastic Agents,0,,,,
16365,Chemical,D001549,18362995,Benzamides,0,,,,
16366,Chemical,D010879,18362995,Piperazines,0,,,,
16367,Chemical,D011743,18362995,Pyrimidines,0,,,,
16368,Chemical,D000068877,18362995,Imatinib Mesylate,8A1O1M485B,,,,
16369,DescriptorName,D000970,18362995,,,1,Antineoplastic Agents,N,
16370,QualifierName,Q000009,18362995,,,1,,Y,adverse effects
16371,DescriptorName,D001549,18362995,,,2,Benzamides,N,
16372,DescriptorName,D017809,18362995,,,3,Fatal Outcome,N,
16373,DescriptorName,D019694,18362995,,,4,"Hepatitis B, Chronic",N,
16374,QualifierName,Q000150,18362995,,,4,,Y,complications
16375,DescriptorName,D006801,18362995,,,5,Humans,N,
16376,DescriptorName,D000068877,18362995,,,6,Imatinib Mesylate,N,
16377,DescriptorName,D015464,18362995,,,7,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
16378,QualifierName,Q000150,18362995,,,7,,N,complications
16379,DescriptorName,D017114,18362995,,,8,"Liver Failure, Acute",N,
16380,QualifierName,Q000139,18362995,,,8,,Y,chemically induced
16381,DescriptorName,D008297,18362995,,,9,Male,N,
16382,DescriptorName,D008875,18362995,,,10,Middle Aged,N,
16383,DescriptorName,D010879,18362995,,,11,Piperazines,N,
16384,QualifierName,Q000009,18362995,,,11,,Y,adverse effects
16385,DescriptorName,D011743,18362995,,,12,Pyrimidines,N,
16386,QualifierName,Q000009,18362995,,,12,,Y,adverse effects
16387,Chemical,D014150,18364401,Antipsychotic Agents,0,,,,
16388,Chemical,D001786,18364401,Blood Glucose,0,,,,
16389,Chemical,D001569,18364401,Benzodiazepines,12794-10-4,,,,
16390,Chemical,D000077152,18364401,Olanzapine,N7U69T4SZR,,,,
16391,DescriptorName,D000369,18364401,,,1,"Aged, 80 and over",N,
16392,DescriptorName,D014150,18364401,,,2,Antipsychotic Agents,N,
16393,QualifierName,Q000008,18364401,,,2,,N,administration & dosage
16394,DescriptorName,D001569,18364401,,,3,Benzodiazepines,N,
16395,QualifierName,Q000008,18364401,,,3,,N,administration & dosage
16396,DescriptorName,D001786,18364401,,,4,Blood Glucose,N,
16397,QualifierName,Q000378,18364401,,,4,,N,metabolism
16398,DescriptorName,D006801,18364401,,,5,Humans,N,
16399,DescriptorName,D006943,18364401,,,6,Hyperglycemia,N,
16400,QualifierName,Q000139,18364401,,,6,,Y,chemically induced
16401,DescriptorName,D008297,18364401,,,7,Male,N,
16402,DescriptorName,D000077152,18364401,,,8,Olanzapine,N,
16403,DescriptorName,D011618,18364401,,,9,Psychotic Disorders,N,
16404,QualifierName,Q000188,18364401,,,9,,N,drug therapy
16405,Chemical,D000998,18371508,Antiviral Agents,0,,,,
16406,Chemical,D000077190,18371508,Interferon alpha-2,0,,,,
16407,Chemical,D016898,18371508,Interferon-alpha,0,,,,
16408,Chemical,D011994,18371508,Recombinant Proteins,0,,,,
16409,Chemical,D011092,18371508,Polyethylene Glycols,3WJQ0SDW1A,,,,
16410,Chemical,D012254,18371508,Ribavirin,49717AWG6K,,,,
16411,Chemical,C100416,18371508,peginterferon alfa-2a,Q46947FE7K,,,,
16412,DescriptorName,D000998,18371508,,,1,Antiviral Agents,N,
16413,QualifierName,Q000008,18371508,,,1,,N,administration & dosage
16414,DescriptorName,D017809,18371508,,,2,Fatal Outcome,N,
16415,DescriptorName,D005260,18371508,,,3,Female,N,
16416,DescriptorName,D006526,18371508,,,4,Hepatitis C,N,
16417,QualifierName,Q000188,18371508,,,4,,Y,drug therapy
16418,DescriptorName,D006801,18371508,,,5,Humans,N,
16419,DescriptorName,D000077190,18371508,,,6,Interferon alpha-2,N,
16420,DescriptorName,D016898,18371508,,,7,Interferon-alpha,N,
16421,QualifierName,Q000008,18371508,,,7,,N,administration & dosage
16422,DescriptorName,D008875,18371508,,,8,Middle Aged,N,
16423,DescriptorName,D009102,18371508,,,9,Multiple Organ Failure,N,
16424,QualifierName,Q000209,18371508,,,9,,N,etiology
16425,DescriptorName,D011092,18371508,,,10,Polyethylene Glycols,N,
16426,QualifierName,Q000008,18371508,,,10,,N,administration & dosage
16427,DescriptorName,D011994,18371508,,,11,Recombinant Proteins,N,
16428,DescriptorName,D012128,18371508,,,12,"Respiratory Distress Syndrome, Adult",N,
16429,QualifierName,Q000139,18371508,,,12,,Y,chemically induced
16430,DescriptorName,D012254,18371508,,,13,Ribavirin,N,
16431,QualifierName,Q000008,18371508,,,13,,N,administration & dosage
16432,DescriptorName,D018805,18371508,,,14,Sepsis,N,
16433,QualifierName,Q000209,18371508,,,14,,N,etiology
16434,Chemical,D005300,18379937,"Fertility Agents, Female",0,,,,
16435,Chemical,D002996,18379937,Clomiphene,1HRS458QU2,,,,
16436,DescriptorName,D000328,18379937,,,1,Adult,N,
16437,DescriptorName,D000858,18379937,,,2,Anovulation,N,
16438,QualifierName,Q000188,18379937,,,2,,N,drug therapy
16439,DescriptorName,D002996,18379937,,,3,Clomiphene,N,
16440,QualifierName,Q000009,18379937,,,3,,Y,adverse effects
16441,DescriptorName,D005260,18379937,,,4,Female,N,
16442,DescriptorName,D005300,18379937,,,5,"Fertility Agents, Female",N,
16443,QualifierName,Q000009,18379937,,,5,,Y,adverse effects
16444,DescriptorName,D006801,18379937,,,6,Humans,N,
16445,DescriptorName,D010062,18379937,,,7,Ovulation Induction,N,
16446,QualifierName,Q000379,18379937,,,7,,N,methods
16447,DescriptorName,D011085,18379937,,,8,Polycystic Ovary Syndrome,N,
16448,QualifierName,Q000150,18379937,,,8,,N,complications
16449,DescriptorName,D012189,18379937,,,9,Retrospective Studies,N,
16450,DescriptorName,D014606,18379937,,,10,"Uveitis, Anterior",N,
16451,QualifierName,Q000139,18379937,,,10,,Y,chemically induced
16452,Chemical,D018759,18408649,Adrenergic Uptake Inhibitors,0,,,,
16453,Chemical,D000927,18408649,Anticonvulsants,0,,,,
16454,Chemical,D011437,18408649,Propylamines,0,,,,
16455,Chemical,D013565,18408649,Sympatholytics,0,,,,
16456,Chemical,D000069445,18408649,Atomoxetine Hydrochloride,57WVB6I2W0,,,,
16457,Chemical,D002998,18408649,Clonazepam,5PE9FDE8GB,,,,
16458,Chemical,D003000,18408649,Clonidine,MN3L5RMN02,,,,
16459,DescriptorName,D000293,18408649,,,1,Adolescent,N,
16460,DescriptorName,D018759,18408649,,,2,Adrenergic Uptake Inhibitors,N,
16461,QualifierName,Q000009,18408649,,,2,,Y,adverse effects
16462,DescriptorName,D000927,18408649,,,3,Anticonvulsants,N,
16463,QualifierName,Q000627,18408649,,,3,,N,therapeutic use
16464,DescriptorName,D000069445,18408649,,,4,Atomoxetine Hydrochloride,N,
16465,DescriptorName,D001289,18408649,,,5,Attention Deficit Disorder with Hyperactivity,N,
16466,QualifierName,Q000188,18408649,,,5,,Y,drug therapy
16467,DescriptorName,D002998,18408649,,,6,Clonazepam,N,
16468,QualifierName,Q000627,18408649,,,6,,N,therapeutic use
16469,DescriptorName,D003000,18408649,,,7,Clonidine,N,
16470,QualifierName,Q000627,18408649,,,7,,N,therapeutic use
16471,DescriptorName,D004359,18408649,,,8,"Drug Therapy, Combination",N,
16472,DescriptorName,D006801,18408649,,,9,Humans,N,
16473,DescriptorName,D008297,18408649,,,10,Male,N,
16474,DescriptorName,D011437,18408649,,,11,Propylamines,N,
16475,QualifierName,Q000009,18408649,,,11,,Y,adverse effects
16476,DescriptorName,D013565,18408649,,,12,Sympatholytics,N,
16477,QualifierName,Q000627,18408649,,,12,,N,therapeutic use
16478,DescriptorName,D013981,18408649,,,13,Tic Disorders,N,
16479,QualifierName,Q000139,18408649,,,13,,Y,chemically induced
16480,Chemical,D000998,18421192,Antiviral Agents,0,,,,
16481,Chemical,D001786,18421192,Blood Glucose,0,,,,
16482,Chemical,D007004,18421192,Hypoglycemic Agents,0,,,,
16483,Chemical,D007328,18421192,Insulin,0,,,,
16484,Chemical,D000077190,18421192,Interferon alpha-2,0,,,,
16485,Chemical,D016898,18421192,Interferon-alpha,0,,,,
16486,Chemical,D011994,18421192,Recombinant Proteins,0,,,,
16487,Chemical,D011092,18421192,Polyethylene Glycols,3WJQ0SDW1A,,,,
16488,Chemical,D012254,18421192,Ribavirin,49717AWG6K,,,,
16489,Chemical,D005968,18421192,Glutamate Decarboxylase,EC 4.1.1.15,,,,
16490,Chemical,C417083,18421192,peginterferon alfa-2b,G8RGG88B68,,,,
16491,DescriptorName,D000998,18421192,,,1,Antiviral Agents,N,
16492,QualifierName,Q000009,18421192,,,1,,N,adverse effects
16493,DescriptorName,D001786,18421192,,,2,Blood Glucose,N,
16494,QualifierName,Q000378,18421192,,,2,,N,metabolism
16495,DescriptorName,D003922,18421192,,,3,"Diabetes Mellitus, Type 1",N,
16496,QualifierName,Q000139,18421192,,,3,,Y,chemically induced
16497,DescriptorName,D004305,18421192,,,4,"Dose-Response Relationship, Drug",N,
16498,DescriptorName,D005968,18421192,,,5,Glutamate Decarboxylase,N,
16499,QualifierName,Q000276,18421192,,,5,,N,immunology
16500,DescriptorName,D019698,18421192,,,6,"Hepatitis C, Chronic",N,
16501,QualifierName,Q000188,18421192,,,6,,Y,drug therapy
16502,DescriptorName,D006801,18421192,,,7,Humans,N,
16503,DescriptorName,D007004,18421192,,,8,Hypoglycemic Agents,N,
16504,QualifierName,Q000627,18421192,,,8,,N,therapeutic use
16505,DescriptorName,D007328,18421192,,,9,Insulin,N,
16506,QualifierName,Q000627,18421192,,,9,,N,therapeutic use
16507,DescriptorName,D000077190,18421192,,,10,Interferon alpha-2,N,
16508,DescriptorName,D016898,18421192,,,11,Interferon-alpha,N,
16509,QualifierName,Q000009,18421192,,,11,,Y,adverse effects
16510,DescriptorName,D008297,18421192,,,12,Male,N,
16511,DescriptorName,D008875,18421192,,,13,Middle Aged,N,
16512,DescriptorName,D011092,18421192,,,14,Polyethylene Glycols,N,
16513,DescriptorName,D011994,18421192,,,15,Recombinant Proteins,N,
16514,DescriptorName,D012254,18421192,,,16,Ribavirin,N,
16515,QualifierName,Q000009,18421192,,,16,,Y,adverse effects
16516,Chemical,D020533,18425523,Angiogenesis Inhibitors,0,,,,
16517,Chemical,D000911,18425523,"Antibodies, Monoclonal",0,,,,
16518,Chemical,D061067,18425523,"Antibodies, Monoclonal, Humanized",0,,,,
16519,Chemical,D000959,18425523,Antihypertensive Agents,0,,,,
16520,Chemical,D042461,18425523,Vascular Endothelial Growth Factor A,0,,,,
16521,Chemical,D000069579,18425523,Ranibizumab,ZL1R02VT79,,,,
16522,DescriptorName,D000368,18425523,,,1,Aged,N,
16523,DescriptorName,D000369,18425523,,,2,"Aged, 80 and over",N,
16524,DescriptorName,D020533,18425523,,,3,Angiogenesis Inhibitors,N,
16525,QualifierName,Q000009,18425523,,,3,,Y,adverse effects
16526,DescriptorName,D000911,18425523,,,4,"Antibodies, Monoclonal",N,
16527,QualifierName,Q000009,18425523,,,4,,Y,adverse effects
16528,DescriptorName,D061067,18425523,,,5,"Antibodies, Monoclonal, Humanized",N,
16529,DescriptorName,D000959,18425523,,,6,Antihypertensive Agents,N,
16530,QualifierName,Q000627,18425523,,,6,,N,therapeutic use
16531,DescriptorName,D020256,18425523,,,7,Choroidal Neovascularization,N,
16532,QualifierName,Q000188,18425523,,,7,,N,drug therapy
16533,DescriptorName,D005260,18425523,,,8,Female,N,
16534,DescriptorName,D006801,18425523,,,9,Humans,N,
16535,DescriptorName,D007267,18425523,,,10,Injections,N,
16536,DescriptorName,D007429,18425523,,,11,Intraocular Pressure,N,
16537,QualifierName,Q000187,18425523,,,11,,Y,drug effects
16538,DescriptorName,D008268,18425523,,,12,Macular Degeneration,N,
16539,QualifierName,Q000150,18425523,,,12,,N,complications
16540,DescriptorName,D008297,18425523,,,13,Male,N,
16541,DescriptorName,D009798,18425523,,,14,Ocular Hypertension,N,
16542,QualifierName,Q000139,18425523,,,14,,Y,chemically induced
16543,DescriptorName,D000069579,18425523,,,15,Ranibizumab,N,
16544,DescriptorName,D014065,18425523,,,16,"Tonometry, Ocular",N,
16545,DescriptorName,D042461,18425523,,,17,Vascular Endothelial Growth Factor A,N,
16546,QualifierName,Q000037,18425523,,,17,,N,antagonists & inhibitors
16547,DescriptorName,D014822,18425523,,,18,Vitreous Body,N,
16548,Chemical,D000697,18431096,Central Nervous System Stimulants,0,,,,
16549,Chemical,D008774,18431096,Methylphenidate,207ZZ9QZ49,,,,
16550,Chemical,D003913,18431096,Dextroamphetamine,TZ47U051FI,,,,
16551,DescriptorName,D000328,18431096,,,1,Adult,N,
16552,DescriptorName,D001289,18431096,,,2,Attention Deficit Disorder with Hyperactivity,N,
16553,QualifierName,Q000188,18431096,,,2,,N,drug therapy
16554,DescriptorName,D000697,18431096,,,3,Central Nervous System Stimulants,N,
16555,QualifierName,Q000009,18431096,,,3,,Y,adverse effects
16556,DescriptorName,D002648,18431096,,,4,Child,N,
16557,DescriptorName,D003913,18431096,,,5,Dextroamphetamine,N,
16558,QualifierName,Q000009,18431096,,,5,,Y,adverse effects
16559,DescriptorName,D005260,18431096,,,6,Female,N,
16560,DescriptorName,D006801,18431096,,,7,Humans,N,
16561,DescriptorName,D054068,18431096,,,8,Livedo Reticularis,N,
16562,QualifierName,Q000139,18431096,,,8,,Y,chemically induced
16563,DescriptorName,D008774,18431096,,,9,Methylphenidate,N,
16564,QualifierName,Q000009,18431096,,,9,,Y,adverse effects
16565,DescriptorName,D016491,18431096,,,10,Peripheral Vascular Diseases,N,
16566,QualifierName,Q000139,18431096,,,10,,Y,chemically induced
16567,DescriptorName,D011928,18431096,,,11,Raynaud Disease,N,
16568,QualifierName,Q000139,18431096,,,11,,Y,chemically induced
16569,Chemical,D000911,18446030,"Antibodies, Monoclonal",0,,,,
16570,Chemical,D061067,18446030,"Antibodies, Monoclonal, Humanized",0,,,,
16571,Chemical,D007155,18446030,Immunologic Factors,0,,,,
16572,Chemical,D007166,18446030,Immunosuppressive Agents,0,,,,
16573,Chemical,C472181,18446030,efalizumab,XX2MN88N5D,,,,
16574,DescriptorName,D000911,18446030,,,1,"Antibodies, Monoclonal",N,
16575,QualifierName,Q000009,18446030,,,1,,Y,adverse effects
16576,DescriptorName,D061067,18446030,,,2,"Antibodies, Monoclonal, Humanized",N,
16577,DescriptorName,D005260,18446030,,,3,Female,N,
16578,DescriptorName,D006801,18446030,,,4,Humans,N,
16579,DescriptorName,D007155,18446030,,,5,Immunologic Factors,N,
16580,QualifierName,Q000009,18446030,,,5,,Y,adverse effects
16581,DescriptorName,D007166,18446030,,,6,Immunosuppressive Agents,N,
16582,QualifierName,Q000009,18446030,,,6,,Y,adverse effects
16583,DescriptorName,D008875,18446030,,,7,Middle Aged,N,
16584,DescriptorName,D008976,18446030,,,8,Molluscum Contagiosum,N,
16585,QualifierName,Q000139,18446030,,,8,,Y,chemically induced
16586,DescriptorName,D011565,18446030,,,9,Psoriasis,N,
16587,QualifierName,Q000188,18446030,,,9,,N,drug therapy
16588,DescriptorName,D012867,18446030,,,10,Skin,N,
16589,QualifierName,Q000473,18446030,,,10,,Y,pathology
16590,Chemical,D020845,18459568,Selective Estrogen Receptor Modulators,0,,,,
16591,Chemical,D013629,18459568,Tamoxifen,094ZI81Y45,,,,
16592,DescriptorName,D000230,18459568,,,1,Adenocarcinoma,N,
16593,QualifierName,Q000139,18459568,,,1,,N,chemically induced
16594,DescriptorName,D000368,18459568,,,2,Aged,N,
16595,DescriptorName,D001943,18459568,,,3,Breast Neoplasms,N,
16596,QualifierName,Q000188,18459568,,,3,,Y,drug therapy
16597,DescriptorName,D002278,18459568,,,4,Carcinoma in Situ,N,
16598,QualifierName,Q000139,18459568,,,4,,N,chemically induced
16599,DescriptorName,D016889,18459568,,,5,Endometrial Neoplasms,N,
16600,QualifierName,Q000139,18459568,,,5,,N,chemically induced
16601,DescriptorName,D005260,18459568,,,6,Female,N,
16602,DescriptorName,D006801,18459568,,,7,Humans,N,
16603,DescriptorName,D008875,18459568,,,8,Middle Aged,N,
16604,DescriptorName,D020845,18459568,,,9,Selective Estrogen Receptor Modulators,N,
16605,QualifierName,Q000009,18459568,,,9,,Y,adverse effects
16606,DescriptorName,D013274,18459568,,,10,Stomach Neoplasms,N,
16607,QualifierName,Q000139,18459568,,,10,,N,chemically induced
16608,DescriptorName,D013629,18459568,,,11,Tamoxifen,N,
16609,QualifierName,Q000009,18459568,,,11,,Y,adverse effects
16610,DescriptorName,D002583,18459568,,,12,Uterine Cervical Neoplasms,N,
16611,QualifierName,Q000139,18459568,,,12,,N,chemically induced
16612,Chemical,D052157,18465737,"Aptamers, Nucleotide",0,,,,
16613,Chemical,D042461,18465737,Vascular Endothelial Growth Factor A,0,,,,
16614,Chemical,C495058,18465737,pegaptanib,2H1PA8H1EN,,,,
16615,DescriptorName,D000368,18465737,,,1,Aged,N,
16616,DescriptorName,D052157,18465737,,,2,"Aptamers, Nucleotide",N,
16617,QualifierName,Q000009,18465737,,,2,,Y,adverse effects
16618,DescriptorName,D003930,18465737,,,3,Diabetic Retinopathy,N,
16619,QualifierName,Q000188,18465737,,,3,,Y,drug therapy
16620,DescriptorName,D006801,18465737,,,4,Humans,N,
16621,DescriptorName,D007267,18465737,,,5,Injections,N,
16622,DescriptorName,D008269,18465737,,,6,Macular Edema,N,
16623,QualifierName,Q000188,18465737,,,6,,Y,drug therapy
16624,DescriptorName,D008297,18465737,,,7,Male,N,
16625,DescriptorName,D011446,18465737,,,8,Prospective Studies,N,
16626,DescriptorName,D019233,18465737,,,9,Retreatment,N,
16627,DescriptorName,D041623,18465737,,,10,"Tomography, Optical Coherence",N,
16628,DescriptorName,D042461,18465737,,,11,Vascular Endothelial Growth Factor A,N,
16629,QualifierName,Q000037,18465737,,,11,,N,antagonists & inhibitors
16630,DescriptorName,D014792,18465737,,,12,Visual Acuity,N,
16631,DescriptorName,D014822,18465737,,,13,Vitreous Body,N,
16632,DescriptorName,D020255,18465737,,,14,Vitreous Detachment,N,
16633,QualifierName,Q000175,18465737,,,14,,N,diagnosis
16634,Chemical,D000959,18472517,Antihypertensive Agents,0,,,,
16635,Chemical,D015773,18472517,Enalaprilat,GV0O7ES0R3,,,,
16636,DescriptorName,D000328,18472517,,,1,Adult,N,
16637,DescriptorName,D000959,18472517,,,2,Antihypertensive Agents,N,
16638,QualifierName,Q000008,18472517,,,2,,N,administration & dosage
16639,DescriptorName,D015773,18472517,,,3,Enalaprilat,N,
16640,QualifierName,Q000008,18472517,,,3,,N,administration & dosage
16641,DescriptorName,D005260,18472517,,,4,Female,N,
16642,DescriptorName,D006801,18472517,,,5,Humans,N,
16643,DescriptorName,D006973,18472517,,,6,Hypertension,N,
16644,QualifierName,Q000188,18472517,,,6,,N,drug therapy
16645,DescriptorName,D010309,18472517,,,7,Parotitis,N,
16646,QualifierName,Q000139,18472517,,,7,,Y,chemically induced
16647,Chemical,D018680,18476934,Cholinergic Antagonists,0,,,,
16648,Chemical,D008333,18476934,Mandelic Acids,0,,,,
16649,Chemical,C005419,18476934,oxybutynin,K9P6MC7092,,,,
16650,DescriptorName,D001766,18476934,,,1,Blindness,N,
16651,QualifierName,Q000139,18476934,,,1,,Y,chemically induced
16652,DescriptorName,D002675,18476934,,,2,"Child, Preschool",N,
16653,DescriptorName,D018680,18476934,,,3,Cholinergic Antagonists,N,
16654,QualifierName,Q000009,18476934,,,3,,Y,adverse effects
16655,DescriptorName,D004775,18476934,,,4,Enuresis,N,
16656,QualifierName,Q000188,18476934,,,4,,Y,drug therapy
16657,DescriptorName,D005260,18476934,,,5,Female,N,
16658,DescriptorName,D006801,18476934,,,6,Humans,N,
16659,DescriptorName,D006973,18476934,,,7,Hypertension,N,
16660,QualifierName,Q000139,18476934,,,7,,N,chemically induced
16661,DescriptorName,D008279,18476934,,,8,Magnetic Resonance Imaging,N,
16662,DescriptorName,D008333,18476934,,,9,Mandelic Acids,N,
16663,QualifierName,Q000009,18476934,,,9,,Y,adverse effects
16664,DescriptorName,D054038,18476934,,,10,Posterior Leukoencephalopathy Syndrome,N,
16665,QualifierName,Q000139,18476934,,,10,,Y,chemically induced
16666,DescriptorName,D012640,18476934,,,11,Seizures,N,
16667,QualifierName,Q000139,18476934,,,11,,N,chemically induced
16668,Chemical,D001067,18487000,Appetite Depressants,0,,,,
16669,Chemical,D003503,18487000,Cyclobutanes,0,,,,
16670,Chemical,C058254,18487000,sibutramine,WV5EC51866,,,,
16671,DescriptorName,D001067,18487000,,,1,Appetite Depressants,N,
16672,QualifierName,Q000008,18487000,,,1,,N,administration & dosage
16673,DescriptorName,D015992,18487000,,,2,Body Mass Index,N,
16674,DescriptorName,D003503,18487000,,,3,Cyclobutanes,N,
16675,QualifierName,Q000008,18487000,,,3,,N,administration & dosage
16676,DescriptorName,D003937,18487000,,,4,"Diagnosis, Differential",N,
16677,DescriptorName,D004636,18487000,,,5,"Emergency Service, Hospital",N,
16678,DescriptorName,D005260,18487000,,,6,Female,N,
16679,DescriptorName,D005500,18487000,,,7,Follow-Up Studies,N,
16680,DescriptorName,D006801,18487000,,,8,Humans,N,
16681,DescriptorName,D007010,18487000,,,9,Hyponatremia,N,
16682,QualifierName,Q000139,18487000,,,9,,Y,chemically induced
16683,DescriptorName,D007177,18487000,,,10,Inappropriate ADH Syndrome,N,
16684,QualifierName,Q000175,18487000,,,10,,N,diagnosis
16685,DescriptorName,D008875,18487000,,,11,Middle Aged,N,
16686,DescriptorName,D009767,18487000,,,12,"Obesity, Morbid",N,
16687,QualifierName,Q000175,18487000,,,12,,N,diagnosis
16688,DescriptorName,D018570,18487000,,,13,Risk Assessment,N,
16689,DescriptorName,D012720,18487000,,,14,Severity of Illness Index,N,
16690,Chemical,D000927,18492617,Anticonvulsants,0,,,,
16691,Chemical,D000069583,18492617,Pregabalin,55JG375S6M,,,,
16692,Chemical,D005680,18492617,gamma-Aminobutyric Acid,56-12-2,,,,
16693,DescriptorName,D000368,18492617,,,1,Aged,N,
16694,DescriptorName,D000927,18492617,,,2,Anticonvulsants,N,
16695,QualifierName,Q000009,18492617,,,2,,Y,adverse effects
16696,DescriptorName,D020968,18492617,,,3,Brachial Plexus Neuritis,N,
16697,QualifierName,Q000188,18492617,,,3,,Y,drug therapy
16698,DescriptorName,D002540,18492617,,,4,Cerebral Cortex,N,
16699,QualifierName,Q000187,18492617,,,4,,N,drug effects
16700,DescriptorName,D004401,18492617,,,5,Dysarthria,N,
16701,QualifierName,Q000139,18492617,,,5,,Y,chemically induced
16702,DescriptorName,D004558,18492617,,,6,Electric Stimulation,N,
16703,DescriptorName,D004569,18492617,,,7,Electroencephalography,N,
16704,QualifierName,Q000187,18492617,,,7,,Y,drug effects
16705,DescriptorName,D004576,18492617,,,8,Electromyography,N,
16706,QualifierName,Q000187,18492617,,,8,,N,drug effects
16707,DescriptorName,D004831,18492617,,,9,"Epilepsies, Myoclonic",N,
16708,QualifierName,Q000139,18492617,,,9,,Y,chemically induced
16709,DescriptorName,D005073,18492617,,,10,"Evoked Potentials, Somatosensory",N,
16710,QualifierName,Q000187,18492617,,,10,,N,drug effects
16711,DescriptorName,D006801,18492617,,,11,Humans,N,
16712,DescriptorName,D008297,18492617,,,12,Male,N,
16713,DescriptorName,D009129,18492617,,,13,Muscle Tonus,N,
16714,QualifierName,Q000187,18492617,,,13,,N,drug effects
16715,DescriptorName,D018482,18492617,,,14,"Muscle, Skeletal",N,
16716,QualifierName,Q000294,18492617,,,14,,N,innervation
16717,DescriptorName,D000069583,18492617,,,15,Pregabalin,N,
16718,DescriptorName,D013003,18492617,,,16,Somatosensory Cortex,N,
16719,QualifierName,Q000187,18492617,,,16,,N,drug effects
16720,DescriptorName,D013979,18492617,,,17,Tibial Nerve,N,
16721,QualifierName,Q000503,18492617,,,17,,N,physiopathology
16722,DescriptorName,D005680,18492617,,,18,gamma-Aminobutyric Acid,N,
16723,QualifierName,Q000009,18492617,,,18,,N,adverse effects
16724,Chemical,D009156,1849334,Muzolimine,07Z36289ZX,,,,
16725,DescriptorName,D000328,1849334,,,1,Adult,N,
16726,DescriptorName,D000368,1849334,,,2,Aged,N,
16727,DescriptorName,D003711,1849334,,,3,Demyelinating Diseases,N,
16728,QualifierName,Q000139,1849334,,,3,,Y,chemically induced
16729,DescriptorName,D005260,1849334,,,4,Female,N,
16730,DescriptorName,D006801,1849334,,,5,Humans,N,
16731,DescriptorName,D007676,1849334,,,6,"Kidney Failure, Chronic",N,
16732,QualifierName,Q000188,1849334,,,6,,Y,drug therapy
16733,DescriptorName,D008297,1849334,,,7,Male,N,
16734,DescriptorName,D008875,1849334,,,8,Middle Aged,N,
16735,DescriptorName,D009133,1849334,,,9,Muscular Atrophy,N,
16736,QualifierName,Q000139,1849334,,,9,,Y,chemically induced
16737,DescriptorName,D009156,1849334,,,10,Muzolimine,N,
16738,QualifierName,Q000008,1849334,,,10,,N,administration & dosage
16739,DescriptorName,D010525,1849334,,,11,Peripheral Nerves,N,
16740,QualifierName,Q000473,1849334,,,11,,N,pathology
16741,DescriptorName,D010523,1849334,,,12,Peripheral Nervous System Diseases,N,
16742,QualifierName,Q000139,1849334,,,12,,Y,chemically induced
16743,DescriptorName,D011712,1849334,,,13,Pyramidal Tracts,N,
16744,QualifierName,Q000473,1849334,,,13,,N,pathology
16745,DescriptorName,D013116,1849334,,,14,Spinal Cord,N,
16746,QualifierName,Q000473,1849334,,,14,,N,pathology
16747,DescriptorName,D013118,1849334,,,15,Spinal Cord Diseases,N,
16748,QualifierName,Q000139,1849334,,,15,,Y,chemically induced
16749,Chemical,D000970,18504683,Antineoplastic Agents,0,,,,
16750,Chemical,D001215,18504683,Asparaginase,EC 3.5.1.1,,,,
16751,DescriptorName,D000293,18504683,,,1,Adolescent,N,
16752,DescriptorName,D000970,18504683,,,2,Antineoplastic Agents,N,
16753,QualifierName,Q000009,18504683,,,2,,N,adverse effects
16754,DescriptorName,D001215,18504683,,,3,Asparaginase,N,
16755,QualifierName,Q000009,18504683,,,3,,Y,adverse effects
16756,DescriptorName,D001921,18504683,,,4,Brain,N,
16757,QualifierName,Q000187,18504683,,,4,,N,drug effects
16758,DescriptorName,D002648,18504683,,,5,Child,N,
16759,DescriptorName,D002675,18504683,,,6,"Child, Preschool",N,
16760,DescriptorName,D005260,18504683,,,7,Female,N,
16761,DescriptorName,D006801,18504683,,,8,Humans,N,
16762,DescriptorName,D008279,18504683,,,9,Magnetic Resonance Imaging,N,
16763,DescriptorName,D008297,18504683,,,10,Male,N,
16764,DescriptorName,D054038,18504683,,,11,Posterior Leukoencephalopathy Syndrome,N,
16765,QualifierName,Q000139,18504683,,,11,,Y,chemically induced
16766,DescriptorName,D054198,18504683,,,12,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
16767,QualifierName,Q000188,18504683,,,12,,Y,drug therapy
16768,DescriptorName,D012640,18504683,,,13,Seizures,N,
16769,QualifierName,Q000139,18504683,,,13,,N,chemically induced
16770,DescriptorName,D012772,18504683,,,14,"Shock, Septic",N,
16771,QualifierName,Q000139,18504683,,,14,,N,chemically induced
16772,Chemical,D018931,18515982,"Antineoplastic Agents, Hormonal",0,,,,
16773,Chemical,D009570,18515982,Nitriles,0,,,,
16774,Chemical,D014230,18515982,Triazoles,0,,,,
16775,Chemical,D000077384,18515982,Anastrozole,2Z07MYW1AZ,,,,
16776,DescriptorName,D000368,18515982,,,1,Aged,N,
16777,DescriptorName,D000077384,18515982,,,2,Anastrozole,N,
16778,DescriptorName,D018931,18515982,,,3,"Antineoplastic Agents, Hormonal",N,
16779,QualifierName,Q000633,18515982,,,3,,Y,toxicity
16780,DescriptorName,D001284,18515982,,,4,Atrophy,N,
16781,DescriptorName,D001943,18515982,,,5,Breast Neoplasms,N,
16782,QualifierName,Q000188,18515982,,,5,,Y,drug therapy
16783,DescriptorName,D017809,18515982,,,6,Fatal Outcome,N,
16784,DescriptorName,D005260,18515982,,,7,Female,N,
16785,DescriptorName,D005923,18515982,,,8,"Glomerulosclerosis, Focal Segmental",N,
16786,QualifierName,Q000139,18515982,,,8,,Y,chemically induced
16787,DescriptorName,D006801,18515982,,,9,Humans,N,
16788,DescriptorName,D007249,18515982,,,10,Inflammation,N,
16789,QualifierName,Q000139,18515982,,,10,,N,chemically induced
16790,DescriptorName,D009570,18515982,,,11,Nitriles,N,
16791,QualifierName,Q000633,18515982,,,11,,Y,toxicity
16792,DescriptorName,D014230,18515982,,,12,Triazoles,N,
16793,QualifierName,Q000633,18515982,,,12,,Y,toxicity
16794,Chemical,D000935,18523232,Antifungal Agents,0,,,,
16795,Chemical,D017964,18523232,Itraconazole,304NUG5GF4,,,,
16796,DescriptorName,D000935,18523232,,,1,Antifungal Agents,N,
16797,QualifierName,Q000009,18523232,,,1,,Y,adverse effects
16798,DescriptorName,D056486,18523232,,,2,Chemical and Drug Induced Liver Injury,N,
16799,QualifierName,Q000209,18523232,,,2,,Y,etiology
16800,DescriptorName,D017809,18523232,,,3,Fatal Outcome,N,
16801,DescriptorName,D005260,18523232,,,4,Female,N,
16802,DescriptorName,D005533,18523232,,,5,Foot Dermatoses,N,
16803,QualifierName,Q000188,18523232,,,5,,Y,drug therapy
16804,DescriptorName,D006801,18523232,,,6,Humans,N,
16805,DescriptorName,D017964,18523232,,,7,Itraconazole,N,
16806,QualifierName,Q000009,18523232,,,7,,Y,adverse effects
16807,DescriptorName,D008875,18523232,,,8,Middle Aged,N,
16808,DescriptorName,D014009,18523232,,,9,Onychomycosis,N,
16809,QualifierName,Q000150,18523232,,,9,,Y,complications
16810,Chemical,D009125,18533420,"Muscle Relaxants, Central",0,,,,
16811,Chemical,D001418,18533420,Baclofen,H789N3FKE8,,,,
16812,DescriptorName,D001418,18533420,,,1,Baclofen,N,
16813,QualifierName,Q000009,18533420,,,1,,Y,adverse effects
16814,DescriptorName,D005260,18533420,,,2,Female,N,
16815,DescriptorName,D006801,18533420,,,3,Humans,N,
16816,DescriptorName,D007278,18533420,,,4,"Injections, Spinal",N,
16817,QualifierName,Q000379,18533420,,,4,,N,methods
16818,DescriptorName,D008297,18533420,,,5,Male,N,
16819,DescriptorName,D009125,18533420,,,6,"Muscle Relaxants, Central",N,
16820,QualifierName,Q000009,18533420,,,6,,Y,adverse effects
16821,DescriptorName,D009128,18533420,,,7,Muscle Spasticity,N,
16822,QualifierName,Q000188,18533420,,,7,,N,drug therapy
16823,DescriptorName,D012735,18533420,,,8,"Sexual Dysfunction, Physiological",N,
16824,QualifierName,Q000139,18533420,,,8,,Y,chemically induced
16825,Chemical,D036341,18556970,Intercellular Signaling Peptides and Proteins,0,,,,
16826,Chemical,D011994,18556970,Recombinant Proteins,0,,,,
16827,Chemical,C065700,18556970,myotrophin,0,,,,
16828,Chemical,D007334,18556970,Insulin-Like Growth Factor I,67763-96-6,,,,
16829,DescriptorName,D000293,18556970,,,1,Adolescent,N,
16830,DescriptorName,D000707,18556970,,,2,Anaphylaxis,N,
16831,QualifierName,Q000139,18556970,,,2,,Y,chemically induced
16832,DescriptorName,D006130,18556970,,,3,Growth Disorders,N,
16833,QualifierName,Q000188,18556970,,,3,,Y,drug therapy
16834,DescriptorName,D006801,18556970,,,4,Humans,N,
16835,DescriptorName,D007334,18556970,,,5,Insulin-Like Growth Factor I,N,
16836,QualifierName,Q000008,18556970,,,5,,N,administration & dosage
16837,DescriptorName,D036341,18556970,,,6,Intercellular Signaling Peptides and Proteins,N,
16838,QualifierName,Q000008,18556970,,,6,,N,administration & dosage
16839,DescriptorName,D008297,18556970,,,7,Male,N,
16840,DescriptorName,D011994,18556970,,,8,Recombinant Proteins,N,
16841,QualifierName,Q000008,18556970,,,8,,N,administration & dosage
16842,Chemical,D014150,18562412,Antipsychotic Agents,0,,,,
16843,Chemical,D001569,18562412,Benzodiazepines,12794-10-4,,,,
16844,Chemical,D000077152,18562412,Olanzapine,N7U69T4SZR,,,,
16845,DescriptorName,D000328,18562412,,,1,Adult,N,
16846,DescriptorName,D014150,18562412,,,2,Antipsychotic Agents,N,
16847,QualifierName,Q000008,18562412,,,2,,N,administration & dosage
16848,DescriptorName,D001569,18562412,,,3,Benzodiazepines,N,
16849,QualifierName,Q000008,18562412,,,3,,N,administration & dosage
16850,DescriptorName,D004305,18562412,,,4,"Dose-Response Relationship, Drug",N,
16851,DescriptorName,D005260,18562412,,,5,Female,N,
16852,DescriptorName,D006801,18562412,,,6,Humans,N,
16853,DescriptorName,D008297,18562412,,,7,Male,N,
16854,DescriptorName,D055118,18562412,,,8,Medication Adherence,N,
16855,DescriptorName,D001523,18562412,,,9,Mental Disorders,N,
16856,QualifierName,Q000188,18562412,,,9,,N,drug therapy
16857,DescriptorName,D008875,18562412,,,10,Middle Aged,N,
16858,DescriptorName,D020189,18562412,,,11,Nocturnal Myoclonus Syndrome,N,
16859,QualifierName,Q000139,18562412,,,11,,Y,chemically induced
16860,DescriptorName,D000077152,18562412,,,12,Olanzapine,N,
16861,DescriptorName,D012148,18562412,,,13,Restless Legs Syndrome,N,
16862,QualifierName,Q000139,18562412,,,13,,Y,chemically induced
16863,Chemical,D000893,18569796,Anti-Inflammatory Agents,0,,,,
16864,Chemical,D050071,18569796,Bone Density Conservation Agents,0,,,,
16865,Chemical,D014221,18569796,Triamcinolone,1ZK20VI6TY,,,,
16866,Chemical,D019386,18569796,Alendronate,X1J18R4W8P,,,,
16867,DescriptorName,D019386,18569796,,,1,Alendronate,N,
16868,QualifierName,Q000009,18569796,,,1,,Y,adverse effects
16869,DescriptorName,D000893,18569796,,,2,Anti-Inflammatory Agents,N,
16870,QualifierName,Q000008,18569796,,,2,,N,administration & dosage
16871,DescriptorName,D050071,18569796,,,3,Bone Density Conservation Agents,N,
16872,QualifierName,Q000009,18569796,,,3,,Y,adverse effects
16873,DescriptorName,D006801,18569796,,,4,Humans,N,
16874,DescriptorName,D015552,18569796,,,5,"Injections, Intralesional",N,
16875,DescriptorName,D008297,18569796,,,6,Male,N,
16876,DescriptorName,D008875,18569796,,,7,Middle Aged,N,
16877,DescriptorName,D012008,18569796,,,8,Recurrence,N,
16878,DescriptorName,D015423,18569796,,,9,Scleritis,N,
16879,QualifierName,Q000139,18569796,,,9,,Y,chemically induced
16880,DescriptorName,D016896,18569796,,,10,Treatment Outcome,N,
16881,DescriptorName,D014221,18569796,,,11,Triamcinolone,N,
16882,QualifierName,Q000008,18569796,,,11,,N,administration & dosage
16883,Chemical,D000900,18580694,Anti-Bacterial Agents,0,,,,
16884,Chemical,D014150,18580694,Antipsychotic Agents,0,,,,
16885,Chemical,D018967,18580694,Risperidone,L6UH7ZF8HC,,,,
16886,Chemical,D010878,18580694,Piperacillin,X00B0D5O0E,,,,
16887,DescriptorName,D000900,18580694,,,1,Anti-Bacterial Agents,N,
16888,QualifierName,Q000009,18580694,,,1,,Y,adverse effects
16889,DescriptorName,D014150,18580694,,,2,Antipsychotic Agents,N,
16890,QualifierName,Q000627,18580694,,,2,,N,therapeutic use
16891,DescriptorName,D004565,18580694,,,3,Electroconvulsive Therapy,N,
16892,QualifierName,Q000009,18580694,,,3,,Y,adverse effects
16893,DescriptorName,D004569,18580694,,,4,Electroencephalography,N,
16894,DescriptorName,D006801,18580694,,,5,Humans,N,
16895,DescriptorName,D008297,18580694,,,6,Male,N,
16896,DescriptorName,D008875,18580694,,,7,Middle Aged,N,
16897,DescriptorName,D009459,18580694,,,8,Neuroleptic Malignant Syndrome,N,
16898,QualifierName,Q000150,18580694,,,8,,N,complications
16899,DescriptorName,D010878,18580694,,,9,Piperacillin,N,
16900,QualifierName,Q000009,18580694,,,9,,N,adverse effects
16901,DescriptorName,D011015,18580694,,,10,"Pneumonia, Aspiration",N,
16902,QualifierName,Q000188,18580694,,,10,,N,drug therapy
16903,DescriptorName,D018967,18580694,,,11,Risperidone,N,
16904,QualifierName,Q000627,18580694,,,11,,N,therapeutic use
16905,DescriptorName,D012560,18580694,,,12,"Schizophrenia, Catatonic",N,
16906,QualifierName,Q000188,18580694,,,12,,N,drug therapy
16907,DescriptorName,D012563,18580694,,,13,"Schizophrenia, Paranoid",N,
16908,QualifierName,Q000150,18580694,,,13,,N,complications
16909,DescriptorName,D012640,18580694,,,14,Seizures,N,
16910,QualifierName,Q000139,18580694,,,14,,Y,chemically induced
16911,DescriptorName,D014552,18580694,,,15,Urinary Tract Infections,N,
16912,QualifierName,Q000150,18580694,,,15,,N,complications
16913,DescriptorName,D055815,18580694,,,16,Young Adult,N,
16914,Chemical,D000900,18585545,Anti-Bacterial Agents,0,,,,
16915,Chemical,D064704,18585545,Levofloxacin,6GNT3Y5LMF,,,,
16916,Chemical,D015242,18585545,Ofloxacin,A4P49JAZ9H,,,,
16917,DescriptorName,D000328,18585545,,,1,Adult,N,
16918,DescriptorName,D000367,18585545,,,2,Age Factors,N,
16919,DescriptorName,D000900,18585545,,,3,Anti-Bacterial Agents,N,
16920,QualifierName,Q000009,18585545,,,3,,Y,adverse effects
16921,DescriptorName,D003693,18585545,,,4,Delirium,N,
16922,QualifierName,Q000139,18585545,,,4,,Y,chemically induced
16923,DescriptorName,D005260,18585545,,,5,Female,N,
16924,DescriptorName,D006304,18585545,,,6,Health Status,N,
16925,DescriptorName,D006801,18585545,,,7,Humans,N,
16926,DescriptorName,D064704,18585545,,,8,Levofloxacin,Y,
16927,DescriptorName,D015242,18585545,,,9,Ofloxacin,N,
16928,QualifierName,Q000009,18585545,,,9,,Y,adverse effects
16929,DescriptorName,D011605,18585545,,,10,"Psychoses, Substance-Induced",N,
16930,QualifierName,Q000175,18585545,,,10,,N,diagnosis
16931,DescriptorName,D012852,18585545,,,11,Sinusitis,N,
16932,QualifierName,Q000188,18585545,,,11,,N,drug therapy
16933,DescriptorName,D014717,18585545,,,12,Vertigo,N,
16934,QualifierName,Q000188,18585545,,,12,,N,drug therapy
16935,Chemical,D007166,18607107,Immunosuppressive Agents,0,,,,
16936,Chemical,D010455,18607107,Peptides,0,,,,
16937,Chemical,D000068717,18607107,Glatiramer Acetate,5M691HL4BO,,,,
16938,DescriptorName,D000328,18607107,,,1,Adult,N,
16939,DescriptorName,D015897,18607107,,,2,Comorbidity,N,
16940,DescriptorName,D003424,18607107,,,3,Crohn Disease,N,
16941,QualifierName,Q000139,18607107,,,3,,Y,chemically induced
16942,DescriptorName,D005260,18607107,,,4,Female,N,
16943,DescriptorName,D000068717,18607107,,,5,Glatiramer Acetate,N,
16944,DescriptorName,D006801,18607107,,,6,Humans,N,
16945,DescriptorName,D007082,18607107,,,7,Ileum,N,
16946,QualifierName,Q000473,18607107,,,7,,N,pathology
16947,DescriptorName,D007166,18607107,,,8,Immunosuppressive Agents,N,
16948,QualifierName,Q000009,18607107,,,8,,Y,adverse effects
16949,DescriptorName,D009103,18607107,,,9,Multiple Sclerosis,N,
16950,QualifierName,Q000188,18607107,,,9,,Y,drug therapy
16951,DescriptorName,D010455,18607107,,,10,Peptides,N,
16952,QualifierName,Q000009,18607107,,,10,,Y,adverse effects
16953,Chemical,D007654,1860779,Ketoconazole,R9400W927I,,,,
16954,DescriptorName,D006212,1860779,,,1,Hallucinations,N,
16955,QualifierName,Q000139,1860779,,,1,,N,chemically induced
16956,DescriptorName,D006801,1860779,,,2,Humans,N,
16957,DescriptorName,D007654,1860779,,,3,Ketoconazole,N,
16958,QualifierName,Q000009,1860779,,,3,,Y,adverse effects
16959,DescriptorName,D008297,1860779,,,4,Male,N,
16960,DescriptorName,D008875,1860779,,,5,Middle Aged,N,
16961,DescriptorName,D019966,1860779,,,6,Substance-Related Disorders,N,
16962,QualifierName,Q000523,1860779,,,6,,Y,psychology
16963,DescriptorName,D013405,1860779,,,7,Suicide,N,
16964,QualifierName,Q000523,1860779,,,7,,Y,psychology
16965,DescriptorName,D014526,1860779,,,8,Urethritis,N,
16966,QualifierName,Q000188,1860779,,,8,,Y,drug therapy
16967,Chemical,D014662,18609153,Vasoconstrictor Agents,0,,,,
16968,Chemical,D008236,18609153,Lypressin,50-57-7,,,,
16969,Chemical,D000077585,18609153,Terlipressin,7Z5X49W53P,,,,
16970,DescriptorName,D000328,18609153,,,1,Adult,N,
16971,DescriptorName,D004554,18609153,,,2,Electric Countershock,N,
16972,DescriptorName,D004562,18609153,,,3,Electrocardiography,N,
16973,DescriptorName,D005500,18609153,,,4,Follow-Up Studies,N,
16974,DescriptorName,D006471,18609153,,,5,Gastrointestinal Hemorrhage,N,
16975,QualifierName,Q000175,18609153,,,5,,N,diagnosis
16976,DescriptorName,D006801,18609153,,,6,Humans,N,
16977,DescriptorName,D007262,18609153,,,7,"Infusions, Intravenous",N,
16978,DescriptorName,D008133,18609153,,,8,Long QT Syndrome,N,
16979,QualifierName,Q000139,18609153,,,8,,Y,chemically induced
16980,DescriptorName,D008236,18609153,,,9,Lypressin,N,
16981,QualifierName,Q000009,18609153,,,9,,N,adverse effects
16982,DescriptorName,D008297,18609153,,,10,Male,N,
16983,DescriptorName,D018570,18609153,,,11,Risk Assessment,N,
16984,DescriptorName,D012720,18609153,,,12,Severity of Illness Index,N,
16985,DescriptorName,D000077585,18609153,,,13,Terlipressin,N,
16986,DescriptorName,D016171,18609153,,,14,Torsades de Pointes,N,
16987,QualifierName,Q000139,18609153,,,14,,Y,chemically induced
16988,DescriptorName,D016896,18609153,,,15,Treatment Outcome,N,
16989,DescriptorName,D014662,18609153,,,16,Vasoconstrictor Agents,N,
16990,QualifierName,Q000009,18609153,,,16,,Y,adverse effects
16991,Chemical,D020533,18622319,Angiogenesis Inhibitors,0,,,,
16992,Chemical,D000911,18622319,"Antibodies, Monoclonal",0,,,,
16993,Chemical,D061067,18622319,"Antibodies, Monoclonal, Humanized",0,,,,
16994,Chemical,D042461,18622319,Vascular Endothelial Growth Factor A,0,,,,
16995,Chemical,D000068258,18622319,Bevacizumab,2S9ZZM9Q9V,,,,
16996,DescriptorName,D020533,18622319,,,1,Angiogenesis Inhibitors,N,
16997,QualifierName,Q000009,18622319,,,1,,Y,adverse effects
16998,DescriptorName,D000911,18622319,,,2,"Antibodies, Monoclonal",N,
16999,QualifierName,Q000009,18622319,,,2,,Y,adverse effects
17000,DescriptorName,D061067,18622319,,,3,"Antibodies, Monoclonal, Humanized",N,
17001,DescriptorName,D000068258,18622319,,,4,Bevacizumab,N,
17002,DescriptorName,D003937,18622319,,,5,"Diagnosis, Differential",N,
17003,DescriptorName,D004724,18622319,,,6,Endoscopy,N,
17004,DescriptorName,D005260,18622319,,,7,Female,N,
17005,DescriptorName,D005500,18622319,,,8,Follow-Up Studies,N,
17006,DescriptorName,D006801,18622319,,,9,Humans,N,
17007,DescriptorName,D008875,18622319,,,10,Middle Aged,N,
17008,DescriptorName,D009300,18622319,,,11,Nasal Septum,N,
17009,QualifierName,Q000187,18622319,,,11,,Y,drug effects
17010,DescriptorName,D009668,18622319,,,12,Nose Diseases,N,
17011,QualifierName,Q000139,18622319,,,12,,Y,chemically induced
17012,DescriptorName,D010051,18622319,,,13,Ovarian Neoplasms,N,
17013,QualifierName,Q000188,18622319,,,13,,N,drug therapy
17014,DescriptorName,D012422,18622319,,,14,"Rupture, Spontaneous",N,
17015,DescriptorName,D042461,18622319,,,15,Vascular Endothelial Growth Factor A,N,
17016,Chemical,D000935,18628507,Antifungal Agents,0,,,,
17017,Chemical,D006634,18628507,Histamine H1 Antagonists,0,,,,
17018,Chemical,D011743,18628507,Pyrimidines,0,,,,
17019,Chemical,D014230,18628507,Triazoles,0,,,,
17020,Chemical,D065819,18628507,Voriconazole,JFU09I87TR,,,,
17021,DescriptorName,D000328,18628507,,,1,Adult,N,
17022,DescriptorName,D000799,18628507,,,2,Angioedema,N,
17023,QualifierName,Q000139,18628507,,,2,,Y,chemically induced
17024,DescriptorName,D000935,18628507,,,3,Antifungal Agents,N,
17025,QualifierName,Q000008,18628507,,,3,,N,administration & dosage
17026,DescriptorName,D001228,18628507,,,4,Aspergillosis,N,
17027,QualifierName,Q000188,18628507,,,4,,Y,drug therapy
17028,DescriptorName,D005260,18628507,,,5,Female,N,
17029,DescriptorName,D006634,18628507,,,6,Histamine H1 Antagonists,N,
17030,QualifierName,Q000008,18628507,,,6,,N,administration & dosage
17031,DescriptorName,D006801,18628507,,,7,Humans,N,
17032,DescriptorName,D007262,18628507,,,8,"Infusions, Intravenous",N,
17033,DescriptorName,D011743,18628507,,,9,Pyrimidines,N,
17034,QualifierName,Q000008,18628507,,,9,,N,administration & dosage
17035,DescriptorName,D016896,18628507,,,10,Treatment Outcome,N,
17036,DescriptorName,D014230,18628507,,,11,Triazoles,N,
17037,QualifierName,Q000008,18628507,,,11,,N,administration & dosage
17038,DescriptorName,D065819,18628507,,,12,Voriconazole,N,
17039,Chemical,D018687,18633310,"Antidepressive Agents, Second-Generation",0,,,,
17040,Chemical,D016642,18633310,Bupropion,01ZG3TPX31,,,,
17041,DescriptorName,D018687,18633310,,,1,"Antidepressive Agents, Second-Generation",N,
17042,QualifierName,Q000506,18633310,,,1,,Y,poisoning
17043,DescriptorName,D016642,18633310,,,2,Bupropion,N,
17044,QualifierName,Q000506,18633310,,,2,,Y,poisoning
17045,DescriptorName,D002648,18633310,,,3,Child,N,
17046,DescriptorName,D062787,18633310,,,4,Drug Overdose,N,
17047,DescriptorName,D004636,18633310,,,5,"Emergency Service, Hospital",N,
17048,DescriptorName,D006212,18633310,,,6,Hallucinations,N,
17049,QualifierName,Q000139,18633310,,,6,,N,chemically induced
17050,DescriptorName,D006801,18633310,,,7,Humans,N,
17051,DescriptorName,D008297,18633310,,,8,Male,N,
17052,DescriptorName,D012640,18633310,,,9,Seizures,N,
17053,QualifierName,Q000139,18633310,,,9,,Y,chemically induced
17054,Chemical,D000697,18644535,Central Nervous System Stimulants,0,,,,
17055,Chemical,D008774,18644535,Methylphenidate,207ZZ9QZ49,,,,
17056,DescriptorName,D001289,18644535,,,1,Attention Deficit Disorder with Hyperactivity,N,
17057,QualifierName,Q000188,18644535,,,1,,Y,drug therapy
17058,DescriptorName,D000697,18644535,,,2,Central Nervous System Stimulants,N,
17059,QualifierName,Q000009,18644535,,,2,,Y,adverse effects
17060,DescriptorName,D002648,18644535,,,3,Child,N,
17061,DescriptorName,D006801,18644535,,,4,Humans,N,
17062,DescriptorName,D008297,18644535,,,5,Male,N,
17063,DescriptorName,D008774,18644535,,,6,Methylphenidate,N,
17064,QualifierName,Q000009,18644535,,,6,,Y,adverse effects
17065,DescriptorName,D053206,18644535,,,7,Nocturnal Enuresis,N,
17066,QualifierName,Q000139,18644535,,,7,,Y,chemically induced
17067,Chemical,D000900,18648015,Anti-Bacterial Agents,0,,,,
17068,Chemical,D002440,18648015,Cefoxitin,6OEV9DX57Y,,,,
17069,DescriptorName,D000328,18648015,,,1,Adult,N,
17070,DescriptorName,D000900,18648015,,,2,Anti-Bacterial Agents,N,
17071,QualifierName,Q000009,18648015,,,2,,Y,adverse effects
17072,DescriptorName,D001424,18648015,,,3,Bacterial Infections,N,
17073,QualifierName,Q000188,18648015,,,3,,N,drug therapy
17074,DescriptorName,D002440,18648015,,,4,Cefoxitin,N,
17075,QualifierName,Q000009,18648015,,,4,,Y,adverse effects
17076,DescriptorName,D006801,18648015,,,5,Humans,N,
17077,DescriptorName,D007958,18648015,,,6,Leukocyte Count,N,
17078,DescriptorName,D007970,18648015,,,7,Leukopenia,N,
17079,QualifierName,Q000139,18648015,,,7,,Y,chemically induced
17080,DescriptorName,D008297,18648015,,,8,Male,N,
17081,Chemical,D007166,18661248,Immunosuppressive Agents,0,,,,
17082,Chemical,D016572,18661248,Cyclosporine,83HN0GTJ6D,,,,
17083,DescriptorName,D000328,18661248,,,1,Adult,N,
17084,DescriptorName,D016572,18661248,,,2,Cyclosporine,N,
17085,QualifierName,Q000009,18661248,,,2,,Y,adverse effects
17086,DescriptorName,D005923,18661248,,,3,"Glomerulosclerosis, Focal Segmental",N,
17087,QualifierName,Q000188,18661248,,,3,,Y,drug therapy
17088,DescriptorName,D006801,18661248,,,4,Humans,N,
17089,DescriptorName,D007166,18661248,,,5,Immunosuppressive Agents,N,
17090,QualifierName,Q000009,18661248,,,5,,Y,adverse effects
17091,DescriptorName,D008279,18661248,,,6,Magnetic Resonance Imaging,N,
17092,DescriptorName,D008297,18661248,,,7,Male,N,
17093,DescriptorName,D054038,18661248,,,8,Posterior Leukoencephalopathy Syndrome,N,
17094,QualifierName,Q000139,18661248,,,8,,Y,chemically induced
17095,Chemical,D000925,18665833,Anticoagulants,0,,,,
17096,Chemical,D017984,18665833,Enoxaparin,0,,,,
17097,Chemical,D014859,18665833,Warfarin,5Q7ZVV76EI,,,,
17098,DescriptorName,D000328,18665833,,,1,Adult,N,
17099,DescriptorName,D000925,18665833,,,2,Anticoagulants,N,
17100,QualifierName,Q000627,18665833,,,2,,Y,therapeutic use
17101,DescriptorName,D017984,18665833,,,3,Enoxaparin,N,
17102,QualifierName,Q000627,18665833,,,3,,N,therapeutic use
17103,DescriptorName,D006801,18665833,,,4,Humans,N,
17104,DescriptorName,D008297,18665833,,,5,Male,N,
17105,DescriptorName,D011317,18665833,,,6,Priapism,N,
17106,QualifierName,Q000209,18665833,,,6,,Y,etiology
17107,DescriptorName,D020151,18665833,,,7,Protein C Deficiency,N,
17108,QualifierName,Q000150,18665833,,,7,,N,complications
17109,DescriptorName,D011655,18665833,,,8,Pulmonary Embolism,N,
17110,QualifierName,Q000209,18665833,,,8,,N,etiology
17111,DescriptorName,D020246,18665833,,,9,Venous Thrombosis,N,
17112,QualifierName,Q000150,18665833,,,9,,Y,complications
17113,DescriptorName,D014859,18665833,,,10,Warfarin,N,
17114,QualifierName,Q000009,18665833,,,10,,Y,adverse effects
17115,Chemical,D000903,18672645,"Antibiotics, Antineoplastic",0,,,,
17116,Chemical,D000970,18672645,Antineoplastic Agents,0,,,,
17117,Chemical,D000972,18672645,"Antineoplastic Agents, Phytogenic",0,,,,
17118,Chemical,D001761,18672645,Bleomycin,11056-06-7,,,,
17119,Chemical,D005047,18672645,Etoposide,6PLQ3CP4P3,,,,
17120,Chemical,D002945,18672645,Cisplatin,Q20Q21Q62J,,,,
17121,DescriptorName,D000028,18672645,,,1,"Abortion, Induced",N,
17122,DescriptorName,D000328,18672645,,,2,Adult,N,
17123,DescriptorName,D000903,18672645,,,3,"Antibiotics, Antineoplastic",N,
17124,QualifierName,Q000009,18672645,,,3,,N,adverse effects
17125,DescriptorName,D000970,18672645,,,4,Antineoplastic Agents,N,
17126,QualifierName,Q000009,18672645,,,4,,N,adverse effects
17127,DescriptorName,D000972,18672645,,,5,"Antineoplastic Agents, Phytogenic",N,
17128,QualifierName,Q000009,18672645,,,5,,N,adverse effects
17129,DescriptorName,D001761,18672645,,,6,Bleomycin,N,
17130,QualifierName,Q000009,18672645,,,6,,N,adverse effects
17131,DescriptorName,D002945,18672645,,,7,Cisplatin,N,
17132,QualifierName,Q000009,18672645,,,7,,N,adverse effects
17133,DescriptorName,D018240,18672645,,,8,Endodermal Sinus Tumor,N,
17134,QualifierName,Q000175,18672645,,,8,,Y,diagnosis
17135,DescriptorName,D005047,18672645,,,9,Etoposide,N,
17136,QualifierName,Q000009,18672645,,,9,,N,adverse effects
17137,DescriptorName,D017809,18672645,,,10,Fatal Outcome,N,
17138,DescriptorName,D005260,18672645,,,11,Female,N,
17139,DescriptorName,D006801,18672645,,,12,Humans,N,
17140,DescriptorName,D010051,18672645,,,13,Ovarian Neoplasms,N,
17141,QualifierName,Q000175,18672645,,,13,,Y,diagnosis
17142,DescriptorName,D010052,18672645,,,14,Ovariectomy,N,
17143,QualifierName,Q000379,18672645,,,14,,N,methods
17144,DescriptorName,D011247,18672645,,,15,Pregnancy,N,
17145,DescriptorName,D011261,18672645,,,16,"Pregnancy Trimester, First",N,
17146,DescriptorName,D011658,18672645,,,17,Pulmonary Fibrosis,N,
17147,QualifierName,Q000139,18672645,,,17,,N,chemically induced
17148,Chemical,D000889,18675768,Anti-Arrhythmia Agents,0,,,,
17149,Chemical,D017367,18675768,Serotonin Uptake Inhibitors,0,,,,
17150,Chemical,D015283,18675768,Citalopram,0DHU5B8D6V,,,,
17151,Chemical,D011405,18675768,Propafenone,68IQX3T69U,,,,
17152,DescriptorName,D000058,18675768,,,1,Accidental Falls,N,
17153,DescriptorName,D000369,18675768,,,2,"Aged, 80 and over",N,
17154,DescriptorName,D000889,18675768,,,3,Anti-Arrhythmia Agents,N,
17155,QualifierName,Q000009,18675768,,,3,,Y,adverse effects
17156,DescriptorName,D001281,18675768,,,4,Atrial Fibrillation,N,
17157,QualifierName,Q000188,18675768,,,4,,N,drug therapy
17158,DescriptorName,D015283,18675768,,,5,Citalopram,N,
17159,QualifierName,Q000009,18675768,,,5,,Y,adverse effects
17160,DescriptorName,D004244,18675768,,,6,Dizziness,N,
17161,QualifierName,Q000139,18675768,,,6,,N,chemically induced
17162,DescriptorName,D004347,18675768,,,7,Drug Interactions,N,
17163,DescriptorName,D005260,18675768,,,8,Female,N,
17164,DescriptorName,D006801,18675768,,,9,Humans,N,
17165,DescriptorName,D011405,18675768,,,10,Propafenone,N,
17166,QualifierName,Q000009,18675768,,,10,,Y,adverse effects
17167,DescriptorName,D017367,18675768,,,11,Serotonin Uptake Inhibitors,N,
17168,QualifierName,Q000009,18675768,,,11,,Y,adverse effects
17169,Chemical,D000900,18682542,Anti-Bacterial Agents,0,,,,
17170,DescriptorName,D000328,18682542,,,1,Adult,N,
17171,DescriptorName,D000900,18682542,,,2,Anti-Bacterial Agents,N,
17172,QualifierName,Q000009,18682542,,,2,,Y,adverse effects
17173,DescriptorName,D020968,18682542,,,3,Brachial Plexus Neuritis,N,
17174,QualifierName,Q000139,18682542,,,3,,Y,chemically induced
17175,DescriptorName,D003550,18682542,,,4,Cystic Fibrosis,N,
17176,DescriptorName,D006801,18682542,,,5,Humans,N,
17177,DescriptorName,D008297,18682542,,,6,Male,N,
17178,DescriptorName,D016106,18682542,,,7,Methicillin Resistance,N,
17179,DescriptorName,D013203,18682542,,,8,Staphylococcal Infections,N,
17180,QualifierName,Q000188,18682542,,,8,,N,drug therapy
17181,DescriptorName,D013211,18682542,,,9,Staphylococcus aureus,N,
17182,QualifierName,Q000187,18682542,,,9,,N,drug effects
17183,Chemical,D008775,1868481,Methylprednisolone,X4W7ZR7023,,,,
17184,DescriptorName,D001766,1868481,,,1,Blindness,N,
17185,QualifierName,Q000139,1868481,,,1,,Y,chemically induced
17186,DescriptorName,D002648,1868481,,,2,Child,N,
17187,DescriptorName,D005260,1868481,,,3,Female,N,
17188,DescriptorName,D005921,1868481,,,4,Glomerulonephritis,N,
17189,QualifierName,Q000188,1868481,,,4,,Y,drug therapy
17190,DescriptorName,D006801,1868481,,,5,Humans,N,
17191,DescriptorName,D007262,1868481,,,6,"Infusions, Intravenous",N,
17192,DescriptorName,D008297,1868481,,,7,Male,N,
17193,DescriptorName,D008775,1868481,,,8,Methylprednisolone,N,
17194,QualifierName,Q000008,1868481,,,8,,N,administration & dosage
17195,DescriptorName,D009402,1868481,,,9,"Nephrosis, Lipoid",N,
17196,QualifierName,Q000188,1868481,,,9,,Y,drug therapy
17197,DescriptorName,D012640,1868481,,,10,Seizures,N,
17198,QualifierName,Q000139,1868481,,,10,,Y,chemically induced
17199,Chemical,D000634,18691992,Aminoquinolines,0,,,,
17200,Chemical,D000970,18691992,Antineoplastic Agents,0,,,,
17201,Chemical,D000077271,18691992,Imiquimod,P1QW714R7M,,,,
17202,Chemical,D006918,18691992,Hydroxyurea,X6Q56QN5QC,,,,
17203,DescriptorName,D000369,18691992,,,1,"Aged, 80 and over",N,
17204,DescriptorName,D000634,18691992,,,2,Aminoquinolines,N,
17205,QualifierName,Q000627,18691992,,,2,,N,therapeutic use
17206,DescriptorName,D000970,18691992,,,3,Antineoplastic Agents,N,
17207,QualifierName,Q000009,18691992,,,3,,Y,adverse effects
17208,DescriptorName,D002294,18691992,,,4,"Carcinoma, Squamous Cell",N,
17209,QualifierName,Q000139,18691992,,,4,,Y,chemically induced
17210,DescriptorName,D006801,18691992,,,5,Humans,N,
17211,DescriptorName,D006918,18691992,,,6,Hydroxyurea,N,
17212,QualifierName,Q000009,18691992,,,6,,Y,adverse effects
17213,DescriptorName,D017495,18691992,,,7,Hyperpigmentation,N,
17214,QualifierName,Q000139,18691992,,,7,,Y,chemically induced
17215,DescriptorName,D000077271,18691992,,,8,Imiquimod,N,
17216,DescriptorName,D008297,18691992,,,9,Male,N,
17217,DescriptorName,D009196,18691992,,,10,Myeloproliferative Disorders,N,
17218,QualifierName,Q000188,18691992,,,10,,N,drug therapy
17219,DescriptorName,D009260,18691992,,,11,Nail Diseases,N,
17220,QualifierName,Q000139,18691992,,,11,,Y,chemically induced
17221,DescriptorName,D012878,18691992,,,12,Skin Neoplasms,N,
17222,QualifierName,Q000139,18691992,,,12,,Y,chemically induced
17223,Chemical,D007166,18698687,Immunosuppressive Agents,0,,,,
17224,Chemical,D002939,18698687,Ciprofloxacin,5E8K9I0O4U,,,,
17225,Chemical,D016559,18698687,Tacrolimus,WM0HAQ4WNM,,,,
17226,DescriptorName,D000328,18698687,,,1,Adult,N,
17227,DescriptorName,D001649,18698687,,,2,Bile Duct Diseases,N,
17228,QualifierName,Q000139,18698687,,,2,,Y,chemically induced
17229,DescriptorName,D002939,18698687,,,3,Ciprofloxacin,N,
17230,QualifierName,Q000009,18698687,,,3,,Y,adverse effects
17231,DescriptorName,D003680,18698687,,,4,Deglutition Disorders,N,
17232,QualifierName,Q000188,18698687,,,4,,N,drug therapy
17233,DescriptorName,D053159,18698687,,,5,Dysuria,N,
17234,QualifierName,Q000188,18698687,,,5,,N,drug therapy
17235,DescriptorName,D005260,18698687,,,6,Female,N,
17236,DescriptorName,D006801,18698687,,,7,Humans,N,
17237,DescriptorName,D007166,18698687,,,8,Immunosuppressive Agents,N,
17238,QualifierName,Q000627,18698687,,,8,,Y,therapeutic use
17239,DescriptorName,D013262,18698687,,,9,Stevens-Johnson Syndrome,N,
17240,QualifierName,Q000139,18698687,,,9,,Y,chemically induced
17241,DescriptorName,D016559,18698687,,,10,Tacrolimus,N,
17242,QualifierName,Q000627,18698687,,,10,,Y,therapeutic use
17243,DescriptorName,D016896,18698687,,,11,Treatment Outcome,N,
17244,Chemical,D010975,18707772,Platelet Aggregation Inhibitors,0,,,,
17245,Chemical,D000077144,18707772,Clopidogrel,A74586SNO7,,,,
17246,Chemical,D013988,18707772,Ticlopidine,OM90ZUW7M1,,,,
17247,Chemical,D001241,18707772,Aspirin,R16CO5Y76E,,,,
17248,DescriptorName,D054058,18707772,,,1,Acute Coronary Syndrome,N,
17249,QualifierName,Q000188,18707772,,,1,,Y,drug therapy
17250,DescriptorName,D001241,18707772,,,2,Aspirin,N,
17251,QualifierName,Q000008,18707772,,,2,,N,administration & dosage
17252,DescriptorName,D001792,18707772,,,3,Blood Platelets,N,
17253,QualifierName,Q000187,18707772,,,3,,N,drug effects
17254,DescriptorName,D000077144,18707772,,,4,Clopidogrel,N,
17255,DescriptorName,D017809,18707772,,,5,Fatal Outcome,N,
17256,DescriptorName,D005260,18707772,,,6,Female,N,
17257,DescriptorName,D006801,18707772,,,7,Humans,N,
17258,DescriptorName,D020300,18707772,,,8,Intracranial Hemorrhages,N,
17259,QualifierName,Q000139,18707772,,,8,,Y,chemically induced
17260,DescriptorName,D008875,18707772,,,9,Middle Aged,N,
17261,DescriptorName,D010975,18707772,,,10,Platelet Aggregation Inhibitors,N,
17262,QualifierName,Q000008,18707772,,,10,,N,administration & dosage
17263,DescriptorName,D018570,18707772,,,11,Risk Assessment,N,
17264,DescriptorName,D012307,18707772,,,12,Risk Factors,N,
17265,DescriptorName,D013988,18707772,,,13,Ticlopidine,N,
17266,QualifierName,Q000008,18707772,,,13,,N,administration & dosage
17267,Chemical,D000890,18715650,Anti-Infective Agents,0,,,,
17268,Chemical,D018906,18715650,"Antineoplastic Agents, Alkylating",0,,,,
17269,Chemical,D001372,18715650,Aza Compounds,0,,,,
17270,Chemical,D024841,18715650,Fluoroquinolones,0,,,,
17271,Chemical,D011804,18715650,Quinolines,0,,,,
17272,Chemical,D003606,18715650,Dacarbazine,7GR28W0FJI,,,,
17273,Chemical,D000077266,18715650,Moxifloxacin,U188XYD42P,,,,
17274,Chemical,D000077204,18715650,Temozolomide,YF1K15M17Y,,,,
17275,DescriptorName,D000328,18715650,,,1,Adult,N,
17276,DescriptorName,D000890,18715650,,,2,Anti-Infective Agents,N,
17277,QualifierName,Q000627,18715650,,,2,,N,therapeutic use
17278,DescriptorName,D018906,18715650,,,3,"Antineoplastic Agents, Alkylating",N,
17279,QualifierName,Q000009,18715650,,,3,,Y,adverse effects
17280,DescriptorName,D001170,18715650,,,4,"Arthritis, Infectious",N,
17281,QualifierName,Q000175,18715650,,,4,,N,diagnosis
17282,DescriptorName,D001254,18715650,,,5,Astrocytoma,N,
17283,QualifierName,Q000188,18715650,,,5,,N,drug therapy
17284,DescriptorName,D001372,18715650,,,6,Aza Compounds,N,
17285,QualifierName,Q000627,18715650,,,6,,N,therapeutic use
17286,DescriptorName,D016470,18715650,,,7,Bacteremia,N,
17287,QualifierName,Q000188,18715650,,,7,,N,drug therapy
17288,DescriptorName,D001932,18715650,,,8,Brain Neoplasms,N,
17289,QualifierName,Q000188,18715650,,,8,,N,drug therapy
17290,DescriptorName,D003606,18715650,,,9,Dacarbazine,N,
17291,QualifierName,Q000009,18715650,,,9,,N,adverse effects
17292,DescriptorName,D004322,18715650,,,10,Drainage,N,
17293,DescriptorName,D024841,18715650,,,11,Fluoroquinolones,N,
17294,DescriptorName,D005490,18715650,,,12,Focal Infection,N,
17295,QualifierName,Q000175,18715650,,,12,,N,diagnosis
17296,DescriptorName,D006801,18715650,,,13,Humans,N,
17297,DescriptorName,D016867,18715650,,,14,Immunocompromised Host,Y,
17298,DescriptorName,D008297,18715650,,,15,Male,N,
17299,DescriptorName,D000077266,18715650,,,16,Moxifloxacin,N,
17300,DescriptorName,D011804,18715650,,,17,Quinolines,N,
17301,QualifierName,Q000627,18715650,,,17,,N,therapeutic use
17302,DescriptorName,D012480,18715650,,,18,Salmonella Infections,N,
17303,QualifierName,Q000175,18715650,,,18,,Y,diagnosis
17304,DescriptorName,D000077204,18715650,,,19,Temozolomide,N,
17305,Chemical,D000900,18717612,Anti-Bacterial Agents,0,,,,
17306,Chemical,D002443,18717612,Ceftriaxone,75J73V1629,,,,
17307,DescriptorName,D000900,18717612,,,1,Anti-Bacterial Agents,N,
17308,QualifierName,Q000009,18717612,,,1,,Y,adverse effects
17309,DescriptorName,D002443,18717612,,,2,Ceftriaxone,N,
17310,QualifierName,Q000009,18717612,,,2,,Y,adverse effects
17311,DescriptorName,D003875,18717612,,,3,Drug Eruptions,N,
17312,QualifierName,Q000209,18717612,,,3,,Y,etiology
17313,DescriptorName,D005145,18717612,,,4,Face,N,
17314,DescriptorName,D005260,18717612,,,5,Female,N,
17315,DescriptorName,D005528,18717612,,,6,Foot,N,
17316,DescriptorName,D006801,18717612,,,7,Humans,N,
17317,DescriptorName,D008875,18717612,,,8,Middle Aged,N,
17318,DescriptorName,D014552,18717612,,,9,Urinary Tract Infections,N,
17319,QualifierName,Q000188,18717612,,,9,,Y,drug therapy
17320,Chemical,D000588,18721173,Amines,0,,,,
17321,Chemical,D003509,18721173,Cyclohexanecarboxylic Acids,0,,,,
17322,Chemical,D005680,18721173,gamma-Aminobutyric Acid,56-12-2,,,,
17323,Chemical,D000077206,18721173,Gabapentin,6CW7F3G59X,,,,
17324,DescriptorName,D058186,18721173,,,1,Acute Kidney Injury,N,
17325,QualifierName,Q000503,18721173,,,1,,Y,physiopathology
17326,DescriptorName,D000368,18721173,,,2,Aged,N,
17327,DescriptorName,D000588,18721173,,,3,Amines,N,
17328,QualifierName,Q000009,18721173,,,3,,Y,adverse effects
17329,DescriptorName,D000818,18721173,,,4,Animals,N,
17330,DescriptorName,D003509,18721173,,,5,Cyclohexanecarboxylic Acids,N,
17331,QualifierName,Q000009,18721173,,,5,,Y,adverse effects
17332,DescriptorName,D005260,18721173,,,6,Female,N,
17333,DescriptorName,D000077206,18721173,,,7,Gabapentin,N,
17334,DescriptorName,D006801,18721173,,,8,Humans,N,
17335,DescriptorName,D007049,18721173,,,9,Iatrogenic Disease,N,
17336,DescriptorName,D010146,18721173,,,10,Pain,N,
17337,QualifierName,Q000188,18721173,,,10,,N,drug therapy
17338,DescriptorName,D005680,18721173,,,11,gamma-Aminobutyric Acid,N,
17339,QualifierName,Q000009,18721173,,,11,,Y,adverse effects
17340,Chemical,D000890,18751717,Anti-Infective Agents,0,,,,
17341,Chemical,D005938,18751717,Glucocorticoids,0,,,,
17342,Chemical,D014222,18751717,Triamcinolone Acetonide,F446C597KA,,,,
17343,DescriptorName,D000208,18751717,,,1,Acute Disease,N,
17344,DescriptorName,D000368,18751717,,,2,Aged,N,
17345,DescriptorName,D000890,18751717,,,3,Anti-Infective Agents,N,
17346,QualifierName,Q000627,18751717,,,3,,N,therapeutic use
17347,DescriptorName,D001284,18751717,,,4,Atrophy,N,
17348,DescriptorName,D002825,18751717,,,5,Chorioretinitis,N,
17349,QualifierName,Q000175,18751717,,,5,,N,diagnosis
17350,DescriptorName,D005260,18751717,,,6,Female,N,
17351,DescriptorName,D005451,18751717,,,7,Fluorescein Angiography,N,
17352,DescriptorName,D005654,18751717,,,8,Fundus Oculi,N,
17353,DescriptorName,D005938,18751717,,,9,Glucocorticoids,N,
17354,QualifierName,Q000008,18751717,,,9,,Y,administration & dosage
17355,DescriptorName,D006801,18751717,,,10,Humans,N,
17356,DescriptorName,D007267,18751717,,,11,Injections,N,
17357,DescriptorName,D008297,18751717,,,12,Male,N,
17358,DescriptorName,D008875,18751717,,,13,Middle Aged,N,
17359,DescriptorName,D009494,18751717,,,14,Neurosyphilis,N,
17360,QualifierName,Q000188,18751717,,,14,,N,drug therapy
17361,DescriptorName,D013587,18751717,,,15,Syphilis,Y,
17362,QualifierName,Q000276,18751717,,,15,,N,immunology
17363,DescriptorName,D041623,18751717,,,16,"Tomography, Optical Coherence",N,
17364,DescriptorName,D017211,18751717,,,17,Treatment Failure,N,
17365,DescriptorName,D014222,18751717,,,18,Triamcinolone Acetonide,N,
17366,QualifierName,Q000008,18751717,,,18,,Y,administration & dosage
17367,DescriptorName,D014792,18751717,,,19,Visual Acuity,N,
17368,DescriptorName,D014822,18751717,,,20,Vitreous Body,N,
17369,Chemical,D005343,18755414,Fibrinolytic Agents,0,,,,
17370,Chemical,D001241,18755414,Aspirin,R16CO5Y76E,,,,
17371,DescriptorName,D000368,18755414,,,1,Aged,N,
17372,DescriptorName,D001241,18755414,,,2,Aspirin,N,
17373,QualifierName,Q000008,18755414,,,2,,N,administration & dosage
17374,DescriptorName,D002544,18755414,,,3,Cerebral Infarction,N,
17375,QualifierName,Q000188,18755414,,,3,,N,drug therapy
17376,DescriptorName,D005260,18755414,,,4,Female,N,
17377,DescriptorName,D005343,18755414,,,5,Fibrinolytic Agents,N,
17378,QualifierName,Q000008,18755414,,,5,,N,administration & dosage
17379,DescriptorName,D006801,18755414,,,6,Humans,N,
17380,DescriptorName,D020300,18755414,,,7,Intracranial Hemorrhages,N,
17381,QualifierName,Q000139,18755414,,,7,,Y,chemically induced
17382,DescriptorName,D008577,18755414,,,8,Meningeal Neoplasms,N,
17383,QualifierName,Q000150,18755414,,,8,,Y,complications
17384,DescriptorName,D008579,18755414,,,9,Meningioma,N,
17385,QualifierName,Q000150,18755414,,,9,,Y,complications
17386,DescriptorName,D016896,18755414,,,10,Treatment Outcome,N,
17387,Chemical,D000911,18765315,"Antibodies, Monoclonal",0,,,,
17388,Chemical,D058846,18765315,"Antibodies, Monoclonal, Murine-Derived",0,,,,
17389,Chemical,D000970,18765315,Antineoplastic Agents,0,,,,
17390,Chemical,D000069283,18765315,Rituximab,4F4X42SYQ6,,,,
17391,DescriptorName,D054058,18765315,,,1,Acute Coronary Syndrome,N,
17392,QualifierName,Q000139,18765315,,,1,,Y,chemically induced
17393,DescriptorName,D000368,18765315,,,2,Aged,N,
17394,DescriptorName,D000911,18765315,,,3,"Antibodies, Monoclonal",N,
17395,QualifierName,Q000008,18765315,,,3,,N,administration & dosage
17396,DescriptorName,D058846,18765315,,,4,"Antibodies, Monoclonal, Murine-Derived",N,
17397,DescriptorName,D000970,18765315,,,5,Antineoplastic Agents,N,
17398,QualifierName,Q000008,18765315,,,5,,N,administration & dosage
17399,DescriptorName,D006801,18765315,,,6,Humans,N,
17400,DescriptorName,D008228,18765315,,,7,"Lymphoma, Non-Hodgkin",N,
17401,QualifierName,Q000188,18765315,,,7,,N,drug therapy
17402,DescriptorName,D008297,18765315,,,8,Male,N,
17403,DescriptorName,D008875,18765315,,,9,Middle Aged,N,
17404,DescriptorName,D000069283,18765315,,,10,Rituximab,N,
17405,Chemical,D000925,18775393,Anticoagulants,0,,,,
17406,Chemical,D000935,18775393,Antifungal Agents,0,,,,
17407,Chemical,D010975,18775393,Platelet Aggregation Inhibitors,0,,,,
17408,Chemical,D004464,18775393,Econazole,6Z1Y2V4A7M,,,,
17409,Chemical,D011516,18775393,Prothrombin,9001-26-7,,,,
17410,Chemical,D000074,18775393,Acenocoumarol,I6WP63U32H,,,,
17411,Chemical,D001241,18775393,Aspirin,R16CO5Y76E,,,,
17412,DescriptorName,D000074,18775393,,,1,Acenocoumarol,N,
17413,QualifierName,Q000009,18775393,,,1,,Y,adverse effects
17414,DescriptorName,D000287,18775393,,,2,"Administration, Topical",N,
17415,DescriptorName,D000369,18775393,,,3,"Aged, 80 and over",N,
17416,DescriptorName,D000925,18775393,,,4,Anticoagulants,N,
17417,QualifierName,Q000009,18775393,,,4,,Y,adverse effects
17418,DescriptorName,D000935,18775393,,,5,Antifungal Agents,N,
17419,QualifierName,Q000008,18775393,,,5,,N,administration & dosage
17420,DescriptorName,D001241,18775393,,,6,Aspirin,N,
17421,QualifierName,Q000627,18775393,,,6,,N,therapeutic use
17422,DescriptorName,D001778,18775393,,,7,Blood Coagulation Disorders,N,
17423,QualifierName,Q000097,18775393,,,7,,N,blood
17424,DescriptorName,D004347,18775393,,,8,Drug Interactions,N,
17425,DescriptorName,D004417,18775393,,,9,Dyspnea,N,
17426,QualifierName,Q000139,18775393,,,9,,Y,chemically induced
17427,DescriptorName,D004464,18775393,,,10,Econazole,N,
17428,QualifierName,Q000008,18775393,,,10,,N,administration & dosage
17429,DescriptorName,D005260,18775393,,,11,Female,N,
17430,DescriptorName,D006406,18775393,,,12,Hematoma,N,
17431,QualifierName,Q000209,18775393,,,12,,N,etiology
17432,DescriptorName,D006801,18775393,,,13,Humans,N,
17433,DescriptorName,D007818,18775393,,,14,Laryngeal Diseases,N,
17434,QualifierName,Q000139,18775393,,,14,,Y,chemically induced
17435,DescriptorName,D007828,18775393,,,15,Laryngoscopy,N,
17436,DescriptorName,D010975,18775393,,,16,Platelet Aggregation Inhibitors,N,
17437,QualifierName,Q000627,18775393,,,16,,N,therapeutic use
17438,DescriptorName,D011516,18775393,,,17,Prothrombin,N,
17439,QualifierName,Q000627,18775393,,,17,,N,therapeutic use
17440,Chemical,D006854,18784429,Hydrocortisone,WI4X0X7BPJ,,,,
17441,Chemical,D008775,18784429,Methylprednisolone,X4W7ZR7023,,,,
17442,DescriptorName,D000309,18784429,,,1,Adrenal Insufficiency,N,
17443,QualifierName,Q000139,18784429,,,1,,Y,chemically induced
17444,DescriptorName,D000328,18784429,,,2,Adult,N,
17445,DescriptorName,D003424,18784429,,,3,Crohn Disease,N,
17446,QualifierName,Q000188,18784429,,,3,,Y,drug therapy
17447,DescriptorName,D004305,18784429,,,4,"Dose-Response Relationship, Drug",N,
17448,DescriptorName,D005260,18784429,,,5,Female,N,
17449,DescriptorName,D006801,18784429,,,6,Humans,N,
17450,DescriptorName,D006854,18784429,,,7,Hydrocortisone,N,
17451,QualifierName,Q000627,18784429,,,7,,Y,therapeutic use
17452,DescriptorName,D007231,18784429,,,8,"Infant, Newborn",N,
17453,DescriptorName,D008297,18784429,,,9,Male,N,
17454,DescriptorName,D008775,18784429,,,10,Methylprednisolone,N,
17455,QualifierName,Q000008,18784429,,,10,,N,administration & dosage
17456,DescriptorName,D011247,18784429,,,11,Pregnancy,N,
17457,DescriptorName,D011248,18784429,,,12,Pregnancy Complications,N,
17458,QualifierName,Q000188,18784429,,,12,,Y,drug therapy
17459,DescriptorName,D011297,18784429,,,13,Prenatal Exposure Delayed Effects,N,
17460,QualifierName,Q000139,18784429,,,13,,Y,chemically induced
17461,Chemical,D006634,18795,Histamine H1 Antagonists,0,,,,
17462,Chemical,D004205,18795,Cromolyn Sodium,Q2WXR1I0PK,,,,
17463,DescriptorName,D001249,18795,,,1,Asthma,N,
17464,QualifierName,Q000188,18795,,,1,,Y,drug therapy
17465,DescriptorName,D002648,18795,,,2,Child,N,
17466,DescriptorName,D004205,18795,,,3,Cromolyn Sodium,N,
17467,QualifierName,Q000009,18795,,,3,,Y,adverse effects
17468,DescriptorName,D003875,18795,,,4,Drug Eruptions,Y,
17469,DescriptorName,D006634,18795,,,5,Histamine H1 Antagonists,N,
17470,QualifierName,Q000627,18795,,,5,,N,therapeutic use
17471,DescriptorName,D006801,18795,,,6,Humans,N,
17472,DescriptorName,D008297,18795,,,7,Male,N,
17473,DescriptorName,D012882,18795,,,8,Skin Tests,N,
17474,DescriptorName,D014581,18795,,,9,Urticaria,N,
17475,QualifierName,Q000139,18795,,,9,,Y,chemically induced
17476,Chemical,D011433,1879988,Propranolol,9Y8NXQ24VQ,,,,
17477,DescriptorName,D002312,1879988,,,1,"Cardiomyopathy, Hypertrophic",N,
17478,QualifierName,Q000188,1879988,,,1,,Y,drug therapy
17479,DescriptorName,D004562,1879988,,,2,Electrocardiography,N,
17480,DescriptorName,D005260,1879988,,,3,Female,N,
17481,DescriptorName,D006327,1879988,,,4,Heart Block,N,
17482,QualifierName,Q000139,1879988,,,4,,Y,chemically induced
17483,DescriptorName,D006801,1879988,,,5,Humans,N,
17484,DescriptorName,D008875,1879988,,,6,Middle Aged,N,
17485,DescriptorName,D011433,1879988,,,7,Propranolol,N,
17486,QualifierName,Q000009,1879988,,,7,,Y,adverse effects
17487,DescriptorName,D013575,1879988,,,8,Syncope,N,
17488,QualifierName,Q000139,1879988,,,8,,Y,chemically induced
17489,Chemical,D014150,18801826,Antipsychotic Agents,0,,,,
17490,Chemical,D001569,18801826,Benzodiazepines,12794-10-4,,,,
17491,Chemical,D000077152,18801826,Olanzapine,N7U69T4SZR,,,,
17492,DescriptorName,D058186,18801826,,,1,Acute Kidney Injury,N,
17493,QualifierName,Q000139,18801826,,,1,,N,chemically induced
17494,DescriptorName,D000328,18801826,,,2,Adult,N,
17495,DescriptorName,D014150,18801826,,,3,Antipsychotic Agents,N,
17496,QualifierName,Q000009,18801826,,,3,,Y,adverse effects
17497,DescriptorName,D001569,18801826,,,4,Benzodiazepines,N,
17498,QualifierName,Q000009,18801826,,,4,,Y,adverse effects
17499,DescriptorName,D001714,18801826,,,5,Bipolar Disorder,N,
17500,QualifierName,Q000188,18801826,,,5,,N,drug therapy
17501,DescriptorName,D003924,18801826,,,6,"Diabetes Mellitus, Type 2",N,
17502,QualifierName,Q000139,18801826,,,6,,N,chemically induced
17503,DescriptorName,D005260,18801826,,,7,Female,N,
17504,DescriptorName,D006801,18801826,,,8,Humans,N,
17505,DescriptorName,D006944,18801826,,,9,Hyperglycemic Hyperosmolar Nonketotic Coma,N,
17506,QualifierName,Q000139,18801826,,,9,,Y,chemically induced
17507,DescriptorName,D009459,18801826,,,10,Neuroleptic Malignant Syndrome,N,
17508,QualifierName,Q000209,18801826,,,10,,Y,etiology
17509,DescriptorName,D000077152,18801826,,,11,Olanzapine,N,
17510,Chemical,D000276,18805724,"Adjuvants, Immunologic",0,,,,
17511,Chemical,D005938,18805724,Glucocorticoids,0,,,,
17512,Chemical,D007475,18805724,Ion Exchange Resins,0,,,,
17513,Chemical,D007555,18805724,Isoxazoles,0,,,,
17514,Chemical,D002792,18805724,Cholestyramine Resin,11041-12-6,,,,
17515,Chemical,D011239,18805724,Prednisolone,9PHQ9Y1OLM,,,,
17516,Chemical,D000077339,18805724,Leflunomide,G162GK9U4W,,,,
17517,DescriptorName,D000276,18805724,,,1,"Adjuvants, Immunologic",N,
17518,QualifierName,Q000009,18805724,,,1,,Y,adverse effects
17519,DescriptorName,D000328,18805724,,,2,Adult,N,
17520,DescriptorName,D001172,18805724,,,3,"Arthritis, Rheumatoid",N,
17521,QualifierName,Q000150,18805724,,,3,,N,complications
17522,DescriptorName,D002792,18805724,,,4,Cholestyramine Resin,N,
17523,QualifierName,Q000627,18805724,,,4,,N,therapeutic use
17524,DescriptorName,D005260,18805724,,,5,Female,N,
17525,DescriptorName,D005938,18805724,,,6,Glucocorticoids,N,
17526,QualifierName,Q000627,18805724,,,6,,N,therapeutic use
17527,DescriptorName,D006801,18805724,,,7,Humans,N,
17528,DescriptorName,D007475,18805724,,,8,Ion Exchange Resins,N,
17529,QualifierName,Q000627,18805724,,,8,,N,therapeutic use
17530,DescriptorName,D007555,18805724,,,9,Isoxazoles,N,
17531,QualifierName,Q000009,18805724,,,9,,Y,adverse effects
17532,DescriptorName,D000077339,18805724,,,10,Leflunomide,N,
17533,DescriptorName,D011239,18805724,,,11,Prednisolone,N,
17534,QualifierName,Q000627,18805724,,,11,,N,therapeutic use
17535,DescriptorName,D013262,18805724,,,12,Stevens-Johnson Syndrome,N,
17536,QualifierName,Q000188,18805724,,,12,,N,drug therapy
17537,Chemical,D018501,18810448,Antirheumatic Agents,0,,,,
17538,Chemical,D007074,18810448,Immunoglobulin G,0,,,,
17539,Chemical,D007155,18810448,Immunologic Factors,0,,,,
17540,Chemical,D018124,18810448,"Receptors, Tumor Necrosis Factor",0,,,,
17541,Chemical,D011993,18810448,Recombinant Fusion Proteins,0,,,,
17542,Chemical,D000068800,18810448,Etanercept,OP401G7OJC,,,,
17543,DescriptorName,D018501,18810448,,,1,Antirheumatic Agents,N,
17544,QualifierName,Q000627,18810448,,,1,,N,therapeutic use
17545,DescriptorName,D001171,18810448,,,2,"Arthritis, Juvenile",N,
17546,QualifierName,Q000188,18810448,,,2,,Y,drug therapy
17547,DescriptorName,D003937,18810448,,,3,"Diagnosis, Differential",N,
17548,DescriptorName,D000068800,18810448,,,4,Etanercept,N,
17549,DescriptorName,D005500,18810448,,,5,Follow-Up Studies,N,
17550,DescriptorName,D006801,18810448,,,6,Humans,N,
17551,DescriptorName,D007074,18810448,,,7,Immunoglobulin G,N,
17552,QualifierName,Q000009,18810448,,,7,,Y,adverse effects
17553,DescriptorName,D007155,18810448,,,8,Immunologic Factors,N,
17554,QualifierName,Q000009,18810448,,,8,,Y,adverse effects
17555,DescriptorName,D008206,18810448,,,9,Lymphatic Diseases,N,
17556,QualifierName,Q000175,18810448,,,9,,N,diagnosis
17557,DescriptorName,D008297,18810448,,,10,Male,N,
17558,DescriptorName,D008479,18810448,,,11,Mediastinal Neoplasms,N,
17559,QualifierName,Q000175,18810448,,,11,,N,diagnosis
17560,DescriptorName,D008481,18810448,,,12,Mediastinoscopy,N,
17561,DescriptorName,D018124,18810448,,,13,"Receptors, Tumor Necrosis Factor",N,
17562,DescriptorName,D011993,18810448,,,14,Recombinant Fusion Proteins,N,
17563,QualifierName,Q000009,18810448,,,14,,Y,adverse effects
17564,DescriptorName,D013950,18810448,,,15,Thymus Gland,N,
17565,QualifierName,Q000000981,18810448,,,15,,N,diagnostic imaging
17566,DescriptorName,D013997,18810448,,,16,Time Factors,N,
17567,DescriptorName,D014057,18810448,,,17,"Tomography, X-Ray Computed",N,
17568,DescriptorName,D016896,18810448,,,18,Treatment Outcome,N,
17569,DescriptorName,D055815,18810448,,,19,Young Adult,N,
17570,Chemical,D000927,18821094,Anticonvulsants,0,,,,
17571,Chemical,D005938,18821094,Glucocorticoids,0,,,,
17572,Chemical,D002220,18821094,Carbamazepine,33CM23913M,,,,
17573,Chemical,D000078330,18821094,Oxcarbazepine,VZI5B1W380,,,,
17574,DescriptorName,D000293,18821094,,,1,Adolescent,N,
17575,DescriptorName,D000927,18821094,,,2,Anticonvulsants,N,
17576,QualifierName,Q000008,18821094,,,2,,N,administration & dosage
17577,DescriptorName,D002220,18821094,,,3,Carbamazepine,N,
17578,QualifierName,Q000008,18821094,,,3,,N,administration & dosage
17579,DescriptorName,D003875,18821094,,,4,Drug Eruptions,N,
17580,QualifierName,Q000097,18821094,,,4,,N,blood
17581,DescriptorName,D004802,18821094,,,5,Eosinophilia,N,
17582,QualifierName,Q000097,18821094,,,5,,N,blood
17583,DescriptorName,D005334,18821094,,,6,Fever,N,
17584,QualifierName,Q000139,18821094,,,6,,N,chemically induced
17585,DescriptorName,D005938,18821094,,,7,Glucocorticoids,N,
17586,QualifierName,Q000627,18821094,,,7,,N,therapeutic use
17587,DescriptorName,D006801,18821094,,,8,Humans,N,
17588,DescriptorName,D008297,18821094,,,9,Male,N,
17589,DescriptorName,D000078330,18821094,,,10,Oxcarbazepine,N,
17590,DescriptorName,D012640,18821094,,,11,Seizures,N,
17591,QualifierName,Q000188,18821094,,,11,,N,drug therapy
17592,DescriptorName,D016896,18821094,,,12,Treatment Outcome,N,
17593,Chemical,D000318,18836269,Adrenergic beta-Agonists,0,,,,
17594,Chemical,D000889,18836269,Anti-Arrhythmia Agents,0,,,,
17595,Chemical,D005280,18836269,Fenoterol,22M9P70OQ9,,,,
17596,Chemical,D005424,18836269,Flecainide,K94FTS1806,,,,
17597,DescriptorName,D000318,18836269,,,1,Adrenergic beta-Agonists,N,
17598,QualifierName,Q000008,18836269,,,1,,N,administration & dosage
17599,DescriptorName,D000328,18836269,,,2,Adult,N,
17600,DescriptorName,D000889,18836269,,,3,Anti-Arrhythmia Agents,N,
17601,QualifierName,Q000008,18836269,,,3,,Y,administration & dosage
17602,DescriptorName,D004452,18836269,,,4,Echocardiography,N,
17603,DescriptorName,D005260,18836269,,,5,Female,N,
17604,DescriptorName,D005280,18836269,,,6,Fenoterol,N,
17605,QualifierName,Q000008,18836269,,,6,,N,administration & dosage
17606,DescriptorName,D005315,18836269,,,7,Fetal Diseases,N,
17607,QualifierName,Q000139,18836269,,,7,,N,chemically induced
17608,DescriptorName,D005424,18836269,,,8,Flecainide,N,
17609,QualifierName,Q000008,18836269,,,8,,Y,administration & dosage
17610,DescriptorName,D006801,18836269,,,9,Humans,N,
17611,DescriptorName,D007231,18836269,,,10,"Infant, Newborn",N,
17612,DescriptorName,D008297,18836269,,,11,Male,N,
17613,DescriptorName,D007752,18836269,,,12,"Obstetric Labor, Premature",N,
17614,QualifierName,Q000188,18836269,,,12,,N,drug therapy
17615,DescriptorName,D011247,18836269,,,13,Pregnancy,N,
17616,DescriptorName,D011256,18836269,,,14,Pregnancy Outcome,N,
17617,DescriptorName,D013617,18836269,,,15,"Tachycardia, Supraventricular",N,
17618,QualifierName,Q000139,18836269,,,15,,N,chemically induced
17619,DescriptorName,D014427,18836269,,,16,Twins,N,
17620,DescriptorName,D016216,18836269,,,17,"Ultrasonography, Prenatal",N,
17621,Chemical,D047428,18837734,Protein Kinase Inhibitors,0,,,,
17622,Chemical,D011799,18837734,Quinazolines,0,,,,
17623,Chemical,D000069347,18837734,Erlotinib Hydrochloride,DA87705X9K,,,,
17624,DescriptorName,D017486,18837734,,,1,Acneiform Eruptions,N,
17625,QualifierName,Q000139,18837734,,,1,,N,chemically induced
17626,DescriptorName,D000369,18837734,,,2,"Aged, 80 and over",N,
17627,DescriptorName,D002289,18837734,,,3,"Carcinoma, Non-Small-Cell Lung",N,
17628,QualifierName,Q000188,18837734,,,3,,Y,drug therapy
17629,DescriptorName,D003875,18837734,,,4,Drug Eruptions,N,
17630,QualifierName,Q000209,18837734,,,4,,Y,etiology
17631,DescriptorName,D000069347,18837734,,,5,Erlotinib Hydrochloride,N,
17632,DescriptorName,D006801,18837734,,,6,Humans,N,
17633,DescriptorName,D008175,18837734,,,7,Lung Neoplasms,N,
17634,QualifierName,Q000188,18837734,,,7,,Y,drug therapy
17635,DescriptorName,D008297,18837734,,,8,Male,N,
17636,DescriptorName,D047428,18837734,,,9,Protein Kinase Inhibitors,N,
17637,QualifierName,Q000009,18837734,,,9,,Y,adverse effects
17638,DescriptorName,D011799,18837734,,,10,Quinazolines,N,
17639,QualifierName,Q000009,18837734,,,10,,Y,adverse effects
17640,Chemical,D008727,18855892,Methotrexate,YL5FZ2Y5U1,,,,
17641,DescriptorName,D000707,18855892,,,1,Anaphylaxis,N,
17642,QualifierName,Q000139,18855892,,,1,,Y,chemically induced
17643,DescriptorName,D002648,18855892,,,2,Child,N,
17644,DescriptorName,D003888,18855892,,,3,"Desensitization, Immunologic",N,
17645,QualifierName,Q000379,18855892,,,3,,Y,methods
17646,DescriptorName,D004342,18855892,,,4,Drug Hypersensitivity,N,
17647,QualifierName,Q000517,18855892,,,4,,Y,prevention & control
17648,DescriptorName,D006801,18855892,,,5,Humans,N,
17649,DescriptorName,D008727,18855892,,,6,Methotrexate,N,
17650,QualifierName,Q000009,18855892,,,6,,Y,adverse effects
17651,DescriptorName,D012516,18855892,,,7,Osteosarcoma,N,
17652,QualifierName,Q000150,18855892,,,7,,N,complications
17653,Chemical,D004110,1888256,Diltiazem,EE92BBP03H,,,,
17654,DescriptorName,D000368,1888256,,,1,Aged,N,
17655,DescriptorName,D004110,1888256,,,2,Diltiazem,N,
17656,QualifierName,Q000009,1888256,,,2,,Y,adverse effects
17657,DescriptorName,D004342,1888256,,,3,Drug Hypersensitivity,N,
17658,QualifierName,Q000209,1888256,,,3,,Y,etiology
17659,DescriptorName,D005334,1888256,,,4,Fever,N,
17660,QualifierName,Q000139,1888256,,,4,,Y,chemically induced
17661,DescriptorName,D006801,1888256,,,5,Humans,N,
17662,DescriptorName,D008297,1888256,,,6,Male,N,
17663,DescriptorName,D009203,1888256,,,7,Myocardial Infarction,N,
17664,QualifierName,Q000188,1888256,,,7,,N,drug therapy
17665,Chemical,D004317,189279,Doxorubicin,80168379AG,,,,
17666,DescriptorName,D006332,189279,,,1,Cardiomegaly,N,
17667,QualifierName,Q000139,189279,,,1,,Y,chemically induced
17668,DescriptorName,D002648,189279,,,2,Child,N,
17669,DescriptorName,D004317,189279,,,3,Doxorubicin,N,
17670,QualifierName,Q000009,189279,,,3,,Y,adverse effects
17671,DescriptorName,D005260,189279,,,4,Female,N,
17672,DescriptorName,D006333,189279,,,5,Heart Failure,N,
17673,QualifierName,Q000139,189279,,,5,,Y,chemically induced
17674,DescriptorName,D006801,189279,,,6,Humans,N,
17675,DescriptorName,D011859,189279,,,7,Radiography,N,
17676,DescriptorName,D009396,189279,,,8,Wilms Tumor,N,
17677,QualifierName,Q000188,189279,,,8,,N,drug therapy
17678,Chemical,D002220,1893404,Carbamazepine,33CM23913M,,,,
17679,DescriptorName,D000328,1893404,,,1,Adult,N,
17680,DescriptorName,D002220,1893404,,,2,Carbamazepine,N,
17681,QualifierName,Q000008,1893404,,,2,,N,administration & dosage
17682,DescriptorName,D003920,1893404,,,3,Diabetes Mellitus,N,
17683,QualifierName,Q000097,1893404,,,3,,N,blood
17684,DescriptorName,D005260,1893404,,,4,Female,N,
17685,DescriptorName,D006801,1893404,,,5,Humans,N,
17686,DescriptorName,D012640,1893404,,,6,Seizures,N,
17687,QualifierName,Q000188,1893404,,,6,,Y,drug therapy
17688,Chemical,D000893,18950384,Anti-Inflammatory Agents,0,,,,
17689,Chemical,D018687,18950384,"Antidepressive Agents, Second-Generation",0,,,,
17690,Chemical,D014150,18950384,Antipsychotic Agents,0,,,,
17691,Chemical,D010879,18950384,Piperazines,0,,,,
17692,Chemical,D015363,18950384,Quinolones,0,,,,
17693,Chemical,D008803,18950384,Mianserin,250PJI13LM,,,,
17694,Chemical,D017374,18950384,Paroxetine,41VRH5220H,,,,
17695,Chemical,D000068180,18950384,Aripiprazole,82VFR53I78,,,,
17696,Chemical,D016572,18950384,Cyclosporine,83HN0GTJ6D,,,,
17697,Chemical,D011239,18950384,Prednisolone,9PHQ9Y1OLM,,,,
17698,Chemical,D020280,18950384,Sertraline,QUC7NX6WMB,,,,
17699,DescriptorName,D000328,18950384,,,1,Adult,N,
17700,DescriptorName,D000893,18950384,,,2,Anti-Inflammatory Agents,N,
17701,QualifierName,Q000009,18950384,,,2,,Y,adverse effects
17702,DescriptorName,D018687,18950384,,,3,"Antidepressive Agents, Second-Generation",N,
17703,QualifierName,Q000009,18950384,,,3,,Y,adverse effects
17704,DescriptorName,D014150,18950384,,,4,Antipsychotic Agents,N,
17705,QualifierName,Q000009,18950384,,,4,,Y,adverse effects
17706,DescriptorName,D001066,18950384,,,5,Appetite,N,
17707,QualifierName,Q000187,18950384,,,5,,N,drug effects
17708,DescriptorName,D000068180,18950384,,,6,Aripiprazole,N,
17709,DescriptorName,D001835,18950384,,,7,Body Weight,N,
17710,QualifierName,Q000187,18950384,,,7,,Y,drug effects
17711,DescriptorName,D016572,18950384,,,8,Cyclosporine,N,
17712,QualifierName,Q000009,18950384,,,8,,N,adverse effects
17713,DescriptorName,D003866,18950384,,,9,Depressive Disorder,N,
17714,QualifierName,Q000139,18950384,,,9,,Y,chemically induced
17715,DescriptorName,D004347,18950384,,,10,Drug Interactions,N,
17716,DescriptorName,D004359,18950384,,,11,"Drug Therapy, Combination",N,
17717,DescriptorName,D004435,18950384,,,12,Eating,N,
17718,QualifierName,Q000187,18950384,,,12,,N,drug effects
17719,DescriptorName,D005260,18950384,,,13,Female,N,
17720,DescriptorName,D006801,18950384,,,14,Humans,N,
17721,DescriptorName,D008803,18950384,,,15,Mianserin,N,
17722,QualifierName,Q000009,18950384,,,15,,Y,adverse effects
17723,DescriptorName,D017374,18950384,,,16,Paroxetine,N,
17724,QualifierName,Q000009,18950384,,,16,,N,adverse effects
17725,DescriptorName,D010879,18950384,,,17,Piperazines,N,
17726,QualifierName,Q000009,18950384,,,17,,Y,adverse effects
17727,DescriptorName,D011239,18950384,,,18,Prednisolone,N,
17728,QualifierName,Q000009,18950384,,,18,,Y,adverse effects
17729,DescriptorName,D015363,18950384,,,19,Quinolones,N,
17730,QualifierName,Q000009,18950384,,,19,,Y,adverse effects
17731,DescriptorName,D020280,18950384,,,20,Sertraline,N,
17732,QualifierName,Q000009,18950384,,,20,,N,adverse effects
17733,DescriptorName,D013625,18950384,,,21,Takayasu Arteritis,N,
17734,QualifierName,Q000188,18950384,,,21,,Y,drug therapy
17735,Chemical,D000906,18957000,Antibodies,0,,,,
17736,Chemical,D000925,18957000,Anticoagulants,0,,,,
17737,Chemical,D010978,18957000,Platelet Factor 4,37270-94-3,,,,
17738,Chemical,D006493,18957000,Heparin,9005-49-6,,,,
17739,DescriptorName,D000328,18957000,,,1,Adult,N,
17740,DescriptorName,D000906,18957000,,,2,Antibodies,N,
17741,QualifierName,Q000276,18957000,,,2,,Y,immunology
17742,DescriptorName,D000925,18957000,,,3,Anticoagulants,N,
17743,QualifierName,Q000009,18957000,,,3,,Y,adverse effects
17744,DescriptorName,D001777,18957000,,,4,Blood Coagulation,N,
17745,QualifierName,Q000187,18957000,,,4,,N,drug effects
17746,DescriptorName,D004797,18957000,,,5,Enzyme-Linked Immunosorbent Assay,N,
17747,DescriptorName,D005260,18957000,,,6,Female,N,
17748,DescriptorName,D006493,18957000,,,7,Heparin,N,
17749,QualifierName,Q000009,18957000,,,7,,Y,adverse effects
17750,DescriptorName,D006801,18957000,,,8,Humans,N,
17751,DescriptorName,D010976,18957000,,,9,Platelet Count,N,
17752,DescriptorName,D010978,18957000,,,10,Platelet Factor 4,N,
17753,QualifierName,Q000378,18957000,,,10,,N,metabolism
17754,DescriptorName,D017131,18957000,,,11,Thrombectomy,N,
17755,DescriptorName,D013921,18957000,,,12,Thrombocytopenia,N,
17756,QualifierName,Q000188,18957000,,,12,,Y,drug therapy
17757,DescriptorName,D013927,18957000,,,13,Thrombosis,N,
17758,QualifierName,Q000188,18957000,,,13,,Y,drug therapy
17759,Chemical,D000925,18977778,Anticoagulants,0,,,,
17760,Chemical,D001779,18977778,Blood Coagulation Factors,0,,,,
17761,Chemical,D017984,18977778,Enoxaparin,0,,,,
17762,Chemical,D014812,18977778,Vitamin K,12001-79-5,,,,
17763,Chemical,C025667,18977778,prothrombin complex concentrates,37224-63-8,,,,
17764,Chemical,D008696,18977778,Methandrostenolone,COZ1R7EOCC,,,,
17765,Chemical,D017985,18977778,Dalteparin,S79O08V79F,,,,
17766,DescriptorName,D000925,18977778,,,1,Anticoagulants,N,
17767,QualifierName,Q000627,18977778,,,1,,N,therapeutic use
17768,DescriptorName,D001779,18977778,,,2,Blood Coagulation Factors,N,
17769,QualifierName,Q000627,18977778,,,2,,N,therapeutic use
17770,DescriptorName,D017985,18977778,,,3,Dalteparin,N,
17771,QualifierName,Q000627,18977778,,,3,,N,therapeutic use
17772,DescriptorName,D004300,18977778,,,4,Doping in Sports,Y,
17773,DescriptorName,D017984,18977778,,,5,Enoxaparin,N,
17774,QualifierName,Q000627,18977778,,,5,,N,therapeutic use
17775,DescriptorName,D006408,18977778,,,6,"Hematoma, Subdural",N,
17776,QualifierName,Q000209,18977778,,,6,,N,etiology
17777,DescriptorName,D006801,18977778,,,7,Humans,N,
17778,DescriptorName,D008297,18977778,,,8,Male,N,
17779,DescriptorName,D008696,18977778,,,9,Methandrostenolone,N,
17780,QualifierName,Q000009,18977778,,,9,,Y,adverse effects
17781,DescriptorName,D010996,18977778,,,10,Pleural Effusion,N,
17782,QualifierName,Q000209,18977778,,,10,,N,etiology
17783,DescriptorName,D020151,18977778,,,11,Protein C Deficiency,N,
17784,QualifierName,Q000150,18977778,,,11,,Y,complications
17785,DescriptorName,D011655,18977778,,,12,Pulmonary Embolism,N,
17786,QualifierName,Q000209,18977778,,,12,,Y,etiology
17787,DescriptorName,D019966,18977778,,,13,Substance-Related Disorders,Y,
17788,DescriptorName,D019851,18977778,,,14,Thrombophilia,N,
17789,QualifierName,Q000139,18977778,,,14,,N,chemically induced
17790,DescriptorName,D013924,18977778,,,15,Thrombophlebitis,N,
17791,QualifierName,Q000188,18977778,,,15,,N,drug therapy
17792,DescriptorName,D016306,18977778,,,16,Vena Cava Filters,N,
17793,DescriptorName,D014812,18977778,,,17,Vitamin K,N,
17794,QualifierName,Q000627,18977778,,,17,,N,therapeutic use
17795,DescriptorName,D055815,18977778,,,18,Young Adult,N,
17796,Chemical,D000935,18983414,Antifungal Agents,0,,,,
17797,Chemical,D007166,18983414,Immunosuppressive Agents,0,,,,
17798,Chemical,D014230,18983414,Triazoles,0,,,,
17799,Chemical,D014640,18983414,Vancomycin,6Q205EH1VU,,,,
17800,Chemical,C101425,18983414,posaconazole,6TK1G07BHZ,,,,
17801,Chemical,D016559,18983414,Tacrolimus,WM0HAQ4WNM,,,,
17802,DescriptorName,D000935,18983414,,,1,Antifungal Agents,N,
17803,QualifierName,Q000627,18983414,,,1,,Y,therapeutic use
17804,DescriptorName,D016984,18983414,,,2,Enterococcus faecium,N,
17805,QualifierName,Q000187,18983414,,,2,,N,drug effects
17806,DescriptorName,D017809,18983414,,,3,Fatal Outcome,N,
17807,DescriptorName,D016469,18983414,,,4,Fungemia,N,
17808,QualifierName,Q000188,18983414,,,4,,Y,drug therapy
17809,DescriptorName,D006801,18983414,,,5,Humans,N,
17810,DescriptorName,D007166,18983414,,,6,Immunosuppressive Agents,N,
17811,QualifierName,Q000009,18983414,,,6,,N,adverse effects
17812,DescriptorName,D016031,18983414,,,7,Liver Transplantation,N,
17813,QualifierName,Q000009,18983414,,,7,,Y,adverse effects
17814,DescriptorName,D008297,18983414,,,8,Male,N,
17815,DescriptorName,D008875,18983414,,,9,Middle Aged,N,
17816,DescriptorName,D009181,18983414,,,10,Mycoses,N,
17817,QualifierName,Q000188,18983414,,,10,,Y,drug therapy
17818,DescriptorName,D010538,18983414,,,11,Peritonitis,N,
17819,QualifierName,Q000382,18983414,,,11,,N,microbiology
17820,DescriptorName,D011183,18983414,,,12,Postoperative Complications,N,
17821,QualifierName,Q000175,18983414,,,12,,N,diagnosis
17822,DescriptorName,D016559,18983414,,,13,Tacrolimus,N,
17823,QualifierName,Q000009,18983414,,,13,,N,adverse effects
17824,DescriptorName,D014230,18983414,,,14,Triazoles,N,
17825,QualifierName,Q000627,18983414,,,14,,Y,therapeutic use
17826,DescriptorName,D014250,18983414,,,15,Trichosporon,Y,
17827,DescriptorName,D014640,18983414,,,16,Vancomycin,N,
17828,QualifierName,Q000494,18983414,,,16,,N,pharmacology
17829,DescriptorName,D020713,18983414,,,17,Vancomycin Resistance,N,
17830,Chemical,D011744,18991509,Pyrimidinones,0,,,,
17831,Chemical,D014221,18991509,Triamcinolone,1ZK20VI6TY,,,,
17832,Chemical,D061466,18991509,Lopinavir,2494G1JF75,,,,
17833,Chemical,D019438,18991509,Ritonavir,O3J8G9O825,,,,
17834,DescriptorName,D000328,18991509,,,1,Adult,N,
17835,DescriptorName,D003480,18991509,,,2,Cushing Syndrome,Y,
17836,DescriptorName,D004347,18991509,,,3,Drug Interactions,N,
17837,DescriptorName,D015658,18991509,,,4,HIV Infections,N,
17838,QualifierName,Q000150,18991509,,,4,,Y,complications
17839,DescriptorName,D015497,18991509,,,5,HIV-1,N,
17840,QualifierName,Q000302,18991509,,,5,,N,isolation & purification
17841,DescriptorName,D006801,18991509,,,6,Humans,N,
17842,DescriptorName,D007049,18991509,,,7,Iatrogenic Disease,Y,
17843,DescriptorName,D061466,18991509,,,8,Lopinavir,N,
17844,DescriptorName,D008297,18991509,,,9,Male,N,
17845,DescriptorName,D011744,18991509,,,10,Pyrimidinones,N,
17846,QualifierName,Q000627,18991509,,,10,,Y,therapeutic use
17847,DescriptorName,D019438,18991509,,,11,Ritonavir,N,
17848,QualifierName,Q000627,18991509,,,11,,Y,therapeutic use
17849,DescriptorName,D014221,18991509,,,12,Triamcinolone,N,
17850,QualifierName,Q000008,18991509,,,12,,Y,administration & dosage
17851,Chemical,D000925,19003750,Anticoagulants,0,,,,
17852,Chemical,D005343,19003750,Fibrinolytic Agents,0,,,,
17853,Chemical,D018757,19003750,GABA Modulators,0,,,,
17854,Chemical,D011453,19003750,Prostaglandins,0,,,,
17855,Chemical,D013607,19003750,Tablets,0,,,,
17856,Chemical,D005445,19003750,Flunitrazepam,620X0222FQ,,,,
17857,DescriptorName,D000208,19003750,,,1,Acute Disease,N,
17858,DescriptorName,D000925,19003750,,,2,Anticoagulants,N,
17859,QualifierName,Q000627,19003750,,,2,,N,therapeutic use
17860,DescriptorName,D001157,19003750,,,3,Arterial Occlusive Diseases,N,
17861,QualifierName,Q000139,19003750,,,3,,Y,chemically induced
17862,DescriptorName,D004359,19003750,,,4,"Drug Therapy, Combination",N,
17863,DescriptorName,D005260,19003750,,,5,Female,N,
17864,DescriptorName,D005263,19003750,,,6,Femoral Artery,N,
17865,DescriptorName,D005343,19003750,,,7,Fibrinolytic Agents,N,
17866,QualifierName,Q000627,19003750,,,7,,N,therapeutic use
17867,DescriptorName,D005445,19003750,,,8,Flunitrazepam,N,
17868,QualifierName,Q000008,19003750,,,8,,N,administration & dosage
17869,DescriptorName,D018757,19003750,,,9,GABA Modulators,N,
17870,QualifierName,Q000008,19003750,,,9,,N,administration & dosage
17871,DescriptorName,D006801,19003750,,,10,Humans,N,
17872,DescriptorName,D007269,19003750,,,11,"Injections, Intra-Arterial",N,
17873,DescriptorName,D007511,19003750,,,12,Ischemia,N,
17874,QualifierName,Q000139,19003750,,,12,,Y,chemically induced
17875,DescriptorName,D007866,19003750,,,13,Leg,N,
17876,QualifierName,Q000098,19003750,,,13,,Y,blood supply
17877,DescriptorName,D011453,19003750,,,14,Prostaglandins,N,
17878,QualifierName,Q000627,19003750,,,14,,N,therapeutic use
17879,DescriptorName,D011859,19003750,,,15,Radiography,N,
17880,DescriptorName,D012206,19003750,,,16,Rhabdomyolysis,N,
17881,QualifierName,Q000139,19003750,,,16,,N,chemically induced
17882,DescriptorName,D012995,19003750,,,17,Solubility,N,
17883,DescriptorName,D015819,19003750,,,18,"Substance Abuse, Intravenous",N,
17884,QualifierName,Q000150,19003750,,,18,,Y,complications
17885,DescriptorName,D013607,19003750,,,19,Tablets,N,
17886,DescriptorName,D016909,19003750,,,20,Tibial Arteries,N,
17887,QualifierName,Q000000981,19003750,,,20,,N,diagnostic imaging
17888,DescriptorName,D016896,19003750,,,21,Treatment Outcome,N,
17889,DescriptorName,D055815,19003750,,,22,Young Adult,N,
17890,Chemical,D000893,19017039,Anti-Inflammatory Agents,0,,,,
17891,Chemical,D000911,19017039,"Antibodies, Monoclonal",0,,,,
17892,Chemical,D007555,19017039,Isoxazoles,0,,,,
17893,Chemical,D000069285,19017039,Infliximab,B72HH48FLU,,,,
17894,Chemical,D000077339,19017039,Leflunomide,G162GK9U4W,,,,
17895,DescriptorName,D000293,19017039,,,1,Adolescent,N,
17896,DescriptorName,D000893,19017039,,,2,Anti-Inflammatory Agents,N,
17897,QualifierName,Q000009,19017039,,,2,,N,adverse effects
17898,DescriptorName,D000911,19017039,,,3,"Antibodies, Monoclonal",N,
17899,QualifierName,Q000009,19017039,,,3,,Y,adverse effects
17900,DescriptorName,D015535,19017039,,,4,"Arthritis, Psoriatic",N,
17901,QualifierName,Q000188,19017039,,,4,,Y,drug therapy
17902,DescriptorName,D004342,19017039,,,5,Drug Hypersensitivity,N,
17903,QualifierName,Q000209,19017039,,,5,,Y,etiology
17904,DescriptorName,D004359,19017039,,,6,"Drug Therapy, Combination",N,
17905,DescriptorName,D006801,19017039,,,7,Humans,N,
17906,DescriptorName,D000069285,19017039,,,8,Infliximab,N,
17907,DescriptorName,D007555,19017039,,,9,Isoxazoles,N,
17908,QualifierName,Q000009,19017039,,,9,,Y,adverse effects
17909,DescriptorName,D000077339,19017039,,,10,Leflunomide,N,
17910,DescriptorName,D008297,19017039,,,11,Male,N,
17911,Chemical,D000970,19018868,Antineoplastic Agents,0,,,,
17912,Chemical,D013792,19018868,Thalidomide,4Z8R6ORS6L,,,,
17913,Chemical,D000077269,19018868,Lenalidomide,F0P408N6V4,,,,
17914,DescriptorName,D000741,19018868,,,1,"Anemia, Aplastic",N,
17915,QualifierName,Q000097,19018868,,,1,,N,blood
17916,DescriptorName,D000970,19018868,,,2,Antineoplastic Agents,N,
17917,QualifierName,Q000009,19018868,,,2,,Y,adverse effects
17918,DescriptorName,D001706,19018868,,,3,Biopsy,N,
17919,DescriptorName,D006801,19018868,,,4,Humans,N,
17920,DescriptorName,D000077269,19018868,,,5,Lenalidomide,N,
17921,DescriptorName,D008297,19018868,,,6,Male,N,
17922,DescriptorName,D008875,19018868,,,7,Middle Aged,N,
17923,DescriptorName,D009101,19018868,,,8,Multiple Myeloma,N,
17924,QualifierName,Q000188,19018868,,,8,,Y,drug therapy
17925,DescriptorName,D013792,19018868,,,9,Thalidomide,N,
17926,QualifierName,Q000009,19018868,,,9,,N,adverse effects
17927,Chemical,D000978,19034138,Antiparkinson Agents,0,,,,
17928,Chemical,D000547,19034138,Amantadine,BF4C9Z1J53,,,,
17929,DescriptorName,D000284,19034138,,,1,"Administration, Oral",N,
17930,DescriptorName,D000547,19034138,,,2,Amantadine,N,
17931,QualifierName,Q000008,19034138,,,2,,N,administration & dosage
17932,DescriptorName,D000978,19034138,,,3,Antiparkinson Agents,N,
17933,QualifierName,Q000008,19034138,,,3,,N,administration & dosage
17934,DescriptorName,D002452,19034138,,,4,Cell Count,N,
17935,DescriptorName,D015715,19034138,,,5,Corneal Edema,N,
17936,QualifierName,Q000139,19034138,,,5,,Y,chemically induced
17937,DescriptorName,D004728,19034138,,,6,"Endothelium, Corneal",N,
17938,QualifierName,Q000187,19034138,,,6,,Y,drug effects
17939,DescriptorName,D005260,19034138,,,7,Female,N,
17940,DescriptorName,D006801,19034138,,,8,Humans,N,
17941,DescriptorName,D008875,19034138,,,9,Middle Aged,N,
17942,DescriptorName,D010300,19034138,,,10,Parkinson Disease,N,
17943,QualifierName,Q000188,19034138,,,10,,Y,drug therapy
17944,DescriptorName,D012189,19034138,,,11,Retrospective Studies,N,
17945,Chemical,D000970,19039026,Antineoplastic Agents,0,,,,
17946,Chemical,D007211,19039026,Indoles,0,,,,
17947,Chemical,D047428,19039026,Protein Kinase Inhibitors,0,,,,
17948,Chemical,D011758,19039026,Pyrroles,0,,,,
17949,Chemical,D000077210,19039026,Sunitinib,V99T50803M,,,,
17950,DescriptorName,D000208,19039026,,,1,Acute Disease,N,
17951,DescriptorName,D058186,19039026,,,2,Acute Kidney Injury,N,
17952,QualifierName,Q000139,19039026,,,2,,N,chemically induced
17953,DescriptorName,D000970,19039026,,,3,Antineoplastic Agents,N,
17954,QualifierName,Q000009,19039026,,,3,,N,adverse effects
17955,DescriptorName,D002292,19039026,,,4,"Carcinoma, Renal Cell",N,
17956,QualifierName,Q000188,19039026,,,4,,N,drug therapy
17957,DescriptorName,D006801,19039026,,,5,Humans,N,
17958,DescriptorName,D007211,19039026,,,6,Indoles,N,
17959,QualifierName,Q000009,19039026,,,6,,Y,adverse effects
17960,DescriptorName,D007680,19039026,,,7,Kidney Neoplasms,N,
17961,QualifierName,Q000188,19039026,,,7,,N,drug therapy
17962,DescriptorName,D008297,19039026,,,8,Male,N,
17963,DescriptorName,D008875,19039026,,,9,Middle Aged,N,
17964,DescriptorName,D009395,19039026,,,10,"Nephritis, Interstitial",N,
17965,QualifierName,Q000139,19039026,,,10,,Y,chemically induced
17966,DescriptorName,D047428,19039026,,,11,Protein Kinase Inhibitors,N,
17967,QualifierName,Q000009,19039026,,,11,,Y,adverse effects
17968,DescriptorName,D011758,19039026,,,12,Pyrroles,N,
17969,QualifierName,Q000009,19039026,,,12,,Y,adverse effects
17970,DescriptorName,D000077210,19039026,,,13,Sunitinib,N,
17971,Chemical,D014150,19047493,Antipsychotic Agents,0,,,,
17972,Chemical,D004155,19047493,Diphenhydramine,8GTS82S83M,,,,
17973,Chemical,D006220,19047493,Haloperidol,J6292F8L3D,,,,
17974,DescriptorName,D000369,19047493,,,1,"Aged, 80 and over",Y,
17975,DescriptorName,D014150,19047493,,,2,Antipsychotic Agents,N,
17976,QualifierName,Q000009,19047493,,,2,,Y,adverse effects
17977,DescriptorName,D001480,19047493,,,3,Basal Ganglia Diseases,N,
17978,QualifierName,Q000139,19047493,,,3,,Y,chemically induced
17979,DescriptorName,D003680,19047493,,,4,Deglutition Disorders,N,
17980,QualifierName,Q000139,19047493,,,4,,Y,chemically induced
17981,DescriptorName,D003937,19047493,,,5,"Diagnosis, Differential",N,
17982,DescriptorName,D004155,19047493,,,6,Diphenhydramine,N,
17983,DescriptorName,D016903,19047493,,,7,Drug Monitoring,N,
17984,QualifierName,Q000379,19047493,,,7,,N,methods
17985,DescriptorName,D005260,19047493,,,8,Female,N,
17986,DescriptorName,D006212,19047493,,,9,Hallucinations,N,
17987,QualifierName,Q000188,19047493,,,9,,N,drug therapy
17988,DescriptorName,D006220,19047493,,,10,Haloperidol,N,
17989,QualifierName,Q000009,19047493,,,10,,Y,adverse effects
17990,DescriptorName,D006801,19047493,,,11,Humans,N,
17991,DescriptorName,D008539,19047493,,,12,Meigs Syndrome,N,
17992,QualifierName,Q000150,19047493,,,12,,N,complications
17993,DescriptorName,D009730,19047493,,,13,Nursing Assessment,N,
17994,DescriptorName,D010051,19047493,,,14,Ovarian Neoplasms,N,
17995,QualifierName,Q000150,19047493,,,14,,N,complications
17996,DescriptorName,D010166,19047493,,,15,Palliative Care,N,
17997,QualifierName,Q000379,19047493,,,15,,N,methods
17998,DescriptorName,D012893,19047493,,,16,Sleep Wake Disorders,N,
17999,QualifierName,Q000188,19047493,,,16,,N,drug therapy
18000,Chemical,D018501,19058340,Antirheumatic Agents,0,,,,
18001,Chemical,D008727,19058340,Methotrexate,YL5FZ2Y5U1,,,,
18002,DescriptorName,D018501,19058340,,,1,Antirheumatic Agents,N,
18003,QualifierName,Q000009,19058340,,,1,,Y,adverse effects
18004,DescriptorName,D001284,19058340,,,2,Atrophy,N,
18005,DescriptorName,D001706,19058340,,,3,Biopsy,N,
18006,DescriptorName,D002446,19058340,,,4,Celiac Disease,N,
18007,QualifierName,Q000139,19058340,,,4,,Y,chemically induced
18008,DescriptorName,D004386,19058340,,,5,Duodenum,N,
18009,QualifierName,Q000473,19058340,,,5,,N,pathology
18010,DescriptorName,D016099,19058340,,,6,"Endoscopy, Gastrointestinal",N,
18011,DescriptorName,D006801,19058340,,,7,Humans,N,
18012,DescriptorName,D008297,19058340,,,8,Male,N,
18013,DescriptorName,D008727,19058340,,,9,Methotrexate,N,
18014,QualifierName,Q000009,19058340,,,9,,Y,adverse effects
18015,DescriptorName,D008875,19058340,,,10,Middle Aged,N,
18016,DescriptorName,D013167,19058340,,,11,"Spondylitis, Ankylosing",N,
18017,QualifierName,Q000188,19058340,,,11,,N,drug therapy
18018,DescriptorName,D013577,19058340,,,12,Syndrome,N,
18019,Chemical,D000970,19097599,Antineoplastic Agents,0,,,,
18020,Chemical,D001549,19097599,Benzamides,0,,,,
18021,Chemical,D010879,19097599,Piperazines,0,,,,
18022,Chemical,D047428,19097599,Protein Kinase Inhibitors,0,,,,
18023,Chemical,D011743,19097599,Pyrimidines,0,,,,
18024,Chemical,D000068877,19097599,Imatinib Mesylate,8A1O1M485B,,,,
18025,DescriptorName,D000328,19097599,,,1,Adult,N,
18026,DescriptorName,D000970,19097599,,,2,Antineoplastic Agents,N,
18027,QualifierName,Q000009,19097599,,,2,,Y,adverse effects
18028,DescriptorName,D001549,19097599,,,3,Benzamides,N,
18029,DescriptorName,D006801,19097599,,,4,Humans,N,
18030,DescriptorName,D000068877,19097599,,,5,Imatinib Mesylate,N,
18031,DescriptorName,D008297,19097599,,,6,Male,N,
18032,DescriptorName,D010879,19097599,,,7,Piperazines,N,
18033,QualifierName,Q000009,19097599,,,7,,Y,adverse effects
18034,DescriptorName,D054198,19097599,,,8,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
18035,QualifierName,Q000188,19097599,,,8,,N,drug therapy
18036,DescriptorName,D047428,19097599,,,9,Protein Kinase Inhibitors,N,
18037,QualifierName,Q000009,19097599,,,9,,Y,adverse effects
18038,DescriptorName,D011743,19097599,,,10,Pyrimidines,N,
18039,QualifierName,Q000009,19097599,,,10,,Y,adverse effects
18040,DescriptorName,D015275,19097599,,,11,Tumor Lysis Syndrome,N,
18041,QualifierName,Q000209,19097599,,,11,,Y,etiology
18042,Chemical,D000998,19104709,Antiviral Agents,0,,,,
18043,Chemical,D016898,19104709,Interferon-alpha,0,,,,
18044,Chemical,D012254,19104709,Ribavirin,49717AWG6K,,,,
18045,Chemical,D013972,19104709,Thyrotropin,9002-71-5,,,,
18046,Chemical,D013974,19104709,Thyroxine,Q51BO43MG4,,,,
18047,DescriptorName,D000998,19104709,,,1,Antiviral Agents,N,
18048,QualifierName,Q000008,19104709,,,1,,Y,administration & dosage
18049,DescriptorName,D004359,19104709,,,2,"Drug Therapy, Combination",N,
18050,DescriptorName,D006111,19104709,,,3,Graves Disease,N,
18051,QualifierName,Q000097,19104709,,,3,,N,blood
18052,DescriptorName,D006526,19104709,,,4,Hepatitis C,N,
18053,QualifierName,Q000150,19104709,,,4,,Y,complications
18054,DescriptorName,D006801,19104709,,,5,Humans,N,
18055,DescriptorName,D016898,19104709,,,6,Interferon-alpha,N,
18056,QualifierName,Q000008,19104709,,,6,,Y,administration & dosage
18057,DescriptorName,D008297,19104709,,,7,Male,N,
18058,DescriptorName,D008875,19104709,,,8,Middle Aged,N,
18059,DescriptorName,D012008,19104709,,,9,Recurrence,N,
18060,DescriptorName,D012254,19104709,,,10,Ribavirin,N,
18061,QualifierName,Q000008,19104709,,,10,,N,administration & dosage
18062,DescriptorName,D013965,19104709,,,11,Thyroidectomy,N,
18063,DescriptorName,D013971,19104709,,,12,Thyrotoxicosis,N,
18064,QualifierName,Q000097,19104709,,,12,,N,blood
18065,DescriptorName,D013972,19104709,,,13,Thyrotropin,N,
18066,QualifierName,Q000097,19104709,,,13,,N,blood
18067,DescriptorName,D013974,19104709,,,14,Thyroxine,N,
18068,QualifierName,Q000097,19104709,,,14,,N,blood
18069,Chemical,D001572,19112808,Benzofurans,0,,,,
18070,Chemical,D018727,19112808,Muscarinic Antagonists,0,,,,
18071,Chemical,D011759,19112808,Pyrrolidines,0,,,,
18072,Chemical,C101207,19112808,darifenacin,APG9819VLM,,,,
18073,DescriptorName,D001572,19112808,,,1,Benzofurans,N,
18074,QualifierName,Q000009,19112808,,,1,,Y,adverse effects
18075,DescriptorName,D003875,19112808,,,2,Drug Eruptions,N,
18076,QualifierName,Q000209,19112808,,,2,,Y,etiology
18077,DescriptorName,D005260,19112808,,,3,Female,N,
18078,DescriptorName,D006099,19112808,,,4,Granuloma,N,
18079,QualifierName,Q000139,19112808,,,4,,N,chemically induced
18080,DescriptorName,D006801,19112808,,,5,Humans,N,
18081,DescriptorName,D008875,19112808,,,6,Middle Aged,N,
18082,DescriptorName,D018727,19112808,,,7,Muscarinic Antagonists,N,
18083,QualifierName,Q000009,19112808,,,7,,Y,adverse effects
18084,DescriptorName,D011759,19112808,,,8,Pyrrolidines,N,
18085,QualifierName,Q000009,19112808,,,8,,Y,adverse effects
18086,DescriptorName,D053201,19112808,,,9,"Urinary Bladder, Overactive",N,
18087,QualifierName,Q000188,19112808,,,9,,N,drug therapy
18088,Chemical,D000911,19116715,"Antibodies, Monoclonal",0,,,,
18089,Chemical,D058846,19116715,"Antibodies, Monoclonal, Murine-Derived",0,,,,
18090,Chemical,D000964,19116715,"Antimetabolites, Antineoplastic",0,,,,
18091,Chemical,D005938,19116715,Glucocorticoids,0,,,,
18092,Chemical,D007155,19116715,Immunologic Factors,0,,,,
18093,Chemical,D003841,19116715,Deoxycytidine,0W860991D6,,,,
18094,Chemical,D000069283,19116715,Rituximab,4F4X42SYQ6,,,,
18095,Chemical,D014750,19116715,Vincristine,5J49Q6B70F,,,,
18096,Chemical,C056507,19116715,gemcitabine,B76N6SBZ8R,,,,
18097,DescriptorName,D000230,19116715,,,1,Adenocarcinoma,N,
18098,QualifierName,Q000188,19116715,,,1,,N,drug therapy
18099,DescriptorName,D000911,19116715,,,2,"Antibodies, Monoclonal",N,
18100,QualifierName,Q000627,19116715,,,2,,Y,therapeutic use
18101,DescriptorName,D058846,19116715,,,3,"Antibodies, Monoclonal, Murine-Derived",N,
18102,DescriptorName,D000964,19116715,,,4,"Antimetabolites, Antineoplastic",N,
18103,QualifierName,Q000009,19116715,,,4,,N,adverse effects
18104,DescriptorName,D003841,19116715,,,5,Deoxycytidine,N,
18105,QualifierName,Q000009,19116715,,,5,,N,adverse effects
18106,DescriptorName,D005260,19116715,,,6,Female,N,
18107,DescriptorName,D005938,19116715,,,7,Glucocorticoids,N,
18108,QualifierName,Q000627,19116715,,,7,,N,therapeutic use
18109,DescriptorName,D006463,19116715,,,8,Hemolytic-Uremic Syndrome,N,
18110,QualifierName,Q000139,19116715,,,8,,N,chemically induced
18111,DescriptorName,D006801,19116715,,,9,Humans,N,
18112,DescriptorName,D007155,19116715,,,10,Immunologic Factors,N,
18113,QualifierName,Q000627,19116715,,,10,,Y,therapeutic use
18114,DescriptorName,D008875,19116715,,,11,Middle Aged,N,
18115,DescriptorName,D010190,19116715,,,12,Pancreatic Neoplasms,N,
18116,QualifierName,Q000188,19116715,,,12,,N,drug therapy
18117,DescriptorName,D010956,19116715,,,13,Plasmapheresis,N,
18118,QualifierName,Q000379,19116715,,,13,,N,methods
18119,DescriptorName,D012189,19116715,,,14,Retrospective Studies,N,
18120,DescriptorName,D000069283,19116715,,,15,Rituximab,N,
18121,DescriptorName,D014750,19116715,,,16,Vincristine,N,
18122,QualifierName,Q000627,19116715,,,16,,N,therapeutic use
18123,Chemical,D000305,19122478,Adrenal Cortex Hormones,0,,,,
18124,Chemical,D002699,19122478,Chlorambucil,18D0SL7309,,,,
18125,DescriptorName,D058186,19122478,,,1,Acute Kidney Injury,N,
18126,QualifierName,Q000188,19122478,,,1,,N,drug therapy
18127,DescriptorName,D000305,19122478,,,2,Adrenal Cortex Hormones,N,
18128,QualifierName,Q000627,19122478,,,2,,Y,therapeutic use
18129,DescriptorName,D000368,19122478,,,3,Aged,N,
18130,DescriptorName,D002699,19122478,,,4,Chlorambucil,N,
18131,QualifierName,Q000009,19122478,,,4,,Y,adverse effects
18132,DescriptorName,D003875,19122478,,,5,Drug Eruptions,N,
18133,QualifierName,Q000175,19122478,,,5,,N,diagnosis
18134,DescriptorName,D004802,19122478,,,6,Eosinophilia,N,
18135,QualifierName,Q000139,19122478,,,6,,Y,chemically induced
18136,DescriptorName,D005076,19122478,,,7,Exanthema,N,
18137,QualifierName,Q000139,19122478,,,7,,N,chemically induced
18138,DescriptorName,D005334,19122478,,,8,Fever,N,
18139,QualifierName,Q000139,19122478,,,8,,Y,chemically induced
18140,DescriptorName,D006801,19122478,,,9,Humans,N,
18141,DescriptorName,D015451,19122478,,,10,"Leukemia, Lymphocytic, Chronic, B-Cell",N,
18142,QualifierName,Q000150,19122478,,,10,,N,complications
18143,DescriptorName,D008297,19122478,,,11,Male,N,
18144,Chemical,D000964,19131789,"Antimetabolites, Antineoplastic",0,,,,
18145,Chemical,D011623,19131789,gamma-Glutamyl Hydrolase,EC 3.4.19.9,,,,
18146,Chemical,D002955,19131789,Leucovorin,Q573I9DVLP,,,,
18147,Chemical,D008727,19131789,Methotrexate,YL5FZ2Y5U1,,,,
18148,DescriptorName,D058186,19131789,,,1,Acute Kidney Injury,N,
18149,QualifierName,Q000139,19131789,,,1,,N,chemically induced
18150,DescriptorName,D000964,19131789,,,2,"Antimetabolites, Antineoplastic",N,
18151,QualifierName,Q000009,19131789,,,2,,Y,adverse effects
18152,DescriptorName,D001859,19131789,,,3,Bone Neoplasms,N,
18153,QualifierName,Q000150,19131789,,,3,,N,complications
18154,DescriptorName,D002648,19131789,,,4,Child,N,
18155,DescriptorName,D016903,19131789,,,5,Drug Monitoring,Y,
18156,DescriptorName,D006801,19131789,,,6,Humans,N,
18157,DescriptorName,D002955,19131789,,,7,Leucovorin,N,
18158,QualifierName,Q000627,19131789,,,7,,N,therapeutic use
18159,DescriptorName,D008297,19131789,,,8,Male,N,
18160,DescriptorName,D008727,19131789,,,9,Methotrexate,N,
18161,QualifierName,Q000009,19131789,,,9,,Y,adverse effects
18162,DescriptorName,D012516,19131789,,,10,Osteosarcoma,N,
18163,QualifierName,Q000150,19131789,,,10,,N,complications
18164,DescriptorName,D011623,19131789,,,11,gamma-Glutamyl Hydrolase,N,
18165,QualifierName,Q000627,19131789,,,11,,N,therapeutic use
18166,Chemical,D000995,19145124,Antitubercular Agents,0,,,,
18167,Chemical,D004977,19145124,Ethambutol,8G167061QZ,,,,
18168,DescriptorName,D000368,19145124,,,1,Aged,N,
18169,DescriptorName,D000995,19145124,,,2,Antitubercular Agents,N,
18170,QualifierName,Q000008,19145124,,,2,,N,administration & dosage
18171,DescriptorName,D004596,19145124,,,3,Electroretinography,N,
18172,DescriptorName,D004977,19145124,,,4,Ethambutol,N,
18173,QualifierName,Q000008,19145124,,,4,,N,administration & dosage
18174,DescriptorName,D005260,19145124,,,5,Female,N,
18175,DescriptorName,D006801,19145124,,,6,Humans,N,
18176,DescriptorName,D008875,19145124,,,7,Middle Aged,N,
18177,DescriptorName,D015270,19145124,,,8,Mycobacterium avium-intracellulare Infection,N,
18178,QualifierName,Q000188,19145124,,,8,,N,drug therapy
18179,DescriptorName,D010364,19145124,,,9,"Pattern Recognition, Visual",N,
18180,QualifierName,Q000187,19145124,,,9,,N,drug effects
18181,DescriptorName,D020419,19145124,,,10,"Photoreceptor Cells, Vertebrate",N,
18182,QualifierName,Q000187,19145124,,,10,,N,drug effects
18183,DescriptorName,D011379,19145124,,,11,Prognosis,N,
18184,DescriptorName,D020127,19145124,,,12,Recovery of Function,N,
18185,QualifierName,Q000187,19145124,,,12,,N,drug effects
18186,DescriptorName,D012160,19145124,,,13,Retina,N,
18187,QualifierName,Q000187,19145124,,,13,,N,drug effects
18188,DescriptorName,D012162,19145124,,,14,Retinal Degeneration,N,
18189,QualifierName,Q000139,19145124,,,14,,Y,chemically induced
18190,DescriptorName,D015354,19145124,,,15,"Vision, Low",N,
18191,QualifierName,Q000139,19145124,,,15,,Y,chemically induced
18192,DescriptorName,D014794,19145124,,,16,Visual Fields,N,
18193,QualifierName,Q000187,19145124,,,16,,N,drug effects
18194,Chemical,D019380,19183077,Anti-HIV Agents,0,,,,
18195,Chemical,D063065,19183077,Organophosphonates,0,,,,
18196,Chemical,D018894,19183077,Reverse Transcriptase Inhibitors,0,,,,
18197,Chemical,D000068698,19183077,Tenofovir,99YXE507IL,,,,
18198,Chemical,D003404,19183077,Creatinine,AYI8EX34EU,,,,
18199,Chemical,D000225,19183077,Adenine,JAC85A2161,,,,
18200,DescriptorName,D000225,19183077,,,1,Adenine,N,
18201,QualifierName,Q000009,19183077,,,1,,N,adverse effects
18202,DescriptorName,D000293,19183077,,,2,Adolescent,N,
18203,DescriptorName,D001741,19183077,,,3,African Americans,N,
18204,QualifierName,Q000208,19183077,,,3,,N,ethnology
18205,DescriptorName,D000367,19183077,,,4,Age Factors,N,
18206,DescriptorName,D019380,19183077,,,5,Anti-HIV Agents,N,
18207,QualifierName,Q000009,19183077,,,5,,Y,adverse effects
18208,DescriptorName,D023241,19183077,,,6,"Antiretroviral Therapy, Highly Active",N,
18209,QualifierName,Q000009,19183077,,,6,,N,adverse effects
18210,DescriptorName,D001806,19183077,,,7,Blood Urea Nitrogen,N,
18211,DescriptorName,D018791,19183077,,,8,CD4 Lymphocyte Count,N,
18212,DescriptorName,D003404,19183077,,,9,Creatinine,N,
18213,QualifierName,Q000097,19183077,,,9,,N,blood
18214,DescriptorName,D003937,19183077,,,10,"Diagnosis, Differential",N,
18215,DescriptorName,D015658,19183077,,,11,HIV Infections,N,
18216,QualifierName,Q000188,19183077,,,11,,Y,drug therapy
18217,DescriptorName,D006801,19183077,,,12,Humans,N,
18218,DescriptorName,D017674,19183077,,,13,Hypophosphatemia,N,
18219,QualifierName,Q000139,19183077,,,13,,N,chemically induced
18220,DescriptorName,D018445,19183077,,,14,"Infectious Disease Transmission, Vertical",N,
18221,DescriptorName,D008297,19183077,,,15,Male,N,
18222,DescriptorName,D063065,19183077,,,16,Organophosphonates,N,
18223,QualifierName,Q000009,19183077,,,16,,Y,adverse effects
18224,DescriptorName,D051437,19183077,,,17,Renal Insufficiency,N,
18225,QualifierName,Q000097,19183077,,,17,,N,blood
18226,DescriptorName,D018894,19183077,,,18,Reverse Transcriptase Inhibitors,N,
18227,QualifierName,Q000009,19183077,,,18,,Y,adverse effects
18228,DescriptorName,D012279,19183077,,,19,Rickets,N,
18229,QualifierName,Q000139,19183077,,,19,,N,chemically induced
18230,DescriptorName,D012307,19183077,,,20,Risk Factors,N,
18231,DescriptorName,D012449,19183077,,,21,Safety,N,
18232,DescriptorName,D000068698,19183077,,,22,Tenofovir,N,
18233,Chemical,D004338,1918672,Drug Combinations,0,,,,
18234,Chemical,D010894,1918672,Piroxicam,13T4O6VMAM,,,,
18235,Chemical,C013591,1918672,"aluminum hydroxide, magnesium hydroxide, drug combination",37317-08-1,,,,
18236,Chemical,D000536,1918672,Aluminum Hydroxide,5QB0T2IUN0,,,,
18237,Chemical,D004155,1918672,Diphenhydramine,8GTS82S83M,,,,
18238,Chemical,D013752,1918672,Tetracycline,F8VB5M810T,,,,
18239,Chemical,D008276,1918672,Magnesium Hydroxide,NBZ3QY004S,,,,
18240,DescriptorName,D000328,1918672,,,1,Adult,N,
18241,DescriptorName,D000536,1918672,,,2,Aluminum Hydroxide,N,
18242,QualifierName,Q000627,1918672,,,2,,N,therapeutic use
18243,DescriptorName,D003937,1918672,,,3,"Diagnosis, Differential",N,
18244,DescriptorName,D004155,1918672,,,4,Diphenhydramine,N,
18245,QualifierName,Q000627,1918672,,,4,,N,therapeutic use
18246,DescriptorName,D004338,1918672,,,5,Drug Combinations,N,
18247,DescriptorName,D006801,1918672,,,6,Humans,N,
18248,DescriptorName,D008276,1918672,,,7,Magnesium Hydroxide,N,
18249,QualifierName,Q000627,1918672,,,7,,N,therapeutic use
18250,DescriptorName,D008297,1918672,,,8,Male,N,
18251,DescriptorName,D010894,1918672,,,9,Piroxicam,N,
18252,QualifierName,Q000009,1918672,,,9,,Y,adverse effects
18253,DescriptorName,D013281,1918672,,,10,"Stomatitis, Aphthous",N,
18254,QualifierName,Q000139,1918672,,,10,,Y,chemically induced
18255,DescriptorName,D013752,1918672,,,11,Tetracycline,N,
18256,QualifierName,Q000627,1918672,,,11,,N,therapeutic use
18257,Chemical,D016756,19203515,"Immunoglobulins, Intravenous",0,,,,
18258,DescriptorName,D058186,19203515,,,1,Acute Kidney Injury,N,
18259,QualifierName,Q000139,19203515,,,1,,Y,chemically induced
18260,DescriptorName,D015658,19203515,,,2,HIV Infections,N,
18261,QualifierName,Q000150,19203515,,,2,,Y,complications
18262,DescriptorName,D015497,19203515,,,3,HIV-1,Y,
18263,DescriptorName,D006801,19203515,,,4,Humans,N,
18264,DescriptorName,D016756,19203515,,,5,"Immunoglobulins, Intravenous",N,
18265,QualifierName,Q000008,19203515,,,5,,N,administration & dosage
18266,DescriptorName,D008297,19203515,,,6,Male,N,
18267,DescriptorName,D008875,19203515,,,7,Middle Aged,N,
18268,DescriptorName,D013921,19203515,,,8,Thrombocytopenia,N,
18269,QualifierName,Q000188,19203515,,,8,,Y,drug therapy
18270,Chemical,D000970,19212144,Antineoplastic Agents,0,,,,
18271,Chemical,C401859,19212144,temsirolimus,624KN6GM2T,,,,
18272,Chemical,D020123,19212144,Sirolimus,W36ZG6FT64,,,,
18273,DescriptorName,D000970,19212144,,,1,Antineoplastic Agents,N,
18274,QualifierName,Q000009,19212144,,,1,,Y,adverse effects
18275,DescriptorName,D002292,19212144,,,2,"Carcinoma, Renal Cell",N,
18276,QualifierName,Q000188,19212144,,,2,,N,drug therapy
18277,DescriptorName,D005923,19212144,,,3,"Glomerulosclerosis, Focal Segmental",N,
18278,QualifierName,Q000139,19212144,,,3,,Y,chemically induced
18279,DescriptorName,D006801,19212144,,,4,Humans,N,
18280,DescriptorName,D007680,19212144,,,5,Kidney Neoplasms,N,
18281,QualifierName,Q000188,19212144,,,5,,N,drug therapy
18282,DescriptorName,D008297,19212144,,,6,Male,N,
18283,DescriptorName,D008875,19212144,,,7,Middle Aged,N,
18284,DescriptorName,D011507,19212144,,,8,Proteinuria,N,
18285,QualifierName,Q000139,19212144,,,8,,N,chemically induced
18286,DescriptorName,D020123,19212144,,,9,Sirolimus,N,
18287,QualifierName,Q000009,19212144,,,9,,N,adverse effects
18288,Chemical,D000894,19217693,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
18289,Chemical,D006442,19217693,Glycated Hemoglobin A,0,,,,
18290,Chemical,D007074,19217693,Immunoglobulin G,0,,,,
18291,Chemical,D018124,19217693,"Receptors, Tumor Necrosis Factor",0,,,,
18292,Chemical,C517652,19217693,"hemoglobin A1c protein, human",0,,,,
18293,Chemical,D000068800,19217693,Etanercept,OP401G7OJC,,,,
18294,DescriptorName,D000368,19217693,,,1,Aged,N,
18295,DescriptorName,D000894,19217693,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
18296,QualifierName,Q000009,19217693,,,2,,Y,adverse effects
18297,DescriptorName,D003924,19217693,,,3,"Diabetes Mellitus, Type 2",N,
18298,QualifierName,Q000150,19217693,,,3,,Y,complications
18299,DescriptorName,D000068800,19217693,,,4,Etanercept,N,
18300,DescriptorName,D006442,19217693,,,5,Glycated Hemoglobin A,N,
18301,QualifierName,Q000032,19217693,,,5,,N,analysis
18302,DescriptorName,D006801,19217693,,,6,Humans,N,
18303,DescriptorName,D007003,19217693,,,7,Hypoglycemia,N,
18304,QualifierName,Q000139,19217693,,,7,,Y,chemically induced
18305,DescriptorName,D007074,19217693,,,8,Immunoglobulin G,N,
18306,QualifierName,Q000009,19217693,,,8,,Y,adverse effects
18307,DescriptorName,D007333,19217693,,,9,Insulin Resistance,N,
18308,QualifierName,Q000502,19217693,,,9,,N,physiology
18309,DescriptorName,D008297,19217693,,,10,Male,N,
18310,DescriptorName,D011565,19217693,,,11,Psoriasis,N,
18311,QualifierName,Q000188,19217693,,,11,,Y,drug therapy
18312,DescriptorName,D018124,19217693,,,12,"Receptors, Tumor Necrosis Factor",N,
18313,Chemical,D000759,19224802,"Adjuvants, Anesthesia",0,,,,
18314,Chemical,D006993,19224802,Hypnotics and Sedatives,0,,,,
18315,Chemical,D020927,19224802,Dexmedetomidine,67VB76HONO,,,,
18316,Chemical,D010100,19224802,Oxygen,S88TT14065,,,,
18317,Chemical,D006024,19224802,Glycopyrrolate,V92SO9WP2I,,,,
18318,DescriptorName,D000759,19224802,,,1,"Adjuvants, Anesthesia",N,
18319,QualifierName,Q000009,19224802,,,1,,Y,adverse effects
18320,DescriptorName,D000293,19224802,,,2,Adolescent,N,
18321,DescriptorName,D001919,19224802,,,3,Bradycardia,N,
18322,QualifierName,Q000139,19224802,,,3,,Y,chemically induced
18323,DescriptorName,D001932,19224802,,,4,Brain Neoplasms,N,
18324,QualifierName,Q000601,19224802,,,4,,N,surgery
18325,DescriptorName,D002648,19224802,,,5,Child,N,
18326,DescriptorName,D002675,19224802,,,6,"Child, Preschool",N,
18327,DescriptorName,D016292,19224802,,,7,Conscious Sedation,Y,
18328,DescriptorName,D003398,19224802,,,8,Craniosynostoses,N,
18329,QualifierName,Q000601,19224802,,,8,,N,surgery
18330,DescriptorName,D020927,19224802,,,9,Dexmedetomidine,N,
18331,QualifierName,Q000009,19224802,,,9,,Y,adverse effects
18332,DescriptorName,D006024,19224802,,,10,Glycopyrrolate,N,
18333,QualifierName,Q000009,19224802,,,10,,Y,adverse effects
18334,DescriptorName,D006339,19224802,,,11,Heart Rate,N,
18335,QualifierName,Q000187,19224802,,,11,,N,drug effects
18336,DescriptorName,D006801,19224802,,,12,Humans,N,
18337,DescriptorName,D006973,19224802,,,13,Hypertension,N,
18338,QualifierName,Q000139,19224802,,,13,,Y,chemically induced
18339,DescriptorName,D006993,19224802,,,14,Hypnotics and Sedatives,N,
18340,QualifierName,Q000009,19224802,,,14,,Y,adverse effects
18341,DescriptorName,D007713,19224802,,,15,Klinefelter Syndrome,N,
18342,QualifierName,Q000601,19224802,,,15,,N,surgery
18343,DescriptorName,D008279,19224802,,,16,Magnetic Resonance Imaging,N,
18344,DescriptorName,D008297,19224802,,,17,Male,N,
18345,DescriptorName,D009456,19224802,,,18,Neurofibromatosis 1,N,
18346,QualifierName,Q000601,19224802,,,18,,N,surgery
18347,DescriptorName,D010100,19224802,,,19,Oxygen,N,
18348,QualifierName,Q000097,19224802,,,19,,N,blood
18349,DescriptorName,D015656,19224802,,,20,Respiratory Mechanics,N,
18350,QualifierName,Q000187,19224802,,,20,,N,drug effects
18351,DescriptorName,D014402,19224802,,,21,Tuberous Sclerosis,N,
18352,QualifierName,Q000150,19224802,,,21,,N,complications
18353,Chemical,D050071,19235747,Bone Density Conservation Agents,0,,,,
18354,Chemical,D004164,19235747,Diphosphonates,0,,,,
18355,Chemical,D007093,19235747,Imidazoles,0,,,,
18356,Chemical,D000077211,19235747,Zoledronic Acid,6XC1PAD3KF,,,,
18357,DescriptorName,D050071,19235747,,,1,Bone Density Conservation Agents,N,
18358,QualifierName,Q000009,19235747,,,1,,N,adverse effects
18359,DescriptorName,D003937,19235747,,,2,"Diagnosis, Differential",N,
18360,DescriptorName,D004164,19235747,,,3,Diphosphonates,N,
18361,QualifierName,Q000009,19235747,,,3,,Y,adverse effects
18362,DescriptorName,D005260,19235747,,,4,Female,N,
18363,DescriptorName,D005500,19235747,,,5,Follow-Up Studies,N,
18364,DescriptorName,D006801,19235747,,,6,Humans,N,
18365,DescriptorName,D007093,19235747,,,7,Imidazoles,N,
18366,QualifierName,Q000009,19235747,,,7,,Y,adverse effects
18367,DescriptorName,D008875,19235747,,,8,Middle Aged,N,
18368,DescriptorName,D009101,19235747,,,9,Multiple Myeloma,N,
18369,QualifierName,Q000188,19235747,,,9,,N,drug therapy
18370,DescriptorName,D019635,19235747,,,10,Neurosurgical Procedures,N,
18371,QualifierName,Q000379,19235747,,,10,,N,methods
18372,DescriptorName,D010020,19235747,,,11,Osteonecrosis,N,
18373,QualifierName,Q000139,19235747,,,11,,Y,chemically induced
18374,DescriptorName,D019291,19235747,,,12,Skull Base,N,
18375,QualifierName,Q000000981,19235747,,,12,,N,diagnostic imaging
18376,DescriptorName,D014057,19235747,,,13,"Tomography, X-Ray Computed",N,
18377,QualifierName,Q000379,19235747,,,13,,Y,methods
18378,DescriptorName,D000077211,19235747,,,14,Zoledronic Acid,N,
18379,Chemical,D005338,19260037,Fibrin Fibrinogen Degradation Products,0,,,,
18380,Chemical,D009125,19260037,"Muscle Relaxants, Central",0,,,,
18381,Chemical,C036309,19260037,fibrin fragment D,0,,,,
18382,Chemical,D011803,19260037,Quinine,A7V27PHC7A,,,,
18383,Chemical,D051722,19260037,ADAM Proteins,EC 3.4.24.-,,,,
18384,Chemical,D000071120,19260037,ADAMTS13 Protein,EC 3.4.24.87,,,,
18385,Chemical,C099604,19260037,"ADAMTS13 protein, human",EC 3.4.24.87,,,,
18386,DescriptorName,D051722,19260037,,,1,ADAM Proteins,N,
18387,QualifierName,Q000097,19260037,,,1,,Y,blood
18388,DescriptorName,D000071120,19260037,,,2,ADAMTS13 Protein,N,
18389,DescriptorName,D000328,19260037,,,3,Adult,N,
18390,DescriptorName,D000368,19260037,,,4,Aged,N,
18391,DescriptorName,D000369,19260037,,,5,"Aged, 80 and over",N,
18392,DescriptorName,D005260,19260037,,,6,Female,N,
18393,DescriptorName,D005338,19260037,,,7,Fibrin Fibrinogen Degradation Products,N,
18394,DescriptorName,D006801,19260037,,,8,Humans,N,
18395,DescriptorName,D008875,19260037,,,9,Middle Aged,N,
18396,DescriptorName,D009120,19260037,,,10,Muscle Cramp,N,
18397,QualifierName,Q000097,19260037,,,10,,N,blood
18398,DescriptorName,D009125,19260037,,,11,"Muscle Relaxants, Central",N,
18399,QualifierName,Q000008,19260037,,,11,,N,administration & dosage
18400,DescriptorName,D010951,19260037,,,12,Plasma Exchange,Y,
18401,DescriptorName,D016553,19260037,,,13,"Purpura, Thrombocytopenic, Idiopathic",N,
18402,QualifierName,Q000097,19260037,,,13,,Y,blood
18403,DescriptorName,D011803,19260037,,,14,Quinine,N,
18404,QualifierName,Q000008,19260037,,,14,,N,administration & dosage
18405,DescriptorName,D006435,19260037,,,15,Renal Dialysis,N,
18406,DescriptorName,D051437,19260037,,,16,Renal Insufficiency,N,
18407,QualifierName,Q000097,19260037,,,16,,N,blood
18408,DescriptorName,D012189,19260037,,,17,Retrospective Studies,N,
18409,Chemical,D015251,19266307,Epirubicin,3Z8479ZZ5X,,,,
18410,DescriptorName,D000283,19266307,,,1,"Administration, Intravesical",Y,
18411,DescriptorName,D000368,19266307,,,2,Aged,N,
18412,DescriptorName,D000369,19266307,,,3,"Aged, 80 and over",N,
18413,DescriptorName,D017024,19266307,,,4,"Chemotherapy, Adjuvant",N,
18414,DescriptorName,D015653,19266307,,,5,Cystectomy,N,
18415,QualifierName,Q000379,19266307,,,5,,N,methods
18416,DescriptorName,D003558,19266307,,,6,Cystoscopy,N,
18417,QualifierName,Q000379,19266307,,,6,,N,methods
18418,DescriptorName,D004305,19266307,,,7,"Dose-Response Relationship, Drug",N,
18419,DescriptorName,D004334,19266307,,,8,Drug Administration Schedule,N,
18420,DescriptorName,D015251,19266307,,,9,Epirubicin,N,
18421,QualifierName,Q000008,19266307,,,9,,Y,administration & dosage
18422,DescriptorName,D005500,19266307,,,10,Follow-Up Studies,N,
18423,DescriptorName,D006801,19266307,,,11,Humans,N,
18424,DescriptorName,D007049,19266307,,,12,Iatrogenic Disease,N,
18425,DescriptorName,D008297,19266307,,,13,Male,N,
18426,DescriptorName,D019060,19266307,,,14,Minimally Invasive Surgical Procedures,N,
18427,QualifierName,Q000379,19266307,,,14,,N,methods
18428,DescriptorName,D018570,19266307,,,15,Risk Assessment,N,
18429,DescriptorName,D012421,19266307,,,16,Rupture,N,
18430,DescriptorName,D016896,19266307,,,17,Treatment Outcome,N,
18431,DescriptorName,D014521,19266307,,,18,Urethra,N,
18432,DescriptorName,D001743,19266307,,,19,Urinary Bladder,N,
18433,QualifierName,Q000293,19266307,,,19,,Y,injuries
18434,DescriptorName,D001749,19266307,,,20,Urinary Bladder Neoplasms,N,
18435,QualifierName,Q000188,19266307,,,20,,Y,drug therapy
18436,DescriptorName,D013521,19266307,,,21,"Urologic Surgical Procedures, Male",N,
18437,QualifierName,Q000379,19266307,,,21,,N,methods
18438,DescriptorName,D014950,19266307,,,22,"Wounds, Penetrating",N,
18439,QualifierName,Q000175,19266307,,,22,,N,diagnosis
18440,Chemical,D000577,19281746,Amides,0,,,,
18441,Chemical,D000959,19281746,Antihypertensive Agents,0,,,,
18442,Chemical,D005650,19281746,Fumarates,0,,,,
18443,Chemical,C446481,19281746,aliskiren,502FWN4Q32,,,,
18444,DescriptorName,D058186,19281746,,,1,Acute Kidney Injury,N,
18445,QualifierName,Q000139,19281746,,,1,,Y,chemically induced
18446,DescriptorName,D000368,19281746,,,2,Aged,N,
18447,DescriptorName,D000577,19281746,,,3,Amides,N,
18448,QualifierName,Q000009,19281746,,,3,,Y,adverse effects
18449,DescriptorName,D000959,19281746,,,4,Antihypertensive Agents,N,
18450,QualifierName,Q000009,19281746,,,4,,Y,adverse effects
18451,DescriptorName,D005260,19281746,,,5,Female,N,
18452,DescriptorName,D005650,19281746,,,6,Fumarates,N,
18453,QualifierName,Q000009,19281746,,,6,,Y,adverse effects
18454,DescriptorName,D006801,19281746,,,7,Humans,N,
18455,DescriptorName,D006947,19281746,,,8,Hyperkalemia,N,
18456,QualifierName,Q000139,19281746,,,8,,Y,chemically induced
18457,DescriptorName,D006973,19281746,,,9,Hypertension,N,
18458,QualifierName,Q000188,19281746,,,9,,Y,drug therapy
18459,DescriptorName,D006435,19281746,,,10,Renal Dialysis,N,
18460,Chemical,D002317,19296063,Cardiovascular Agents,0,,,,
18461,Chemical,D000697,19296063,Central Nervous System Stimulants,0,,,,
18462,Chemical,D008774,19296063,Methylphenidate,207ZZ9QZ49,,,,
18463,DescriptorName,D000208,19296063,,,1,Acute Disease,N,
18464,DescriptorName,D000293,19296063,,,2,Adolescent,N,
18465,DescriptorName,D000787,19296063,,,3,Angina Pectoris,N,
18466,QualifierName,Q000139,19296063,,,3,,N,chemically induced
18467,DescriptorName,D001289,19296063,,,4,Attention Deficit Disorder with Hyperactivity,N,
18468,QualifierName,Q000188,19296063,,,4,,Y,drug therapy
18469,DescriptorName,D009202,19296063,,,5,Cardiomyopathies,N,
18470,QualifierName,Q000139,19296063,,,5,,Y,chemically induced
18471,DescriptorName,D002317,19296063,,,6,Cardiovascular Agents,N,
18472,QualifierName,Q000627,19296063,,,6,,N,therapeutic use
18473,DescriptorName,D000697,19296063,,,7,Central Nervous System Stimulants,N,
18474,QualifierName,Q000009,19296063,,,7,,Y,adverse effects
18475,DescriptorName,D004359,19296063,,,8,"Drug Therapy, Combination",N,
18476,DescriptorName,D004562,19296063,,,9,Electrocardiography,N,
18477,DescriptorName,D006801,19296063,,,10,Humans,N,
18478,DescriptorName,D008297,19296063,,,11,Male,N,
18479,DescriptorName,D008774,19296063,,,12,Methylphenidate,N,
18480,QualifierName,Q000009,19296063,,,12,,Y,adverse effects
18481,DescriptorName,D010493,19296063,,,13,Pericarditis,N,
18482,QualifierName,Q000139,19296063,,,13,,Y,chemically induced
18483,DescriptorName,D018487,19296063,,,14,"Ventricular Dysfunction, Left",N,
18484,QualifierName,Q000139,19296063,,,14,,N,chemically induced
18485,Chemical,D000925,19299370,Anticoagulants,0,,,,
18486,Chemical,D017984,19299370,Enoxaparin,0,,,,
18487,DescriptorName,D000328,19299370,,,1,Adult,N,
18488,DescriptorName,D000925,19299370,,,2,Anticoagulants,N,
18489,QualifierName,Q000009,19299370,,,2,,Y,adverse effects
18490,DescriptorName,D056486,19299370,,,3,Chemical and Drug Induced Liver Injury,N,
18491,QualifierName,Q000000981,19299370,,,3,,N,diagnostic imaging
18492,DescriptorName,D017984,19299370,,,4,Enoxaparin,N,
18493,QualifierName,Q000009,19299370,,,4,,Y,adverse effects
18494,DescriptorName,D005260,19299370,,,5,Female,N,
18495,DescriptorName,D006801,19299370,,,6,Humans,N,
18496,DescriptorName,D007279,19299370,,,7,"Injections, Subcutaneous",N,
18497,DescriptorName,D008099,19299370,,,8,Liver,N,
18498,QualifierName,Q000000981,19299370,,,8,,N,diagnostic imaging
18499,DescriptorName,D008111,19299370,,,9,Liver Function Tests,N,
18500,DescriptorName,D011655,19299370,,,10,Pulmonary Embolism,N,
18501,QualifierName,Q000188,19299370,,,10,,N,drug therapy
18502,DescriptorName,D014057,19299370,,,11,"Tomography, X-Ray Computed",N,
18503,Chemical,D000964,19307676,"Antimetabolites, Antineoplastic",0,,,,
18504,Chemical,D008727,19307676,Methotrexate,YL5FZ2Y5U1,,,,
18505,DescriptorName,D000293,19307676,,,1,Adolescent,N,
18506,DescriptorName,D000964,19307676,,,2,"Antimetabolites, Antineoplastic",N,
18507,QualifierName,Q000008,19307676,,,2,,N,administration & dosage
18508,DescriptorName,D001921,19307676,,,3,Brain,N,
18509,QualifierName,Q000098,19307676,,,3,,N,blood supply
18510,DescriptorName,D001927,19307676,,,4,Brain Diseases,N,
18511,QualifierName,Q000139,19307676,,,4,,Y,chemically induced
18512,DescriptorName,D038524,19307676,,,5,Diffusion Magnetic Resonance Imaging,N,
18513,DescriptorName,D005260,19307676,,,6,Female,N,
18514,DescriptorName,D005500,19307676,,,7,Follow-Up Studies,N,
18515,DescriptorName,D006801,19307676,,,8,Humans,N,
18516,DescriptorName,D007278,19307676,,,9,"Injections, Spinal",N,
18517,DescriptorName,D008279,19307676,,,10,Magnetic Resonance Imaging,N,
18518,DescriptorName,D008727,19307676,,,11,Methotrexate,N,
18519,QualifierName,Q000008,19307676,,,11,,N,administration & dosage
18520,DescriptorName,D010690,19307676,,,12,Phlebography,N,
18521,DescriptorName,D054198,19307676,,,13,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
18522,QualifierName,Q000188,19307676,,,13,,N,drug therapy
18523,DescriptorName,D013226,19307676,,,14,Status Epilepticus,N,
18524,QualifierName,Q000139,19307676,,,14,,Y,chemically induced
18525,DescriptorName,D013577,19307676,,,15,Syndrome,N,
18526,Chemical,D002121,19318596,Calcium Channel Blockers,0,,,,
18527,Chemical,D016572,19318596,Cyclosporine,83HN0GTJ6D,,,,
18528,DescriptorName,D002121,19318596,,,1,Calcium Channel Blockers,N,
18529,QualifierName,Q000627,19318596,,,1,,N,therapeutic use
18530,DescriptorName,D002648,19318596,,,2,Child,N,
18531,DescriptorName,D016572,19318596,,,3,Cyclosporine,N,
18532,QualifierName,Q000009,19318596,,,3,,Y,adverse effects
18533,DescriptorName,D018380,19318596,,,4,Hematopoietic Stem Cell Transplantation,N,
18534,QualifierName,Q000009,19318596,,,4,,Y,adverse effects
18535,DescriptorName,D006801,19318596,,,5,Humans,N,
18536,DescriptorName,D008297,19318596,,,6,Male,N,
18537,DescriptorName,D010146,19318596,,,7,Pain,N,
18538,QualifierName,Q000139,19318596,,,7,,N,chemically induced
18539,DescriptorName,D012019,19318596,,,8,Reflex Sympathetic Dystrophy,N,
18540,QualifierName,Q000139,19318596,,,8,,Y,chemically induced
18541,Chemical,D018712,19331262,"Analgesics, Non-Narcotic",0,,,,
18542,Chemical,D014150,19331262,Antipsychotic Agents,0,,,,
18543,Chemical,D018492,19331262,Dopamine Antagonists,0,,,,
18544,Chemical,D018727,19331262,Muscarinic Antagonists,0,,,,
18545,Chemical,D012702,19331262,Serotonin Antagonists,0,,,,
18546,Chemical,D001712,19331262,Biperiden,0FRP6G56LD,,,,
18547,Chemical,D000082,19331262,Acetaminophen,362O9ITL9D,,,,
18548,Chemical,D018967,19331262,Risperidone,L6UH7ZF8HC,,,,
18549,DescriptorName,D000015,19331262,,,1,"Abnormalities, Multiple",N,
18550,QualifierName,Q000188,19331262,,,1,,Y,drug therapy
18551,DescriptorName,D000082,19331262,,,2,Acetaminophen,N,
18552,QualifierName,Q000627,19331262,,,2,,N,therapeutic use
18553,DescriptorName,D000293,19331262,,,3,Adolescent,N,
18554,DescriptorName,D018712,19331262,,,4,"Analgesics, Non-Narcotic",N,
18555,QualifierName,Q000627,19331262,,,4,,N,therapeutic use
18556,DescriptorName,D014150,19331262,,,5,Antipsychotic Agents,N,
18557,QualifierName,Q000009,19331262,,,5,,Y,adverse effects
18558,DescriptorName,D001712,19331262,,,6,Biperiden,N,
18559,QualifierName,Q000627,19331262,,,6,,N,therapeutic use
18560,DescriptorName,D017679,19331262,,,7,Cryotherapy,N,
18561,DescriptorName,D018492,19331262,,,8,Dopamine Antagonists,N,
18562,QualifierName,Q000009,19331262,,,8,,Y,adverse effects
18563,DescriptorName,D006801,19331262,,,9,Humans,N,
18564,DescriptorName,D008297,19331262,,,10,Male,N,
18565,DescriptorName,D018727,19331262,,,11,Muscarinic Antagonists,N,
18566,QualifierName,Q000627,19331262,,,11,,N,therapeutic use
18567,DescriptorName,D009459,19331262,,,12,Neuroleptic Malignant Syndrome,Y,
18568,DescriptorName,D018967,19331262,,,13,Risperidone,N,
18569,QualifierName,Q000009,19331262,,,13,,Y,adverse effects
18570,DescriptorName,D012702,19331262,,,14,Serotonin Antagonists,N,
18571,QualifierName,Q000009,19331262,,,14,,Y,adverse effects
18572,Chemical,D000911,19336028,"Antibodies, Monoclonal",0,,,,
18573,Chemical,D061067,19336028,"Antibodies, Monoclonal, Humanized",0,,,,
18574,Chemical,D000995,19336028,Antitubercular Agents,0,,,,
18575,Chemical,D007074,19336028,Immunoglobulin G,0,,,,
18576,Chemical,D018124,19336028,"Receptors, Tumor Necrosis Factor",0,,,,
18577,Chemical,D000068800,19336028,Etanercept,OP401G7OJC,,,,
18578,Chemical,C472181,19336028,efalizumab,XX2MN88N5D,,,,
18579,DescriptorName,D000911,19336028,,,1,"Antibodies, Monoclonal",N,
18580,QualifierName,Q000008,19336028,,,1,,Y,administration & dosage
18581,DescriptorName,D061067,19336028,,,2,"Antibodies, Monoclonal, Humanized",N,
18582,DescriptorName,D000995,19336028,,,3,Antitubercular Agents,N,
18583,QualifierName,Q000627,19336028,,,3,,N,therapeutic use
18584,DescriptorName,D015535,19336028,,,4,"Arthritis, Psoriatic",N,
18585,QualifierName,Q000150,19336028,,,4,,N,complications
18586,DescriptorName,D018450,19336028,,,5,Disease Progression,N,
18587,DescriptorName,D004359,19336028,,,6,"Drug Therapy, Combination",N,
18588,DescriptorName,D000068800,19336028,,,7,Etanercept,N,
18589,DescriptorName,D005260,19336028,,,8,Female,N,
18590,DescriptorName,D005500,19336028,,,9,Follow-Up Studies,N,
18591,DescriptorName,D006801,19336028,,,10,Humans,N,
18592,DescriptorName,D007074,19336028,,,11,Immunoglobulin G,N,
18593,QualifierName,Q000008,19336028,,,11,,Y,administration & dosage
18594,DescriptorName,D008875,19336028,,,12,Middle Aged,N,
18595,DescriptorName,D011565,19336028,,,13,Psoriasis,N,
18596,QualifierName,Q000150,19336028,,,13,,N,complications
18597,DescriptorName,D018124,19336028,,,14,"Receptors, Tumor Necrosis Factor",N,
18598,QualifierName,Q000008,19336028,,,14,,Y,administration & dosage
18599,DescriptorName,D018570,19336028,,,15,Risk Assessment,N,
18600,DescriptorName,D012720,19336028,,,16,Severity of Illness Index,N,
18601,DescriptorName,D017211,19336028,,,17,Treatment Failure,N,
18602,DescriptorName,D014374,19336028,,,18,Tuberculin Test,N,
18603,DescriptorName,D014376,19336028,,,19,Tuberculosis,N,
18604,QualifierName,Q000150,19336028,,,19,,N,complications
18605,Chemical,D000925,19354059,Anticoagulants,0,,,,
18606,Chemical,D011994,19354059,Recombinant Proteins,0,,,,
18607,Chemical,D014859,19354059,Warfarin,5Q7ZVV76EI,,,,
18608,Chemical,C103587,19354059,recombinant FVIIa,AC71R787OV,,,,
18609,Chemical,D015942,19354059,Factor VIIa,EC 3.4.21.21,,,,
18610,DescriptorName,D000369,19354059,,,1,"Aged, 80 and over",N,
18611,DescriptorName,D000925,19354059,,,2,Anticoagulants,N,
18612,QualifierName,Q000009,19354059,,,2,,Y,adverse effects
18613,DescriptorName,D015942,19354059,,,3,Factor VIIa,N,
18614,QualifierName,Q000627,19354059,,,3,,Y,therapeutic use
18615,DescriptorName,D005260,19354059,,,4,Female,N,
18616,DescriptorName,D005440,19354059,,,5,Fluid Therapy,N,
18617,DescriptorName,D006406,19354059,,,6,Hematoma,N,
18618,QualifierName,Q000188,19354059,,,6,,Y,drug therapy
18619,DescriptorName,D006801,19354059,,,7,Humans,N,
18620,DescriptorName,D011994,19354059,,,8,Recombinant Proteins,N,
18621,QualifierName,Q000627,19354059,,,8,,N,therapeutic use
18622,DescriptorName,D012187,19354059,,,9,Retroperitoneal Space,N,
18623,QualifierName,Q000473,19354059,,,9,,N,pathology
18624,DescriptorName,D013997,19354059,,,10,Time Factors,N,
18625,DescriptorName,D014859,19354059,,,11,Warfarin,N,
18626,QualifierName,Q000009,19354059,,,11,,Y,adverse effects
18627,DescriptorName,D014947,19354059,,,12,Wounds and Injuries,N,
18628,QualifierName,Q000150,19354059,,,12,,Y,complications
18629,Chemical,D019380,19357764,Anti-HIV Agents,0,,,,
18630,Chemical,D015215,19357764,Zidovudine,4B9XT59T7S,,,,
18631,Chemical,D018119,19357764,Stavudine,BO9LE4QFZF,,,,
18632,DescriptorName,D000140,19357764,,,1,"Acidosis, Lactic",N,
18633,QualifierName,Q000097,19357764,,,1,,N,blood
18634,DescriptorName,D000163,19357764,,,2,Acquired Immunodeficiency Syndrome,N,
18635,QualifierName,Q000188,19357764,,,2,,Y,drug therapy
18636,DescriptorName,D019380,19357764,,,3,Anti-HIV Agents,N,
18637,QualifierName,Q000009,19357764,,,3,,Y,adverse effects
18638,DescriptorName,D005260,19357764,,,4,Female,N,
18639,DescriptorName,D006801,19357764,,,5,Humans,N,
18640,DescriptorName,D008875,19357764,,,6,Middle Aged,N,
18641,DescriptorName,D018119,19357764,,,7,Stavudine,N,
18642,QualifierName,Q000009,19357764,,,7,,Y,adverse effects
18643,DescriptorName,D016896,19357764,,,8,Treatment Outcome,N,
18644,DescriptorName,D014454,19357764,,,9,Uganda,N,
18645,DescriptorName,D015215,19357764,,,10,Zidovudine,N,
18646,QualifierName,Q000009,19357764,,,10,,Y,adverse effects
18647,Chemical,D000900,19363904,Anti-Bacterial Agents,0,,,,
18648,Chemical,D009824,19363904,Ointments,0,,,,
18649,Chemical,D001414,19363904,Bacitracin,1405-87-4,,,,
18650,DescriptorName,D000279,19363904,,,1,"Administration, Cutaneous",N,
18651,DescriptorName,D000707,19363904,,,2,Anaphylaxis,N,
18652,QualifierName,Q000139,19363904,,,2,,Y,chemically induced
18653,DescriptorName,D000900,19363904,,,3,Anti-Bacterial Agents,N,
18654,QualifierName,Q000009,19363904,,,3,,Y,adverse effects
18655,DescriptorName,D001414,19363904,,,4,Bacitracin,N,
18656,QualifierName,Q000009,19363904,,,4,,Y,adverse effects
18657,DescriptorName,D002648,19363904,,,5,Child,N,
18658,DescriptorName,D006801,19363904,,,6,Humans,N,
18659,DescriptorName,D008297,19363904,,,7,Male,N,
18660,DescriptorName,D009824,19363904,,,8,Ointments,N,
18661,DescriptorName,D014950,19363904,,,9,"Wounds, Penetrating",N,
18662,QualifierName,Q000188,19363904,,,9,,Y,drug therapy
18663,Chemical,D018931,19365885,"Antineoplastic Agents, Hormonal",0,,,,
18664,Chemical,D001786,19365885,Blood Glucose,0,,,,
18665,Chemical,D003692,19365885,Delayed-Action Preparations,0,,,,
18666,Chemical,D004040,19365885,Dietary Carbohydrates,0,,,,
18667,Chemical,D005938,19365885,Glucocorticoids,0,,,,
18668,Chemical,D013004,19365885,Somatostatin,51110-01-1,,,,
18669,Chemical,D005947,19365885,Glucose,IY9XDZ35W2,,,,
18670,Chemical,D015282,19365885,Octreotide,RWM8CCW8GP,,,,
18671,Chemical,D008775,19365885,Methylprednisolone,X4W7ZR7023,,,,
18672,DescriptorName,D018931,19365885,,,1,"Antineoplastic Agents, Hormonal",N,
18673,QualifierName,Q000009,19365885,,,1,,Y,adverse effects
18674,DescriptorName,D001786,19365885,,,2,Blood Glucose,N,
18675,QualifierName,Q000378,19365885,,,2,,N,metabolism
18676,DescriptorName,D003692,19365885,,,3,Delayed-Action Preparations,N,
18677,DescriptorName,D004040,19365885,,,4,Dietary Carbohydrates,N,
18678,QualifierName,Q000008,19365885,,,4,,N,administration & dosage
18679,DescriptorName,D017809,19365885,,,5,Fatal Outcome,N,
18680,DescriptorName,D005260,19365885,,,6,Female,N,
18681,DescriptorName,D005938,19365885,,,7,Glucocorticoids,N,
18682,QualifierName,Q000008,19365885,,,7,,N,administration & dosage
18683,DescriptorName,D005947,19365885,,,8,Glucose,N,
18684,QualifierName,Q000008,19365885,,,8,,N,administration & dosage
18685,DescriptorName,D006801,19365885,,,9,Humans,N,
18686,DescriptorName,D007003,19365885,,,10,Hypoglycemia,N,
18687,QualifierName,Q000097,19365885,,,10,,N,blood
18688,DescriptorName,D007150,19365885,,,11,Immunohistochemistry,N,
18689,DescriptorName,D007262,19365885,,,12,"Infusions, Intravenous",N,
18690,DescriptorName,D008775,19365885,,,13,Methylprednisolone,N,
18691,QualifierName,Q000008,19365885,,,13,,N,administration & dosage
18692,DescriptorName,D008875,19365885,,,14,Middle Aged,N,
18693,DescriptorName,D018358,19365885,,,15,Neuroendocrine Tumors,N,
18694,QualifierName,Q000175,19365885,,,15,,N,diagnosis
18695,DescriptorName,D015282,19365885,,,16,Octreotide,N,
18696,QualifierName,Q000009,19365885,,,16,,Y,adverse effects
18697,DescriptorName,D010190,19365885,,,17,Pancreatic Neoplasms,N,
18698,QualifierName,Q000175,19365885,,,17,,N,diagnosis
18699,DescriptorName,D011877,19365885,,,18,Radionuclide Imaging,N,
18700,DescriptorName,D013004,19365885,,,19,Somatostatin,N,
18701,QualifierName,Q000009,19365885,,,19,,Y,adverse effects
18702,DescriptorName,D014057,19365885,,,20,"Tomography, X-Ray Computed",N,
18703,Chemical,D007166,19390192,Immunosuppressive Agents,0,,,,
18704,Chemical,D001379,19390192,Azathioprine,MRK240IY2L,,,,
18705,DescriptorName,D000328,19390192,,,1,Adult,N,
18706,DescriptorName,D001379,19390192,,,2,Azathioprine,N,
18707,QualifierName,Q000009,19390192,,,2,,Y,adverse effects
18708,DescriptorName,D003424,19390192,,,3,Crohn Disease,N,
18709,QualifierName,Q000150,19390192,,,3,,N,complications
18710,DescriptorName,D016731,19390192,,,4,Erythema Infectiosum,N,
18711,QualifierName,Q000209,19390192,,,4,,Y,etiology
18712,DescriptorName,D005260,19390192,,,5,Female,N,
18713,DescriptorName,D006801,19390192,,,6,Humans,N,
18714,DescriptorName,D007166,19390192,,,7,Immunosuppressive Agents,N,
18715,QualifierName,Q000009,19390192,,,7,,Y,adverse effects
18716,DescriptorName,D007970,19390192,,,8,Leukopenia,N,
18717,QualifierName,Q000821,19390192,,,8,,Y,virology
18718,DescriptorName,D016732,19390192,,,9,"Parvovirus B19, Human",Y,
18719,Chemical,D000995,19402273,Antitubercular Agents,0,,,,
18720,Chemical,D011718,19402273,Pyrazinamide,2KNI5N06TI,,,,
18721,Chemical,D004977,19402273,Ethambutol,8G167061QZ,,,,
18722,Chemical,D007538,19402273,Isoniazid,V83O1VOZ8L,,,,
18723,Chemical,D012293,19402273,Rifampin,VJT6J7R4TR,,,,
18724,DescriptorName,D000995,19402273,,,1,Antitubercular Agents,N,
18725,QualifierName,Q000008,19402273,,,1,,N,administration & dosage
18726,DescriptorName,D004359,19402273,,,2,"Drug Therapy, Combination",N,
18727,DescriptorName,D004977,19402273,,,3,Ethambutol,N,
18728,QualifierName,Q000008,19402273,,,3,,N,administration & dosage
18729,DescriptorName,D006177,19402273,,,4,Gynecomastia,N,
18730,QualifierName,Q000139,19402273,,,4,,Y,chemically induced
18731,DescriptorName,D006801,19402273,,,5,Humans,N,
18732,DescriptorName,D007538,19402273,,,6,Isoniazid,N,
18733,QualifierName,Q000008,19402273,,,6,,N,administration & dosage
18734,DescriptorName,D008297,19402273,,,7,Male,N,
18735,DescriptorName,D008327,19402273,,,8,Mammography,N,
18736,DescriptorName,D008875,19402273,,,9,Middle Aged,N,
18737,DescriptorName,D011718,19402273,,,10,Pyrazinamide,N,
18738,QualifierName,Q000008,19402273,,,10,,N,administration & dosage
18739,DescriptorName,D012293,19402273,,,11,Rifampin,N,
18740,QualifierName,Q000008,19402273,,,11,,N,administration & dosage
18741,DescriptorName,D014397,19402273,,,12,"Tuberculosis, Pulmonary",N,
18742,QualifierName,Q000188,19402273,,,12,,N,drug therapy
18743,Chemical,D000911,19423476,"Antibodies, Monoclonal",0,,,,
18744,Chemical,D061067,19423476,"Antibodies, Monoclonal, Humanized",0,,,,
18745,Chemical,D000912,19423476,"Antibodies, Neoplasm",0,,,,
18746,Chemical,D000935,19423476,Antifungal Agents,0,,,,
18747,Chemical,D000970,19423476,Antineoplastic Agents,0,,,,
18748,Chemical,C068538,19423476,liposomal amphotericin B,0,,,,
18749,Chemical,D000074323,19423476,Alemtuzumab,3A189DH42V,,,,
18750,Chemical,D000666,19423476,Amphotericin B,7XU7A7DROE,,,,
18751,DescriptorName,D000368,19423476,,,1,Aged,N,
18752,DescriptorName,D000074323,19423476,,,2,Alemtuzumab,N,
18753,DescriptorName,D000666,19423476,,,3,Amphotericin B,N,
18754,QualifierName,Q000627,19423476,,,3,,N,therapeutic use
18755,DescriptorName,D000911,19423476,,,4,"Antibodies, Monoclonal",N,
18756,QualifierName,Q000009,19423476,,,4,,Y,adverse effects
18757,DescriptorName,D061067,19423476,,,5,"Antibodies, Monoclonal, Humanized",N,
18758,DescriptorName,D000912,19423476,,,6,"Antibodies, Neoplasm",N,
18759,QualifierName,Q000009,19423476,,,6,,Y,adverse effects
18760,DescriptorName,D000935,19423476,,,7,Antifungal Agents,N,
18761,QualifierName,Q000627,19423476,,,7,,N,therapeutic use
18762,DescriptorName,D000970,19423476,,,8,Antineoplastic Agents,N,
18763,QualifierName,Q000009,19423476,,,8,,Y,adverse effects
18764,DescriptorName,D003453,19423476,,,9,Cryptococcosis,N,
18765,QualifierName,Q000150,19423476,,,9,,Y,complications
18766,DescriptorName,D003455,19423476,,,10,Cryptococcus neoformans,N,
18767,DescriptorName,D017809,19423476,,,11,Fatal Outcome,N,
18768,DescriptorName,D016469,19423476,,,12,Fungemia,N,
18769,QualifierName,Q000150,19423476,,,12,,Y,complications
18770,DescriptorName,D006801,19423476,,,13,Humans,N,
18771,DescriptorName,D015451,19423476,,,14,"Leukemia, Lymphocytic, Chronic, B-Cell",N,
18772,QualifierName,Q000150,19423476,,,14,,Y,complications
18773,DescriptorName,D008297,19423476,,,15,Male,N,
18774,DescriptorName,D009503,19423476,,,16,Neutropenia,N,
18775,QualifierName,Q000139,19423476,,,16,,N,chemically induced
18776,DescriptorName,D009894,19423476,,,17,Opportunistic Infections,N,
18777,QualifierName,Q000150,19423476,,,17,,Y,complications
18778,Chemical,D000972,19434733,"Antineoplastic Agents, Phytogenic",0,,,,
18779,Chemical,D005047,19434733,Etoposide,6PLQ3CP4P3,,,,
18780,DescriptorName,D000972,19434733,,,1,"Antineoplastic Agents, Phytogenic",N,
18781,QualifierName,Q000009,19434733,,,1,,Y,adverse effects
18782,DescriptorName,D002675,19434733,,,2,"Child, Preschool",N,
18783,DescriptorName,D005047,19434733,,,3,Etoposide,N,
18784,QualifierName,Q000009,19434733,,,3,,Y,adverse effects
18785,DescriptorName,D005260,19434733,,,4,Female,N,
18786,DescriptorName,D006801,19434733,,,5,Humans,N,
18787,DescriptorName,D007223,19434733,,,6,Infant,N,
18788,DescriptorName,D015470,19434733,,,7,"Leukemia, Myeloid, Acute",N,
18789,QualifierName,Q000139,19434733,,,7,,Y,chemically induced
18790,DescriptorName,D051359,19434733,,,8,"Lymphohistiocytosis, Hemophagocytic",N,
18791,QualifierName,Q000188,19434733,,,8,,Y,drug therapy
18792,DescriptorName,D008297,19434733,,,9,Male,N,
18793,DescriptorName,D016609,19434733,,,10,"Neoplasms, Second Primary",N,
18794,QualifierName,Q000139,19434733,,,10,,Y,chemically induced
18795,Chemical,D000927,19448237,Anticonvulsants,0,,,,
18796,Chemical,D000933,19448237,Antifibrinolytic Agents,0,,,,
18797,Chemical,D010672,19448237,Phenytoin,6158TKW0C5,,,,
18798,Chemical,D014148,19448237,Tranexamic Acid,6T84R30KC1,,,,
18799,Chemical,D013874,19448237,Thiopental,JI8Z5M7NA3,,,,
18800,DescriptorName,D000768,19448237,,,1,"Anesthesia, General",N,
18801,DescriptorName,D000775,19448237,,,2,"Anesthesia, Spinal",Y,
18802,DescriptorName,D000927,19448237,,,3,Anticonvulsants,N,
18803,QualifierName,Q000627,19448237,,,3,,N,therapeutic use
18804,DescriptorName,D000933,19448237,,,4,Antifibrinolytic Agents,N,
18805,QualifierName,Q000008,19448237,,,4,,N,administration & dosage
18806,DescriptorName,D003422,19448237,,,5,Critical Care,N,
18807,DescriptorName,D006801,19448237,,,6,Humans,N,
18808,DescriptorName,D008297,19448237,,,7,Male,N,
18809,DescriptorName,D008508,19448237,,,8,Medication Errors,Y,
18810,DescriptorName,D008875,19448237,,,9,Middle Aged,N,
18811,DescriptorName,D009207,19448237,,,10,Myoclonus,N,
18812,QualifierName,Q000139,19448237,,,10,,Y,chemically induced
18813,DescriptorName,D019637,19448237,,,11,Orthopedic Procedures,N,
18814,DescriptorName,D010672,19448237,,,12,Phenytoin,N,
18815,QualifierName,Q000627,19448237,,,12,,N,therapeutic use
18816,DescriptorName,D012640,19448237,,,13,Seizures,N,
18817,QualifierName,Q000139,19448237,,,13,,N,chemically induced
18818,DescriptorName,D013874,19448237,,,14,Thiopental,N,
18819,QualifierName,Q000627,19448237,,,14,,N,therapeutic use
18820,DescriptorName,D014148,19448237,,,15,Tranexamic Acid,N,
18821,QualifierName,Q000008,19448237,,,15,,N,administration & dosage
18822,Chemical,D000900,19474653,Anti-Bacterial Agents,0,,,,
18823,Chemical,D017291,19474653,Clarithromycin,H1250JIK0A,,,,
18824,DescriptorName,D000900,19474653,,,1,Anti-Bacterial Agents,N,
18825,QualifierName,Q000009,19474653,,,1,,Y,adverse effects
18826,DescriptorName,D017291,19474653,,,2,Clarithromycin,N,
18827,QualifierName,Q000009,19474653,,,2,,Y,adverse effects
18828,DescriptorName,D006801,19474653,,,3,Humans,N,
18829,DescriptorName,D008297,19474653,,,4,Male,N,
18830,DescriptorName,D008875,19474653,,,5,Middle Aged,N,
18831,DescriptorName,D018908,19474653,,,6,Muscle Weakness,N,
18832,QualifierName,Q000209,19474653,,,6,,N,etiology
18833,DescriptorName,D012206,19474653,,,7,Rhabdomyolysis,N,
18834,QualifierName,Q000139,19474653,,,7,,Y,chemically induced
18835,DescriptorName,D012852,19474653,,,8,Sinusitis,N,
18836,QualifierName,Q000188,19474653,,,8,,N,drug therapy
18837,Chemical,D000970,19499966,Antineoplastic Agents,0,,,,
18838,Chemical,D007211,19499966,Indoles,0,,,,
18839,Chemical,D047428,19499966,Protein Kinase Inhibitors,0,,,,
18840,Chemical,D011758,19499966,Pyrroles,0,,,,
18841,Chemical,D000077210,19499966,Sunitinib,V99T50803M,,,,
18842,DescriptorName,D000284,19499966,,,1,"Administration, Oral",N,
18843,DescriptorName,D000368,19499966,,,2,Aged,N,
18844,DescriptorName,D000970,19499966,,,3,Antineoplastic Agents,N,
18845,QualifierName,Q000008,19499966,,,3,,N,administration & dosage
18846,DescriptorName,D002292,19499966,,,4,"Carcinoma, Renal Cell",N,
18847,QualifierName,Q000188,19499966,,,4,,Y,drug therapy
18848,DescriptorName,D006177,19499966,,,5,Gynecomastia,N,
18849,QualifierName,Q000139,19499966,,,5,,Y,chemically induced
18850,DescriptorName,D006801,19499966,,,6,Humans,N,
18851,DescriptorName,D007211,19499966,,,7,Indoles,N,
18852,QualifierName,Q000008,19499966,,,7,,N,administration & dosage
18853,DescriptorName,D007680,19499966,,,8,Kidney Neoplasms,N,
18854,QualifierName,Q000188,19499966,,,8,,Y,drug therapy
18855,DescriptorName,D008297,19499966,,,9,Male,N,
18856,DescriptorName,D047428,19499966,,,10,Protein Kinase Inhibitors,N,
18857,QualifierName,Q000008,19499966,,,10,,N,administration & dosage
18858,DescriptorName,D011758,19499966,,,11,Pyrroles,N,
18859,QualifierName,Q000008,19499966,,,11,,N,administration & dosage
18860,DescriptorName,D000077210,19499966,,,12,Sunitinib,N,
18861,Chemical,D000927,19512997,Anticonvulsants,0,,,,
18862,Chemical,D014635,19512997,Valproic Acid,614OI1Z5WI,,,,
18863,DescriptorName,D000927,19512997,,,1,Anticonvulsants,N,
18864,QualifierName,Q000009,19512997,,,1,,Y,adverse effects
18865,DescriptorName,D004802,19512997,,,2,Eosinophilia,N,
18866,QualifierName,Q000139,19512997,,,2,,Y,chemically induced
18867,DescriptorName,D005260,19512997,,,3,Female,N,
18868,DescriptorName,D006801,19512997,,,4,Humans,N,
18869,DescriptorName,D008875,19512997,,,5,Middle Aged,N,
18870,DescriptorName,D010996,19512997,,,6,Pleural Effusion,N,
18871,QualifierName,Q000139,19512997,,,6,,Y,chemically induced
18872,DescriptorName,D012640,19512997,,,7,Seizures,N,
18873,QualifierName,Q000188,19512997,,,7,,N,drug therapy
18874,DescriptorName,D014635,19512997,,,8,Valproic Acid,N,
18875,QualifierName,Q000009,19512997,,,8,,Y,adverse effects
18876,Chemical,D005480,1951476,Flurbiprofen,5GRO578KLP,,,,
18877,Chemical,D007052,1951476,Ibuprofen,WK2XYI10QM,,,,
18878,DescriptorName,D000328,1951476,,,1,Adult,N,
18879,DescriptorName,D001706,1951476,,,2,Biopsy,N,
18880,DescriptorName,D005480,1951476,,,3,Flurbiprofen,N,
18881,QualifierName,Q000009,1951476,,,3,,Y,adverse effects
18882,DescriptorName,D006801,1951476,,,4,Humans,N,
18883,DescriptorName,D007052,1951476,,,5,Ibuprofen,N,
18884,QualifierName,Q000627,1951476,,,5,,N,therapeutic use
18885,DescriptorName,D007668,1951476,,,6,Kidney,N,
18886,QualifierName,Q000473,1951476,,,6,,N,pathology
18887,DescriptorName,D008297,1951476,,,7,Male,N,
18888,DescriptorName,D009395,1951476,,,8,"Nephritis, Interstitial",N,
18889,QualifierName,Q000139,1951476,,,8,,Y,chemically induced
18890,DescriptorName,D010146,1951476,,,9,Pain,N,
18891,QualifierName,Q000188,1951476,,,9,,N,drug therapy
18892,Chemical,D018682,19520277,GABA Agents,0,,,,
18893,Chemical,D014635,19520277,Valproic Acid,614OI1Z5WI,,,,
18894,DescriptorName,D001921,19520277,,,1,Brain,N,
18895,QualifierName,Q000187,19520277,,,1,,Y,drug effects
18896,DescriptorName,D002675,19520277,,,2,"Child, Preschool",N,
18897,DescriptorName,D004569,19520277,,,3,Electroencephalography,N,
18898,DescriptorName,D004827,19520277,,,4,Epilepsy,N,
18899,QualifierName,Q000188,19520277,,,4,,N,drug therapy
18900,DescriptorName,D005260,19520277,,,5,Female,N,
18901,DescriptorName,D018682,19520277,,,6,GABA Agents,N,
18902,QualifierName,Q000009,19520277,,,6,,Y,adverse effects
18903,DescriptorName,D006801,19520277,,,7,Humans,N,
18904,DescriptorName,D053608,19520277,,,8,Stupor,N,
18905,QualifierName,Q000139,19520277,,,8,,Y,chemically induced
18906,DescriptorName,D014635,19520277,,,9,Valproic Acid,N,
18907,QualifierName,Q000009,19520277,,,9,,Y,adverse effects
18908,Chemical,D001557,19537383,Benzenesulfonates,0,,,,
18909,Chemical,D010671,19537383,Phenylurea Compounds,0,,,,
18910,Chemical,D047428,19537383,Protein Kinase Inhibitors,0,,,,
18911,Chemical,D011725,19537383,Pyridines,0,,,,
18912,Chemical,D009536,19537383,Niacinamide,25X51I8RD4,,,,
18913,Chemical,D000077157,19537383,Sorafenib,9ZOQ3TZI87,,,,
18914,DescriptorName,D000051,19537383,,,1,Acantholysis,N,
18915,QualifierName,Q000139,19537383,,,1,,Y,chemically induced
18916,DescriptorName,D001557,19537383,,,2,Benzenesulfonates,N,
18917,QualifierName,Q000008,19537383,,,2,,N,administration & dosage
18918,DescriptorName,D006528,19537383,,,3,"Carcinoma, Hepatocellular",N,
18919,QualifierName,Q000150,19537383,,,3,,N,complications
18920,DescriptorName,D003920,19537383,,,4,Diabetes Mellitus,N,
18921,DescriptorName,D003875,19537383,,,5,Drug Eruptions,N,
18922,QualifierName,Q000209,19537383,,,5,,Y,etiology
18923,DescriptorName,D006509,19537383,,,6,Hepatitis B,N,
18924,QualifierName,Q000150,19537383,,,6,,N,complications
18925,DescriptorName,D006801,19537383,,,7,Humans,N,
18926,DescriptorName,D007642,19537383,,,8,Keratosis,N,
18927,QualifierName,Q000139,19537383,,,8,,Y,chemically induced
18928,DescriptorName,D008113,19537383,,,9,Liver Neoplasms,N,
18929,QualifierName,Q000150,19537383,,,9,,N,complications
18930,DescriptorName,D008297,19537383,,,10,Male,N,
18931,DescriptorName,D008875,19537383,,,11,Middle Aged,N,
18932,DescriptorName,D009536,19537383,,,12,Niacinamide,N,
18933,QualifierName,Q000031,19537383,,,12,,N,analogs & derivatives
18934,DescriptorName,D010671,19537383,,,13,Phenylurea Compounds,N,
18935,DescriptorName,D047428,19537383,,,14,Protein Kinase Inhibitors,N,
18936,QualifierName,Q000008,19537383,,,14,,N,administration & dosage
18937,DescriptorName,D011725,19537383,,,15,Pyridines,N,
18938,QualifierName,Q000008,19537383,,,15,,N,administration & dosage
18939,DescriptorName,D000077157,19537383,,,16,Sorafenib,N,
18940,Chemical,D000900,19540093,Anti-Bacterial Agents,0,,,,
18941,Chemical,D000078304,19540093,Tigecycline,70JE2N95KR,,,,
18942,Chemical,D008911,19540093,Minocycline,FYY3R43WGO,,,,
18943,DescriptorName,D000368,19540093,,,1,Aged,N,
18944,DescriptorName,D000900,19540093,,,2,Anti-Bacterial Agents,N,
18945,QualifierName,Q000009,19540093,,,2,,Y,adverse effects
18946,DescriptorName,D005260,19540093,,,3,Female,N,
18947,DescriptorName,D006801,19540093,,,4,Humans,N,
18948,DescriptorName,D008911,19540093,,,5,Minocycline,N,
18949,QualifierName,Q000009,19540093,,,5,,N,adverse effects
18950,DescriptorName,D010195,19540093,,,6,Pancreatitis,N,
18951,QualifierName,Q000139,19540093,,,6,,Y,chemically induced
18952,DescriptorName,D017192,19540093,,,7,"Skin Diseases, Bacterial",N,
18953,QualifierName,Q000188,19540093,,,7,,N,drug therapy
18954,DescriptorName,D000078304,19540093,,,8,Tigecycline,N,
18955,Chemical,D016729,1954704,Leuprolide,EFY6W0M8TG,,,,
18956,DescriptorName,D000368,1954704,,,1,Aged,N,
18957,DescriptorName,D001706,1954704,,,2,Biopsy,N,
18958,DescriptorName,D006801,1954704,,,3,Humans,N,
18959,DescriptorName,D016729,1954704,,,4,Leuprolide,N,
18960,QualifierName,Q000009,1954704,,,4,,Y,adverse effects
18961,DescriptorName,D008297,1954704,,,5,Male,N,
18962,DescriptorName,D008854,1954704,,,6,"Microscopy, Electron",N,
18963,DescriptorName,D009132,1954704,,,7,Muscles,N,
18964,QualifierName,Q000473,1954704,,,7,,N,pathology
18965,DescriptorName,D009220,1954704,,,8,Myositis,N,
18966,QualifierName,Q000139,1954704,,,8,,Y,chemically induced
18967,DescriptorName,D011471,1954704,,,9,Prostatic Neoplasms,N,
18968,QualifierName,Q000188,1954704,,,9,,Y,drug therapy
18969,Chemical,D018692,19555801,Antimanic Agents,0,,,,
18970,Chemical,D014150,19555801,Antipsychotic Agents,0,,,,
18971,Chemical,D010879,19555801,Piperazines,0,,,,
18972,Chemical,D015363,19555801,Quinolones,0,,,,
18973,Chemical,D011954,19555801,"Receptors, Dopamine",0,,,,
18974,Chemical,D011985,19555801,"Receptors, Serotonin",0,,,,
18975,Chemical,D012701,19555801,Serotonin,333DO1RDJY,,,,
18976,Chemical,D002220,19555801,Carbamazepine,33CM23913M,,,,
18977,Chemical,D005680,19555801,gamma-Aminobutyric Acid,56-12-2,,,,
18978,Chemical,D000068180,19555801,Aripiprazole,82VFR53I78,,,,
18979,Chemical,D004298,19555801,Dopamine,VTD58H1Z2X,,,,
18980,DescriptorName,D000328,19555801,,,1,Adult,N,
18981,DescriptorName,D018692,19555801,,,2,Antimanic Agents,N,
18982,QualifierName,Q000009,19555801,,,2,,N,adverse effects
18983,DescriptorName,D014150,19555801,,,3,Antipsychotic Agents,N,
18984,QualifierName,Q000009,19555801,,,3,,Y,adverse effects
18985,DescriptorName,D000068180,19555801,,,4,Aripiprazole,N,
18986,DescriptorName,D001714,19555801,,,5,Bipolar Disorder,N,
18987,QualifierName,Q000175,19555801,,,5,,N,diagnosis
18988,DescriptorName,D002220,19555801,,,6,Carbamazepine,N,
18989,QualifierName,Q000009,19555801,,,6,,N,adverse effects
18990,DescriptorName,D015984,19555801,,,7,Causality,N,
18991,DescriptorName,D004298,19555801,,,8,Dopamine,N,
18992,QualifierName,Q000502,19555801,,,8,,N,physiology
18993,DescriptorName,D004347,19555801,,,9,Drug Interactions,N,
18994,DescriptorName,D006207,19555801,,,10,Half-Life,N,
18995,DescriptorName,D016489,19555801,,,11,"Head Injuries, Closed",N,
18996,QualifierName,Q000150,19555801,,,11,,N,complications
18997,DescriptorName,D006606,19555801,,,12,Hiccup,N,
18998,QualifierName,Q000139,19555801,,,12,,Y,chemically induced
18999,DescriptorName,D006801,19555801,,,13,Humans,N,
19000,DescriptorName,D008297,19555801,,,14,Male,N,
19001,DescriptorName,D010879,19555801,,,15,Piperazines,N,
19002,QualifierName,Q000009,19555801,,,15,,Y,adverse effects
19003,DescriptorName,D015363,19555801,,,16,Quinolones,N,
19004,QualifierName,Q000009,19555801,,,16,,Y,adverse effects
19005,DescriptorName,D011954,19555801,,,17,"Receptors, Dopamine",N,
19006,QualifierName,Q000187,19555801,,,17,,N,drug effects
19007,DescriptorName,D011985,19555801,,,18,"Receptors, Serotonin",N,
19008,QualifierName,Q000187,19555801,,,18,,N,drug effects
19009,DescriptorName,D012701,19555801,,,19,Serotonin,N,
19010,QualifierName,Q000502,19555801,,,19,,N,physiology
19011,DescriptorName,D013997,19555801,,,20,Time Factors,N,
19012,DescriptorName,D005680,19555801,,,21,gamma-Aminobutyric Acid,N,
19013,QualifierName,Q000187,19555801,,,21,,N,drug effects
19014,Chemical,D017367,19567656,Serotonin Uptake Inhibitors,0,,,,
19015,Chemical,D020280,19567656,Sertraline,QUC7NX6WMB,,,,
19016,DescriptorName,D000368,19567656,,,1,Aged,N,
19017,DescriptorName,D015140,19567656,,,2,"Dementia, Vascular",N,
19018,QualifierName,Q000150,19567656,,,2,,N,complications
19019,DescriptorName,D003863,19567656,,,3,Depression,N,
19020,QualifierName,Q000150,19567656,,,3,,N,complications
19021,DescriptorName,D005260,19567656,,,4,Female,N,
19022,DescriptorName,D006801,19567656,,,5,Humans,N,
19023,DescriptorName,D012206,19567656,,,6,Rhabdomyolysis,N,
19024,QualifierName,Q000139,19567656,,,6,,Y,chemically induced
19025,DescriptorName,D017367,19567656,,,7,Serotonin Uptake Inhibitors,N,
19026,QualifierName,Q000009,19567656,,,7,,Y,adverse effects
19027,DescriptorName,D020280,19567656,,,8,Sertraline,N,
19028,QualifierName,Q000009,19567656,,,8,,Y,adverse effects
19029,Chemical,D000970,19570088,Antineoplastic Agents,0,,,,
19030,Chemical,D002945,19570088,Cisplatin,Q20Q21Q62J,,,,
19031,DescriptorName,D000970,19570088,,,1,Antineoplastic Agents,N,
19032,QualifierName,Q000009,19570088,,,1,,Y,adverse effects
19033,DescriptorName,D002945,19570088,,,2,Cisplatin,N,
19034,QualifierName,Q000009,19570088,,,2,,Y,adverse effects
19035,DescriptorName,D003131,19570088,,,3,Combined Modality Therapy,N,
19036,DescriptorName,D004621,19570088,,,4,"Embolization, Therapeutic",Y,
19037,DescriptorName,D006801,19570088,,,5,Humans,N,
19038,DescriptorName,D007261,19570088,,,6,"Infusions, Intra-Arterial",N,
19039,DescriptorName,D008113,19570088,,,7,Liver Neoplasms,N,
19040,QualifierName,Q000188,19570088,,,7,,Y,drug therapy
19041,DescriptorName,D008297,19570088,,,8,Male,N,
19042,DescriptorName,D008545,19570088,,,9,Melanoma,N,
19043,QualifierName,Q000188,19570088,,,9,,Y,drug therapy
19044,DescriptorName,D008875,19570088,,,10,Middle Aged,N,
19045,DescriptorName,D012878,19570088,,,11,Skin Neoplasms,N,
19046,QualifierName,Q000473,19570088,,,11,,N,pathology
19047,DescriptorName,D015275,19570088,,,12,Tumor Lysis Syndrome,N,
19048,QualifierName,Q000209,19570088,,,12,,Y,etiology
19049,Chemical,D014150,19579947,Antipsychotic Agents,0,,,,
19050,Chemical,D017367,19579947,Serotonin Uptake Inhibitors,0,,,,
19051,Chemical,D001569,19579947,Benzodiazepines,12794-10-4,,,,
19052,Chemical,D000077152,19579947,Olanzapine,N7U69T4SZR,,,,
19053,DescriptorName,D014150,19579947,,,1,Antipsychotic Agents,N,
19054,QualifierName,Q000009,19579947,,,1,,Y,adverse effects
19055,DescriptorName,D001569,19579947,,,2,Benzodiazepines,N,
19056,QualifierName,Q000009,19579947,,,2,,Y,adverse effects
19057,DescriptorName,D006801,19579947,,,3,Humans,N,
19058,DescriptorName,D008297,19579947,,,4,Male,N,
19059,DescriptorName,D001523,19579947,,,5,Mental Disorders,N,
19060,QualifierName,Q000188,19579947,,,5,,N,drug therapy
19061,DescriptorName,D000077152,19579947,,,6,Olanzapine,N,
19062,DescriptorName,D011317,19579947,,,7,Priapism,N,
19063,QualifierName,Q000139,19579947,,,7,,Y,chemically induced
19064,DescriptorName,D017367,19579947,,,8,Serotonin Uptake Inhibitors,N,
19065,QualifierName,Q000009,19579947,,,8,,Y,adverse effects
19066,DescriptorName,D055815,19579947,,,9,Young Adult,N,
19067,Chemical,D000700,19648225,Analgesics,0,,,,
19068,Chemical,D007649,19648225,Ketamine,690G0D6V8H,,,,
19069,DescriptorName,D000328,19648225,,,1,Adult,N,
19070,DescriptorName,D000368,19648225,,,2,Aged,N,
19071,DescriptorName,D000700,19648225,,,3,Analgesics,N,
19072,QualifierName,Q000008,19648225,,,3,,N,administration & dosage
19073,DescriptorName,D017809,19648225,,,4,Fatal Outcome,N,
19074,DescriptorName,D005260,19648225,,,5,Female,N,
19075,DescriptorName,D006801,19648225,,,6,Humans,N,
19076,DescriptorName,D007649,19648225,,,7,Ketamine,N,
19077,QualifierName,Q000008,19648225,,,7,,N,administration & dosage
19078,DescriptorName,D008297,19648225,,,8,Male,N,
19079,DescriptorName,D008875,19648225,,,9,Middle Aged,N,
19080,DescriptorName,D010146,19648225,,,10,Pain,N,
19081,QualifierName,Q000139,19648225,,,10,,N,chemically induced
19082,DescriptorName,D010166,19648225,,,11,Palliative Care,N,
19083,DescriptorName,D014570,19648225,,,12,Urologic Diseases,N,
19084,QualifierName,Q000139,19648225,,,12,,Y,chemically induced
19085,Chemical,D019380,19653965,Anti-HIV Agents,0,,,,
19086,Chemical,D011744,19653965,Pyrimidinones,0,,,,
19087,Chemical,D061466,19653965,Lopinavir,2494G1JF75,,,,
19088,Chemical,D019438,19653965,Ritonavir,O3J8G9O825,,,,
19089,DescriptorName,D000328,19653965,,,1,Adult,N,
19090,DescriptorName,D019380,19653965,,,2,Anti-HIV Agents,N,
19091,QualifierName,Q000008,19653965,,,2,,N,administration & dosage
19092,DescriptorName,D001145,19653965,,,3,"Arrhythmias, Cardiac",N,
19093,QualifierName,Q000139,19653965,,,3,,Y,chemically induced
19094,DescriptorName,D004562,19653965,,,4,Electrocardiography,N,
19095,DescriptorName,D015658,19653965,,,5,HIV Infections,N,
19096,QualifierName,Q000188,19653965,,,5,,N,drug therapy
19097,DescriptorName,D006801,19653965,,,6,Humans,N,
19098,DescriptorName,D061466,19653965,,,7,Lopinavir,N,
19099,DescriptorName,D008297,19653965,,,8,Male,N,
19100,DescriptorName,D008875,19653965,,,9,Middle Aged,N,
19101,DescriptorName,D011744,19653965,,,10,Pyrimidinones,N,
19102,QualifierName,Q000008,19653965,,,10,,N,administration & dosage
19103,DescriptorName,D019438,19653965,,,11,Ritonavir,N,
19104,QualifierName,Q000008,19653965,,,11,,N,administration & dosage
19105,Chemical,D000893,19660974,Anti-Inflammatory Agents,0,,,,
19106,Chemical,D000911,19660974,"Antibodies, Monoclonal",0,,,,
19107,Chemical,D000935,19660974,Antifungal Agents,0,,,,
19108,Chemical,D000069285,19660974,Infliximab,B72HH48FLU,,,,
19109,DescriptorName,D000893,19660974,,,1,Anti-Inflammatory Agents,N,
19110,QualifierName,Q000627,19660974,,,1,,N,therapeutic use
19111,DescriptorName,D000911,19660974,,,2,"Antibodies, Monoclonal",N,
19112,QualifierName,Q000009,19660974,,,2,,Y,adverse effects
19113,DescriptorName,D000935,19660974,,,3,Antifungal Agents,N,
19114,QualifierName,Q000627,19660974,,,3,,N,therapeutic use
19115,DescriptorName,D003092,19660974,,,4,Colitis,N,
19116,QualifierName,Q000139,19660974,,,4,,N,chemically induced
19117,DescriptorName,D003424,19660974,,,5,Crohn Disease,N,
19118,QualifierName,Q000188,19660974,,,5,,N,drug therapy
19119,DescriptorName,D003453,19660974,,,6,Cryptococcosis,N,
19120,QualifierName,Q000175,19660974,,,6,,Y,diagnosis
19121,DescriptorName,D003454,19660974,,,7,Cryptococcus,N,
19122,QualifierName,Q000254,19660974,,,7,,Y,growth & development
19123,DescriptorName,D003937,19660974,,,8,"Diagnosis, Differential",N,
19124,DescriptorName,D006801,19660974,,,9,Humans,N,
19125,DescriptorName,D000069285,19660974,,,10,Infliximab,N,
19126,DescriptorName,D008297,19660974,,,11,Male,N,
19127,DescriptorName,D008875,19660974,,,12,Middle Aged,N,
19128,Chemical,D018692,19667003,Antimanic Agents,0,,,,
19129,Chemical,D002220,19667003,Carbamazepine,33CM23913M,,,,
19130,DescriptorName,D000328,19667003,,,1,Adult,N,
19131,DescriptorName,D000374,19667003,,,2,Aggression,N,
19132,DescriptorName,D017109,19667003,,,3,"Akathisia, Drug-Induced",N,
19133,QualifierName,Q000209,19667003,,,3,,N,etiology
19134,DescriptorName,D018692,19667003,,,4,Antimanic Agents,N,
19135,QualifierName,Q000009,19667003,,,4,,Y,adverse effects
19136,DescriptorName,D001714,19667003,,,5,Bipolar Disorder,N,
19137,QualifierName,Q000188,19667003,,,5,,N,drug therapy
19138,DescriptorName,D002220,19667003,,,6,Carbamazepine,N,
19139,QualifierName,Q000009,19667003,,,6,,Y,adverse effects
19140,DescriptorName,D006801,19667003,,,7,Humans,N,
19141,DescriptorName,D022124,19667003,,,8,Hyperammonemia,N,
19142,QualifierName,Q000139,19667003,,,8,,Y,chemically induced
19143,DescriptorName,D008297,19667003,,,9,Male,N,
19144,Chemical,D004317,1966850,Doxorubicin,80168379AG,,,,
19145,Chemical,D002945,1966850,Cisplatin,Q20Q21Q62J,,,,
19146,DescriptorName,D058186,1966850,,,1,Acute Kidney Injury,N,
19147,QualifierName,Q000139,1966850,,,1,,N,chemically induced
19148,DescriptorName,D002303,1966850,,,2,"Cardiac Output, Low",N,
19149,QualifierName,Q000139,1966850,,,2,,Y,chemically induced
19150,DescriptorName,D002648,1966850,,,3,Child,N,
19151,DescriptorName,D002945,1966850,,,4,Cisplatin,N,
19152,QualifierName,Q000009,1966850,,,4,,Y,adverse effects
19153,DescriptorName,D004317,1966850,,,5,Doxorubicin,N,
19154,QualifierName,Q000009,1966850,,,5,,Y,adverse effects
19155,DescriptorName,D005266,1966850,,,6,Femoral Neoplasms,N,
19156,QualifierName,Q000188,1966850,,,6,,N,drug therapy
19157,DescriptorName,D018219,1966850,,,7,"Histiocytoma, Benign Fibrous",N,
19158,QualifierName,Q000188,1966850,,,7,,N,drug therapy
19159,DescriptorName,D006801,1966850,,,8,Humans,N,
19160,DescriptorName,D008275,1966850,,,9,Magnesium Deficiency,N,
19161,QualifierName,Q000139,1966850,,,9,,N,chemically induced
19162,DescriptorName,D008297,1966850,,,10,Male,N,
19163,DescriptorName,D010530,1966850,,,11,Peritoneal Dialysis,N,
19164,Chemical,D000893,19669617,Anti-Inflammatory Agents,0,,,,
19165,Chemical,D000911,19669617,"Antibodies, Monoclonal",0,,,,
19166,Chemical,D061067,19669617,"Antibodies, Monoclonal, Humanized",0,,,,
19167,Chemical,D025101,19669617,Vitamin B 6,8059-24-3,,,,
19168,Chemical,D000068879,19669617,Adalimumab,FYS6T7F842,,,,
19169,Chemical,D007538,19669617,Isoniazid,V83O1VOZ8L,,,,
19170,DescriptorName,D000208,19669617,,,1,Acute Disease,N,
19171,DescriptorName,D000068879,19669617,,,2,Adalimumab,N,
19172,DescriptorName,D000368,19669617,,,3,Aged,N,
19173,DescriptorName,D000893,19669617,,,4,Anti-Inflammatory Agents,N,
19174,QualifierName,Q000009,19669617,,,4,,Y,adverse effects
19175,DescriptorName,D000911,19669617,,,5,"Antibodies, Monoclonal",N,
19176,QualifierName,Q000009,19669617,,,5,,Y,adverse effects
19177,DescriptorName,D061067,19669617,,,6,"Antibodies, Monoclonal, Humanized",N,
19178,DescriptorName,D056486,19669617,,,7,Chemical and Drug Induced Liver Injury,N,
19179,QualifierName,Q000209,19669617,,,7,,N,etiology
19180,DescriptorName,D004359,19669617,,,8,"Drug Therapy, Combination",N,
19181,DescriptorName,D004417,19669617,,,9,Dyspnea,N,
19182,QualifierName,Q000139,19669617,,,9,,N,chemically induced
19183,DescriptorName,D005260,19669617,,,10,Female,N,
19184,DescriptorName,D006801,19669617,,,11,Humans,N,
19185,DescriptorName,D007538,19669617,,,12,Isoniazid,N,
19186,QualifierName,Q000009,19669617,,,12,,N,adverse effects
19187,DescriptorName,D007565,19669617,,,13,Jaundice,N,
19188,QualifierName,Q000139,19669617,,,13,,N,chemically induced
19189,DescriptorName,D020422,19669617,,,14,Mononeuropathies,N,
19190,QualifierName,Q000139,19669617,,,14,,Y,chemically induced
19191,DescriptorName,D010791,19669617,,,15,Phrenic Nerve,N,
19192,QualifierName,Q000187,19669617,,,15,,Y,drug effects
19193,DescriptorName,D011565,19669617,,,16,Psoriasis,N,
19194,QualifierName,Q000188,19669617,,,16,,N,drug therapy
19195,DescriptorName,D012129,19669617,,,17,Respiratory Function Tests,N,
19196,DescriptorName,D012131,19669617,,,18,Respiratory Insufficiency,N,
19197,QualifierName,Q000139,19669617,,,18,,Y,chemically induced
19198,DescriptorName,D016896,19669617,,,19,Treatment Outcome,N,
19199,DescriptorName,D025101,19669617,,,20,Vitamin B 6,N,
19200,QualifierName,Q000008,19669617,,,20,,N,administration & dosage
19201,Chemical,D000900,19687711,Anti-Bacterial Agents,0,,,,
19202,Chemical,D016756,19687711,"Immunoglobulins, Intravenous",0,,,,
19203,Chemical,D015662,19687711,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
19204,DescriptorName,D000293,19687711,,,1,Adolescent,N,
19205,DescriptorName,D000900,19687711,,,2,Anti-Bacterial Agents,N,
19206,QualifierName,Q000009,19687711,,,2,,Y,adverse effects
19207,DescriptorName,D002481,19687711,,,3,Cellulitis,N,
19208,QualifierName,Q000150,19687711,,,3,,N,complications
19209,DescriptorName,D021821,19687711,,,4,"Communicable Diseases, Emerging",N,
19210,QualifierName,Q000188,19687711,,,4,,Y,drug therapy
19211,DescriptorName,D017714,19687711,,,5,Community-Acquired Infections,N,
19212,QualifierName,Q000150,19687711,,,5,,N,complications
19213,DescriptorName,D003951,19687711,,,6,Diagnostic Errors,N,
19214,DescriptorName,D006801,19687711,,,7,Humans,N,
19215,DescriptorName,D016756,19687711,,,8,"Immunoglobulins, Intravenous",N,
19216,QualifierName,Q000627,19687711,,,8,,N,therapeutic use
19217,DescriptorName,D008297,19687711,,,9,Male,N,
19218,DescriptorName,D055624,19687711,,,10,Methicillin-Resistant Staphylococcus aureus,Y,
19219,QualifierName,Q000187,19687711,,,10,,N,drug effects
19220,DescriptorName,D011014,19687711,,,11,Pneumonia,N,
19221,QualifierName,Q000209,19687711,,,11,,N,etiology
19222,DescriptorName,D012008,19687711,,,12,Recurrence,N,
19223,DescriptorName,D012541,19687711,,,13,Scarlet Fever,N,
19224,QualifierName,Q000175,19687711,,,13,,N,diagnosis
19225,DescriptorName,D018805,19687711,,,14,Sepsis,N,
19226,QualifierName,Q000209,19687711,,,14,,N,etiology
19227,DescriptorName,D018461,19687711,,,15,Soft Tissue Infections,N,
19228,QualifierName,Q000150,19687711,,,15,,N,complications
19229,DescriptorName,D013203,19687711,,,16,Staphylococcal Infections,N,
19230,QualifierName,Q000150,19687711,,,16,,N,complications
19231,DescriptorName,D013207,19687711,,,17,Staphylococcal Skin Infections,N,
19232,QualifierName,Q000150,19687711,,,17,,N,complications
19233,DescriptorName,D013262,19687711,,,18,Stevens-Johnson Syndrome,N,
19234,QualifierName,Q000139,19687711,,,18,,Y,chemically induced
19235,DescriptorName,D015662,19687711,,,19,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
19236,QualifierName,Q000009,19687711,,,19,,Y,adverse effects
19237,Chemical,D000925,19690222,Anticoagulants,0,,,,
19238,Chemical,D017985,19690222,Dalteparin,S79O08V79F,,,,
19239,DescriptorName,D000368,19690222,,,1,Aged,N,
19240,DescriptorName,D000792,19690222,,,2,Angiography,N,
19241,QualifierName,Q000379,19690222,,,2,,N,methods
19242,DescriptorName,D000925,19690222,,,3,Anticoagulants,N,
19243,QualifierName,Q000009,19690222,,,3,,Y,adverse effects
19244,DescriptorName,D017985,19690222,,,4,Dalteparin,N,
19245,QualifierName,Q000009,19690222,,,4,,Y,adverse effects
19246,DescriptorName,D004322,19690222,,,5,Drainage,N,
19247,DescriptorName,D006491,19690222,,,6,Hemothorax,N,
19248,QualifierName,Q000139,19690222,,,6,,Y,chemically induced
19249,DescriptorName,D006801,19690222,,,7,Humans,N,
19250,DescriptorName,D008297,19690222,,,8,Male,N,
19251,DescriptorName,D011655,19690222,,,9,Pulmonary Embolism,N,
19252,QualifierName,Q000188,19690222,,,9,,N,drug therapy
19253,DescriptorName,D014057,19690222,,,10,"Tomography, X-Ray Computed",N,
19254,QualifierName,Q000379,19690222,,,10,,N,methods
19255,Chemical,D020533,19707032,Angiogenesis Inhibitors,0,,,,
19256,Chemical,D000911,19707032,"Antibodies, Monoclonal",0,,,,
19257,Chemical,D061067,19707032,"Antibodies, Monoclonal, Humanized",0,,,,
19258,Chemical,D042461,19707032,Vascular Endothelial Growth Factor A,0,,,,
19259,Chemical,D000068258,19707032,Bevacizumab,2S9ZZM9Q9V,,,,
19260,DescriptorName,D000208,19707032,,,1,Acute Disease,N,
19261,DescriptorName,D020533,19707032,,,2,Angiogenesis Inhibitors,N,
19262,QualifierName,Q000009,19707032,,,2,,Y,adverse effects
19263,DescriptorName,D000911,19707032,,,3,"Antibodies, Monoclonal",N,
19264,QualifierName,Q000009,19707032,,,3,,Y,adverse effects
19265,DescriptorName,D061067,19707032,,,4,"Antibodies, Monoclonal, Humanized",N,
19266,DescriptorName,D000068258,19707032,,,5,Bevacizumab,N,
19267,DescriptorName,D001766,19707032,,,6,Blindness,N,
19268,QualifierName,Q000139,19707032,,,6,,Y,chemically induced
19269,DescriptorName,D002343,19707032,,,7,"Carotid Artery, Internal",N,
19270,QualifierName,Q000473,19707032,,,7,,N,pathology
19271,DescriptorName,D016893,19707032,,,8,Carotid Stenosis,N,
19272,QualifierName,Q000150,19707032,,,8,,N,complications
19273,DescriptorName,D003930,19707032,,,9,Diabetic Retinopathy,N,
19274,QualifierName,Q000150,19707032,,,9,,N,complications
19275,DescriptorName,D005451,19707032,,,10,Fluorescein Angiography,N,
19276,DescriptorName,D015355,19707032,,,11,"Glaucoma, Neovascular",N,
19277,QualifierName,Q000188,19707032,,,11,,N,drug therapy
19278,DescriptorName,D006801,19707032,,,12,Humans,N,
19279,DescriptorName,D007267,19707032,,,13,Injections,N,
19280,DescriptorName,D007511,19707032,,,14,Ischemia,N,
19281,QualifierName,Q000139,19707032,,,14,,Y,chemically induced
19282,DescriptorName,D008279,19707032,,,15,Magnetic Resonance Imaging,N,
19283,DescriptorName,D008297,19707032,,,16,Male,N,
19284,DescriptorName,D008875,19707032,,,17,Middle Aged,N,
19285,DescriptorName,D012171,19707032,,,18,Retinal Vessels,N,
19286,QualifierName,Q000187,19707032,,,18,,Y,drug effects
19287,DescriptorName,D020521,19707032,,,19,Stroke,N,
19288,QualifierName,Q000139,19707032,,,19,,N,chemically induced
19289,DescriptorName,D013577,19707032,,,20,Syndrome,N,
19290,DescriptorName,D018608,19707032,,,21,"Ultrasonography, Doppler",N,
19291,DescriptorName,D042461,19707032,,,22,Vascular Endothelial Growth Factor A,N,
19292,QualifierName,Q000037,19707032,,,22,,N,antagonists & inhibitors
19293,DescriptorName,D014792,19707032,,,23,Visual Acuity,N,
19294,DescriptorName,D014822,19707032,,,24,Vitreous Body,N,
19295,Chemical,C497422,19717383,"KMT2A protein, human",0,,,,
19296,Chemical,D051788,19717383,Myeloid-Lymphoid Leukemia Protein,149025-06-9,,,,
19297,Chemical,D011495,19717383,Histone-Lysine N-Methyltransferase,EC 2.1.1.43,,,,
19298,DescriptorName,D000328,19717383,,,1,Adult,N,
19299,DescriptorName,D000971,19717383,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
19300,QualifierName,Q000009,19717383,,,2,,Y,adverse effects
19301,DescriptorName,D002869,19717383,,,3,Chromosome Aberrations,N,
19302,DescriptorName,D002879,19717383,,,4,"Chromosomes, Human, Pair 10",N,
19303,QualifierName,Q000235,19717383,,,4,,N,genetics
19304,DescriptorName,D002880,19717383,,,5,"Chromosomes, Human, Pair 11",N,
19305,QualifierName,Q000235,19717383,,,5,,N,genetics
19306,DescriptorName,D020732,19717383,,,6,Cytogenetic Analysis,N,
19307,DescriptorName,D017809,19717383,,,7,Fatal Outcome,N,
19308,DescriptorName,D005500,19717383,,,8,Follow-Up Studies,N,
19309,DescriptorName,D011495,19717383,,,9,Histone-Lysine N-Methyltransferase,N,
19310,DescriptorName,D006801,19717383,,,10,Humans,N,
19311,DescriptorName,D015470,19717383,,,11,"Leukemia, Myeloid, Acute",N,
19312,QualifierName,Q000139,19717383,,,11,,Y,chemically induced
19313,DescriptorName,D016483,19717383,,,12,"Lymphoma, AIDS-Related",N,
19314,QualifierName,Q000175,19717383,,,12,,N,diagnosis
19315,DescriptorName,D008297,19717383,,,13,Male,N,
19316,DescriptorName,D051788,19717383,,,14,Myeloid-Lymphoid Leukemia Protein,N,
19317,QualifierName,Q000235,19717383,,,14,,N,genetics
19318,Chemical,D000998,19725909,Antiviral Agents,0,,,,
19319,Chemical,D063065,19725909,Organophosphonates,0,,,,
19320,Chemical,D019259,19725909,Lamivudine,2T8Q726O95,,,,
19321,Chemical,C053001,19725909,adefovir,6GQP90I798,,,,
19322,Chemical,D000225,19725909,Adenine,JAC85A2161,,,,
19323,DescriptorName,D000225,19725909,,,1,Adenine,N,
19324,QualifierName,Q000008,19725909,,,1,,N,administration & dosage
19325,DescriptorName,D000998,19725909,,,2,Antiviral Agents,Y,
19326,QualifierName,Q000008,19725909,,,2,,N,administration & dosage
19327,DescriptorName,D004359,19725909,,,3,"Drug Therapy, Combination",N,
19328,DescriptorName,D005260,19725909,,,4,Female,N,
19329,DescriptorName,D006509,19725909,,,5,Hepatitis B,N,
19330,QualifierName,Q000188,19725909,,,5,,Y,drug therapy
19331,DescriptorName,D006515,19725909,,,6,Hepatitis B virus,N,
19332,QualifierName,Q000187,19725909,,,6,,Y,drug effects
19333,DescriptorName,D006801,19725909,,,7,Humans,N,
19334,DescriptorName,D019259,19725909,,,8,Lamivudine,Y,
19335,QualifierName,Q000008,19725909,,,8,,N,administration & dosage
19336,DescriptorName,D008105,19725909,,,9,"Liver Cirrhosis, Biliary",N,
19337,QualifierName,Q000628,19725909,,,9,,Y,therapy
19338,DescriptorName,D016031,19725909,,,10,Liver Transplantation,N,
19339,QualifierName,Q000009,19725909,,,10,,Y,adverse effects
19340,DescriptorName,D008875,19725909,,,11,Middle Aged,N,
19341,DescriptorName,D063065,19725909,,,12,Organophosphonates,Y,
19342,QualifierName,Q000008,19725909,,,12,,N,administration & dosage
19343,DescriptorName,D016896,19725909,,,13,Treatment Outcome,N,
19344,Chemical,D000081,19733945,Acetamides,0,,,,
19345,Chemical,D000890,19733945,Anti-Infective Agents,0,,,,
19346,Chemical,D023303,19733945,Oxazolidinones,0,,,,
19347,Chemical,D014640,19733945,Vancomycin,6Q205EH1VU,,,,
19348,Chemical,D000069349,19733945,Linezolid,ISQ9I6J12J,,,,
19349,DescriptorName,D000081,19733945,,,1,Acetamides,N,
19350,QualifierName,Q000009,19733945,,,1,,Y,adverse effects
19351,DescriptorName,D000208,19733945,,,2,Acute Disease,N,
19352,DescriptorName,D000369,19733945,,,3,"Aged, 80 and over",N,
19353,DescriptorName,D000890,19733945,,,4,Anti-Infective Agents,N,
19354,QualifierName,Q000009,19733945,,,4,,Y,adverse effects
19355,DescriptorName,D004802,19733945,,,5,Eosinophilia,N,
19356,QualifierName,Q000139,19733945,,,5,,Y,chemically induced
19357,DescriptorName,D005076,19733945,,,6,Exanthema,N,
19358,QualifierName,Q000139,19733945,,,6,,Y,chemically induced
19359,DescriptorName,D005260,19733945,,,7,Female,N,
19360,DescriptorName,D006801,19733945,,,8,Humans,N,
19361,DescriptorName,D000069349,19733945,,,9,Linezolid,N,
19362,DescriptorName,D055624,19733945,,,10,Methicillin-Resistant Staphylococcus aureus,N,
19363,DescriptorName,D009395,19733945,,,11,"Nephritis, Interstitial",N,
19364,QualifierName,Q000139,19733945,,,11,,Y,chemically induced
19365,DescriptorName,D023303,19733945,,,12,Oxazolidinones,N,
19366,QualifierName,Q000009,19733945,,,12,,Y,adverse effects
19367,DescriptorName,D016459,19733945,,,13,Prosthesis-Related Infections,N,
19368,QualifierName,Q000188,19733945,,,13,,N,drug therapy
19369,DescriptorName,D013203,19733945,,,14,Staphylococcal Infections,N,
19370,QualifierName,Q000188,19733945,,,14,,N,drug therapy
19371,DescriptorName,D013577,19733945,,,15,Syndrome,N,
19372,DescriptorName,D014640,19733945,,,16,Vancomycin,N,
19373,QualifierName,Q000627,19733945,,,16,,N,therapeutic use
19374,Chemical,D018501,19745701,Antirheumatic Agents,0,,,,
19375,Chemical,D008727,19745701,Methotrexate,YL5FZ2Y5U1,,,,
19376,DescriptorName,D000368,19745701,,,1,Aged,N,
19377,DescriptorName,D018501,19745701,,,2,Antirheumatic Agents,N,
19378,QualifierName,Q000009,19745701,,,2,,Y,adverse effects
19379,DescriptorName,D001172,19745701,,,3,"Arthritis, Rheumatoid",N,
19380,QualifierName,Q000150,19745701,,,3,,N,complications
19381,DescriptorName,D005260,19745701,,,4,Female,N,
19382,DescriptorName,D006801,19745701,,,5,Humans,N,
19383,DescriptorName,D008232,19745701,,,6,Lymphoproliferative Disorders,N,
19384,QualifierName,Q000139,19745701,,,6,,N,chemically induced
19385,DescriptorName,D008727,19745701,,,7,Methotrexate,N,
19386,QualifierName,Q000009,19745701,,,7,,Y,adverse effects
19387,DescriptorName,D013274,19745701,,,8,Stomach Neoplasms,N,
19388,QualifierName,Q000139,19745701,,,8,,Y,chemically induced
19389,DescriptorName,D016896,19745701,,,9,Treatment Outcome,N,
19390,Chemical,D001557,19764104,Benzenesulfonates,0,,,,
19391,Chemical,D010671,19764104,Phenylurea Compounds,0,,,,
19392,Chemical,D047428,19764104,Protein Kinase Inhibitors,0,,,,
19393,Chemical,D011725,19764104,Pyridines,0,,,,
19394,Chemical,D009536,19764104,Niacinamide,25X51I8RD4,,,,
19395,Chemical,D000077157,19764104,Sorafenib,9ZOQ3TZI87,,,,
19396,DescriptorName,D001557,19764104,,,1,Benzenesulfonates,N,
19397,QualifierName,Q000009,19764104,,,1,,Y,adverse effects
19398,DescriptorName,D006528,19764104,,,2,"Carcinoma, Hepatocellular",N,
19399,QualifierName,Q000188,19764104,,,2,,Y,drug therapy
19400,DescriptorName,D017809,19764104,,,3,Fatal Outcome,N,
19401,DescriptorName,D006801,19764104,,,4,Humans,N,
19402,DescriptorName,D008113,19764104,,,5,Liver Neoplasms,N,
19403,QualifierName,Q000188,19764104,,,5,,Y,drug therapy
19404,DescriptorName,D008297,19764104,,,6,Male,N,
19405,DescriptorName,D008875,19764104,,,7,Middle Aged,N,
19406,DescriptorName,D009536,19764104,,,8,Niacinamide,N,
19407,QualifierName,Q000031,19764104,,,8,,N,analogs & derivatives
19408,DescriptorName,D010671,19764104,,,9,Phenylurea Compounds,N,
19409,DescriptorName,D047428,19764104,,,10,Protein Kinase Inhibitors,N,
19410,QualifierName,Q000009,19764104,,,10,,Y,adverse effects
19411,DescriptorName,D011725,19764104,,,11,Pyridines,N,
19412,QualifierName,Q000009,19764104,,,11,,Y,adverse effects
19413,DescriptorName,D000077157,19764104,,,12,Sorafenib,N,
19414,DescriptorName,D015275,19764104,,,13,Tumor Lysis Syndrome,N,
19415,QualifierName,Q000188,19764104,,,13,,N,drug therapy
19416,Chemical,D014663,19775485,Nasal Decongestants,0,,,,
19417,Chemical,D010109,19775485,Oxymetazoline,8VLN5B44ZY,,,,
19418,DescriptorName,D001919,19775485,,,1,Bradycardia,N,
19419,QualifierName,Q000139,19775485,,,1,,N,chemically induced
19420,DescriptorName,D003937,19775485,,,2,"Diagnosis, Differential",N,
19421,DescriptorName,D004452,19775485,,,3,Echocardiography,N,
19422,DescriptorName,D004562,19775485,,,4,Electrocardiography,N,
19423,DescriptorName,D006801,19775485,,,5,Humans,N,
19424,DescriptorName,D007223,19775485,,,6,Infant,N,
19425,DescriptorName,D008297,19775485,,,7,Male,N,
19426,DescriptorName,D014663,19775485,,,8,Nasal Decongestants,N,
19427,QualifierName,Q000009,19775485,,,8,,Y,adverse effects
19428,DescriptorName,D010109,19775485,,,9,Oxymetazoline,N,
19429,QualifierName,Q000009,19775485,,,9,,Y,adverse effects
19430,DescriptorName,D012220,19775485,,,10,Rhinitis,N,
19431,QualifierName,Q000188,19775485,,,10,,N,drug therapy
19432,DescriptorName,D013575,19775485,,,11,Syncope,N,
19433,QualifierName,Q000139,19775485,,,11,,Y,chemically induced
19434,Chemical,D000892,19789166,"Anti-Infective Agents, Urinary",0,,,,
19435,Chemical,D009582,19789166,Nitrofurantoin,927AH8112L,,,,
19436,DescriptorName,D000208,19789166,,,1,Acute Disease,N,
19437,DescriptorName,D000328,19789166,,,2,Adult,N,
19438,DescriptorName,D000892,19789166,,,3,"Anti-Infective Agents, Urinary",N,
19439,QualifierName,Q000009,19789166,,,3,,Y,adverse effects
19440,DescriptorName,D056486,19789166,,,4,Chemical and Drug Induced Liver Injury,N,
19441,QualifierName,Q000209,19789166,,,4,,Y,etiology
19442,DescriptorName,D005260,19789166,,,5,Female,N,
19443,DescriptorName,D006801,19789166,,,6,Humans,N,
19444,DescriptorName,D009582,19789166,,,7,Nitrofurantoin,N,
19445,QualifierName,Q000009,19789166,,,7,,Y,adverse effects
19446,DescriptorName,D011247,19789166,,,8,Pregnancy,N,
19447,DescriptorName,D011248,19789166,,,9,Pregnancy Complications,N,
19448,QualifierName,Q000139,19789166,,,9,,Y,chemically induced
19449,DescriptorName,D011251,19789166,,,10,"Pregnancy Complications, Infectious",N,
19450,QualifierName,Q000188,19789166,,,10,,N,drug therapy
19451,DescriptorName,D014552,19789166,,,11,Urinary Tract Infections,N,
19452,QualifierName,Q000188,19789166,,,11,,N,drug therapy
19453,Chemical,D000911,19798640,"Antibodies, Monoclonal",0,,,,
19454,Chemical,D061067,19798640,"Antibodies, Monoclonal, Humanized",0,,,,
19455,Chemical,D000069442,19798640,Natalizumab,0,,,,
19456,DescriptorName,D000328,19798640,,,1,Adult,N,
19457,DescriptorName,D000911,19798640,,,2,"Antibodies, Monoclonal",N,
19458,QualifierName,Q000009,19798640,,,2,,Y,adverse effects
19459,DescriptorName,D061067,19798640,,,3,"Antibodies, Monoclonal, Humanized",N,
19460,DescriptorName,D001921,19798640,,,4,Brain,N,
19461,QualifierName,Q000473,19798640,,,4,,N,pathology
19462,DescriptorName,D016543,19798640,,,5,Central Nervous System Neoplasms,N,
19463,QualifierName,Q000139,19798640,,,5,,Y,chemically induced
19464,DescriptorName,D003937,19798640,,,6,"Diagnosis, Differential",N,
19465,DescriptorName,D006801,19798640,,,7,Humans,N,
19466,DescriptorName,D008228,19798640,,,8,"Lymphoma, Non-Hodgkin",N,
19467,QualifierName,Q000139,19798640,,,8,,Y,chemically induced
19468,DescriptorName,D008279,19798640,,,9,Magnetic Resonance Imaging,N,
19469,DescriptorName,D008297,19798640,,,10,Male,N,
19470,DescriptorName,D020529,19798640,,,11,"Multiple Sclerosis, Relapsing-Remitting",N,
19471,QualifierName,Q000175,19798640,,,11,,N,diagnosis
19472,DescriptorName,D000069442,19798640,,,12,Natalizumab,N,
19473,Chemical,D000970,19815480,Antineoplastic Agents,0,,,,
19474,Chemical,D007211,19815480,Indoles,0,,,,
19475,Chemical,D011758,19815480,Pyrroles,0,,,,
19476,Chemical,D000077210,19815480,Sunitinib,V99T50803M,,,,
19477,DescriptorName,D000368,19815480,,,1,Aged,N,
19478,DescriptorName,D000970,19815480,,,2,Antineoplastic Agents,N,
19479,QualifierName,Q000009,19815480,,,2,,Y,adverse effects
19480,DescriptorName,D002292,19815480,,,3,"Carcinoma, Renal Cell",N,
19481,QualifierName,Q000188,19815480,,,3,,Y,drug therapy
19482,DescriptorName,D006801,19815480,,,4,Humans,N,
19483,DescriptorName,D007211,19815480,,,5,Indoles,N,
19484,QualifierName,Q000009,19815480,,,5,,Y,adverse effects
19485,DescriptorName,D007680,19815480,,,6,Kidney Neoplasms,N,
19486,QualifierName,Q000188,19815480,,,6,,Y,drug therapy
19487,DescriptorName,D008297,19815480,,,7,Male,N,
19488,DescriptorName,D008875,19815480,,,8,Middle Aged,N,
19489,DescriptorName,D009362,19815480,,,9,Neoplasm Metastasis,N,
19490,DescriptorName,D010530,19815480,,,10,Peritoneal Dialysis,N,
19491,DescriptorName,D011758,19815480,,,11,Pyrroles,N,
19492,QualifierName,Q000009,19815480,,,11,,Y,adverse effects
19493,DescriptorName,D006435,19815480,,,12,Renal Dialysis,N,
19494,DescriptorName,D000077210,19815480,,,13,Sunitinib,N,
19495,Chemical,D014227,19826099,Triazines,0,,,,
19496,Chemical,D000077213,19826099,Lamotrigine,U3H27498KS,,,,
19497,DescriptorName,D000328,19826099,,,1,Adult,N,
19498,DescriptorName,D001049,19826099,,,2,Apnea,N,
19499,QualifierName,Q000139,19826099,,,2,,Y,chemically induced
19500,DescriptorName,D001942,19826099,,,3,Breast Feeding,N,
19501,QualifierName,Q000009,19826099,,,3,,Y,adverse effects
19502,DescriptorName,D004827,19826099,,,4,Epilepsy,N,
19503,QualifierName,Q000188,19826099,,,4,,N,drug therapy
19504,DescriptorName,D005260,19826099,,,5,Female,N,
19505,DescriptorName,D006801,19826099,,,6,Humans,N,
19506,DescriptorName,D007231,19826099,,,7,"Infant, Newborn",N,
19507,DescriptorName,D000077213,19826099,,,8,Lamotrigine,N,
19508,DescriptorName,D008297,19826099,,,9,Male,N,
19509,DescriptorName,D008895,19826099,,,10,"Milk, Human",Y,
19510,QualifierName,Q000378,19826099,,,10,,N,metabolism
19511,DescriptorName,D011247,19826099,,,11,Pregnancy,N,
19512,DescriptorName,D014227,19826099,,,12,Triazines,N,
19513,QualifierName,Q000009,19826099,,,12,,Y,adverse effects
19514,Chemical,D047428,19838099,Protein Kinase Inhibitors,0,,,,
19515,Chemical,D011743,19838099,Pyrimidines,0,,,,
19516,Chemical,D013844,19838099,Thiazoles,0,,,,
19517,Chemical,D000069439,19838099,Dasatinib,RBZ1571X5H,,,,
19518,DescriptorName,D000328,19838099,,,1,Adult,N,
19519,DescriptorName,D000368,19838099,,,2,Aged,N,
19520,DescriptorName,D000069439,19838099,,,3,Dasatinib,N,
19521,DescriptorName,D005260,19838099,,,4,Female,N,
19522,DescriptorName,D006801,19838099,,,5,Humans,N,
19523,DescriptorName,D015464,19838099,,,6,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
19524,QualifierName,Q000188,19838099,,,6,,N,drug therapy
19525,DescriptorName,D008297,19838099,,,7,Male,N,
19526,DescriptorName,D010996,19838099,,,8,Pleural Effusion,N,
19527,QualifierName,Q000139,19838099,,,8,,Y,chemically induced
19528,DescriptorName,D047428,19838099,,,9,Protein Kinase Inhibitors,N,
19529,QualifierName,Q000008,19838099,,,9,,N,administration & dosage
19530,DescriptorName,D011743,19838099,,,10,Pyrimidines,N,
19531,QualifierName,Q000008,19838099,,,10,,N,administration & dosage
19532,DescriptorName,D013844,19838099,,,11,Thiazoles,N,
19533,QualifierName,Q000008,19838099,,,11,,N,administration & dosage
19534,Chemical,D000970,19844714,Antineoplastic Agents,0,,,,
19535,Chemical,D016190,19844714,Carboplatin,BG3F62OND5,,,,
19536,Chemical,D002945,19844714,Cisplatin,Q20Q21Q62J,,,,
19537,DescriptorName,D000368,19844714,,,1,Aged,N,
19538,DescriptorName,D000970,19844714,,,2,Antineoplastic Agents,N,
19539,QualifierName,Q000008,19844714,,,2,,N,administration & dosage
19540,DescriptorName,D016190,19844714,,,3,Carboplatin,N,
19541,QualifierName,Q000009,19844714,,,3,,Y,adverse effects
19542,DescriptorName,D002945,19844714,,,4,Cisplatin,N,
19543,QualifierName,Q000008,19844714,,,4,,N,administration & dosage
19544,DescriptorName,D004342,19844714,,,5,Drug Hypersensitivity,N,
19545,QualifierName,Q000628,19844714,,,5,,Y,therapy
19546,DescriptorName,D005260,19844714,,,6,Female,N,
19547,DescriptorName,D006801,19844714,,,7,Humans,N,
19548,DescriptorName,D010051,19844714,,,8,Ovarian Neoplasms,N,
19549,QualifierName,Q000188,19844714,,,8,,N,drug therapy
19550,DescriptorName,D010534,19844714,,,9,Peritoneal Neoplasms,N,
19551,QualifierName,Q000188,19844714,,,9,,Y,drug therapy
19552,DescriptorName,D017211,19844714,,,10,Treatment Failure,N,
19553,Chemical,D000893,19875411,Anti-Inflammatory Agents,0,,,,
19554,Chemical,D000911,19875411,"Antibodies, Monoclonal",0,,,,
19555,Chemical,D061067,19875411,"Antibodies, Monoclonal, Humanized",0,,,,
19556,Chemical,D014409,19875411,Tumor Necrosis Factor-alpha,0,,,,
19557,Chemical,D000068879,19875411,Adalimumab,FYS6T7F842,,,,
19558,DescriptorName,D000068879,19875411,,,1,Adalimumab,N,
19559,DescriptorName,D000328,19875411,,,2,Adult,N,
19560,DescriptorName,D000893,19875411,,,3,Anti-Inflammatory Agents,N,
19561,QualifierName,Q000008,19875411,,,3,,N,administration & dosage
19562,DescriptorName,D000911,19875411,,,4,"Antibodies, Monoclonal",N,
19563,QualifierName,Q000008,19875411,,,4,,N,administration & dosage
19564,DescriptorName,D061067,19875411,,,5,"Antibodies, Monoclonal, Humanized",N,
19565,DescriptorName,D009202,19875411,,,6,Cardiomyopathies,N,
19566,QualifierName,Q000139,19875411,,,6,,Y,chemically induced
19567,DescriptorName,D003424,19875411,,,7,Crohn Disease,N,
19568,QualifierName,Q000188,19875411,,,7,,Y,drug therapy
19569,DescriptorName,D015199,19875411,,,8,Extracorporeal Membrane Oxygenation,N,
19570,DescriptorName,D005260,19875411,,,9,Female,N,
19571,DescriptorName,D006801,19875411,,,10,Humans,N,
19572,DescriptorName,D016896,19875411,,,11,Treatment Outcome,N,
19573,DescriptorName,D014409,19875411,,,12,Tumor Necrosis Factor-alpha,N,
19574,QualifierName,Q000037,19875411,,,12,,Y,antagonists & inhibitors
19575,Chemical,D000900,19884751,Anti-Bacterial Agents,0,,,,
19576,Chemical,D000583,19884751,Amikacin,84319SGC3C,,,,
19577,Chemical,D002118,19884751,Calcium,SY7Q814VUP,,,,
19578,DescriptorName,D000328,19884751,,,1,Adult,N,
19579,DescriptorName,D000583,19884751,,,2,Amikacin,N,
19580,QualifierName,Q000008,19884751,,,2,,N,administration & dosage
19581,DescriptorName,D000900,19884751,,,3,Anti-Bacterial Agents,N,
19582,QualifierName,Q000008,19884751,,,3,,N,administration & dosage
19583,DescriptorName,D001477,19884751,,,4,Bartter Syndrome,N,
19584,QualifierName,Q000139,19884751,,,4,,Y,chemically induced
19585,DescriptorName,D002118,19884751,,,5,Calcium,N,
19586,QualifierName,Q000097,19884751,,,5,,N,blood
19587,DescriptorName,D003937,19884751,,,6,"Diagnosis, Differential",N,
19588,DescriptorName,D017809,19884751,,,7,Fatal Outcome,N,
19589,DescriptorName,D006801,19884751,,,8,Humans,N,
19590,DescriptorName,D006996,19884751,,,9,Hypocalcemia,N,
19591,QualifierName,Q000097,19884751,,,9,,N,blood
19592,DescriptorName,D007275,19884751,,,10,"Injections, Intravenous",N,
19593,DescriptorName,D008297,19884751,,,11,Male,N,
19594,DescriptorName,D012720,19884751,,,12,Severity of Illness Index,N,
19595,DescriptorName,D014552,19884751,,,13,Urinary Tract Infections,N,
19596,QualifierName,Q000188,19884751,,,13,,N,drug therapy
19597,Chemical,D013917,1988604,Thrombin,EC 3.4.21.5,,,,
19598,DescriptorName,D000293,1988604,,,1,Adolescent,N,
19599,DescriptorName,D000328,1988604,,,2,Adult,N,
19600,DescriptorName,D001158,1988604,,,3,Arteries,N,
19601,DescriptorName,D001706,1988604,,,4,Biopsy,N,
19602,QualifierName,Q000009,1988604,,,4,,Y,adverse effects
19603,DescriptorName,D001921,1988604,,,5,Brain,N,
19604,QualifierName,Q000473,1988604,,,5,,Y,pathology
19605,DescriptorName,D002543,1988604,,,6,Cerebral Hemorrhage,N,
19606,QualifierName,Q000188,1988604,,,6,,N,drug therapy
19607,DescriptorName,D002544,1988604,,,7,Cerebral Infarction,N,
19608,QualifierName,Q000000981,1988604,,,7,,N,diagnostic imaging
19609,DescriptorName,D005260,1988604,,,8,Female,N,
19610,DescriptorName,D006487,1988604,,,9,Hemostasis,N,
19611,DescriptorName,D006801,1988604,,,10,Humans,N,
19612,DescriptorName,D008297,1988604,,,11,Male,N,
19613,DescriptorName,D011859,1988604,,,12,Radiography,N,
19614,DescriptorName,D013238,1988604,,,13,Stereotaxic Techniques,N,
19615,QualifierName,Q000009,1988604,,,13,,Y,adverse effects
19616,DescriptorName,D013917,1988604,,,14,Thrombin,N,
19617,QualifierName,Q000627,1988604,,,14,,Y,therapeutic use
19618,Chemical,D000890,19892516,Anti-Infective Agents,0,,,,
19619,Chemical,D002939,19892516,Ciprofloxacin,5E8K9I0O4U,,,,
19620,DescriptorName,D000368,19892516,,,1,Aged,N,
19621,DescriptorName,D000369,19892516,,,2,"Aged, 80 and over",N,
19622,DescriptorName,D000671,19892516,,,3,Amputation,N,
19623,DescriptorName,D000890,19892516,,,4,Anti-Infective Agents,N,
19624,QualifierName,Q000009,19892516,,,4,,Y,adverse effects
19625,DescriptorName,D002939,19892516,,,5,Ciprofloxacin,N,
19626,QualifierName,Q000009,19892516,,,5,,Y,adverse effects
19627,DescriptorName,D017719,19892516,,,6,Diabetic Foot,N,
19628,QualifierName,Q000188,19892516,,,6,,Y,drug therapy
19629,DescriptorName,D016972,19892516,,,7,Enterobacter cloacae,N,
19630,QualifierName,Q000302,19892516,,,7,,N,isolation & purification
19631,DescriptorName,D005260,19892516,,,8,Female,N,
19632,DescriptorName,D005734,19892516,,,9,Gangrene,N,
19633,DescriptorName,D006801,19892516,,,10,Humans,N,
19634,DescriptorName,D007866,19892516,,,11,Leg,N,
19635,QualifierName,Q000473,19892516,,,11,,N,pathology
19636,DescriptorName,D008297,19892516,,,12,Male,N,
19637,DescriptorName,D011513,19892516,,,13,Proteus mirabilis,N,
19638,QualifierName,Q000302,19892516,,,13,,N,isolation & purification
19639,DescriptorName,D011695,19892516,,,14,"Purpura, Schoenlein-Henoch",N,
19640,QualifierName,Q000139,19892516,,,14,,Y,chemically induced
19641,DescriptorName,D013211,19892516,,,15,Staphylococcus aureus,N,
19642,QualifierName,Q000302,19892516,,,15,,N,isolation & purification
19643,Chemical,D000970,19897274,Antineoplastic Agents,0,,,,
19644,Chemical,D001557,19897274,Benzenesulfonates,0,,,,
19645,Chemical,D010671,19897274,Phenylurea Compounds,0,,,,
19646,Chemical,D011725,19897274,Pyridines,0,,,,
19647,Chemical,D009536,19897274,Niacinamide,25X51I8RD4,,,,
19648,Chemical,D000077157,19897274,Sorafenib,9ZOQ3TZI87,,,,
19649,DescriptorName,D000970,19897274,,,1,Antineoplastic Agents,N,
19650,QualifierName,Q000009,19897274,,,1,,Y,adverse effects
19651,DescriptorName,D044466,19897274,,,2,Asian Continental Ancestry Group,N,
19652,DescriptorName,D001557,19897274,,,3,Benzenesulfonates,N,
19653,QualifierName,Q000009,19897274,,,3,,Y,adverse effects
19654,DescriptorName,D001859,19897274,,,4,Bone Neoplasms,N,
19655,QualifierName,Q000188,19897274,,,4,,N,drug therapy
19656,DescriptorName,D002292,19897274,,,5,"Carcinoma, Renal Cell",N,
19657,QualifierName,Q000188,19897274,,,5,,N,drug therapy
19658,DescriptorName,D006801,19897274,,,6,Humans,N,
19659,DescriptorName,D007680,19897274,,,7,Kidney Neoplasms,N,
19660,QualifierName,Q000188,19897274,,,7,,N,drug therapy
19661,DescriptorName,D017563,19897274,,,8,"Lung Diseases, Interstitial",N,
19662,QualifierName,Q000139,19897274,,,8,,Y,chemically induced
19663,DescriptorName,D008175,19897274,,,9,Lung Neoplasms,N,
19664,QualifierName,Q000473,19897274,,,9,,N,pathology
19665,DescriptorName,D008297,19897274,,,10,Male,N,
19666,DescriptorName,D008875,19897274,,,11,Middle Aged,N,
19667,DescriptorName,D009536,19897274,,,12,Niacinamide,N,
19668,QualifierName,Q000031,19897274,,,12,,N,analogs & derivatives
19669,DescriptorName,D010671,19897274,,,13,Phenylurea Compounds,N,
19670,DescriptorName,D011725,19897274,,,14,Pyridines,N,
19671,QualifierName,Q000009,19897274,,,14,,Y,adverse effects
19672,DescriptorName,D000077157,19897274,,,15,Sorafenib,N,
19673,Chemical,D000964,19904536,"Antimetabolites, Antineoplastic",0,,,,
19674,Chemical,D003841,19904536,Deoxycytidine,0W860991D6,,,,
19675,Chemical,C056507,19904536,gemcitabine,B76N6SBZ8R,,,,
19676,DescriptorName,D000230,19904536,,,1,Adenocarcinoma,N,
19677,QualifierName,Q000188,19904536,,,1,,Y,drug therapy
19678,DescriptorName,D000368,19904536,,,2,Aged,N,
19679,DescriptorName,D000964,19904536,,,3,"Antimetabolites, Antineoplastic",N,
19680,QualifierName,Q000009,19904536,,,3,,N,adverse effects
19681,DescriptorName,D003841,19904536,,,4,Deoxycytidine,N,
19682,QualifierName,Q000009,19904536,,,4,,N,adverse effects
19683,DescriptorName,D017809,19904536,,,5,Fatal Outcome,N,
19684,DescriptorName,D005706,19904536,,,6,Gallbladder Neoplasms,N,
19685,QualifierName,Q000188,19904536,,,6,,Y,drug therapy
19686,DescriptorName,D006801,19904536,,,7,Humans,N,
19687,DescriptorName,D017563,19904536,,,8,"Lung Diseases, Interstitial",N,
19688,QualifierName,Q000139,19904536,,,8,,Y,chemically induced
19689,DescriptorName,D008297,19904536,,,9,Male,N,
19690,DescriptorName,D009362,19904536,,,10,Neoplasm Metastasis,N,
19691,Chemical,D000889,19915794,Anti-Arrhythmia Agents,0,,,,
19692,Chemical,D000900,19915794,Anti-Bacterial Agents,0,,,,
19693,Chemical,D024841,19915794,Fluoroquinolones,0,,,,
19694,Chemical,D051544,19915794,Cytochrome P-450 CYP3A,EC 1.14.14.1,,,,
19695,Chemical,C510163,19915794,"CYP3A4 protein, human",EC 1.14.14.55,,,,
19696,Chemical,D004206,19915794,Disopyramide,GFO928U8MQ,,,,
19697,Chemical,C419689,19915794,garenoxacin,V72H9867WB,,,,
19698,DescriptorName,D000369,19915794,,,1,"Aged, 80 and over",N,
19699,DescriptorName,D000889,19915794,,,2,Anti-Arrhythmia Agents,N,
19700,QualifierName,Q000009,19915794,,,2,,N,adverse effects
19701,DescriptorName,D000900,19915794,,,3,Anti-Bacterial Agents,N,
19702,QualifierName,Q000009,19915794,,,3,,N,adverse effects
19703,DescriptorName,D051544,19915794,,,4,Cytochrome P-450 CYP3A,N,
19704,QualifierName,Q000378,19915794,,,4,,N,metabolism
19705,DescriptorName,D004206,19915794,,,5,Disopyramide,N,
19706,QualifierName,Q000009,19915794,,,5,,Y,adverse effects
19707,DescriptorName,D024841,19915794,,,6,Fluoroquinolones,N,
19708,QualifierName,Q000009,19915794,,,6,,Y,adverse effects
19709,DescriptorName,D006035,19915794,,,7,Glycyrrhiza,N,
19710,QualifierName,Q000009,19915794,,,7,,Y,adverse effects
19711,DescriptorName,D006801,19915794,,,8,Humans,N,
19712,DescriptorName,D007008,19915794,,,9,Hypokalemia,N,
19713,QualifierName,Q000139,19915794,,,9,,N,chemically induced
19714,DescriptorName,D008297,19915794,,,10,Male,N,
19715,DescriptorName,D016171,19915794,,,11,Torsades de Pointes,N,
19716,QualifierName,Q000139,19915794,,,11,,Y,chemically induced
19717,Chemical,D011564,1993143,Furocoumarins,0,,,,
19718,Chemical,C044264,1993143,"pyrido(3,4-c)-7-methylpsoralen",85878-63-3,,,,
19719,Chemical,C017104,1993143,3-carbethoxypsoralen,BB04Z808HM,,,,
19720,Chemical,C041621,1993143,"4,4',6-trimethylangelicin",T2MYR3390L,,,,
19721,Chemical,D008730,1993143,Methoxsalen,U4VJ29L7BQ,,,,
19722,DescriptorName,D000328,1993143,,,1,Adult,N,
19723,DescriptorName,D003877,1993143,,,2,"Dermatitis, Contact",N,
19724,QualifierName,Q000209,1993143,,,2,,Y,etiology
19725,DescriptorName,D005260,1993143,,,3,Female,N,
19726,DescriptorName,D011564,1993143,,,4,Furocoumarins,N,
19727,QualifierName,Q000009,1993143,,,4,,Y,adverse effects
19728,DescriptorName,D006801,1993143,,,5,Humans,N,
19729,DescriptorName,D015994,1993143,,,6,Incidence,N,
19730,DescriptorName,D008297,1993143,,,7,Male,N,
19731,DescriptorName,D008730,1993143,,,8,Methoxsalen,N,
19732,QualifierName,Q000009,1993143,,,8,,N,adverse effects
19733,DescriptorName,D008875,1993143,,,9,Middle Aged,N,
19734,DescriptorName,D011701,1993143,,,10,PUVA Therapy,N,
19735,QualifierName,Q000009,1993143,,,10,,Y,adverse effects
19736,DescriptorName,D010787,1993143,,,11,Photosensitivity Disorders,N,
19737,QualifierName,Q000139,1993143,,,11,,Y,chemically induced
19738,DescriptorName,D011565,1993143,,,12,Psoriasis,N,
19739,QualifierName,Q000188,1993143,,,12,,Y,drug therapy
19740,DescriptorName,D012882,1993143,,,13,Skin Tests,N,
19741,Chemical,D000893,19935411,Anti-Inflammatory Agents,0,,,,
19742,Chemical,D008775,19935411,Methylprednisolone,X4W7ZR7023,,,,
19743,DescriptorName,D000328,19935411,,,1,Adult,N,
19744,DescriptorName,D000893,19935411,,,2,Anti-Inflammatory Agents,N,
19745,QualifierName,Q000009,19935411,,,2,,Y,adverse effects
19746,DescriptorName,D056486,19935411,,,3,Chemical and Drug Induced Liver Injury,N,
19747,QualifierName,Q000209,19935411,,,3,,Y,etiology
19748,DescriptorName,D003711,19935411,,,4,Demyelinating Diseases,N,
19749,QualifierName,Q000188,19935411,,,4,,N,drug therapy
19750,DescriptorName,D064420,19935411,,,5,Drug-Related Side Effects and Adverse Reactions,N,
19751,QualifierName,Q000139,19935411,,,5,,N,chemically induced
19752,DescriptorName,D005260,19935411,,,6,Female,N,
19753,DescriptorName,D006801,19935411,,,7,Humans,N,
19754,DescriptorName,D008297,19935411,,,8,Male,N,
19755,DescriptorName,D008775,19935411,,,9,Methylprednisolone,N,
19756,QualifierName,Q000009,19935411,,,9,,Y,adverse effects
19757,Chemical,D011137,19949685,Polystyrenes,0,,,,
19758,Chemical,C003321,19949685,polystyrene sulfonic acid,70KO0R01RY,,,,
19759,DescriptorName,D000328,19949685,,,1,Adult,N,
19760,DescriptorName,D003106,19949685,,,2,Colon,N,
19761,QualifierName,Q000473,19949685,,,2,,Y,pathology
19762,DescriptorName,D006471,19949685,,,3,Gastrointestinal Hemorrhage,N,
19763,QualifierName,Q000209,19949685,,,3,,N,etiology
19764,DescriptorName,D006801,19949685,,,4,Humans,N,
19765,DescriptorName,D006947,19949685,,,5,Hyperkalemia,N,
19766,QualifierName,Q000188,19949685,,,5,,N,drug therapy
19767,DescriptorName,D007413,19949685,,,6,Intestinal Mucosa,N,
19768,QualifierName,Q000473,19949685,,,6,,Y,pathology
19769,DescriptorName,D008297,19949685,,,7,Male,N,
19770,DescriptorName,D009336,19949685,,,8,Necrosis,N,
19771,QualifierName,Q000139,19949685,,,8,,Y,chemically induced
19772,DescriptorName,D011137,19949685,,,9,Polystyrenes,N,
19773,QualifierName,Q000009,19949685,,,9,,Y,adverse effects
19774,DescriptorName,D014511,19949685,,,10,Uremia,N,
19775,QualifierName,Q000503,19949685,,,10,,Y,physiopathology
19776,Chemical,D014150,19995222,Antipsychotic Agents,0,,,,
19777,Chemical,D017382,19995222,Reactive Oxygen Species,0,,,,
19778,Chemical,D003024,19995222,Clozapine,J60AR2IKIC,,,,
19779,DescriptorName,D000328,19995222,,,1,Adult,N,
19780,DescriptorName,D014150,19995222,,,2,Antipsychotic Agents,N,
19781,QualifierName,Q000009,19995222,,,2,,Y,adverse effects
19782,DescriptorName,D001480,19995222,,,3,Basal Ganglia Diseases,N,
19783,QualifierName,Q000139,19995222,,,3,,N,chemically induced
19784,DescriptorName,D002681,19995222,,,4,China,N,
19785,QualifierName,Q000453,19995222,,,4,,N,epidemiology
19786,DescriptorName,D003024,19995222,,,5,Clozapine,N,
19787,QualifierName,Q000009,19995222,,,5,,Y,adverse effects
19788,DescriptorName,D004334,19995222,,,6,Drug Administration Schedule,N,
19789,DescriptorName,D004409,19995222,,,7,"Dyskinesia, Drug-Induced",N,
19790,QualifierName,Q000175,19995222,,,7,,N,diagnosis
19791,DescriptorName,D005260,19995222,,,8,Female,N,
19792,DescriptorName,D006801,19995222,,,9,Humans,N,
19793,DescriptorName,D008297,19995222,,,10,Male,N,
19794,DescriptorName,D008875,19995222,,,11,Middle Aged,N,
19795,DescriptorName,D015995,19995222,,,12,Prevalence,N,
19796,DescriptorName,D017382,19995222,,,13,Reactive Oxygen Species,N,
19797,QualifierName,Q000378,19995222,,,13,,N,metabolism
19798,DescriptorName,D012559,19995222,,,14,Schizophrenia,N,
19799,QualifierName,Q000188,19995222,,,14,,Y,drug therapy
19800,DescriptorName,D012720,19995222,,,15,Severity of Illness Index,N,
19801,DescriptorName,D011795,19995222,,,16,Surveys and Questionnaires,N,
19802,Chemical,D000305,20009973,Adrenal Cortex Hormones,0,,,,
19803,Chemical,D000970,20009973,Antineoplastic Agents,0,,,,
19804,Chemical,D014212,20009973,Tretinoin,5688UTC01R,,,,
19805,DescriptorName,D000305,20009973,,,1,Adrenal Cortex Hormones,N,
19806,QualifierName,Q000627,20009973,,,1,,N,therapeutic use
19807,DescriptorName,D000970,20009973,,,2,Antineoplastic Agents,N,
19808,QualifierName,Q000009,20009973,,,2,,N,adverse effects
19809,DescriptorName,D005260,20009973,,,3,Female,N,
19810,DescriptorName,D006801,20009973,,,4,Humans,N,
19811,DescriptorName,D015473,20009973,,,5,"Leukemia, Promyelocytic, Acute",N,
19812,QualifierName,Q000188,20009973,,,5,,N,drug therapy
19813,DescriptorName,D008875,20009973,,,6,Middle Aged,N,
19814,DescriptorName,D020422,20009973,,,7,Mononeuropathies,N,
19815,QualifierName,Q000139,20009973,,,7,,Y,chemically induced
19816,DescriptorName,D009220,20009973,,,8,Myositis,N,
19817,QualifierName,Q000139,20009973,,,8,,Y,chemically induced
19818,DescriptorName,D013585,20009973,,,9,Synovitis,N,
19819,QualifierName,Q000139,20009973,,,9,,Y,chemically induced
19820,DescriptorName,D016896,20009973,,,10,Treatment Outcome,N,
19821,DescriptorName,D014212,20009973,,,11,Tretinoin,N,
19822,QualifierName,Q000009,20009973,,,11,,Y,adverse effects
19823,DescriptorName,D028761,20009973,,,12,Withholding Treatment,N,
19824,Chemical,D000998,20020238,Antiviral Agents,0,,,,
19825,Chemical,D000077190,20020238,Interferon alpha-2,0,,,,
19826,Chemical,D016898,20020238,Interferon-alpha,0,,,,
19827,Chemical,D011994,20020238,Recombinant Proteins,0,,,,
19828,Chemical,D011092,20020238,Polyethylene Glycols,3WJQ0SDW1A,,,,
19829,Chemical,D012254,20020238,Ribavirin,49717AWG6K,,,,
19830,Chemical,C417083,20020238,peginterferon alfa-2b,G8RGG88B68,,,,
19831,DescriptorName,D000328,20020238,,,1,Adult,N,
19832,DescriptorName,D000998,20020238,,,2,Antiviral Agents,N,
19833,QualifierName,Q000009,20020238,,,2,,Y,adverse effects
19834,DescriptorName,D004359,20020238,,,3,"Drug Therapy, Combination",N,
19835,DescriptorName,D005260,20020238,,,4,Female,N,
19836,DescriptorName,D005451,20020238,,,5,Fluorescein Angiography,N,
19837,DescriptorName,D019698,20020238,,,6,"Hepatitis C, Chronic",N,
19838,QualifierName,Q000188,20020238,,,6,,Y,drug therapy
19839,DescriptorName,D006801,20020238,,,7,Humans,N,
19840,DescriptorName,D006973,20020238,,,8,Hypertension,N,
19841,QualifierName,Q000150,20020238,,,8,,N,complications
19842,DescriptorName,D015994,20020238,,,9,Incidence,N,
19843,DescriptorName,D000077190,20020238,,,10,Interferon alpha-2,N,
19844,DescriptorName,D016898,20020238,,,11,Interferon-alpha,N,
19845,QualifierName,Q000009,20020238,,,11,,Y,adverse effects
19846,DescriptorName,D008297,20020238,,,12,Male,N,
19847,DescriptorName,D008875,20020238,,,13,Middle Aged,N,
19848,DescriptorName,D011092,20020238,,,14,Polyethylene Glycols,N,
19849,QualifierName,Q000009,20020238,,,14,,Y,adverse effects
19850,DescriptorName,D011446,20020238,,,15,Prospective Studies,N,
19851,DescriptorName,D011994,20020238,,,16,Recombinant Proteins,N,
19852,DescriptorName,D012164,20020238,,,17,Retinal Diseases,N,
19853,QualifierName,Q000139,20020238,,,17,,Y,chemically induced
19854,DescriptorName,D012254,20020238,,,18,Ribavirin,N,
19855,QualifierName,Q000009,20020238,,,18,,Y,adverse effects
19856,DescriptorName,D012307,20020238,,,19,Risk Factors,N,
19857,DescriptorName,D014792,20020238,,,20,Visual Acuity,N,
19858,QualifierName,Q000187,20020238,,,20,,N,drug effects
19859,Chemical,D000970,20038831,Antineoplastic Agents,0,,,,
19860,Chemical,D007073,20038831,Immunoglobulin E,37341-29-0,,,,
19861,Chemical,D016190,20038831,Carboplatin,BG3F62OND5,,,,
19862,Chemical,D002945,20038831,Cisplatin,Q20Q21Q62J,,,,
19863,DescriptorName,D002282,20038831,,,1,"Adenocarcinoma, Bronchiolo-Alveolar",N,
19864,QualifierName,Q000188,20038831,,,1,,N,drug therapy
19865,DescriptorName,D000368,20038831,,,2,Aged,N,
19866,DescriptorName,D000970,20038831,,,3,Antineoplastic Agents,N,
19867,QualifierName,Q000008,20038831,,,3,,N,administration & dosage
19868,DescriptorName,D016190,20038831,,,4,Carboplatin,N,
19869,QualifierName,Q000008,20038831,,,4,,N,administration & dosage
19870,DescriptorName,D002945,20038831,,,5,Cisplatin,N,
19871,QualifierName,Q000008,20038831,,,5,,N,administration & dosage
19872,DescriptorName,D004342,20038831,,,6,Drug Hypersensitivity,N,
19873,QualifierName,Q000175,20038831,,,6,,Y,diagnosis
19874,DescriptorName,D005260,20038831,,,7,Female,N,
19875,DescriptorName,D006801,20038831,,,8,Humans,N,
19876,DescriptorName,D007073,20038831,,,9,Immunoglobulin E,N,
19877,DescriptorName,D007428,20038831,,,10,Intradermal Tests,N,
19878,DescriptorName,D008175,20038831,,,11,Lung Neoplasms,N,
19879,QualifierName,Q000188,20038831,,,11,,N,drug therapy
19880,DescriptorName,D008297,20038831,,,12,Male,N,
19881,DescriptorName,D008654,20038831,,,13,Mesothelioma,N,
19882,QualifierName,Q000188,20038831,,,13,,N,drug therapy
19883,DescriptorName,D008875,20038831,,,14,Middle Aged,N,
19884,DescriptorName,D010051,20038831,,,15,Ovarian Neoplasms,N,
19885,QualifierName,Q000188,20038831,,,15,,N,drug therapy
19886,DescriptorName,D012882,20038831,,,16,Skin Tests,N,
19887,Chemical,D000892,20065266,"Anti-Infective Agents, Urinary",0,,,,
19888,Chemical,D015662,20065266,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
19889,DescriptorName,D000328,20065266,,,1,Adult,N,
19890,DescriptorName,D000743,20065266,,,2,"Anemia, Hemolytic",N,
19891,QualifierName,Q000139,20065266,,,2,,Y,chemically induced
19892,DescriptorName,D000892,20065266,,,3,"Anti-Infective Agents, Urinary",N,
19893,QualifierName,Q000009,20065266,,,3,,Y,adverse effects
19894,DescriptorName,D056486,20065266,,,4,Chemical and Drug Induced Liver Injury,N,
19895,QualifierName,Q000209,20065266,,,4,,Y,etiology
19896,DescriptorName,D005955,20065266,,,5,Glucosephosphate Dehydrogenase Deficiency,N,
19897,QualifierName,Q000139,20065266,,,5,,N,chemically induced
19898,DescriptorName,D006461,20065266,,,6,Hemolysis,N,
19899,QualifierName,Q000187,20065266,,,6,,N,drug effects
19900,DescriptorName,D006801,20065266,,,7,Humans,N,
19901,DescriptorName,D007024,20065266,,,8,"Hypotension, Orthostatic",N,
19902,QualifierName,Q000139,20065266,,,8,,Y,chemically induced
19903,DescriptorName,D008111,20065266,,,9,Liver Function Tests,N,
19904,DescriptorName,D008297,20065266,,,10,Male,N,
19905,DescriptorName,D008582,20065266,,,11,"Meningitis, Aseptic",N,
19906,QualifierName,Q000139,20065266,,,11,,Y,chemically induced
19907,DescriptorName,D015662,20065266,,,12,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
19908,QualifierName,Q000009,20065266,,,12,,Y,adverse effects
19909,DescriptorName,D014552,20065266,,,13,Urinary Tract Infections,N,
19910,QualifierName,Q000188,20065266,,,13,,N,drug therapy
19911,Chemical,D003402,2006943,Creatine Kinase,EC 2.7.3.2,,,,
19912,Chemical,D012312,2006943,Ritodrine,I0Q6O6740J,,,,
19913,DescriptorName,D000328,2006943,,,1,Adult,N,
19914,DescriptorName,D003402,2006943,,,2,Creatine Kinase,N,
19915,QualifierName,Q000032,2006943,,,2,,N,analysis
19916,DescriptorName,D004562,2006943,,,3,Electrocardiography,N,
19917,DescriptorName,D005260,2006943,,,4,Female,N,
19918,DescriptorName,D006327,2006943,,,5,Heart Block,N,
19919,QualifierName,Q000139,2006943,,,5,,Y,chemically induced
19920,DescriptorName,D006801,2006943,,,6,Humans,N,
19921,DescriptorName,D007752,2006943,,,7,"Obstetric Labor, Premature",N,
19922,QualifierName,Q000188,2006943,,,7,,Y,drug therapy
19923,DescriptorName,D011247,2006943,,,8,Pregnancy,N,
19924,DescriptorName,D012312,2006943,,,9,Ritodrine,N,
19925,QualifierName,Q000009,2006943,,,9,,Y,adverse effects
19926,Chemical,D000903,20098333,"Antibiotics, Antineoplastic",0,,,,
19927,Chemical,D020097,20098333,"Natriuretic Peptide, Brain",114471-18-0,,,,
19928,Chemical,D014212,20098333,Tretinoin,5688UTC01R,,,,
19929,Chemical,D003630,20098333,Daunorubicin,ZS7284E0ZP,,,,
19930,DescriptorName,D000293,20098333,,,1,Adolescent,N,
19931,DescriptorName,D000903,20098333,,,2,"Antibiotics, Antineoplastic",N,
19932,QualifierName,Q000009,20098333,,,2,,Y,adverse effects
19933,DescriptorName,D009202,20098333,,,3,Cardiomyopathies,N,
19934,QualifierName,Q000139,20098333,,,3,,Y,chemically induced
19935,DescriptorName,D002908,20098333,,,4,Chronic Disease,N,
19936,DescriptorName,D003630,20098333,,,5,Daunorubicin,N,
19937,QualifierName,Q000009,20098333,,,5,,Y,adverse effects
19938,DescriptorName,D005260,20098333,,,6,Female,N,
19939,DescriptorName,D006801,20098333,,,7,Humans,N,
19940,DescriptorName,D015473,20098333,,,8,"Leukemia, Promyelocytic, Acute",N,
19941,QualifierName,Q000150,20098333,,,8,,N,complications
19942,DescriptorName,D020097,20098333,,,9,"Natriuretic Peptide, Brain",N,
19943,QualifierName,Q000097,20098333,,,9,,Y,blood
19944,DescriptorName,D014212,20098333,,,10,Tretinoin,N,
19945,QualifierName,Q000009,20098333,,,10,,Y,adverse effects
19946,Chemical,D000305,20110001,Adrenal Cortex Hormones,0,,,,
19947,Chemical,D000970,20110001,Antineoplastic Agents,0,,,,
19948,Chemical,D001549,20110001,Benzamides,0,,,,
19949,Chemical,D004279,20110001,"DNA, Viral",0,,,,
19950,Chemical,D010879,20110001,Piperazines,0,,,,
19951,Chemical,D011743,20110001,Pyrimidines,0,,,,
19952,Chemical,D000068877,20110001,Imatinib Mesylate,8A1O1M485B,,,,
19953,Chemical,D016044,20110001,"Fusion Proteins, bcr-abl",EC 2.7.10.2,,,,
19954,DescriptorName,D000305,20110001,,,1,Adrenal Cortex Hormones,N,
19955,QualifierName,Q000627,20110001,,,1,,N,therapeutic use
19956,DescriptorName,D000970,20110001,,,2,Antineoplastic Agents,N,
19957,QualifierName,Q000009,20110001,,,2,,Y,adverse effects
19958,DescriptorName,D001549,20110001,,,3,Benzamides,N,
19959,DescriptorName,D004279,20110001,,,4,"DNA, Viral",N,
19960,QualifierName,Q000032,20110001,,,4,,N,analysis
19961,DescriptorName,D016044,20110001,,,5,"Fusion Proteins, bcr-abl",N,
19962,QualifierName,Q000378,20110001,,,5,,N,metabolism
19963,DescriptorName,D018023,20110001,,,6,HIV Seronegativity,N,
19964,DescriptorName,D019288,20110001,,,7,"Herpesvirus 8, Human",N,
19965,QualifierName,Q000235,20110001,,,7,,N,genetics
19966,DescriptorName,D006801,20110001,,,8,Humans,N,
19967,DescriptorName,D000068877,20110001,,,9,Imatinib Mesylate,N,
19968,DescriptorName,D007150,20110001,,,10,Immunohistochemistry,N,
19969,DescriptorName,D015464,20110001,,,11,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",N,
19970,QualifierName,Q000150,20110001,,,11,,Y,complications
19971,DescriptorName,D008297,20110001,,,12,Male,N,
19972,DescriptorName,D008875,20110001,,,13,Middle Aged,N,
19973,DescriptorName,D010879,20110001,,,14,Piperazines,N,
19974,QualifierName,Q000009,20110001,,,14,,Y,adverse effects
19975,DescriptorName,D011743,20110001,,,15,Pyrimidines,N,
19976,QualifierName,Q000009,20110001,,,15,,Y,adverse effects
19977,DescriptorName,D020133,20110001,,,16,Reverse Transcriptase Polymerase Chain Reaction,N,
19978,DescriptorName,D012514,20110001,,,17,"Sarcoma, Kaposi",N,
19979,QualifierName,Q000150,20110001,,,17,,Y,complications
19980,DescriptorName,D012867,20110001,,,18,Skin,N,
19981,QualifierName,Q000473,20110001,,,18,,N,pathology
19982,Chemical,D003561,2011096,Cytarabine,04079A1RDZ,,,,
19983,DescriptorName,D000293,2011096,,,1,Adolescent,N,
19984,DescriptorName,D010244,2011096,,,2,"Bulbar Palsy, Progressive",N,
19985,QualifierName,Q000139,2011096,,,2,,Y,chemically induced
19986,DescriptorName,D002524,2011096,,,3,Cerebellar Ataxia,N,
19987,QualifierName,Q000139,2011096,,,3,,N,chemically induced
19988,DescriptorName,D002648,2011096,,,4,Child,N,
19989,DescriptorName,D003561,2011096,,,5,Cytarabine,N,
19990,QualifierName,Q000008,2011096,,,5,,N,administration & dosage
19991,DescriptorName,D005260,2011096,,,6,Female,N,
19992,DescriptorName,D006801,2011096,,,7,Humans,N,
19993,DescriptorName,D007275,2011096,,,8,"Injections, Intravenous",N,
19994,DescriptorName,D007565,2011096,,,9,Jaundice,N,
19995,QualifierName,Q000139,2011096,,,9,,N,chemically induced
19996,DescriptorName,D015479,2011096,,,10,"Leukemia, Myelomonocytic, Acute",N,
19997,QualifierName,Q000188,2011096,,,10,,N,drug therapy
19998,DescriptorName,D015473,2011096,,,11,"Leukemia, Promyelocytic, Acute",N,
19999,QualifierName,Q000188,2011096,,,11,,N,drug therapy
20000,DescriptorName,D008297,2011096,,,12,Male,N,
20001,DescriptorName,D010243,2011096,,,13,Paralysis,N,
20002,QualifierName,Q000139,2011096,,,13,,Y,chemically induced
20003,DescriptorName,D054198,2011096,,,14,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
20004,QualifierName,Q000188,2011096,,,14,,N,drug therapy
20005,Chemical,D000998,20118434,Antiviral Agents,0,,,,
20006,Chemical,D012254,20118434,Ribavirin,49717AWG6K,,,,
20007,Chemical,D007372,20118434,Interferons,9008-11-1,,,,
20008,DescriptorName,D000328,20118434,,,1,Adult,N,
20009,DescriptorName,D000998,20118434,,,2,Antiviral Agents,N,
20010,QualifierName,Q000009,20118434,,,2,,Y,adverse effects
20011,DescriptorName,D005260,20118434,,,3,Female,N,
20012,DescriptorName,D006526,20118434,,,4,Hepatitis C,N,
20013,QualifierName,Q000188,20118434,,,4,,Y,drug therapy
20014,DescriptorName,D006801,20118434,,,5,Humans,N,
20015,DescriptorName,D007372,20118434,,,6,Interferons,N,
20016,QualifierName,Q000009,20118434,,,6,,Y,adverse effects
20017,DescriptorName,D011605,20118434,,,7,"Psychoses, Substance-Induced",N,
20018,QualifierName,Q000175,20118434,,,7,,N,diagnosis
20019,DescriptorName,D012254,20118434,,,8,Ribavirin,N,
20020,QualifierName,Q000009,20118434,,,8,,Y,adverse effects
20021,DescriptorName,D012720,20118434,,,9,Severity of Illness Index,N,
20022,Chemical,D019380,20120657,Anti-HIV Agents,0,,,,
20023,Chemical,D015215,20120657,Zidovudine,4B9XT59T7S,,,,
20024,DescriptorName,D000328,20120657,,,1,Adult,N,
20025,DescriptorName,D000741,20120657,,,2,"Anemia, Aplastic",N,
20026,QualifierName,Q000139,20120657,,,2,,N,chemically induced
20027,DescriptorName,D019380,20120657,,,3,Anti-HIV Agents,N,
20028,QualifierName,Q000009,20120657,,,3,,Y,adverse effects
20029,DescriptorName,D023241,20120657,,,4,"Antiretroviral Therapy, Highly Active",N,
20030,DescriptorName,D005260,20120657,,,5,Female,N,
20031,DescriptorName,D015658,20120657,,,6,HIV Infections,N,
20032,QualifierName,Q000188,20120657,,,6,,Y,drug therapy
20033,DescriptorName,D015497,20120657,,,7,HIV-1,Y,
20034,DescriptorName,D006801,20120657,,,8,Humans,N,
20035,DescriptorName,D012010,20120657,,,9,"Red-Cell Aplasia, Pure",N,
20036,QualifierName,Q000139,20120657,,,9,,Y,chemically induced
20037,DescriptorName,D015215,20120657,,,10,Zidovudine,N,
20038,QualifierName,Q000009,20120657,,,10,,Y,adverse effects
20039,Chemical,D018501,20126479,Antirheumatic Agents,0,,,,
20040,Chemical,D012168,20126479,Retinal Pigments,0,,,,
20041,Chemical,D006886,20126479,Hydroxychloroquine,4QWG6N8QKH,,,,
20042,DescriptorName,D018501,20126479,,,1,Antirheumatic Agents,N,
20043,QualifierName,Q000009,20126479,,,1,,Y,adverse effects
20044,DescriptorName,D005260,20126479,,,2,Female,N,
20045,DescriptorName,D005451,20126479,,,3,Fluorescein Angiography,N,
20046,DescriptorName,D006801,20126479,,,4,Humans,N,
20047,DescriptorName,D006886,20126479,,,5,Hydroxychloroquine,N,
20048,QualifierName,Q000009,20126479,,,5,,Y,adverse effects
20049,DescriptorName,D008180,20126479,,,6,"Lupus Erythematosus, Systemic",N,
20050,QualifierName,Q000188,20126479,,,6,,N,drug therapy
20051,DescriptorName,D008875,20126479,,,7,Middle Aged,N,
20052,DescriptorName,D009887,20126479,,,8,Ophthalmoscopy,N,
20053,DescriptorName,D055095,20126479,,,9,Optics and Photonics,N,
20054,QualifierName,Q000379,20126479,,,9,,Y,methods
20055,DescriptorName,D012160,20126479,,,10,Retina,N,
20056,QualifierName,Q000187,20126479,,,10,,N,drug effects
20057,DescriptorName,D017949,20126479,,,11,Retinal Cone Photoreceptor Cells,N,
20058,QualifierName,Q000473,20126479,,,11,,N,pathology
20059,DescriptorName,D012164,20126479,,,12,Retinal Diseases,N,
20060,QualifierName,Q000139,20126479,,,12,,Y,chemically induced
20061,DescriptorName,D012168,20126479,,,13,Retinal Pigments,N,
20062,QualifierName,Q000378,20126479,,,13,,N,metabolism
20063,DescriptorName,D012859,20126479,,,14,Sjogren's Syndrome,N,
20064,QualifierName,Q000188,20126479,,,14,,N,drug therapy
20065,DescriptorName,D041623,20126479,,,15,"Tomography, Optical Coherence",N,
20066,QualifierName,Q000379,20126479,,,15,,Y,methods
20067,DescriptorName,D014786,20126479,,,16,Vision Disorders,N,
20068,QualifierName,Q000209,20126479,,,16,,Y,etiology
20069,DescriptorName,D058609,20126479,,,17,Visual Field Tests,N,
20070,DescriptorName,D014794,20126479,,,18,Visual Fields,N,
20071,Chemical,D014196,2012922,Trazodone,YBK48BXK30,,,,
20072,DescriptorName,D000328,2012922,,,1,Adult,N,
20073,DescriptorName,D000368,2012922,,,2,Aged,N,
20074,DescriptorName,D001714,2012922,,,3,Bipolar Disorder,N,
20075,QualifierName,Q000139,2012922,,,3,,Y,chemically induced
20076,DescriptorName,D003866,2012922,,,4,Depressive Disorder,N,
20077,QualifierName,Q000188,2012922,,,4,,Y,drug therapy
20078,DescriptorName,D004305,2012922,,,5,"Dose-Response Relationship, Drug",N,
20079,DescriptorName,D005260,2012922,,,6,Female,N,
20080,DescriptorName,D006801,2012922,,,7,Humans,N,
20081,DescriptorName,D008297,2012922,,,8,Male,N,
20082,DescriptorName,D008875,2012922,,,9,Middle Aged,N,
20083,DescriptorName,D014196,2012922,,,10,Trazodone,N,
20084,QualifierName,Q000008,2012922,,,10,,N,administration & dosage
20085,Chemical,D000889,20130478,Anti-Arrhythmia Agents,0,,,,
20086,Chemical,D004232,20130478,Diuretics,0,,,,
20087,Chemical,D007074,20130478,Immunoglobulin G,0,,,,
20088,Chemical,D007155,20130478,Immunologic Factors,0,,,,
20089,Chemical,D018124,20130478,"Receptors, Tumor Necrosis Factor",0,,,,
20090,Chemical,D004077,20130478,Digoxin,73K4184T59,,,,
20091,Chemical,D000068800,20130478,Etanercept,OP401G7OJC,,,,
20092,DescriptorName,D000328,20130478,,,1,Adult,N,
20093,DescriptorName,D000889,20130478,,,2,Anti-Arrhythmia Agents,N,
20094,QualifierName,Q000627,20130478,,,2,,N,therapeutic use
20095,DescriptorName,D004077,20130478,,,3,Digoxin,N,
20096,QualifierName,Q000627,20130478,,,3,,N,therapeutic use
20097,DescriptorName,D004232,20130478,,,4,Diuretics,N,
20098,QualifierName,Q000627,20130478,,,4,,N,therapeutic use
20099,DescriptorName,D000068800,20130478,,,5,Etanercept,N,
20100,DescriptorName,D006333,20130478,,,6,Heart Failure,N,
20101,QualifierName,Q000139,20130478,,,6,,Y,chemically induced
20102,DescriptorName,D006801,20130478,,,7,Humans,N,
20103,DescriptorName,D007074,20130478,,,8,Immunoglobulin G,N,
20104,QualifierName,Q000009,20130478,,,8,,Y,adverse effects
20105,DescriptorName,D007155,20130478,,,9,Immunologic Factors,N,
20106,QualifierName,Q000009,20130478,,,9,,Y,adverse effects
20107,DescriptorName,D008297,20130478,,,10,Male,N,
20108,DescriptorName,D018124,20130478,,,11,"Receptors, Tumor Necrosis Factor",N,
20109,DescriptorName,D013167,20130478,,,12,"Spondylitis, Ankylosing",N,
20110,QualifierName,Q000188,20130478,,,12,,Y,drug therapy
20111,Chemical,D004365,20154441,"Drugs, Chinese Herbal",0,,,,
20112,Chemical,D013566,20154441,Sympathomimetics,0,,,,
20113,Chemical,C041707,20154441,N-methylephedrine,60VH42A1KJ,,,,
20114,Chemical,D004809,20154441,Ephedrine,GN83C131XS,,,,
20115,DescriptorName,D000328,20154441,,,1,Adult,N,
20116,DescriptorName,D002531,20154441,,,2,Cerebellum,N,
20117,QualifierName,Q000000981,20154441,,,2,,N,diagnostic imaging
20118,DescriptorName,D003139,20154441,,,3,Common Cold,N,
20119,QualifierName,Q000188,20154441,,,3,,Y,drug therapy
20120,DescriptorName,D003371,20154441,,,4,Cough,N,
20121,QualifierName,Q000188,20154441,,,4,,Y,drug therapy
20122,DescriptorName,D019587,20154441,,,5,Dietary Supplements,N,
20123,QualifierName,Q000009,20154441,,,5,,Y,adverse effects
20124,DescriptorName,D004365,20154441,,,6,"Drugs, Chinese Herbal",N,
20125,QualifierName,Q000008,20154441,,,6,,N,administration & dosage
20126,DescriptorName,D004809,20154441,,,7,Ephedrine,N,
20127,QualifierName,Q000008,20154441,,,7,,N,administration & dosage
20128,DescriptorName,D005260,20154441,,,8,Female,N,
20129,DescriptorName,D006801,20154441,,,9,Humans,N,
20130,DescriptorName,D018810,20154441,,,10,Magnetic Resonance Angiography,N,
20131,DescriptorName,D020521,20154441,,,11,Stroke,N,
20132,QualifierName,Q000139,20154441,,,11,,Y,chemically induced
20133,DescriptorName,D013566,20154441,,,12,Sympathomimetics,N,
20134,QualifierName,Q000008,20154441,,,12,,N,administration & dosage
20135,DescriptorName,D014057,20154441,,,13,"Tomography, X-Ray Computed",N,
20136,Chemical,D009022,2016556,Morphine Derivatives,0,,,,
20137,Chemical,C035349,2016556,morphine-6-glucuronide,64Y9KYM60R,,,,
20138,Chemical,D009020,2016556,Morphine,76I7G6D29C,,,,
20139,DescriptorName,D000230,2016556,,,1,Adenocarcinoma,N,
20140,QualifierName,Q000150,2016556,,,1,,N,complications
20141,DescriptorName,D003221,2016556,,,2,Confusion,N,
20142,QualifierName,Q000139,2016556,,,2,,N,chemically induced
20143,DescriptorName,D005260,2016556,,,3,Female,N,
20144,DescriptorName,D006801,2016556,,,4,Humans,N,
20145,DescriptorName,D007676,2016556,,,5,"Kidney Failure, Chronic",N,
20146,QualifierName,Q000097,2016556,,,5,,Y,blood
20147,DescriptorName,D008875,2016556,,,6,Middle Aged,N,
20148,DescriptorName,D009020,2016556,,,7,Morphine,N,
20149,QualifierName,Q000378,2016556,,,7,,Y,metabolism
20150,DescriptorName,D009022,2016556,,,8,Morphine Derivatives,N,
20151,QualifierName,Q000009,2016556,,,8,,Y,adverse effects
20152,DescriptorName,D009325,2016556,,,9,Nausea,N,
20153,QualifierName,Q000139,2016556,,,9,,N,chemically induced
20154,DescriptorName,D010146,2016556,,,10,Pain,N,
20155,QualifierName,Q000188,2016556,,,10,,Y,drug therapy
20156,DescriptorName,D010190,2016556,,,11,Pancreatic Neoplasms,N,
20157,QualifierName,Q000150,2016556,,,11,,N,complications
20158,Chemical,D000081,20171144,Acetamides,0,,,,
20159,Chemical,D000927,20171144,Anticonvulsants,0,,,,
20160,Chemical,D000078334,20171144,Lacosamide,563KS2PQY5,,,,
20161,DescriptorName,D000081,20171144,,,1,Acetamides,N,
20162,QualifierName,Q000008,20171144,,,1,,Y,administration & dosage
20163,DescriptorName,D000328,20171144,,,2,Adult,N,
20164,DescriptorName,D000927,20171144,,,3,Anticonvulsants,N,
20165,QualifierName,Q000008,20171144,,,3,,Y,administration & dosage
20166,DescriptorName,D003128,20171144,,,4,Coma,N,
20167,QualifierName,Q000139,20171144,,,4,,N,chemically induced
20168,DescriptorName,D004333,20171144,,,5,Drug Administration Routes,N,
20169,DescriptorName,D004334,20171144,,,6,Drug Administration Schedule,N,
20170,DescriptorName,D004359,20171144,,,7,"Drug Therapy, Combination",N,
20171,DescriptorName,D004827,20171144,,,8,Epilepsy,N,
20172,QualifierName,Q000188,20171144,,,8,,N,drug therapy
20173,DescriptorName,D005260,20171144,,,9,Female,N,
20174,DescriptorName,D006801,20171144,,,10,Humans,N,
20175,DescriptorName,D000078334,20171144,,,11,Lacosamide,N,
20176,DescriptorName,D013406,20171144,,,12,"Suicide, Attempted",N,
20177,QualifierName,Q000523,20171144,,,12,,Y,psychology
20178,Chemical,D000893,20178709,Anti-Inflammatory Agents,0,,,,
20179,Chemical,D003879,20178709,Dermatologic Agents,0,,,,
20180,Chemical,D001241,20178709,Aspirin,R16CO5Y76E,,,,
20181,Chemical,D003078,20178709,Colchicine,SML2Y3J35T,,,,
20182,Chemical,D008727,20178709,Methotrexate,YL5FZ2Y5U1,,,,
20183,DescriptorName,D000893,20178709,,,1,Anti-Inflammatory Agents,N,
20184,QualifierName,Q000627,20178709,,,1,,N,therapeutic use
20185,DescriptorName,D001241,20178709,,,2,Aspirin,N,
20186,QualifierName,Q000627,20178709,,,2,,N,therapeutic use
20187,DescriptorName,D002908,20178709,,,3,Chronic Disease,N,
20188,DescriptorName,D003078,20178709,,,4,Colchicine,N,
20189,QualifierName,Q000627,20178709,,,4,,N,therapeutic use
20190,DescriptorName,D003879,20178709,,,5,Dermatologic Agents,N,
20191,QualifierName,Q000009,20178709,,,5,,Y,adverse effects
20192,DescriptorName,D004359,20178709,,,6,"Drug Therapy, Combination",N,
20193,DescriptorName,D006801,20178709,,,7,Humans,N,
20194,DescriptorName,D008297,20178709,,,8,Male,N,
20195,DescriptorName,D008727,20178709,,,9,Methotrexate,N,
20196,QualifierName,Q000009,20178709,,,9,,Y,adverse effects
20197,DescriptorName,D008875,20178709,,,10,Middle Aged,N,
20198,DescriptorName,D010493,20178709,,,11,Pericarditis,N,
20199,QualifierName,Q000139,20178709,,,11,,Y,chemically induced
20200,DescriptorName,D010998,20178709,,,12,Pleurisy,N,
20201,QualifierName,Q000139,20178709,,,12,,Y,chemically induced
20202,DescriptorName,D011565,20178709,,,13,Psoriasis,N,
20203,QualifierName,Q000188,20178709,,,13,,Y,drug therapy
20204,Chemical,D000935,20185472,Antifungal Agents,0,,,,
20205,Chemical,D017964,20185472,Itraconazole,304NUG5GF4,,,,
20206,DescriptorName,D000368,20185472,,,1,Aged,N,
20207,DescriptorName,D000935,20185472,,,2,Antifungal Agents,N,
20208,QualifierName,Q000009,20185472,,,2,,Y,adverse effects
20209,DescriptorName,D001229,20185472,,,3,"Aspergillosis, Allergic Bronchopulmonary",N,
20210,QualifierName,Q000097,20185472,,,3,,N,blood
20211,DescriptorName,D004305,20185472,,,4,"Dose-Response Relationship, Drug",N,
20212,DescriptorName,D005260,20185472,,,5,Female,N,
20213,DescriptorName,D006801,20185472,,,6,Humans,N,
20214,DescriptorName,D017964,20185472,,,7,Itraconazole,N,
20215,QualifierName,Q000009,20185472,,,7,,Y,adverse effects
20216,DescriptorName,D008134,20185472,,,8,Long-Term Care,N,
20217,DescriptorName,D008297,20185472,,,9,Male,N,
20218,DescriptorName,D008875,20185472,,,10,Middle Aged,N,
20219,DescriptorName,D009165,20185472,,,11,"Mycobacterium Infections, Nontuberculous",N,
20220,QualifierName,Q000097,20185472,,,11,,N,blood
20221,DescriptorName,D055732,20185472,,,12,Pulmonary Aspergillosis,N,
20222,QualifierName,Q000097,20185472,,,12,,N,blood
20223,DescriptorName,D014202,20185472,,,13,Tremor,N,
20224,QualifierName,Q000097,20185472,,,13,,N,blood
20225,Chemical,D000305,20190474,Adrenal Cortex Hormones,0,,,,
20226,Chemical,D000927,20190474,Anticonvulsants,0,,,,
20227,Chemical,D007555,20190474,Isoxazoles,0,,,,
20228,Chemical,D000078305,20190474,Zonisamide,459384H98V,,,,
20229,DescriptorName,D058186,20190474,,,1,Acute Kidney Injury,N,
20230,QualifierName,Q000175,20190474,,,1,,Y,diagnosis
20231,DescriptorName,D000305,20190474,,,2,Adrenal Cortex Hormones,N,
20232,QualifierName,Q000627,20190474,,,2,,N,therapeutic use
20233,DescriptorName,D000328,20190474,,,3,Adult,N,
20234,DescriptorName,D000927,20190474,,,4,Anticonvulsants,N,
20235,QualifierName,Q000009,20190474,,,4,,Y,adverse effects
20236,DescriptorName,D004342,20190474,,,5,Drug Hypersensitivity,N,
20237,QualifierName,Q000150,20190474,,,5,,Y,complications
20238,DescriptorName,D004827,20190474,,,6,Epilepsy,N,
20239,QualifierName,Q000188,20190474,,,6,,N,drug therapy
20240,DescriptorName,D005076,20190474,,,7,Exanthema,N,
20241,QualifierName,Q000139,20190474,,,7,,N,chemically induced
20242,DescriptorName,D006801,20190474,,,8,Humans,N,
20243,DescriptorName,D007555,20190474,,,9,Isoxazoles,N,
20244,QualifierName,Q000009,20190474,,,9,,Y,adverse effects
20245,DescriptorName,D008297,20190474,,,10,Male,N,
20246,DescriptorName,D010328,20190474,,,11,Patch Tests,N,
20247,DescriptorName,D016896,20190474,,,12,Treatment Outcome,N,
20248,DescriptorName,D000078305,20190474,,,13,Zonisamide,N,
20249,Chemical,D000081222,20199429,Monocyclic Sesquiterpenes,0,,,,
20250,Chemical,D010936,20199429,Plant Extracts,0,,,,
20251,Chemical,D012717,20199429,Sesquiterpenes,0,,,,
20252,Chemical,C004497,20199429,bisabolol,24WE03BX2T,,,,
20253,DescriptorName,D020843,20199429,,,1,Chamomile,Y,
20254,DescriptorName,D002648,20199429,,,2,Child,N,
20255,DescriptorName,D002675,20199429,,,3,"Child, Preschool",N,
20256,DescriptorName,D017449,20199429,,,4,"Dermatitis, Allergic Contact",N,
20257,QualifierName,Q000209,20199429,,,4,,Y,etiology
20258,DescriptorName,D003876,20199429,,,5,"Dermatitis, Atopic",N,
20259,QualifierName,Q000188,20199429,,,5,,Y,drug therapy
20260,DescriptorName,D005260,20199429,,,6,Female,N,
20261,DescriptorName,D006801,20199429,,,7,Humans,N,
20262,DescriptorName,D008297,20199429,,,8,Male,N,
20263,DescriptorName,D000081222,20199429,,,9,Monocyclic Sesquiterpenes,N,
20264,DescriptorName,D010936,20199429,,,10,Plant Extracts,N,
20265,QualifierName,Q000009,20199429,,,10,,Y,adverse effects
20266,DescriptorName,D012717,20199429,,,11,Sesquiterpenes,N,
20267,QualifierName,Q000009,20199429,,,11,,Y,adverse effects
20268,Chemical,D016756,20203465,"Immunoglobulins, Intravenous",0,,,,
20269,Chemical,D007155,20203465,Immunologic Factors,0,,,,
20270,Chemical,D013395,20203465,Sucrose,57-50-1,,,,
20271,DescriptorName,D058186,20203465,,,1,Acute Kidney Injury,N,
20272,QualifierName,Q000139,20203465,,,1,,Y,chemically induced
20273,DescriptorName,D000369,20203465,,,2,"Aged, 80 and over",N,
20274,DescriptorName,D005260,20203465,,,3,Female,N,
20275,DescriptorName,D006801,20203465,,,4,Humans,N,
20276,DescriptorName,D016756,20203465,,,5,"Immunoglobulins, Intravenous",N,
20277,QualifierName,Q000008,20203465,,,5,,N,administration & dosage
20278,DescriptorName,D007155,20203465,,,6,Immunologic Factors,N,
20279,QualifierName,Q000008,20203465,,,6,,N,administration & dosage
20280,DescriptorName,D009157,20203465,,,7,Myasthenia Gravis,N,
20281,QualifierName,Q000150,20203465,,,7,,N,complications
20282,DescriptorName,D013395,20203465,,,8,Sucrose,N,
20283,QualifierName,Q000008,20203465,,,8,,N,administration & dosage
20284,Chemical,D008094,2022118,Lithium,9FN79X2M3F,,,,
20285,DescriptorName,D000328,2022118,,,1,Adult,N,
20286,DescriptorName,D001714,2022118,,,2,Bipolar Disorder,N,
20287,QualifierName,Q000150,2022118,,,2,,Y,complications
20288,DescriptorName,D002032,2022118,,,3,Bulimia,N,
20289,QualifierName,Q000150,2022118,,,3,,Y,complications
20290,DescriptorName,D015897,2022118,,,4,Comorbidity,N,
20291,DescriptorName,D005260,2022118,,,5,Female,N,
20292,DescriptorName,D006801,2022118,,,6,Humans,N,
20293,DescriptorName,D008094,2022118,,,7,Lithium,N,
20294,QualifierName,Q000009,2022118,,,7,,N,adverse effects
20295,Chemical,D000900,20234160,Anti-Bacterial Agents,0,,,,
20296,Chemical,D000893,20234160,Anti-Inflammatory Agents,0,,,,
20297,Chemical,D014640,20234160,Vancomycin,6Q205EH1VU,,,,
20298,Chemical,D011239,20234160,Prednisolone,9PHQ9Y1OLM,,,,
20299,Chemical,D008775,20234160,Methylprednisolone,X4W7ZR7023,,,,
20300,DescriptorName,D000284,20234160,,,1,"Administration, Oral",N,
20301,DescriptorName,D000328,20234160,,,2,Adult,N,
20302,DescriptorName,D000707,20234160,,,3,Anaphylaxis,N,
20303,QualifierName,Q000139,20234160,,,3,,Y,chemically induced
20304,DescriptorName,D000900,20234160,,,4,Anti-Bacterial Agents,N,
20305,QualifierName,Q000008,20234160,,,4,,N,administration & dosage
20306,DescriptorName,D000893,20234160,,,5,Anti-Inflammatory Agents,N,
20307,QualifierName,Q000008,20234160,,,5,,N,administration & dosage
20308,DescriptorName,D005260,20234160,,,6,Female,N,
20309,DescriptorName,D006801,20234160,,,7,Humans,N,
20310,DescriptorName,D007223,20234160,,,8,Infant,N,
20311,DescriptorName,D008297,20234160,,,9,Male,N,
20312,DescriptorName,D016106,20234160,,,10,Methicillin Resistance,N,
20313,DescriptorName,D055624,20234160,,,11,Methicillin-Resistant Staphylococcus aureus,Y,
20314,DescriptorName,D008775,20234160,,,12,Methylprednisolone,N,
20315,QualifierName,Q000008,20234160,,,12,,N,administration & dosage
20316,DescriptorName,D008875,20234160,,,13,Middle Aged,N,
20317,DescriptorName,D011239,20234160,,,14,Prednisolone,N,
20318,QualifierName,Q000008,20234160,,,14,,N,administration & dosage
20319,DescriptorName,D013203,20234160,,,15,Staphylococcal Infections,N,
20320,QualifierName,Q000188,20234160,,,15,,Y,drug therapy
20321,DescriptorName,D013997,20234160,,,16,Time Factors,N,
20322,DescriptorName,D016896,20234160,,,17,Treatment Outcome,N,
20323,DescriptorName,D014640,20234160,,,18,Vancomycin,N,
20324,QualifierName,Q000008,20234160,,,18,,N,administration & dosage
20325,Chemical,D006594,2028358,Hexoprenaline,G9L6B3W684,,,,
20326,DescriptorName,D000328,2028358,,,1,Adult,N,
20327,DescriptorName,D005260,2028358,,,2,Female,N,
20328,DescriptorName,D006594,2028358,,,3,Hexoprenaline,N,
20329,QualifierName,Q000009,2028358,,,3,,Y,adverse effects
20330,DescriptorName,D006801,2028358,,,4,Humans,N,
20331,DescriptorName,D007752,2028358,,,5,"Obstetric Labor, Premature",N,
20332,QualifierName,Q000188,2028358,,,5,,Y,drug therapy
20333,DescriptorName,D011247,2028358,,,6,Pregnancy,N,
20334,DescriptorName,D011654,2028358,,,7,Pulmonary Edema,N,
20335,QualifierName,Q000139,2028358,,,7,,Y,chemically induced
20336,Chemical,D047428,20298401,Protein Kinase Inhibitors,0,,,,
20337,Chemical,D011799,20298401,Quinazolines,0,,,,
20338,Chemical,D000069347,20298401,Erlotinib Hydrochloride,DA87705X9K,,,,
20339,DescriptorName,D002289,20298401,,,1,"Carcinoma, Non-Small-Cell Lung",N,
20340,QualifierName,Q000188,20298401,,,1,,Y,drug therapy
20341,DescriptorName,D003131,20298401,,,2,Combined Modality Therapy,N,
20342,DescriptorName,D000069347,20298401,,,3,Erlotinib Hydrochloride,N,
20343,DescriptorName,D017809,20298401,,,4,Fatal Outcome,N,
20344,DescriptorName,D006801,20298401,,,5,Humans,N,
20345,DescriptorName,D017563,20298401,,,6,"Lung Diseases, Interstitial",N,
20346,QualifierName,Q000139,20298401,,,6,,Y,chemically induced
20347,DescriptorName,D008175,20298401,,,7,Lung Neoplasms,N,
20348,QualifierName,Q000188,20298401,,,7,,Y,drug therapy
20349,DescriptorName,D008297,20298401,,,8,Male,N,
20350,DescriptorName,D008875,20298401,,,9,Middle Aged,N,
20351,DescriptorName,D047428,20298401,,,10,Protein Kinase Inhibitors,N,
20352,QualifierName,Q000009,20298401,,,10,,Y,adverse effects
20353,DescriptorName,D011799,20298401,,,11,Quinazolines,N,
20354,QualifierName,Q000009,20298401,,,11,,Y,adverse effects
20355,DescriptorName,D017564,20298401,,,12,Radiation Pneumonitis,N,
20356,QualifierName,Q000150,20298401,,,12,,Y,complications
20357,Chemical,D004837,20338114,Epinephrine,YKH834O4BH,,,,
20358,DescriptorName,D000287,20338114,,,1,"Administration, Topical",N,
20359,DescriptorName,D000328,20338114,,,2,Adult,N,
20360,DescriptorName,D017023,20338114,,,3,Coronary Angiography,N,
20361,DescriptorName,D003329,20338114,,,4,Coronary Vasospasm,N,
20362,QualifierName,Q000139,20338114,,,4,,N,chemically induced
20363,DescriptorName,D004562,20338114,,,5,Electrocardiography,N,
20364,DescriptorName,D004724,20338114,,,6,Endoscopy,N,
20365,DescriptorName,D004837,20338114,,,7,Epinephrine,N,
20366,QualifierName,Q000008,20338114,,,7,,Y,administration & dosage
20367,DescriptorName,D005260,20338114,,,8,Female,N,
20368,DescriptorName,D006470,20338114,,,9,Hemorrhage,N,
20369,QualifierName,Q000188,20338114,,,9,,Y,drug therapy
20370,DescriptorName,D006488,20338114,,,10,"Hemostasis, Surgical",Y,
20371,DescriptorName,D006801,20338114,,,11,Humans,N,
20372,DescriptorName,D006976,20338114,,,12,"Hypertension, Pulmonary",N,
20373,QualifierName,Q000139,20338114,,,12,,N,chemically induced
20374,DescriptorName,D007431,20338114,,,13,Intraoperative Complications,Y,
20375,DescriptorName,D008508,20338114,,,14,Medication Errors,Y,
20376,DescriptorName,D008875,20338114,,,15,Middle Aged,N,
20377,DescriptorName,D010256,20338114,,,16,Paranasal Sinuses,N,
20378,QualifierName,Q000187,20338114,,,16,,Y,drug effects
20379,DescriptorName,D012189,20338114,,,17,Retrospective Studies,N,
20380,Chemical,D000970,20349794,Antineoplastic Agents,0,,,,
20381,Chemical,D002945,20349794,Cisplatin,Q20Q21Q62J,,,,
20382,DescriptorName,D000328,20349794,,,1,Adult,N,
20383,DescriptorName,D000970,20349794,,,2,Antineoplastic Agents,N,
20384,QualifierName,Q000009,20349794,,,2,,Y,adverse effects
20385,DescriptorName,D018278,20349794,,,3,"Carcinoma, Neuroendocrine",N,
20386,QualifierName,Q000188,20349794,,,3,,Y,drug therapy
20387,DescriptorName,D002945,20349794,,,4,Cisplatin,N,
20388,QualifierName,Q000009,20349794,,,4,,Y,adverse effects
20389,DescriptorName,D005260,20349794,,,5,Female,N,
20390,DescriptorName,D006801,20349794,,,6,Humans,N,
20391,DescriptorName,D007177,20349794,,,7,Inappropriate ADH Syndrome,N,
20392,QualifierName,Q000139,20349794,,,7,,Y,chemically induced
20393,DescriptorName,D002583,20349794,,,8,Uterine Cervical Neoplasms,N,
20394,QualifierName,Q000188,20349794,,,8,,Y,drug therapy
20395,Chemical,D000925,20367573,Anticoagulants,0,,,,
20396,Chemical,D017984,20367573,Enoxaparin,0,,,,
20397,DescriptorName,D000293,20367573,,,1,Adolescent,N,
20398,DescriptorName,D000328,20367573,,,2,Adult,N,
20399,DescriptorName,D000925,20367573,,,3,Anticoagulants,N,
20400,QualifierName,Q000009,20367573,,,3,,Y,adverse effects
20401,DescriptorName,D017984,20367573,,,4,Enoxaparin,N,
20402,QualifierName,Q000009,20367573,,,4,,Y,adverse effects
20403,DescriptorName,D005260,20367573,,,5,Female,N,
20404,DescriptorName,D006801,20367573,,,6,Humans,N,
20405,DescriptorName,D007231,20367573,,,7,"Infant, Newborn",N,
20406,DescriptorName,D007232,20367573,,,8,"Infant, Newborn, Diseases",N,
20407,QualifierName,Q000188,20367573,,,8,,N,drug therapy
20408,DescriptorName,D011247,20367573,,,9,Pregnancy,N,
20409,DescriptorName,D013922,20367573,,,10,Thrombocytosis,N,
20410,QualifierName,Q000139,20367573,,,10,,Y,chemically induced
20411,DescriptorName,D013927,20367573,,,11,Thrombosis,N,
20412,QualifierName,Q000188,20367573,,,11,,N,drug therapy
20413,Chemical,D000911,20378385,"Antibodies, Monoclonal",0,,,,
20414,Chemical,D061067,20378385,"Antibodies, Monoclonal, Humanized",0,,,,
20415,Chemical,D018501,20378385,Antirheumatic Agents,0,,,,
20416,Chemical,D014409,20378385,Tumor Necrosis Factor-alpha,0,,,,
20417,Chemical,D000068879,20378385,Adalimumab,FYS6T7F842,,,,
20418,DescriptorName,D000068879,20378385,,,1,Adalimumab,N,
20419,DescriptorName,D000911,20378385,,,2,"Antibodies, Monoclonal",N,
20420,QualifierName,Q000008,20378385,,,2,,N,administration & dosage
20421,DescriptorName,D061067,20378385,,,3,"Antibodies, Monoclonal, Humanized",N,
20422,DescriptorName,D018501,20378385,,,4,Antirheumatic Agents,N,
20423,QualifierName,Q000008,20378385,,,4,,Y,administration & dosage
20424,DescriptorName,D001172,20378385,,,5,"Arthritis, Rheumatoid",N,
20425,QualifierName,Q000150,20378385,,,5,,N,complications
20426,DescriptorName,D006801,20378385,,,6,Humans,N,
20427,DescriptorName,D016867,20378385,,,7,Immunocompromised Host,N,
20428,DescriptorName,D007898,20378385,,,8,"Leishmaniasis, Visceral",N,
20429,QualifierName,Q000150,20378385,,,8,,N,complications
20430,DescriptorName,D055501,20378385,,,9,Macrophage Activation Syndrome,N,
20431,QualifierName,Q000150,20378385,,,9,,N,complications
20432,DescriptorName,D008297,20378385,,,10,Male,N,
20433,DescriptorName,D008875,20378385,,,11,Middle Aged,N,
20434,DescriptorName,D014409,20378385,,,12,Tumor Necrosis Factor-alpha,N,
20435,QualifierName,Q000037,20378385,,,12,,N,antagonists & inhibitors
20436,Chemical,D011346,2038845,Prochlorperazine,YHP6YLT61T,,,,
20437,DescriptorName,D000328,2038845,,,1,Adult,N,
20438,DescriptorName,D004342,2038845,,,2,Drug Hypersensitivity,N,
20439,QualifierName,Q000209,2038845,,,2,,Y,etiology
20440,DescriptorName,D004826,2038845,,,3,Epiglottitis,N,
20441,QualifierName,Q000139,2038845,,,3,,Y,chemically induced
20442,DescriptorName,D005260,2038845,,,4,Female,N,
20443,DescriptorName,D005759,2038845,,,5,Gastroenteritis,N,
20444,QualifierName,Q000188,2038845,,,5,,Y,drug therapy
20445,DescriptorName,D006801,2038845,,,6,Humans,N,
20446,DescriptorName,D011346,2038845,,,7,Prochlorperazine,N,
20447,QualifierName,Q000008,2038845,,,7,,N,administration & dosage
20448,Chemical,D018501,20397038,Antirheumatic Agents,0,,,,
20449,Chemical,D006886,20397038,Hydroxychloroquine,4QWG6N8QKH,,,,
20450,DescriptorName,D018501,20397038,,,1,Antirheumatic Agents,N,
20451,QualifierName,Q000009,20397038,,,1,,Y,adverse effects
20452,DescriptorName,D015350,20397038,,,2,Contrast Sensitivity,N,
20453,QualifierName,Q000502,20397038,,,2,,N,physiology
20454,DescriptorName,D018450,20397038,,,3,Disease Progression,N,
20455,DescriptorName,D004596,20397038,,,4,Electroretinography,N,
20456,DescriptorName,D005260,20397038,,,5,Female,N,
20457,DescriptorName,D005451,20397038,,,6,Fluorescein Angiography,N,
20458,DescriptorName,D005500,20397038,,,7,Follow-Up Studies,N,
20459,DescriptorName,D006801,20397038,,,8,Humans,N,
20460,DescriptorName,D006886,20397038,,,9,Hydroxychloroquine,N,
20461,QualifierName,Q000009,20397038,,,9,,Y,adverse effects
20462,DescriptorName,D008180,20397038,,,10,"Lupus Erythematosus, Systemic",N,
20463,QualifierName,Q000188,20397038,,,10,,N,drug therapy
20464,DescriptorName,D008875,20397038,,,11,Middle Aged,N,
20465,DescriptorName,D012160,20397038,,,12,Retina,N,
20466,QualifierName,Q000187,20397038,,,12,,N,drug effects
20467,DescriptorName,D012164,20397038,,,13,Retinal Diseases,N,
20468,QualifierName,Q000139,20397038,,,13,,Y,chemically induced
20469,DescriptorName,D012607,20397038,,,14,Scotoma,N,
20470,QualifierName,Q000503,20397038,,,14,,N,physiopathology
20471,DescriptorName,D014792,20397038,,,15,Visual Acuity,N,
20472,QualifierName,Q000187,20397038,,,15,,N,drug effects
20473,DescriptorName,D014794,20397038,,,16,Visual Fields,N,
20474,QualifierName,Q000187,20397038,,,16,,N,drug effects
20475,Chemical,D000900,20412003,Anti-Bacterial Agents,0,,,,
20476,Chemical,D015662,20412003,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
20477,DescriptorName,D000900,20412003,,,1,Anti-Bacterial Agents,N,
20478,QualifierName,Q000008,20412003,,,1,,N,administration & dosage
20479,DescriptorName,D056486,20412003,,,2,Chemical and Drug Induced Liver Injury,Y,
20480,QualifierName,Q000097,20412003,,,2,,N,blood
20481,DescriptorName,D002648,20412003,,,3,Child,N,
20482,DescriptorName,D004342,20412003,,,4,Drug Hypersensitivity,N,
20483,QualifierName,Q000097,20412003,,,4,,N,blood
20484,DescriptorName,D042241,20412003,,,5,Early Diagnosis,N,
20485,DescriptorName,D004802,20412003,,,6,Eosinophilia,N,
20486,QualifierName,Q000139,20412003,,,6,,N,chemically induced
20487,DescriptorName,D006801,20412003,,,7,Humans,N,
20488,DescriptorName,D008099,20412003,,,8,Liver,N,
20489,QualifierName,Q000187,20412003,,,8,,N,drug effects
20490,DescriptorName,D008297,20412003,,,9,Male,N,
20491,DescriptorName,D055624,20412003,,,10,Methicillin-Resistant Staphylococcus aureus,N,
20492,DescriptorName,D013203,20412003,,,11,Staphylococcal Infections,N,
20493,QualifierName,Q000188,20412003,,,11,,N,drug therapy
20494,DescriptorName,D016896,20412003,,,12,Treatment Outcome,N,
20495,DescriptorName,D015662,20412003,,,13,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
20496,QualifierName,Q000008,20412003,,,13,,N,administration & dosage
20497,Chemical,D000638,2042691,Amiodarone,N3RQ532IUT,,,,
20498,DescriptorName,D000638,2042691,,,1,Amiodarone,N,
20499,QualifierName,Q000009,2042691,,,1,,Y,adverse effects
20500,DescriptorName,D005260,2042691,,,2,Female,N,
20501,DescriptorName,D006042,2042691,,,3,Goiter,N,
20502,QualifierName,Q000139,2042691,,,3,,Y,chemically induced
20503,DescriptorName,D006801,2042691,,,4,Humans,N,
20504,DescriptorName,D007037,2042691,,,5,Hypothyroidism,N,
20505,QualifierName,Q000139,2042691,,,5,,Y,chemically induced
20506,DescriptorName,D008875,2042691,,,6,Middle Aged,N,
20507,DescriptorName,D013617,2042691,,,7,"Tachycardia, Supraventricular",N,
20508,QualifierName,Q000188,2042691,,,7,,N,drug therapy
20509,DescriptorName,D013971,2042691,,,8,Thyrotoxicosis,N,
20510,QualifierName,Q000139,2042691,,,8,,N,chemically induced
20511,Chemical,D065095,20465622,Calcineurin Inhibitors,0,,,,
20512,Chemical,D007166,20465622,Immunosuppressive Agents,0,,,,
20513,Chemical,D047908,20465622,Intracellular Signaling Peptides and Proteins,0,,,,
20514,Chemical,C546842,20465622,"MTOR protein, human",EC 2.7.1.1,,,,
20515,Chemical,D058570,20465622,TOR Serine-Threonine Kinases,EC 2.7.1.1,,,,
20516,Chemical,D017346,20465622,Protein-Serine-Threonine Kinases,EC 2.7.11.1,,,,
20517,Chemical,D020123,20465622,Sirolimus,W36ZG6FT64,,,,
20518,DescriptorName,D000284,20465622,,,1,"Administration, Oral",N,
20519,DescriptorName,D006502,20465622,,,2,Budd-Chiari Syndrome,N,
20520,QualifierName,Q000188,20465622,,,2,,Y,drug therapy
20521,DescriptorName,D065095,20465622,,,3,Calcineurin Inhibitors,Y,
20522,DescriptorName,D002648,20465622,,,4,Child,N,
20523,DescriptorName,D006801,20465622,,,5,Humans,N,
20524,DescriptorName,D007166,20465622,,,6,Immunosuppressive Agents,N,
20525,QualifierName,Q000009,20465622,,,6,,Y,adverse effects
20526,DescriptorName,D047908,20465622,,,7,Intracellular Signaling Peptides and Proteins,N,
20527,QualifierName,Q000037,20465622,,,7,,Y,antagonists & inhibitors
20528,DescriptorName,D008297,20465622,,,8,Male,N,
20529,DescriptorName,D017346,20465622,,,9,Protein-Serine-Threonine Kinases,N,
20530,QualifierName,Q000037,20465622,,,9,,Y,antagonists & inhibitors
20531,DescriptorName,D012720,20465622,,,10,Severity of Illness Index,N,
20532,DescriptorName,D020123,20465622,,,11,Sirolimus,N,
20533,QualifierName,Q000009,20465622,,,11,,Y,adverse effects
20534,DescriptorName,D013281,20465622,,,12,"Stomatitis, Aphthous",N,
20535,QualifierName,Q000139,20465622,,,12,,Y,chemically induced
20536,DescriptorName,D058570,20465622,,,13,TOR Serine-Threonine Kinases,N,
20537,DescriptorName,D014060,20465622,,,14,Tongue Diseases,N,
20538,QualifierName,Q000139,20465622,,,14,,N,chemically induced
20539,Chemical,D008775,2048579,Methylprednisolone,X4W7ZR7023,,,,
20540,DescriptorName,D058186,2048579,,,1,Acute Kidney Injury,N,
20541,QualifierName,Q000139,2048579,,,1,,Y,chemically induced
20542,DescriptorName,D000328,2048579,,,2,Adult,N,
20543,DescriptorName,D000368,2048579,,,3,Aged,N,
20544,DescriptorName,D005260,2048579,,,4,Female,N,
20545,DescriptorName,D006801,2048579,,,5,Humans,N,
20546,DescriptorName,D007668,2048579,,,6,Kidney,N,
20547,QualifierName,Q000187,2048579,,,6,,N,drug effects
20548,DescriptorName,D007674,2048579,,,7,Kidney Diseases,N,
20549,QualifierName,Q000188,2048579,,,7,,Y,drug therapy
20550,DescriptorName,D007677,2048579,,,8,Kidney Function Tests,N,
20551,DescriptorName,D008181,2048579,,,9,Lupus Nephritis,N,
20552,QualifierName,Q000188,2048579,,,9,,Y,drug therapy
20553,DescriptorName,D008297,2048579,,,10,Male,N,
20554,DescriptorName,D008775,2048579,,,11,Methylprednisolone,N,
20555,QualifierName,Q000008,2048579,,,11,,N,administration & dosage
20556,DescriptorName,D008875,2048579,,,12,Middle Aged,N,
20557,DescriptorName,D009404,2048579,,,13,Nephrotic Syndrome,N,
20558,QualifierName,Q000188,2048579,,,13,,Y,drug therapy
20559,Chemical,D001379,2051906,Azathioprine,MRK240IY2L,,,,
20560,DescriptorName,D001379,2051906,,,1,Azathioprine,N,
20561,QualifierName,Q000009,2051906,,,1,,Y,adverse effects
20562,DescriptorName,D001653,2051906,,,2,"Bile Ducts, Intrahepatic",N,
20563,QualifierName,Q000473,2051906,,,2,,Y,pathology
20564,DescriptorName,D001706,2051906,,,3,Biopsy,N,
20565,DescriptorName,D002780,2051906,,,4,"Cholestasis, Intrahepatic",N,
20566,QualifierName,Q000139,2051906,,,4,,Y,chemically induced
20567,DescriptorName,D006801,2051906,,,5,Humans,N,
20568,DescriptorName,D008297,2051906,,,6,Male,N,
20569,DescriptorName,D008875,2051906,,,7,Middle Aged,N,
20570,DescriptorName,D009220,2051906,,,8,Myositis,N,
20571,QualifierName,Q000188,2051906,,,8,,N,drug therapy
20572,Chemical,D001786,2063999,Blood Glucose,0,,,,
20573,Chemical,D002264,2063999,Carboxylic Acids,0,,,,
20574,Chemical,C016030,2063999,pantogab,1977-33-9,,,,
20575,Chemical,D010205,2063999,Pantothenic Acid,19F5HK2737,,,,
20576,Chemical,D005680,2063999,gamma-Aminobutyric Acid,56-12-2,,,,
20577,DescriptorName,D000208,2063999,,,1,Acute Disease,N,
20578,DescriptorName,D001786,2063999,,,2,Blood Glucose,N,
20579,QualifierName,Q000378,2063999,,,2,,N,metabolism
20580,DescriptorName,D001927,2063999,,,3,Brain Diseases,N,
20581,QualifierName,Q000139,2063999,,,3,,Y,chemically induced
20582,DescriptorName,D002264,2063999,,,4,Carboxylic Acids,N,
20583,QualifierName,Q000652,2063999,,,4,,N,urine
20584,DescriptorName,D002675,2063999,,,5,"Child, Preschool",N,
20585,DescriptorName,D005260,2063999,,,6,Female,N,
20586,DescriptorName,D006801,2063999,,,7,Humans,N,
20587,DescriptorName,D008607,2063999,,,8,Intellectual Disability,N,
20588,QualifierName,Q000188,2063999,,,8,,Y,drug therapy
20589,DescriptorName,D010205,2063999,,,9,Pantothenic Acid,N,
20590,QualifierName,Q000009,2063999,,,9,,N,adverse effects
20591,DescriptorName,D015518,2063999,,,10,Rett Syndrome,N,
20592,QualifierName,Q000139,2063999,,,10,,Y,chemically induced
20593,DescriptorName,D005680,2063999,,,11,gamma-Aminobutyric Acid,N,
20594,QualifierName,Q000009,2063999,,,11,,N,adverse effects
20595,Chemical,D011803,2076372,Quinine,A7V27PHC7A,,,,
20596,DescriptorName,D000328,2076372,,,1,Adult,N,
20597,DescriptorName,D002908,2076372,,,2,Chronic Disease,N,
20598,DescriptorName,D005260,2076372,,,3,Female,N,
20599,DescriptorName,D006801,2076372,,,4,Humans,N,
20600,DescriptorName,D010787,2076372,,,5,Photosensitivity Disorders,N,
20601,QualifierName,Q000139,2076372,,,5,,Y,chemically induced
20602,DescriptorName,D011565,2076372,,,6,Psoriasis,N,
20603,QualifierName,Q000188,2076372,,,6,,N,drug therapy
20604,DescriptorName,D011803,2076372,,,7,Quinine,N,
20605,QualifierName,Q000009,2076372,,,7,,Y,adverse effects
20606,DescriptorName,D012008,2076372,,,8,Recurrence,N,
20607,DescriptorName,D014467,2076372,,,9,Ultraviolet Therapy,N,
20608,QualifierName,Q000009,2076372,,,9,,N,adverse effects
20609,Chemical,D000970,2104570,Antineoplastic Agents,0,,,,
20610,Chemical,D008937,2104570,Mitomycins,0,,,,
20611,Chemical,D005009,2104570,Ethoglucid,4F9KUA0T4D,,,,
20612,Chemical,D016685,2104570,Mitomycin,50SG953SK6,,,,
20613,Chemical,D004317,2104570,Doxorubicin,80168379AG,,,,
20614,DescriptorName,D000368,2104570,,,1,Aged,N,
20615,DescriptorName,D000970,2104570,,,2,Antineoplastic Agents,N,
20616,QualifierName,Q000009,2104570,,,2,,Y,adverse effects
20617,DescriptorName,D004317,2104570,,,3,Doxorubicin,N,
20618,QualifierName,Q000009,2104570,,,3,,N,adverse effects
20619,DescriptorName,D005009,2104570,,,4,Ethoglucid,N,
20620,QualifierName,Q000009,2104570,,,4,,N,adverse effects
20621,DescriptorName,D005260,2104570,,,5,Female,N,
20622,DescriptorName,D006801,2104570,,,6,Humans,N,
20623,DescriptorName,D015470,2104570,,,7,"Leukemia, Myeloid, Acute",N,
20624,QualifierName,Q000139,2104570,,,7,,Y,chemically induced
20625,DescriptorName,D008228,2104570,,,8,"Lymphoma, Non-Hodgkin",N,
20626,QualifierName,Q000139,2104570,,,8,,Y,chemically induced
20627,DescriptorName,D008297,2104570,,,9,Male,N,
20628,DescriptorName,D008875,2104570,,,10,Middle Aged,N,
20629,DescriptorName,D016685,2104570,,,11,Mitomycin,N,
20630,DescriptorName,D008937,2104570,,,12,Mitomycins,N,
20631,QualifierName,Q000009,2104570,,,12,,N,adverse effects
20632,DescriptorName,D001749,2104570,,,13,Urinary Bladder Neoplasms,N,
20633,QualifierName,Q000188,2104570,,,13,,Y,drug therapy
20634,Chemical,D002245,2113320,Carbon Dioxide,142M471B3J,,,,
20635,Chemical,D003520,2113320,Cyclophosphamide,8N3DW7272P,,,,
20636,Chemical,D011239,2113320,Prednisolone,9PHQ9Y1OLM,,,,
20637,DescriptorName,D000328,2113320,,,1,Adult,N,
20638,DescriptorName,D002245,2113320,,,2,Carbon Dioxide,N,
20639,DescriptorName,D003520,2113320,,,3,Cyclophosphamide,N,
20640,QualifierName,Q000009,2113320,,,3,,N,adverse effects
20641,DescriptorName,D014890,2113320,,,4,Granulomatosis with Polyangiitis,N,
20642,QualifierName,Q000150,2113320,,,4,,Y,complications
20643,DescriptorName,D006801,2113320,,,5,Humans,N,
20644,DescriptorName,D053685,2113320,,,6,Laser Therapy,N,
20645,DescriptorName,D011239,2113320,,,7,Prednisolone,N,
20646,QualifierName,Q000627,2113320,,,7,,N,therapeutic use
20647,DescriptorName,D014135,2113320,,,8,Tracheal Stenosis,N,
20648,QualifierName,Q000139,2113320,,,8,,N,chemically induced
20649,Chemical,D010959,2116935,Tissue Plasminogen Activator,EC 3.4.21.68,,,,
20650,DescriptorName,D000368,2116935,,,1,Aged,N,
20651,DescriptorName,D005260,2116935,,,2,Female,N,
20652,DescriptorName,D006470,2116935,,,3,Hemorrhage,N,
20653,QualifierName,Q000139,2116935,,,3,,Y,chemically induced
20654,DescriptorName,D006801,2116935,,,4,Humans,N,
20655,DescriptorName,D007022,2116935,,,5,Hypotension,N,
20656,QualifierName,Q000209,2116935,,,5,,N,etiology
20657,DescriptorName,D009203,2116935,,,6,Myocardial Infarction,N,
20658,QualifierName,Q000188,2116935,,,6,,N,drug therapy
20659,DescriptorName,D013161,2116935,,,7,Splenic Rupture,N,
20660,QualifierName,Q000139,2116935,,,7,,Y,chemically induced
20661,DescriptorName,D010959,2116935,,,8,Tissue Plasminogen Activator,N,
20662,QualifierName,Q000009,2116935,,,8,,Y,adverse effects
20663,Chemical,D017373,2140997,Cyproterone Acetate,4KM2BN5JHF,,,,
20664,Chemical,D003534,2140997,Cyproterone,E61Q31EK2F,,,,
20665,Chemical,D001219,2140997,Aspartate Aminotransferases,EC 2.6.1.1,,,,
20666,Chemical,D001663,2140997,Bilirubin,RFM9X3LJ49,,,,
20667,DescriptorName,D000230,2140997,,,1,Adenocarcinoma,N,
20668,QualifierName,Q000188,2140997,,,1,,N,drug therapy
20669,DescriptorName,D000368,2140997,,,2,Aged,N,
20670,DescriptorName,D001219,2140997,,,3,Aspartate Aminotransferases,N,
20671,QualifierName,Q000097,2140997,,,3,,N,blood
20672,DescriptorName,D001663,2140997,,,4,Bilirubin,N,
20673,QualifierName,Q000097,2140997,,,4,,N,blood
20674,DescriptorName,D056486,2140997,,,5,Chemical and Drug Induced Liver Injury,N,
20675,QualifierName,Q000097,2140997,,,5,,N,blood
20676,DescriptorName,D003534,2140997,,,6,Cyproterone,N,
20677,QualifierName,Q000009,2140997,,,6,,Y,adverse effects
20678,DescriptorName,D017373,2140997,,,7,Cyproterone Acetate,N,
20679,DescriptorName,D006801,2140997,,,8,Humans,N,
20680,DescriptorName,D008099,2140997,,,9,Liver,N,
20681,QualifierName,Q000473,2140997,,,9,,N,pathology
20682,DescriptorName,D008297,2140997,,,10,Male,N,
20683,DescriptorName,D011471,2140997,,,11,Prostatic Neoplasms,N,
20684,QualifierName,Q000188,2140997,,,11,,N,drug therapy
20685,Chemical,D007483,2144305,Iothalamic Acid,16CHD79MIX,,,,
20686,Chemical,D004009,2144305,Dicloxacillin,COF19H7WBK,,,,
20687,Chemical,D006854,2144305,Hydrocortisone,WI4X0X7BPJ,,,,
20688,DescriptorName,D004009,2144305,,,1,Dicloxacillin,N,
20689,QualifierName,Q000627,2144305,,,1,,N,therapeutic use
20690,DescriptorName,D003875,2144305,,,2,Drug Eruptions,N,
20691,QualifierName,Q000188,2144305,,,2,,N,drug therapy
20692,DescriptorName,D005260,2144305,,,3,Female,N,
20693,DescriptorName,D006801,2144305,,,4,Humans,N,
20694,DescriptorName,D006854,2144305,,,5,Hydrocortisone,N,
20695,QualifierName,Q000627,2144305,,,5,,N,therapeutic use
20696,DescriptorName,D007483,2144305,,,6,Iothalamic Acid,N,
20697,QualifierName,Q000009,2144305,,,6,,Y,adverse effects
20698,DescriptorName,D008875,2144305,,,7,Middle Aged,N,
20699,DescriptorName,D012008,2144305,,,8,Recurrence,N,
20700,DescriptorName,D012880,2144305,,,9,Skin Pigmentation,N,
20701,QualifierName,Q000187,2144305,,,9,,Y,drug effects
20702,Chemical,D006118,2147700,Griseofulvin,32HRV3E3D5,,,,
20703,DescriptorName,D000328,2147700,,,1,Adult,N,
20704,DescriptorName,D000368,2147700,,,2,Aged,N,
20705,DescriptorName,D003881,2147700,,,3,Dermatomycoses,N,
20706,QualifierName,Q000175,2147700,,,3,,Y,diagnosis
20707,DescriptorName,D003937,2147700,,,4,"Diagnosis, Differential",N,
20708,DescriptorName,D003875,2147700,,,5,Drug Eruptions,N,
20709,QualifierName,Q000175,2147700,,,5,,Y,diagnosis
20710,DescriptorName,D005260,2147700,,,6,Female,N,
20711,DescriptorName,D006118,2147700,,,7,Griseofulvin,N,
20712,QualifierName,Q000008,2147700,,,7,,N,administration & dosage
20713,DescriptorName,D006801,2147700,,,8,Humans,N,
20714,DescriptorName,D008180,2147700,,,9,"Lupus Erythematosus, Systemic",N,
20715,QualifierName,Q000188,2147700,,,9,,Y,drug therapy
20716,DescriptorName,D008864,2147700,,,10,Microsporum,Y,
20717,DescriptorName,D014005,2147700,,,11,Tinea,N,
20718,QualifierName,Q000175,2147700,,,11,,N,diagnosis
20719,DescriptorName,D014249,2147700,,,12,Trichophyton,N,
20720,Chemical,D011838,2154663,Radiation-Sensitizing Agents,0,,,,
20721,Chemical,D000616,2154663,Aminoglutethimide,0O54ZQ14I9,,,,
20722,DescriptorName,D000616,2154663,,,1,Aminoglutethimide,N,
20723,QualifierName,Q000633,2154663,,,1,,Y,toxicity
20724,DescriptorName,D001859,2154663,,,2,Bone Neoplasms,N,
20725,QualifierName,Q000188,2154663,,,2,,N,drug therapy
20726,DescriptorName,D001943,2154663,,,3,Breast Neoplasms,N,
20727,DescriptorName,D002285,2154663,,,4,"Carcinoma, Intraductal, Noninfiltrating",N,
20728,QualifierName,Q000188,2154663,,,4,,N,drug therapy
20729,DescriptorName,D003875,2154663,,,5,Drug Eruptions,N,
20730,QualifierName,Q000209,2154663,,,5,,Y,etiology
20731,DescriptorName,D004342,2154663,,,6,Drug Hypersensitivity,N,
20732,QualifierName,Q000209,2154663,,,6,,Y,etiology
20733,DescriptorName,D005260,2154663,,,7,Female,N,
20734,DescriptorName,D006801,2154663,,,8,Humans,N,
20735,DescriptorName,D011838,2154663,,,9,Radiation-Sensitizing Agents,N,
20736,QualifierName,Q000633,2154663,,,9,,Y,toxicity
20737,Chemical,D004967,2161782,Estrogens,0,,,,
20738,Chemical,D013629,2161782,Tamoxifen,094ZI81Y45,,,,
20739,DescriptorName,D000230,2161782,,,1,Adenocarcinoma,Y,
20740,QualifierName,Q000139,2161782,,,1,,N,chemically induced
20741,DescriptorName,D000328,2161782,,,2,Adult,N,
20742,DescriptorName,D000368,2161782,,,3,Aged,N,
20743,DescriptorName,D001943,2161782,,,4,Breast Neoplasms,Y,
20744,QualifierName,Q000188,2161782,,,4,,N,drug therapy
20745,DescriptorName,D002285,2161782,,,5,"Carcinoma, Intraductal, Noninfiltrating",Y,
20746,QualifierName,Q000188,2161782,,,5,,N,drug therapy
20747,DescriptorName,D004967,2161782,,,6,Estrogens,N,
20748,QualifierName,Q000009,2161782,,,6,,N,adverse effects
20749,DescriptorName,D005260,2161782,,,7,Female,N,
20750,DescriptorName,D006801,2161782,,,8,Humans,N,
20751,DescriptorName,D008875,2161782,,,9,Middle Aged,N,
20752,DescriptorName,D009378,2161782,,,10,"Neoplasms, Multiple Primary",Y,
20753,DescriptorName,D012307,2161782,,,11,Risk Factors,N,
20754,DescriptorName,D013629,2161782,,,12,Tamoxifen,N,
20755,QualifierName,Q000009,2161782,,,12,,N,adverse effects
20756,DescriptorName,D014594,2161782,,,13,Uterine Neoplasms,Y,
20757,QualifierName,Q000139,2161782,,,13,,N,chemically induced
20758,Chemical,D004221,2196696,Disulfiram,TR3MLJ1UAI,,,,
20759,DescriptorName,D000437,2196696,,,1,Alcoholism,N,
20760,QualifierName,Q000188,2196696,,,1,,N,drug therapy
20761,DescriptorName,D056486,2196696,,,2,Chemical and Drug Induced Liver Injury,N,
20762,QualifierName,Q000209,2196696,,,2,,Y,etiology
20763,DescriptorName,D004221,2196696,,,3,Disulfiram,N,
20764,QualifierName,Q000009,2196696,,,3,,Y,adverse effects
20765,DescriptorName,D006801,2196696,,,4,Humans,N,
20766,DescriptorName,D008297,2196696,,,5,Male,N,
20767,DescriptorName,D008875,2196696,,,6,Middle Aged,N,
20768,Chemical,D002955,2204409,Leucovorin,Q573I9DVLP,,,,
20769,Chemical,D008727,2204409,Methotrexate,YL5FZ2Y5U1,,,,
20770,DescriptorName,D000293,2204409,,,1,Adolescent,N,
20771,DescriptorName,D004305,2204409,,,2,"Dose-Response Relationship, Drug",N,
20772,DescriptorName,D005260,2204409,,,3,Female,N,
20773,DescriptorName,D006801,2204409,,,4,Humans,N,
20774,DescriptorName,D002955,2204409,,,5,Leucovorin,N,
20775,QualifierName,Q000627,2204409,,,5,,Y,therapeutic use
20776,DescriptorName,D007968,2204409,,,6,"Leukoencephalopathy, Progressive Multifocal",N,
20777,QualifierName,Q000139,2204409,,,6,,Y,chemically induced
20778,DescriptorName,D008727,2204409,,,7,Methotrexate,N,
20779,QualifierName,Q000009,2204409,,,7,,Y,adverse effects
20780,Chemical,D006493,2212262,Heparin,9005-49-6,,,,
20781,DescriptorName,D058186,2212262,,,1,Acute Kidney Injury,N,
20782,QualifierName,Q000188,2212262,,,1,,N,drug therapy
20783,DescriptorName,D003937,2212262,,,2,"Diagnosis, Differential",N,
20784,DescriptorName,D006440,2212262,,,3,Hemofiltration,N,
20785,QualifierName,Q000009,2212262,,,3,,Y,adverse effects
20786,DescriptorName,D006493,2212262,,,4,Heparin,N,
20787,QualifierName,Q000008,2212262,,,4,,N,administration & dosage
20788,DescriptorName,D006801,2212262,,,5,Humans,N,
20789,DescriptorName,D008297,2212262,,,6,Male,N,
20790,DescriptorName,D008875,2212262,,,7,Middle Aged,N,
20791,DescriptorName,D018805,2212262,,,8,Sepsis,N,
20792,QualifierName,Q000150,2212262,,,8,,N,complications
20793,DescriptorName,D013921,2212262,,,9,Thrombocytopenia,N,
20794,QualifierName,Q000139,2212262,,,9,,Y,chemically induced
20795,DescriptorName,D013927,2212262,,,10,Thrombosis,N,
20796,QualifierName,Q000209,2212262,,,10,,Y,etiology
20797,Chemical,D000534,2219619,Alum Compounds,0,,,,
20798,Chemical,C041524,2219619,aluminum sulfate,34S289N54E,,,,
20799,Chemical,D000535,2219619,Aluminum,CPD4NFA903,,,,
20800,DescriptorName,D000283,2219619,,,1,"Administration, Intravesical",N,
20801,DescriptorName,D000293,2219619,,,2,Adolescent,N,
20802,DescriptorName,D000534,2219619,,,3,Alum Compounds,N,
20803,QualifierName,Q000008,2219619,,,3,,Y,administration & dosage
20804,DescriptorName,D000535,2219619,,,4,Aluminum,N,
20805,QualifierName,Q000506,2219619,,,4,,Y,poisoning
20806,DescriptorName,D003556,2219619,,,5,Cystitis,N,
20807,QualifierName,Q000188,2219619,,,5,,Y,drug therapy
20808,DescriptorName,D005260,2219619,,,6,Female,N,
20809,DescriptorName,D006470,2219619,,,7,Hemorrhage,N,
20810,QualifierName,Q000188,2219619,,,7,,Y,drug therapy
20811,DescriptorName,D006801,2219619,,,8,Humans,N,
20812,DescriptorName,D007507,2219619,,,9,Therapeutic Irrigation,N,
20813,DescriptorName,D000971,2224786,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
20814,QualifierName,Q000009,2224786,,,1,,Y,adverse effects
20815,DescriptorName,D001996,2224786,,,2,Bronchopneumonia,N,
20816,QualifierName,Q000139,2224786,,,2,,N,chemically induced
20817,DescriptorName,D002294,2224786,,,3,"Carcinoma, Squamous Cell",N,
20818,QualifierName,Q000188,2224786,,,3,,Y,drug therapy
20819,DescriptorName,D005260,2224786,,,4,Female,N,
20820,DescriptorName,D005355,2224786,,,5,Fibrosis,N,
20821,DescriptorName,D006258,2224786,,,6,Head and Neck Neoplasms,N,
20822,QualifierName,Q000188,2224786,,,6,,Y,drug therapy
20823,DescriptorName,D006463,2224786,,,7,Hemolytic-Uremic Syndrome,N,
20824,QualifierName,Q000139,2224786,,,7,,Y,chemically induced
20825,DescriptorName,D006470,2224786,,,8,Hemorrhage,N,
20826,QualifierName,Q000139,2224786,,,8,,N,chemically induced
20827,DescriptorName,D006801,2224786,,,9,Humans,N,
20828,DescriptorName,D007668,2224786,,,10,Kidney,N,
20829,QualifierName,Q000187,2224786,,,10,,N,drug effects
20830,DescriptorName,D008875,2224786,,,11,Middle Aged,N,
20831,DescriptorName,D011650,2224786,,,12,Pulmonary Alveoli,N,
20832,QualifierName,Q000187,2224786,,,12,,N,drug effects
20833,Chemical,D009824,2229534,Ointments,0,,,,
20834,Chemical,D008012,2229534,Lidocaine,98PI200987,,,,
20835,DescriptorName,D005260,2229534,,,1,Female,N,
20836,DescriptorName,D006801,2229534,,,2,Humans,N,
20837,DescriptorName,D008012,2229534,,,3,Lidocaine,N,
20838,QualifierName,Q000008,2229534,,,3,,N,administration & dosage
20839,DescriptorName,D016410,2229534,,,4,"Lymphoma, T-Cell, Cutaneous",N,
20840,QualifierName,Q000378,2229534,,,4,,N,metabolism
20841,DescriptorName,D008875,2229534,,,5,Middle Aged,N,
20842,DescriptorName,D009824,2229534,,,6,Ointments,N,
20843,DescriptorName,D010146,2229534,,,7,Pain,N,
20844,QualifierName,Q000188,2229534,,,7,,N,drug therapy
20845,DescriptorName,D012869,2229534,,,8,Skin Absorption,Y,
20846,Chemical,D011506,2234880,Proteins,0,,,,
20847,Chemical,D009568,2234880,Nitrendipine,9B627AW319,,,,
20848,DescriptorName,D000368,2234880,,,1,Aged,N,
20849,DescriptorName,D004789,2234880,,,2,Enzyme Activation,N,
20850,QualifierName,Q000187,2234880,,,2,,N,drug effects
20851,DescriptorName,D005494,2234880,,,3,Folic Acid Deficiency,N,
20852,QualifierName,Q000139,2234880,,,3,,N,chemically induced
20853,DescriptorName,D005885,2234880,,,4,Gingival Hyperplasia,N,
20854,QualifierName,Q000139,2234880,,,4,,Y,chemically induced
20855,DescriptorName,D006801,2234880,,,5,Humans,N,
20856,DescriptorName,D006973,2234880,,,6,Hypertension,N,
20857,QualifierName,Q000188,2234880,,,6,,N,drug therapy
20858,DescriptorName,D008297,2234880,,,7,Male,N,
20859,DescriptorName,D009568,2234880,,,8,Nitrendipine,N,
20860,QualifierName,Q000009,2234880,,,8,,Y,adverse effects
20861,DescriptorName,D011506,2234880,,,9,Proteins,N,
20862,QualifierName,Q000037,2234880,,,9,,N,antagonists & inhibitors
20863,Chemical,D013411,2241449,Sulfadiazine,0N7609K889,,,,
20864,Chemical,D011739,2241449,Pyrimethamine,Z3614QOX8W,,,,
20865,DescriptorName,D000163,2241449,,,1,Acquired Immunodeficiency Syndrome,N,
20866,QualifierName,Q000150,2241449,,,1,,Y,complications
20867,DescriptorName,D058186,2241449,,,2,Acute Kidney Injury,N,
20868,QualifierName,Q000139,2241449,,,2,,Y,chemically induced
20869,DescriptorName,D000328,2241449,,,3,Adult,N,
20870,DescriptorName,D003460,2241449,,,4,Crystallization,N,
20871,DescriptorName,D004359,2241449,,,5,"Drug Therapy, Combination",N,
20872,DescriptorName,D004660,2241449,,,6,Encephalitis,N,
20873,QualifierName,Q000150,2241449,,,6,,N,complications
20874,DescriptorName,D006801,2241449,,,7,Humans,N,
20875,DescriptorName,D008297,2241449,,,8,Male,N,
20876,DescriptorName,D011739,2241449,,,9,Pyrimethamine,N,
20877,QualifierName,Q000008,2241449,,,9,,N,administration & dosage
20878,DescriptorName,D013411,2241449,,,10,Sulfadiazine,N,
20879,QualifierName,Q000008,2241449,,,10,,N,administration & dosage
20880,DescriptorName,D014123,2241449,,,11,Toxoplasmosis,N,
20881,QualifierName,Q000150,2241449,,,11,,N,complications
20882,Chemical,D005472,2250853,Fluorouracil,U3P01618RT,,,,
20883,DescriptorName,D000867,2250853,,,1,Anterior Chamber,N,
20884,QualifierName,Q000473,2250853,,,1,,N,pathology
20885,DescriptorName,D002387,2250853,,,2,Cataract Extraction,N,
20886,QualifierName,Q000009,2250853,,,2,,Y,adverse effects
20887,DescriptorName,D002455,2250853,,,3,Cell Division,N,
20888,QualifierName,Q000187,2250853,,,3,,N,drug effects
20889,DescriptorName,D003316,2250853,,,4,Corneal Diseases,N,
20890,QualifierName,Q000150,2250853,,,4,,N,complications
20891,DescriptorName,D004848,2250853,,,5,Epithelium,N,
20892,QualifierName,Q000473,2250853,,,5,,N,pathology
20893,DescriptorName,D015353,2250853,,,6,Eye Enucleation,N,
20894,DescriptorName,D005260,2250853,,,7,Female,N,
20895,DescriptorName,D005472,2250853,,,8,Fluorouracil,N,
20896,QualifierName,Q000627,2250853,,,8,,Y,therapeutic use
20897,DescriptorName,D005901,2250853,,,9,Glaucoma,N,
20898,QualifierName,Q000209,2250853,,,9,,Y,etiology
20899,DescriptorName,D006801,2250853,,,10,Humans,N,
20900,DescriptorName,D008875,2250853,,,11,Middle Aged,N,
20901,DescriptorName,D014130,2250853,,,12,Trabeculectomy,N,
20902,Chemical,D000863,2257522,Antacids,0,,,,
20903,Chemical,D004338,2257522,Drug Combinations,0,,,,
20904,Chemical,D010710,2257522,Phosphates,0,,,,
20905,Chemical,C013591,2257522,"aluminum hydroxide, magnesium hydroxide, drug combination",37317-08-1,,,,
20906,Chemical,D013392,2257522,Sucralfate,54182-58-0,,,,
20907,Chemical,D000536,2257522,Aluminum Hydroxide,5QB0T2IUN0,,,,
20908,Chemical,D008276,2257522,Magnesium Hydroxide,NBZ3QY004S,,,,
20909,DescriptorName,D000328,2257522,,,1,Adult,N,
20910,DescriptorName,D000536,2257522,,,2,Aluminum Hydroxide,N,
20911,QualifierName,Q000009,2257522,,,2,,Y,adverse effects
20912,DescriptorName,D000863,2257522,,,3,Antacids,N,
20913,QualifierName,Q000009,2257522,,,3,,N,adverse effects
20914,DescriptorName,D004338,2257522,,,4,Drug Combinations,N,
20915,DescriptorName,D004381,2257522,,,5,Duodenal Ulcer,N,
20916,QualifierName,Q000188,2257522,,,5,,N,drug therapy
20917,DescriptorName,D005260,2257522,,,6,Female,N,
20918,DescriptorName,D006801,2257522,,,7,Humans,N,
20919,DescriptorName,D008276,2257522,,,8,Magnesium Hydroxide,N,
20920,QualifierName,Q000009,2257522,,,8,,Y,adverse effects
20921,DescriptorName,D010018,2257522,,,9,Osteomalacia,N,
20922,QualifierName,Q000097,2257522,,,9,,N,blood
20923,DescriptorName,D010710,2257522,,,10,Phosphates,N,
20924,QualifierName,Q000097,2257522,,,10,,Y,blood
20925,DescriptorName,D013392,2257522,,,11,Sucralfate,N,
20926,QualifierName,Q000009,2257522,,,11,,Y,adverse effects
20927,Chemical,D010406,2276822,Penicillins,0,,,,
20928,Chemical,D002437,2276822,Cefazolin,IHS69L0Y4T,,,,
20929,DescriptorName,D000328,2276822,,,1,Adult,N,
20930,DescriptorName,D002437,2276822,,,2,Cefazolin,N,
20931,QualifierName,Q000494,2276822,,,2,,N,pharmacology
20932,DescriptorName,D003131,2276822,,,3,Combined Modality Therapy,N,
20933,DescriptorName,D004342,2276822,,,4,Drug Hypersensitivity,Y,
20934,DescriptorName,D004697,2276822,,,5,"Endocarditis, Bacterial",N,
20935,QualifierName,Q000188,2276822,,,5,,N,drug therapy
20936,DescriptorName,D006089,2276822,,,6,Gram-Negative Anaerobic Bacteria,N,
20937,QualifierName,Q000187,2276822,,,6,,N,drug effects
20938,DescriptorName,D006801,2276822,,,7,Humans,N,
20939,DescriptorName,D008297,2276822,,,8,Male,N,
20940,DescriptorName,D008943,2276822,,,9,Mitral Valve,N,
20941,QualifierName,Q000601,2276822,,,9,,Y,surgery
20942,DescriptorName,D010406,2276822,,,10,Penicillins,N,
20943,QualifierName,Q000009,2276822,,,10,,Y,adverse effects
20944,Chemical,D000907,228648,"Antibodies, Bacterial",0,,,,
20945,Chemical,D011239,228648,Prednisolone,9PHQ9Y1OLM,,,,
20946,Chemical,D001379,228648,Azathioprine,MRK240IY2L,,,,
20947,DescriptorName,D000328,228648,,,1,Adult,N,
20948,DescriptorName,D000907,228648,,,2,"Antibodies, Bacterial",N,
20949,DescriptorName,D001379,228648,,,3,Azathioprine,N,
20950,QualifierName,Q000009,228648,,,3,,Y,adverse effects
20951,DescriptorName,D001925,228648,,,4,"Brain Damage, Chronic",N,
20952,QualifierName,Q000209,228648,,,4,,N,etiology
20953,DescriptorName,D003586,228648,,,5,Cytomegalovirus Infections,N,
20954,QualifierName,Q000150,228648,,,5,,N,complications
20955,DescriptorName,D005260,228648,,,6,Female,N,
20956,DescriptorName,D005315,228648,,,7,Fetal Diseases,N,
20957,QualifierName,Q000209,228648,,,7,,Y,etiology
20958,DescriptorName,D006801,228648,,,8,Humans,N,
20959,DescriptorName,D007165,228648,,,9,Immunosuppression,N,
20960,QualifierName,Q000009,228648,,,9,,Y,adverse effects
20961,DescriptorName,D007231,228648,,,10,"Infant, Newborn",N,
20962,DescriptorName,D008180,228648,,,11,"Lupus Erythematosus, Systemic",N,
20963,QualifierName,Q000188,228648,,,11,,Y,drug therapy
20964,DescriptorName,D011239,228648,,,12,Prednisolone,N,
20965,QualifierName,Q000009,228648,,,12,,Y,adverse effects
20966,DescriptorName,D011247,228648,,,13,Pregnancy,N,
20967,DescriptorName,D011248,228648,,,14,Pregnancy Complications,N,
20968,QualifierName,Q000188,228648,,,14,,Y,drug therapy
20969,DescriptorName,D011251,228648,,,15,"Pregnancy Complications, Infectious",N,
20970,QualifierName,Q000209,228648,,,15,,Y,etiology
20971,Chemical,D002945,2292051,Cisplatin,Q20Q21Q62J,,,,
20972,DescriptorName,D000368,2292051,,,1,Aged,N,
20973,DescriptorName,D002945,2292051,,,2,Cisplatin,N,
20974,QualifierName,Q000009,2292051,,,2,,Y,adverse effects
20975,DescriptorName,D003327,2292051,,,3,Coronary Disease,N,
20976,QualifierName,Q000139,2292051,,,3,,Y,chemically induced
20977,DescriptorName,D005260,2292051,,,4,Female,N,
20978,DescriptorName,D006801,2292051,,,5,Humans,N,
20979,DescriptorName,D006973,2292051,,,6,Hypertension,N,
20980,DescriptorName,D008297,2292051,,,7,Male,N,
20981,DescriptorName,D008875,2292051,,,8,Middle Aged,N,
20982,DescriptorName,D009369,2292051,,,9,Neoplasms,N,
20983,QualifierName,Q000188,2292051,,,9,,N,drug therapy
20984,DescriptorName,D012907,2292051,,,10,Smoking,N,
20985,Chemical,D017608,2295443,Chromium Compounds,0,,,,
20986,Chemical,D010710,2295443,Phosphates,0,,,,
20987,Chemical,D002857,2295443,Chromium,0R0008Q3JB,,,,
20988,Chemical,C509369,2295443,chromic phosphate,AQ86ZJ9U98,,,,
20989,DescriptorName,D002857,2295443,,,1,Chromium,N,
20990,QualifierName,Q000008,2295443,,,1,,N,administration & dosage
20991,DescriptorName,D017608,2295443,,,2,Chromium Compounds,Y,
20992,DescriptorName,D003108,2295443,,,3,Colonic Diseases,N,
20993,QualifierName,Q000209,2295443,,,3,,Y,etiology
20994,DescriptorName,D003536,2295443,,,4,Cystadenocarcinoma,N,
20995,QualifierName,Q000188,2295443,,,4,,Y,drug therapy
20996,DescriptorName,D005260,2295443,,,5,Female,N,
20997,DescriptorName,D006801,2295443,,,6,Humans,N,
20998,DescriptorName,D007416,2295443,,,7,Intestinal Perforation,N,
20999,QualifierName,Q000209,2295443,,,7,,Y,etiology
21000,DescriptorName,D008875,2295443,,,8,Middle Aged,N,
21001,DescriptorName,D010051,2295443,,,9,Ovarian Neoplasms,N,
21002,QualifierName,Q000188,2295443,,,9,,Y,drug therapy
21003,DescriptorName,D010710,2295443,,,10,Phosphates,N,
21004,QualifierName,Q000008,2295443,,,10,,N,administration & dosage
21005,Chemical,D003561,2297635,Cytarabine,04079A1RDZ,,,,
21006,Chemical,D008727,2297635,Methotrexate,YL5FZ2Y5U1,,,,
21007,DescriptorName,D000230,2297635,,,1,Adenocarcinoma,N,
21008,QualifierName,Q000188,2297635,,,1,,Y,drug therapy
21009,DescriptorName,D000328,2297635,,,2,Adult,N,
21010,DescriptorName,D000971,2297635,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
21011,QualifierName,Q000008,2297635,,,3,,N,administration & dosage
21012,DescriptorName,D001766,2297635,,,4,Blindness,N,
21013,QualifierName,Q000139,2297635,,,4,,Y,chemically induced
21014,DescriptorName,D001943,2297635,,,5,Breast Neoplasms,N,
21015,DescriptorName,D003128,2297635,,,6,Coma,N,
21016,QualifierName,Q000139,2297635,,,6,,Y,chemically induced
21017,DescriptorName,D003561,2297635,,,7,Cytarabine,N,
21018,QualifierName,Q000008,2297635,,,7,,N,administration & dosage
21019,DescriptorName,D003711,2297635,,,8,Demyelinating Diseases,N,
21020,QualifierName,Q000139,2297635,,,8,,N,chemically induced
21021,DescriptorName,D005260,2297635,,,9,Female,N,
21022,DescriptorName,D006801,2297635,,,10,Humans,N,
21023,DescriptorName,D007276,2297635,,,11,"Injections, Intraventricular",N,
21024,DescriptorName,D008577,2297635,,,12,Meningeal Neoplasms,N,
21025,QualifierName,Q000188,2297635,,,12,,Y,drug therapy
21026,DescriptorName,D008727,2297635,,,13,Methotrexate,N,
21027,QualifierName,Q000008,2297635,,,13,,N,administration & dosage
21028,Chemical,D001965,2299784,Bromides,0,,,,
21029,Chemical,D011729,2299784,Pyridostigmine Bromide,KVI301NA53,,,,
21030,DescriptorName,D001965,2299784,,,1,Bromides,N,
21031,QualifierName,Q000506,2299784,,,1,,Y,poisoning
21032,DescriptorName,D005260,2299784,,,2,Female,N,
21033,DescriptorName,D006801,2299784,,,3,Humans,N,
21034,DescriptorName,D008875,2299784,,,4,Middle Aged,N,
21035,DescriptorName,D009157,2299784,,,5,Myasthenia Gravis,N,
21036,QualifierName,Q000188,2299784,,,5,,Y,drug therapy
21037,DescriptorName,D011605,2299784,,,6,"Psychoses, Substance-Induced",N,
21038,QualifierName,Q000209,2299784,,,6,,N,etiology
21039,DescriptorName,D011729,2299784,,,7,Pyridostigmine Bromide,N,
21040,QualifierName,Q000008,2299784,,,7,,N,administration & dosage
21041,Chemical,D010276,2302898,Parasympatholytics,0,,,,
21042,Chemical,D009892,2302898,Opium,8008-60-4,,,,
21043,Chemical,C017652,2302898,paregoric,8029-99-0,,,,
21044,Chemical,D003975,2302898,Diazepam,Q3JTX2Q7TU,,,,
21045,Chemical,D008691,2302898,Methadone,UC6VBE7V1Z,,,,
21046,Chemical,D010634,2302898,Phenobarbital,YQE403BP4D,,,,
21047,DescriptorName,D000328,2302898,,,1,Adult,N,
21048,DescriptorName,D003975,2302898,,,2,Diazepam,Y,
21049,QualifierName,Q000009,2302898,,,2,,N,adverse effects
21050,DescriptorName,D004359,2302898,,,3,"Drug Therapy, Combination",N,
21051,DescriptorName,D005260,2302898,,,4,Female,N,
21052,DescriptorName,D006801,2302898,,,5,Humans,N,
21053,DescriptorName,D007231,2302898,,,6,"Infant, Newborn",N,
21054,DescriptorName,D007232,2302898,,,7,"Infant, Newborn, Diseases",N,
21055,QualifierName,Q000139,2302898,,,7,,Y,chemically induced
21056,DescriptorName,D008297,2302898,,,8,Male,N,
21057,DescriptorName,D008691,2302898,,,9,Methadone,N,
21058,QualifierName,Q000008,2302898,,,9,,Y,administration & dosage
21059,DescriptorName,D009892,2302898,,,10,Opium,N,
21060,QualifierName,Q000627,2302898,,,10,,N,therapeutic use
21061,DescriptorName,D010276,2302898,,,11,Parasympatholytics,N,
21062,QualifierName,Q000627,2302898,,,11,,N,therapeutic use
21063,DescriptorName,D010634,2302898,,,12,Phenobarbital,N,
21064,QualifierName,Q000627,2302898,,,12,,N,therapeutic use
21065,DescriptorName,D011247,2302898,,,13,Pregnancy,N,
21066,DescriptorName,D011248,2302898,,,14,Pregnancy Complications,N,
21067,QualifierName,Q000139,2302898,,,14,,Y,chemically induced
21068,DescriptorName,D013375,2302898,,,15,Substance Withdrawal Syndrome,N,
21069,QualifierName,Q000188,2302898,,,15,,N,drug therapy
21070,DescriptorName,D019966,2302898,,,16,Substance-Related Disorders,N,
21071,QualifierName,Q000150,2302898,,,16,,Y,complications
21072,DescriptorName,D013997,2302898,,,17,Time Factors,N,
21073,Chemical,D009553,2305654,Nimodipine,57WA9QZ5WH,,,,
21074,DescriptorName,D003108,2305654,,,1,Colonic Diseases,N,
21075,QualifierName,Q000139,2305654,,,1,,Y,chemically induced
21076,DescriptorName,D006801,2305654,,,2,Humans,N,
21077,DescriptorName,D007418,2305654,,,3,Intestinal Pseudo-Obstruction,N,
21078,QualifierName,Q000139,2305654,,,3,,Y,chemically induced
21079,DescriptorName,D008297,2305654,,,4,Male,N,
21080,DescriptorName,D008875,2305654,,,5,Middle Aged,N,
21081,DescriptorName,D009553,2305654,,,6,Nimodipine,N,
21082,QualifierName,Q000009,2305654,,,6,,Y,adverse effects
21083,DescriptorName,D013345,2305654,,,7,Subarachnoid Hemorrhage,N,
21084,QualifierName,Q000188,2305654,,,7,,N,drug therapy
21085,Chemical,D001786,2309833,Blood Glucose,0,,,,
21086,Chemical,D011245,2309833,Pregnadienes,0,,,,
21087,Chemical,D003613,2309833,Danazol,N29QWW3BUO,,,,
21088,DescriptorName,D000328,2309833,,,1,Adult,N,
21089,DescriptorName,D001786,2309833,,,2,Blood Glucose,N,
21090,QualifierName,Q000378,2309833,,,2,,N,metabolism
21091,DescriptorName,D003613,2309833,,,3,Danazol,N,
21092,QualifierName,Q000009,2309833,,,3,,Y,adverse effects
21093,DescriptorName,D003922,2309833,,,4,"Diabetes Mellitus, Type 1",N,
21094,QualifierName,Q000139,2309833,,,4,,Y,chemically induced
21095,DescriptorName,D004715,2309833,,,5,Endometriosis,N,
21096,QualifierName,Q000188,2309833,,,5,,N,drug therapy
21097,DescriptorName,D005260,2309833,,,6,Female,N,
21098,DescriptorName,D006801,2309833,,,7,Humans,N,
21099,DescriptorName,D011245,2309833,,,8,Pregnadienes,N,
21100,QualifierName,Q000009,2309833,,,8,,Y,adverse effects
21101,DescriptorName,D011247,2309833,,,9,Pregnancy,N,
21102,Chemical,D001786,2316232,Blood Glucose,0,,,,
21103,Chemical,D013453,2316232,Sulfonylurea Compounds,0,,,,
21104,Chemical,D015662,2316232,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
21105,Chemical,D005913,2316232,Glipizide,X7WDT95N5C,,,,
21106,DescriptorName,D000368,2316232,,,1,Aged,N,
21107,DescriptorName,D000369,2316232,,,2,"Aged, 80 and over",N,
21108,DescriptorName,D001786,2316232,,,3,Blood Glucose,N,
21109,QualifierName,Q000378,2316232,,,3,,N,metabolism
21110,DescriptorName,D003924,2316232,,,4,"Diabetes Mellitus, Type 2",N,
21111,QualifierName,Q000150,2316232,,,4,,N,complications
21112,DescriptorName,D004347,2316232,,,5,Drug Interactions,N,
21113,DescriptorName,D005913,2316232,,,6,Glipizide,N,
21114,QualifierName,Q000009,2316232,,,6,,Y,adverse effects
21115,DescriptorName,D006801,2316232,,,7,Humans,N,
21116,DescriptorName,D007003,2316232,,,8,Hypoglycemia,N,
21117,QualifierName,Q000139,2316232,,,8,,Y,chemically induced
21118,DescriptorName,D008297,2316232,,,9,Male,N,
21119,DescriptorName,D013453,2316232,,,10,Sulfonylurea Compounds,N,
21120,QualifierName,Q000009,2316232,,,10,,Y,adverse effects
21121,DescriptorName,D015662,2316232,,,11,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
21122,QualifierName,Q000009,2316232,,,11,,Y,adverse effects
21123,Chemical,D007069,2320800,Ifosfamide,UM20QQM95Y,,,,
21124,DescriptorName,D000971,2320800,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
21125,QualifierName,Q000627,2320800,,,1,,N,therapeutic use
21126,DescriptorName,D001002,2320800,,,2,Anuria,N,
21127,QualifierName,Q000139,2320800,,,2,,Y,chemically induced
21128,DescriptorName,D001943,2320800,,,3,Breast Neoplasms,N,
21129,QualifierName,Q000150,2320800,,,3,,N,complications
21130,DescriptorName,D004305,2320800,,,4,"Dose-Response Relationship, Drug",N,
21131,DescriptorName,D005260,2320800,,,5,Female,N,
21132,DescriptorName,D006801,2320800,,,6,Humans,N,
21133,DescriptorName,D007069,2320800,,,7,Ifosfamide,N,
21134,QualifierName,Q000008,2320800,,,7,,N,administration & dosage
21135,DescriptorName,D007684,2320800,,,8,Kidney Tubules,N,
21136,QualifierName,Q000187,2320800,,,8,,N,drug effects
21137,DescriptorName,D008875,2320800,,,9,Middle Aged,N,
21138,Chemical,D002939,2327115,Ciprofloxacin,5E8K9I0O4U,,,,
21139,Chemical,D003404,2327115,Creatinine,AYI8EX34EU,,,,
21140,DescriptorName,D000368,2327115,,,1,Aged,N,
21141,DescriptorName,D000369,2327115,,,2,"Aged, 80 and over",N,
21142,DescriptorName,D001806,2327115,,,3,Blood Urea Nitrogen,N,
21143,DescriptorName,D002939,2327115,,,4,Ciprofloxacin,N,
21144,QualifierName,Q000009,2327115,,,4,,Y,adverse effects
21145,DescriptorName,D003404,2327115,,,5,Creatinine,N,
21146,QualifierName,Q000097,2327115,,,5,,N,blood
21147,DescriptorName,D005260,2327115,,,6,Female,N,
21148,DescriptorName,D006801,2327115,,,7,Humans,N,
21149,DescriptorName,D007677,2327115,,,8,Kidney Function Tests,N,
21150,DescriptorName,D009395,2327115,,,9,"Nephritis, Interstitial",N,
21151,QualifierName,Q000139,2327115,,,9,,Y,chemically induced
21152,DescriptorName,D011014,2327115,,,10,Pneumonia,N,
21153,QualifierName,Q000188,2327115,,,10,,N,drug therapy
21154,Chemical,D004317,2329972,Doxorubicin,80168379AG,,,,
21155,DescriptorName,D000971,2329972,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
21156,QualifierName,Q000627,2329972,,,1,,N,therapeutic use
21157,DescriptorName,D001927,2329972,,,2,Brain Diseases,N,
21158,QualifierName,Q000139,2329972,,,2,,Y,chemically induced
21159,DescriptorName,D002648,2329972,,,3,Child,N,
21160,DescriptorName,D004317,2329972,,,4,Doxorubicin,N,
21161,QualifierName,Q000008,2329972,,,4,,N,administration & dosage
21162,DescriptorName,D005260,2329972,,,5,Female,N,
21163,DescriptorName,D006801,2329972,,,6,Humans,N,
21164,DescriptorName,D007278,2329972,,,7,"Injections, Spinal",N,
21165,DescriptorName,D008508,2329972,,,8,Medication Errors,Y,
21166,DescriptorName,D054198,2329972,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
21167,QualifierName,Q000188,2329972,,,9,,N,drug therapy
21168,Chemical,D002220,2332596,Carbamazepine,33CM23913M,,,,
21169,Chemical,D010672,2332596,Phenytoin,6158TKW0C5,,,,
21170,Chemical,D008775,2332596,Methylprednisolone,X4W7ZR7023,,,,
21171,Chemical,D010634,2332596,Phenobarbital,YQE403BP4D,,,,
21172,DescriptorName,D002220,2332596,,,1,Carbamazepine,N,
21173,QualifierName,Q000009,2332596,,,1,,N,adverse effects
21174,DescriptorName,D002470,2332596,,,2,Cell Survival,N,
21175,QualifierName,Q000187,2332596,,,2,,N,drug effects
21176,DescriptorName,D056486,2332596,,,3,Chemical and Drug Induced Liver Injury,N,
21177,QualifierName,Q000188,2332596,,,3,,N,drug therapy
21178,DescriptorName,D006801,2332596,,,4,Humans,N,
21179,DescriptorName,D007223,2332596,,,5,Infant,N,
21180,DescriptorName,D008214,2332596,,,6,Lymphocytes,N,
21181,QualifierName,Q000187,2332596,,,6,,N,drug effects
21182,DescriptorName,D008297,2332596,,,7,Male,N,
21183,DescriptorName,D008775,2332596,,,8,Methylprednisolone,N,
21184,QualifierName,Q000627,2332596,,,8,,N,therapeutic use
21185,DescriptorName,D010634,2332596,,,9,Phenobarbital,N,
21186,QualifierName,Q000009,2332596,,,9,,Y,adverse effects
21187,DescriptorName,D010672,2332596,,,10,Phenytoin,N,
21188,QualifierName,Q000009,2332596,,,10,,N,adverse effects
21189,Chemical,D001262,2347102,Atenolol,50VV3VW0TI,,,,
21190,DescriptorName,D000368,2347102,,,1,Aged,N,
21191,DescriptorName,D001262,2347102,,,2,Atenolol,N,
21192,QualifierName,Q000009,2347102,,,2,,Y,adverse effects
21193,DescriptorName,D006801,2347102,,,3,Humans,N,
21194,DescriptorName,D006973,2347102,,,4,Hypertension,N,
21195,QualifierName,Q000188,2347102,,,4,,N,drug therapy
21196,DescriptorName,D008223,2347102,,,5,Lymphoma,N,
21197,QualifierName,Q000139,2347102,,,5,,Y,chemically induced
21198,DescriptorName,D008297,2347102,,,6,Male,N,
21199,DescriptorName,D012867,2347102,,,7,Skin,N,
21200,QualifierName,Q000473,2347102,,,7,,N,pathology
21201,DescriptorName,D013577,2347102,,,8,Syndrome,N,
21202,Chemical,D013469,2357706,Sulpiride,7MNE9M8287,,,,
21203,DescriptorName,D000368,2357706,,,1,Aged,N,
21204,DescriptorName,D003863,2357706,,,2,Depression,N,
21205,QualifierName,Q000188,2357706,,,2,,N,drug therapy
21206,DescriptorName,D004409,2357706,,,3,"Dyskinesia, Drug-Induced",N,
21207,QualifierName,Q000209,2357706,,,3,,Y,etiology
21208,DescriptorName,D005260,2357706,,,4,Female,N,
21209,DescriptorName,D005767,2357706,,,5,Gastrointestinal Diseases,N,
21210,QualifierName,Q000188,2357706,,,5,,N,drug therapy
21211,DescriptorName,D006801,2357706,,,6,Humans,N,
21212,DescriptorName,D008297,2357706,,,7,Male,N,
21213,DescriptorName,D008875,2357706,,,8,Middle Aged,N,
21214,DescriptorName,D013469,2357706,,,9,Sulpiride,N,
21215,QualifierName,Q000009,2357706,,,9,,Y,adverse effects
21216,Chemical,D008727,2369419,Methotrexate,YL5FZ2Y5U1,,,,
21217,DescriptorName,D001172,2369419,,,1,"Arthritis, Rheumatoid",N,
21218,QualifierName,Q000150,2369419,,,1,,Y,complications
21219,DescriptorName,D005260,2369419,,,2,Female,N,
21220,DescriptorName,D006505,2369419,,,3,Hepatitis,N,
21221,QualifierName,Q000150,2369419,,,3,,Y,complications
21222,DescriptorName,D006801,2369419,,,4,Humans,N,
21223,DescriptorName,D008103,2369419,,,5,Liver Cirrhosis,N,
21224,QualifierName,Q000139,2369419,,,5,,Y,chemically induced
21225,DescriptorName,D008107,2369419,,,6,Liver Diseases,N,
21226,QualifierName,Q000209,2369419,,,6,,Y,etiology
21227,DescriptorName,D008727,2369419,,,7,Methotrexate,N,
21228,QualifierName,Q000009,2369419,,,7,,N,adverse effects
21229,DescriptorName,D008875,2369419,,,8,Middle Aged,N,
21230,DescriptorName,D009336,2369419,,,9,Necrosis,N,
21231,Chemical,D008727,2378415,Methotrexate,YL5FZ2Y5U1,,,,
21232,DescriptorName,D000293,2378415,,,1,Adolescent,N,
21233,DescriptorName,D003131,2378415,,,2,Combined Modality Therapy,N,
21234,DescriptorName,D004677,2378415,,,3,Encephalocele,N,
21235,QualifierName,Q000209,2378415,,,3,,Y,etiology
21236,DescriptorName,D005134,2378415,,,4,Eye Neoplasms,N,
21237,QualifierName,Q000188,2378415,,,4,,N,drug therapy
21238,DescriptorName,D005260,2378415,,,5,Female,N,
21239,DescriptorName,D006801,2378415,,,6,Humans,N,
21240,DescriptorName,D007262,2378415,,,7,"Infusions, Intravenous",N,
21241,QualifierName,Q000009,2378415,,,7,,N,adverse effects
21242,DescriptorName,D007427,2378415,,,8,Intracranial Pressure,N,
21243,DescriptorName,D008727,2378415,,,9,Methotrexate,N,
21244,QualifierName,Q000009,2378415,,,9,,Y,adverse effects
21245,DescriptorName,D009336,2378415,,,10,Necrosis,N,
21246,DescriptorName,D009378,2378415,,,11,"Neoplasms, Multiple Primary",Y,
21247,DescriptorName,D009381,2378415,,,12,"Neoplasms, Radiation-Induced",N,
21248,QualifierName,Q000150,2378415,,,12,,Y,complications
21249,DescriptorName,D009918,2378415,,,13,Orbital Neoplasms,N,
21250,QualifierName,Q000150,2378415,,,13,,Y,complications
21251,DescriptorName,D012516,2378415,,,14,Osteosarcoma,N,
21252,QualifierName,Q000150,2378415,,,14,,Y,complications
21253,DescriptorName,D012175,2378415,,,15,Retinoblastoma,N,
21254,QualifierName,Q000188,2378415,,,15,,N,drug therapy
21255,Chemical,D000212,2394154,Acyclovir,X4HES1O11F,,,,
21256,DescriptorName,D000212,2394154,,,1,Acyclovir,N,
21257,QualifierName,Q000009,2394154,,,1,,Y,adverse effects
21258,DescriptorName,D000368,2394154,,,2,Aged,N,
21259,DescriptorName,D005334,2394154,,,3,Fever,N,
21260,QualifierName,Q000139,2394154,,,3,,Y,chemically induced
21261,DescriptorName,D006563,2394154,,,4,Herpes Zoster Ophthalmicus,N,
21262,QualifierName,Q000188,2394154,,,4,,Y,drug therapy
21263,DescriptorName,D006801,2394154,,,5,Humans,N,
21264,DescriptorName,D008168,2394154,,,6,Lung,N,
21265,QualifierName,Q000000981,2394154,,,6,,N,diagnostic imaging
21266,DescriptorName,D008171,2394154,,,7,Lung Diseases,N,
21267,QualifierName,Q000139,2394154,,,7,,Y,chemically induced
21268,DescriptorName,D008297,2394154,,,8,Male,N,
21269,DescriptorName,D010996,2394154,,,9,Pleural Effusion,N,
21270,QualifierName,Q000139,2394154,,,9,,Y,chemically induced
21271,DescriptorName,D011859,2394154,,,10,Radiography,N,
21272,Chemical,D011803,2406680,Quinine,A7V27PHC7A,,,,
21273,DescriptorName,D000328,2406680,,,1,Adult,N,
21274,DescriptorName,D000818,2406680,,,2,Animals,N,
21275,DescriptorName,D001299,2406680,,,3,Audiometry,N,
21276,QualifierName,Q000379,2406680,,,3,,N,methods
21277,DescriptorName,D006319,2406680,,,4,"Hearing Loss, Sensorineural",N,
21278,QualifierName,Q000139,2406680,,,4,,Y,chemically induced
21279,DescriptorName,D006801,2406680,,,5,Humans,N,
21280,DescriptorName,D008288,2406680,,,6,Malaria,N,
21281,QualifierName,Q000188,2406680,,,6,,Y,drug therapy
21282,DescriptorName,D008297,2406680,,,7,Male,N,
21283,DescriptorName,D010963,2406680,,,8,Plasmodium falciparum,N,
21284,DescriptorName,D011803,2406680,,,9,Quinine,N,
21285,QualifierName,Q000009,2406680,,,9,,Y,adverse effects
21286,Chemical,D001761,2413037,Bleomycin,11056-06-7,,,,
21287,Chemical,D014747,2413037,Vinblastine,5V9KLZ54CY,,,,
21288,Chemical,D002945,2413037,Cisplatin,Q20Q21Q62J,,,,
21289,DescriptorName,D000328,2413037,,,1,Adult,N,
21290,DescriptorName,D000743,2413037,,,2,"Anemia, Hemolytic",N,
21291,QualifierName,Q000139,2413037,,,2,,Y,chemically induced
21292,DescriptorName,D000971,2413037,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
21293,QualifierName,Q000009,2413037,,,3,,Y,adverse effects
21294,DescriptorName,D001761,2413037,,,4,Bleomycin,N,
21295,QualifierName,Q000009,2413037,,,4,,N,adverse effects
21296,DescriptorName,D002945,2413037,,,5,Cisplatin,N,
21297,QualifierName,Q000009,2413037,,,5,,N,adverse effects
21298,DescriptorName,D005260,2413037,,,6,Female,N,
21299,DescriptorName,D006801,2413037,,,7,Humans,N,
21300,DescriptorName,D007984,2413037,,,8,Leydig Cell Tumor,N,
21301,QualifierName,Q000188,2413037,,,8,,N,drug therapy
21302,DescriptorName,D010051,2413037,,,9,Ovarian Neoplasms,N,
21303,QualifierName,Q000188,2413037,,,9,,N,drug therapy
21304,DescriptorName,D010386,2413037,,,10,Pelvic Neoplasms,N,
21305,QualifierName,Q000556,2413037,,,10,,N,secondary
21306,DescriptorName,D012707,2413037,,,11,Sertoli Cell Tumor,N,
21307,QualifierName,Q000188,2413037,,,11,,N,drug therapy
21308,DescriptorName,D013577,2413037,,,12,Syndrome,N,
21309,DescriptorName,D014511,2413037,,,13,Uremia,N,
21310,QualifierName,Q000139,2413037,,,13,,Y,chemically induced
21311,DescriptorName,D014747,2413037,,,14,Vinblastine,N,
21312,QualifierName,Q000009,2413037,,,14,,N,adverse effects
21313,Chemical,D001761,2417800,Bleomycin,11056-06-7,,,,
21314,DescriptorName,D001761,2417800,,,1,Bleomycin,N,
21315,QualifierName,Q000009,2417800,,,1,,Y,adverse effects
21316,DescriptorName,D004357,2417800,,,2,Drug Synergism,N,
21317,DescriptorName,D006801,2417800,,,3,Humans,N,
21318,DescriptorName,D008297,2417800,,,4,Male,N,
21319,DescriptorName,D008875,2417800,,,5,Middle Aged,N,
21320,DescriptorName,D009369,2417800,,,6,Neoplasms,N,
21321,QualifierName,Q000188,2417800,,,6,,N,drug therapy
21322,DescriptorName,D010102,2417800,,,7,Oxygen Inhalation Therapy,N,
21323,QualifierName,Q000009,2417800,,,7,,Y,adverse effects
21324,DescriptorName,D011014,2417800,,,8,Pneumonia,N,
21325,QualifierName,Q000139,2417800,,,8,,Y,chemically induced
21326,DescriptorName,D012306,2417800,,,9,Risk,N,
21327,Chemical,D011342,2429270,Procainamide,L39WTC366D,,,,
21328,DescriptorName,D004594,2429270,,,1,Electrophysiology,N,
21329,DescriptorName,D005260,2429270,,,2,Female,N,
21330,DescriptorName,D006801,2429270,,,3,Humans,N,
21331,DescriptorName,D008875,2429270,,,4,Middle Aged,N,
21332,DescriptorName,D011342,2429270,,,5,Procainamide,N,
21333,QualifierName,Q000009,2429270,,,5,,Y,adverse effects
21334,DescriptorName,D013610,2429270,,,6,Tachycardia,N,
21335,QualifierName,Q000139,2429270,,,6,,N,chemically induced
21336,DescriptorName,D014927,2429270,,,7,Wolff-Parkinson-White Syndrome,N,
21337,QualifierName,Q000150,2429270,,,7,,Y,complications
21338,Chemical,D000509,2442958,alpha-Fetoproteins,0,,,,
21339,Chemical,C048587,2442958,diethylstilbestrol monophosphate,47341-71-9,,,,
21340,Chemical,D004054,2442958,Diethylstilbestrol,731DCA35BT,,,,
21341,DescriptorName,D000236,2442958,,,1,Adenoma,N,
21342,QualifierName,Q000473,2442958,,,1,,N,pathology
21343,DescriptorName,D000368,2442958,,,2,Aged,N,
21344,DescriptorName,D006528,2442958,,,3,"Carcinoma, Hepatocellular",N,
21345,QualifierName,Q000473,2442958,,,3,,N,pathology
21346,DescriptorName,D004054,2442958,,,4,Diethylstilbestrol,N,
21347,QualifierName,Q000009,2442958,,,4,,N,adverse effects
21348,DescriptorName,D006801,2442958,,,5,Humans,N,
21349,DescriptorName,D008099,2442958,,,6,Liver,N,
21350,QualifierName,Q000473,2442958,,,6,,N,pathology
21351,DescriptorName,D008113,2442958,,,7,Liver Neoplasms,N,
21352,QualifierName,Q000473,2442958,,,7,,N,pathology
21353,DescriptorName,D008297,2442958,,,8,Male,N,
21354,DescriptorName,D011471,2442958,,,9,Prostatic Neoplasms,N,
21355,QualifierName,Q000188,2442958,,,9,,Y,drug therapy
21356,DescriptorName,D000509,2442958,,,10,alpha-Fetoproteins,N,
21357,QualifierName,Q000032,2442958,,,10,,N,analysis
21358,Chemical,D000638,2445709,Amiodarone,N3RQ532IUT,,,,
21359,DescriptorName,D000638,2445709,,,1,Amiodarone,N,
21360,QualifierName,Q000009,2445709,,,1,,Y,adverse effects
21361,DescriptorName,D001706,2445709,,,2,Biopsy,N,
21362,DescriptorName,D005117,2445709,,,3,"Cardiac Complexes, Premature",N,
21363,QualifierName,Q000188,2445709,,,3,,N,drug therapy
21364,DescriptorName,D002526,2445709,,,4,Cerebellar Diseases,N,
21365,QualifierName,Q000139,2445709,,,4,,Y,chemically induced
21366,DescriptorName,D005260,2445709,,,5,Female,N,
21367,DescriptorName,D006801,2445709,,,6,Humans,N,
21368,DescriptorName,D008875,2445709,,,7,Middle Aged,N,
21369,DescriptorName,D010523,2445709,,,8,Peripheral Nervous System Diseases,N,
21370,QualifierName,Q000139,2445709,,,8,,Y,chemically induced
21371,DescriptorName,D013497,2445709,,,9,Sural Nerve,N,
21372,QualifierName,Q000473,2445709,,,9,,N,pathology
21373,DescriptorName,D013577,2445709,,,10,Syndrome,N,
21374,DescriptorName,D013997,2445709,,,11,Time Factors,N,
21375,Chemical,D014667,2452936,Vasopressins,11000-17-2,,,,
21376,Chemical,D001761,2452936,Bleomycin,11056-06-7,,,,
21377,Chemical,D014750,2452936,Vincristine,5J49Q6B70F,,,,
21378,Chemical,D014747,2452936,Vinblastine,5V9KLZ54CY,,,,
21379,Chemical,D003606,2452936,Dacarbazine,7GR28W0FJI,,,,
21380,Chemical,D004317,2452936,Doxorubicin,80168379AG,,,,
21381,DescriptorName,D000328,2452936,,,1,Adult,N,
21382,DescriptorName,D000971,2452936,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
21383,QualifierName,Q000627,2452936,,,2,,N,therapeutic use
21384,DescriptorName,D001761,2452936,,,3,Bleomycin,N,
21385,QualifierName,Q000008,2452936,,,3,,N,administration & dosage
21386,DescriptorName,D003606,2452936,,,4,Dacarbazine,N,
21387,QualifierName,Q000008,2452936,,,4,,N,administration & dosage
21388,DescriptorName,D004317,2452936,,,5,Doxorubicin,N,
21389,QualifierName,Q000008,2452936,,,5,,N,administration & dosage
21390,DescriptorName,D005260,2452936,,,6,Female,N,
21391,DescriptorName,D006801,2452936,,,7,Humans,N,
21392,DescriptorName,D007010,2452936,,,8,Hyponatremia,N,
21393,QualifierName,Q000139,2452936,,,8,,Y,chemically induced
21394,DescriptorName,D007684,2452936,,,9,Kidney Tubules,N,
21395,QualifierName,Q000187,2452936,,,9,,N,drug effects
21396,DescriptorName,D008228,2452936,,,10,"Lymphoma, Non-Hodgkin",N,
21397,QualifierName,Q000188,2452936,,,10,,N,drug therapy
21398,DescriptorName,D014667,2452936,,,11,Vasopressins,N,
21399,QualifierName,Q000097,2452936,,,11,,N,blood
21400,DescriptorName,D014747,2452936,,,12,Vinblastine,N,
21401,QualifierName,Q000009,2452936,,,12,,Y,adverse effects
21402,DescriptorName,D014750,2452936,,,13,Vincristine,N,
21403,QualifierName,Q000008,2452936,,,13,,N,administration & dosage
21404,Chemical,D001761,2461837,Bleomycin,11056-06-7,,,,
21405,DescriptorName,D000163,2461837,,,1,Acquired Immunodeficiency Syndrome,N,
21406,QualifierName,Q000150,2461837,,,1,,Y,complications
21407,DescriptorName,D000328,2461837,,,2,Adult,N,
21408,DescriptorName,D001761,2461837,,,3,Bleomycin,N,
21409,QualifierName,Q000009,2461837,,,3,,Y,adverse effects
21410,DescriptorName,D006801,2461837,,,4,Humans,N,
21411,DescriptorName,D008297,2461837,,,5,Male,N,
21412,DescriptorName,D010859,2461837,,,6,Pigmentation Disorders,N,
21413,QualifierName,Q000139,2461837,,,6,,Y,chemically induced
21414,DescriptorName,D012514,2461837,,,7,"Sarcoma, Kaposi",N,
21415,QualifierName,Q000188,2461837,,,7,,Y,drug therapy
21416,DescriptorName,D012878,2461837,,,8,Skin Neoplasms,N,
21417,QualifierName,Q000188,2461837,,,8,,Y,drug therapy
21418,Chemical,D003911,2483959,Dextrans,0,,,,
21419,DescriptorName,D058186,2483959,,,1,Acute Kidney Injury,N,
21420,QualifierName,Q000139,2483959,,,1,,Y,chemically induced
21421,DescriptorName,D000368,2483959,,,2,Aged,N,
21422,DescriptorName,D003327,2483959,,,3,Coronary Disease,N,
21423,QualifierName,Q000188,2483959,,,3,,N,drug therapy
21424,DescriptorName,D003911,2483959,,,4,Dextrans,N,
21425,QualifierName,Q000009,2483959,,,4,,Y,adverse effects
21426,DescriptorName,D006801,2483959,,,5,Humans,N,
21427,DescriptorName,D008297,2483959,,,6,Male,N,
21428,DescriptorName,D010951,2483959,,,7,Plasma Exchange,N,
21429,Chemical,D008727,2505541,Methotrexate,YL5FZ2Y5U1,,,,
21430,DescriptorName,D000293,2505541,,,1,Adolescent,N,
21431,DescriptorName,D000328,2505541,,,2,Adult,N,
21432,DescriptorName,D001284,2505541,,,3,Atrophy,N,
21433,DescriptorName,D001921,2505541,,,4,Brain,N,
21434,QualifierName,Q000187,2505541,,,4,,N,drug effects
21435,DescriptorName,D001929,2505541,,,5,Brain Edema,N,
21436,QualifierName,Q000139,2505541,,,5,,N,chemically induced
21437,DescriptorName,D002648,2505541,,,6,Child,N,
21438,DescriptorName,D005260,2505541,,,7,Female,N,
21439,DescriptorName,D006801,2505541,,,8,Humans,N,
21440,DescriptorName,D008279,2505541,,,9,Magnetic Resonance Imaging,Y,
21441,DescriptorName,D008297,2505541,,,10,Male,N,
21442,DescriptorName,D008727,2505541,,,11,Methotrexate,N,
21443,QualifierName,Q000008,2505541,,,11,,N,administration & dosage
21444,DescriptorName,D009336,2505541,,,12,Necrosis,N,
21445,DescriptorName,D012516,2505541,,,13,Osteosarcoma,N,
21446,QualifierName,Q000188,2505541,,,13,,N,drug therapy
21447,Chemical,D001971,2523364,Bromocriptine,3A64E3G5ZO,,,,
21448,DescriptorName,D001706,2523364,,,1,Biopsy,N,
21449,DescriptorName,D001971,2523364,,,2,Bromocriptine,N,
21450,QualifierName,Q000009,2523364,,,2,,Y,adverse effects
21451,DescriptorName,D003875,2523364,,,3,Drug Eruptions,N,
21452,QualifierName,Q000209,2523364,,,3,,Y,etiology
21453,DescriptorName,D006801,2523364,,,4,Humans,N,
21454,DescriptorName,D006966,2523364,,,5,Hyperprolactinemia,N,
21455,QualifierName,Q000188,2523364,,,5,,N,drug therapy
21456,DescriptorName,D008297,2523364,,,6,Male,N,
21457,DescriptorName,D008875,2523364,,,7,Middle Aged,N,
21458,DescriptorName,D012594,2523364,,,8,"Scleroderma, Localized",N,
21459,QualifierName,Q000139,2523364,,,8,,Y,chemically induced
21460,DescriptorName,D012867,2523364,,,9,Skin,N,
21461,QualifierName,Q000473,2523364,,,9,,N,pathology
21462,Chemical,D003622,2532694,Dapsone,8W5C518302,,,,
21463,DescriptorName,D000328,2532694,,,1,Adult,N,
21464,DescriptorName,D003622,2532694,,,2,Dapsone,N,
21465,QualifierName,Q000009,2532694,,,2,,Y,adverse effects
21466,DescriptorName,D003873,2532694,,,3,"Dermatitis, Exfoliative",N,
21467,QualifierName,Q000139,2532694,,,3,,Y,chemically induced
21468,DescriptorName,D005260,2532694,,,4,Female,N,
21469,DescriptorName,D006801,2532694,,,5,Humans,N,
21470,DescriptorName,D015440,2532694,,,6,"Leprosy, Lepromatous",N,
21471,QualifierName,Q000188,2532694,,,6,,N,drug therapy
21472,DescriptorName,D009264,2532694,,,7,"Nails, Malformed",N,
21473,QualifierName,Q000139,2532694,,,7,,Y,chemically induced
21474,Chemical,D005473,2549018,Fluoxetine,01K63SUP8D,,,,
21475,Chemical,D012701,2549018,Serotonin,333DO1RDJY,,,,
21476,Chemical,D004298,2549018,Dopamine,VTD58H1Z2X,,,,
21477,DescriptorName,D000293,2549018,,,1,Adolescent,N,
21478,DescriptorName,D000328,2549018,,,2,Adult,N,
21479,DescriptorName,D017109,2549018,,,3,"Akathisia, Drug-Induced",Y,
21480,DescriptorName,D003866,2549018,,,4,Depressive Disorder,N,
21481,QualifierName,Q000188,2549018,,,4,,Y,drug therapy
21482,DescriptorName,D004298,2549018,,,5,Dopamine,N,
21483,QualifierName,Q000502,2549018,,,5,,N,physiology
21484,DescriptorName,D004409,2549018,,,6,"Dyskinesia, Drug-Induced",N,
21485,QualifierName,Q000503,2549018,,,6,,N,physiopathology
21486,DescriptorName,D005260,2549018,,,7,Female,N,
21487,DescriptorName,D005473,2549018,,,8,Fluoxetine,N,
21488,QualifierName,Q000009,2549018,,,8,,Y,adverse effects
21489,DescriptorName,D006801,2549018,,,9,Humans,N,
21490,DescriptorName,D008297,2549018,,,10,Male,N,
21491,DescriptorName,D009771,2549018,,,11,Obsessive-Compulsive Disorder,N,
21492,QualifierName,Q000188,2549018,,,11,,Y,drug therapy
21493,DescriptorName,D011595,2549018,,,12,Psychomotor Agitation,N,
21494,QualifierName,Q000503,2549018,,,12,,N,physiopathology
21495,DescriptorName,D012701,2549018,,,13,Serotonin,N,
21496,QualifierName,Q000502,2549018,,,13,,N,physiology
21497,DescriptorName,D009435,2549018,,,14,Synaptic Transmission,N,
21498,QualifierName,Q000187,2549018,,,14,,N,drug effects
21499,Chemical,D003561,2554727,Cytarabine,04079A1RDZ,,,,
21500,Chemical,D003630,2554727,Daunorubicin,ZS7284E0ZP,,,,
21501,DescriptorName,D000328,2554727,,,1,Adult,N,
21502,DescriptorName,D000971,2554727,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
21503,QualifierName,Q000627,2554727,,,2,,N,therapeutic use
21504,DescriptorName,D003561,2554727,,,3,Cytarabine,N,
21505,QualifierName,Q000008,2554727,,,3,,N,administration & dosage
21506,DescriptorName,D003630,2554727,,,4,Daunorubicin,N,
21507,QualifierName,Q000008,2554727,,,4,,N,administration & dosage
21508,DescriptorName,D003711,2554727,,,5,Demyelinating Diseases,N,
21509,QualifierName,Q000139,2554727,,,5,,Y,chemically induced
21510,DescriptorName,D006732,2554727,,,6,Horner Syndrome,N,
21511,QualifierName,Q000139,2554727,,,6,,Y,chemically induced
21512,DescriptorName,D006801,2554727,,,7,Humans,N,
21513,DescriptorName,D015473,2554727,,,8,"Leukemia, Promyelocytic, Acute",N,
21514,QualifierName,Q000188,2554727,,,8,,Y,drug therapy
21515,DescriptorName,D008297,2554727,,,9,Male,N,
21516,DescriptorName,D010523,2554727,,,10,Peripheral Nervous System Diseases,N,
21517,QualifierName,Q000139,2554727,,,10,,Y,chemically induced
21518,Chemical,D010396,2568058,Penicillamine,GNN1DV99GX,,,,
21519,DescriptorName,D000368,2568058,,,1,Aged,N,
21520,DescriptorName,D001172,2568058,,,2,"Arthritis, Rheumatoid",N,
21521,QualifierName,Q000188,2568058,,,2,,N,drug therapy
21522,DescriptorName,D005260,2568058,,,3,Female,N,
21523,DescriptorName,D006801,2568058,,,4,Humans,N,
21524,DescriptorName,D009260,2568058,,,5,Nail Diseases,N,
21525,QualifierName,Q000139,2568058,,,5,,Y,chemically induced
21526,DescriptorName,D010396,2568058,,,6,Penicillamine,N,
21527,QualifierName,Q000009,2568058,,,6,,Y,adverse effects
21528,DescriptorName,D012008,2568058,,,7,Recurrence,N,
21529,Chemical,D007074,2586773,Immunoglobulin G,0,,,,
21530,Chemical,D010400,2586773,Penicillin G,Q42T66VG0C,,,,
21531,Chemical,D007052,2586773,Ibuprofen,WK2XYI10QM,,,,
21532,DescriptorName,D000328,2586773,,,1,Adult,N,
21533,DescriptorName,D002555,2586773,,,2,Cerebrospinal Fluid,N,
21534,QualifierName,Q000032,2586773,,,2,,N,analysis
21535,DescriptorName,D006801,2586773,,,3,Humans,N,
21536,DescriptorName,D007052,2586773,,,4,Ibuprofen,N,
21537,QualifierName,Q000009,2586773,,,4,,Y,adverse effects
21538,DescriptorName,D007074,2586773,,,5,Immunoglobulin G,N,
21539,QualifierName,Q000032,2586773,,,5,,N,analysis
21540,DescriptorName,D008297,2586773,,,6,Male,N,
21541,DescriptorName,D008581,2586773,,,7,Meningitis,N,
21542,QualifierName,Q000139,2586773,,,7,,Y,chemically induced
21543,DescriptorName,D009422,2586773,,,8,Nervous System Diseases,N,
21544,QualifierName,Q000188,2586773,,,8,,N,drug therapy
21545,DescriptorName,D010400,2586773,,,9,Penicillin G,N,
21546,QualifierName,Q000627,2586773,,,9,,N,therapeutic use
21547,DescriptorName,D013126,2586773,,,10,Spinal Nerve Roots,N,
21548,Chemical,D008787,2595431,Metoclopramide,L4YEB44I46,,,,
21549,DescriptorName,D000328,2595431,,,1,Adult,N,
21550,DescriptorName,D000368,2595431,,,2,Aged,N,
21551,DescriptorName,D005260,2595431,,,3,Female,N,
21552,DescriptorName,D005500,2595431,,,4,Follow-Up Studies,N,
21553,DescriptorName,D006801,2595431,,,5,Humans,N,
21554,DescriptorName,D007676,2595431,,,6,"Kidney Failure, Chronic",N,
21555,QualifierName,Q000188,2595431,,,6,,N,drug therapy
21556,DescriptorName,D008297,2595431,,,7,Male,N,
21557,DescriptorName,D008787,2595431,,,8,Metoclopramide,N,
21558,QualifierName,Q000009,2595431,,,8,,Y,adverse effects
21559,DescriptorName,D008875,2595431,,,9,Middle Aged,N,
21560,DescriptorName,D010302,2595431,,,10,"Parkinson Disease, Secondary",N,
21561,QualifierName,Q000139,2595431,,,10,,Y,chemically induced
21562,DescriptorName,D013997,2595431,,,11,Time Factors,N,
21563,Chemical,D004878,2611886,Ergotamine,PR834Q503T,,,,
21564,DescriptorName,D001921,2611886,,,1,Brain,N,
21565,QualifierName,Q000000981,2611886,,,1,,N,diagnostic imaging
21566,DescriptorName,D002544,2611886,,,2,Cerebral Infarction,N,
21567,QualifierName,Q000473,2611886,,,2,,N,pathology
21568,DescriptorName,D002561,2611886,,,3,Cerebrovascular Disorders,N,
21569,QualifierName,Q000150,2611886,,,3,,Y,complications
21570,DescriptorName,D004878,2611886,,,4,Ergotamine,N,
21571,QualifierName,Q000009,2611886,,,4,,N,adverse effects
21572,DescriptorName,D005260,2611886,,,5,Female,N,
21573,DescriptorName,D006801,2611886,,,6,Humans,N,
21574,DescriptorName,D008875,2611886,,,7,Middle Aged,N,
21575,DescriptorName,D008881,2611886,,,8,Migraine Disorders,N,
21576,QualifierName,Q000150,2611886,,,8,,Y,complications
21577,DescriptorName,D014057,2611886,,,9,"Tomography, X-Ray Computed",N,
21578,Chemical,D003520,2616440,Cyclophosphamide,8N3DW7272P,,,,
21579,Chemical,D007213,2616440,Indomethacin,XXE1CET956,,,,
21580,DescriptorName,D000368,2616440,,,1,Aged,N,
21581,DescriptorName,D003520,2616440,,,2,Cyclophosphamide,N,
21582,QualifierName,Q000009,2616440,,,2,,Y,adverse effects
21583,DescriptorName,D004347,2616440,,,3,Drug Interactions,N,
21584,DescriptorName,D006801,2616440,,,4,Humans,N,
21585,DescriptorName,D007010,2616440,,,5,Hyponatremia,N,
21586,QualifierName,Q000139,2616440,,,5,,Y,chemically induced
21587,DescriptorName,D007213,2616440,,,6,Indomethacin,N,
21588,QualifierName,Q000009,2616440,,,6,,Y,adverse effects
21589,DescriptorName,D008297,2616440,,,7,Male,N,
21590,DescriptorName,D009101,2616440,,,8,Multiple Myeloma,N,
21591,QualifierName,Q000188,2616440,,,8,,N,drug therapy
21592,DescriptorName,D014869,2616440,,,9,Water Intoxication,N,
21593,QualifierName,Q000139,2616440,,,9,,Y,chemically induced
21594,Chemical,D002991,2621382,Clofazimine,D959AE5USF,,,,
21595,DescriptorName,D002991,2621382,,,1,Clofazimine,N,
21596,QualifierName,Q000009,2621382,,,1,,Y,adverse effects
21597,DescriptorName,D006801,2621382,,,2,Humans,N,
21598,DescriptorName,D015440,2621382,,,3,"Leprosy, Lepromatous",N,
21599,QualifierName,Q000188,2621382,,,3,,Y,drug therapy
21600,DescriptorName,D009260,2621382,,,4,Nail Diseases,N,
21601,QualifierName,Q000139,2621382,,,4,,Y,chemically induced
21602,DescriptorName,D012871,2621382,,,5,Skin Diseases,N,
21603,QualifierName,Q000139,2621382,,,5,,N,chemically induced
21604,Chemical,D014750,2643458,Vincristine,5J49Q6B70F,,,,
21605,Chemical,D001215,2643458,Asparaginase,EC 3.5.1.1,,,,
21606,Chemical,D011241,2643458,Prednisone,VB0R961HZT,,,,
21607,DescriptorName,D000293,2643458,,,1,Adolescent,N,
21608,DescriptorName,D000971,2643458,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
21609,QualifierName,Q000627,2643458,,,2,,N,therapeutic use
21610,DescriptorName,D001215,2643458,,,3,Asparaginase,N,
21611,QualifierName,Q000008,2643458,,,3,,N,administration & dosage
21612,DescriptorName,D002675,2643458,,,4,"Child, Preschool",N,
21613,DescriptorName,D004885,2643458,,,5,Erwinia,N,
21614,QualifierName,Q000201,2643458,,,5,,Y,enzymology
21615,DescriptorName,D004926,2643458,,,6,Escherichia coli,N,
21616,QualifierName,Q000201,2643458,,,6,,Y,enzymology
21617,DescriptorName,D005260,2643458,,,7,Female,N,
21618,DescriptorName,D006801,2643458,,,8,Humans,N,
21619,DescriptorName,D006943,2643458,,,9,Hyperglycemia,N,
21620,QualifierName,Q000139,2643458,,,9,,Y,chemically induced
21621,DescriptorName,D008297,2643458,,,10,Male,N,
21622,DescriptorName,D054198,2643458,,,11,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
21623,QualifierName,Q000188,2643458,,,11,,N,drug therapy
21624,DescriptorName,D011241,2643458,,,12,Prednisone,N,
21625,QualifierName,Q000008,2643458,,,12,,N,administration & dosage
21626,DescriptorName,D014750,2643458,,,13,Vincristine,N,
21627,QualifierName,Q000008,2643458,,,13,,N,administration & dosage
21628,Chemical,D002216,2663536,Captopril,9G64RSX1XD,,,,
21629,DescriptorName,D000368,2663536,,,1,Aged,N,
21630,DescriptorName,D001249,2663536,,,2,Asthma,N,
21631,QualifierName,Q000139,2663536,,,2,,Y,chemically induced
21632,DescriptorName,D002216,2663536,,,3,Captopril,N,
21633,QualifierName,Q000009,2663536,,,3,,Y,adverse effects
21634,DescriptorName,D004342,2663536,,,4,Drug Hypersensitivity,N,
21635,DescriptorName,D006801,2663536,,,5,Humans,N,
21636,DescriptorName,D006973,2663536,,,6,Hypertension,N,
21637,QualifierName,Q000150,2663536,,,6,,N,complications
21638,DescriptorName,D008297,2663536,,,7,Male,N,
21639,Chemical,D000970,2669373,Antineoplastic Agents,0,,,,
21640,DescriptorName,D000970,2669373,,,1,Antineoplastic Agents,N,
21641,QualifierName,Q000009,2669373,,,1,,Y,adverse effects
21642,DescriptorName,D002294,2669373,,,2,"Carcinoma, Squamous Cell",N,
21643,QualifierName,Q000188,2669373,,,2,,N,drug therapy
21644,DescriptorName,D006801,2669373,,,3,Humans,N,
21645,DescriptorName,D008297,2669373,,,4,Male,N,
21646,DescriptorName,D008833,2669373,,,5,Microcirculation,N,
21647,QualifierName,Q000187,2669373,,,5,,N,drug effects
21648,DescriptorName,D008875,2669373,,,6,Middle Aged,N,
21649,DescriptorName,D009062,2669373,,,7,Mouth Neoplasms,N,
21650,QualifierName,Q000188,2669373,,,7,,N,drug therapy
21651,DescriptorName,D013927,2669373,,,8,Thrombosis,N,
21652,QualifierName,Q000139,2669373,,,8,,Y,chemically induced
21653,Chemical,D002066,267281,Busulfan,G1LN9045DK,,,,
21654,DescriptorName,D002066,267281,,,1,Busulfan,N,
21655,QualifierName,Q000009,267281,,,1,,Y,adverse effects
21656,DescriptorName,D006801,267281,,,2,Humans,N,
21657,DescriptorName,D006975,267281,,,3,"Hypertension, Portal",N,
21658,QualifierName,Q000139,267281,,,3,,Y,chemically induced
21659,DescriptorName,D007951,267281,,,4,"Leukemia, Myeloid",N,
21660,QualifierName,Q000150,267281,,,4,,Y,complications
21661,DescriptorName,D008099,267281,,,5,Liver,N,
21662,QualifierName,Q000473,267281,,,5,,N,pathology
21663,DescriptorName,D008297,267281,,,6,Male,N,
21664,DescriptorName,D008875,267281,,,7,Middle Aged,N,
21665,Chemical,D000638,2690546,Amiodarone,N3RQ532IUT,,,,
21666,DescriptorName,D000368,2690546,,,1,Aged,N,
21667,DescriptorName,D000369,2690546,,,2,"Aged, 80 and over",N,
21668,DescriptorName,D000638,2690546,,,3,Amiodarone,N,
21669,QualifierName,Q000009,2690546,,,3,,Y,adverse effects
21670,DescriptorName,D001281,2690546,,,4,Atrial Fibrillation,N,
21671,QualifierName,Q000188,2690546,,,4,,N,drug therapy
21672,DescriptorName,D004347,2690546,,,5,Drug Interactions,N,
21673,DescriptorName,D004562,2690546,,,6,Electrocardiography,N,
21674,DescriptorName,D005260,2690546,,,7,Female,N,
21675,DescriptorName,D006801,2690546,,,8,Humans,N,
21676,DescriptorName,D008297,2690546,,,9,Male,N,
21677,DescriptorName,D012307,2690546,,,10,Risk Factors,N,
21678,DescriptorName,D013610,2690546,,,11,Tachycardia,N,
21679,QualifierName,Q000139,2690546,,,11,,Y,chemically induced
21680,Chemical,D008094,2717661,Lithium,9FN79X2M3F,,,,
21681,DescriptorName,D001714,2717661,,,1,Bipolar Disorder,N,
21682,QualifierName,Q000150,2717661,,,1,,N,complications
21683,DescriptorName,D005260,2717661,,,2,Female,N,
21684,DescriptorName,D006801,2717661,,,3,Humans,N,
21685,DescriptorName,D008094,2717661,,,4,Lithium,N,
21686,QualifierName,Q000009,2717661,,,4,,Y,adverse effects
21687,DescriptorName,D008875,2717661,,,5,Middle Aged,N,
21688,DescriptorName,D009422,2717661,,,6,Nervous System Diseases,N,
21689,QualifierName,Q000139,2717661,,,6,,Y,chemically induced
21690,DescriptorName,D013577,2717661,,,7,Syndrome,N,
21691,Chemical,D009022,2719905,Morphine Derivatives,0,,,,
21692,Chemical,C035349,2719905,morphine-6-glucuronide,64Y9KYM60R,,,,
21693,Chemical,C018108,2719905,morphine-3-glucuronide,O27Z9CH39A,,,,
21694,DescriptorName,D002648,2719905,,,1,Child,N,
21695,DescriptorName,D003864,2719905,,,2,"Depression, Chemical",N,
21696,DescriptorName,D005260,2719905,,,3,Female,N,
21697,DescriptorName,D006463,2719905,,,4,Hemolytic-Uremic Syndrome,N,
21698,QualifierName,Q000150,2719905,,,4,,N,complications
21699,DescriptorName,D006801,2719905,,,5,Humans,N,
21700,DescriptorName,D009022,2719905,,,6,Morphine Derivatives,N,
21701,QualifierName,Q000009,2719905,,,6,,Y,adverse effects
21702,DescriptorName,D010149,2719905,,,7,"Pain, Postoperative",N,
21703,QualifierName,Q000188,2719905,,,7,,N,drug therapy
21704,DescriptorName,D012120,2719905,,,8,Respiration Disorders,N,
21705,QualifierName,Q000139,2719905,,,8,,Y,chemically induced
21706,Chemical,D012293,2728526,Rifampin,VJT6J7R4TR,,,,
21707,DescriptorName,D000328,2728526,,,1,Adult,N,
21708,DescriptorName,D006801,2728526,,,2,Humans,N,
21709,DescriptorName,D008297,2728526,,,3,Male,N,
21710,DescriptorName,D010349,2728526,,,4,Patient Compliance,N,
21711,DescriptorName,D010976,2728526,,,5,Platelet Count,N,
21712,DescriptorName,D012293,2728526,,,6,Rifampin,N,
21713,QualifierName,Q000009,2728526,,,6,,Y,adverse effects
21714,DescriptorName,D013921,2728526,,,7,Thrombocytopenia,N,
21715,QualifierName,Q000139,2728526,,,7,,Y,chemically induced
21716,DescriptorName,D014376,2728526,,,8,Tuberculosis,N,
21717,QualifierName,Q000188,2728526,,,8,,N,drug therapy
21718,Chemical,D006220,2738729,Haloperidol,J6292F8L3D,,,,
21719,DescriptorName,D000328,2738729,,,1,Adult,N,
21720,DescriptorName,D004409,2738729,,,2,"Dyskinesia, Drug-Induced",N,
21721,QualifierName,Q000151,2738729,,,2,,Y,congenital
21722,DescriptorName,D005260,2738729,,,3,Female,N,
21723,DescriptorName,D006220,2738729,,,4,Haloperidol,N,
21724,QualifierName,Q000009,2738729,,,4,,Y,adverse effects
21725,DescriptorName,D006801,2738729,,,5,Humans,N,
21726,DescriptorName,D007223,2738729,,,6,Infant,N,
21727,DescriptorName,D007231,2738729,,,7,"Infant, Newborn",N,
21728,DescriptorName,D008297,2738729,,,8,Male,N,
21729,DescriptorName,D009357,2738729,,,9,Neonatal Abstinence Syndrome,N,
21730,QualifierName,Q000209,2738729,,,9,,Y,etiology
21731,DescriptorName,D011247,2738729,,,10,Pregnancy,N,
21732,DescriptorName,D011248,2738729,,,11,Pregnancy Complications,N,
21733,QualifierName,Q000188,2738729,,,11,,Y,drug therapy
21734,DescriptorName,D012559,2738729,,,12,Schizophrenia,N,
21735,QualifierName,Q000188,2738729,,,12,,Y,drug therapy
21736,DescriptorName,D014061,2738729,,,13,Tongue Habits,N,
21737,DescriptorName,D014202,2738729,,,14,Tremor,N,
21738,QualifierName,Q000139,2738729,,,14,,N,chemically induced
21739,Chemical,D003520,2743258,Cyclophosphamide,8N3DW7272P,,,,
21740,Chemical,D005472,2743258,Fluorouracil,U3P01618RT,,,,
21741,Chemical,D008727,2743258,Methotrexate,YL5FZ2Y5U1,,,,
21742,DescriptorName,D000368,2743258,,,1,Aged,N,
21743,DescriptorName,D000971,2743258,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
21744,QualifierName,Q000009,2743258,,,2,,Y,adverse effects
21745,DescriptorName,D001943,2743258,,,3,Breast Neoplasms,N,
21746,QualifierName,Q000188,2743258,,,3,,Y,drug therapy
21747,DescriptorName,D003520,2743258,,,4,Cyclophosphamide,N,
21748,QualifierName,Q000008,2743258,,,4,,N,administration & dosage
21749,DescriptorName,D005260,2743258,,,5,Female,N,
21750,DescriptorName,D005472,2743258,,,6,Fluorouracil,N,
21751,QualifierName,Q000008,2743258,,,6,,N,administration & dosage
21752,DescriptorName,D006801,2743258,,,7,Humans,N,
21753,DescriptorName,D015470,2743258,,,8,"Leukemia, Myeloid, Acute",N,
21754,QualifierName,Q000139,2743258,,,8,,Y,chemically induced
21755,DescriptorName,D008727,2743258,,,9,Methotrexate,N,
21756,QualifierName,Q000008,2743258,,,9,,N,administration & dosage
21757,Chemical,D007052,2746565,Ibuprofen,WK2XYI10QM,,,,
21758,DescriptorName,D000293,2746565,,,1,Adolescent,N,
21759,DescriptorName,D005260,2746565,,,2,Female,N,
21760,DescriptorName,D006801,2746565,,,3,Humans,N,
21761,DescriptorName,D007052,2746565,,,4,Ibuprofen,N,
21762,QualifierName,Q000009,2746565,,,4,,Y,adverse effects
21763,DescriptorName,D008180,2746565,,,5,"Lupus Erythematosus, Systemic",N,
21764,QualifierName,Q000150,2746565,,,5,,Y,complications
21765,DescriptorName,D011349,2746565,,,6,Proctitis,N,
21766,QualifierName,Q000139,2746565,,,6,,Y,chemically induced
21767,DescriptorName,D014456,2746565,,,7,Ulcer,N,
21768,QualifierName,Q000139,2746565,,,7,,N,chemically induced
21769,Chemical,D003561,2768785,Cytarabine,04079A1RDZ,,,,
21770,Chemical,D008727,2768785,Methotrexate,YL5FZ2Y5U1,,,,
21771,DescriptorName,D002648,2768785,,,1,Child,N,
21772,DescriptorName,D002675,2768785,,,2,"Child, Preschool",N,
21773,DescriptorName,D003561,2768785,,,3,Cytarabine,N,
21774,QualifierName,Q000009,2768785,,,3,,N,adverse effects
21775,DescriptorName,D004357,2768785,,,4,Drug Synergism,N,
21776,DescriptorName,D004359,2768785,,,5,"Drug Therapy, Combination",N,
21777,DescriptorName,D006801,2768785,,,6,Humans,N,
21778,DescriptorName,D007968,2768785,,,7,"Leukoencephalopathy, Progressive Multifocal",N,
21779,QualifierName,Q000139,2768785,,,7,,Y,chemically induced
21780,DescriptorName,D008297,2768785,,,8,Male,N,
21781,DescriptorName,D008727,2768785,,,9,Methotrexate,N,
21782,QualifierName,Q000009,2768785,,,9,,N,adverse effects
21783,DescriptorName,D054198,2768785,,,10,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
21784,QualifierName,Q000188,2768785,,,10,,Y,drug therapy
21785,Chemical,D011441,2781955,Propylthiouracil,721M9407IY,,,,
21786,Chemical,D003907,2781955,Dexamethasone,7S5I7G3JQL,,,,
21787,Chemical,D000638,2781955,Amiodarone,N3RQ532IUT,,,,
21788,DescriptorName,D000638,2781955,,,1,Amiodarone,N,
21789,QualifierName,Q000009,2781955,,,1,,Y,adverse effects
21790,DescriptorName,D003907,2781955,,,2,Dexamethasone,N,
21791,QualifierName,Q000627,2781955,,,2,,Y,therapeutic use
21792,DescriptorName,D006801,2781955,,,3,Humans,N,
21793,DescriptorName,D008297,2781955,,,4,Male,N,
21794,DescriptorName,D008875,2781955,,,5,Middle Aged,N,
21795,DescriptorName,D011441,2781955,,,6,Propylthiouracil,N,
21796,QualifierName,Q000627,2781955,,,6,,N,therapeutic use
21797,DescriptorName,D013610,2781955,,,7,Tachycardia,N,
21798,QualifierName,Q000188,2781955,,,7,,N,drug therapy
21799,DescriptorName,D013971,2781955,,,8,Thyrotoxicosis,N,
21800,QualifierName,Q000139,2781955,,,8,,Y,chemically induced
21801,Chemical,D002699,278642,Chlorambucil,18D0SL7309,,,,
21802,DescriptorName,D000328,278642,,,1,Adult,N,
21803,DescriptorName,D000368,278642,,,2,Aged,N,
21804,DescriptorName,D001943,278642,,,3,Breast Neoplasms,N,
21805,QualifierName,Q000188,278642,,,3,,Y,drug therapy
21806,DescriptorName,D002699,278642,,,4,Chlorambucil,N,
21807,QualifierName,Q000009,278642,,,4,,Y,adverse effects
21808,DescriptorName,D005260,278642,,,5,Female,N,
21809,DescriptorName,D006801,278642,,,6,Humans,N,
21810,DescriptorName,D015470,278642,,,7,"Leukemia, Myeloid, Acute",N,
21811,QualifierName,Q000139,278642,,,7,,Y,chemically induced
21812,DescriptorName,D008875,278642,,,8,Middle Aged,N,
21813,DescriptorName,D013997,278642,,,9,Time Factors,N,
21814,Chemical,D008803,2796025,Mianserin,250PJI13LM,,,,
21815,DescriptorName,D000328,2796025,,,1,Adult,N,
21816,DescriptorName,D001008,2796025,,,2,Anxiety Disorders,N,
21817,QualifierName,Q000139,2796025,,,2,,Y,chemically induced
21818,DescriptorName,D003866,2796025,,,3,Depressive Disorder,N,
21819,QualifierName,Q000188,2796025,,,3,,Y,drug therapy
21820,DescriptorName,D005239,2796025,,,4,Fear,N,
21821,DescriptorName,D005260,2796025,,,5,Female,N,
21822,DescriptorName,D006801,2796025,,,6,Humans,N,
21823,DescriptorName,D008803,2796025,,,7,Mianserin,N,
21824,QualifierName,Q000009,2796025,,,7,,Y,adverse effects
21825,DescriptorName,D010200,2796025,,,8,Panic,N,
21826,QualifierName,Q000187,2796025,,,8,,Y,drug effects
21827,DescriptorName,D013375,2796025,,,9,Substance Withdrawal Syndrome,N,
21828,QualifierName,Q000209,2796025,,,9,,Y,etiology
21829,Chemical,D008094,2803154,Lithium,9FN79X2M3F,,,,
21830,DescriptorName,D000328,2803154,,,1,Adult,N,
21831,DescriptorName,D001714,2803154,,,2,Bipolar Disorder,N,
21832,QualifierName,Q000188,2803154,,,2,,Y,drug therapy
21833,DescriptorName,D002544,2803154,,,3,Cerebral Infarction,N,
21834,QualifierName,Q000150,2803154,,,3,,Y,complications
21835,DescriptorName,D003937,2803154,,,4,"Diagnosis, Differential",N,
21836,DescriptorName,D004305,2803154,,,5,"Dose-Response Relationship, Drug",N,
21837,DescriptorName,D006429,2803154,,,6,Hemiplegia,N,
21838,QualifierName,Q000150,2803154,,,6,,N,complications
21839,DescriptorName,D006801,2803154,,,7,Humans,N,
21840,DescriptorName,D008094,2803154,,,8,Lithium,N,
21841,QualifierName,Q000008,2803154,,,8,,N,administration & dosage
21842,DescriptorName,D008297,2803154,,,9,Male,N,
21843,DescriptorName,D011605,2803154,,,10,"Psychoses, Substance-Induced",N,
21844,QualifierName,Q000209,2803154,,,10,,Y,etiology
21845,Chemical,D014282,2811895,Trihexyphenidyl,6RC5V8B7PO,,,,
21846,DescriptorName,D000368,2811895,,,1,Aged,N,
21847,DescriptorName,D000402,2811895,,,2,Airway Obstruction,N,
21848,QualifierName,Q000209,2811895,,,2,,Y,etiology
21849,DescriptorName,D001764,2811895,,,3,Blepharospasm,N,
21850,QualifierName,Q000150,2811895,,,3,,N,complications
21851,DescriptorName,D003680,2811895,,,4,Deglutition Disorders,N,
21852,QualifierName,Q000150,2811895,,,4,,N,complications
21853,DescriptorName,D004421,2811895,,,5,Dystonia,N,
21854,QualifierName,Q000139,2811895,,,5,,Y,chemically induced
21855,DescriptorName,D005260,2811895,,,6,Female,N,
21856,DescriptorName,D006801,2811895,,,7,Humans,N,
21857,DescriptorName,D013375,2811895,,,8,Substance Withdrawal Syndrome,Y,
21858,DescriptorName,D014282,2811895,,,9,Trihexyphenidyl,N,
21859,QualifierName,Q000009,2811895,,,9,,Y,adverse effects
21860,Chemical,D008727,2816647,Methotrexate,YL5FZ2Y5U1,,,,
21861,DescriptorName,D000293,2816647,,,1,Adolescent,N,
21862,DescriptorName,D000328,2816647,,,2,Adult,N,
21863,DescriptorName,D001921,2816647,,,3,Brain,N,
21864,QualifierName,Q000473,2816647,,,3,,N,pathology
21865,DescriptorName,D001927,2816647,,,4,Brain Diseases,N,
21866,QualifierName,Q000139,2816647,,,4,,N,chemically induced
21867,DescriptorName,D002648,2816647,,,5,Child,N,
21868,DescriptorName,D005260,2816647,,,6,Female,N,
21869,DescriptorName,D006801,2816647,,,7,Humans,N,
21870,DescriptorName,D008279,2816647,,,8,Magnetic Resonance Imaging,Y,
21871,DescriptorName,D008297,2816647,,,9,Male,N,
21872,DescriptorName,D008727,2816647,,,10,Methotrexate,N,
21873,QualifierName,Q000009,2816647,,,10,,Y,adverse effects
21874,DescriptorName,D012516,2816647,,,11,Osteosarcoma,N,
21875,QualifierName,Q000188,2816647,,,11,,N,drug therapy
21876,Chemical,D003561,282937,Cytarabine,04079A1RDZ,,,,
21877,DescriptorName,D000328,282937,,,1,Adult,N,
21878,DescriptorName,D003561,282937,,,2,Cytarabine,N,
21879,QualifierName,Q000008,282937,,,2,,N,administration & dosage
21880,DescriptorName,D006801,282937,,,3,Humans,N,
21881,DescriptorName,D007278,282937,,,4,"Injections, Spinal",N,
21882,DescriptorName,D015470,282937,,,5,"Leukemia, Myeloid, Acute",N,
21883,QualifierName,Q000134,282937,,,5,,N,cerebrospinal fluid
21884,DescriptorName,D008297,282937,,,6,Male,N,
21885,DescriptorName,D010264,282937,,,7,Paraplegia,N,
21886,QualifierName,Q000139,282937,,,7,,Y,chemically induced
21887,Chemical,D008939,2830062,Mitotane,78E4J5IB5J,,,,
21888,Chemical,D003907,2830062,Dexamethasone,7S5I7G3JQL,,,,
21889,Chemical,D000324,2830062,Adrenocorticotropic Hormone,9002-60-2,,,,
21890,DescriptorName,D000310,2830062,,,1,Adrenal Gland Neoplasms,N,
21891,QualifierName,Q000188,2830062,,,1,,Y,drug therapy
21892,DescriptorName,D000309,2830062,,,2,Adrenal Insufficiency,N,
21893,QualifierName,Q000097,2830062,,,2,,N,blood
21894,DescriptorName,D000324,2830062,,,3,Adrenocorticotropic Hormone,N,
21895,QualifierName,Q000097,2830062,,,3,,N,blood
21896,DescriptorName,D000328,2830062,,,4,Adult,N,
21897,DescriptorName,D003907,2830062,,,5,Dexamethasone,N,
21898,QualifierName,Q000493,2830062,,,5,,N,pharmacokinetics
21899,DescriptorName,D005260,2830062,,,6,Female,N,
21900,DescriptorName,D006801,2830062,,,7,Humans,N,
21901,DescriptorName,D008297,2830062,,,8,Male,N,
21902,DescriptorName,D008939,2830062,,,9,Mitotane,N,
21903,QualifierName,Q000009,2830062,,,9,,Y,adverse effects
21904,Chemical,D014151,2857534,Anti-Anxiety Agents,0,,,,
21905,Chemical,D001569,2857534,Benzodiazepines,12794-10-4,,,,
21906,Chemical,D016651,2857534,Lithium Carbonate,2BMD2GNA4V,,,,
21907,Chemical,D008094,2857534,Lithium,9FN79X2M3F,,,,
21908,Chemical,D000525,2857534,Alprazolam,YU55MQ3IZY,,,,
21909,DescriptorName,D000328,2857534,,,1,Adult,N,
21910,DescriptorName,D000525,2857534,,,2,Alprazolam,N,
21911,DescriptorName,D014151,2857534,,,3,Anti-Anxiety Agents,N,
21912,QualifierName,Q000009,2857534,,,3,,Y,adverse effects
21913,DescriptorName,D001569,2857534,,,4,Benzodiazepines,N,
21914,QualifierName,Q000009,2857534,,,4,,Y,adverse effects
21915,DescriptorName,D001714,2857534,,,5,Bipolar Disorder,N,
21916,QualifierName,Q000139,2857534,,,5,,Y,chemically induced
21917,DescriptorName,D006801,2857534,,,6,Humans,N,
21918,DescriptorName,D008094,2857534,,,7,Lithium,N,
21919,QualifierName,Q000627,2857534,,,7,,N,therapeutic use
21920,DescriptorName,D016651,2857534,,,8,Lithium Carbonate,N,
21921,DescriptorName,D008297,2857534,,,9,Male,N,
21922,Chemical,D014151,2862137,Anti-Anxiety Agents,0,,,,
21923,Chemical,D011963,2862137,"Receptors, GABA-A",0,,,,
21924,Chemical,D001569,2862137,Benzodiazepines,12794-10-4,,,,
21925,Chemical,D003975,2862137,Diazepam,Q3JTX2Q7TU,,,,
21926,Chemical,D000525,2862137,Alprazolam,YU55MQ3IZY,,,,
21927,DescriptorName,D000368,2862137,,,1,Aged,N,
21928,DescriptorName,D000525,2862137,,,2,Alprazolam,N,
21929,DescriptorName,D014151,2862137,,,3,Anti-Anxiety Agents,N,
21930,QualifierName,Q000009,2862137,,,3,,Y,adverse effects
21931,DescriptorName,D001569,2862137,,,4,Benzodiazepines,N,
21932,QualifierName,Q000009,2862137,,,4,,Y,adverse effects
21933,DescriptorName,D003693,2862137,,,5,Delirium,N,
21934,QualifierName,Q000139,2862137,,,5,,Y,chemically induced
21935,DescriptorName,D003975,2862137,,,6,Diazepam,N,
21936,QualifierName,Q000627,2862137,,,6,,Y,therapeutic use
21937,DescriptorName,D006207,2862137,,,7,Half-Life,N,
21938,DescriptorName,D006801,2862137,,,8,Humans,N,
21939,DescriptorName,D008297,2862137,,,9,Male,N,
21940,DescriptorName,D011963,2862137,,,10,"Receptors, GABA-A",N,
21941,QualifierName,Q000187,2862137,,,10,,N,drug effects
21942,DescriptorName,D013375,2862137,,,11,Substance Withdrawal Syndrome,N,
21943,QualifierName,Q000188,2862137,,,11,,N,drug therapy
21944,Chemical,D012460,2863342,Sulfasalazine,3XC8GUZ6CB,,,,
21945,DescriptorName,D000293,2863342,,,1,Adolescent,N,
21946,DescriptorName,D001706,2863342,,,2,Biopsy,N,
21947,DescriptorName,D003093,2863342,,,3,"Colitis, Ulcerative",N,
21948,QualifierName,Q000150,2863342,,,3,,Y,complications
21949,DescriptorName,D006801,2863342,,,4,Humans,N,
21950,DescriptorName,D008099,2863342,,,5,Liver,N,
21951,QualifierName,Q000473,2863342,,,5,,N,pathology
21952,DescriptorName,D008103,2863342,,,6,Liver Cirrhosis,N,
21953,QualifierName,Q000209,2863342,,,6,,Y,etiology
21954,DescriptorName,D008168,2863342,,,7,Lung,N,
21955,QualifierName,Q000473,2863342,,,7,,N,pathology
21956,DescriptorName,D008297,2863342,,,8,Male,N,
21957,DescriptorName,D011658,2863342,,,9,Pulmonary Fibrosis,N,
21958,QualifierName,Q000209,2863342,,,9,,Y,etiology
21959,DescriptorName,D012460,2863342,,,10,Sulfasalazine,N,
21960,QualifierName,Q000009,2863342,,,10,,Y,adverse effects
21961,DescriptorName,D013997,2863342,,,11,Time Factors,N,
21962,Chemical,D014150,2875665,Antipsychotic Agents,0,,,,
21963,Chemical,D000547,2875665,Amantadine,BF4C9Z1J53,,,,
21964,DescriptorName,D000208,2875665,,,1,Acute Disease,N,
21965,DescriptorName,D000328,2875665,,,2,Adult,N,
21966,DescriptorName,D000547,2875665,,,3,Amantadine,N,
21967,QualifierName,Q000009,2875665,,,3,,Y,adverse effects
21968,DescriptorName,D014150,2875665,,,4,Antipsychotic Agents,N,
21969,QualifierName,Q000009,2875665,,,4,,N,adverse effects
21970,DescriptorName,D001480,2875665,,,5,Basal Ganglia Diseases,N,
21971,QualifierName,Q000517,2875665,,,5,,Y,prevention & control
21972,DescriptorName,D004359,2875665,,,6,"Drug Therapy, Combination",N,
21973,DescriptorName,D006801,2875665,,,7,Humans,N,
21974,DescriptorName,D008297,2875665,,,8,Male,N,
21975,DescriptorName,D012559,2875665,,,9,Schizophrenia,N,
21976,QualifierName,Q000139,2875665,,,9,,N,chemically induced
21977,DescriptorName,D012565,2875665,,,10,Schizophrenic Psychology,Y,
21978,Chemical,D014150,2887555,Antipsychotic Agents,0,,,,
21979,Chemical,D002746,2887555,Chlorpromazine,U42B7VYA4P,,,,
21980,DescriptorName,D000328,2887555,,,1,Adult,N,
21981,DescriptorName,D014150,2887555,,,2,Antipsychotic Agents,N,
21982,QualifierName,Q000009,2887555,,,2,,Y,adverse effects
21983,DescriptorName,D001294,2887555,,,3,Attitude to Health,N,
21984,DescriptorName,D001480,2887555,,,4,Basal Ganglia Diseases,N,
21985,QualifierName,Q000139,2887555,,,4,,Y,chemically induced
21986,DescriptorName,D002746,2887555,,,5,Chlorpromazine,N,
21987,QualifierName,Q000009,2887555,,,5,,N,adverse effects
21988,DescriptorName,D003866,2887555,,,6,Depressive Disorder,N,
21989,QualifierName,Q000139,2887555,,,6,,N,chemically induced
21990,DescriptorName,D006801,2887555,,,7,Humans,N,
21991,DescriptorName,D008297,2887555,,,8,Male,N,
21992,DescriptorName,D001523,2887555,,,9,Mental Disorders,N,
21993,QualifierName,Q000188,2887555,,,9,,N,drug therapy
21994,DescriptorName,D010302,2887555,,,10,"Parkinson Disease, Secondary",N,
21995,QualifierName,Q000139,2887555,,,10,,N,chemically induced
21996,DescriptorName,D012559,2887555,,,11,Schizophrenia,N,
21997,QualifierName,Q000188,2887555,,,11,,N,drug therapy
21998,DescriptorName,D012917,2887555,,,12,Social Adjustment,N,
21999,Chemical,D000974,2894766,"Antibodies, Antinuclear",0,,,,
22000,Chemical,D012460,2894766,Sulfasalazine,3XC8GUZ6CB,,,,
22001,DescriptorName,D000328,2894766,,,1,Adult,N,
22002,DescriptorName,D000974,2894766,,,2,"Antibodies, Antinuclear",N,
22003,QualifierName,Q000032,2894766,,,2,,N,analysis
22004,DescriptorName,D002305,2894766,,,3,Cardiac Tamponade,N,
22005,QualifierName,Q000139,2894766,,,3,,N,chemically induced
22006,DescriptorName,D003093,2894766,,,4,"Colitis, Ulcerative",N,
22007,QualifierName,Q000188,2894766,,,4,,N,drug therapy
22008,DescriptorName,D006801,2894766,,,5,Humans,N,
22009,DescriptorName,D008180,2894766,,,6,"Lupus Erythematosus, Systemic",N,
22010,QualifierName,Q000139,2894766,,,6,,Y,chemically induced
22011,DescriptorName,D008297,2894766,,,7,Male,N,
22012,DescriptorName,D010996,2894766,,,8,Pleural Effusion,N,
22013,QualifierName,Q000139,2894766,,,8,,N,chemically induced
22014,DescriptorName,D011014,2894766,,,9,Pneumonia,N,
22015,QualifierName,Q000139,2894766,,,9,,N,chemically induced
22016,DescriptorName,D012460,2894766,,,10,Sulfasalazine,N,
22017,QualifierName,Q000009,2894766,,,10,,Y,adverse effects
22018,Chemical,D013974,2924444,Thyroxine,Q51BO43MG4,,,,
22019,DescriptorName,D000792,2924444,,,1,Angiography,N,
22020,DescriptorName,D017023,2924444,,,2,Coronary Angiography,N,
22021,DescriptorName,D003329,2924444,,,3,Coronary Vasospasm,N,
22022,QualifierName,Q000139,2924444,,,3,,Y,chemically induced
22023,DescriptorName,D004562,2924444,,,4,Electrocardiography,N,
22024,DescriptorName,D006801,2924444,,,5,Humans,N,
22025,DescriptorName,D007037,2924444,,,6,Hypothyroidism,N,
22026,QualifierName,Q000188,2924444,,,6,,Y,drug therapy
22027,DescriptorName,D008297,2924444,,,7,Male,N,
22028,DescriptorName,D008875,2924444,,,8,Middle Aged,N,
22029,DescriptorName,D009203,2924444,,,9,Myocardial Infarction,N,
22030,QualifierName,Q000139,2924444,,,9,,Y,chemically induced
22031,DescriptorName,D013974,2924444,,,10,Thyroxine,N,
22032,QualifierName,Q000009,2924444,,,10,,Y,adverse effects
22033,Chemical,D013974,2931445,Thyroxine,Q51BO43MG4,,,,
22034,DescriptorName,D005260,2931445,,,1,Female,N,
22035,DescriptorName,D006801,2931445,,,2,Humans,N,
22036,DescriptorName,D007970,2931445,,,3,Leukopenia,N,
22037,QualifierName,Q000139,2931445,,,3,,Y,chemically induced
22038,DescriptorName,D008875,2931445,,,4,Middle Aged,N,
22039,DescriptorName,D013602,2931445,,,5,"T-Lymphocytes, Cytotoxic",N,
22040,QualifierName,Q000276,2931445,,,5,,Y,immunology
22041,DescriptorName,D050378,2931445,,,6,"T-Lymphocytes, Regulatory",N,
22042,QualifierName,Q000276,2931445,,,6,,Y,immunology
22043,DescriptorName,D013967,2931445,,,7,"Thyroiditis, Autoimmune",N,
22044,QualifierName,Q000188,2931445,,,7,,Y,drug therapy
22045,DescriptorName,D013974,2931445,,,8,Thyroxine,N,
22046,QualifierName,Q000009,2931445,,,8,,Y,adverse effects
22047,Chemical,D000667,2935070,Ampicillin,7C782967RD,,,,
22048,DescriptorName,D058186,2935070,,,1,Acute Kidney Injury,N,
22049,QualifierName,Q000139,2935070,,,1,,Y,chemically induced
22050,DescriptorName,D000328,2935070,,,2,Adult,N,
22051,DescriptorName,D000667,2935070,,,3,Ampicillin,N,
22052,QualifierName,Q000009,2935070,,,3,,Y,adverse effects
22053,DescriptorName,D003873,2935070,,,4,"Dermatitis, Exfoliative",N,
22054,QualifierName,Q000139,2935070,,,4,,Y,chemically induced
22055,DescriptorName,D005260,2935070,,,5,Female,N,
22056,DescriptorName,D006801,2935070,,,6,Humans,N,
22057,DescriptorName,D009395,2935070,,,7,"Nephritis, Interstitial",N,
22058,QualifierName,Q000139,2935070,,,7,,Y,chemically induced
22059,DescriptorName,D014552,2935070,,,8,Urinary Tract Infections,N,
22060,QualifierName,Q000188,2935070,,,8,,N,drug therapy
22061,Chemical,D014640,2937155,Vancomycin,6Q205EH1VU,,,,
22062,DescriptorName,D003875,2937155,,,1,Drug Eruptions,N,
22063,QualifierName,Q000209,2937155,,,1,,N,etiology
22064,DescriptorName,D005260,2937155,,,2,Female,N,
22065,DescriptorName,D006801,2937155,,,3,Humans,N,
22066,DescriptorName,D008875,2937155,,,4,Middle Aged,N,
22067,DescriptorName,D010538,2937155,,,5,Peritonitis,N,
22068,QualifierName,Q000188,2937155,,,5,,N,drug therapy
22069,DescriptorName,D013203,2937155,,,6,Staphylococcal Infections,N,
22070,QualifierName,Q000188,2937155,,,6,,N,drug therapy
22071,DescriptorName,D014640,2937155,,,7,Vancomycin,N,
22072,QualifierName,Q000009,2937155,,,7,,Y,adverse effects
22073,DescriptorName,D014657,2937155,,,8,Vasculitis,N,
22074,QualifierName,Q000139,2937155,,,8,,Y,chemically induced
22075,Chemical,D014212,2940999,Tretinoin,5688UTC01R,,,,
22076,Chemical,D015474,2940999,Isotretinoin,EH28UP18IF,,,,
22077,DescriptorName,D000152,2940999,,,1,Acne Vulgaris,N,
22078,QualifierName,Q000150,2940999,,,1,,Y,complications
22079,DescriptorName,D000293,2940999,,,2,Adolescent,N,
22080,DescriptorName,D000328,2940999,,,3,Adult,N,
22081,DescriptorName,D003623,2940999,,,4,Dark Adaptation,N,
22082,QualifierName,Q000187,2940999,,,4,,N,drug effects
22083,DescriptorName,D004585,2940999,,,5,Electrooculography,N,
22084,DescriptorName,D004596,2940999,,,6,Electroretinography,N,
22085,DescriptorName,D005500,2940999,,,7,Follow-Up Studies,N,
22086,DescriptorName,D006801,2940999,,,8,Humans,N,
22087,DescriptorName,D015474,2940999,,,9,Isotretinoin,N,
22088,DescriptorName,D008297,2940999,,,10,Male,N,
22089,DescriptorName,D012160,2940999,,,11,Retina,N,
22090,QualifierName,Q000187,2940999,,,11,,Y,drug effects
22091,DescriptorName,D013997,2940999,,,12,Time Factors,N,
22092,DescriptorName,D014212,2940999,,,13,Tretinoin,N,
22093,QualifierName,Q000009,2940999,,,13,,Y,adverse effects
22094,DescriptorName,D014785,2940999,,,14,"Vision, Ocular",N,
22095,QualifierName,Q000187,2940999,,,14,,N,drug effects
22096,Chemical,D005467,2943526,Floxuridine,039LU44I5M,,,,
22097,DescriptorName,D000230,2943526,,,1,Adenocarcinoma,N,
22098,QualifierName,Q000188,2943526,,,1,,N,drug therapy
22099,DescriptorName,D000368,2943526,,,2,Aged,N,
22100,DescriptorName,D001927,2943526,,,3,Brain Diseases,N,
22101,QualifierName,Q000139,2943526,,,3,,Y,chemically induced
22102,DescriptorName,D005467,2943526,,,4,Floxuridine,N,
22103,QualifierName,Q000008,2943526,,,4,,Y,administration & dosage
22104,DescriptorName,D006499,2943526,,,5,Hepatic Artery,N,
22105,DescriptorName,D006801,2943526,,,6,Humans,N,
22106,DescriptorName,D007261,2943526,,,7,"Infusions, Intra-Arterial",N,
22107,DescriptorName,D008113,2943526,,,8,Liver Neoplasms,N,
22108,QualifierName,Q000188,2943526,,,8,,N,drug therapy
22109,DescriptorName,D008297,2943526,,,9,Male,N,
22110,Chemical,D004977,2956288,Ethambutol,8G167061QZ,,,,
22111,DescriptorName,D000328,2956288,,,1,Adult,N,
22112,DescriptorName,D000368,2956288,,,2,Aged,N,
22113,DescriptorName,D004977,2956288,,,3,Ethambutol,N,
22114,QualifierName,Q000009,2956288,,,3,,Y,adverse effects
22115,DescriptorName,D005260,2956288,,,4,Female,N,
22116,DescriptorName,D005451,2956288,,,5,Fluorescein Angiography,N,
22117,DescriptorName,D006801,2956288,,,6,Humans,N,
22118,DescriptorName,D008297,2956288,,,7,Male,N,
22119,DescriptorName,D008875,2956288,,,8,Middle Aged,N,
22120,DescriptorName,D009902,2956288,,,9,Optic Neuritis,N,
22121,QualifierName,Q000139,2956288,,,9,,Y,chemically induced
22122,DescriptorName,D014398,2956288,,,10,"Tuberculosis, Renal",N,
22123,QualifierName,Q000188,2956288,,,10,,Y,drug therapy
22124,DescriptorName,D014792,2956288,,,11,Visual Acuity,N,
22125,QualifierName,Q000187,2956288,,,11,,N,drug effects
22126,DescriptorName,D014794,2956288,,,12,Visual Fields,N,
22127,QualifierName,Q000187,2956288,,,12,,N,drug effects
22128,Chemical,D009543,2979256,Nifedipine,I9ZF7L6G2L,,,,
22129,DescriptorName,D000328,2979256,,,1,Adult,N,
22130,DescriptorName,D003680,2979256,,,2,Deglutition Disorders,N,
22131,QualifierName,Q000188,2979256,,,2,,N,drug therapy
22132,DescriptorName,D005260,2979256,,,3,Female,N,
22133,DescriptorName,D005764,2979256,,,4,Gastroesophageal Reflux,N,
22134,QualifierName,Q000139,2979256,,,4,,Y,chemically induced
22135,DescriptorName,D006801,2979256,,,5,Humans,N,
22136,DescriptorName,D008875,2979256,,,6,Middle Aged,N,
22137,DescriptorName,D009543,2979256,,,7,Nifedipine,N,
22138,QualifierName,Q000009,2979256,,,7,,Y,adverse effects
22139,Chemical,D000932,3003260,Antiemetics,0,,,,
22140,Chemical,C004180,3003260,dexamethasone 21-phosphate,2BP70L44PR,,,,
22141,Chemical,D003907,3003260,Dexamethasone,7S5I7G3JQL,,,,
22142,Chemical,D002945,3003260,Cisplatin,Q20Q21Q62J,,,,
22143,DescriptorName,D000328,3003260,,,1,Adult,N,
22144,DescriptorName,D000932,3003260,,,2,Antiemetics,Y,
22145,DescriptorName,D000971,3003260,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
22146,QualifierName,Q000009,3003260,,,3,,N,adverse effects
22147,DescriptorName,D002386,3003260,,,4,Cataract,N,
22148,QualifierName,Q000139,3003260,,,4,,Y,chemically induced
22149,DescriptorName,D002945,3003260,,,5,Cisplatin,N,
22150,QualifierName,Q000008,3003260,,,5,,N,administration & dosage
22151,DescriptorName,D003907,3003260,,,6,Dexamethasone,N,
22152,QualifierName,Q000009,3003260,,,6,,N,adverse effects
22153,DescriptorName,D004359,3003260,,,7,"Drug Therapy, Combination",N,
22154,DescriptorName,D006801,3003260,,,8,Humans,N,
22155,DescriptorName,D008297,3003260,,,9,Male,N,
22156,DescriptorName,D008479,3003260,,,10,Mediastinal Neoplasms,N,
22157,QualifierName,Q000188,3003260,,,10,,N,drug therapy
22158,DescriptorName,D009373,3003260,,,11,"Neoplasms, Germ Cell and Embryonal",N,
22159,QualifierName,Q000188,3003260,,,11,,N,drug therapy
22160,Chemical,D000927,3030084,Anticonvulsants,0,,,,
22161,Chemical,D007071,3030084,"Immunoglobulin A, Secretory",0,,,,
22162,Chemical,D007073,3030084,Immunoglobulin E,37341-29-0,,,,
22163,Chemical,D010672,3030084,Phenytoin,6158TKW0C5,,,,
22164,Chemical,D000324,3030084,Adrenocorticotropic Hormone,9002-60-2,,,,
22165,DescriptorName,D000324,3030084,,,1,Adrenocorticotropic Hormone,N,
22166,QualifierName,Q000627,3030084,,,1,,N,therapeutic use
22167,DescriptorName,D000927,3030084,,,2,Anticonvulsants,N,
22168,QualifierName,Q000009,3030084,,,2,,N,adverse effects
22169,DescriptorName,D002648,3030084,,,3,Child,N,
22170,DescriptorName,D004406,3030084,,,4,Dysgammaglobulinemia,N,
22171,QualifierName,Q000139,3030084,,,4,,Y,chemically induced
22172,DescriptorName,D004827,3030084,,,5,Epilepsy,N,
22173,QualifierName,Q000150,3030084,,,5,,N,complications
22174,DescriptorName,D006801,3030084,,,6,Humans,N,
22175,DescriptorName,D017098,3030084,,,7,IgA Deficiency,Y,
22176,DescriptorName,D007071,3030084,,,8,"Immunoglobulin A, Secretory",N,
22177,QualifierName,Q000172,3030084,,,8,,N,deficiency
22178,DescriptorName,D007073,3030084,,,9,Immunoglobulin E,N,
22179,QualifierName,Q000032,3030084,,,9,,N,analysis
22180,DescriptorName,D007153,3030084,,,10,Immunologic Deficiency Syndromes,N,
22181,QualifierName,Q000150,3030084,,,10,,N,complications
22182,DescriptorName,D007958,3030084,,,11,Leukocyte Count,N,
22183,DescriptorName,D008297,3030084,,,12,Male,N,
22184,DescriptorName,D010672,3030084,,,13,Phenytoin,N,
22185,QualifierName,Q000009,3030084,,,13,,Y,adverse effects
22186,DescriptorName,D013601,3030084,,,14,T-Lymphocytes,N,
22187,QualifierName,Q000145,3030084,,,14,,N,classification
22188,Chemical,D002697,3059159,Chloral Hydrate,418M5916WG,,,,
22189,Chemical,D008012,3059159,Lidocaine,98PI200987,,,,
22190,Chemical,D011433,3059159,Propranolol,9Y8NXQ24VQ,,,,
22191,DescriptorName,D000328,3059159,,,1,Adult,N,
22192,DescriptorName,D001145,3059159,,,2,"Arrhythmias, Cardiac",N,
22193,QualifierName,Q000139,3059159,,,2,,N,chemically induced
22194,DescriptorName,D002697,3059159,,,3,Chloral Hydrate,N,
22195,QualifierName,Q000506,3059159,,,3,,Y,poisoning
22196,DescriptorName,D005260,3059159,,,4,Female,N,
22197,DescriptorName,D006801,3059159,,,5,Humans,N,
22198,DescriptorName,D008012,3059159,,,6,Lidocaine,N,
22199,QualifierName,Q000627,3059159,,,6,,N,therapeutic use
22200,DescriptorName,D008297,3059159,,,7,Male,N,
22201,DescriptorName,D008875,3059159,,,8,Middle Aged,N,
22202,DescriptorName,D011433,3059159,,,9,Propranolol,N,
22203,QualifierName,Q000627,3059159,,,9,,N,therapeutic use
22204,Chemical,D004837,3067748,Epinephrine,YKH834O4BH,,,,
22205,DescriptorName,D000368,3067748,,,1,Aged,N,
22206,DescriptorName,D004837,3067748,,,2,Epinephrine,N,
22207,QualifierName,Q000009,3067748,,,2,,Y,adverse effects
22208,DescriptorName,D005260,3067748,,,3,Female,N,
22209,DescriptorName,D005902,3067748,,,4,"Glaucoma, Open-Angle",N,
22210,QualifierName,Q000188,3067748,,,4,,N,drug therapy
22211,DescriptorName,D006801,3067748,,,5,Humans,N,
22212,DescriptorName,D007765,3067748,,,6,Lacrimal Apparatus,Y,
22213,DescriptorName,D007766,3067748,,,7,Lacrimal Apparatus Diseases,N,
22214,QualifierName,Q000139,3067748,,,7,,N,chemically induced
22215,DescriptorName,D009301,3067748,,,8,Nasolacrimal Duct,Y,
22216,DescriptorName,D014463,3067748,,,9,Ultrasonography,N,
22217,Chemical,D014635,3084231,Valproic Acid,614OI1Z5WI,,,,
22218,Chemical,D000641,3084231,Ammonia,7664-41-7,,,,
22219,DescriptorName,D000328,3084231,,,1,Adult,N,
22220,DescriptorName,D000641,3084231,,,2,Ammonia,N,
22221,QualifierName,Q000097,3084231,,,2,,N,blood
22222,DescriptorName,D003704,3084231,,,3,Dementia,N,
22223,QualifierName,Q000139,3084231,,,3,,Y,chemically induced
22224,DescriptorName,D004827,3084231,,,4,Epilepsy,N,
22225,QualifierName,Q000097,3084231,,,4,,N,blood
22226,DescriptorName,D006801,3084231,,,5,Humans,N,
22227,DescriptorName,D008297,3084231,,,6,Male,N,
22228,DescriptorName,D011581,3084231,,,7,Psychological Tests,N,
22229,DescriptorName,D014635,3084231,,,8,Valproic Acid,N,
22230,QualifierName,Q000009,3084231,,,8,,Y,adverse effects
22231,Chemical,D000890,3101617,Anti-Infective Agents,0,,,,
22232,Chemical,D004338,3101617,Drug Combinations,0,,,,
22233,Chemical,D015662,3101617,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
22234,Chemical,D014295,3101617,Trimethoprim,AN164J8Y0X,,,,
22235,Chemical,D013420,3101617,Sulfamethoxazole,JE42381TNV,,,,
22236,DescriptorName,D000890,3101617,,,1,Anti-Infective Agents,N,
22237,QualifierName,Q000009,3101617,,,1,,Y,adverse effects
22238,DescriptorName,D002675,3101617,,,2,"Child, Preschool",N,
22239,DescriptorName,D004338,3101617,,,3,Drug Combinations,N,
22240,QualifierName,Q000009,3101617,,,3,,N,adverse effects
22241,DescriptorName,D006801,3101617,,,4,Humans,N,
22242,DescriptorName,D007945,3101617,,,5,"Leukemia, Lymphoid",N,
22243,QualifierName,Q000150,3101617,,,5,,N,complications
22244,DescriptorName,D008297,3101617,,,6,Male,N,
22245,DescriptorName,D011020,3101617,,,7,"Pneumonia, Pneumocystis",N,
22246,QualifierName,Q000517,3101617,,,7,,Y,prevention & control
22247,DescriptorName,D012010,3101617,,,8,"Red-Cell Aplasia, Pure",N,
22248,QualifierName,Q000139,3101617,,,8,,Y,chemically induced
22249,DescriptorName,D013420,3101617,,,9,Sulfamethoxazole,N,
22250,QualifierName,Q000009,3101617,,,9,,Y,adverse effects
22251,DescriptorName,D014295,3101617,,,10,Trimethoprim,N,
22252,QualifierName,Q000009,3101617,,,10,,Y,adverse effects
22253,DescriptorName,D015662,3101617,,,11,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
22254,Chemical,D004977,3115809,Ethambutol,8G167061QZ,,,,
22255,Chemical,D007538,3115809,Isoniazid,V83O1VOZ8L,,,,
22256,DescriptorName,D000368,3115809,,,1,Aged,N,
22257,DescriptorName,D003924,3115809,,,2,"Diabetes Mellitus, Type 2",N,
22258,QualifierName,Q000150,3115809,,,2,,N,complications
22259,DescriptorName,D004357,3115809,,,3,Drug Synergism,N,
22260,DescriptorName,D004977,3115809,,,4,Ethambutol,N,
22261,QualifierName,Q000009,3115809,,,4,,Y,adverse effects
22262,DescriptorName,D006801,3115809,,,5,Humans,N,
22263,DescriptorName,D007538,3115809,,,6,Isoniazid,N,
22264,QualifierName,Q000009,3115809,,,6,,Y,adverse effects
22265,DescriptorName,D008297,3115809,,,7,Male,N,
22266,DescriptorName,D009169,3115809,,,8,Mycobacterium tuberculosis,N,
22267,QualifierName,Q000302,3115809,,,8,,N,isolation & purification
22268,DescriptorName,D009898,3115809,,,9,Optic Disk,N,
22269,QualifierName,Q000473,3115809,,,9,,Y,pathology
22270,DescriptorName,D012607,3115809,,,10,Scotoma,N,
22271,QualifierName,Q000139,3115809,,,10,,Y,chemically induced
22272,DescriptorName,D014397,3115809,,,11,"Tuberculosis, Pulmonary",N,
22273,QualifierName,Q000150,3115809,,,11,,N,complications
22274,Chemical,D000893,3124393,Anti-Inflammatory Agents,0,,,,
22275,Chemical,D000077555,3124393,Methylprednisolone Acetate,43502P7F0P,,,,
22276,Chemical,D008775,3124393,Methylprednisolone,X4W7ZR7023,,,,
22277,DescriptorName,D000328,3124393,,,1,Adult,N,
22278,DescriptorName,D000893,3124393,,,2,Anti-Inflammatory Agents,N,
22279,QualifierName,Q000008,3124393,,,2,,N,administration & dosage
22280,DescriptorName,D001099,3124393,,,3,Arachnoid,N,
22281,QualifierName,Q000187,3124393,,,3,,Y,drug effects
22282,DescriptorName,D002114,3124393,,,4,Calcinosis,N,
22283,QualifierName,Q000139,3124393,,,4,,Y,chemically induced
22284,DescriptorName,D005260,3124393,,,5,Female,N,
22285,DescriptorName,D006801,3124393,,,6,Humans,N,
22286,DescriptorName,D007278,3124393,,,7,"Injections, Spinal",N,
22287,DescriptorName,D008775,3124393,,,8,Methylprednisolone,N,
22288,QualifierName,Q000008,3124393,,,8,,N,administration & dosage
22289,DescriptorName,D000077555,3124393,,,9,Methylprednisolone Acetate,N,
22290,DescriptorName,D009103,3124393,,,10,Multiple Sclerosis,N,
22291,QualifierName,Q000188,3124393,,,10,,Y,drug therapy
22292,DescriptorName,D009999,3124393,,,11,"Ossification, Heterotopic",N,
22293,QualifierName,Q000139,3124393,,,11,,Y,chemically induced
22294,Chemical,D002220,3128415,Carbamazepine,33CM23913M,,,,
22295,Chemical,D014635,3128415,Valproic Acid,614OI1Z5WI,,,,
22296,Chemical,D010672,3128415,Phenytoin,6158TKW0C5,,,,
22297,Chemical,D004317,3128415,Doxorubicin,80168379AG,,,,
22298,Chemical,D003520,3128415,Cyclophosphamide,8N3DW7272P,,,,
22299,Chemical,D002945,3128415,Cisplatin,Q20Q21Q62J,,,,
22300,Chemical,D006585,3128415,Altretamine,Q8BIH59O7H,,,,
22301,DescriptorName,D000231,3128415,,,1,"Adenocarcinoma, Papillary",N,
22302,QualifierName,Q000150,3128415,,,1,,N,complications
22303,DescriptorName,D000328,3128415,,,2,Adult,N,
22304,DescriptorName,D006585,3128415,,,3,Altretamine,N,
22305,QualifierName,Q000008,3128415,,,3,,N,administration & dosage
22306,DescriptorName,D000971,3128415,,,4,Antineoplastic Combined Chemotherapy Protocols,N,
22307,QualifierName,Q000009,3128415,,,4,,Y,adverse effects
22308,DescriptorName,D002220,3128415,,,5,Carbamazepine,N,
22309,QualifierName,Q000097,3128415,,,5,,Y,blood
22310,DescriptorName,D002945,3128415,,,6,Cisplatin,N,
22311,QualifierName,Q000008,3128415,,,6,,N,administration & dosage
22312,DescriptorName,D003520,3128415,,,7,Cyclophosphamide,N,
22313,QualifierName,Q000008,3128415,,,7,,N,administration & dosage
22314,DescriptorName,D004317,3128415,,,8,Doxorubicin,N,
22315,QualifierName,Q000008,3128415,,,8,,N,administration & dosage
22316,DescriptorName,D004347,3128415,,,9,Drug Interactions,N,
22317,DescriptorName,D004827,3128415,,,10,Epilepsy,N,
22318,QualifierName,Q000150,3128415,,,10,,N,complications
22319,DescriptorName,D005260,3128415,,,11,Female,N,
22320,DescriptorName,D006801,3128415,,,12,Humans,N,
22321,DescriptorName,D010051,3128415,,,13,Ovarian Neoplasms,N,
22322,QualifierName,Q000150,3128415,,,13,,N,complications
22323,DescriptorName,D010672,3128415,,,14,Phenytoin,N,
22324,QualifierName,Q000097,3128415,,,14,,Y,blood
22325,DescriptorName,D014635,3128415,,,15,Valproic Acid,N,
22326,QualifierName,Q000097,3128415,,,15,,Y,blood
22327,Chemical,D003366,3136101,Cosyntropin,16960-16-0,,,,
22328,Chemical,C006418,3136101,adrenocorticotropin zinc,53468-06-7,,,,
22329,DescriptorName,D003366,3136101,,,1,Cosyntropin,N,
22330,QualifierName,Q000009,3136101,,,1,,Y,adverse effects
22331,DescriptorName,D004569,3136101,,,2,Electroencephalography,N,
22332,DescriptorName,D005260,3136101,,,3,Female,N,
22333,DescriptorName,D006801,3136101,,,4,Humans,N,
22334,DescriptorName,D006947,3136101,,,5,Hyperkalemia,N,
22335,QualifierName,Q000139,3136101,,,5,,Y,chemically induced
22336,DescriptorName,D007223,3136101,,,6,Infant,N,
22337,DescriptorName,D008134,3136101,,,7,Long-Term Care,N,
22338,DescriptorName,D008297,3136101,,,8,Male,N,
22339,DescriptorName,D013036,3136101,,,9,"Spasms, Infantile",N,
22340,QualifierName,Q000188,3136101,,,9,,Y,drug therapy
22341,Chemical,D014635,3143551,Valproic Acid,614OI1Z5WI,,,,
22342,DescriptorName,D000328,3143551,,,1,Adult,N,
22343,DescriptorName,D004831,3143551,,,2,"Epilepsies, Myoclonic",N,
22344,QualifierName,Q000150,3143551,,,2,,N,complications
22345,DescriptorName,D005260,3143551,,,3,Female,N,
22346,DescriptorName,D006801,3143551,,,4,Humans,N,
22347,DescriptorName,D009069,3143551,,,5,Movement Disorders,N,
22348,QualifierName,Q000139,3143551,,,5,,Y,chemically induced
22349,DescriptorName,D011187,3143551,,,6,Posture,Y,
22350,DescriptorName,D014635,3143551,,,7,Valproic Acid,N,
22351,QualifierName,Q000009,3143551,,,7,,Y,adverse effects
22352,Chemical,D008140,3149484,Lorazepam,O26FZP769L,,,,
22353,DescriptorName,D002648,3149484,,,1,Child,N,
22354,DescriptorName,D004832,3149484,,,2,"Epilepsy, Absence",N,
22355,QualifierName,Q000150,3149484,,,2,,N,complications
22356,DescriptorName,D005260,3149484,,,3,Female,N,
22357,DescriptorName,D006801,3149484,,,4,Humans,N,
22358,DescriptorName,D008140,3149484,,,5,Lorazepam,N,
22359,QualifierName,Q000009,3149484,,,5,,Y,adverse effects
22360,DescriptorName,D013226,3149484,,,6,Status Epilepticus,N,
22361,QualifierName,Q000139,3149484,,,6,,Y,chemically induced
22362,Chemical,D008775,3152997,Methylprednisolone,X4W7ZR7023,,,,
22363,DescriptorName,D000293,3152997,,,1,Adolescent,N,
22364,DescriptorName,D001281,3152997,,,2,Atrial Fibrillation,N,
22365,QualifierName,Q000139,3152997,,,2,,Y,chemically induced
22366,DescriptorName,D002648,3152997,,,3,Child,N,
22367,DescriptorName,D005260,3152997,,,4,Female,N,
22368,DescriptorName,D006801,3152997,,,5,Humans,N,
22369,DescriptorName,D008181,3152997,,,6,Lupus Nephritis,N,
22370,QualifierName,Q000188,3152997,,,6,,N,drug therapy
22371,DescriptorName,D008297,3152997,,,7,Male,N,
22372,DescriptorName,D008775,3152997,,,8,Methylprednisolone,N,
22373,QualifierName,Q000008,3152997,,,8,,N,administration & dosage
22374,DescriptorName,D009404,3152997,,,9,Nephrotic Syndrome,N,
22375,QualifierName,Q000188,3152997,,,9,,N,drug therapy
22376,Chemical,D013723,3156465,Teratogens,0,,,,
22377,Chemical,D014212,3156465,Tretinoin,5688UTC01R,,,,
22378,Chemical,D015474,3156465,Isotretinoin,EH28UP18IF,,,,
22379,DescriptorName,D000014,3156465,,,1,"Abnormalities, Drug-Induced",N,
22380,QualifierName,Q000209,3156465,,,1,,Y,etiology
22381,DescriptorName,D000015,3156465,,,2,"Abnormalities, Multiple",N,
22382,QualifierName,Q000139,3156465,,,2,,Y,chemically induced
22383,DescriptorName,D000152,3156465,,,3,Acne Vulgaris,N,
22384,QualifierName,Q000188,3156465,,,3,,N,drug therapy
22385,DescriptorName,D000328,3156465,,,4,Adult,N,
22386,DescriptorName,D001921,3156465,,,5,Brain,N,
22387,QualifierName,Q000002,3156465,,,5,,Y,abnormalities
22388,DescriptorName,D005260,3156465,,,6,Female,N,
22389,DescriptorName,D006801,3156465,,,7,Humans,N,
22390,DescriptorName,D007231,3156465,,,8,"Infant, Newborn",N,
22391,DescriptorName,D015474,3156465,,,9,Isotretinoin,N,
22392,DescriptorName,D013723,3156465,,,10,Teratogens,Y,
22393,DescriptorName,D014212,3156465,,,11,Tretinoin,N,
22394,QualifierName,Q000009,3156465,,,11,,Y,adverse effects
22395,Chemical,D000493,3159106,Allopurinol,63CZ7GJN5I,,,,
22396,DescriptorName,D000493,3159106,,,1,Allopurinol,N,
22397,QualifierName,Q000009,3159106,,,1,,Y,adverse effects
22398,DescriptorName,D003873,3159106,,,2,"Dermatitis, Exfoliative",N,
22399,QualifierName,Q000139,3159106,,,2,,Y,chemically induced
22400,DescriptorName,D004342,3159106,,,3,Drug Hypersensitivity,N,
22401,QualifierName,Q000209,3159106,,,3,,Y,etiology
22402,DescriptorName,D006801,3159106,,,4,Humans,N,
22403,DescriptorName,D008297,3159106,,,5,Male,N,
22404,DescriptorName,D008875,3159106,,,6,Middle Aged,N,
22405,DescriptorName,D009101,3159106,,,7,Multiple Myeloma,N,
22406,QualifierName,Q000188,3159106,,,7,,Y,drug therapy
22407,Chemical,D011458,3166573,Prostaglandins E,0,,,,
22408,Chemical,D015232,3166573,Dinoprostone,K7Q1JQR04M,,,,
22409,DescriptorName,D001846,3166573,,,1,Bone Development,N,
22410,QualifierName,Q000187,3166573,,,1,,Y,drug effects
22411,DescriptorName,D001847,3166573,,,2,Bone Diseases,N,
22412,QualifierName,Q000139,3166573,,,2,,Y,chemically induced
22413,DescriptorName,D015232,3166573,,,3,Dinoprostone,N,
22414,DescriptorName,D004374,3166573,,,4,"Ductus Arteriosus, Patent",N,
22415,QualifierName,Q000188,3166573,,,4,,N,drug therapy
22416,DescriptorName,D005260,3166573,,,5,Female,N,
22417,DescriptorName,D006330,3166573,,,6,"Heart Defects, Congenital",N,
22418,QualifierName,Q000188,3166573,,,6,,N,drug therapy
22419,DescriptorName,D006801,3166573,,,7,Humans,N,
22420,DescriptorName,D007231,3166573,,,8,"Infant, Newborn",N,
22421,DescriptorName,D011458,3166573,,,9,Prostaglandins E,N,
22422,QualifierName,Q000009,3166573,,,9,,Y,adverse effects
22423,Chemical,D014750,3171334,Vincristine,5J49Q6B70F,,,,
22424,DescriptorName,D001254,3171334,,,1,Astrocytoma,N,
22425,QualifierName,Q000188,3171334,,,1,,Y,drug therapy
22426,DescriptorName,D002648,3171334,,,2,Child,N,
22427,DescriptorName,D005260,3171334,,,3,Female,N,
22428,DescriptorName,D006801,3171334,,,4,Humans,N,
22429,DescriptorName,D013120,3171334,,,5,Spinal Cord Neoplasms,N,
22430,QualifierName,Q000188,3171334,,,5,,Y,drug therapy
22431,DescriptorName,D014750,3171334,,,6,Vincristine,N,
22432,QualifierName,Q000009,3171334,,,6,,Y,adverse effects
22433,DescriptorName,D014786,3171334,,,7,Vision Disorders,N,
22434,QualifierName,Q000139,3171334,,,7,,Y,chemically induced
22435,Chemical,D009525,3174043,Niacin,2679MF687A,,,,
22436,DescriptorName,D000328,3174043,,,1,Adult,N,
22437,DescriptorName,D005451,3174043,,,2,Fluorescein Angiography,N,
22438,DescriptorName,D005654,3174043,,,3,Fundus Oculi,N,
22439,DescriptorName,D006801,3174043,,,4,Humans,N,
22440,DescriptorName,D006938,3174043,,,5,Hyperlipoproteinemia Type II,N,
22441,QualifierName,Q000188,3174043,,,5,,N,drug therapy
22442,DescriptorName,D008266,3174043,,,6,Macula Lutea,Y,
22443,DescriptorName,D008297,3174043,,,7,Male,N,
22444,DescriptorName,D008875,3174043,,,8,Middle Aged,N,
22445,DescriptorName,D009525,3174043,,,9,Niacin,N,
22446,QualifierName,Q000009,3174043,,,9,,Y,adverse effects
22447,DescriptorName,D012164,3174043,,,10,Retinal Diseases,N,
22448,QualifierName,Q000139,3174043,,,10,,Y,chemically induced
22449,DescriptorName,D012651,3174043,,,11,Self Medication,N,
22450,DescriptorName,D014786,3174043,,,12,Vision Disorders,N,
22451,QualifierName,Q000139,3174043,,,12,,N,chemically induced
22452,DescriptorName,D014792,3174043,,,13,Visual Acuity,N,
22453,Chemical,D003622,3195622,Dapsone,8W5C518302,,,,
22454,DescriptorName,D000743,3195622,,,1,"Anemia, Hemolytic",N,
22455,QualifierName,Q000209,3195622,,,1,,N,etiology
22456,DescriptorName,D003622,3195622,,,2,Dapsone,N,
22457,QualifierName,Q000009,3195622,,,2,,Y,adverse effects
22458,DescriptorName,D004342,3195622,,,3,Drug Hypersensitivity,N,
22459,QualifierName,Q000209,3195622,,,3,,Y,etiology
22460,DescriptorName,D005334,3195622,,,4,Fever,N,
22461,QualifierName,Q000209,3195622,,,4,,N,etiology
22462,DescriptorName,D006261,3195622,,,5,Headache,N,
22463,QualifierName,Q000209,3195622,,,5,,N,etiology
22464,DescriptorName,D006505,3195622,,,6,Hepatitis,N,
22465,QualifierName,Q000209,3195622,,,6,,N,etiology
22466,DescriptorName,D006801,3195622,,,7,Humans,N,
22467,DescriptorName,D008297,3195622,,,8,Male,N,
22468,DescriptorName,D008875,3195622,,,9,Middle Aged,N,
22469,DescriptorName,D009325,3195622,,,10,Nausea,N,
22470,QualifierName,Q000209,3195622,,,10,,N,etiology
22471,DescriptorName,D001098,3195622,,,11,Spider Bites,N,
22472,QualifierName,Q000188,3195622,,,11,,Y,drug therapy
22473,DescriptorName,D013577,3195622,,,12,Syndrome,N,
22474,DescriptorName,D014839,3195622,,,13,Vomiting,N,
22475,QualifierName,Q000209,3195622,,,13,,N,etiology
22476,Chemical,D012293,3200786,Rifampin,VJT6J7R4TR,,,,
22477,DescriptorName,D000163,3200786,,,1,Acquired Immunodeficiency Syndrome,N,
22478,QualifierName,Q000188,3200786,,,1,,Y,drug therapy
22479,DescriptorName,D000302,3200786,,,2,Adrenal Cortex,N,
22480,QualifierName,Q000187,3200786,,,2,,N,drug effects
22481,DescriptorName,D000304,3200786,,,3,Adrenal Cortex Function Tests,N,
22482,DescriptorName,D000309,3200786,,,4,Adrenal Insufficiency,N,
22483,QualifierName,Q000139,3200786,,,4,,Y,chemically induced
22484,DescriptorName,D000328,3200786,,,5,Adult,N,
22485,DescriptorName,D006801,3200786,,,6,Humans,N,
22486,DescriptorName,D008099,3200786,,,7,Liver,N,
22487,QualifierName,Q000187,3200786,,,7,,N,drug effects
22488,DescriptorName,D008297,3200786,,,8,Male,N,
22489,DescriptorName,D012293,3200786,,,9,Rifampin,N,
22490,QualifierName,Q000009,3200786,,,9,,Y,adverse effects
22491,Chemical,D004110,3211830,Diltiazem,EE92BBP03H,,,,
22492,DescriptorName,D000368,3211830,,,1,Aged,N,
22493,DescriptorName,D000787,3211830,,,2,Angina Pectoris,N,
22494,QualifierName,Q000188,3211830,,,2,,N,drug therapy
22495,DescriptorName,D004110,3211830,,,3,Diltiazem,N,
22496,QualifierName,Q000009,3211830,,,3,,Y,adverse effects
22497,DescriptorName,D005260,3211830,,,4,Female,N,
22498,DescriptorName,D006801,3211830,,,5,Humans,N,
22499,DescriptorName,D008875,3211830,,,6,Middle Aged,N,
22500,DescriptorName,D018366,3211830,,,7,"Vasculitis, Leukocytoclastic, Cutaneous",N,
22501,QualifierName,Q000139,3211830,,,7,,Y,chemically induced
22502,Chemical,D009254,3242521,Nafcillin,4CNZ27M7RV,,,,
22503,DescriptorName,D000038,3242521,,,1,Abscess,N,
22504,QualifierName,Q000188,3242521,,,1,,Y,drug therapy
22505,DescriptorName,D002557,3242521,,,2,Cerebrospinal Fluid Shunts,N,
22506,DescriptorName,D006801,3242521,,,3,Humans,N,
22507,DescriptorName,D006849,3242521,,,4,Hydrocephalus,N,
22508,QualifierName,Q000601,3242521,,,4,,N,surgery
22509,DescriptorName,D007231,3242521,,,5,"Infant, Newborn",N,
22510,DescriptorName,D007235,3242521,,,6,"Infant, Premature, Diseases",N,
22511,QualifierName,Q000188,3242521,,,6,,Y,drug therapy
22512,DescriptorName,D007276,3242521,,,7,"Injections, Intraventricular",N,
22513,DescriptorName,D008297,3242521,,,8,Male,N,
22514,DescriptorName,D009254,3242521,,,9,Nafcillin,N,
22515,QualifierName,Q000008,3242521,,,9,,N,administration & dosage
22516,DescriptorName,D011183,3242521,,,10,Postoperative Complications,N,
22517,QualifierName,Q000188,3242521,,,10,,N,drug therapy
22518,DescriptorName,D013036,3242521,,,11,"Spasms, Infantile",N,
22519,QualifierName,Q000139,3242521,,,11,,Y,chemically induced
22520,DescriptorName,D013203,3242521,,,12,Staphylococcal Infections,N,
22521,QualifierName,Q000188,3242521,,,12,,Y,drug therapy
22522,Chemical,D005338,3259776,Fibrin Fibrinogen Degradation Products,0,,,,
22523,Chemical,D005340,3259776,Fibrinogen,9001-32-5,,,,
22524,Chemical,D013300,3259776,Streptokinase,EC 3.4.-,,,,
22525,DescriptorName,D001026,3259776,,,1,Coronary Artery Bypass,N,
22526,DescriptorName,D005338,3259776,,,2,Fibrin Fibrinogen Degradation Products,N,
22527,QualifierName,Q000378,3259776,,,2,,N,metabolism
22528,DescriptorName,D005340,3259776,,,3,Fibrinogen,N,
22529,QualifierName,Q000378,3259776,,,3,,N,metabolism
22530,DescriptorName,D006801,3259776,,,4,Humans,N,
22531,DescriptorName,D002542,3259776,,,5,Intracranial Embolism and Thrombosis,N,
22532,QualifierName,Q000139,3259776,,,5,,Y,chemically induced
22533,DescriptorName,D008297,3259776,,,6,Male,N,
22534,DescriptorName,D008875,3259776,,,7,Middle Aged,N,
22535,DescriptorName,D011183,3259776,,,8,Postoperative Complications,N,
22536,QualifierName,Q000188,3259776,,,8,,N,drug therapy
22537,DescriptorName,D011655,3259776,,,9,Pulmonary Embolism,N,
22538,QualifierName,Q000188,3259776,,,9,,Y,drug therapy
22539,DescriptorName,D011669,3259776,,,10,Pulmonary Wedge Pressure,N,
22540,QualifierName,Q000187,3259776,,,10,,N,drug effects
22541,DescriptorName,D013300,3259776,,,11,Streptokinase,N,
22542,QualifierName,Q000008,3259776,,,11,,N,administration & dosage
22543,Chemical,D010710,3277077,Phosphates,0,,,,
22544,Chemical,D004318,3277077,Doxycycline,N12000U13O,,,,
22545,DescriptorName,D004318,3277077,,,1,Doxycycline,N,
22546,QualifierName,Q000009,3277077,,,1,,Y,adverse effects
22547,DescriptorName,D005260,3277077,,,2,Female,N,
22548,DescriptorName,D006801,3277077,,,3,Humans,N,
22549,DescriptorName,D007177,3277077,,,4,Inappropriate ADH Syndrome,N,
22550,QualifierName,Q000097,3277077,,,4,,N,blood
22551,DescriptorName,D008875,3277077,,,5,Middle Aged,N,
22552,DescriptorName,D010710,3277077,,,6,Phosphates,N,
22553,QualifierName,Q000097,3277077,,,6,,Y,blood
22554,DescriptorName,D014397,3277077,,,7,"Tuberculosis, Pulmonary",N,
22555,QualifierName,Q000150,3277077,,,7,,N,complications
22556,Chemical,D000682,3290702,Amyloid,0,,,,
22557,Chemical,D002556,3290702,Cerebrospinal Fluid Proteins,0,,,,
22558,Chemical,D009419,3290702,Nerve Tissue Proteins,0,,,,
22559,Chemical,D013006,3290702,Growth Hormone,9002-72-6,,,,
22560,DescriptorName,D000328,3290702,,,1,Adult,N,
22561,DescriptorName,D000682,3290702,,,2,Amyloid,N,
22562,QualifierName,Q000302,3290702,,,2,,N,isolation & purification
22563,DescriptorName,D001921,3290702,,,3,Brain,N,
22564,QualifierName,Q000473,3290702,,,3,,Y,pathology
22565,DescriptorName,D001923,3290702,,,4,Brain Chemistry,N,
22566,DescriptorName,D002531,3290702,,,5,Cerebellum,N,
22567,QualifierName,Q000473,3290702,,,5,,N,pathology
22568,DescriptorName,D002540,3290702,,,6,Cerebral Cortex,N,
22569,QualifierName,Q000473,3290702,,,6,,N,pathology
22570,DescriptorName,D002556,3290702,,,7,Cerebrospinal Fluid Proteins,N,
22571,QualifierName,Q000032,3290702,,,7,,N,analysis
22572,DescriptorName,D007562,3290702,,,8,Creutzfeldt-Jakob Syndrome,N,
22573,QualifierName,Q000209,3290702,,,8,,Y,etiology
22574,DescriptorName,D004591,3290702,,,9,"Electrophoresis, Polyacrylamide Gel",N,
22575,DescriptorName,D005260,3290702,,,10,Female,N,
22576,DescriptorName,D013006,3290702,,,11,Growth Hormone,N,
22577,QualifierName,Q000009,3290702,,,11,,Y,adverse effects
22578,DescriptorName,D006801,3290702,,,12,Humans,N,
22579,DescriptorName,D007018,3290702,,,13,Hypopituitarism,N,
22580,QualifierName,Q000188,3290702,,,13,,Y,drug therapy
22581,DescriptorName,D009419,3290702,,,14,Nerve Tissue Proteins,N,
22582,QualifierName,Q000032,3290702,,,14,,N,analysis
22583,Chemical,D000894,3301251,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
22584,Chemical,D012459,3301251,Salicylates,0,,,,
22585,Chemical,C017959,3301251,choline magnesium trisalicylate,DJJ95FJP1H,,,,
22586,Chemical,D002794,3301251,Choline,N91BDP6H0X,,,,
22587,DescriptorName,D000328,3301251,,,1,Adult,N,
22588,DescriptorName,D000894,3301251,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
22589,QualifierName,Q000009,3301251,,,2,,Y,adverse effects
22590,DescriptorName,D056486,3301251,,,3,Chemical and Drug Induced Liver Injury,N,
22591,QualifierName,Q000209,3301251,,,3,,Y,etiology
22592,DescriptorName,D002794,3301251,,,4,Choline,N,
22593,QualifierName,Q000009,3301251,,,4,,N,adverse effects
22594,DescriptorName,D005260,3301251,,,5,Female,N,
22595,DescriptorName,D005335,3301251,,,6,Fever of Unknown Origin,N,
22596,QualifierName,Q000188,3301251,,,6,,N,drug therapy
22597,DescriptorName,D006801,3301251,,,7,Humans,N,
22598,DescriptorName,D008099,3301251,,,8,Liver,N,
22599,QualifierName,Q000187,3301251,,,8,,Y,drug effects
22600,DescriptorName,D012459,3301251,,,9,Salicylates,N,
22601,QualifierName,Q000009,3301251,,,9,,Y,adverse effects
22602,Chemical,D004338,3310776,Drug Combinations,0,,,,
22603,Chemical,D006852,3310776,Hydrochlorothiazide,0J48LPH2TH,,,,
22604,Chemical,C020743,3310776,hydrochlorothiazide-triamterene,14124-50-6,,,,
22605,Chemical,D009248,3310776,Nadolol,42200-33-9,,,,
22606,Chemical,D002216,3310776,Captopril,9G64RSX1XD,,,,
22607,Chemical,D014223,3310776,Triamterene,WS821Z52LQ,,,,
22608,DescriptorName,D001249,3310776,,,1,Asthma,N,
22609,QualifierName,Q000139,3310776,,,1,,Y,chemically induced
22610,DescriptorName,D002216,3310776,,,2,Captopril,N,
22611,QualifierName,Q000009,3310776,,,2,,Y,adverse effects
22612,DescriptorName,D004338,3310776,,,3,Drug Combinations,N,
22613,QualifierName,Q000627,3310776,,,3,,N,therapeutic use
22614,DescriptorName,D004359,3310776,,,4,"Drug Therapy, Combination",N,
22615,DescriptorName,D005541,3310776,,,5,Forced Expiratory Volume,N,
22616,DescriptorName,D006801,3310776,,,6,Humans,N,
22617,DescriptorName,D006852,3310776,,,7,Hydrochlorothiazide,N,
22618,QualifierName,Q000627,3310776,,,7,,N,therapeutic use
22619,DescriptorName,D006973,3310776,,,8,Hypertension,N,
22620,QualifierName,Q000150,3310776,,,8,,N,complications
22621,DescriptorName,D008297,3310776,,,9,Male,N,
22622,DescriptorName,D008875,3310776,,,10,Middle Aged,N,
22623,DescriptorName,D009248,3310776,,,11,Nadolol,N,
22624,QualifierName,Q000627,3310776,,,11,,N,therapeutic use
22625,DescriptorName,D014223,3310776,,,12,Triamterene,N,
22626,QualifierName,Q000627,3310776,,,12,,N,therapeutic use
22627,Chemical,D009883,3318771,Ophthalmic Solutions,0,,,,
22628,Chemical,D010862,3318771,Pilocarpine,01MI4Q9DI3,,,,
22629,Chemical,D013999,3318771,Timolol,817W3C6175,,,,
22630,DescriptorName,D000368,3318771,,,1,Aged,N,
22631,DescriptorName,D000369,3318771,,,2,"Aged, 80 and over",N,
22632,DescriptorName,D005128,3318771,,,3,Eye Diseases,N,
22633,QualifierName,Q000139,3318771,,,3,,Y,chemically induced
22634,DescriptorName,D005260,3318771,,,4,Female,N,
22635,DescriptorName,D005901,3318771,,,5,Glaucoma,N,
22636,QualifierName,Q000188,3318771,,,5,,N,drug therapy
22637,DescriptorName,D006801,3318771,,,6,Humans,N,
22638,DescriptorName,D008875,3318771,,,7,Middle Aged,N,
22639,DescriptorName,D009883,3318771,,,8,Ophthalmic Solutions,N,
22640,DescriptorName,D010390,3318771,,,9,"Pemphigoid, Benign Mucous Membrane",N,
22641,QualifierName,Q000139,3318771,,,9,,N,chemically induced
22642,DescriptorName,D010391,3318771,,,10,"Pemphigoid, Bullous",N,
22643,QualifierName,Q000139,3318771,,,10,,Y,chemically induced
22644,DescriptorName,D010862,3318771,,,11,Pilocarpine,N,
22645,QualifierName,Q000009,3318771,,,11,,N,adverse effects
22646,DescriptorName,D012872,3318771,,,12,"Skin Diseases, Vesiculobullous",N,
22647,QualifierName,Q000139,3318771,,,12,,Y,chemically induced
22648,DescriptorName,D013999,3318771,,,13,Timolol,N,
22649,QualifierName,Q000009,3318771,,,13,,N,adverse effects
22650,Chemical,D001798,331881,Blood Proteins,0,,,,
22651,Chemical,D007136,331881,Immunoglobulins,0,,,,
22652,Chemical,D002220,331881,Carbamazepine,33CM23913M,,,,
22653,Chemical,D010672,331881,Phenytoin,6158TKW0C5,,,,
22654,DescriptorName,D000328,331881,,,1,Adult,N,
22655,DescriptorName,D000368,331881,,,2,Aged,N,
22656,DescriptorName,D001798,331881,,,3,Blood Proteins,Y,
22657,DescriptorName,D002220,331881,,,4,Carbamazepine,N,
22658,QualifierName,Q000009,331881,,,4,,Y,adverse effects
22659,DescriptorName,D004827,331881,,,5,Epilepsy,N,
22660,QualifierName,Q000188,331881,,,5,,N,drug therapy
22661,DescriptorName,D005260,331881,,,6,Female,N,
22662,DescriptorName,D005455,331881,,,7,Fluorescent Antibody Technique,N,
22663,DescriptorName,D006801,331881,,,8,Humans,N,
22664,DescriptorName,D007136,331881,,,9,Immunoglobulins,N,
22665,QualifierName,Q000032,331881,,,9,,N,analysis
22666,DescriptorName,D008297,331881,,,10,Male,N,
22667,DescriptorName,D008875,331881,,,11,Middle Aged,N,
22668,DescriptorName,D010672,331881,,,12,Phenytoin,N,
22669,QualifierName,Q000009,331881,,,12,,Y,adverse effects
22670,DescriptorName,D012867,331881,,,13,Skin,N,
22671,QualifierName,Q000032,331881,,,13,,N,analysis
22672,Chemical,D003891,3335488,Desipramine,TG537D343B,,,,
22673,DescriptorName,D001714,3335488,,,1,Bipolar Disorder,N,
22674,QualifierName,Q000188,3335488,,,1,,N,drug therapy
22675,DescriptorName,D003866,3335488,,,2,Depressive Disorder,N,
22676,QualifierName,Q000188,3335488,,,2,,N,drug therapy
22677,DescriptorName,D003891,3335488,,,3,Desipramine,N,
22678,QualifierName,Q000009,3335488,,,3,,Y,adverse effects
22679,DescriptorName,D006801,3335488,,,4,Humans,N,
22680,DescriptorName,D008297,3335488,,,5,Male,N,
22681,DescriptorName,D008875,3335488,,,6,Middle Aged,N,
22682,DescriptorName,D010146,3335488,,,7,Pain,N,
22683,QualifierName,Q000139,3335488,,,7,,N,chemically induced
22684,DescriptorName,D013733,3335488,,,8,Testicular Diseases,N,
22685,QualifierName,Q000139,3335488,,,8,,Y,chemically induced
22686,Chemical,D008751,3343188,Methylene Blue,T42P99266K,,,,
22687,Chemical,D001566,3343188,Benzocaine,U3RSY48JW5,,,,
22688,DescriptorName,D000279,3343188,,,1,"Administration, Cutaneous",N,
22689,DescriptorName,D000818,3343188,,,2,Animals,N,
22690,DescriptorName,D001566,3343188,,,3,Benzocaine,N,
22691,QualifierName,Q000008,3343188,,,3,,N,administration & dosage
22692,DescriptorName,D002371,3343188,,,4,Cat Diseases,N,
22693,QualifierName,Q000139,3343188,,,4,,Y,chemically induced
22694,DescriptorName,D002415,3343188,,,5,Cats,N,
22695,DescriptorName,D005260,3343188,,,6,Female,N,
22696,DescriptorName,D008708,3343188,,,7,Methemoglobinemia,N,
22697,QualifierName,Q000139,3343188,,,7,,N,chemically induced
22698,DescriptorName,D008751,3343188,,,8,Methylene Blue,N,
22699,QualifierName,Q000627,3343188,,,8,,N,therapeutic use
22700,Chemical,D008727,3346128,Methotrexate,YL5FZ2Y5U1,,,,
22701,DescriptorName,D000328,3346128,,,1,Adult,N,
22702,DescriptorName,D006801,3346128,,,2,Humans,N,
22703,DescriptorName,D008297,3346128,,,3,Male,N,
22704,DescriptorName,D008727,3346128,,,4,Methotrexate,N,
22705,QualifierName,Q000009,3346128,,,4,,Y,adverse effects
22706,DescriptorName,D011565,3346128,,,5,Psoriasis,N,
22707,QualifierName,Q000188,3346128,,,5,,Y,drug therapy
22708,DescriptorName,D012883,3346128,,,6,Skin Ulcer,N,
22709,QualifierName,Q000139,3346128,,,6,,Y,chemically induced
22710,Chemical,D003524,3359700,Cyclosporins,0,,,,
22711,DescriptorName,D000328,3359700,,,1,Adult,N,
22712,DescriptorName,D003524,3359700,,,2,Cyclosporins,N,
22713,QualifierName,Q000009,3359700,,,2,,Y,adverse effects
22714,DescriptorName,D005260,3359700,,,3,Female,N,
22715,DescriptorName,D006801,3359700,,,4,Humans,N,
22716,DescriptorName,D007668,3359700,,,5,Kidney,N,
22717,QualifierName,Q000187,3359700,,,5,,Y,drug effects
22718,DescriptorName,D008180,3359700,,,6,"Lupus Erythematosus, Systemic",N,
22719,QualifierName,Q000188,3359700,,,6,,Y,drug therapy
22720,DescriptorName,D009395,3359700,,,7,"Nephritis, Interstitial",N,
22721,QualifierName,Q000150,3359700,,,7,,Y,complications
22722,Chemical,D011441,3365032,Propylthiouracil,721M9407IY,,,,
22723,DescriptorName,D000328,3365032,,,1,Adult,N,
22724,DescriptorName,D005260,3365032,,,2,Female,N,
22725,DescriptorName,D006801,3365032,,,3,Humans,N,
22726,DescriptorName,D006980,3365032,,,4,Hyperthyroidism,N,
22727,QualifierName,Q000188,3365032,,,4,,Y,drug therapy
22728,DescriptorName,D009132,3365032,,,5,Muscles,N,
22729,QualifierName,Q000473,3365032,,,5,,N,pathology
22730,DescriptorName,D009220,3365032,,,6,Myositis,N,
22731,QualifierName,Q000139,3365032,,,6,,Y,chemically induced
22732,DescriptorName,D011441,3365032,,,7,Propylthiouracil,N,
22733,QualifierName,Q000009,3365032,,,7,,Y,adverse effects
22734,Chemical,D010672,3370103,Phenytoin,6158TKW0C5,,,,
22735,DescriptorName,D000368,3370103,,,1,Aged,N,
22736,DescriptorName,D005260,3370103,,,2,Female,N,
22737,DescriptorName,D006323,3370103,,,3,Heart Arrest,N,
22738,QualifierName,Q000139,3370103,,,3,,Y,chemically induced
22739,DescriptorName,D006801,3370103,,,4,Humans,N,
22740,DescriptorName,D007262,3370103,,,5,"Infusions, Intravenous",N,
22741,QualifierName,Q000009,3370103,,,5,,N,adverse effects
22742,DescriptorName,D008297,3370103,,,6,Male,N,
22743,DescriptorName,D008875,3370103,,,7,Middle Aged,N,
22744,DescriptorName,D010672,3370103,,,8,Phenytoin,N,
22745,QualifierName,Q000008,3370103,,,8,,N,administration & dosage
22746,DescriptorName,D012640,3370103,,,9,Seizures,N,
22747,QualifierName,Q000188,3370103,,,9,,Y,drug therapy
22748,Chemical,C016030,3379435,pantogab,1977-33-9,,,,
22749,Chemical,D010205,3379435,Pantothenic Acid,19F5HK2737,,,,
22750,Chemical,D005680,3379435,gamma-Aminobutyric Acid,56-12-2,,,,
22751,DescriptorName,D000368,3379435,,,1,Aged,N,
22752,DescriptorName,D001706,3379435,,,2,Biopsy,N,
22753,DescriptorName,D003704,3379435,,,3,Dementia,N,
22754,QualifierName,Q000188,3379435,,,3,,Y,drug therapy
22755,DescriptorName,D005260,3379435,,,4,Female,N,
22756,DescriptorName,D006801,3379435,,,5,Humans,N,
22757,DescriptorName,D008099,3379435,,,6,Liver,N,
22758,QualifierName,Q000187,3379435,,,6,,N,drug effects
22759,DescriptorName,D008854,3379435,,,7,"Microscopy, Electron",N,
22760,DescriptorName,D010205,3379435,,,8,Pantothenic Acid,N,
22761,QualifierName,Q000009,3379435,,,8,,N,adverse effects
22762,DescriptorName,D012202,3379435,,,9,Reye Syndrome,N,
22763,QualifierName,Q000139,3379435,,,9,,Y,chemically induced
22764,DescriptorName,D005680,3379435,,,10,gamma-Aminobutyric Acid,N,
22765,QualifierName,Q000009,3379435,,,10,,N,adverse effects
22766,Chemical,D003692,3391110,Delayed-Action Preparations,0,,,,
22767,Chemical,D009020,3391110,Morphine,76I7G6D29C,,,,
22768,DescriptorName,D000230,3391110,,,1,Adenocarcinoma,N,
22769,QualifierName,Q000503,3391110,,,1,,N,physiopathology
22770,DescriptorName,D000368,3391110,,,2,Aged,N,
22771,DescriptorName,D003692,3391110,,,3,Delayed-Action Preparations,N,
22772,DescriptorName,D004417,3391110,,,4,Dyspnea,N,
22773,QualifierName,Q000139,3391110,,,4,,Y,chemically induced
22774,DescriptorName,D006801,3391110,,,5,Humans,N,
22775,DescriptorName,D008297,3391110,,,6,Male,N,
22776,DescriptorName,D009020,3391110,,,7,Morphine,N,
22777,QualifierName,Q000008,3391110,,,7,,N,administration & dosage
22778,DescriptorName,D010148,3391110,,,8,"Pain, Intractable",N,
22779,QualifierName,Q000188,3391110,,,8,,N,drug therapy
22780,DescriptorName,D011471,3391110,,,9,Prostatic Neoplasms,N,
22781,QualifierName,Q000503,3391110,,,9,,N,physiopathology
22782,Chemical,D003891,3397227,Desipramine,TG537D343B,,,,
22783,DescriptorName,D001288,3397227,,,1,Attention,N,
22784,QualifierName,Q000187,3397227,,,1,,Y,drug effects
22785,DescriptorName,D001289,3397227,,,2,Attention Deficit Disorder with Hyperactivity,N,
22786,QualifierName,Q000188,3397227,,,2,,Y,drug therapy
22787,DescriptorName,D003866,3397227,,,3,Depressive Disorder,N,
22788,QualifierName,Q000188,3397227,,,3,,Y,drug therapy
22789,DescriptorName,D003891,3397227,,,4,Desipramine,N,
22790,QualifierName,Q000009,3397227,,,4,,Y,adverse effects
22791,DescriptorName,D004542,3397227,,,5,Ejaculation,N,
22792,QualifierName,Q000187,3397227,,,5,,Y,drug effects
22793,DescriptorName,D006801,3397227,,,6,Humans,N,
22794,DescriptorName,D008297,3397227,,,7,Male,N,
22795,DescriptorName,D008875,3397227,,,8,Middle Aged,N,
22796,DescriptorName,D009948,3397227,,,9,Orgasm,N,
22797,QualifierName,Q000187,3397227,,,9,,N,drug effects
22798,DescriptorName,D012677,3397227,,,10,Sensation,N,
22799,QualifierName,Q000187,3397227,,,10,,Y,drug effects
22800,Chemical,D009020,3400849,Morphine,76I7G6D29C,,,,
22801,DescriptorName,D005260,3400849,,,1,Female,N,
22802,DescriptorName,D006801,3400849,,,2,Humans,N,
22803,DescriptorName,D007263,3400849,,,3,"Infusions, Parenteral",N,
22804,DescriptorName,D008875,3400849,,,4,Middle Aged,N,
22805,DescriptorName,D009020,3400849,,,5,Morphine,N,
22806,QualifierName,Q000009,3400849,,,5,,Y,adverse effects
22807,DescriptorName,D009207,3400849,,,6,Myoclonus,N,
22808,QualifierName,Q000139,3400849,,,6,,Y,chemically induced
22809,DescriptorName,D010148,3400849,,,7,"Pain, Intractable",N,
22810,QualifierName,Q000188,3400849,,,7,,N,drug therapy
22811,Chemical,D008715,3405528,Methionine,AE28F7PNPL,,,,
22812,Chemical,D001663,3405528,Bilirubin,RFM9X3LJ49,,,,
22813,Chemical,D006221,3405528,Halothane,UQT9G45D1P,,,,
22814,DescriptorName,D000328,3405528,,,1,Adult,N,
22815,DescriptorName,D000769,3405528,,,2,"Anesthesia, Inhalation",N,
22816,QualifierName,Q000009,3405528,,,2,,N,adverse effects
22817,DescriptorName,D001663,3405528,,,3,Bilirubin,N,
22818,QualifierName,Q000097,3405528,,,3,,N,blood
22819,DescriptorName,D056486,3405528,,,4,Chemical and Drug Induced Liver Injury,N,
22820,QualifierName,Q000188,3405528,,,4,,N,drug therapy
22821,DescriptorName,D005260,3405528,,,5,Female,N,
22822,DescriptorName,D006221,3405528,,,6,Halothane,N,
22823,QualifierName,Q000009,3405528,,,6,,Y,adverse effects
22824,DescriptorName,D006801,3405528,,,7,Humans,N,
22825,DescriptorName,D007565,3405528,,,8,Jaundice,N,
22826,QualifierName,Q000139,3405528,,,8,,N,chemically induced
22827,DescriptorName,D008715,3405528,,,9,Methionine,N,
22828,QualifierName,Q000627,3405528,,,9,,Y,therapeutic use
22829,Chemical,D011166,3410226,Porphyrins,0,,,,
22830,Chemical,D003520,3410226,Cyclophosphamide,8N3DW7272P,,,,
22831,Chemical,D002945,3410226,Cisplatin,Q20Q21Q62J,,,,
22832,DescriptorName,D002945,3410226,,,1,Cisplatin,N,
22833,QualifierName,Q000627,3410226,,,1,,N,therapeutic use
22834,DescriptorName,D003520,3410226,,,2,Cyclophosphamide,N,
22835,QualifierName,Q000009,3410226,,,2,,Y,adverse effects
22836,DescriptorName,D003536,3410226,,,3,Cystadenocarcinoma,N,
22837,QualifierName,Q000188,3410226,,,3,,Y,drug therapy
22838,DescriptorName,D005260,3410226,,,4,Female,N,
22839,DescriptorName,D006801,3410226,,,5,Humans,N,
22840,DescriptorName,D008875,3410226,,,6,Middle Aged,N,
22841,DescriptorName,D010051,3410226,,,7,Ovarian Neoplasms,N,
22842,QualifierName,Q000188,3410226,,,7,,Y,drug therapy
22843,DescriptorName,D011164,3410226,,,8,Porphyrias,N,
22844,QualifierName,Q000139,3410226,,,8,,Y,chemically induced
22845,DescriptorName,D011166,3410226,,,9,Porphyrins,N,
22846,QualifierName,Q000652,3410226,,,9,,N,urine
22847,DescriptorName,D012871,3410226,,,10,Skin Diseases,N,
22848,QualifierName,Q000139,3410226,,,10,,Y,chemically induced
22849,Chemical,D011206,3417739,Povidone-Iodine,85H0HZU99M,,,,
22850,Chemical,D011205,3417739,Povidone,FZ989GH94E,,,,
22851,DescriptorName,D058186,3417739,,,1,Acute Kidney Injury,N,
22852,QualifierName,Q000139,3417739,,,1,,Y,chemically induced
22853,DescriptorName,D005260,3417739,,,2,Female,N,
22854,DescriptorName,D006801,3417739,,,3,Humans,N,
22855,DescriptorName,D008480,3417739,,,4,Mediastinitis,N,
22856,QualifierName,Q000188,3417739,,,4,,Y,drug therapy
22857,DescriptorName,D008875,3417739,,,5,Middle Aged,N,
22858,DescriptorName,D011205,3417739,,,6,Povidone,N,
22859,QualifierName,Q000031,3417739,,,6,,Y,analogs & derivatives
22860,DescriptorName,D011206,3417739,,,7,Povidone-Iodine,N,
22861,QualifierName,Q000008,3417739,,,7,,N,administration & dosage
22862,DescriptorName,D013530,3417739,,,8,Surgical Wound Infection,N,
22863,QualifierName,Q000188,3417739,,,8,,N,drug therapy
22864,DescriptorName,D007507,3417739,,,9,Therapeutic Irrigation,N,
22865,Chemical,D010396,3430507,Penicillamine,GNN1DV99GX,,,,
22866,DescriptorName,D001706,3430507,,,1,Biopsy,N,
22867,DescriptorName,D005260,3430507,,,2,Female,N,
22868,DescriptorName,D005921,3430507,,,3,Glomerulonephritis,N,
22869,QualifierName,Q000139,3430507,,,3,,Y,chemically induced
22870,DescriptorName,D006469,3430507,,,4,Hemoptysis,N,
22871,QualifierName,Q000139,3430507,,,4,,N,chemically induced
22872,DescriptorName,D006801,3430507,,,5,Humans,N,
22873,DescriptorName,D007678,3430507,,,6,Kidney Glomerulus,N,
22874,QualifierName,Q000473,3430507,,,6,,N,pathology
22875,DescriptorName,D008854,3430507,,,7,"Microscopy, Electron",N,
22876,DescriptorName,D008875,3430507,,,8,Middle Aged,N,
22877,DescriptorName,D010396,3430507,,,9,Penicillamine,N,
22878,QualifierName,Q000009,3430507,,,9,,Y,adverse effects
22879,DescriptorName,D012595,3430507,,,10,"Scleroderma, Systemic",N,
22880,QualifierName,Q000188,3430507,,,10,,Y,drug therapy
22881,Chemical,D000305,3438585,Adrenal Cortex Hormones,0,,,,
22882,Chemical,D006046,3438585,Gold,7440-57-5,,,,
22883,DescriptorName,D000305,3438585,,,1,Adrenal Cortex Hormones,N,
22884,QualifierName,Q000627,3438585,,,1,,N,therapeutic use
22885,DescriptorName,D001992,3438585,,,2,Bronchoalveolar Lavage Fluid,N,
22886,QualifierName,Q000032,3438585,,,2,,N,analysis
22887,DescriptorName,D005260,3438585,,,3,Female,N,
22888,DescriptorName,D006046,3438585,,,4,Gold,N,
22889,QualifierName,Q000009,3438585,,,4,,Y,adverse effects
22890,DescriptorName,D006801,3438585,,,5,Humans,N,
22891,DescriptorName,D008875,3438585,,,6,Middle Aged,N,
22892,DescriptorName,D011658,3438585,,,7,Pulmonary Fibrosis,N,
22893,QualifierName,Q000139,3438585,,,7,,Y,chemically induced
22894,DescriptorName,D011859,3438585,,,8,Radiography,N,
22895,DescriptorName,D012129,3438585,,,9,Respiratory Function Tests,N,
22896,Chemical,D008667,3449312,Metalloproteins,0,,,,
22897,Chemical,D050607,3449312,Organogold Compounds,0,,,,
22898,Chemical,D009942,3449312,Organometallic Compounds,0,,,,
22899,Chemical,D020005,3449312,Propanols,0,,,,
22900,Chemical,D013438,3449312,Sulfhydryl Compounds,0,,,,
22901,Chemical,D004112,3449312,Dimercaprol,0CPP32S55X,,,,
22902,Chemical,C013394,3449312,aurotioprol,G7097J63E9,,,,
22903,DescriptorName,D000328,3449312,,,1,Adult,N,
22904,DescriptorName,D000368,3449312,,,2,Aged,N,
22905,DescriptorName,D000741,3449312,,,3,"Anemia, Aplastic",N,
22906,QualifierName,Q000139,3449312,,,3,,Y,chemically induced
22907,DescriptorName,D001172,3449312,,,4,"Arthritis, Rheumatoid",N,
22908,QualifierName,Q000188,3449312,,,4,,N,drug therapy
22909,DescriptorName,D004112,3449312,,,5,Dimercaprol,N,
22910,QualifierName,Q000009,3449312,,,5,,N,adverse effects
22911,DescriptorName,D005260,3449312,,,6,Female,N,
22912,DescriptorName,D006801,3449312,,,7,Humans,N,
22913,DescriptorName,D008667,3449312,,,8,Metalloproteins,N,
22914,QualifierName,Q000009,3449312,,,8,,Y,adverse effects
22915,DescriptorName,D008875,3449312,,,9,Middle Aged,N,
22916,DescriptorName,D050607,3449312,,,10,Organogold Compounds,N,
22917,DescriptorName,D009942,3449312,,,11,Organometallic Compounds,Y,
22918,DescriptorName,D020005,3449312,,,12,Propanols,N,
22919,DescriptorName,D012772,3449312,,,13,"Shock, Septic",N,
22920,QualifierName,Q000209,3449312,,,13,,N,etiology
22921,DescriptorName,D013438,3449312,,,14,Sulfhydryl Compounds,N,
22922,Chemical,D015122,3465489,Mercaptopurine,E7WED276I5,,,,
22923,DescriptorName,D000284,3465489,,,1,"Administration, Oral",N,
22924,DescriptorName,D000293,3465489,,,2,Adolescent,N,
22925,DescriptorName,D002648,3465489,,,3,Child,N,
22926,DescriptorName,D002675,3465489,,,4,"Child, Preschool",N,
22927,DescriptorName,D002851,3465489,,,5,"Chromatography, High Pressure Liquid",N,
22928,DescriptorName,D005260,3465489,,,6,Female,N,
22929,DescriptorName,D006801,3465489,,,7,Humans,N,
22930,DescriptorName,D007700,3465489,,,8,Kinetics,N,
22931,DescriptorName,D007945,3465489,,,9,"Leukemia, Lymphoid",N,
22932,QualifierName,Q000188,3465489,,,9,,N,drug therapy
22933,DescriptorName,D008297,3465489,,,10,Male,N,
22934,DescriptorName,D015122,3465489,,,11,Mercaptopurine,N,
22935,QualifierName,Q000009,3465489,,,11,,N,adverse effects
22936,DescriptorName,D009503,3465489,,,12,Neutropenia,N,
22937,QualifierName,Q000139,3465489,,,12,,N,chemically induced
22938,Chemical,D003561,3470173,Cytarabine,04079A1RDZ,,,,
22939,DescriptorName,D002526,3470173,,,1,Cerebellar Diseases,N,
22940,QualifierName,Q000139,3470173,,,1,,Y,chemically induced
22941,DescriptorName,D003561,3470173,,,2,Cytarabine,N,
22942,QualifierName,Q000009,3470173,,,2,,Y,adverse effects
22943,DescriptorName,D006801,3470173,,,3,Humans,N,
22944,DescriptorName,D007951,3470173,,,4,"Leukemia, Myeloid",N,
22945,QualifierName,Q000188,3470173,,,4,,N,drug therapy
22946,DescriptorName,D008297,3470173,,,5,Male,N,
22947,DescriptorName,D008875,3470173,,,6,Middle Aged,N,
22948,Chemical,D005839,3485422,Gentamicins,0,,,,
22949,DescriptorName,D000328,3485422,,,1,Adult,N,
22950,DescriptorName,D009877,3485422,,,2,Endophthalmitis,N,
22951,QualifierName,Q000209,3485422,,,2,,N,etiology
22952,DescriptorName,D005131,3485422,,,3,Eye Injuries,N,
22953,QualifierName,Q000150,3485422,,,3,,N,complications
22954,DescriptorName,D005260,3485422,,,4,Female,N,
22955,DescriptorName,D005451,3485422,,,5,Fluorescein Angiography,N,
22956,DescriptorName,D005839,3485422,,,6,Gentamicins,N,
22957,QualifierName,Q000008,3485422,,,6,,Y,administration & dosage
22958,DescriptorName,D006801,3485422,,,7,Humans,N,
22959,DescriptorName,D007238,3485422,,,8,Infarction,N,
22960,QualifierName,Q000175,3485422,,,8,,N,diagnosis
22961,DescriptorName,D008266,3485422,,,9,Macula Lutea,Y,
22962,DescriptorName,D008297,3485422,,,10,Male,N,
22963,DescriptorName,D008875,3485422,,,11,Middle Aged,N,
22964,DescriptorName,D011183,3485422,,,12,Postoperative Complications,N,
22965,DescriptorName,D012164,3485422,,,13,Retinal Diseases,N,
22966,QualifierName,Q000175,3485422,,,13,,N,diagnosis
22967,DescriptorName,D013203,3485422,,,14,Staphylococcal Infections,N,
22968,QualifierName,Q000188,3485422,,,14,,N,drug therapy
22969,DescriptorName,D013212,3485422,,,15,Staphylococcus epidermidis,N,
22970,DescriptorName,D014821,3485422,,,16,Vitrectomy,Y,
22971,DescriptorName,D014822,3485422,,,17,Vitreous Body,N,
22972,Chemical,D010879,3493797,Piperazines,0,,,,
22973,Chemical,D011929,3493797,Razoxane,5AR83PR647,,,,
22974,DescriptorName,D000368,3493797,,,1,Aged,N,
22975,DescriptorName,D001402,3493797,,,2,B-Lymphocytes,N,
22976,DescriptorName,D005260,3493797,,,3,Female,N,
22977,DescriptorName,D006801,3493797,,,4,Humans,N,
22978,DescriptorName,D008048,3493797,,,5,Lip Neoplasms,N,
22979,QualifierName,Q000139,3493797,,,5,,Y,chemically induced
22980,DescriptorName,D008223,3493797,,,6,Lymphoma,N,
22981,QualifierName,Q000139,3493797,,,6,,Y,chemically induced
22982,DescriptorName,D010879,3493797,,,7,Piperazines,N,
22983,QualifierName,Q000009,3493797,,,7,,Y,adverse effects
22984,DescriptorName,D011565,3493797,,,8,Psoriasis,N,
22985,QualifierName,Q000188,3493797,,,8,,Y,drug therapy
22986,DescriptorName,D011929,3493797,,,9,Razoxane,N,
22987,QualifierName,Q000009,3493797,,,9,,Y,adverse effects
22988,Chemical,D000893,3501467,Anti-Inflammatory Agents,0,,,,
22989,Chemical,D008667,3501467,Metalloproteins,0,,,,
22990,Chemical,D050607,3501467,Organogold Compounds,0,,,,
22991,Chemical,D009942,3501467,Organometallic Compounds,0,,,,
22992,Chemical,D020005,3501467,Propanols,0,,,,
22993,Chemical,D013256,3501467,Steroids,0,,,,
22994,Chemical,D013438,3501467,Sulfhydryl Compounds,0,,,,
22995,Chemical,D004112,3501467,Dimercaprol,0CPP32S55X,,,,
22996,Chemical,C013394,3501467,aurotioprol,G7097J63E9,,,,
22997,DescriptorName,D000361,3501467,,,1,Agammaglobulinemia,N,
22998,QualifierName,Q000139,3501467,,,1,,Y,chemically induced
22999,DescriptorName,D000893,3501467,,,2,Anti-Inflammatory Agents,N,
23000,QualifierName,Q000009,3501467,,,2,,Y,adverse effects
23001,DescriptorName,D001172,3501467,,,3,"Arthritis, Rheumatoid",N,
23002,QualifierName,Q000188,3501467,,,3,,Y,drug therapy
23003,DescriptorName,D001402,3501467,,,4,B-Lymphocytes,N,
23004,QualifierName,Q000187,3501467,,,4,,Y,drug effects
23005,DescriptorName,D004112,3501467,,,5,Dimercaprol,N,
23006,QualifierName,Q000009,3501467,,,5,,N,adverse effects
23007,DescriptorName,D006801,3501467,,,6,Humans,N,
23008,DescriptorName,D008213,3501467,,,7,Lymphocyte Activation,N,
23009,QualifierName,Q000187,3501467,,,7,,N,drug effects
23010,DescriptorName,D008297,3501467,,,8,Male,N,
23011,DescriptorName,D008667,3501467,,,9,Metalloproteins,N,
23012,QualifierName,Q000009,3501467,,,9,,Y,adverse effects
23013,DescriptorName,D008875,3501467,,,10,Middle Aged,N,
23014,DescriptorName,D050607,3501467,,,11,Organogold Compounds,N,
23015,DescriptorName,D009942,3501467,,,12,Organometallic Compounds,Y,
23016,DescriptorName,D020005,3501467,,,13,Propanols,N,
23017,DescriptorName,D013256,3501467,,,14,Steroids,N,
23018,DescriptorName,D013438,3501467,,,15,Sulfhydryl Compounds,N,
23019,Chemical,D005292,3508194,Ferricyanides,0,,,,
23020,Chemical,D009599,3508194,Nitroprusside,169D1260KM,,,,
23021,DescriptorName,D000328,3508194,,,1,Adult,N,
23022,DescriptorName,D005292,3508194,,,2,Ferricyanides,N,
23023,QualifierName,Q000009,3508194,,,2,,Y,adverse effects
23024,DescriptorName,D006801,3508194,,,3,Humans,N,
23025,DescriptorName,D006973,3508194,,,4,Hypertension,N,
23026,QualifierName,Q000188,3508194,,,4,,N,drug therapy
23027,DescriptorName,D007263,3508194,,,5,"Infusions, Parenteral",N,
23028,DescriptorName,D007970,3508194,,,6,Leukopenia,N,
23029,QualifierName,Q000139,3508194,,,6,,Y,chemically induced
23030,DescriptorName,D008297,3508194,,,7,Male,N,
23031,DescriptorName,D009599,3508194,,,8,Nitroprusside,N,
23032,QualifierName,Q000008,3508194,,,8,,N,administration & dosage
23033,DescriptorName,D013921,3508194,,,9,Thrombocytopenia,N,
23034,QualifierName,Q000139,3508194,,,9,,Y,chemically induced
23035,Chemical,D003524,3513544,Cyclosporins,0,,,,
23036,Chemical,D008012,3513544,Lidocaine,98PI200987,,,,
23037,Chemical,D011239,3513544,Prednisolone,9PHQ9Y1OLM,,,,
23038,DescriptorName,D000284,3513544,,,1,"Administration, Oral",N,
23039,DescriptorName,D000287,3513544,,,2,"Administration, Topical",N,
23040,DescriptorName,D000328,3513544,,,3,Adult,N,
23041,DescriptorName,D002177,3513544,,,4,Candidiasis,N,
23042,QualifierName,Q000175,3513544,,,4,,N,diagnosis
23043,DescriptorName,D003524,3513544,,,5,Cyclosporins,N,
23044,QualifierName,Q000008,3513544,,,5,,N,administration & dosage
23045,DescriptorName,D003937,3513544,,,6,"Diagnosis, Differential",N,
23046,DescriptorName,D004359,3513544,,,7,"Drug Therapy, Combination",N,
23047,DescriptorName,D004941,3513544,,,8,Esophagitis,N,
23048,QualifierName,Q000175,3513544,,,8,,N,diagnosis
23049,DescriptorName,D004947,3513544,,,9,Esophagus,N,
23050,QualifierName,Q000473,3513544,,,9,,N,pathology
23051,DescriptorName,D005260,3513544,,,10,Female,N,
23052,DescriptorName,D006561,3513544,,,11,Herpes Simplex,N,
23053,QualifierName,Q000175,3513544,,,11,,N,diagnosis
23054,DescriptorName,D006801,3513544,,,12,Humans,N,
23055,DescriptorName,D016030,3513544,,,13,Kidney Transplantation,Y,
23056,DescriptorName,D008012,3513544,,,14,Lidocaine,N,
23057,QualifierName,Q000008,3513544,,,14,,N,administration & dosage
23058,DescriptorName,D011183,3513544,,,15,Postoperative Complications,Y,
23059,DescriptorName,D011239,3513544,,,16,Prednisolone,N,
23060,QualifierName,Q000008,3513544,,,16,,N,administration & dosage
23061,DescriptorName,D013997,3513544,,,17,Time Factors,N,
23062,Chemical,D007328,3528096,Insulin,0,,,,
23063,DescriptorName,D000818,3528096,,,1,Animals,N,
23064,DescriptorName,D002371,3528096,,,2,Cat Diseases,N,
23065,QualifierName,Q000188,3528096,,,2,,Y,drug therapy
23066,DescriptorName,D002415,3528096,,,3,Cats,N,
23067,DescriptorName,D003920,3528096,,,4,Diabetes Mellitus,N,
23068,QualifierName,Q000188,3528096,,,4,,N,drug therapy
23069,DescriptorName,D005260,3528096,,,5,Female,N,
23070,DescriptorName,D006943,3528096,,,6,Hyperglycemia,N,
23071,QualifierName,Q000139,3528096,,,6,,N,chemically induced
23072,DescriptorName,D007328,3528096,,,7,Insulin,N,
23073,QualifierName,Q000009,3528096,,,7,,Y,adverse effects
23074,DescriptorName,D008297,3528096,,,8,Male,N,
23075,Chemical,D001323,3542612,Autoantibodies,0,,,,
23076,Chemical,D002216,3542612,Captopril,9G64RSX1XD,,,,
23077,DescriptorName,D001323,3542612,,,1,Autoantibodies,N,
23078,QualifierName,Q000096,3542612,,,1,,N,biosynthesis
23079,DescriptorName,D001485,3542612,,,2,Basement Membrane,N,
23080,QualifierName,Q000276,3542612,,,2,,N,immunology
23081,DescriptorName,D001706,3542612,,,3,Biopsy,N,
23082,DescriptorName,D002216,3542612,,,4,Captopril,N,
23083,QualifierName,Q000009,3542612,,,4,,Y,adverse effects
23084,DescriptorName,D005110,3542612,,,5,Extracellular Space,N,
23085,QualifierName,Q000276,3542612,,,5,,N,immunology
23086,DescriptorName,D005455,3542612,,,6,Fluorescent Antibody Technique,N,
23087,DescriptorName,D006801,3542612,,,7,Humans,N,
23088,DescriptorName,D006973,3542612,,,8,Hypertension,N,
23089,QualifierName,Q000188,3542612,,,8,,Y,drug therapy
23090,DescriptorName,D008010,3542612,,,9,Lichen Planus,N,
23091,QualifierName,Q000139,3542612,,,9,,Y,chemically induced
23092,DescriptorName,D008297,3542612,,,10,Male,N,
23093,DescriptorName,D008875,3542612,,,11,Middle Aged,N,
23094,DescriptorName,D010392,3542612,,,12,Pemphigus,N,
23095,QualifierName,Q000139,3542612,,,12,,Y,chemically induced
23096,DescriptorName,D012867,3542612,,,13,Skin,N,
23097,QualifierName,Q000473,3542612,,,13,,N,pathology
23098,Chemical,D001500,354311,BCG Vaccine,0,,,,
23099,Chemical,D004917,354311,Erythromycin,63937KV33D,,,,
23100,Chemical,D007538,354311,Isoniazid,V83O1VOZ8L,,,,
23101,Chemical,D013307,354311,Streptomycin,Y45QSO73OB,,,,
23102,DescriptorName,D000038,354311,,,1,Abscess,N,
23103,QualifierName,Q000139,354311,,,1,,Y,chemically induced
23104,DescriptorName,D001500,354311,,,2,BCG Vaccine,N,
23105,QualifierName,Q000009,354311,,,2,,Y,adverse effects
23106,DescriptorName,D002111,354311,,,3,Calcaneus,N,
23107,QualifierName,Q000473,354311,,,3,,Y,pathology
23108,DescriptorName,D002648,354311,,,4,Child,N,
23109,DescriptorName,D004917,354311,,,5,Erythromycin,N,
23110,QualifierName,Q000627,354311,,,5,,N,therapeutic use
23111,DescriptorName,D005260,354311,,,6,Female,N,
23112,DescriptorName,D006801,354311,,,7,Humans,N,
23113,DescriptorName,D007538,354311,,,8,Isoniazid,N,
23114,QualifierName,Q000627,354311,,,8,,N,therapeutic use
23115,DescriptorName,D009163,354311,,,9,Mycobacterium bovis,N,
23116,QualifierName,Q000302,354311,,,9,,N,isolation & purification
23117,DescriptorName,D010019,354311,,,10,Osteomyelitis,N,
23118,QualifierName,Q000139,354311,,,10,,Y,chemically induced
23119,DescriptorName,D013307,354311,,,11,Streptomycin,N,
23120,QualifierName,Q000627,354311,,,11,,N,therapeutic use
23121,Chemical,D008914,3549808,Minoxidil,5965120SH1,,,,
23122,DescriptorName,D000287,3549808,,,1,"Administration, Topical",N,
23123,DescriptorName,D000328,3549808,,,2,Adult,N,
23124,DescriptorName,D000368,3549808,,,3,Aged,N,
23125,DescriptorName,D000505,3549808,,,4,Alopecia,N,
23126,QualifierName,Q000188,3549808,,,4,,Y,drug therapy
23127,DescriptorName,D002986,3549808,,,5,Clinical Trials as Topic,N,
23128,DescriptorName,D005260,3549808,,,6,Female,N,
23129,DescriptorName,D006801,3549808,,,7,Humans,N,
23130,DescriptorName,D008297,3549808,,,8,Male,N,
23131,DescriptorName,D008875,3549808,,,9,Middle Aged,N,
23132,DescriptorName,D008914,3549808,,,10,Minoxidil,N,
23133,QualifierName,Q000009,3549808,,,10,,Y,adverse effects
23134,DescriptorName,D011897,3549808,,,11,Random Allocation,N,
23135,Chemical,D003989,3558331,Dibenzoxazepines,0,,,,
23136,Chemical,D000657,3558331,Amoxapine,R63VQ857OT,,,,
23137,DescriptorName,D000368,3558331,,,1,Aged,N,
23138,DescriptorName,D000369,3558331,,,2,"Aged, 80 and over",N,
23139,DescriptorName,D000657,3558331,,,3,Amoxapine,N,
23140,QualifierName,Q000009,3558331,,,3,,Y,adverse effects
23141,DescriptorName,D003072,3558331,,,4,Cognition Disorders,N,
23142,QualifierName,Q000139,3558331,,,4,,Y,chemically induced
23143,DescriptorName,D003704,3558331,,,5,Dementia,N,
23144,QualifierName,Q000150,3558331,,,5,,N,complications
23145,DescriptorName,D003866,3558331,,,6,Depressive Disorder,N,
23146,QualifierName,Q000150,3558331,,,6,,N,complications
23147,DescriptorName,D003989,3558331,,,7,Dibenzoxazepines,N,
23148,QualifierName,Q000009,3558331,,,7,,Y,adverse effects
23149,DescriptorName,D005260,3558331,,,8,Female,N,
23150,DescriptorName,D006801,3558331,,,9,Humans,N,
23151,DescriptorName,D008297,3558331,,,10,Male,N,
23152,Chemical,D007052,3565435,Ibuprofen,WK2XYI10QM,,,,
23153,DescriptorName,D000328,3565435,,,1,Adult,N,
23154,DescriptorName,D003937,3565435,,,2,"Diagnosis, Differential",N,
23155,DescriptorName,D004342,3565435,,,3,Drug Hypersensitivity,N,
23156,QualifierName,Q000175,3565435,,,3,,N,diagnosis
23157,DescriptorName,D005260,3565435,,,4,Female,N,
23158,DescriptorName,D006801,3565435,,,5,Humans,N,
23159,DescriptorName,D007052,3565435,,,6,Ibuprofen,N,
23160,QualifierName,Q000009,3565435,,,6,,Y,adverse effects
23161,DescriptorName,D008180,3565435,,,7,"Lupus Erythematosus, Systemic",N,
23162,QualifierName,Q000188,3565435,,,7,,N,drug therapy
23163,DescriptorName,D013997,3565435,,,8,Time Factors,N,
23164,Chemical,D002701,3569037,Chloramphenicol,66974FR9Q1,,,,
23165,Chemical,D000667,3569037,Ampicillin,7C782967RD,,,,
23166,DescriptorName,D000328,3569037,,,1,Adult,N,
23167,DescriptorName,D000667,3569037,,,2,Ampicillin,N,
23168,QualifierName,Q000009,3569037,,,2,,N,adverse effects
23169,DescriptorName,D002701,3569037,,,3,Chloramphenicol,N,
23170,QualifierName,Q000009,3569037,,,3,,Y,adverse effects
23171,DescriptorName,D004342,3569037,,,4,Drug Hypersensitivity,N,
23172,QualifierName,Q000209,3569037,,,4,,Y,etiology
23173,DescriptorName,D004417,3569037,,,5,Dyspnea,N,
23174,QualifierName,Q000139,3569037,,,5,,N,chemically induced
23175,DescriptorName,D006801,3569037,,,6,Humans,N,
23176,DescriptorName,D008297,3569037,,,7,Male,N,
23177,DescriptorName,D014435,3569037,,,8,Typhoid Fever,N,
23178,QualifierName,Q000188,3569037,,,8,,Y,drug therapy
23179,DescriptorName,D014581,3569037,,,9,Urticaria,N,
23180,QualifierName,Q000139,3569037,,,9,,N,chemically induced
23181,Chemical,D010396,3579660,Penicillamine,GNN1DV99GX,,,,
23182,Chemical,D015032,3579660,Zinc,J41CSQ7QDS,,,,
23183,DescriptorName,D000293,3579660,,,1,Adolescent,N,
23184,DescriptorName,D000328,3579660,,,2,Adult,N,
23185,DescriptorName,D001479,3579660,,,3,Basal Ganglia,N,
23186,QualifierName,Q000473,3579660,,,3,,N,pathology
23187,DescriptorName,D005260,3579660,,,4,Female,N,
23188,DescriptorName,D005625,3579660,,,5,Frontal Lobe,N,
23189,QualifierName,Q000473,3579660,,,5,,N,pathology
23190,DescriptorName,D006527,3579660,,,6,Hepatolenticular Degeneration,N,
23191,QualifierName,Q000188,3579660,,,6,,Y,drug therapy
23192,DescriptorName,D006801,3579660,,,7,Humans,N,
23193,DescriptorName,D009682,3579660,,,8,Magnetic Resonance Spectroscopy,N,
23194,DescriptorName,D008297,3579660,,,9,Male,N,
23195,DescriptorName,D008875,3579660,,,10,Middle Aged,N,
23196,DescriptorName,D010396,3579660,,,11,Penicillamine,N,
23197,QualifierName,Q000009,3579660,,,11,,Y,adverse effects
23198,DescriptorName,D012189,3579660,,,12,Retrospective Studies,N,
23199,DescriptorName,D012640,3579660,,,13,Seizures,N,
23200,QualifierName,Q000139,3579660,,,13,,N,chemically induced
23201,DescriptorName,D015032,3579660,,,14,Zinc,N,
23202,QualifierName,Q000627,3579660,,,14,,N,therapeutic use
23203,Chemical,D003520,3586163,Cyclophosphamide,8N3DW7272P,,,,
23204,DescriptorName,D000368,3586163,,,1,Aged,N,
23205,DescriptorName,D002295,3586163,,,2,"Carcinoma, Transitional Cell",N,
23206,QualifierName,Q000139,3586163,,,2,,Y,chemically induced
23207,DescriptorName,D003520,3586163,,,3,Cyclophosphamide,N,
23208,QualifierName,Q000009,3586163,,,3,,Y,adverse effects
23209,DescriptorName,D005260,3586163,,,4,Female,N,
23210,DescriptorName,D006801,3586163,,,5,Humans,N,
23211,DescriptorName,D007680,3586163,,,6,Kidney Neoplasms,N,
23212,QualifierName,Q000139,3586163,,,6,,Y,chemically induced
23213,DescriptorName,D007682,3586163,,,7,Kidney Pelvis,N,
23214,DescriptorName,D008228,3586163,,,8,"Lymphoma, Non-Hodgkin",N,
23215,QualifierName,Q000188,3586163,,,8,,N,drug therapy
23216,DescriptorName,D014516,3586163,,,9,Ureteral Neoplasms,N,
23217,QualifierName,Q000139,3586163,,,9,,Y,chemically induced
23218,Chemical,D003520,3604756,Cyclophosphamide,8N3DW7272P,,,,
23219,DescriptorName,D000328,3604756,,,1,Adult,N,
23220,DescriptorName,D003520,3604756,,,2,Cyclophosphamide,N,
23221,QualifierName,Q000009,3604756,,,2,,Y,adverse effects
23222,DescriptorName,D005260,3604756,,,3,Female,N,
23223,DescriptorName,D014890,3604756,,,4,Granulomatosis with Polyangiitis,N,
23224,QualifierName,Q000188,3604756,,,4,,N,drug therapy
23225,DescriptorName,D006801,3604756,,,5,Humans,N,
23226,DescriptorName,D011658,3604756,,,6,Pulmonary Fibrosis,N,
23227,QualifierName,Q000139,3604756,,,6,,Y,chemically induced
23228,DescriptorName,D011859,3604756,,,7,Radiography,N,
23229,Chemical,D000638,3609047,Amiodarone,N3RQ532IUT,,,,
23230,DescriptorName,D000284,3609047,,,1,"Administration, Oral",N,
23231,DescriptorName,D000638,3609047,,,2,Amiodarone,N,
23232,QualifierName,Q000009,3609047,,,2,,Y,adverse effects
23233,DescriptorName,D001282,3609047,,,3,Atrial Flutter,N,
23234,QualifierName,Q000188,3609047,,,3,,Y,drug therapy
23235,DescriptorName,D002304,3609047,,,4,"Cardiac Pacing, Artificial",N,
23236,DescriptorName,D004305,3609047,,,5,"Dose-Response Relationship, Drug",N,
23237,DescriptorName,D004562,3609047,,,6,Electrocardiography,N,
23238,DescriptorName,D006801,3609047,,,7,Humans,N,
23239,DescriptorName,D007262,3609047,,,8,"Infusions, Intravenous",N,
23240,DescriptorName,D008133,3609047,,,9,Long QT Syndrome,N,
23241,QualifierName,Q000139,3609047,,,9,,N,chemically induced
23242,DescriptorName,D008297,3609047,,,10,Male,N,
23243,DescriptorName,D008875,3609047,,,11,Middle Aged,N,
23244,DescriptorName,D013610,3609047,,,12,Tachycardia,N,
23245,QualifierName,Q000139,3609047,,,12,,Y,chemically induced
23246,Chemical,D012312,3612639,Ritodrine,I0Q6O6740J,,,,
23247,DescriptorName,D000293,3612639,,,1,Adolescent,N,
23248,DescriptorName,D005260,3612639,,,2,Female,N,
23249,DescriptorName,D006801,3612639,,,3,Humans,N,
23250,DescriptorName,D007231,3612639,,,4,"Infant, Newborn",N,
23251,DescriptorName,D007752,3612639,,,5,"Obstetric Labor, Premature",N,
23252,QualifierName,Q000188,3612639,,,5,,Y,drug therapy
23253,DescriptorName,D011247,3612639,,,6,Pregnancy,N,
23254,DescriptorName,D011654,3612639,,,7,Pulmonary Edema,N,
23255,QualifierName,Q000139,3612639,,,7,,Y,chemically induced
23256,DescriptorName,D011859,3612639,,,8,Radiography,N,
23257,DescriptorName,D012312,3612639,,,9,Ritodrine,N,
23258,QualifierName,Q000009,3612639,,,9,,Y,adverse effects
23259,Chemical,D003524,3620420,Cyclosporins,0,,,,
23260,DescriptorName,D000328,3620420,,,1,Adult,N,
23261,DescriptorName,D002908,3620420,,,2,Chronic Disease,N,
23262,DescriptorName,D003320,3620420,,,3,Corneal Ulcer,N,
23263,QualifierName,Q000097,3620420,,,3,,N,blood
23264,DescriptorName,D003524,3620420,,,4,Cyclosporins,N,
23265,QualifierName,Q000008,3620420,,,4,,N,administration & dosage
23266,DescriptorName,D005260,3620420,,,5,Female,N,
23267,DescriptorName,D006801,3620420,,,6,Humans,N,
23268,DescriptorName,D008111,3620420,,,7,Liver Function Tests,N,
23269,Chemical,D009543,3628148,Nifedipine,I9ZF7L6G2L,,,,
23270,DescriptorName,D000328,3628148,,,1,Adult,N,
23271,DescriptorName,D005260,3628148,,,2,Female,N,
23272,DescriptorName,D006801,3628148,,,3,Humans,N,
23273,DescriptorName,D006973,3628148,,,4,Hypertension,N,
23274,QualifierName,Q000150,3628148,,,4,,N,complications
23275,DescriptorName,D002532,3628148,,,5,Intracranial Aneurysm,N,
23276,QualifierName,Q000150,3628148,,,5,,Y,complications
23277,DescriptorName,D009543,3628148,,,6,Nifedipine,N,
23278,QualifierName,Q000009,3628148,,,6,,Y,adverse effects
23279,DescriptorName,D012422,3628148,,,7,"Rupture, Spontaneous",N,
23280,DescriptorName,D013345,3628148,,,8,Subarachnoid Hemorrhage,N,
23281,QualifierName,Q000139,3628148,,,8,,Y,chemically induced
23282,Chemical,D011224,3652934,Prazosin,XM03YJ541D,,,,
23283,DescriptorName,D002543,3652934,,,1,Cerebral Hemorrhage,N,
23284,QualifierName,Q000150,3652934,,,1,,Y,complications
23285,DescriptorName,D002561,3652934,,,2,Cerebrovascular Disorders,N,
23286,QualifierName,Q000150,3652934,,,2,,Y,complications
23287,DescriptorName,D004305,3652934,,,3,"Dose-Response Relationship, Drug",N,
23288,DescriptorName,D005260,3652934,,,4,Female,N,
23289,DescriptorName,D006801,3652934,,,5,Humans,N,
23290,DescriptorName,D006973,3652934,,,6,Hypertension,N,
23291,QualifierName,Q000188,3652934,,,6,,Y,drug therapy
23292,DescriptorName,D007022,3652934,,,7,Hypotension,N,
23293,QualifierName,Q000139,3652934,,,7,,Y,chemically induced
23294,DescriptorName,D008297,3652934,,,8,Male,N,
23295,DescriptorName,D008875,3652934,,,9,Middle Aged,N,
23296,DescriptorName,D011224,3652934,,,10,Prazosin,N,
23297,QualifierName,Q000009,3652934,,,10,,Y,adverse effects
23298,DescriptorName,D012307,3652934,,,11,Risk Factors,N,
23299,DescriptorName,D014474,3652934,,,12,Unconsciousness,N,
23300,QualifierName,Q000139,3652934,,,12,,Y,chemically induced
23301,Chemical,D013300,3659584,Streptokinase,EC 3.4.-,,,,
23302,DescriptorName,D006801,3659584,,,1,Humans,N,
23303,DescriptorName,D008297,3659584,,,2,Male,N,
23304,DescriptorName,D008875,3659584,,,3,Middle Aged,N,
23305,DescriptorName,D011655,3659584,,,4,Pulmonary Embolism,N,
23306,QualifierName,Q000139,3659584,,,4,,Y,chemically induced
23307,DescriptorName,D013300,3659584,,,5,Streptokinase,N,
23308,QualifierName,Q000009,3659584,,,5,,Y,adverse effects
23309,DescriptorName,D013924,3659584,,,6,Thrombophlebitis,N,
23310,QualifierName,Q000188,3659584,,,6,,Y,drug therapy
23311,Chemical,D000906,3663292,Antibodies,0,,,,
23312,Chemical,D004077,3663292,Digoxin,73K4184T59,,,,
23313,DescriptorName,D000906,3663292,,,1,Antibodies,N,
23314,QualifierName,Q000627,3663292,,,1,,N,therapeutic use
23315,DescriptorName,D004077,3663292,,,2,Digoxin,N,
23316,QualifierName,Q000009,3663292,,,2,,Y,adverse effects
23317,DescriptorName,D004630,3663292,,,3,Emergencies,N,
23318,DescriptorName,D006323,3663292,,,4,Heart Arrest,N,
23319,QualifierName,Q000139,3663292,,,4,,Y,chemically induced
23320,DescriptorName,D006333,3663292,,,5,Heart Failure,N,
23321,QualifierName,Q000150,3663292,,,5,,N,complications
23322,DescriptorName,D006801,3663292,,,6,Humans,N,
23323,DescriptorName,D007231,3663292,,,7,"Infant, Newborn",N,
23324,DescriptorName,D008297,3663292,,,8,Male,N,
23325,DescriptorName,D012151,3663292,,,9,Resuscitation,Y,
23326,Chemical,D010672,3677571,Phenytoin,6158TKW0C5,,,,
23327,DescriptorName,D000328,3677571,,,1,Adult,N,
23328,DescriptorName,D056486,3677571,,,2,Chemical and Drug Induced Liver Injury,N,
23329,QualifierName,Q000209,3677571,,,2,,Y,etiology
23330,DescriptorName,D004342,3677571,,,3,Drug Hypersensitivity,N,
23331,QualifierName,Q000209,3677571,,,3,,Y,etiology
23332,DescriptorName,D005260,3677571,,,4,Female,N,
23333,DescriptorName,D006801,3677571,,,5,Humans,N,
23334,DescriptorName,D008206,3677571,,,6,Lymphatic Diseases,N,
23335,QualifierName,Q000139,3677571,,,6,,Y,chemically induced
23336,DescriptorName,D010672,3677571,,,7,Phenytoin,N,
23337,QualifierName,Q000009,3677571,,,7,,Y,adverse effects
23338,DescriptorName,D012640,3677571,,,8,Seizures,N,
23339,QualifierName,Q000188,3677571,,,8,,N,drug therapy
23340,Chemical,D009525,3680913,Niacin,2679MF687A,,,,
23341,DescriptorName,D056486,3680913,,,1,Chemical and Drug Induced Liver Injury,N,
23342,QualifierName,Q000209,3680913,,,1,,N,etiology
23343,DescriptorName,D006501,3680913,,,2,Hepatic Encephalopathy,N,
23344,QualifierName,Q000139,3680913,,,2,,Y,chemically induced
23345,DescriptorName,D006801,3680913,,,3,Humans,N,
23346,DescriptorName,D006937,3680913,,,4,Hypercholesterolemia,N,
23347,QualifierName,Q000188,3680913,,,4,,Y,drug therapy
23348,DescriptorName,D008111,3680913,,,5,Liver Function Tests,N,
23349,DescriptorName,D008297,3680913,,,6,Male,N,
23350,DescriptorName,D008875,3680913,,,7,Middle Aged,N,
23351,DescriptorName,D009525,3680913,,,8,Niacin,N,
23352,QualifierName,Q000009,3680913,,,8,,Y,adverse effects
23353,Chemical,D008713,3688031,Methimazole,554Z48XN5E,,,,
23354,DescriptorName,D000014,3688031,,,1,"Abnormalities, Drug-Induced",N,
23355,QualifierName,Q000209,3688031,,,1,,Y,etiology
23356,DescriptorName,D000328,3688031,,,2,Adult,N,
23357,DescriptorName,D001940,3688031,,,3,Breast,N,
23358,QualifierName,Q000002,3688031,,,3,,Y,abnormalities
23359,DescriptorName,D002675,3688031,,,4,"Child, Preschool",N,
23360,DescriptorName,D002754,3688031,,,5,Choanal Atresia,N,
23361,QualifierName,Q000139,3688031,,,5,,Y,chemically induced
23362,DescriptorName,D005260,3688031,,,6,Female,N,
23363,DescriptorName,D005500,3688031,,,7,Follow-Up Studies,N,
23364,DescriptorName,D006801,3688031,,,8,Humans,N,
23365,DescriptorName,D006980,3688031,,,9,Hyperthyroidism,N,
23366,QualifierName,Q000188,3688031,,,9,,N,drug therapy
23367,DescriptorName,D007223,3688031,,,10,Infant,N,
23368,DescriptorName,D007231,3688031,,,11,"Infant, Newborn",N,
23369,DescriptorName,D008713,3688031,,,12,Methimazole,N,
23370,QualifierName,Q000009,3688031,,,12,,Y,adverse effects
23371,DescriptorName,D009558,3688031,,,13,Nipples,N,
23372,QualifierName,Q000002,3688031,,,13,,Y,abnormalities
23373,DescriptorName,D011247,3688031,,,14,Pregnancy,N,
23374,DescriptorName,D011248,3688031,,,15,Pregnancy Complications,N,
23375,QualifierName,Q000188,3688031,,,15,,N,drug therapy
23376,DescriptorName,D013577,3688031,,,16,Syndrome,N,
23377,Chemical,D000935,3693034,Antifungal Agents,0,,,,
23378,Chemical,D000666,3693034,Amphotericin B,7XU7A7DROE,,,,
23379,Chemical,D005437,3693034,Flucytosine,D83282DT06,,,,
23380,Chemical,D007654,3693034,Ketoconazole,R9400W927I,,,,
23381,DescriptorName,D000666,3693034,,,1,Amphotericin B,N,
23382,QualifierName,Q000009,3693034,,,1,,N,adverse effects
23383,DescriptorName,D000818,3693034,,,2,Animals,N,
23384,DescriptorName,D000935,3693034,,,3,Antifungal Agents,N,
23385,QualifierName,Q000009,3693034,,,3,,N,adverse effects
23386,DescriptorName,D003453,3693034,,,4,Cryptococcosis,N,
23387,QualifierName,Q000150,3693034,,,4,,N,complications
23388,DescriptorName,D004283,3693034,,,5,Dog Diseases,N,
23389,QualifierName,Q000188,3693034,,,5,,Y,drug therapy
23390,DescriptorName,D004285,3693034,,,6,Dogs,N,
23391,DescriptorName,D004359,3693034,,,7,"Drug Therapy, Combination",N,
23392,DescriptorName,D005260,3693034,,,8,Female,N,
23393,DescriptorName,D005437,3693034,,,9,Flucytosine,N,
23394,QualifierName,Q000009,3693034,,,9,,N,adverse effects
23395,DescriptorName,D007654,3693034,,,10,Ketoconazole,N,
23396,QualifierName,Q000009,3693034,,,10,,N,adverse effects
23397,DescriptorName,D013262,3693034,,,11,Stevens-Johnson Syndrome,N,
23398,QualifierName,Q000188,3693034,,,11,,N,drug therapy
23399,Chemical,D003520,369675,Cyclophosphamide,8N3DW7272P,,,,
23400,DescriptorName,D002430,369675,,,1,Cecal Neoplasms,N,
23401,QualifierName,Q000139,369675,,,1,,Y,chemically induced
23402,DescriptorName,D003520,369675,,,2,Cyclophosphamide,N,
23403,QualifierName,Q000009,369675,,,2,,Y,adverse effects
23404,DescriptorName,D006801,369675,,,3,Humans,N,
23405,DescriptorName,D007080,369675,,,4,Ileocecal Valve,N,
23406,DescriptorName,D016403,369675,,,5,"Lymphoma, Large B-Cell, Diffuse",N,
23407,QualifierName,Q000139,369675,,,5,,Y,chemically induced
23408,DescriptorName,D008297,369675,,,6,Male,N,
23409,DescriptorName,D008875,369675,,,7,Middle Aged,N,
23410,DescriptorName,D009101,369675,,,8,Multiple Myeloma,N,
23411,QualifierName,Q000188,369675,,,8,,Y,drug therapy
23412,DescriptorName,D009378,369675,,,9,"Neoplasms, Multiple Primary",N,
23413,QualifierName,Q000139,369675,,,9,,Y,chemically induced
23414,DescriptorName,D012075,369675,,,10,"Remission, Spontaneous",N,
23415,DescriptorName,D013997,369675,,,11,Time Factors,N,
23416,Chemical,D001572,3708949,Benzofurans,0,,,,
23417,Chemical,D000638,3708949,Amiodarone,N3RQ532IUT,,,,
23418,DescriptorName,D000368,3708949,,,1,Aged,N,
23419,DescriptorName,D000638,3708949,,,2,Amiodarone,N,
23420,QualifierName,Q000009,3708949,,,2,,Y,adverse effects
23421,DescriptorName,D001145,3708949,,,3,"Arrhythmias, Cardiac",N,
23422,QualifierName,Q000188,3708949,,,3,,Y,drug therapy
23423,DescriptorName,D001572,3708949,,,4,Benzofurans,N,
23424,QualifierName,Q000009,3708949,,,4,,Y,adverse effects
23425,DescriptorName,D001706,3708949,,,5,Biopsy,N,
23426,DescriptorName,D056486,3708949,,,6,Chemical and Drug Induced Liver Injury,N,
23427,QualifierName,Q000209,3708949,,,6,,Y,etiology
23428,DescriptorName,D003327,3708949,,,7,Coronary Disease,N,
23429,QualifierName,Q000188,3708949,,,7,,Y,drug therapy
23430,DescriptorName,D004305,3708949,,,8,"Dose-Response Relationship, Drug",N,
23431,DescriptorName,D006801,3708949,,,9,Humans,N,
23432,DescriptorName,D007263,3708949,,,10,"Infusions, Parenteral",N,
23433,DescriptorName,D008099,3708949,,,11,Liver,N,
23434,QualifierName,Q000473,3708949,,,11,,N,pathology
23435,DescriptorName,D008111,3708949,,,12,Liver Function Tests,N,
23436,DescriptorName,D008297,3708949,,,13,Male,N,
23437,Chemical,D009883,3718111,Ophthalmic Solutions,0,,,,
23438,Chemical,D013999,3718111,Timolol,817W3C6175,,,,
23439,Chemical,D011188,3718111,Potassium,RWP5GA015D,,,,
23440,Chemical,D011241,3718111,Prednisone,VB0R961HZT,,,,
23441,DescriptorName,D000368,3718111,,,1,Aged,N,
23442,DescriptorName,D002908,3718111,,,2,Chronic Disease,N,
23443,DescriptorName,D005901,3718111,,,3,Glaucoma,N,
23444,QualifierName,Q000150,3718111,,,3,,N,complications
23445,DescriptorName,D006801,3718111,,,4,Humans,N,
23446,DescriptorName,D006947,3718111,,,5,Hyperkalemia,N,
23447,QualifierName,Q000097,3718111,,,5,,N,blood
23448,DescriptorName,D008297,3718111,,,6,Male,N,
23449,DescriptorName,D009883,3718111,,,7,Ophthalmic Solutions,N,
23450,DescriptorName,D011014,3718111,,,8,Pneumonia,N,
23451,QualifierName,Q000150,3718111,,,8,,N,complications
23452,DescriptorName,D011188,3718111,,,9,Potassium,N,
23453,QualifierName,Q000097,3718111,,,9,,N,blood
23454,DescriptorName,D011241,3718111,,,10,Prednisone,N,
23455,QualifierName,Q000627,3718111,,,10,,N,therapeutic use
23456,DescriptorName,D011832,3718111,,,11,Radiation Injuries,N,
23457,QualifierName,Q000150,3718111,,,11,,N,complications
23458,DescriptorName,D013999,3718111,,,12,Timolol,N,
23459,QualifierName,Q000009,3718111,,,12,,Y,adverse effects
23460,Chemical,D002210,3720318,Caprylates,0,,,,
23461,Chemical,D005989,3720318,Glycerides,0,,,,
23462,Chemical,C025343,3720318,monooctanoin,VFU0OU98LO,,,,
23463,DescriptorName,D000328,3720318,,,1,Adult,N,
23464,DescriptorName,D001649,3720318,,,2,Bile Duct Diseases,N,
23465,QualifierName,Q000000981,3720318,,,2,,N,diagnostic imaging
23466,DescriptorName,D002210,3720318,,,3,Caprylates,N,
23467,DescriptorName,D002769,3720318,,,4,Cholelithiasis,N,
23468,QualifierName,Q000000981,3720318,,,4,,N,diagnostic imaging
23469,DescriptorName,D005260,3720318,,,5,Female,N,
23470,DescriptorName,D005989,3720318,,,6,Glycerides,N,
23471,QualifierName,Q000009,3720318,,,6,,Y,adverse effects
23472,DescriptorName,D006801,3720318,,,7,Humans,N,
23473,DescriptorName,D011654,3720318,,,8,Pulmonary Edema,N,
23474,QualifierName,Q000139,3720318,,,8,,Y,chemically induced
23475,DescriptorName,D011859,3720318,,,9,Radiography,N,
23476,Chemical,D005047,3725284,Etoposide,6PLQ3CP4P3,,,,
23477,Chemical,D002945,3725284,Cisplatin,Q20Q21Q62J,,,,
23478,DescriptorName,D000971,3725284,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
23479,QualifierName,Q000009,3725284,,,1,,Y,adverse effects
23480,DescriptorName,D002294,3725284,,,2,"Carcinoma, Squamous Cell",N,
23481,QualifierName,Q000188,3725284,,,2,,N,drug therapy
23482,DescriptorName,D002945,3725284,,,3,Cisplatin,N,
23483,QualifierName,Q000008,3725284,,,3,,N,administration & dosage
23484,DescriptorName,D004562,3725284,,,4,Electrocardiography,N,
23485,DescriptorName,D005047,3725284,,,5,Etoposide,N,
23486,QualifierName,Q000008,3725284,,,5,,N,administration & dosage
23487,DescriptorName,D005260,3725284,,,6,Female,N,
23488,DescriptorName,D006801,3725284,,,7,Humans,N,
23489,DescriptorName,D008175,3725284,,,8,Lung Neoplasms,N,
23490,QualifierName,Q000188,3725284,,,8,,N,drug therapy
23491,DescriptorName,D008875,3725284,,,9,Middle Aged,N,
23492,DescriptorName,D009367,3725284,,,10,Neoplasm Staging,N,
23493,DescriptorName,D013614,3725284,,,11,"Tachycardia, Paroxysmal",N,
23494,QualifierName,Q000139,3725284,,,11,,Y,chemically induced
23495,Chemical,D009025,3732375,Morpholines,0,,,,
23496,Chemical,D014745,3732375,Viloxazine,5I5Y2789ZF,,,,
23497,Chemical,D013806,3732375,Theophylline,C137DTR5RG,,,,
23498,DescriptorName,D000368,3732375,,,1,Aged,N,
23499,DescriptorName,D002908,3732375,,,2,Chronic Disease,N,
23500,DescriptorName,D003864,3732375,,,3,"Depression, Chemical",N,
23501,DescriptorName,D004347,3732375,,,4,Drug Interactions,N,
23502,DescriptorName,D005260,3732375,,,5,Female,N,
23503,DescriptorName,D006801,3732375,,,6,Humans,N,
23504,DescriptorName,D007700,3732375,,,7,Kinetics,N,
23505,DescriptorName,D008173,3732375,,,8,"Lung Diseases, Obstructive",N,
23506,QualifierName,Q000188,3732375,,,8,,N,drug therapy
23507,DescriptorName,D009025,3732375,,,9,Morpholines,N,
23508,QualifierName,Q000009,3732375,,,9,,Y,adverse effects
23509,DescriptorName,D013806,3732375,,,10,Theophylline,N,
23510,QualifierName,Q000378,3732375,,,10,,N,metabolism
23511,DescriptorName,D014745,3732375,,,11,Viloxazine,N,
23512,QualifierName,Q000009,3732375,,,11,,Y,adverse effects
23513,Chemical,D009582,3744305,Nitrofurantoin,927AH8112L,,,,
23514,DescriptorName,D000368,3744305,,,1,Aged,N,
23515,DescriptorName,D005260,3744305,,,2,Female,N,
23516,DescriptorName,D006801,3744305,,,3,Humans,N,
23517,DescriptorName,D007249,3744305,,,4,Inflammation,N,
23518,DescriptorName,D008168,3744305,,,5,Lung,N,
23519,QualifierName,Q000187,3744305,,,5,,N,drug effects
23520,DescriptorName,D008171,3744305,,,6,Lung Diseases,N,
23521,QualifierName,Q000139,3744305,,,6,,N,chemically induced
23522,DescriptorName,D008297,3744305,,,7,Male,N,
23523,DescriptorName,D009582,3744305,,,8,Nitrofurantoin,N,
23524,QualifierName,Q000009,3744305,,,8,,Y,adverse effects
23525,DescriptorName,D012129,3744305,,,9,Respiratory Function Tests,N,
23526,DescriptorName,D014552,3744305,,,10,Urinary Tract Infections,N,
23527,QualifierName,Q000188,3744305,,,10,,N,drug therapy
23528,Chemical,D000609,3753891,Aminoacridines,0,,,,
23529,Chemical,D000970,3753891,Antineoplastic Agents,0,,,,
23530,Chemical,D000677,3753891,Amsacrine,00DPD30SOY,,,,
23531,DescriptorName,D000609,3753891,,,1,Aminoacridines,N,
23532,QualifierName,Q000009,3753891,,,1,,Y,adverse effects
23533,DescriptorName,D000677,3753891,,,2,Amsacrine,N,
23534,DescriptorName,D000970,3753891,,,3,Antineoplastic Agents,N,
23535,QualifierName,Q000009,3753891,,,3,,Y,adverse effects
23536,DescriptorName,D004562,3753891,,,4,Electrocardiography,N,
23537,DescriptorName,D005260,3753891,,,5,Female,N,
23538,DescriptorName,D006801,3753891,,,6,Humans,N,
23539,DescriptorName,D007938,3753891,,,7,Leukemia,N,
23540,QualifierName,Q000188,3753891,,,7,,N,drug therapy
23541,DescriptorName,D008875,3753891,,,8,Middle Aged,N,
23542,DescriptorName,D009203,3753891,,,9,Myocardial Infarction,N,
23543,QualifierName,Q000139,3753891,,,9,,Y,chemically induced
23544,DescriptorName,D009206,3753891,,,10,Myocardium,N,
23545,QualifierName,Q000473,3753891,,,10,,Y,pathology
23546,DescriptorName,D009336,3753891,,,11,Necrosis,N,
23547,QualifierName,Q000473,3753891,,,11,,N,pathology
23548,Chemical,D000936,3763264,Antigen-Antibody Complex,0,,,,
23549,Chemical,D010634,3763264,Phenobarbital,YQE403BP4D,,,,
23550,DescriptorName,D000936,3763264,,,1,Antigen-Antibody Complex,N,
23551,QualifierName,Q000032,3763264,,,1,,N,analysis
23552,DescriptorName,D001327,3763264,,,2,Autoimmune Diseases,N,
23553,QualifierName,Q000139,3763264,,,2,,N,chemically induced
23554,DescriptorName,D001706,3763264,,,3,Biopsy,N,
23555,DescriptorName,D002648,3763264,,,4,Child,N,
23556,DescriptorName,D004342,3763264,,,5,Drug Hypersensitivity,N,
23557,QualifierName,Q000175,3763264,,,5,,N,diagnosis
23558,DescriptorName,D005260,3763264,,,6,Female,N,
23559,DescriptorName,D006086,3763264,,,7,Graft vs Host Disease,N,
23560,QualifierName,Q000175,3763264,,,7,,Y,diagnosis
23561,DescriptorName,D006801,3763264,,,8,Humans,N,
23562,DescriptorName,D007583,3763264,,,9,Jejunum,N,
23563,QualifierName,Q000473,3763264,,,9,,N,pathology
23564,DescriptorName,D010634,3763264,,,10,Phenobarbital,N,
23565,QualifierName,Q000009,3763264,,,10,,Y,adverse effects
23566,DescriptorName,D012640,3763264,,,11,Seizures,N,
23567,QualifierName,Q000188,3763264,,,11,,N,drug therapy
23568,DescriptorName,D012867,3763264,,,12,Skin,N,
23569,QualifierName,Q000473,3763264,,,12,,N,pathology
23570,Chemical,D014043,3767790,Tolazoline,CHH9H12AQ3,,,,
23571,DescriptorName,D004381,3767790,,,1,Duodenal Ulcer,N,
23572,QualifierName,Q000139,3767790,,,1,,Y,chemically induced
23573,DescriptorName,D005260,3767790,,,2,Female,N,
23574,DescriptorName,D006801,3767790,,,3,Humans,N,
23575,DescriptorName,D006976,3767790,,,4,"Hypertension, Pulmonary",N,
23576,QualifierName,Q000188,3767790,,,4,,Y,drug therapy
23577,DescriptorName,D007231,3767790,,,5,"Infant, Newborn",N,
23578,DescriptorName,D010439,3767790,,,6,Peptic Ulcer Perforation,N,
23579,QualifierName,Q000139,3767790,,,6,,Y,chemically induced
23580,DescriptorName,D014043,3767790,,,7,Tolazoline,N,
23581,QualifierName,Q000009,3767790,,,7,,Y,adverse effects
23582,Chemical,D009582,3773837,Nitrofurantoin,927AH8112L,,,,
23583,DescriptorName,D005260,3773837,,,1,Female,N,
23584,DescriptorName,D006801,3773837,,,2,Humans,N,
23585,DescriptorName,D008875,3773837,,,3,Middle Aged,N,
23586,DescriptorName,D009582,3773837,,,4,Nitrofurantoin,N,
23587,QualifierName,Q000009,3773837,,,4,,Y,adverse effects
23588,DescriptorName,D014552,3773837,,,5,Urinary Tract Infections,N,
23589,QualifierName,Q000188,3773837,,,5,,N,drug therapy
23590,Chemical,D014196,3790438,Trazodone,YBK48BXK30,,,,
23591,DescriptorName,D000328,3790438,,,1,Adult,N,
23592,DescriptorName,D003863,3790438,,,2,Depression,N,
23593,QualifierName,Q000188,3790438,,,2,,Y,drug therapy
23594,DescriptorName,D006801,3790438,,,3,Humans,N,
23595,DescriptorName,D008297,3790438,,,4,Male,N,
23596,DescriptorName,D011565,3790438,,,5,Psoriasis,N,
23597,QualifierName,Q000139,3790438,,,5,,Y,chemically induced
23598,DescriptorName,D014196,3790438,,,6,Trazodone,N,
23599,QualifierName,Q000009,3790438,,,6,,Y,adverse effects
23600,Chemical,D014700,3797173,Verapamil,CJ0O37KU29,,,,
23601,Chemical,D011802,3797173,Quinidine,ITX08688JL,,,,
23602,DescriptorName,D001145,3797173,,,1,"Arrhythmias, Cardiac",N,
23603,QualifierName,Q000628,3797173,,,1,,Y,therapy
23604,DescriptorName,D002648,3797173,,,2,Child,N,
23605,DescriptorName,D002675,3797173,,,3,"Child, Preschool",N,
23606,DescriptorName,D006801,3797173,,,4,Humans,N,
23607,DescriptorName,D007231,3797173,,,5,"Infant, Newborn",N,
23608,DescriptorName,D008133,3797173,,,6,Long QT Syndrome,N,
23609,QualifierName,Q000175,3797173,,,6,,N,diagnosis
23610,DescriptorName,D008318,3797173,,,7,Malpractice,N,
23611,QualifierName,Q000331,3797173,,,7,,Y,legislation & jurisprudence
23612,DescriptorName,D011802,3797173,,,8,Quinidine,N,
23613,QualifierName,Q000009,3797173,,,8,,N,adverse effects
23614,DescriptorName,D012804,3797173,,,9,Sick Sinus Syndrome,N,
23615,QualifierName,Q000188,3797173,,,9,,N,drug therapy
23616,DescriptorName,D013617,3797173,,,10,"Tachycardia, Supraventricular",N,
23617,QualifierName,Q000175,3797173,,,10,,N,diagnosis
23618,DescriptorName,D014700,3797173,,,11,Verapamil,N,
23619,QualifierName,Q000009,3797173,,,11,,N,adverse effects
23620,Chemical,D008713,3804181,Methimazole,554Z48XN5E,,,,
23621,DescriptorName,D002780,3804181,,,1,"Cholestasis, Intrahepatic",N,
23622,QualifierName,Q000139,3804181,,,1,,Y,chemically induced
23623,DescriptorName,D005260,3804181,,,2,Female,N,
23624,DescriptorName,D006801,3804181,,,3,Humans,N,
23625,DescriptorName,D006980,3804181,,,4,Hyperthyroidism,N,
23626,QualifierName,Q000188,3804181,,,4,,N,drug therapy
23627,DescriptorName,D008099,3804181,,,5,Liver,N,
23628,QualifierName,Q000473,3804181,,,5,,N,pathology
23629,DescriptorName,D008713,3804181,,,6,Methimazole,N,
23630,QualifierName,Q000009,3804181,,,6,,Y,adverse effects
23631,DescriptorName,D008875,3804181,,,7,Middle Aged,N,
23632,Chemical,D004338,3806824,Drug Combinations,0,,,,
23633,Chemical,D010208,3806824,Papaverine,DAA13NKG2Q,,,,
23634,Chemical,D010646,3806824,Phentolamine,Z468598HBV,,,,
23635,DescriptorName,D000328,3806824,,,1,Adult,N,
23636,DescriptorName,D004338,3806824,,,2,Drug Combinations,N,
23637,DescriptorName,D007172,3806824,,,3,Erectile Dysfunction,N,
23638,QualifierName,Q000188,3806824,,,3,,N,drug therapy
23639,DescriptorName,D005355,3806824,,,4,Fibrosis,N,
23640,QualifierName,Q000209,3806824,,,4,,N,etiology
23641,DescriptorName,D006801,3806824,,,5,Humans,N,
23642,DescriptorName,D007267,3806824,,,6,Injections,N,
23643,QualifierName,Q000009,3806824,,,6,,N,adverse effects
23644,DescriptorName,D008297,3806824,,,7,Male,N,
23645,DescriptorName,D010208,3806824,,,8,Papaverine,N,
23646,QualifierName,Q000008,3806824,,,8,,Y,administration & dosage
23647,DescriptorName,D010413,3806824,,,9,Penis,N,
23648,QualifierName,Q000473,3806824,,,9,,Y,pathology
23649,DescriptorName,D010646,3806824,,,10,Phentolamine,N,
23650,QualifierName,Q000008,3806824,,,10,,Y,administration & dosage
23651,DescriptorName,D012646,3806824,,,11,Self Administration,N,
23652,Chemical,D007370,3815268,Interferon Type I,0,,,,
23653,Chemical,D014747,3815268,Vinblastine,5V9KLZ54CY,,,,
23654,DescriptorName,D000971,3815268,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
23655,QualifierName,Q000627,3815268,,,1,,N,therapeutic use
23656,DescriptorName,D002292,3815268,,,2,"Carcinoma, Renal Cell",N,
23657,QualifierName,Q000150,3815268,,,2,,N,complications
23658,DescriptorName,D005260,3815268,,,3,Female,N,
23659,DescriptorName,D006801,3815268,,,4,Humans,N,
23660,DescriptorName,D007370,3815268,,,5,Interferon Type I,N,
23661,QualifierName,Q000009,3815268,,,5,,Y,adverse effects
23662,DescriptorName,D008171,3815268,,,6,Lung Diseases,N,
23663,QualifierName,Q000139,3815268,,,6,,Y,chemically induced
23664,DescriptorName,D008207,3815268,,,7,Lymphatic Metastasis,N,
23665,QualifierName,Q000188,3815268,,,7,,N,drug therapy
23666,DescriptorName,D008875,3815268,,,8,Middle Aged,N,
23667,DescriptorName,D012507,3815268,,,9,Sarcoidosis,N,
23668,QualifierName,Q000139,3815268,,,9,,Y,chemically induced
23669,DescriptorName,D014747,3815268,,,10,Vinblastine,N,
23670,QualifierName,Q000627,3815268,,,10,,N,therapeutic use
23671,Chemical,D005557,3824704,Formaldehyde,1HG84L3525,,,,
23672,DescriptorName,D003556,3824704,,,1,Cystitis,N,
23673,QualifierName,Q000188,3824704,,,1,,N,drug therapy
23674,DescriptorName,D005557,3824704,,,2,Formaldehyde,N,
23675,QualifierName,Q000009,3824704,,,2,,Y,adverse effects
23676,DescriptorName,D006417,3824704,,,3,Hematuria,N,
23677,QualifierName,Q000188,3824704,,,3,,Y,drug therapy
23678,DescriptorName,D006470,3824704,,,4,Hemorrhage,N,
23679,QualifierName,Q000628,3824704,,,4,,N,therapy
23680,DescriptorName,D006801,3824704,,,5,Humans,N,
23681,DescriptorName,D008297,3824704,,,6,Male,N,
23682,DescriptorName,D008875,3824704,,,7,Middle Aged,N,
23683,DescriptorName,D011859,3824704,,,8,Radiography,N,
23684,DescriptorName,D014515,3824704,,,9,Ureteral Diseases,N,
23685,QualifierName,Q000139,3824704,,,9,,Y,chemically induced
23686,DescriptorName,D001749,3824704,,,10,Urinary Bladder Neoplasms,N,
23687,QualifierName,Q000628,3824704,,,10,,Y,therapy
23688,Chemical,D008463,3868420,Mebendazole,81G6I5V05I,,,,
23689,DescriptorName,D000380,3868420,,,1,Agranulocytosis,N,
23690,QualifierName,Q000139,3868420,,,1,,N,chemically induced
23691,DescriptorName,D000505,3868420,,,2,Alopecia,N,
23692,QualifierName,Q000139,3868420,,,2,,N,chemically induced
23693,DescriptorName,D001315,3868420,,,3,Australia,N,
23694,DescriptorName,D004444,3868420,,,4,"Echinococcosis, Hepatic",N,
23695,QualifierName,Q000188,3868420,,,4,,N,drug therapy
23696,DescriptorName,D005260,3868420,,,5,Female,N,
23697,DescriptorName,D006801,3868420,,,6,Humans,N,
23698,DescriptorName,D007564,3868420,,,7,Japan,N,
23699,DescriptorName,D008099,3868420,,,8,Liver,N,
23700,QualifierName,Q000469,3868420,,,8,,N,parasitology
23701,DescriptorName,D008463,3868420,,,9,Mebendazole,N,
23702,QualifierName,Q000009,3868420,,,9,,Y,adverse effects
23703,DescriptorName,D008875,3868420,,,10,Middle Aged,N,
23704,Chemical,D000892,3873709,"Anti-Infective Agents, Urinary",0,,,,
23705,Chemical,D004338,3873709,Drug Combinations,0,,,,
23706,Chemical,D015662,3873709,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
23707,Chemical,D014295,3873709,Trimethoprim,AN164J8Y0X,,,,
23708,Chemical,D013420,3873709,Sulfamethoxazole,JE42381TNV,,,,
23709,DescriptorName,D000328,3873709,,,1,Adult,N,
23710,DescriptorName,D000892,3873709,,,2,"Anti-Infective Agents, Urinary",N,
23711,QualifierName,Q000009,3873709,,,2,,Y,adverse effects
23712,DescriptorName,D003015,3873709,,,3,Clostridium Infections,N,
23713,QualifierName,Q000139,3873709,,,3,,Y,chemically induced
23714,DescriptorName,D003967,3873709,,,4,Diarrhea,N,
23715,QualifierName,Q000139,3873709,,,4,,N,chemically induced
23716,DescriptorName,D004338,3873709,,,5,Drug Combinations,N,
23717,QualifierName,Q000009,3873709,,,5,,N,adverse effects
23718,DescriptorName,D004761,3873709,,,6,"Enterocolitis, Pseudomembranous",N,
23719,QualifierName,Q000139,3873709,,,6,,Y,chemically induced
23720,DescriptorName,D006801,3873709,,,7,Humans,N,
23721,DescriptorName,D008297,3873709,,,8,Male,N,
23722,DescriptorName,D008875,3873709,,,9,Middle Aged,N,
23723,DescriptorName,D011292,3873709,,,10,Premedication,N,
23724,DescriptorName,D013119,3873709,,,11,Spinal Cord Injuries,N,
23725,QualifierName,Q000150,3873709,,,11,,Y,complications
23726,DescriptorName,D013420,3873709,,,12,Sulfamethoxazole,N,
23727,QualifierName,Q000009,3873709,,,12,,Y,adverse effects
23728,DescriptorName,D014295,3873709,,,13,Trimethoprim,N,
23729,QualifierName,Q000009,3873709,,,13,,Y,adverse effects
23730,DescriptorName,D015662,3873709,,,14,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
23731,DescriptorName,D014552,3873709,,,15,Urinary Tract Infections,N,
23732,QualifierName,Q000188,3873709,,,15,,Y,drug therapy
23733,Chemical,D014667,3878320,Vasopressins,11000-17-2,,,,
23734,DescriptorName,D000368,3878320,,,1,Aged,N,
23735,DescriptorName,D004932,3878320,,,2,Esophageal and Gastric Varices,N,
23736,QualifierName,Q000188,3878320,,,2,,Y,drug therapy
23737,DescriptorName,D005260,3878320,,,3,Female,N,
23738,DescriptorName,D006471,3878320,,,4,Gastrointestinal Hemorrhage,N,
23739,QualifierName,Q000188,3878320,,,4,,Y,drug therapy
23740,DescriptorName,D006801,3878320,,,5,Humans,N,
23741,DescriptorName,D007238,3878320,,,6,Infarction,N,
23742,QualifierName,Q000209,3878320,,,6,,N,etiology
23743,DescriptorName,D007263,3878320,,,7,"Infusions, Parenteral",N,
23744,QualifierName,Q000009,3878320,,,7,,N,adverse effects
23745,DescriptorName,D007422,3878320,,,8,Intestines,N,
23746,QualifierName,Q000098,3878320,,,8,,N,blood supply
23747,DescriptorName,D008641,3878320,,,9,Mesenteric Vascular Occlusion,N,
23748,QualifierName,Q000139,3878320,,,9,,Y,chemically induced
23749,DescriptorName,D008642,3878320,,,10,Mesenteric Veins,N,
23750,DescriptorName,D011169,3878320,,,11,Portal Vein,N,
23751,DescriptorName,D013927,3878320,,,12,Thrombosis,N,
23752,QualifierName,Q000139,3878320,,,12,,Y,chemically induced
23753,DescriptorName,D014667,3878320,,,13,Vasopressins,N,
23754,QualifierName,Q000008,3878320,,,13,,N,administration & dosage
23755,Chemical,D007328,3892171,Insulin,0,,,,
23756,Chemical,D011479,3892171,Protamines,0,,,,
23757,Chemical,D007073,3892171,Immunoglobulin E,37341-29-0,,,,
23758,DescriptorName,D000293,3892171,,,1,Adolescent,N,
23759,DescriptorName,D000328,3892171,,,2,Adult,N,
23760,DescriptorName,D000707,3892171,,,3,Anaphylaxis,N,
23761,QualifierName,Q000139,3892171,,,3,,Y,chemically induced
23762,DescriptorName,D002315,3892171,,,4,Cardiopulmonary Bypass,N,
23763,DescriptorName,D048909,3892171,,,5,Diabetes Complications,N,
23764,DescriptorName,D003920,3892171,,,6,Diabetes Mellitus,N,
23765,QualifierName,Q000188,3892171,,,6,,N,drug therapy
23766,DescriptorName,D004797,3892171,,,7,Enzyme-Linked Immunosorbent Assay,N,
23767,DescriptorName,D005260,3892171,,,8,Female,N,
23768,DescriptorName,D006801,3892171,,,9,Humans,N,
23769,DescriptorName,D007073,3892171,,,10,Immunoglobulin E,N,
23770,QualifierName,Q000032,3892171,,,10,,Y,analysis
23771,DescriptorName,D007328,3892171,,,11,Insulin,N,
23772,QualifierName,Q000008,3892171,,,11,,N,administration & dosage
23773,DescriptorName,D008297,3892171,,,12,Male,N,
23774,DescriptorName,D008875,3892171,,,13,Middle Aged,N,
23775,DescriptorName,D011479,3892171,,,14,Protamines,N,
23776,QualifierName,Q000009,3892171,,,14,,Y,adverse effects
23777,DescriptorName,D014693,3892171,,,15,Ventricular Fibrillation,N,
23778,QualifierName,Q000139,3892171,,,15,,N,chemically induced
23779,Chemical,D009944,3899068,Organoplatinum Compounds,0,,,,
23780,Chemical,D016190,3899068,Carboplatin,BG3F62OND5,,,,
23781,Chemical,D002945,3899068,Cisplatin,Q20Q21Q62J,,,,
23782,DescriptorName,D000328,3899068,,,1,Adult,N,
23783,DescriptorName,D001299,3899068,,,2,Audiometry,Y,
23784,DescriptorName,D001301,3899068,,,3,"Audiometry, Pure-Tone",Y,
23785,DescriptorName,D001309,3899068,,,4,Auditory Threshold,N,
23786,QualifierName,Q000187,3899068,,,4,,N,drug effects
23787,DescriptorName,D016190,3899068,,,5,Carboplatin,N,
23788,DescriptorName,D002945,3899068,,,6,Cisplatin,N,
23789,QualifierName,Q000009,3899068,,,6,,Y,adverse effects
23790,DescriptorName,D004305,3899068,,,7,"Dose-Response Relationship, Drug",N,
23791,DescriptorName,D034381,3899068,,,8,Hearing Loss,N,
23792,QualifierName,Q000139,3899068,,,8,,Y,chemically induced
23793,DescriptorName,D006316,3899068,,,9,"Hearing Loss, High-Frequency",N,
23794,QualifierName,Q000139,3899068,,,9,,Y,chemically induced
23795,DescriptorName,D006801,3899068,,,10,Humans,N,
23796,DescriptorName,D008297,3899068,,,11,Male,N,
23797,DescriptorName,D009369,3899068,,,12,Neoplasms,N,
23798,QualifierName,Q000188,3899068,,,12,,Y,drug therapy
23799,DescriptorName,D009944,3899068,,,13,Organoplatinum Compounds,N,
23800,QualifierName,Q000009,3899068,,,13,,Y,adverse effects
23801,DescriptorName,D013736,3899068,,,14,Testicular Neoplasms,N,
23802,QualifierName,Q000188,3899068,,,14,,N,drug therapy
23803,Chemical,D016651,3917429,Lithium Carbonate,2BMD2GNA4V,,,,
23804,Chemical,D008094,3917429,Lithium,9FN79X2M3F,,,,
23805,DescriptorName,D058186,3917429,,,1,Acute Kidney Injury,N,
23806,QualifierName,Q000139,3917429,,,1,,N,chemically induced
23807,DescriptorName,D000328,3917429,,,2,Adult,N,
23808,DescriptorName,D000368,3917429,,,3,Aged,N,
23809,DescriptorName,D001714,3917429,,,4,Bipolar Disorder,N,
23810,QualifierName,Q000150,3917429,,,4,,N,complications
23811,DescriptorName,D003681,3917429,,,5,Dehydration,N,
23812,QualifierName,Q000150,3917429,,,5,,N,complications
23813,DescriptorName,D003937,3917429,,,6,"Diagnosis, Differential",N,
23814,DescriptorName,D005260,3917429,,,7,Female,N,
23815,DescriptorName,D006801,3917429,,,8,Humans,N,
23816,DescriptorName,D008094,3917429,,,9,Lithium,N,
23817,QualifierName,Q000009,3917429,,,9,,Y,adverse effects
23818,DescriptorName,D016651,3917429,,,10,Lithium Carbonate,N,
23819,DescriptorName,D008297,3917429,,,11,Male,N,
23820,DescriptorName,D001748,3917429,,,12,Urinary Bladder Neck Obstruction,N,
23821,QualifierName,Q000150,3917429,,,12,,N,complications
23822,Chemical,D005996,3926849,Nitroglycerin,G59M7S0WS3,,,,
23823,DescriptorName,D000293,3926849,,,1,Adolescent,N,
23824,DescriptorName,D006328,3926849,,,2,Cardiac Catheterization,N,
23825,DescriptorName,D003251,3926849,,,3,"Constriction, Pathologic",N,
23826,DescriptorName,D005260,3926849,,,4,Female,N,
23827,DescriptorName,D006801,3926849,,,5,Humans,N,
23828,DescriptorName,D006976,3926849,,,6,"Hypertension, Pulmonary",N,
23829,QualifierName,Q000139,3926849,,,6,,Y,chemically induced
23830,DescriptorName,D005996,3926849,,,7,Nitroglycerin,N,
23831,QualifierName,Q000009,3926849,,,7,,Y,adverse effects
23832,DescriptorName,D011652,3926849,,,8,Pulmonary Circulation,N,
23833,QualifierName,Q000187,3926849,,,8,,Y,drug effects
23834,DescriptorName,D014655,3926849,,,9,Vascular Resistance,N,
23835,QualifierName,Q000187,3926849,,,9,,Y,drug effects
23836,Chemical,D001572,3941210,Benzofurans,0,,,,
23837,Chemical,D000638,3941210,Amiodarone,N3RQ532IUT,,,,
23838,Chemical,D013974,3941210,Thyroxine,Q51BO43MG4,,,,
23839,DescriptorName,D000638,3941210,,,1,Amiodarone,N,
23840,QualifierName,Q000009,3941210,,,1,,Y,adverse effects
23841,DescriptorName,D001572,3941210,,,2,Benzofurans,N,
23842,QualifierName,Q000009,3941210,,,2,,Y,adverse effects
23843,DescriptorName,D002037,3941210,,,3,Bundle-Branch Block,N,
23844,QualifierName,Q000188,3941210,,,3,,N,drug therapy
23845,DescriptorName,D004562,3941210,,,4,Electrocardiography,N,
23846,DescriptorName,D004594,3941210,,,5,Electrophysiology,N,
23847,DescriptorName,D005260,3941210,,,6,Female,N,
23848,DescriptorName,D006327,3941210,,,7,Heart Block,N,
23849,QualifierName,Q000188,3941210,,,7,,N,drug therapy
23850,DescriptorName,D006801,3941210,,,8,Humans,N,
23851,DescriptorName,D007037,3941210,,,9,Hypothyroidism,N,
23852,QualifierName,Q000139,3941210,,,9,,N,chemically induced
23853,DescriptorName,D008875,3941210,,,10,Middle Aged,N,
23854,DescriptorName,D011226,3941210,,,11,Pre-Excitation Syndromes,N,
23855,QualifierName,Q000188,3941210,,,11,,N,drug therapy
23856,DescriptorName,D013974,3941210,,,12,Thyroxine,N,
23857,QualifierName,Q000627,3941210,,,12,,N,therapeutic use
23858,Chemical,D000667,3947272,Ampicillin,7C782967RD,,,,
23859,DescriptorName,D000667,3947272,,,1,Ampicillin,N,
23860,QualifierName,Q000009,3947272,,,1,,Y,adverse effects
23861,DescriptorName,D000818,3947272,,,2,Animals,N,
23862,DescriptorName,D005260,3947272,,,3,Female,N,
23863,DescriptorName,D006801,3947272,,,4,Humans,N,
23864,DescriptorName,D008875,3947272,,,5,Middle Aged,N,
23865,DescriptorName,D009157,3947272,,,6,Myasthenia Gravis,N,
23866,QualifierName,Q000139,3947272,,,6,,Y,chemically induced
23867,DescriptorName,D011817,3947272,,,7,Rabbits,N,
23868,DescriptorName,D051381,3947272,,,8,Rats,N,
23869,DescriptorName,D011919,3947272,,,9,"Rats, Inbred Strains",N,
23870,Chemical,D013806,3954165,Theophylline,C137DTR5RG,,,,
23871,Chemical,D011241,3954165,Prednisone,VB0R961HZT,,,,
23872,DescriptorName,D000293,3954165,,,1,Adolescent,N,
23873,DescriptorName,D001249,3954165,,,2,Asthma,N,
23874,QualifierName,Q000188,3954165,,,2,,Y,drug therapy
23875,DescriptorName,D005260,3954165,,,3,Female,N,
23876,DescriptorName,D006801,3954165,,,4,Humans,N,
23877,DescriptorName,D010439,3954165,,,5,Peptic Ulcer Perforation,N,
23878,QualifierName,Q000139,3954165,,,5,,Y,chemically induced
23879,DescriptorName,D011241,3954165,,,6,Prednisone,N,
23880,QualifierName,Q000009,3954165,,,6,,Y,adverse effects
23881,DescriptorName,D013224,3954165,,,7,Status Asthmaticus,N,
23882,QualifierName,Q000188,3954165,,,7,,Y,drug therapy
23883,DescriptorName,D013276,3954165,,,8,Stomach Ulcer,N,
23884,QualifierName,Q000139,3954165,,,8,,Y,chemically induced
23885,DescriptorName,D013806,3954165,,,9,Theophylline,N,
23886,QualifierName,Q000009,3954165,,,9,,Y,adverse effects
23887,Chemical,D005934,3964363,Glucagon,9007-92-5,,,,
23888,Chemical,D011433,3964363,Propranolol,9Y8NXQ24VQ,,,,
23889,DescriptorName,D004935,3964363,,,1,Esophageal Diseases,N,
23890,QualifierName,Q000139,3964363,,,1,,Y,chemically induced
23891,DescriptorName,D005260,3964363,,,2,Female,N,
23892,DescriptorName,D005751,3964363,,,3,Gastric Lavage,N,
23893,DescriptorName,D005934,3964363,,,4,Glucagon,N,
23894,QualifierName,Q000627,3964363,,,4,,Y,therapeutic use
23895,DescriptorName,D006801,3964363,,,5,Humans,N,
23896,DescriptorName,D008875,3964363,,,6,Middle Aged,N,
23897,DescriptorName,D011433,3964363,,,7,Propranolol,N,
23898,QualifierName,Q000506,3964363,,,7,,Y,poisoning
23899,DescriptorName,D013035,3964363,,,8,Spasm,N,
23900,QualifierName,Q000139,3964363,,,8,,N,chemically induced
23901,Chemical,D009543,3967536,Nifedipine,I9ZF7L6G2L,,,,
23902,DescriptorName,D001146,3967536,,,1,"Arrhythmia, Sinus",N,
23903,QualifierName,Q000139,3967536,,,1,,Y,chemically induced
23904,DescriptorName,D005260,3967536,,,2,Female,N,
23905,DescriptorName,D006801,3967536,,,3,Humans,N,
23906,DescriptorName,D006976,3967536,,,4,"Hypertension, Pulmonary",N,
23907,QualifierName,Q000188,3967536,,,4,,N,drug therapy
23908,DescriptorName,D007022,3967536,,,5,Hypotension,N,
23909,QualifierName,Q000139,3967536,,,5,,Y,chemically induced
23910,DescriptorName,D008875,3967536,,,6,Middle Aged,N,
23911,DescriptorName,D009543,3967536,,,7,Nifedipine,N,
23912,QualifierName,Q000009,3967536,,,7,,Y,adverse effects
23913,Chemical,D008774,3970339,Methylphenidate,207ZZ9QZ49,,,,
23914,Chemical,D003932,3970339,Heroin,70D95007SX,,,,
23915,Chemical,D014568,3970339,Urokinase-Type Plasminogen Activator,EC 3.4.21.73,,,,
23916,DescriptorName,D000059,3970339,,,1,Accidents,N,
23917,DescriptorName,D000328,3970339,,,2,Adult,N,
23918,DescriptorName,D005542,3970339,,,3,Forearm,N,
23919,QualifierName,Q000098,3970339,,,3,,Y,blood supply
23920,DescriptorName,D003932,3970339,,,4,Heroin,N,
23921,QualifierName,Q000506,3970339,,,4,,Y,poisoning
23922,DescriptorName,D006801,3970339,,,5,Humans,N,
23923,DescriptorName,D007269,3970339,,,6,"Injections, Intra-Arterial",N,
23924,QualifierName,Q000009,3970339,,,6,,N,adverse effects
23925,DescriptorName,D007511,3970339,,,7,Ischemia,N,
23926,QualifierName,Q000139,3970339,,,7,,Y,chemically induced
23927,DescriptorName,D008297,3970339,,,8,Male,N,
23928,DescriptorName,D008774,3970339,,,9,Methylphenidate,N,
23929,QualifierName,Q000506,3970339,,,9,,Y,poisoning
23930,DescriptorName,D019966,3970339,,,10,Substance-Related Disorders,Y,
23931,DescriptorName,D014568,3970339,,,11,Urokinase-Type Plasminogen Activator,N,
23932,QualifierName,Q000627,3970339,,,11,,N,therapeutic use
23933,Chemical,D006852,3977377,Hydrochlorothiazide,0J48LPH2TH,,,,
23934,DescriptorName,D000328,3977377,,,1,Adult,N,
23935,DescriptorName,D000368,3977377,,,2,Aged,N,
23936,DescriptorName,D002908,3977377,,,3,Chronic Disease,N,
23937,DescriptorName,D005260,3977377,,,4,Female,N,
23938,DescriptorName,D006801,3977377,,,5,Humans,N,
23939,DescriptorName,D006852,3977377,,,6,Hydrochlorothiazide,N,
23940,QualifierName,Q000009,3977377,,,6,,Y,adverse effects
23941,DescriptorName,D008297,3977377,,,7,Male,N,
23942,DescriptorName,D008875,3977377,,,8,Middle Aged,N,
23943,DescriptorName,D011701,3977377,,,9,PUVA Therapy,N,
23944,DescriptorName,D010787,3977377,,,10,Photosensitivity Disorders,N,
23945,QualifierName,Q000139,3977377,,,10,,Y,chemically induced
23946,DescriptorName,D012867,3977377,,,11,Skin,N,
23947,QualifierName,Q000473,3977377,,,11,,N,pathology
23948,Chemical,D014700,3982906,Verapamil,CJ0O37KU29,,,,
23949,DescriptorName,D004554,3982906,,,1,Electric Countershock,N,
23950,DescriptorName,D004562,3982906,,,2,Electrocardiography,N,
23951,DescriptorName,D005260,3982906,,,3,Female,N,
23952,DescriptorName,D006323,3982906,,,4,Heart Arrest,N,
23953,QualifierName,Q000139,3982906,,,4,,N,chemically induced
23954,DescriptorName,D006333,3982906,,,5,Heart Failure,N,
23955,QualifierName,Q000150,3982906,,,5,,N,complications
23956,DescriptorName,D006439,3982906,,,6,Hemodynamics,N,
23957,QualifierName,Q000187,3982906,,,6,,Y,drug effects
23958,DescriptorName,D006801,3982906,,,7,Humans,N,
23959,DescriptorName,D007223,3982906,,,8,Infant,N,
23960,DescriptorName,D007231,3982906,,,9,"Infant, Newborn",N,
23961,DescriptorName,D012151,3982906,,,10,Resuscitation,N,
23962,QualifierName,Q000379,3982906,,,10,,N,methods
23963,DescriptorName,D013610,3982906,,,11,Tachycardia,N,
23964,QualifierName,Q000150,3982906,,,11,,N,complications
23965,DescriptorName,D014700,3982906,,,12,Verapamil,N,
23966,QualifierName,Q000009,3982906,,,12,,Y,adverse effects
23967,Chemical,D001572,3997294,Benzofurans,0,,,,
23968,Chemical,D000638,3997294,Amiodarone,N3RQ532IUT,,,,
23969,DescriptorName,D000328,3997294,,,1,Adult,N,
23970,DescriptorName,D000638,3997294,,,2,Amiodarone,N,
23971,QualifierName,Q000009,3997294,,,2,,Y,adverse effects
23972,DescriptorName,D001281,3997294,,,3,Atrial Fibrillation,N,
23973,QualifierName,Q000188,3997294,,,3,,N,drug therapy
23974,DescriptorName,D001282,3997294,,,4,Atrial Flutter,N,
23975,QualifierName,Q000188,3997294,,,4,,N,drug therapy
23976,DescriptorName,D001572,3997294,,,5,Benzofurans,N,
23977,QualifierName,Q000009,3997294,,,5,,Y,adverse effects
23978,DescriptorName,D003131,3997294,,,6,Combined Modality Therapy,N,
23979,DescriptorName,D005080,3997294,,,7,Exercise Test,N,
23980,DescriptorName,D006801,3997294,,,8,Humans,N,
23981,DescriptorName,D008297,3997294,,,9,Male,N,
23982,DescriptorName,D009046,3997294,,,10,Motor Neurons,N,
23983,QualifierName,Q000187,3997294,,,10,,Y,drug effects
23984,DescriptorName,D009431,3997294,,,11,Neural Conduction,N,
23985,QualifierName,Q000187,3997294,,,11,,N,drug effects
23986,DescriptorName,D009468,3997294,,,12,Neuromuscular Diseases,N,
23987,QualifierName,Q000139,3997294,,,12,,Y,chemically induced
23988,DescriptorName,D010138,3997294,,,13,"Pacemaker, Artificial",N,
23989,DescriptorName,D010490,3997294,,,14,Pericardial Effusion,N,
23990,QualifierName,Q000139,3997294,,,14,,Y,chemically induced
23991,DescriptorName,D010996,3997294,,,15,Pleural Effusion,N,
23992,QualifierName,Q000139,3997294,,,15,,Y,chemically induced
23993,DescriptorName,D011015,3997294,,,16,"Pneumonia, Aspiration",N,
23994,QualifierName,Q000139,3997294,,,16,,Y,chemically induced
23995,DescriptorName,D011017,3997294,,,17,"Pneumonia, Lipid",N,
23996,QualifierName,Q000139,3997294,,,17,,Y,chemically induced
23997,DescriptorName,D013610,3997294,,,18,Tachycardia,N,
23998,QualifierName,Q000188,3997294,,,18,,Y,drug therapy
23999,Chemical,D011137,4004433,Polystyrenes,0,,,,
24000,Chemical,C003321,4004433,polystyrene sulfonic acid,70KO0R01RY,,,,
24001,Chemical,D006493,4004433,Heparin,9005-49-6,,,,
24002,Chemical,D003404,4004433,Creatinine,AYI8EX34EU,,,,
24003,Chemical,D011188,4004433,Potassium,RWP5GA015D,,,,
24004,DescriptorName,D000368,4004433,,,1,Aged,N,
24005,DescriptorName,D001806,4004433,,,2,Blood Urea Nitrogen,N,
24006,DescriptorName,D003404,4004433,,,3,Creatinine,N,
24007,QualifierName,Q000097,4004433,,,3,,N,blood
24008,DescriptorName,D005260,4004433,,,4,Female,N,
24009,DescriptorName,D006493,4004433,,,5,Heparin,N,
24010,QualifierName,Q000009,4004433,,,5,,Y,adverse effects
24011,DescriptorName,D006801,4004433,,,6,Humans,N,
24012,DescriptorName,D006947,4004433,,,7,Hyperkalemia,N,
24013,QualifierName,Q000097,4004433,,,7,,N,blood
24014,DescriptorName,D008297,4004433,,,8,Male,N,
24015,DescriptorName,D008875,4004433,,,9,Middle Aged,N,
24016,DescriptorName,D011137,4004433,,,10,Polystyrenes,N,
24017,QualifierName,Q000627,4004433,,,10,,N,therapeutic use
24018,DescriptorName,D011188,4004433,,,11,Potassium,N,
24019,QualifierName,Q000097,4004433,,,11,,N,blood
24020,Chemical,D049528,4014301,"Insulin, Long-Acting",0,,,,
24021,DescriptorName,D000368,4014301,,,1,Aged,N,
24022,DescriptorName,D003924,4014301,,,2,"Diabetes Mellitus, Type 2",N,
24023,QualifierName,Q000188,4014301,,,2,,N,drug therapy
24024,DescriptorName,D005260,4014301,,,3,Female,N,
24025,DescriptorName,D006333,4014301,,,4,Heart Failure,N,
24026,QualifierName,Q000139,4014301,,,4,,Y,chemically induced
24027,DescriptorName,D006801,4014301,,,5,Humans,N,
24028,DescriptorName,D049528,4014301,,,6,"Insulin, Long-Acting",N,
24029,QualifierName,Q000009,4014301,,,6,,Y,adverse effects
24030,DescriptorName,D011654,4014301,,,7,Pulmonary Edema,N,
24031,QualifierName,Q000139,4014301,,,7,,N,chemically induced
24032,DescriptorName,D011859,4014301,,,8,Radiography,N,
24033,Chemical,D011736,4018433,Pyridoxine,KV2JZ1BI6Z,,,,
24034,DescriptorName,D004569,4018433,,,1,Electroencephalography,N,
24035,DescriptorName,D005071,4018433,,,2,Evoked Potentials,N,
24036,QualifierName,Q000187,4018433,,,2,,N,drug effects
24037,DescriptorName,D006801,4018433,,,3,Humans,N,
24038,DescriptorName,D007231,4018433,,,4,"Infant, Newborn",N,
24039,DescriptorName,D008297,4018433,,,5,Male,N,
24040,DescriptorName,D009123,4018433,,,6,Muscle Hypotonia,N,
24041,QualifierName,Q000139,4018433,,,6,,N,chemically induced
24042,DescriptorName,D011736,4018433,,,7,Pyridoxine,N,
24043,QualifierName,Q000009,4018433,,,7,,Y,adverse effects
24044,DescriptorName,D013036,4018433,,,8,"Spasms, Infantile",N,
24045,QualifierName,Q000188,4018433,,,8,,Y,drug therapy
24046,Chemical,D010068,4025011,Oxacillin,UH95VD7V76,,,,
24047,DescriptorName,D000328,4025011,,,1,Adult,N,
24048,DescriptorName,D000368,4025011,,,2,Aged,N,
24049,DescriptorName,D002779,4025011,,,3,Cholestasis,N,
24050,QualifierName,Q000139,4025011,,,3,,Y,chemically induced
24051,DescriptorName,D006801,4025011,,,4,Humans,N,
24052,DescriptorName,D008099,4025011,,,5,Liver,N,
24053,QualifierName,Q000473,4025011,,,5,,N,pathology
24054,DescriptorName,D008297,4025011,,,6,Male,N,
24055,DescriptorName,D010019,4025011,,,7,Osteomyelitis,N,
24056,QualifierName,Q000188,4025011,,,7,,N,drug therapy
24057,DescriptorName,D010068,4025011,,,8,Oxacillin,N,
24058,QualifierName,Q000009,4025011,,,8,,Y,adverse effects
24059,DescriptorName,D013997,4025011,,,9,Time Factors,N,
24060,Chemical,D007538,4031907,Isoniazid,V83O1VOZ8L,,,,
24061,DescriptorName,D000328,4031907,,,1,Adult,N,
24062,DescriptorName,D000368,4031907,,,2,Aged,N,
24063,DescriptorName,D001921,4031907,,,3,Brain,N,
24064,QualifierName,Q000473,4031907,,,3,,N,pathology
24065,DescriptorName,D001927,4031907,,,4,Brain Diseases,N,
24066,QualifierName,Q000139,4031907,,,4,,Y,chemically induced
24067,DescriptorName,D004359,4031907,,,5,"Drug Therapy, Combination",N,
24068,DescriptorName,D006801,4031907,,,6,Humans,N,
24069,DescriptorName,D007538,4031907,,,7,Isoniazid,N,
24070,QualifierName,Q000009,4031907,,,7,,Y,adverse effects
24071,DescriptorName,D008297,4031907,,,8,Male,N,
24072,DescriptorName,D008875,4031907,,,9,Middle Aged,N,
24073,DescriptorName,D009474,4031907,,,10,Neurons,N,
24074,QualifierName,Q000648,4031907,,,10,,N,ultrastructure
24075,DescriptorName,D009562,4031907,,,11,Nissl Bodies,N,
24076,QualifierName,Q000648,4031907,,,11,,N,ultrastructure
24077,DescriptorName,D010383,4031907,,,12,Pellagra,N,
24078,QualifierName,Q000139,4031907,,,12,,Y,chemically induced
24079,DescriptorName,D011605,4031907,,,13,"Psychoses, Substance-Induced",N,
24080,QualifierName,Q000473,4031907,,,13,,N,pathology
24081,DescriptorName,D014397,4031907,,,14,"Tuberculosis, Pulmonary",N,
24082,QualifierName,Q000188,4031907,,,14,,Y,drug therapy
24083,Chemical,D001241,4036917,Aspirin,R16CO5Y76E,,,,
24084,DescriptorName,D001171,4036917,,,1,"Arthritis, Juvenile",N,
24085,QualifierName,Q000188,4036917,,,1,,Y,drug therapy
24086,DescriptorName,D001241,4036917,,,2,Aspirin,N,
24087,QualifierName,Q000009,4036917,,,2,,Y,adverse effects
24088,DescriptorName,D002648,4036917,,,3,Child,N,
24089,DescriptorName,D002675,4036917,,,4,"Child, Preschool",N,
24090,DescriptorName,D005260,4036917,,,5,Female,N,
24091,DescriptorName,D006801,4036917,,,6,Humans,N,
24092,DescriptorName,D008297,4036917,,,7,Male,N,
24093,DescriptorName,D008824,4036917,,,8,Michigan,N,
24094,DescriptorName,D012202,4036917,,,9,Reye Syndrome,N,
24095,QualifierName,Q000139,4036917,,,9,,Y,chemically induced
24096,Chemical,D001552,4038927,Benzazepines,0,,,,
24097,Chemical,D011433,4038927,Propranolol,9Y8NXQ24VQ,,,,
24098,Chemical,D014700,4038927,Verapamil,CJ0O37KU29,,,,
24099,Chemical,D004110,4038927,Diltiazem,EE92BBP03H,,,,
24100,DescriptorName,D000328,4038927,,,1,Adult,N,
24101,DescriptorName,D001281,4038927,,,2,Atrial Fibrillation,N,
24102,QualifierName,Q000139,4038927,,,2,,Y,chemically induced
24103,DescriptorName,D001552,4038927,,,3,Benzazepines,N,
24104,QualifierName,Q000009,4038927,,,3,,Y,adverse effects
24105,DescriptorName,D002312,4038927,,,4,"Cardiomyopathy, Hypertrophic",N,
24106,QualifierName,Q000188,4038927,,,4,,Y,drug therapy
24107,DescriptorName,D004110,4038927,,,5,Diltiazem,N,
24108,QualifierName,Q000009,4038927,,,5,,Y,adverse effects
24109,DescriptorName,D004452,4038927,,,6,Echocardiography,N,
24110,DescriptorName,D004562,4038927,,,7,Electrocardiography,N,
24111,DescriptorName,D005260,4038927,,,8,Female,N,
24112,DescriptorName,D006339,4038927,,,9,Heart Rate,N,
24113,QualifierName,Q000187,4038927,,,9,,N,drug effects
24114,DescriptorName,D006801,4038927,,,10,Humans,N,
24115,DescriptorName,D008297,4038927,,,11,Male,N,
24116,DescriptorName,D008875,4038927,,,12,Middle Aged,N,
24117,DescriptorName,D011433,4038927,,,13,Propranolol,N,
24118,QualifierName,Q000627,4038927,,,13,,N,therapeutic use
24119,DescriptorName,D013575,4038927,,,14,Syncope,N,
24120,QualifierName,Q000139,4038927,,,14,,Y,chemically induced
24121,DescriptorName,D014700,4038927,,,15,Verapamil,N,
24122,QualifierName,Q000009,4038927,,,15,,Y,adverse effects
24123,Chemical,D001572,4044222,Benzofurans,0,,,,
24124,Chemical,D000638,4044222,Amiodarone,N3RQ532IUT,,,,
24125,DescriptorName,D000638,4044222,,,1,Amiodarone,N,
24126,QualifierName,Q000009,4044222,,,1,,N,adverse effects
24127,DescriptorName,D001572,4044222,,,2,Benzofurans,N,
24128,QualifierName,Q000627,4044222,,,2,,Y,therapeutic use
24129,DescriptorName,D003327,4044222,,,3,Coronary Disease,N,
24130,QualifierName,Q000188,4044222,,,3,,Y,drug therapy
24131,DescriptorName,D006801,4044222,,,4,Humans,N,
24132,DescriptorName,D006980,4044222,,,5,Hyperthyroidism,N,
24133,QualifierName,Q000139,4044222,,,5,,Y,chemically induced
24134,DescriptorName,D007037,4044222,,,6,Hypothyroidism,N,
24135,QualifierName,Q000139,4044222,,,6,,Y,chemically induced
24136,DescriptorName,D008297,4044222,,,7,Male,N,
24137,DescriptorName,D008875,4044222,,,8,Middle Aged,N,
24138,DescriptorName,D013961,4044222,,,9,Thyroid Gland,N,
24139,QualifierName,Q000187,4044222,,,9,,N,drug effects
24140,Chemical,D009599,4051280,Nitroprusside,169D1260KM,,,,
24141,Chemical,D011433,4051280,Propranolol,9Y8NXQ24VQ,,,,
24142,Chemical,D003042,4051280,Cocaine,I5Y540LHVR,,,,
24143,DescriptorName,D003042,4051280,,,1,Cocaine,N,
24144,QualifierName,Q000009,4051280,,,1,,Y,adverse effects
24145,DescriptorName,D004630,4051280,,,2,Emergencies,Y,
24146,DescriptorName,D006801,4051280,,,3,Humans,N,
24147,DescriptorName,D008297,4051280,,,4,Male,N,
24148,DescriptorName,D008875,4051280,,,5,Middle Aged,N,
24149,DescriptorName,D009599,4051280,,,6,Nitroprusside,N,
24150,QualifierName,Q000627,4051280,,,6,,N,therapeutic use
24151,DescriptorName,D011041,4051280,,,7,Poisoning,N,
24152,QualifierName,Q000188,4051280,,,7,,N,drug therapy
24153,DescriptorName,D011433,4051280,,,8,Propranolol,N,
24154,QualifierName,Q000009,4051280,,,8,,Y,adverse effects
24155,Chemical,D002699,4054170,Chlorambucil,18D0SL7309,,,,
24156,Chemical,D011239,4054170,Prednisolone,9PHQ9Y1OLM,,,,
24157,DescriptorName,D001921,4054170,,,1,Brain,N,
24158,QualifierName,Q000187,4054170,,,1,,Y,drug effects
24159,DescriptorName,D002493,4054170,,,2,Central Nervous System Diseases,N,
24160,QualifierName,Q000139,4054170,,,2,,Y,chemically induced
24161,DescriptorName,D002648,4054170,,,3,Child,N,
24162,DescriptorName,D002699,4054170,,,4,Chlorambucil,N,
24163,QualifierName,Q000009,4054170,,,4,,Y,adverse effects
24164,DescriptorName,D004359,4054170,,,5,"Drug Therapy, Combination",N,
24165,DescriptorName,D004569,4054170,,,6,Electroencephalography,N,
24166,DescriptorName,D006801,4054170,,,7,Humans,N,
24167,DescriptorName,D008297,4054170,,,8,Male,N,
24168,DescriptorName,D009404,4054170,,,9,Nephrotic Syndrome,N,
24169,QualifierName,Q000188,4054170,,,9,,Y,drug therapy
24170,DescriptorName,D011239,4054170,,,10,Prednisolone,N,
24171,QualifierName,Q000627,4054170,,,10,,N,therapeutic use
24172,Chemical,D000893,4063627,Anti-Inflammatory Agents,0,,,,
24173,Chemical,D007070,4063627,Immunoglobulin A,0,,,,
24174,Chemical,D010648,4063627,Phenylacetates,0,,,,
24175,Chemical,C012970,4063627,fenclofenac,Y01JW64D01,,,,
24176,DescriptorName,D000328,4063627,,,1,Adult,N,
24177,DescriptorName,D000893,4063627,,,2,Anti-Inflammatory Agents,N,
24178,QualifierName,Q000009,4063627,,,2,,Y,adverse effects
24179,DescriptorName,D001172,4063627,,,3,"Arthritis, Rheumatoid",N,
24180,QualifierName,Q000150,4063627,,,3,,Y,complications
24181,DescriptorName,D004406,4063627,,,4,Dysgammaglobulinemia,N,
24182,QualifierName,Q000139,4063627,,,4,,Y,chemically induced
24183,DescriptorName,D006801,4063627,,,5,Humans,N,
24184,DescriptorName,D017098,4063627,,,6,IgA Deficiency,Y,
24185,DescriptorName,D007070,4063627,,,7,Immunoglobulin A,N,
24186,QualifierName,Q000032,4063627,,,7,,N,analysis
24187,DescriptorName,D008297,4063627,,,8,Male,N,
24188,DescriptorName,D010648,4063627,,,9,Phenylacetates,N,
24189,QualifierName,Q000009,4063627,,,9,,Y,adverse effects
24190,Chemical,D008094,4066620,Lithium,9FN79X2M3F,,,,
24191,Chemical,D014196,4066620,Trazodone,YBK48BXK30,,,,
24192,DescriptorName,D000368,4066620,,,1,Aged,N,
24193,DescriptorName,D003866,4066620,,,2,Depressive Disorder,N,
24194,QualifierName,Q000188,4066620,,,2,,N,drug therapy
24195,DescriptorName,D004305,4066620,,,3,"Dose-Response Relationship, Drug",N,
24196,DescriptorName,D004359,4066620,,,4,"Drug Therapy, Combination",N,
24197,DescriptorName,D005260,4066620,,,5,Female,N,
24198,DescriptorName,D006801,4066620,,,6,Humans,N,
24199,DescriptorName,D008094,4066620,,,7,Lithium,N,
24200,QualifierName,Q000627,4066620,,,7,,N,therapeutic use
24201,DescriptorName,D009069,4066620,,,8,Movement Disorders,N,
24202,QualifierName,Q000139,4066620,,,8,,Y,chemically induced
24203,DescriptorName,D014196,4066620,,,9,Trazodone,N,
24204,QualifierName,Q000008,4066620,,,9,,N,administration & dosage
24205,Chemical,D008140,4075534,Lorazepam,O26FZP769L,,,,
24206,Chemical,D003975,4075534,Diazepam,Q3JTX2Q7TU,,,,
24207,DescriptorName,D000328,4075534,,,1,Adult,N,
24208,DescriptorName,D000430,4075534,,,2,Alcohol Withdrawal Delirium,N,
24209,QualifierName,Q000188,4075534,,,2,,N,drug therapy
24210,DescriptorName,D003128,4075534,,,3,Coma,N,
24211,QualifierName,Q000139,4075534,,,3,,Y,chemically induced
24212,DescriptorName,D003975,4075534,,,4,Diazepam,N,
24213,QualifierName,Q000009,4075534,,,4,,Y,adverse effects
24214,DescriptorName,D004359,4075534,,,5,"Drug Therapy, Combination",N,
24215,DescriptorName,D004569,4075534,,,6,Electroencephalography,Y,
24216,DescriptorName,D005071,4075534,,,7,Evoked Potentials,N,
24217,QualifierName,Q000187,4075534,,,7,,N,drug effects
24218,DescriptorName,D005260,4075534,,,8,Female,N,
24219,DescriptorName,D006801,4075534,,,9,Humans,N,
24220,DescriptorName,D008104,4075534,,,10,"Liver Cirrhosis, Alcoholic",N,
24221,QualifierName,Q000150,4075534,,,10,,N,complications
24222,DescriptorName,D008140,4075534,,,11,Lorazepam,N,
24223,QualifierName,Q000009,4075534,,,11,,Y,adverse effects
24224,Chemical,D012293,4082283,Rifampin,VJT6J7R4TR,,,,
24225,DescriptorName,D058186,4082283,,,1,Acute Kidney Injury,N,
24226,QualifierName,Q000139,4082283,,,1,,Y,chemically induced
24227,DescriptorName,D000368,4082283,,,2,Aged,N,
24228,DescriptorName,D005260,4082283,,,3,Female,N,
24229,DescriptorName,D006801,4082283,,,4,Humans,N,
24230,DescriptorName,D008297,4082283,,,5,Male,N,
24231,DescriptorName,D008875,4082283,,,6,Middle Aged,N,
24232,DescriptorName,D012293,4082283,,,7,Rifampin,N,
24233,QualifierName,Q000009,4082283,,,7,,Y,adverse effects
24234,DescriptorName,D012306,4082283,,,8,Risk,N,
24235,DescriptorName,D014376,4082283,,,9,Tuberculosis,N,
24236,QualifierName,Q000188,4082283,,,9,,N,drug therapy
24237,Chemical,D008670,4095247,Metals,0,,,,
24238,Chemical,D003676,4095247,Deferoxamine,J06Y7MXW4D,,,,
24239,Chemical,D011346,4095247,Prochlorperazine,YHP6YLT61T,,,,
24240,DescriptorName,D000328,4095247,,,1,Adult,N,
24241,DescriptorName,D000368,4095247,,,2,Aged,N,
24242,DescriptorName,D000818,4095247,,,3,Animals,N,
24243,DescriptorName,D001921,4095247,,,4,Brain,N,
24244,QualifierName,Q000187,4095247,,,4,,Y,drug effects
24245,DescriptorName,D003676,4095247,,,5,Deferoxamine,N,
24246,QualifierName,Q000009,4095247,,,5,,Y,adverse effects
24247,DescriptorName,D004347,4095247,,,6,Drug Interactions,N,
24248,DescriptorName,D004359,4095247,,,7,"Drug Therapy, Combination",N,
24249,DescriptorName,D005260,4095247,,,8,Female,N,
24250,DescriptorName,D005654,4095247,,,9,Fundus Oculi,N,
24251,QualifierName,Q000187,4095247,,,9,,N,drug effects
24252,DescriptorName,D006801,4095247,,,10,Humans,N,
24253,DescriptorName,D007592,4095247,,,11,Joint Diseases,N,
24254,QualifierName,Q000134,4095247,,,11,,N,cerebrospinal fluid
24255,DescriptorName,D008297,4095247,,,12,Male,N,
24256,DescriptorName,D008670,4095247,,,13,Metals,N,
24257,QualifierName,Q000378,4095247,,,13,,N,metabolism
24258,DescriptorName,D008875,4095247,,,14,Middle Aged,N,
24259,DescriptorName,D009902,4095247,,,15,Optic Neuritis,N,
24260,QualifierName,Q000139,4095247,,,15,,Y,chemically induced
24261,DescriptorName,D011346,4095247,,,16,Prochlorperazine,N,
24262,QualifierName,Q000009,4095247,,,16,,N,adverse effects
24263,DescriptorName,D051381,4095247,,,17,Rats,N,
24264,DescriptorName,D011919,4095247,,,18,"Rats, Inbred Strains",N,
24265,Chemical,D007136,412488,Immunoglobulins,0,,,,
24266,Chemical,D006052,412488,Gold Sodium Thiomalate,12244-57-4,,,,
24267,Chemical,D006046,412488,Gold,7440-57-5,,,,
24268,DescriptorName,D000328,412488,,,1,Adult,N,
24269,DescriptorName,D001172,412488,,,2,"Arthritis, Rheumatoid",N,
24270,QualifierName,Q000188,412488,,,2,,N,drug therapy
24271,DescriptorName,D001485,412488,,,3,Basement Membrane,N,
24272,QualifierName,Q000276,412488,,,3,,N,immunology
24273,DescriptorName,D005260,412488,,,4,Female,N,
24274,DescriptorName,D006046,412488,,,5,Gold,N,
24275,QualifierName,Q000032,412488,,,5,,N,analysis
24276,DescriptorName,D006052,412488,,,6,Gold Sodium Thiomalate,N,
24277,QualifierName,Q000009,412488,,,6,,Y,adverse effects
24278,DescriptorName,D006801,412488,,,7,Humans,N,
24279,DescriptorName,D007136,412488,,,8,Immunoglobulins,N,
24280,QualifierName,Q000032,412488,,,8,,N,analysis
24281,DescriptorName,D007668,412488,,,9,Kidney,N,
24282,QualifierName,Q000276,412488,,,9,,N,immunology
24283,DescriptorName,D007678,412488,,,10,Kidney Glomerulus,N,
24284,QualifierName,Q000032,412488,,,10,,N,analysis
24285,DescriptorName,D007687,412488,,,11,"Kidney Tubules, Proximal",N,
24286,QualifierName,Q000648,412488,,,11,,N,ultrastructure
24287,DescriptorName,D008297,412488,,,12,Male,N,
24288,DescriptorName,D011507,412488,,,13,Proteinuria,N,
24289,QualifierName,Q000139,412488,,,13,,N,chemically induced
24290,DescriptorName,D013052,412488,,,14,"Spectrometry, X-Ray Emission",N,
24291,Chemical,D008055,417679,Lipids,0,,,,
24292,DescriptorName,D002196,417679,,,1,Capillaries,N,
24293,QualifierName,Q000473,417679,,,1,,N,pathology
24294,DescriptorName,D004620,417679,,,2,"Embolism, Fat",N,
24295,QualifierName,Q000139,417679,,,2,,Y,chemically induced
24296,DescriptorName,D005260,417679,,,3,Female,N,
24297,DescriptorName,D006801,417679,,,4,Humans,N,
24298,DescriptorName,D007223,417679,,,5,Infant,N,
24299,DescriptorName,D007231,417679,,,6,"Infant, Newborn",N,
24300,DescriptorName,D007232,417679,,,7,"Infant, Newborn, Diseases",N,
24301,QualifierName,Q000139,417679,,,7,,Y,chemically induced
24302,DescriptorName,D008055,417679,,,8,Lipids,N,
24303,QualifierName,Q000008,417679,,,8,,N,administration & dosage
24304,DescriptorName,D008168,417679,,,9,Lung,N,
24305,QualifierName,Q000098,417679,,,9,,N,blood supply
24306,DescriptorName,D008297,417679,,,10,Male,N,
24307,DescriptorName,D009748,417679,,,11,Nutrition Disorders,N,
24308,QualifierName,Q000188,417679,,,11,,N,drug therapy
24309,DescriptorName,D010288,417679,,,12,Parenteral Nutrition,N,
24310,QualifierName,Q000009,417679,,,12,,Y,adverse effects
24311,Chemical,D008727,424824,Methotrexate,YL5FZ2Y5U1,,,,
24312,DescriptorName,D000368,424824,,,1,Aged,N,
24313,DescriptorName,D001932,424824,,,2,Brain Neoplasms,N,
24314,QualifierName,Q000188,424824,,,2,,N,drug therapy
24315,DescriptorName,D002294,424824,,,3,"Carcinoma, Squamous Cell",N,
24316,QualifierName,Q000188,424824,,,3,,N,drug therapy
24317,DescriptorName,D003937,424824,,,4,"Diagnosis, Differential",N,
24318,DescriptorName,D006801,424824,,,5,Humans,N,
24319,DescriptorName,D008175,424824,,,6,Lung Neoplasms,N,
24320,QualifierName,Q000188,424824,,,6,,N,drug therapy
24321,DescriptorName,D008297,424824,,,7,Male,N,
24322,DescriptorName,D008727,424824,,,8,Methotrexate,N,
24323,QualifierName,Q000009,424824,,,8,,Y,adverse effects
24324,DescriptorName,D008875,424824,,,9,Middle Aged,N,
24325,DescriptorName,D011565,424824,,,10,Psoriasis,N,
24326,QualifierName,Q000188,424824,,,10,,N,drug therapy
24327,DescriptorName,D011658,424824,,,11,Pulmonary Fibrosis,N,
24328,QualifierName,Q000139,424824,,,11,,Y,chemically induced
24329,Chemical,D014740,426502,Vidarabine,FA2DM6879K,,,,
24330,DescriptorName,D000328,426502,,,1,Adult,N,
24331,DescriptorName,D006562,426502,,,2,Herpes Zoster,N,
24332,QualifierName,Q000188,426502,,,2,,Y,drug therapy
24333,DescriptorName,D006801,426502,,,3,Humans,N,
24334,DescriptorName,D007177,426502,,,4,Inappropriate ADH Syndrome,N,
24335,QualifierName,Q000139,426502,,,4,,Y,chemically induced
24336,DescriptorName,D008297,426502,,,5,Male,N,
24337,DescriptorName,D014740,426502,,,6,Vidarabine,N,
24338,QualifierName,Q000009,426502,,,6,,Y,adverse effects
24339,Chemical,D011241,433855,Prednisone,VB0R961HZT,,,,
24340,Chemical,D008727,433855,Methotrexate,YL5FZ2Y5U1,,,,
24341,DescriptorName,D002648,433855,,,1,Child,N,
24342,DescriptorName,D002675,433855,,,2,"Child, Preschool",N,
24343,DescriptorName,D003882,433855,,,3,Dermatomyositis,N,
24344,QualifierName,Q000188,433855,,,3,,N,drug therapy
24345,DescriptorName,D004359,433855,,,4,"Drug Therapy, Combination",N,
24346,DescriptorName,D005260,433855,,,5,Female,N,
24347,DescriptorName,D006801,433855,,,6,Humans,N,
24348,DescriptorName,D008297,433855,,,7,Male,N,
24349,DescriptorName,D008727,433855,,,8,Methotrexate,N,
24350,QualifierName,Q000009,433855,,,8,,N,adverse effects
24351,DescriptorName,D009220,433855,,,9,Myositis,N,
24352,QualifierName,Q000188,433855,,,9,,Y,drug therapy
24353,DescriptorName,D011241,433855,,,10,Prednisone,N,
24354,QualifierName,Q000627,433855,,,10,,Y,therapeutic use
24355,Chemical,D002220,440873,Carbamazepine,33CM23913M,,,,
24356,DescriptorName,D002220,440873,,,1,Carbamazepine,N,
24357,QualifierName,Q000009,440873,,,1,,Y,adverse effects
24358,DescriptorName,D002675,440873,,,2,"Child, Preschool",N,
24359,DescriptorName,D004421,440873,,,3,Dystonia,N,
24360,QualifierName,Q000139,440873,,,3,,Y,chemically induced
24361,DescriptorName,D006801,440873,,,4,Humans,N,
24362,DescriptorName,D007223,440873,,,5,Infant,N,
24363,DescriptorName,D008297,440873,,,6,Male,N,
24364,DescriptorName,D012640,440873,,,7,Seizures,N,
24365,QualifierName,Q000188,440873,,,7,,N,drug therapy
24366,Chemical,D013830,448845,Thiadiazoles,0,,,,
24367,Chemical,D008704,448845,Methazolamide,W733B0S9SD,,,,
24368,DescriptorName,D000368,448845,,,1,Aged,N,
24369,DescriptorName,D000380,448845,,,2,Agranulocytosis,N,
24370,QualifierName,Q000139,448845,,,2,,Y,chemically induced
24371,DescriptorName,D000741,448845,,,3,"Anemia, Aplastic",N,
24372,QualifierName,Q000139,448845,,,3,,Y,chemically induced
24373,DescriptorName,D005260,448845,,,4,Female,N,
24374,DescriptorName,D005901,448845,,,5,Glaucoma,N,
24375,QualifierName,Q000188,448845,,,5,,Y,drug therapy
24376,DescriptorName,D006801,448845,,,6,Humans,N,
24377,DescriptorName,D008297,448845,,,7,Male,N,
24378,DescriptorName,D008704,448845,,,8,Methazolamide,N,
24379,QualifierName,Q000009,448845,,,8,,Y,adverse effects
24380,DescriptorName,D013830,448845,,,9,Thiadiazoles,N,
24381,QualifierName,Q000009,448845,,,9,,Y,adverse effects
24382,Chemical,D005472,458006,Fluorouracil,U3P01618RT,,,,
24383,DescriptorName,D000328,458006,,,1,Adult,N,
24384,DescriptorName,D002280,458006,,,2,"Carcinoma, Basal Cell",N,
24385,QualifierName,Q000150,458006,,,2,,Y,complications
24386,DescriptorName,D002294,458006,,,3,"Carcinoma, Squamous Cell",N,
24387,QualifierName,Q000139,458006,,,3,,Y,chemically induced
24388,DescriptorName,D005472,458006,,,4,Fluorouracil,N,
24389,QualifierName,Q000009,458006,,,4,,Y,adverse effects
24390,DescriptorName,D006801,458006,,,5,Humans,N,
24391,DescriptorName,D008297,458006,,,6,Male,N,
24392,DescriptorName,D009378,458006,,,7,"Neoplasms, Multiple Primary",N,
24393,QualifierName,Q000473,458006,,,7,,Y,pathology
24394,DescriptorName,D012878,458006,,,8,Skin Neoplasms,N,
24395,QualifierName,Q000139,458006,,,8,,Y,chemically induced
24396,Chemical,D008784,464813,Methysergide,XZA9HY6Z98,,,,
24397,DescriptorName,D003251,464813,,,1,"Constriction, Pathologic",N,
24398,QualifierName,Q000139,464813,,,1,,N,chemically induced
24399,DescriptorName,D005260,464813,,,2,Female,N,
24400,DescriptorName,D005263,464813,,,3,Femoral Artery,Y,
24401,QualifierName,Q000187,464813,,,3,,N,drug effects
24402,DescriptorName,D006801,464813,,,4,Humans,N,
24403,DescriptorName,D007383,464813,,,5,Intermittent Claudication,N,
24404,QualifierName,Q000139,464813,,,5,,Y,chemically induced
24405,DescriptorName,D008784,464813,,,6,Methysergide,N,
24406,QualifierName,Q000009,464813,,,6,,Y,adverse effects
24407,DescriptorName,D008875,464813,,,7,Middle Aged,N,
24408,DescriptorName,D008881,464813,,,8,Migraine Disorders,N,
24409,QualifierName,Q000188,464813,,,8,,Y,drug therapy
24410,DescriptorName,D011150,464813,,,9,Popliteal Artery,Y,
24411,QualifierName,Q000187,464813,,,9,,N,drug effects
24412,Chemical,D012293,480917,Rifampin,VJT6J7R4TR,,,,
24413,DescriptorName,D000328,480917,,,1,Adult,N,
24414,DescriptorName,D004892,480917,,,2,Erythema Multiforme,N,
24415,QualifierName,Q000139,480917,,,2,,Y,chemically induced
24416,DescriptorName,D006801,480917,,,3,Humans,N,
24417,DescriptorName,D007918,480917,,,4,Leprosy,N,
24418,QualifierName,Q000150,480917,,,4,,N,complications
24419,DescriptorName,D008297,480917,,,5,Male,N,
24420,DescriptorName,D012293,480917,,,6,Rifampin,N,
24421,QualifierName,Q000009,480917,,,6,,Y,adverse effects
24422,DescriptorName,D014397,480917,,,7,"Tuberculosis, Pulmonary",N,
24423,QualifierName,Q000150,480917,,,7,,N,complications
24424,Chemical,D008094,489527,Lithium,9FN79X2M3F,,,,
24425,Chemical,D003404,489527,Creatinine,AYI8EX34EU,,,,
24426,DescriptorName,D000328,489527,,,1,Adult,N,
24427,DescriptorName,D001714,489527,,,2,Bipolar Disorder,N,
24428,QualifierName,Q000188,489527,,,2,,N,drug therapy
24429,DescriptorName,D001806,489527,,,3,Blood Urea Nitrogen,N,
24430,DescriptorName,D003404,489527,,,4,Creatinine,N,
24431,QualifierName,Q000097,489527,,,4,,N,blood
24432,DescriptorName,D004305,489527,,,5,"Dose-Response Relationship, Drug",N,
24433,DescriptorName,D005919,489527,,,6,Glomerular Filtration Rate,N,
24434,QualifierName,Q000187,489527,,,6,,N,drug effects
24435,DescriptorName,D006801,489527,,,7,Humans,N,
24436,DescriptorName,D007668,489527,,,8,Kidney,N,
24437,QualifierName,Q000187,489527,,,8,,Y,drug effects
24438,DescriptorName,D007671,489527,,,9,Kidney Concentrating Ability,N,
24439,QualifierName,Q000187,489527,,,9,,N,drug effects
24440,DescriptorName,D008094,489527,,,10,Lithium,N,
24441,QualifierName,Q000009,489527,,,10,,Y,adverse effects
24442,DescriptorName,D008297,489527,,,11,Male,N,
24443,Chemical,D011564,507889,Furocoumarins,0,,,,
24444,Chemical,D008730,507889,Methoxsalen,U4VJ29L7BQ,,,,
24445,DescriptorName,D000368,507889,,,1,Aged,N,
24446,DescriptorName,D002294,507889,,,2,"Carcinoma, Squamous Cell",N,
24447,QualifierName,Q000209,507889,,,2,,Y,etiology
24448,DescriptorName,D011564,507889,,,3,Furocoumarins,N,
24449,QualifierName,Q000627,507889,,,3,,Y,therapeutic use
24450,DescriptorName,D006801,507889,,,4,Humans,N,
24451,DescriptorName,D008297,507889,,,5,Male,N,
24452,DescriptorName,D008730,507889,,,6,Methoxsalen,N,
24453,QualifierName,Q000009,507889,,,6,,N,adverse effects
24454,DescriptorName,D008875,507889,,,7,Middle Aged,N,
24455,DescriptorName,D009182,507889,,,8,Mycosis Fungoides,N,
24456,QualifierName,Q000150,507889,,,8,,Y,complications
24457,DescriptorName,D009381,507889,,,9,"Neoplasms, Radiation-Induced",Y,
24458,DescriptorName,D010778,507889,,,10,Photochemotherapy,N,
24459,QualifierName,Q000009,507889,,,10,,Y,adverse effects
24460,DescriptorName,D011879,507889,,,11,Radiotherapy Dosage,N,
24461,DescriptorName,D012878,507889,,,12,Skin Neoplasms,N,
24462,QualifierName,Q000209,507889,,,12,,Y,etiology
24463,DescriptorName,D014467,507889,,,13,Ultraviolet Therapy,N,
24464,QualifierName,Q000009,507889,,,13,,Y,adverse effects
24465,Chemical,D004232,515777,Diuretics,0,,,,
24466,Chemical,D007328,515777,Insulin,0,,,,
24467,Chemical,D006852,515777,Hydrochlorothiazide,0J48LPH2TH,,,,
24468,Chemical,D011433,515777,Propranolol,9Y8NXQ24VQ,,,,
24469,DescriptorName,D003926,515777,,,1,Diabetic Coma,N,
24470,QualifierName,Q000139,515777,,,1,,Y,chemically induced
24471,DescriptorName,D004232,515777,,,2,Diuretics,N,
24472,QualifierName,Q000009,515777,,,2,,N,adverse effects
24473,DescriptorName,D004359,515777,,,3,"Drug Therapy, Combination",N,
24474,DescriptorName,D006801,515777,,,4,Humans,N,
24475,DescriptorName,D006852,515777,,,5,Hydrochlorothiazide,N,
24476,QualifierName,Q000009,515777,,,5,,Y,adverse effects
24477,DescriptorName,D006943,515777,,,6,Hyperglycemia,N,
24478,QualifierName,Q000139,515777,,,6,,Y,chemically induced
24479,DescriptorName,D006944,515777,,,7,Hyperglycemic Hyperosmolar Nonketotic Coma,N,
24480,QualifierName,Q000139,515777,,,7,,Y,chemically induced
24481,DescriptorName,D007328,515777,,,8,Insulin,N,
24482,QualifierName,Q000627,515777,,,8,,N,therapeutic use
24483,DescriptorName,D008297,515777,,,9,Male,N,
24484,DescriptorName,D008875,515777,,,10,Middle Aged,N,
24485,DescriptorName,D011433,515777,,,11,Propranolol,N,
24486,QualifierName,Q000009,515777,,,11,,Y,adverse effects
24487,Chemical,D000086,527355,Acetazolamide,O3FX965V0I,,,,
24488,DescriptorName,D000086,527355,,,1,Acetazolamide,N,
24489,QualifierName,Q000009,527355,,,1,,Y,adverse effects
24490,DescriptorName,D000138,527355,,,2,Acidosis,N,
24491,QualifierName,Q000139,527355,,,2,,Y,chemically induced
24492,DescriptorName,D000328,527355,,,3,Adult,N,
24493,DescriptorName,D048909,527355,,,4,Diabetes Complications,Y,
24494,DescriptorName,D003920,527355,,,5,Diabetes Mellitus,N,
24495,QualifierName,Q000188,527355,,,5,,N,drug therapy
24496,DescriptorName,D005260,527355,,,6,Female,N,
24497,DescriptorName,D006801,527355,,,7,Humans,N,
24498,Chemical,D001728,53128,Dicumarol,7QID3E7BG7,,,,
24499,DescriptorName,D000402,53128,,,1,Airway Obstruction,N,
24500,QualifierName,Q000209,53128,,,1,,Y,etiology
24501,DescriptorName,D001161,53128,,,2,Arteriosclerosis,N,
24502,QualifierName,Q000188,53128,,,2,,N,drug therapy
24503,DescriptorName,D003251,53128,,,3,"Constriction, Pathologic",N,
24504,DescriptorName,D001728,53128,,,4,Dicumarol,N,
24505,QualifierName,Q000009,53128,,,4,,Y,adverse effects
24506,DescriptorName,D004438,53128,,,5,Ecchymosis,N,
24507,QualifierName,Q000209,53128,,,5,,N,etiology
24508,DescriptorName,D006406,53128,,,6,Hematoma,N,
24509,QualifierName,Q000150,53128,,,6,,Y,complications
24510,DescriptorName,D006801,53128,,,7,Humans,N,
24511,DescriptorName,D008297,53128,,,8,Male,N,
24512,DescriptorName,D008875,53128,,,9,Middle Aged,N,
24513,DescriptorName,D009333,53128,,,10,Neck,Y,
24514,QualifierName,Q000098,53128,,,10,,N,blood supply
24515,DescriptorName,D010608,53128,,,11,Pharyngeal Diseases,N,
24516,QualifierName,Q000209,53128,,,11,,N,etiology
24517,DescriptorName,D011087,53128,,,12,Polycythemia Vera,N,
24518,QualifierName,Q000150,53128,,,12,,N,complications
24519,DescriptorName,D014133,53128,,,13,Tracheal Diseases,N,
24520,QualifierName,Q000209,53128,,,13,,Y,etiology
24521,DescriptorName,D014140,53128,,,14,Tracheotomy,N,
24522,Chemical,D002981,536461,Clindamycin,3U02EL437C,,,,
24523,DescriptorName,D000328,536461,,,1,Adult,N,
24524,DescriptorName,D002981,536461,,,2,Clindamycin,N,
24525,QualifierName,Q000009,536461,,,2,,Y,adverse effects
24526,DescriptorName,D003106,536461,,,3,Colon,N,
24527,QualifierName,Q000473,536461,,,3,,N,pathology
24528,DescriptorName,D004761,536461,,,4,"Enterocolitis, Pseudomembranous",N,
24529,QualifierName,Q000139,536461,,,4,,Y,chemically induced
24530,DescriptorName,D005260,536461,,,5,Female,N,
24531,DescriptorName,D006801,536461,,,6,Humans,N,
24532,DescriptorName,D007938,536461,,,7,Leukemia,N,
24533,QualifierName,Q000150,536461,,,7,,Y,complications
24534,DescriptorName,D008875,536461,,,8,Middle Aged,N,
24535,Chemical,D003276,556126,"Contraceptives, Oral",0,,,,
24536,Chemical,D001971,556126,Bromocriptine,3A64E3G5ZO,,,,
24537,DescriptorName,D000238,556126,,,1,"Adenoma, Chromophobe",N,
24538,QualifierName,Q000150,556126,,,1,,Y,complications
24539,DescriptorName,D000293,556126,,,2,Adolescent,N,
24540,DescriptorName,D000328,556126,,,3,Adult,N,
24541,DescriptorName,D001971,556126,,,4,Bromocriptine,N,
24542,QualifierName,Q000627,556126,,,4,,N,therapeutic use
24543,DescriptorName,D002648,556126,,,5,Child,N,
24544,DescriptorName,D003276,556126,,,6,"Contraceptives, Oral",N,
24545,QualifierName,Q000009,556126,,,6,,Y,adverse effects
24546,DescriptorName,D005260,556126,,,7,Female,N,
24547,DescriptorName,D006801,556126,,,8,Humans,N,
24548,DescriptorName,D007231,556126,,,9,"Infant, Newborn",N,
24549,DescriptorName,D007247,556126,,,10,"Infertility, Female",N,
24550,QualifierName,Q000150,556126,,,10,,N,complications
24551,DescriptorName,D008297,556126,,,11,Male,N,
24552,DescriptorName,D010911,556126,,,12,Pituitary Neoplasms,N,
24553,QualifierName,Q000150,556126,,,12,,Y,complications
24554,DescriptorName,D011247,556126,,,13,Pregnancy,N,
24555,DescriptorName,D011248,556126,,,14,Pregnancy Complications,N,
24556,QualifierName,Q000209,556126,,,14,,Y,etiology
24557,DescriptorName,D014786,556126,,,15,Vision Disorders,N,
24558,QualifierName,Q000139,556126,,,15,,Y,chemically induced
24559,Chemical,D005557,566977,Formaldehyde,1HG84L3525,,,,
24560,DescriptorName,D058186,566977,,,1,Acute Kidney Injury,N,
24561,QualifierName,Q000139,566977,,,1,,Y,chemically induced
24562,DescriptorName,D000328,566977,,,2,Adult,N,
24563,DescriptorName,D003556,566977,,,3,Cystitis,N,
24564,QualifierName,Q000150,566977,,,3,,N,complications
24565,DescriptorName,D005557,566977,,,4,Formaldehyde,N,
24566,QualifierName,Q000009,566977,,,4,,Y,adverse effects
24567,DescriptorName,D006470,566977,,,5,Hemorrhage,N,
24568,QualifierName,Q000188,566977,,,5,,Y,drug therapy
24569,DescriptorName,D006801,566977,,,6,Humans,N,
24570,DescriptorName,D007267,566977,,,7,Injections,N,
24571,DescriptorName,D007683,566977,,,8,"Kidney Tubular Necrosis, Acute",N,
24572,QualifierName,Q000139,566977,,,8,,Y,chemically induced
24573,DescriptorName,D008297,566977,,,9,Male,N,
24574,DescriptorName,D011832,566977,,,10,Radiation Injuries,N,
24575,DescriptorName,D001743,566977,,,11,Urinary Bladder,N,
24576,DescriptorName,D001745,566977,,,12,Urinary Bladder Diseases,N,
24577,QualifierName,Q000188,566977,,,12,,Y,drug therapy
24578,Chemical,D003989,573779,Dibenzoxazepines,0,,,,
24579,Chemical,D000657,573779,Amoxapine,R63VQ857OT,,,,
24580,DescriptorName,D000328,573779,,,1,Adult,N,
24581,DescriptorName,D000657,573779,,,2,Amoxapine,N,
24582,QualifierName,Q000009,573779,,,2,,N,adverse effects
24583,DescriptorName,D001711,573779,,,3,Biotransformation,N,
24584,DescriptorName,D003863,573779,,,4,Depression,N,
24585,QualifierName,Q000188,573779,,,4,,N,drug therapy
24586,DescriptorName,D003989,573779,,,5,Dibenzoxazepines,N,
24587,QualifierName,Q000378,573779,,,5,,Y,metabolism
24588,DescriptorName,D005260,573779,,,6,Female,N,
24589,DescriptorName,D005687,573779,,,7,Galactorrhea,N,
24590,QualifierName,Q000139,573779,,,7,,N,chemically induced
24591,DescriptorName,D006801,573779,,,8,Humans,N,
24592,DescriptorName,D008895,573779,,,9,"Milk, Human",N,
24593,QualifierName,Q000378,573779,,,9,,Y,metabolism
24594,DescriptorName,D011247,573779,,,10,Pregnancy,N,
24595,Chemical,D010666,576675,Phenylpropionates,0,,,,
24596,Chemical,D007052,576675,Ibuprofen,WK2XYI10QM,,,,
24597,DescriptorName,D000368,576675,,,1,Aged,N,
24598,DescriptorName,D004231,576675,,,2,Diuresis,N,
24599,QualifierName,Q000187,576675,,,2,,N,drug effects
24600,DescriptorName,D004487,576675,,,3,Edema,N,
24601,QualifierName,Q000139,576675,,,3,,Y,chemically induced
24602,DescriptorName,D006801,576675,,,4,Humans,N,
24603,DescriptorName,D007052,576675,,,5,Ibuprofen,N,
24604,QualifierName,Q000009,576675,,,5,,Y,adverse effects
24605,DescriptorName,D008297,576675,,,6,Male,N,
24606,DescriptorName,D010146,576675,,,7,Pain,N,
24607,QualifierName,Q000188,576675,,,7,,N,drug therapy
24608,DescriptorName,D010666,576675,,,8,Phenylpropionates,N,
24609,QualifierName,Q000009,576675,,,8,,Y,adverse effects
24610,Chemical,D000493,578255,Allopurinol,63CZ7GJN5I,,,,
24611,DescriptorName,D000368,578255,,,1,Aged,N,
24612,DescriptorName,D000493,578255,,,2,Allopurinol,N,
24613,QualifierName,Q000008,578255,,,2,,N,administration & dosage
24614,DescriptorName,D002908,578255,,,3,Chronic Disease,N,
24615,DescriptorName,D005531,578255,,,4,"Foot Deformities, Acquired",N,
24616,QualifierName,Q000139,578255,,,4,,Y,chemically induced
24617,DescriptorName,D006073,578255,,,5,Gout,N,
24618,QualifierName,Q000188,578255,,,5,,Y,drug therapy
24619,DescriptorName,D006227,578255,,,6,"Hand Deformities, Acquired",N,
24620,QualifierName,Q000139,578255,,,6,,Y,chemically induced
24621,DescriptorName,D006801,578255,,,7,Humans,N,
24622,DescriptorName,D008297,578255,,,8,Male,N,
24623,Chemical,D000666,582099,Amphotericin B,7XU7A7DROE,,,,
24624,DescriptorName,D000208,582099,,,1,Acute Disease,N,
24625,DescriptorName,D000328,582099,,,2,Adult,N,
24626,DescriptorName,D000666,582099,,,3,Amphotericin B,N,
24627,QualifierName,Q000008,582099,,,3,,N,administration & dosage
24628,DescriptorName,D003047,582099,,,4,Coccidioidomycosis,N,
24629,QualifierName,Q000188,582099,,,4,,N,drug therapy
24630,DescriptorName,D004569,582099,,,5,Electroencephalography,N,
24631,DescriptorName,D006801,582099,,,6,Humans,N,
24632,DescriptorName,D007278,582099,,,7,"Injections, Spinal",N,
24633,DescriptorName,D008297,582099,,,8,Male,N,
24634,DescriptorName,D008581,582099,,,9,Meningitis,N,
24635,QualifierName,Q000188,582099,,,9,,N,drug therapy
24636,DescriptorName,D011605,582099,,,10,"Psychoses, Substance-Induced",N,
24637,QualifierName,Q000175,582099,,,10,,N,diagnosis
24638,Chemical,D001761,58443,Bleomycin,11056-06-7,,,,
24639,DescriptorName,D000368,58443,,,1,Aged,N,
24640,DescriptorName,D001011,58443,,,2,Aorta,N,
24641,QualifierName,Q000473,58443,,,2,,N,pathology
24642,DescriptorName,D001019,58443,,,3,Aortic Rupture,N,
24643,QualifierName,Q000209,58443,,,3,,Y,etiology
24644,DescriptorName,D001761,58443,,,4,Bleomycin,N,
24645,QualifierName,Q000009,58443,,,4,,N,adverse effects
24646,DescriptorName,D002294,58443,,,5,"Carcinoma, Squamous Cell",N,
24647,QualifierName,Q000150,58443,,,5,,Y,complications
24648,DescriptorName,D004937,58443,,,6,Esophageal Fistula,N,
24649,QualifierName,Q000209,58443,,,6,,Y,etiology
24650,DescriptorName,D004938,58443,,,7,Esophageal Neoplasms,N,
24651,QualifierName,Q000150,58443,,,7,,Y,complications
24652,DescriptorName,D004947,58443,,,8,Esophagus,N,
24653,QualifierName,Q000473,58443,,,8,,N,pathology
24654,DescriptorName,D005402,58443,,,9,Fistula,N,
24655,QualifierName,Q000209,58443,,,9,,Y,etiology
24656,DescriptorName,D006801,58443,,,10,Humans,N,
24657,DescriptorName,D008297,58443,,,11,Male,N,
24658,DescriptorName,D009336,58443,,,12,Necrosis,N,
24659,DescriptorName,D011832,58443,,,13,Radiation Injuries,Y,
24660,DescriptorName,D011878,58443,,,14,Radiotherapy,N,
24661,QualifierName,Q000009,58443,,,14,,Y,adverse effects
24662,Chemical,D010042,589261,Ouabain,5ACL011P69,,,,
24663,Chemical,D004077,589261,Digoxin,73K4184T59,,,,
24664,Chemical,D004317,589261,Doxorubicin,80168379AG,,,,
24665,DescriptorName,D004077,589261,,,1,Digoxin,N,
24666,QualifierName,Q000627,589261,,,1,,Y,therapeutic use
24667,DescriptorName,D004317,589261,,,2,Doxorubicin,N,
24668,QualifierName,Q000009,589261,,,2,,Y,adverse effects
24669,DescriptorName,D004562,589261,,,3,Electrocardiography,N,
24670,DescriptorName,D005260,589261,,,4,Female,N,
24671,DescriptorName,D005833,589261,,,5,"Genital Neoplasms, Female",N,
24672,QualifierName,Q000188,589261,,,5,,N,drug therapy
24673,DescriptorName,D006331,589261,,,6,Heart Diseases,N,
24674,QualifierName,Q000139,589261,,,6,,N,chemically induced
24675,DescriptorName,D006801,589261,,,7,Humans,N,
24676,DescriptorName,D010042,589261,,,8,Ouabain,N,
24677,QualifierName,Q000627,589261,,,8,,N,therapeutic use
24678,Chemical,D007192,6093724,Indenes,0,,,,
24679,Chemical,D013467,6093724,Sulindac,184SNS8VUH,,,,
24680,DescriptorName,D000328,6093724,,,1,Adult,N,
24681,DescriptorName,D004342,6093724,,,2,Drug Hypersensitivity,N,
24682,QualifierName,Q000209,6093724,,,2,,Y,etiology
24683,DescriptorName,D006801,6093724,,,3,Humans,N,
24684,DescriptorName,D007192,6093724,,,4,Indenes,N,
24685,QualifierName,Q000009,6093724,,,4,,Y,adverse effects
24686,DescriptorName,D008297,6093724,,,5,Male,N,
24687,DescriptorName,D010146,6093724,,,6,Pain,N,
24688,QualifierName,Q000188,6093724,,,6,,N,drug therapy
24689,DescriptorName,D010292,6093724,,,7,Paresthesia,N,
24690,QualifierName,Q000139,6093724,,,7,,Y,chemically induced
24691,DescriptorName,D010523,6093724,,,8,Peripheral Nervous System Diseases,N,
24692,QualifierName,Q000139,6093724,,,8,,Y,chemically induced
24693,DescriptorName,D013467,6093724,,,9,Sulindac,N,
24694,QualifierName,Q000009,6093724,,,9,,Y,adverse effects
24695,Chemical,D014150,6102186,Antipsychotic Agents,0,,,,
24696,Chemical,D012694,6102186,Serine,452VLY9402,,,,
24697,Chemical,D005998,6102186,Glycine,TE7660XO1C,,,,
24698,DescriptorName,D000293,6102186,,,1,Adolescent,N,
24699,DescriptorName,D000328,6102186,,,2,Adult,N,
24700,DescriptorName,D014150,6102186,,,3,Antipsychotic Agents,N,
24701,QualifierName,Q000627,6102186,,,3,,N,therapeutic use
24702,DescriptorName,D003937,6102186,,,4,"Diagnosis, Differential",N,
24703,DescriptorName,D005260,6102186,,,5,Female,N,
24704,DescriptorName,D005998,6102186,,,6,Glycine,N,
24705,QualifierName,Q000378,6102186,,,6,,Y,metabolism
24706,DescriptorName,D006801,6102186,,,7,Humans,N,
24707,DescriptorName,D011164,6102186,,,8,Porphyrias,N,
24708,QualifierName,Q000175,6102186,,,8,,Y,diagnosis
24709,DescriptorName,D011605,6102186,,,9,"Psychoses, Substance-Induced",N,
24710,QualifierName,Q000175,6102186,,,9,,N,diagnosis
24711,DescriptorName,D011618,6102186,,,10,Psychotic Disorders,N,
24712,QualifierName,Q000209,6102186,,,10,,Y,etiology
24713,DescriptorName,D012559,6102186,,,11,Schizophrenia,N,
24714,QualifierName,Q000175,6102186,,,11,,N,diagnosis
24715,DescriptorName,D012694,6102186,,,12,Serine,N,
24716,QualifierName,Q000009,6102186,,,12,,N,adverse effects
24717,DescriptorName,D012871,6102186,,,13,Skin Diseases,N,
24718,Chemical,D004878,6108450,Ergotamine,PR834Q503T,,,,
24719,DescriptorName,D000328,6108450,,,1,Adult,N,
24720,DescriptorName,D001132,6108450,,,2,Arm,N,
24721,QualifierName,Q000098,6108450,,,2,,N,blood supply
24722,DescriptorName,D001158,6108450,,,3,Arteries,N,
24723,QualifierName,Q000187,6108450,,,3,,Y,drug effects
24724,DescriptorName,D002404,6108450,,,4,Catheterization,N,
24725,QualifierName,Q000379,6108450,,,4,,N,methods
24726,DescriptorName,D004106,6108450,,,5,Dilatation,N,
24727,QualifierName,Q000295,6108450,,,5,,N,instrumentation
24728,DescriptorName,D004878,6108450,,,6,Ergotamine,N,
24729,QualifierName,Q000009,6108450,,,6,,Y,adverse effects
24730,DescriptorName,D005260,6108450,,,7,Female,N,
24731,DescriptorName,D005734,6108450,,,8,Gangrene,N,
24732,QualifierName,Q000517,6108450,,,8,,N,prevention & control
24733,DescriptorName,D006801,6108450,,,9,Humans,N,
24734,DescriptorName,D007866,6108450,,,10,Leg,N,
24735,QualifierName,Q000098,6108450,,,10,,N,blood supply
24736,DescriptorName,D008875,6108450,,,11,Middle Aged,N,
24737,DescriptorName,D008881,6108450,,,12,Migraine Disorders,N,
24738,QualifierName,Q000188,6108450,,,12,,N,drug therapy
24739,DescriptorName,D009131,6108450,,,13,"Muscle, Smooth, Vascular",N,
24740,QualifierName,Q000187,6108450,,,13,,N,drug effects
24741,DescriptorName,D013035,6108450,,,14,Spasm,N,
24742,QualifierName,Q000139,6108450,,,14,,N,chemically induced
24743,Chemical,D014150,6113770,Antipsychotic Agents,0,,,,
24744,Chemical,D010640,6113770,Phenothiazines,0,,,,
24745,Chemical,D008094,6113770,Lithium,9FN79X2M3F,,,,
24746,Chemical,D006220,6113770,Haloperidol,J6292F8L3D,,,,
24747,DescriptorName,D014150,6113770,,,1,Antipsychotic Agents,N,
24748,QualifierName,Q000009,6113770,,,1,,N,adverse effects
24749,DescriptorName,D001714,6113770,,,2,Bipolar Disorder,N,
24750,QualifierName,Q000188,6113770,,,2,,Y,drug therapy
24751,DescriptorName,D004344,6113770,,,3,Drug Incompatibility,N,
24752,DescriptorName,D004359,6113770,,,4,"Drug Therapy, Combination",N,
24753,DescriptorName,D004409,6113770,,,5,"Dyskinesia, Drug-Induced",N,
24754,QualifierName,Q000209,6113770,,,5,,N,etiology
24755,DescriptorName,D005334,6113770,,,6,Fever,N,
24756,QualifierName,Q000139,6113770,,,6,,N,chemically induced
24757,DescriptorName,D006220,6113770,,,7,Haloperidol,N,
24758,QualifierName,Q000009,6113770,,,7,,Y,adverse effects
24759,DescriptorName,D006801,6113770,,,8,Humans,N,
24760,DescriptorName,D008094,6113770,,,9,Lithium,N,
24761,QualifierName,Q000009,6113770,,,9,,Y,adverse effects
24762,DescriptorName,D008297,6113770,,,10,Male,N,
24763,DescriptorName,D008875,6113770,,,11,Middle Aged,N,
24764,DescriptorName,D010640,6113770,,,12,Phenothiazines,N,
24765,Chemical,D002699,6142995,Chlorambucil,18D0SL7309,,,,
24766,DescriptorName,D000328,6142995,,,1,Adult,N,
24767,DescriptorName,D001528,6142995,,,2,Behcet Syndrome,N,
24768,QualifierName,Q000188,6142995,,,2,,N,drug therapy
24769,DescriptorName,D002699,6142995,,,3,Chlorambucil,N,
24770,QualifierName,Q000009,6142995,,,3,,Y,adverse effects
24771,DescriptorName,D002877,6142995,,,4,"Chromosomes, Human",N,
24772,QualifierName,Q000187,6142995,,,4,,Y,drug effects
24773,DescriptorName,D004305,6142995,,,5,"Dose-Response Relationship, Drug",N,
24774,DescriptorName,D005260,6142995,,,6,Female,N,
24775,DescriptorName,D006801,6142995,,,7,Humans,N,
24776,DescriptorName,D015470,6142995,,,8,"Leukemia, Myeloid, Acute",N,
24777,QualifierName,Q000139,6142995,,,8,,N,chemically induced
24778,DescriptorName,D008297,6142995,,,9,Male,N,
24779,DescriptorName,D008677,6142995,,,10,Metaphase,N,
24780,DescriptorName,D012854,6142995,,,11,Sister Chromatid Exchange,N,
24781,QualifierName,Q000187,6142995,,,11,,N,drug effects
24782,DescriptorName,D013997,6142995,,,12,Time Factors,N,
24783,DescriptorName,D014605,6142995,,,13,Uveitis,N,
24784,QualifierName,Q000188,6142995,,,13,,N,drug therapy
24785,Chemical,D006632,6159523,Histamine,820484N8I3,,,,
24786,Chemical,D005947,6159523,Glucose,IY9XDZ35W2,,,,
24787,DescriptorName,D000368,6159523,,,1,Aged,N,
24788,DescriptorName,D000707,6159523,,,2,Anaphylaxis,N,
24789,QualifierName,Q000139,6159523,,,2,,Y,chemically induced
24790,DescriptorName,D001249,6159523,,,3,Asthma,N,
24791,QualifierName,Q000150,6159523,,,3,,N,complications
24792,DescriptorName,D002648,6159523,,,4,Child,N,
24793,DescriptorName,D048909,6159523,,,5,Diabetes Complications,N,
24794,DescriptorName,D003920,6159523,,,6,Diabetes Mellitus,N,
24795,QualifierName,Q000097,6159523,,,6,,N,blood
24796,DescriptorName,D005260,6159523,,,7,Female,N,
24797,DescriptorName,D005947,6159523,,,8,Glucose,N,
24798,QualifierName,Q000009,6159523,,,8,,Y,adverse effects
24799,DescriptorName,D006632,6159523,,,9,Histamine,N,
24800,QualifierName,Q000097,6159523,,,9,,N,blood
24801,DescriptorName,D006636,6159523,,,10,Histamine Release,N,
24802,QualifierName,Q000187,6159523,,,10,,N,drug effects
24803,DescriptorName,D006801,6159523,,,11,Humans,N,
24804,DescriptorName,D007003,6159523,,,12,Hypoglycemia,N,
24805,QualifierName,Q000188,6159523,,,12,,N,drug therapy
24806,DescriptorName,D008297,6159523,,,13,Male,N,
24807,Chemical,D001219,6197014,Aspartate Aminotransferases,EC 2.6.1.1,,,,
24808,Chemical,D001241,6197014,Aspirin,R16CO5Y76E,,,,
24809,DescriptorName,D001219,6197014,,,1,Aspartate Aminotransferases,N,
24810,QualifierName,Q000097,6197014,,,1,,N,blood
24811,DescriptorName,D001241,6197014,,,2,Aspirin,N,
24812,QualifierName,Q000008,6197014,,,2,,N,administration & dosage
24813,DescriptorName,D056486,6197014,,,3,Chemical and Drug Induced Liver Injury,N,
24814,QualifierName,Q000097,6197014,,,3,,N,blood
24815,DescriptorName,D002648,6197014,,,4,Child,N,
24816,DescriptorName,D002675,6197014,,,5,"Child, Preschool",N,
24817,DescriptorName,D004305,6197014,,,6,"Dose-Response Relationship, Drug",N,
24818,DescriptorName,D005260,6197014,,,7,Female,N,
24819,DescriptorName,D006801,6197014,,,8,Humans,N,
24820,DescriptorName,D008297,6197014,,,9,Male,N,
24821,DescriptorName,D012213,6197014,,,10,Rheumatic Fever,N,
24822,QualifierName,Q000188,6197014,,,10,,Y,drug therapy
24823,Chemical,D001761,6199475,Bleomycin,11056-06-7,,,,
24824,Chemical,D014747,6199475,Vinblastine,5V9KLZ54CY,,,,
24825,Chemical,D002945,6199475,Cisplatin,Q20Q21Q62J,,,,
24826,DescriptorName,D000328,6199475,,,1,Adult,N,
24827,DescriptorName,D000971,6199475,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
24828,QualifierName,Q000009,6199475,,,2,,Y,adverse effects
24829,DescriptorName,D001761,6199475,,,3,Bleomycin,N,
24830,QualifierName,Q000008,6199475,,,3,,N,administration & dosage
24831,DescriptorName,D001927,6199475,,,4,Brain Diseases,N,
24832,QualifierName,Q000139,6199475,,,4,,Y,chemically induced
24833,DescriptorName,D002945,6199475,,,5,Cisplatin,N,
24834,QualifierName,Q000008,6199475,,,5,,N,administration & dosage
24835,DescriptorName,D006423,6199475,,,6,Hemianopsia,N,
24836,QualifierName,Q000139,6199475,,,6,,Y,chemically induced
24837,DescriptorName,D006801,6199475,,,7,Humans,N,
24838,DescriptorName,D008297,6199475,,,8,Male,N,
24839,DescriptorName,D013724,6199475,,,9,Teratoma,N,
24840,QualifierName,Q000188,6199475,,,9,,Y,drug therapy
24841,DescriptorName,D013736,6199475,,,10,Testicular Neoplasms,N,
24842,QualifierName,Q000188,6199475,,,10,,Y,drug therapy
24843,DescriptorName,D013997,6199475,,,11,Time Factors,N,
24844,DescriptorName,D014747,6199475,,,12,Vinblastine,N,
24845,QualifierName,Q000008,6199475,,,12,,N,administration & dosage
24846,Chemical,D011441,6221046,Propylthiouracil,721M9407IY,,,,
24847,DescriptorName,D000380,6221046,,,1,Agranulocytosis,N,
24848,QualifierName,Q000139,6221046,,,1,,Y,chemically induced
24849,DescriptorName,D056486,6221046,,,2,Chemical and Drug Induced Liver Injury,Y,
24850,DescriptorName,D003875,6221046,,,3,Drug Eruptions,N,
24851,QualifierName,Q000209,6221046,,,3,,Y,etiology
24852,DescriptorName,D004802,6221046,,,4,Eosinophilia,N,
24853,QualifierName,Q000139,6221046,,,4,,Y,chemically induced
24854,DescriptorName,D005260,6221046,,,5,Female,N,
24855,DescriptorName,D006801,6221046,,,6,Humans,N,
24856,DescriptorName,D006980,6221046,,,7,Hyperthyroidism,N,
24857,QualifierName,Q000188,6221046,,,7,,N,drug therapy
24858,DescriptorName,D066298,6221046,,,8,In Vitro Techniques,N,
24859,DescriptorName,D008213,6221046,,,9,Lymphocyte Activation,N,
24860,QualifierName,Q000187,6221046,,,9,,N,drug effects
24861,DescriptorName,D008875,6221046,,,10,Middle Aged,N,
24862,DescriptorName,D011441,6221046,,,11,Propylthiouracil,N,
24863,QualifierName,Q000009,6221046,,,11,,Y,adverse effects
24864,Chemical,D004338,623061,Drug Combinations,0,,,,
24865,Chemical,D011725,623061,Pyridines,0,,,,
24866,Chemical,D011738,623061,Pyrilamine,HPE317O9TL,,,,
24867,Chemical,D010424,623061,Pentobarbital,I4744080IR,,,,
24868,DescriptorName,D001927,623061,,,1,Brain Diseases,N,
24869,QualifierName,Q000139,623061,,,1,,Y,chemically induced
24870,DescriptorName,D002675,623061,,,2,"Child, Preschool",N,
24871,DescriptorName,D004338,623061,,,3,Drug Combinations,N,
24872,DescriptorName,D005260,623061,,,4,Female,N,
24873,DescriptorName,D006801,623061,,,5,Humans,N,
24874,DescriptorName,D007223,623061,,,6,Infant,N,
24875,DescriptorName,D008297,623061,,,7,Male,N,
24876,DescriptorName,D010424,623061,,,8,Pentobarbital,N,
24877,QualifierName,Q000008,623061,,,8,,N,administration & dosage
24878,DescriptorName,D011725,623061,,,9,Pyridines,N,
24879,QualifierName,Q000009,623061,,,9,,Y,adverse effects
24880,DescriptorName,D011738,623061,,,10,Pyrilamine,N,
24881,QualifierName,Q000008,623061,,,10,,N,administration & dosage
24882,DescriptorName,D014839,623061,,,11,Vomiting,N,
24883,QualifierName,Q000188,623061,,,11,,N,drug therapy
24884,Chemical,D010396,6233326,Penicillamine,GNN1DV99GX,,,,
24885,DescriptorName,D001172,6233326,,,1,"Arthritis, Rheumatoid",N,
24886,QualifierName,Q000188,6233326,,,1,,Y,drug therapy
24887,DescriptorName,D005451,6233326,,,2,Fluorescein Angiography,N,
24888,DescriptorName,D006801,6233326,,,3,Humans,N,
24889,DescriptorName,D008297,6233326,,,4,Male,N,
24890,DescriptorName,D008875,6233326,,,5,Middle Aged,N,
24891,DescriptorName,D009901,6233326,,,6,Optic Nerve Diseases,N,
24892,QualifierName,Q000139,6233326,,,6,,Y,chemically induced
24893,DescriptorName,D010211,6233326,,,7,Papilledema,N,
24894,QualifierName,Q000139,6233326,,,7,,N,chemically induced
24895,DescriptorName,D010396,6233326,,,8,Penicillamine,N,
24896,QualifierName,Q000009,6233326,,,8,,Y,adverse effects
24897,DescriptorName,D014786,6233326,,,9,Vision Disorders,N,
24898,QualifierName,Q000139,6233326,,,9,,N,chemically induced
24899,Chemical,D014212,6236730,Tretinoin,5688UTC01R,,,,
24900,Chemical,D015474,6236730,Isotretinoin,EH28UP18IF,,,,
24901,DescriptorName,D000152,6236730,,,1,Acne Vulgaris,N,
24902,QualifierName,Q000188,6236730,,,1,,N,drug therapy
24903,DescriptorName,D000208,6236730,,,2,Acute Disease,N,
24904,DescriptorName,D000328,6236730,,,3,Adult,N,
24905,DescriptorName,D005260,6236730,,,4,Female,N,
24906,DescriptorName,D006801,6236730,,,5,Humans,N,
24907,DescriptorName,D015474,6236730,,,6,Isotretinoin,N,
24908,DescriptorName,D009216,6236730,,,7,Myopia,N,
24909,QualifierName,Q000139,6236730,,,7,,Y,chemically induced
24910,DescriptorName,D014212,6236730,,,8,Tretinoin,N,
24911,QualifierName,Q000009,6236730,,,8,,Y,adverse effects
24912,Chemical,C457659,6239881,Benzoin Gum,0,,,,
24913,Chemical,D000069997,6239881,Mastic Resin,0,,,,
24914,Chemical,D010936,6239881,Plant Extracts,0,,,,
24915,Chemical,D012116,6239881,"Resins, Plant",0,,,,
24916,DescriptorName,D000293,6239881,,,1,Adolescent,N,
24917,DescriptorName,D000328,6239881,,,2,Adult,N,
24918,DescriptorName,D000368,6239881,,,3,Aged,N,
24919,DescriptorName,D001768,6239881,,,4,Blister,N,
24920,QualifierName,Q000188,6239881,,,4,,Y,drug therapy
24921,DescriptorName,D002648,6239881,,,5,Child,N,
24922,DescriptorName,D003875,6239881,,,6,Drug Eruptions,N,
24923,QualifierName,Q000209,6239881,,,6,,Y,etiology
24924,DescriptorName,D005260,6239881,,,7,Female,N,
24925,DescriptorName,D005533,6239881,,,8,Foot Dermatoses,N,
24926,QualifierName,Q000139,6239881,,,8,,N,chemically induced
24927,DescriptorName,D006801,6239881,,,9,Humans,N,
24928,DescriptorName,D008297,6239881,,,10,Male,N,
24929,DescriptorName,D000069997,6239881,,,11,Mastic Resin,N,
24930,DescriptorName,D008887,6239881,,,12,Military Medicine,N,
24931,DescriptorName,D010328,6239881,,,13,Patch Tests,N,
24932,DescriptorName,D005082,6239881,,,14,Physical Exertion,N,
24933,DescriptorName,D010936,6239881,,,15,Plant Extracts,N,
24934,QualifierName,Q000009,6239881,,,15,,N,adverse effects
24935,DescriptorName,D012116,6239881,,,16,"Resins, Plant",N,
24936,QualifierName,Q000009,6239881,,,16,,N,adverse effects
24937,DescriptorName,D032362,6239881,,,17,Styrax,N,
24938,Chemical,D003561,6245286,Cytarabine,04079A1RDZ,,,,
24939,DescriptorName,D000328,6245286,,,1,Adult,N,
24940,DescriptorName,D003561,6245286,,,2,Cytarabine,N,
24941,QualifierName,Q000009,6245286,,,2,,Y,adverse effects
24942,DescriptorName,D005260,6245286,,,3,Female,N,
24943,DescriptorName,D006566,6245286,,,4,Herpesviridae Infections,N,
24944,QualifierName,Q000209,6245286,,,4,,Y,etiology
24945,DescriptorName,D006801,6245286,,,5,Humans,N,
24946,DescriptorName,D007165,6245286,,,6,Immunosuppression,N,
24947,QualifierName,Q000009,6245286,,,6,,N,adverse effects
24948,DescriptorName,D007938,6245286,,,7,Leukemia,N,
24949,QualifierName,Q000150,6245286,,,7,,Y,complications
24950,DescriptorName,D008297,6245286,,,8,Male,N,
24951,DescriptorName,D012306,6245286,,,9,Risk,N,
24952,DescriptorName,D012883,6245286,,,10,Skin Ulcer,N,
24953,QualifierName,Q000209,6245286,,,10,,N,etiology
24954,DescriptorName,D013276,6245286,,,11,Stomach Ulcer,N,
24955,QualifierName,Q000209,6245286,,,11,,N,etiology
24956,DescriptorName,D014456,6245286,,,12,Ulcer,N,
24957,QualifierName,Q000209,6245286,,,12,,Y,etiology
24958,Chemical,D006046,6251941,Gold,7440-57-5,,,,
24959,DescriptorName,D000328,6251941,,,1,Adult,N,
24960,DescriptorName,D000368,6251941,,,2,Aged,N,
24961,DescriptorName,D000818,6251941,,,3,Animals,N,
24962,DescriptorName,D001172,6251941,,,4,"Arthritis, Rheumatoid",N,
24963,QualifierName,Q000188,6251941,,,4,,N,drug therapy
24964,DescriptorName,D002645,6251941,,,5,Chickens,N,
24965,DescriptorName,D005260,6251941,,,6,Female,N,
24966,DescriptorName,D006046,6251941,,,7,Gold,N,
24967,QualifierName,Q000009,6251941,,,7,,Y,adverse effects
24968,DescriptorName,D006801,6251941,,,8,Humans,N,
24969,DescriptorName,D008297,6251941,,,9,Male,N,
24970,DescriptorName,D008875,6251941,,,10,Middle Aged,N,
24971,DescriptorName,D010525,6251941,,,11,Peripheral Nerves,N,
24972,QualifierName,Q000473,6251941,,,11,,N,pathology
24973,DescriptorName,D010523,6251941,,,12,Peripheral Nervous System Diseases,N,
24974,QualifierName,Q000139,6251941,,,12,,Y,chemically induced
24975,DescriptorName,D013497,6251941,,,13,Sural Nerve,N,
24976,QualifierName,Q000473,6251941,,,13,,N,pathology
24977,Chemical,D002566,6260900,Ceroid,0,,,,
24978,Chemical,D010860,6260900,"Pigments, Biological",0,,,,
24979,Chemical,D003622,6260900,Dapsone,8W5C518302,,,,
24980,Chemical,D002991,6260900,Clofazimine,D959AE5USF,,,,
24981,Chemical,D012293,6260900,Rifampin,VJT6J7R4TR,,,,
24982,DescriptorName,D000328,6260900,,,1,Adult,N,
24983,DescriptorName,D002566,6260900,,,2,Ceroid,N,
24984,QualifierName,Q000378,6260900,,,2,,Y,metabolism
24985,DescriptorName,D002991,6260900,,,3,Clofazimine,N,
24986,QualifierName,Q000009,6260900,,,3,,Y,adverse effects
24987,DescriptorName,D003622,6260900,,,4,Dapsone,N,
24988,QualifierName,Q000008,6260900,,,4,,N,administration & dosage
24989,DescriptorName,D004359,6260900,,,5,"Drug Therapy, Combination",N,
24990,DescriptorName,D006651,6260900,,,6,Histocytochemistry,N,
24991,DescriptorName,D006801,6260900,,,7,Humans,N,
24992,DescriptorName,D007918,6260900,,,8,Leprosy,N,
24993,QualifierName,Q000188,6260900,,,8,,Y,drug therapy
24994,DescriptorName,D008264,6260900,,,9,Macrophages,N,
24995,QualifierName,Q000378,6260900,,,9,,N,metabolism
24996,DescriptorName,D008297,6260900,,,10,Male,N,
24997,DescriptorName,D010525,6260900,,,11,Peripheral Nerves,N,
24998,QualifierName,Q000378,6260900,,,11,,Y,metabolism
24999,DescriptorName,D010523,6260900,,,12,Peripheral Nervous System Diseases,N,
25000,QualifierName,Q000139,6260900,,,12,,N,chemically induced
25001,DescriptorName,D010859,6260900,,,13,Pigmentation Disorders,N,
25002,QualifierName,Q000139,6260900,,,13,,Y,chemically induced
25003,DescriptorName,D010860,6260900,,,14,"Pigments, Biological",N,
25004,QualifierName,Q000378,6260900,,,14,,Y,metabolism
25005,DescriptorName,D012293,6260900,,,15,Rifampin,N,
25006,QualifierName,Q000008,6260900,,,15,,N,administration & dosage
25007,Chemical,D006146,6292681,Guanidines,0,,,,
25008,Chemical,D008935,6292681,Mitoguazone,OD5Q0L447W,,,,
25009,DescriptorName,D000368,6292681,,,1,Aged,N,
25010,DescriptorName,D002294,6292681,,,2,"Carcinoma, Squamous Cell",N,
25011,QualifierName,Q000188,6292681,,,2,,Y,drug therapy
25012,DescriptorName,D004334,6292681,,,3,Drug Administration Schedule,N,
25013,DescriptorName,D004341,6292681,,,4,Drug Evaluation,N,
25014,DescriptorName,D006146,6292681,,,5,Guanidines,N,
25015,QualifierName,Q000009,6292681,,,5,,Y,adverse effects
25016,DescriptorName,D006801,6292681,,,6,Humans,N,
25017,DescriptorName,D008175,6292681,,,7,Lung Neoplasms,N,
25018,QualifierName,Q000188,6292681,,,7,,Y,drug therapy
25019,DescriptorName,D008297,6292681,,,8,Male,N,
25020,DescriptorName,D008875,6292681,,,9,Middle Aged,N,
25021,DescriptorName,D008935,6292681,,,10,Mitoguazone,N,
25022,QualifierName,Q000009,6292681,,,10,,Y,adverse effects
25023,DescriptorName,D010523,6292681,,,11,Peripheral Nervous System Diseases,N,
25024,QualifierName,Q000139,6292681,,,11,,Y,chemically induced
25025,DescriptorName,D013997,6292681,,,12,Time Factors,N,
25026,Chemical,D013759,6303138,Dronabinol,7J8897W37S,,,,
25027,Chemical,D011433,6303138,Propranolol,9Y8NXQ24VQ,,,,
25028,Chemical,D009661,6303138,Nortriptyline,BL03SY4LXB,,,,
25029,DescriptorName,D000328,6303138,,,1,Adult,N,
25030,DescriptorName,D013759,6303138,,,2,Dronabinol,N,
25031,QualifierName,Q000494,6303138,,,2,,Y,pharmacology
25032,DescriptorName,D004357,6303138,,,3,Drug Synergism,N,
25033,DescriptorName,D005260,6303138,,,4,Female,N,
25034,DescriptorName,D006801,6303138,,,5,Humans,N,
25035,DescriptorName,D002189,6303138,,,6,Marijuana Abuse,N,
25036,QualifierName,Q000150,6303138,,,6,,Y,complications
25037,DescriptorName,D009661,6303138,,,7,Nortriptyline,N,
25038,QualifierName,Q000009,6303138,,,7,,Y,adverse effects
25039,DescriptorName,D011433,6303138,,,8,Propranolol,N,
25040,QualifierName,Q000627,6303138,,,8,,N,therapeutic use
25041,DescriptorName,D013610,6303138,,,9,Tachycardia,N,
25042,QualifierName,Q000139,6303138,,,9,,Y,chemically induced
25043,Chemical,D000324,6311654,Adrenocorticotropic Hormone,9002-60-2,,,,
25044,DescriptorName,D000324,6311654,,,1,Adrenocorticotropic Hormone,N,
25045,QualifierName,Q000009,6311654,,,1,,N,adverse effects
25046,DescriptorName,D001284,6311654,,,2,Atrophy,N,
25047,DescriptorName,D001921,6311654,,,3,Brain,N,
25048,QualifierName,Q000000981,6311654,,,3,,Y,diagnostic imaging
25049,DescriptorName,D006801,6311654,,,4,Humans,N,
25050,DescriptorName,D006849,6311654,,,5,Hydrocephalus,N,
25051,QualifierName,Q000139,6311654,,,5,,N,chemically induced
25052,DescriptorName,D007223,6311654,,,6,Infant,N,
25053,DescriptorName,D008297,6311654,,,7,Male,N,
25054,DescriptorName,D013036,6311654,,,8,"Spasms, Infantile",N,
25055,QualifierName,Q000000981,6311654,,,8,,N,diagnostic imaging
25056,DescriptorName,D014057,6311654,,,9,"Tomography, X-Ray Computed",Y,
25057,Chemical,D000082,6324592,Acetaminophen,362O9ITL9D,,,,
25058,Chemical,D000431,6324592,Ethanol,3K9958V90M,,,,
25059,Chemical,D015281,6324592,Cefmenoxime,KBZ4844CXN,,,,
25060,Chemical,D002439,6324592,Cefotaxime,N2GI8B1GK7,,,,
25061,Chemical,D004221,6324592,Disulfiram,TR3MLJ1UAI,,,,
25062,DescriptorName,D000082,6324592,,,1,Acetaminophen,N,
25063,QualifierName,Q000008,6324592,,,1,,N,administration & dosage
25064,DescriptorName,D015281,6324592,,,2,Cefmenoxime,N,
25065,DescriptorName,D002439,6324592,,,3,Cefotaxime,N,
25066,QualifierName,Q000009,6324592,,,3,,N,adverse effects
25067,DescriptorName,D004221,6324592,,,4,Disulfiram,N,
25068,QualifierName,Q000494,6324592,,,4,,Y,pharmacology
25069,DescriptorName,D004347,6324592,,,5,Drug Interactions,N,
25070,DescriptorName,D000431,6324592,,,6,Ethanol,N,
25071,QualifierName,Q000494,6324592,,,6,,Y,pharmacology
25072,DescriptorName,D005260,6324592,,,7,Female,N,
25073,DescriptorName,D006801,6324592,,,8,Humans,N,
25074,DescriptorName,D008875,6324592,,,9,Middle Aged,N,
25075,DescriptorName,D014552,6324592,,,10,Urinary Tract Infections,N,
25076,QualifierName,Q000188,6324592,,,10,,Y,drug therapy
25077,Chemical,D014282,6329575,Trihexyphenidyl,6RC5V8B7PO,,,,
25078,Chemical,D008094,6329575,Lithium,9FN79X2M3F,,,,
25079,Chemical,D011398,6329575,Promethazine,FF28EJQ494,,,,
25080,DescriptorName,D017109,6329575,,,1,"Akathisia, Drug-Induced",Y,
25081,DescriptorName,D004359,6329575,,,2,"Drug Therapy, Combination",N,
25082,DescriptorName,D004409,6329575,,,3,"Dyskinesia, Drug-Induced",N,
25083,QualifierName,Q000188,6329575,,,3,,N,drug therapy
25084,DescriptorName,D006801,6329575,,,4,Humans,N,
25085,DescriptorName,D008094,6329575,,,5,Lithium,N,
25086,QualifierName,Q000009,6329575,,,5,,Y,adverse effects
25087,DescriptorName,D008297,6329575,,,6,Male,N,
25088,DescriptorName,D008875,6329575,,,7,Middle Aged,N,
25089,DescriptorName,D011398,6329575,,,8,Promethazine,N,
25090,QualifierName,Q000008,6329575,,,8,,N,administration & dosage
25091,DescriptorName,D011595,6329575,,,9,Psychomotor Agitation,N,
25092,QualifierName,Q000188,6329575,,,9,,N,drug therapy
25093,DescriptorName,D014282,6329575,,,10,Trihexyphenidyl,N,
25094,QualifierName,Q000008,6329575,,,10,,N,administration & dosage
25095,Chemical,D013411,633424,Sulfadiazine,0N7609K889,,,,
25096,Chemical,D012837,633424,Silver Sulfadiazine,W46JY43EJR,,,,
25097,DescriptorName,D000208,633424,,,1,Acute Disease,N,
25098,DescriptorName,D002056,633424,,,2,Burns,N,
25099,QualifierName,Q000188,633424,,,2,,N,drug therapy
25100,DescriptorName,D006801,633424,,,3,Humans,N,
25101,DescriptorName,D007970,633424,,,4,Leukopenia,N,
25102,QualifierName,Q000139,633424,,,4,,Y,chemically induced
25103,DescriptorName,D008297,633424,,,5,Male,N,
25104,DescriptorName,D008875,633424,,,6,Middle Aged,N,
25105,DescriptorName,D012837,633424,,,7,Silver Sulfadiazine,N,
25106,QualifierName,Q000009,633424,,,7,,Y,adverse effects
25107,DescriptorName,D013411,633424,,,8,Sulfadiazine,N,
25108,QualifierName,Q000009,633424,,,8,,Y,adverse effects
25109,Chemical,D011241,6340463,Prednisone,VB0R961HZT,,,,
25110,DescriptorName,D000328,6340463,,,1,Adult,N,
25111,DescriptorName,D016026,6340463,,,2,Bone Marrow Transplantation,Y,
25112,DescriptorName,D006087,6340463,,,3,Graft vs Host Reaction,N,
25113,QualifierName,Q000187,6340463,,,3,,N,drug effects
25114,DescriptorName,D006660,6340463,,,4,Histoplasmosis,N,
25115,QualifierName,Q000209,6340463,,,4,,Y,etiology
25116,DescriptorName,D006801,6340463,,,5,Humans,N,
25117,DescriptorName,D007165,6340463,,,6,Immunosuppression,N,
25118,QualifierName,Q000009,6340463,,,6,,Y,adverse effects
25119,DescriptorName,D015470,6340463,,,7,"Leukemia, Myeloid, Acute",N,
25120,QualifierName,Q000188,6340463,,,7,,N,drug therapy
25121,DescriptorName,D008297,6340463,,,8,Male,N,
25122,DescriptorName,D011183,6340463,,,9,Postoperative Complications,N,
25123,DescriptorName,D011241,6340463,,,10,Prednisone,N,
25124,QualifierName,Q000009,6340463,,,10,,N,adverse effects
25125,Chemical,D011392,6344831,Proline,9DLQ4CIU6V,,,,
25126,Chemical,D002216,6344831,Captopril,9G64RSX1XD,,,,
25127,Chemical,D003404,6344831,Creatinine,AYI8EX34EU,,,,
25128,DescriptorName,D058186,6344831,,,1,Acute Kidney Injury,N,
25129,QualifierName,Q000139,6344831,,,1,,Y,chemically induced
25130,DescriptorName,D002216,6344831,,,2,Captopril,N,
25131,QualifierName,Q000009,6344831,,,2,,Y,adverse effects
25132,DescriptorName,D003404,6344831,,,3,Creatinine,N,
25133,QualifierName,Q000097,6344831,,,3,,N,blood
25134,DescriptorName,D005260,6344831,,,4,Female,N,
25135,DescriptorName,D006801,6344831,,,5,Humans,N,
25136,DescriptorName,D006978,6344831,,,6,"Hypertension, Renovascular",N,
25137,QualifierName,Q000188,6344831,,,6,,N,drug therapy
25138,DescriptorName,D008875,6344831,,,7,Middle Aged,N,
25139,DescriptorName,D009846,6344831,,,8,Oliguria,N,
25140,DescriptorName,D011392,6344831,,,9,Proline,N,
25141,QualifierName,Q000031,6344831,,,9,,Y,analogs & derivatives
25142,Chemical,D011392,6353252,Proline,9DLQ4CIU6V,,,,
25143,Chemical,D002216,6353252,Captopril,9G64RSX1XD,,,,
25144,DescriptorName,D058186,6353252,,,1,Acute Kidney Injury,N,
25145,QualifierName,Q000139,6353252,,,1,,Y,chemically induced
25146,DescriptorName,D000328,6353252,,,2,Adult,N,
25147,DescriptorName,D000368,6353252,,,3,Aged,N,
25148,DescriptorName,D001794,6353252,,,4,Blood Pressure,N,
25149,QualifierName,Q000187,6353252,,,4,,N,drug effects
25150,DescriptorName,D002216,6353252,,,5,Captopril,N,
25151,QualifierName,Q000009,6353252,,,5,,Y,adverse effects
25152,DescriptorName,D005260,6353252,,,6,Female,N,
25153,DescriptorName,D006439,6353252,,,7,Hemodynamics,N,
25154,QualifierName,Q000187,6353252,,,7,,N,drug effects
25155,DescriptorName,D006801,6353252,,,8,Humans,N,
25156,DescriptorName,D006973,6353252,,,9,Hypertension,N,
25157,QualifierName,Q000188,6353252,,,9,,N,drug therapy
25158,DescriptorName,D007668,6353252,,,10,Kidney,N,
25159,QualifierName,Q000098,6353252,,,10,,N,blood supply
25160,DescriptorName,D008297,6353252,,,11,Male,N,
25161,DescriptorName,D011392,6353252,,,12,Proline,N,
25162,QualifierName,Q000031,6353252,,,12,,Y,analogs & derivatives
25163,Chemical,D011437,6362443,Propylamines,0,,,,
25164,Chemical,D005473,6362443,Fluoxetine,01K63SUP8D,,,,
25165,DescriptorName,D000328,6362443,,,1,Adult,N,
25166,DescriptorName,D001714,6362443,,,2,Bipolar Disorder,N,
25167,QualifierName,Q000139,6362443,,,2,,Y,chemically induced
25168,DescriptorName,D002986,6362443,,,3,Clinical Trials as Topic,N,
25169,DescriptorName,D003866,6362443,,,4,Depressive Disorder,N,
25170,QualifierName,Q000188,6362443,,,4,,N,drug therapy
25171,DescriptorName,D005260,6362443,,,5,Female,N,
25172,DescriptorName,D005473,6362443,,,6,Fluoxetine,N,
25173,QualifierName,Q000009,6362443,,,6,,Y,adverse effects
25174,DescriptorName,D006801,6362443,,,7,Humans,N,
25175,DescriptorName,D011437,6362443,,,8,Propylamines,N,
25176,QualifierName,Q000009,6362443,,,8,,Y,adverse effects
25177,Chemical,D000880,6385260,Anthraquinones,0,,,,
25178,Chemical,D000970,6385260,Antineoplastic Agents,0,,,,
25179,Chemical,D003520,6385260,Cyclophosphamide,8N3DW7272P,,,,
25180,Chemical,D008942,6385260,Mitoxantrone,BZ114NVM5P,,,,
25181,DescriptorName,D000328,6385260,,,1,Adult,N,
25182,DescriptorName,D000368,6385260,,,2,Aged,N,
25183,DescriptorName,D000880,6385260,,,3,Anthraquinones,N,
25184,QualifierName,Q000008,6385260,,,3,,N,administration & dosage
25185,DescriptorName,D000970,6385260,,,4,Antineoplastic Agents,N,
25186,QualifierName,Q000008,6385260,,,4,,N,administration & dosage
25187,DescriptorName,D000971,6385260,,,5,Antineoplastic Combined Chemotherapy Protocols,N,
25188,QualifierName,Q000627,6385260,,,5,,Y,therapeutic use
25189,DescriptorName,D001943,6385260,,,6,Breast Neoplasms,N,
25190,QualifierName,Q000188,6385260,,,6,,Y,drug therapy
25191,DescriptorName,D002986,6385260,,,7,Clinical Trials as Topic,N,
25192,DescriptorName,D003520,6385260,,,8,Cyclophosphamide,N,
25193,QualifierName,Q000008,6385260,,,8,,N,administration & dosage
25194,DescriptorName,D005260,6385260,,,9,Female,N,
25195,DescriptorName,D006801,6385260,,,10,Humans,N,
25196,DescriptorName,D008875,6385260,,,11,Middle Aged,N,
25197,DescriptorName,D008942,6385260,,,12,Mitoxantrone,N,
25198,DescriptorName,D009362,6385260,,,13,Neoplasm Metastasis,N,
25199,DescriptorName,D009367,6385260,,,14,Neoplasm Staging,N,
25200,Chemical,D000903,6401771,"Antibiotics, Antineoplastic",0,,,,
25201,Chemical,D008937,6401771,Mitomycins,0,,,,
25202,Chemical,D016685,6401771,Mitomycin,50SG953SK6,,,,
25203,Chemical,D005472,6401771,Fluorouracil,U3P01618RT,,,,
25204,DescriptorName,D000328,6401771,,,1,Adult,N,
25205,DescriptorName,D000368,6401771,,,2,Aged,N,
25206,DescriptorName,D000903,6401771,,,3,"Antibiotics, Antineoplastic",N,
25207,QualifierName,Q000009,6401771,,,3,,Y,adverse effects
25208,DescriptorName,D004359,6401771,,,4,"Drug Therapy, Combination",N,
25209,DescriptorName,D005260,6401771,,,5,Female,N,
25210,DescriptorName,D005472,6401771,,,6,Fluorouracil,N,
25211,QualifierName,Q000009,6401771,,,6,,Y,adverse effects
25212,DescriptorName,D006463,6401771,,,7,Hemolytic-Uremic Syndrome,N,
25213,QualifierName,Q000139,6401771,,,7,,Y,chemically induced
25214,DescriptorName,D006801,6401771,,,8,Humans,N,
25215,DescriptorName,D007668,6401771,,,9,Kidney,N,
25216,QualifierName,Q000473,6401771,,,9,,N,pathology
25217,DescriptorName,D008168,6401771,,,10,Lung,N,
25218,QualifierName,Q000473,6401771,,,10,,N,pathology
25219,DescriptorName,D008297,6401771,,,11,Male,N,
25220,DescriptorName,D008875,6401771,,,12,Middle Aged,N,
25221,DescriptorName,D016685,6401771,,,13,Mitomycin,N,
25222,DescriptorName,D008937,6401771,,,14,Mitomycins,N,
25223,QualifierName,Q000009,6401771,,,14,,Y,adverse effects
25224,DescriptorName,D013274,6401771,,,15,Stomach Neoplasms,N,
25225,QualifierName,Q000188,6401771,,,15,,Y,drug therapy
25226,Chemical,D006887,640344,Hydroxycholecalciferols,0,,,,
25227,Chemical,D010710,640344,Phosphates,0,,,,
25228,Chemical,D002792,640344,Cholestyramine Resin,11041-12-6,,,,
25229,Chemical,D000469,640344,Alkaline Phosphatase,EC 3.1.3.1,,,,
25230,Chemical,D002118,640344,Calcium,SY7Q814VUP,,,,
25231,DescriptorName,D000284,640344,,,1,"Administration, Oral",N,
25232,DescriptorName,D000469,640344,,,2,Alkaline Phosphatase,N,
25233,QualifierName,Q000097,640344,,,2,,N,blood
25234,DescriptorName,D002118,640344,,,3,Calcium,N,
25235,QualifierName,Q000097,640344,,,3,,N,blood
25236,DescriptorName,D002792,640344,,,4,Cholestyramine Resin,N,
25237,QualifierName,Q000009,640344,,,4,,Y,adverse effects
25238,DescriptorName,D003967,640344,,,5,Diarrhea,N,
25239,QualifierName,Q000188,640344,,,5,,N,drug therapy
25240,DescriptorName,D005260,640344,,,6,Female,N,
25241,DescriptorName,D006801,640344,,,7,Humans,N,
25242,DescriptorName,D006887,640344,,,8,Hydroxycholecalciferols,N,
25243,QualifierName,Q000008,640344,,,8,,Y,administration & dosage
25244,DescriptorName,D007082,640344,,,9,Ileum,N,
25245,QualifierName,Q000601,640344,,,9,,Y,surgery
25246,DescriptorName,D008875,640344,,,10,Middle Aged,N,
25247,DescriptorName,D010018,640344,,,11,Osteomalacia,N,
25248,QualifierName,Q000139,640344,,,11,,N,chemically induced
25249,DescriptorName,D010710,640344,,,12,Phosphates,N,
25250,QualifierName,Q000097,640344,,,12,,N,blood
25251,DescriptorName,D011183,640344,,,13,Postoperative Complications,Y,
25252,Chemical,D011412,6405633,Propanolamines,0,,,,
25253,Chemical,D016651,6405633,Lithium Carbonate,2BMD2GNA4V,,,,
25254,Chemical,D008094,6405633,Lithium,9FN79X2M3F,,,,
25255,Chemical,D008790,6405633,Metoprolol,GEB06NHM23,,,,
25256,DescriptorName,D000328,6405633,,,1,Adult,N,
25257,DescriptorName,D001714,6405633,,,2,Bipolar Disorder,N,
25258,QualifierName,Q000188,6405633,,,2,,N,drug therapy
25259,DescriptorName,D005260,6405633,,,3,Female,N,
25260,DescriptorName,D006801,6405633,,,4,Humans,N,
25261,DescriptorName,D008094,6405633,,,5,Lithium,N,
25262,QualifierName,Q000009,6405633,,,5,,Y,adverse effects
25263,DescriptorName,D016651,6405633,,,6,Lithium Carbonate,N,
25264,DescriptorName,D008790,6405633,,,7,Metoprolol,N,
25265,QualifierName,Q000627,6405633,,,7,,Y,therapeutic use
25266,DescriptorName,D011412,6405633,,,8,Propanolamines,N,
25267,QualifierName,Q000627,6405633,,,8,,Y,therapeutic use
25268,DescriptorName,D014202,6405633,,,9,Tremor,N,
25269,QualifierName,Q000139,6405633,,,9,,Y,chemically induced
25270,Chemical,D008774,6408978,Methylphenidate,207ZZ9QZ49,,,,
25271,Chemical,D014635,6408978,Valproic Acid,614OI1Z5WI,,,,
25272,Chemical,D010672,6408978,Phenytoin,6158TKW0C5,,,,
25273,Chemical,D003975,6408978,Diazepam,Q3JTX2Q7TU,,,,
25274,Chemical,D010634,6408978,Phenobarbital,YQE403BP4D,,,,
25275,DescriptorName,D000293,6408978,,,1,Adolescent,N,
25276,DescriptorName,D003072,6408978,,,2,Cognition Disorders,N,
25277,QualifierName,Q000209,6408978,,,2,,Y,etiology
25278,DescriptorName,D003221,6408978,,,3,Confusion,N,
25279,QualifierName,Q000209,6408978,,,3,,Y,etiology
25280,DescriptorName,D003975,6408978,,,4,Diazepam,N,
25281,QualifierName,Q000009,6408978,,,4,,N,adverse effects
25282,DescriptorName,D004569,6408978,,,5,Electroencephalography,N,
25283,DescriptorName,D006801,6408978,,,6,Humans,N,
25284,DescriptorName,D008297,6408978,,,7,Male,N,
25285,DescriptorName,D008774,6408978,,,8,Methylphenidate,N,
25286,QualifierName,Q000627,6408978,,,8,,N,therapeutic use
25287,DescriptorName,D010634,6408978,,,9,Phenobarbital,N,
25288,QualifierName,Q000627,6408978,,,9,,N,therapeutic use
25289,DescriptorName,D010672,6408978,,,10,Phenytoin,N,
25290,QualifierName,Q000627,6408978,,,10,,N,therapeutic use
25291,DescriptorName,D012890,6408978,,,11,Sleep,N,
25292,QualifierName,Q000502,6408978,,,11,,N,physiology
25293,DescriptorName,D013226,6408978,,,12,Status Epilepticus,N,
25294,QualifierName,Q000150,6408978,,,12,,Y,complications
25295,DescriptorName,D014635,6408978,,,13,Valproic Acid,N,
25296,QualifierName,Q000627,6408978,,,13,,N,therapeutic use
25297,Chemical,D010672,6414095,Phenytoin,6158TKW0C5,,,,
25298,DescriptorName,D004834,6414095,,,1,"Epilepsy, Post-Traumatic",N,
25299,QualifierName,Q000188,6414095,,,1,,N,drug therapy
25300,DescriptorName,D005260,6414095,,,2,Female,N,
25301,DescriptorName,D006429,6414095,,,3,Hemiplegia,N,
25302,QualifierName,Q000139,6414095,,,3,,Y,chemically induced
25303,DescriptorName,D006801,6414095,,,4,Humans,N,
25304,DescriptorName,D008875,6414095,,,5,Middle Aged,N,
25305,DescriptorName,D010672,6414095,,,6,Phenytoin,N,
25306,QualifierName,Q000009,6414095,,,6,,Y,adverse effects
25307,Chemical,D014635,6416845,Valproic Acid,614OI1Z5WI,,,,
25308,DescriptorName,D056486,6416845,,,1,Chemical and Drug Induced Liver Injury,Y,
25309,DescriptorName,D002648,6416845,,,2,Child,N,
25310,DescriptorName,D004830,6416845,,,3,"Epilepsy, Tonic-Clonic",N,
25311,QualifierName,Q000188,6416845,,,3,,N,drug therapy
25312,DescriptorName,D006801,6416845,,,4,Humans,N,
25313,DescriptorName,D008107,6416845,,,5,Liver Diseases,N,
25314,QualifierName,Q000378,6416845,,,5,,N,metabolism
25315,DescriptorName,D008297,6416845,,,6,Male,N,
25316,DescriptorName,D010530,6416845,,,7,Peritoneal Dialysis,N,
25317,DescriptorName,D014635,6416845,,,8,Valproic Acid,N,
25318,QualifierName,Q000009,6416845,,,8,,Y,adverse effects
25319,Chemical,D002440,6422563,Cefoxitin,6OEV9DX57Y,,,,
25320,DescriptorName,D000328,6422563,,,1,Adult,N,
25321,DescriptorName,D002408,6422563,,,2,"Catheters, Indwelling",N,
25322,QualifierName,Q000009,6422563,,,2,,N,adverse effects
25323,DescriptorName,D002440,6422563,,,3,Cefoxitin,N,
25324,QualifierName,Q000008,6422563,,,3,,N,administration & dosage
25325,DescriptorName,D003354,6422563,,,4,Corynebacterium Infections,N,
25326,QualifierName,Q000175,6422563,,,4,,N,diagnosis
25327,DescriptorName,D003937,6422563,,,5,"Diagnosis, Differential",N,
25328,DescriptorName,D005260,6422563,,,6,Female,N,
25329,DescriptorName,D006099,6422563,,,7,Granuloma,N,
25330,QualifierName,Q000150,6422563,,,7,,N,complications
25331,DescriptorName,D006505,6422563,,,8,Hepatitis,N,
25332,QualifierName,Q000150,6422563,,,8,,N,complications
25333,DescriptorName,D006801,6422563,,,9,Humans,N,
25334,DescriptorName,D007263,6422563,,,10,"Infusions, Parenteral",N,
25335,DescriptorName,D009164,6422563,,,11,Mycobacterium Infections,N,
25336,QualifierName,Q000175,6422563,,,11,,N,diagnosis
25337,DescriptorName,D009165,6422563,,,12,"Mycobacterium Infections, Nontuberculous",N,
25338,QualifierName,Q000188,6422563,,,12,,Y,drug therapy
25339,DescriptorName,D009170,6422563,,,13,Nontuberculous Mycobacteria,N,
25340,QualifierName,Q000302,6422563,,,13,,N,isolation & purification
25341,DescriptorName,D010288,6422563,,,14,Parenteral Nutrition,N,
25342,QualifierName,Q000009,6422563,,,14,,N,adverse effects
25343,DescriptorName,D018805,6422563,,,15,Sepsis,N,
25344,QualifierName,Q000175,6422563,,,15,,N,diagnosis
25345,Chemical,D006052,6427463,Gold Sodium Thiomalate,12244-57-4,,,,
25346,DescriptorName,D002561,6427463,,,1,Cerebrovascular Disorders,N,
25347,QualifierName,Q000139,6427463,,,1,,Y,chemically induced
25348,DescriptorName,D005260,6427463,,,2,Female,N,
25349,DescriptorName,D006052,6427463,,,3,Gold Sodium Thiomalate,N,
25350,QualifierName,Q000009,6427463,,,3,,Y,adverse effects
25351,DescriptorName,D006801,6427463,,,4,Humans,N,
25352,DescriptorName,D008875,6427463,,,5,Middle Aged,N,
25353,DescriptorName,D013577,6427463,,,6,Syndrome,N,
25354,DescriptorName,D013585,6427463,,,7,Synovitis,N,
25355,QualifierName,Q000188,6427463,,,7,,N,drug therapy
25356,DescriptorName,D014666,6427463,,,8,Vasomotor System,N,
25357,QualifierName,Q000187,6427463,,,8,,Y,drug effects
25358,Chemical,D000893,6430252,Anti-Inflammatory Agents,0,,,,
25359,Chemical,D011758,6430252,Pyrroles,0,,,,
25360,Chemical,D006051,6430252,Aurothioglucose,2P2V9Q0E78,,,,
25361,Chemical,D001310,6430252,Auranofin,3H04W2810V,,,,
25362,Chemical,D006046,6430252,Gold,7440-57-5,,,,
25363,Chemical,D014046,6430252,Tolmetin,D8K2JPN18B,,,,
25364,DescriptorName,D000893,6430252,,,1,Anti-Inflammatory Agents,N,
25365,QualifierName,Q000009,6430252,,,1,,Y,adverse effects
25366,DescriptorName,D001172,6430252,,,2,"Arthritis, Rheumatoid",N,
25367,QualifierName,Q000188,6430252,,,2,,N,drug therapy
25368,DescriptorName,D001310,6430252,,,3,Auranofin,N,
25369,DescriptorName,D006051,6430252,,,4,Aurothioglucose,N,
25370,QualifierName,Q000009,6430252,,,4,,N,adverse effects
25371,DescriptorName,D005260,6430252,,,5,Female,N,
25372,DescriptorName,D005921,6430252,,,6,Glomerulonephritis,N,
25373,QualifierName,Q000139,6430252,,,6,,Y,chemically induced
25374,DescriptorName,D006046,6430252,,,7,Gold,N,
25375,QualifierName,Q000031,6430252,,,7,,Y,analogs & derivatives
25376,DescriptorName,D006801,6430252,,,8,Humans,N,
25377,DescriptorName,D008875,6430252,,,9,Middle Aged,N,
25378,DescriptorName,D011507,6430252,,,10,Proteinuria,N,
25379,QualifierName,Q000139,6430252,,,10,,Y,chemically induced
25380,DescriptorName,D011758,6430252,,,11,Pyrroles,N,
25381,QualifierName,Q000009,6430252,,,11,,Y,adverse effects
25382,DescriptorName,D014046,6430252,,,12,Tolmetin,N,
25383,QualifierName,Q000009,6430252,,,12,,Y,adverse effects
25384,Chemical,D006052,6440806,Gold Sodium Thiomalate,12244-57-4,,,,
25385,DescriptorName,D001172,6440806,,,1,"Arthritis, Rheumatoid",N,
25386,QualifierName,Q000188,6440806,,,1,,N,drug therapy
25387,DescriptorName,D005260,6440806,,,2,Female,N,
25388,DescriptorName,D006052,6440806,,,3,Gold Sodium Thiomalate,N,
25389,QualifierName,Q000009,6440806,,,3,,Y,adverse effects
25390,DescriptorName,D006801,6440806,,,4,Humans,N,
25391,DescriptorName,D008168,6440806,,,5,Lung,N,
25392,QualifierName,Q000473,6440806,,,5,,N,pathology
25393,DescriptorName,D008875,6440806,,,6,Middle Aged,N,
25394,DescriptorName,D011658,6440806,,,7,Pulmonary Fibrosis,N,
25395,QualifierName,Q000139,6440806,,,7,,Y,chemically induced
25396,Chemical,D003520,644545,Cyclophosphamide,8N3DW7272P,,,,
25397,DescriptorName,D000328,644545,,,1,Adult,N,
25398,DescriptorName,D003520,644545,,,2,Cyclophosphamide,N,
25399,QualifierName,Q000009,644545,,,2,,Y,adverse effects
25400,DescriptorName,D005921,644545,,,3,Glomerulonephritis,N,
25401,QualifierName,Q000188,644545,,,3,,N,drug therapy
25402,DescriptorName,D006801,644545,,,4,Humans,N,
25403,DescriptorName,D008168,644545,,,5,Lung,N,
25404,QualifierName,Q000473,644545,,,5,,N,pathology
25405,DescriptorName,D008297,644545,,,6,Male,N,
25406,DescriptorName,D011658,644545,,,7,Pulmonary Fibrosis,N,
25407,QualifierName,Q000139,644545,,,7,,Y,chemically induced
25408,Chemical,D004221,6453500,Disulfiram,TR3MLJ1UAI,,,,
25409,DescriptorName,D056486,6453500,,,1,Chemical and Drug Induced Liver Injury,N,
25410,QualifierName,Q000209,6453500,,,1,,Y,etiology
25411,DescriptorName,D004221,6453500,,,2,Disulfiram,N,
25412,QualifierName,Q000009,6453500,,,2,,Y,adverse effects
25413,DescriptorName,D011146,6453500,,,3,"Eczema, Dyshidrotic",N,
25414,QualifierName,Q000188,6453500,,,3,,N,drug therapy
25415,DescriptorName,D005260,6453500,,,4,Female,N,
25416,DescriptorName,D006801,6453500,,,5,Humans,N,
25417,DescriptorName,D008875,6453500,,,6,Middle Aged,N,
25418,Chemical,D007464,6460590,Clioquinol,7BHQ856EJ5,,,,
25419,DescriptorName,D000169,6460590,,,1,Acrodermatitis,N,
25420,QualifierName,Q000188,6460590,,,1,,Y,drug therapy
25421,DescriptorName,D000328,6460590,,,2,Adult,N,
25422,DescriptorName,D007464,6460590,,,3,Clioquinol,N,
25423,QualifierName,Q000009,6460590,,,3,,Y,adverse effects
25424,DescriptorName,D014943,6460590,,,4,Global Health,N,
25425,DescriptorName,D006801,6460590,,,5,Humans,N,
25426,DescriptorName,D007564,6460590,,,6,Japan,N,
25427,DescriptorName,D008297,6460590,,,7,Male,N,
25428,DescriptorName,D009187,6460590,,,8,Myelitis,N,
25429,QualifierName,Q000139,6460590,,,8,,Y,chemically induced
25430,DescriptorName,D009902,6460590,,,9,Optic Neuritis,N,
25431,QualifierName,Q000139,6460590,,,9,,Y,chemically induced
25432,DescriptorName,D013577,6460590,,,10,Syndrome,N,
25433,Chemical,D013629,647693,Tamoxifen,094ZI81Y45,,,,
25434,DescriptorName,D000368,647693,,,1,Aged,N,
25435,DescriptorName,D001943,647693,,,2,Breast Neoplasms,N,
25436,QualifierName,Q000188,647693,,,2,,N,drug therapy
25437,DescriptorName,D005260,647693,,,3,Female,N,
25438,DescriptorName,D006801,647693,,,4,Humans,N,
25439,DescriptorName,D008875,647693,,,5,Middle Aged,N,
25440,DescriptorName,D012164,647693,,,6,Retinal Diseases,N,
25441,QualifierName,Q000139,647693,,,6,,Y,chemically induced
25442,DescriptorName,D013629,647693,,,7,Tamoxifen,N,
25443,QualifierName,Q000009,647693,,,7,,Y,adverse effects
25444,DescriptorName,D014786,647693,,,8,Vision Disorders,N,
25445,QualifierName,Q000139,647693,,,8,,N,chemically induced
25446,Chemical,D010396,6478628,Penicillamine,GNN1DV99GX,,,,
25447,Chemical,D003613,6478628,Danazol,N29QWW3BUO,,,,
25448,DescriptorName,D000328,6478628,,,1,Adult,N,
25449,DescriptorName,D001941,6478628,,,2,Breast Diseases,N,
25450,QualifierName,Q000139,6478628,,,2,,Y,chemically induced
25451,DescriptorName,D002369,6478628,,,3,Castration,N,
25452,DescriptorName,D003613,6478628,,,4,Danazol,N,
25453,QualifierName,Q000627,6478628,,,4,,N,therapeutic use
25454,DescriptorName,D005260,6478628,,,5,Female,N,
25455,DescriptorName,D005877,6478628,,,6,Gigantism,N,
25456,QualifierName,Q000139,6478628,,,6,,Y,chemically induced
25457,DescriptorName,D006801,6478628,,,7,Humans,N,
25458,DescriptorName,D010396,6478628,,,8,Penicillamine,N,
25459,QualifierName,Q000009,6478628,,,8,,Y,adverse effects
25460,Chemical,D000667,6484655,Ampicillin,7C782967RD,,,,
25461,DescriptorName,D000328,6484655,,,1,Adult,N,
25462,DescriptorName,D000667,6484655,,,2,Ampicillin,N,
25463,QualifierName,Q000008,6484655,,,2,,N,administration & dosage
25464,DescriptorName,D005260,6484655,,,3,Female,N,
25465,DescriptorName,D006801,6484655,,,4,Humans,N,
25466,DescriptorName,D008180,6484655,,,5,"Lupus Erythematosus, Systemic",N,
25467,QualifierName,Q000150,6484655,,,5,,N,complications
25468,DescriptorName,D008875,6484655,,,6,Middle Aged,N,
25469,DescriptorName,D009393,6484655,,,7,Nephritis,N,
25470,QualifierName,Q000150,6484655,,,7,,N,complications
25471,DescriptorName,D011183,6484655,,,8,Postoperative Complications,N,
25472,QualifierName,Q000188,6484655,,,8,,N,drug therapy
25473,DescriptorName,D012640,6484655,,,9,Seizures,N,
25474,QualifierName,Q000139,6484655,,,9,,Y,chemically induced
25475,Chemical,D011736,6498095,Pyridoxine,KV2JZ1BI6Z,,,,
25476,Chemical,D007538,6498095,Isoniazid,V83O1VOZ8L,,,,
25477,Chemical,D012293,6498095,Rifampin,VJT6J7R4TR,,,,
25478,DescriptorName,D006801,6498095,,,1,Humans,N,
25479,DescriptorName,D007538,6498095,,,2,Isoniazid,N,
25480,QualifierName,Q000627,6498095,,,2,,N,therapeutic use
25481,DescriptorName,D008297,6498095,,,3,Male,N,
25482,DescriptorName,D008875,6498095,,,4,Middle Aged,N,
25483,DescriptorName,D010392,6498095,,,5,Pemphigus,N,
25484,QualifierName,Q000139,6498095,,,5,,Y,chemically induced
25485,DescriptorName,D011736,6498095,,,6,Pyridoxine,N,
25486,QualifierName,Q000627,6498095,,,6,,N,therapeutic use
25487,DescriptorName,D012293,6498095,,,7,Rifampin,N,
25488,QualifierName,Q000009,6498095,,,7,,Y,adverse effects
25489,DescriptorName,D014397,6498095,,,8,"Tuberculosis, Pulmonary",N,
25490,QualifierName,Q000188,6498095,,,8,,N,drug therapy
25491,Chemical,D000889,6507240,Anti-Arrhythmia Agents,0,,,,
25492,Chemical,D044482,6507240,Benzeneacetamides,0,,,,
25493,Chemical,D010880,6507240,Piperidines,0,,,,
25494,Chemical,D014667,6507240,Vasopressins,11000-17-2,,,,
25495,Chemical,D012964,6507240,Sodium,9NEZ333N27,,,,
25496,Chemical,C015970,6507240,lorcainide,KGJ2T0N7IQ,,,,
25497,Chemical,D011188,6507240,Potassium,RWP5GA015D,,,,
25498,DescriptorName,D000328,6507240,,,1,Adult,N,
25499,DescriptorName,D000368,6507240,,,2,Aged,N,
25500,DescriptorName,D000889,6507240,,,3,Anti-Arrhythmia Agents,N,
25501,QualifierName,Q000009,6507240,,,3,,Y,adverse effects
25502,DescriptorName,D001145,6507240,,,4,"Arrhythmias, Cardiac",N,
25503,QualifierName,Q000097,6507240,,,4,,N,blood
25504,DescriptorName,D044482,6507240,,,5,Benzeneacetamides,Y,
25505,DescriptorName,D005260,6507240,,,6,Female,N,
25506,DescriptorName,D006801,6507240,,,7,Humans,N,
25507,DescriptorName,D007010,6507240,,,8,Hyponatremia,N,
25508,QualifierName,Q000139,6507240,,,8,,Y,chemically induced
25509,DescriptorName,D007177,6507240,,,9,Inappropriate ADH Syndrome,N,
25510,QualifierName,Q000139,6507240,,,9,,N,chemically induced
25511,DescriptorName,D008297,6507240,,,10,Male,N,
25512,DescriptorName,D008875,6507240,,,11,Middle Aged,N,
25513,DescriptorName,D010880,6507240,,,12,Piperidines,N,
25514,QualifierName,Q000009,6507240,,,12,,Y,adverse effects
25515,DescriptorName,D011188,6507240,,,13,Potassium,N,
25516,QualifierName,Q000097,6507240,,,13,,N,blood
25517,DescriptorName,D012964,6507240,,,14,Sodium,N,
25518,QualifierName,Q000097,6507240,,,14,,N,blood
25519,DescriptorName,D014667,6507240,,,15,Vasopressins,N,
25520,QualifierName,Q000097,6507240,,,15,,N,blood
25521,Chemical,D002747,6510223,Chlorpropamide,WTM2C3IL2X,,,,
25522,DescriptorName,D000743,6510223,,,1,"Anemia, Hemolytic",N,
25523,QualifierName,Q000139,6510223,,,1,,Y,chemically induced
25524,DescriptorName,D002747,6510223,,,2,Chlorpropamide,N,
25525,QualifierName,Q000009,6510223,,,2,,Y,adverse effects
25526,DescriptorName,D003924,6510223,,,3,"Diabetes Mellitus, Type 2",N,
25527,QualifierName,Q000188,6510223,,,3,,N,drug therapy
25528,DescriptorName,D005260,6510223,,,4,Female,N,
25529,DescriptorName,D006801,6510223,,,5,Humans,N,
25530,DescriptorName,D008875,6510223,,,6,Middle Aged,N,
25531,Chemical,D001572,6519218,Benzofurans,0,,,,
25532,Chemical,D000638,6519218,Amiodarone,N3RQ532IUT,,,,
25533,DescriptorName,D000638,6519218,,,1,Amiodarone,N,
25534,QualifierName,Q000008,6519218,,,1,,N,administration & dosage
25535,DescriptorName,D001281,6519218,,,2,Atrial Fibrillation,N,
25536,QualifierName,Q000188,6519218,,,2,,N,drug therapy
25537,DescriptorName,D001572,6519218,,,3,Benzofurans,N,
25538,QualifierName,Q000009,6519218,,,3,,Y,adverse effects
25539,DescriptorName,D001706,6519218,,,4,Biopsy,N,
25540,DescriptorName,D006801,6519218,,,5,Humans,N,
25541,DescriptorName,D008168,6519218,,,6,Lung,N,
25542,QualifierName,Q000473,6519218,,,6,,N,pathology
25543,DescriptorName,D008297,6519218,,,7,Male,N,
25544,DescriptorName,D008875,6519218,,,8,Middle Aged,N,
25545,DescriptorName,D011658,6519218,,,9,Pulmonary Fibrosis,N,
25546,QualifierName,Q000139,6519218,,,9,,Y,chemically induced
25547,DescriptorName,D013997,6519218,,,10,Time Factors,N,
25548,Chemical,D001285,6529939,Atropine,7C0697DR9I,,,,
25549,Chemical,D011433,6529939,Propranolol,9Y8NXQ24VQ,,,,
25550,DescriptorName,D001146,6529939,,,1,"Arrhythmia, Sinus",N,
25551,QualifierName,Q000139,6529939,,,1,,Y,chemically induced
25552,DescriptorName,D001285,6529939,,,2,Atropine,N,
25553,QualifierName,Q000627,6529939,,,2,,N,therapeutic use
25554,DescriptorName,D004562,6529939,,,3,Electrocardiography,N,
25555,DescriptorName,D005260,6529939,,,4,Female,N,
25556,DescriptorName,D006327,6529939,,,5,Heart Block,N,
25557,QualifierName,Q000139,6529939,,,5,,Y,chemically induced
25558,DescriptorName,D006339,6529939,,,6,Heart Rate,N,
25559,QualifierName,Q000187,6529939,,,6,,N,drug effects
25560,DescriptorName,D006801,6529939,,,7,Humans,N,
25561,DescriptorName,D008875,6529939,,,8,Middle Aged,N,
25562,DescriptorName,D011433,6529939,,,9,Propranolol,N,
25563,QualifierName,Q000009,6529939,,,9,,Y,adverse effects
25564,DescriptorName,D012848,6529939,,,10,Sinoatrial Block,N,
25565,QualifierName,Q000139,6529939,,,10,,Y,chemically induced
25566,Chemical,D008775,6540393,Methylprednisolone,X4W7ZR7023,,,,
25567,DescriptorName,D000707,6540393,,,1,Anaphylaxis,N,
25568,QualifierName,Q000139,6540393,,,1,,Y,chemically induced
25569,DescriptorName,D006801,6540393,,,2,Humans,N,
25570,DescriptorName,D008297,6540393,,,3,Male,N,
25571,DescriptorName,D008775,6540393,,,4,Methylprednisolone,N,
25572,QualifierName,Q000009,6540393,,,4,,Y,adverse effects
25573,DescriptorName,D008875,6540393,,,5,Middle Aged,N,
25574,DescriptorName,D009103,6540393,,,6,Multiple Sclerosis,N,
25575,QualifierName,Q000188,6540393,,,6,,Y,drug therapy
25576,Chemical,D009607,6572542,Nitrosourea Compounds,0,,,,
25577,Chemical,D008130,6572542,Lomustine,7BRF0Z81KG,,,,
25578,Chemical,D002330,6572542,Carmustine,U68WG3173Y,,,,
25579,DescriptorName,D000328,6572542,,,1,Adult,N,
25580,DescriptorName,D002330,6572542,,,2,Carmustine,N,
25581,QualifierName,Q000009,6572542,,,2,,N,adverse effects
25582,DescriptorName,D005260,6572542,,,3,Female,N,
25583,DescriptorName,D006801,6572542,,,4,Humans,N,
25584,DescriptorName,D007951,6572542,,,5,"Leukemia, Myeloid",N,
25585,QualifierName,Q000188,6572542,,,5,,Y,drug therapy
25586,DescriptorName,D008130,6572542,,,6,Lomustine,N,
25587,QualifierName,Q000008,6572542,,,6,,N,administration & dosage
25588,DescriptorName,D008297,6572542,,,7,Male,N,
25589,DescriptorName,D009607,6572542,,,8,Nitrosourea Compounds,N,
25590,QualifierName,Q000009,6572542,,,8,,Y,adverse effects
25591,DescriptorName,D011658,6572542,,,9,Pulmonary Fibrosis,N,
25592,QualifierName,Q000139,6572542,,,9,,Y,chemically induced
25593,Chemical,D002066,6578007,Busulfan,G1LN9045DK,,,,
25594,Chemical,D008558,6578007,Melphalan,Q41OR9510P,,,,
25595,DescriptorName,D002066,6578007,,,1,Busulfan,N,
25596,QualifierName,Q000627,6578007,,,1,,N,therapeutic use
25597,DescriptorName,D004357,6578007,,,2,Drug Synergism,N,
25598,DescriptorName,D006801,6578007,,,3,Humans,N,
25599,DescriptorName,D007951,6578007,,,4,"Leukemia, Myeloid",N,
25600,QualifierName,Q000188,6578007,,,4,,N,drug therapy
25601,DescriptorName,D008297,6578007,,,5,Male,N,
25602,DescriptorName,D008558,6578007,,,6,Melphalan,N,
25603,QualifierName,Q000627,6578007,,,6,,N,therapeutic use
25604,DescriptorName,D008875,6578007,,,7,Middle Aged,N,
25605,DescriptorName,D011658,6578007,,,8,Pulmonary Fibrosis,N,
25606,QualifierName,Q000139,6578007,,,8,,Y,chemically induced
25607,Chemical,D002712,6597713,Chlorides,0,,,,
25608,Chemical,D002792,6597713,Cholestyramine Resin,11041-12-6,,,,
25609,Chemical,D013148,6597713,Spironolactone,27O7W4T232,,,,
25610,DescriptorName,D000138,6597713,,,1,Acidosis,N,
25611,QualifierName,Q000139,6597713,,,1,,Y,chemically induced
25612,DescriptorName,D000368,6597713,,,2,Aged,N,
25613,DescriptorName,D002712,6597713,,,3,Chlorides,N,
25614,QualifierName,Q000097,6597713,,,3,,Y,blood
25615,DescriptorName,D002792,6597713,,,4,Cholestyramine Resin,N,
25616,QualifierName,Q000009,6597713,,,4,,Y,adverse effects
25617,DescriptorName,D005260,6597713,,,5,Female,N,
25618,DescriptorName,D006801,6597713,,,6,Humans,N,
25619,DescriptorName,D006863,6597713,,,7,Hydrogen-Ion Concentration,N,
25620,DescriptorName,D008105,6597713,,,8,"Liver Cirrhosis, Biliary",N,
25621,QualifierName,Q000188,6597713,,,8,,N,drug therapy
25622,DescriptorName,D011537,6597713,,,9,Pruritus,N,
25623,QualifierName,Q000188,6597713,,,9,,N,drug therapy
25624,DescriptorName,D013148,6597713,,,10,Spironolactone,N,
25625,QualifierName,Q000627,6597713,,,10,,N,therapeutic use
25626,Chemical,D012263,6608139,Ribonucleosides,0,,,,
25627,Chemical,D003070,6608139,Coformycin,11033-22-0,,,,
25628,Chemical,D015649,6608139,Pentostatin,395575MZO7,,,,
25629,DescriptorName,D000328,6608139,,,1,Adult,N,
25630,DescriptorName,D003070,6608139,,,2,Coformycin,N,
25631,QualifierName,Q000031,6608139,,,2,,N,analogs & derivatives
25632,DescriptorName,D005260,6608139,,,3,Female,N,
25633,DescriptorName,D006562,6608139,,,4,Herpes Zoster,N,
25634,QualifierName,Q000209,6608139,,,4,,N,etiology
25635,DescriptorName,D006801,6608139,,,5,Humans,N,
25636,DescriptorName,D007634,6608139,,,6,Keratitis,N,
25637,QualifierName,Q000139,6608139,,,6,,N,chemically induced
25638,DescriptorName,D008223,6608139,,,7,Lymphoma,N,
25639,QualifierName,Q000188,6608139,,,7,,Y,drug therapy
25640,DescriptorName,D008297,6608139,,,8,Male,N,
25641,DescriptorName,D015649,6608139,,,9,Pentostatin,N,
25642,DescriptorName,D012263,6608139,,,10,Ribonucleosides,N,
25643,QualifierName,Q000627,6608139,,,10,,Y,therapeutic use
25644,Chemical,D014667,6610943,Vasopressins,11000-17-2,,,,
25645,DescriptorName,D058186,6610943,,,1,Acute Kidney Injury,N,
25646,QualifierName,Q000139,6610943,,,1,,Y,chemically induced
25647,DescriptorName,D000368,6610943,,,2,Aged,N,
25648,DescriptorName,D005260,6610943,,,3,Female,N,
25649,DescriptorName,D006471,6610943,,,4,Gastrointestinal Hemorrhage,N,
25650,QualifierName,Q000188,6610943,,,4,,N,drug therapy
25651,DescriptorName,D006801,6610943,,,5,Humans,N,
25652,DescriptorName,D007263,6610943,,,6,"Infusions, Parenteral",N,
25653,DescriptorName,D007511,6610943,,,7,Ischemia,N,
25654,QualifierName,Q000139,6610943,,,7,,N,chemically induced
25655,DescriptorName,D008297,6610943,,,8,Male,N,
25656,DescriptorName,D008875,6610943,,,9,Middle Aged,N,
25657,DescriptorName,D009132,6610943,,,10,Muscles,N,
25658,QualifierName,Q000098,6610943,,,10,,N,blood supply
25659,DescriptorName,D009212,6610943,,,11,Myoglobinuria,N,
25660,QualifierName,Q000139,6610943,,,11,,Y,chemically induced
25661,DescriptorName,D012206,6610943,,,12,Rhabdomyolysis,N,
25662,QualifierName,Q000139,6610943,,,12,,Y,chemically induced
25663,DescriptorName,D014667,6610943,,,13,Vasopressins,N,
25664,QualifierName,Q000008,6610943,,,13,,N,administration & dosage
25665,Chemical,D012965,6614033,Sodium Chloride,451W47IQ8X,,,,
25666,Chemical,D000666,6614033,Amphotericin B,7XU7A7DROE,,,,
25667,Chemical,D014508,6614033,Urea,8W8T17847W,,,,
25668,Chemical,D012964,6614033,Sodium,9NEZ333N27,,,,
25669,Chemical,D003404,6614033,Creatinine,AYI8EX34EU,,,,
25670,DescriptorName,D000368,6614033,,,1,Aged,N,
25671,DescriptorName,D000666,6614033,,,2,Amphotericin B,N,
25672,QualifierName,Q000009,6614033,,,2,,Y,adverse effects
25673,DescriptorName,D003404,6614033,,,3,Creatinine,N,
25674,QualifierName,Q000097,6614033,,,3,,N,blood
25675,DescriptorName,D004032,6614033,,,4,Diet,N,
25676,DescriptorName,D005260,6614033,,,5,Female,N,
25677,DescriptorName,D006801,6614033,,,6,Humans,N,
25678,DescriptorName,D007674,6614033,,,7,Kidney Diseases,N,
25679,QualifierName,Q000139,6614033,,,7,,Y,chemically induced
25680,DescriptorName,D008297,6614033,,,8,Male,N,
25681,DescriptorName,D008875,6614033,,,9,Middle Aged,N,
25682,DescriptorName,D012964,6614033,,,10,Sodium,N,
25683,QualifierName,Q000172,6614033,,,10,,Y,deficiency
25684,DescriptorName,D012965,6614033,,,11,Sodium Chloride,N,
25685,QualifierName,Q000627,6614033,,,11,,Y,therapeutic use
25686,DescriptorName,D014508,6614033,,,12,Urea,N,
25687,QualifierName,Q000097,6614033,,,12,,N,blood
25688,Chemical,D013450,6618859,Sulfones,0,,,,
25689,Chemical,C038907,6618859,fluoresone,343BH0S0XR,,,,
25690,Chemical,D010672,6618859,Phenytoin,6158TKW0C5,,,,
25691,Chemical,D011388,6618859,Prolactin,9002-62-4,,,,
25692,Chemical,D010634,6618859,Phenobarbital,YQE403BP4D,,,,
25693,DescriptorName,D000328,6618859,,,1,Adult,N,
25694,DescriptorName,D004359,6618859,,,2,"Drug Therapy, Combination",N,
25695,DescriptorName,D004827,6618859,,,3,Epilepsy,N,
25696,QualifierName,Q000188,6618859,,,3,,Y,drug therapy
25697,DescriptorName,D006177,6618859,,,4,Gynecomastia,N,
25698,QualifierName,Q000139,6618859,,,4,,Y,chemically induced
25699,DescriptorName,D006801,6618859,,,5,Humans,N,
25700,DescriptorName,D008297,6618859,,,6,Male,N,
25701,DescriptorName,D010634,6618859,,,7,Phenobarbital,N,
25702,QualifierName,Q000009,6618859,,,7,,Y,adverse effects
25703,DescriptorName,D010672,6618859,,,8,Phenytoin,N,
25704,QualifierName,Q000009,6618859,,,8,,Y,adverse effects
25705,DescriptorName,D011388,6618859,,,9,Prolactin,N,
25706,QualifierName,Q000097,6618859,,,9,,N,blood
25707,DescriptorName,D013450,6618859,,,10,Sulfones,N,
25708,QualifierName,Q000009,6618859,,,10,,Y,adverse effects
25709,Chemical,D003989,6625005,Dibenzoxazepines,0,,,,
25710,Chemical,D000657,6625005,Amoxapine,R63VQ857OT,,,,
25711,DescriptorName,D000657,6625005,,,1,Amoxapine,N,
25712,QualifierName,Q000009,6625005,,,1,,Y,adverse effects
25713,DescriptorName,D001714,6625005,,,2,Bipolar Disorder,N,
25714,QualifierName,Q000188,6625005,,,2,,N,drug therapy
25715,DescriptorName,D003989,6625005,,,3,Dibenzoxazepines,N,
25716,QualifierName,Q000009,6625005,,,3,,Y,adverse effects
25717,DescriptorName,D004409,6625005,,,4,"Dyskinesia, Drug-Induced",N,
25718,QualifierName,Q000209,6625005,,,4,,Y,etiology
25719,DescriptorName,D005260,6625005,,,5,Female,N,
25720,DescriptorName,D006801,6625005,,,6,Humans,N,
25721,DescriptorName,D008875,6625005,,,7,Middle Aged,N,
25722,DescriptorName,D013375,6625005,,,8,Substance Withdrawal Syndrome,N,
25723,QualifierName,Q000209,6625005,,,8,,Y,etiology
25724,Chemical,D014212,6628806,Tretinoin,5688UTC01R,,,,
25725,Chemical,D008727,6628806,Methotrexate,YL5FZ2Y5U1,,,,
25726,DescriptorName,D056486,6628806,,,1,Chemical and Drug Induced Liver Injury,N,
25727,QualifierName,Q000175,6628806,,,1,,N,diagnosis
25728,DescriptorName,D004359,6628806,,,2,"Drug Therapy, Combination",N,
25729,DescriptorName,D005260,6628806,,,3,Female,N,
25730,DescriptorName,D006801,6628806,,,4,Humans,N,
25731,DescriptorName,D008111,6628806,,,5,Liver Function Tests,N,
25732,DescriptorName,D008727,6628806,,,6,Methotrexate,N,
25733,QualifierName,Q000009,6628806,,,6,,Y,adverse effects
25734,DescriptorName,D008875,6628806,,,7,Middle Aged,N,
25735,DescriptorName,D011565,6628806,,,8,Psoriasis,N,
25736,QualifierName,Q000188,6628806,,,8,,Y,drug therapy
25737,DescriptorName,D014212,6628806,,,9,Tretinoin,N,
25738,QualifierName,Q000009,6628806,,,9,,Y,adverse effects
25739,Chemical,D004338,6635723,Drug Combinations,0,,,,
25740,Chemical,D006852,6635723,Hydrochlorothiazide,0J48LPH2TH,,,,
25741,Chemical,D014667,6635723,Vasopressins,11000-17-2,,,,
25742,Chemical,C020743,6635723,hydrochlorothiazide-triamterene,14124-50-6,,,,
25743,Chemical,D012964,6635723,Sodium,9NEZ333N27,,,,
25744,Chemical,D014223,6635723,Triamterene,WS821Z52LQ,,,,
25745,DescriptorName,D004338,6635723,,,1,Drug Combinations,N,
25746,QualifierName,Q000009,6635723,,,1,,N,adverse effects
25747,DescriptorName,D005260,6635723,,,2,Female,N,
25748,DescriptorName,D006801,6635723,,,3,Humans,N,
25749,DescriptorName,D006852,6635723,,,4,Hydrochlorothiazide,N,
25750,QualifierName,Q000009,6635723,,,4,,Y,adverse effects
25751,DescriptorName,D006973,6635723,,,5,Hypertension,N,
25752,QualifierName,Q000188,6635723,,,5,,N,drug therapy
25753,DescriptorName,D007010,6635723,,,6,Hyponatremia,N,
25754,QualifierName,Q000139,6635723,,,6,,Y,chemically induced
25755,DescriptorName,D008875,6635723,,,7,Middle Aged,N,
25756,DescriptorName,D009461,6635723,,,8,Neurologic Manifestations,N,
25757,DescriptorName,D009994,6635723,,,9,Osmolar Concentration,N,
25758,DescriptorName,D012008,6635723,,,10,Recurrence,N,
25759,DescriptorName,D012640,6635723,,,11,Seizures,N,
25760,QualifierName,Q000139,6635723,,,11,,N,chemically induced
25761,DescriptorName,D012964,6635723,,,12,Sodium,N,
25762,QualifierName,Q000097,6635723,,,12,,N,blood
25763,DescriptorName,D014223,6635723,,,13,Triamterene,N,
25764,QualifierName,Q000009,6635723,,,13,,Y,adverse effects
25765,DescriptorName,D014667,6635723,,,14,Vasopressins,N,
25766,QualifierName,Q000097,6635723,,,14,,N,blood
25767,Chemical,D003692,6651138,Delayed-Action Preparations,0,,,,
25768,Chemical,D012601,6651138,Scopolamine,DL48G20X8X,,,,
25769,DescriptorName,D000208,6651138,,,1,Acute Disease,N,
25770,DescriptorName,D003692,6651138,,,2,Delayed-Action Preparations,N,
25771,DescriptorName,D048909,6651138,,,3,Diabetes Complications,N,
25772,DescriptorName,D005260,6651138,,,4,Female,N,
25773,DescriptorName,D005901,6651138,,,5,Glaucoma,N,
25774,QualifierName,Q000139,6651138,,,5,,Y,chemically induced
25775,DescriptorName,D006801,6651138,,,6,Humans,N,
25776,DescriptorName,D008875,6651138,,,7,Middle Aged,N,
25777,DescriptorName,D009041,6651138,,,8,Motion Sickness,N,
25778,QualifierName,Q000150,6651138,,,8,,N,complications
25779,DescriptorName,D012601,6651138,,,9,Scopolamine,N,
25780,QualifierName,Q000009,6651138,,,9,,Y,adverse effects
25781,Chemical,D014149,665845,Tranquilizing Agents,0,,,,
25782,Chemical,D003642,665845,Deanol,2N6K9DRA24,,,,
25783,Chemical,D008094,665845,Lithium,9FN79X2M3F,,,,
25784,DescriptorName,D000293,665845,,,1,Adolescent,N,
25785,DescriptorName,D000367,665845,,,2,Age Factors,N,
25786,DescriptorName,D002648,665845,,,3,Child,N,
25787,DescriptorName,D002653,665845,,,4,Child Behavior Disorders,N,
25788,QualifierName,Q000188,665845,,,4,,Y,drug therapy
25789,DescriptorName,D003642,665845,,,5,Deanol,N,
25790,QualifierName,Q000627,665845,,,5,,N,therapeutic use
25791,DescriptorName,D003937,665845,,,6,"Diagnosis, Differential",N,
25792,DescriptorName,D004409,665845,,,7,"Dyskinesia, Drug-Induced",N,
25793,QualifierName,Q000175,665845,,,7,,N,diagnosis
25794,DescriptorName,D006801,665845,,,8,Humans,N,
25795,DescriptorName,D008094,665845,,,9,Lithium,N,
25796,QualifierName,Q000627,665845,,,9,,N,therapeutic use
25797,DescriptorName,D008297,665845,,,10,Male,N,
25798,DescriptorName,D014149,665845,,,11,Tranquilizing Agents,N,
25799,QualifierName,Q000009,665845,,,11,,Y,adverse effects
25800,Chemical,D002511,6671350,Cephalosporins,0,,,,
25801,Chemical,D009070,6671350,Moxalactam,VUF6C936Z3,,,,
25802,DescriptorName,D058186,6671350,,,1,Acute Kidney Injury,N,
25803,QualifierName,Q000150,6671350,,,1,,N,complications
25804,DescriptorName,D000328,6671350,,,2,Adult,N,
25805,DescriptorName,D000368,6671350,,,3,Aged,N,
25806,DescriptorName,D001778,6671350,,,4,Blood Coagulation Disorders,N,
25807,QualifierName,Q000139,6671350,,,4,,Y,chemically induced
25808,DescriptorName,D002511,6671350,,,5,Cephalosporins,N,
25809,QualifierName,Q000009,6671350,,,5,,Y,adverse effects
25810,DescriptorName,D005260,6671350,,,6,Female,N,
25811,DescriptorName,D006801,6671350,,,7,Humans,N,
25812,DescriptorName,D007020,6671350,,,8,Hypoprothrombinemias,N,
25813,QualifierName,Q000139,6671350,,,8,,N,chemically induced
25814,DescriptorName,D007676,6671350,,,9,"Kidney Failure, Chronic",N,
25815,QualifierName,Q000150,6671350,,,9,,N,complications
25816,DescriptorName,D008297,6671350,,,10,Male,N,
25817,DescriptorName,D008875,6671350,,,11,Middle Aged,N,
25818,DescriptorName,D009070,6671350,,,12,Moxalactam,N,
25819,QualifierName,Q000009,6671350,,,12,,Y,adverse effects
25820,DescriptorName,D010530,6671350,,,13,Peritoneal Dialysis,N,
25821,DescriptorName,D011517,6671350,,,14,Prothrombin Time,N,
25822,DescriptorName,D006435,6671350,,,15,Renal Dialysis,N,
25823,Chemical,D002330,667809,Carmustine,U68WG3173Y,,,,
25824,DescriptorName,D002330,667809,,,1,Carmustine,N,
25825,QualifierName,Q000009,667809,,,1,,Y,adverse effects
25826,DescriptorName,D002528,667809,,,2,Cerebellar Neoplasms,N,
25827,QualifierName,Q000188,667809,,,2,,Y,drug therapy
25828,DescriptorName,D005260,667809,,,3,Female,N,
25829,DescriptorName,D006801,667809,,,4,Humans,N,
25830,DescriptorName,D007223,667809,,,5,Infant,N,
25831,DescriptorName,D008527,667809,,,6,Medulloblastoma,N,
25832,QualifierName,Q000188,667809,,,6,,Y,drug therapy
25833,DescriptorName,D011018,667809,,,7,"Pneumonia, Pneumococcal",N,
25834,QualifierName,Q000150,667809,,,7,,N,complications
25835,DescriptorName,D011658,667809,,,8,Pulmonary Fibrosis,N,
25836,QualifierName,Q000139,667809,,,8,,Y,chemically induced
25837,Chemical,D010396,6683487,Penicillamine,GNN1DV99GX,,,,
25838,DescriptorName,D001172,6683487,,,1,"Arthritis, Rheumatoid",N,
25839,QualifierName,Q000188,6683487,,,1,,Y,drug therapy
25840,DescriptorName,D006801,6683487,,,2,Humans,N,
25841,DescriptorName,D008297,6683487,,,3,Male,N,
25842,DescriptorName,D008875,6683487,,,4,Middle Aged,N,
25843,DescriptorName,D010396,6683487,,,5,Penicillamine,N,
25844,QualifierName,Q000009,6683487,,,5,,Y,adverse effects
25845,DescriptorName,D010976,6683487,,,6,Platelet Count,N,
25846,DescriptorName,D011696,6683487,,,7,"Purpura, Thrombocytopenic",N,
25847,QualifierName,Q000139,6683487,,,7,,Y,chemically induced
25848,Chemical,D000305,6692713,Adrenal Cortex Hormones,0,,,,
25849,Chemical,D001572,6692713,Benzofurans,0,,,,
25850,Chemical,D000638,6692713,Amiodarone,N3RQ532IUT,,,,
25851,DescriptorName,D000305,6692713,,,1,Adrenal Cortex Hormones,N,
25852,QualifierName,Q000627,6692713,,,1,,Y,therapeutic use
25853,DescriptorName,D000638,6692713,,,2,Amiodarone,N,
25854,QualifierName,Q000009,6692713,,,2,,Y,adverse effects
25855,DescriptorName,D001145,6692713,,,3,"Arrhythmias, Cardiac",N,
25856,QualifierName,Q000150,6692713,,,3,,N,complications
25857,DescriptorName,D001572,6692713,,,4,Benzofurans,N,
25858,QualifierName,Q000009,6692713,,,4,,Y,adverse effects
25859,DescriptorName,D001706,6692713,,,5,Biopsy,N,
25860,DescriptorName,D006801,6692713,,,6,Humans,N,
25861,DescriptorName,D008168,6692713,,,7,Lung,N,
25862,QualifierName,Q000187,6692713,,,7,,Y,drug effects
25863,DescriptorName,D008297,6692713,,,8,Male,N,
25864,DescriptorName,D008854,6692713,,,9,"Microscopy, Electron",N,
25865,DescriptorName,D008875,6692713,,,10,Middle Aged,N,
25866,DescriptorName,D012008,6692713,,,11,Recurrence,N,
25867,Chemical,D013806,6693840,Theophylline,C137DTR5RG,,,,
25868,DescriptorName,D001249,6693840,,,1,Asthma,N,
25869,QualifierName,Q000188,6693840,,,1,,N,drug therapy
25870,DescriptorName,D006177,6693840,,,2,Gynecomastia,N,
25871,QualifierName,Q000139,6693840,,,2,,Y,chemically induced
25872,DescriptorName,D006801,6693840,,,3,Humans,N,
25873,DescriptorName,D008297,6693840,,,4,Male,N,
25874,DescriptorName,D008875,6693840,,,5,Middle Aged,N,
25875,DescriptorName,D013806,6693840,,,6,Theophylline,N,
25876,QualifierName,Q000009,6693840,,,6,,Y,adverse effects
25877,Chemical,D011433,6697887,Propranolol,9Y8NXQ24VQ,,,,
25878,Chemical,D014700,6697887,Verapamil,CJ0O37KU29,,,,
25879,Chemical,D004298,6697887,Dopamine,VTD58H1Z2X,,,,
25880,DescriptorName,D004298,6697887,,,1,Dopamine,N,
25881,QualifierName,Q000627,6697887,,,1,,N,therapeutic use
25882,DescriptorName,D004347,6697887,,,2,Drug Interactions,N,
25883,DescriptorName,D006801,6697887,,,3,Humans,N,
25884,DescriptorName,D007022,6697887,,,4,Hypotension,N,
25885,QualifierName,Q000139,6697887,,,4,,Y,chemically induced
25886,DescriptorName,D007275,6697887,,,5,"Injections, Intravenous",N,
25887,DescriptorName,D008297,6697887,,,6,Male,N,
25888,DescriptorName,D008875,6697887,,,7,Middle Aged,N,
25889,DescriptorName,D011433,6697887,,,8,Propranolol,N,
25890,QualifierName,Q000009,6697887,,,8,,N,adverse effects
25891,DescriptorName,D014700,6697887,,,9,Verapamil,N,
25892,QualifierName,Q000008,6697887,,,9,,N,administration & dosage
25893,Chemical,D010666,6702890,Phenylpropionates,0,,,,
25894,Chemical,D005279,6702890,Fenoprofen,RA33EAC7KY,,,,
25895,DescriptorName,D000368,6702890,,,1,Aged,N,
25896,DescriptorName,D000741,6702890,,,2,"Anemia, Aplastic",N,
25897,QualifierName,Q000139,6702890,,,2,,Y,chemically induced
25898,DescriptorName,D001168,6702890,,,3,Arthritis,N,
25899,QualifierName,Q000188,6702890,,,3,,N,drug therapy
25900,DescriptorName,D005279,6702890,,,4,Fenoprofen,N,
25901,QualifierName,Q000008,6702890,,,4,,N,administration & dosage
25902,DescriptorName,D006801,6702890,,,5,Humans,N,
25903,DescriptorName,D008297,6702890,,,6,Male,N,
25904,DescriptorName,D010666,6702890,,,7,Phenylpropionates,N,
25905,QualifierName,Q000009,6702890,,,7,,Y,adverse effects
25906,Chemical,D011796,6721543,Quinacrine,H0C805XYDE,,,,
25907,DescriptorName,D005260,6721543,,,1,Female,N,
25908,DescriptorName,D006801,6721543,,,2,Humans,N,
25909,DescriptorName,D008179,6721543,,,3,"Lupus Erythematosus, Discoid",N,
25910,QualifierName,Q000188,6721543,,,3,,Y,drug therapy
25911,DescriptorName,D008875,6721543,,,4,Middle Aged,N,
25912,DescriptorName,D011605,6721543,,,5,"Psychoses, Substance-Induced",N,
25913,QualifierName,Q000209,6721543,,,5,,Y,etiology
25914,DescriptorName,D011796,6721543,,,6,Quinacrine,N,
25915,QualifierName,Q000008,6721543,,,6,,N,administration & dosage
25916,Chemical,D010879,6725214,Piperazines,0,,,,
25917,Chemical,D014196,6725214,Trazodone,YBK48BXK30,,,,
25918,DescriptorName,D000328,6725214,,,1,Adult,N,
25919,DescriptorName,D003866,6725214,,,2,Depressive Disorder,N,
25920,QualifierName,Q000188,6725214,,,2,,N,drug therapy
25921,DescriptorName,D006801,6725214,,,3,Humans,N,
25922,DescriptorName,D008297,6725214,,,4,Male,N,
25923,DescriptorName,D010879,6725214,,,5,Piperazines,N,
25924,QualifierName,Q000009,6725214,,,5,,Y,adverse effects
25925,DescriptorName,D011317,6725214,,,6,Priapism,N,
25926,QualifierName,Q000139,6725214,,,6,,Y,chemically induced
25927,DescriptorName,D014196,6725214,,,7,Trazodone,N,
25928,QualifierName,Q000009,6725214,,,7,,Y,adverse effects
25929,Chemical,D002606,672731,Charcoal,16291-96-6,,,,
25930,Chemical,D000082,672731,Acetaminophen,362O9ITL9D,,,,
25931,Chemical,D003543,672731,Cysteamine,5UX2SD1KE2,,,,
25932,DescriptorName,D000082,672731,,,1,Acetaminophen,N,
25933,QualifierName,Q000097,672731,,,1,,N,blood
25934,DescriptorName,D002606,672731,,,2,Charcoal,Y,
25935,DescriptorName,D003543,672731,,,3,Cysteamine,N,
25936,QualifierName,Q000627,672731,,,3,,Y,therapeutic use
25937,DescriptorName,D005260,672731,,,4,Female,N,
25938,DescriptorName,D006464,672731,,,5,Hemoperfusion,Y,
25939,DescriptorName,D006801,672731,,,6,Humans,N,
25940,DescriptorName,D008875,672731,,,7,Middle Aged,N,
25941,DescriptorName,D011041,672731,,,8,Poisoning,N,
25942,QualifierName,Q000097,672731,,,8,,N,blood
25943,Chemical,D000700,6731466,Analgesics,0,,,,
25944,Chemical,D011758,6731466,Pyrroles,0,,,,
25945,Chemical,D007073,6731466,Immunoglobulin E,37341-29-0,,,,
25946,Chemical,C020549,6731466,zomepirac,822G987U9J,,,,
25947,Chemical,D014046,6731466,Tolmetin,D8K2JPN18B,,,,
25948,DescriptorName,D000700,6731466,,,1,Analgesics,N,
25949,QualifierName,Q000009,6731466,,,1,,Y,adverse effects
25950,DescriptorName,D000707,6731466,,,2,Anaphylaxis,N,
25951,QualifierName,Q000139,6731466,,,2,,Y,chemically induced
25952,DescriptorName,D005260,6731466,,,3,Female,N,
25953,DescriptorName,D006801,6731466,,,4,Humans,N,
25954,DescriptorName,D007073,6731466,,,5,Immunoglobulin E,N,
25955,QualifierName,Q000032,6731466,,,5,,N,analysis
25956,DescriptorName,D007672,6731466,,,6,Kidney Cortex,N,
25957,QualifierName,Q000473,6731466,,,6,,N,pathology
25958,DescriptorName,D007673,6731466,,,7,Kidney Cortex Necrosis,N,
25959,QualifierName,Q000139,6731466,,,7,,Y,chemically induced
25960,DescriptorName,D008213,6731466,,,8,Lymphocyte Activation,N,
25961,DescriptorName,D008875,6731466,,,9,Middle Aged,N,
25962,DescriptorName,D011758,6731466,,,10,Pyrroles,N,
25963,QualifierName,Q000009,6731466,,,10,,Y,adverse effects
25964,DescriptorName,D014046,6731466,,,11,Tolmetin,N,
25965,QualifierName,Q000009,6731466,,,11,,Y,adverse effects
25966,DescriptorName,D014098,6731466,,,12,Toothache,N,
25967,QualifierName,Q000188,6731466,,,12,,N,drug therapy
25968,Chemical,D002927,6733633,Cimetidine,80061L1WGD,,,,
25969,DescriptorName,D000284,6733633,,,1,"Administration, Oral",N,
25970,DescriptorName,D000368,6733633,,,2,Aged,N,
25971,DescriptorName,D002927,6733633,,,3,Cimetidine,N,
25972,QualifierName,Q000008,6733633,,,3,,N,administration & dosage
25973,DescriptorName,D004381,6733633,,,4,Duodenal Ulcer,N,
25974,QualifierName,Q000188,6733633,,,4,,N,drug therapy
25975,DescriptorName,D005260,6733633,,,5,Female,N,
25976,DescriptorName,D005334,6733633,,,6,Fever,N,
25977,QualifierName,Q000139,6733633,,,6,,Y,chemically induced
25978,DescriptorName,D006801,6733633,,,7,Humans,N,
25979,Chemical,D000978,6738830,Antiparkinson Agents,0,,,,
25980,Chemical,D010879,6738830,Piperazines,0,,,,
25981,Chemical,D014665,6738830,Vasodilator Agents,0,,,,
25982,Chemical,C026896,6738830,cinepazide,67Y4P5C84X,,,,
25983,DescriptorName,D000978,6738830,,,1,Antiparkinson Agents,Y,
25984,DescriptorName,D006801,6738830,,,2,Humans,N,
25985,DescriptorName,D008297,6738830,,,3,Male,N,
25986,DescriptorName,D001523,6738830,,,4,Mental Disorders,N,
25987,QualifierName,Q000139,6738830,,,4,,Y,chemically induced
25988,DescriptorName,D008875,6738830,,,5,Middle Aged,N,
25989,DescriptorName,D010300,6738830,,,6,Parkinson Disease,N,
25990,QualifierName,Q000188,6738830,,,6,,Y,drug therapy
25991,DescriptorName,D010879,6738830,,,7,Piperazines,N,
25992,QualifierName,Q000009,6738830,,,7,,Y,adverse effects
25993,DescriptorName,D012725,6738830,,,8,Sexual Behavior,N,
25994,QualifierName,Q000187,6738830,,,8,,Y,drug effects
25995,DescriptorName,D014665,6738830,,,9,Vasodilator Agents,N,
25996,QualifierName,Q000009,6738830,,,9,,Y,adverse effects
25997,Chemical,D000863,6744146,Antacids,0,,,,
25998,Chemical,D000536,6744146,Aluminum Hydroxide,5QB0T2IUN0,,,,
25999,DescriptorName,D058186,6744146,,,1,Acute Kidney Injury,N,
26000,QualifierName,Q000188,6744146,,,1,,N,drug therapy
26001,DescriptorName,D000368,6744146,,,2,Aged,N,
26002,DescriptorName,D000536,6744146,,,3,Aluminum Hydroxide,N,
26003,QualifierName,Q000009,6744146,,,3,,Y,adverse effects
26004,DescriptorName,D000863,6744146,,,4,Antacids,N,
26005,QualifierName,Q000009,6744146,,,4,,Y,adverse effects
26006,DescriptorName,D001630,6744146,,,5,Bezoars,N,
26007,QualifierName,Q000209,6744146,,,5,,Y,etiology
26008,DescriptorName,D005260,6744146,,,6,Female,N,
26009,DescriptorName,D006801,6744146,,,7,Humans,N,
26010,DescriptorName,D007415,6744146,,,8,Intestinal Obstruction,N,
26011,QualifierName,Q000209,6744146,,,8,,Y,etiology
26012,DescriptorName,D007421,6744146,,,9,"Intestine, Small",Y,
26013,DescriptorName,D012772,6744146,,,10,"Shock, Septic",N,
26014,QualifierName,Q000150,6744146,,,10,,N,complications
26015,Chemical,D010672,6766717,Phenytoin,6158TKW0C5,,,,
26016,DescriptorName,D000437,6766717,,,1,Alcoholism,N,
26017,QualifierName,Q000150,6766717,,,1,,N,complications
26018,DescriptorName,D002524,6766717,,,2,Cerebellar Ataxia,N,
26019,QualifierName,Q000139,6766717,,,2,,N,chemically induced
26020,DescriptorName,D004834,6766717,,,3,"Epilepsy, Post-Traumatic",N,
26021,QualifierName,Q000188,6766717,,,3,,N,drug therapy
26022,DescriptorName,D006801,6766717,,,4,Humans,N,
26023,DescriptorName,D008297,6766717,,,5,Male,N,
26024,DescriptorName,D008875,6766717,,,6,Middle Aged,N,
26025,DescriptorName,D009759,6766717,,,7,"Nystagmus, Pathologic",N,
26026,QualifierName,Q000139,6766717,,,7,,Y,chemically induced
26027,DescriptorName,D010672,6766717,,,8,Phenytoin,N,
26028,QualifierName,Q000506,6766717,,,8,,Y,poisoning
26029,Chemical,D006052,6788011,Gold Sodium Thiomalate,12244-57-4,,,,
26030,DescriptorName,D000328,6788011,,,1,Adult,N,
26031,DescriptorName,D001172,6788011,,,2,"Arthritis, Rheumatoid",N,
26032,QualifierName,Q000188,6788011,,,2,,N,drug therapy
26033,DescriptorName,D004577,6788011,,,3,Electron Probe Microanalysis,N,
26034,DescriptorName,D005260,6788011,,,4,Female,N,
26035,DescriptorName,D005455,6788011,,,5,Fluorescent Antibody Technique,N,
26036,DescriptorName,D006052,6788011,,,6,Gold Sodium Thiomalate,N,
26037,QualifierName,Q000009,6788011,,,6,,Y,adverse effects
26038,DescriptorName,D006801,6788011,,,7,Humans,N,
26039,DescriptorName,D007684,6788011,,,8,Kidney Tubules,N,
26040,QualifierName,Q000032,6788011,,,8,,N,analysis
26041,DescriptorName,D009404,6788011,,,9,Nephrotic Syndrome,N,
26042,QualifierName,Q000139,6788011,,,9,,Y,chemically induced
26043,DescriptorName,D011859,6788011,,,10,Radiography,N,
26044,Chemical,D005905,6794018,Glyburide,SX6K58TVWC,,,,
26045,DescriptorName,D001768,6794018,,,1,Blister,N,
26046,QualifierName,Q000139,6794018,,,1,,Y,chemically induced
26047,DescriptorName,D002780,6794018,,,2,"Cholestasis, Intrahepatic",N,
26048,QualifierName,Q000139,6794018,,,2,,Y,chemically induced
26049,DescriptorName,D003920,6794018,,,3,Diabetes Mellitus,N,
26050,QualifierName,Q000188,6794018,,,3,,N,drug therapy
26051,DescriptorName,D005905,6794018,,,4,Glyburide,N,
26052,QualifierName,Q000009,6794018,,,4,,Y,adverse effects
26053,DescriptorName,D006801,6794018,,,5,Humans,N,
26054,DescriptorName,D008297,6794018,,,6,Male,N,
26055,DescriptorName,D008875,6794018,,,7,Middle Aged,N,
26056,Chemical,D005996,6797753,Nitroglycerin,G59M7S0WS3,,,,
26057,Chemical,D004874,6797753,Ergonovine,WH41D8433D,,,,
26058,DescriptorName,D000328,6797753,,,1,Adult,N,
26059,DescriptorName,D000787,6797753,,,2,Angina Pectoris,N,
26060,QualifierName,Q000188,6797753,,,2,,Y,drug therapy
26061,DescriptorName,D000788,6797753,,,3,"Angina Pectoris, Variant",N,
26062,QualifierName,Q000188,6797753,,,3,,Y,drug therapy
26063,DescriptorName,D003329,6797753,,,4,Coronary Vasospasm,N,
26064,QualifierName,Q000139,6797753,,,4,,N,chemically induced
26065,DescriptorName,D003331,6797753,,,5,Coronary Vessels,N,
26066,DescriptorName,D004874,6797753,,,6,Ergonovine,N,
26067,QualifierName,Q000009,6797753,,,6,,N,adverse effects
26068,DescriptorName,D006801,6797753,,,7,Humans,N,
26069,DescriptorName,D007267,6797753,,,8,Injections,N,
26070,DescriptorName,D008297,6797753,,,9,Male,N,
26071,DescriptorName,D008875,6797753,,,10,Middle Aged,N,
26072,DescriptorName,D005996,6797753,,,11,Nitroglycerin,N,
26073,QualifierName,Q000627,6797753,,,11,,Y,therapeutic use
26074,DescriptorName,D014693,6797753,,,12,Ventricular Fibrillation,N,
26075,QualifierName,Q000150,6797753,,,12,,N,complications
26076,Chemical,D011433,6810714,Propranolol,9Y8NXQ24VQ,,,,
26077,Chemical,D002746,6810714,Chlorpromazine,U42B7VYA4P,,,,
26078,DescriptorName,D000328,6810714,,,1,Adult,N,
26079,DescriptorName,D002746,6810714,,,2,Chlorpromazine,N,
26080,QualifierName,Q000009,6810714,,,2,,Y,adverse effects
26081,DescriptorName,D003693,6810714,,,3,Delirium,N,
26082,QualifierName,Q000139,6810714,,,3,,Y,chemically induced
26083,DescriptorName,D004359,6810714,,,4,"Drug Therapy, Combination",N,
26084,DescriptorName,D004830,6810714,,,5,"Epilepsy, Tonic-Clonic",N,
26085,QualifierName,Q000139,6810714,,,5,,N,chemically induced
26086,DescriptorName,D005260,6810714,,,6,Female,N,
26087,DescriptorName,D006801,6810714,,,7,Humans,N,
26088,DescriptorName,D010787,6810714,,,8,Photosensitivity Disorders,N,
26089,QualifierName,Q000139,6810714,,,8,,N,chemically induced
26090,DescriptorName,D011433,6810714,,,9,Propranolol,N,
26091,QualifierName,Q000009,6810714,,,9,,Y,adverse effects
26092,DescriptorName,D011605,6810714,,,10,"Psychoses, Substance-Induced",N,
26093,QualifierName,Q000209,6810714,,,10,,N,etiology
26094,DescriptorName,D012563,6810714,,,11,"Schizophrenia, Paranoid",N,
26095,QualifierName,Q000188,6810714,,,11,,N,drug therapy
26096,Chemical,D004221,681921,Disulfiram,TR3MLJ1UAI,,,,
26097,DescriptorName,D000437,681921,,,1,Alcoholism,N,
26098,QualifierName,Q000188,681921,,,1,,N,drug therapy
26099,DescriptorName,D002389,681921,,,2,Catatonia,N,
26100,QualifierName,Q000139,681921,,,2,,Y,chemically induced
26101,DescriptorName,D004221,681921,,,3,Disulfiram,N,
26102,QualifierName,Q000009,681921,,,3,,Y,adverse effects
26103,DescriptorName,D006801,681921,,,4,Humans,N,
26104,DescriptorName,D008297,681921,,,5,Male,N,
26105,DescriptorName,D008875,681921,,,6,Middle Aged,N,
26106,Chemical,D003408,6826112,Cresols,0,,,,
26107,Chemical,D003506,6826112,Cyclofenil,J468V64WZ1,,,,
26108,DescriptorName,D000328,6826112,,,1,Adult,N,
26109,DescriptorName,D056486,6826112,,,2,Chemical and Drug Induced Liver Injury,Y,
26110,DescriptorName,D003408,6826112,,,3,Cresols,N,
26111,QualifierName,Q000009,6826112,,,3,,Y,adverse effects
26112,DescriptorName,D003506,6826112,,,4,Cyclofenil,N,
26113,QualifierName,Q000009,6826112,,,4,,Y,adverse effects
26114,DescriptorName,D005260,6826112,,,5,Female,N,
26115,DescriptorName,D006801,6826112,,,6,Humans,N,
26116,DescriptorName,D008099,6826112,,,7,Liver,N,
26117,QualifierName,Q000201,6826112,,,7,,N,enzymology
26118,DescriptorName,D008107,6826112,,,8,Liver Diseases,N,
26119,QualifierName,Q000201,6826112,,,8,,N,enzymology
26120,DescriptorName,D012595,6826112,,,9,"Scleroderma, Systemic",N,
26121,QualifierName,Q000188,6826112,,,9,,N,drug therapy
26122,Chemical,D002927,6830388,Cimetidine,80061L1WGD,,,,
26123,Chemical,D013806,6830388,Theophylline,C137DTR5RG,,,,
26124,DescriptorName,D000368,6830388,,,1,Aged,N,
26125,DescriptorName,D002927,6830388,,,2,Cimetidine,N,
26126,QualifierName,Q000009,6830388,,,2,,N,adverse effects
26127,DescriptorName,D004334,6830388,,,3,Drug Administration Schedule,N,
26128,DescriptorName,D004347,6830388,,,4,Drug Interactions,N,
26129,DescriptorName,D006801,6830388,,,5,Humans,N,
26130,DescriptorName,D008297,6830388,,,6,Male,N,
26131,DescriptorName,D010437,6830388,,,7,Peptic Ulcer,N,
26132,QualifierName,Q000188,6830388,,,7,,N,drug therapy
26133,DescriptorName,D013806,6830388,,,8,Theophylline,N,
26134,QualifierName,Q000008,6830388,,,8,,N,administration & dosage
26135,Chemical,D003891,6833205,Desipramine,TG537D343B,,,,
26136,DescriptorName,D000368,6833205,,,1,Aged,N,
26137,DescriptorName,D003866,6833205,,,2,Depressive Disorder,N,
26138,QualifierName,Q000188,6833205,,,2,,Y,drug therapy
26139,DescriptorName,D003891,6833205,,,3,Desipramine,N,
26140,QualifierName,Q000009,6833205,,,3,,Y,adverse effects
26141,DescriptorName,D005260,6833205,,,4,Female,N,
26142,DescriptorName,D006801,6833205,,,5,Humans,N,
26143,DescriptorName,D007177,6833205,,,6,Inappropriate ADH Syndrome,N,
26144,QualifierName,Q000139,6833205,,,6,,Y,chemically induced
26145,Chemical,D007538,6837655,Isoniazid,V83O1VOZ8L,,,,
26146,Chemical,D012293,6837655,Rifampin,VJT6J7R4TR,,,,
26147,DescriptorName,D058186,6837655,,,1,Acute Kidney Injury,N,
26148,QualifierName,Q000139,6837655,,,1,,N,chemically induced
26149,DescriptorName,D005921,6837655,,,2,Glomerulonephritis,N,
26150,QualifierName,Q000139,6837655,,,2,,Y,chemically induced
26151,DescriptorName,D006801,6837655,,,3,Humans,N,
26152,DescriptorName,D007538,6837655,,,4,Isoniazid,N,
26153,QualifierName,Q000009,6837655,,,4,,N,adverse effects
26154,DescriptorName,D007668,6837655,,,5,Kidney,N,
26155,QualifierName,Q000473,6837655,,,5,,N,pathology
26156,DescriptorName,D008297,6837655,,,6,Male,N,
26157,DescriptorName,D008875,6837655,,,7,Middle Aged,N,
26158,DescriptorName,D012293,6837655,,,8,Rifampin,N,
26159,QualifierName,Q000009,6837655,,,8,,Y,adverse effects
26160,DescriptorName,D014397,6837655,,,9,"Tuberculosis, Pulmonary",N,
26161,QualifierName,Q000188,6837655,,,9,,Y,drug therapy
26162,Chemical,D011758,6851259,Pyrroles,0,,,,
26163,Chemical,D014046,6851259,Tolmetin,D8K2JPN18B,,,,
26164,DescriptorName,D005189,6851259,,,1,False Positive Reactions,N,
26165,DescriptorName,D005260,6851259,,,2,Female,N,
26166,DescriptorName,D006801,6851259,,,3,Humans,N,
26167,DescriptorName,D008180,6851259,,,4,"Lupus Erythematosus, Systemic",N,
26168,QualifierName,Q000188,6851259,,,4,,N,drug therapy
26169,DescriptorName,D008875,6851259,,,5,Middle Aged,N,
26170,DescriptorName,D009404,6851259,,,6,Nephrotic Syndrome,N,
26171,QualifierName,Q000139,6851259,,,6,,N,chemically induced
26172,DescriptorName,D011233,6851259,,,7,Precipitin Tests,N,
26173,DescriptorName,D011507,6851259,,,8,Proteinuria,N,
26174,QualifierName,Q000139,6851259,,,8,,Y,chemically induced
26175,DescriptorName,D011758,6851259,,,9,Pyrroles,N,
26176,QualifierName,Q000009,6851259,,,9,,Y,adverse effects
26177,DescriptorName,D014046,6851259,,,10,Tolmetin,N,
26178,QualifierName,Q000009,6851259,,,10,,Y,adverse effects
26179,Chemical,D006632,6854698,Histamine,820484N8I3,,,,
26180,Chemical,D007538,6854698,Isoniazid,V83O1VOZ8L,,,,
26181,DescriptorName,D000328,6854698,,,1,Adult,N,
26182,DescriptorName,D000818,6854698,,,2,Animals,N,
26183,DescriptorName,D005260,6854698,,,3,Female,N,
26184,DescriptorName,D005396,6854698,,,4,Fish Products,N,
26185,QualifierName,Q000009,6854698,,,4,,Y,adverse effects
26186,DescriptorName,D006632,6854698,,,5,Histamine,N,
26187,QualifierName,Q000506,6854698,,,5,,Y,poisoning
26188,DescriptorName,D006801,6854698,,,6,Humans,N,
26189,DescriptorName,D007538,6854698,,,7,Isoniazid,N,
26190,QualifierName,Q000009,6854698,,,7,,Y,adverse effects
26191,DescriptorName,D008875,6854698,,,8,Middle Aged,N,
26192,DescriptorName,D014397,6854698,,,9,"Tuberculosis, Pulmonary",N,
26193,QualifierName,Q000188,6854698,,,9,,N,drug therapy
26194,DescriptorName,D014413,6854698,,,10,Tuna,N,
26195,Chemical,D004221,6860059,Disulfiram,TR3MLJ1UAI,,,,
26196,DescriptorName,D000208,6860059,,,1,Acute Disease,N,
26197,DescriptorName,D000328,6860059,,,2,Adult,N,
26198,DescriptorName,D000437,6860059,,,3,Alcoholism,N,
26199,QualifierName,Q000188,6860059,,,3,,N,drug therapy
26200,DescriptorName,D056486,6860059,,,4,Chemical and Drug Induced Liver Injury,N,
26201,QualifierName,Q000209,6860059,,,4,,Y,etiology
26202,DescriptorName,D004221,6860059,,,5,Disulfiram,N,
26203,QualifierName,Q000009,6860059,,,5,,Y,adverse effects
26204,DescriptorName,D006801,6860059,,,6,Humans,N,
26205,DescriptorName,D008099,6860059,,,7,Liver,N,
26206,QualifierName,Q000473,6860059,,,7,,N,pathology
26207,DescriptorName,D008297,6860059,,,8,Male,N,
26208,DescriptorName,D009336,6860059,,,9,Necrosis,N,
26209,Chemical,D008713,6865827,Methimazole,554Z48XN5E,,,,
26210,Chemical,D011441,6865827,Propylthiouracil,721M9407IY,,,,
26211,DescriptorName,D000380,6865827,,,1,Agranulocytosis,N,
26212,QualifierName,Q000139,6865827,,,1,,Y,chemically induced
26213,DescriptorName,D005260,6865827,,,2,Female,N,
26214,DescriptorName,D006801,6865827,,,3,Humans,N,
26215,DescriptorName,D006980,6865827,,,4,Hyperthyroidism,N,
26216,QualifierName,Q000188,6865827,,,4,,N,drug therapy
26217,DescriptorName,D008713,6865827,,,5,Methimazole,N,
26218,QualifierName,Q000009,6865827,,,5,,Y,adverse effects
26219,DescriptorName,D008875,6865827,,,6,Middle Aged,N,
26220,DescriptorName,D011441,6865827,,,7,Propylthiouracil,N,
26221,QualifierName,Q000009,6865827,,,7,,Y,adverse effects
26222,DescriptorName,D012008,6865827,,,8,Recurrence,N,
26223,Chemical,D013827,6873616,Thiabendazole,N1Q45E87DT,,,,
26224,DescriptorName,D001706,6873616,,,1,Biopsy,N,
26225,DescriptorName,D002760,6873616,,,2,"Cholangiopancreatography, Endoscopic Retrograde",N,
26226,DescriptorName,D002780,6873616,,,3,"Cholestasis, Intrahepatic",N,
26227,QualifierName,Q000139,6873616,,,3,,Y,chemically induced
26228,DescriptorName,D006801,6873616,,,4,Humans,N,
26229,DescriptorName,D008099,6873616,,,5,Liver,N,
26230,QualifierName,Q000473,6873616,,,5,,N,pathology
26231,DescriptorName,D008297,6873616,,,6,Male,N,
26232,DescriptorName,D008875,6873616,,,7,Middle Aged,N,
26233,DescriptorName,D012859,6873616,,,8,Sjogren's Syndrome,N,
26234,QualifierName,Q000139,6873616,,,8,,Y,chemically induced
26235,DescriptorName,D013322,6873616,,,9,Strongyloidiasis,N,
26236,QualifierName,Q000188,6873616,,,9,,N,drug therapy
26237,DescriptorName,D013827,6873616,,,10,Thiabendazole,N,
26238,QualifierName,Q000009,6873616,,,10,,Y,adverse effects
26239,DescriptorName,D013997,6873616,,,11,Time Factors,N,
26240,Chemical,D004317,6928097,Doxorubicin,80168379AG,,,,
26241,DescriptorName,D000328,6928097,,,1,Adult,N,
26242,DescriptorName,D004317,6928097,,,2,Doxorubicin,N,
26243,QualifierName,Q000009,6928097,,,2,,N,adverse effects
26244,DescriptorName,D005260,6928097,,,3,Female,N,
26245,DescriptorName,D006338,6928097,,,4,Heart Neoplasms,N,
26246,QualifierName,Q000188,6928097,,,4,,N,drug therapy
26247,DescriptorName,D006352,6928097,,,5,Heart Ventricles,N,
26248,DescriptorName,D006801,6928097,,,6,Humans,N,
26249,DescriptorName,D012516,6928097,,,7,Osteosarcoma,N,
26250,QualifierName,Q000188,6928097,,,7,,N,drug therapy
26251,Chemical,D014750,6933231,Vincristine,5J49Q6B70F,,,,
26252,Chemical,D001215,6933231,Asparaginase,EC 3.5.1.1,,,,
26253,Chemical,D011241,6933231,Prednisone,VB0R961HZT,,,,
26254,DescriptorName,D000347,6933231,,,1,Afibrinogenemia,N,
26255,QualifierName,Q000139,6933231,,,1,,N,chemically induced
26256,DescriptorName,D001215,6933231,,,2,Asparaginase,N,
26257,QualifierName,Q000009,6933231,,,2,,Y,adverse effects
26258,DescriptorName,D001778,6933231,,,3,Blood Coagulation Disorders,N,
26259,QualifierName,Q000139,6933231,,,3,,N,chemically induced
26260,DescriptorName,D002543,6933231,,,4,Cerebral Hemorrhage,N,
26261,QualifierName,Q000139,6933231,,,4,,Y,chemically induced
26262,DescriptorName,D002675,6933231,,,5,"Child, Preschool",N,
26263,DescriptorName,D004359,6933231,,,6,"Drug Therapy, Combination",N,
26264,DescriptorName,D005260,6933231,,,7,Female,N,
26265,DescriptorName,D006429,6933231,,,8,Hemiplegia,N,
26266,QualifierName,Q000139,6933231,,,8,,N,chemically induced
26267,DescriptorName,D006801,6933231,,,9,Humans,N,
26268,DescriptorName,D007945,6933231,,,10,"Leukemia, Lymphoid",N,
26269,QualifierName,Q000188,6933231,,,10,,Y,drug therapy
26270,DescriptorName,D008297,6933231,,,11,Male,N,
26271,DescriptorName,D011241,6933231,,,12,Prednisone,N,
26272,QualifierName,Q000008,6933231,,,12,,N,administration & dosage
26273,DescriptorName,D012640,6933231,,,13,Seizures,N,
26274,QualifierName,Q000139,6933231,,,13,,Y,chemically induced
26275,DescriptorName,D014750,6933231,,,14,Vincristine,N,
26276,QualifierName,Q000008,6933231,,,14,,N,administration & dosage
26277,Chemical,D006493,6947095,Heparin,9005-49-6,,,,
26278,Chemical,D001215,6947095,Asparaginase,EC 3.5.1.1,,,,
26279,DescriptorName,D000367,6947095,,,1,Age Factors,N,
26280,DescriptorName,D020152,6947095,,,2,Antithrombin III Deficiency,N,
26281,DescriptorName,D001215,6947095,,,3,Asparaginase,N,
26282,QualifierName,Q000009,6947095,,,3,,Y,adverse effects
26283,DescriptorName,D001778,6947095,,,4,Blood Coagulation Disorders,N,
26284,QualifierName,Q000139,6947095,,,4,,Y,chemically induced
26285,DescriptorName,D002648,6947095,,,5,Child,N,
26286,DescriptorName,D002675,6947095,,,6,"Child, Preschool",N,
26287,DescriptorName,D004359,6947095,,,7,"Drug Therapy, Combination",N,
26288,DescriptorName,D006493,6947095,,,8,Heparin,N,
26289,QualifierName,Q000627,6947095,,,8,,N,therapeutic use
26290,DescriptorName,D006801,6947095,,,9,Humans,N,
26291,DescriptorName,D007945,6947095,,,10,"Leukemia, Lymphoid",N,
26292,QualifierName,Q000188,6947095,,,10,,Y,drug therapy
26293,DescriptorName,D008297,6947095,,,11,Male,N,
26294,DescriptorName,D012851,6947095,,,12,"Sinus Thrombosis, Intracranial",N,
26295,QualifierName,Q000209,6947095,,,12,,Y,etiology
26296,Chemical,D006680,6958210,HLA Antigens,0,,,,
26297,Chemical,D000949,6958210,Histocompatibility Antigens Class II,0,,,,
26298,Chemical,D010396,6958210,Penicillamine,GNN1DV99GX,,,,
26299,DescriptorName,D000328,6958210,,,1,Adult,N,
26300,DescriptorName,D000368,6958210,,,2,Aged,N,
26301,DescriptorName,D001172,6958210,,,3,"Arthritis, Rheumatoid",N,
26302,QualifierName,Q000188,6958210,,,3,,Y,drug therapy
26303,DescriptorName,D004342,6958210,,,4,Drug Hypersensitivity,N,
26304,QualifierName,Q000209,6958210,,,4,,N,etiology
26305,DescriptorName,D005260,6958210,,,5,Female,N,
26306,DescriptorName,D006680,6958210,,,6,HLA Antigens,N,
26307,QualifierName,Q000032,6958210,,,6,,N,analysis
26308,DescriptorName,D000949,6958210,,,7,Histocompatibility Antigens Class II,N,
26309,QualifierName,Q000032,6958210,,,7,,N,analysis
26310,DescriptorName,D006801,6958210,,,8,Humans,N,
26311,DescriptorName,D008180,6958210,,,9,"Lupus Erythematosus, Systemic",N,
26312,QualifierName,Q000139,6958210,,,9,,Y,chemically induced
26313,DescriptorName,D008875,6958210,,,10,Middle Aged,N,
26314,DescriptorName,D010396,6958210,,,11,Penicillamine,N,
26315,QualifierName,Q000009,6958210,,,11,,Y,adverse effects
26316,Chemical,D006889,6987607,Hydroxycorticosteroids,0,,,,
26317,Chemical,D013148,6987607,Spironolactone,27O7W4T232,,,,
26318,Chemical,D000450,6987607,Aldosterone,4964P6T9RB,,,,
26319,Chemical,D003907,6987607,Dexamethasone,7S5I7G3JQL,,,,
26320,Chemical,D012083,6987607,Renin,EC 3.4.23.15,,,,
26321,Chemical,D011188,6987607,Potassium,RWP5GA015D,,,,
26322,DescriptorName,D000328,6987607,,,1,Adult,N,
26323,DescriptorName,D000450,6987607,,,2,Aldosterone,N,
26324,QualifierName,Q000097,6987607,,,2,,N,blood
26325,DescriptorName,D002648,6987607,,,3,Child,N,
26326,DescriptorName,D002940,6987607,,,4,Circadian Rhythm,N,
26327,DescriptorName,D003907,6987607,,,5,Dexamethasone,N,
26328,QualifierName,Q000627,6987607,,,5,,Y,therapeutic use
26329,DescriptorName,D006801,6987607,,,6,Humans,N,
26330,DescriptorName,D006889,6987607,,,7,Hydroxycorticosteroids,N,
26331,QualifierName,Q000652,6987607,,,7,,N,urine
26332,DescriptorName,D006929,6987607,,,8,Hyperaldosteronism,N,
26333,QualifierName,Q000188,6987607,,,8,,N,drug therapy
26334,DescriptorName,D008297,6987607,,,9,Male,N,
26335,DescriptorName,D011188,6987607,,,10,Potassium,N,
26336,QualifierName,Q000097,6987607,,,10,,N,blood
26337,DescriptorName,D012083,6987607,,,11,Renin,N,
26338,QualifierName,Q000097,6987607,,,11,,N,blood
26339,DescriptorName,D013148,6987607,,,12,Spironolactone,N,
26340,QualifierName,Q000009,6987607,,,12,,N,adverse effects
26341,Chemical,D007328,6998294,Insulin,0,,,,
26342,Chemical,D011725,6998294,Pyridines,0,,,,
26343,Chemical,D005934,6998294,Glucagon,9007-92-5,,,,
26344,Chemical,D004206,6998294,Disopyramide,GFO928U8MQ,,,,
26345,Chemical,D000409,6998294,Alanine,OF5P57N2ZX,,,,
26346,DescriptorName,D000368,6998294,,,1,Aged,N,
26347,DescriptorName,D000409,6998294,,,2,Alanine,N,
26348,QualifierName,Q000378,6998294,,,2,,N,metabolism
26349,DescriptorName,D001282,6998294,,,3,Atrial Flutter,N,
26350,QualifierName,Q000188,6998294,,,3,,N,drug therapy
26351,DescriptorName,D004206,6998294,,,4,Disopyramide,N,
26352,QualifierName,Q000009,6998294,,,4,,Y,adverse effects
26353,DescriptorName,D005260,6998294,,,5,Female,N,
26354,DescriptorName,D005934,6998294,,,6,Glucagon,N,
26355,DescriptorName,D005943,6998294,,,7,Gluconeogenesis,N,
26356,QualifierName,Q000187,6998294,,,7,,N,drug effects
26357,DescriptorName,D005951,6998294,,,8,Glucose Tolerance Test,N,
26358,DescriptorName,D006801,6998294,,,9,Humans,N,
26359,DescriptorName,D007003,6998294,,,10,Hypoglycemia,N,
26360,QualifierName,Q000139,6998294,,,10,,Y,chemically induced
26361,DescriptorName,D007328,6998294,,,11,Insulin,N,
26362,QualifierName,Q000378,6998294,,,11,,N,metabolism
26363,DescriptorName,D011725,6998294,,,12,Pyridines,N,
26364,QualifierName,Q000009,6998294,,,12,,Y,adverse effects
26365,Chemical,D000617,7019786,Aminoglycosides,0,,,,
26366,Chemical,D005839,7019786,Gentamicins,0,,,,
26367,Chemical,D002440,7019786,Cefoxitin,6OEV9DX57Y,,,,
26368,Chemical,D014508,7019786,Urea,8W8T17847W,,,,
26369,Chemical,D003404,7019786,Creatinine,AYI8EX34EU,,,,
26370,DescriptorName,D058186,7019786,,,1,Acute Kidney Injury,N,
26371,QualifierName,Q000139,7019786,,,1,,Y,chemically induced
26372,DescriptorName,D000368,7019786,,,2,Aged,N,
26373,DescriptorName,D000617,7019786,,,3,Aminoglycosides,N,
26374,QualifierName,Q000009,7019786,,,3,,N,adverse effects
26375,DescriptorName,D001172,7019786,,,4,"Arthritis, Rheumatoid",N,
26376,QualifierName,Q000188,7019786,,,4,,N,drug therapy
26377,DescriptorName,D002440,7019786,,,5,Cefoxitin,N,
26378,QualifierName,Q000008,7019786,,,5,,N,administration & dosage
26379,DescriptorName,D003404,7019786,,,6,Creatinine,N,
26380,QualifierName,Q000097,7019786,,,6,,N,blood
26381,DescriptorName,D004927,7019786,,,7,Escherichia coli Infections,N,
26382,QualifierName,Q000188,7019786,,,7,,N,drug therapy
26383,DescriptorName,D005260,7019786,,,8,Female,N,
26384,DescriptorName,D005839,7019786,,,9,Gentamicins,N,
26385,QualifierName,Q000009,7019786,,,9,,N,adverse effects
26386,DescriptorName,D006801,7019786,,,10,Humans,N,
26387,DescriptorName,D007668,7019786,,,11,Kidney,N,
26388,QualifierName,Q000503,7019786,,,11,,N,physiopathology
26389,DescriptorName,D014508,7019786,,,12,Urea,N,
26390,QualifierName,Q000097,7019786,,,12,,N,blood
26391,DescriptorName,D014552,7019786,,,13,Urinary Tract Infections,N,
26392,QualifierName,Q000188,7019786,,,13,,N,drug therapy
26393,Chemical,D011392,7035691,Proline,9DLQ4CIU6V,,,,
26394,Chemical,D002216,7035691,Captopril,9G64RSX1XD,,,,
26395,DescriptorName,D000328,7035691,,,1,Adult,N,
26396,DescriptorName,D001002,7035691,,,2,Anuria,N,
26397,QualifierName,Q000209,7035691,,,2,,Y,etiology
26398,DescriptorName,D002216,7035691,,,3,Captopril,N,
26399,QualifierName,Q000009,7035691,,,3,,Y,adverse effects
26400,DescriptorName,D006801,7035691,,,4,Humans,N,
26401,DescriptorName,D006973,7035691,,,5,Hypertension,N,
26402,QualifierName,Q000188,7035691,,,5,,N,drug therapy
26403,DescriptorName,D016030,7035691,,,6,Kidney Transplantation,Y,
26404,DescriptorName,D008297,7035691,,,7,Male,N,
26405,DescriptorName,D011392,7035691,,,8,Proline,N,
26406,QualifierName,Q000031,7035691,,,8,,Y,analogs & derivatives
26407,DescriptorName,D012078,7035691,,,9,Renal Artery Obstruction,N,
26408,QualifierName,Q000188,7035691,,,9,,Y,drug therapy
26409,DescriptorName,D013997,7035691,,,10,Time Factors,N,
26410,Chemical,D001572,7056119,Benzofurans,0,,,,
26411,Chemical,D011725,7056119,Pyridines,0,,,,
26412,Chemical,D011219,7056119,Prajmaline,75934UD4GJ,,,,
26413,Chemical,D004206,7056119,Disopyramide,GFO928U8MQ,,,,
26414,Chemical,D011802,7056119,Quinidine,ITX08688JL,,,,
26415,Chemical,D000638,7056119,Amiodarone,N3RQ532IUT,,,,
26416,DescriptorName,D000328,7056119,,,1,Adult,N,
26417,DescriptorName,D000638,7056119,,,2,Amiodarone,N,
26418,QualifierName,Q000009,7056119,,,2,,Y,adverse effects
26419,DescriptorName,D001281,7056119,,,3,Atrial Fibrillation,N,
26420,QualifierName,Q000188,7056119,,,3,,N,drug therapy
26421,DescriptorName,D001572,7056119,,,4,Benzofurans,N,
26422,QualifierName,Q000009,7056119,,,4,,Y,adverse effects
26423,DescriptorName,D004206,7056119,,,5,Disopyramide,N,
26424,QualifierName,Q000009,7056119,,,5,,Y,adverse effects
26425,DescriptorName,D004305,7056119,,,6,"Dose-Response Relationship, Drug",N,
26426,DescriptorName,D004562,7056119,,,7,Electrocardiography,N,
26427,DescriptorName,D005260,7056119,,,8,Female,N,
26428,DescriptorName,D006352,7056119,,,9,Heart Ventricles,N,
26429,DescriptorName,D006801,7056119,,,10,Humans,N,
26430,DescriptorName,D011219,7056119,,,11,Prajmaline,N,
26431,QualifierName,Q000627,7056119,,,11,,N,therapeutic use
26432,DescriptorName,D011725,7056119,,,12,Pyridines,N,
26433,QualifierName,Q000009,7056119,,,12,,Y,adverse effects
26434,DescriptorName,D011802,7056119,,,13,Quinidine,N,
26435,QualifierName,Q000009,7056119,,,13,,Y,adverse effects
26436,DescriptorName,D013610,7056119,,,14,Tachycardia,N,
26437,QualifierName,Q000139,7056119,,,14,,Y,chemically induced
26438,Chemical,D004298,7067510,Dopamine,VTD58H1Z2X,,,,
26439,DescriptorName,D000328,7067510,,,1,Adult,N,
26440,DescriptorName,D002764,7067510,,,2,Cholecystitis,N,
26441,QualifierName,Q000150,7067510,,,2,,N,complications
26442,DescriptorName,D004298,7067510,,,3,Dopamine,N,
26443,QualifierName,Q000008,7067510,,,3,,N,administration & dosage
26444,DescriptorName,D004562,7067510,,,4,Electrocardiography,N,
26445,DescriptorName,D005260,7067510,,,5,Female,N,
26446,DescriptorName,D006321,7067510,,,6,Heart,N,
26447,QualifierName,Q000187,7067510,,,6,,N,drug effects
26448,DescriptorName,D006801,7067510,,,7,Humans,N,
26449,DescriptorName,D008297,7067510,,,8,Male,N,
26450,DescriptorName,D008875,7067510,,,9,Middle Aged,N,
26451,DescriptorName,D011018,7067510,,,10,"Pneumonia, Pneumococcal",N,
26452,QualifierName,Q000150,7067510,,,10,,N,complications
26453,DescriptorName,D012772,7067510,,,11,"Shock, Septic",N,
26454,QualifierName,Q000188,7067510,,,11,,N,drug therapy
26455,Chemical,D006886,7071645,Hydroxychloroquine,4QWG6N8QKH,,,,
26456,Chemical,D011241,7071645,Prednisone,VB0R961HZT,,,,
26457,DescriptorName,D000328,7071645,,,1,Adult,N,
26458,DescriptorName,D001172,7071645,,,2,"Arthritis, Rheumatoid",N,
26459,QualifierName,Q000188,7071645,,,2,,Y,drug therapy
26460,DescriptorName,D005921,7071645,,,3,Glomerulonephritis,N,
26461,QualifierName,Q000139,7071645,,,3,,Y,chemically induced
26462,DescriptorName,D006801,7071645,,,4,Humans,N,
26463,DescriptorName,D006886,7071645,,,5,Hydroxychloroquine,N,
26464,QualifierName,Q000009,7071645,,,5,,N,adverse effects
26465,DescriptorName,D007678,7071645,,,6,Kidney Glomerulus,N,
26466,QualifierName,Q000187,7071645,,,6,,N,drug effects
26467,DescriptorName,D008297,7071645,,,7,Male,N,
26468,DescriptorName,D008854,7071645,,,8,"Microscopy, Electron",N,
26469,DescriptorName,D009401,7071645,,,9,Nephrosis,N,
26470,QualifierName,Q000139,7071645,,,9,,N,chemically induced
26471,DescriptorName,D009404,7071645,,,10,Nephrotic Syndrome,N,
26472,QualifierName,Q000139,7071645,,,10,,N,chemically induced
26473,DescriptorName,D011241,7071645,,,11,Prednisone,N,
26474,QualifierName,Q000627,7071645,,,11,,N,therapeutic use
26475,Chemical,D006146,7081289,Guanidines,0,,,,
26476,Chemical,D008655,7081289,Mesterolone,0SRQ75X9I9,,,,
26477,Chemical,D002927,7081289,Cimetidine,80061L1WGD,,,,
26478,Chemical,D000637,7081289,Transaminases,EC 2.6.1.-,,,,
26479,DescriptorName,D000368,7081289,,,1,Aged,N,
26480,DescriptorName,D002464,7081289,,,2,Cell Migration Inhibition,N,
26481,DescriptorName,D056486,7081289,,,3,Chemical and Drug Induced Liver Injury,N,
26482,QualifierName,Q000201,7081289,,,3,,N,enzymology
26483,DescriptorName,D002927,7081289,,,4,Cimetidine,N,
26484,QualifierName,Q000009,7081289,,,4,,Y,adverse effects
26485,DescriptorName,D004342,7081289,,,5,Drug Hypersensitivity,N,
26486,QualifierName,Q000276,7081289,,,5,,N,immunology
26487,DescriptorName,D004381,7081289,,,6,Duodenal Ulcer,N,
26488,QualifierName,Q000188,7081289,,,6,,N,drug therapy
26489,DescriptorName,D006146,7081289,,,7,Guanidines,N,
26490,QualifierName,Q000009,7081289,,,7,,Y,adverse effects
26491,DescriptorName,D006801,7081289,,,8,Humans,N,
26492,DescriptorName,D008264,7081289,,,9,Macrophages,N,
26493,QualifierName,Q000276,7081289,,,9,,N,immunology
26494,DescriptorName,D008297,7081289,,,10,Male,N,
26495,DescriptorName,D008655,7081289,,,11,Mesterolone,N,
26496,QualifierName,Q000627,7081289,,,11,,N,therapeutic use
26497,DescriptorName,D000637,7081289,,,12,Transaminases,N,
26498,QualifierName,Q000032,7081289,,,12,,N,analysis
26499,Chemical,D000906,7098384,Antibodies,0,,,,
26500,Chemical,D007140,7098384,Immunoglobulin Fab Fragments,0,,,,
26501,Chemical,D004077,7098384,Digoxin,73K4184T59,,,,
26502,DescriptorName,D000368,7098384,,,1,Aged,N,
26503,DescriptorName,D000906,7098384,,,2,Antibodies,N,
26504,QualifierName,Q000008,7098384,,,2,,Y,administration & dosage
26505,DescriptorName,D001145,7098384,,,3,"Arrhythmias, Cardiac",N,
26506,QualifierName,Q000139,7098384,,,3,,N,chemically induced
26507,DescriptorName,D004077,7098384,,,4,Digoxin,N,
26508,QualifierName,Q000276,7098384,,,4,,N,immunology
26509,DescriptorName,D006333,7098384,,,5,Heart Failure,N,
26510,QualifierName,Q000188,7098384,,,5,,N,drug therapy
26511,DescriptorName,D006801,7098384,,,6,Humans,N,
26512,DescriptorName,D007140,7098384,,,7,Immunoglobulin Fab Fragments,N,
26513,QualifierName,Q000008,7098384,,,7,,Y,administration & dosage
26514,DescriptorName,D008297,7098384,,,8,Male,N,
26515,DescriptorName,D013406,7098384,,,9,"Suicide, Attempted",Y,
26516,DescriptorName,D014882,7098384,,,10,Water-Electrolyte Balance,N,
26517,QualifierName,Q000187,7098384,,,10,,N,drug effects
26518,Chemical,D011433,7105508,Propranolol,9Y8NXQ24VQ,,,,
26519,Chemical,D014700,7105508,Verapamil,CJ0O37KU29,,,,
26520,DescriptorName,D000787,7105508,,,1,Angina Pectoris,N,
26521,QualifierName,Q000175,7105508,,,1,,N,diagnosis
26522,DescriptorName,D017023,7105508,,,2,Coronary Angiography,N,
26523,DescriptorName,D003331,7105508,,,3,Coronary Vessels,N,
26524,QualifierName,Q000503,7105508,,,3,,Y,physiopathology
26525,DescriptorName,D005080,7105508,,,4,Exercise Test,N,
26526,DescriptorName,D005260,7105508,,,5,Female,N,
26527,DescriptorName,D006801,7105508,,,6,Humans,N,
26528,DescriptorName,D008875,7105508,,,7,Middle Aged,N,
26529,DescriptorName,D011433,7105508,,,8,Propranolol,N,
26530,QualifierName,Q000009,7105508,,,8,,N,adverse effects
26531,DescriptorName,D014700,7105508,,,9,Verapamil,N,
26532,QualifierName,Q000627,7105508,,,9,,Y,therapeutic use
26533,Chemical,D000666,7117795,Amphotericin B,7XU7A7DROE,,,,
26534,Chemical,D003596,7117795,Cytosine,8J337D1HZY,,,,
26535,Chemical,D005437,7117795,Flucytosine,D83282DT06,,,,
26536,DescriptorName,D000368,7117795,,,1,Aged,N,
26537,DescriptorName,D000666,7117795,,,2,Amphotericin B,N,
26538,QualifierName,Q000627,7117795,,,2,,N,therapeutic use
26539,DescriptorName,D001706,7117795,,,3,Biopsy,N,
26540,DescriptorName,D003453,7117795,,,4,Cryptococcosis,N,
26541,QualifierName,Q000188,7117795,,,4,,N,drug therapy
26542,DescriptorName,D003596,7117795,,,5,Cytosine,N,
26543,QualifierName,Q000031,7117795,,,5,,Y,analogs & derivatives
26544,DescriptorName,D003967,7117795,,,6,Diarrhea,N,
26545,QualifierName,Q000139,7117795,,,6,,N,chemically induced
26546,DescriptorName,D005437,7117795,,,7,Flucytosine,N,
26547,QualifierName,Q000009,7117795,,,7,,Y,adverse effects
26548,DescriptorName,D006801,7117795,,,8,Humans,N,
26549,DescriptorName,D007079,7117795,,,9,Ileitis,N,
26550,QualifierName,Q000139,7117795,,,9,,Y,chemically induced
26551,DescriptorName,D007082,7117795,,,10,Ileum,N,
26552,QualifierName,Q000473,7117795,,,10,,N,pathology
26553,DescriptorName,D008297,7117795,,,11,Male,N,
26554,DescriptorName,D011859,7117795,,,12,Radiography,N,
26555,DescriptorName,D014456,7117795,,,13,Ulcer,N,
26556,QualifierName,Q000139,7117795,,,13,,N,chemically induced
26557,Chemical,D010880,7127202,Piperidines,0,,,,
26558,Chemical,C023470,7127202,perhexiline maleate,K7V8Y90G0H,,,,
26559,Chemical,D010480,7127202,Perhexiline,KU65374X44,,,,
26560,DescriptorName,D000328,7127202,,,1,Adult,N,
26561,DescriptorName,D000787,7127202,,,2,Angina Pectoris,N,
26562,QualifierName,Q000188,7127202,,,2,,N,drug therapy
26563,DescriptorName,D005451,7127202,,,3,Fluorescein Angiography,N,
26564,DescriptorName,D006801,7127202,,,4,Humans,N,
26565,DescriptorName,D008297,7127202,,,5,Male,N,
26566,DescriptorName,D010211,7127202,,,6,Papilledema,N,
26567,QualifierName,Q000139,7127202,,,6,,Y,chemically induced
26568,DescriptorName,D010480,7127202,,,7,Perhexiline,N,
26569,QualifierName,Q000009,7127202,,,7,,Y,adverse effects
26570,DescriptorName,D010880,7127202,,,8,Piperidines,N,
26571,QualifierName,Q000009,7127202,,,8,,Y,adverse effects
26572,DescriptorName,D014794,7127202,,,9,Visual Fields,N,
26573,Chemical,D014750,7139589,Vincristine,5J49Q6B70F,,,,
26574,Chemical,D001215,7139589,Asparaginase,EC 3.5.1.1,,,,
26575,Chemical,D011241,7139589,Prednisone,VB0R961HZT,,,,
26576,DescriptorName,D000208,7139589,,,1,Acute Disease,N,
26577,DescriptorName,D000328,7139589,,,2,Adult,N,
26578,DescriptorName,D001215,7139589,,,3,Asparaginase,N,
26579,QualifierName,Q000009,7139589,,,3,,Y,adverse effects
26580,DescriptorName,D006801,7139589,,,4,Humans,N,
26581,DescriptorName,D007273,7139589,,,5,"Injections, Intramuscular",N,
26582,DescriptorName,D008206,7139589,,,6,Lymphatic Diseases,N,
26583,QualifierName,Q000150,7139589,,,6,,N,complications
26584,DescriptorName,D008297,7139589,,,7,Male,N,
26585,DescriptorName,D010195,7139589,,,8,Pancreatitis,N,
26586,DescriptorName,D011241,7139589,,,9,Prednisone,N,
26587,QualifierName,Q000627,7139589,,,9,,N,therapeutic use
26588,DescriptorName,D014465,7139589,,,10,Ultrasonics,N,
26589,DescriptorName,D014750,7139589,,,11,Vincristine,N,
26590,QualifierName,Q000627,7139589,,,11,,N,therapeutic use
26591,Chemical,D000085,7151655,Acetates,0,,,,
26592,Chemical,D001786,7151655,Blood Glucose,0,,,,
26593,Chemical,D007773,7151655,Lactates,0,,,,
26594,Chemical,D003999,7151655,Dichloroacetic Acid,9LSH52S3LQ,,,,
26595,DescriptorName,D000085,7151655,,,1,Acetates,N,
26596,QualifierName,Q000627,7151655,,,1,,Y,therapeutic use
26597,DescriptorName,D000138,7151655,,,2,Acidosis,N,
26598,QualifierName,Q000188,7151655,,,2,,Y,drug therapy
26599,DescriptorName,D001786,7151655,,,3,Blood Glucose,N,
26600,QualifierName,Q000032,7151655,,,3,,N,analysis
26601,DescriptorName,D003999,7151655,,,4,Dichloroacetic Acid,N,
26602,QualifierName,Q000009,7151655,,,4,,N,adverse effects
26603,DescriptorName,D006801,7151655,,,5,Humans,N,
26604,DescriptorName,D007773,7151655,,,6,Lactates,N,
26605,QualifierName,Q000378,7151655,,,6,,Y,metabolism
26606,DescriptorName,D008297,7151655,,,7,Male,N,
26607,DescriptorName,D008875,7151655,,,8,Middle Aged,N,
26608,Chemical,D008094,7174620,Lithium,9FN79X2M3F,,,,
26609,DescriptorName,D000328,7174620,,,1,Adult,N,
26610,DescriptorName,D001714,7174620,,,2,Bipolar Disorder,N,
26611,QualifierName,Q000188,7174620,,,2,,N,drug therapy
26612,DescriptorName,D003693,7174620,,,3,Delirium,N,
26613,QualifierName,Q000097,7174620,,,3,,N,blood
26614,DescriptorName,D005260,7174620,,,4,Female,N,
26615,DescriptorName,D006801,7174620,,,5,Humans,N,
26616,DescriptorName,D008094,7174620,,,6,Lithium,N,
26617,QualifierName,Q000097,7174620,,,6,,N,blood
26618,DescriptorName,D008297,7174620,,,7,Male,N,
26619,DescriptorName,D008875,7174620,,,8,Middle Aged,N,
26620,DescriptorName,D011581,7174620,,,9,Psychological Tests,N,
26621,DescriptorName,D013997,7174620,,,10,Time Factors,N,
26622,Chemical,D001120,717931,Arginine,94ZLA3W45F,,,,
26623,DescriptorName,D000328,717931,,,1,Adult,N,
26624,DescriptorName,D000368,717931,,,2,Aged,N,
26625,DescriptorName,D001120,717931,,,3,Arginine,N,
26626,QualifierName,Q000009,717931,,,3,,Y,adverse effects
26627,DescriptorName,D001145,717931,,,4,"Arrhythmias, Cardiac",N,
26628,QualifierName,Q000150,717931,,,4,,N,complications
26629,DescriptorName,D006801,717931,,,5,Humans,N,
26630,DescriptorName,D006947,717931,,,6,Hyperkalemia,N,
26631,QualifierName,Q000097,717931,,,6,,N,blood
26632,DescriptorName,D008104,717931,,,7,"Liver Cirrhosis, Alcoholic",N,
26633,QualifierName,Q000188,717931,,,7,,N,drug therapy
26634,DescriptorName,D008297,717931,,,8,Male,N,
26635,Chemical,D006052,71813,Gold Sodium Thiomalate,12244-57-4,,,,
26636,DescriptorName,D000152,71813,,,1,Acne Vulgaris,N,
26637,QualifierName,Q000139,71813,,,1,,Y,chemically induced
26638,DescriptorName,D001172,71813,,,2,"Arthritis, Rheumatoid",N,
26639,QualifierName,Q000188,71813,,,2,,N,drug therapy
26640,DescriptorName,D006052,71813,,,3,Gold Sodium Thiomalate,N,
26641,QualifierName,Q000009,71813,,,3,,Y,adverse effects
26642,DescriptorName,D006801,71813,,,4,Humans,N,
26643,DescriptorName,D008010,71813,,,5,Lichen Planus,N,
26644,QualifierName,Q000139,71813,,,5,,Y,chemically induced
26645,DescriptorName,D008297,71813,,,6,Male,N,
26646,DescriptorName,D008875,71813,,,7,Middle Aged,N,
26647,Chemical,D010281,7212107,Parathyroid Hormone,0,,,,
26648,Chemical,D010710,7212107,Phosphates,0,,,,
26649,Chemical,D008094,7212107,Lithium,9FN79X2M3F,,,,
26650,Chemical,D008274,7212107,Magnesium,I38ZP9992A,,,,
26651,Chemical,D002118,7212107,Calcium,SY7Q814VUP,,,,
26652,DescriptorName,D000328,7212107,,,1,Adult,N,
26653,DescriptorName,D001714,7212107,,,2,Bipolar Disorder,N,
26654,QualifierName,Q000097,7212107,,,2,,N,blood
26655,DescriptorName,D002118,7212107,,,3,Calcium,N,
26656,QualifierName,Q000097,7212107,,,3,,N,blood
26657,DescriptorName,D005260,7212107,,,4,Female,N,
26658,DescriptorName,D006801,7212107,,,5,Humans,N,
26659,DescriptorName,D006961,7212107,,,6,Hyperparathyroidism,N,
26660,QualifierName,Q000139,7212107,,,6,,Y,chemically induced
26661,DescriptorName,D007674,7212107,,,7,Kidney Diseases,N,
26662,QualifierName,Q000139,7212107,,,7,,N,chemically induced
26663,DescriptorName,D008094,7212107,,,8,Lithium,N,
26664,QualifierName,Q000009,7212107,,,8,,Y,adverse effects
26665,DescriptorName,D008274,7212107,,,9,Magnesium,N,
26666,QualifierName,Q000097,7212107,,,9,,N,blood
26667,DescriptorName,D008297,7212107,,,10,Male,N,
26668,DescriptorName,D008875,7212107,,,11,Middle Aged,N,
26669,DescriptorName,D010281,7212107,,,12,Parathyroid Hormone,N,
26670,QualifierName,Q000097,7212107,,,12,,N,blood
26671,DescriptorName,D010710,7212107,,,13,Phosphates,N,
26672,QualifierName,Q000097,7212107,,,13,,N,blood
26673,Chemical,D011725,7226916,Pyridines,0,,,,
26674,Chemical,D004206,7226916,Disopyramide,GFO928U8MQ,,,,
26675,DescriptorName,D002037,7226916,,,1,Bundle-Branch Block,N,
26676,QualifierName,Q000188,7226916,,,1,,N,drug therapy
26677,DescriptorName,D004206,7226916,,,2,Disopyramide,N,
26678,QualifierName,Q000009,7226916,,,2,,Y,adverse effects
26679,DescriptorName,D005260,7226916,,,3,Female,N,
26680,DescriptorName,D006327,7226916,,,4,Heart Block,N,
26681,QualifierName,Q000139,7226916,,,4,,Y,chemically induced
26682,DescriptorName,D006329,7226916,,,5,Heart Conduction System,N,
26683,QualifierName,Q000187,7226916,,,5,,N,drug effects
26684,DescriptorName,D006801,7226916,,,6,Humans,N,
26685,DescriptorName,D008875,7226916,,,7,Middle Aged,N,
26686,DescriptorName,D011725,7226916,,,8,Pyridines,N,
26687,QualifierName,Q000009,7226916,,,8,,Y,adverse effects
26688,Chemical,D001949,7235792,Bretylium Compounds,0,,,,
26689,Chemical,D001950,7235792,Bretylium Tosylate,78ZP3YR353,,,,
26690,DescriptorName,D000328,7235792,,,1,Adult,N,
26691,DescriptorName,D001949,7235792,,,2,Bretylium Compounds,N,
26692,QualifierName,Q000009,7235792,,,2,,Y,adverse effects
26693,DescriptorName,D001950,7235792,,,3,Bretylium Tosylate,N,
26694,QualifierName,Q000008,7235792,,,3,,N,administration & dosage
26695,DescriptorName,D005260,7235792,,,4,Female,N,
26696,DescriptorName,D006323,7235792,,,5,Heart Arrest,N,
26697,QualifierName,Q000139,7235792,,,5,,N,chemically induced
26698,DescriptorName,D006801,7235792,,,6,Humans,N,
26699,DescriptorName,D007275,7235792,,,7,"Injections, Intravenous",N,
26700,DescriptorName,D008297,7235792,,,8,Male,N,
26701,DescriptorName,D008875,7235792,,,9,Middle Aged,N,
26702,DescriptorName,D013610,7235792,,,10,Tachycardia,N,
26703,QualifierName,Q000139,7235792,,,10,,Y,chemically induced
26704,DescriptorName,D014693,7235792,,,11,Ventricular Fibrillation,N,
26705,QualifierName,Q000139,7235792,,,11,,Y,chemically induced
26706,Chemical,D008094,7249424,Lithium,9FN79X2M3F,,,,
26707,DescriptorName,D000328,7249424,,,1,Adult,N,
26708,DescriptorName,D001706,7249424,,,2,Biopsy,N,
26709,DescriptorName,D001714,7249424,,,3,Bipolar Disorder,N,
26710,QualifierName,Q000188,7249424,,,3,,N,drug therapy
26711,DescriptorName,D005260,7249424,,,4,Female,N,
26712,DescriptorName,D006801,7249424,,,5,Humans,N,
26713,DescriptorName,D008094,7249424,,,6,Lithium,N,
26714,QualifierName,Q000009,7249424,,,6,,Y,adverse effects
26715,DescriptorName,D008297,7249424,,,7,Male,N,
26716,DescriptorName,D008875,7249424,,,8,Middle Aged,N,
26717,DescriptorName,D009404,7249424,,,9,Nephrotic Syndrome,N,
26718,QualifierName,Q000139,7249424,,,9,,Y,chemically induced
26719,Chemical,D008795,7258204,Metronidazole,140QMO216E,,,,
26720,Chemical,D000667,7258204,Ampicillin,7C782967RD,,,,
26721,DescriptorName,D000368,7258204,,,1,Aged,N,
26722,DescriptorName,D000667,7258204,,,2,Ampicillin,N,
26723,QualifierName,Q000009,7258204,,,2,,N,adverse effects
26724,DescriptorName,D003015,7258204,,,3,Clostridium Infections,N,
26725,QualifierName,Q000188,7258204,,,3,,N,drug therapy
26726,DescriptorName,D004761,7258204,,,4,"Enterocolitis, Pseudomembranous",N,
26727,QualifierName,Q000139,7258204,,,4,,N,chemically induced
26728,DescriptorName,D006801,7258204,,,5,Humans,N,
26729,DescriptorName,D008297,7258204,,,6,Male,N,
26730,DescriptorName,D008795,7258204,,,7,Metronidazole,N,
26731,QualifierName,Q000627,7258204,,,7,,Y,therapeutic use
26732,Chemical,D014750,7272895,Vincristine,5J49Q6B70F,,,,
26733,DescriptorName,D000368,7272895,,,1,Aged,N,
26734,DescriptorName,D003638,7272895,,,2,Deafness,N,
26735,QualifierName,Q000139,7272895,,,2,,N,chemically induced
26736,DescriptorName,D005260,7272895,,,3,Female,N,
26737,DescriptorName,D006312,7272895,,,4,"Hearing Loss, Bilateral",N,
26738,QualifierName,Q000139,7272895,,,4,,N,chemically induced
26739,DescriptorName,D006801,7272895,,,5,Humans,N,
26740,DescriptorName,D008223,7272895,,,6,Lymphoma,N,
26741,QualifierName,Q000188,7272895,,,6,,Y,drug therapy
26742,DescriptorName,D000159,7272895,,,7,Vestibulocochlear Nerve,N,
26743,QualifierName,Q000187,7272895,,,7,,N,drug effects
26744,DescriptorName,D000160,7272895,,,8,Vestibulocochlear Nerve Diseases,N,
26745,QualifierName,Q000139,7272895,,,8,,Y,chemically induced
26746,DescriptorName,D014750,7272895,,,9,Vincristine,N,
26747,QualifierName,Q000009,7272895,,,9,,Y,adverse effects
26748,Chemical,D009883,7282702,Ophthalmic Solutions,0,,,,
26749,Chemical,D011412,7282702,Propanolamines,0,,,,
26750,Chemical,D013999,7282702,Timolol,817W3C6175,,,,
26751,DescriptorName,D000368,7282702,,,1,Aged,N,
26752,DescriptorName,D001919,7282702,,,2,Bradycardia,N,
26753,QualifierName,Q000139,7282702,,,2,,Y,chemically induced
26754,DescriptorName,D005901,7282702,,,3,Glaucoma,N,
26755,QualifierName,Q000188,7282702,,,3,,N,drug therapy
26756,DescriptorName,D006333,7282702,,,4,Heart Failure,N,
26757,QualifierName,Q000139,7282702,,,4,,Y,chemically induced
26758,DescriptorName,D006801,7282702,,,5,Humans,N,
26759,DescriptorName,D008297,7282702,,,6,Male,N,
26760,DescriptorName,D009883,7282702,,,7,Ophthalmic Solutions,N,
26761,DescriptorName,D011412,7282702,,,8,Propanolamines,N,
26762,QualifierName,Q000009,7282702,,,8,,Y,adverse effects
26763,DescriptorName,D013999,7282702,,,9,Timolol,N,
26764,QualifierName,Q000008,7282702,,,9,,N,administration & dosage
26765,Chemical,D004077,7295427,Digoxin,73K4184T59,,,,
26766,DescriptorName,D000328,7295427,,,1,Adult,N,
26767,DescriptorName,D004077,7295427,,,2,Digoxin,N,
26768,QualifierName,Q000009,7295427,,,2,,Y,adverse effects
26769,DescriptorName,D004562,7295427,,,3,Electrocardiography,N,
26770,DescriptorName,D006801,7295427,,,4,Humans,N,
26771,DescriptorName,D008297,7295427,,,5,Male,N,
26772,DescriptorName,D008943,7295427,,,6,Mitral Valve,N,
26773,QualifierName,Q000473,7295427,,,6,,N,pathology
26774,DescriptorName,D008945,7295427,,,7,Mitral Valve Prolapse,N,
26775,QualifierName,Q000188,7295427,,,7,,Y,drug therapy
26776,DescriptorName,D014693,7295427,,,8,Ventricular Fibrillation,N,
26777,QualifierName,Q000139,7295427,,,8,,Y,chemically induced
26778,Chemical,D007980,7304798,Levodopa,46627O600J,,,,
26779,Chemical,D008734,7304798,Methoxyhydroxyphenylglycol,534-82-7,,,,
26780,DescriptorName,D001714,7304798,,,1,Bipolar Disorder,N,
26781,QualifierName,Q000139,7304798,,,1,,Y,chemically induced
26782,DescriptorName,D004305,7304798,,,2,"Dose-Response Relationship, Drug",N,
26783,DescriptorName,D004311,7304798,,,3,Double-Blind Method,N,
26784,DescriptorName,D005260,7304798,,,4,Female,N,
26785,DescriptorName,D006801,7304798,,,5,Humans,N,
26786,DescriptorName,D007980,7304798,,,6,Levodopa,N,
26787,QualifierName,Q000009,7304798,,,6,,Y,adverse effects
26788,DescriptorName,D008734,7304798,,,7,Methoxyhydroxyphenylglycol,N,
26789,QualifierName,Q000652,7304798,,,7,,N,urine
26790,DescriptorName,D008875,7304798,,,8,Middle Aged,N,
26791,Chemical,D010880,7321956,Piperidines,0,,,,
26792,Chemical,D000637,7321956,Transaminases,EC 2.6.1.-,,,,
26793,Chemical,D010480,7321956,Perhexiline,KU65374X44,,,,
26794,DescriptorName,D000787,7321956,,,1,Angina Pectoris,N,
26795,QualifierName,Q000188,7321956,,,1,,N,drug therapy
26796,DescriptorName,D056486,7321956,,,2,Chemical and Drug Induced Liver Injury,Y,
26797,DescriptorName,D006801,7321956,,,3,Humans,N,
26798,DescriptorName,D008099,7321956,,,4,Liver,N,
26799,QualifierName,Q000201,7321956,,,4,,N,enzymology
26800,DescriptorName,D008104,7321956,,,5,"Liver Cirrhosis, Alcoholic",N,
26801,QualifierName,Q000201,7321956,,,5,,N,enzymology
26802,DescriptorName,D008107,7321956,,,6,Liver Diseases,N,
26803,QualifierName,Q000201,7321956,,,6,,N,enzymology
26804,DescriptorName,D008297,7321956,,,7,Male,N,
26805,DescriptorName,D008875,7321956,,,8,Middle Aged,N,
26806,DescriptorName,D010003,7321956,,,9,Osteoarthritis,N,
26807,QualifierName,Q000201,7321956,,,9,,N,enzymology
26808,DescriptorName,D010480,7321956,,,10,Perhexiline,N,
26809,QualifierName,Q000009,7321956,,,10,,Y,adverse effects
26810,DescriptorName,D010880,7321956,,,11,Piperidines,N,
26811,QualifierName,Q000009,7321956,,,11,,Y,adverse effects
26812,DescriptorName,D011183,7321956,,,12,Postoperative Complications,N,
26813,QualifierName,Q000209,7321956,,,12,,N,etiology
26814,DescriptorName,D000637,7321956,,,13,Transaminases,N,
26815,QualifierName,Q000097,7321956,,,13,,N,blood
26816,Chemical,C018404,7351000,treosulfan,CO61ER3EPI,,,,
26817,Chemical,D002066,7351000,Busulfan,G1LN9045DK,,,,
26818,DescriptorName,D000328,7351000,,,1,Adult,N,
26819,DescriptorName,D000368,7351000,,,2,Aged,N,
26820,DescriptorName,D002066,7351000,,,3,Busulfan,N,
26821,QualifierName,Q000009,7351000,,,3,,N,adverse effects
26822,DescriptorName,D002869,7351000,,,4,Chromosome Aberrations,N,
26823,DescriptorName,D005260,7351000,,,5,Female,N,
26824,DescriptorName,D006801,7351000,,,6,Humans,N,
26825,DescriptorName,D007938,7351000,,,7,Leukemia,N,
26826,QualifierName,Q000139,7351000,,,7,,Y,chemically induced
26827,DescriptorName,D008875,7351000,,,8,Middle Aged,N,
26828,DescriptorName,D009378,7351000,,,9,"Neoplasms, Multiple Primary",N,
26829,QualifierName,Q000139,7351000,,,9,,Y,chemically induced
26830,DescriptorName,D010051,7351000,,,10,Ovarian Neoplasms,N,
26831,QualifierName,Q000188,7351000,,,10,,Y,drug therapy
26832,DescriptorName,D012306,7351000,,,11,Risk,N,
26833,DescriptorName,D013997,7351000,,,12,Time Factors,N,
26834,Chemical,D011433,7355327,Propranolol,9Y8NXQ24VQ,,,,
26835,DescriptorName,D001986,7355327,,,1,Bronchial Spasm,N,
26836,QualifierName,Q000139,7355327,,,1,,Y,chemically induced
26837,DescriptorName,D005260,7355327,,,2,Female,N,
26838,DescriptorName,D006801,7355327,,,3,Humans,N,
26839,DescriptorName,D006973,7355327,,,4,Hypertension,N,
26840,QualifierName,Q000188,7355327,,,4,,N,drug therapy
26841,DescriptorName,D008297,7355327,,,5,Male,N,
26842,DescriptorName,D008875,7355327,,,6,Middle Aged,N,
26843,DescriptorName,D011433,7355327,,,7,Propranolol,N,
26844,QualifierName,Q000009,7355327,,,7,,Y,adverse effects
26845,Chemical,D011433,7362333,Propranolol,9Y8NXQ24VQ,,,,
26846,DescriptorName,D000784,7362333,,,1,"Aneurysm, Dissecting",N,
26847,QualifierName,Q000601,7362333,,,1,,N,surgery
26848,DescriptorName,D001014,7362333,,,2,Aortic Aneurysm,N,
26849,QualifierName,Q000601,7362333,,,2,,N,surgery
26850,DescriptorName,D002315,7362333,,,3,Cardiopulmonary Bypass,Y,
26851,DescriptorName,D006801,7362333,,,4,Humans,N,
26852,DescriptorName,D006973,7362333,,,5,Hypertension,N,
26853,QualifierName,Q000188,7362333,,,5,,N,drug therapy
26854,DescriptorName,D008297,7362333,,,6,Male,N,
26855,DescriptorName,D008875,7362333,,,7,Middle Aged,N,
26856,DescriptorName,D011433,7362333,,,8,Propranolol,N,
26857,QualifierName,Q000009,7362333,,,8,,Y,adverse effects
26858,DescriptorName,D011605,7362333,,,9,"Psychoses, Substance-Induced",N,
26859,QualifierName,Q000209,7362333,,,9,,Y,etiology
26860,Chemical,D008727,736591,Methotrexate,YL5FZ2Y5U1,,,,
26861,DescriptorName,D000368,736591,,,1,Aged,N,
26862,DescriptorName,D006801,736591,,,2,Humans,N,
26863,DescriptorName,D008171,736591,,,3,Lung Diseases,N,
26864,QualifierName,Q000139,736591,,,3,,Y,chemically induced
26865,DescriptorName,D008297,736591,,,4,Male,N,
26866,DescriptorName,D008727,736591,,,5,Methotrexate,N,
26867,QualifierName,Q000009,736591,,,5,,Y,adverse effects
26868,DescriptorName,D011565,736591,,,6,Psoriasis,N,
26869,QualifierName,Q000188,736591,,,6,,N,drug therapy
26870,DescriptorName,D011658,736591,,,7,Pulmonary Fibrosis,N,
26871,QualifierName,Q000139,736591,,,7,,N,chemically induced
26872,DescriptorName,D011859,736591,,,8,Radiography,N,
26873,Chemical,D011803,7369302,Quinine,A7V27PHC7A,,,,
26874,DescriptorName,D001766,7369302,,,1,Blindness,N,
26875,QualifierName,Q000139,7369302,,,1,,Y,chemically induced
26876,DescriptorName,D003714,7369302,,,2,Denervation,N,
26877,DescriptorName,D005071,7369302,,,3,Evoked Potentials,Y,
26878,DescriptorName,D006801,7369302,,,4,Humans,N,
26879,DescriptorName,D007498,7369302,,,5,Iris,N,
26880,QualifierName,Q000294,7369302,,,5,,N,innervation
26881,DescriptorName,D008297,7369302,,,6,Male,N,
26882,DescriptorName,D008875,7369302,,,7,Middle Aged,N,
26883,DescriptorName,D009120,7369302,,,8,Muscle Cramp,N,
26884,QualifierName,Q000188,7369302,,,8,,N,drug therapy
26885,DescriptorName,D010775,7369302,,,9,Photic Stimulation,N,
26886,DescriptorName,D011680,7369302,,,10,Pupil,Y,
26887,DescriptorName,D011803,7369302,,,11,Quinine,N,
26888,QualifierName,Q000009,7369302,,,11,,Y,adverse effects
26889,DescriptorName,D012075,7369302,,,12,"Remission, Spontaneous",N,
26890,DescriptorName,D014794,7369302,,,13,Visual Fields,N,
26891,Chemical,D011217,7375145,Practolol,SUG9176GRW,,,,
26892,DescriptorName,D000787,7375145,,,1,Angina Pectoris,N,
26893,QualifierName,Q000188,7375145,,,1,,N,drug therapy
26894,DescriptorName,D005260,7375145,,,2,Female,N,
26895,DescriptorName,D006801,7375145,,,3,Humans,N,
26896,DescriptorName,D008875,7375145,,,4,Middle Aged,N,
26897,DescriptorName,D010537,7375145,,,5,Peritoneum,N,
26898,QualifierName,Q000473,7375145,,,5,,N,pathology
26899,DescriptorName,D010538,7375145,,,6,Peritonitis,N,
26900,QualifierName,Q000139,7375145,,,6,,Y,chemically induced
26901,DescriptorName,D011217,7375145,,,7,Practolol,N,
26902,QualifierName,Q000009,7375145,,,7,,Y,adverse effects
26903,DescriptorName,D012598,7375145,,,8,Sclerosis,N,
26904,Chemical,D009539,7379406,Nicotinic Acids,0,,,,
26905,Chemical,D009544,7379406,Niflumic Acid,4U5MP5IUD8,,,,
26906,DescriptorName,D000328,7379406,,,1,Adult,N,
26907,DescriptorName,D001847,7379406,,,2,Bone Diseases,N,
26908,QualifierName,Q000139,7379406,,,2,,Y,chemically induced
26909,DescriptorName,D005260,7379406,,,3,Female,N,
26910,DescriptorName,D005458,7379406,,,4,Fluoride Poisoning,N,
26911,QualifierName,Q000209,7379406,,,4,,Y,etiology
26912,DescriptorName,D006801,7379406,,,5,Humans,N,
26913,DescriptorName,D009539,7379406,,,6,Nicotinic Acids,N,
26914,QualifierName,Q000009,7379406,,,6,,Y,adverse effects
26915,DescriptorName,D009544,7379406,,,7,Niflumic Acid,N,
26916,QualifierName,Q000009,7379406,,,7,,Y,adverse effects
26917,DescriptorName,D010024,7379406,,,8,Osteoporosis,N,
26918,QualifierName,Q000188,7379406,,,8,,N,drug therapy
26919,Chemical,D010396,7387219,Penicillamine,GNN1DV99GX,,,,
26920,DescriptorName,D000328,7387219,,,1,Adult,N,
26921,DescriptorName,D001172,7387219,,,2,"Arthritis, Rheumatoid",N,
26922,QualifierName,Q000188,7387219,,,2,,Y,drug therapy
26923,DescriptorName,D056486,7387219,,,3,Chemical and Drug Induced Liver Injury,Y,
26924,DescriptorName,D005260,7387219,,,4,Female,N,
26925,DescriptorName,D006801,7387219,,,5,Humans,N,
26926,DescriptorName,D008297,7387219,,,6,Male,N,
26927,DescriptorName,D008875,7387219,,,7,Middle Aged,N,
26928,DescriptorName,D010396,7387219,,,8,Penicillamine,N,
26929,QualifierName,Q000009,7387219,,,8,,Y,adverse effects
26930,Chemical,D000636,7393795,Aminosalicylic Acids,0,,,,
26931,Chemical,D000995,7393795,Antitubercular Agents,0,,,,
26932,Chemical,D010131,7393795,Aminosalicylic Acid,5B2658E0N2,,,,
26933,DescriptorName,D010131,7393795,,,1,Aminosalicylic Acid,N,
26934,QualifierName,Q000009,7393795,,,1,,Y,adverse effects
26935,DescriptorName,D000636,7393795,,,2,Aminosalicylic Acids,N,
26936,QualifierName,Q000009,7393795,,,2,,Y,adverse effects
26937,DescriptorName,D000995,7393795,,,3,Antitubercular Agents,N,
26938,QualifierName,Q000009,7393795,,,3,,N,adverse effects
26939,DescriptorName,D003928,7393795,,,4,Diabetic Nephropathies,N,
26940,QualifierName,Q000150,7393795,,,4,,Y,complications
26941,DescriptorName,D006801,7393795,,,5,Humans,N,
26942,DescriptorName,D007003,7393795,,,6,Hypoglycemia,N,
26943,QualifierName,Q000139,7393795,,,6,,Y,chemically induced
26944,DescriptorName,D008297,7393795,,,7,Male,N,
26945,DescriptorName,D008875,7393795,,,8,Middle Aged,N,
26946,DescriptorName,D014391,7393795,,,9,"Tuberculosis, Miliary",N,
26947,QualifierName,Q000150,7393795,,,9,,N,complications
26948,Chemical,D010880,7397053,Piperidines,0,,,,
26949,Chemical,D010480,7397053,Perhexiline,KU65374X44,,,,
26950,DescriptorName,D000787,7397053,,,1,Angina Pectoris,N,
26951,QualifierName,Q000188,7397053,,,1,,N,drug therapy
26952,DescriptorName,D056486,7397053,,,2,Chemical and Drug Induced Liver Injury,Y,
26953,DescriptorName,D006801,7397053,,,3,Humans,N,
26954,DescriptorName,D008297,7397053,,,4,Male,N,
26955,DescriptorName,D008875,7397053,,,5,Middle Aged,N,
26956,DescriptorName,D010211,7397053,,,6,Papilledema,N,
26957,QualifierName,Q000139,7397053,,,6,,Y,chemically induced
26958,DescriptorName,D010480,7397053,,,7,Perhexiline,N,
26959,QualifierName,Q000009,7397053,,,7,,Y,adverse effects
26960,DescriptorName,D010880,7397053,,,8,Piperidines,N,
26961,QualifierName,Q000009,7397053,,,8,,Y,adverse effects
26962,Chemical,D005472,7408538,Fluorouracil,U3P01618RT,,,,
26963,DescriptorName,D005472,7408538,,,1,Fluorouracil,N,
26964,QualifierName,Q000009,7408538,,,1,,Y,adverse effects
26965,DescriptorName,D006801,7408538,,,2,Humans,N,
26966,DescriptorName,D008297,7408538,,,3,Male,N,
26967,DescriptorName,D008875,7408538,,,4,Middle Aged,N,
26968,DescriptorName,D010859,7408538,,,5,Pigmentation Disorders,N,
26969,QualifierName,Q000139,7408538,,,5,,Y,chemically induced
26970,DescriptorName,D011471,7408538,,,6,Prostatic Neoplasms,N,
26971,QualifierName,Q000188,7408538,,,6,,N,drug therapy
26972,Chemical,D004221,7416268,Disulfiram,TR3MLJ1UAI,,,,
26973,DescriptorName,D000328,7416268,,,1,Adult,N,
26974,DescriptorName,D000437,7416268,,,2,Alcoholism,N,
26975,QualifierName,Q000188,7416268,,,2,,N,drug therapy
26976,DescriptorName,D002389,7416268,,,3,Catatonia,N,
26977,QualifierName,Q000139,7416268,,,3,,Y,chemically induced
26978,DescriptorName,D004221,7416268,,,4,Disulfiram,N,
26979,QualifierName,Q000009,7416268,,,4,,Y,adverse effects
26980,DescriptorName,D006801,7416268,,,5,Humans,N,
26981,DescriptorName,D008297,7416268,,,6,Male,N,
26982,DescriptorName,D013375,7416268,,,7,Substance Withdrawal Syndrome,N,
26983,QualifierName,Q000209,7416268,,,7,,N,etiology
26984,DescriptorName,D019966,7416268,,,8,Substance-Related Disorders,N,
26985,QualifierName,Q000209,7416268,,,8,,Y,etiology
26986,Chemical,D014747,7420580,Vinblastine,5V9KLZ54CY,,,,
26987,DescriptorName,D000328,7420580,,,1,Adult,N,
26988,DescriptorName,D006801,7420580,,,2,Humans,N,
26989,DescriptorName,D007177,7420580,,,3,Inappropriate ADH Syndrome,N,
26990,QualifierName,Q000139,7420580,,,3,,Y,chemically induced
26991,DescriptorName,D008297,7420580,,,4,Male,N,
26992,DescriptorName,D013724,7420580,,,5,Teratoma,N,
26993,QualifierName,Q000188,7420580,,,5,,Y,drug therapy
26994,DescriptorName,D013736,7420580,,,6,Testicular Neoplasms,N,
26995,QualifierName,Q000188,7420580,,,6,,Y,drug therapy
26996,DescriptorName,D014747,7420580,,,7,Vinblastine,N,
26997,QualifierName,Q000009,7420580,,,7,,Y,adverse effects
26998,Chemical,D000644,7428724,Quaternary Ammonium Compounds,0,,,,
26999,Chemical,D004629,7428724,Emepronium,04QQ8SWA4U,,,,
27000,DescriptorName,D000328,7428724,,,1,Adult,N,
27001,DescriptorName,D000368,7428724,,,2,Aged,N,
27002,DescriptorName,D004629,7428724,,,3,Emepronium,N,
27003,QualifierName,Q000009,7428724,,,3,,Y,adverse effects
27004,DescriptorName,D004935,7428724,,,4,Esophageal Diseases,N,
27005,QualifierName,Q000139,7428724,,,4,,Y,chemically induced
27006,DescriptorName,D004941,7428724,,,5,Esophagitis,N,
27007,QualifierName,Q000139,7428724,,,5,,N,chemically induced
27008,DescriptorName,D004945,7428724,,,6,Esophagoscopy,N,
27009,DescriptorName,D005260,7428724,,,7,Female,N,
27010,DescriptorName,D006801,7428724,,,8,Humans,N,
27011,DescriptorName,D008297,7428724,,,9,Male,N,
27012,DescriptorName,D000644,7428724,,,10,Quaternary Ammonium Compounds,N,
27013,QualifierName,Q000009,7428724,,,10,,Y,adverse effects
27014,DescriptorName,D014456,7428724,,,11,Ulcer,N,
27015,QualifierName,Q000139,7428724,,,11,,N,chemically induced
27016,DescriptorName,D014555,7428724,,,12,Urination Disorders,N,
27017,QualifierName,Q000188,7428724,,,12,,N,drug therapy
27018,Chemical,D007093,7436161,Imidazoles,0,,,,
27019,Chemical,D008825,7436161,Miconazole,7NNO0D7S5M,,,,
27020,DescriptorName,D000328,7436161,,,1,Adult,N,
27021,DescriptorName,D000707,7436161,,,2,Anaphylaxis,N,
27022,QualifierName,Q000139,7436161,,,2,,Y,chemically induced
27023,DescriptorName,D005260,7436161,,,3,Female,N,
27024,DescriptorName,D006323,7436161,,,4,Heart Arrest,N,
27025,QualifierName,Q000139,7436161,,,4,,Y,chemically induced
27026,DescriptorName,D006801,7436161,,,5,Humans,N,
27027,DescriptorName,D007093,7436161,,,6,Imidazoles,N,
27028,QualifierName,Q000009,7436161,,,6,,Y,adverse effects
27029,DescriptorName,D007938,7436161,,,7,Leukemia,N,
27030,QualifierName,Q000150,7436161,,,7,,N,complications
27031,DescriptorName,D008297,7436161,,,8,Male,N,
27032,DescriptorName,D008825,7436161,,,9,Miconazole,N,
27033,QualifierName,Q000009,7436161,,,9,,Y,adverse effects
27034,DescriptorName,D008875,7436161,,,10,Middle Aged,N,
27035,DescriptorName,D009181,7436161,,,11,Mycoses,N,
27036,QualifierName,Q000150,7436161,,,11,,N,complications
27037,DescriptorName,D012131,7436161,,,12,Respiratory Insufficiency,N,
27038,QualifierName,Q000139,7436161,,,12,,Y,chemically induced
27039,Chemical,D001219,7439122,Aspartate Aminotransferases,EC 2.6.1.1,,,,
27040,Chemical,D000410,7439122,Alanine Transaminase,EC 2.6.1.2,,,,
27041,Chemical,D003402,7439122,Creatine Kinase,EC 2.7.3.2,,,,
27042,Chemical,D002994,7439122,Clofibrate,HPN91K7FU3,,,,
27043,DescriptorName,D000293,7439122,,,1,Adolescent,N,
27044,DescriptorName,D000410,7439122,,,2,Alanine Transaminase,N,
27045,QualifierName,Q000097,7439122,,,2,,N,blood
27046,DescriptorName,D001219,7439122,,,3,Aspartate Aminotransferases,N,
27047,QualifierName,Q000097,7439122,,,3,,N,blood
27048,DescriptorName,D002994,7439122,,,4,Clofibrate,N,
27049,QualifierName,Q000009,7439122,,,4,,Y,adverse effects
27050,DescriptorName,D003402,7439122,,,5,Creatine Kinase,N,
27051,QualifierName,Q000097,7439122,,,5,,N,blood
27052,DescriptorName,D003919,7439122,,,6,Diabetes Insipidus,N,
27053,QualifierName,Q000188,7439122,,,6,,Y,drug therapy
27054,DescriptorName,D006801,7439122,,,7,Humans,N,
27055,DescriptorName,D008297,7439122,,,8,Male,N,
27056,DescriptorName,D008875,7439122,,,9,Middle Aged,N,
27057,DescriptorName,D009135,7439122,,,10,Muscular Diseases,N,
27058,QualifierName,Q000139,7439122,,,10,,Y,chemically induced
27059,Chemical,D000970,7448830,Antineoplastic Agents,0,,,,
27060,Chemical,D013892,7448830,Thioxanthenes,0,,,,
27061,Chemical,D006826,7448830,Hycanthone,2BXX5EVN2A,,,,
27062,DescriptorName,D000328,7448830,,,1,Adult,N,
27063,DescriptorName,D000970,7448830,,,2,Antineoplastic Agents,N,
27064,QualifierName,Q000008,7448830,,,2,,N,administration & dosage
27065,DescriptorName,D001943,7448830,,,3,Breast Neoplasms,N,
27066,QualifierName,Q000188,7448830,,,3,,Y,drug therapy
27067,DescriptorName,D056486,7448830,,,4,Chemical and Drug Induced Liver Injury,Y,
27068,DescriptorName,D006801,7448830,,,5,Humans,N,
27069,DescriptorName,D006826,7448830,,,6,Hycanthone,N,
27070,QualifierName,Q000008,7448830,,,6,,N,administration & dosage
27071,DescriptorName,D008107,7448830,,,7,Liver Diseases,N,
27072,QualifierName,Q000175,7448830,,,7,,N,diagnosis
27073,DescriptorName,D008297,7448830,,,8,Male,N,
27074,DescriptorName,D008875,7448830,,,9,Middle Aged,N,
27075,DescriptorName,D013892,7448830,,,10,Thioxanthenes,N,
27076,QualifierName,Q000009,7448830,,,10,,Y,adverse effects
27077,Chemical,D002699,7459812,Chlorambucil,18D0SL7309,,,,
27078,Chemical,D011241,7459812,Prednisone,VB0R961HZT,,,,
27079,DescriptorName,D000368,7459812,,,1,Aged,N,
27080,DescriptorName,D000542,7459812,,,2,"Alveolitis, Extrinsic Allergic",N,
27081,QualifierName,Q000139,7459812,,,2,,Y,chemically induced
27082,DescriptorName,D001706,7459812,,,3,Biopsy,N,
27083,DescriptorName,D002699,7459812,,,4,Chlorambucil,N,
27084,QualifierName,Q000009,7459812,,,4,,Y,adverse effects
27085,DescriptorName,D004305,7459812,,,5,"Dose-Response Relationship, Drug",N,
27086,DescriptorName,D006801,7459812,,,6,Humans,N,
27087,DescriptorName,D007945,7459812,,,7,"Leukemia, Lymphoid",N,
27088,QualifierName,Q000188,7459812,,,7,,Y,drug therapy
27089,DescriptorName,D008168,7459812,,,8,Lung,N,
27090,QualifierName,Q000473,7459812,,,8,,N,pathology
27091,DescriptorName,D008297,7459812,,,9,Male,N,
27092,DescriptorName,D011241,7459812,,,10,Prednisone,N,
27093,QualifierName,Q000627,7459812,,,10,,N,therapeutic use
27094,Chemical,D010672,7468565,Phenytoin,6158TKW0C5,,,,
27095,DescriptorName,D000368,7468565,,,1,Aged,N,
27096,DescriptorName,D001706,7468565,,,2,Biopsy,N,
27097,DescriptorName,D056486,7468565,,,3,Chemical and Drug Induced Liver Injury,Y,
27098,DescriptorName,D005260,7468565,,,4,Female,N,
27099,DescriptorName,D006801,7468565,,,5,Humans,N,
27100,DescriptorName,D008099,7468565,,,6,Liver,N,
27101,QualifierName,Q000187,7468565,,,6,,Y,drug effects
27102,DescriptorName,D009336,7468565,,,7,Necrosis,N,
27103,DescriptorName,D010672,7468565,,,8,Phenytoin,N,
27104,QualifierName,Q000009,7468565,,,8,,Y,adverse effects
27105,DescriptorName,D012640,7468565,,,9,Seizures,N,
27106,QualifierName,Q000188,7468565,,,9,,N,drug therapy
27107,Chemical,D000889,7474364,Anti-Arrhythmia Agents,0,,,,
27108,Chemical,D003692,7474364,Delayed-Action Preparations,0,,,,
27109,Chemical,D011342,7474364,Procainamide,L39WTC366D,,,,
27110,DescriptorName,D000368,7474364,,,1,Aged,N,
27111,DescriptorName,D000380,7474364,,,2,Agranulocytosis,N,
27112,QualifierName,Q000139,7474364,,,2,,Y,chemically induced
27113,DescriptorName,D000889,7474364,,,3,Anti-Arrhythmia Agents,N,
27114,QualifierName,Q000009,7474364,,,3,,N,adverse effects
27115,DescriptorName,D001281,7474364,,,4,Atrial Fibrillation,N,
27116,QualifierName,Q000188,7474364,,,4,,Y,drug therapy
27117,DescriptorName,D001772,7474364,,,5,Blood Cell Count,N,
27118,DescriptorName,D003692,7474364,,,6,Delayed-Action Preparations,N,
27119,DescriptorName,D006801,7474364,,,7,Humans,N,
27120,DescriptorName,D008297,7474364,,,8,Male,N,
27121,DescriptorName,D009203,7474364,,,9,Myocardial Infarction,N,
27122,QualifierName,Q000150,7474364,,,9,,Y,complications
27123,DescriptorName,D011342,7474364,,,10,Procainamide,N,
27124,QualifierName,Q000009,7474364,,,10,,Y,adverse effects
27125,Chemical,D010672,748238,Phenytoin,6158TKW0C5,,,,
27126,DescriptorName,D004827,748238,,,1,Epilepsy,N,
27127,QualifierName,Q000188,748238,,,1,,Y,drug therapy
27128,DescriptorName,D006801,748238,,,2,Humans,N,
27129,DescriptorName,D008297,748238,,,3,Male,N,
27130,DescriptorName,D008875,748238,,,4,Middle Aged,N,
27131,DescriptorName,D009101,748238,,,5,Multiple Myeloma,N,
27132,QualifierName,Q000139,748238,,,5,,Y,chemically induced
27133,DescriptorName,D010672,748238,,,6,Phenytoin,N,
27134,QualifierName,Q000009,748238,,,6,,Y,adverse effects
27135,Chemical,D000935,7485371,Antifungal Agents,0,,,,
27136,Chemical,D009285,7485371,Naphthoquinones,0,,,,
27137,Chemical,D053626,7485371,Atovaquone,Y883P1Z2LT,,,,
27138,DescriptorName,D017088,7485371,,,1,AIDS-Related Opportunistic Infections,N,
27139,QualifierName,Q000188,7485371,,,1,,N,drug therapy
27140,DescriptorName,D000935,7485371,,,2,Antifungal Agents,N,
27141,QualifierName,Q000009,7485371,,,2,,Y,adverse effects
27142,DescriptorName,D053626,7485371,,,3,Atovaquone,N,
27143,DescriptorName,D003315,7485371,,,4,Cornea,N,
27144,QualifierName,Q000187,7485371,,,4,,Y,drug effects
27145,DescriptorName,D003316,7485371,,,5,Corneal Diseases,N,
27146,QualifierName,Q000139,7485371,,,5,,Y,chemically induced
27147,DescriptorName,D004848,7485371,,,6,Epithelium,N,
27148,QualifierName,Q000187,7485371,,,6,,N,drug effects
27149,DescriptorName,D006801,7485371,,,7,Humans,N,
27150,DescriptorName,D008297,7485371,,,8,Male,N,
27151,DescriptorName,D008875,7485371,,,9,Middle Aged,N,
27152,DescriptorName,D009285,7485371,,,10,Naphthoquinones,N,
27153,QualifierName,Q000009,7485371,,,10,,Y,adverse effects
27154,DescriptorName,D011020,7485371,,,11,"Pneumonia, Pneumocystis",N,
27155,QualifierName,Q000188,7485371,,,11,,N,drug therapy
27156,Chemical,D009294,7495990,Narcotics,0,,,,
27157,Chemical,D009270,7495990,Naloxone,36B82AMQ7N,,,,
27158,DescriptorName,D000328,7495990,,,1,Adult,N,
27159,DescriptorName,D001291,7495990,,,2,Attitude of Health Personnel,N,
27160,DescriptorName,D005260,7495990,,,3,Female,N,
27161,DescriptorName,D015658,7495990,,,4,HIV Infections,N,
27162,QualifierName,Q000150,7495990,,,4,,Y,complications
27163,DescriptorName,D006801,7495990,,,5,Humans,N,
27164,DescriptorName,D009270,7495990,,,6,Naloxone,N,
27165,QualifierName,Q000009,7495990,,,6,,N,adverse effects
27166,DescriptorName,D009294,7495990,,,7,Narcotics,N,
27167,QualifierName,Q000627,7495990,,,7,,Y,therapeutic use
27168,DescriptorName,D009422,7495990,,,8,Nervous System Diseases,N,
27169,QualifierName,Q000209,7495990,,,8,,Y,etiology
27170,DescriptorName,D010146,7495990,,,9,Pain,N,
27171,QualifierName,Q000188,7495990,,,9,,Y,drug therapy
27172,DescriptorName,D010147,7495990,,,10,Pain Measurement,N,
27173,Chemical,D013956,7519913,Antithyroid Agents,0,,,,
27174,Chemical,D013723,7519913,Teratogens,0,,,,
27175,Chemical,D008713,7519913,Methimazole,554Z48XN5E,,,,
27176,Chemical,D011441,7519913,Propylthiouracil,721M9407IY,,,,
27177,Chemical,D013974,7519913,Thyroxine,Q51BO43MG4,,,,
27178,DescriptorName,D000014,7519913,,,1,"Abnormalities, Drug-Induced",N,
27179,QualifierName,Q000473,7519913,,,1,,N,pathology
27180,DescriptorName,D000328,7519913,,,2,Adult,N,
27181,DescriptorName,D013956,7519913,,,3,Antithyroid Agents,N,
27182,QualifierName,Q000008,7519913,,,3,,N,administration & dosage
27183,DescriptorName,D002657,7519913,,,4,Child Development,N,
27184,QualifierName,Q000187,7519913,,,4,,N,drug effects
27185,DescriptorName,D005260,7519913,,,5,Female,N,
27186,DescriptorName,D006801,7519913,,,6,Humans,N,
27187,DescriptorName,D006980,7519913,,,7,Hyperthyroidism,N,
27188,QualifierName,Q000097,7519913,,,7,,N,blood
27189,DescriptorName,D007231,7519913,,,8,"Infant, Newborn",N,
27190,DescriptorName,D008431,7519913,,,9,Maternal-Fetal Exchange,N,
27191,DescriptorName,D008713,7519913,,,10,Methimazole,N,
27192,QualifierName,Q000009,7519913,,,10,,Y,adverse effects
27193,DescriptorName,D011247,7519913,,,11,Pregnancy,N,
27194,DescriptorName,D011248,7519913,,,12,Pregnancy Complications,N,
27195,QualifierName,Q000097,7519913,,,12,,N,blood
27196,DescriptorName,D011441,7519913,,,13,Propylthiouracil,N,
27197,QualifierName,Q000009,7519913,,,13,,N,adverse effects
27198,DescriptorName,D012868,7519913,,,14,Skin Abnormalities,Y,
27199,DescriptorName,D013723,7519913,,,15,Teratogens,N,
27200,DescriptorName,D013959,7519913,,,16,Thyroid Diseases,N,
27201,QualifierName,Q000139,7519913,,,16,,N,chemically induced
27202,DescriptorName,D013974,7519913,,,17,Thyroxine,N,
27203,QualifierName,Q000097,7519913,,,17,,N,blood
27204,Chemical,D005424,7526455,Flecainide,K94FTS1806,,,,
27205,DescriptorName,D000368,7526455,,,1,Aged,N,
27206,DescriptorName,D002524,7526455,,,2,Cerebellar Ataxia,N,
27207,QualifierName,Q000139,7526455,,,2,,Y,chemically induced
27208,DescriptorName,D004347,7526455,,,3,Drug Interactions,N,
27209,DescriptorName,D004359,7526455,,,4,"Drug Therapy, Combination",N,
27210,DescriptorName,D005424,7526455,,,5,Flecainide,N,
27211,QualifierName,Q000008,7526455,,,5,,N,administration & dosage
27212,DescriptorName,D006801,7526455,,,6,Humans,N,
27213,DescriptorName,D008297,7526455,,,7,Male,N,
27214,DescriptorName,D009207,7526455,,,8,Myoclonus,N,
27215,QualifierName,Q000139,7526455,,,8,,Y,chemically induced
27216,DescriptorName,D009460,7526455,,,9,Neurologic Examination,N,
27217,QualifierName,Q000187,7526455,,,9,,N,drug effects
27218,DescriptorName,D012307,7526455,,,10,Risk Factors,N,
27219,DescriptorName,D013617,7526455,,,11,"Tachycardia, Supraventricular",N,
27220,QualifierName,Q000188,7526455,,,11,,Y,drug therapy
27221,DescriptorName,D014927,7526455,,,12,Wolff-Parkinson-White Syndrome,N,
27222,QualifierName,Q000188,7526455,,,12,,Y,drug therapy
27223,Chemical,D007155,7538828,Immunologic Factors,0,,,,
27224,Chemical,D016179,7538828,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
27225,Chemical,D008727,7538828,Methotrexate,YL5FZ2Y5U1,,,,
27226,DescriptorName,D002294,7538828,,,1,"Carcinoma, Squamous Cell",N,
27227,QualifierName,Q000188,7538828,,,1,,N,drug therapy
27228,DescriptorName,D003131,7538828,,,2,Combined Modality Therapy,N,
27229,DescriptorName,D003875,7538828,,,3,Drug Eruptions,N,
27230,QualifierName,Q000209,7538828,,,3,,Y,etiology
27231,DescriptorName,D016179,7538828,,,4,Granulocyte Colony-Stimulating Factor,N,
27232,QualifierName,Q000627,7538828,,,4,,N,therapeutic use
27233,DescriptorName,D006801,7538828,,,5,Humans,N,
27234,DescriptorName,D007155,7538828,,,6,Immunologic Factors,N,
27235,QualifierName,Q000627,7538828,,,6,,N,therapeutic use
27236,DescriptorName,D007822,7538828,,,7,Laryngeal Neoplasms,N,
27237,QualifierName,Q000188,7538828,,,7,,Y,drug therapy
27238,DescriptorName,D008297,7538828,,,8,Male,N,
27239,DescriptorName,D008727,7538828,,,9,Methotrexate,N,
27240,QualifierName,Q000009,7538828,,,9,,Y,adverse effects
27241,DescriptorName,D008875,7538828,,,10,Middle Aged,N,
27242,DescriptorName,D010198,7538828,,,11,Pancytopenia,N,
27243,QualifierName,Q000139,7538828,,,11,,Y,chemically induced
27244,Chemical,D014408,7545251,"Biomarkers, Tumor",0,,,,
27245,Chemical,D002715,7545251,Chlormadinone Acetate,0SY050L61N,,,,
27246,Chemical,D007987,7545251,Gonadotropin-Releasing Hormone,33515-09-2,,,,
27247,Chemical,D013739,7545251,Testosterone,3XMK78S47O,,,,
27248,Chemical,D017430,7545251,Prostate-Specific Antigen,EC 3.4.21.77,,,,
27249,DescriptorName,D000230,7545251,,,1,Adenocarcinoma,N,
27250,QualifierName,Q000188,7545251,,,1,,Y,drug therapy
27251,DescriptorName,D000368,7545251,,,2,Aged,N,
27252,DescriptorName,D014408,7545251,,,3,"Biomarkers, Tumor",N,
27253,QualifierName,Q000097,7545251,,,3,,N,blood
27254,DescriptorName,D002715,7545251,,,4,Chlormadinone Acetate,N,
27255,QualifierName,Q000009,7545251,,,4,,Y,adverse effects
27256,DescriptorName,D007987,7545251,,,5,Gonadotropin-Releasing Hormone,N,
27257,QualifierName,Q000031,7545251,,,5,,Y,analogs & derivatives
27258,DescriptorName,D006801,7545251,,,6,Humans,N,
27259,DescriptorName,D008297,7545251,,,7,Male,N,
27260,DescriptorName,D009919,7545251,,,8,Orchiectomy,N,
27261,DescriptorName,D017430,7545251,,,9,Prostate-Specific Antigen,N,
27262,QualifierName,Q000097,7545251,,,9,,Y,blood
27263,DescriptorName,D011471,7545251,,,10,Prostatic Neoplasms,N,
27264,QualifierName,Q000188,7545251,,,10,,Y,drug therapy
27265,DescriptorName,D013739,7545251,,,11,Testosterone,N,
27266,QualifierName,Q000097,7545251,,,11,,N,blood
27267,Chemical,D006852,7549443,Hydrochlorothiazide,0J48LPH2TH,,,,
27268,Chemical,D008795,7549443,Metronidazole,140QMO216E,,,,
27269,Chemical,D015662,7549443,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
27270,DescriptorName,D000208,7549443,,,1,Acute Disease,N,
27271,DescriptorName,D000328,7549443,,,2,Adult,N,
27272,DescriptorName,D000867,7549443,,,3,Anterior Chamber,N,
27273,QualifierName,Q000000981,7549443,,,3,,N,diagnostic imaging
27274,DescriptorName,D005260,7549443,,,4,Female,N,
27275,DescriptorName,D005831,7549443,,,5,"Genital Diseases, Female",N,
27276,QualifierName,Q000188,7549443,,,5,,Y,drug therapy
27277,DescriptorName,D006801,7549443,,,6,Humans,N,
27278,DescriptorName,D006852,7549443,,,7,Hydrochlorothiazide,N,
27279,QualifierName,Q000009,7549443,,,7,,Y,adverse effects
27280,DescriptorName,D007908,7549443,,,8,"Lens, Crystalline",N,
27281,QualifierName,Q000187,7549443,,,8,,N,drug effects
27282,DescriptorName,D008795,7549443,,,9,Metronidazole,N,
27283,QualifierName,Q000009,7549443,,,9,,Y,adverse effects
27284,DescriptorName,D009216,7549443,,,10,Myopia,N,
27285,QualifierName,Q000139,7549443,,,10,,Y,chemically induced
27286,DescriptorName,D015662,7549443,,,11,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
27287,QualifierName,Q000009,7549443,,,11,,Y,adverse effects
27288,DescriptorName,D014463,7549443,,,12,Ultrasonography,N,
27289,Chemical,D000974,7577414,"Antibodies, Antinuclear",0,,,,
27290,Chemical,D000935,7577414,Antifungal Agents,0,,,,
27291,Chemical,D006118,7577414,Griseofulvin,32HRV3E3D5,,,,
27292,DescriptorName,D000293,7577414,,,1,Adolescent,N,
27293,DescriptorName,D000974,7577414,,,2,"Antibodies, Antinuclear",N,
27294,QualifierName,Q000032,7577414,,,2,,N,analysis
27295,DescriptorName,D000935,7577414,,,3,Antifungal Agents,N,
27296,QualifierName,Q000009,7577414,,,3,,Y,adverse effects
27297,DescriptorName,D019084,7577414,,,4,"Fluorescent Antibody Technique, Indirect",N,
27298,DescriptorName,D006118,7577414,,,5,Griseofulvin,N,
27299,QualifierName,Q000009,7577414,,,5,,Y,adverse effects
27300,DescriptorName,D006801,7577414,,,6,Humans,N,
27301,DescriptorName,D007678,7577414,,,7,Kidney Glomerulus,N,
27302,QualifierName,Q000473,7577414,,,7,,N,pathology
27303,DescriptorName,D008180,7577414,,,8,"Lupus Erythematosus, Systemic",N,
27304,QualifierName,Q000139,7577414,,,8,,Y,chemically induced
27305,DescriptorName,D008297,7577414,,,9,Male,N,
27306,DescriptorName,D008854,7577414,,,10,"Microscopy, Electron",N,
27307,DescriptorName,D009404,7577414,,,11,Nephrotic Syndrome,N,
27308,QualifierName,Q000139,7577414,,,11,,Y,chemically induced
27309,DescriptorName,D014006,7577414,,,12,Tinea Capitis,N,
27310,QualifierName,Q000188,7577414,,,12,,N,drug therapy
27311,Chemical,D018501,7582710,Antirheumatic Agents,0,,,,
27312,Chemical,D006052,7582710,Gold Sodium Thiomalate,12244-57-4,,,,
27313,DescriptorName,D000328,7582710,,,1,Adult,N,
27314,DescriptorName,D018501,7582710,,,2,Antirheumatic Agents,N,
27315,QualifierName,Q000008,7582710,,,2,,N,administration & dosage
27316,DescriptorName,D001172,7582710,,,3,"Arthritis, Rheumatoid",N,
27317,QualifierName,Q000188,7582710,,,3,,Y,drug therapy
27318,DescriptorName,D005260,7582710,,,4,Female,N,
27319,DescriptorName,D006052,7582710,,,5,Gold Sodium Thiomalate,N,
27320,QualifierName,Q000008,7582710,,,5,,N,administration & dosage
27321,DescriptorName,D006429,7582710,,,6,Hemiplegia,N,
27322,QualifierName,Q000209,7582710,,,6,,Y,etiology
27323,DescriptorName,D006801,7582710,,,7,Humans,N,
27324,DescriptorName,D007275,7582710,,,8,"Injections, Intravenous",N,
27325,DescriptorName,D007511,7582710,,,9,Ischemia,N,
27326,QualifierName,Q000209,7582710,,,9,,Y,etiology
27327,DescriptorName,D008875,7582710,,,10,Middle Aged,N,
27328,DescriptorName,D013116,7582710,,,11,Spinal Cord,N,
27329,QualifierName,Q000098,7582710,,,11,,Y,blood supply
27330,Chemical,D000894,7594371,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
27331,Chemical,D014325,7594371,Tromethamine,023C2WHX2V,,,,
27332,Chemical,D020911,7594371,Ketorolac Tromethamine,4EVE5946BQ,,,,
27333,Chemical,D014046,7594371,Tolmetin,D8K2JPN18B,,,,
27334,DescriptorName,D000208,7594371,,,1,Acute Disease,N,
27335,DescriptorName,D000328,7594371,,,2,Adult,N,
27336,DescriptorName,D000894,7594371,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
27337,QualifierName,Q000009,7594371,,,3,,Y,adverse effects
27338,DescriptorName,D001299,7594371,,,4,Audiometry,N,
27339,DescriptorName,D005260,7594371,,,5,Female,N,
27340,DescriptorName,D006319,7594371,,,6,"Hearing Loss, Sensorineural",N,
27341,QualifierName,Q000139,7594371,,,6,,Y,chemically induced
27342,DescriptorName,D006801,7594371,,,7,Humans,N,
27343,DescriptorName,D007275,7594371,,,8,"Injections, Intravenous",N,
27344,DescriptorName,D020911,7594371,,,9,Ketorolac Tromethamine,N,
27345,DescriptorName,D009443,7594371,,,10,Neuritis,N,
27346,QualifierName,Q000150,7594371,,,10,,N,complications
27347,DescriptorName,D010488,7594371,,,11,Polyarteritis Nodosa,N,
27348,QualifierName,Q000150,7594371,,,11,,Y,complications
27349,DescriptorName,D014046,7594371,,,12,Tolmetin,N,
27350,QualifierName,Q000009,7594371,,,12,,N,adverse effects
27351,DescriptorName,D014325,7594371,,,13,Tromethamine,N,
27352,QualifierName,Q000009,7594371,,,13,,N,adverse effects
27353,Chemical,D002945,7606071,Cisplatin,Q20Q21Q62J,,,,
27354,DescriptorName,D000328,7606071,,,1,Adult,N,
27355,DescriptorName,D000707,7606071,,,2,Anaphylaxis,N,
27356,QualifierName,Q000139,7606071,,,2,,Y,chemically induced
27357,DescriptorName,D002945,7606071,,,3,Cisplatin,N,
27358,QualifierName,Q000008,7606071,,,3,,N,administration & dosage
27359,DescriptorName,D004305,7606071,,,4,"Dose-Response Relationship, Drug",N,
27360,DescriptorName,D005260,7606071,,,5,Female,N,
27361,DescriptorName,D006801,7606071,,,6,Humans,N,
27362,DescriptorName,D007263,7606071,,,7,"Infusions, Parenteral",N,
27363,DescriptorName,D008875,7606071,,,8,Middle Aged,N,
27364,DescriptorName,D010051,7606071,,,9,Ovarian Neoplasms,N,
27365,QualifierName,Q000188,7606071,,,9,,N,drug therapy
27366,Chemical,D005047,7619765,Etoposide,6PLQ3CP4P3,,,,
27367,DescriptorName,D000328,7619765,,,1,Adult,N,
27368,DescriptorName,D005047,7619765,,,2,Etoposide,N,
27369,QualifierName,Q000009,7619765,,,2,,Y,adverse effects
27370,DescriptorName,D006801,7619765,,,3,Humans,N,
27371,DescriptorName,D008297,7619765,,,4,Male,N,
27372,DescriptorName,D009203,7619765,,,5,Myocardial Infarction,N,
27373,QualifierName,Q000139,7619765,,,5,,Y,chemically induced
27374,DescriptorName,D018239,7619765,,,6,Seminoma,N,
27375,QualifierName,Q000188,7619765,,,6,,N,drug therapy
27376,DescriptorName,D013724,7619765,,,7,Teratoma,N,
27377,QualifierName,Q000188,7619765,,,7,,N,drug therapy
27378,DescriptorName,D013736,7619765,,,8,Testicular Neoplasms,N,
27379,QualifierName,Q000188,7619765,,,8,,N,drug therapy
27380,Chemical,D000212,7632529,Acyclovir,X4HES1O11F,,,,
27381,DescriptorName,D058186,7632529,,,1,Acute Kidney Injury,N,
27382,QualifierName,Q000139,7632529,,,1,,Y,chemically induced
27383,DescriptorName,D000212,7632529,,,2,Acyclovir,N,
27384,QualifierName,Q000009,7632529,,,2,,Y,adverse effects
27385,DescriptorName,D002648,7632529,,,3,Child,N,
27386,DescriptorName,D018792,7632529,,,4,"Encephalitis, Viral",N,
27387,QualifierName,Q000188,7632529,,,4,,N,drug therapy
27388,DescriptorName,D006801,7632529,,,5,Humans,N,
27389,DescriptorName,D007262,7632529,,,6,"Infusions, Intravenous",N,
27390,DescriptorName,D008297,7632529,,,7,Male,N,
27391,Chemical,D016898,7639655,Interferon-alpha,0,,,,
27392,Chemical,D001241,7639655,Aspirin,R16CO5Y76E,,,,
27393,Chemical,D011241,7639655,Prednisone,VB0R961HZT,,,,
27394,DescriptorName,D000208,7639655,,,1,Acute Disease,N,
27395,DescriptorName,D000328,7639655,,,2,Adult,N,
27396,DescriptorName,D001241,7639655,,,3,Aspirin,N,
27397,QualifierName,Q000627,7639655,,,3,,N,therapeutic use
27398,DescriptorName,D002292,7639655,,,4,"Carcinoma, Renal Cell",N,
27399,QualifierName,Q000628,7639655,,,4,,N,therapy
27400,DescriptorName,D005654,7639655,,,5,Fundus Oculi,N,
27401,DescriptorName,D006801,7639655,,,6,Humans,N,
27402,DescriptorName,D016898,7639655,,,7,Interferon-alpha,N,
27403,QualifierName,Q000009,7639655,,,7,,Y,adverse effects
27404,DescriptorName,D007511,7639655,,,8,Ischemia,N,
27405,QualifierName,Q000139,7639655,,,8,,Y,chemically induced
27406,DescriptorName,D007680,7639655,,,9,Kidney Neoplasms,N,
27407,QualifierName,Q000628,7639655,,,9,,N,therapy
27408,DescriptorName,D008297,7639655,,,10,Male,N,
27409,DescriptorName,D008875,7639655,,,11,Middle Aged,N,
27410,DescriptorName,D009101,7639655,,,12,Multiple Myeloma,N,
27411,QualifierName,Q000628,7639655,,,12,,N,therapy
27412,DescriptorName,D009900,7639655,,,13,Optic Nerve,N,
27413,QualifierName,Q000098,7639655,,,13,,Y,blood supply
27414,DescriptorName,D009901,7639655,,,14,Optic Nerve Diseases,N,
27415,QualifierName,Q000139,7639655,,,14,,Y,chemically induced
27416,DescriptorName,D011241,7639655,,,15,Prednisone,N,
27417,QualifierName,Q000627,7639655,,,15,,N,therapeutic use
27418,DescriptorName,D014786,7639655,,,16,Vision Disorders,N,
27419,QualifierName,Q000139,7639655,,,16,,N,chemically induced
27420,DescriptorName,D014792,7639655,,,17,Visual Acuity,N,
27421,DescriptorName,D014794,7639655,,,18,Visual Fields,N,
27422,Chemical,D000639,7647084,Amitriptyline,1806D8D52K,,,,
27423,Chemical,D016651,7647084,Lithium Carbonate,2BMD2GNA4V,,,,
27424,DescriptorName,D000639,7647084,,,1,Amitriptyline,N,
27425,QualifierName,Q000008,7647084,,,1,,N,administration & dosage
27426,DescriptorName,D001714,7647084,,,2,Bipolar Disorder,N,
27427,QualifierName,Q000188,7647084,,,2,,Y,drug therapy
27428,DescriptorName,D004359,7647084,,,3,"Drug Therapy, Combination",N,
27429,DescriptorName,D006801,7647084,,,4,Humans,N,
27430,DescriptorName,D007418,7647084,,,5,Intestinal Pseudo-Obstruction,N,
27431,QualifierName,Q000139,7647084,,,5,,N,chemically induced
27432,DescriptorName,D016651,7647084,,,6,Lithium Carbonate,N,
27433,QualifierName,Q000008,7647084,,,6,,N,administration & dosage
27434,DescriptorName,D008297,7647084,,,7,Male,N,
27435,DescriptorName,D008875,7647084,,,8,Middle Aged,N,
27436,DescriptorName,D009459,7647084,,,9,Neuroleptic Malignant Syndrome,N,
27437,QualifierName,Q000175,7647084,,,9,,N,diagnosis
27438,Chemical,D016568,7655130,"Drugs, Generic",0,,,,
27439,Chemical,D013972,7655130,Thyrotropin,9002-71-5,,,,
27440,Chemical,D013974,7655130,Thyroxine,Q51BO43MG4,,,,
27441,DescriptorName,D000328,7655130,,,1,Adult,N,
27442,DescriptorName,D016568,7655130,,,2,"Drugs, Generic",N,
27443,DescriptorName,D005260,7655130,,,3,Female,N,
27444,DescriptorName,D006801,7655130,,,4,Humans,N,
27445,DescriptorName,D007037,7655130,,,5,Hypothyroidism,N,
27446,QualifierName,Q000097,7655130,,,5,,N,blood
27447,DescriptorName,D011247,7655130,,,6,Pregnancy,N,
27448,DescriptorName,D011248,7655130,,,7,Pregnancy Complications,N,
27449,QualifierName,Q000097,7655130,,,7,,N,blood
27450,DescriptorName,D013810,7655130,,,8,Therapeutic Equivalency,N,
27451,DescriptorName,D013972,7655130,,,9,Thyrotropin,N,
27452,QualifierName,Q000097,7655130,,,9,,Y,blood
27453,DescriptorName,D013974,7655130,,,10,Thyroxine,N,
27454,QualifierName,Q000009,7655130,,,10,,Y,adverse effects
27455,Chemical,D000241,7661076,Adenosine,K72T3FS567,,,,
27456,DescriptorName,D000241,7661076,,,1,Adenosine,N,
27457,QualifierName,Q000008,7661076,,,1,,N,administration & dosage
27458,DescriptorName,D000368,7661076,,,2,Aged,N,
27459,DescriptorName,D001145,7661076,,,3,"Arrhythmias, Cardiac",N,
27460,QualifierName,Q000139,7661076,,,3,,N,chemically induced
27461,DescriptorName,D001282,7661076,,,4,Atrial Flutter,N,
27462,QualifierName,Q000150,7661076,,,4,,N,complications
27463,DescriptorName,D004562,7661076,,,5,Electrocardiography,N,
27464,QualifierName,Q000187,7661076,,,5,,N,drug effects
27465,DescriptorName,D004630,7661076,,,6,Emergencies,N,
27466,DescriptorName,D006339,7661076,,,7,Heart Rate,N,
27467,QualifierName,Q000187,7661076,,,7,,Y,drug effects
27468,DescriptorName,D006801,7661076,,,8,Humans,N,
27469,DescriptorName,D008297,7661076,,,9,Male,N,
27470,DescriptorName,D008875,7661076,,,10,Middle Aged,N,
27471,Chemical,D011405,7663030,Propafenone,68IQX3T69U,,,,
27472,DescriptorName,D000647,7663030,,,1,Amnesia,N,
27473,QualifierName,Q000139,7663030,,,1,,Y,chemically induced
27474,DescriptorName,D001281,7663030,,,2,Atrial Fibrillation,N,
27475,QualifierName,Q000150,7663030,,,2,,N,complications
27476,DescriptorName,D006801,7663030,,,3,Humans,N,
27477,DescriptorName,D008297,7663030,,,4,Male,N,
27478,DescriptorName,D008875,7663030,,,5,Middle Aged,N,
27479,DescriptorName,D011405,7663030,,,6,Propafenone,N,
27480,QualifierName,Q000009,7663030,,,6,,Y,adverse effects
27481,DescriptorName,D012804,7663030,,,7,Sick Sinus Syndrome,N,
27482,QualifierName,Q000150,7663030,,,7,,N,complications
27483,Chemical,D001241,7668127,Aspirin,R16CO5Y76E,,,,
27484,DescriptorName,D000368,7668127,,,1,Aged,N,
27485,DescriptorName,D001241,7668127,,,2,Aspirin,N,
27486,QualifierName,Q000008,7668127,,,2,,N,administration & dosage
27487,DescriptorName,D003399,7668127,,,3,Craniotomy,N,
27488,DescriptorName,D005260,7668127,,,4,Female,N,
27489,DescriptorName,D006408,7668127,,,5,"Hematoma, Subdural",N,
27490,QualifierName,Q000139,7668127,,,5,,Y,chemically induced
27491,DescriptorName,D006801,7668127,,,6,Humans,N,
27492,DescriptorName,D002546,7668127,,,7,"Ischemic Attack, Transient",N,
27493,QualifierName,Q000188,7668127,,,7,,Y,drug therapy
27494,DescriptorName,D008577,7668127,,,8,Meningeal Neoplasms,N,
27495,QualifierName,Q000150,7668127,,,8,,Y,complications
27496,DescriptorName,D008579,7668127,,,9,Meningioma,N,
27497,QualifierName,Q000150,7668127,,,9,,Y,complications
27498,DescriptorName,D011183,7668127,,,10,Postoperative Complications,N,
27499,QualifierName,Q000000981,7668127,,,10,,N,diagnostic imaging
27500,DescriptorName,D014057,7668127,,,11,"Tomography, X-Ray Computed",N,
27501,Chemical,D001712,7673653,Biperiden,0FRP6G56LD,,,,
27502,Chemical,D008803,7673653,Mianserin,250PJI13LM,,,,
27503,Chemical,D016666,7673653,Fluvoxamine,O4L1XPO44W,,,,
27504,DescriptorName,D000328,7673653,,,1,Adult,N,
27505,DescriptorName,D017109,7673653,,,2,"Akathisia, Drug-Induced",N,
27506,QualifierName,Q000188,7673653,,,2,,Y,drug therapy
27507,DescriptorName,D001712,7673653,,,3,Biperiden,N,
27508,QualifierName,Q000494,7673653,,,3,,N,pharmacology
27509,DescriptorName,D016666,7673653,,,4,Fluvoxamine,N,
27510,QualifierName,Q000009,7673653,,,4,,Y,adverse effects
27511,DescriptorName,D005500,7673653,,,5,Follow-Up Studies,N,
27512,DescriptorName,D006801,7673653,,,6,Humans,N,
27513,DescriptorName,D008297,7673653,,,7,Male,N,
27514,DescriptorName,D008803,7673653,,,8,Mianserin,N,
27515,QualifierName,Q000627,7673653,,,8,,Y,therapeutic use
27516,DescriptorName,D009771,7673653,,,9,Obsessive-Compulsive Disorder,N,
27517,QualifierName,Q000188,7673653,,,9,,Y,drug therapy
27518,Chemical,D001761,7679525,Bleomycin,11056-06-7,,,,
27519,Chemical,D011239,7679525,Prednisolone,9PHQ9Y1OLM,,,,
27520,Chemical,D001379,7679525,Azathioprine,MRK240IY2L,,,,
27521,DescriptorName,D000328,7679525,,,1,Adult,N,
27522,DescriptorName,D001379,7679525,,,2,Azathioprine,N,
27523,QualifierName,Q000627,7679525,,,2,,Y,therapeutic use
27524,DescriptorName,D001761,7679525,,,3,Bleomycin,N,
27525,QualifierName,Q000009,7679525,,,3,,Y,adverse effects
27526,DescriptorName,D004334,7679525,,,4,Drug Administration Schedule,N,
27527,DescriptorName,D004359,7679525,,,5,"Drug Therapy, Combination",N,
27528,DescriptorName,D006801,7679525,,,6,Humans,N,
27529,DescriptorName,D008168,7679525,,,7,Lung,N,
27530,QualifierName,Q000187,7679525,,,7,,Y,drug effects
27531,DescriptorName,D008297,7679525,,,8,Male,N,
27532,DescriptorName,D011239,7679525,,,9,Prednisolone,N,
27533,QualifierName,Q000627,7679525,,,9,,Y,therapeutic use
27534,DescriptorName,D011658,7679525,,,10,Pulmonary Fibrosis,N,
27535,QualifierName,Q000139,7679525,,,10,,Y,chemically induced
27536,Chemical,D006052,7685228,Gold Sodium Thiomalate,12244-57-4,,,,
27537,Chemical,D016179,7685228,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
27538,DescriptorName,D000368,7685228,,,1,Aged,N,
27539,DescriptorName,D001172,7685228,,,2,"Arthritis, Rheumatoid",N,
27540,QualifierName,Q000188,7685228,,,2,,Y,drug therapy
27541,DescriptorName,D005260,7685228,,,3,Female,N,
27542,DescriptorName,D006052,7685228,,,4,Gold Sodium Thiomalate,N,
27543,QualifierName,Q000009,7685228,,,4,,Y,adverse effects
27544,DescriptorName,D016179,7685228,,,5,Granulocyte Colony-Stimulating Factor,N,
27545,QualifierName,Q000627,7685228,,,5,,Y,therapeutic use
27546,DescriptorName,D006801,7685228,,,6,Humans,N,
27547,DescriptorName,D009503,7685228,,,7,Neutropenia,N,
27548,QualifierName,Q000139,7685228,,,7,,N,chemically induced
27549,Chemical,D000666,7696938,Amphotericin B,7XU7A7DROE,,,,
27550,Chemical,D012964,7696938,Sodium,9NEZ333N27,,,,
27551,Chemical,D011188,7696938,Potassium,RWP5GA015D,,,,
27552,Chemical,D002118,7696938,Calcium,SY7Q814VUP,,,,
27553,DescriptorName,D000328,7696938,,,1,Adult,N,
27554,DescriptorName,D000666,7696938,,,2,Amphotericin B,N,
27555,QualifierName,Q000009,7696938,,,2,,Y,adverse effects
27556,DescriptorName,D001145,7696938,,,3,"Arrhythmias, Cardiac",N,
27557,QualifierName,Q000209,7696938,,,3,,N,etiology
27558,DescriptorName,D002118,7696938,,,4,Calcium,N,
27559,QualifierName,Q000097,7696938,,,4,,N,blood
27560,DescriptorName,D002648,7696938,,,5,Child,N,
27561,DescriptorName,D005260,7696938,,,6,Female,N,
27562,DescriptorName,D006323,7696938,,,7,Heart Arrest,N,
27563,QualifierName,Q000209,7696938,,,7,,N,etiology
27564,DescriptorName,D006801,7696938,,,8,Humans,N,
27565,DescriptorName,D007898,7696938,,,9,"Leishmaniasis, Visceral",N,
27566,QualifierName,Q000188,7696938,,,9,,Y,drug therapy
27567,DescriptorName,D008297,7696938,,,10,Male,N,
27568,DescriptorName,D011188,7696938,,,11,Potassium,N,
27569,QualifierName,Q000097,7696938,,,11,,N,blood
27570,DescriptorName,D012964,7696938,,,12,Sodium,N,
27571,QualifierName,Q000097,7696938,,,12,,N,blood
27572,DescriptorName,D014883,7696938,,,13,Water-Electrolyte Imbalance,N,
27573,QualifierName,Q000097,7696938,,,13,,N,blood
27574,Chemical,D016651,7712052,Lithium Carbonate,2BMD2GNA4V,,,,
27575,DescriptorName,D000328,7712052,,,1,Adult,N,
27576,DescriptorName,D000786,7712052,,,2,Anger,N,
27577,QualifierName,Q000187,7712052,,,2,,Y,drug effects
27578,DescriptorName,D003130,7712052,,,3,Combat Disorders,N,
27579,QualifierName,Q000188,7712052,,,3,,Y,drug therapy
27580,DescriptorName,D006801,7712052,,,4,Humans,N,
27581,DescriptorName,D007398,7712052,,,5,Interpersonal Relations,N,
27582,DescriptorName,D007508,7712052,,,6,Irritable Mood,N,
27583,QualifierName,Q000187,7712052,,,6,,Y,drug effects
27584,DescriptorName,D016651,7712052,,,7,Lithium Carbonate,N,
27585,QualifierName,Q000009,7712052,,,7,,N,adverse effects
27586,DescriptorName,D008297,7712052,,,8,Male,N,
27587,DescriptorName,D014728,7712052,,,9,Veterans,N,
27588,QualifierName,Q000523,7712052,,,9,,Y,psychology
27589,DescriptorName,D014754,7712052,,,10,Violence,N,
27590,Chemical,D001323,7718983,Autoantibodies,0,,,,
27591,Chemical,D016898,7718983,Interferon-alpha,0,,,,
27592,Chemical,D011989,7718983,"Receptors, Thyrotropin",0,,,,
27593,DescriptorName,D001323,7718983,,,1,Autoantibodies,N,
27594,QualifierName,Q000097,7718983,,,1,,N,blood
27595,DescriptorName,D005260,7718983,,,2,Female,N,
27596,DescriptorName,D006111,7718983,,,3,Graves Disease,N,
27597,QualifierName,Q000139,7718983,,,3,,Y,chemically induced
27598,DescriptorName,D006526,7718983,,,4,Hepatitis C,N,
27599,QualifierName,Q000188,7718983,,,4,,Y,drug therapy
27600,DescriptorName,D006521,7718983,,,5,"Hepatitis, Chronic",N,
27601,QualifierName,Q000188,7718983,,,5,,Y,drug therapy
27602,DescriptorName,D006801,7718983,,,6,Humans,N,
27603,DescriptorName,D016898,7718983,,,7,Interferon-alpha,N,
27604,QualifierName,Q000009,7718983,,,7,,Y,adverse effects
27605,DescriptorName,D008875,7718983,,,8,Middle Aged,N,
27606,DescriptorName,D011863,7718983,,,9,Radioimmunoassay,N,
27607,DescriptorName,D011989,7718983,,,10,"Receptors, Thyrotropin",N,
27608,QualifierName,Q000276,7718983,,,10,,N,immunology
27609,DescriptorName,D013971,7718983,,,11,Thyrotoxicosis,N,
27610,QualifierName,Q000150,7718983,,,11,,Y,complications
27611,Chemical,D011736,7724306,Pyridoxine,KV2JZ1BI6Z,,,,
27612,Chemical,D007538,7724306,Isoniazid,V83O1VOZ8L,,,,
27613,DescriptorName,D000208,7724306,,,1,Acute Disease,N,
27614,DescriptorName,D000293,7724306,,,2,Adolescent,N,
27615,DescriptorName,D002648,7724306,,,3,Child,N,
27616,DescriptorName,D005260,7724306,,,4,Female,N,
27617,DescriptorName,D006801,7724306,,,5,Humans,N,
27618,DescriptorName,D007231,7724306,,,6,"Infant, Newborn",N,
27619,DescriptorName,D007262,7724306,,,7,"Infusions, Intravenous",N,
27620,DescriptorName,D007538,7724306,,,8,Isoniazid,N,
27621,QualifierName,Q000506,7724306,,,8,,Y,poisoning
27622,DescriptorName,D008297,7724306,,,9,Male,N,
27623,DescriptorName,D011041,7724306,,,10,Poisoning,N,
27624,QualifierName,Q000188,7724306,,,10,,N,drug therapy
27625,DescriptorName,D011736,7724306,,,11,Pyridoxine,N,
27626,QualifierName,Q000627,7724306,,,11,,Y,therapeutic use
27627,DescriptorName,D012189,7724306,,,12,Retrospective Studies,N,
27628,DescriptorName,D012640,7724306,,,13,Seizures,N,
27629,QualifierName,Q000139,7724306,,,13,,Y,chemically induced
27630,DescriptorName,D013406,7724306,,,14,"Suicide, Attempted",N,
27631,DescriptorName,D014397,7724306,,,15,"Tuberculosis, Pulmonary",N,
27632,QualifierName,Q000188,7724306,,,15,,N,drug therapy
27633,Chemical,D009883,7730124,Ophthalmic Solutions,0,,,,
27634,Chemical,D010656,7730124,Phenylephrine,1WS297W6MV,,,,
27635,Chemical,D000075,7730124,Acepromazine,54EJ303F0R,,,,
27636,DescriptorName,D000075,7730124,,,1,Acepromazine,N,
27637,QualifierName,Q000627,7730124,,,1,,N,therapeutic use
27638,DescriptorName,D000818,7730124,,,2,Animals,N,
27639,DescriptorName,D001794,7730124,,,3,Blood Pressure,N,
27640,QualifierName,Q000187,7730124,,,3,,N,drug effects
27641,DescriptorName,D002387,7730124,,,4,Cataract Extraction,N,
27642,QualifierName,Q000662,7730124,,,4,,N,veterinary
27643,DescriptorName,D004283,7730124,,,5,Dog Diseases,N,
27644,QualifierName,Q000139,7730124,,,5,,Y,chemically induced
27645,DescriptorName,D004285,7730124,,,6,Dogs,N,
27646,DescriptorName,D005260,7730124,,,7,Female,N,
27647,DescriptorName,D006973,7730124,,,8,Hypertension,N,
27648,QualifierName,Q000139,7730124,,,8,,N,chemically induced
27649,DescriptorName,D008297,7730124,,,9,Male,N,
27650,DescriptorName,D009883,7730124,,,10,Ophthalmic Solutions,N,
27651,DescriptorName,D010656,7730124,,,11,Phenylephrine,N,
27652,QualifierName,Q000008,7730124,,,11,,N,administration & dosage
27653,Chemical,D011372,7748076,Progestins,0,,,,
27654,DescriptorName,D000328,7748076,,,1,Adult,N,
27655,DescriptorName,D001706,7748076,,,2,Biopsy,N,
27656,DescriptorName,D004714,7748076,,,3,Endometrial Hyperplasia,N,
27657,QualifierName,Q000188,7748076,,,3,,Y,drug therapy
27658,DescriptorName,D004717,7748076,,,4,Endometrium,N,
27659,QualifierName,Q000473,7748076,,,4,,Y,pathology
27660,DescriptorName,D005260,7748076,,,5,Female,N,
27661,DescriptorName,D006801,7748076,,,6,Humans,N,
27662,DescriptorName,D008679,7748076,,,7,Metaplasia,N,
27663,QualifierName,Q000139,7748076,,,7,,N,chemically induced
27664,DescriptorName,D008875,7748076,,,8,Middle Aged,N,
27665,DescriptorName,D011372,7748076,,,9,Progestins,N,
27666,QualifierName,Q000009,7748076,,,9,,Y,adverse effects
27667,DescriptorName,D012189,7748076,,,10,Retrospective Studies,N,
27668,Chemical,D005665,7752014,Furosemide,7LXU5N7ZO5,,,,
27669,DescriptorName,D002675,7752014,,,1,"Child, Preschool",N,
27670,DescriptorName,D005260,7752014,,,2,Female,N,
27671,DescriptorName,D005335,7752014,,,3,Fever of Unknown Origin,N,
27672,QualifierName,Q000139,7752014,,,3,,Y,chemically induced
27673,DescriptorName,D005500,7752014,,,4,Follow-Up Studies,N,
27674,DescriptorName,D005665,7752014,,,5,Furosemide,N,
27675,QualifierName,Q000009,7752014,,,5,,Y,adverse effects
27676,DescriptorName,D006333,7752014,,,6,Heart Failure,N,
27677,QualifierName,Q000188,7752014,,,6,,Y,drug therapy
27678,DescriptorName,D006801,7752014,,,7,Humans,N,
27679,DescriptorName,D012008,7752014,,,8,Recurrence,N,
27680,DescriptorName,D013997,7752014,,,9,Time Factors,N,
27681,Chemical,D000970,7756684,Antineoplastic Agents,0,,,,
27682,Chemical,D008937,7756684,Mitomycins,0,,,,
27683,Chemical,C057625,7756684,KW 2149,118359-59-4,,,,
27684,Chemical,D016685,7756684,Mitomycin,50SG953SK6,,,,
27685,DescriptorName,D000230,7756684,,,1,Adenocarcinoma,N,
27686,QualifierName,Q000188,7756684,,,1,,N,drug therapy
27687,DescriptorName,D000328,7756684,,,2,Adult,N,
27688,DescriptorName,D000368,7756684,,,3,Aged,N,
27689,DescriptorName,D000970,7756684,,,4,Antineoplastic Agents,N,
27690,QualifierName,Q000008,7756684,,,4,,N,administration & dosage
27691,DescriptorName,D001711,7756684,,,5,Biotransformation,N,
27692,DescriptorName,D001855,7756684,,,6,Bone Marrow Diseases,N,
27693,QualifierName,Q000139,7756684,,,6,,N,chemically induced
27694,DescriptorName,D002289,7756684,,,7,"Carcinoma, Non-Small-Cell Lung",N,
27695,QualifierName,Q000188,7756684,,,7,,N,drug therapy
27696,DescriptorName,D004305,7756684,,,8,"Dose-Response Relationship, Drug",N,
27697,DescriptorName,D004334,7756684,,,9,Drug Administration Schedule,N,
27698,DescriptorName,D005260,7756684,,,10,Female,N,
27699,DescriptorName,D005767,7756684,,,11,Gastrointestinal Diseases,N,
27700,QualifierName,Q000139,7756684,,,11,,N,chemically induced
27701,DescriptorName,D006207,7756684,,,12,Half-Life,N,
27702,DescriptorName,D006801,7756684,,,13,Humans,N,
27703,DescriptorName,D008113,7756684,,,14,Liver Neoplasms,N,
27704,QualifierName,Q000188,7756684,,,14,,N,drug therapy
27705,DescriptorName,D008171,7756684,,,15,Lung Diseases,N,
27706,QualifierName,Q000139,7756684,,,15,,N,chemically induced
27707,DescriptorName,D008175,7756684,,,16,Lung Neoplasms,N,
27708,QualifierName,Q000188,7756684,,,16,,N,drug therapy
27709,DescriptorName,D008297,7756684,,,17,Male,N,
27710,DescriptorName,D008875,7756684,,,18,Middle Aged,N,
27711,DescriptorName,D016685,7756684,,,19,Mitomycin,N,
27712,QualifierName,Q000008,7756684,,,19,,N,administration & dosage
27713,DescriptorName,D008937,7756684,,,20,Mitomycins,Y,
27714,DescriptorName,D009369,7756684,,,21,Neoplasms,N,
27715,QualifierName,Q000188,7756684,,,21,,Y,drug therapy
27716,DescriptorName,D009382,7756684,,,22,"Neoplasms, Unknown Primary",N,
27717,QualifierName,Q000188,7756684,,,22,,N,drug therapy
27718,DescriptorName,D016879,7756684,,,23,Salvage Therapy,N,
27719,Chemical,D001639,7761316,Bicarbonates,0,,,,
27720,Chemical,D002117,7761316,Calcitriol,FXC9231JVH,,,,
27721,Chemical,D007069,7761316,Ifosfamide,UM20QQM95Y,,,,
27722,DescriptorName,D000971,7761316,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
27723,QualifierName,Q000009,7761316,,,1,,Y,adverse effects
27724,DescriptorName,D001639,7761316,,,2,Bicarbonates,N,
27725,QualifierName,Q000627,7761316,,,2,,N,therapeutic use
27726,DescriptorName,D002117,7761316,,,3,Calcitriol,N,
27727,QualifierName,Q000627,7761316,,,3,,N,therapeutic use
27728,DescriptorName,D002648,7761316,,,4,Child,N,
27729,DescriptorName,D002675,7761316,,,5,"Child, Preschool",N,
27730,DescriptorName,D005198,7761316,,,6,Fanconi Syndrome,N,
27731,QualifierName,Q000139,7761316,,,6,,N,chemically induced
27732,DescriptorName,D005260,7761316,,,7,Female,N,
27733,DescriptorName,D005598,7761316,,,8,"Fractures, Spontaneous",N,
27734,QualifierName,Q000000981,7761316,,,8,,N,diagnostic imaging
27735,DescriptorName,D006801,7761316,,,9,Humans,N,
27736,DescriptorName,D007069,7761316,,,10,Ifosfamide,N,
27737,QualifierName,Q000008,7761316,,,10,,N,administration & dosage
27738,DescriptorName,D007223,7761316,,,11,Infant,N,
27739,DescriptorName,D007680,7761316,,,12,Kidney Neoplasms,N,
27740,QualifierName,Q000188,7761316,,,12,,Y,drug therapy
27741,DescriptorName,D008297,7761316,,,13,Male,N,
27742,DescriptorName,D009364,7761316,,,14,"Neoplasm Recurrence, Local",N,
27743,QualifierName,Q000188,7761316,,,14,,Y,drug therapy
27744,DescriptorName,D011859,7761316,,,15,Radiography,N,
27745,DescriptorName,D012279,7761316,,,16,Rickets,N,
27746,QualifierName,Q000139,7761316,,,16,,Y,chemically induced
27747,DescriptorName,D009396,7761316,,,17,Wilms Tumor,N,
27748,QualifierName,Q000188,7761316,,,17,,Y,drug therapy
27749,Chemical,D005343,7776854,Fibrinolytic Agents,0,,,,
27750,Chemical,C004528,7776854,benzarone,23ZW4BG89C,,,,
27751,Chemical,D001553,7776854,Benzbromarone,4POG0RL69O,,,,
27752,DescriptorName,D000328,7776854,,,1,Adult,N,
27753,DescriptorName,D000368,7776854,,,2,Aged,N,
27754,DescriptorName,D001553,7776854,,,3,Benzbromarone,N,
27755,QualifierName,Q000008,7776854,,,3,,N,administration & dosage
27756,DescriptorName,D001706,7776854,,,4,Biopsy,N,
27757,DescriptorName,D056486,7776854,,,5,Chemical and Drug Induced Liver Injury,N,
27758,QualifierName,Q000473,7776854,,,5,,Y,pathology
27759,DescriptorName,D056487,7776854,,,6,"Chemical and Drug Induced Liver Injury, Chronic",N,
27760,DescriptorName,D017809,7776854,,,7,Fatal Outcome,N,
27761,DescriptorName,D005260,7776854,,,8,Female,N,
27762,DescriptorName,D005343,7776854,,,9,Fibrinolytic Agents,N,
27763,QualifierName,Q000008,7776854,,,9,,N,administration & dosage
27764,DescriptorName,D006501,7776854,,,10,Hepatic Encephalopathy,N,
27765,QualifierName,Q000139,7776854,,,10,,Y,chemically induced
27766,DescriptorName,D006521,7776854,,,11,"Hepatitis, Chronic",N,
27767,QualifierName,Q000473,7776854,,,11,,N,pathology
27768,DescriptorName,D006801,7776854,,,12,Humans,N,
27769,DescriptorName,D008099,7776854,,,13,Liver,N,
27770,QualifierName,Q000187,7776854,,,13,,N,drug effects
27771,DescriptorName,D008103,7776854,,,14,Liver Cirrhosis,N,
27772,QualifierName,Q000139,7776854,,,14,,N,chemically induced
27773,DescriptorName,D008297,7776854,,,15,Male,N,
27774,DescriptorName,D013924,7776854,,,16,Thrombophlebitis,N,
27775,QualifierName,Q000188,7776854,,,16,,N,drug therapy
27776,DescriptorName,D014689,7776854,,,17,Venous Insufficiency,N,
27777,QualifierName,Q000188,7776854,,,17,,N,drug therapy
27778,Chemical,D004338,7779233,Drug Combinations,0,,,,
27779,Chemical,D012965,7779233,Sodium Chloride,451W47IQ8X,,,,
27780,Chemical,D014859,7779233,Warfarin,5Q7ZVV76EI,,,,
27781,Chemical,D000536,7779233,Aluminum Hydroxide,5QB0T2IUN0,,,,
27782,Chemical,D015032,7779233,Zinc,J41CSQ7QDS,,,,
27783,Chemical,D012837,7779233,Silver Sulfadiazine,W46JY43EJR,,,,
27784,DescriptorName,D000279,7779233,,,1,"Administration, Cutaneous",N,
27785,DescriptorName,D000536,7779233,,,2,Aluminum Hydroxide,N,
27786,QualifierName,Q000627,7779233,,,2,,N,therapeutic use
27787,DescriptorName,D001458,7779233,,,3,Bandages,N,
27788,DescriptorName,D004338,7779233,,,4,Drug Combinations,N,
27789,DescriptorName,D005208,7779233,,,5,Fasciitis,N,
27790,QualifierName,Q000139,7779233,,,5,,Y,chemically induced
27791,DescriptorName,D005260,7779233,,,6,Female,N,
27792,DescriptorName,D006801,7779233,,,7,Humans,N,
27793,DescriptorName,D008875,7779233,,,8,Middle Aged,N,
27794,DescriptorName,D009336,7779233,,,9,Necrosis,N,
27795,DescriptorName,D012837,7779233,,,10,Silver Sulfadiazine,N,
27796,QualifierName,Q000627,7779233,,,10,,Y,therapeutic use
27797,DescriptorName,D012965,7779233,,,11,Sodium Chloride,N,
27798,QualifierName,Q000627,7779233,,,11,,N,therapeutic use
27799,DescriptorName,D014859,7779233,,,12,Warfarin,N,
27800,QualifierName,Q000009,7779233,,,12,,Y,adverse effects
27801,DescriptorName,D015032,7779233,,,13,Zinc,N,
27802,QualifierName,Q000627,7779233,,,13,,N,therapeutic use
27803,Chemical,D015767,7781845,Mefloquine,TML814419R,,,,
27804,DescriptorName,D000163,7781845,,,1,Acquired Immunodeficiency Syndrome,N,
27805,QualifierName,Q000150,7781845,,,1,,Y,complications
27806,DescriptorName,D000328,7781845,,,2,Adult,N,
27807,DescriptorName,D002100,7781845,,,3,Cachexia,N,
27808,QualifierName,Q000209,7781845,,,3,,Y,etiology
27809,DescriptorName,D003457,7781845,,,4,Cryptosporidiosis,N,
27810,QualifierName,Q000150,7781845,,,4,,N,complications
27811,DescriptorName,D006801,7781845,,,5,Humans,N,
27812,DescriptorName,D007003,7781845,,,6,Hypoglycemia,N,
27813,QualifierName,Q000139,7781845,,,6,,Y,chemically induced
27814,DescriptorName,D008297,7781845,,,7,Male,N,
27815,DescriptorName,D015767,7781845,,,8,Mefloquine,N,
27816,QualifierName,Q000009,7781845,,,8,,Y,adverse effects
27817,Chemical,D018170,7783891,Sumatriptan,8R78F6L9VO,,,,
27818,DescriptorName,D000328,7783891,,,1,Adult,N,
27819,DescriptorName,D003327,7783891,,,2,Coronary Disease,N,
27820,QualifierName,Q000150,7783891,,,2,,N,complications
27821,DescriptorName,D005260,7783891,,,3,Female,N,
27822,DescriptorName,D006323,7783891,,,4,Heart Arrest,N,
27823,QualifierName,Q000139,7783891,,,4,,Y,chemically induced
27824,DescriptorName,D006801,7783891,,,5,Humans,N,
27825,DescriptorName,D008881,7783891,,,6,Migraine Disorders,N,
27826,QualifierName,Q000150,7783891,,,6,,N,complications
27827,DescriptorName,D018170,7783891,,,7,Sumatriptan,N,
27828,QualifierName,Q000009,7783891,,,7,,Y,adverse effects
27829,Chemical,D005934,7787496,Glucagon,9007-92-5,,,,
27830,Chemical,D013015,7787496,Sotalol,A6D97U294I,,,,
27831,DescriptorName,D000368,7787496,,,1,Aged,N,
27832,DescriptorName,D000369,7787496,,,2,"Aged, 80 and over",N,
27833,DescriptorName,D001919,7787496,,,3,Bradycardia,N,
27834,QualifierName,Q000139,7787496,,,3,,N,chemically induced
27835,DescriptorName,D004562,7787496,,,4,Electrocardiography,N,
27836,DescriptorName,D005260,7787496,,,5,Female,N,
27837,DescriptorName,D005934,7787496,,,6,Glucagon,N,
27838,QualifierName,Q000494,7787496,,,6,,N,pharmacology
27839,DescriptorName,D006801,7787496,,,7,Humans,N,
27840,DescriptorName,D013015,7787496,,,8,Sotalol,N,
27841,QualifierName,Q000009,7787496,,,8,,Y,adverse effects
27842,Chemical,D013629,7789881,Tamoxifen,094ZI81Y45,,,,
27843,DescriptorName,D000230,7789881,,,1,Adenocarcinoma,N,
27844,QualifierName,Q000139,7789881,,,1,,Y,chemically induced
27845,DescriptorName,D000368,7789881,,,2,Aged,N,
27846,DescriptorName,D001943,7789881,,,3,Breast Neoplasms,N,
27847,QualifierName,Q000188,7789881,,,3,,Y,drug therapy
27848,DescriptorName,D016889,7789881,,,4,Endometrial Neoplasms,N,
27849,QualifierName,Q000139,7789881,,,4,,Y,chemically induced
27850,DescriptorName,D005260,7789881,,,5,Female,N,
27851,DescriptorName,D006801,7789881,,,6,Humans,N,
27852,DescriptorName,D013629,7789881,,,7,Tamoxifen,N,
27853,QualifierName,Q000009,7789881,,,7,,Y,adverse effects
27854,Chemical,D009853,7797283,Omeprazole,KG60484QX9,,,,
27855,Chemical,D007654,7797283,Ketoconazole,R9400W927I,,,,
27856,DescriptorName,D015746,7797283,,,1,Abdominal Pain,N,
27857,QualifierName,Q000188,7797283,,,1,,N,drug therapy
27858,DescriptorName,D000293,7797283,,,2,Adolescent,N,
27859,DescriptorName,D000328,7797283,,,3,Adult,N,
27860,DescriptorName,D002177,7797283,,,4,Candidiasis,N,
27861,QualifierName,Q000139,7797283,,,4,,Y,chemically induced
27862,DescriptorName,D004935,7797283,,,5,Esophageal Diseases,N,
27863,QualifierName,Q000382,7797283,,,5,,Y,microbiology
27864,DescriptorName,D005260,7797283,,,6,Female,N,
27865,DescriptorName,D005756,7797283,,,7,Gastritis,N,
27866,QualifierName,Q000188,7797283,,,7,,N,drug therapy
27867,DescriptorName,D006801,7797283,,,8,Humans,N,
27868,DescriptorName,D007654,7797283,,,9,Ketoconazole,N,
27869,QualifierName,Q000627,7797283,,,9,,N,therapeutic use
27870,DescriptorName,D008297,7797283,,,10,Male,N,
27871,DescriptorName,D009853,7797283,,,11,Omeprazole,N,
27872,QualifierName,Q000009,7797283,,,11,,Y,adverse effects
27873,Chemical,D000628,7814182,Aminophylline,27Y3KJK423,,,,
27874,Chemical,D004176,7814182,Dipyridamole,64ALC7F90C,,,,
27875,DescriptorName,D000368,7814182,,,1,Aged,N,
27876,DescriptorName,D000628,7814182,,,2,Aminophylline,N,
27877,QualifierName,Q000627,7814182,,,2,,N,therapeutic use
27878,DescriptorName,D003327,7814182,,,3,Coronary Disease,N,
27879,QualifierName,Q000175,7814182,,,3,,N,diagnosis
27880,DescriptorName,D004176,7814182,,,4,Dipyridamole,N,
27881,QualifierName,Q000009,7814182,,,4,,Y,adverse effects
27882,DescriptorName,D004562,7814182,,,5,Electrocardiography,N,
27883,DescriptorName,D006327,7814182,,,6,Heart Block,N,
27884,QualifierName,Q000139,7814182,,,6,,Y,chemically induced
27885,DescriptorName,D006801,7814182,,,7,Humans,N,
27886,DescriptorName,D008297,7814182,,,8,Male,N,
27887,Chemical,D004317,7831179,Doxorubicin,80168379AG,,,,
27888,DescriptorName,D000293,7831179,,,1,Adolescent,N,
27889,DescriptorName,D002311,7831179,,,2,"Cardiomyopathy, Dilated",N,
27890,QualifierName,Q000139,7831179,,,2,,Y,chemically induced
27891,DescriptorName,D004305,7831179,,,3,"Dose-Response Relationship, Drug",N,
27892,DescriptorName,D004317,7831179,,,4,Doxorubicin,N,
27893,QualifierName,Q000008,7831179,,,4,,N,administration & dosage
27894,DescriptorName,D004334,7831179,,,5,Drug Administration Schedule,N,
27895,DescriptorName,D005260,7831179,,,6,Female,N,
27896,DescriptorName,D016027,7831179,,,7,Heart Transplantation,N,
27897,DescriptorName,D006801,7831179,,,8,Humans,N,
27898,DescriptorName,D016393,7831179,,,9,"Lymphoma, B-Cell",N,
27899,QualifierName,Q000188,7831179,,,9,,N,drug therapy
27900,DescriptorName,D008875,7831179,,,10,Middle Aged,N,
27901,DescriptorName,D018233,7831179,,,11,"Rhabdomyosarcoma, Embryonal",N,
27902,QualifierName,Q000188,7831179,,,11,,N,drug therapy
27903,Chemical,D013629,7835785,Tamoxifen,094ZI81Y45,,,,
27904,DescriptorName,D000368,7835785,,,1,Aged,N,
27905,DescriptorName,D001943,7835785,,,2,Breast Neoplasms,N,
27906,QualifierName,Q000188,7835785,,,2,,Y,drug therapy
27907,DescriptorName,D018269,7835785,,,3,"Carcinoma, Endometrioid",N,
27908,QualifierName,Q000139,7835785,,,3,,Y,chemically induced
27909,DescriptorName,D004715,7835785,,,4,Endometriosis,N,
27910,QualifierName,Q000139,7835785,,,4,,Y,chemically induced
27911,DescriptorName,D005260,7835785,,,5,Female,N,
27912,DescriptorName,D006801,7835785,,,6,Humans,N,
27913,DescriptorName,D016609,7835785,,,7,"Neoplasms, Second Primary",N,
27914,QualifierName,Q000139,7835785,,,7,,Y,chemically induced
27915,DescriptorName,D010051,7835785,,,8,Ovarian Neoplasms,N,
27916,QualifierName,Q000139,7835785,,,8,,Y,chemically induced
27917,DescriptorName,D017698,7835785,,,9,Postmenopause,Y,
27918,DescriptorName,D013629,7835785,,,10,Tamoxifen,N,
27919,QualifierName,Q000009,7835785,,,10,,Y,adverse effects
27920,Chemical,D000970,7854541,Antineoplastic Agents,0,,,,
27921,Chemical,D007978,7854541,Levamisole,2880D3468G,,,,
27922,Chemical,D003907,7854541,Dexamethasone,7S5I7G3JQL,,,,
27923,DescriptorName,D000970,7854541,,,1,Antineoplastic Agents,N,
27924,QualifierName,Q000009,7854541,,,1,,Y,adverse effects
27925,DescriptorName,D001921,7854541,,,2,Brain,N,
27926,QualifierName,Q000473,7854541,,,2,,Y,pathology
27927,DescriptorName,D017024,7854541,,,3,"Chemotherapy, Adjuvant",N,
27928,DescriptorName,D003711,7854541,,,4,Demyelinating Diseases,N,
27929,QualifierName,Q000139,7854541,,,4,,Y,chemically induced
27930,DescriptorName,D003907,7854541,,,5,Dexamethasone,N,
27931,QualifierName,Q000627,7854541,,,5,,N,therapeutic use
27932,DescriptorName,D005260,7854541,,,6,Female,N,
27933,DescriptorName,D006801,7854541,,,7,Humans,N,
27934,DescriptorName,D007978,7854541,,,8,Levamisole,N,
27935,QualifierName,Q000009,7854541,,,8,,Y,adverse effects
27936,DescriptorName,D008279,7854541,,,9,Magnetic Resonance Imaging,N,
27937,DescriptorName,D008545,7854541,,,10,Melanoma,N,
27938,QualifierName,Q000188,7854541,,,10,,N,drug therapy
27939,DescriptorName,D008875,7854541,,,11,Middle Aged,N,
27940,DescriptorName,D012878,7854541,,,12,Skin Neoplasms,N,
27941,QualifierName,Q000188,7854541,,,12,,N,drug therapy
27942,Chemical,D009829,7865488,Oleic Acids,0,,,,
27943,Chemical,C033343,7865488,ethanolamine oleate,U4RY8MRX7C,,,,
27944,DescriptorName,D004932,7865488,,,1,Esophageal and Gastric Varices,N,
27945,QualifierName,Q000188,7865488,,,1,,N,drug therapy
27946,DescriptorName,D004945,7865488,,,2,Esophagoscopy,N,
27947,DescriptorName,D006801,7865488,,,3,Humans,N,
27948,DescriptorName,D008297,7865488,,,4,Male,N,
27949,DescriptorName,D008875,7865488,,,5,Middle Aged,N,
27950,DescriptorName,D009829,7865488,,,6,Oleic Acids,N,
27951,QualifierName,Q000009,7865488,,,6,,Y,adverse effects
27952,DescriptorName,D011654,7865488,,,7,Pulmonary Edema,N,
27953,QualifierName,Q000139,7865488,,,7,,Y,chemically induced
27954,DescriptorName,D011859,7865488,,,8,Radiography,N,
27955,Chemical,D005839,788666,Gentamicins,0,,,,
27956,DescriptorName,D058186,788666,,,1,Acute Kidney Injury,N,
27957,QualifierName,Q000139,788666,,,1,,Y,chemically induced
27958,DescriptorName,D000368,788666,,,2,Aged,N,
27959,DescriptorName,D004305,788666,,,3,"Dose-Response Relationship, Drug",N,
27960,DescriptorName,D004359,788666,,,4,"Drug Therapy, Combination",N,
27961,DescriptorName,D004927,788666,,,5,Escherichia coli Infections,N,
27962,QualifierName,Q000188,788666,,,5,,N,drug therapy
27963,DescriptorName,D005260,788666,,,6,Female,N,
27964,DescriptorName,D005839,788666,,,7,Gentamicins,N,
27965,QualifierName,Q000008,788666,,,7,,N,administration & dosage
27966,DescriptorName,D006801,788666,,,8,Humans,N,
27967,DescriptorName,D007677,788666,,,9,Kidney Function Tests,N,
27968,DescriptorName,D007684,788666,,,10,Kidney Tubules,N,
27969,QualifierName,Q000473,788666,,,10,,N,pathology
27970,DescriptorName,D007710,788666,,,11,Klebsiella Infections,N,
27971,QualifierName,Q000188,788666,,,11,,N,drug therapy
27972,DescriptorName,D008297,788666,,,12,Male,N,
27973,DescriptorName,D008875,788666,,,13,Middle Aged,N,
27974,DescriptorName,D010019,788666,,,14,Osteomyelitis,N,
27975,QualifierName,Q000188,788666,,,14,,N,drug therapy
27976,DescriptorName,D011552,788666,,,15,Pseudomonas Infections,N,
27977,QualifierName,Q000188,788666,,,15,,N,drug therapy
27978,DescriptorName,D018805,788666,,,16,Sepsis,N,
27979,QualifierName,Q000188,788666,,,16,,N,drug therapy
27980,Chemical,D002220,7887138,Carbamazepine,33CM23913M,,,,
27981,Chemical,D010672,7887138,Phenytoin,6158TKW0C5,,,,
27982,DescriptorName,D000328,7887138,,,1,Adult,N,
27983,DescriptorName,D002220,7887138,,,2,Carbamazepine,N,
27984,QualifierName,Q000008,7887138,,,2,,N,administration & dosage
27985,DescriptorName,D002544,7887138,,,3,Cerebral Infarction,N,
27986,QualifierName,Q000150,7887138,,,3,,N,complications
27987,DescriptorName,D004305,7887138,,,4,"Dose-Response Relationship, Drug",N,
27988,DescriptorName,D004828,7887138,,,5,"Epilepsies, Partial",N,
27989,QualifierName,Q000097,7887138,,,5,,N,blood
27990,DescriptorName,D005260,7887138,,,6,Female,N,
27991,DescriptorName,D005500,7887138,,,7,Follow-Up Studies,N,
27992,DescriptorName,D005885,7887138,,,8,Gingival Hyperplasia,N,
27993,QualifierName,Q000097,7887138,,,8,,N,blood
27994,DescriptorName,D006801,7887138,,,9,Humans,N,
27995,DescriptorName,D008875,7887138,,,10,Middle Aged,N,
27996,DescriptorName,D009910,7887138,,,11,Oral Hygiene,N,
27997,DescriptorName,D010672,7887138,,,12,Phenytoin,N,
27998,QualifierName,Q000009,7887138,,,12,,Y,adverse effects
27999,Chemical,D006540,7889679,Herbicides,0,,,,
28000,Chemical,D011239,7889679,Prednisolone,9PHQ9Y1OLM,,,,
28001,DescriptorName,D006540,7889679,,,1,Herbicides,N,
28002,QualifierName,Q000009,7889679,,,1,,Y,adverse effects
28003,DescriptorName,D006801,7889679,,,2,Humans,N,
28004,DescriptorName,D008297,7889679,,,3,Male,N,
28005,DescriptorName,D008875,7889679,,,4,Middle Aged,N,
28006,DescriptorName,D009784,7889679,,,5,Occupational Diseases,N,
28007,QualifierName,Q000139,7889679,,,5,,Y,chemically induced
28008,DescriptorName,D011239,7889679,,,6,Prednisolone,N,
28009,QualifierName,Q000627,7889679,,,6,,Y,therapeutic use
28010,DescriptorName,D012595,7889679,,,7,"Scleroderma, Systemic",N,
28011,QualifierName,Q000139,7889679,,,7,,Y,chemically induced
28012,Chemical,D000420,7893301,Albuterol,QF8SVZ843E,,,,
28013,DescriptorName,D000328,7893301,,,1,Adult,N,
28014,DescriptorName,D000420,7893301,,,2,Albuterol,N,
28015,QualifierName,Q000008,7893301,,,2,,N,administration & dosage
28016,DescriptorName,D001249,7893301,,,3,Asthma,N,
28017,QualifierName,Q000188,7893301,,,3,,Y,drug therapy
28018,DescriptorName,D004562,7893301,,,4,Electrocardiography,N,
28019,DescriptorName,D006801,7893301,,,5,Humans,N,
28020,DescriptorName,D007008,7893301,,,6,Hypokalemia,N,
28021,QualifierName,Q000139,7893301,,,6,,Y,chemically induced
28022,DescriptorName,D008297,7893301,,,7,Male,N,
28023,Chemical,D000894,7897759,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
28024,Chemical,D005473,7897759,Fluoxetine,01K63SUP8D,,,,
28025,Chemical,D017693,7897759,Sodium Bicarbonate,8MDF5V39QO,,,,
28026,Chemical,D011431,7897759,Dextropropoxyphene,S2F83W92TK,,,,
28027,DescriptorName,D000894,7897759,,,1,"Anti-Inflammatory Agents, Non-Steroidal",N,
28028,QualifierName,Q000506,7897759,,,1,,N,poisoning
28029,DescriptorName,D001145,7897759,,,2,"Arrhythmias, Cardiac",N,
28030,QualifierName,Q000097,7897759,,,2,,N,blood
28031,DescriptorName,D011431,7897759,,,3,Dextropropoxyphene,N,
28032,QualifierName,Q000506,7897759,,,3,,Y,poisoning
28033,DescriptorName,D004347,7897759,,,4,Drug Interactions,N,
28034,DescriptorName,D004562,7897759,,,5,Electrocardiography,N,
28035,QualifierName,Q000187,7897759,,,5,,Y,drug effects
28036,DescriptorName,D005260,7897759,,,6,Female,N,
28037,DescriptorName,D005473,7897759,,,7,Fluoxetine,N,
28038,QualifierName,Q000506,7897759,,,7,,N,poisoning
28039,DescriptorName,D006801,7897759,,,8,Humans,N,
28040,DescriptorName,D008875,7897759,,,9,Middle Aged,N,
28041,DescriptorName,D017693,7897759,,,10,Sodium Bicarbonate,N,
28042,QualifierName,Q000627,7897759,,,10,,Y,therapeutic use
28043,Chemical,D008353,7900744,Mannitol,3OWL53L36A,,,,
28044,DescriptorName,D058186,7900744,,,1,Acute Kidney Injury,N,
28045,QualifierName,Q000139,7900744,,,1,,Y,chemically induced
28046,DescriptorName,D000368,7900744,,,2,Aged,N,
28047,DescriptorName,D005260,7900744,,,3,Female,N,
28048,DescriptorName,D015812,7900744,,,4,"Glaucoma, Angle-Closure",N,
28049,QualifierName,Q000188,7900744,,,4,,N,drug therapy
28050,DescriptorName,D006801,7900744,,,5,Humans,N,
28051,DescriptorName,D007262,7900744,,,6,"Infusions, Intravenous",N,
28052,DescriptorName,D008353,7900744,,,7,Mannitol,N,
28053,QualifierName,Q000008,7900744,,,7,,N,administration & dosage
28054,DescriptorName,D006435,7900744,,,8,Renal Dialysis,Y,
28055,Chemical,D014150,7907218,Antipsychotic Agents,0,,,,
28056,Chemical,D003692,7907218,Delayed-Action Preparations,0,,,,
28057,Chemical,D065127,7907218,Dopamine D2 Receptor Antagonists,0,,,,
28058,Chemical,C011825,7907218,fluphenazine depot,FMU62K1L3C,,,,
28059,Chemical,D005476,7907218,Fluphenazine,S79426A41Z,,,,
28060,DescriptorName,D014150,7907218,,,1,Antipsychotic Agents,N,
28061,QualifierName,Q000008,7907218,,,1,,N,administration & dosage
28062,DescriptorName,D001480,7907218,,,2,Basal Ganglia Diseases,N,
28063,QualifierName,Q000139,7907218,,,2,,N,chemically induced
28064,DescriptorName,D003692,7907218,,,3,Delayed-Action Preparations,N,
28065,DescriptorName,D065127,7907218,,,4,Dopamine D2 Receptor Antagonists,Y,
28066,DescriptorName,D005260,7907218,,,5,Female,N,
28067,DescriptorName,D005476,7907218,,,6,Fluphenazine,N,
28068,QualifierName,Q000009,7907218,,,6,,N,adverse effects
28069,DescriptorName,D006801,7907218,,,7,Humans,N,
28070,DescriptorName,D008297,7907218,,,8,Male,N,
28071,DescriptorName,D008875,7907218,,,9,Middle Aged,N,
28072,DescriptorName,D012563,7907218,,,10,"Schizophrenia, Paranoid",N,
28073,QualifierName,Q000150,7907218,,,10,,N,complications
28074,DescriptorName,D015899,7907218,,,11,"Tomography, Emission-Computed, Single-Photon",N,
28075,Chemical,D014151,7914463,Anti-Anxiety Agents,0,,,,
28076,Chemical,D005442,7914463,Flumazenil,40P7XK9392,,,,
28077,Chemical,D008140,7914463,Lorazepam,O26FZP769L,,,,
28078,Chemical,D008874,7914463,Midazolam,R60L0SM5BC,,,,
28079,DescriptorName,D000328,7914463,,,1,Adult,N,
28080,DescriptorName,D014151,7914463,,,2,Anti-Anxiety Agents,N,
28081,QualifierName,Q000009,7914463,,,2,,Y,adverse effects
28082,DescriptorName,D001007,7914463,,,3,Anxiety,N,
28083,QualifierName,Q000188,7914463,,,3,,Y,drug therapy
28084,DescriptorName,D004565,7914463,,,4,Electroconvulsive Therapy,Y,
28085,QualifierName,Q000009,7914463,,,4,,N,adverse effects
28086,DescriptorName,D005442,7914463,,,5,Flumazenil,N,
28087,QualifierName,Q000627,7914463,,,5,,Y,therapeutic use
28088,DescriptorName,D006801,7914463,,,6,Humans,N,
28089,DescriptorName,D008140,7914463,,,7,Lorazepam,N,
28090,QualifierName,Q000009,7914463,,,7,,N,adverse effects
28091,DescriptorName,D008297,7914463,,,8,Male,N,
28092,DescriptorName,D008874,7914463,,,9,Midazolam,N,
28093,QualifierName,Q000009,7914463,,,9,,N,adverse effects
28094,DescriptorName,D012559,7914463,,,10,Schizophrenia,N,
28095,QualifierName,Q000628,7914463,,,10,,Y,therapy
28096,Chemical,D000806,7919557,Angiotensin-Converting Enzyme Inhibitors,0,,,,
28097,Chemical,D007546,7919557,Isoquinolines,0,,,,
28098,Chemical,D044005,7919557,Tetrahydroisoquinolines,0,,,,
28099,Chemical,D017328,7919557,Fosinopril,R43D2573WO,,,,
28100,Chemical,D000077583,7919557,Quinapril,RJ84Y44811,,,,
28101,DescriptorName,D000368,7919557,,,1,Aged,N,
28102,DescriptorName,D000806,7919557,,,2,Angiotensin-Converting Enzyme Inhibitors,N,
28103,QualifierName,Q000009,7919557,,,2,,Y,adverse effects
28104,DescriptorName,D003371,7919557,,,3,Cough,N,
28105,QualifierName,Q000139,7919557,,,3,,Y,chemically induced
28106,DescriptorName,D005260,7919557,,,4,Female,N,
28107,DescriptorName,D017328,7919557,,,5,Fosinopril,N,
28108,QualifierName,Q000627,7919557,,,5,,Y,therapeutic use
28109,DescriptorName,D006801,7919557,,,6,Humans,N,
28110,DescriptorName,D006973,7919557,,,7,Hypertension,N,
28111,QualifierName,Q000188,7919557,,,7,,N,drug therapy
28112,DescriptorName,D007546,7919557,,,8,Isoquinolines,N,
28113,QualifierName,Q000009,7919557,,,8,,Y,adverse effects
28114,DescriptorName,D000077583,7919557,,,9,Quinapril,N,
28115,DescriptorName,D044005,7919557,,,10,Tetrahydroisoquinolines,Y,
28116,Chemical,D011239,7933665,Prednisolone,9PHQ9Y1OLM,,,,
28117,DescriptorName,D058186,7933665,,,1,Acute Kidney Injury,N,
28118,QualifierName,Q000139,7933665,,,1,,N,chemically induced
28119,DescriptorName,D000284,7933665,,,2,"Administration, Oral",N,
28120,DescriptorName,D000368,7933665,,,3,Aged,N,
28121,DescriptorName,D000369,7933665,,,4,"Aged, 80 and over",N,
28122,DescriptorName,D005260,7933665,,,5,Female,N,
28123,DescriptorName,D005265,7933665,,,6,Femoral Neck Fractures,N,
28124,QualifierName,Q000139,7933665,,,6,,N,chemically induced
28125,DescriptorName,D006801,7933665,,,7,Humans,N,
28126,DescriptorName,D008297,7933665,,,8,Male,N,
28127,DescriptorName,D009404,7933665,,,9,Nephrotic Syndrome,N,
28128,QualifierName,Q000188,7933665,,,9,,Y,drug therapy
28129,DescriptorName,D011239,7933665,,,10,Prednisolone,N,
28130,QualifierName,Q000008,7933665,,,10,,Y,administration & dosage
28131,Chemical,D002444,7937287,Cefuroxime,O1R9FJ93ED,,,,
28132,DescriptorName,D058186,7937287,,,1,Acute Kidney Injury,N,
28133,QualifierName,Q000139,7937287,,,1,,Y,chemically induced
28134,DescriptorName,D002444,7937287,,,2,Cefuroxime,N,
28135,QualifierName,Q000009,7937287,,,2,,Y,adverse effects
28136,DescriptorName,D004342,7937287,,,3,Drug Hypersensitivity,N,
28137,QualifierName,Q000209,7937287,,,3,,Y,etiology
28138,DescriptorName,D005260,7937287,,,4,Female,N,
28139,DescriptorName,D005440,7937287,,,5,Fluid Therapy,N,
28140,DescriptorName,D006801,7937287,,,6,Humans,N,
28141,DescriptorName,D007710,7937287,,,7,Klebsiella Infections,N,
28142,QualifierName,Q000150,7937287,,,7,,N,complications
28143,DescriptorName,D007711,7937287,,,8,Klebsiella pneumoniae,N,
28144,DescriptorName,D008875,7937287,,,9,Middle Aged,N,
28145,DescriptorName,D009395,7937287,,,10,"Nephritis, Interstitial",N,
28146,QualifierName,Q000139,7937287,,,10,,Y,chemically induced
28147,Chemical,D010672,7946029,Phenytoin,6158TKW0C5,,,,
28148,DescriptorName,D000328,7946029,,,1,Adult,N,
28149,DescriptorName,D001139,7946029,,,2,Arnold-Chiari Malformation,N,
28150,QualifierName,Q000139,7946029,,,2,,N,chemically induced
28151,DescriptorName,D016025,7946029,,,3,Bone Transplantation,N,
28152,DescriptorName,D002971,7946029,,,4,Cleft Lip,N,
28153,QualifierName,Q000139,7946029,,,4,,Y,chemically induced
28154,DescriptorName,D002972,7946029,,,5,Cleft Palate,N,
28155,QualifierName,Q000139,7946029,,,5,,Y,chemically induced
28156,DescriptorName,D004200,7946029,,,6,Diseases in Twins,N,
28157,DescriptorName,D004827,7946029,,,7,Epilepsy,N,
28158,QualifierName,Q000188,7946029,,,7,,Y,drug therapy
28159,DescriptorName,D005147,7946029,,,8,Facial Bones,N,
28160,QualifierName,Q000002,7946029,,,8,,Y,abnormalities
28161,DescriptorName,D005260,7946029,,,9,Female,N,
28162,DescriptorName,D006801,7946029,,,10,Humans,N,
28163,DescriptorName,D007796,7946029,,,11,Laminectomy,N,
28164,DescriptorName,D008279,7946029,,,12,Magnetic Resonance Imaging,N,
28165,DescriptorName,D008297,7946029,,,13,Male,N,
28166,DescriptorName,D009460,7946029,,,14,Neurologic Examination,N,
28167,DescriptorName,D010672,7946029,,,15,Phenytoin,N,
28168,QualifierName,Q000009,7946029,,,15,,Y,adverse effects
28169,DescriptorName,D010985,7946029,,,16,Platybasia,N,
28170,QualifierName,Q000139,7946029,,,16,,Y,chemically induced
28171,DescriptorName,D011247,7946029,,,17,Pregnancy,N,
28172,DescriptorName,D011248,7946029,,,18,Pregnancy Complications,N,
28173,QualifierName,Q000188,7946029,,,18,,Y,drug therapy
28174,DescriptorName,D012086,7946029,,,19,Reoperation,N,
28175,DescriptorName,D012886,7946029,,,20,Skull,N,
28176,QualifierName,Q000002,7946029,,,20,,Y,abnormalities
28177,DescriptorName,D014057,7946029,,,21,"Tomography, X-Ray Computed",N,
28178,DescriptorName,D014429,7946029,,,22,"Twins, Dizygotic",N,
28179,Chemical,D002955,7949255,Leucovorin,Q573I9DVLP,,,,
28180,Chemical,D008727,7949255,Methotrexate,YL5FZ2Y5U1,,,,
28181,DescriptorName,D000293,7949255,,,1,Adolescent,N,
28182,DescriptorName,D001859,7949255,,,2,Bone Neoplasms,N,
28183,QualifierName,Q000188,7949255,,,2,,Y,drug therapy
28184,DescriptorName,D004305,7949255,,,3,"Dose-Response Relationship, Drug",N,
28185,DescriptorName,D006801,7949255,,,4,Humans,N,
28186,DescriptorName,D002955,7949255,,,5,Leucovorin,N,
28187,QualifierName,Q000627,7949255,,,5,,N,therapeutic use
28188,DescriptorName,D008297,7949255,,,6,Male,N,
28189,DescriptorName,D008727,7949255,,,7,Methotrexate,N,
28190,QualifierName,Q000009,7949255,,,7,,Y,adverse effects
28191,DescriptorName,D009422,7949255,,,8,Nervous System Diseases,N,
28192,QualifierName,Q000139,7949255,,,8,,Y,chemically induced
28193,DescriptorName,D012516,7949255,,,9,Osteosarcoma,N,
28194,QualifierName,Q000188,7949255,,,9,,Y,drug therapy
28195,Chemical,D010194,7953234,Pancreatin,8049-47-6,,,,
28196,DescriptorName,D002675,7953234,,,1,"Child, Preschool",N,
28197,DescriptorName,D003106,7953234,,,2,Colon,N,
28198,QualifierName,Q000000981,7953234,,,2,,N,diagnostic imaging
28199,DescriptorName,D003108,7953234,,,3,Colonic Diseases,N,
28200,QualifierName,Q000139,7953234,,,3,,Y,chemically induced
28201,DescriptorName,D003550,7953234,,,4,Cystic Fibrosis,N,
28202,QualifierName,Q000188,7953234,,,4,,Y,drug therapy
28203,DescriptorName,D005355,7953234,,,5,Fibrosis,N,
28204,DescriptorName,D005500,7953234,,,6,Follow-Up Studies,N,
28205,DescriptorName,D006801,7953234,,,7,Humans,N,
28206,DescriptorName,D007415,7953234,,,8,Intestinal Obstruction,N,
28207,QualifierName,Q000139,7953234,,,8,,Y,chemically induced
28208,DescriptorName,D008297,7953234,,,9,Male,N,
28209,DescriptorName,D010194,7953234,,,10,Pancreatin,N,
28210,QualifierName,Q000009,7953234,,,10,,Y,adverse effects
28211,DescriptorName,D011859,7953234,,,11,Radiography,N,
28212,Chemical,D003613,7962394,Danazol,N29QWW3BUO,,,,
28213,DescriptorName,D000208,7962394,,,1,Acute Disease,N,
28214,DescriptorName,D000328,7962394,,,2,Adult,N,
28215,DescriptorName,D003613,7962394,,,3,Danazol,N,
28216,QualifierName,Q000009,7962394,,,3,,Y,adverse effects
28217,DescriptorName,D004715,7962394,,,4,Endometriosis,N,
28218,QualifierName,Q000188,7962394,,,4,,Y,drug therapy
28219,DescriptorName,D005260,7962394,,,5,Female,N,
28220,DescriptorName,D006801,7962394,,,6,Humans,N,
28221,DescriptorName,D010195,7962394,,,7,Pancreatitis,N,
28222,QualifierName,Q000139,7962394,,,7,,Y,chemically induced
28223,Chemical,D000212,7973922,Acyclovir,X4HES1O11F,,,,
28224,DescriptorName,D000212,7973922,,,1,Acyclovir,N,
28225,QualifierName,Q000009,7973922,,,1,,Y,adverse effects
28226,DescriptorName,D000328,7973922,,,2,Adult,N,
28227,DescriptorName,D000368,7973922,,,3,Aged,N,
28228,DescriptorName,D000369,7973922,,,4,"Aged, 80 and over",N,
28229,DescriptorName,D002493,7973922,,,5,Central Nervous System Diseases,N,
28230,QualifierName,Q000139,7973922,,,5,,Y,chemically induced
28231,DescriptorName,D003586,7973922,,,6,Cytomegalovirus Infections,N,
28232,QualifierName,Q000188,7973922,,,6,,N,drug therapy
28233,DescriptorName,D005260,7973922,,,7,Female,N,
28234,DescriptorName,D006561,7973922,,,8,Herpes Simplex,N,
28235,QualifierName,Q000188,7973922,,,8,,N,drug therapy
28236,DescriptorName,D006562,7973922,,,9,Herpes Zoster,N,
28237,QualifierName,Q000188,7973922,,,9,,N,drug therapy
28238,DescriptorName,D006801,7973922,,,10,Humans,N,
28239,DescriptorName,D007676,7973922,,,11,"Kidney Failure, Chronic",N,
28240,QualifierName,Q000150,7973922,,,11,,N,complications
28241,DescriptorName,D008297,7973922,,,12,Male,N,
28242,DescriptorName,D008875,7973922,,,13,Middle Aged,N,
28243,DescriptorName,D006435,7973922,,,14,Renal Dialysis,N,
28244,Chemical,D005442,7978578,Flumazenil,40P7XK9392,,,,
28245,Chemical,D011398,7978578,Promethazine,FF28EJQ494,,,,
28246,DescriptorName,D000368,7978578,,,1,Aged,N,
28247,DescriptorName,D000369,7978578,,,2,"Aged, 80 and over",N,
28248,DescriptorName,D003128,7978578,,,3,Coma,N,
28249,QualifierName,Q000139,7978578,,,3,,Y,chemically induced
28250,DescriptorName,D005442,7978578,,,4,Flumazenil,N,
28251,QualifierName,Q000494,7978578,,,4,,N,pharmacology
28252,DescriptorName,D015600,7978578,,,5,Glasgow Coma Scale,N,
28253,DescriptorName,D006801,7978578,,,6,Humans,N,
28254,DescriptorName,D008297,7978578,,,7,Male,N,
28255,DescriptorName,D008508,7978578,,,8,Medication Errors,N,
28256,DescriptorName,D011398,7978578,,,9,Promethazine,N,
28257,QualifierName,Q000506,7978578,,,9,,Y,poisoning
28258,Chemical,D014011,7986915,Tinidazole,033KF7V46H,,,,
28259,Chemical,D008795,7986915,Metronidazole,140QMO216E,,,,
28260,DescriptorName,D000328,7986915,,,1,Adult,N,
28261,DescriptorName,D000562,7986915,,,2,Amebiasis,N,
28262,QualifierName,Q000188,7986915,,,2,,N,drug therapy
28263,DescriptorName,D001259,7986915,,,3,Ataxia,N,
28264,DescriptorName,D002493,7986915,,,4,Central Nervous System Diseases,N,
28265,QualifierName,Q000139,7986915,,,4,,Y,chemically induced
28266,DescriptorName,D006801,7986915,,,5,Humans,N,
28267,DescriptorName,D008101,7986915,,,6,"Liver Abscess, Amebic",N,
28268,QualifierName,Q000150,7986915,,,6,,N,complications
28269,DescriptorName,D008297,7986915,,,7,Male,N,
28270,DescriptorName,D008795,7986915,,,8,Metronidazole,N,
28271,QualifierName,Q000009,7986915,,,8,,Y,adverse effects
28272,DescriptorName,D013158,7986915,,,9,Splenic Diseases,N,
28273,QualifierName,Q000188,7986915,,,9,,N,drug therapy
28274,DescriptorName,D014011,7986915,,,10,Tinidazole,N,
28275,QualifierName,Q000627,7986915,,,10,,N,therapeutic use
28276,Chemical,D003609,7991279,Dactinomycin,1CC1JFE158,,,,
28277,DescriptorName,D002675,7991279,,,1,"Child, Preschool",N,
28278,DescriptorName,D003609,7991279,,,2,Dactinomycin,N,
28279,QualifierName,Q000009,7991279,,,2,,Y,adverse effects
28280,DescriptorName,D005260,7991279,,,3,Female,N,
28281,DescriptorName,D006504,7991279,,,4,Hepatic Veno-Occlusive Disease,N,
28282,QualifierName,Q000139,7991279,,,4,,Y,chemically induced
28283,DescriptorName,D006801,7991279,,,5,Humans,N,
28284,DescriptorName,D007223,7991279,,,6,Infant,N,
28285,DescriptorName,D007680,7991279,,,7,Kidney Neoplasms,N,
28286,QualifierName,Q000188,7991279,,,7,,N,drug therapy
28287,DescriptorName,D009396,7991279,,,8,Wilms Tumor,N,
28288,QualifierName,Q000188,7991279,,,8,,N,drug therapy
28289,Chemical,D010665,7995508,Phenylpropanolamine,33RU150WUN,,,,
28290,DescriptorName,D000328,7995508,,,1,Adult,N,
28291,DescriptorName,D004305,7995508,,,2,"Dose-Response Relationship, Drug",N,
28292,DescriptorName,D005260,7995508,,,3,Female,N,
28293,DescriptorName,D006801,7995508,,,4,Humans,N,
28294,DescriptorName,D010259,7995508,,,5,Paranoid Disorders,N,
28295,QualifierName,Q000139,7995508,,,5,,N,chemically induced
28296,DescriptorName,D010665,7995508,,,6,Phenylpropanolamine,N,
28297,QualifierName,Q000008,7995508,,,6,,N,administration & dosage
28298,DescriptorName,D012307,7995508,,,7,Risk Factors,N,
28299,DescriptorName,D012852,7995508,,,8,Sinusitis,N,
28300,QualifierName,Q000188,7995508,,,8,,N,drug therapy
28301,DescriptorName,D019966,7995508,,,9,Substance-Related Disorders,N,
28302,QualifierName,Q000209,7995508,,,9,,Y,etiology
28303,Chemical,D000893,8002140,Anti-Inflammatory Agents,0,,,,
28304,Chemical,D005938,8002140,Glucocorticoids,0,,,,
28305,Chemical,D011282,8002140,Pregnenediones,0,,,,
28306,Chemical,D019819,8002140,Budesonide,51333-22-3,,,,
28307,DescriptorName,D000287,8002140,,,1,"Administration, Topical",N,
28308,DescriptorName,D000328,8002140,,,2,Adult,N,
28309,DescriptorName,D000368,8002140,,,3,Aged,N,
28310,DescriptorName,D000893,8002140,,,4,Anti-Inflammatory Agents,N,
28311,QualifierName,Q000009,8002140,,,4,,Y,adverse effects
28312,DescriptorName,D019819,8002140,,,5,Budesonide,N,
28313,DescriptorName,D002908,8002140,,,6,Chronic Disease,N,
28314,DescriptorName,D003872,8002140,,,7,Dermatitis,N,
28315,QualifierName,Q000188,8002140,,,7,,N,drug therapy
28316,DescriptorName,D017449,8002140,,,8,"Dermatitis, Allergic Contact",N,
28317,QualifierName,Q000209,8002140,,,8,,Y,etiology
28318,DescriptorName,D012628,8002140,,,9,"Dermatitis, Seborrheic",N,
28319,QualifierName,Q000188,8002140,,,9,,N,drug therapy
28320,DescriptorName,D003875,8002140,,,10,Drug Eruptions,N,
28321,QualifierName,Q000209,8002140,,,10,,N,etiology
28322,DescriptorName,D004485,8002140,,,11,Eczema,N,
28323,QualifierName,Q000188,8002140,,,11,,N,drug therapy
28324,DescriptorName,D004890,8002140,,,12,Erythema,N,
28325,QualifierName,Q000188,8002140,,,12,,N,drug therapy
28326,DescriptorName,D005260,8002140,,,13,Female,N,
28327,DescriptorName,D005938,8002140,,,14,Glucocorticoids,N,
28328,QualifierName,Q000009,8002140,,,14,,Y,adverse effects
28329,DescriptorName,D006801,8002140,,,15,Humans,N,
28330,DescriptorName,D007564,8002140,,,16,Japan,N,
28331,DescriptorName,D007868,8002140,,,17,Leg Dermatoses,N,
28332,QualifierName,Q000188,8002140,,,17,,N,drug therapy
28333,DescriptorName,D008297,8002140,,,18,Male,N,
28334,DescriptorName,D011282,8002140,,,19,Pregnenediones,N,
28335,QualifierName,Q000009,8002140,,,19,,Y,adverse effects
28336,DescriptorName,D011565,8002140,,,20,Psoriasis,N,
28337,QualifierName,Q000188,8002140,,,20,,N,drug therapy
28338,Chemical,D009573,8007037,Nitrites,0,,,,
28339,Chemical,D010665,8007037,Phenylpropanolamine,33RU150WUN,,,,
28340,Chemical,C037538,8007037,methyl nitrite,96TLP8RN37,,,,
28341,Chemical,D008751,8007037,Methylene Blue,T42P99266K,,,,
28342,DescriptorName,D000328,8007037,,,1,Adult,N,
28343,DescriptorName,D006801,8007037,,,2,Humans,N,
28344,DescriptorName,D008297,8007037,,,3,Male,N,
28345,DescriptorName,D008708,8007037,,,4,Methemoglobinemia,N,
28346,QualifierName,Q000139,8007037,,,4,,Y,chemically induced
28347,DescriptorName,D008751,8007037,,,5,Methylene Blue,N,
28348,QualifierName,Q000627,8007037,,,5,,N,therapeutic use
28349,DescriptorName,D009573,8007037,,,6,Nitrites,N,
28350,QualifierName,Q000037,8007037,,,6,,N,antagonists & inhibitors
28351,DescriptorName,D009784,8007037,,,7,Occupational Diseases,N,
28352,QualifierName,Q000139,8007037,,,7,,Y,chemically induced
28353,DescriptorName,D016273,8007037,,,8,Occupational Exposure,Y,
28354,DescriptorName,D010665,8007037,,,9,Phenylpropanolamine,Y,
28355,Chemical,D001323,8013261,Autoantibodies,0,,,,
28356,Chemical,D006442,8013261,Glycated Hemoglobin A,0,,,,
28357,Chemical,D006513,8013261,Hepatitis B e Antigens,0,,,,
28358,Chemical,D007328,8013261,Insulin,0,,,,
28359,Chemical,D016898,8013261,Interferon-alpha,0,,,,
28360,Chemical,C024211,8013261,islet cell antibody,0,,,,
28361,Chemical,D016899,8013261,Interferon-beta,77238-31-4,,,,
28362,DescriptorName,D000328,8013261,,,1,Adult,N,
28363,DescriptorName,D001323,8013261,,,2,Autoantibodies,N,
28364,QualifierName,Q000097,8013261,,,2,,Y,blood
28365,DescriptorName,D003922,8013261,,,3,"Diabetes Mellitus, Type 1",N,
28366,QualifierName,Q000097,8013261,,,3,,N,blood
28367,DescriptorName,D005500,8013261,,,4,Follow-Up Studies,N,
28368,DescriptorName,D006442,8013261,,,5,Glycated Hemoglobin A,N,
28369,QualifierName,Q000032,8013261,,,5,,N,analysis
28370,DescriptorName,D006509,8013261,,,6,Hepatitis B,N,
28371,QualifierName,Q000628,8013261,,,6,,Y,therapy
28372,DescriptorName,D006513,8013261,,,7,Hepatitis B e Antigens,N,
28373,QualifierName,Q000032,8013261,,,7,,N,analysis
28374,DescriptorName,D006801,8013261,,,8,Humans,N,
28375,DescriptorName,D007328,8013261,,,9,Insulin,N,
28376,QualifierName,Q000627,8013261,,,9,,Y,therapeutic use
28377,DescriptorName,D016898,8013261,,,10,Interferon-alpha,N,
28378,QualifierName,Q000009,8013261,,,10,,Y,adverse effects
28379,DescriptorName,D016899,8013261,,,11,Interferon-beta,N,
28380,QualifierName,Q000009,8013261,,,11,,Y,adverse effects
28381,DescriptorName,D007515,8013261,,,12,Islets of Langerhans,N,
28382,QualifierName,Q000276,8013261,,,12,,N,immunology
28383,DescriptorName,D008297,8013261,,,13,Male,N,
28384,Chemical,D000927,8024670,Anticonvulsants,0,,,,
28385,Chemical,D002220,8024670,Carbamazepine,33CM23913M,,,,
28386,Chemical,D014635,8024670,Valproic Acid,614OI1Z5WI,,,,
28387,DescriptorName,D000293,8024670,,,1,Adolescent,N,
28388,DescriptorName,D000927,8024670,,,2,Anticonvulsants,N,
28389,QualifierName,Q000008,8024670,,,2,,N,administration & dosage
28390,DescriptorName,D002220,8024670,,,3,Carbamazepine,N,
28391,QualifierName,Q000008,8024670,,,3,,N,administration & dosage
28392,DescriptorName,D002648,8024670,,,4,Child,N,
28393,DescriptorName,D002675,8024670,,,5,"Child, Preschool",N,
28394,DescriptorName,D003429,8024670,,,6,Cross Reactions,N,
28395,DescriptorName,D004342,8024670,,,7,Drug Hypersensitivity,N,
28396,QualifierName,Q000209,8024670,,,7,,Y,etiology
28397,DescriptorName,D004827,8024670,,,8,Epilepsy,N,
28398,QualifierName,Q000188,8024670,,,8,,Y,drug therapy
28399,DescriptorName,D006801,8024670,,,9,Humans,N,
28400,DescriptorName,D007223,8024670,,,10,Infant,N,
28401,DescriptorName,D008213,8024670,,,11,Lymphocyte Activation,N,
28402,QualifierName,Q000187,8024670,,,11,,N,drug effects
28403,DescriptorName,D008297,8024670,,,12,Male,N,
28404,DescriptorName,D014635,8024670,,,13,Valproic Acid,N,
28405,QualifierName,Q000008,8024670,,,13,,N,administration & dosage
28406,Chemical,D015222,8031432,Sodium Channels,0,,,,
28407,Chemical,D009661,8031432,Nortriptyline,BL03SY4LXB,,,,
28408,Chemical,D008874,8031432,Midazolam,R60L0SM5BC,,,,
28409,Chemical,D009638,8031432,Norepinephrine,X4W3ENH1CV,,,,
28410,DescriptorName,D001682,8031432,,,1,Biological Availability,N,
28411,DescriptorName,D001794,8031432,,,2,Blood Pressure,N,
28412,DescriptorName,D062787,8031432,,,3,Drug Overdose,N,
28413,QualifierName,Q000097,8031432,,,3,,N,blood
28414,DescriptorName,D005260,8031432,,,4,Female,N,
28415,DescriptorName,D006321,8031432,,,5,Heart,N,
28416,QualifierName,Q000187,8031432,,,5,,N,drug effects
28417,DescriptorName,D006801,8031432,,,6,Humans,N,
28418,DescriptorName,D007022,8031432,,,7,Hypotension,N,
28419,QualifierName,Q000139,8031432,,,7,,Y,chemically induced
28420,DescriptorName,D008874,8031432,,,8,Midazolam,N,
28421,QualifierName,Q000627,8031432,,,8,,N,therapeutic use
28422,DescriptorName,D008875,8031432,,,9,Middle Aged,N,
28423,DescriptorName,D009638,8031432,,,10,Norepinephrine,N,
28424,QualifierName,Q000627,8031432,,,10,,N,therapeutic use
28425,DescriptorName,D009661,8031432,,,11,Nortriptyline,N,
28426,QualifierName,Q000097,8031432,,,11,,N,blood
28427,DescriptorName,D012008,8031432,,,12,Recurrence,N,
28428,DescriptorName,D012640,8031432,,,13,Seizures,N,
28429,QualifierName,Q000139,8031432,,,13,,Y,chemically induced
28430,DescriptorName,D015222,8031432,,,14,Sodium Channels,N,
28431,QualifierName,Q000187,8031432,,,14,,N,drug effects
28432,DescriptorName,D013997,8031432,,,15,Time Factors,N,
28433,Chemical,D008727,8034807,Methotrexate,YL5FZ2Y5U1,,,,
28434,DescriptorName,D017088,8034807,,,1,AIDS-Related Opportunistic Infections,N,
28435,QualifierName,Q000139,8034807,,,1,,N,chemically induced
28436,DescriptorName,D000163,8034807,,,2,Acquired Immunodeficiency Syndrome,N,
28437,QualifierName,Q000150,8034807,,,2,,N,complications
28438,DescriptorName,D000328,8034807,,,3,Adult,N,
28439,DescriptorName,D015535,8034807,,,4,"Arthritis, Psoriatic",N,
28440,QualifierName,Q000150,8034807,,,4,,N,complications
28441,DescriptorName,D000075202,8034807,,,5,Contraindications,N,
28442,DescriptorName,D015658,8034807,,,6,HIV Infections,N,
28443,QualifierName,Q000150,8034807,,,6,,Y,complications
28444,DescriptorName,D006801,8034807,,,7,Humans,N,
28445,DescriptorName,D008297,8034807,,,8,Male,N,
28446,DescriptorName,D008727,8034807,,,9,Methotrexate,N,
28447,QualifierName,Q000009,8034807,,,9,,N,adverse effects
28448,Chemical,D007978,8038468,Levamisole,2880D3468G,,,,
28449,Chemical,D014859,8038468,Warfarin,5Q7ZVV76EI,,,,
28450,Chemical,D005472,8038468,Fluorouracil,U3P01618RT,,,,
28451,DescriptorName,D000368,8038468,,,1,Aged,N,
28452,DescriptorName,D000971,8038468,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
28453,QualifierName,Q000009,8038468,,,2,,Y,adverse effects
28454,DescriptorName,D003110,8038468,,,3,Colonic Neoplasms,N,
28455,QualifierName,Q000188,8038468,,,3,,N,drug therapy
28456,DescriptorName,D004347,8038468,,,4,Drug Interactions,N,
28457,DescriptorName,D005472,8038468,,,5,Fluorouracil,N,
28458,QualifierName,Q000009,8038468,,,5,,Y,adverse effects
28459,DescriptorName,D006801,8038468,,,6,Humans,N,
28460,DescriptorName,D007978,8038468,,,7,Levamisole,N,
28461,QualifierName,Q000009,8038468,,,7,,Y,adverse effects
28462,DescriptorName,D008297,8038468,,,8,Male,N,
28463,DescriptorName,D014859,8038468,,,9,Warfarin,N,
28464,QualifierName,Q000009,8038468,,,9,,Y,adverse effects
28465,Chemical,D002981,8053440,Clindamycin,3U02EL437C,,,,
28466,Chemical,D000667,8053440,Ampicillin,7C782967RD,,,,
28467,Chemical,D015662,8053440,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
28468,DescriptorName,D000038,8053440,,,1,Abscess,N,
28469,QualifierName,Q000188,8053440,,,1,,N,drug therapy
28470,DescriptorName,D000328,8053440,,,2,Adult,N,
28471,DescriptorName,D000368,8053440,,,3,Aged,N,
28472,DescriptorName,D000667,8053440,,,4,Ampicillin,N,
28473,QualifierName,Q000009,8053440,,,4,,N,adverse effects
28474,DescriptorName,D001653,8053440,,,5,"Bile Ducts, Intrahepatic",N,
28475,QualifierName,Q000187,8053440,,,5,,N,drug effects
28476,DescriptorName,D001706,8053440,,,6,Biopsy,N,
28477,DescriptorName,D002780,8053440,,,7,"Cholestasis, Intrahepatic",N,
28478,QualifierName,Q000139,8053440,,,7,,Y,chemically induced
28479,DescriptorName,D002981,8053440,,,8,Clindamycin,N,
28480,QualifierName,Q000009,8053440,,,8,,Y,adverse effects
28481,DescriptorName,D003429,8053440,,,9,Cross Reactions,N,
28482,DescriptorName,D006801,8053440,,,10,Humans,N,
28483,DescriptorName,D008297,8053440,,,11,Male,N,
28484,DescriptorName,D012141,8053440,,,12,Respiratory Tract Infections,N,
28485,QualifierName,Q000188,8053440,,,12,,N,drug therapy
28486,DescriptorName,D013997,8053440,,,13,Time Factors,N,
28487,DescriptorName,D015662,8053440,,,14,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
28488,QualifierName,Q000009,8053440,,,14,,Y,adverse effects
28489,Chemical,D004977,8071504,Ethambutol,8G167061QZ,,,,
28490,Chemical,D007538,8071504,Isoniazid,V83O1VOZ8L,,,,
28491,DescriptorName,D001766,8071504,,,1,Blindness,N,
28492,QualifierName,Q000139,8071504,,,1,,N,chemically induced
28493,DescriptorName,D004977,8071504,,,2,Ethambutol,N,
28494,QualifierName,Q000009,8071504,,,2,,Y,adverse effects
28495,DescriptorName,D006801,8071504,,,3,Humans,N,
28496,DescriptorName,D007538,8071504,,,4,Isoniazid,N,
28497,QualifierName,Q000009,8071504,,,4,,N,adverse effects
28498,DescriptorName,D008297,8071504,,,5,Male,N,
28499,DescriptorName,D008875,8071504,,,6,Middle Aged,N,
28500,DescriptorName,D009901,8071504,,,7,Optic Nerve Diseases,N,
28501,QualifierName,Q000139,8071504,,,7,,Y,chemically induced
28502,DescriptorName,D014397,8071504,,,8,"Tuberculosis, Pulmonary",N,
28503,QualifierName,Q000188,8071504,,,8,,N,drug therapy
28504,DescriptorName,D014792,8071504,,,9,Visual Acuity,N,
28505,Chemical,D015215,8083821,Zidovudine,4B9XT59T7S,,,,
28506,DescriptorName,D000014,8083821,,,1,"Abnormalities, Drug-Induced",Y,
28507,DescriptorName,D005260,8083821,,,2,Female,N,
28508,DescriptorName,D015658,8083821,,,3,HIV Infections,N,
28509,QualifierName,Q000188,8083821,,,3,,Y,drug therapy
28510,DescriptorName,D015497,8083821,,,4,HIV-1,Y,
28511,DescriptorName,D006801,8083821,,,5,Humans,N,
28512,DescriptorName,D007231,8083821,,,6,"Infant, Newborn",N,
28513,DescriptorName,D008297,8083821,,,7,Male,N,
28514,DescriptorName,D011247,8083821,,,8,Pregnancy,N,
28515,DescriptorName,D011251,8083821,,,9,"Pregnancy Complications, Infectious",N,
28516,QualifierName,Q000188,8083821,,,9,,Y,drug therapy
28517,DescriptorName,D011256,8083821,,,10,Pregnancy Outcome,N,
28518,DescriptorName,D012189,8083821,,,11,Retrospective Studies,N,
28519,DescriptorName,D015215,8083821,,,12,Zidovudine,N,
28520,QualifierName,Q000009,8083821,,,12,,Y,adverse effects
28521,Chemical,D000319,8098286,Adrenergic beta-Antagonists,0,,,,
28522,Chemical,D017272,8098286,Celiprolol,DRB57K47QC,,,,
28523,DescriptorName,D000319,8098286,,,1,Adrenergic beta-Antagonists,N,
28524,QualifierName,Q000009,8098286,,,1,,N,adverse effects
28525,DescriptorName,D000542,8098286,,,2,"Alveolitis, Extrinsic Allergic",N,
28526,QualifierName,Q000139,8098286,,,2,,Y,chemically induced
28527,DescriptorName,D017272,8098286,,,3,Celiprolol,N,
28528,QualifierName,Q000009,8098286,,,3,,Y,adverse effects
28529,DescriptorName,D006801,8098286,,,4,Humans,N,
28530,DescriptorName,D006973,8098286,,,5,Hypertension,N,
28531,QualifierName,Q000188,8098286,,,5,,N,drug therapy
28532,DescriptorName,D008168,8098286,,,6,Lung,N,
28533,QualifierName,Q000000981,8098286,,,6,,N,diagnostic imaging
28534,DescriptorName,D008297,8098286,,,7,Male,N,
28535,DescriptorName,D008875,8098286,,,8,Middle Aged,N,
28536,DescriptorName,D011859,8098286,,,9,Radiography,N,
28537,Chemical,D015259,8104147,Dopamine Agents,0,,,,
28538,Chemical,C023487,8104147,ibopamine,8ZCA2I2L11,,,,
28539,Chemical,D003846,8104147,Deoxyepinephrine,R7339QLN1C,,,,
28540,DescriptorName,D000368,8104147,,,1,Aged,N,
28541,DescriptorName,D000369,8104147,,,2,"Aged, 80 and over",N,
28542,DescriptorName,D003846,8104147,,,3,Deoxyepinephrine,N,
28543,QualifierName,Q000009,8104147,,,3,,N,adverse effects
28544,DescriptorName,D015259,8104147,,,4,Dopamine Agents,N,
28545,QualifierName,Q000009,8104147,,,4,,Y,adverse effects
28546,DescriptorName,D005260,8104147,,,5,Female,N,
28547,DescriptorName,D006333,8104147,,,6,Heart Failure,N,
28548,QualifierName,Q000188,8104147,,,6,,Y,drug therapy
28549,DescriptorName,D006801,8104147,,,7,Humans,N,
28550,DescriptorName,D007970,8104147,,,8,Leukopenia,N,
28551,QualifierName,Q000139,8104147,,,8,,Y,chemically induced
28552,Chemical,D001965,812008,Bromides,0,,,,
28553,Chemical,D010672,812008,Phenytoin,6158TKW0C5,,,,
28554,Chemical,D000624,812008,5-Aminolevulinate Synthetase,EC 2.3.1.37,,,,
28555,DescriptorName,D000624,812008,,,1,5-Aminolevulinate Synthetase,N,
28556,QualifierName,Q000378,812008,,,1,,N,metabolism
28557,DescriptorName,D000328,812008,,,2,Adult,N,
28558,DescriptorName,D001965,812008,,,3,Bromides,N,
28559,QualifierName,Q000627,812008,,,3,,N,therapeutic use
28560,DescriptorName,D003937,812008,,,4,"Diagnosis, Differential",N,
28561,DescriptorName,D004830,812008,,,5,"Epilepsy, Tonic-Clonic",N,
28562,QualifierName,Q000175,812008,,,5,,Y,diagnosis
28563,DescriptorName,D006801,812008,,,6,Humans,N,
28564,DescriptorName,D008297,812008,,,7,Male,N,
28565,DescriptorName,D010672,812008,,,8,Phenytoin,N,
28566,QualifierName,Q000009,812008,,,8,,N,adverse effects
28567,DescriptorName,D011164,812008,,,9,Porphyrias,N,
28568,QualifierName,Q000139,812008,,,9,,N,chemically induced
28569,Chemical,D001971,8120934,Bromocriptine,3A64E3G5ZO,,,,
28570,DescriptorName,D001971,8120934,,,1,Bromocriptine,N,
28571,QualifierName,Q000009,8120934,,,1,,Y,adverse effects
28572,DescriptorName,D006801,8120934,,,2,Humans,N,
28573,DescriptorName,D008297,8120934,,,3,Male,N,
28574,DescriptorName,D008875,8120934,,,4,Middle Aged,N,
28575,DescriptorName,D010911,8120934,,,5,Pituitary Neoplasms,N,
28576,QualifierName,Q000188,8120934,,,5,,N,drug therapy
28577,DescriptorName,D015175,8120934,,,6,Prolactinoma,N,
28578,QualifierName,Q000188,8120934,,,6,,N,drug therapy
28579,DescriptorName,D012559,8120934,,,7,Schizophrenia,N,
28580,QualifierName,Q000139,8120934,,,7,,Y,chemically induced
28581,Chemical,D011239,8124920,Prednisolone,9PHQ9Y1OLM,,,,
28582,Chemical,D002955,8124920,Leucovorin,Q573I9DVLP,,,,
28583,Chemical,D008727,8124920,Methotrexate,YL5FZ2Y5U1,,,,
28584,DescriptorName,D000208,8124920,,,1,Acute Disease,N,
28585,DescriptorName,D000749,8124920,,,2,"Anemia, Megaloblastic",N,
28586,QualifierName,Q000139,8124920,,,2,,Y,chemically induced
28587,DescriptorName,D001172,8124920,,,3,"Arthritis, Rheumatoid",N,
28588,QualifierName,Q000188,8124920,,,3,,Y,drug therapy
28589,DescriptorName,D006801,8124920,,,4,Humans,N,
28590,DescriptorName,D002955,8124920,,,5,Leucovorin,N,
28591,QualifierName,Q000627,8124920,,,5,,Y,therapeutic use
28592,DescriptorName,D017563,8124920,,,6,"Lung Diseases, Interstitial",N,
28593,QualifierName,Q000139,8124920,,,6,,Y,chemically induced
28594,DescriptorName,D008297,8124920,,,7,Male,N,
28595,DescriptorName,D008727,8124920,,,8,Methotrexate,N,
28596,QualifierName,Q000009,8124920,,,8,,Y,adverse effects
28597,DescriptorName,D008875,8124920,,,9,Middle Aged,N,
28598,DescriptorName,D011239,8124920,,,10,Prednisolone,N,
28599,QualifierName,Q000627,8124920,,,10,,Y,therapeutic use
28600,Chemical,D008728,8145359,Methotrimeprazine,9G0LAW7ATQ,,,,
28601,DescriptorName,D002648,8145359,,,1,Child,N,
28602,DescriptorName,D004305,8145359,,,2,"Dose-Response Relationship, Drug",N,
28603,DescriptorName,D062787,8145359,,,3,Drug Overdose,N,
28604,QualifierName,Q000378,8145359,,,3,,N,metabolism
28605,DescriptorName,D006801,8145359,,,4,Humans,N,
28606,DescriptorName,D008297,8145359,,,5,Male,N,
28607,DescriptorName,D008728,8145359,,,6,Methotrimeprazine,N,
28608,QualifierName,Q000506,8145359,,,6,,Y,poisoning
28609,DescriptorName,D019964,8145359,,,7,Mood Disorders,N,
28610,QualifierName,Q000188,8145359,,,7,,N,drug therapy
28611,DescriptorName,D012120,8145359,,,8,Respiration Disorders,N,
28612,QualifierName,Q000139,8145359,,,8,,Y,chemically induced
28613,Chemical,D007980,8149366,Levodopa,46627O600J,,,,
28614,Chemical,D001058,8149366,Apomorphine,N21FAR7B4S,,,,
28615,DescriptorName,D000368,8149366,,,1,Aged,N,
28616,DescriptorName,D001058,8149366,,,2,Apomorphine,N,
28617,QualifierName,Q000627,8149366,,,2,,Y,therapeutic use
28618,DescriptorName,D002940,8149366,,,3,Circadian Rhythm,N,
28619,QualifierName,Q000502,8149366,,,3,,N,physiology
28620,DescriptorName,D004409,8149366,,,4,"Dyskinesia, Drug-Induced",N,
28621,QualifierName,Q000188,8149366,,,4,,Y,drug therapy
28622,DescriptorName,D005260,8149366,,,5,Female,N,
28623,DescriptorName,D006801,8149366,,,6,Humans,N,
28624,DescriptorName,D007980,8149366,,,7,Levodopa,N,
28625,QualifierName,Q000009,8149366,,,7,,Y,adverse effects
28626,DescriptorName,D008297,8149366,,,8,Male,N,
28627,DescriptorName,D008875,8149366,,,9,Middle Aged,N,
28628,DescriptorName,D010300,8149366,,,10,Parkinson Disease,N,
28629,QualifierName,Q000188,8149366,,,10,,Y,drug therapy
28630,Chemical,D016049,8151270,Didanosine,K3GDH6OH08,,,,
28631,DescriptorName,D017088,8151270,,,1,AIDS-Related Opportunistic Infections,N,
28632,QualifierName,Q000188,8151270,,,1,,N,drug therapy
28633,DescriptorName,D000140,8151270,,,2,"Acidosis, Lactic",N,
28634,QualifierName,Q000139,8151270,,,2,,Y,chemically induced
28635,DescriptorName,D000163,8151270,,,3,Acquired Immunodeficiency Syndrome,N,
28636,QualifierName,Q000188,8151270,,,3,,N,drug therapy
28637,DescriptorName,D000368,8151270,,,4,Aged,N,
28638,DescriptorName,D016049,8151270,,,5,Didanosine,N,
28639,QualifierName,Q000009,8151270,,,5,,Y,adverse effects
28640,DescriptorName,D015658,8151270,,,6,HIV Infections,N,
28641,QualifierName,Q000188,8151270,,,6,,Y,drug therapy
28642,DescriptorName,D006501,8151270,,,7,Hepatic Encephalopathy,N,
28643,QualifierName,Q000139,8151270,,,7,,Y,chemically induced
28644,DescriptorName,D006801,8151270,,,8,Humans,N,
28645,DescriptorName,D008297,8151270,,,9,Male,N,
28646,DescriptorName,D008875,8151270,,,10,Middle Aged,N,
28647,Chemical,D012834,8157823,Silver,3M4G523W1G,,,,
28648,Chemical,D012835,8157823,Silver Nitrate,95IT3W8JZE,,,,
28649,DescriptorName,D000328,8157823,,,1,Adult,N,
28650,DescriptorName,D001129,8157823,,,2,Argyria,N,
28651,QualifierName,Q000209,8157823,,,2,,N,etiology
28652,DescriptorName,D004577,8157823,,,3,Electron Probe Microanalysis,N,
28653,DescriptorName,D005260,8157823,,,4,Female,N,
28654,DescriptorName,D006801,8157823,,,5,Humans,N,
28655,DescriptorName,D012834,8157823,,,6,Silver,N,
28656,QualifierName,Q000032,8157823,,,6,,N,analysis
28657,DescriptorName,D012835,8157823,,,7,Silver Nitrate,N,
28658,QualifierName,Q000009,8157823,,,7,,Y,adverse effects
28659,DescriptorName,D012867,8157823,,,8,Skin,N,
28660,QualifierName,Q000737,8157823,,,8,,N,chemistry
28661,DescriptorName,D013281,8157823,,,9,"Stomatitis, Aphthous",N,
28662,QualifierName,Q000188,8157823,,,9,,N,drug therapy
28663,Chemical,D005473,8162401,Fluoxetine,01K63SUP8D,,,,
28664,DescriptorName,D000328,8162401,,,1,Adult,N,
28665,DescriptorName,D003866,8162401,,,2,Depressive Disorder,N,
28666,QualifierName,Q000188,8162401,,,2,,Y,drug therapy
28667,DescriptorName,D004830,8162401,,,3,"Epilepsy, Tonic-Clonic",N,
28668,QualifierName,Q000188,8162401,,,3,,N,drug therapy
28669,DescriptorName,D005260,8162401,,,4,Female,N,
28670,DescriptorName,D005473,8162401,,,5,Fluoxetine,N,
28671,QualifierName,Q000009,8162401,,,5,,Y,adverse effects
28672,DescriptorName,D006801,8162401,,,6,Humans,N,
28673,DescriptorName,D011618,8162401,,,7,Psychotic Disorders,N,
28674,QualifierName,Q000188,8162401,,,7,,Y,drug therapy
28675,DescriptorName,D012640,8162401,,,8,Seizures,N,
28676,QualifierName,Q000139,8162401,,,8,,Y,chemically induced
28677,Chemical,D005473,8164831,Fluoxetine,01K63SUP8D,,,,
28678,DescriptorName,D000368,8164831,,,1,Aged,N,
28679,DescriptorName,D002385,8164831,,,2,Cataplexy,N,
28680,QualifierName,Q000150,8164831,,,2,,N,complications
28681,DescriptorName,D004305,8164831,,,3,"Dose-Response Relationship, Drug",N,
28682,DescriptorName,D005260,8164831,,,4,Female,N,
28683,DescriptorName,D005473,8164831,,,5,Fluoxetine,N,
28684,QualifierName,Q000008,8164831,,,5,,N,administration & dosage
28685,DescriptorName,D005500,8164831,,,6,Follow-Up Studies,N,
28686,DescriptorName,D006801,8164831,,,7,Humans,N,
28687,DescriptorName,D008297,8164831,,,8,Male,N,
28688,DescriptorName,D008875,8164831,,,9,Middle Aged,N,
28689,DescriptorName,D010865,8164831,,,10,Pilot Projects,N,
28690,DescriptorName,D013312,8164831,,,11,"Stress, Physiological",N,
28691,QualifierName,Q000150,8164831,,,11,,N,complications
28692,DescriptorName,D016896,8164831,,,12,Treatment Outcome,N,
28693,Chemical,D002220,8175330,Carbamazepine,33CM23913M,,,,
28694,Chemical,D014635,8175330,Valproic Acid,614OI1Z5WI,,,,
28695,DescriptorName,D000328,8175330,,,1,Adult,N,
28696,DescriptorName,D002220,8175330,,,2,Carbamazepine,N,
28697,QualifierName,Q000009,8175330,,,2,,Y,adverse effects
28698,DescriptorName,D003875,8175330,,,3,Drug Eruptions,N,
28699,QualifierName,Q000209,8175330,,,3,,Y,etiology
28700,DescriptorName,D004827,8175330,,,4,Epilepsy,N,
28701,QualifierName,Q000188,8175330,,,4,,N,drug therapy
28702,DescriptorName,D005260,8175330,,,5,Female,N,
28703,DescriptorName,D006801,8175330,,,6,Humans,N,
28704,DescriptorName,D008297,8175330,,,7,Male,N,
28705,DescriptorName,D008875,8175330,,,8,Middle Aged,N,
28706,DescriptorName,D011565,8175330,,,9,Psoriasis,N,
28707,QualifierName,Q000139,8175330,,,9,,Y,chemically induced
28708,DescriptorName,D014635,8175330,,,10,Valproic Acid,N,
28709,QualifierName,Q000009,8175330,,,10,,Y,adverse effects
28710,Chemical,D002330,8181372,Carmustine,U68WG3173Y,,,,
28711,DescriptorName,D000208,8181372,,,1,Acute Disease,N,
28712,DescriptorName,D000328,8181372,,,2,Adult,N,
28713,DescriptorName,D001932,8181372,,,3,Brain Neoplasms,N,
28714,QualifierName,Q000188,8181372,,,3,,N,drug therapy
28715,DescriptorName,D002330,8181372,,,4,Carmustine,N,
28716,QualifierName,Q000009,8181372,,,4,,Y,adverse effects
28717,DescriptorName,D017809,8181372,,,5,Fatal Outcome,N,
28718,DescriptorName,D006801,8181372,,,6,Humans,N,
28719,DescriptorName,D017563,8181372,,,7,"Lung Diseases, Interstitial",N,
28720,QualifierName,Q000139,8181372,,,7,,Y,chemically induced
28721,DescriptorName,D008297,8181372,,,8,Male,N,
28722,DescriptorName,D011859,8181372,,,9,Radiography,N,
28723,Chemical,D008801,8186884,Mexiletine,1U511HHV4Z,,,,
28724,Chemical,D004206,8186884,Disopyramide,GFO928U8MQ,,,,
28725,Chemical,D011342,8186884,Procainamide,L39WTC366D,,,,
28726,DescriptorName,D000368,8186884,,,1,Aged,N,
28727,DescriptorName,D017147,8186884,,,2,"Defibrillators, Implantable",N,
28728,QualifierName,Q000009,8186884,,,2,,Y,adverse effects
28729,DescriptorName,D004206,8186884,,,3,Disopyramide,N,
28730,QualifierName,Q000627,8186884,,,3,,N,therapeutic use
28731,DescriptorName,D006801,8186884,,,4,Humans,N,
28732,DescriptorName,D008297,8186884,,,5,Male,N,
28733,DescriptorName,D008801,8186884,,,6,Mexiletine,N,
28734,QualifierName,Q000627,8186884,,,6,,N,therapeutic use
28735,DescriptorName,D011342,8186884,,,7,Procainamide,N,
28736,QualifierName,Q000009,8186884,,,7,,Y,adverse effects
28737,DescriptorName,D017180,8186884,,,8,"Tachycardia, Ventricular",N,
28738,QualifierName,Q000188,8186884,,,8,,N,drug therapy
28739,Chemical,D014635,8192712,Valproic Acid,614OI1Z5WI,,,,
28740,Chemical,D000641,8192712,Ammonia,7664-41-7,,,,
28741,DescriptorName,D000328,8192712,,,1,Adult,N,
28742,DescriptorName,D000641,8192712,,,2,Ammonia,N,
28743,QualifierName,Q000097,8192712,,,2,,Y,blood
28744,DescriptorName,D017029,8192712,,,3,"Epilepsy, Complex Partial",N,
28745,QualifierName,Q000188,8192712,,,3,,N,drug therapy
28746,DescriptorName,D006801,8192712,,,4,Humans,N,
28747,DescriptorName,D008297,8192712,,,5,Male,N,
28748,DescriptorName,D008659,8192712,,,6,Metabolic Diseases,N,
28749,QualifierName,Q000139,8192712,,,6,,N,chemically induced
28750,DescriptorName,D014635,8192712,,,7,Valproic Acid,N,
28751,QualifierName,Q000009,8192712,,,7,,Y,adverse effects
28752,Chemical,D008614,8197046,Meperidine,9E338QE28F,,,,
28753,DescriptorName,D000328,8197046,,,1,Adult,N,
28754,DescriptorName,D002493,8197046,,,2,Central Nervous System Diseases,N,
28755,QualifierName,Q000139,8197046,,,2,,Y,chemically induced
28756,DescriptorName,D002908,8197046,,,3,Chronic Disease,N,
28757,DescriptorName,D003693,8197046,,,4,Delirium,N,
28758,QualifierName,Q000139,8197046,,,4,,N,chemically induced
28759,DescriptorName,D006212,8197046,,,5,Hallucinations,N,
28760,QualifierName,Q000139,8197046,,,5,,N,chemically induced
28761,DescriptorName,D006801,8197046,,,6,Humans,N,
28762,DescriptorName,D008103,8197046,,,7,Liver Cirrhosis,N,
28763,QualifierName,Q000188,8197046,,,7,,Y,drug therapy
28764,DescriptorName,D008297,8197046,,,8,Male,N,
28765,DescriptorName,D008614,8197046,,,9,Meperidine,N,
28766,QualifierName,Q000009,8197046,,,9,,Y,adverse effects
28767,DescriptorName,D010195,8197046,,,10,Pancreatitis,N,
28768,QualifierName,Q000188,8197046,,,10,,Y,drug therapy
28769,DescriptorName,D014202,8197046,,,11,Tremor,N,
28770,QualifierName,Q000139,8197046,,,11,,N,chemically induced
28771,Chemical,D009599,8207519,Nitroprusside,169D1260KM,,,,
28772,Chemical,D009270,8207519,Naloxone,36B82AMQ7N,,,,
28773,Chemical,D010672,8207519,Phenytoin,6158TKW0C5,,,,
28774,Chemical,D009020,8207519,Morphine,76I7G6D29C,,,,
28775,DescriptorName,D062787,8207519,,,1,Drug Overdose,N,
28776,QualifierName,Q000188,8207519,,,1,,N,drug therapy
28777,DescriptorName,D005260,8207519,,,2,Female,N,
28778,DescriptorName,D006801,8207519,,,3,Humans,N,
28779,DescriptorName,D007260,8207519,,,4,Infusion Pumps,N,
28780,DescriptorName,D007278,8207519,,,5,"Injections, Spinal",N,
28781,DescriptorName,D008875,8207519,,,6,Middle Aged,N,
28782,DescriptorName,D009020,8207519,,,7,Morphine,N,
28783,QualifierName,Q000008,8207519,,,7,,N,administration & dosage
28784,DescriptorName,D009270,8207519,,,8,Naloxone,N,
28785,QualifierName,Q000627,8207519,,,8,,N,therapeutic use
28786,DescriptorName,D009599,8207519,,,9,Nitroprusside,N,
28787,QualifierName,Q000627,8207519,,,9,,N,therapeutic use
28788,DescriptorName,D010672,8207519,,,10,Phenytoin,N,
28789,QualifierName,Q000627,8207519,,,10,,N,therapeutic use
28790,DescriptorName,D013226,8207519,,,11,Status Epilepticus,N,
28791,QualifierName,Q000139,8207519,,,11,,N,chemically induced
28792,Chemical,D016685,8222875,Mitomycin,50SG953SK6,,,,
28793,DescriptorName,D000230,8222875,,,1,Adenocarcinoma,N,
28794,QualifierName,Q000188,8222875,,,1,,N,drug therapy
28795,DescriptorName,D000328,8222875,,,2,Adult,N,
28796,DescriptorName,D002430,8222875,,,3,Cecal Neoplasms,N,
28797,QualifierName,Q000188,8222875,,,3,,N,drug therapy
28798,DescriptorName,D003110,8222875,,,4,Colonic Neoplasms,N,
28799,QualifierName,Q000188,8222875,,,4,,N,drug therapy
28800,DescriptorName,D005260,8222875,,,5,Female,N,
28801,DescriptorName,D006463,8222875,,,6,Hemolytic-Uremic Syndrome,N,
28802,QualifierName,Q000139,8222875,,,6,,Y,chemically induced
28803,DescriptorName,D006470,8222875,,,7,Hemorrhage,N,
28804,QualifierName,Q000209,8222875,,,7,,Y,etiology
28805,DescriptorName,D006801,8222875,,,8,Humans,N,
28806,DescriptorName,D008171,8222875,,,9,Lung Diseases,N,
28807,QualifierName,Q000209,8222875,,,9,,Y,etiology
28808,DescriptorName,D008875,8222875,,,10,Middle Aged,N,
28809,DescriptorName,D016685,8222875,,,11,Mitomycin,N,
28810,QualifierName,Q000009,8222875,,,11,,Y,adverse effects
28811,Chemical,D003000,8239963,Clonidine,MN3L5RMN02,,,,
28812,DescriptorName,D000328,8239963,,,1,Adult,N,
28813,DescriptorName,D001919,8239963,,,2,Bradycardia,N,
28814,QualifierName,Q000139,8239963,,,2,,Y,chemically induced
28815,DescriptorName,D003000,8239963,,,3,Clonidine,N,
28816,QualifierName,Q000009,8239963,,,3,,Y,adverse effects
28817,DescriptorName,D006801,8239963,,,4,Humans,N,
28818,DescriptorName,D008297,8239963,,,5,Male,N,
28819,DescriptorName,D009128,8239963,,,6,Muscle Spasticity,N,
28820,QualifierName,Q000188,8239963,,,6,,N,drug therapy
28821,DescriptorName,D013119,8239963,,,7,Spinal Cord Injuries,N,
28822,QualifierName,Q000188,8239963,,,7,,Y,drug therapy
28823,Chemical,D015662,8244201,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
28824,DescriptorName,D000368,8244201,,,1,Aged,N,
28825,DescriptorName,D006801,8244201,,,2,Humans,N,
28826,DescriptorName,D006947,8244201,,,3,Hyperkalemia,N,
28827,QualifierName,Q000139,8244201,,,3,,Y,chemically induced
28828,DescriptorName,D007010,8244201,,,4,Hyponatremia,N,
28829,QualifierName,Q000139,8244201,,,4,,N,chemically induced
28830,DescriptorName,D007674,8244201,,,5,Kidney Diseases,N,
28831,QualifierName,Q000097,8244201,,,5,,N,blood
28832,DescriptorName,D007684,8244201,,,6,Kidney Tubules,N,
28833,QualifierName,Q000187,8244201,,,6,,Y,drug effects
28834,DescriptorName,D015458,8244201,,,7,"Leukemia, T-Cell",N,
28835,QualifierName,Q000150,8244201,,,7,,Y,complications
28836,DescriptorName,D008228,8244201,,,8,"Lymphoma, Non-Hodgkin",N,
28837,QualifierName,Q000150,8244201,,,8,,Y,complications
28838,DescriptorName,D008297,8244201,,,9,Male,N,
28839,DescriptorName,D008875,8244201,,,10,Middle Aged,N,
28840,DescriptorName,D011020,8244201,,,11,"Pneumonia, Pneumocystis",N,
28841,QualifierName,Q000150,8244201,,,11,,N,complications
28842,DescriptorName,D015662,8244201,,,12,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
28843,QualifierName,Q000009,8244201,,,12,,Y,adverse effects
28844,Chemical,D009609,8250714,Nitrous Oxide,K50XQU1029,,,,
28845,Chemical,D014805,8250714,Vitamin B 12,P6YC3EG204,,,,
28846,DescriptorName,D000758,8250714,,,1,Anesthesia,N,
28847,QualifierName,Q000009,8250714,,,1,,Y,adverse effects
28848,DescriptorName,D004347,8250714,,,2,Drug Interactions,N,
28849,DescriptorName,D005684,8250714,,,3,Gait,N,
28850,DescriptorName,D006801,8250714,,,4,Humans,N,
28851,DescriptorName,D008297,8250714,,,5,Male,N,
28852,DescriptorName,D008875,8250714,,,6,Middle Aged,N,
28853,DescriptorName,D009609,8250714,,,7,Nitrous Oxide,N,
28854,QualifierName,Q000009,8250714,,,7,,Y,adverse effects
28855,DescriptorName,D013118,8250714,,,8,Spinal Cord Diseases,N,
28856,QualifierName,Q000139,8250714,,,8,,Y,chemically induced
28857,DescriptorName,D014805,8250714,,,9,Vitamin B 12,N,
28858,QualifierName,Q000627,8250714,,,9,,N,therapeutic use
28859,DescriptorName,D014806,8250714,,,10,Vitamin B 12 Deficiency,N,
28860,QualifierName,Q000097,8250714,,,10,,N,blood
28861,Chemical,D005473,8253700,Fluoxetine,01K63SUP8D,,,,
28862,DescriptorName,D000367,8253700,,,1,Age Factors,N,
28863,DescriptorName,D000368,8253700,,,2,Aged,N,
28864,DescriptorName,D015897,8253700,,,3,Comorbidity,N,
28865,DescriptorName,D003866,8253700,,,4,Depressive Disorder,N,
28866,QualifierName,Q000188,8253700,,,4,,Y,drug therapy
28867,DescriptorName,D007172,8253700,,,5,Erectile Dysfunction,N,
28868,QualifierName,Q000188,8253700,,,5,,Y,drug therapy
28869,DescriptorName,D005473,8253700,,,6,Fluoxetine,N,
28870,QualifierName,Q000009,8253700,,,6,,N,adverse effects
28871,DescriptorName,D006801,8253700,,,7,Humans,N,
28872,DescriptorName,D007989,8253700,,,8,Libido,N,
28873,QualifierName,Q000187,8253700,,,8,,N,drug effects
28874,DescriptorName,D008297,8253700,,,9,Male,N,
28875,DescriptorName,D008875,8253700,,,10,Middle Aged,N,
28876,DescriptorName,D009771,8253700,,,11,Obsessive-Compulsive Disorder,N,
28877,QualifierName,Q000188,8253700,,,11,,Y,drug therapy
28878,DescriptorName,D010410,8253700,,,12,Penile Erection,N,
28879,QualifierName,Q000187,8253700,,,12,,N,drug effects
28880,DescriptorName,D011317,8253700,,,13,Priapism,N,
28881,QualifierName,Q000139,8253700,,,13,,N,chemically induced
28882,Chemical,D002216,8255797,Captopril,9G64RSX1XD,,,,
28883,DescriptorName,D001853,8255797,,,1,Bone Marrow,N,
28884,QualifierName,Q000187,8255797,,,1,,Y,drug effects
28885,DescriptorName,D002216,8255797,,,2,Captopril,N,
28886,QualifierName,Q000009,8255797,,,2,,Y,adverse effects
28887,DescriptorName,D004314,8255797,,,3,Down Syndrome,N,
28888,QualifierName,Q000150,8255797,,,3,,Y,complications
28889,DescriptorName,D005260,8255797,,,4,Female,N,
28890,DescriptorName,D006330,8255797,,,5,"Heart Defects, Congenital",N,
28891,QualifierName,Q000235,8255797,,,5,,Y,genetics
28892,DescriptorName,D006333,8255797,,,6,Heart Failure,N,
28893,QualifierName,Q000188,8255797,,,6,,N,drug therapy
28894,DescriptorName,D006801,8255797,,,7,Humans,N,
28895,DescriptorName,D006973,8255797,,,8,Hypertension,N,
28896,QualifierName,Q000188,8255797,,,8,,N,drug therapy
28897,DescriptorName,D007223,8255797,,,9,Infant,N,
28898,DescriptorName,D008297,8255797,,,10,Male,N,
28899,DescriptorName,D009503,8255797,,,11,Neutropenia,N,
28900,QualifierName,Q000139,8255797,,,11,,Y,chemically induced
28901,DescriptorName,D011182,8255797,,,12,Postoperative Care,N,
28902,Chemical,D008278,8260059,Magnesium Sulfate,7487-88-9,,,,
28903,DescriptorName,D000328,8260059,,,1,Adult,N,
28904,DescriptorName,D005260,8260059,,,2,Female,N,
28905,DescriptorName,D006801,8260059,,,3,Humans,N,
28906,DescriptorName,D007775,8260059,,,4,Lactation Disorders,N,
28907,QualifierName,Q000139,8260059,,,4,,Y,chemically induced
28908,DescriptorName,D008278,8260059,,,5,Magnesium Sulfate,N,
28909,QualifierName,Q000009,8260059,,,5,,Y,adverse effects
28910,DescriptorName,D011225,8260059,,,6,Pre-Eclampsia,N,
28911,QualifierName,Q000188,8260059,,,6,,Y,drug therapy
28912,DescriptorName,D011247,8260059,,,7,Pregnancy,N,
28913,Chemical,D017273,8266863,Goserelin,0F65R8P09N,,,,
28914,DescriptorName,D000230,8266863,,,1,Adenocarcinoma,N,
28915,QualifierName,Q000188,8266863,,,1,,Y,drug therapy
28916,DescriptorName,D000368,8266863,,,2,Aged,N,
28917,DescriptorName,D004322,8266863,,,3,Drainage,N,
28918,DescriptorName,D017273,8266863,,,4,Goserelin,N,
28919,QualifierName,Q000009,8266863,,,4,,Y,adverse effects
28920,DescriptorName,D006801,8266863,,,5,Humans,N,
28921,DescriptorName,D008175,8266863,,,6,Lung Neoplasms,N,
28922,QualifierName,Q000556,8266863,,,6,,N,secondary
28923,DescriptorName,D008207,8266863,,,7,Lymphatic Metastasis,N,
28924,DescriptorName,D008297,8266863,,,8,Male,N,
28925,DescriptorName,D016066,8266863,,,9,"Pleural Effusion, Malignant",N,
28926,QualifierName,Q000139,8266863,,,9,,Y,chemically induced
28927,DescriptorName,D011471,8266863,,,10,Prostatic Neoplasms,N,
28928,QualifierName,Q000188,8266863,,,10,,Y,drug therapy
28929,Chemical,D009278,8276031,Naphazoline,H231GF11BV,,,,
28930,DescriptorName,D000281,8276031,,,1,"Administration, Intranasal",N,
28931,DescriptorName,D003128,8276031,,,2,Coma,N,
28932,QualifierName,Q000139,8276031,,,2,,N,chemically induced
28933,DescriptorName,D005260,8276031,,,3,Female,N,
28934,DescriptorName,D006801,8276031,,,4,Humans,N,
28935,DescriptorName,D007223,8276031,,,5,Infant,N,
28936,DescriptorName,D009278,8276031,,,6,Naphazoline,N,
28937,QualifierName,Q000008,8276031,,,6,,N,administration & dosage
28938,DescriptorName,D009304,8276031,,,7,Nasopharyngitis,N,
28939,QualifierName,Q000188,8276031,,,7,,Y,drug therapy
28940,Chemical,D001215,8292513,Asparaginase,EC 3.5.1.1,,,,
28941,DescriptorName,D000293,8292513,,,1,Adolescent,N,
28942,DescriptorName,D001037,8292513,,,2,Aphasia,N,
28943,QualifierName,Q000209,8292513,,,2,,Y,etiology
28944,DescriptorName,D001215,8292513,,,3,Asparaginase,N,
28945,QualifierName,Q000009,8292513,,,3,,Y,adverse effects
28946,DescriptorName,D002561,8292513,,,4,Cerebrovascular Disorders,N,
28947,QualifierName,Q000139,8292513,,,4,,Y,chemically induced
28948,DescriptorName,D002648,8292513,,,5,Child,N,
28949,DescriptorName,D005260,8292513,,,6,Female,N,
28950,DescriptorName,D006801,8292513,,,7,Humans,N,
28951,DescriptorName,D008297,8292513,,,8,Male,N,
28952,DescriptorName,D009483,8292513,,,9,Neuropsychological Tests,N,
28953,DescriptorName,D054198,8292513,,,10,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
28954,QualifierName,Q000188,8292513,,,10,,Y,drug therapy
28955,Chemical,D007980,8301877,Levodopa,46627O600J,,,,
28956,Chemical,D014635,8301877,Valproic Acid,614OI1Z5WI,,,,
28957,DescriptorName,D000368,8301877,,,1,Aged,N,
28958,DescriptorName,D004569,8301877,,,2,Electroencephalography,N,
28959,QualifierName,Q000187,8301877,,,2,,N,drug effects
28960,DescriptorName,D004576,8301877,,,3,Electromyography,N,
28961,QualifierName,Q000187,8301877,,,3,,N,drug effects
28962,DescriptorName,D004831,8301877,,,4,"Epilepsies, Myoclonic",N,
28963,QualifierName,Q000139,8301877,,,4,,Y,chemically induced
28964,DescriptorName,D004829,8301877,,,5,"Epilepsy, Generalized",N,
28965,QualifierName,Q000139,8301877,,,5,,N,chemically induced
28966,DescriptorName,D005073,8301877,,,6,"Evoked Potentials, Somatosensory",N,
28967,QualifierName,Q000187,8301877,,,6,,Y,drug effects
28968,DescriptorName,D005260,8301877,,,7,Female,N,
28969,DescriptorName,D006801,8301877,,,8,Humans,N,
28970,DescriptorName,D007980,8301877,,,9,Levodopa,N,
28971,QualifierName,Q000008,8301877,,,9,,N,administration & dosage
28972,DescriptorName,D009460,8301877,,,10,Neurologic Examination,N,
28973,QualifierName,Q000187,8301877,,,10,,N,drug effects
28974,DescriptorName,D010300,8301877,,,11,Parkinson Disease,N,
28975,QualifierName,Q000188,8301877,,,11,,Y,drug therapy
28976,DescriptorName,D012640,8301877,,,12,Seizures,N,
28977,QualifierName,Q000139,8301877,,,12,,Y,chemically induced
28978,DescriptorName,D014635,8301877,,,13,Valproic Acid,N,
28979,QualifierName,Q000008,8301877,,,13,,N,administration & dosage
28980,Chemical,D013723,8308511,Teratogens,0,,,,
28981,Chemical,D000212,8308511,Acyclovir,X4HES1O11F,,,,
28982,DescriptorName,D000212,8308511,,,1,Acyclovir,N,
28983,QualifierName,Q000009,8308511,,,1,,Y,adverse effects
28984,DescriptorName,D000328,8308511,,,2,Adult,N,
28985,DescriptorName,D005260,8308511,,,3,Female,N,
28986,DescriptorName,D005333,8308511,,,4,Fetus,N,
28987,QualifierName,Q000187,8308511,,,4,,N,drug effects
28988,DescriptorName,D006561,8308511,,,5,Herpes Simplex,N,
28989,QualifierName,Q000188,8308511,,,5,,Y,drug therapy
28990,DescriptorName,D006801,8308511,,,6,Humans,N,
28991,DescriptorName,D007231,8308511,,,7,"Infant, Newborn",N,
28992,DescriptorName,D011247,8308511,,,8,Pregnancy,N,
28993,DescriptorName,D011261,8308511,,,9,"Pregnancy Trimester, First",N,
28994,DescriptorName,D013723,8308511,,,10,Teratogens,N,
28995,QualifierName,Q000493,8308511,,,10,,N,pharmacokinetics
28996,Chemical,D008094,8313300,Lithium,9FN79X2M3F,,,,
28997,DescriptorName,D001714,8313300,,,1,Bipolar Disorder,N,
28998,QualifierName,Q000097,8313300,,,1,,N,blood
28999,DescriptorName,D004305,8313300,,,2,"Dose-Response Relationship, Drug",N,
29000,DescriptorName,D004334,8313300,,,3,Drug Administration Schedule,N,
29001,DescriptorName,D004359,8313300,,,4,"Drug Therapy, Combination",N,
29002,DescriptorName,D006111,8313300,,,5,Graves Disease,N,
29003,QualifierName,Q000097,8313300,,,5,,N,blood
29004,DescriptorName,D006801,8313300,,,6,Humans,N,
29005,DescriptorName,D008094,8313300,,,7,Lithium,N,
29006,QualifierName,Q000009,8313300,,,7,,Y,adverse effects
29007,DescriptorName,D008297,8313300,,,8,Male,N,
29008,DescriptorName,D008875,8313300,,,9,Middle Aged,N,
29009,DescriptorName,D013375,8313300,,,10,Substance Withdrawal Syndrome,N,
29010,QualifierName,Q000097,8313300,,,10,,N,blood
29011,Chemical,D002991,8316494,Clofazimine,D959AE5USF,,,,
29012,DescriptorName,D015746,8316494,,,1,Abdominal Pain,N,
29013,QualifierName,Q000209,8316494,,,1,,Y,etiology
29014,DescriptorName,D000328,8316494,,,2,Adult,N,
29015,DescriptorName,D002991,8316494,,,3,Clofazimine,N,
29016,QualifierName,Q000009,8316494,,,3,,Y,adverse effects
29017,DescriptorName,D006801,8316494,,,4,Humans,N,
29018,DescriptorName,D007918,8316494,,,5,Leprosy,N,
29019,QualifierName,Q000188,8316494,,,5,,Y,drug therapy
29020,DescriptorName,D008198,8316494,,,6,Lymph Nodes,N,
29021,QualifierName,Q000473,8316494,,,6,,N,pathology
29022,DescriptorName,D008297,8316494,,,7,Male,N,
29023,Chemical,D000666,8329789,Amphotericin B,7XU7A7DROE,,,,
29024,Chemical,D014700,8329789,Verapamil,CJ0O37KU29,,,,
29025,Chemical,D006854,8329789,Hydrocortisone,WI4X0X7BPJ,,,,
29026,DescriptorName,D000666,8329789,,,1,Amphotericin B,N,
29027,QualifierName,Q000009,8329789,,,1,,Y,adverse effects
29028,DescriptorName,D001145,8329789,,,2,"Arrhythmias, Cardiac",N,
29029,QualifierName,Q000139,8329789,,,2,,N,chemically induced
29030,DescriptorName,D002177,8329789,,,3,Candidiasis,N,
29031,QualifierName,Q000188,8329789,,,3,,N,drug therapy
29032,DescriptorName,D002648,8329789,,,4,Child,N,
29033,DescriptorName,D002675,8329789,,,5,"Child, Preschool",N,
29034,DescriptorName,D062787,8329789,,,6,Drug Overdose,N,
29035,DescriptorName,D005260,8329789,,,7,Female,N,
29036,DescriptorName,D006323,8329789,,,8,Heart Arrest,N,
29037,QualifierName,Q000139,8329789,,,8,,Y,chemically induced
29038,DescriptorName,D006801,8329789,,,9,Humans,N,
29039,DescriptorName,D006854,8329789,,,10,Hydrocortisone,N,
29040,QualifierName,Q000627,8329789,,,10,,N,therapeutic use
29041,DescriptorName,D007223,8329789,,,11,Infant,N,
29042,DescriptorName,D008297,8329789,,,12,Male,N,
29043,DescriptorName,D011292,8329789,,,13,Premedication,N,
29044,DescriptorName,D014700,8329789,,,14,Verapamil,N,
29045,QualifierName,Q000627,8329789,,,14,,N,therapeutic use
29046,Chemical,D016572,8340162,Cyclosporine,83HN0GTJ6D,,,,
29047,Chemical,D001379,8340162,Azathioprine,MRK240IY2L,,,,
29048,Chemical,D007741,8340162,Labetalol,R5H8897N95,,,,
29049,Chemical,D011241,8340162,Prednisone,VB0R961HZT,,,,
29050,DescriptorName,D000328,8340162,,,1,Adult,N,
29051,DescriptorName,D001379,8340162,,,2,Azathioprine,N,
29052,QualifierName,Q000627,8340162,,,2,,N,therapeutic use
29053,DescriptorName,D016572,8340162,,,3,Cyclosporine,N,
29054,QualifierName,Q000627,8340162,,,3,,N,therapeutic use
29055,DescriptorName,D006801,8340162,,,4,Humans,N,
29056,DescriptorName,D006973,8340162,,,5,Hypertension,N,
29057,QualifierName,Q000188,8340162,,,5,,N,drug therapy
29058,DescriptorName,D007165,8340162,,,6,Immunosuppression,N,
29059,QualifierName,Q000009,8340162,,,6,,N,adverse effects
29060,DescriptorName,D007741,8340162,,,7,Labetalol,N,
29061,QualifierName,Q000627,8340162,,,7,,N,therapeutic use
29062,DescriptorName,D016031,8340162,,,8,Liver Transplantation,Y,
29063,DescriptorName,D008297,8340162,,,9,Male,N,
29064,DescriptorName,D009894,8340162,,,10,Opportunistic Infections,N,
29065,QualifierName,Q000209,8340162,,,10,,N,etiology
29066,DescriptorName,D011182,8340162,,,11,Postoperative Care,N,
29067,DescriptorName,D011183,8340162,,,12,Postoperative Complications,Y,
29068,DescriptorName,D011241,8340162,,,13,Prednisone,N,
29069,QualifierName,Q000627,8340162,,,13,,N,therapeutic use
29070,Chemical,D009573,834512,Nitrites,0,,,,
29071,Chemical,D004366,834512,Nonprescription Drugs,0,,,,
29072,Chemical,D008751,834512,Methylene Blue,T42P99266K,,,,
29073,DescriptorName,D003645,834512,,,1,"Death, Sudden",N,
29074,QualifierName,Q000209,834512,,,1,,Y,etiology
29075,DescriptorName,D004200,834512,,,2,Diseases in Twins,N,
29076,DescriptorName,D006452,834512,,,3,Hemoglobinometry,N,
29077,DescriptorName,D006801,834512,,,4,Humans,N,
29078,DescriptorName,D007223,834512,,,5,Infant,N,
29079,DescriptorName,D008297,834512,,,6,Male,N,
29080,DescriptorName,D008708,834512,,,7,Methemoglobinemia,N,
29081,QualifierName,Q000139,834512,,,7,,Y,chemically induced
29082,DescriptorName,D008751,834512,,,8,Methylene Blue,N,
29083,QualifierName,Q000627,834512,,,8,,N,therapeutic use
29084,DescriptorName,D009573,834512,,,9,Nitrites,N,
29085,QualifierName,Q000506,834512,,,9,,Y,poisoning
29086,DescriptorName,D004366,834512,,,10,Nonprescription Drugs,N,
29087,DescriptorName,D012141,834512,,,11,Respiratory Tract Infections,N,
29088,QualifierName,Q000188,834512,,,11,,N,drug therapy
29089,Chemical,D014635,8345435,Valproic Acid,614OI1Z5WI,,,,
29090,Chemical,D002331,8345435,Carnitine,S7UI8SM58A,,,,
29091,DescriptorName,D002331,8345435,,,1,Carnitine,N,
29092,QualifierName,Q000627,8345435,,,1,,Y,therapeutic use
29093,DescriptorName,D056486,8345435,,,2,Chemical and Drug Induced Liver Injury,N,
29094,QualifierName,Q000188,8345435,,,2,,Y,drug therapy
29095,DescriptorName,D006801,8345435,,,3,Humans,N,
29096,DescriptorName,D007223,8345435,,,4,Infant,N,
29097,DescriptorName,D008297,8345435,,,5,Male,N,
29098,DescriptorName,D017211,8345435,,,6,Treatment Failure,N,
29099,DescriptorName,D014635,8345435,,,7,Valproic Acid,N,
29100,QualifierName,Q000009,8345435,,,7,,Y,adverse effects
29101,Chemical,D007376,8360712,Interleukin-2,0,,,,
29102,DescriptorName,D000328,8360712,,,1,Adult,N,
29103,DescriptorName,D001927,8360712,,,2,Brain Diseases,N,
29104,QualifierName,Q000139,8360712,,,2,,Y,chemically induced
29105,DescriptorName,D002493,8360712,,,3,Central Nervous System Diseases,N,
29106,QualifierName,Q000188,8360712,,,3,,Y,drug therapy
29107,DescriptorName,D003072,8360712,,,4,Cognition Disorders,N,
29108,QualifierName,Q000139,8360712,,,4,,N,chemically induced
29109,DescriptorName,D005260,8360712,,,5,Female,N,
29110,DescriptorName,D005500,8360712,,,6,Follow-Up Studies,N,
29111,DescriptorName,D006801,8360712,,,7,Humans,N,
29112,DescriptorName,D007276,8360712,,,8,"Injections, Intraventricular",N,
29113,DescriptorName,D007376,8360712,,,9,Interleukin-2,N,
29114,QualifierName,Q000008,8360712,,,9,,N,administration & dosage
29115,DescriptorName,D013997,8360712,,,10,Time Factors,N,
29116,Chemical,D013963,8363533,Thyroid Hormones,0,,,,
29117,Chemical,D016651,8363533,Lithium Carbonate,2BMD2GNA4V,,,,
29118,DescriptorName,D000293,8363533,,,1,Adolescent,N,
29119,DescriptorName,D000328,8363533,,,2,Adult,N,
29120,DescriptorName,D001714,8363533,,,3,Bipolar Disorder,N,
29121,QualifierName,Q000097,8363533,,,3,,N,blood
29122,DescriptorName,D005260,8363533,,,4,Female,N,
29123,DescriptorName,D006801,8363533,,,5,Humans,N,
29124,DescriptorName,D016651,8363533,,,6,Lithium Carbonate,N,
29125,QualifierName,Q000009,8363533,,,6,,Y,adverse effects
29126,DescriptorName,D013960,8363533,,,7,Thyroid Function Tests,N,
29127,DescriptorName,D013963,8363533,,,8,Thyroid Hormones,N,
29128,QualifierName,Q000097,8363533,,,8,,N,blood
29129,DescriptorName,D013967,8363533,,,9,"Thyroiditis, Autoimmune",N,
29130,QualifierName,Q000097,8363533,,,9,,N,blood
29131,DescriptorName,D013971,8363533,,,10,Thyrotoxicosis,N,
29132,QualifierName,Q000097,8363533,,,10,,N,blood
29133,Chemical,D014212,8375752,Tretinoin,5688UTC01R,,,,
29134,Chemical,D003907,8375752,Dexamethasone,7S5I7G3JQL,,,,
29135,DescriptorName,D000328,8375752,,,1,Adult,N,
29136,DescriptorName,D003907,8375752,,,2,Dexamethasone,N,
29137,QualifierName,Q000627,8375752,,,2,,N,therapeutic use
29138,DescriptorName,D006801,8375752,,,3,Humans,N,
29139,DescriptorName,D015473,8375752,,,4,"Leukemia, Promyelocytic, Acute",N,
29140,QualifierName,Q000097,8375752,,,4,,N,blood
29141,DescriptorName,D007958,8375752,,,5,Leukocyte Count,N,
29142,DescriptorName,D008297,8375752,,,6,Male,N,
29143,DescriptorName,D012074,8375752,,,7,Remission Induction,N,
29144,DescriptorName,D013577,8375752,,,8,Syndrome,N,
29145,DescriptorName,D014212,8375752,,,9,Tretinoin,N,
29146,QualifierName,Q000009,8375752,,,9,,Y,adverse effects
29147,Chemical,D010758,8384030,Phosphorus,27YLU75U4W,,,,
29148,Chemical,D017245,8384030,Foscarnet,364P9RVW4X,,,,
29149,DescriptorName,D000328,8384030,,,1,Adult,N,
29150,DescriptorName,D003586,8384030,,,2,Cytomegalovirus Infections,N,
29151,QualifierName,Q000188,8384030,,,2,,N,drug therapy
29152,DescriptorName,D017245,8384030,,,3,Foscarnet,N,
29153,QualifierName,Q000008,8384030,,,3,,N,administration & dosage
29154,DescriptorName,D015658,8384030,,,4,HIV Infections,N,
29155,QualifierName,Q000150,8384030,,,4,,N,complications
29156,DescriptorName,D006764,8384030,,,5,"Hospitals, Community",N,
29157,DescriptorName,D006784,8384030,,,6,"Hospitals, Teaching",N,
29158,DescriptorName,D006801,8384030,,,7,Humans,N,
29159,DescriptorName,D006996,8384030,,,8,Hypocalcemia,N,
29160,QualifierName,Q000139,8384030,,,8,,N,chemically induced
29161,DescriptorName,D007008,8384030,,,9,Hypokalemia,N,
29162,QualifierName,Q000139,8384030,,,9,,N,chemically induced
29163,DescriptorName,D008275,8384030,,,10,Magnesium Deficiency,N,
29164,QualifierName,Q000139,8384030,,,10,,Y,chemically induced
29165,DescriptorName,D008297,8384030,,,11,Male,N,
29166,DescriptorName,D010758,8384030,,,12,Phosphorus,N,
29167,QualifierName,Q000097,8384030,,,12,,N,blood
29168,DescriptorName,D012173,8384030,,,13,Retinitis,N,
29169,QualifierName,Q000188,8384030,,,13,,N,drug therapy
29170,DescriptorName,D014883,8384030,,,14,Water-Electrolyte Imbalance,N,
29171,QualifierName,Q000139,8384030,,,14,,Y,chemically induced
29172,Chemical,D000894,8396491,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
29173,Chemical,C059428,8396491,CPH 82,0,,,,
29174,Chemical,D006027,8396491,Glycosides,0,,,,
29175,Chemical,D017705,8396491,Lignans,0,,,,
29176,Chemical,D010936,8396491,Plant Extracts,0,,,,
29177,Chemical,D000324,8396491,Adrenocorticotropic Hormone,9002-60-2,,,,
29178,Chemical,D006854,8396491,Hydrocortisone,WI4X0X7BPJ,,,,
29179,DescriptorName,D000324,8396491,,,1,Adrenocorticotropic Hormone,N,
29180,QualifierName,Q000097,8396491,,,1,,Y,blood
29181,DescriptorName,D000328,8396491,,,2,Adult,N,
29182,DescriptorName,D000894,8396491,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
29183,QualifierName,Q000009,8396491,,,3,,Y,adverse effects
29184,DescriptorName,D001172,8396491,,,4,"Arthritis, Rheumatoid",N,
29185,QualifierName,Q000097,8396491,,,4,,N,blood
29186,DescriptorName,D005260,8396491,,,5,Female,N,
29187,DescriptorName,D006027,8396491,,,6,Glycosides,N,
29188,QualifierName,Q000009,8396491,,,6,,Y,adverse effects
29189,DescriptorName,D006801,8396491,,,7,Humans,N,
29190,DescriptorName,D006854,8396491,,,8,Hydrocortisone,N,
29191,QualifierName,Q000097,8396491,,,8,,Y,blood
29192,DescriptorName,D007030,8396491,,,9,Hypothalamo-Hypophyseal System,N,
29193,QualifierName,Q000187,8396491,,,9,,Y,drug effects
29194,DescriptorName,D017705,8396491,,,10,Lignans,Y,
29195,DescriptorName,D008870,8396491,,,11,Microtubules,N,
29196,QualifierName,Q000187,8396491,,,11,,N,drug effects
29197,DescriptorName,D010913,8396491,,,12,Pituitary-Adrenal System,N,
29198,QualifierName,Q000187,8396491,,,12,,Y,drug effects
29199,DescriptorName,D010936,8396491,,,13,Plant Extracts,N,
29200,QualifierName,Q000009,8396491,,,13,,Y,adverse effects
29201,Chemical,D002220,8404753,Carbamazepine,33CM23913M,,,,
29202,DescriptorName,D000293,8404753,,,1,Adolescent,N,
29203,DescriptorName,D001921,8404753,,,2,Brain,N,
29204,QualifierName,Q000473,8404753,,,2,,N,pathology
29205,DescriptorName,D002220,8404753,,,3,Carbamazepine,N,
29206,QualifierName,Q000008,8404753,,,3,,N,administration & dosage
29207,DescriptorName,D002648,8404753,,,4,Child,N,
29208,DescriptorName,D002675,8404753,,,5,"Child, Preschool",N,
29209,DescriptorName,D017029,8404753,,,6,"Epilepsy, Complex Partial",N,
29210,QualifierName,Q000188,8404753,,,6,,Y,drug therapy
29211,DescriptorName,D006801,8404753,,,7,Humans,N,
29212,DescriptorName,D008279,8404753,,,8,Magnetic Resonance Imaging,N,
29213,DescriptorName,D008297,8404753,,,9,Male,N,
29214,DescriptorName,D013981,8404753,,,10,Tic Disorders,N,
29215,QualifierName,Q000139,8404753,,,10,,Y,chemically induced
29216,Chemical,D000212,8430717,Acyclovir,X4HES1O11F,,,,
29217,DescriptorName,D000212,8430717,,,1,Acyclovir,N,
29218,QualifierName,Q000097,8430717,,,1,,N,blood
29219,DescriptorName,D000368,8430717,,,2,Aged,N,
29220,DescriptorName,D001921,8430717,,,3,Brain,N,
29221,QualifierName,Q000187,8430717,,,3,,Y,drug effects
29222,DescriptorName,D062787,8430717,,,4,Drug Overdose,N,
29223,DescriptorName,D004569,8430717,,,5,Electroencephalography,N,
29224,QualifierName,Q000187,8430717,,,5,,N,drug effects
29225,DescriptorName,D005260,8430717,,,6,Female,N,
29226,DescriptorName,D006563,8430717,,,7,Herpes Zoster Ophthalmicus,N,
29227,QualifierName,Q000188,8430717,,,7,,N,drug therapy
29228,DescriptorName,D006801,8430717,,,8,Humans,N,
29229,DescriptorName,D007668,8430717,,,9,Kidney,N,
29230,QualifierName,Q000187,8430717,,,9,,N,drug effects
29231,DescriptorName,D013997,8430717,,,10,Time Factors,N,
29232,DescriptorName,D014474,8430717,,,11,Unconsciousness,N,
29233,QualifierName,Q000139,8430717,,,11,,Y,chemically induced
29234,Chemical,D012996,8435665,Solutions,0,,,,
29235,Chemical,D014364,8435665,Tryptophan,8DUH1N11BX,,,,
29236,DescriptorName,D000293,8435665,,,1,Adolescent,N,
29237,DescriptorName,D000971,8435665,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
29238,QualifierName,Q000627,8435665,,,2,,N,therapeutic use
29239,DescriptorName,D016026,8435665,,,3,Bone Marrow Transplantation,Y,
29240,DescriptorName,D003131,8435665,,,4,Combined Modality Therapy,N,
29241,DescriptorName,D016603,8435665,,,5,Eosinophilia-Myalgia Syndrome,N,
29242,QualifierName,Q000139,8435665,,,5,,Y,chemically induced
29243,DescriptorName,D006801,8435665,,,6,Humans,N,
29244,DescriptorName,D008297,8435665,,,7,Male,N,
29245,DescriptorName,D010289,8435665,,,8,"Parenteral Nutrition, Total",Y,
29246,DescriptorName,D054198,8435665,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
29247,QualifierName,Q000188,8435665,,,9,,N,drug therapy
29248,DescriptorName,D012996,8435665,,,10,Solutions,N,
29249,DescriptorName,D014364,8435665,,,11,Tryptophan,N,
29250,QualifierName,Q000008,8435665,,,11,,N,administration & dosage
29251,Chemical,D014667,8438851,Vasopressins,11000-17-2,,,,
29252,DescriptorName,D000368,8438851,,,1,Aged,N,
29253,DescriptorName,D004932,8438851,,,2,Esophageal and Gastric Varices,N,
29254,QualifierName,Q000188,8438851,,,2,,N,drug therapy
29255,DescriptorName,D006471,8438851,,,3,Gastrointestinal Hemorrhage,N,
29256,QualifierName,Q000188,8438851,,,3,,N,drug therapy
29257,DescriptorName,D006801,8438851,,,4,Humans,N,
29258,DescriptorName,D007262,8438851,,,5,"Infusions, Intravenous",N,
29259,DescriptorName,D008297,8438851,,,6,Male,N,
29260,DescriptorName,D012206,8438851,,,7,Rhabdomyolysis,N,
29261,QualifierName,Q000139,8438851,,,7,,Y,chemically induced
29262,DescriptorName,D012307,8438851,,,8,Risk Factors,N,
29263,DescriptorName,D014667,8438851,,,9,Vasopressins,N,
29264,QualifierName,Q000008,8438851,,,9,,N,administration & dosage
29265,Chemical,D004221,8442800,Disulfiram,TR3MLJ1UAI,,,,
29266,DescriptorName,D000014,8442800,,,1,"Abnormalities, Drug-Induced",N,
29267,QualifierName,Q000517,8442800,,,1,,N,prevention & control
29268,DescriptorName,D000328,8442800,,,2,Adult,N,
29269,DescriptorName,D000437,8442800,,,3,Alcoholism,N,
29270,QualifierName,Q000188,8442800,,,3,,Y,drug therapy
29271,DescriptorName,D004221,8442800,,,4,Disulfiram,N,
29272,QualifierName,Q000627,8442800,,,4,,Y,therapeutic use
29273,DescriptorName,D005260,8442800,,,5,Female,N,
29274,DescriptorName,D005333,8442800,,,6,Fetus,N,
29275,QualifierName,Q000187,8442800,,,6,,Y,drug effects
29276,DescriptorName,D006801,8442800,,,7,Humans,N,
29277,DescriptorName,D007231,8442800,,,8,"Infant, Newborn",N,
29278,DescriptorName,D008297,8442800,,,9,Male,N,
29279,DescriptorName,D011247,8442800,,,10,Pregnancy,N,
29280,DescriptorName,D011248,8442800,,,11,Pregnancy Complications,N,
29281,QualifierName,Q000188,8442800,,,11,,Y,drug therapy
29282,DescriptorName,D011256,8442800,,,12,Pregnancy Outcome,N,
29283,QualifierName,Q000453,8442800,,,12,,N,epidemiology
29284,DescriptorName,D011261,8442800,,,13,"Pregnancy Trimester, First",N,
29285,DescriptorName,D011297,8442800,,,14,Prenatal Exposure Delayed Effects,N,
29286,Chemical,D015725,8445549,Fluconazole,8VZV102JFY,,,,
29287,Chemical,D008687,8445549,Metformin,9100L32L2N,,,,
29288,Chemical,D011239,8445549,Prednisolone,9PHQ9Y1OLM,,,,
29289,Chemical,D001379,8445549,Azathioprine,MRK240IY2L,,,,
29290,Chemical,D005905,8445549,Glyburide,SX6K58TVWC,,,,
29291,DescriptorName,D000368,8445549,,,1,Aged,N,
29292,DescriptorName,D001379,8445549,,,2,Azathioprine,N,
29293,QualifierName,Q000627,8445549,,,2,,N,therapeutic use
29294,DescriptorName,D002180,8445549,,,3,"Candidiasis, Oral",N,
29295,QualifierName,Q000188,8445549,,,3,,N,drug therapy
29296,DescriptorName,D003924,8445549,,,4,"Diabetes Mellitus, Type 2",N,
29297,QualifierName,Q000188,8445549,,,4,,N,drug therapy
29298,DescriptorName,D004342,8445549,,,5,Drug Hypersensitivity,N,
29299,QualifierName,Q000209,8445549,,,5,,Y,etiology
29300,DescriptorName,D015725,8445549,,,6,Fluconazole,N,
29301,QualifierName,Q000627,8445549,,,6,,N,therapeutic use
29302,DescriptorName,D005905,8445549,,,7,Glyburide,N,
29303,QualifierName,Q000009,8445549,,,7,,Y,adverse effects
29304,DescriptorName,D006801,8445549,,,8,Humans,N,
29305,DescriptorName,D006943,8445549,,,9,Hyperglycemia,N,
29306,QualifierName,Q000139,8445549,,,9,,N,chemically induced
29307,DescriptorName,D008297,8445549,,,10,Male,N,
29308,DescriptorName,D008687,8445549,,,11,Metformin,N,
29309,QualifierName,Q000627,8445549,,,11,,N,therapeutic use
29310,DescriptorName,D010392,8445549,,,12,Pemphigus,N,
29311,QualifierName,Q000139,8445549,,,12,,Y,chemically induced
29312,DescriptorName,D011239,8445549,,,13,Prednisolone,N,
29313,QualifierName,Q000009,8445549,,,13,,N,adverse effects
29314,Chemical,D000970,8452107,Antineoplastic Agents,0,,,,
29315,Chemical,D011743,8452107,Pyrimidines,0,,,,
29316,Chemical,C024530,8452107,piritrexim,MK2A783ZUT,,,,
29317,DescriptorName,D000368,8452107,,,1,Aged,N,
29318,DescriptorName,D000970,8452107,,,2,Antineoplastic Agents,N,
29319,QualifierName,Q000009,8452107,,,2,,Y,adverse effects
29320,DescriptorName,D002295,8452107,,,3,"Carcinoma, Transitional Cell",N,
29321,QualifierName,Q000188,8452107,,,3,,N,drug therapy
29322,DescriptorName,D006801,8452107,,,4,Humans,N,
29323,DescriptorName,D007680,8452107,,,5,Kidney Neoplasms,N,
29324,QualifierName,Q000473,8452107,,,5,,N,pathology
29325,DescriptorName,D008175,8452107,,,6,Lung Neoplasms,N,
29326,QualifierName,Q000188,8452107,,,6,,N,drug therapy
29327,DescriptorName,D008297,8452107,,,7,Male,N,
29328,DescriptorName,D011658,8452107,,,8,Pulmonary Fibrosis,N,
29329,QualifierName,Q000139,8452107,,,8,,Y,chemically induced
29330,DescriptorName,D011743,8452107,,,9,Pyrimidines,N,
29331,QualifierName,Q000009,8452107,,,9,,Y,adverse effects
29332,Chemical,D000241,8461228,Adenosine,K72T3FS567,,,,
29333,DescriptorName,D000241,8461228,,,1,Adenosine,N,
29334,QualifierName,Q000008,8461228,,,1,,N,administration & dosage
29335,DescriptorName,D001145,8461228,,,2,"Arrhythmias, Cardiac",N,
29336,QualifierName,Q000139,8461228,,,2,,Y,chemically induced
29337,DescriptorName,D001282,8461228,,,3,Atrial Flutter,N,
29338,QualifierName,Q000188,8461228,,,3,,Y,drug therapy
29339,DescriptorName,D002648,8461228,,,4,Child,N,
29340,DescriptorName,D004562,8461228,,,5,Electrocardiography,N,
29341,QualifierName,Q000187,8461228,,,5,,N,drug effects
29342,DescriptorName,D006321,8461228,,,6,Heart,N,
29343,QualifierName,Q000503,8461228,,,6,,N,physiopathology
29344,DescriptorName,D006352,8461228,,,7,Heart Ventricles,N,
29345,DescriptorName,D006801,8461228,,,8,Humans,N,
29346,DescriptorName,D007275,8461228,,,9,"Injections, Intravenous",N,
29347,DescriptorName,D008297,8461228,,,10,Male,N,
29348,Chemical,D008727,8467620,Methotrexate,YL5FZ2Y5U1,,,,
29349,DescriptorName,D000368,8467620,,,1,Aged,N,
29350,DescriptorName,D001172,8467620,,,2,"Arthritis, Rheumatoid",N,
29351,QualifierName,Q000188,8467620,,,2,,Y,drug therapy
29352,DescriptorName,D001706,8467620,,,3,Biopsy,N,
29353,DescriptorName,D004305,8467620,,,4,"Dose-Response Relationship, Drug",N,
29354,DescriptorName,D006801,8467620,,,5,Humans,N,
29355,DescriptorName,D008228,8467620,,,6,"Lymphoma, Non-Hodgkin",N,
29356,QualifierName,Q000139,8467620,,,6,,Y,chemically induced
29357,DescriptorName,D008297,8467620,,,7,Male,N,
29358,DescriptorName,D008727,8467620,,,8,Methotrexate,N,
29359,QualifierName,Q000009,8467620,,,8,,Y,adverse effects
29360,Chemical,D000082,847572,Acetaminophen,362O9ITL9D,,,,
29361,Chemical,D003543,847572,Cysteamine,5UX2SD1KE2,,,,
29362,DescriptorName,D000082,847572,,,1,Acetaminophen,N,
29363,QualifierName,Q000506,847572,,,1,,Y,poisoning
29364,DescriptorName,D000328,847572,,,2,Adult,N,
29365,DescriptorName,D000437,847572,,,3,Alcoholism,N,
29366,QualifierName,Q000150,847572,,,3,,N,complications
29367,DescriptorName,D056486,847572,,,4,Chemical and Drug Induced Liver Injury,Y,
29368,DescriptorName,D003543,847572,,,5,Cysteamine,N,
29369,QualifierName,Q000627,847572,,,5,,N,therapeutic use
29370,DescriptorName,D005260,847572,,,6,Female,N,
29371,DescriptorName,D006801,847572,,,7,Humans,N,
29372,DescriptorName,D008107,847572,,,8,Liver Diseases,N,
29373,QualifierName,Q000188,847572,,,8,,N,drug therapy
29374,DescriptorName,D008297,847572,,,9,Male,N,
29375,DescriptorName,D008875,847572,,,10,Middle Aged,N,
29376,DescriptorName,D009336,847572,,,11,Necrosis,N,
29377,Chemical,D000995,8485005,Antitubercular Agents,0,,,,
29378,Chemical,D011239,8485005,Prednisolone,9PHQ9Y1OLM,,,,
29379,DescriptorName,D000368,8485005,,,1,Aged,N,
29380,DescriptorName,D000995,8485005,,,2,Antitubercular Agents,N,
29381,QualifierName,Q000627,8485005,,,2,,N,therapeutic use
29382,DescriptorName,D001706,8485005,,,3,Biopsy,N,
29383,DescriptorName,D004359,8485005,,,4,"Drug Therapy, Combination",N,
29384,DescriptorName,D005534,8485005,,,5,Foot Diseases,N,
29385,QualifierName,Q000139,8485005,,,5,,Y,chemically induced
29386,DescriptorName,D006679,8485005,,,6,HIV Seropositivity,N,
29387,QualifierName,Q000175,8485005,,,6,,N,diagnosis
29388,DescriptorName,D006801,8485005,,,7,Humans,N,
29389,DescriptorName,D007049,8485005,,,8,Iatrogenic Disease,Y,
29390,DescriptorName,D008297,8485005,,,9,Male,N,
29391,DescriptorName,D009365,8485005,,,10,"Neoplasm Regression, Spontaneous",Y,
29392,QualifierName,Q000473,8485005,,,10,,N,pathology
29393,DescriptorName,D010490,8485005,,,11,Pericardial Effusion,N,
29394,QualifierName,Q000150,8485005,,,11,,N,complications
29395,DescriptorName,D010495,8485005,,,12,"Pericarditis, Tuberculous",N,
29396,QualifierName,Q000150,8485005,,,12,,Y,complications
29397,DescriptorName,D011239,8485005,,,13,Prednisolone,N,
29398,QualifierName,Q000009,8485005,,,13,,Y,adverse effects
29399,DescriptorName,D012514,8485005,,,14,"Sarcoma, Kaposi",N,
29400,QualifierName,Q000139,8485005,,,14,,Y,chemically induced
29401,DescriptorName,D012867,8485005,,,15,Skin,N,
29402,QualifierName,Q000473,8485005,,,15,,N,pathology
29403,DescriptorName,D012878,8485005,,,16,Skin Neoplasms,N,
29404,QualifierName,Q000139,8485005,,,16,,Y,chemically induced
29405,DescriptorName,D013997,8485005,,,17,Time Factors,N,
29406,Chemical,D010868,8496127,Pimozide,1HIZ4DL86F,,,,
29407,DescriptorName,D001321,8496127,,,1,Autistic Disorder,N,
29408,QualifierName,Q000188,8496127,,,1,,Y,drug therapy
29409,DescriptorName,D001479,8496127,,,2,Basal Ganglia,N,
29410,QualifierName,Q000187,8496127,,,2,,N,drug effects
29411,DescriptorName,D001480,8496127,,,3,Basal Ganglia Diseases,N,
29412,QualifierName,Q000139,8496127,,,3,,N,chemically induced
29413,DescriptorName,D002648,8496127,,,4,Child,N,
29414,DescriptorName,D004421,8496127,,,5,Dystonia,N,
29415,QualifierName,Q000139,8496127,,,5,,Y,chemically induced
29416,DescriptorName,D006801,8496127,,,6,Humans,N,
29417,DescriptorName,D008297,8496127,,,7,Male,N,
29418,DescriptorName,D010868,8496127,,,8,Pimozide,N,
29419,QualifierName,Q000008,8496127,,,8,,N,administration & dosage
29420,Chemical,D011994,8503421,Recombinant Proteins,0,,,,
29421,Chemical,D002784,8503421,Cholesterol,97C5T2UQ7J,,,,
29422,Chemical,D010959,8503421,Tissue Plasminogen Activator,EC 3.4.21.68,,,,
29423,DescriptorName,D058186,8503421,,,1,Acute Kidney Injury,N,
29424,QualifierName,Q000209,8503421,,,1,,Y,etiology
29425,DescriptorName,D000368,8503421,,,2,Aged,N,
29426,DescriptorName,D002784,8503421,,,3,Cholesterol,N,
29427,QualifierName,Q000737,8503421,,,3,,N,chemistry
29428,DescriptorName,D003460,8503421,,,4,Crystallization,N,
29429,DescriptorName,D004617,8503421,,,5,Embolism,N,
29430,QualifierName,Q000139,8503421,,,5,,Y,chemically induced
29431,DescriptorName,D006801,8503421,,,6,Humans,N,
29432,DescriptorName,D008297,8503421,,,7,Male,N,
29433,DescriptorName,D009203,8503421,,,8,Myocardial Infarction,N,
29434,QualifierName,Q000188,8503421,,,8,,Y,drug therapy
29435,DescriptorName,D011994,8503421,,,9,Recombinant Proteins,N,
29436,QualifierName,Q000009,8503421,,,9,,N,adverse effects
29437,DescriptorName,D015912,8503421,,,10,Thrombolytic Therapy,N,
29438,QualifierName,Q000009,8503421,,,10,,Y,adverse effects
29439,DescriptorName,D010959,8503421,,,11,Tissue Plasminogen Activator,N,
29440,QualifierName,Q000009,8503421,,,11,,Y,adverse effects
29441,Chemical,D014150,8520081,Antipsychotic Agents,0,,,,
29442,Chemical,D006220,8520081,Haloperidol,J6292F8L3D,,,,
29443,DescriptorName,D000328,8520081,,,1,Adult,N,
29444,DescriptorName,D000368,8520081,,,2,Aged,N,
29445,DescriptorName,D014150,8520081,,,3,Antipsychotic Agents,N,
29446,QualifierName,Q000008,8520081,,,3,,Y,administration & dosage
29447,DescriptorName,D003693,8520081,,,4,Delirium,N,
29448,QualifierName,Q000188,8520081,,,4,,Y,drug therapy
29449,DescriptorName,D005260,8520081,,,5,Female,N,
29450,DescriptorName,D006220,8520081,,,6,Haloperidol,N,
29451,QualifierName,Q000008,8520081,,,6,,Y,administration & dosage
29452,DescriptorName,D006801,8520081,,,7,Humans,N,
29453,DescriptorName,D007262,8520081,,,8,"Infusions, Intravenous",N,
29454,DescriptorName,D007362,8520081,,,9,Intensive Care Units,N,
29455,DescriptorName,D008297,8520081,,,10,Male,N,
29456,DescriptorName,D008875,8520081,,,11,Middle Aged,N,
29457,DescriptorName,D008991,8520081,,,12,"Monitoring, Physiologic",N,
29458,DescriptorName,D011595,8520081,,,13,Psychomotor Agitation,N,
29459,QualifierName,Q000188,8520081,,,13,,Y,drug therapy
29460,Chemical,D018501,8523340,Antirheumatic Agents,0,,,,
29461,Chemical,D050607,8523340,Organogold Compounds,0,,,,
29462,DescriptorName,D000328,8523340,,,1,Adult,N,
29463,DescriptorName,D000368,8523340,,,2,Aged,N,
29464,DescriptorName,D018501,8523340,,,3,Antirheumatic Agents,N,
29465,QualifierName,Q000008,8523340,,,3,,Y,administration & dosage
29466,DescriptorName,D001172,8523340,,,4,"Arthritis, Rheumatoid",N,
29467,QualifierName,Q000188,8523340,,,4,,Y,drug therapy
29468,DescriptorName,D004334,8523340,,,5,Drug Administration Schedule,N,
29469,DescriptorName,D003875,8523340,,,6,Drug Eruptions,N,
29470,QualifierName,Q000209,8523340,,,6,,N,etiology
29471,DescriptorName,D005260,8523340,,,7,Female,N,
29472,DescriptorName,D006801,8523340,,,8,Humans,N,
29473,DescriptorName,D007273,8523340,,,9,"Injections, Intramuscular",N,
29474,DescriptorName,D008297,8523340,,,10,Male,N,
29475,DescriptorName,D008875,8523340,,,11,Middle Aged,N,
29476,DescriptorName,D009092,8523340,,,12,Mucous Membrane,N,
29477,DescriptorName,D050607,8523340,,,13,Organogold Compounds,N,
29478,DescriptorName,D016896,8523340,,,14,Treatment Outcome,N,
29479,Chemical,D010636,85289,Phenols,0,,,,
29480,DescriptorName,D000328,85289,,,1,Adult,N,
29481,DescriptorName,D001157,85289,,,2,Arterial Occlusive Diseases,N,
29482,QualifierName,Q000139,85289,,,2,,Y,chemically induced
29483,DescriptorName,D006801,85289,,,3,Humans,N,
29484,DescriptorName,D007278,85289,,,4,"Injections, Spinal",N,
29485,DescriptorName,D008297,85289,,,5,Male,N,
29486,DescriptorName,D008545,85289,,,6,Melanoma,N,
29487,QualifierName,Q000150,85289,,,6,,N,complications
29488,DescriptorName,D009362,85289,,,7,Neoplasm Metastasis,N,
29489,DescriptorName,D009407,85289,,,8,Nerve Block,N,
29490,DescriptorName,D010148,85289,,,9,"Pain, Intractable",N,
29491,QualifierName,Q000188,85289,,,9,,N,drug therapy
29492,DescriptorName,D010166,85289,,,10,Palliative Care,N,
29493,DescriptorName,D010636,85289,,,11,Phenols,N,
29494,QualifierName,Q000009,85289,,,11,,Y,adverse effects
29495,DescriptorName,D011782,85289,,,12,Quadriplegia,N,
29496,QualifierName,Q000139,85289,,,12,,N,chemically induced
29497,DescriptorName,D012878,85289,,,13,Skin Neoplasms,N,
29498,QualifierName,Q000150,85289,,,13,,N,complications
29499,DescriptorName,D013116,85289,,,14,Spinal Cord,N,
29500,QualifierName,Q000098,85289,,,14,,Y,blood supply
29501,Chemical,D000978,8530331,Antiparkinson Agents,0,,,,
29502,Chemical,D003024,8530331,Clozapine,J60AR2IKIC,,,,
29503,Chemical,D018967,8530331,Risperidone,L6UH7ZF8HC,,,,
29504,DescriptorName,D000368,8530331,,,1,Aged,N,
29505,DescriptorName,D000978,8530331,,,2,Antiparkinson Agents,N,
29506,QualifierName,Q000009,8530331,,,2,,Y,adverse effects
29507,DescriptorName,D003024,8530331,,,3,Clozapine,N,
29508,QualifierName,Q000627,8530331,,,3,,Y,therapeutic use
29509,DescriptorName,D004409,8530331,,,4,"Dyskinesia, Drug-Induced",N,
29510,QualifierName,Q000188,8530331,,,4,,N,drug therapy
29511,DescriptorName,D006801,8530331,,,5,Humans,N,
29512,DescriptorName,D008297,8530331,,,6,Male,N,
29513,DescriptorName,D010300,8530331,,,7,Parkinson Disease,N,
29514,QualifierName,Q000150,8530331,,,7,,N,complications
29515,DescriptorName,D010302,8530331,,,8,"Parkinson Disease, Secondary",N,
29516,QualifierName,Q000139,8530331,,,8,,N,chemically induced
29517,DescriptorName,D011605,8530331,,,9,"Psychoses, Substance-Induced",N,
29518,QualifierName,Q000188,8530331,,,9,,Y,drug therapy
29519,DescriptorName,D018967,8530331,,,10,Risperidone,N,
29520,QualifierName,Q000009,8530331,,,10,,Y,adverse effects
29521,Chemical,D007166,8551001,Immunosuppressive Agents,0,,,,
29522,Chemical,D008780,8551001,Methyltransferases,EC 2.1.1.-,,,,
29523,Chemical,C022745,8551001,thiopurine methyltransferase,EC 2.1.1.67,,,,
29524,Chemical,D001379,8551001,Azathioprine,MRK240IY2L,,,,
29525,DescriptorName,D000328,8551001,,,1,Adult,N,
29526,DescriptorName,D001327,8551001,,,2,Autoimmune Diseases,N,
29527,QualifierName,Q000150,8551001,,,2,,Y,complications
29528,DescriptorName,D001379,8551001,,,3,Azathioprine,N,
29529,QualifierName,Q000009,8551001,,,3,,Y,adverse effects
29530,DescriptorName,D001855,8551001,,,4,Bone Marrow Diseases,N,
29531,QualifierName,Q000209,8551001,,,4,,Y,etiology
29532,DescriptorName,D006505,8551001,,,5,Hepatitis,N,
29533,QualifierName,Q000150,8551001,,,5,,Y,complications
29534,DescriptorName,D006801,8551001,,,6,Humans,N,
29535,DescriptorName,D007166,8551001,,,7,Immunosuppressive Agents,N,
29536,QualifierName,Q000009,8551001,,,7,,Y,adverse effects
29537,DescriptorName,D008297,8551001,,,8,Male,N,
29538,DescriptorName,D008780,8551001,,,9,Methyltransferases,N,
29539,QualifierName,Q000172,8551001,,,9,,Y,deficiency
29540,DescriptorName,D010198,8551001,,,10,Pancytopenia,N,
29541,QualifierName,Q000139,8551001,,,10,,N,chemically induced
29542,Chemical,D000894,8570441,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
29543,Chemical,D002074,8570441,Butanones,0,,,,
29544,Chemical,D004232,8570441,Diuretics,0,,,,
29545,Chemical,D000077430,8570441,Nabumetone,LW0TIW155Z,,,,
29546,DescriptorName,D000368,8570441,,,1,Aged,N,
29547,DescriptorName,D000369,8570441,,,2,"Aged, 80 and over",N,
29548,DescriptorName,D000894,8570441,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
29549,QualifierName,Q000009,8570441,,,3,,Y,adverse effects
29550,DescriptorName,D002074,8570441,,,4,Butanones,N,
29551,QualifierName,Q000009,8570441,,,4,,Y,adverse effects
29552,DescriptorName,D004232,8570441,,,5,Diuretics,N,
29553,QualifierName,Q000627,8570441,,,5,,N,therapeutic use
29554,DescriptorName,D004487,8570441,,,6,Edema,N,
29555,QualifierName,Q000139,8570441,,,6,,N,chemically induced
29556,DescriptorName,D017809,8570441,,,7,Fatal Outcome,N,
29557,DescriptorName,D005260,8570441,,,8,Female,N,
29558,DescriptorName,D006333,8570441,,,9,Heart Failure,N,
29559,QualifierName,Q000150,8570441,,,9,,N,complications
29560,DescriptorName,D006801,8570441,,,10,Humans,N,
29561,DescriptorName,D000077430,8570441,,,11,Nabumetone,N,
29562,DescriptorName,D009395,8570441,,,12,"Nephritis, Interstitial",N,
29563,QualifierName,Q000139,8570441,,,12,,Y,chemically induced
29564,DescriptorName,D006435,8570441,,,13,Renal Dialysis,N,
29565,Chemical,D000970,8579054,Antineoplastic Agents,0,,,,
29566,Chemical,D006918,8579054,Hydroxyurea,X6Q56QN5QC,,,,
29567,DescriptorName,D000208,8579054,,,1,Acute Disease,N,
29568,DescriptorName,D000970,8579054,,,2,Antineoplastic Agents,N,
29569,QualifierName,Q000009,8579054,,,2,,Y,adverse effects
29570,DescriptorName,D006801,8579054,,,3,Humans,N,
29571,DescriptorName,D006918,8579054,,,4,Hydroxyurea,N,
29572,QualifierName,Q000009,8579054,,,4,,Y,adverse effects
29573,DescriptorName,D007951,8579054,,,5,"Leukemia, Myeloid",N,
29574,QualifierName,Q000209,8579054,,,5,,Y,etiology
29575,DescriptorName,D008297,8579054,,,6,Male,N,
29576,DescriptorName,D008875,8579054,,,7,Middle Aged,N,
29577,DescriptorName,D013920,8579054,,,8,"Thrombocythemia, Essential",N,
29578,QualifierName,Q000188,8579054,,,8,,Y,drug therapy
29579,Chemical,D000962,8586895,Antimalarials,0,,,,
29580,Chemical,D010616,8586895,Phenanthrenes,0,,,,
29581,Chemical,C023768,8586895,halofantrine,Q2OS4303HZ,,,,
29582,DescriptorName,D000328,8586895,,,1,Adult,N,
29583,DescriptorName,D000818,8586895,,,2,Animals,N,
29584,DescriptorName,D000962,8586895,,,3,Antimalarials,N,
29585,QualifierName,Q000009,8586895,,,3,,Y,adverse effects
29586,DescriptorName,D004562,8586895,,,4,Electrocardiography,N,
29587,QualifierName,Q000187,8586895,,,4,,Y,drug effects
29588,DescriptorName,D006801,8586895,,,5,Humans,N,
29589,DescriptorName,D016780,8586895,,,6,"Malaria, Vivax",N,
29590,QualifierName,Q000188,8586895,,,6,,Y,drug therapy
29591,DescriptorName,D008297,8586895,,,7,Male,N,
29592,DescriptorName,D010616,8586895,,,8,Phenanthrenes,N,
29593,QualifierName,Q000009,8586895,,,8,,Y,adverse effects
29594,DescriptorName,D010966,8586895,,,9,Plasmodium vivax,Y,
29595,DescriptorName,D014195,8586895,,,10,Travel,N,
29596,Chemical,D014750,8589490,Vincristine,5J49Q6B70F,,,,
29597,Chemical,D004317,8589490,Doxorubicin,80168379AG,,,,
29598,Chemical,D003520,8589490,Cyclophosphamide,8N3DW7272P,,,,
29599,Chemical,D011241,8589490,Prednisone,VB0R961HZT,,,,
29600,DescriptorName,D000328,8589490,,,1,Adult,N,
29601,DescriptorName,D000971,8589490,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
29602,QualifierName,Q000009,8589490,,,2,,Y,adverse effects
29603,DescriptorName,D002081,8589490,,,3,Buttocks,N,
29604,DescriptorName,D003520,8589490,,,4,Cyclophosphamide,N,
29605,QualifierName,Q000008,8589490,,,4,,N,administration & dosage
29606,DescriptorName,D004317,8589490,,,5,Doxorubicin,N,
29607,QualifierName,Q000008,8589490,,,5,,N,administration & dosage
29608,DescriptorName,D005542,8589490,,,6,Forearm,N,
29609,QualifierName,Q000098,8589490,,,6,,Y,blood supply
29610,DescriptorName,D006801,8589490,,,7,Humans,N,
29611,DescriptorName,D017495,8589490,,,8,Hyperpigmentation,N,
29612,QualifierName,Q000139,8589490,,,8,,Y,chemically induced
29613,DescriptorName,D017728,8589490,,,9,"Lymphoma, Large-Cell, Anaplastic",N,
29614,QualifierName,Q000188,8589490,,,9,,Y,drug therapy
29615,DescriptorName,D008297,8589490,,,10,Male,N,
29616,DescriptorName,D011241,8589490,,,11,Prednisone,N,
29617,QualifierName,Q000008,8589490,,,11,,N,administration & dosage
29618,DescriptorName,D012983,8589490,,,12,Soft Tissue Neoplasms,N,
29619,QualifierName,Q000188,8589490,,,12,,Y,drug therapy
29620,DescriptorName,D014680,8589490,,,13,Veins,N,
29621,DescriptorName,D014750,8589490,,,14,Vincristine,N,
29622,QualifierName,Q000008,8589490,,,14,,N,administration & dosage
29623,Chemical,D000927,8597009,Anticonvulsants,0,,,,
29624,Chemical,D000995,8597009,Antitubercular Agents,0,,,,
29625,Chemical,D010672,8597009,Phenytoin,6158TKW0C5,,,,
29626,Chemical,D007538,8597009,Isoniazid,V83O1VOZ8L,,,,
29627,DescriptorName,D000107,8597009,,,1,Acetylation,N,
29628,DescriptorName,D000927,8597009,,,2,Anticonvulsants,N,
29629,QualifierName,Q000378,8597009,,,2,,N,metabolism
29630,DescriptorName,D000995,8597009,,,3,Antitubercular Agents,N,
29631,QualifierName,Q000009,8597009,,,3,,Y,adverse effects
29632,DescriptorName,D004347,8597009,,,4,Drug Interactions,N,
29633,DescriptorName,D006801,8597009,,,5,Humans,N,
29634,DescriptorName,D007538,8597009,,,6,Isoniazid,N,
29635,QualifierName,Q000009,8597009,,,6,,Y,adverse effects
29636,DescriptorName,D008875,8597009,,,7,Middle Aged,N,
29637,DescriptorName,D010672,8597009,,,8,Phenytoin,N,
29638,QualifierName,Q000378,8597009,,,8,,N,metabolism
29639,DescriptorName,D014376,8597009,,,9,Tuberculosis,N,
29640,QualifierName,Q000188,8597009,,,9,,Y,drug therapy
29641,Chemical,D000998,8604715,Antiviral Agents,0,,,,
29642,Chemical,D017245,8604715,Foscarnet,364P9RVW4X,,,,
29643,DescriptorName,D017088,8604715,,,1,AIDS-Related Opportunistic Infections,N,
29644,QualifierName,Q000150,8604715,,,1,,N,complications
29645,DescriptorName,D000141,8604715,,,2,"Acidosis, Renal Tubular",N,
29646,QualifierName,Q000139,8604715,,,2,,Y,chemically induced
29647,DescriptorName,D000328,8604715,,,3,Adult,N,
29648,DescriptorName,D000998,8604715,,,4,Antiviral Agents,N,
29649,QualifierName,Q000008,8604715,,,4,,N,administration & dosage
29650,DescriptorName,D017726,8604715,,,5,Cytomegalovirus Retinitis,N,
29651,QualifierName,Q000150,8604715,,,5,,N,complications
29652,DescriptorName,D003919,8604715,,,6,Diabetes Insipidus,N,
29653,QualifierName,Q000139,8604715,,,6,,Y,chemically induced
29654,DescriptorName,D017245,8604715,,,7,Foscarnet,N,
29655,QualifierName,Q000008,8604715,,,7,,N,administration & dosage
29656,DescriptorName,D015497,8604715,,,8,HIV-1,N,
29657,DescriptorName,D006801,8604715,,,9,Humans,N,
29658,DescriptorName,D007668,8604715,,,10,Kidney,N,
29659,QualifierName,Q000187,8604715,,,10,,Y,drug effects
29660,DescriptorName,D008297,8604715,,,11,Male,N,
29661,DescriptorName,D015819,8604715,,,12,"Substance Abuse, Intravenous",N,
29662,QualifierName,Q000150,8604715,,,12,,N,complications
29663,Chemical,D010960,8610807,Plasminogen Activators,EC 3.4.21.-,,,,
29664,Chemical,D010959,8610807,Tissue Plasminogen Activator,EC 3.4.21.68,,,,
29665,DescriptorName,D000368,8610807,,,1,Aged,N,
29666,DescriptorName,D002829,8610807,,,2,Choroid,N,
29667,QualifierName,Q000000981,8610807,,,2,,N,diagnostic imaging
29668,DescriptorName,D015862,8610807,,,3,Choroid Diseases,N,
29669,QualifierName,Q000139,8610807,,,3,,N,chemically induced
29670,DescriptorName,D002832,8610807,,,4,Choroid Hemorrhage,N,
29671,QualifierName,Q000139,8610807,,,4,,Y,chemically induced
29672,DescriptorName,D005654,8610807,,,5,Fundus Oculi,N,
29673,DescriptorName,D006801,8610807,,,6,Humans,N,
29674,DescriptorName,D008297,8610807,,,7,Male,N,
29675,DescriptorName,D009203,8610807,,,8,Myocardial Infarction,N,
29676,QualifierName,Q000188,8610807,,,8,,N,drug therapy
29677,DescriptorName,D010960,8610807,,,9,Plasminogen Activators,N,
29678,QualifierName,Q000009,8610807,,,9,,Y,adverse effects
29679,DescriptorName,D010959,8610807,,,10,Tissue Plasminogen Activator,N,
29680,QualifierName,Q000009,8610807,,,10,,Y,adverse effects
29681,DescriptorName,D014463,8610807,,,11,Ultrasonography,N,
29682,DescriptorName,D014792,8610807,,,12,Visual Acuity,N,
29683,Chemical,D006886,8627446,Hydroxychloroquine,4QWG6N8QKH,,,,
29684,Chemical,D012217,8627446,Rheumatoid Factor,9009-79-4,,,,
29685,Chemical,D008727,8627446,Methotrexate,YL5FZ2Y5U1,,,,
29686,DescriptorName,D000293,8627446,,,1,Adolescent,N,
29687,DescriptorName,D001171,8627446,,,2,"Arthritis, Juvenile",N,
29688,QualifierName,Q000188,8627446,,,2,,Y,drug therapy
29689,DescriptorName,D005260,8627446,,,3,Female,N,
29690,DescriptorName,D006801,8627446,,,4,Humans,N,
29691,DescriptorName,D006886,8627446,,,5,Hydroxychloroquine,N,
29692,QualifierName,Q000627,8627446,,,5,,N,therapeutic use
29693,DescriptorName,D008727,8627446,,,6,Methotrexate,N,
29694,QualifierName,Q000009,8627446,,,6,,Y,adverse effects
29695,DescriptorName,D012217,8627446,,,7,Rheumatoid Factor,N,
29696,QualifierName,Q000097,8627446,,,7,,N,blood
29697,DescriptorName,D012218,8627446,,,8,Rheumatoid Nodule,N,
29698,QualifierName,Q000139,8627446,,,8,,Y,chemically induced
29699,Chemical,D000890,8636829,Anti-Infective Agents,0,,,,
29700,Chemical,D018501,8636829,Antirheumatic Agents,0,,,,
29701,Chemical,D016572,8636829,Cyclosporine,83HN0GTJ6D,,,,
29702,Chemical,D014295,8636829,Trimethoprim,AN164J8Y0X,,,,
29703,Chemical,D013420,8636829,Sulfamethoxazole,JE42381TNV,,,,
29704,Chemical,D008727,8636829,Methotrexate,YL5FZ2Y5U1,,,,
29705,DescriptorName,D000890,8636829,,,1,Anti-Infective Agents,N,
29706,QualifierName,Q000008,8636829,,,1,,N,administration & dosage
29707,DescriptorName,D018501,8636829,,,2,Antirheumatic Agents,N,
29708,QualifierName,Q000008,8636829,,,2,,N,administration & dosage
29709,DescriptorName,D001171,8636829,,,3,"Arthritis, Juvenile",N,
29710,QualifierName,Q000188,8636829,,,3,,Y,drug therapy
29711,DescriptorName,D001853,8636829,,,4,Bone Marrow,N,
29712,QualifierName,Q000648,8636829,,,4,,N,ultrastructure
29713,DescriptorName,D002648,8636829,,,5,Child,N,
29714,DescriptorName,D016572,8636829,,,6,Cyclosporine,N,
29715,QualifierName,Q000008,8636829,,,6,,N,administration & dosage
29716,DescriptorName,D006801,8636829,,,7,Humans,N,
29717,DescriptorName,D008262,8636829,,,8,Macrophage Activation,N,
29718,QualifierName,Q000187,8636829,,,8,,Y,drug effects
29719,DescriptorName,D008297,8636829,,,9,Male,N,
29720,DescriptorName,D008727,8636829,,,10,Methotrexate,N,
29721,QualifierName,Q000008,8636829,,,10,,N,administration & dosage
29722,DescriptorName,D010586,8636829,,,11,Phagocytes,N,
29723,QualifierName,Q000648,8636829,,,11,,N,ultrastructure
29724,DescriptorName,D011020,8636829,,,12,"Pneumonia, Pneumocystis",N,
29725,QualifierName,Q000188,8636829,,,12,,N,drug therapy
29726,DescriptorName,D013420,8636829,,,13,Sulfamethoxazole,N,
29727,QualifierName,Q000008,8636829,,,13,,N,administration & dosage
29728,DescriptorName,D014295,8636829,,,14,Trimethoprim,N,
29729,QualifierName,Q000008,8636829,,,14,,N,administration & dosage
29730,Chemical,D000925,8638872,Anticoagulants,0,,,,
29731,Chemical,D005343,8638872,Fibrinolytic Agents,0,,,,
29732,Chemical,D006493,8638872,Heparin,9005-49-6,,,,
29733,Chemical,D000637,8638872,Transaminases,EC 2.6.1.-,,,,
29734,Chemical,D013300,8638872,Streptokinase,EC 3.4.-,,,,
29735,DescriptorName,D000925,8638872,,,1,Anticoagulants,N,
29736,QualifierName,Q000627,8638872,,,1,,N,therapeutic use
29737,DescriptorName,D003490,8638872,,,2,Cyanosis,N,
29738,QualifierName,Q000139,8638872,,,2,,N,chemically induced
29739,DescriptorName,D004342,8638872,,,3,Drug Hypersensitivity,N,
29740,QualifierName,Q000209,8638872,,,3,,N,etiology
29741,DescriptorName,D005334,8638872,,,4,Fever,N,
29742,QualifierName,Q000139,8638872,,,4,,N,chemically induced
29743,DescriptorName,D005343,8638872,,,5,Fibrinolytic Agents,N,
29744,QualifierName,Q000009,8638872,,,5,,Y,adverse effects
29745,DescriptorName,D006493,8638872,,,6,Heparin,N,
29746,QualifierName,Q000627,8638872,,,6,,N,therapeutic use
29747,DescriptorName,D006801,8638872,,,7,Humans,N,
29748,DescriptorName,D007565,8638872,,,8,Jaundice,N,
29749,QualifierName,Q000139,8638872,,,8,,Y,chemically induced
29750,DescriptorName,D008297,8638872,,,9,Male,N,
29751,DescriptorName,D008875,8638872,,,10,Middle Aged,N,
29752,DescriptorName,D009203,8638872,,,11,Myocardial Infarction,N,
29753,QualifierName,Q000188,8638872,,,11,,N,drug therapy
29754,DescriptorName,D011654,8638872,,,12,Pulmonary Edema,N,
29755,QualifierName,Q000139,8638872,,,12,,N,chemically induced
29756,DescriptorName,D012640,8638872,,,13,Seizures,N,
29757,QualifierName,Q000139,8638872,,,13,,N,chemically induced
29758,DescriptorName,D013300,8638872,,,14,Streptokinase,N,
29759,QualifierName,Q000009,8638872,,,14,,Y,adverse effects
29760,DescriptorName,D015912,8638872,,,15,Thrombolytic Therapy,N,
29761,QualifierName,Q000009,8638872,,,15,,N,adverse effects
29762,DescriptorName,D000637,8638872,,,16,Transaminases,N,
29763,QualifierName,Q000097,8638872,,,16,,N,blood
29764,Chemical,D016190,8641617,Carboplatin,BG3F62OND5,,,,
29765,Chemical,D002945,8641617,Cisplatin,Q20Q21Q62J,,,,
29766,DescriptorName,D000328,8641617,,,1,Adult,N,
29767,DescriptorName,D000971,8641617,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
29768,QualifierName,Q000009,8641617,,,2,,Y,adverse effects
29769,DescriptorName,D016190,8641617,,,3,Carboplatin,N,
29770,QualifierName,Q000008,8641617,,,3,,N,administration & dosage
29771,DescriptorName,D002945,8641617,,,4,Cisplatin,N,
29772,QualifierName,Q000008,8641617,,,4,,N,administration & dosage
29773,DescriptorName,D016360,8641617,,,5,Clostridium difficile,Y,
29774,DescriptorName,D003092,8641617,,,6,Colitis,N,
29775,QualifierName,Q000209,8641617,,,6,,N,etiology
29776,DescriptorName,D005260,8641617,,,7,Female,N,
29777,DescriptorName,D006801,8641617,,,8,Humans,N,
29778,DescriptorName,D010051,8641617,,,9,Ovarian Neoplasms,N,
29779,QualifierName,Q000188,8641617,,,9,,Y,drug therapy
29780,Chemical,D002216,8645078,Captopril,9G64RSX1XD,,,,
29781,DescriptorName,D000368,8645078,,,1,Aged,N,
29782,DescriptorName,D002216,8645078,,,2,Captopril,N,
29783,QualifierName,Q000009,8645078,,,2,,Y,adverse effects
29784,DescriptorName,D002761,8645078,,,3,Cholangitis,N,
29785,QualifierName,Q000139,8645078,,,3,,Y,chemically induced
29786,DescriptorName,D002779,8645078,,,4,Cholestasis,N,
29787,QualifierName,Q000139,8645078,,,4,,Y,chemically induced
29788,DescriptorName,D003937,8645078,,,5,"Diagnosis, Differential",N,
29789,DescriptorName,D005260,8645078,,,6,Female,N,
29790,DescriptorName,D006801,8645078,,,7,Humans,N,
29791,DescriptorName,D006973,8645078,,,8,Hypertension,N,
29792,QualifierName,Q000188,8645078,,,8,,N,drug therapy
29793,Chemical,D016173,8651254,Macrophage Colony-Stimulating Factor,81627-83-0,,,,
29794,DescriptorName,D000971,8651254,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
29795,QualifierName,Q000627,8651254,,,1,,N,therapeutic use
29796,DescriptorName,D006801,8651254,,,2,Humans,N,
29797,DescriptorName,D007678,8651254,,,3,Kidney Glomerulus,N,
29798,QualifierName,Q000473,8651254,,,3,,N,pathology
29799,DescriptorName,D015470,8651254,,,4,"Leukemia, Myeloid, Acute",N,
29800,QualifierName,Q000188,8651254,,,4,,N,drug therapy
29801,DescriptorName,D016173,8651254,,,5,Macrophage Colony-Stimulating Factor,N,
29802,QualifierName,Q000009,8651254,,,5,,Y,adverse effects
29803,DescriptorName,D008264,8651254,,,6,Macrophages,N,
29804,QualifierName,Q000473,8651254,,,6,,N,pathology
29805,DescriptorName,D008297,8651254,,,7,Male,N,
29806,DescriptorName,D008875,8651254,,,8,Middle Aged,N,
29807,DescriptorName,D009404,8651254,,,9,Nephrotic Syndrome,N,
29808,QualifierName,Q000188,8651254,,,9,,N,drug therapy
29809,DescriptorName,D012074,8651254,,,10,Remission Induction,N,
29810,Chemical,D005938,8656412,Glucocorticoids,0,,,,
29811,Chemical,D015149,8656412,Tocolytic Agents,0,,,,
29812,Chemical,D008278,8656412,Magnesium Sulfate,7487-88-9,,,,
29813,Chemical,D001623,8656412,Betamethasone,9842X06Q6M,,,,
29814,Chemical,D009543,8656412,Nifedipine,I9ZF7L6G2L,,,,
29815,Chemical,D013726,8656412,Terbutaline,N8ONU3L3PG,,,,
29816,DescriptorName,D000328,8656412,,,1,Adult,N,
29817,DescriptorName,D001623,8656412,,,2,Betamethasone,N,
29818,QualifierName,Q000009,8656412,,,2,,N,adverse effects
29819,DescriptorName,D004359,8656412,,,3,"Drug Therapy, Combination",N,
29820,DescriptorName,D004487,8656412,,,4,Edema,N,
29821,QualifierName,Q000139,8656412,,,4,,Y,chemically induced
29822,DescriptorName,D005260,8656412,,,5,Female,N,
29823,DescriptorName,D005938,8656412,,,6,Glucocorticoids,N,
29824,QualifierName,Q000009,8656412,,,6,,N,adverse effects
29825,DescriptorName,D006801,8656412,,,7,Humans,N,
29826,DescriptorName,D007231,8656412,,,8,"Infant, Newborn",N,
29827,DescriptorName,D007958,8656412,,,9,Leukocyte Count,N,
29828,DescriptorName,D008278,8656412,,,10,Magnesium Sulfate,N,
29829,QualifierName,Q000009,8656412,,,10,,N,adverse effects
29830,DescriptorName,D008297,8656412,,,11,Male,N,
29831,DescriptorName,D009543,8656412,,,12,Nifedipine,N,
29832,QualifierName,Q000009,8656412,,,12,,N,adverse effects
29833,DescriptorName,D007752,8656412,,,13,"Obstetric Labor, Premature",N,
29834,QualifierName,Q000188,8656412,,,13,,Y,drug therapy
29835,DescriptorName,D011247,8656412,,,14,Pregnancy,N,
29836,DescriptorName,D013726,8656412,,,15,Terbutaline,N,
29837,QualifierName,Q000009,8656412,,,15,,N,adverse effects
29838,DescriptorName,D015149,8656412,,,16,Tocolytic Agents,N,
29839,QualifierName,Q000009,8656412,,,16,,Y,adverse effects
29840,DescriptorName,D014427,8656412,,,17,Twins,Y,
29841,DescriptorName,D014845,8656412,,,18,Vulvar Diseases,N,
29842,QualifierName,Q000139,8656412,,,18,,Y,chemically induced
29843,Chemical,D000893,8667442,Anti-Inflammatory Agents,0,,,,
29844,Chemical,D004164,8667442,Diphosphonates,0,,,,
29845,Chemical,D002117,8667442,Calcitriol,FXC9231JVH,,,,
29846,Chemical,D002119,8667442,Calcium Carbonate,H0G9379FGK,,,,
29847,Chemical,D000077268,8667442,Pamidronate,OYY3447OMC,,,,
29848,Chemical,D006854,8667442,Hydrocortisone,WI4X0X7BPJ,,,,
29849,DescriptorName,D000368,8667442,,,1,Aged,N,
29850,DescriptorName,D000893,8667442,,,2,Anti-Inflammatory Agents,N,
29851,QualifierName,Q000627,8667442,,,2,,N,therapeutic use
29852,DescriptorName,D002117,8667442,,,3,Calcitriol,N,
29853,QualifierName,Q000009,8667442,,,3,,Y,adverse effects
29854,DescriptorName,D002119,8667442,,,4,Calcium Carbonate,N,
29855,QualifierName,Q000009,8667442,,,4,,Y,adverse effects
29856,DescriptorName,D004164,8667442,,,5,Diphosphonates,N,
29857,QualifierName,Q000627,8667442,,,5,,N,therapeutic use
29858,DescriptorName,D004630,8667442,,,6,Emergencies,N,
29859,DescriptorName,D005260,8667442,,,7,Female,N,
29860,DescriptorName,D006801,8667442,,,8,Humans,N,
29861,DescriptorName,D006854,8667442,,,9,Hydrocortisone,N,
29862,QualifierName,Q000627,8667442,,,9,,N,therapeutic use
29863,DescriptorName,D006934,8667442,,,10,Hypercalcemia,N,
29864,QualifierName,Q000139,8667442,,,10,,Y,chemically induced
29865,DescriptorName,D007011,8667442,,,11,Hypoparathyroidism,N,
29866,QualifierName,Q000188,8667442,,,11,,N,drug therapy
29867,DescriptorName,D000077268,8667442,,,12,Pamidronate,N,
29868,Chemical,D018906,8672829,"Antineoplastic Agents, Alkylating",0,,,,
29869,Chemical,D007069,8672829,Ifosfamide,UM20QQM95Y,,,,
29870,DescriptorName,D000368,8672829,,,1,Aged,N,
29871,DescriptorName,D018906,8672829,,,2,"Antineoplastic Agents, Alkylating",N,
29872,QualifierName,Q000009,8672829,,,2,,Y,adverse effects
29873,DescriptorName,D002296,8672829,,,3,Carcinosarcoma,N,
29874,QualifierName,Q000188,8672829,,,3,,N,drug therapy
29875,DescriptorName,D005260,8672829,,,4,Female,N,
29876,DescriptorName,D005833,8672829,,,5,"Genital Neoplasms, Female",N,
29877,QualifierName,Q000188,8672829,,,5,,N,drug therapy
29878,DescriptorName,D006801,8672829,,,6,Humans,N,
29879,DescriptorName,D007069,8672829,,,7,Ifosfamide,N,
29880,QualifierName,Q000009,8672829,,,7,,Y,adverse effects
29881,DescriptorName,D009364,8672829,,,8,"Neoplasm Recurrence, Local",N,
29882,QualifierName,Q000188,8672829,,,8,,N,drug therapy
29883,DescriptorName,D013226,8672829,,,9,Status Epilepticus,N,
29884,QualifierName,Q000139,8672829,,,9,,Y,chemically induced
29885,Chemical,D000871,8678015,Anthelmintics,0,,,,
29886,Chemical,D015766,8678015,Albendazole,F4216019LN,,,,
29887,DescriptorName,D017088,8678015,,,1,AIDS-Related Opportunistic Infections,N,
29888,QualifierName,Q000150,8678015,,,1,,N,complications
29889,DescriptorName,D000328,8678015,,,2,Adult,N,
29890,DescriptorName,D015766,8678015,,,3,Albendazole,N,
29891,QualifierName,Q000009,8678015,,,3,,Y,adverse effects
29892,DescriptorName,D000871,8678015,,,4,Anthelmintics,N,
29893,QualifierName,Q000009,8678015,,,4,,Y,adverse effects
29894,DescriptorName,D002908,8678015,,,5,Chronic Disease,N,
29895,DescriptorName,D003967,8678015,,,6,Diarrhea,N,
29896,QualifierName,Q000150,8678015,,,6,,N,complications
29897,DescriptorName,D004761,8678015,,,7,"Enterocolitis, Pseudomembranous",N,
29898,QualifierName,Q000139,8678015,,,7,,Y,chemically induced
29899,DescriptorName,D015497,8678015,,,8,HIV-1,N,
29900,DescriptorName,D006801,8678015,,,9,Humans,N,
29901,DescriptorName,D007411,8678015,,,10,"Intestinal Diseases, Parasitic",N,
29902,QualifierName,Q000150,8678015,,,10,,N,complications
29903,DescriptorName,D008297,8678015,,,11,Male,N,
29904,DescriptorName,D016881,8678015,,,12,Microsporidiosis,N,
29905,QualifierName,Q000150,8678015,,,12,,N,complications
29906,Chemical,D000975,8684546,Antioxidants,0,,,,
29907,Chemical,D002614,8684546,Chelating Agents,0,,,,
29908,Chemical,D013885,8684546,Thiosulfates,0,,,,
29909,Chemical,C017717,8684546,sodium thiosulfate,HX1032V43M,,,,
29910,DescriptorName,D000975,8684546,,,1,Antioxidants,N,
29911,QualifierName,Q000627,8684546,,,1,,Y,therapeutic use
29912,DescriptorName,D002114,8684546,,,2,Calcinosis,N,
29913,QualifierName,Q000000981,8684546,,,2,,N,diagnostic imaging
29914,DescriptorName,D002614,8684546,,,3,Chelating Agents,N,
29915,DescriptorName,D005260,8684546,,,4,Female,N,
29916,DescriptorName,D006801,8684546,,,5,Humans,N,
29917,DescriptorName,D006961,8684546,,,6,Hyperparathyroidism,Y,
29918,DescriptorName,D007592,8684546,,,7,Joint Diseases,N,
29919,QualifierName,Q000000981,8684546,,,7,,N,diagnostic imaging
29920,DescriptorName,D007676,8684546,,,8,"Kidney Failure, Chronic",N,
29921,QualifierName,Q000628,8684546,,,8,,N,therapy
29922,DescriptorName,D008875,8684546,,,9,Middle Aged,N,
29923,DescriptorName,D011859,8684546,,,10,Radiography,N,
29924,DescriptorName,D006435,8684546,,,11,Renal Dialysis,N,
29925,QualifierName,Q000009,8684546,,,11,,Y,adverse effects
29926,DescriptorName,D013885,8684546,,,12,Thiosulfates,N,
29927,QualifierName,Q000627,8684546,,,12,,Y,therapeutic use
29928,Chemical,D005472,868978,Fluorouracil,U3P01618RT,,,,
29929,DescriptorName,D000230,868978,,,1,Adenocarcinoma,N,
29930,QualifierName,Q000188,868978,,,1,,N,drug therapy
29931,DescriptorName,D000328,868978,,,2,Adult,N,
29932,DescriptorName,D001933,868978,,,3,Brain Stem,N,
29933,QualifierName,Q000187,868978,,,3,,N,drug effects
29934,DescriptorName,D002526,868978,,,4,Cerebellar Diseases,N,
29935,QualifierName,Q000139,868978,,,4,,N,chemically induced
29936,DescriptorName,D003110,868978,,,5,Colonic Neoplasms,N,
29937,QualifierName,Q000188,868978,,,5,,N,drug therapy
29938,DescriptorName,D005133,868978,,,6,Eye Movements,N,
29939,QualifierName,Q000187,868978,,,6,,Y,drug effects
29940,DescriptorName,D005260,868978,,,7,Female,N,
29941,DescriptorName,D005472,868978,,,8,Fluorouracil,N,
29942,QualifierName,Q000009,868978,,,8,,Y,adverse effects
29943,DescriptorName,D006801,868978,,,9,Humans,N,
29944,DescriptorName,D008297,868978,,,10,Male,N,
29945,DescriptorName,D009802,868978,,,11,Oculomotor Nerve,N,
29946,QualifierName,Q000187,868978,,,11,,N,drug effects
29947,DescriptorName,D009886,868978,,,12,Ophthalmoplegia,N,
29948,QualifierName,Q000139,868978,,,12,,Y,chemically induced
29949,Chemical,D000730,8691927,Androstadienes,0,,,,
29950,Chemical,D018927,8691927,Anti-Asthmatic Agents,0,,,,
29951,Chemical,D000893,8691927,Anti-Inflammatory Agents,0,,,,
29952,Chemical,D005938,8691927,Glucocorticoids,0,,,,
29953,Chemical,D000068298,8691927,Fluticasone,CUT2W21N7U,,,,
29954,DescriptorName,D000287,8691927,,,1,"Administration, Topical",N,
29955,DescriptorName,D000302,8691927,,,2,Adrenal Cortex,N,
29956,QualifierName,Q000187,8691927,,,2,,Y,drug effects
29957,DescriptorName,D000730,8691927,,,3,Androstadienes,N,
29958,QualifierName,Q000008,8691927,,,3,,Y,administration & dosage
29959,DescriptorName,D018927,8691927,,,4,Anti-Asthmatic Agents,N,
29960,QualifierName,Q000008,8691927,,,4,,Y,administration & dosage
29961,DescriptorName,D000893,8691927,,,5,Anti-Inflammatory Agents,N,
29962,QualifierName,Q000008,8691927,,,5,,Y,administration & dosage
29963,DescriptorName,D001249,8691927,,,6,Asthma,N,
29964,QualifierName,Q000188,8691927,,,6,,Y,drug therapy
29965,DescriptorName,D002648,8691927,,,7,Child,N,
29966,DescriptorName,D002675,8691927,,,8,"Child, Preschool",N,
29967,DescriptorName,D003864,8691927,,,9,"Depression, Chemical",N,
29968,DescriptorName,D005260,8691927,,,10,Female,N,
29969,DescriptorName,D000068298,8691927,,,11,Fluticasone,N,
29970,DescriptorName,D005938,8691927,,,12,Glucocorticoids,N,
29971,DescriptorName,D006130,8691927,,,13,Growth Disorders,N,
29972,QualifierName,Q000139,8691927,,,13,,Y,chemically induced
29973,DescriptorName,D006801,8691927,,,14,Humans,N,
29974,DescriptorName,D008297,8691927,,,15,Male,N,
29975,Chemical,D000319,8696525,Adrenergic beta-Antagonists,0,,,,
29976,Chemical,D000959,8696525,Antihypertensive Agents,0,,,,
29977,Chemical,D014290,8696525,Metipranolol,X39AL81KEB,,,,
29978,DescriptorName,D000319,8696525,,,1,Adrenergic beta-Antagonists,N,
29979,QualifierName,Q000009,8696525,,,1,,Y,adverse effects
29980,DescriptorName,D000368,8696525,,,2,Aged,N,
29981,DescriptorName,D000369,8696525,,,3,"Aged, 80 and over",N,
29982,DescriptorName,D000959,8696525,,,4,Antihypertensive Agents,N,
29983,QualifierName,Q000009,8696525,,,4,,Y,adverse effects
29984,DescriptorName,D005260,8696525,,,5,Female,N,
29985,DescriptorName,D005901,8696525,,,6,Glaucoma,N,
29986,QualifierName,Q000188,8696525,,,6,,N,drug therapy
29987,DescriptorName,D006099,8696525,,,7,Granuloma,N,
29988,QualifierName,Q000139,8696525,,,7,,Y,chemically induced
29989,DescriptorName,D006801,8696525,,,8,Humans,N,
29990,DescriptorName,D008297,8696525,,,9,Male,N,
29991,DescriptorName,D014290,8696525,,,10,Metipranolol,N,
29992,QualifierName,Q000009,8696525,,,10,,Y,adverse effects
29993,DescriptorName,D008875,8696525,,,11,Middle Aged,N,
29994,DescriptorName,D014606,8696525,,,12,"Uveitis, Anterior",N,
29995,QualifierName,Q000139,8696525,,,12,,Y,chemically induced
29996,Chemical,D012076,8700794,Renal Agents,0,,,,
29997,Chemical,D003894,8700794,Deamino Arginine Vasopressin,ENR1LLB0FP,,,,
29998,DescriptorName,D000281,8700794,,,1,"Administration, Intranasal",N,
29999,DescriptorName,D000328,8700794,,,2,Adult,N,
30000,DescriptorName,D003894,8700794,,,3,Deamino Arginine Vasopressin,N,
30001,QualifierName,Q000008,8700794,,,3,,N,administration & dosage
30002,DescriptorName,D004775,8700794,,,4,Enuresis,N,
30003,QualifierName,Q000188,8700794,,,4,,N,drug therapy
30004,DescriptorName,D005260,8700794,,,5,Female,N,
30005,DescriptorName,D006801,8700794,,,6,Humans,N,
30006,DescriptorName,D007010,8700794,,,7,Hyponatremia,N,
30007,QualifierName,Q000145,8700794,,,7,,Y,classification
30008,DescriptorName,D012076,8700794,,,8,Renal Agents,N,
30009,QualifierName,Q000008,8700794,,,8,,N,administration & dosage
30010,DescriptorName,D014869,8700794,,,9,Water Intoxication,N,
30011,QualifierName,Q000145,8700794,,,9,,N,classification
30012,Chemical,D000900,8710040,Anti-Bacterial Agents,0,,,,
30013,Chemical,D000904,8710040,"Antibiotics, Antitubercular",0,,,,
30014,Chemical,D017828,8710040,Rifabutin,1W306TDA6S,,,,
30015,Chemical,D004977,8710040,Ethambutol,8G167061QZ,,,,
30016,Chemical,D017291,8710040,Clarithromycin,H1250JIK0A,,,,
30017,DescriptorName,D017088,8710040,,,1,AIDS-Related Opportunistic Infections,N,
30018,QualifierName,Q000188,8710040,,,1,,Y,drug therapy
30019,DescriptorName,D000328,8710040,,,2,Adult,N,
30020,DescriptorName,D000900,8710040,,,3,Anti-Bacterial Agents,N,
30021,QualifierName,Q000009,8710040,,,3,,N,adverse effects
30022,DescriptorName,D000904,8710040,,,4,"Antibiotics, Antitubercular",N,
30023,QualifierName,Q000009,8710040,,,4,,Y,adverse effects
30024,DescriptorName,D017291,8710040,,,5,Clarithromycin,N,
30025,QualifierName,Q000009,8710040,,,5,,N,adverse effects
30026,DescriptorName,D004359,8710040,,,6,"Drug Therapy, Combination",N,
30027,QualifierName,Q000009,8710040,,,6,,Y,adverse effects
30028,DescriptorName,D004977,8710040,,,7,Ethambutol,N,
30029,QualifierName,Q000009,8710040,,,7,,N,adverse effects
30030,DescriptorName,D005260,8710040,,,8,Female,N,
30031,DescriptorName,D006801,8710040,,,9,Humans,N,
30032,DescriptorName,D008297,8710040,,,10,Male,N,
30033,DescriptorName,D008875,8710040,,,11,Middle Aged,N,
30034,DescriptorName,D015270,8710040,,,12,Mycobacterium avium-intracellulare Infection,N,
30035,QualifierName,Q000188,8710040,,,12,,Y,drug therapy
30036,DescriptorName,D017828,8710040,,,13,Rifabutin,N,
30037,QualifierName,Q000009,8710040,,,13,,N,adverse effects
30038,DescriptorName,D014605,8710040,,,14,Uveitis,N,
30039,QualifierName,Q000139,8710040,,,14,,Y,chemically induced
30040,Chemical,D018692,8726608,Antimanic Agents,0,,,,
30041,Chemical,D000998,8726608,Antiviral Agents,0,,,,
30042,Chemical,D016651,8726608,Lithium Carbonate,2BMD2GNA4V,,,,
30043,Chemical,D000212,8726608,Acyclovir,X4HES1O11F,,,,
30044,DescriptorName,D000212,8726608,,,1,Acyclovir,N,
30045,QualifierName,Q000494,8726608,,,1,,Y,pharmacology
30046,DescriptorName,D000328,8726608,,,2,Adult,N,
30047,DescriptorName,D018692,8726608,,,3,Antimanic Agents,N,
30048,QualifierName,Q000506,8726608,,,3,,Y,poisoning
30049,DescriptorName,D000998,8726608,,,4,Antiviral Agents,N,
30050,QualifierName,Q000494,8726608,,,4,,Y,pharmacology
30051,DescriptorName,D004347,8726608,,,5,Drug Interactions,N,
30052,DescriptorName,D005260,8726608,,,6,Female,N,
30053,DescriptorName,D006562,8726608,,,7,Herpes Zoster,N,
30054,QualifierName,Q000188,8726608,,,7,,Y,drug therapy
30055,DescriptorName,D006801,8726608,,,8,Humans,N,
30056,DescriptorName,D016651,8726608,,,9,Lithium Carbonate,N,
30057,QualifierName,Q000506,8726608,,,9,,Y,poisoning
30058,Chemical,D007917,8730143,Leprostatic Agents,0,,,,
30059,Chemical,D003622,8730143,Dapsone,8W5C518302,,,,
30060,DescriptorName,D000328,8730143,,,1,Adult,N,
30061,DescriptorName,D003622,8730143,,,2,Dapsone,N,
30062,QualifierName,Q000009,8730143,,,2,,Y,adverse effects
30063,DescriptorName,D017809,8730143,,,3,Fatal Outcome,N,
30064,DescriptorName,D005260,8730143,,,4,Female,N,
30065,DescriptorName,D006801,8730143,,,5,Humans,N,
30066,DescriptorName,D007917,8730143,,,6,Leprostatic Agents,N,
30067,QualifierName,Q000009,8730143,,,6,,Y,adverse effects
30068,DescriptorName,D008178,8730143,,,7,"Lupus Erythematosus, Cutaneous",N,
30069,QualifierName,Q000188,8730143,,,7,,Y,drug therapy
30070,DescriptorName,D008297,8730143,,,8,Male,N,
30071,DescriptorName,D013577,8730143,,,9,Syndrome,N,
30072,Chemical,D000959,8733532,Antihypertensive Agents,0,,,,
30073,Chemical,D008914,8733532,Minoxidil,5965120SH1,,,,
30074,DescriptorName,D000368,8733532,,,1,Aged,N,
30075,DescriptorName,D000959,8733532,,,2,Antihypertensive Agents,N,
30076,QualifierName,Q000009,8733532,,,2,,Y,adverse effects
30077,DescriptorName,D001778,8733532,,,3,Blood Coagulation Disorders,N,
30078,QualifierName,Q000150,8733532,,,3,,Y,complications
30079,DescriptorName,D017809,8733532,,,4,Fatal Outcome,N,
30080,DescriptorName,D006801,8733532,,,5,Humans,N,
30081,DescriptorName,D006973,8733532,,,6,Hypertension,N,
30082,QualifierName,Q000150,8733532,,,6,,N,complications
30083,DescriptorName,D008297,8733532,,,7,Male,N,
30084,DescriptorName,D008914,8733532,,,8,Minoxidil,N,
30085,QualifierName,Q000009,8733532,,,8,,Y,adverse effects
30086,DescriptorName,D011655,8733532,,,9,Pulmonary Embolism,N,
30087,QualifierName,Q000209,8733532,,,9,,Y,etiology
30088,DescriptorName,D013923,8733532,,,10,Thromboembolism,N,
30089,QualifierName,Q000209,8733532,,,10,,Y,etiology
30090,Chemical,D018692,8739289,Antimanic Agents,0,,,,
30091,Chemical,D016651,8739289,Lithium Carbonate,2BMD2GNA4V,,,,
30092,DescriptorName,D000368,8739289,,,1,Aged,N,
30093,DescriptorName,D018692,8739289,,,2,Antimanic Agents,N,
30094,QualifierName,Q000009,8739289,,,2,,Y,adverse effects
30095,DescriptorName,D001714,8739289,,,3,Bipolar Disorder,N,
30096,QualifierName,Q000188,8739289,,,3,,N,drug therapy
30097,DescriptorName,D002908,8739289,,,4,Chronic Disease,N,
30098,DescriptorName,D003919,8739289,,,5,Diabetes Insipidus,N,
30099,QualifierName,Q000139,8739289,,,5,,Y,chemically induced
30100,DescriptorName,D018500,8739289,,,6,"Diabetes Insipidus, Nephrogenic",N,
30101,QualifierName,Q000150,8739289,,,6,,Y,complications
30102,DescriptorName,D005260,8739289,,,7,Female,N,
30103,DescriptorName,D006801,8739289,,,8,Humans,N,
30104,DescriptorName,D016651,8739289,,,9,Lithium Carbonate,N,
30105,QualifierName,Q000009,8739289,,,9,,Y,adverse effects
30106,Chemical,D006442,8742573,Glycated Hemoglobin A,0,,,,
30107,Chemical,D007328,8742573,Insulin,0,,,,
30108,Chemical,D011994,8742573,Recombinant Proteins,0,,,,
30109,DescriptorName,D000328,8742573,,,1,Adult,N,
30110,DescriptorName,D003923,8742573,,,2,"Diabetes Mellitus, Lipoatrophic",N,
30111,QualifierName,Q000139,8742573,,,2,,Y,chemically induced
30112,DescriptorName,D003922,8742573,,,3,"Diabetes Mellitus, Type 1",N,
30113,QualifierName,Q000188,8742573,,,3,,Y,drug therapy
30114,DescriptorName,D004867,8742573,,,4,Equipment Design,N,
30115,DescriptorName,D005260,8742573,,,5,Female,N,
30116,DescriptorName,D006442,8742573,,,6,Glycated Hemoglobin A,N,
30117,QualifierName,Q000032,8742573,,,6,,N,analysis
30118,DescriptorName,D006801,8742573,,,7,Humans,N,
30119,DescriptorName,D007279,8742573,,,8,"Injections, Subcutaneous",N,
30120,QualifierName,Q000009,8742573,,,8,,Y,adverse effects
30121,DescriptorName,D007328,8742573,,,9,Insulin,N,
30122,QualifierName,Q000008,8742573,,,9,,Y,administration & dosage
30123,DescriptorName,D011994,8742573,,,10,Recombinant Proteins,N,
30124,QualifierName,Q000627,8742573,,,10,,N,therapeutic use
30125,DescriptorName,D013594,8742573,,,11,Syringes,N,
30126,Chemical,D015242,8749646,Ofloxacin,A4P49JAZ9H,,,,
30127,DescriptorName,D000368,8749646,,,1,Aged,N,
30128,DescriptorName,D000369,8749646,,,2,"Aged, 80 and over",N,
30129,DescriptorName,D005260,8749646,,,3,Female,N,
30130,DescriptorName,D006192,8749646,,,4,Haemophilus Infections,N,
30131,QualifierName,Q000150,8749646,,,4,,N,complications
30132,DescriptorName,D006193,8749646,,,5,Haemophilus influenzae,N,
30133,DescriptorName,D006801,8749646,,,6,Humans,N,
30134,DescriptorName,D007710,8749646,,,7,Klebsiella Infections,N,
30135,QualifierName,Q000188,8749646,,,7,,N,drug therapy
30136,DescriptorName,D007711,8749646,,,8,Klebsiella pneumoniae,N,
30137,DescriptorName,D008297,8749646,,,9,Male,N,
30138,DescriptorName,D008875,8749646,,,10,Middle Aged,N,
30139,DescriptorName,D015242,8749646,,,11,Ofloxacin,N,
30140,QualifierName,Q000009,8749646,,,11,,Y,adverse effects
30141,DescriptorName,D011014,8749646,,,12,Pneumonia,N,
30142,QualifierName,Q000188,8749646,,,12,,N,drug therapy
30143,DescriptorName,D012640,8749646,,,13,Seizures,N,
30144,QualifierName,Q000139,8749646,,,13,,Y,chemically induced
30145,Chemical,D000893,8763435,Anti-Inflammatory Agents,0,,,,
30146,Chemical,D000927,8763435,Anticonvulsants,0,,,,
30147,Chemical,D010672,8763435,Phenytoin,6158TKW0C5,,,,
30148,Chemical,D011239,8763435,Prednisolone,9PHQ9Y1OLM,,,,
30149,DescriptorName,D000893,8763435,,,1,Anti-Inflammatory Agents,N,
30150,QualifierName,Q000627,8763435,,,1,,Y,therapeutic use
30151,DescriptorName,D000927,8763435,,,2,Anticonvulsants,N,
30152,QualifierName,Q000009,8763435,,,2,,Y,adverse effects
30153,DescriptorName,D003875,8763435,,,3,Drug Eruptions,N,
30154,QualifierName,Q000188,8763435,,,3,,Y,drug therapy
30155,DescriptorName,D005260,8763435,,,4,Female,N,
30156,DescriptorName,D006801,8763435,,,5,Humans,N,
30157,DescriptorName,D008875,8763435,,,6,Middle Aged,N,
30158,DescriptorName,D010672,8763435,,,7,Phenytoin,N,
30159,QualifierName,Q000009,8763435,,,7,,Y,adverse effects
30160,DescriptorName,D011239,8763435,,,8,Prednisolone,N,
30161,QualifierName,Q000627,8763435,,,8,,Y,therapeutic use
30162,DescriptorName,D013577,8763435,,,9,Syndrome,N,
30163,Chemical,D003520,876914,Cyclophosphamide,8N3DW7272P,,,,
30164,DescriptorName,D001172,876914,,,1,"Arthritis, Rheumatoid",N,
30165,QualifierName,Q000188,876914,,,1,,N,drug therapy
30166,DescriptorName,D003520,876914,,,2,Cyclophosphamide,N,
30167,QualifierName,Q000009,876914,,,2,,Y,adverse effects
30168,DescriptorName,D006801,876914,,,3,Humans,N,
30169,DescriptorName,D008297,876914,,,4,Male,N,
30170,DescriptorName,D008875,876914,,,5,Middle Aged,N,
30171,DescriptorName,D010997,876914,,,6,Pleural Neoplasms,N,
30172,QualifierName,Q000139,876914,,,6,,Y,chemically induced
30173,DescriptorName,D012509,876914,,,7,Sarcoma,N,
30174,QualifierName,Q000139,876914,,,7,,Y,chemically induced
30175,Chemical,D000892,8771575,"Anti-Infective Agents, Urinary",0,,,,
30176,Chemical,D009582,8771575,Nitrofurantoin,927AH8112L,,,,
30177,DescriptorName,D000328,8771575,,,1,Adult,N,
30178,DescriptorName,D000892,8771575,,,2,"Anti-Infective Agents, Urinary",N,
30179,QualifierName,Q000009,8771575,,,2,,Y,adverse effects
30180,DescriptorName,D005260,8771575,,,3,Female,N,
30181,DescriptorName,D005322,8771575,,,4,"Fetal Membranes, Premature Rupture",N,
30182,QualifierName,Q000209,8771575,,,4,,N,etiology
30183,DescriptorName,D006801,8771575,,,5,Humans,N,
30184,DescriptorName,D007231,8771575,,,6,"Infant, Newborn",N,
30185,DescriptorName,D007234,8771575,,,7,"Infant, Premature",N,
30186,DescriptorName,D008171,8771575,,,8,Lung Diseases,N,
30187,QualifierName,Q000139,8771575,,,8,,Y,chemically induced
30188,DescriptorName,D009582,8771575,,,9,Nitrofurantoin,N,
30189,QualifierName,Q000009,8771575,,,9,,Y,adverse effects
30190,DescriptorName,D011247,8771575,,,10,Pregnancy,N,
30191,DescriptorName,D011248,8771575,,,11,Pregnancy Complications,N,
30192,QualifierName,Q000139,8771575,,,11,,Y,chemically induced
30193,Chemical,D000894,8792511,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
30194,Chemical,D018501,8792511,Antirheumatic Agents,0,,,,
30195,Chemical,D003622,8792511,Dapsone,8W5C518302,,,,
30196,Chemical,D011241,8792511,Prednisone,VB0R961HZT,,,,
30197,DescriptorName,D000894,8792511,,,1,"Anti-Inflammatory Agents, Non-Steroidal",N,
30198,QualifierName,Q000627,8792511,,,1,,N,therapeutic use
30199,DescriptorName,D018501,8792511,,,2,Antirheumatic Agents,N,
30200,QualifierName,Q000627,8792511,,,2,,N,therapeutic use
30201,DescriptorName,D001172,8792511,,,3,"Arthritis, Rheumatoid",N,
30202,QualifierName,Q000188,8792511,,,3,,Y,drug therapy
30203,DescriptorName,D002986,8792511,,,4,Clinical Trials as Topic,N,
30204,DescriptorName,D003622,8792511,,,5,Dapsone,N,
30205,QualifierName,Q000009,8792511,,,5,,N,adverse effects
30206,DescriptorName,D005260,8792511,,,6,Female,N,
30207,DescriptorName,D006801,8792511,,,7,Humans,N,
30208,DescriptorName,D008297,8792511,,,8,Male,N,
30209,DescriptorName,D008875,8792511,,,9,Middle Aged,N,
30210,DescriptorName,D011241,8792511,,,10,Prednisone,N,
30211,QualifierName,Q000627,8792511,,,10,,N,therapeutic use
30212,Chemical,D000927,879939,Anticonvulsants,0,,,,
30213,Chemical,D010710,879939,Phosphates,0,,,,
30214,Chemical,D008618,879939,Mephobarbital,5NC67NU76B,,,,
30215,Chemical,D010672,879939,Phenytoin,6158TKW0C5,,,,
30216,Chemical,D000086,879939,Acetazolamide,O3FX965V0I,,,,
30217,Chemical,D002118,879939,Calcium,SY7Q814VUP,,,,
30218,Chemical,D010634,879939,Phenobarbital,YQE403BP4D,,,,
30219,DescriptorName,D000086,879939,,,1,Acetazolamide,N,
30220,QualifierName,Q000009,879939,,,1,,Y,adverse effects
30221,DescriptorName,D000328,879939,,,2,Adult,N,
30222,DescriptorName,D000927,879939,,,3,Anticonvulsants,N,
30223,QualifierName,Q000009,879939,,,3,,Y,adverse effects
30224,DescriptorName,D002118,879939,,,4,Calcium,N,
30225,QualifierName,Q000378,879939,,,4,,N,metabolism
30226,DescriptorName,D004827,879939,,,5,Epilepsy,N,
30227,QualifierName,Q000188,879939,,,5,,N,drug therapy
30228,DescriptorName,D005260,879939,,,6,Female,N,
30229,DescriptorName,D006801,879939,,,7,Humans,N,
30230,DescriptorName,D008618,879939,,,8,Mephobarbital,N,
30231,QualifierName,Q000627,879939,,,8,,N,therapeutic use
30232,DescriptorName,D010018,879939,,,9,Osteomalacia,N,
30233,QualifierName,Q000139,879939,,,9,,Y,chemically induced
30234,DescriptorName,D010634,879939,,,10,Phenobarbital,N,
30235,QualifierName,Q000627,879939,,,10,,N,therapeutic use
30236,DescriptorName,D010672,879939,,,11,Phenytoin,N,
30237,QualifierName,Q000627,879939,,,11,,N,therapeutic use
30238,DescriptorName,D010710,879939,,,12,Phosphates,N,
30239,QualifierName,Q000378,879939,,,12,,N,metabolism
30240,DescriptorName,D000971,8816294,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
30241,QualifierName,Q000009,8816294,,,1,,Y,adverse effects
30242,DescriptorName,D002557,8816294,,,2,Cerebrospinal Fluid Shunts,Y,
30243,DescriptorName,D002675,8816294,,,3,"Child, Preschool",N,
30244,DescriptorName,D004200,8816294,,,4,Diseases in Twins,N,
30245,QualifierName,Q000175,8816294,,,4,,N,diagnosis
30246,DescriptorName,D006801,8816294,,,5,Humans,N,
30247,DescriptorName,D007968,8816294,,,6,"Leukoencephalopathy, Progressive Multifocal",N,
30248,QualifierName,Q000139,8816294,,,6,,Y,chemically induced
30249,DescriptorName,D008279,8816294,,,7,Magnetic Resonance Imaging,N,
30250,DescriptorName,D008297,8816294,,,8,Male,N,
30251,DescriptorName,D054198,8816294,,,9,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
30252,QualifierName,Q000188,8816294,,,9,,N,drug therapy
30253,Chemical,D000930,8825747,Antidiarrheals,0,,,,
30254,Chemical,D009292,8825747,Narcotic Antagonists,0,,,,
30255,Chemical,D009270,8825747,Naloxone,36B82AMQ7N,,,,
30256,Chemical,D008139,8825747,Loperamide,6X9OC3H4II,,,,
30257,DescriptorName,D000818,8825747,,,1,Animals,N,
30258,DescriptorName,D000930,8825747,,,2,Antidiarrheals,N,
30259,QualifierName,Q000506,8825747,,,2,,Y,poisoning
30260,DescriptorName,D004066,8825747,,,3,Digestive System Diseases,N,
30261,QualifierName,Q000139,8825747,,,3,,N,chemically induced
30262,DescriptorName,D004283,8825747,,,4,Dog Diseases,N,
30263,QualifierName,Q000139,8825747,,,4,,Y,chemically induced
30264,DescriptorName,D004285,8825747,,,5,Dogs,N,
30265,DescriptorName,D005260,8825747,,,6,Female,N,
30266,DescriptorName,D005500,8825747,,,7,Follow-Up Studies,N,
30267,DescriptorName,D008139,8825747,,,8,Loperamide,N,
30268,QualifierName,Q000506,8825747,,,8,,Y,poisoning
30269,DescriptorName,D008297,8825747,,,9,Male,N,
30270,DescriptorName,D009270,8825747,,,10,Naloxone,N,
30271,QualifierName,Q000008,8825747,,,10,,N,administration & dosage
30272,DescriptorName,D009292,8825747,,,11,Narcotic Antagonists,N,
30273,QualifierName,Q000008,8825747,,,11,,N,administration & dosage
30274,DescriptorName,D011041,8825747,,,12,Poisoning,N,
30275,QualifierName,Q000188,8825747,,,12,,N,drug therapy
30276,DescriptorName,D012189,8825747,,,13,Retrospective Studies,N,
30277,Chemical,D008094,8828999,Lithium,9FN79X2M3F,,,,
30278,DescriptorName,D000368,8828999,,,1,Aged,N,
30279,DescriptorName,D001714,8828999,,,2,Bipolar Disorder,N,
30280,QualifierName,Q000188,8828999,,,2,,Y,drug therapy
30281,DescriptorName,D007562,8828999,,,3,Creutzfeldt-Jakob Syndrome,N,
30282,QualifierName,Q000139,8828999,,,3,,Y,chemically induced
30283,DescriptorName,D006801,8828999,,,4,Humans,N,
30284,DescriptorName,D008094,8828999,,,5,Lithium,N,
30285,QualifierName,Q000009,8828999,,,5,,Y,adverse effects
30286,DescriptorName,D008297,8828999,,,6,Male,N,
30287,Chemical,D000959,8832451,Antihypertensive Agents,0,,,,
30288,Chemical,D003473,8832451,Neuromuscular Nondepolarizing Agents,0,,,,
30289,Chemical,D008278,8832451,Magnesium Sulfate,7487-88-9,,,,
30290,Chemical,D014673,8832451,Vecuronium Bromide,7E4PHP5N1D,,,,
30291,Chemical,D008274,8832451,Magnesium,I38ZP9992A,,,,
30292,DescriptorName,D000328,8832451,,,1,Adult,N,
30293,DescriptorName,D000773,8832451,,,2,"Anesthesia, Obstetrical",N,
30294,DescriptorName,D000959,8832451,,,3,Antihypertensive Agents,N,
30295,QualifierName,Q000008,8832451,,,3,,N,administration & dosage
30296,DescriptorName,D002585,8832451,,,4,Cesarean Section,N,
30297,DescriptorName,D003937,8832451,,,5,"Diagnosis, Differential",N,
30298,DescriptorName,D004357,8832451,,,6,Drug Synergism,N,
30299,DescriptorName,D004576,8832451,,,7,Electromyography,Y,
30300,QualifierName,Q000187,8832451,,,7,,N,drug effects
30301,DescriptorName,D005071,8832451,,,8,Evoked Potentials,N,
30302,QualifierName,Q000187,8832451,,,8,,N,drug effects
30303,DescriptorName,D005260,8832451,,,9,Female,N,
30304,DescriptorName,D006801,8832451,,,10,Humans,N,
30305,DescriptorName,D008274,8832451,,,11,Magnesium,N,
30306,QualifierName,Q000097,8832451,,,11,,N,blood
30307,DescriptorName,D008278,8832451,,,12,Magnesium Sulfate,N,
30308,QualifierName,Q000008,8832451,,,12,,N,administration & dosage
30309,DescriptorName,D008991,8832451,,,13,"Monitoring, Physiologic",N,
30310,QualifierName,Q000379,8832451,,,13,,N,methods
30311,DescriptorName,D019148,8832451,,,14,Neuromuscular Blockade,Y,
30312,DescriptorName,D003473,8832451,,,15,Neuromuscular Nondepolarizing Agents,N,
30313,QualifierName,Q000009,8832451,,,15,,Y,adverse effects
30314,DescriptorName,D011225,8832451,,,16,Pre-Eclampsia,N,
30315,QualifierName,Q000188,8832451,,,16,,N,drug therapy
30316,DescriptorName,D011247,8832451,,,17,Pregnancy,N,
30317,DescriptorName,D012032,8832451,,,18,"Refractory Period, Electrophysiological",N,
30318,QualifierName,Q000187,8832451,,,18,,N,drug effects
30319,DescriptorName,D014459,8832451,,,19,Ulnar Nerve,N,
30320,QualifierName,Q000187,8832451,,,19,,N,drug effects
30321,DescriptorName,D014673,8832451,,,20,Vecuronium Bromide,N,
30322,QualifierName,Q000009,8832451,,,20,,Y,adverse effects
30323,Chemical,D000935,8835752,Antifungal Agents,0,,,,
30324,Chemical,D009281,8835752,Naphthalenes,0,,,,
30325,Chemical,D000077291,8835752,Terbinafine,G7RIW8S0XP,,,,
30326,DescriptorName,D000284,8835752,,,1,"Administration, Oral",N,
30327,DescriptorName,D000935,8835752,,,2,Antifungal Agents,N,
30328,QualifierName,Q000009,8835752,,,2,,Y,adverse effects
30329,DescriptorName,D003883,8835752,,,3,Arthrodermataceae,N,
30330,DescriptorName,D002780,8835752,,,4,"Cholestasis, Intrahepatic",N,
30331,QualifierName,Q000139,8835752,,,4,,Y,chemically induced
30332,DescriptorName,D005260,8835752,,,5,Female,N,
30333,DescriptorName,D005500,8835752,,,6,Follow-Up Studies,N,
30334,DescriptorName,D006801,8835752,,,7,Humans,N,
30335,DescriptorName,D008875,8835752,,,8,Middle Aged,N,
30336,DescriptorName,D009281,8835752,,,9,Naphthalenes,N,
30337,QualifierName,Q000009,8835752,,,9,,Y,adverse effects
30338,DescriptorName,D014009,8835752,,,10,Onychomycosis,N,
30339,QualifierName,Q000188,8835752,,,10,,N,drug therapy
30340,DescriptorName,D000077291,8835752,,,11,Terbinafine,N,
30341,Chemical,D000891,8840640,"Anti-Infective Agents, Local",0,,,,
30342,Chemical,D000923,8840640,Anticestodal Agents,0,,,,
30343,Chemical,D002593,8840640,Cetrimonium Compounds,0,,,,
30344,Chemical,D004338,8840640,Drug Combinations,0,,,,
30345,Chemical,D002710,8840640,Chlorhexidine,R4KO0DY52L,,,,
30346,Chemical,D000077286,8840640,Cetrimonium,Z7FF1XKL7A,,,,
30347,DescriptorName,D000138,8840640,,,1,Acidosis,N,
30348,QualifierName,Q000139,8840640,,,1,,Y,chemically induced
30349,DescriptorName,D000328,8840640,,,2,Adult,N,
30350,DescriptorName,D000891,8840640,,,3,"Anti-Infective Agents, Local",N,
30351,QualifierName,Q000009,8840640,,,3,,Y,adverse effects
30352,DescriptorName,D000923,8840640,,,4,Anticestodal Agents,N,
30353,QualifierName,Q000009,8840640,,,4,,Y,adverse effects
30354,DescriptorName,D000077286,8840640,,,5,Cetrimonium,N,
30355,DescriptorName,D002593,8840640,,,6,Cetrimonium Compounds,N,
30356,QualifierName,Q000009,8840640,,,6,,Y,adverse effects
30357,DescriptorName,D002710,8840640,,,7,Chlorhexidine,N,
30358,QualifierName,Q000009,8840640,,,7,,Y,adverse effects
30359,DescriptorName,D004338,8840640,,,8,Drug Combinations,N,
30360,DescriptorName,D004444,8840640,,,9,"Echinococcosis, Hepatic",N,
30361,QualifierName,Q000188,8840640,,,9,,Y,drug therapy
30362,DescriptorName,D005260,8840640,,,10,Female,N,
30363,DescriptorName,D006801,8840640,,,11,Humans,N,
30364,Chemical,D009125,8844232,"Muscle Relaxants, Central",0,,,,
30365,Chemical,D003402,8844232,Creatine Kinase,EC 2.7.3.2,,,,
30366,Chemical,D003620,8844232,Dantrolene,F64QU97QCR,,,,
30367,Chemical,D018817,8844232,"N-Methyl-3,4-methylenedioxyamphetamine",KE1SEN21RM,,,,
30368,DescriptorName,D000328,8844232,,,1,Adult,N,
30369,DescriptorName,D003402,8844232,,,2,Creatine Kinase,N,
30370,QualifierName,Q000097,8844232,,,2,,N,blood
30371,DescriptorName,D003620,8844232,,,3,Dantrolene,N,
30372,QualifierName,Q000627,8844232,,,3,,N,therapeutic use
30373,DescriptorName,D006801,8844232,,,4,Humans,N,
30374,DescriptorName,D008297,8844232,,,5,Male,N,
30375,DescriptorName,D009125,8844232,,,6,"Muscle Relaxants, Central",N,
30376,QualifierName,Q000627,8844232,,,6,,N,therapeutic use
30377,DescriptorName,D018817,8844232,,,7,"N-Methyl-3,4-methylenedioxyamphetamine",N,
30378,QualifierName,Q000506,8844232,,,7,,Y,poisoning
30379,DescriptorName,D010264,8844232,,,8,Paraplegia,N,
30380,QualifierName,Q000150,8844232,,,8,,N,complications
30381,DescriptorName,D011041,8844232,,,9,Poisoning,N,
30382,QualifierName,Q000097,8844232,,,9,,N,blood
30383,DescriptorName,D012128,8844232,,,10,"Respiratory Distress Syndrome, Adult",N,
30384,QualifierName,Q000139,8844232,,,10,,N,chemically induced
30385,DescriptorName,D013226,8844232,,,11,Status Epilepticus,N,
30386,QualifierName,Q000139,8844232,,,11,,N,chemically induced
30387,Chemical,D018492,8850251,Dopamine Antagonists,0,,,,
30388,Chemical,D006634,8850251,Histamine H1 Antagonists,0,,,,
30389,Chemical,D007166,8850251,Immunosuppressive Agents,0,,,,
30390,Chemical,D010640,8850251,Phenothiazines,0,,,,
30391,Chemical,D003520,8850251,Cyclophosphamide,8N3DW7272P,,,,
30392,Chemical,D011398,8850251,Promethazine,FF28EJQ494,,,,
30393,Chemical,D002746,8850251,Chlorpromazine,U42B7VYA4P,,,,
30394,Chemical,C006069,8850251,mequitazine,Y463242LY2,,,,
30395,DescriptorName,D002746,8850251,,,1,Chlorpromazine,N,
30396,QualifierName,Q000009,8850251,,,1,,N,adverse effects
30397,DescriptorName,D003429,8850251,,,2,Cross Reactions,N,
30398,DescriptorName,D003520,8850251,,,3,Cyclophosphamide,N,
30399,QualifierName,Q000627,8850251,,,3,,N,therapeutic use
30400,DescriptorName,D017449,8850251,,,4,"Dermatitis, Allergic Contact",N,
30401,QualifierName,Q000209,8850251,,,4,,N,etiology
30402,DescriptorName,D017454,8850251,,,5,"Dermatitis, Photoallergic",N,
30403,QualifierName,Q000188,8850251,,,5,,N,drug therapy
30404,DescriptorName,D018492,8850251,,,6,Dopamine Antagonists,N,
30405,QualifierName,Q000009,8850251,,,6,,N,adverse effects
30406,DescriptorName,D005500,8850251,,,7,Follow-Up Studies,N,
30407,DescriptorName,D006634,8850251,,,8,Histamine H1 Antagonists,N,
30408,QualifierName,Q000009,8850251,,,8,,Y,adverse effects
30409,DescriptorName,D006801,8850251,,,9,Humans,N,
30410,DescriptorName,D007166,8850251,,,10,Immunosuppressive Agents,N,
30411,QualifierName,Q000627,8850251,,,10,,N,therapeutic use
30412,DescriptorName,D008297,8850251,,,11,Male,N,
30413,DescriptorName,D008875,8850251,,,12,Middle Aged,N,
30414,DescriptorName,D010328,8850251,,,13,Patch Tests,N,
30415,DescriptorName,D010640,8850251,,,14,Phenothiazines,N,
30416,QualifierName,Q000009,8850251,,,14,,Y,adverse effects
30417,DescriptorName,D011398,8850251,,,15,Promethazine,N,
30418,QualifierName,Q000009,8850251,,,15,,N,adverse effects
30419,DescriptorName,D014466,8850251,,,16,Ultraviolet Rays,N,
30420,Chemical,D000900,8862924,Anti-Bacterial Agents,0,,,,
30421,Chemical,D000697,8862924,Central Nervous System Stimulants,0,,,,
30422,Chemical,D008694,8862924,Methamphetamine,44RAL3456C,,,,
30423,DescriptorName,D000328,8862924,,,1,Adult,N,
30424,DescriptorName,D000900,8862924,,,2,Anti-Bacterial Agents,N,
30425,DescriptorName,D000697,8862924,,,3,Central Nervous System Stimulants,Y,
30426,DescriptorName,D003315,8862924,,,4,Cornea,N,
30427,QualifierName,Q000187,8862924,,,4,,Y,drug effects
30428,DescriptorName,D003320,8862924,,,5,Corneal Ulcer,N,
30429,QualifierName,Q000209,8862924,,,5,,Y,etiology
30430,DescriptorName,D004359,8862924,,,6,"Drug Therapy, Combination",N,
30431,QualifierName,Q000627,8862924,,,6,,N,therapeutic use
30432,DescriptorName,D015818,8862924,,,7,"Eye Infections, Bacterial",N,
30433,QualifierName,Q000188,8862924,,,7,,N,drug therapy
30434,DescriptorName,D015821,8862924,,,8,"Eye Infections, Fungal",N,
30435,QualifierName,Q000188,8862924,,,8,,N,drug therapy
30436,DescriptorName,D005260,8862924,,,9,Female,N,
30437,DescriptorName,D006801,8862924,,,10,Humans,N,
30438,DescriptorName,D008297,8862924,,,11,Male,N,
30439,DescriptorName,D008694,8862924,,,12,Methamphetamine,Y,
30440,DescriptorName,D008875,8862924,,,13,Middle Aged,N,
30441,DescriptorName,D012907,8862924,,,14,Smoking,N,
30442,QualifierName,Q000009,8862924,,,14,,N,adverse effects
30443,DescriptorName,D019966,8862924,,,15,Substance-Related Disorders,N,
30444,QualifierName,Q000150,8862924,,,15,,Y,complications
30445,Chemical,D015415,8864370,Biomarkers,0,,,,
30446,Chemical,D003879,8864370,Dermatologic Agents,0,,,,
30447,Chemical,D010446,8864370,Peptide Fragments,0,,,,
30448,Chemical,D011347,8864370,Procollagen,0,,,,
30449,Chemical,C041876,8864370,procollagen Type III-N-terminal peptide,0,,,,
30450,Chemical,D008727,8864370,Methotrexate,YL5FZ2Y5U1,,,,
30451,DescriptorName,D000328,8864370,,,1,Adult,N,
30452,DescriptorName,D000368,8864370,,,2,Aged,N,
30453,DescriptorName,D000369,8864370,,,3,"Aged, 80 and over",N,
30454,DescriptorName,D015415,8864370,,,4,Biomarkers,N,
30455,QualifierName,Q000097,8864370,,,4,,N,blood
30456,DescriptorName,D003879,8864370,,,5,Dermatologic Agents,N,
30457,QualifierName,Q000009,8864370,,,5,,Y,adverse effects
30458,DescriptorName,D005260,8864370,,,6,Female,N,
30459,DescriptorName,D005500,8864370,,,7,Follow-Up Studies,N,
30460,DescriptorName,D006801,8864370,,,8,Humans,N,
30461,DescriptorName,D008103,8864370,,,9,Liver Cirrhosis,N,
30462,QualifierName,Q000097,8864370,,,9,,N,blood
30463,DescriptorName,D008297,8864370,,,10,Male,N,
30464,DescriptorName,D008727,8864370,,,11,Methotrexate,N,
30465,QualifierName,Q000009,8864370,,,11,,Y,adverse effects
30466,DescriptorName,D008875,8864370,,,12,Middle Aged,N,
30467,DescriptorName,D010446,8864370,,,13,Peptide Fragments,N,
30468,QualifierName,Q000097,8864370,,,13,,N,blood
30469,DescriptorName,D011347,8864370,,,14,Procollagen,N,
30470,QualifierName,Q000097,8864370,,,14,,N,blood
30471,DescriptorName,D011565,8864370,,,15,Psoriasis,N,
30472,QualifierName,Q000188,8864370,,,15,,N,drug therapy
30473,Chemical,D003408,8880251,Cresols,0,,,,
30474,Chemical,D009125,8880251,"Muscle Relaxants, Central",0,,,,
30475,Chemical,D002110,8880251,Caffeine,3G6A5W338E,,,,
30476,Chemical,D003620,8880251,Dantrolene,F64QU97QCR,,,,
30477,Chemical,C077977,8880251,cresol,GF3CGH8D7Z,,,,
30478,Chemical,D006221,8880251,Halothane,UQT9G45D1P,,,,
30479,DescriptorName,D000328,8880251,,,1,Adult,N,
30480,DescriptorName,D002110,8880251,,,2,Caffeine,N,
30481,DescriptorName,D003408,8880251,,,3,Cresols,N,
30482,QualifierName,Q000009,8880251,,,3,,N,adverse effects
30483,DescriptorName,D003620,8880251,,,4,Dantrolene,N,
30484,QualifierName,Q000627,8880251,,,4,,N,therapeutic use
30485,DescriptorName,D003926,8880251,,,5,Diabetic Coma,N,
30486,QualifierName,Q000150,8880251,,,5,,N,complications
30487,DescriptorName,D016883,8880251,,,6,Diabetic Ketoacidosis,N,
30488,QualifierName,Q000150,8880251,,,6,,Y,complications
30489,DescriptorName,D005334,8880251,,,7,Fever,N,
30490,QualifierName,Q000188,8880251,,,7,,N,drug therapy
30491,DescriptorName,D006221,8880251,,,8,Halothane,N,
30492,DescriptorName,D006801,8880251,,,9,Humans,N,
30493,DescriptorName,D008297,8880251,,,10,Male,N,
30494,DescriptorName,D009125,8880251,,,11,"Muscle Relaxants, Central",N,
30495,QualifierName,Q000627,8880251,,,11,,N,therapeutic use
30496,Chemical,D000335,889156,Aerosol Propellants,0,,,,
30497,Chemical,D000336,889156,Aerosols,0,,,,
30498,Chemical,D009829,889156,Oleic Acids,0,,,,
30499,Chemical,D001507,889156,Beclomethasone,KGZ1SLC28Z,,,,
30500,DescriptorName,D000335,889156,,,1,Aerosol Propellants,N,
30501,QualifierName,Q000009,889156,,,1,,N,adverse effects
30502,DescriptorName,D000336,889156,,,2,Aerosols,N,
30503,DescriptorName,D000368,889156,,,3,Aged,N,
30504,DescriptorName,D001249,889156,,,4,Asthma,N,
30505,QualifierName,Q000150,889156,,,4,,Y,complications
30506,DescriptorName,D001507,889156,,,5,Beclomethasone,N,
30507,QualifierName,Q000008,889156,,,5,,N,administration & dosage
30508,DescriptorName,D005260,889156,,,6,Female,N,
30509,DescriptorName,D006801,889156,,,7,Humans,N,
30510,DescriptorName,D009829,889156,,,8,Oleic Acids,N,
30511,QualifierName,Q000009,889156,,,8,,N,adverse effects
30512,DescriptorName,D011657,889156,,,9,Pulmonary Eosinophilia,N,
30513,QualifierName,Q000209,889156,,,9,,Y,etiology
30514,Chemical,D000970,8891729,Antineoplastic Agents,0,,,,
30515,Chemical,D007166,8891729,Immunosuppressive Agents,0,,,,
30516,Chemical,D014740,8891729,Vidarabine,FA2DM6879K,,,,
30517,Chemical,C024352,8891729,fludarabine,P2K93U8740,,,,
30518,DescriptorName,D000368,8891729,,,1,Aged,N,
30519,DescriptorName,D000744,8891729,,,2,"Anemia, Hemolytic, Autoimmune",N,
30520,QualifierName,Q000139,8891729,,,2,,Y,chemically induced
30521,DescriptorName,D000970,8891729,,,3,Antineoplastic Agents,N,
30522,QualifierName,Q000009,8891729,,,3,,Y,adverse effects
30523,DescriptorName,D017809,8891729,,,4,Fatal Outcome,N,
30524,DescriptorName,D006801,8891729,,,5,Humans,N,
30525,DescriptorName,D007166,8891729,,,6,Immunosuppressive Agents,N,
30526,QualifierName,Q000009,8891729,,,6,,Y,adverse effects
30527,DescriptorName,D015451,8891729,,,7,"Leukemia, Lymphocytic, Chronic, B-Cell",N,
30528,QualifierName,Q000150,8891729,,,7,,N,complications
30529,DescriptorName,D008297,8891729,,,8,Male,N,
30530,DescriptorName,D014740,8891729,,,9,Vidarabine,N,
30531,QualifierName,Q000009,8891729,,,9,,N,adverse effects
30532,Chemical,D000900,8903300,Anti-Bacterial Agents,0,,,,
30533,Chemical,D014031,8903300,Tobramycin,VZ8RRZ51VK,,,,
30534,DescriptorName,D017088,8903300,,,1,AIDS-Related Opportunistic Infections,N,
30535,QualifierName,Q000188,8903300,,,1,,Y,drug therapy
30536,DescriptorName,D000900,8903300,,,2,Anti-Bacterial Agents,N,
30537,QualifierName,Q000009,8903300,,,2,,Y,adverse effects
30538,DescriptorName,D001987,8903300,,,3,Bronchiectasis,N,
30539,QualifierName,Q000188,8903300,,,3,,Y,drug therapy
30540,DescriptorName,D002648,8903300,,,4,Child,N,
30541,DescriptorName,D016903,8903300,,,5,Drug Monitoring,N,
30542,DescriptorName,D005260,8903300,,,6,Female,N,
30543,DescriptorName,D006801,8903300,,,7,Humans,N,
30544,DescriptorName,D006996,8903300,,,8,Hypocalcemia,N,
30545,QualifierName,Q000139,8903300,,,8,,N,chemically induced
30546,DescriptorName,D007008,8903300,,,9,Hypokalemia,N,
30547,QualifierName,Q000139,8903300,,,9,,N,chemically induced
30548,DescriptorName,D007674,8903300,,,10,Kidney Diseases,N,
30549,QualifierName,Q000139,8903300,,,10,,N,chemically induced
30550,DescriptorName,D008275,8903300,,,11,Magnesium Deficiency,N,
30551,QualifierName,Q000139,8903300,,,11,,N,chemically induced
30552,DescriptorName,D011552,8903300,,,12,Pseudomonas Infections,N,
30553,QualifierName,Q000188,8903300,,,12,,Y,drug therapy
30554,DescriptorName,D013746,8903300,,,13,Tetany,N,
30555,QualifierName,Q000139,8903300,,,13,,Y,chemically induced
30556,DescriptorName,D014031,8903300,,,14,Tobramycin,N,
30557,QualifierName,Q000009,8903300,,,14,,Y,adverse effects
30558,Chemical,D016207,8908396,Cytokines,0,,,,
30559,Chemical,D007328,8908396,Insulin,0,,,,
30560,Chemical,D015850,8908396,Interleukin-6,0,,,,
30561,Chemical,D014409,8908396,Tumor Necrosis Factor-alpha,0,,,,
30562,DescriptorName,D017667,8908396,,,1,Adipocytes,N,
30563,QualifierName,Q000187,8908396,,,1,,N,drug effects
30564,DescriptorName,D000273,8908396,,,2,Adipose Tissue,N,
30565,QualifierName,Q000187,8908396,,,2,,N,drug effects
30566,DescriptorName,D000328,8908396,,,3,Adult,N,
30567,DescriptorName,D001284,8908396,,,4,Atrophy,N,
30568,DescriptorName,D002454,8908396,,,5,Cell Differentiation,N,
30569,DescriptorName,D016207,8908396,,,6,Cytokines,N,
30570,QualifierName,Q000096,8908396,,,6,,N,biosynthesis
30571,DescriptorName,D003922,8908396,,,7,"Diabetes Mellitus, Type 1",N,
30572,QualifierName,Q000188,8908396,,,7,,Y,drug therapy
30573,DescriptorName,D005260,8908396,,,8,Female,N,
30574,DescriptorName,D006801,8908396,,,9,Humans,N,
30575,DescriptorName,D007328,8908396,,,10,Insulin,N,
30576,QualifierName,Q000009,8908396,,,10,,Y,adverse effects
30577,DescriptorName,D015850,8908396,,,11,Interleukin-6,N,
30578,QualifierName,Q000096,8908396,,,11,,N,biosynthesis
30579,DescriptorName,D008213,8908396,,,12,Lymphocyte Activation,N,
30580,DescriptorName,D008214,8908396,,,13,Lymphocytes,N,
30581,QualifierName,Q000276,8908396,,,13,,N,immunology
30582,DescriptorName,D012016,8908396,,,14,Reference Values,N,
30583,DescriptorName,D014409,8908396,,,15,Tumor Necrosis Factor-alpha,N,
30584,QualifierName,Q000096,8908396,,,15,,N,biosynthesis
30585,Chemical,D003879,8912599,Dermatologic Agents,0,,,,
30586,Chemical,D008727,8912599,Methotrexate,YL5FZ2Y5U1,,,,
30587,DescriptorName,D000328,8912599,,,1,Adult,N,
30588,DescriptorName,D003879,8912599,,,2,Dermatologic Agents,N,
30589,QualifierName,Q000009,8912599,,,2,,Y,adverse effects
30590,DescriptorName,D003875,8912599,,,3,Drug Eruptions,N,
30591,QualifierName,Q000209,8912599,,,3,,Y,etiology
30592,DescriptorName,D005260,8912599,,,4,Female,N,
30593,DescriptorName,D006801,8912599,,,5,Humans,N,
30594,DescriptorName,D008727,8912599,,,6,Methotrexate,N,
30595,QualifierName,Q000009,8912599,,,6,,Y,adverse effects
30596,DescriptorName,D008875,8912599,,,7,Middle Aged,N,
30597,DescriptorName,D011565,8912599,,,8,Psoriasis,N,
30598,QualifierName,Q000150,8912599,,,8,,Y,complications
30599,Chemical,D006635,8921647,Histamine H2 Antagonists,0,,,,
30600,Chemical,D014665,8921647,Vasodilator Agents,0,,,,
30601,Chemical,D002927,8921647,Cimetidine,80061L1WGD,,,,
30602,Chemical,D014043,8921647,Tolazoline,CHH9H12AQ3,,,,
30603,DescriptorName,D002927,8921647,,,1,Cimetidine,N,
30604,QualifierName,Q000009,8921647,,,1,,Y,adverse effects
30605,DescriptorName,D004347,8921647,,,2,Drug Interactions,N,
30606,DescriptorName,D006471,8921647,,,3,Gastrointestinal Hemorrhage,N,
30607,QualifierName,Q000517,8921647,,,3,,Y,prevention & control
30608,DescriptorName,D006635,8921647,,,4,Histamine H2 Antagonists,N,
30609,QualifierName,Q000009,8921647,,,4,,Y,adverse effects
30610,DescriptorName,D006801,8921647,,,5,Humans,N,
30611,DescriptorName,D007231,8921647,,,6,"Infant, Newborn",N,
30612,DescriptorName,D008297,8921647,,,7,Male,N,
30613,DescriptorName,D010547,8921647,,,8,Persistent Fetal Circulation Syndrome,N,
30614,QualifierName,Q000188,8921647,,,8,,Y,drug therapy
30615,DescriptorName,D014043,8921647,,,9,Tolazoline,N,
30616,QualifierName,Q000009,8921647,,,9,,Y,adverse effects
30617,DescriptorName,D014665,8921647,,,10,Vasodilator Agents,N,
30618,QualifierName,Q000009,8921647,,,10,,Y,adverse effects
30619,Chemical,D006993,8926752,Hypnotics and Sedatives,0,,,,
30620,Chemical,D009294,8926752,Narcotics,0,,,,
30621,Chemical,D011725,8926752,Pyridines,0,,,,
30622,Chemical,D006853,8926752,Hydrocodone,6YKS4Y3WQ7,,,,
30623,Chemical,D009020,8926752,Morphine,76I7G6D29C,,,,
30624,Chemical,D000077334,8926752,Zolpidem,7K383OQI23,,,,
30625,DescriptorName,D000284,8926752,,,1,"Administration, Oral",N,
30626,DescriptorName,D000328,8926752,,,2,Adult,N,
30627,DescriptorName,D003863,8926752,,,3,Depression,N,
30628,QualifierName,Q000188,8926752,,,3,,N,drug therapy
30629,DescriptorName,D062787,8926752,,,4,Drug Overdose,Y,
30630,DescriptorName,D017809,8926752,,,5,Fatal Outcome,N,
30631,DescriptorName,D008401,8926752,,,6,Gas Chromatography-Mass Spectrometry,N,
30632,DescriptorName,D005766,8926752,,,7,Gastrointestinal Contents,N,
30633,QualifierName,Q000187,8926752,,,7,,N,drug effects
30634,DescriptorName,D006801,8926752,,,8,Humans,N,
30635,DescriptorName,D006853,8926752,,,9,Hydrocodone,N,
30636,QualifierName,Q000009,8926752,,,9,,N,adverse effects
30637,DescriptorName,D006993,8926752,,,10,Hypnotics and Sedatives,N,
30638,QualifierName,Q000009,8926752,,,10,,Y,adverse effects
30639,DescriptorName,D008099,8926752,,,11,Liver,N,
30640,QualifierName,Q000187,8926752,,,11,,N,drug effects
30641,DescriptorName,D008297,8926752,,,12,Male,N,
30642,DescriptorName,D009020,8926752,,,13,Morphine,N,
30643,QualifierName,Q000009,8926752,,,13,,N,adverse effects
30644,DescriptorName,D009294,8926752,,,14,Narcotics,N,
30645,QualifierName,Q000009,8926752,,,14,,N,adverse effects
30646,DescriptorName,D009765,8926752,,,15,Obesity,N,
30647,DescriptorName,D011725,8926752,,,16,Pyridines,N,
30648,QualifierName,Q000009,8926752,,,16,,Y,adverse effects
30649,DescriptorName,D007319,8926752,,,17,Sleep Initiation and Maintenance Disorders,N,
30650,QualifierName,Q000188,8926752,,,17,,N,drug therapy
30651,DescriptorName,D000077334,8926752,,,18,Zolpidem,N,
30652,Chemical,D000931,8933322,Antidotes,0,,,,
30653,Chemical,D008751,8933322,Methylene Blue,T42P99266K,,,,
30654,DescriptorName,D000931,8933322,,,1,Antidotes,N,
30655,QualifierName,Q000627,8933322,,,1,,N,therapeutic use
30656,DescriptorName,D001505,8933322,,,2,Beauty Culture,N,
30657,DescriptorName,D004630,8933322,,,3,Emergencies,N,
30658,DescriptorName,D006795,8933322,,,4,Household Products,N,
30659,QualifierName,Q000506,8933322,,,4,,Y,poisoning
30660,DescriptorName,D006801,8933322,,,5,Humans,N,
30661,DescriptorName,D007223,8933322,,,6,Infant,N,
30662,DescriptorName,D008297,8933322,,,7,Male,N,
30663,DescriptorName,D008708,8933322,,,8,Methemoglobinemia,N,
30664,QualifierName,Q000188,8933322,,,8,,N,drug therapy
30665,DescriptorName,D008751,8933322,,,9,Methylene Blue,N,
30666,QualifierName,Q000627,8933322,,,9,,N,therapeutic use
30667,DescriptorName,D010092,8933322,,,10,Oximetry,N,
30668,Chemical,D000319,8936932,Adrenergic beta-Antagonists,0,,,,
30669,Chemical,D011412,8936932,Propanolamines,0,,,,
30670,Chemical,D002122,8936932,Calcium Chloride,M4I0D6VV5M,,,,
30671,Chemical,C036604,8936932,esmolol,MDY902UXSR,,,,
30672,DescriptorName,D000319,8936932,,,1,Adrenergic beta-Antagonists,N,
30673,QualifierName,Q000009,8936932,,,1,,Y,adverse effects
30674,DescriptorName,D000758,8936932,,,2,Anesthesia,N,
30675,QualifierName,Q000009,8936932,,,2,,N,adverse effects
30676,DescriptorName,D002122,8936932,,,3,Calcium Chloride,N,
30677,QualifierName,Q000627,8936932,,,3,,N,therapeutic use
30678,DescriptorName,D002648,8936932,,,4,Child,N,
30679,DescriptorName,D005260,8936932,,,5,Female,N,
30680,DescriptorName,D006323,8936932,,,6,Heart Arrest,N,
30681,QualifierName,Q000139,8936932,,,6,,Y,chemically induced
30682,DescriptorName,D006801,8936932,,,7,Humans,N,
30683,DescriptorName,D007431,8936932,,,8,Intraoperative Complications,N,
30684,QualifierName,Q000209,8936932,,,8,,Y,etiology
30685,DescriptorName,D008591,8936932,,,9,Meningomyelocele,N,
30686,QualifierName,Q000601,8936932,,,9,,N,surgery
30687,DescriptorName,D011412,8936932,,,10,Propanolamines,N,
30688,QualifierName,Q000009,8936932,,,10,,Y,adverse effects
30689,Chemical,D000319,8942269,Adrenergic beta-Antagonists,0,,,,
30690,Chemical,D001262,8942269,Atenolol,50VV3VW0TI,,,,
30691,DescriptorName,D000319,8942269,,,1,Adrenergic beta-Antagonists,N,
30692,QualifierName,Q000009,8942269,,,1,,Y,adverse effects
30693,DescriptorName,D000647,8942269,,,2,Amnesia,N,
30694,QualifierName,Q000139,8942269,,,2,,Y,chemically induced
30695,DescriptorName,D001262,8942269,,,3,Atenolol,N,
30696,QualifierName,Q000009,8942269,,,3,,Y,adverse effects
30697,DescriptorName,D003937,8942269,,,4,"Diagnosis, Differential",N,
30698,DescriptorName,D006801,8942269,,,5,Humans,N,
30699,DescriptorName,D006973,8942269,,,6,Hypertension,N,
30700,QualifierName,Q000188,8942269,,,6,,N,drug therapy
30701,DescriptorName,D008297,8942269,,,7,Male,N,
30702,DescriptorName,D008875,8942269,,,8,Middle Aged,N,
30703,Chemical,D000889,8949576,Anti-Arrhythmia Agents,0,,,,
30704,Chemical,D000893,8949576,Anti-Inflammatory Agents,0,,,,
30705,Chemical,D013956,8949576,Antithyroid Agents,0,,,,
30706,Chemical,D010472,8949576,Perchlorates,0,,,,
30707,Chemical,D017670,8949576,Sodium Compounds,0,,,,
30708,Chemical,C031068,8949576,sodium perchlorate,97F4MTY3VA,,,,
30709,Chemical,D008094,8949576,Lithium,9FN79X2M3F,,,,
30710,Chemical,D011239,8949576,Prednisolone,9PHQ9Y1OLM,,,,
30711,Chemical,D000638,8949576,Amiodarone,N3RQ532IUT,,,,
30712,DescriptorName,D000638,8949576,,,1,Amiodarone,N,
30713,QualifierName,Q000009,8949576,,,1,,Y,adverse effects
30714,DescriptorName,D000889,8949576,,,2,Anti-Arrhythmia Agents,N,
30715,QualifierName,Q000009,8949576,,,2,,Y,adverse effects
30716,DescriptorName,D000893,8949576,,,3,Anti-Inflammatory Agents,N,
30717,QualifierName,Q000627,8949576,,,3,,N,therapeutic use
30718,DescriptorName,D013956,8949576,,,4,Antithyroid Agents,N,
30719,QualifierName,Q000627,8949576,,,4,,N,therapeutic use
30720,DescriptorName,D017809,8949576,,,5,Fatal Outcome,N,
30721,DescriptorName,D006801,8949576,,,6,Humans,N,
30722,DescriptorName,D008094,8949576,,,7,Lithium,N,
30723,QualifierName,Q000627,8949576,,,7,,N,therapeutic use
30724,DescriptorName,D008297,8949576,,,8,Male,N,
30725,DescriptorName,D008875,8949576,,,9,Middle Aged,N,
30726,DescriptorName,D010472,8949576,,,10,Perchlorates,N,
30727,QualifierName,Q000627,8949576,,,10,,N,therapeutic use
30728,DescriptorName,D010956,8949576,,,11,Plasmapheresis,N,
30729,DescriptorName,D011239,8949576,,,12,Prednisolone,N,
30730,QualifierName,Q000627,8949576,,,12,,N,therapeutic use
30731,DescriptorName,D017670,8949576,,,13,Sodium Compounds,N,
30732,QualifierName,Q000627,8949576,,,13,,N,therapeutic use
30733,DescriptorName,D013958,8949576,,,14,Thyroid Crisis,N,
30734,QualifierName,Q000139,8949576,,,14,,Y,chemically induced
30735,DescriptorName,D013966,8949576,,,15,Thyroiditis,N,
30736,QualifierName,Q000139,8949576,,,15,,Y,chemically induced
30737,Chemical,D000995,8961730,Antitubercular Agents,0,,,,
30738,Chemical,D007538,8961730,Isoniazid,V83O1VOZ8L,,,,
30739,DescriptorName,D000328,8961730,,,1,Adult,N,
30740,DescriptorName,D000995,8961730,,,2,Antitubercular Agents,N,
30741,QualifierName,Q000009,8961730,,,2,,Y,adverse effects
30742,DescriptorName,D006801,8961730,,,3,Humans,N,
30743,DescriptorName,D007538,8961730,,,4,Isoniazid,N,
30744,QualifierName,Q000009,8961730,,,4,,Y,adverse effects
30745,DescriptorName,D008297,8961730,,,5,Male,N,
30746,DescriptorName,D011605,8961730,,,6,"Psychoses, Substance-Induced",N,
30747,QualifierName,Q000209,8961730,,,6,,Y,etiology
30748,DescriptorName,D014376,8961730,,,7,Tuberculosis,N,
30749,QualifierName,Q000188,8961730,,,7,,N,drug therapy
30750,Chemical,D006494,8969033,Heparin Antagonists,0,,,,
30751,Chemical,D011479,8969033,Protamines,0,,,,
30752,Chemical,D012702,8969033,Serotonin Antagonists,0,,,,
30753,Chemical,D007650,8969033,Ketanserin,97F9DE4CT4,,,,
30754,DescriptorName,D000368,8969033,,,1,Aged,N,
30755,DescriptorName,D001026,8969033,,,2,Coronary Artery Bypass,N,
30756,DescriptorName,D006350,8969033,,,3,Heart Valve Prosthesis,N,
30757,DescriptorName,D006494,8969033,,,4,Heparin Antagonists,N,
30758,QualifierName,Q000009,8969033,,,4,,Y,adverse effects
30759,DescriptorName,D006801,8969033,,,5,Humans,N,
30760,DescriptorName,D006976,8969033,,,6,"Hypertension, Pulmonary",N,
30761,QualifierName,Q000139,8969033,,,6,,Y,chemically induced
30762,DescriptorName,D007650,8969033,,,7,Ketanserin,N,
30763,QualifierName,Q000627,8969033,,,7,,Y,therapeutic use
30764,DescriptorName,D008297,8969033,,,8,Male,N,
30765,DescriptorName,D008944,8969033,,,9,Mitral Valve Insufficiency,N,
30766,QualifierName,Q000601,8969033,,,9,,N,surgery
30767,DescriptorName,D011479,8969033,,,10,Protamines,N,
30768,QualifierName,Q000009,8969033,,,10,,Y,adverse effects
30769,DescriptorName,D012702,8969033,,,11,Serotonin Antagonists,N,
30770,QualifierName,Q000627,8969033,,,11,,Y,therapeutic use
30771,Chemical,D008712,897744,Methicillin,Q91FH1328A,,,,
30772,DescriptorName,D000328,897744,,,1,Adult,N,
30773,DescriptorName,D004697,897744,,,2,"Endocarditis, Bacterial",N,
30774,QualifierName,Q000188,897744,,,2,,N,drug therapy
30775,DescriptorName,D005921,897744,,,3,Glomerulonephritis,N,
30776,QualifierName,Q000139,897744,,,3,,Y,chemically induced
30777,DescriptorName,D006556,897744,,,4,Heroin Dependence,N,
30778,QualifierName,Q000150,897744,,,4,,Y,complications
30779,DescriptorName,D006801,897744,,,5,Humans,N,
30780,DescriptorName,D008297,897744,,,6,Male,N,
30781,DescriptorName,D008712,897744,,,7,Methicillin,N,
30782,QualifierName,Q000009,897744,,,7,,Y,adverse effects
30783,DescriptorName,D009395,897744,,,8,"Nephritis, Interstitial",N,
30784,QualifierName,Q000139,897744,,,8,,Y,chemically induced
30785,DescriptorName,D009404,897744,,,9,Nephrotic Syndrome,N,
30786,QualifierName,Q000139,897744,,,9,,N,chemically induced
30787,DescriptorName,D011507,897744,,,10,Proteinuria,N,
30788,QualifierName,Q000139,897744,,,10,,N,chemically induced
30789,DescriptorName,D013203,897744,,,11,Staphylococcal Infections,Y,
30790,QualifierName,Q000188,897744,,,11,,N,drug therapy
30791,Chemical,D000904,8979664,"Antibiotics, Antitubercular",0,,,,
30792,Chemical,D017828,8979664,Rifabutin,1W306TDA6S,,,,
30793,DescriptorName,D017088,8979664,,,1,AIDS-Related Opportunistic Infections,N,
30794,QualifierName,Q000188,8979664,,,1,,Y,drug therapy
30795,DescriptorName,D000328,8979664,,,2,Adult,N,
30796,DescriptorName,D000904,8979664,,,3,"Antibiotics, Antitubercular",N,
30797,QualifierName,Q000009,8979664,,,3,,Y,adverse effects
30798,DescriptorName,D018791,8979664,,,4,CD4 Lymphocyte Count,N,
30799,DescriptorName,D005654,8979664,,,5,Fundus Oculi,N,
30800,DescriptorName,D006801,8979664,,,6,Humans,N,
30801,DescriptorName,D008297,8979664,,,7,Male,N,
30802,DescriptorName,D015270,8979664,,,8,Mycobacterium avium-intracellulare Infection,N,
30803,QualifierName,Q000188,8979664,,,8,,Y,drug therapy
30804,DescriptorName,D017828,8979664,,,9,Rifabutin,N,
30805,QualifierName,Q000009,8979664,,,9,,Y,adverse effects
30806,DescriptorName,D014606,8979664,,,10,"Uveitis, Anterior",N,
30807,QualifierName,Q000139,8979664,,,10,,Y,chemically induced
30808,DescriptorName,D014792,8979664,,,11,Visual Acuity,N,
30809,Chemical,D000980,8996514,Antiplatyhelmintic Agents,0,,,,
30810,Chemical,D011223,8996514,Praziquantel,6490C9U457,,,,
30811,DescriptorName,D000980,8996514,,,1,Antiplatyhelmintic Agents,N,
30812,QualifierName,Q000009,8996514,,,1,,Y,adverse effects
30813,DescriptorName,D001479,8996514,,,2,Basal Ganglia,N,
30814,QualifierName,Q000000981,8996514,,,2,,N,diagnostic imaging
30815,DescriptorName,D001927,8996514,,,3,Brain Diseases,N,
30816,QualifierName,Q000188,8996514,,,3,,N,drug therapy
30817,DescriptorName,D002343,8996514,,,4,"Carotid Artery, Internal",N,
30818,QualifierName,Q000000981,8996514,,,4,,N,diagnostic imaging
30819,DescriptorName,D002533,8996514,,,5,Cerebral Angiography,N,
30820,DescriptorName,D002544,8996514,,,6,Cerebral Infarction,N,
30821,QualifierName,Q000175,8996514,,,6,,N,diagnosis
30822,DescriptorName,D003551,8996514,,,7,Cysticercosis,N,
30823,QualifierName,Q000188,8996514,,,7,,Y,drug therapy
30824,DescriptorName,D006801,8996514,,,8,Humans,N,
30825,DescriptorName,D007249,8996514,,,9,Inflammation,N,
30826,DescriptorName,D008279,8996514,,,10,Magnetic Resonance Imaging,N,
30827,DescriptorName,D008297,8996514,,,11,Male,N,
30828,DescriptorName,D008636,8996514,,,12,Mesencephalon,N,
30829,QualifierName,Q000473,8996514,,,12,,N,pathology
30830,DescriptorName,D008875,8996514,,,13,Middle Aged,N,
30831,DescriptorName,D010296,8996514,,,14,Parietal Lobe,N,
30832,QualifierName,Q000000981,8996514,,,14,,N,diagnostic imaging
30833,DescriptorName,D011223,8996514,,,15,Praziquantel,N,
30834,QualifierName,Q000009,8996514,,,15,,Y,adverse effects
30835,DescriptorName,D014057,8996514,,,16,"Tomography, X-Ray Computed",N,
30836,Chemical,D000964,9007910,"Antimetabolites, Antineoplastic",0,,,,
30837,Chemical,D010088,9007910,Oxidoreductases,EC 1.-,,,,
30838,Chemical,D042943,9007910,Dihydrouracil Dehydrogenase (NADP),EC 1.3.1.2,,,,
30839,Chemical,D005472,9007910,Fluorouracil,U3P01618RT,,,,
30840,DescriptorName,D000328,9007910,,,1,Adult,N,
30841,DescriptorName,D000964,9007910,,,2,"Antimetabolites, Antineoplastic",N,
30842,QualifierName,Q000009,9007910,,,2,,Y,adverse effects
30843,DescriptorName,D006528,9007910,,,3,"Carcinoma, Hepatocellular",N,
30844,QualifierName,Q000188,9007910,,,3,,N,drug therapy
30845,DescriptorName,D042943,9007910,,,4,Dihydrouracil Dehydrogenase (NADP),N,
30846,DescriptorName,D005260,9007910,,,5,Female,N,
30847,DescriptorName,D005472,9007910,,,6,Fluorouracil,N,
30848,QualifierName,Q000009,9007910,,,6,,Y,adverse effects
30849,DescriptorName,D006801,9007910,,,7,Humans,N,
30850,DescriptorName,D008113,9007910,,,8,Liver Neoplasms,N,
30851,QualifierName,Q000188,9007910,,,8,,N,drug therapy
30852,DescriptorName,D008297,9007910,,,9,Male,N,
30853,DescriptorName,D008661,9007910,,,10,"Metabolism, Inborn Errors",N,
30854,QualifierName,Q000150,9007910,,,10,,Y,complications
30855,DescriptorName,D008875,9007910,,,11,Middle Aged,N,
30856,DescriptorName,D009369,9007910,,,12,Neoplasms,N,
30857,QualifierName,Q000188,9007910,,,12,,Y,drug therapy
30858,DescriptorName,D010088,9007910,,,13,Oxidoreductases,N,
30859,QualifierName,Q000172,9007910,,,13,,Y,deficiency
30860,DescriptorName,D010997,9007910,,,14,Pleural Neoplasms,N,
30861,QualifierName,Q000188,9007910,,,14,,N,drug therapy
30862,DescriptorName,D012720,9007910,,,15,Severity of Illness Index,N,
30863,Chemical,D000636,9013348,Aminosalicylic Acids,0,,,,
30864,Chemical,D000894,9013348,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
30865,Chemical,D019804,9013348,Mesalamine,4Q81I59GXC,,,,
30866,DescriptorName,D000542,9013348,,,1,"Alveolitis, Extrinsic Allergic",N,
30867,QualifierName,Q000139,9013348,,,1,,Y,chemically induced
30868,DescriptorName,D000636,9013348,,,2,Aminosalicylic Acids,N,
30869,QualifierName,Q000009,9013348,,,2,,Y,adverse effects
30870,DescriptorName,D000894,9013348,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
30871,QualifierName,Q000009,9013348,,,3,,Y,adverse effects
30872,DescriptorName,D004342,9013348,,,4,Drug Hypersensitivity,N,
30873,QualifierName,Q000175,9013348,,,4,,N,diagnosis
30874,DescriptorName,D006801,9013348,,,5,Humans,N,
30875,DescriptorName,D015212,9013348,,,6,Inflammatory Bowel Diseases,N,
30876,QualifierName,Q000188,9013348,,,6,,N,drug therapy
30877,DescriptorName,D008297,9013348,,,7,Male,N,
30878,DescriptorName,D019804,9013348,,,8,Mesalamine,N,
30879,DescriptorName,D008875,9013348,,,9,Middle Aged,N,
30880,Chemical,D007306,9017913,Insecticides,0,,,,
30881,Chemical,D014052,9017913,Toluidines,0,,,,
30882,Chemical,C014983,9017913,amitraz,33IAH5017S,,,,
30883,Chemical,D007559,9017913,Ivermectin,70288-86-7,,,,
30884,Chemical,D011239,9017913,Prednisolone,9PHQ9Y1OLM,,,,
30885,DescriptorName,D000818,9017913,,,1,Animals,N,
30886,DescriptorName,D004283,9017913,,,2,Dog Diseases,N,
30887,QualifierName,Q000188,9017913,,,2,,N,drug therapy
30888,DescriptorName,D004285,9017913,,,3,Dogs,N,
30889,DescriptorName,D005260,9017913,,,4,Female,N,
30890,DescriptorName,D016867,9017913,,,5,Immunocompromised Host,N,
30891,DescriptorName,D007165,9017913,,,6,Immunosuppression,N,
30892,DescriptorName,D007306,9017913,,,7,Insecticides,N,
30893,QualifierName,Q000008,9017913,,,7,,N,administration & dosage
30894,DescriptorName,D007559,9017913,,,8,Ivermectin,N,
30895,QualifierName,Q000008,9017913,,,8,,N,administration & dosage
30896,DescriptorName,D008924,9017913,,,9,Mite Infestations,N,
30897,QualifierName,Q000188,9017913,,,9,,N,drug therapy
30898,DescriptorName,D008925,9017913,,,10,Mites,N,
30899,QualifierName,Q000648,9017913,,,10,,N,ultrastructure
30900,DescriptorName,D011239,9017913,,,11,Prednisolone,N,
30901,QualifierName,Q000009,9017913,,,11,,N,adverse effects
30902,DescriptorName,D014052,9017913,,,12,Toluidines,N,
30903,QualifierName,Q000008,9017913,,,12,,N,administration & dosage
30904,Chemical,D000900,9022114,Anti-Bacterial Agents,0,,,,
30905,Chemical,D018501,9022114,Antirheumatic Agents,0,,,,
30906,Chemical,D005839,9022114,Gentamicins,0,,,,
30907,Chemical,D005938,9022114,Glucocorticoids,0,,,,
30908,Chemical,D003078,9022114,Colchicine,SML2Y3J35T,,,,
30909,Chemical,D011241,9022114,Prednisone,VB0R961HZT,,,,
30910,DescriptorName,D000368,9022114,,,1,Aged,N,
30911,DescriptorName,D000369,9022114,,,2,"Aged, 80 and over",N,
30912,DescriptorName,D000900,9022114,,,3,Anti-Bacterial Agents,N,
30913,QualifierName,Q000627,9022114,,,3,,N,therapeutic use
30914,DescriptorName,D018501,9022114,,,4,Antirheumatic Agents,N,
30915,QualifierName,Q000009,9022114,,,4,,Y,adverse effects
30916,DescriptorName,D001172,9022114,,,5,"Arthritis, Rheumatoid",N,
30917,QualifierName,Q000188,9022114,,,5,,N,drug therapy
30918,DescriptorName,D003078,9022114,,,6,Colchicine,N,
30919,QualifierName,Q000009,9022114,,,6,,Y,adverse effects
30920,DescriptorName,D003315,9022114,,,7,Cornea,N,
30921,QualifierName,Q000187,9022114,,,7,,N,drug effects
30922,DescriptorName,D003320,9022114,,,8,Corneal Ulcer,N,
30923,QualifierName,Q000188,9022114,,,8,,N,drug therapy
30924,DescriptorName,D005260,9022114,,,9,Female,N,
30925,DescriptorName,D005839,9022114,,,10,Gentamicins,N,
30926,QualifierName,Q000627,9022114,,,10,,N,therapeutic use
30927,DescriptorName,D005938,9022114,,,11,Glucocorticoids,N,
30928,QualifierName,Q000627,9022114,,,11,,N,therapeutic use
30929,DescriptorName,D006801,9022114,,,12,Humans,N,
30930,DescriptorName,D011241,9022114,,,13,Prednisone,N,
30931,QualifierName,Q000627,9022114,,,13,,N,therapeutic use
30932,DescriptorName,D014945,9022114,,,14,Wound Healing,N,
30933,QualifierName,Q000187,9022114,,,14,,Y,drug effects
30934,Chemical,D000726,9037299,Androgen Antagonists,0,,,,
30935,Chemical,D000813,9037299,Anilides,0,,,,
30936,Chemical,D009570,9037299,Nitriles,0,,,,
30937,Chemical,D014105,9037299,Tosyl Compounds,0,,,,
30938,Chemical,C053541,9037299,bicalutamide,A0Z3NAU9DP,,,,
30939,DescriptorName,D000230,9037299,,,1,Adenocarcinoma,N,
30940,QualifierName,Q000188,9037299,,,1,,N,drug therapy
30941,DescriptorName,D000726,9037299,,,2,Androgen Antagonists,N,
30942,QualifierName,Q000009,9037299,,,2,,Y,adverse effects
30943,DescriptorName,D000813,9037299,,,3,Anilides,N,
30944,QualifierName,Q000009,9037299,,,3,,Y,adverse effects
30945,DescriptorName,D006501,9037299,,,4,Hepatic Encephalopathy,N,
30946,QualifierName,Q000139,9037299,,,4,,Y,chemically induced
30947,DescriptorName,D006801,9037299,,,5,Humans,N,
30948,DescriptorName,D008297,9037299,,,6,Male,N,
30949,DescriptorName,D008875,9037299,,,7,Middle Aged,N,
30950,DescriptorName,D009570,9037299,,,8,Nitriles,N,
30951,DescriptorName,D011471,9037299,,,9,Prostatic Neoplasms,N,
30952,QualifierName,Q000188,9037299,,,9,,N,drug therapy
30953,DescriptorName,D014105,9037299,,,10,Tosyl Compounds,N,
30954,Chemical,D000900,9039216,Anti-Bacterial Agents,0,,,,
30955,Chemical,D008911,9039216,Minocycline,FYY3R43WGO,,,,
30956,DescriptorName,D000152,9039216,,,1,Acne Vulgaris,N,
30957,QualifierName,Q000188,9039216,,,1,,N,drug therapy
30958,DescriptorName,D000293,9039216,,,2,Adolescent,N,
30959,DescriptorName,D000900,9039216,,,3,Anti-Bacterial Agents,N,
30960,QualifierName,Q000009,9039216,,,3,,Y,adverse effects
30961,DescriptorName,D056486,9039216,,,4,Chemical and Drug Induced Liver Injury,N,
30962,QualifierName,Q000209,9039216,,,4,,Y,etiology
30963,DescriptorName,D003875,9039216,,,5,Drug Eruptions,N,
30964,QualifierName,Q000209,9039216,,,5,,Y,etiology
30965,DescriptorName,D004802,9039216,,,6,Eosinophilia,N,
30966,QualifierName,Q000139,9039216,,,6,,N,chemically induced
30967,DescriptorName,D005260,9039216,,,7,Female,N,
30968,DescriptorName,D005334,9039216,,,8,Fever,N,
30969,QualifierName,Q000139,9039216,,,8,,Y,chemically induced
30970,DescriptorName,D006402,9039216,,,9,Hematologic Diseases,N,
30971,QualifierName,Q000139,9039216,,,9,,Y,chemically induced
30972,DescriptorName,D006801,9039216,,,10,Humans,N,
30973,DescriptorName,D008218,9039216,,,11,Lymphocytosis,N,
30974,QualifierName,Q000139,9039216,,,11,,N,chemically induced
30975,DescriptorName,D008911,9039216,,,12,Minocycline,N,
30976,QualifierName,Q000009,9039216,,,12,,Y,adverse effects
30977,Chemical,D000894,9042097,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
30978,Chemical,D005480,9042097,Flurbiprofen,5GRO578KLP,,,,
30979,DescriptorName,D000328,9042097,,,1,Adult,N,
30980,DescriptorName,D000894,9042097,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
30981,QualifierName,Q000009,9042097,,,2,,Y,adverse effects
30982,DescriptorName,D003875,9042097,,,3,Drug Eruptions,N,
30983,QualifierName,Q000209,9042097,,,3,,Y,etiology
30984,DescriptorName,D005260,9042097,,,4,Female,N,
30985,DescriptorName,D005480,9042097,,,5,Flurbiprofen,N,
30986,QualifierName,Q000009,9042097,,,5,,Y,adverse effects
30987,DescriptorName,D006801,9042097,,,6,Humans,N,
30988,DescriptorName,D006968,9042097,,,7,"Hypersensitivity, Delayed",N,
30989,QualifierName,Q000139,9042097,,,7,,Y,chemically induced
30990,DescriptorName,D010328,9042097,,,8,Patch Tests,N,
30991,DescriptorName,D010612,9042097,,,9,Pharyngitis,N,
30992,QualifierName,Q000188,9042097,,,9,,N,drug therapy
30993,Chemical,D000998,9052919,Antiviral Agents,0,,,,
30994,Chemical,D007166,9052919,Immunosuppressive Agents,0,,,,
30995,Chemical,D016572,9052919,Cyclosporine,83HN0GTJ6D,,,,
30996,Chemical,D015774,9052919,Ganciclovir,P9G3CKZ4P5,,,,
30997,DescriptorName,D000010,9052919,,,1,Abducens Nerve,Y,
30998,DescriptorName,D000293,9052919,,,2,Adolescent,N,
30999,DescriptorName,D000328,9052919,,,3,Adult,N,
31000,DescriptorName,D000998,9052919,,,4,Antiviral Agents,N,
31001,QualifierName,Q000009,9052919,,,4,,Y,adverse effects
31002,DescriptorName,D001763,9052919,,,5,Blepharoptosis,N,
31003,QualifierName,Q000139,9052919,,,5,,Y,chemically induced
31004,DescriptorName,D016026,9052919,,,6,Bone Marrow Transplantation,Y,
31005,DescriptorName,D003389,9052919,,,7,Cranial Nerve Diseases,N,
31006,QualifierName,Q000139,9052919,,,7,,N,chemically induced
31007,DescriptorName,D016572,9052919,,,8,Cyclosporine,N,
31008,QualifierName,Q000009,9052919,,,8,,Y,adverse effects
31009,DescriptorName,D003586,9052919,,,9,Cytomegalovirus Infections,N,
31010,QualifierName,Q000188,9052919,,,9,,N,drug therapy
31011,DescriptorName,D004172,9052919,,,10,Diplopia,N,
31012,QualifierName,Q000139,9052919,,,10,,N,chemically induced
31013,DescriptorName,D005260,9052919,,,11,Female,N,
31014,DescriptorName,D015774,9052919,,,12,Ganciclovir,N,
31015,QualifierName,Q000009,9052919,,,12,,Y,adverse effects
31016,DescriptorName,D006086,9052919,,,13,Graft vs Host Disease,N,
31017,QualifierName,Q000517,9052919,,,13,,N,prevention & control
31018,DescriptorName,D006801,9052919,,,14,Humans,N,
31019,DescriptorName,D007166,9052919,,,15,Immunosuppressive Agents,N,
31020,QualifierName,Q000009,9052919,,,15,,Y,adverse effects
31021,DescriptorName,D007938,9052919,,,16,Leukemia,N,
31022,QualifierName,Q000628,9052919,,,16,,N,therapy
31023,DescriptorName,D008297,9052919,,,17,Male,N,
31024,DescriptorName,D009886,9052919,,,18,Ophthalmoplegia,N,
31025,QualifierName,Q000139,9052919,,,18,,Y,chemically induced
31026,DescriptorName,D014766,9052919,,,19,Viremia,N,
31027,QualifierName,Q000188,9052919,,,19,,N,drug therapy
31028,Chemical,D000925,9058350,Anticoagulants,0,,,,
31029,Chemical,D003692,9058350,Delayed-Action Preparations,0,,,,
31030,Chemical,D016729,9058350,Leuprolide,EFY6W0M8TG,,,,
31031,DescriptorName,D000328,9058350,,,1,Adult,N,
31032,DescriptorName,D000925,9058350,,,2,Anticoagulants,N,
31033,QualifierName,Q000627,9058350,,,2,,N,therapeutic use
31034,DescriptorName,D003692,9058350,,,3,Delayed-Action Preparations,N,
31035,DescriptorName,D005260,9058350,,,4,Female,N,
31036,DescriptorName,D006801,9058350,,,5,Humans,N,
31037,DescriptorName,D007889,9058350,,,6,Leiomyoma,N,
31038,QualifierName,Q000188,9058350,,,6,,Y,drug therapy
31039,DescriptorName,D016729,9058350,,,7,Leuprolide,N,
31040,QualifierName,Q000008,9058350,,,7,,N,administration & dosage
31041,DescriptorName,D008642,9058350,,,8,Mesenteric Veins,Y,
31042,DescriptorName,D011169,9058350,,,9,Portal Vein,Y,
31043,DescriptorName,D013927,9058350,,,10,Thrombosis,N,
31044,QualifierName,Q000139,9058350,,,10,,Y,chemically induced
31045,DescriptorName,D014594,9058350,,,11,Uterine Neoplasms,N,
31046,QualifierName,Q000188,9058350,,,11,,Y,drug therapy
31047,Chemical,D000970,9094821,Antineoplastic Agents,0,,,,
31048,Chemical,D013629,9094821,Tamoxifen,094ZI81Y45,,,,
31049,DescriptorName,D000291,9094821,,,1,Adnexal Diseases,N,
31050,QualifierName,Q000139,9094821,,,1,,Y,chemically induced
31051,DescriptorName,D000328,9094821,,,2,Adult,N,
31052,DescriptorName,D000970,9094821,,,3,Antineoplastic Agents,N,
31053,QualifierName,Q000009,9094821,,,3,,Y,adverse effects
31054,DescriptorName,D001943,9094821,,,4,Breast Neoplasms,N,
31055,QualifierName,Q000150,9094821,,,4,,N,complications
31056,DescriptorName,D003560,9094821,,,5,Cysts,N,
31057,QualifierName,Q000150,9094821,,,5,,N,complications
31058,DescriptorName,D016889,9094821,,,6,Endometrial Neoplasms,N,
31059,QualifierName,Q000150,9094821,,,6,,N,complications
31060,DescriptorName,D004715,9094821,,,7,Endometriosis,N,
31061,QualifierName,Q000139,9094821,,,7,,Y,chemically induced
31062,DescriptorName,D004717,9094821,,,8,Endometrium,N,
31063,QualifierName,Q000000981,9094821,,,8,,N,diagnostic imaging
31064,DescriptorName,D005260,9094821,,,9,Female,N,
31065,DescriptorName,D006801,9094821,,,10,Humans,N,
31066,DescriptorName,D007889,9094821,,,11,Leiomyoma,N,
31067,QualifierName,Q000150,9094821,,,11,,N,complications
31068,DescriptorName,D011247,9094821,,,12,Pregnancy,N,
31069,DescriptorName,D013629,9094821,,,13,Tamoxifen,N,
31070,QualifierName,Q000009,9094821,,,13,,Y,adverse effects
31071,DescriptorName,D014057,9094821,,,14,"Tomography, X-Ray Computed",N,
31072,DescriptorName,D014599,9094821,,,15,Uterus,N,
31073,QualifierName,Q000601,9094821,,,15,,N,surgery
31074,Chemical,D000316,9100429,Adrenergic alpha-Agonists,0,,,,
31075,Chemical,D003000,9100429,Clonidine,MN3L5RMN02,,,,
31076,DescriptorName,D000316,9100429,,,1,Adrenergic alpha-Agonists,N,
31077,QualifierName,Q000009,9100429,,,1,,Y,adverse effects
31078,DescriptorName,D001289,9100429,,,2,Attention Deficit Disorder with Hyperactivity,N,
31079,QualifierName,Q000188,9100429,,,2,,Y,drug therapy
31080,DescriptorName,D002648,9100429,,,3,Child,N,
31081,DescriptorName,D003000,9100429,,,4,Clonidine,N,
31082,QualifierName,Q000009,9100429,,,4,,Y,adverse effects
31083,DescriptorName,D017809,9100429,,,5,Fatal Outcome,N,
31084,DescriptorName,D005260,9100429,,,6,Female,N,
31085,DescriptorName,D006339,9100429,,,7,Heart Rate,N,
31086,QualifierName,Q000187,9100429,,,7,,N,drug effects
31087,DescriptorName,D006801,9100429,,,8,Humans,N,
31088,DescriptorName,D008297,9100429,,,9,Male,N,
31089,DescriptorName,D012640,9100429,,,10,Seizures,N,
31090,QualifierName,Q000139,9100429,,,10,,N,chemically induced
31091,DescriptorName,D013575,9100429,,,11,Syncope,N,
31092,QualifierName,Q000139,9100429,,,11,,N,chemically induced
31093,Chemical,D000092,910864,Acetohexamide,QGC8W08I6I,,,,
31094,DescriptorName,D000092,910864,,,1,Acetohexamide,N,
31095,QualifierName,Q000009,910864,,,1,,Y,adverse effects
31096,DescriptorName,D000328,910864,,,2,Adult,N,
31097,DescriptorName,D000368,910864,,,3,Aged,N,
31098,DescriptorName,D002387,910864,,,4,Cataract Extraction,N,
31099,DescriptorName,D006259,910864,,,5,Craniocerebral Trauma,N,
31100,QualifierName,Q000209,910864,,,5,,N,etiology
31101,DescriptorName,D004349,910864,,,6,Drug Packaging,N,
31102,QualifierName,Q000592,910864,,,6,,Y,standards
31103,DescriptorName,D005260,910864,,,7,Female,N,
31104,DescriptorName,D005901,910864,,,8,Glaucoma,N,
31105,QualifierName,Q000188,910864,,,8,,N,drug therapy
31106,DescriptorName,D006801,910864,,,9,Humans,N,
31107,DescriptorName,D007003,910864,,,10,Hypoglycemia,N,
31108,QualifierName,Q000139,910864,,,10,,N,chemically induced
31109,DescriptorName,D007429,910864,,,11,Intraocular Pressure,N,
31110,QualifierName,Q000187,910864,,,11,,N,drug effects
31111,DescriptorName,D008297,910864,,,12,Male,N,
31112,DescriptorName,D008508,910864,,,13,Medication Errors,Y,
31113,DescriptorName,D008875,910864,,,14,Middle Aged,N,
31114,Chemical,D000935,9111724,Antifungal Agents,0,,,,
31115,Chemical,D017964,9111724,Itraconazole,304NUG5GF4,,,,
31116,Chemical,D007654,9111724,Ketoconazole,R9400W927I,,,,
31117,DescriptorName,D000818,9111724,,,1,Animals,N,
31118,DescriptorName,D000935,9111724,,,2,Antifungal Agents,N,
31119,QualifierName,Q000009,9111724,,,2,,Y,adverse effects
31120,DescriptorName,D003047,9111724,,,3,Coccidioidomycosis,N,
31121,QualifierName,Q000188,9111724,,,3,,N,drug therapy
31122,DescriptorName,D004283,9111724,,,4,Dog Diseases,N,
31123,QualifierName,Q000139,9111724,,,4,,Y,chemically induced
31124,DescriptorName,D004285,9111724,,,5,Dogs,N,
31125,DescriptorName,D003875,9111724,,,6,Drug Eruptions,N,
31126,QualifierName,Q000209,9111724,,,6,,N,etiology
31127,DescriptorName,D005260,9111724,,,7,Female,N,
31128,DescriptorName,D017964,9111724,,,8,Itraconazole,N,
31129,QualifierName,Q000009,9111724,,,8,,Y,adverse effects
31130,DescriptorName,D007654,9111724,,,9,Ketoconazole,N,
31131,QualifierName,Q000627,9111724,,,9,,N,therapeutic use
31132,DescriptorName,D008198,9111724,,,10,Lymph Nodes,N,
31133,QualifierName,Q000473,9111724,,,10,,N,pathology
31134,DescriptorName,D012867,9111724,,,11,Skin,N,
31135,QualifierName,Q000473,9111724,,,11,,N,pathology
31136,Chemical,D000970,9128433,Antineoplastic Agents,0,,,,
31137,Chemical,D005938,9128433,Glucocorticoids,0,,,,
31138,Chemical,D014212,9128433,Tretinoin,5688UTC01R,,,,
31139,Chemical,D003907,9128433,Dexamethasone,7S5I7G3JQL,,,,
31140,DescriptorName,D000970,9128433,,,1,Antineoplastic Agents,N,
31141,QualifierName,Q000009,9128433,,,1,,Y,adverse effects
31142,DescriptorName,D003907,9128433,,,2,Dexamethasone,N,
31143,QualifierName,Q000627,9128433,,,2,,N,therapeutic use
31144,DescriptorName,D004417,9128433,,,3,Dyspnea,N,
31145,QualifierName,Q000139,9128433,,,3,,Y,chemically induced
31146,DescriptorName,D005938,9128433,,,4,Glucocorticoids,N,
31147,QualifierName,Q000627,9128433,,,4,,Y,therapeutic use
31148,DescriptorName,D006801,9128433,,,5,Humans,N,
31149,DescriptorName,D015473,9128433,,,6,"Leukemia, Promyelocytic, Acute",N,
31150,QualifierName,Q000188,9128433,,,6,,Y,drug therapy
31151,DescriptorName,D007964,9128433,,,7,Leukocytosis,N,
31152,QualifierName,Q000139,9128433,,,7,,N,chemically induced
31153,DescriptorName,D008297,9128433,,,8,Male,N,
31154,DescriptorName,D008875,9128433,,,9,Middle Aged,N,
31155,DescriptorName,D011654,9128433,,,10,Pulmonary Edema,N,
31156,QualifierName,Q000139,9128433,,,10,,Y,chemically induced
31157,DescriptorName,D013577,9128433,,,11,Syndrome,N,
31158,DescriptorName,D014212,9128433,,,12,Tretinoin,N,
31159,QualifierName,Q000009,9128433,,,12,,Y,adverse effects
31160,Chemical,D000889,9149614,Anti-Arrhythmia Agents,0,,,,
31161,Chemical,D008278,9149614,Magnesium Sulfate,7487-88-9,,,,
31162,Chemical,D000638,9149614,Amiodarone,N3RQ532IUT,,,,
31163,DescriptorName,D000368,9149614,,,1,Aged,N,
31164,DescriptorName,D000638,9149614,,,2,Amiodarone,N,
31165,QualifierName,Q000009,9149614,,,2,,Y,adverse effects
31166,DescriptorName,D000889,9149614,,,3,Anti-Arrhythmia Agents,N,
31167,QualifierName,Q000008,9149614,,,3,,N,administration & dosage
31168,DescriptorName,D001281,9149614,,,4,Atrial Fibrillation,N,
31169,QualifierName,Q000150,9149614,,,4,,N,complications
31170,DescriptorName,D009202,9149614,,,5,Cardiomyopathies,N,
31171,QualifierName,Q000150,9149614,,,5,,Y,complications
31172,DescriptorName,D006801,9149614,,,6,Humans,N,
31173,DescriptorName,D007262,9149614,,,7,"Infusions, Intravenous",N,
31174,DescriptorName,D007275,9149614,,,8,"Injections, Intravenous",N,
31175,DescriptorName,D008278,9149614,,,9,Magnesium Sulfate,N,
31176,QualifierName,Q000008,9149614,,,9,,N,administration & dosage
31177,DescriptorName,D008297,9149614,,,10,Male,N,
31178,DescriptorName,D012008,9149614,,,11,Recurrence,N,
31179,DescriptorName,D013575,9149614,,,12,Syncope,N,
31180,QualifierName,Q000139,9149614,,,12,,N,chemically induced
31181,DescriptorName,D017180,9149614,,,13,"Tachycardia, Ventricular",N,
31182,QualifierName,Q000139,9149614,,,13,,Y,chemically induced
31183,Chemical,D002121,9161656,Calcium Channel Blockers,0,,,,
31184,Chemical,D003692,9161656,Delayed-Action Preparations,0,,,,
31185,Chemical,D014700,9161656,Verapamil,CJ0O37KU29,,,,
31186,DescriptorName,D000208,9161656,,,1,Acute Disease,N,
31187,DescriptorName,D000368,9161656,,,2,Aged,N,
31188,DescriptorName,D001249,9161656,,,3,Asthma,N,
31189,QualifierName,Q000139,9161656,,,3,,Y,chemically induced
31190,DescriptorName,D001794,9161656,,,4,Blood Pressure,N,
31191,QualifierName,Q000187,9161656,,,4,,N,drug effects
31192,DescriptorName,D002121,9161656,,,5,Calcium Channel Blockers,N,
31193,QualifierName,Q000008,9161656,,,5,,N,administration & dosage
31194,DescriptorName,D003692,9161656,,,6,Delayed-Action Preparations,N,
31195,DescriptorName,D005260,9161656,,,7,Female,N,
31196,DescriptorName,D006801,9161656,,,8,Humans,N,
31197,DescriptorName,D006973,9161656,,,9,Hypertension,N,
31198,QualifierName,Q000188,9161656,,,9,,N,drug therapy
31199,DescriptorName,D014700,9161656,,,10,Verapamil,N,
31200,QualifierName,Q000008,9161656,,,10,,N,administration & dosage
31201,Chemical,D002511,9169264,Cephalosporins,0,,,,
31202,Chemical,D002506,9169264,Cephalexin,OBN7UDS42Y,,,,
31203,DescriptorName,D000328,9169264,,,1,Adult,N,
31204,DescriptorName,D002506,9169264,,,2,Cephalexin,N,
31205,QualifierName,Q000009,9169264,,,2,,Y,adverse effects
31206,DescriptorName,D002511,9169264,,,3,Cephalosporins,N,
31207,QualifierName,Q000009,9169264,,,3,,Y,adverse effects
31208,DescriptorName,D003875,9169264,,,4,Drug Eruptions,N,
31209,QualifierName,Q000209,9169264,,,4,,Y,etiology
31210,DescriptorName,D004890,9169264,,,5,Erythema,N,
31211,QualifierName,Q000139,9169264,,,5,,Y,chemically induced
31212,DescriptorName,D005260,9169264,,,6,Female,N,
31213,DescriptorName,D006801,9169264,,,7,Humans,N,
31214,DescriptorName,D007244,9169264,,,8,Infectious Mononucleosis,N,
31215,QualifierName,Q000150,9169264,,,8,,N,complications
31216,Chemical,D000927,9177620,Anticonvulsants,0,,,,
31217,Chemical,D002220,9177620,Carbamazepine,33CM23913M,,,,
31218,DescriptorName,D000208,9177620,,,1,Acute Disease,N,
31219,DescriptorName,D000328,9177620,,,2,Adult,N,
31220,DescriptorName,D000927,9177620,,,3,Anticonvulsants,N,
31221,QualifierName,Q000009,9177620,,,3,,Y,adverse effects
31222,DescriptorName,D002220,9177620,,,4,Carbamazepine,N,
31223,QualifierName,Q000009,9177620,,,4,,Y,adverse effects
31224,DescriptorName,D004832,9177620,,,5,"Epilepsy, Absence",N,
31225,QualifierName,Q000150,9177620,,,5,,N,complications
31226,DescriptorName,D006801,9177620,,,6,Humans,N,
31227,DescriptorName,D008297,9177620,,,7,Male,N,
31228,DescriptorName,D010195,9177620,,,8,Pancreatitis,N,
31229,QualifierName,Q000139,9177620,,,8,,Y,chemically induced
31230,Chemical,D018501,9184269,Antirheumatic Agents,0,,,,
31231,Chemical,D008727,9184269,Methotrexate,YL5FZ2Y5U1,,,,
31232,DescriptorName,D000368,9184269,,,1,Aged,N,
31233,DescriptorName,D000542,9184269,,,2,"Alveolitis, Extrinsic Allergic",N,
31234,QualifierName,Q000139,9184269,,,2,,Y,chemically induced
31235,DescriptorName,D018501,9184269,,,3,Antirheumatic Agents,N,
31236,QualifierName,Q000008,9184269,,,3,,N,administration & dosage
31237,DescriptorName,D015535,9184269,,,4,"Arthritis, Psoriatic",N,
31238,QualifierName,Q000188,9184269,,,4,,Y,drug therapy
31239,DescriptorName,D001172,9184269,,,5,"Arthritis, Rheumatoid",N,
31240,QualifierName,Q000188,9184269,,,5,,Y,drug therapy
31241,DescriptorName,D004305,9184269,,,6,"Dose-Response Relationship, Drug",N,
31242,DescriptorName,D005260,9184269,,,7,Female,N,
31243,DescriptorName,D006801,9184269,,,8,Humans,N,
31244,DescriptorName,D015994,9184269,,,9,Incidence,N,
31245,DescriptorName,D008297,9184269,,,10,Male,N,
31246,DescriptorName,D008727,9184269,,,11,Methotrexate,N,
31247,QualifierName,Q000008,9184269,,,11,,N,administration & dosage
31248,DescriptorName,D008875,9184269,,,12,Middle Aged,N,
31249,DescriptorName,D011379,9184269,,,13,Prognosis,N,
31250,DescriptorName,D012129,9184269,,,14,Respiratory Function Tests,N,
31251,DescriptorName,D012307,9184269,,,15,Risk Factors,N,
31252,Chemical,D000731,91848,Androstanes,0,,,,
31253,Chemical,D013739,91848,Testosterone,3XMK78S47O,,,,
31254,Chemical,D013197,91848,Stanozolol,4R1VB9P8V3,,,,
31255,Chemical,D005474,91848,Fluoxymesterone,9JU12S4YFY,,,,
31256,Chemical,D008696,91848,Methandrostenolone,COZ1R7EOCC,,,,
31257,DescriptorName,D000731,91848,,,1,Androstanes,N,
31258,QualifierName,Q000009,91848,,,1,,Y,adverse effects
31259,DescriptorName,D005260,91848,,,2,Female,N,
31260,DescriptorName,D005474,91848,,,3,Fluoxymesterone,N,
31261,QualifierName,Q000009,91848,,,3,,N,adverse effects
31262,DescriptorName,D006394,91848,,,4,Hemangiosarcoma,N,
31263,QualifierName,Q000139,91848,,,4,,Y,chemically induced
31264,DescriptorName,D006801,91848,,,5,Humans,N,
31265,DescriptorName,D007006,91848,,,6,Hypogonadism,N,
31266,QualifierName,Q000188,91848,,,6,,N,drug therapy
31267,DescriptorName,D008099,91848,,,7,Liver,N,
31268,QualifierName,Q000473,91848,,,7,,N,pathology
31269,DescriptorName,D008113,91848,,,8,Liver Neoplasms,N,
31270,QualifierName,Q000139,91848,,,8,,Y,chemically induced
31271,DescriptorName,D008297,91848,,,9,Male,N,
31272,DescriptorName,D008599,91848,,,10,Menstruation Disturbances,N,
31273,QualifierName,Q000188,91848,,,10,,N,drug therapy
31274,DescriptorName,D008696,91848,,,11,Methandrostenolone,N,
31275,QualifierName,Q000009,91848,,,11,,N,adverse effects
31276,DescriptorName,D008875,91848,,,12,Middle Aged,N,
31277,DescriptorName,D009101,91848,,,13,Multiple Myeloma,N,
31278,QualifierName,Q000188,91848,,,13,,N,drug therapy
31279,DescriptorName,D013197,91848,,,14,Stanozolol,N,
31280,QualifierName,Q000009,91848,,,14,,N,adverse effects
31281,DescriptorName,D013739,91848,,,15,Testosterone,N,
31282,QualifierName,Q000009,91848,,,15,,N,adverse effects
31283,Chemical,D005296,9191742,Ferrous Compounds,0,,,,
31284,Chemical,C020748,9191742,ferrous sulfate,39R4TAN1VT,,,,
31285,Chemical,D013972,9191742,Thyrotropin,9002-71-5,,,,
31286,Chemical,D013974,9191742,Thyroxine,Q51BO43MG4,,,,
31287,DescriptorName,D000284,9191742,,,1,"Administration, Oral",N,
31288,DescriptorName,D000328,9191742,,,2,Adult,N,
31289,DescriptorName,D018798,9191742,,,3,"Anemia, Iron-Deficiency",N,
31290,QualifierName,Q000188,9191742,,,3,,N,drug therapy
31291,DescriptorName,D004347,9191742,,,4,Drug Interactions,N,
31292,DescriptorName,D005260,9191742,,,5,Female,N,
31293,DescriptorName,D005296,9191742,,,6,Ferrous Compounds,N,
31294,QualifierName,Q000008,9191742,,,6,,N,administration & dosage
31295,DescriptorName,D006801,9191742,,,7,Humans,N,
31296,DescriptorName,D006980,9191742,,,8,Hyperthyroidism,N,
31297,QualifierName,Q000139,9191742,,,8,,N,chemically induced
31298,DescriptorName,D007037,9191742,,,9,Hypothyroidism,N,
31299,QualifierName,Q000188,9191742,,,9,,Y,drug therapy
31300,DescriptorName,D007408,9191742,,,10,Intestinal Absorption,N,
31301,QualifierName,Q000187,9191742,,,10,,N,drug effects
31302,DescriptorName,D013967,9191742,,,11,"Thyroiditis, Autoimmune",N,
31303,QualifierName,Q000150,9191742,,,11,,N,complications
31304,DescriptorName,D013972,9191742,,,12,Thyrotropin,N,
31305,QualifierName,Q000097,9191742,,,12,,N,blood
31306,DescriptorName,D013974,9191742,,,13,Thyroxine,N,
31307,QualifierName,Q000008,9191742,,,13,,N,administration & dosage
31308,Chemical,D000893,9195619,Anti-Inflammatory Agents,0,,,,
31309,Chemical,C075659,9195619,HB-VAX,0,,,,
31310,Chemical,D017325,9195619,Hepatitis B Vaccines,0,,,,
31311,Chemical,D013256,9195619,Steroids,0,,,,
31312,DescriptorName,D000328,9195619,,,1,Adult,N,
31313,DescriptorName,D000893,9195619,,,2,Anti-Inflammatory Agents,N,
31314,QualifierName,Q000627,9195619,,,2,,N,therapeutic use
31315,DescriptorName,D001168,9195619,,,3,Arthritis,N,
31316,QualifierName,Q000188,9195619,,,3,,N,drug therapy
31317,DescriptorName,D002680,9195619,,,4,Chin,N,
31318,QualifierName,Q000293,9195619,,,4,,Y,injuries
31319,DescriptorName,D005260,9195619,,,5,Female,N,
31320,DescriptorName,D006509,9195619,,,6,Hepatitis B,N,
31321,QualifierName,Q000517,9195619,,,6,,N,prevention & control
31322,DescriptorName,D017325,9195619,,,7,Hepatitis B Vaccines,N,
31323,QualifierName,Q000009,9195619,,,7,,Y,adverse effects
31324,DescriptorName,D006801,9195619,,,8,Humans,N,
31325,DescriptorName,D008046,9195619,,,9,Lip,N,
31326,QualifierName,Q000294,9195619,,,9,,N,innervation
31327,DescriptorName,D010292,9195619,,,10,Paresthesia,N,
31328,QualifierName,Q000188,9195619,,,10,,N,drug therapy
31329,DescriptorName,D010523,9195619,,,11,Peripheral Nervous System Diseases,N,
31330,QualifierName,Q000188,9195619,,,11,,N,drug therapy
31331,DescriptorName,D013256,9195619,,,12,Steroids,N,
31332,DescriptorName,D014611,9195619,,,13,Vaccination,N,
31333,QualifierName,Q000009,9195619,,,13,,Y,adverse effects
31334,Chemical,D018931,9205466,"Antineoplastic Agents, Hormonal",0,,,,
31335,Chemical,D013629,9205466,Tamoxifen,094ZI81Y45,,,,
31336,DescriptorName,D000368,9205466,,,1,Aged,N,
31337,DescriptorName,D018931,9205466,,,2,"Antineoplastic Agents, Hormonal",N,
31338,QualifierName,Q000009,9205466,,,2,,Y,adverse effects
31339,DescriptorName,D001943,9205466,,,3,Breast Neoplasms,N,
31340,QualifierName,Q000188,9205466,,,3,,Y,drug therapy
31341,DescriptorName,D016889,9205466,,,4,Endometrial Neoplasms,N,
31342,QualifierName,Q000139,9205466,,,4,,Y,chemically induced
31343,DescriptorName,D005260,9205466,,,5,Female,N,
31344,DescriptorName,D006801,9205466,,,6,Humans,N,
31345,DescriptorName,D016609,9205466,,,7,"Neoplasms, Second Primary",N,
31346,QualifierName,Q000139,9205466,,,7,,Y,chemically induced
31347,DescriptorName,D011127,9205466,,,8,Polyps,N,
31348,QualifierName,Q000139,9205466,,,8,,Y,chemically induced
31349,DescriptorName,D013629,9205466,,,9,Tamoxifen,N,
31350,QualifierName,Q000009,9205466,,,9,,Y,adverse effects
31351,Chemical,D001761,9211543,Bleomycin,11056-06-7,,,,
31352,Chemical,D003520,9211543,Cyclophosphamide,8N3DW7272P,,,,
31353,DescriptorName,D000293,9211543,,,1,Adolescent,N,
31354,DescriptorName,D000971,9211543,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
31355,QualifierName,Q000009,9211543,,,2,,Y,adverse effects
31356,DescriptorName,D001761,9211543,,,3,Bleomycin,N,
31357,QualifierName,Q000009,9211543,,,3,,Y,adverse effects
31358,DescriptorName,D001859,9211543,,,4,Bone Neoplasms,N,
31359,QualifierName,Q000188,9211543,,,4,,Y,drug therapy
31360,DescriptorName,D002648,9211543,,,5,Child,N,
31361,DescriptorName,D003520,9211543,,,6,Cyclophosphamide,N,
31362,QualifierName,Q000009,9211543,,,6,,Y,adverse effects
31363,DescriptorName,D003937,9211543,,,7,"Diagnosis, Differential",N,
31364,DescriptorName,D005260,9211543,,,8,Female,N,
31365,DescriptorName,D005500,9211543,,,9,Follow-Up Studies,N,
31366,DescriptorName,D018237,9211543,,,10,Germinoma,N,
31367,QualifierName,Q000188,9211543,,,10,,Y,drug therapy
31368,DescriptorName,D006801,9211543,,,11,Humans,N,
31369,DescriptorName,D008168,9211543,,,12,Lung,N,
31370,QualifierName,Q000000981,9211543,,,12,,N,diagnostic imaging
31371,DescriptorName,D008175,9211543,,,13,Lung Neoplasms,N,
31372,QualifierName,Q000175,9211543,,,13,,N,diagnosis
31373,DescriptorName,D008297,9211543,,,14,Male,N,
31374,DescriptorName,D013902,9211543,,,15,"Radiography, Thoracic",N,
31375,DescriptorName,D012512,9211543,,,16,"Sarcoma, Ewing",N,
31376,QualifierName,Q000188,9211543,,,16,,Y,drug therapy
31377,DescriptorName,D014057,9211543,,,17,"Tomography, X-Ray Computed",N,
31378,Chemical,D005338,921427,Fibrin Fibrinogen Degradation Products,0,,,,
31379,Chemical,D005172,921427,Factor XI,9013-55-2,,,,
31380,Chemical,D011342,921427,Procainamide,L39WTC366D,,,,
31381,DescriptorName,D000368,921427,,,1,Aged,N,
31382,DescriptorName,D001145,921427,,,2,"Arrhythmias, Cardiac",N,
31383,QualifierName,Q000188,921427,,,2,,N,drug therapy
31384,DescriptorName,D001777,921427,,,3,Blood Coagulation,Y,
31385,QualifierName,Q000187,921427,,,3,,N,drug effects
31386,DescriptorName,D003937,921427,,,4,"Diagnosis, Differential",N,
31387,DescriptorName,D005172,921427,,,5,Factor XI,N,
31388,DescriptorName,D005338,921427,,,6,Fibrin Fibrinogen Degradation Products,N,
31389,QualifierName,Q000032,921427,,,6,,N,analysis
31390,DescriptorName,D006801,921427,,,7,Humans,N,
31391,DescriptorName,D008180,921427,,,8,"Lupus Erythematosus, Systemic",N,
31392,QualifierName,Q000139,921427,,,8,,Y,chemically induced
31393,DescriptorName,D008297,921427,,,9,Male,N,
31394,DescriptorName,D010490,921427,,,10,Pericardial Effusion,N,
31395,QualifierName,Q000139,921427,,,10,,N,chemically induced
31396,DescriptorName,D010996,921427,,,11,Pleural Effusion,N,
31397,QualifierName,Q000139,921427,,,11,,N,chemically induced
31398,DescriptorName,D011342,921427,,,12,Procainamide,N,
31399,QualifierName,Q000009,921427,,,12,,Y,adverse effects
31400,Chemical,D002400,9215418,Cathartics,0,,,,
31401,Chemical,D008278,9215418,Magnesium Sulfate,7487-88-9,,,,
31402,Chemical,D008274,9215418,Magnesium,I38ZP9992A,,,,
31403,Chemical,D002125,9215418,Calcium Gluconate,SQE6VB453K,,,,
31404,DescriptorName,D000818,9215418,,,1,Animals,N,
31405,DescriptorName,D002125,9215418,,,2,Calcium Gluconate,N,
31406,QualifierName,Q000008,9215418,,,2,,N,administration & dosage
31407,DescriptorName,D002400,9215418,,,3,Cathartics,N,
31408,QualifierName,Q000506,9215418,,,3,,Y,poisoning
31409,DescriptorName,D062787,9215418,,,4,Drug Overdose,N,
31410,QualifierName,Q000188,9215418,,,4,,N,drug therapy
31411,DescriptorName,D005244,9215418,,,5,Fecal Impaction,N,
31412,QualifierName,Q000188,9215418,,,5,,N,drug therapy
31413,DescriptorName,D005260,9215418,,,6,Female,N,
31414,DescriptorName,D006734,9215418,,,7,Horse Diseases,N,
31415,QualifierName,Q000139,9215418,,,7,,Y,chemically induced
31416,DescriptorName,D006736,9215418,,,8,Horses,N,
31417,DescriptorName,D007262,9215418,,,9,"Infusions, Intravenous",N,
31418,QualifierName,Q000662,9215418,,,9,,N,veterinary
31419,DescriptorName,D008274,9215418,,,10,Magnesium,N,
31420,QualifierName,Q000097,9215418,,,10,,N,blood
31421,DescriptorName,D008278,9215418,,,11,Magnesium Sulfate,N,
31422,QualifierName,Q000506,9215418,,,11,,Y,poisoning
31423,DescriptorName,D008297,9215418,,,12,Male,N,
31424,Chemical,D000900,9220046,Anti-Bacterial Agents,0,,,,
31425,Chemical,D000924,9220046,Anticholesteremic Agents,0,,,,
31426,Chemical,D017963,9220046,Azithromycin,83905-01-5,,,,
31427,Chemical,D008148,9220046,Lovastatin,9LHU78OQFD,,,,
31428,Chemical,D017291,9220046,Clarithromycin,H1250JIK0A,,,,
31429,DescriptorName,D000368,9220046,,,1,Aged,N,
31430,DescriptorName,D000900,9220046,,,2,Anti-Bacterial Agents,N,
31431,QualifierName,Q000378,9220046,,,2,,N,metabolism
31432,DescriptorName,D000924,9220046,,,3,Anticholesteremic Agents,N,
31433,QualifierName,Q000009,9220046,,,3,,Y,adverse effects
31434,DescriptorName,D017963,9220046,,,4,Azithromycin,N,
31435,QualifierName,Q000378,9220046,,,4,,N,metabolism
31436,DescriptorName,D017291,9220046,,,5,Clarithromycin,N,
31437,QualifierName,Q000378,9220046,,,5,,N,metabolism
31438,DescriptorName,D004347,9220046,,,6,Drug Interactions,N,
31439,DescriptorName,D005260,9220046,,,7,Female,N,
31440,DescriptorName,D006801,9220046,,,8,Humans,N,
31441,DescriptorName,D008148,9220046,,,9,Lovastatin,N,
31442,QualifierName,Q000009,9220046,,,9,,Y,adverse effects
31443,DescriptorName,D008297,9220046,,,10,Male,N,
31444,DescriptorName,D008875,9220046,,,11,Middle Aged,N,
31445,DescriptorName,D011014,9220046,,,12,Pneumonia,N,
31446,QualifierName,Q000188,9220046,,,12,,N,drug therapy
31447,DescriptorName,D012206,9220046,,,13,Rhabdomyolysis,N,
31448,QualifierName,Q000139,9220046,,,13,,Y,chemically induced
31449,DescriptorName,D012852,9220046,,,14,Sinusitis,N,
31450,QualifierName,Q000188,9220046,,,14,,N,drug therapy
31451,Chemical,D000893,9224230,Anti-Inflammatory Agents,0,,,,
31452,Chemical,D007166,9224230,Immunosuppressive Agents,0,,,,
31453,Chemical,D011241,9224230,Prednisone,VB0R961HZT,,,,
31454,DescriptorName,D000328,9224230,,,1,Adult,N,
31455,DescriptorName,D000893,9224230,,,2,Anti-Inflammatory Agents,N,
31456,QualifierName,Q000009,9224230,,,2,,Y,adverse effects
31457,DescriptorName,D003882,9224230,,,3,Dermatomyositis,N,
31458,QualifierName,Q000188,9224230,,,3,,Y,drug therapy
31459,DescriptorName,D017809,9224230,,,4,Fatal Outcome,N,
31460,DescriptorName,D005260,9224230,,,5,Female,N,
31461,DescriptorName,D006801,9224230,,,6,Humans,N,
31462,DescriptorName,D007166,9224230,,,7,Immunosuppressive Agents,N,
31463,QualifierName,Q000009,9224230,,,7,,Y,adverse effects
31464,DescriptorName,D008297,9224230,,,8,Male,N,
31465,DescriptorName,D008875,9224230,,,9,Middle Aged,N,
31466,DescriptorName,D011020,9224230,,,10,"Pneumonia, Pneumocystis",N,
31467,QualifierName,Q000209,9224230,,,10,,Y,etiology
31468,DescriptorName,D011241,9224230,,,11,Prednisone,N,
31469,QualifierName,Q000009,9224230,,,11,,Y,adverse effects
31470,Chemical,D000316,9230324,Adrenergic alpha-Agonists,0,,,,
31471,Chemical,D000319,9230324,Adrenergic beta-Antagonists,0,,,,
31472,Chemical,D011412,9230324,Propanolamines,0,,,,
31473,Chemical,D010656,9230324,Phenylephrine,1WS297W6MV,,,,
31474,Chemical,C036604,9230324,esmolol,MDY902UXSR,,,,
31475,Chemical,D007741,9230324,Labetalol,R5H8897N95,,,,
31476,Chemical,D004837,9230324,Epinephrine,YKH834O4BH,,,,
31477,DescriptorName,D000281,9230324,,,1,"Administration, Intranasal",N,
31478,DescriptorName,D000316,9230324,,,2,Adrenergic alpha-Agonists,N,
31479,QualifierName,Q000009,9230324,,,2,,Y,adverse effects
31480,DescriptorName,D000319,9230324,,,3,Adrenergic beta-Antagonists,N,
31481,QualifierName,Q000009,9230324,,,3,,Y,adverse effects
31482,DescriptorName,D002648,9230324,,,4,Child,N,
31483,DescriptorName,D004837,9230324,,,5,Epinephrine,N,
31484,QualifierName,Q000009,9230324,,,5,,N,adverse effects
31485,DescriptorName,D005260,9230324,,,6,Female,N,
31486,DescriptorName,D006323,9230324,,,7,Heart Arrest,N,
31487,QualifierName,Q000139,9230324,,,7,,N,chemically induced
31488,DescriptorName,D006801,9230324,,,8,Humans,N,
31489,DescriptorName,D006973,9230324,,,9,Hypertension,N,
31490,QualifierName,Q000139,9230324,,,9,,Y,chemically induced
31491,DescriptorName,D007431,9230324,,,10,Intraoperative Complications,N,
31492,QualifierName,Q000139,9230324,,,10,,Y,chemically induced
31493,DescriptorName,D007442,9230324,,,11,"Intubation, Intratracheal",N,
31494,DescriptorName,D007741,9230324,,,12,Labetalol,N,
31495,QualifierName,Q000009,9230324,,,12,,N,adverse effects
31496,DescriptorName,D008297,9230324,,,13,Male,N,
31497,DescriptorName,D010656,9230324,,,14,Phenylephrine,N,
31498,QualifierName,Q000009,9230324,,,14,,N,adverse effects
31499,DescriptorName,D011412,9230324,,,15,Propanolamines,N,
31500,QualifierName,Q000009,9230324,,,15,,N,adverse effects
31501,DescriptorName,D011654,9230324,,,16,Pulmonary Edema,N,
31502,QualifierName,Q000139,9230324,,,16,,N,chemically induced
31503,Chemical,D018931,9232614,"Antineoplastic Agents, Hormonal",0,,,,
31504,Chemical,D013629,9232614,Tamoxifen,094ZI81Y45,,,,
31505,DescriptorName,D018931,9232614,,,1,"Antineoplastic Agents, Hormonal",N,
31506,QualifierName,Q000009,9232614,,,1,,Y,adverse effects
31507,DescriptorName,D001943,9232614,,,2,Breast Neoplasms,N,
31508,QualifierName,Q000188,9232614,,,2,,N,drug therapy
31509,DescriptorName,D005260,9232614,,,3,Female,N,
31510,DescriptorName,D006801,9232614,,,4,Humans,N,
31511,DescriptorName,D015470,9232614,,,5,"Leukemia, Myeloid, Acute",N,
31512,QualifierName,Q000139,9232614,,,5,,Y,chemically induced
31513,DescriptorName,D008875,9232614,,,6,Middle Aged,N,
31514,DescriptorName,D016609,9232614,,,7,"Neoplasms, Second Primary",N,
31515,QualifierName,Q000139,9232614,,,7,,Y,chemically induced
31516,DescriptorName,D013629,9232614,,,8,Tamoxifen,N,
31517,QualifierName,Q000009,9232614,,,8,,Y,adverse effects
31518,Chemical,D014408,9240497,"Biomarkers, Tumor",0,,,,
31519,Chemical,D009363,9240497,Neoplasm Proteins,0,,,,
31520,Chemical,D015514,9240497,"Oncogene Proteins, Fusion",0,,,,
31521,Chemical,C093476,9240497,promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein,0,,,,
31522,Chemical,D003561,9240497,Cytarabine,04079A1RDZ,,,,
31523,Chemical,D016179,9240497,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
31524,Chemical,D014212,9240497,Tretinoin,5688UTC01R,,,,
31525,Chemical,C015019,9240497,enocitabine,9YVR68W306,,,,
31526,Chemical,D008942,9240497,Mitoxantrone,BZ114NVM5P,,,,
31527,Chemical,D015122,9240497,Mercaptopurine,E7WED276I5,,,,
31528,Chemical,D014751,9240497,Vindesine,RSA8KO39WH,,,,
31529,Chemical,D015255,9240497,Idarubicin,ZRP63D75JW,,,,
31530,Chemical,D003630,9240497,Daunorubicin,ZS7284E0ZP,,,,
31531,DescriptorName,D000380,9240497,,,1,Agranulocytosis,N,
31532,QualifierName,Q000139,9240497,,,1,,N,chemically induced
31533,DescriptorName,D000971,9240497,,,2,Antineoplastic Combined Chemotherapy Protocols,N,
31534,QualifierName,Q000009,9240497,,,2,,N,adverse effects
31535,DescriptorName,D014408,9240497,,,3,"Biomarkers, Tumor",N,
31536,QualifierName,Q000032,9240497,,,3,,N,analysis
31537,DescriptorName,D003131,9240497,,,4,Combined Modality Therapy,N,
31538,DescriptorName,D003561,9240497,,,5,Cytarabine,N,
31539,QualifierName,Q000008,9240497,,,5,,N,administration & dosage
31540,DescriptorName,D003630,9240497,,,6,Daunorubicin,N,
31541,QualifierName,Q000008,9240497,,,6,,N,administration & dosage
31542,DescriptorName,D004424,9240497,,,7,Ear Canal,Y,
31543,DescriptorName,D005260,9240497,,,8,Female,N,
31544,DescriptorName,D016179,9240497,,,9,Granulocyte Colony-Stimulating Factor,N,
31545,QualifierName,Q000627,9240497,,,9,,N,therapeutic use
31546,DescriptorName,D006801,9240497,,,10,Humans,N,
31547,DescriptorName,D015255,9240497,,,11,Idarubicin,N,
31548,QualifierName,Q000008,9240497,,,11,,N,administration & dosage
31549,DescriptorName,D015473,9240497,,,12,"Leukemia, Promyelocytic, Acute",N,
31550,QualifierName,Q000188,9240497,,,12,,N,drug therapy
31551,DescriptorName,D015122,9240497,,,13,Mercaptopurine,N,
31552,QualifierName,Q000008,9240497,,,13,,N,administration & dosage
31553,DescriptorName,D008875,9240497,,,14,Middle Aged,N,
31554,DescriptorName,D008942,9240497,,,15,Mitoxantrone,N,
31555,QualifierName,Q000008,9240497,,,15,,N,administration & dosage
31556,DescriptorName,D009363,9240497,,,16,Neoplasm Proteins,N,
31557,QualifierName,Q000032,9240497,,,16,,N,analysis
31558,DescriptorName,D015514,9240497,,,17,"Oncogene Proteins, Fusion",N,
31559,QualifierName,Q000032,9240497,,,17,,N,analysis
31560,DescriptorName,D011878,9240497,,,18,Radiotherapy,N,
31561,DescriptorName,D012008,9240497,,,19,Recurrence,N,
31562,DescriptorName,D012074,9240497,,,20,Remission Induction,N,
31563,DescriptorName,D016879,9240497,,,21,Salvage Therapy,N,
31564,DescriptorName,D014212,9240497,,,22,Tretinoin,N,
31565,QualifierName,Q000008,9240497,,,22,,N,administration & dosage
31566,DescriptorName,D014751,9240497,,,23,Vindesine,N,
31567,QualifierName,Q000008,9240497,,,23,,N,administration & dosage
31568,Chemical,D013956,9247841,Antithyroid Agents,0,,,,
31569,Chemical,D011441,9247841,Propylthiouracil,721M9407IY,,,,
31570,DescriptorName,D000328,9247841,,,1,Adult,N,
31571,DescriptorName,D013956,9247841,,,2,Antithyroid Agents,N,
31572,QualifierName,Q000009,9247841,,,2,,Y,adverse effects
31573,DescriptorName,D005260,9247841,,,3,Female,N,
31574,DescriptorName,D006111,9247841,,,4,Graves Disease,N,
31575,QualifierName,Q000188,9247841,,,4,,N,drug therapy
31576,DescriptorName,D006801,9247841,,,5,Humans,N,
31577,DescriptorName,D008297,9247841,,,6,Male,N,
31578,DescriptorName,D008875,9247841,,,7,Middle Aged,N,
31579,DescriptorName,D011441,9247841,,,8,Propylthiouracil,N,
31580,QualifierName,Q000009,9247841,,,8,,Y,adverse effects
31581,DescriptorName,D012871,9247841,,,9,Skin Diseases,N,
31582,QualifierName,Q000139,9247841,,,9,,Y,chemically induced
31583,DescriptorName,D018366,9247841,,,10,"Vasculitis, Leukocytoclastic, Cutaneous",N,
31584,QualifierName,Q000139,9247841,,,10,,Y,chemically induced
31585,Chemical,D000927,9253492,Anticonvulsants,0,,,,
31586,Chemical,D007555,9253492,Isoxazoles,0,,,,
31587,Chemical,D000078305,9253492,Zonisamide,459384H98V,,,,
31588,DescriptorName,D000927,9253492,,,1,Anticonvulsants,N,
31589,QualifierName,Q000009,9253492,,,1,,Y,adverse effects
31590,DescriptorName,D001706,9253492,,,2,Biopsy,N,
31591,DescriptorName,D002675,9253492,,,3,"Child, Preschool",N,
31592,DescriptorName,D004827,9253492,,,4,Epilepsy,N,
31593,QualifierName,Q000188,9253492,,,4,,Y,drug therapy
31594,DescriptorName,D005334,9253492,,,5,Fever,N,
31595,QualifierName,Q000139,9253492,,,5,,N,chemically induced
31596,DescriptorName,D018883,9253492,,,6,Heat Stroke,N,
31597,QualifierName,Q000139,9253492,,,6,,Y,chemically induced
31598,DescriptorName,D006801,9253492,,,7,Humans,N,
31599,DescriptorName,D007007,9253492,,,8,Hypohidrosis,N,
31600,QualifierName,Q000139,9253492,,,8,,N,chemically induced
31601,DescriptorName,D007555,9253492,,,9,Isoxazoles,N,
31602,QualifierName,Q000009,9253492,,,9,,Y,adverse effects
31603,DescriptorName,D008297,9253492,,,10,Male,N,
31604,DescriptorName,D012867,9253492,,,11,Skin,N,
31605,QualifierName,Q000473,9253492,,,11,,N,pathology
31606,DescriptorName,D000078305,9253492,,,12,Zonisamide,N,
31607,Chemical,D000726,9256906,Androgen Antagonists,0,,,,
31608,Chemical,D000893,9256906,Anti-Inflammatory Agents,0,,,,
31609,Chemical,D000970,9256906,Antineoplastic Agents,0,,,,
31610,Chemical,D018931,9256906,"Antineoplastic Agents, Hormonal",0,,,,
31611,Chemical,D013498,9256906,Suramin,6032D45BEM,,,,
31612,Chemical,D005485,9256906,Flutamide,76W6J0943E,,,,
31613,Chemical,D016729,9256906,Leuprolide,EFY6W0M8TG,,,,
31614,Chemical,D006854,9256906,Hydrocortisone,WI4X0X7BPJ,,,,
31615,DescriptorName,D058186,9256906,,,1,Acute Kidney Injury,N,
31616,QualifierName,Q000139,9256906,,,1,,Y,chemically induced
31617,DescriptorName,D000230,9256906,,,2,Adenocarcinoma,N,
31618,QualifierName,Q000188,9256906,,,2,,N,drug therapy
31619,DescriptorName,D000726,9256906,,,3,Androgen Antagonists,N,
31620,QualifierName,Q000008,9256906,,,3,,N,administration & dosage
31621,DescriptorName,D000893,9256906,,,4,Anti-Inflammatory Agents,N,
31622,QualifierName,Q000008,9256906,,,4,,N,administration & dosage
31623,DescriptorName,D000970,9256906,,,5,Antineoplastic Agents,N,
31624,QualifierName,Q000008,9256906,,,5,,N,administration & dosage
31625,DescriptorName,D018931,9256906,,,6,"Antineoplastic Agents, Hormonal",N,
31626,QualifierName,Q000008,9256906,,,6,,N,administration & dosage
31627,DescriptorName,D000971,9256906,,,7,Antineoplastic Combined Chemotherapy Protocols,N,
31628,QualifierName,Q000627,9256906,,,7,,N,therapeutic use
31629,DescriptorName,D005485,9256906,,,8,Flutamide,N,
31630,QualifierName,Q000008,9256906,,,8,,N,administration & dosage
31631,DescriptorName,D006801,9256906,,,9,Humans,N,
31632,DescriptorName,D006854,9256906,,,10,Hydrocortisone,N,
31633,QualifierName,Q000008,9256906,,,10,,N,administration & dosage
31634,DescriptorName,D016729,9256906,,,11,Leuprolide,N,
31635,QualifierName,Q000008,9256906,,,11,,N,administration & dosage
31636,DescriptorName,D008159,9256906,,,12,Lumbar Vertebrae,N,
31637,DescriptorName,D008297,9256906,,,13,Male,N,
31638,DescriptorName,D008875,9256906,,,14,Middle Aged,N,
31639,DescriptorName,D011471,9256906,,,15,Prostatic Neoplasms,N,
31640,QualifierName,Q000473,9256906,,,15,,Y,pathology
31641,DescriptorName,D012447,9256906,,,16,Sacrum,N,
31642,DescriptorName,D013125,9256906,,,17,Spinal Neoplasms,N,
31643,QualifierName,Q000188,9256906,,,17,,N,drug therapy
31644,DescriptorName,D013498,9256906,,,18,Suramin,N,
31645,QualifierName,Q000008,9256906,,,18,,N,administration & dosage
31646,DescriptorName,D013904,9256906,,,19,Thoracic Vertebrae,N,
31647,Chemical,D014150,9260733,Antipsychotic Agents,0,,,,
31648,Chemical,D003024,9260733,Clozapine,J60AR2IKIC,,,,
31649,DescriptorName,D000328,9260733,,,1,Adult,N,
31650,DescriptorName,D014150,9260733,,,2,Antipsychotic Agents,N,
31651,QualifierName,Q000009,9260733,,,2,,Y,adverse effects
31652,DescriptorName,D003024,9260733,,,3,Clozapine,N,
31653,QualifierName,Q000009,9260733,,,3,,Y,adverse effects
31654,DescriptorName,D006801,9260733,,,4,Humans,N,
31655,DescriptorName,D008297,9260733,,,5,Male,N,
31656,DescriptorName,D012559,9260733,,,6,Schizophrenia,N,
31657,QualifierName,Q000150,9260733,,,6,,N,complications
31658,DescriptorName,D012700,9260733,,,7,Serositis,N,
31659,QualifierName,Q000139,9260733,,,7,,Y,chemically induced
31660,Chemical,D000935,9279731,Antifungal Agents,0,,,,
31661,Chemical,D000666,9279731,Amphotericin B,7XU7A7DROE,,,,
31662,Chemical,D015725,9279731,Fluconazole,8VZV102JFY,,,,
31663,DescriptorName,D000666,9279731,,,1,Amphotericin B,N,
31664,QualifierName,Q000627,9279731,,,1,,Y,therapeutic use
31665,DescriptorName,D000935,9279731,,,2,Antifungal Agents,N,
31666,QualifierName,Q000627,9279731,,,2,,Y,therapeutic use
31667,DescriptorName,D002177,9279731,,,3,Candidiasis,N,
31668,QualifierName,Q000188,9279731,,,3,,Y,drug therapy
31669,DescriptorName,D004696,9279731,,,4,Endocarditis,N,
31670,QualifierName,Q000188,9279731,,,4,,Y,drug therapy
31671,DescriptorName,D005260,9279731,,,5,Female,N,
31672,DescriptorName,D015725,9279731,,,6,Fluconazole,N,
31673,QualifierName,Q000627,9279731,,,6,,Y,therapeutic use
31674,DescriptorName,D006350,9279731,,,7,Heart Valve Prosthesis,N,
31675,QualifierName,Q000009,9279731,,,7,,Y,adverse effects
31676,DescriptorName,D006801,9279731,,,8,Humans,N,
31677,DescriptorName,D008875,9279731,,,9,Middle Aged,N,
31678,DescriptorName,D016459,9279731,,,10,Prosthesis-Related Infections,N,
31679,QualifierName,Q000188,9279731,,,10,,Y,drug therapy
31680,DescriptorName,D012008,9279731,,,11,Recurrence,N,
31681,DescriptorName,D000293,9291634,,,1,Adolescent,N,
31682,DescriptorName,D000328,9291634,,,2,Adult,N,
31683,DescriptorName,D000971,9291634,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
31684,QualifierName,Q000009,9291634,,,3,,Y,adverse effects
31685,DescriptorName,D005260,9291634,,,4,Female,N,
31686,DescriptorName,D006801,9291634,,,5,Humans,N,
31687,DescriptorName,D008297,9291634,,,6,Male,N,
31688,DescriptorName,D054198,9291634,,,7,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
31689,QualifierName,Q000150,9291634,,,7,,Y,complications
31690,DescriptorName,D012206,9291634,,,8,Rhabdomyolysis,N,
31691,QualifierName,Q000139,9291634,,,8,,N,chemically induced
31692,Chemical,D004164,9302445,Diphosphonates,0,,,,
31693,Chemical,C470121,9302445,"PTHLH protein, human",0,,,,
31694,Chemical,D010281,9302445,Parathyroid Hormone,0,,,,
31695,Chemical,D044162,9302445,Parathyroid Hormone-Related Protein,0,,,,
31696,Chemical,D011506,9302445,Proteins,0,,,,
31697,Chemical,D014807,9302445,Vitamin D,1406-16-2,,,,
31698,Chemical,C097949,9302445,"1,25-dihydroxyvitamin D",66772-14-3,,,,
31699,Chemical,D013006,9302445,Growth Hormone,9002-72-6,,,,
31700,Chemical,D000077268,9302445,Pamidronate,OYY3447OMC,,,,
31701,Chemical,D002118,9302445,Calcium,SY7Q814VUP,,,,
31702,DescriptorName,D000163,9302445,,,1,Acquired Immunodeficiency Syndrome,N,
31703,QualifierName,Q000188,9302445,,,1,,Y,drug therapy
31704,DescriptorName,D000328,9302445,,,2,Adult,N,
31705,DescriptorName,D002118,9302445,,,3,Calcium,N,
31706,QualifierName,Q000032,9302445,,,3,,N,analysis
31707,DescriptorName,D004164,9302445,,,4,Diphosphonates,N,
31708,QualifierName,Q000008,9302445,,,4,,N,administration & dosage
31709,DescriptorName,D013006,9302445,,,5,Growth Hormone,N,
31710,QualifierName,Q000008,9302445,,,5,,N,administration & dosage
31711,DescriptorName,D019247,9302445,,,6,HIV Wasting Syndrome,N,
31712,QualifierName,Q000188,9302445,,,6,,N,drug therapy
31713,DescriptorName,D006801,9302445,,,7,Humans,N,
31714,DescriptorName,D006934,9302445,,,8,Hypercalcemia,N,
31715,QualifierName,Q000139,9302445,,,8,,N,chemically induced
31716,DescriptorName,D008297,9302445,,,9,Male,N,
31717,DescriptorName,D000077268,9302445,,,10,Pamidronate,N,
31718,DescriptorName,D010281,9302445,,,11,Parathyroid Hormone,N,
31719,QualifierName,Q000032,9302445,,,11,,N,analysis
31720,DescriptorName,D044162,9302445,,,12,Parathyroid Hormone-Related Protein,N,
31721,DescriptorName,D011506,9302445,,,13,Proteins,N,
31722,QualifierName,Q000032,9302445,,,13,,N,analysis
31723,DescriptorName,D014807,9302445,,,14,Vitamin D,N,
31724,QualifierName,Q000031,9302445,,,14,,N,analogs & derivatives
31725,Chemical,D000970,9311175,Antineoplastic Agents,0,,,,
31726,Chemical,D011838,9311175,Radiation-Sensitizing Agents,0,,,,
31727,Chemical,D002945,9311175,Cisplatin,Q20Q21Q62J,,,,
31728,DescriptorName,D000328,9311175,,,1,Adult,N,
31729,DescriptorName,D000970,9311175,,,2,Antineoplastic Agents,N,
31730,QualifierName,Q000008,9311175,,,2,,N,administration & dosage
31731,DescriptorName,D002945,9311175,,,3,Cisplatin,N,
31732,QualifierName,Q000008,9311175,,,3,,N,administration & dosage
31733,DescriptorName,D004342,9311175,,,4,Drug Hypersensitivity,N,
31734,QualifierName,Q000209,9311175,,,4,,Y,etiology
31735,DescriptorName,D005260,9311175,,,5,Female,N,
31736,DescriptorName,D006801,9311175,,,6,Humans,N,
31737,DescriptorName,D007261,9311175,,,7,"Infusions, Intra-Arterial",N,
31738,DescriptorName,D007262,9311175,,,8,"Infusions, Intravenous",N,
31739,DescriptorName,D008875,9311175,,,9,Middle Aged,N,
31740,DescriptorName,D010051,9311175,,,10,Ovarian Neoplasms,N,
31741,QualifierName,Q000188,9311175,,,10,,Y,drug therapy
31742,DescriptorName,D011838,9311175,,,11,Radiation-Sensitizing Agents,N,
31743,QualifierName,Q000008,9311175,,,11,,N,administration & dosage
31744,Chemical,D000970,9315405,Antineoplastic Agents,0,,,,
31745,Chemical,D002945,9315405,Cisplatin,Q20Q21Q62J,,,,
31746,DescriptorName,D000328,9315405,,,1,Adult,N,
31747,DescriptorName,D000970,9315405,,,2,Antineoplastic Agents,N,
31748,QualifierName,Q000009,9315405,,,2,,Y,adverse effects
31749,DescriptorName,D002945,9315405,,,3,Cisplatin,N,
31750,QualifierName,Q000009,9315405,,,3,,Y,adverse effects
31751,DescriptorName,D006801,9315405,,,4,Humans,N,
31752,DescriptorName,D007683,9315405,,,5,"Kidney Tubular Necrosis, Acute",N,
31753,QualifierName,Q000139,9315405,,,5,,Y,chemically induced
31754,DescriptorName,D008297,9315405,,,6,Male,N,
31755,DescriptorName,D013724,9315405,,,7,Teratoma,N,
31756,QualifierName,Q000188,9315405,,,7,,N,drug therapy
31757,DescriptorName,D013736,9315405,,,8,Testicular Neoplasms,N,
31758,QualifierName,Q000188,9315405,,,8,,N,drug therapy
31759,Chemical,D002400,9337441,Cathartics,0,,,,
31760,Chemical,D004338,9337441,Drug Combinations,0,,,,
31761,Chemical,D010635,9337441,Phenolphthaleins,0,,,,
31762,Chemical,D004143,9337441,Dioctyl Sulfosuccinic Acid,10041-19-7,,,,
31763,Chemical,D008776,9337441,Methylprednisolone Hemisuccinate,5GMR90S4KN,,,,
31764,Chemical,D020113,9337441,Phenolphthalein,6QK969R2IF,,,,
31765,Chemical,C038509,9337441,docusate sodium mixt. with phenolphtalein,89066-78-4,,,,
31766,Chemical,D002437,9337441,Cefazolin,IHS69L0Y4T,,,,
31767,Chemical,D012837,9337441,Silver Sulfadiazine,W46JY43EJR,,,,
31768,DescriptorName,D000368,9337441,,,1,Aged,N,
31769,DescriptorName,D002400,9337441,,,2,Cathartics,N,
31770,QualifierName,Q000009,9337441,,,2,,Y,adverse effects
31771,DescriptorName,D002437,9337441,,,3,Cefazolin,N,
31772,QualifierName,Q000627,9337441,,,3,,N,therapeutic use
31773,DescriptorName,D004143,9337441,,,4,Dioctyl Sulfosuccinic Acid,N,
31774,QualifierName,Q000009,9337441,,,4,,Y,adverse effects
31775,DescriptorName,D004338,9337441,,,5,Drug Combinations,N,
31776,DescriptorName,D006801,9337441,,,6,Humans,N,
31777,DescriptorName,D008297,9337441,,,7,Male,N,
31778,DescriptorName,D008776,9337441,,,8,Methylprednisolone Hemisuccinate,N,
31779,QualifierName,Q000627,9337441,,,8,,N,therapeutic use
31780,DescriptorName,D020113,9337441,,,9,Phenolphthalein,Y,
31781,DescriptorName,D010635,9337441,,,10,Phenolphthaleins,N,
31782,QualifierName,Q000009,9337441,,,10,,Y,adverse effects
31783,DescriptorName,D012837,9337441,,,11,Silver Sulfadiazine,N,
31784,QualifierName,Q000627,9337441,,,11,,N,therapeutic use
31785,DescriptorName,D013262,9337441,,,12,Stevens-Johnson Syndrome,N,
31786,QualifierName,Q000188,9337441,,,12,,N,drug therapy
31787,Chemical,D000900,9347384,Anti-Bacterial Agents,0,,,,
31788,Chemical,D000927,9347384,Anticonvulsants,0,,,,
31789,Chemical,D002220,9347384,Carbamazepine,33CM23913M,,,,
31790,Chemical,D017291,9347384,Clarithromycin,H1250JIK0A,,,,
31791,DescriptorName,D000368,9347384,,,1,Aged,N,
31792,DescriptorName,D000900,9347384,,,2,Anti-Bacterial Agents,N,
31793,QualifierName,Q000627,9347384,,,2,,Y,therapeutic use
31794,DescriptorName,D000927,9347384,,,3,Anticonvulsants,N,
31795,QualifierName,Q000009,9347384,,,3,,Y,adverse effects
31796,DescriptorName,D001714,9347384,,,4,Bipolar Disorder,N,
31797,QualifierName,Q000188,9347384,,,4,,N,drug therapy
31798,DescriptorName,D002220,9347384,,,5,Carbamazepine,N,
31799,QualifierName,Q000008,9347384,,,5,,N,administration & dosage
31800,DescriptorName,D002493,9347384,,,6,Central Nervous System Diseases,N,
31801,QualifierName,Q000139,9347384,,,6,,Y,chemically induced
31802,DescriptorName,D017291,9347384,,,7,Clarithromycin,N,
31803,QualifierName,Q000008,9347384,,,7,,N,administration & dosage
31804,DescriptorName,D004347,9347384,,,8,Drug Interactions,N,
31805,DescriptorName,D005260,9347384,,,9,Female,N,
31806,DescriptorName,D006801,9347384,,,10,Humans,N,
31807,DescriptorName,D008297,9347384,,,11,Male,N,
31808,DescriptorName,D008875,9347384,,,12,Middle Aged,N,
31809,DescriptorName,D011014,9347384,,,13,Pneumonia,N,
31810,QualifierName,Q000188,9347384,,,13,,N,drug therapy
31811,DescriptorName,D011618,9347384,,,14,Psychotic Disorders,N,
31812,QualifierName,Q000188,9347384,,,14,,N,drug therapy
31813,Chemical,D000086,9352164,Acetazolamide,O3FX965V0I,,,,
31814,DescriptorName,D000086,9352164,,,1,Acetazolamide,N,
31815,QualifierName,Q000009,9352164,,,1,,Y,adverse effects
31816,DescriptorName,D000368,9352164,,,2,Aged,N,
31817,DescriptorName,D017809,9352164,,,3,Fatal Outcome,N,
31818,DescriptorName,D005260,9352164,,,4,Female,N,
31819,DescriptorName,D005756,9352164,,,5,Gastritis,N,
31820,QualifierName,Q000139,9352164,,,5,,Y,chemically induced
31821,DescriptorName,D006471,9352164,,,6,Gastrointestinal Hemorrhage,N,
31822,QualifierName,Q000139,9352164,,,6,,Y,chemically induced
31823,DescriptorName,D005773,9352164,,,7,Gastroscopy,N,
31824,DescriptorName,D005901,9352164,,,8,Glaucoma,N,
31825,QualifierName,Q000150,9352164,,,8,,N,complications
31826,DescriptorName,D006801,9352164,,,9,Humans,N,
31827,DescriptorName,D007676,9352164,,,10,"Kidney Failure, Chronic",N,
31828,QualifierName,Q000150,9352164,,,10,,Y,complications
31829,Chemical,D017616,9360190,Magnesium Compounds,0,,,,
31830,Chemical,D010710,9360190,Phosphates,0,,,,
31831,Chemical,D015149,9360190,Tocolytic Agents,0,,,,
31832,Chemical,D008278,9360190,Magnesium Sulfate,7487-88-9,,,,
31833,Chemical,D000069877,9360190,Struvite,AW3EJL1462,,,,
31834,DescriptorName,D000328,9360190,,,1,Adult,N,
31835,DescriptorName,D005260,9360190,,,2,Female,N,
31836,DescriptorName,D005865,9360190,,,3,Gestational Age,N,
31837,DescriptorName,D006801,9360190,,,4,Humans,N,
31838,DescriptorName,D017616,9360190,,,5,Magnesium Compounds,N,
31839,QualifierName,Q000032,9360190,,,5,,N,analysis
31840,DescriptorName,D008278,9360190,,,6,Magnesium Sulfate,N,
31841,QualifierName,Q000009,9360190,,,6,,Y,adverse effects
31842,DescriptorName,D007752,9360190,,,7,"Obstetric Labor, Premature",N,
31843,QualifierName,Q000188,9360190,,,7,,N,drug therapy
31844,DescriptorName,D010710,9360190,,,8,Phosphates,N,
31845,QualifierName,Q000032,9360190,,,8,,N,analysis
31846,DescriptorName,D011247,9360190,,,9,Pregnancy,N,
31847,DescriptorName,D011248,9360190,,,10,Pregnancy Complications,N,
31848,QualifierName,Q000139,9360190,,,10,,Y,chemically induced
31849,DescriptorName,D000069877,9360190,,,11,Struvite,N,
31850,DescriptorName,D015149,9360190,,,12,Tocolytic Agents,N,
31851,QualifierName,Q000009,9360190,,,12,,Y,adverse effects
31852,DescriptorName,D014463,9360190,,,13,Ultrasonography,N,
31853,DescriptorName,D014545,9360190,,,14,Urinary Calculi,N,
31854,QualifierName,Q000139,9360190,,,14,,Y,chemically induced
31855,Chemical,D011239,9362107,Prednisolone,9PHQ9Y1OLM,,,,
31856,Chemical,D003613,9362107,Danazol,N29QWW3BUO,,,,
31857,DescriptorName,D000328,9362107,,,1,Adult,N,
31858,DescriptorName,D003613,9362107,,,2,Danazol,N,
31859,QualifierName,Q000009,9362107,,,2,,Y,adverse effects
31860,DescriptorName,D004715,9362107,,,3,Endometriosis,N,
31861,QualifierName,Q000150,9362107,,,3,,N,complications
31862,DescriptorName,D005260,9362107,,,4,Female,N,
31863,DescriptorName,D005884,9362107,,,5,Gingival Hemorrhage,N,
31864,QualifierName,Q000139,9362107,,,5,,N,chemically induced
31865,DescriptorName,D006801,9362107,,,6,Humans,N,
31866,DescriptorName,D010048,9362107,,,7,Ovarian Cysts,N,
31867,QualifierName,Q000150,9362107,,,7,,N,complications
31868,DescriptorName,D011239,9362107,,,8,Prednisolone,N,
31869,QualifierName,Q000627,9362107,,,8,,N,therapeutic use
31870,DescriptorName,D011696,9362107,,,9,"Purpura, Thrombocytopenic",N,
31871,QualifierName,Q000139,9362107,,,9,,Y,chemically induced
31872,Chemical,D000925,9366852,Anticoagulants,0,,,,
31873,Chemical,D006495,9366852,"Heparin, Low-Molecular-Weight",0,,,,
31874,DescriptorName,D000328,9366852,,,1,Adult,N,
31875,DescriptorName,D000925,9366852,,,2,Anticoagulants,N,
31876,QualifierName,Q000009,9366852,,,2,,Y,adverse effects
31877,DescriptorName,D016736,9366852,,,3,Antiphospholipid Syndrome,N,
31878,QualifierName,Q000150,9366852,,,3,,Y,complications
31879,DescriptorName,D006495,9366852,,,4,"Heparin, Low-Molecular-Weight",N,
31880,QualifierName,Q000009,9366852,,,4,,Y,adverse effects
31881,DescriptorName,D006801,9366852,,,5,Humans,N,
31882,DescriptorName,D008297,9366852,,,6,Male,N,
31883,DescriptorName,D009336,9366852,,,7,Necrosis,N,
31884,DescriptorName,D011655,9366852,,,8,Pulmonary Embolism,N,
31885,QualifierName,Q000150,9366852,,,8,,N,complications
31886,DescriptorName,D012867,9366852,,,9,Skin,N,
31887,QualifierName,Q000473,9366852,,,9,,Y,pathology
31888,DescriptorName,D012871,9366852,,,10,Skin Diseases,N,
31889,QualifierName,Q000139,9366852,,,10,,Y,chemically induced
31890,DescriptorName,D013924,9366852,,,11,Thrombophlebitis,N,
31891,QualifierName,Q000150,9366852,,,11,,N,complications
31892,Chemical,D001463,937377,Barbiturates,0,,,,
31893,Chemical,D046948,937377,Secologanin Tryptamine Alkaloids,0,,,,
31894,Chemical,D012110,937377,Reserpine,8B1QWR724A,,,,
31895,DescriptorName,D000284,937377,,,1,"Administration, Oral",N,
31896,DescriptorName,D000328,937377,,,2,Adult,N,
31897,DescriptorName,D000368,937377,,,3,Aged,N,
31898,DescriptorName,D001463,937377,,,4,Barbiturates,N,
31899,QualifierName,Q000009,937377,,,4,,N,adverse effects
31900,DescriptorName,D001900,937377,,,5,Boston,N,
31901,DescriptorName,D002493,937377,,,6,Central Nervous System Diseases,N,
31902,QualifierName,Q000139,937377,,,6,,N,chemically induced
31903,DescriptorName,D004357,937377,,,7,Drug Synergism,N,
31904,DescriptorName,D005260,937377,,,8,Female,N,
31905,DescriptorName,D005767,937377,,,9,Gastrointestinal Diseases,N,
31906,QualifierName,Q000139,937377,,,9,,N,chemically induced
31907,DescriptorName,D006801,937377,,,10,Humans,N,
31908,DescriptorName,D006973,937377,,,11,Hypertension,N,
31909,QualifierName,Q000188,937377,,,11,,N,drug therapy
31910,DescriptorName,D007022,937377,,,12,Hypotension,N,
31911,QualifierName,Q000139,937377,,,12,,N,chemically induced
31912,DescriptorName,D007273,937377,,,13,"Injections, Intramuscular",N,
31913,DescriptorName,D008297,937377,,,14,Male,N,
31914,DescriptorName,D008875,937377,,,15,Middle Aged,N,
31915,DescriptorName,D011446,937377,,,16,Prospective Studies,N,
31916,DescriptorName,D012110,937377,,,17,Reserpine,N,
31917,QualifierName,Q000008,937377,,,17,,N,administration & dosage
31918,DescriptorName,D046948,937377,,,18,Secologanin Tryptamine Alkaloids,N,
31919,QualifierName,Q000009,937377,,,18,,N,adverse effects
31920,DescriptorName,D012769,937377,,,19,Shock,N,
31921,QualifierName,Q000139,937377,,,19,,N,chemically induced
31922,Chemical,D000975,9375469,Antioxidants,0,,,,
31923,Chemical,D009883,9375469,Ophthalmic Solutions,0,,,,
31924,Chemical,D013447,9375469,Sulfites,0,,,,
31925,Chemical,C009279,9375469,sodium bisulfite,TZX5469Z6I,,,,
31926,DescriptorName,D000368,9375469,,,1,Aged,N,
31927,DescriptorName,D000975,9375469,,,2,Antioxidants,N,
31928,QualifierName,Q000009,9375469,,,2,,Y,adverse effects
31929,DescriptorName,D002386,9375469,,,3,Cataract,N,
31930,QualifierName,Q000188,9375469,,,3,,N,drug therapy
31931,DescriptorName,D003877,9375469,,,4,"Dermatitis, Contact",N,
31932,QualifierName,Q000209,9375469,,,4,,Y,etiology
31933,DescriptorName,D005260,9375469,,,5,Female,N,
31934,DescriptorName,D006801,9375469,,,6,Humans,N,
31935,DescriptorName,D009883,9375469,,,7,Ophthalmic Solutions,N,
31936,DescriptorName,D013447,9375469,,,8,Sulfites,N,
31937,QualifierName,Q000009,9375469,,,8,,Y,adverse effects
31938,Chemical,D000894,9399776,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
31939,Chemical,D019804,9399776,Mesalamine,4Q81I59GXC,,,,
31940,Chemical,D008049,9399776,Lipase,EC 3.1.1.3,,,,
31941,Chemical,D000681,9399776,Amylases,EC 3.2.1.-,,,,
31942,DescriptorName,D000208,9399776,,,1,Acute Disease,N,
31943,DescriptorName,D000328,9399776,,,2,Adult,N,
31944,DescriptorName,D000681,9399776,,,3,Amylases,N,
31945,QualifierName,Q000097,9399776,,,3,,N,blood
31946,DescriptorName,D000894,9399776,,,4,"Anti-Inflammatory Agents, Non-Steroidal",N,
31947,QualifierName,Q000008,9399776,,,4,,N,administration & dosage
31948,DescriptorName,D003093,9399776,,,5,"Colitis, Ulcerative",N,
31949,QualifierName,Q000188,9399776,,,5,,N,drug therapy
31950,DescriptorName,D005260,9399776,,,6,Female,N,
31951,DescriptorName,D006801,9399776,,,7,Humans,N,
31952,DescriptorName,D008049,9399776,,,8,Lipase,N,
31953,QualifierName,Q000097,9399776,,,8,,N,blood
31954,DescriptorName,D008297,9399776,,,9,Male,N,
31955,DescriptorName,D019804,9399776,,,10,Mesalamine,N,
31956,QualifierName,Q000008,9399776,,,10,,N,administration & dosage
31957,DescriptorName,D010195,9399776,,,11,Pancreatitis,N,
31958,QualifierName,Q000139,9399776,,,11,,Y,chemically induced
31959,DescriptorName,D012008,9399776,,,12,Recurrence,N,
31960,Chemical,D004656,9403220,Enalapril,69PN84IO1A,,,,
31961,Chemical,D003520,9403220,Cyclophosphamide,8N3DW7272P,,,,
31962,Chemical,D011241,9403220,Prednisone,VB0R961HZT,,,,
31963,Chemical,D008775,9403220,Methylprednisolone,X4W7ZR7023,,,,
31964,DescriptorName,D058186,9403220,,,1,Acute Kidney Injury,N,
31965,QualifierName,Q000139,9403220,,,1,,N,chemically induced
31966,DescriptorName,D000328,9403220,,,2,Adult,N,
31967,DescriptorName,D003520,9403220,,,3,Cyclophosphamide,N,
31968,QualifierName,Q000627,9403220,,,3,,N,therapeutic use
31969,DescriptorName,D004656,9403220,,,4,Enalapril,N,
31970,QualifierName,Q000009,9403220,,,4,,Y,adverse effects
31971,DescriptorName,D006801,9403220,,,5,Humans,N,
31972,DescriptorName,D007668,9403220,,,6,Kidney,N,
31973,QualifierName,Q000473,9403220,,,6,,N,pathology
31974,DescriptorName,D007684,9403220,,,7,Kidney Tubules,N,
31975,QualifierName,Q000473,9403220,,,7,,Y,pathology
31976,DescriptorName,D008297,9403220,,,8,Male,N,
31977,DescriptorName,D008775,9403220,,,9,Methylprednisolone,N,
31978,QualifierName,Q000627,9403220,,,9,,N,therapeutic use
31979,DescriptorName,D008854,9403220,,,10,"Microscopy, Electron",N,
31980,DescriptorName,D009402,9403220,,,11,"Nephrosis, Lipoid",N,
31981,QualifierName,Q000188,9403220,,,11,,Y,drug therapy
31982,DescriptorName,D011241,9403220,,,12,Prednisone,N,
31983,QualifierName,Q000627,9403220,,,12,,N,therapeutic use
31984,Chemical,D019380,9407188,Anti-HIV Agents,0,,,,
31985,Chemical,D017320,9407188,HIV Protease Inhibitors,0,,,,
31986,Chemical,D019438,9407188,Ritonavir,O3J8G9O825,,,,
31987,DescriptorName,D000328,9407188,,,1,Adult,N,
31988,DescriptorName,D019380,9407188,,,2,Anti-HIV Agents,N,
31989,QualifierName,Q000009,9407188,,,2,,Y,adverse effects
31990,DescriptorName,D003875,9407188,,,3,Drug Eruptions,N,
31991,QualifierName,Q000209,9407188,,,3,,Y,etiology
31992,DescriptorName,D015658,9407188,,,4,HIV Infections,N,
31993,QualifierName,Q000150,9407188,,,4,,N,complications
31994,DescriptorName,D017320,9407188,,,5,HIV Protease Inhibitors,N,
31995,QualifierName,Q000009,9407188,,,5,,Y,adverse effects
31996,DescriptorName,D006801,9407188,,,6,Humans,N,
31997,DescriptorName,D008297,9407188,,,7,Male,N,
31998,DescriptorName,D008875,9407188,,,8,Middle Aged,N,
31999,DescriptorName,D019438,9407188,,,9,Ritonavir,N,
32000,QualifierName,Q000009,9407188,,,9,,Y,adverse effects
32001,Chemical,D002981,941054,Clindamycin,3U02EL437C,,,,
32002,Chemical,D008712,941054,Methicillin,Q91FH1328A,,,,
32003,DescriptorName,D000293,941054,,,1,Adolescent,N,
32004,DescriptorName,D002981,941054,,,2,Clindamycin,N,
32005,QualifierName,Q000009,941054,,,2,,N,adverse effects
32006,DescriptorName,D003429,941054,,,3,Cross Reactions,N,
32007,DescriptorName,D004342,941054,,,4,Drug Hypersensitivity,N,
32008,DescriptorName,D004802,941054,,,5,Eosinophilia,N,
32009,QualifierName,Q000139,941054,,,5,,N,chemically induced
32010,DescriptorName,D005334,941054,,,6,Fever,N,
32011,QualifierName,Q000139,941054,,,6,,N,chemically induced
32012,DescriptorName,D006801,941054,,,7,Humans,N,
32013,DescriptorName,D007674,941054,,,8,Kidney Diseases,N,
32014,QualifierName,Q000139,941054,,,8,,Y,chemically induced
32015,DescriptorName,D008297,941054,,,9,Male,N,
32016,DescriptorName,D008712,941054,,,10,Methicillin,N,
32017,QualifierName,Q000009,941054,,,10,,Y,adverse effects
32018,DescriptorName,D018805,941054,,,11,Sepsis,N,
32019,QualifierName,Q000188,941054,,,11,,N,drug therapy
32020,DescriptorName,D013203,941054,,,12,Staphylococcal Infections,N,
32021,QualifierName,Q000188,941054,,,12,,N,drug therapy
32022,Chemical,D014662,9413296,Vasoconstrictor Agents,0,,,,
32023,Chemical,D008784,9413296,Methysergide,XZA9HY6Z98,,,,
32024,DescriptorName,D000328,9413296,,,1,Adult,N,
32025,DescriptorName,D005260,9413296,,,2,Female,N,
32026,DescriptorName,D006801,9413296,,,3,Humans,N,
32027,DescriptorName,D008784,9413296,,,4,Methysergide,N,
32028,QualifierName,Q000009,9413296,,,4,,Y,adverse effects
32029,DescriptorName,D008881,9413296,,,5,Migraine Disorders,N,
32030,QualifierName,Q000188,9413296,,,5,,N,drug therapy
32031,DescriptorName,D012185,9413296,,,6,Retroperitoneal Fibrosis,N,
32032,QualifierName,Q000097,9413296,,,6,,N,blood
32033,DescriptorName,D014662,9413296,,,7,Vasoconstrictor Agents,N,
32034,QualifierName,Q000009,9413296,,,7,,Y,adverse effects
32035,Chemical,D000998,9426968,Antiviral Agents,0,,,,
32036,Chemical,D000077190,9426968,Interferon alpha-2,0,,,,
32037,Chemical,D016898,9426968,Interferon-alpha,0,,,,
32038,Chemical,D011994,9426968,Recombinant Proteins,0,,,,
32039,DescriptorName,D000998,9426968,,,1,Antiviral Agents,N,
32040,QualifierName,Q000009,9426968,,,1,,Y,adverse effects
32041,DescriptorName,D019698,9426968,,,2,"Hepatitis C, Chronic",N,
32042,QualifierName,Q000188,9426968,,,2,,Y,drug therapy
32043,DescriptorName,D006801,9426968,,,3,Humans,N,
32044,DescriptorName,D000077190,9426968,,,4,Interferon alpha-2,N,
32045,DescriptorName,D016898,9426968,,,5,Interferon-alpha,N,
32046,QualifierName,Q000009,9426968,,,5,,Y,adverse effects
32047,DescriptorName,D008297,9426968,,,6,Male,N,
32048,DescriptorName,D008875,9426968,,,7,Middle Aged,N,
32049,DescriptorName,D011994,9426968,,,8,Recombinant Proteins,N,
32050,DescriptorName,D014820,9426968,,,9,Vitiligo,N,
32051,QualifierName,Q000139,9426968,,,9,,Y,chemically induced
32052,Chemical,D010975,9433539,Platelet Aggregation Inhibitors,0,,,,
32053,Chemical,D011994,9433539,Recombinant Proteins,0,,,,
32054,Chemical,D016179,9433539,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
32055,Chemical,D013988,9433539,Ticlopidine,OM90ZUW7M1,,,,
32056,Chemical,D000069585,9433539,Filgrastim,PVI5M0M1GW,,,,
32057,DescriptorName,D000368,9433539,,,1,Aged,N,
32058,DescriptorName,D000369,9433539,,,2,"Aged, 80 and over",N,
32059,DescriptorName,D000380,9433539,,,3,Agranulocytosis,N,
32060,QualifierName,Q000139,9433539,,,3,,Y,chemically induced
32061,DescriptorName,D005260,9433539,,,4,Female,N,
32062,DescriptorName,D000069585,9433539,,,5,Filgrastim,N,
32063,DescriptorName,D016179,9433539,,,6,Granulocyte Colony-Stimulating Factor,N,
32064,QualifierName,Q000627,9433539,,,6,,Y,therapeutic use
32065,DescriptorName,D006801,9433539,,,7,Humans,N,
32066,DescriptorName,D009503,9433539,,,8,Neutropenia,N,
32067,QualifierName,Q000139,9433539,,,8,,N,chemically induced
32068,DescriptorName,D010975,9433539,,,9,Platelet Aggregation Inhibitors,N,
32069,QualifierName,Q000009,9433539,,,9,,Y,adverse effects
32070,DescriptorName,D011994,9433539,,,10,Recombinant Proteins,N,
32071,DescriptorName,D013988,9433539,,,11,Ticlopidine,N,
32072,QualifierName,Q000009,9433539,,,11,,Y,adverse effects
32073,Chemical,D018906,9443627,"Antineoplastic Agents, Alkylating",0,,,,
32074,Chemical,D007069,9443627,Ifosfamide,UM20QQM95Y,,,,
32075,DescriptorName,D018906,9443627,,,1,"Antineoplastic Agents, Alkylating",N,
32076,QualifierName,Q000009,9443627,,,1,,Y,adverse effects
32077,DescriptorName,D004334,9443627,,,2,Drug Administration Schedule,N,
32078,DescriptorName,D006801,9443627,,,3,Humans,N,
32079,DescriptorName,D007069,9443627,,,4,Ifosfamide,N,
32080,QualifierName,Q000009,9443627,,,4,,Y,adverse effects
32081,DescriptorName,D007223,9443627,,,5,Infant,N,
32082,DescriptorName,D007680,9443627,,,6,Kidney Neoplasms,N,
32083,QualifierName,Q000188,9443627,,,6,,N,drug therapy
32084,DescriptorName,D008954,9443627,,,7,"Models, Biological",N,
32085,DescriptorName,D006435,9443627,,,8,Renal Dialysis,N,
32086,DescriptorName,D009396,9443627,,,9,Wilms Tumor,N,
32087,QualifierName,Q000188,9443627,,,9,,N,drug therapy
32088,Chemical,D000305,946400,Adrenal Cortex Hormones,0,,,,
32089,Chemical,D008750,946400,Methyldopa,56LH93261Y,,,,
32090,DescriptorName,D000305,946400,,,1,Adrenal Cortex Hormones,N,
32091,QualifierName,Q000627,946400,,,1,,N,therapeutic use
32092,DescriptorName,D056486,946400,,,2,Chemical and Drug Induced Liver Injury,N,
32093,QualifierName,Q000188,946400,,,2,,N,drug therapy
32094,DescriptorName,D005260,946400,,,3,Female,N,
32095,DescriptorName,D006801,946400,,,4,Humans,N,
32096,DescriptorName,D006973,946400,,,5,Hypertension,N,
32097,QualifierName,Q000188,946400,,,5,,N,drug therapy
32098,DescriptorName,D008099,946400,,,6,Liver,N,
32099,QualifierName,Q000473,946400,,,6,,N,pathology
32100,DescriptorName,D008750,946400,,,7,Methyldopa,N,
32101,QualifierName,Q000009,946400,,,7,,Y,adverse effects
32102,DescriptorName,D008875,946400,,,8,Middle Aged,N,
32103,Chemical,D000701,9466030,"Analgesics, Opioid",0,,,,
32104,Chemical,D000806,9466030,Angiotensin-Converting Enzyme Inhibitors,0,,,,
32105,Chemical,D000893,9466030,Anti-Inflammatory Agents,0,,,,
32106,Chemical,D000959,9466030,Antihypertensive Agents,0,,,,
32107,Chemical,D001993,9466030,Bronchodilator Agents,0,,,,
32108,Chemical,D005938,9466030,Glucocorticoids,0,,,,
32109,Chemical,D004656,9466030,Enalapril,69PN84IO1A,,,,
32110,Chemical,D009020,9466030,Morphine,76I7G6D29C,,,,
32111,Chemical,D003907,9466030,Dexamethasone,7S5I7G3JQL,,,,
32112,DescriptorName,D000208,9466030,,,1,Acute Disease,N,
32113,DescriptorName,D000280,9466030,,,2,"Administration, Inhalation",N,
32114,DescriptorName,D000284,9466030,,,3,"Administration, Oral",N,
32115,DescriptorName,D000368,9466030,,,4,Aged,N,
32116,DescriptorName,D000701,9466030,,,5,"Analgesics, Opioid",N,
32117,QualifierName,Q000008,9466030,,,5,,N,administration & dosage
32118,DescriptorName,D000806,9466030,,,6,Angiotensin-Converting Enzyme Inhibitors,N,
32119,QualifierName,Q000627,9466030,,,6,,N,therapeutic use
32120,DescriptorName,D000893,9466030,,,7,Anti-Inflammatory Agents,N,
32121,QualifierName,Q000008,9466030,,,7,,N,administration & dosage
32122,DescriptorName,D000959,9466030,,,8,Antihypertensive Agents,N,
32123,QualifierName,Q000627,9466030,,,8,,N,therapeutic use
32124,DescriptorName,D001859,9466030,,,9,Bone Neoplasms,N,
32125,QualifierName,Q000188,9466030,,,9,,N,drug therapy
32126,DescriptorName,D001993,9466030,,,10,Bronchodilator Agents,N,
32127,QualifierName,Q000008,9466030,,,10,,N,administration & dosage
32128,DescriptorName,D003907,9466030,,,11,Dexamethasone,N,
32129,QualifierName,Q000008,9466030,,,11,,N,administration & dosage
32130,DescriptorName,D004417,9466030,,,12,Dyspnea,N,
32131,QualifierName,Q000139,9466030,,,12,,Y,chemically induced
32132,DescriptorName,D004656,9466030,,,13,Enalapril,N,
32133,QualifierName,Q000627,9466030,,,13,,N,therapeutic use
32134,DescriptorName,D005260,9466030,,,14,Female,N,
32135,DescriptorName,D005938,9466030,,,15,Glucocorticoids,N,
32136,QualifierName,Q000008,9466030,,,15,,N,administration & dosage
32137,DescriptorName,D006801,9466030,,,16,Humans,N,
32138,DescriptorName,D006973,9466030,,,17,Hypertension,N,
32139,QualifierName,Q000188,9466030,,,17,,N,drug therapy
32140,DescriptorName,D007442,9466030,,,18,"Intubation, Intratracheal",N,
32141,DescriptorName,D008175,9466030,,,19,Lung Neoplasms,N,
32142,QualifierName,Q000188,9466030,,,19,,N,drug therapy
32143,DescriptorName,D009020,9466030,,,20,Morphine,N,
32144,QualifierName,Q000008,9466030,,,20,,N,administration & dosage
32145,DescriptorName,D009330,9466030,,,21,Nebulizers and Vaporizers,N,
32146,DescriptorName,D010102,9466030,,,22,Oxygen Inhalation Therapy,N,
32147,DescriptorName,D010146,9466030,,,23,Pain,N,
32148,QualifierName,Q000188,9466030,,,23,,N,drug therapy
32149,DescriptorName,D010166,9466030,,,24,Palliative Care,N,
32150,DescriptorName,D012119,9466030,,,25,Respiration,N,
32151,QualifierName,Q000187,9466030,,,25,,N,drug effects
32152,DescriptorName,D012121,9466030,,,26,"Respiration, Artificial",N,
32153,DescriptorName,D012131,9466030,,,27,Respiratory Insufficiency,N,
32154,QualifierName,Q000139,9466030,,,27,,Y,chemically induced
32155,DescriptorName,D012135,9466030,,,28,Respiratory Sounds,N,
32156,QualifierName,Q000187,9466030,,,28,,N,drug effects
32157,Chemical,D010396,9476721,Penicillamine,GNN1DV99GX,,,,
32158,DescriptorName,D000293,9476721,,,1,Adolescent,N,
32159,DescriptorName,D000328,9476721,,,2,Adult,N,
32160,DescriptorName,D001933,9476721,,,3,Brain Stem,N,
32161,QualifierName,Q000187,9476721,,,3,,Y,drug effects
32162,DescriptorName,D004421,9476721,,,4,Dystonia,N,
32163,QualifierName,Q000139,9476721,,,4,,Y,chemically induced
32164,DescriptorName,D005260,9476721,,,5,Female,N,
32165,DescriptorName,D006527,9476721,,,6,Hepatolenticular Degeneration,N,
32166,QualifierName,Q000188,9476721,,,6,,Y,drug therapy
32167,DescriptorName,D006801,9476721,,,7,Humans,N,
32168,DescriptorName,D008279,9476721,,,8,Magnetic Resonance Imaging,N,
32169,DescriptorName,D008297,9476721,,,9,Male,N,
32170,DescriptorName,D010396,9476721,,,10,Penicillamine,N,
32171,QualifierName,Q000009,9476721,,,10,,Y,adverse effects
32172,DescriptorName,D013786,9476721,,,11,Thalamic Diseases,N,
32173,QualifierName,Q000139,9476721,,,11,,Y,chemically induced
32174,Chemical,D018726,9491301,Anti-Dyskinesia Agents,0,,,,
32175,Chemical,D009292,9491301,Narcotic Antagonists,0,,,,
32176,Chemical,D009270,9491301,Naloxone,36B82AMQ7N,,,,
32177,Chemical,D003932,9491301,Heroin,70D95007SX,,,,
32178,Chemical,D006220,9491301,Haloperidol,J6292F8L3D,,,,
32179,DescriptorName,D000328,9491301,,,1,Adult,N,
32180,DescriptorName,D018726,9491301,,,2,Anti-Dyskinesia Agents,N,
32181,QualifierName,Q000627,9491301,,,2,,N,therapeutic use
32182,DescriptorName,D001479,9491301,,,3,Basal Ganglia,N,
32183,QualifierName,Q000000981,9491301,,,3,,N,diagnostic imaging
32184,DescriptorName,D002545,9491301,,,4,Brain Ischemia,N,
32185,QualifierName,Q000139,9491301,,,4,,Y,chemically induced
32186,DescriptorName,D003128,9491301,,,5,Coma,N,
32187,QualifierName,Q000150,9491301,,,5,,N,complications
32188,DescriptorName,D003342,9491301,,,6,Corpus Striatum,N,
32189,QualifierName,Q000000981,9491301,,,6,,N,diagnostic imaging
32190,DescriptorName,D062787,9491301,,,7,Drug Overdose,N,
32191,DescriptorName,D005917,9491301,,,8,Globus Pallidus,N,
32192,QualifierName,Q000473,9491301,,,8,,N,pathology
32193,DescriptorName,D006220,9491301,,,9,Haloperidol,N,
32194,QualifierName,Q000627,9491301,,,9,,N,therapeutic use
32195,DescriptorName,D003932,9491301,,,10,Heroin,N,
32196,QualifierName,Q000009,9491301,,,10,,Y,adverse effects
32197,DescriptorName,D006801,9491301,,,11,Humans,N,
32198,DescriptorName,D008279,9491301,,,12,Magnetic Resonance Imaging,N,
32199,DescriptorName,D008297,9491301,,,13,Male,N,
32200,DescriptorName,D009069,9491301,,,14,Movement Disorders,N,
32201,QualifierName,Q000188,9491301,,,14,,N,drug therapy
32202,DescriptorName,D009270,9491301,,,15,Naloxone,N,
32203,QualifierName,Q000627,9491301,,,15,,N,therapeutic use
32204,DescriptorName,D009292,9491301,,,16,Narcotic Antagonists,N,
32205,QualifierName,Q000627,9491301,,,16,,N,therapeutic use
32206,DescriptorName,D015819,9491301,,,17,"Substance Abuse, Intravenous",N,
32207,QualifierName,Q000150,9491301,,,17,,Y,complications
32208,DescriptorName,D014057,9491301,,,18,"Tomography, X-Ray Computed",N,
32209,Chemical,D000900,9494448,Anti-Bacterial Agents,0,,,,
32210,Chemical,D016572,9494448,Cyclosporine,83HN0GTJ6D,,,,
32211,DescriptorName,D000284,9494448,,,1,"Administration, Oral",N,
32212,DescriptorName,D000328,9494448,,,2,Adult,N,
32213,DescriptorName,D000707,9494448,,,3,Anaphylaxis,N,
32214,QualifierName,Q000139,9494448,,,3,,Y,chemically induced
32215,DescriptorName,D000900,9494448,,,4,Anti-Bacterial Agents,N,
32216,QualifierName,Q000627,9494448,,,4,,N,therapeutic use
32217,DescriptorName,D016572,9494448,,,5,Cyclosporine,N,
32218,QualifierName,Q000008,9494448,,,5,,N,administration & dosage
32219,DescriptorName,D004342,9494448,,,6,Drug Hypersensitivity,N,
32220,QualifierName,Q000517,9494448,,,6,,N,prevention & control
32221,DescriptorName,D004361,9494448,,,7,Drug Tolerance,N,
32222,DescriptorName,D006801,9494448,,,8,Humans,N,
32223,DescriptorName,D007262,9494448,,,9,"Infusions, Intravenous",N,
32224,DescriptorName,D016239,9494448,,,10,MEDLINE,N,
32225,DescriptorName,D008297,9494448,,,11,Male,N,
32226,DescriptorName,D012882,9494448,,,12,Skin Tests,N,
32227,Chemical,D014150,9497597,Antipsychotic Agents,0,,,,
32228,Chemical,D010640,9497597,Phenothiazines,0,,,,
32229,Chemical,D013843,9497597,Thiazines,0,,,,
32230,Chemical,C069248,9497597,prothipendyl,5O6VWA87VA,,,,
32231,DescriptorName,D014150,9497597,,,1,Antipsychotic Agents,N,
32232,QualifierName,Q000009,9497597,,,1,,Y,adverse effects
32233,DescriptorName,D003863,9497597,,,2,Depression,N,
32234,QualifierName,Q000188,9497597,,,2,,N,drug therapy
32235,DescriptorName,D006801,9497597,,,3,Humans,N,
32236,DescriptorName,D008297,9497597,,,4,Male,N,
32237,DescriptorName,D008875,9497597,,,5,Middle Aged,N,
32238,DescriptorName,D010640,9497597,,,6,Phenothiazines,N,
32239,DescriptorName,D011317,9497597,,,7,Priapism,N,
32240,QualifierName,Q000139,9497597,,,7,,Y,chemically induced
32241,DescriptorName,D013843,9497597,,,8,Thiazines,N,
32242,QualifierName,Q000009,9497597,,,8,,Y,adverse effects
32243,Chemical,D003609,9509511,Dactinomycin,1CC1JFE158,,,,
32244,Chemical,D015251,9509511,Epirubicin,3Z8479ZZ5X,,,,
32245,Chemical,D014750,9509511,Vincristine,5J49Q6B70F,,,,
32246,DescriptorName,D000971,9509511,,,1,Antineoplastic Combined Chemotherapy Protocols,N,
32247,QualifierName,Q000009,9509511,,,1,,Y,adverse effects
32248,DescriptorName,D003609,9509511,,,2,Dactinomycin,N,
32249,QualifierName,Q000008,9509511,,,2,,N,administration & dosage
32250,DescriptorName,D003937,9509511,,,3,"Diagnosis, Differential",N,
32251,DescriptorName,D015251,9509511,,,4,Epirubicin,N,
32252,QualifierName,Q000008,9509511,,,4,,N,administration & dosage
32253,DescriptorName,D006504,9509511,,,5,Hepatic Veno-Occlusive Disease,N,
32254,QualifierName,Q000139,9509511,,,5,,Y,chemically induced
32255,DescriptorName,D006801,9509511,,,6,Humans,N,
32256,DescriptorName,D007223,9509511,,,7,Infant,N,
32257,DescriptorName,D007680,9509511,,,8,Kidney Neoplasms,N,
32258,QualifierName,Q000188,9509511,,,8,,Y,drug therapy
32259,DescriptorName,D008099,9509511,,,9,Liver,N,
32260,QualifierName,Q000187,9509511,,,9,,N,drug effects
32261,DescriptorName,D008297,9509511,,,10,Male,N,
32262,DescriptorName,D018227,9509511,,,11,"Sarcoma, Clear Cell",N,
32263,QualifierName,Q000188,9509511,,,11,,Y,drug therapy
32264,DescriptorName,D014750,9509511,,,12,Vincristine,N,
32265,QualifierName,Q000008,9509511,,,12,,N,administration & dosage
32266,DescriptorName,D009396,9509511,,,13,Wilms Tumor,N,
32267,QualifierName,Q000188,9509511,,,13,,Y,drug therapy
32268,Chemical,D001761,9512187,Bleomycin,11056-06-7,,,,
32269,Chemical,D014750,9512187,Vincristine,5J49Q6B70F,,,,
32270,Chemical,D014747,9512187,Vinblastine,5V9KLZ54CY,,,,
32271,DescriptorName,D017088,9512187,,,1,AIDS-Related Opportunistic Infections,N,
32272,QualifierName,Q000188,9512187,,,1,,Y,drug therapy
32273,DescriptorName,D000328,9512187,,,2,Adult,N,
32274,DescriptorName,D000971,9512187,,,3,Antineoplastic Combined Chemotherapy Protocols,N,
32275,QualifierName,Q000009,9512187,,,3,,Y,adverse effects
32276,DescriptorName,D001761,9512187,,,4,Bleomycin,N,
32277,QualifierName,Q000009,9512187,,,4,,N,adverse effects
32278,DescriptorName,D005385,9512187,,,5,Fingers,N,
32279,DescriptorName,D005734,9512187,,,6,Gangrene,N,
32280,QualifierName,Q000139,9512187,,,6,,Y,chemically induced
32281,DescriptorName,D006801,9512187,,,7,Humans,N,
32282,DescriptorName,D008297,9512187,,,8,Male,N,
32283,DescriptorName,D011928,9512187,,,9,Raynaud Disease,N,
32284,QualifierName,Q000139,9512187,,,9,,Y,chemically induced
32285,DescriptorName,D012514,9512187,,,10,"Sarcoma, Kaposi",N,
32286,QualifierName,Q000188,9512187,,,10,,Y,drug therapy
32287,DescriptorName,D014747,9512187,,,11,Vinblastine,N,
32288,QualifierName,Q000009,9512187,,,11,,N,adverse effects
32289,DescriptorName,D014750,9512187,,,12,Vincristine,N,
32290,QualifierName,Q000009,9512187,,,12,,N,adverse effects
32291,Chemical,D000903,9517515,"Antibiotics, Antineoplastic",0,,,,
32292,Chemical,D000970,9517515,Antineoplastic Agents,0,,,,
32293,Chemical,D016898,9517515,Interferon-alpha,0,,,,
32294,Chemical,D015649,9517515,Pentostatin,395575MZO7,,,,
32295,DescriptorName,D000368,9517515,,,1,Aged,N,
32296,DescriptorName,D000903,9517515,,,2,"Antibiotics, Antineoplastic",N,
32297,QualifierName,Q000627,9517515,,,2,,Y,therapeutic use
32298,DescriptorName,D000970,9517515,,,3,Antineoplastic Agents,N,
32299,QualifierName,Q000009,9517515,,,3,,N,adverse effects
32300,DescriptorName,D001706,9517515,,,4,Biopsy,N,
32301,DescriptorName,D001854,9517515,,,5,Bone Marrow Cells,N,
32302,QualifierName,Q000473,9517515,,,5,,N,pathology
32303,DescriptorName,D006801,9517515,,,6,Humans,N,
32304,DescriptorName,D016898,9517515,,,7,Interferon-alpha,N,
32305,QualifierName,Q000009,9517515,,,7,,N,adverse effects
32306,DescriptorName,D007943,9517515,,,8,"Leukemia, Hairy Cell",N,
32307,QualifierName,Q000150,9517515,,,8,,Y,complications
32308,DescriptorName,D008297,9517515,,,9,Male,N,
32309,DescriptorName,D015649,9517515,,,10,Pentostatin,N,
32310,QualifierName,Q000627,9517515,,,10,,Y,therapeutic use
32311,DescriptorName,D012008,9517515,,,11,Recurrence,N,
32312,DescriptorName,D013922,9517515,,,12,Thrombocytosis,N,
32313,QualifierName,Q000139,9517515,,,12,,N,chemically induced
32314,Chemical,D000319,9527943,Adrenergic beta-Antagonists,0,,,,
32315,Chemical,D005938,9527943,Glucocorticoids,0,,,,
32316,Chemical,D003907,9527943,Dexamethasone,7S5I7G3JQL,,,,
32317,Chemical,D011433,9527943,Propranolol,9Y8NXQ24VQ,,,,
32318,DescriptorName,D000319,9527943,,,1,Adrenergic beta-Antagonists,N,
32319,QualifierName,Q000627,9527943,,,1,,Y,therapeutic use
32320,DescriptorName,D001997,9527943,,,2,Bronchopulmonary Dysplasia,N,
32321,QualifierName,Q000188,9527943,,,2,,N,drug therapy
32322,DescriptorName,D002312,9527943,,,3,"Cardiomyopathy, Hypertrophic",N,
32323,QualifierName,Q000139,9527943,,,3,,Y,chemically induced
32324,DescriptorName,D003907,9527943,,,4,Dexamethasone,N,
32325,QualifierName,Q000009,9527943,,,4,,Y,adverse effects
32326,DescriptorName,D005260,9527943,,,5,Female,N,
32327,DescriptorName,D005938,9527943,,,6,Glucocorticoids,N,
32328,QualifierName,Q000009,9527943,,,6,,Y,adverse effects
32329,DescriptorName,D006801,9527943,,,7,Humans,N,
32330,DescriptorName,D007231,9527943,,,8,"Infant, Newborn",N,
32331,DescriptorName,D007234,9527943,,,9,"Infant, Premature",Y,
32332,DescriptorName,D008297,9527943,,,10,Male,N,
32333,DescriptorName,D011433,9527943,,,11,Propranolol,N,
32334,QualifierName,Q000627,9527943,,,11,,Y,therapeutic use
32335,DescriptorName,D014463,9527943,,,12,Ultrasonography,N,
32336,Chemical,D000900,9533061,Anti-Bacterial Agents,0,,,,
32337,Chemical,D001427,9533061,Bacterial Toxins,0,,,,
32338,Chemical,D004768,9533061,Enterotoxins,0,,,,
32339,Chemical,D014622,9533061,"Vaginal Creams, Foams, and Jellies",0,,,,
32340,Chemical,C041348,9533061,"tcdA protein, Clostridium difficile",0,,,,
32341,Chemical,D002981,9533061,Clindamycin,3U02EL437C,,,,
32342,Chemical,C007084,9533061,clindamycin phosphate,EH6D7113I8,,,,
32343,DescriptorName,D000328,9533061,,,1,Adult,N,
32344,DescriptorName,D000900,9533061,,,2,Anti-Bacterial Agents,N,
32345,QualifierName,Q000009,9533061,,,2,,Y,adverse effects
32346,DescriptorName,D001427,9533061,,,3,Bacterial Toxins,Y,
32347,DescriptorName,D002981,9533061,,,4,Clindamycin,N,
32348,QualifierName,Q000009,9533061,,,4,,N,adverse effects
32349,DescriptorName,D016360,9533061,,,5,Clostridium difficile,Y,
32350,QualifierName,Q000302,9533061,,,5,,N,isolation & purification
32351,DescriptorName,D003092,9533061,,,6,Colitis,N,
32352,QualifierName,Q000139,9533061,,,6,,N,chemically induced
32353,DescriptorName,D003967,9533061,,,7,Diarrhea,N,
32354,QualifierName,Q000628,9533061,,,7,,N,therapy
32355,DescriptorName,D004761,9533061,,,8,"Enterocolitis, Pseudomembranous",N,
32356,QualifierName,Q000188,9533061,,,8,,Y,drug therapy
32357,DescriptorName,D004768,9533061,,,9,Enterotoxins,N,
32358,QualifierName,Q000032,9533061,,,9,,Y,analysis
32359,DescriptorName,D005260,9533061,,,10,Female,N,
32360,DescriptorName,D006801,9533061,,,11,Humans,N,
32361,DescriptorName,D014622,9533061,,,12,"Vaginal Creams, Foams, and Jellies",N,
32362,DescriptorName,D016585,9533061,,,13,"Vaginosis, Bacterial",N,
32363,QualifierName,Q000188,9533061,,,13,,N,drug therapy
32364,Chemical,D000927,9545161,Anticonvulsants,0,,,,
32365,Chemical,D014227,9545161,Triazines,0,,,,
32366,Chemical,D000077213,9545161,Lamotrigine,U3H27498KS,,,,
32367,DescriptorName,D000927,9545161,,,1,Anticonvulsants,N,
32368,QualifierName,Q000008,9545161,,,1,,N,administration & dosage
32369,DescriptorName,D017809,9545161,,,2,Fatal Outcome,N,
32370,DescriptorName,D006801,9545161,,,3,Humans,N,
32371,DescriptorName,D000077213,9545161,,,4,Lamotrigine,N,
32372,DescriptorName,D008297,9545161,,,5,Male,N,
32373,DescriptorName,D008875,9545161,,,6,Middle Aged,N,
32374,DescriptorName,D012640,9545161,,,7,Seizures,N,
32375,QualifierName,Q000188,9545161,,,7,,N,drug therapy
32376,DescriptorName,D013262,9545161,,,8,Stevens-Johnson Syndrome,N,
32377,QualifierName,Q000209,9545161,,,8,,Y,etiology
32378,DescriptorName,D014227,9545161,,,9,Triazines,N,
32379,QualifierName,Q000008,9545161,,,9,,N,administration & dosage
32380,Chemical,D014150,9550246,Antipsychotic Agents,0,,,,
32381,Chemical,D018967,9550246,Risperidone,L6UH7ZF8HC,,,,
32382,DescriptorName,D000328,9550246,,,1,Adult,N,
32383,DescriptorName,D014150,9550246,,,2,Antipsychotic Agents,N,
32384,QualifierName,Q000009,9550246,,,2,,Y,adverse effects
32385,DescriptorName,D001007,9550246,,,3,Anxiety,N,
32386,QualifierName,Q000150,9550246,,,3,,N,complications
32387,DescriptorName,D004198,9550246,,,4,Disease Susceptibility,N,
32388,DescriptorName,D005500,9550246,,,5,Follow-Up Studies,N,
32389,DescriptorName,D006801,9550246,,,6,Humans,N,
32390,DescriptorName,D008297,9550246,,,7,Male,N,
32391,DescriptorName,D008875,9550246,,,8,Middle Aged,N,
32392,DescriptorName,D019964,9550246,,,9,Mood Disorders,N,
32393,QualifierName,Q000139,9550246,,,9,,Y,chemically induced
32394,DescriptorName,D018967,9550246,,,10,Risperidone,N,
32395,QualifierName,Q000009,9550246,,,10,,Y,adverse effects
32396,DescriptorName,D012559,9550246,,,11,Schizophrenia,N,
32397,QualifierName,Q000150,9550246,,,11,,N,complications
32398,DescriptorName,D013577,9550246,,,12,Syndrome,N,
32399,DescriptorName,D016896,9550246,,,13,Treatment Outcome,N,
32400,Chemical,D001639,9554064,Bicarbonates,0,,,,
32401,Chemical,D012997,9554064,Solvents,0,,,,
32402,Chemical,D000432,9554064,Methanol,Y4S76JWI15,,,,
32403,DescriptorName,D000328,9554064,,,1,Adult,N,
32404,DescriptorName,D001479,9554064,,,2,Basal Ganglia,N,
32405,QualifierName,Q000187,9554064,,,2,,N,drug effects
32406,DescriptorName,D001639,9554064,,,3,Bicarbonates,N,
32407,QualifierName,Q000627,9554064,,,3,,N,therapeutic use
32408,DescriptorName,D001929,9554064,,,4,Brain Edema,N,
32409,QualifierName,Q000139,9554064,,,4,,N,chemically induced
32410,DescriptorName,D002544,9554064,,,5,Cerebral Infarction,N,
32411,QualifierName,Q000139,9554064,,,5,,Y,chemically induced
32412,DescriptorName,D017809,9554064,,,6,Fatal Outcome,N,
32413,DescriptorName,D005260,9554064,,,7,Female,N,
32414,DescriptorName,D006801,9554064,,,8,Humans,N,
32415,DescriptorName,D000432,9554064,,,9,Methanol,N,
32416,QualifierName,Q000506,9554064,,,9,,Y,poisoning
32417,DescriptorName,D009336,9554064,,,10,Necrosis,N,
32418,DescriptorName,D011699,9554064,,,11,Putamen,N,
32419,QualifierName,Q000000981,9554064,,,11,,N,diagnostic imaging
32420,DescriptorName,D012997,9554064,,,12,Solvents,N,
32421,QualifierName,Q000506,9554064,,,12,,Y,poisoning
32422,DescriptorName,D014057,9554064,,,13,"Tomography, X-Ray Computed",N,
32423,Chemical,D014150,9562211,Antipsychotic Agents,0,,,,
32424,Chemical,D018967,9562211,Risperidone,L6UH7ZF8HC,,,,
32425,DescriptorName,D000328,9562211,,,1,Adult,N,
32426,DescriptorName,D014150,9562211,,,2,Antipsychotic Agents,N,
32427,QualifierName,Q000009,9562211,,,2,,Y,adverse effects
32428,DescriptorName,D004409,9562211,,,3,"Dyskinesia, Drug-Induced",N,
32429,QualifierName,Q000503,9562211,,,3,,Y,physiopathology
32430,DescriptorName,D006801,9562211,,,4,Humans,N,
32431,DescriptorName,D008297,9562211,,,5,Male,N,
32432,DescriptorName,D018967,9562211,,,6,Risperidone,N,
32433,QualifierName,Q000009,9562211,,,6,,Y,adverse effects
32434,DescriptorName,D012559,9562211,,,7,Schizophrenia,N,
32435,QualifierName,Q000150,9562211,,,7,,N,complications
32436,Chemical,D018687,9579301,"Antidepressive Agents, Second-Generation",0,,,,
32437,Chemical,D003511,9579301,Cyclohexanols,0,,,,
32438,Chemical,D000069470,9579301,Venlafaxine Hydrochloride,7D7RX5A8MO,,,,
32439,DescriptorName,D000368,9579301,,,1,Aged,N,
32440,DescriptorName,D018687,9579301,,,2,"Antidepressive Agents, Second-Generation",N,
32441,QualifierName,Q000009,9579301,,,2,,Y,adverse effects
32442,DescriptorName,D003511,9579301,,,3,Cyclohexanols,N,
32443,QualifierName,Q000009,9579301,,,3,,Y,adverse effects
32444,DescriptorName,D005260,9579301,,,4,Female,N,
32445,DescriptorName,D015812,9579301,,,5,"Glaucoma, Angle-Closure",N,
32446,QualifierName,Q000188,9579301,,,5,,Y,drug therapy
32447,DescriptorName,D006801,9579301,,,6,Humans,N,
32448,DescriptorName,D007429,9579301,,,7,Intraocular Pressure,N,
32449,QualifierName,Q000187,9579301,,,7,,Y,drug effects
32450,DescriptorName,D009798,9579301,,,8,Ocular Hypertension,N,
32451,QualifierName,Q000139,9579301,,,8,,N,chemically induced
32452,DescriptorName,D010146,9579301,,,9,Pain,N,
32453,QualifierName,Q000188,9579301,,,9,,N,drug therapy
32454,DescriptorName,D000069470,9579301,,,10,Venlafaxine Hydrochloride,N,
32455,Chemical,D011342,95811,Procainamide,L39WTC366D,,,,
32456,Chemical,D001379,95811,Azathioprine,MRK240IY2L,,,,
32457,Chemical,D011241,95811,Prednisone,VB0R961HZT,,,,
32458,DescriptorName,D001379,95811,,,1,Azathioprine,N,
32459,QualifierName,Q000627,95811,,,1,,N,therapeutic use
32460,DescriptorName,D001706,95811,,,2,Biopsy,N,
32461,DescriptorName,D005921,95811,,,3,Glomerulonephritis,N,
32462,QualifierName,Q000139,95811,,,3,,Y,chemically induced
32463,DescriptorName,D006801,95811,,,4,Humans,N,
32464,DescriptorName,D007678,95811,,,5,Kidney Glomerulus,N,
32465,QualifierName,Q000648,95811,,,5,,N,ultrastructure
32466,DescriptorName,D008180,95811,,,6,"Lupus Erythematosus, Systemic",N,
32467,QualifierName,Q000139,95811,,,6,,Y,chemically induced
32468,DescriptorName,D008297,95811,,,7,Male,N,
32469,DescriptorName,D008875,95811,,,8,Middle Aged,N,
32470,DescriptorName,D011241,95811,,,9,Prednisone,N,
32471,QualifierName,Q000627,95811,,,9,,N,therapeutic use
32472,DescriptorName,D011342,95811,,,10,Procainamide,N,
32473,QualifierName,Q000009,95811,,,10,,Y,adverse effects
32474,DescriptorName,D018754,95811,,,11,Ventricular Dysfunction,N,
32475,QualifierName,Q000188,95811,,,11,,N,drug therapy
32476,Chemical,D000906,9602881,Antibodies,0,,,,
32477,Chemical,D007070,9602881,Immunoglobulin A,0,,,,
32478,Chemical,D003094,9602881,Collagen,9007-34-5,,,,
32479,Chemical,D010400,9602881,Penicillin G,Q42T66VG0C,,,,
32480,DescriptorName,D000368,9602881,,,1,Aged,N,
32481,DescriptorName,D000906,9602881,,,2,Antibodies,N,
32482,QualifierName,Q000032,9602881,,,2,,Y,analysis
32483,DescriptorName,D001485,9602881,,,3,Basement Membrane,N,
32484,QualifierName,Q000276,9602881,,,3,,N,immunology
32485,DescriptorName,D003094,9602881,,,4,Collagen,N,
32486,QualifierName,Q000276,9602881,,,4,,Y,immunology
32487,DescriptorName,D004334,9602881,,,5,Drug Administration Schedule,N,
32488,DescriptorName,D019084,9602881,,,6,"Fluorescent Antibody Technique, Indirect",N,
32489,DescriptorName,D006801,9602881,,,7,Humans,N,
32490,DescriptorName,D007070,9602881,,,8,Immunoglobulin A,N,
32491,QualifierName,Q000276,9602881,,,8,,Y,immunology
32492,DescriptorName,D007262,9602881,,,9,"Infusions, Intravenous",N,
32493,DescriptorName,D008297,9602881,,,10,Male,N,
32494,DescriptorName,D010400,9602881,,,11,Penicillin G,N,
32495,QualifierName,Q000009,9602881,,,11,,Y,adverse effects
32496,DescriptorName,D011008,9602881,,,12,Pneumococcal Infections,N,
32497,QualifierName,Q000188,9602881,,,12,,N,drug therapy
32498,DescriptorName,D012872,9602881,,,13,"Skin Diseases, Vesiculobullous",N,
32499,QualifierName,Q000139,9602881,,,13,,Y,chemically induced
32500,Chemical,D000759,961329,"Adjuvants, Anesthesia",0,,,,
32501,Chemical,D002802,961329,Cholinesterases,EC 3.1.1.8,,,,
32502,Chemical,D013390,961329,Succinylcholine,J2R869A8YF,,,,
32503,DescriptorName,D000759,961329,,,1,"Adjuvants, Anesthesia",N,
32504,QualifierName,Q000009,961329,,,1,,Y,adverse effects
32505,DescriptorName,D001049,961329,,,2,Apnea,N,
32506,QualifierName,Q000139,961329,,,2,,Y,chemically induced
32507,DescriptorName,D002802,961329,,,3,Cholinesterases,N,
32508,QualifierName,Q000008,961329,,,3,,N,administration & dosage
32509,DescriptorName,D006801,961329,,,4,Humans,N,
32510,DescriptorName,D007275,961329,,,5,"Injections, Intravenous",N,
32511,DescriptorName,D008297,961329,,,6,Male,N,
32512,DescriptorName,D008875,961329,,,7,Middle Aged,N,
32513,DescriptorName,D013390,961329,,,8,Succinylcholine,N,
32514,QualifierName,Q000528,961329,,,8,,Y,radiation effects
32515,DescriptorName,D013997,961329,,,9,Time Factors,N,
32516,Chemical,D013566,9619226,Sympathomimetics,0,,,,
32517,Chemical,C016767,9619226,sulprostone,501Q5EQ1GM,,,,
32518,Chemical,D015232,9619226,Dinoprostone,K7Q1JQR04M,,,,
32519,Chemical,D004837,9619226,Epinephrine,YKH834O4BH,,,,
32520,DescriptorName,D000328,9619226,,,1,Adult,N,
32521,DescriptorName,D000768,9619226,,,2,"Anesthesia, General",N,
32522,DescriptorName,D002585,9619226,,,3,Cesarean Section,Y,
32523,DescriptorName,D015232,9619226,,,4,Dinoprostone,N,
32524,QualifierName,Q000008,9619226,,,4,,N,administration & dosage
32525,DescriptorName,D004837,9619226,,,5,Epinephrine,N,
32526,QualifierName,Q000627,9619226,,,5,,N,therapeutic use
32527,DescriptorName,D005260,9619226,,,6,Female,N,
32528,DescriptorName,D006323,9619226,,,7,Heart Arrest,N,
32529,QualifierName,Q000139,9619226,,,7,,Y,chemically induced
32530,DescriptorName,D006327,9619226,,,8,Heart Block,N,
32531,QualifierName,Q000139,9619226,,,8,,Y,chemically induced
32532,DescriptorName,D006801,9619226,,,9,Humans,N,
32533,DescriptorName,D007275,9619226,,,10,"Injections, Intravenous",N,
32534,DescriptorName,D006473,9619226,,,11,Postpartum Hemorrhage,N,
32535,QualifierName,Q000188,9619226,,,11,,Y,drug therapy
32536,DescriptorName,D011247,9619226,,,12,Pregnancy,N,
32537,DescriptorName,D012151,9619226,,,13,Resuscitation,N,
32538,DescriptorName,D013566,9619226,,,14,Sympathomimetics,N,
32539,QualifierName,Q000627,9619226,,,14,,N,therapeutic use
32540,DescriptorName,D014693,9619226,,,15,Ventricular Fibrillation,N,
32541,QualifierName,Q000139,9619226,,,15,,Y,chemically induced
32542,Chemical,D000927,9627209,Anticonvulsants,0,,,,
32543,Chemical,D017367,9627209,Serotonin Uptake Inhibitors,0,,,,
32544,Chemical,D014227,9627209,Triazines,0,,,,
32545,Chemical,D015057,9627209,1-Naphthylamine,9753I242R5,,,,
32546,Chemical,D020280,9627209,Sertraline,QUC7NX6WMB,,,,
32547,Chemical,D000077213,9627209,Lamotrigine,U3H27498KS,,,,
32548,DescriptorName,D015057,9627209,,,1,1-Naphthylamine,N,
32549,QualifierName,Q000008,9627209,,,1,,N,administration & dosage
32550,DescriptorName,D000293,9627209,,,2,Adolescent,N,
32551,DescriptorName,D000328,9627209,,,3,Adult,N,
32552,DescriptorName,D000927,9627209,,,4,Anticonvulsants,N,
32553,QualifierName,Q000008,9627209,,,4,,N,administration & dosage
32554,DescriptorName,D004305,9627209,,,5,"Dose-Response Relationship, Drug",N,
32555,DescriptorName,D004359,9627209,,,6,"Drug Therapy, Combination",N,
32556,DescriptorName,D004827,9627209,,,7,Epilepsy,N,
32557,QualifierName,Q000097,9627209,,,7,,N,blood
32558,DescriptorName,D005260,9627209,,,8,Female,N,
32559,DescriptorName,D006801,9627209,,,9,Humans,N,
32560,DescriptorName,D000077213,9627209,,,10,Lamotrigine,N,
32561,DescriptorName,D008657,9627209,,,11,Metabolic Clearance Rate,N,
32562,QualifierName,Q000187,9627209,,,11,,N,drug effects
32563,DescriptorName,D019965,9627209,,,12,Neurocognitive Disorders,N,
32564,QualifierName,Q000097,9627209,,,12,,N,blood
32565,DescriptorName,D017367,9627209,,,13,Serotonin Uptake Inhibitors,N,
32566,QualifierName,Q000008,9627209,,,13,,N,administration & dosage
32567,DescriptorName,D020280,9627209,,,14,Sertraline,N,
32568,DescriptorName,D014227,9627209,,,15,Triazines,N,
32569,QualifierName,Q000008,9627209,,,15,,N,administration & dosage
32570,Chemical,D000726,9634122,Androgen Antagonists,0,,,,
32571,Chemical,D018931,9634122,"Antineoplastic Agents, Hormonal",0,,,,
32572,Chemical,D014408,9634122,"Biomarkers, Tumor",0,,,,
32573,Chemical,D011944,9634122,"Receptors, Androgen",0,,,,
32574,Chemical,D005485,9634122,Flutamide,76W6J0943E,,,,
32575,Chemical,D017430,9634122,Prostate-Specific Antigen,EC 3.4.21.77,,,,
32576,DescriptorName,D000368,9634122,,,1,Aged,N,
32577,DescriptorName,D000726,9634122,,,2,Androgen Antagonists,N,
32578,QualifierName,Q000008,9634122,,,2,,N,administration & dosage
32579,DescriptorName,D018931,9634122,,,3,"Antineoplastic Agents, Hormonal",N,
32580,QualifierName,Q000008,9634122,,,3,,N,administration & dosage
32581,DescriptorName,D014408,9634122,,,4,"Biomarkers, Tumor",N,
32582,QualifierName,Q000097,9634122,,,4,,Y,blood
32583,DescriptorName,D001859,9634122,,,5,Bone Neoplasms,N,
32584,QualifierName,Q000097,9634122,,,5,,N,blood
32585,DescriptorName,D001918,9634122,,,6,Brachytherapy,N,
32586,DescriptorName,D003131,9634122,,,7,Combined Modality Therapy,N,
32587,DescriptorName,D018450,9634122,,,8,Disease Progression,N,
32588,DescriptorName,D005485,9634122,,,9,Flutamide,N,
32589,QualifierName,Q000008,9634122,,,9,,N,administration & dosage
32590,DescriptorName,D006801,9634122,,,10,Humans,N,
32591,DescriptorName,D008297,9634122,,,11,Male,N,
32592,DescriptorName,D017354,9634122,,,12,Point Mutation,N,
32593,DescriptorName,D017430,9634122,,,13,Prostate-Specific Antigen,N,
32594,QualifierName,Q000097,9634122,,,13,,Y,blood
32595,DescriptorName,D011471,9634122,,,14,Prostatic Neoplasms,N,
32596,QualifierName,Q000097,9634122,,,14,,Y,blood
32597,DescriptorName,D018714,9634122,,,15,"Radiotherapy, Adjuvant",N,
32598,DescriptorName,D011944,9634122,,,16,"Receptors, Androgen",N,
32599,QualifierName,Q000235,9634122,,,16,,N,genetics
32600,DescriptorName,D013375,9634122,,,17,Substance Withdrawal Syndrome,N,
32601,QualifierName,Q000097,9634122,,,17,,Y,blood
32602,Chemical,D000893,9642842,Anti-Inflammatory Agents,0,,,,
32603,Chemical,D001241,9642842,Aspirin,R16CO5Y76E,,,,
32604,Chemical,D011241,9642842,Prednisone,VB0R961HZT,,,,
32605,DescriptorName,D000284,9642842,,,1,"Administration, Oral",N,
32606,DescriptorName,D000293,9642842,,,2,Adolescent,N,
32607,DescriptorName,D000707,9642842,,,3,Anaphylaxis,N,
32608,QualifierName,Q000139,9642842,,,3,,Y,chemically induced
32609,DescriptorName,D000893,9642842,,,4,Anti-Inflammatory Agents,N,
32610,QualifierName,Q000009,9642842,,,4,,Y,adverse effects
32611,DescriptorName,D001241,9642842,,,5,Aspirin,N,
32612,DescriptorName,D001249,9642842,,,6,Asthma,N,
32613,QualifierName,Q000188,9642842,,,6,,N,drug therapy
32614,DescriptorName,D004342,9642842,,,7,Drug Hypersensitivity,N,
32615,DescriptorName,D005260,9642842,,,8,Female,N,
32616,DescriptorName,D006801,9642842,,,9,Humans,N,
32617,DescriptorName,D011241,9642842,,,10,Prednisone,N,
32618,QualifierName,Q000008,9642842,,,10,,N,administration & dosage
32619,Chemical,D014150,9647315,Antipsychotic Agents,0,,,,
32620,Chemical,D014446,9647315,Tyrosine 3-Monooxygenase,EC 1.14.16.2,,,,
32621,Chemical,D006220,9647315,Haloperidol,J6292F8L3D,,,,
32622,DescriptorName,D000704,9647315,,,1,Analysis of Variance,N,
32623,DescriptorName,D000818,9647315,,,2,Animals,N,
32624,DescriptorName,D014150,9647315,,,3,Antipsychotic Agents,N,
32625,QualifierName,Q000627,9647315,,,3,,Y,therapeutic use
32626,DescriptorName,D003712,9647315,,,4,Dendrites,N,
32627,QualifierName,Q000187,9647315,,,4,,N,drug effects
32628,DescriptorName,D005260,9647315,,,5,Female,N,
32629,DescriptorName,D006220,9647315,,,6,Haloperidol,N,
32630,QualifierName,Q000009,9647315,,,6,,Y,adverse effects
32631,DescriptorName,D006801,9647315,,,7,Humans,N,
32632,DescriptorName,D008297,9647315,,,8,Male,N,
32633,DescriptorName,D010302,9647315,,,9,"Parkinson Disease, Secondary",N,
32634,QualifierName,Q000201,9647315,,,9,,Y,enzymology
32635,DescriptorName,D011618,9647315,,,10,Psychotic Disorders,N,
32636,QualifierName,Q000188,9647315,,,10,,N,drug therapy
32637,DescriptorName,D051381,9647315,,,11,Rats,N,
32638,DescriptorName,D017207,9647315,,,12,"Rats, Sprague-Dawley",N,
32639,DescriptorName,D013378,9647315,,,13,Substantia Nigra,N,
32640,QualifierName,Q000187,9647315,,,13,,N,drug effects
32641,DescriptorName,D013997,9647315,,,14,Time Factors,N,
32642,DescriptorName,D014446,9647315,,,15,Tyrosine 3-Monooxygenase,N,
32643,QualifierName,Q000276,9647315,,,15,,N,immunology
32644,Chemical,D010184,9651465,Pancreatic Extracts,0,,,,
32645,DescriptorName,D002675,9651465,,,1,"Child, Preschool",N,
32646,DescriptorName,D003550,9651465,,,2,Cystic Fibrosis,N,
32647,QualifierName,Q000188,9651465,,,2,,Y,drug therapy
32648,DescriptorName,D003888,9651465,,,3,"Desensitization, Immunologic",N,
32649,QualifierName,Q000379,9651465,,,3,,Y,methods
32650,DescriptorName,D003967,9651465,,,4,Diarrhea,N,
32651,QualifierName,Q000139,9651465,,,4,,N,chemically induced
32652,DescriptorName,D004311,9651465,,,5,Double-Blind Method,N,
32653,DescriptorName,D004342,9651465,,,6,Drug Hypersensitivity,N,
32654,QualifierName,Q000209,9651465,,,6,,N,etiology
32655,DescriptorName,D005260,9651465,,,7,Female,N,
32656,DescriptorName,D006801,9651465,,,8,Humans,N,
32657,DescriptorName,D010184,9651465,,,9,Pancreatic Extracts,N,
32658,QualifierName,Q000009,9651465,,,9,,Y,adverse effects
32659,DescriptorName,D015431,9651465,,,10,Weight Loss,N,
32660,Chemical,D000931,9655664,Antidotes,0,,,,
32661,Chemical,D002606,9655664,Charcoal,16291-96-6,,,,
32662,Chemical,D014635,9655664,Valproic Acid,614OI1Z5WI,,,,
32663,Chemical,D008751,9655664,Methylene Blue,T42P99266K,,,,
32664,DescriptorName,D000208,9655664,,,1,Acute Disease,N,
32665,DescriptorName,D000931,9655664,,,2,Antidotes,N,
32666,QualifierName,Q000627,9655664,,,2,,N,therapeutic use
32667,DescriptorName,D002606,9655664,,,3,Charcoal,N,
32668,QualifierName,Q000627,9655664,,,3,,N,therapeutic use
32669,DescriptorName,D002675,9655664,,,4,"Child, Preschool",N,
32670,DescriptorName,D005260,9655664,,,5,Female,N,
32671,DescriptorName,D006801,9655664,,,6,Humans,N,
32672,DescriptorName,D008708,9655664,,,7,Methemoglobinemia,N,
32673,QualifierName,Q000139,9655664,,,7,,Y,chemically induced
32674,DescriptorName,D008751,9655664,,,8,Methylene Blue,N,
32675,QualifierName,Q000627,9655664,,,8,,N,therapeutic use
32676,DescriptorName,D011041,9655664,,,9,Poisoning,N,
32677,QualifierName,Q000628,9655664,,,9,,N,therapy
32678,DescriptorName,D014635,9655664,,,10,Valproic Acid,N,
32679,QualifierName,Q000506,9655664,,,10,,Y,poisoning
32680,Chemical,D000903,9660541,"Antibiotics, Antineoplastic",0,,,,
32681,Chemical,D016685,9660541,Mitomycin,50SG953SK6,,,,
32682,DescriptorName,D000230,9660541,,,1,Adenocarcinoma,N,
32683,QualifierName,Q000188,9660541,,,1,,Y,drug therapy
32684,DescriptorName,D000328,9660541,,,2,Adult,N,
32685,DescriptorName,D000903,9660541,,,3,"Antibiotics, Antineoplastic",N,
32686,QualifierName,Q000009,9660541,,,3,,Y,adverse effects
32687,DescriptorName,D001943,9660541,,,4,Breast Neoplasms,N,
32688,QualifierName,Q000188,9660541,,,4,,Y,drug therapy
32689,DescriptorName,D005260,9660541,,,5,Female,N,
32690,DescriptorName,D006463,9660541,,,6,Hemolytic-Uremic Syndrome,N,
32691,QualifierName,Q000139,9660541,,,6,,Y,chemically induced
32692,DescriptorName,D006801,9660541,,,7,Humans,N,
32693,DescriptorName,D008297,9660541,,,8,Male,N,
32694,DescriptorName,D016685,9660541,,,9,Mitomycin,N,
32695,QualifierName,Q000009,9660541,,,9,,Y,adverse effects
32696,Chemical,D000970,9671138,Antineoplastic Agents,0,,,,
32697,Chemical,D000998,9671138,Antiviral Agents,0,,,,
32698,Chemical,D012254,9671138,Ribavirin,49717AWG6K,,,,
32699,Chemical,D014740,9671138,Vidarabine,FA2DM6879K,,,,
32700,Chemical,C024352,9671138,fludarabine,P2K93U8740,,,,
32701,DescriptorName,D000280,9671138,,,1,"Administration, Inhalation",N,
32702,DescriptorName,D000328,9671138,,,2,Adult,N,
32703,DescriptorName,D000970,9671138,,,3,Antineoplastic Agents,N,
32704,QualifierName,Q000009,9671138,,,3,,Y,adverse effects
32705,DescriptorName,D000998,9671138,,,4,Antiviral Agents,N,
32706,QualifierName,Q000008,9671138,,,4,,N,administration & dosage
32707,DescriptorName,D005260,9671138,,,5,Female,N,
32708,DescriptorName,D006801,9671138,,,6,Humans,N,
32709,DescriptorName,D015451,9671138,,,7,"Leukemia, Lymphocytic, Chronic, B-Cell",N,
32710,QualifierName,Q000150,9671138,,,7,,Y,complications
32711,DescriptorName,D018357,9671138,,,8,Respiratory Syncytial Virus Infections,N,
32712,QualifierName,Q000188,9671138,,,8,,N,drug therapy
32713,DescriptorName,D018113,9671138,,,9,"Respiratory Syncytial Virus, Human",N,
32714,QualifierName,Q000302,9671138,,,9,,N,isolation & purification
32715,DescriptorName,D012254,9671138,,,10,Ribavirin,N,
32716,QualifierName,Q000008,9671138,,,10,,N,administration & dosage
32717,DescriptorName,D014740,9671138,,,11,Vidarabine,N,
32718,QualifierName,Q000009,9671138,,,11,,N,adverse effects
32719,Chemical,D003511,9674820,Cyclohexanols,0,,,,
32720,Chemical,D008996,9674820,Monoamine Oxidase Inhibitors,0,,,,
32721,Chemical,D017367,9674820,Serotonin Uptake Inhibitors,0,,,,
32722,Chemical,D012701,9674820,Serotonin,333DO1RDJY,,,,
32723,Chemical,D000069470,9674820,Venlafaxine Hydrochloride,7D7RX5A8MO,,,,
32724,Chemical,D010624,9674820,Phenelzine,O408N561GF,,,,
32725,DescriptorName,D000328,9674820,,,1,Adult,N,
32726,DescriptorName,D002493,9674820,,,2,Central Nervous System Diseases,N,
32727,QualifierName,Q000139,9674820,,,2,,Y,chemically induced
32728,DescriptorName,D003511,9674820,,,3,Cyclohexanols,N,
32729,QualifierName,Q000009,9674820,,,3,,Y,adverse effects
32730,DescriptorName,D004347,9674820,,,4,Drug Interactions,N,
32731,DescriptorName,D005260,9674820,,,5,Female,N,
32732,DescriptorName,D006801,9674820,,,6,Humans,N,
32733,DescriptorName,D008297,9674820,,,7,Male,N,
32734,DescriptorName,D008875,9674820,,,8,Middle Aged,N,
32735,DescriptorName,D008881,9674820,,,9,Migraine Disorders,N,
32736,QualifierName,Q000188,9674820,,,9,,Y,drug therapy
32737,DescriptorName,D008996,9674820,,,10,Monoamine Oxidase Inhibitors,N,
32738,QualifierName,Q000009,9674820,,,10,,Y,adverse effects
32739,DescriptorName,D010624,9674820,,,11,Phenelzine,N,
32740,QualifierName,Q000009,9674820,,,11,,Y,adverse effects
32741,DescriptorName,D012701,9674820,,,12,Serotonin,N,
32742,QualifierName,Q000378,9674820,,,12,,Y,metabolism
32743,DescriptorName,D017367,9674820,,,13,Serotonin Uptake Inhibitors,N,
32744,QualifierName,Q000009,9674820,,,13,,Y,adverse effects
32745,DescriptorName,D000069470,9674820,,,14,Venlafaxine Hydrochloride,N,
32746,Chemical,D016179,9681211,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
32747,DescriptorName,D000368,9681211,,,1,Aged,N,
32748,DescriptorName,D016179,9681211,,,2,Granulocyte Colony-Stimulating Factor,N,
32749,QualifierName,Q000009,9681211,,,2,,Y,adverse effects
32750,DescriptorName,D006801,9681211,,,3,Humans,N,
32751,DescriptorName,D015479,9681211,,,4,"Leukemia, Myelomonocytic, Acute",N,
32752,QualifierName,Q000150,9681211,,,4,,Y,complications
32753,DescriptorName,D007955,9681211,,,5,Leukemoid Reaction,N,
32754,QualifierName,Q000209,9681211,,,5,,Y,etiology
32755,DescriptorName,D007964,9681211,,,6,Leukocytosis,N,
32756,QualifierName,Q000139,9681211,,,6,,N,chemically induced
32757,DescriptorName,D008297,9681211,,,7,Male,N,
32758,DescriptorName,D009000,9681211,,,8,Monocytes,N,
32759,QualifierName,Q000473,9681211,,,8,,Y,pathology
32760,Chemical,D002699,968449,Chlorambucil,18D0SL7309,,,,
32761,DescriptorName,D000368,968449,,,1,Aged,N,
32762,DescriptorName,D001853,968449,,,2,Bone Marrow,N,
32763,QualifierName,Q000648,968449,,,2,,N,ultrastructure
32764,DescriptorName,D001854,968449,,,3,Bone Marrow Cells,N,
32765,DescriptorName,D002699,968449,,,4,Chlorambucil,N,
32766,QualifierName,Q000009,968449,,,4,,Y,adverse effects
32767,DescriptorName,D002869,968449,,,5,Chromosome Aberrations,Y,
32768,DescriptorName,D002872,968449,,,6,Chromosome Deletion,N,
32769,DescriptorName,D005260,968449,,,7,Female,N,
32770,DescriptorName,D006801,968449,,,8,Humans,N,
32771,DescriptorName,D008297,968449,,,9,Male,N,
32772,DescriptorName,D008875,968449,,,10,Middle Aged,N,
32773,DescriptorName,D011087,968449,,,11,Polycythemia Vera,N,
32774,QualifierName,Q000188,968449,,,11,,Y,drug therapy
32775,DescriptorName,D014178,968449,,,12,"Translocation, Genetic",N,
32776,Chemical,D019268,9695308,"Antibodies, Antineutrophil Cytoplasmic",0,,,,
32777,Chemical,D013956,9695308,Antithyroid Agents,0,,,,
32778,Chemical,D011441,9695308,Propylthiouracil,721M9407IY,,,,
32779,DescriptorName,D000293,9695308,,,1,Adolescent,N,
32780,DescriptorName,D019268,9695308,,,2,"Antibodies, Antineutrophil Cytoplasmic",N,
32781,QualifierName,Q000097,9695308,,,2,,Y,blood
32782,DescriptorName,D013956,9695308,,,3,Antithyroid Agents,N,
32783,QualifierName,Q000009,9695308,,,3,,Y,adverse effects
32784,DescriptorName,D005260,9695308,,,4,Female,N,
32785,DescriptorName,D005921,9695308,,,5,Glomerulonephritis,N,
32786,QualifierName,Q000139,9695308,,,5,,Y,chemically induced
32787,DescriptorName,D005923,9695308,,,6,"Glomerulosclerosis, Focal Segmental",N,
32788,QualifierName,Q000139,9695308,,,6,,N,chemically induced
32789,DescriptorName,D006801,9695308,,,7,Humans,N,
32790,DescriptorName,D006980,9695308,,,8,Hyperthyroidism,N,
32791,QualifierName,Q000150,9695308,,,8,,Y,complications
32792,DescriptorName,D009336,9695308,,,9,Necrosis,N,
32793,DescriptorName,D011441,9695308,,,10,Propylthiouracil,N,
32794,QualifierName,Q000009,9695308,,,10,,Y,adverse effects
32795,Chemical,D018927,9701106,Anti-Asthmatic Agents,0,,,,
32796,Chemical,D020024,9701106,Leukotriene Antagonists,0,,,,
32797,Chemical,D014105,9701106,Tosyl Compounds,0,,,,
32798,Chemical,D013806,9701106,Theophylline,C137DTR5RG,,,,
32799,Chemical,C062735,9701106,zafirlukast,XZ629S5L50,,,,
32800,DescriptorName,D000293,9701106,,,1,Adolescent,N,
32801,DescriptorName,D018927,9701106,,,2,Anti-Asthmatic Agents,N,
32802,QualifierName,Q000009,9701106,,,2,,Y,adverse effects
32803,DescriptorName,D001249,9701106,,,3,Asthma,N,
32804,QualifierName,Q000188,9701106,,,3,,Y,drug therapy
32805,DescriptorName,D004347,9701106,,,4,Drug Interactions,N,
32806,DescriptorName,D004359,9701106,,,5,"Drug Therapy, Combination",N,
32807,DescriptorName,D005260,9701106,,,6,Female,N,
32808,DescriptorName,D006801,9701106,,,7,Humans,N,
32809,DescriptorName,D020024,9701106,,,8,Leukotriene Antagonists,N,
32810,DescriptorName,D013806,9701106,,,9,Theophylline,N,
32811,QualifierName,Q000097,9701106,,,9,,Y,blood
32812,DescriptorName,D014105,9701106,,,10,Tosyl Compounds,N,
32813,QualifierName,Q000009,9701106,,,10,,Y,adverse effects
32814,Chemical,D014150,9704170,Antipsychotic Agents,0,,,,
32815,Chemical,D003024,9704170,Clozapine,J60AR2IKIC,,,,
32816,Chemical,D011188,9704170,Potassium,RWP5GA015D,,,,
32817,Chemical,D002118,9704170,Calcium,SY7Q814VUP,,,,
32818,DescriptorName,D000328,9704170,,,1,Adult,N,
32819,DescriptorName,D014150,9704170,,,2,Antipsychotic Agents,N,
32820,QualifierName,Q000009,9704170,,,2,,Y,adverse effects
32821,DescriptorName,D002118,9704170,,,3,Calcium,N,
32822,QualifierName,Q000502,9704170,,,3,,Y,physiology
32823,DescriptorName,D002463,9704170,,,4,Cell Membrane Permeability,N,
32824,QualifierName,Q000502,9704170,,,4,,Y,physiology
32825,DescriptorName,D003024,9704170,,,5,Clozapine,N,
32826,QualifierName,Q000009,9704170,,,5,,Y,adverse effects
32827,DescriptorName,D006801,9704170,,,6,Humans,N,
32828,DescriptorName,D008297,9704170,,,7,Male,N,
32829,DescriptorName,D009212,9704170,,,8,Myoglobinuria,N,
32830,QualifierName,Q000139,9704170,,,8,,N,chemically induced
32831,DescriptorName,D011188,9704170,,,9,Potassium,N,
32832,QualifierName,Q000378,9704170,,,9,,Y,metabolism
32833,DescriptorName,D012206,9704170,,,10,Rhabdomyolysis,N,
32834,QualifierName,Q000139,9704170,,,10,,Y,chemically induced
32835,DescriptorName,D012559,9704170,,,11,Schizophrenia,N,
32836,QualifierName,Q000188,9704170,,,11,,Y,drug therapy
32837,Chemical,D006634,9709726,Histamine H1 Antagonists,0,,,,
32838,Chemical,D004155,9709726,Diphenhydramine,8GTS82S83M,,,,
32839,DescriptorName,D000293,9709726,,,1,Adolescent,N,
32840,DescriptorName,D000328,9709726,,,2,Adult,N,
32841,DescriptorName,D002648,9709726,,,3,Child,N,
32842,DescriptorName,D002908,9709726,,,4,Chronic Disease,N,
32843,DescriptorName,D004155,9709726,,,5,Diphenhydramine,N,
32844,QualifierName,Q000009,9709726,,,5,,Y,adverse effects
32845,DescriptorName,D005260,9709726,,,6,Female,N,
32846,DescriptorName,D006402,9709726,,,7,Hematologic Diseases,N,
32847,QualifierName,Q000188,9709726,,,7,,N,drug therapy
32848,DescriptorName,D006634,9709726,,,8,Histamine H1 Antagonists,N,
32849,QualifierName,Q000009,9709726,,,8,,Y,adverse effects
32850,DescriptorName,D006801,9709726,,,9,Humans,N,
32851,DescriptorName,D008297,9709726,,,10,Male,N,
32852,DescriptorName,D009369,9709726,,,11,Neoplasms,N,
32853,QualifierName,Q000188,9709726,,,11,,N,drug therapy
32854,DescriptorName,D012306,9709726,,,12,Risk,N,
32855,DescriptorName,D019966,9709726,,,13,Substance-Related Disorders,N,
32856,QualifierName,Q000209,9709726,,,13,,Y,etiology
32857,Chemical,D000894,9719245,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
32858,Chemical,D019804,9719245,Mesalamine,4Q81I59GXC,,,,
32859,DescriptorName,D000328,9719245,,,1,Adult,N,
32860,DescriptorName,D000894,9719245,,,2,"Anti-Inflammatory Agents, Non-Steroidal",N,
32861,QualifierName,Q000009,9719245,,,2,,Y,adverse effects
32862,DescriptorName,D003424,9719245,,,3,Crohn Disease,N,
32863,QualifierName,Q000188,9719245,,,3,,Y,drug therapy
32864,DescriptorName,D003937,9719245,,,4,"Diagnosis, Differential",N,
32865,DescriptorName,D006801,9719245,,,5,Humans,N,
32866,DescriptorName,D008297,9719245,,,6,Male,N,
32867,DescriptorName,D019804,9719245,,,7,Mesalamine,N,
32868,QualifierName,Q000009,9719245,,,7,,Y,adverse effects
32869,DescriptorName,D010198,9719245,,,8,Pancytopenia,N,
32870,QualifierName,Q000139,9719245,,,8,,Y,chemically induced
32871,DescriptorName,D013997,9719245,,,9,Time Factors,N,
32872,Chemical,D014151,9723127,Anti-Anxiety Agents,0,,,,
32873,Chemical,D006728,9723127,Hormones,0,,,,
32874,Chemical,D006854,9723127,Hydrocortisone,WI4X0X7BPJ,,,,
32875,Chemical,D000525,9723127,Alprazolam,YU55MQ3IZY,,,,
32876,DescriptorName,D000328,9723127,,,1,Adult,N,
32877,DescriptorName,D000525,9723127,,,2,Alprazolam,N,
32878,QualifierName,Q000008,9723127,,,2,,N,administration & dosage
32879,DescriptorName,D014151,9723127,,,3,Anti-Anxiety Agents,N,
32880,QualifierName,Q000008,9723127,,,3,,N,administration & dosage
32881,DescriptorName,D004305,9723127,,,4,"Dose-Response Relationship, Drug",N,
32882,DescriptorName,D006728,9723127,,,5,Hormones,N,
32883,QualifierName,Q000097,9723127,,,5,,N,blood
32884,DescriptorName,D006801,9723127,,,6,Humans,N,
32885,DescriptorName,D006854,9723127,,,7,Hydrocortisone,N,
32886,QualifierName,Q000097,9723127,,,7,,Y,blood
32887,DescriptorName,D008297,9723127,,,8,Male,N,
32888,DescriptorName,D016584,9723127,,,9,Panic Disorder,N,
32889,QualifierName,Q000188,9723127,,,9,,Y,drug therapy
32890,Chemical,D007166,9725786,Immunosuppressive Agents,0,,,,
32891,Chemical,D002443,9725786,Ceftriaxone,75J73V1629,,,,
32892,Chemical,D015662,9725786,"Trimethoprim, Sulfamethoxazole Drug Combination",8064-90-2,,,,
32893,Chemical,D000583,9725786,Amikacin,84319SGC3C,,,,
32894,DescriptorName,D000583,9725786,,,1,Amikacin,N,
32895,QualifierName,Q000627,9725786,,,1,,N,therapeutic use
32896,DescriptorName,D001922,9725786,,,2,Brain Abscess,N,
32897,QualifierName,Q000188,9725786,,,2,,Y,drug therapy
32898,DescriptorName,D002443,9725786,,,3,Ceftriaxone,N,
32899,QualifierName,Q000627,9725786,,,3,,N,therapeutic use
32900,DescriptorName,D004359,9725786,,,4,"Drug Therapy, Combination",N,
32901,QualifierName,Q000627,9725786,,,4,,Y,therapeutic use
32902,DescriptorName,D006801,9725786,,,5,Humans,N,
32903,DescriptorName,D007165,9725786,,,6,Immunosuppression,N,
32904,QualifierName,Q000009,9725786,,,6,,Y,adverse effects
32905,DescriptorName,D007166,9725786,,,7,Immunosuppressive Agents,N,
32906,QualifierName,Q000627,9725786,,,7,,N,therapeutic use
32907,DescriptorName,D016030,9725786,,,8,Kidney Transplantation,Y,
32908,DescriptorName,D008297,9725786,,,9,Male,N,
32909,DescriptorName,D008875,9725786,,,10,Middle Aged,N,
32910,DescriptorName,D009617,9725786,,,11,Nocardia Infections,N,
32911,QualifierName,Q000188,9725786,,,11,,Y,drug therapy
32912,DescriptorName,D009616,9725786,,,12,Nocardia asteroides,Y,
32913,DescriptorName,D009894,9725786,,,13,Opportunistic Infections,N,
32914,QualifierName,Q000188,9725786,,,13,,Y,drug therapy
32915,DescriptorName,D016896,9725786,,,14,Treatment Outcome,N,
32916,DescriptorName,D015662,9725786,,,15,"Trimethoprim, Sulfamethoxazole Drug Combination",N,
32917,QualifierName,Q000627,9725786,,,15,,N,therapeutic use
32918,Chemical,D000970,9733234,Antineoplastic Agents,0,,,,
32919,DescriptorName,D000158,9733234,,,1,Acoustic Impedance Tests,N,
32920,QualifierName,Q000379,9733234,,,1,,N,methods
32921,DescriptorName,D000161,9733234,,,2,Acoustic Stimulation,N,
32922,QualifierName,Q000379,9733234,,,2,,Y,methods
32923,DescriptorName,D000970,9733234,,,3,Antineoplastic Agents,N,
32924,QualifierName,Q000009,9733234,,,3,,Y,adverse effects
32925,DescriptorName,D001301,9733234,,,4,"Audiometry, Pure-Tone",N,
32926,QualifierName,Q000379,9733234,,,4,,N,methods
32927,DescriptorName,D001309,9733234,,,5,Auditory Threshold,N,
32928,DescriptorName,D002675,9733234,,,6,"Child, Preschool",N,
32929,DescriptorName,D003051,9733234,,,7,Cochlea,N,
32930,QualifierName,Q000187,9733234,,,7,,Y,drug effects
32931,DescriptorName,D003388,9733234,,,8,"Cranial Fossa, Posterior",N,
32932,DescriptorName,D018450,9733234,,,9,Disease Progression,N,
32933,DescriptorName,D016057,9733234,,,10,"Evoked Potentials, Auditory, Brain Stem",N,
32934,DescriptorName,D006319,9733234,,,11,"Hearing Loss, Sensorineural",N,
32935,QualifierName,Q000139,9733234,,,11,,Y,chemically induced
32936,DescriptorName,D006801,9733234,,,12,Humans,N,
32937,DescriptorName,D008527,9733234,,,13,Medulloblastoma,N,
32938,QualifierName,Q000188,9733234,,,13,,N,drug therapy
32939,DescriptorName,D012888,9733234,,,14,Skull Neoplasms,N,
32940,QualifierName,Q000188,9733234,,,14,,N,drug therapy
32941,Chemical,D010423,9737132,Pentazocine,RP4A60D26L,,,,
32942,DescriptorName,D001706,9737132,,,1,Biopsy,N,
32943,DescriptorName,D002081,9737132,,,2,Buttocks,N,
32944,QualifierName,Q000294,9737132,,,2,,N,innervation
32945,DescriptorName,D005260,9737132,,,3,Female,N,
32946,DescriptorName,D005356,9737132,,,4,Fibromyalgia,N,
32947,QualifierName,Q000139,9737132,,,4,,Y,chemically induced
32948,DescriptorName,D006801,9737132,,,5,Humans,N,
32949,DescriptorName,D007273,9737132,,,6,"Injections, Intramuscular",N,
32950,DescriptorName,D008875,9737132,,,7,Middle Aged,N,
32951,DescriptorName,D009455,9737132,,,8,Neurofibroma,N,
32952,QualifierName,Q000139,9737132,,,8,,Y,chemically induced
32953,DescriptorName,D010146,9737132,,,9,Pain,N,
32954,QualifierName,Q000188,9737132,,,9,,N,drug therapy
32955,DescriptorName,D010423,9737132,,,10,Pentazocine,N,
32956,QualifierName,Q000008,9737132,,,10,,Y,administration & dosage
32957,DescriptorName,D011129,9737132,,,11,Polyradiculoneuropathy,N,
32958,QualifierName,Q000139,9737132,,,11,,Y,chemically induced
32959,DescriptorName,D013848,9737132,,,12,Thigh,N,
32960,QualifierName,Q000294,9737132,,,12,,N,innervation
32961,Chemical,D014150,9754850,Antipsychotic Agents,0,,,,
32962,Chemical,D001569,9754850,Benzodiazepines,12794-10-4,,,,
32963,Chemical,D010890,9754850,Pirenzepine,3G0285N20N,,,,
32964,Chemical,D000077152,9754850,Olanzapine,N7U69T4SZR,,,,
32965,DescriptorName,D000328,9754850,,,1,Adult,N,
32966,DescriptorName,D017109,9754850,,,2,"Akathisia, Drug-Induced",N,
32967,QualifierName,Q000209,9754850,,,2,,Y,etiology
32968,DescriptorName,D014150,9754850,,,3,Antipsychotic Agents,N,
32969,QualifierName,Q000009,9754850,,,3,,Y,adverse effects
32970,DescriptorName,D001569,9754850,,,4,Benzodiazepines,N,
32971,DescriptorName,D005260,9754850,,,5,Female,N,
32972,DescriptorName,D006801,9754850,,,6,Humans,N,
32973,DescriptorName,D008875,9754850,,,7,Middle Aged,N,
32974,DescriptorName,D000077152,9754850,,,8,Olanzapine,N,
32975,DescriptorName,D010890,9754850,,,9,Pirenzepine,N,
32976,QualifierName,Q000009,9754850,,,9,,N,adverse effects
32977,DescriptorName,D012559,9754850,,,10,Schizophrenia,N,
32978,QualifierName,Q000188,9754850,,,10,,Y,drug therapy
32979,Chemical,D002800,9758325,Cholinesterase Inhibitors,0,,,,
32980,Chemical,D018727,9758325,Muscarinic Antagonists,0,,,,
32981,Chemical,D004316,9758325,Doxepin,1668-19-5,,,,
32982,Chemical,D001285,9758325,Atropine,7C0697DR9I,,,,
32983,Chemical,D014236,9758325,Trichlorfon,DBF2DG4G2K,,,,
32984,DescriptorName,D000368,9758325,,,1,Aged,N,
32985,DescriptorName,D000544,9758325,,,2,Alzheimer Disease,N,
32986,QualifierName,Q000188,9758325,,,2,,N,drug therapy
32987,DescriptorName,D001285,9758325,,,3,Atropine,N,
32988,QualifierName,Q000009,9758325,,,3,,Y,adverse effects
32989,DescriptorName,D002800,9758325,,,4,Cholinesterase Inhibitors,N,
32990,QualifierName,Q000009,9758325,,,4,,Y,adverse effects
32991,DescriptorName,D004316,9758325,,,5,Doxepin,N,
32992,QualifierName,Q000009,9758325,,,5,,Y,adverse effects
32993,DescriptorName,D004347,9758325,,,6,Drug Interactions,N,
32994,DescriptorName,D005260,9758325,,,7,Female,N,
32995,DescriptorName,D006801,9758325,,,8,Humans,N,
32996,DescriptorName,D008875,9758325,,,9,Middle Aged,N,
32997,DescriptorName,D018727,9758325,,,10,Muscarinic Antagonists,N,
32998,QualifierName,Q000009,9758325,,,10,,Y,adverse effects
32999,DescriptorName,D012640,9758325,,,11,Seizures,N,
33000,QualifierName,Q000139,9758325,,,11,,Y,chemically induced
33001,DescriptorName,D014236,9758325,,,12,Trichlorfon,N,
33002,QualifierName,Q000009,9758325,,,12,,Y,adverse effects
33003,Chemical,D005343,9760614,Fibrinolytic Agents,0,,,,
33004,Chemical,D011994,9760614,Recombinant Proteins,0,,,,
33005,Chemical,D010959,9760614,Tissue Plasminogen Activator,EC 3.4.21.68,,,,
33006,DescriptorName,D000328,9760614,,,1,Adult,N,
33007,DescriptorName,D000368,9760614,,,2,Aged,N,
33008,DescriptorName,D000867,9760614,,,3,Anterior Chamber,N,
33009,QualifierName,Q000000981,9760614,,,3,,N,diagnostic imaging
33010,DescriptorName,D002387,9760614,,,4,Cataract Extraction,N,
33011,QualifierName,Q000009,9760614,,,4,,N,adverse effects
33012,DescriptorName,D002648,9760614,,,5,Child,N,
33013,DescriptorName,D048909,9760614,,,6,Diabetes Complications,N,
33014,DescriptorName,D005131,9760614,,,7,Eye Injuries,N,
33015,QualifierName,Q000150,9760614,,,7,,N,complications
33016,DescriptorName,D005260,9760614,,,8,Female,N,
33017,DescriptorName,D005343,9760614,,,9,Fibrinolytic Agents,N,
33018,QualifierName,Q000008,9760614,,,9,,Y,administration & dosage
33019,DescriptorName,D005500,9760614,,,10,Follow-Up Studies,N,
33020,DescriptorName,D006801,9760614,,,11,Humans,N,
33021,DescriptorName,D006988,9760614,,,12,Hyphema,N,
33022,QualifierName,Q000175,9760614,,,12,,N,diagnosis
33023,DescriptorName,D007267,9760614,,,13,Injections,N,
33024,DescriptorName,D008297,9760614,,,14,Male,N,
33025,DescriptorName,D011183,9760614,,,15,Postoperative Complications,N,
33026,QualifierName,Q000175,9760614,,,15,,N,diagnosis
33027,DescriptorName,D011994,9760614,,,16,Recombinant Proteins,N,
33028,DescriptorName,D010959,9760614,,,17,Tissue Plasminogen Activator,N,
33029,QualifierName,Q000008,9760614,,,17,,Y,administration & dosage
33030,DescriptorName,D014463,9760614,,,18,Ultrasonography,N,
33031,DescriptorName,D014792,9760614,,,19,Visual Acuity,N,
33032,DescriptorName,D014821,9760614,,,20,Vitrectomy,N,
33033,QualifierName,Q000009,9760614,,,20,,N,adverse effects
33034,DescriptorName,D014949,9760614,,,21,"Wounds, Nonpenetrating",N,
33035,QualifierName,Q000150,9760614,,,21,,N,complications
33036,Chemical,D000923,9770151,Anticestodal Agents,0,,,,
33037,Chemical,D011223,9770151,Praziquantel,6490C9U457,,,,
33038,DescriptorName,D000328,9770151,,,1,Adult,N,
33039,DescriptorName,D000818,9770151,,,2,Animals,N,
33040,DescriptorName,D000923,9770151,,,3,Anticestodal Agents,N,
33041,QualifierName,Q000009,9770151,,,3,,N,adverse effects
33042,DescriptorName,D002675,9770151,,,4,"Child, Preschool",N,
33043,DescriptorName,D005260,9770151,,,5,Female,N,
33044,DescriptorName,D006801,9770151,,,6,Humans,N,
33045,DescriptorName,D007814,9770151,,,7,Larva,N,
33046,DescriptorName,D008297,9770151,,,8,Male,N,
33047,DescriptorName,D009656,9770151,,,9,North America,N,
33048,DescriptorName,D011223,9770151,,,10,Praziquantel,N,
33049,QualifierName,Q000009,9770151,,,10,,N,adverse effects
33050,DescriptorName,D011817,9770151,,,11,Rabbits,N,
33051,DescriptorName,D013621,9770151,,,12,Taenia,N,
33052,QualifierName,Q000254,9770151,,,12,,N,growth & development
33053,DescriptorName,D013622,9770151,,,13,Taeniasis,Y,
33054,QualifierName,Q000188,9770151,,,13,,N,drug therapy
33055,Chemical,D014150,9776099,Antipsychotic Agents,0,,,,
33056,Chemical,D018491,9776099,Dopamine Agonists,0,,,,
33057,Chemical,D009125,9776099,"Muscle Relaxants, Central",0,,,,
33058,Chemical,D001971,9776099,Bromocriptine,3A64E3G5ZO,,,,
33059,Chemical,D003620,9776099,Dantrolene,F64QU97QCR,,,,
33060,Chemical,D006220,9776099,Haloperidol,J6292F8L3D,,,,
33061,DescriptorName,D000062,9776099,,,1,"Accidents, Occupational",N,
33062,DescriptorName,D000328,9776099,,,2,Adult,N,
33063,DescriptorName,D014150,9776099,,,3,Antipsychotic Agents,N,
33064,QualifierName,Q000009,9776099,,,3,,Y,adverse effects
33065,DescriptorName,D001971,9776099,,,4,Bromocriptine,N,
33066,QualifierName,Q000627,9776099,,,4,,N,therapeutic use
33067,DescriptorName,D002056,9776099,,,5,Burns,N,
33068,QualifierName,Q000150,9776099,,,5,,Y,complications
33069,DescriptorName,D003620,9776099,,,6,Dantrolene,N,
33070,QualifierName,Q000627,9776099,,,6,,N,therapeutic use
33071,DescriptorName,D003646,9776099,,,7,Debridement,N,
33072,DescriptorName,D003693,9776099,,,8,Delirium,N,
33073,QualifierName,Q000150,9776099,,,8,,N,complications
33074,DescriptorName,D018491,9776099,,,9,Dopamine Agonists,N,
33075,QualifierName,Q000627,9776099,,,9,,N,therapeutic use
33076,DescriptorName,D005334,9776099,,,10,Fever,N,
33077,QualifierName,Q000150,9776099,,,10,,N,complications
33078,DescriptorName,D005500,9776099,,,11,Follow-Up Studies,N,
33079,DescriptorName,D006220,9776099,,,12,Haloperidol,N,
33080,QualifierName,Q000009,9776099,,,12,,Y,adverse effects
33081,DescriptorName,D006801,9776099,,,13,Humans,N,
33082,DescriptorName,D008297,9776099,,,14,Male,N,
33083,DescriptorName,D009125,9776099,,,15,"Muscle Relaxants, Central",N,
33084,QualifierName,Q000627,9776099,,,15,,N,therapeutic use
33085,DescriptorName,D009459,9776099,,,16,Neuroleptic Malignant Syndrome,N,
33086,QualifierName,Q000175,9776099,,,16,,N,diagnosis
33087,DescriptorName,D011595,9776099,,,17,Psychomotor Agitation,N,
33088,QualifierName,Q000150,9776099,,,17,,N,complications
33089,DescriptorName,D013530,9776099,,,18,Surgical Wound Infection,N,
33090,QualifierName,Q000150,9776099,,,18,,N,complications
33091,Chemical,D011994,9777751,Recombinant Proteins,0,,,,
33092,Chemical,D016179,9777751,Granulocyte Colony-Stimulating Factor,143011-72-7,,,,
33093,Chemical,D008713,9777751,Methimazole,554Z48XN5E,,,,
33094,DescriptorName,D000741,9777751,,,1,"Anemia, Aplastic",N,
33095,QualifierName,Q000139,9777751,,,1,,Y,chemically induced
33096,DescriptorName,D001773,9777751,,,2,Blood Cells,N,
33097,QualifierName,Q000473,9777751,,,2,,N,pathology
33098,DescriptorName,D001853,9777751,,,3,Bone Marrow,N,
33099,QualifierName,Q000473,9777751,,,3,,N,pathology
33100,DescriptorName,D005260,9777751,,,4,Female,N,
33101,DescriptorName,D016179,9777751,,,5,Granulocyte Colony-Stimulating Factor,N,
33102,QualifierName,Q000627,9777751,,,5,,Y,therapeutic use
33103,DescriptorName,D006111,9777751,,,6,Graves Disease,N,
33104,QualifierName,Q000188,9777751,,,6,,N,drug therapy
33105,DescriptorName,D006801,9777751,,,7,Humans,N,
33106,DescriptorName,D008713,9777751,,,8,Methimazole,N,
33107,QualifierName,Q000009,9777751,,,8,,Y,adverse effects
33108,DescriptorName,D008875,9777751,,,9,Middle Aged,N,
33109,DescriptorName,D011994,9777751,,,10,Recombinant Proteins,N,
33110,Chemical,D018943,9787325,Anthracyclines,0,,,,
33111,Chemical,D000964,9787325,"Antimetabolites, Antineoplastic",0,,,,
33112,Chemical,D008727,9787325,Methotrexate,YL5FZ2Y5U1,,,,
33113,DescriptorName,D000293,9787325,,,1,Adolescent,N,
33114,DescriptorName,D000818,9787325,,,2,Animals,N,
33115,DescriptorName,D018943,9787325,,,3,Anthracyclines,N,
33116,QualifierName,Q000009,9787325,,,3,,N,adverse effects
33117,DescriptorName,D000964,9787325,,,4,"Antimetabolites, Antineoplastic",N,
33118,QualifierName,Q000009,9787325,,,4,,N,adverse effects
33119,DescriptorName,D000971,9787325,,,5,Antineoplastic Combined Chemotherapy Protocols,N,
33120,QualifierName,Q000627,9787325,,,5,,N,therapeutic use
33121,DescriptorName,D002648,9787325,,,6,Child,N,
33122,DescriptorName,D005260,9787325,,,7,Female,N,
33123,DescriptorName,D005923,9787325,,,8,"Glomerulosclerosis, Focal Segmental",N,
33124,QualifierName,Q000209,9787325,,,8,,Y,etiology
33125,DescriptorName,D006801,9787325,,,9,Humans,N,
33126,DescriptorName,D008727,9787325,,,10,Methotrexate,N,
33127,QualifierName,Q000009,9787325,,,10,,N,adverse effects
33128,DescriptorName,D054198,9787325,,,11,Precursor Cell Lymphoblastic Leukemia-Lymphoma,N,
33129,QualifierName,Q000150,9787325,,,11,,Y,complications
33130,DescriptorName,D051381,9787325,,,12,Rats,N,
33131,Chemical,D002867,9792602,Chromones,0,,,,
33132,Chemical,D020024,9792602,Leukotriene Antagonists,0,,,,
33133,Chemical,D003404,9792602,Creatinine,AYI8EX34EU,,,,
33134,Chemical,C047681,9792602,pranlukast,TB8Z891092,,,,
33135,DescriptorName,D000208,9792602,,,1,Acute Disease,N,
33136,DescriptorName,D001249,9792602,,,2,Asthma,N,
33137,QualifierName,Q000188,9792602,,,2,,N,drug therapy
33138,DescriptorName,D001706,9792602,,,3,Biopsy,N,
33139,DescriptorName,D002648,9792602,,,4,Child,N,
33140,DescriptorName,D002867,9792602,,,5,Chromones,N,
33141,QualifierName,Q000009,9792602,,,5,,Y,adverse effects
33142,DescriptorName,D003404,9792602,,,6,Creatinine,N,
33143,QualifierName,Q000097,9792602,,,6,,N,blood
33144,DescriptorName,D005500,9792602,,,7,Follow-Up Studies,N,
33145,DescriptorName,D006029,9792602,,,8,Glycosuria,N,
33146,QualifierName,Q000209,9792602,,,8,,N,etiology
33147,DescriptorName,D006417,9792602,,,9,Hematuria,N,
33148,QualifierName,Q000209,9792602,,,9,,N,etiology
33149,DescriptorName,D006801,9792602,,,10,Humans,N,
33150,DescriptorName,D020024,9792602,,,11,Leukotriene Antagonists,N,
33151,QualifierName,Q000009,9792602,,,11,,Y,adverse effects
33152,DescriptorName,D008297,9792602,,,12,Male,N,
33153,DescriptorName,D009395,9792602,,,13,"Nephritis, Interstitial",N,
33154,QualifierName,Q000139,9792602,,,13,,Y,chemically induced
33155,DescriptorName,D011507,9792602,,,14,Proteinuria,N,
33156,QualifierName,Q000209,9792602,,,14,,N,etiology
33157,Chemical,D014665,9796135,Vasodilator Agents,0,,,,
33158,Chemical,D007548,9796135,Isosorbide Dinitrate,IA7306519N,,,,
33159,DescriptorName,D000286,9796135,,,1,"Administration, Sublingual",N,
33160,DescriptorName,D000368,9796135,,,2,Aged,N,
33161,DescriptorName,D000787,9796135,,,3,Angina Pectoris,N,
33162,QualifierName,Q000188,9796135,,,3,,N,drug therapy
33163,DescriptorName,D005260,9796135,,,4,Female,N,
33164,DescriptorName,D006801,9796135,,,5,Humans,N,
33165,DescriptorName,D007024,9796135,,,6,"Hypotension, Orthostatic",N,
33166,QualifierName,Q000139,9796135,,,6,,Y,chemically induced
33167,DescriptorName,D007548,9796135,,,7,Isosorbide Dinitrate,N,
33168,QualifierName,Q000008,9796135,,,7,,N,administration & dosage
33169,DescriptorName,D016683,9796135,,,8,Supine Position,N,
33170,DescriptorName,D013575,9796135,,,9,Syncope,N,
33171,QualifierName,Q000139,9796135,,,9,,Y,chemically induced
33172,DescriptorName,D014665,9796135,,,10,Vasodilator Agents,N,
33173,QualifierName,Q000008,9796135,,,10,,N,administration & dosage
33174,Chemical,D004791,9804082,Enzyme Inhibitors,0,,,,
33175,Chemical,D065089,9804082,Glycoside Hydrolase Inhibitors,0,,,,
33176,Chemical,D007004,9804082,Hypoglycemic Agents,0,,,,
33177,Chemical,D007294,9804082,Inositol,4L6452S749,,,,
33178,Chemical,C102817,9804082,voglibose,S77P977AG8,,,,
33179,DescriptorName,D000368,9804082,,,1,Aged,N,
33180,DescriptorName,D000369,9804082,,,2,"Aged, 80 and over",N,
33181,DescriptorName,D002544,9804082,,,3,Cerebral Infarction,N,
33182,QualifierName,Q000150,9804082,,,3,,N,complications
33183,DescriptorName,D002560,9804082,,,4,Cerebrovascular Circulation,N,
33184,QualifierName,Q000187,9804082,,,4,,N,drug effects
33185,DescriptorName,D003924,9804082,,,5,"Diabetes Mellitus, Type 2",N,
33186,QualifierName,Q000150,9804082,,,5,,N,complications
33187,DescriptorName,D003925,9804082,,,6,Diabetic Angiopathies,N,
33188,QualifierName,Q000150,9804082,,,6,,N,complications
33189,DescriptorName,D004244,9804082,,,7,Dizziness,N,
33190,QualifierName,Q000139,9804082,,,7,,Y,chemically induced
33191,DescriptorName,D004791,9804082,,,8,Enzyme Inhibitors,N,
33192,QualifierName,Q000009,9804082,,,8,,Y,adverse effects
33193,DescriptorName,D005260,9804082,,,9,Female,N,
33194,DescriptorName,D065089,9804082,,,10,Glycoside Hydrolase Inhibitors,Y,
33195,DescriptorName,D006801,9804082,,,11,Humans,N,
33196,DescriptorName,D007004,9804082,,,12,Hypoglycemic Agents,N,
33197,QualifierName,Q000009,9804082,,,12,,Y,adverse effects
33198,DescriptorName,D007294,9804082,,,13,Inositol,N,
33199,QualifierName,Q000009,9804082,,,13,,N,adverse effects
33200,DescriptorName,D008297,9804082,,,14,Male,N,
33201,DescriptorName,D008875,9804082,,,15,Middle Aged,N,
33202,DescriptorName,D009325,9804082,,,16,Nausea,N,
33203,QualifierName,Q000139,9804082,,,16,,N,chemically induced
33204,DescriptorName,D014839,9804082,,,17,Vomiting,N,
33205,QualifierName,Q000139,9804082,,,17,,N,chemically induced
33206,Chemical,D000893,9819544,Anti-Inflammatory Agents,0,,,,
33207,Chemical,D000894,9819544,"Anti-Inflammatory Agents, Non-Steroidal",0,,,,
33208,Chemical,D009288,9819544,Naproxen,57Y76R9ATQ,,,,
33209,Chemical,D011241,9819544,Prednisone,VB0R961HZT,,,,
33210,DescriptorName,D000328,9819544,,,1,Adult,N,
33211,DescriptorName,D000893,9819544,,,2,Anti-Inflammatory Agents,N,
33212,QualifierName,Q000627,9819544,,,2,,N,therapeutic use
33213,DescriptorName,D000894,9819544,,,3,"Anti-Inflammatory Agents, Non-Steroidal",N,
33214,QualifierName,Q000009,9819544,,,3,,Y,adverse effects
33215,DescriptorName,D005260,9819544,,,4,Female,N,
33216,DescriptorName,D006319,9819544,,,5,"Hearing Loss, Sensorineural",N,
33217,QualifierName,Q000139,9819544,,,5,,Y,chemically induced
33218,DescriptorName,D006801,9819544,,,6,Humans,N,
33219,DescriptorName,D008889,9819544,,,7,Military Personnel,N,
33220,DescriptorName,D009288,9819544,,,8,Naproxen,N,
33221,QualifierName,Q000009,9819544,,,8,,Y,adverse effects
33222,DescriptorName,D011241,9819544,,,9,Prednisone,N,
33223,QualifierName,Q000627,9819544,,,9,,N,therapeutic use
33224,DescriptorName,D014012,9819544,,,10,Tinnitus,N,
33225,QualifierName,Q000139,9819544,,,10,,Y,chemically induced
33226,Chemical,D000960,9824032,Hypolipidemic Agents,0,,,,
33227,Chemical,D009525,9824032,Niacin,2679MF687A,,,,
33228,DescriptorName,D000368,9824032,,,1,Aged,N,
33229,DescriptorName,D005881,9824032,,,2,Gingiva,Y,
33230,DescriptorName,D006801,9824032,,,3,Humans,N,
33231,DescriptorName,D006949,9824032,,,4,Hyperlipidemias,N,
33232,QualifierName,Q000188,9824032,,,4,,N,drug therapy
33233,DescriptorName,D000960,9824032,,,5,Hypolipidemic Agents,N,
33234,QualifierName,Q000009,9824032,,,5,,Y,adverse effects
33235,DescriptorName,D008297,9824032,,,6,Male,N,
33236,DescriptorName,D009525,9824032,,,7,Niacin,N,
33237,QualifierName,Q000009,9824032,,,7,,Y,adverse effects
33238,DescriptorName,D010146,9824032,,,8,Pain,N,
33239,QualifierName,Q000139,9824032,,,8,,Y,chemically induced
33240,DescriptorName,D014098,9824032,,,9,Toothache,N,
33241,QualifierName,Q000139,9824032,,,9,,Y,chemically induced
33242,Chemical,D010710,9831311,Phosphates,0,,,,
33243,Chemical,D011188,9831311,Potassium,RWP5GA015D,,,,
33244,DescriptorName,D000328,9831311,,,1,Adult,N,
33245,DescriptorName,D006801,9831311,,,2,Humans,N,
33246,DescriptorName,D007008,9831311,,,3,Hypokalemia,N,
33247,QualifierName,Q000139,9831311,,,3,,Y,chemically induced
33248,DescriptorName,D007015,9831311,,,4,"Hypophosphatemia, Familial",N,
33249,QualifierName,Q000150,9831311,,,4,,N,complications
33250,DescriptorName,D007684,9831311,,,5,Kidney Tubules,N,
33251,QualifierName,Q000378,9831311,,,5,,N,metabolism
33252,DescriptorName,D008297,9831311,,,6,Male,N,
33253,DescriptorName,D010018,9831311,,,7,Osteomalacia,N,
33254,QualifierName,Q000209,9831311,,,7,,Y,etiology
33255,DescriptorName,D010710,9831311,,,8,Phosphates,N,
33256,QualifierName,Q000008,9831311,,,8,,N,administration & dosage
33257,DescriptorName,D011188,9831311,,,9,Potassium,N,
33258,QualifierName,Q000097,9831311,,,9,,N,blood
33259,DescriptorName,D012016,9831311,,,10,Reference Values,N,
33260,Chemical,D000893,9840249,Anti-Inflammatory Agents,0,,,,
33261,Chemical,D018501,9840249,Antirheumatic Agents,0,,,,
33262,Chemical,D050607,9840249,Organogold Compounds,0,,,,
33263,Chemical,D008775,9840249,Methylprednisolone,X4W7ZR7023,,,,
33264,DescriptorName,D000368,9840249,,,1,Aged,N,
33265,DescriptorName,D000893,9840249,,,2,Anti-Inflammatory Agents,N,
33266,QualifierName,Q000627,9840249,,,2,,N,therapeutic use
33267,DescriptorName,D018501,9840249,,,3,Antirheumatic Agents,N,
33268,QualifierName,Q000009,9840249,,,3,,Y,adverse effects
33269,DescriptorName,D001172,9840249,,,4,"Arthritis, Rheumatoid",N,
33270,QualifierName,Q000188,9840249,,,4,,Y,drug therapy
33271,DescriptorName,D001989,9840249,,,5,Bronchiolitis Obliterans,N,
33272,QualifierName,Q000139,9840249,,,5,,N,chemically induced
33273,DescriptorName,D003937,9840249,,,6,"Diagnosis, Differential",N,
33274,DescriptorName,D006801,9840249,,,7,Humans,N,
33275,DescriptorName,D017563,9840249,,,8,"Lung Diseases, Interstitial",N,
33276,QualifierName,Q000139,9840249,,,8,,Y,chemically induced
33277,DescriptorName,D008297,9840249,,,9,Male,N,
33278,DescriptorName,D008775,9840249,,,10,Methylprednisolone,N,
33279,QualifierName,Q000627,9840249,,,10,,N,therapeutic use
33280,DescriptorName,D050607,9840249,,,11,Organogold Compounds,N,
33281,DescriptorName,D011175,9840249,,,12,Positive-Pressure Respiration,N,
33282,DescriptorName,D011379,9840249,,,13,Prognosis,N,
33283,DescriptorName,D011859,9840249,,,14,Radiography,N,
33284,Chemical,D019380,9847899,Anti-HIV Agents,0,,,,
33285,DescriptorName,D017088,9847899,,,1,AIDS-Related Opportunistic Infections,N,
33286,QualifierName,Q000188,9847899,,,1,,Y,drug therapy
33287,DescriptorName,D000328,9847899,,,2,Adult,N,
33288,DescriptorName,D019380,9847899,,,3,Anti-HIV Agents,N,
33289,QualifierName,Q000008,9847899,,,3,,N,administration & dosage
33290,DescriptorName,D004342,9847899,,,4,Drug Hypersensitivity,N,
33291,QualifierName,Q000276,9847899,,,4,,Y,immunology
33292,DescriptorName,D004359,9847899,,,5,"Drug Therapy, Combination",N,
33293,DescriptorName,D006801,9847899,,,6,Humans,N,
33294,DescriptorName,D006968,9847899,,,7,"Hypersensitivity, Delayed",N,
33295,QualifierName,Q000139,9847899,,,7,,Y,chemically induced
33296,DescriptorName,D007111,9847899,,,8,"Immunity, Cellular",N,
33297,QualifierName,Q000187,9847899,,,8,,N,drug effects
33298,DescriptorName,D008297,9847899,,,9,Male,N,
33299,DescriptorName,D009169,9847899,,,10,Mycobacterium tuberculosis,N,
33300,QualifierName,Q000276,9847899,,,10,,Y,immunology
33301,DescriptorName,D012307,9847899,,,11,Risk Factors,N,
33302,DescriptorName,D014374,9847899,,,12,Tuberculin Test,Y,
33303,DescriptorName,D014397,9847899,,,13,"Tuberculosis, Pulmonary",N,
33304,QualifierName,Q000188,9847899,,,13,,Y,drug therapy
33305,Chemical,D000305,984862,Adrenal Cortex Hormones,0,,,,
33306,Chemical,D001624,984862,Betamethasone Valerate,9IFA5XM7R2,,,,
33307,DescriptorName,D000287,984862,,,1,"Administration, Topical",N,
33308,DescriptorName,D000305,984862,,,2,Adrenal Cortex Hormones,N,
33309,QualifierName,Q000008,984862,,,2,,N,administration & dosage
33310,DescriptorName,D000328,984862,,,3,Adult,N,
33311,DescriptorName,D001624,984862,,,4,Betamethasone Valerate,N,
33312,QualifierName,Q000009,984862,,,4,,N,adverse effects
33313,DescriptorName,D005260,984862,,,5,Female,N,
33314,DescriptorName,D005951,984862,,,6,Glucose Tolerance Test,N,
33315,DescriptorName,D006029,984862,,,7,Glycosuria,N,
33316,QualifierName,Q000139,984862,,,7,,Y,chemically induced
33317,DescriptorName,D006801,984862,,,8,Humans,N,
33318,DescriptorName,D006943,984862,,,9,Hyperglycemia,N,
33319,QualifierName,Q000139,984862,,,9,,Y,chemically induced
33320,DescriptorName,D008297,984862,,,10,Male,N,
33321,DescriptorName,D008875,984862,,,11,Middle Aged,N,
33322,DescriptorName,D011236,984862,,,12,Prediabetic State,N,
33323,QualifierName,Q000175,984862,,,12,,N,diagnosis
33324,DescriptorName,D011565,984862,,,13,Psoriasis,N,
33325,QualifierName,Q000188,984862,,,13,,N,drug therapy
33326,Chemical,D018687,9855339,"Antidepressive Agents, Second-Generation",0,,,,
33327,Chemical,D007166,9855339,Immunosuppressive Agents,0,,,,
33328,Chemical,D010879,9855339,Piperazines,0,,,,
33329,Chemical,D014230,9855339,Triazoles,0,,,,
33330,Chemical,C051752,9855339,nefazodone,59H4FCV1TF,,,,
33331,Chemical,D016559,9855339,Tacrolimus,WM0HAQ4WNM,,,,
33332,DescriptorName,D018687,9855339,,,1,"Antidepressive Agents, Second-Generation",N,
33333,QualifierName,Q000009,9855339,,,1,,Y,adverse effects
33334,DescriptorName,D003221,9855339,,,2,Confusion,N,
33335,QualifierName,Q000139,9855339,,,2,,N,chemically induced
33336,DescriptorName,D003863,9855339,,,3,Depression,N,
33337,QualifierName,Q000188,9855339,,,3,,N,drug therapy
33338,DescriptorName,D004347,9855339,,,4,Drug Interactions,N,
33339,DescriptorName,D005260,9855339,,,5,Female,N,
33340,DescriptorName,D006261,9855339,,,6,Headache,N,
33341,QualifierName,Q000139,9855339,,,6,,N,chemically induced
33342,DescriptorName,D006801,9855339,,,7,Humans,N,
33343,DescriptorName,D007166,9855339,,,8,Immunosuppressive Agents,N,
33344,QualifierName,Q000009,9855339,,,8,,Y,adverse effects
33345,DescriptorName,D007676,9855339,,,9,"Kidney Failure, Chronic",N,
33346,QualifierName,Q000188,9855339,,,9,,N,drug therapy
33347,DescriptorName,D016030,9855339,,,10,Kidney Transplantation,Y,
33348,DescriptorName,D008875,9855339,,,11,Middle Aged,N,
33349,DescriptorName,D010879,9855339,,,12,Piperazines,N,
33350,DescriptorName,D016559,9855339,,,13,Tacrolimus,N,
33351,QualifierName,Q000009,9855339,,,13,,Y,adverse effects
33352,DescriptorName,D014230,9855339,,,14,Triazoles,N,
33353,QualifierName,Q000009,9855339,,,14,,Y,adverse effects
33354,DescriptorName,D014786,9855339,,,15,Vision Disorders,N,
33355,QualifierName,Q000139,9855339,,,15,,N,chemically induced
33356,Chemical,D000929,9861579,"Antidepressive Agents, Tricyclic",0,,,,
33357,Chemical,D008803,9861579,Mianserin,250PJI13LM,,,,
33358,Chemical,D000078785,9861579,Mirtazapine,A051Q2099Q,,,,
33359,DescriptorName,D000328,9861579,,,1,Adult,N,
33360,DescriptorName,D000929,9861579,,,2,"Antidepressive Agents, Tricyclic",N,
33361,QualifierName,Q000097,9861579,,,2,,N,blood
33362,DescriptorName,D003866,9861579,,,3,Depressive Disorder,N,
33363,QualifierName,Q000188,9861579,,,3,,N,drug therapy
33364,DescriptorName,D062787,9861579,,,4,Drug Overdose,N,
33365,DescriptorName,D005260,9861579,,,5,Female,N,
33366,DescriptorName,D006801,9861579,,,6,Humans,N,
33367,DescriptorName,D007035,9861579,,,7,Hypothermia,N,
33368,QualifierName,Q000150,9861579,,,7,,N,complications
33369,DescriptorName,D008803,9861579,,,8,Mianserin,N,
33370,QualifierName,Q000031,9861579,,,8,,Y,analogs & derivatives
33371,DescriptorName,D000078785,9861579,,,9,Mirtazapine,N,
33372,DescriptorName,D013406,9861579,,,10,"Suicide, Attempted",Y,
33373,Chemical,D004164,9865241,Diphosphonates,0,,,,
33374,Chemical,D014807,9865241,Vitamin D,1406-16-2,,,,
33375,Chemical,D000077268,9865241,Pamidronate,OYY3447OMC,,,,
33376,DescriptorName,D000368,9865241,,,1,Aged,N,
33377,DescriptorName,D004164,9865241,,,2,Diphosphonates,N,
33378,QualifierName,Q000627,9865241,,,2,,Y,therapeutic use
33379,DescriptorName,D062787,9865241,,,3,Drug Overdose,N,
33380,DescriptorName,D005260,9865241,,,4,Female,N,
33381,DescriptorName,D006801,9865241,,,5,Humans,N,
33382,DescriptorName,D006934,9865241,,,6,Hypercalcemia,N,
33383,QualifierName,Q000139,9865241,,,6,,N,chemically induced
33384,DescriptorName,D007049,9865241,,,7,Iatrogenic Disease,N,
33385,DescriptorName,D000077268,9865241,,,8,Pamidronate,N,
33386,DescriptorName,D014807,9865241,,,9,Vitamin D,N,
33387,QualifierName,Q000506,9865241,,,9,,Y,poisoning
33388,Chemical,D018501,9870779,Antirheumatic Agents,0,,,,
33389,Chemical,D008727,9870779,Methotrexate,YL5FZ2Y5U1,,,,
33390,DescriptorName,D000328,9870779,,,1,Adult,N,
33391,DescriptorName,D018501,9870779,,,2,Antirheumatic Agents,N,
33392,QualifierName,Q000009,9870779,,,2,,Y,adverse effects
33393,DescriptorName,D001172,9870779,,,3,"Arthritis, Rheumatoid",N,
33394,QualifierName,Q000150,9870779,,,3,,N,complications
33395,DescriptorName,D056486,9870779,,,4,Chemical and Drug Induced Liver Injury,Y,
33396,DescriptorName,D006801,9870779,,,5,Humans,N,
33397,DescriptorName,D008107,9870779,,,6,Liver Diseases,N,
33398,QualifierName,Q000150,9870779,,,6,,N,complications
33399,DescriptorName,D016031,9870779,,,7,Liver Transplantation,N,
33400,DescriptorName,D008297,9870779,,,8,Male,N,
33401,DescriptorName,D008727,9870779,,,9,Methotrexate,N,
33402,QualifierName,Q000009,9870779,,,9,,Y,adverse effects
33403,DescriptorName,D009336,9870779,,,10,Necrosis,N,
33404,Chemical,D000972,9876812,"Antineoplastic Agents, Phytogenic",0,,,,
33405,Chemical,D014747,9876812,Vinblastine,5V9KLZ54CY,,,,
33406,Chemical,D012964,9876812,Sodium,9NEZ333N27,,,,
33407,Chemical,D000077235,9876812,Vinorelbine,Q6C979R91Y,,,,
33408,Chemical,D011188,9876812,Potassium,RWP5GA015D,,,,
33409,DescriptorName,D000972,9876812,,,1,"Antineoplastic Agents, Phytogenic",N,
33410,QualifierName,Q000009,9876812,,,1,,Y,adverse effects
33411,DescriptorName,D001943,9876812,,,2,Breast Neoplasms,N,
33412,QualifierName,Q000188,9876812,,,2,,Y,drug therapy
33413,DescriptorName,D005260,9876812,,,3,Female,N,
33414,DescriptorName,D006801,9876812,,,4,Humans,N,
33415,DescriptorName,D007177,9876812,,,5,Inappropriate ADH Syndrome,N,
33416,QualifierName,Q000097,9876812,,,5,,N,blood
33417,DescriptorName,D008875,9876812,,,6,Middle Aged,N,
33418,DescriptorName,D011188,9876812,,,7,Potassium,N,
33419,QualifierName,Q000097,9876812,,,7,,N,blood
33420,DescriptorName,D012964,9876812,,,8,Sodium,N,
33421,QualifierName,Q000097,9876812,,,8,,N,blood
33422,DescriptorName,D014747,9876812,,,9,Vinblastine,N,
33423,QualifierName,Q000009,9876812,,,9,,N,adverse effects
33424,DescriptorName,D000077235,9876812,,,10,Vinorelbine,N,
33425,Chemical,D000889,9883483,Anti-Arrhythmia Agents,0,,,,
33426,Chemical,D010880,9883483,Piperidines,0,,,,
33427,Chemical,C024318,9883483,pirmenol,VZ3B6ACV72,,,,
33428,DescriptorName,D000889,9883483,,,1,Anti-Arrhythmia Agents,N,
33429,QualifierName,Q000009,9883483,,,1,,Y,adverse effects
33430,DescriptorName,D001281,9883483,,,2,Atrial Fibrillation,N,
33431,QualifierName,Q000188,9883483,,,2,,Y,drug therapy
33432,DescriptorName,D004562,9883483,,,3,Electrocardiography,N,
33433,QualifierName,Q000187,9883483,,,3,,Y,drug effects
33434,DescriptorName,D005260,9883483,,,4,Female,N,
33435,DescriptorName,D006801,9883483,,,5,Humans,N,
33436,DescriptorName,D008133,9883483,,,6,Long QT Syndrome,N,
33437,QualifierName,Q000139,9883483,,,6,,Y,chemically induced
33438,DescriptorName,D008875,9883483,,,7,Middle Aged,N,
33439,DescriptorName,D010880,9883483,,,8,Piperidines,N,
33440,QualifierName,Q000009,9883483,,,8,,Y,adverse effects
33441,Chemical,D000923,9886213,Anticestodal Agents,0,,,,
33442,Chemical,D011223,9886213,Praziquantel,6490C9U457,,,,
33443,DescriptorName,D000328,9886213,,,1,Adult,N,
33444,DescriptorName,D000923,9886213,,,2,Anticestodal Agents,N,
33445,QualifierName,Q000009,9886213,,,2,,Y,adverse effects
33446,DescriptorName,D003551,9886213,,,3,Cysticercosis,N,
33447,QualifierName,Q000150,9886213,,,3,,N,complications
33448,DescriptorName,D005260,9886213,,,4,Female,N,
33449,DescriptorName,D006801,9886213,,,5,Humans,N,
33450,DescriptorName,D009135,9886213,,,6,Muscular Diseases,N,
33451,QualifierName,Q000150,9886213,,,6,,N,complications
33452,DescriptorName,D009220,9886213,,,7,Myositis,N,
33453,QualifierName,Q000139,9886213,,,7,,Y,chemically induced
33454,DescriptorName,D011223,9886213,,,8,Praziquantel,N,
33455,QualifierName,Q000009,9886213,,,8,,Y,adverse effects
33456,Chemical,D005343,9892272,Fibrinolytic Agents,0,,,,
33457,Chemical,D010959,9892272,Tissue Plasminogen Activator,EC 3.4.21.68,,,,
33458,DescriptorName,D000368,9892272,,,1,Aged,N,
33459,DescriptorName,D005205,9892272,,,2,Fascia,N,
33460,DescriptorName,D005260,9892272,,,3,Female,N,
33461,DescriptorName,D005343,9892272,,,4,Fibrinolytic Agents,N,
33462,QualifierName,Q000009,9892272,,,4,,Y,adverse effects
33463,DescriptorName,D006406,9892272,,,5,Hematoma,N,
33464,QualifierName,Q000139,9892272,,,5,,Y,chemically induced
33465,DescriptorName,D006801,9892272,,,6,Humans,N,
33466,DescriptorName,D009203,9892272,,,7,Myocardial Infarction,N,
33467,QualifierName,Q000188,9892272,,,7,,Y,drug therapy
33468,DescriptorName,D013896,9892272,,,8,Thoracic Diseases,N,
33469,QualifierName,Q000139,9892272,,,8,,Y,chemically induced
33470,DescriptorName,D010959,9892272,,,9,Tissue Plasminogen Activator,N,
33471,QualifierName,Q000009,9892272,,,9,,Y,adverse effects
33472,DescriptorName,D014057,9892272,,,10,"Tomography, X-Ray Computed",N,
33473,Chemical,D008094,990658,Lithium,9FN79X2M3F,,,,
33474,Chemical,D008728,990658,Methotrimeprazine,9G0LAW7ATQ,,,,
33475,Chemical,D003975,990658,Diazepam,Q3JTX2Q7TU,,,,
33476,DescriptorName,D000328,990658,,,1,Adult,N,
33477,DescriptorName,D001714,990658,,,2,Bipolar Disorder,N,
33478,QualifierName,Q000188,990658,,,2,,Y,drug therapy
33479,DescriptorName,D003975,990658,,,3,Diazepam,N,
33480,QualifierName,Q000627,990658,,,3,,N,therapeutic use
33481,DescriptorName,D004347,990658,,,4,Drug Interactions,N,
33482,DescriptorName,D004359,990658,,,5,"Drug Therapy, Combination",N,
33483,DescriptorName,D005260,990658,,,6,Female,N,
33484,DescriptorName,D006801,990658,,,7,Humans,N,
33485,DescriptorName,D008094,990658,,,8,Lithium,N,
33486,QualifierName,Q000627,990658,,,8,,N,therapeutic use
33487,DescriptorName,D008728,990658,,,9,Methotrimeprazine,N,
33488,QualifierName,Q000009,990658,,,9,,Y,adverse effects
33489,DescriptorName,D010198,990658,,,10,Pancytopenia,N,
33490,QualifierName,Q000139,990658,,,10,,Y,chemically induced
33491,Chemical,D000889,9920368,Anti-Arrhythmia Agents,0,,,,
33492,Chemical,D001323,9920368,Autoantibodies,0,,,,
33493,Chemical,D018828,9920368,"Immunoglobulins, Thyroid-Stimulating",0,,,,
33494,Chemical,D007454,9920368,Iodides,0,,,,
33495,Chemical,D011989,9920368,"Receptors, Thyrotropin",0,,,,
33496,Chemical,C094372,9920368,thyrotropin-binding inhibitory immunoglobulin,0,,,,
33497,Chemical,D000638,9920368,Amiodarone,N3RQ532IUT,,,,
33498,DescriptorName,D000328,9920368,,,1,Adult,N,
33499,DescriptorName,D000638,9920368,,,2,Amiodarone,N,
33500,QualifierName,Q000009,9920368,,,2,,Y,adverse effects
33501,DescriptorName,D000889,9920368,,,3,Anti-Arrhythmia Agents,Y,
33502,DescriptorName,D019571,9920368,,,4,Arrhythmogenic Right Ventricular Dysplasia,N,
33503,QualifierName,Q000188,9920368,,,4,,N,drug therapy
33504,DescriptorName,D001323,9920368,,,5,Autoantibodies,N,
33505,QualifierName,Q000097,9920368,,,5,,Y,blood
33506,DescriptorName,D006801,9920368,,,6,Humans,N,
33507,DescriptorName,D018828,9920368,,,7,"Immunoglobulins, Thyroid-Stimulating",N,
33508,DescriptorName,D007454,9920368,,,8,Iodides,N,
33509,QualifierName,Q000652,9920368,,,8,,N,urine
33510,DescriptorName,D008297,9920368,,,9,Male,N,
33511,DescriptorName,D011989,9920368,,,10,"Receptors, Thyrotropin",N,
33512,QualifierName,Q000097,9920368,,,10,,Y,blood
33513,DescriptorName,D013971,9920368,,,11,Thyrotoxicosis,N,
33514,QualifierName,Q000139,9920368,,,11,,Y,chemically induced
33515,Chemical,D008899,9925865,Mineral Oil,8020-83-5,,,,
33516,DescriptorName,D018893,9925865,,,1,Bronchoalveolar Lavage,N,
33517,DescriptorName,D002648,9925865,,,2,Child,N,
33518,DescriptorName,D002908,9925865,,,3,Chronic Disease,N,
33519,DescriptorName,D003248,9925865,,,4,Constipation,N,
33520,QualifierName,Q000188,9925865,,,4,,N,drug therapy
33521,DescriptorName,D002658,9925865,,,5,Developmental Disabilities,N,
33522,QualifierName,Q000150,9925865,,,5,,N,complications
33523,DescriptorName,D008401,9925865,,,6,Gas Chromatography-Mass Spectrometry,N,
33524,DescriptorName,D006801,9925865,,,7,Humans,N,
33525,DescriptorName,D008297,9925865,,,8,Male,N,
33526,DescriptorName,D008899,9925865,,,9,Mineral Oil,N,
33527,QualifierName,Q000009,9925865,,,9,,Y,adverse effects
33528,DescriptorName,D011017,9925865,,,10,"Pneumonia, Lipid",N,
33529,QualifierName,Q000000981,9925865,,,10,,N,diagnostic imaging
33530,DescriptorName,D011859,9925865,,,11,Radiography,N,
33531,Chemical,D017319,9934637,Photosensitizing Agents,0,,,,
33532,Chemical,D008730,9934637,Methoxsalen,U4VJ29L7BQ,,,,
33533,DescriptorName,D000287,9934637,,,1,"Administration, Topical",N,
33534,DescriptorName,D005260,9934637,,,2,Female,N,
33535,DescriptorName,D006801,9934637,,,3,Humans,N,
33536,DescriptorName,D008730,9934637,,,4,Methoxsalen,N,
33537,QualifierName,Q000009,9934637,,,4,,Y,adverse effects
33538,DescriptorName,D008875,9934637,,,5,Middle Aged,N,
33539,DescriptorName,D011701,9934637,,,6,PUVA Therapy,Y,
33540,DescriptorName,D017319,9934637,,,7,Photosensitizing Agents,N,
33541,QualifierName,Q000009,9934637,,,7,,Y,adverse effects
33542,DescriptorName,D013471,9934637,,,8,Sunburn,Y,
33543,DescriptorName,D014820,9934637,,,9,Vitiligo,N,
33544,QualifierName,Q000188,9934637,,,9,,Y,drug therapy
33545,Chemical,D008787,9972383,Metoclopramide,L4YEB44I46,,,,
33546,DescriptorName,D015746,9972383,,,1,Abdominal Pain,N,
33547,QualifierName,Q000188,9972383,,,1,,N,drug therapy
33548,DescriptorName,D000368,9972383,,,2,Aged,N,
33549,DescriptorName,D003922,9972383,,,3,"Diabetes Mellitus, Type 1",N,
33550,QualifierName,Q000503,9972383,,,3,,N,physiopathology
33551,DescriptorName,D006801,9972383,,,4,Humans,N,
33552,DescriptorName,D016239,9972383,,,5,MEDLINE,N,
33553,DescriptorName,D008297,9972383,,,6,Male,N,
33554,DescriptorName,D008787,9972383,,,7,Metoclopramide,N,
33555,QualifierName,Q000009,9972383,,,7,,Y,adverse effects
33556,DescriptorName,D011695,9972383,,,8,"Purpura, Schoenlein-Henoch",N,
33557,QualifierName,Q000139,9972383,,,8,,Y,chemically induced
33558,Chemical,D008094,998323,Lithium,9FN79X2M3F,,,,
33559,DescriptorName,D002389,998323,,,1,Catatonia,N,
33560,QualifierName,Q000188,998323,,,1,,Y,drug therapy
33561,DescriptorName,D003919,998323,,,2,Diabetes Insipidus,N,
33562,QualifierName,Q000139,998323,,,2,,N,chemically induced
33563,DescriptorName,D005260,998323,,,3,Female,N,
33564,DescriptorName,D006801,998323,,,4,Humans,N,
33565,DescriptorName,D008094,998323,,,5,Lithium,N,
33566,QualifierName,Q000009,998323,,,5,,N,adverse effects
33567,DescriptorName,D008875,998323,,,6,Middle Aged,N,
33568,DescriptorName,D012008,998323,,,7,Recurrence,N,
33569,Chemical,D014150,9988365,Antipsychotic Agents,0,,,,
33570,Chemical,D003024,9988365,Clozapine,J60AR2IKIC,,,,
33571,DescriptorName,D000293,9988365,,,1,Adolescent,N,
33572,DescriptorName,D000328,9988365,,,2,Adult,N,
33573,DescriptorName,D014150,9988365,,,3,Antipsychotic Agents,N,
33574,QualifierName,Q000008,9988365,,,3,,N,administration & dosage
33575,DescriptorName,D003024,9988365,,,4,Clozapine,N,
33576,QualifierName,Q000008,9988365,,,4,,N,administration & dosage
33577,DescriptorName,D003866,9988365,,,5,Depressive Disorder,N,
33578,QualifierName,Q000188,9988365,,,5,,N,drug therapy
33579,DescriptorName,D004802,9988365,,,6,Eosinophilia,N,
33580,QualifierName,Q000139,9988365,,,6,,Y,chemically induced
33581,DescriptorName,D006801,9988365,,,7,Humans,N,
33582,DescriptorName,D008297,9988365,,,8,Male,N,
33583,DescriptorName,D012559,9988365,,,9,Schizophrenia,N,
33584,QualifierName,Q000188,9988365,,,9,,N,drug therapy
33585,DescriptorName,D016896,9988365,,,10,Treatment Outcome,N,
